<SEC-DOCUMENT>0001062822-23-000007.txt : 20230303
<SEC-HEADER>0001062822-23-000007.hdr.sgml : 20230303
<ACCEPTANCE-DATETIME>20230303072533
ACCESSION NUMBER:		0001062822-23-000007
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		76
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230303
DATE AS OF CHANGE:		20230303

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LEXICON PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001062822
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				760474169
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30111
		FILM NUMBER:		23701633

	BUSINESS ADDRESS:	
		STREET 1:		2445 TECHNOLOGY FOREST BLVD.
		STREET 2:		SUITE 1100
		CITY:			THE WOODLANDS
		STATE:			TX
		ZIP:			77381
		BUSINESS PHONE:		2818633000

	MAIL ADDRESS:	
		STREET 1:		2445 TECHNOLOGY FOREST BLVD.
		STREET 2:		SUITE 1100
		CITY:			THE WOODLANDS
		STATE:			TX
		ZIP:			77381

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXICON PHARMACEUTICALS, INC./DE
		DATE OF NAME CHANGE:	20070426

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXICON GENETICS INC/TX
		DATE OF NAME CHANGE:	20000126
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>lxrx-20221231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:379d89f1-f5df-4675-bf23-f82d2f2c7aaf,g:c8f45f50-51f6-43ab-b86a-02bdbec3750c,d:122d3ae3d73245b585bd7f040afd795c--><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:lxrx="http://www.lexpharma.com/20221231" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:utr="http://www.xbrl.org/2009/utr" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>lxrx-20221231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y180L2ZyYWc6MWY2MGQ5ZGY4NjNlNGI3Njk2NTQxZDVhNTJiMGE1ZTgvdGFibGU6YjZmMzk2ZDZhNjllNGRkNmI2N2E3MWE5MzgyOGZiYmMvdGFibGVyYW5nZTpiNmYzOTZkNmE2OWU0ZGQ2YjY3YTcxYTkzODI4ZmJiY180LTEtMS0xLTMzMjAz_ef5abe66-3c7b-491d-a4b2-b13f869b5e65">0001062822</ix:nonNumeric><ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y180L2ZyYWc6MWY2MGQ5ZGY4NjNlNGI3Njk2NTQxZDVhNTJiMGE1ZTgvdGFibGU6YjZmMzk2ZDZhNjllNGRkNmI2N2E3MWE5MzgyOGZiYmMvdGFibGVyYW5nZTpiNmYzOTZkNmE2OWU0ZGQ2YjY3YTcxYTkzODI4ZmJiY181LTEtMS0xLTMzMjAz_a26bcd1d-b12f-47a7-b7aa-4a34d853fb72">2019</ix:nonNumeric><ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y180L2ZyYWc6MWY2MGQ5ZGY4NjNlNGI3Njk2NTQxZDVhNTJiMGE1ZTgvdGFibGU6YjZmMzk2ZDZhNjllNGRkNmI2N2E3MWE5MzgyOGZiYmMvdGFibGVyYW5nZTpiNmYzOTZkNmE2OWU0ZGQ2YjY3YTcxYTkzODI4ZmJiY182LTEtMS0xLTMzMjAz_33395e2d-f04d-4387-b832-a82139b31a8d">FY</ix:nonNumeric><ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y180L2ZyYWc6MWY2MGQ5ZGY4NjNlNGI3Njk2NTQxZDVhNTJiMGE1ZTgvdGFibGU6YjZmMzk2ZDZhNjllNGRkNmI2N2E3MWE5MzgyOGZiYmMvdGFibGVyYW5nZTpiNmYzOTZkNmE2OWU0ZGQ2YjY3YTcxYTkzODI4ZmJiY183LTEtMS0xLTMzMjAz_1d0c1d46-4a68-4c01-ab7f-bb8382ba59b8">false</ix:nonNumeric><ix:nonNumeric contextRef="i38cd1975ba6645358dfa68c819a70fb8_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzM5MTE_558fa410-9f8f-4ae0-80f8-17c88e115072">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="idb9d77e7bb0d49ef814ea91873a8ee6f_D20180801-20180831" name="us-gaap:DebtInstrumentTerm" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzIzNzk_9029d41a-c8aa-4619-a57b-c3c4b9a9cbad">P2Y</ix:nonNumeric><ix:nonNumeric contextRef="i38cd1975ba6645358dfa68c819a70fb8_D20220101-20221231" name="lxrx:DeferredCompensationArrangementWithIndividualPaymentPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzgvZnJhZzplN2M4MTQ2M2ZkZWE0YWU5ODVmMWZmN2Q0YjI1ZTliNy90ZXh0cmVnaW9uOmU3YzgxNDYzZmRlYTRhZTk4NWYxZmY3ZDRiMjVlOWI3XzEzMzM_0e763c45-71c7-4867-9a1b-bb54280dc662">P6M</ix:nonNumeric><ix:nonNumeric contextRef="i431b23e0248d40349e27b0f5be856e54_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzM2NTc_da5a4fdb-478f-48e1-83dd-2888411ee7f9">P3Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="lxrx-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf43ab9deda34d99b2dc4e7beae89d69_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="iba28186a17904066a6f7804d947264f5_I20230301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i024c9d1784a74539a536ca837e05f772_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if253b46ef2a74bc69b4c2082a05ba597_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i55a81403781f47ae9d02222240bdb36d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i940ed9833e654f3e88d67e4c166a14f2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26b899de75ec4971bee2701c59fba66c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25c577e3042140158482c3aaff32919b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d199e0bcee94bea905035d961fbf255_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0476085741da4ed6ae45811b14d11523_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45c9e62c4e06465f8dea40fec66356eb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9edf2464575242e584cd5272e2783ba2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica463ea57f7c4e77aece9c9b75812753_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e407eae82ed45778d1645f5a4b283c9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb1c532e55244fa7aaed402560483d25_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08c5d241fccc478597d48a4e079af792_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f65a415e8d8463d8ca0eb8a49eab0a1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9c28386ac3f4264b971d6c2d1d20518_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie40de31d8a53466dbe16c3026141f0bf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i127c83dde28a497289a43680bd2d274e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i811c34b23fae41e08987de7c90d2a75f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a9aae42bd8341688cde38a2a191ea99_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief9b221acfd5465cb83500067a09fff2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99a04acc720b46cabd4ee3c5a2dd0674_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib42da41ca5a14b988815a9effcc674cd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d1bda838f674f4eaaa6f31e5ff61ec4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1922c7bd454f43a4af07205eb1f1b25a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbbc5e8a454e4cb5bff0e55c593bf0bd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4acd250f6fd84660b1b2a85f4f5e4a20_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i325272f405d94467a8e21c4ffc1fe333_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a0a6b3dd9e245ab82da25e46d931740_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d9d5924ae0a4ce3964a5ae029dd6486_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1198e2c5aacd45858d7c4371b727d5b2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56c0cc327a1d4ed19387c28bde2e3ffb_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd14ef30697244ac8b81d3b8376f5d6b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9a66cc8a08d4b5d95fc1a3de8f017a0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4961ca3cf71d48c3a2dc88cfab3d52f8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f6ebc10d76e49c0bef5f073adb72d4b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i959cffadb372413d8e83d72e239e6ded_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2fcd93af513045eba562f9ff41a202ac_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1e8bc9bcf1a4a439d70f50e536be574_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>lxrx:segment</xbrli:measure></xbrli:unit><xbrli:context id="i38cd1975ba6645358dfa68c819a70fb8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief3a42398bf74858b5aa075d327d0116_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0126e8a6d33142d5912c3766ac53314e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1ed3c23317249048fd1e594aaae930b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic47b53ad6bac40f099489e67c81c19de_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f10e15a388c4c8a99f1402fbd71ee00_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i841f2e01285341bc84e68db28065de33_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05102cf0094245939ba4bd0df2517905_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib86823c5a00d40e98853633ef7fadf56_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5904a39d50aa48738bfa16090d0521a4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idde6749a549b4ccc8f95351b92d40bce_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45721c6af18946ed9ca1743c070424b5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i512fe0c004b04e38b6d7b9742c09feab_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9dfe8c84430c424597db1dafc1f3fd2e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70df917b1e21470f80121f484c414360_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4663c2e38d1a45debc09ce327eed516d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i116622a8a31c498b8b13d9c3ba470fd3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d9a3d2b722d442a81512dcfc7684e90_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80407335c811483eb7ec1795e3a17f08_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iada15b389ba44ae5ad53399ba96f0121_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifaa3a61f9810465ab321c51897417ed6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3c76eaf4e9546efa476fcd01ad729ac_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i152a1c1f46d945e2acc800b6dd644332_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib432f651cb92444fa72128093d268fb8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2362482683d4d88854d2053c48290a6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1b08918d03a41e9ba2aa7258f976949_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c2e209ef7da4beea635d107d3eae5eb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3fa401e333b4caead7644933a30b5df_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i572e39a39bbe428abb0ea4530d55ece2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7709100c2ea472b8bf3b0dacf1d3df5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e34aff763f34fe18a41ebd0245a5197_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c4b46c8c9cd4829a9a8f58250be63e9_I20010712"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2001-07-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ca5f952951f4661bc87adf40c2f03b1_I20100730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2010-07-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e6700e3a4984b19b27e50bda5764ecb_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5082f56c08c74c63a4b9fbd86c1e2db5_D20250101-20251231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2f7712d90c8455ebf945f797fd6c4c5_D20260101-20261231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58efde7a50b54415affc844b791d1774_D20270101-20271231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2027-01-01</xbrli:startDate><xbrli:endDate>2027-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if284e805242a400b99ebf80651bc00de_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="rate"><xbrli:measure>utr:Rate</xbrli:measure></xbrli:unit><xbrli:context id="ifaed8b1899ba47ddb389bc7180e9188b_D20141101-20141130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2014-11-01</xbrli:startDate><xbrli:endDate>2014-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb9d77e7bb0d49ef814ea91873a8ee6f_D20180801-20180831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-08-01</xbrli:startDate><xbrli:endDate>2018-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84cdb8b224f3426da99041ee143ab064_I20180830"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-08-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d539018a70542119bc755c3276bee16_I20171218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-12-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28b8859c0c154ed482c84e3ab218642d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8686f139ef8d4193a880a31b12d0ce30_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i038e4801d2d648b38d0de7b8dab0f316_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib525d01afa1f498e883536f24362d124_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1be397a2eed340ea9795e0c692981bed_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94f2adcb200344b890fec8dc81de1ae6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1754ae6b09344ad1a9be3815a19dcd30_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i431b23e0248d40349e27b0f5be856e54_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idba6d48abf934e46bb6d9906a7959407_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0b2ee1a17b243b4a95803b356639783_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc54e15956a14d6a8516b3a8816e8281_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4aff0769c8dc406faa9ff4224da35cc9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">naics:ZZ541713</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9c84c90905348f0bcea48d159d00b8e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i122d3ae3d73245b585bd7f040afd795c_1"></div><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.926%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xL2ZyYWc6ODMzN2RkMDhiM2IzNDVhN2ExNDdkZDVlNzUwNTA1NzMvdGV4dHJlZ2lvbjo4MzM3ZGQwOGIzYjM0NWE3YTE0N2RkNWU3NTA1MDU3M184NA_fbb7b189-e056-4e85-a2d9-858bf8134d83">10-K</ix:nonNumeric></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.762%"><tr><td style="width:1.0%"></td><td style="width:9.371%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.708%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Mark One)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xL2ZyYWc6ODMzN2RkMDhiM2IzNDVhN2ExNDdkZDVlNzUwNTA1NzMvdGFibGU6ZjhmNzAyMDJhZTJmNDc2ZThkZWM1NTBkY2UyODBiMWIvdGFibGVyYW5nZTpmOGY3MDIwMmFlMmY0NzZlOGRlYzU1MGRjZTI4MGIxYl8xLTAtMS0xLTMzMjAz_89d58c01-fd4a-45b8-908a-e5e95927cf1b">&#9745;</ix:nonNumeric></span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Fiscal Year Ended </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xL2ZyYWc6ODMzN2RkMDhiM2IzNDVhN2ExNDdkZDVlNzUwNTA1NzMvdGFibGU6ZjhmNzAyMDJhZTJmNDc2ZThkZWM1NTBkY2UyODBiMWIvdGFibGVyYW5nZTpmOGY3MDIwMmFlMmY0NzZlOGRlYzU1MGRjZTI4MGIxYl8zLTItMS0xLTMzMjAz_e307e203-a105-4330-846d-9e1af664e1bd"><ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xL2ZyYWc6ODMzN2RkMDhiM2IzNDVhN2ExNDdkZDVlNzUwNTA1NzMvdGFibGU6ZjhmNzAyMDJhZTJmNDc2ZThkZWM1NTBkY2UyODBiMWIvdGFibGVyYW5nZTpmOGY3MDIwMmFlMmY0NzZlOGRlYzU1MGRjZTI4MGIxYl8zLTItMS0xLTMzMjAz_092776f3-6f03-4220-9ad5-6c05936ce1ba">December 31</ix:nonNumeric>, 2022</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">or</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.305%"><tr><td style="width:1.0%"></td><td style="width:9.101%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.699%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xL2ZyYWc6ODMzN2RkMDhiM2IzNDVhN2ExNDdkZDVlNzUwNTA1NzMvdGFibGU6MTdhNzQ3NWJjM2UyNGYxNjlkYmUxMWJmMDE3YTFmZDkvdGFibGVyYW5nZToxN2E3NDc1YmMzZTI0ZjE2OWRiZTExYmYwMTdhMWZkOV8wLTAtMS0xLTMzMjAz_2a327825-5519-4592-a797-e8c5fbf49c89">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Transition Period from _____________ to _____________</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number:&#160;&#160;<ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xL2ZyYWc6ODMzN2RkMDhiM2IzNDVhN2ExNDdkZDVlNzUwNTA1NzMvdGV4dHJlZ2lvbjo4MzM3ZGQwOGIzYjM0NWE3YTE0N2RkNWU3NTA1MDU3M18xMTg_1eb24bdd-ab03-4245-afea-1aec7196f983">000-30111</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xL2ZyYWc6ODMzN2RkMDhiM2IzNDVhN2ExNDdkZDVlNzUwNTA1NzMvdGV4dHJlZ2lvbjo4MzM3ZGQwOGIzYjM0NWE3YTE0N2RkNWU3NTA1MDU3M18zNDQ2_3820ce96-4453-4a17-bd2b-866b6b2f9a75">Lexicon Pharmaceuticals, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Exact Name of Registrant as Specified in its Charter)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.446%"><tr><td style="width:0.1%"></td><td style="width:2.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.208%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.529%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xL2ZyYWc6ODMzN2RkMDhiM2IzNDVhN2ExNDdkZDVlNzUwNTA1NzMvdGFibGU6MmQ0YTJmZmEwMTU4NGM4NzgzNTU2NTRiMzRkZWEwOWEvdGFibGVyYW5nZToyZDRhMmZmYTAxNTg0Yzg3ODM1NTY1NGIzNGRlYTA5YV8wLTEtMS0xLTMzMjAz_11a6bed2-62e6-4da1-8d93-fb8d4be406da">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xL2ZyYWc6ODMzN2RkMDhiM2IzNDVhN2ExNDdkZDVlNzUwNTA1NzMvdGFibGU6MmQ0YTJmZmEwMTU4NGM4NzgzNTU2NTRiMzRkZWEwOWEvdGFibGVyYW5nZToyZDRhMmZmYTAxNTg0Yzg3ODM1NTY1NGIzNGRlYTA5YV8wLTMtMS0xLTMzMjAz_5f31f940-8a9b-40bf-8e63-3502ff09607a">76-0474169</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(State or Other Jurisdiction of Incorporation or Organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification Number)</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.581%"><tr><td style="width:1.0%"></td><td style="width:1.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.219%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.298%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.785%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xL2ZyYWc6ODMzN2RkMDhiM2IzNDVhN2ExNDdkZDVlNzUwNTA1NzMvdGFibGU6NWVhMmRiNzIzOGU1NDkyYmI0YjAyYmZiNjJiZDc3NDIvdGFibGVyYW5nZTo1ZWEyZGI3MjM4ZTU0OTJiYjRiMDJiZmI2MmJkNzc0Ml8wLTEtMS0xLTMzMjAz_1f6be936-447b-45e4-9f8c-8b085aba81a6">2445 Technology Forest Blvd., 11th Floor</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xL2ZyYWc6ODMzN2RkMDhiM2IzNDVhN2ExNDdkZDVlNzUwNTA1NzMvdGFibGU6NWVhMmRiNzIzOGU1NDkyYmI0YjAyYmZiNjJiZDc3NDIvdGFibGVyYW5nZTo1ZWEyZGI3MjM4ZTU0OTJiYjRiMDJiZmI2MmJkNzc0Ml8xLTEtMS0xLTMzMjAz_aeeff42e-8f4d-413e-880a-688e205991eb">The Woodlands,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xL2ZyYWc6ODMzN2RkMDhiM2IzNDVhN2ExNDdkZDVlNzUwNTA1NzMvdGFibGU6NWVhMmRiNzIzOGU1NDkyYmI0YjAyYmZiNjJiZDc3NDIvdGFibGVyYW5nZTo1ZWEyZGI3MjM4ZTU0OTJiYjRiMDJiZmI2MmJkNzc0Ml8xLTItMS0xLTMzMjAz_eb856af6-11ca-4290-a1f2-c8279f77e0df">TX</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xL2ZyYWc6ODMzN2RkMDhiM2IzNDVhN2ExNDdkZDVlNzUwNTA1NzMvdGFibGU6NWVhMmRiNzIzOGU1NDkyYmI0YjAyYmZiNjJiZDc3NDIvdGFibGVyYW5nZTo1ZWEyZGI3MjM4ZTU0OTJiYjRiMDJiZmI2MmJkNzc0Ml8xLTMtMS0xLTMzMjAz_129e4ae6-73d0-4aa6-855c-3c8d3cc10fc9">77381</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xL2ZyYWc6ODMzN2RkMDhiM2IzNDVhN2ExNDdkZDVlNzUwNTA1NzMvdGFibGU6NWVhMmRiNzIzOGU1NDkyYmI0YjAyYmZiNjJiZDc3NDIvdGFibGVyYW5nZTo1ZWEyZGI3MjM4ZTU0OTJiYjRiMDJiZmI2MmJkNzc0Ml8xLTUtMS0xLTQwOTQy_07d496d6-ca65-4ba3-972f-375dc74d2a9f">(281)</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xL2ZyYWc6ODMzN2RkMDhiM2IzNDVhN2ExNDdkZDVlNzUwNTA1NzMvdGFibGU6NWVhMmRiNzIzOGU1NDkyYmI0YjAyYmZiNjJiZDc3NDIvdGFibGVyYW5nZTo1ZWEyZGI3MjM4ZTU0OTJiYjRiMDJiZmI2MmJkNzc0Ml8xLTYtMS0xLTQwOTQy_002d890f-44e9-4a85-8b4d-b6a889103407">863-3000</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Address of Principal Executive Offices and Zip Code)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Registrant&#8217;s Telephone Number, Including Area Code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.491%"><tr><td style="width:1.0%"></td><td style="width:3.085%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.027%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.317%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.870%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Title of Each Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Name of Each Exchange on which Registered</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;<ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xL2ZyYWc6ODMzN2RkMDhiM2IzNDVhN2ExNDdkZDVlNzUwNTA1NzMvdGFibGU6MGUxOGMwY2M0NGM1NDU5YTg4YmIxNzAzYWE0ZGFmZDUvdGFibGVyYW5nZTowZTE4YzBjYzQ0YzU0NTlhODhiYjE3MDNhYTRkYWZkNV8xLTEtMS0xLTMzMjAz_7e323f52-cb28-45f4-b507-01d952890053">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xL2ZyYWc6ODMzN2RkMDhiM2IzNDVhN2ExNDdkZDVlNzUwNTA1NzMvdGFibGU6MGUxOGMwY2M0NGM1NDU5YTg4YmIxNzAzYWE0ZGFmZDUvdGFibGVyYW5nZTowZTE4YzBjYzQ0YzU0NTlhODhiYjE3MDNhYTRkYWZkNV8xLTItMS0xLTMzMjAz_5d36a8b8-ea8b-4ce4-bd2f-39e0383af31d">LXRX</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;<ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xL2ZyYWc6ODMzN2RkMDhiM2IzNDVhN2ExNDdkZDVlNzUwNTA1NzMvdGFibGU6MGUxOGMwY2M0NGM1NDU5YTg4YmIxNzAzYWE0ZGFmZDUvdGFibGVyYW5nZTowZTE4YzBjYzQ0YzU0NTlhODhiYjE3MDNhYTRkYWZkNV8xLTMtMS0xLTMzMjAz_18ab8b72-5cda-4543-a5dc-a6b71b69d5c0">Nasdaq Global Select Market</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(g) of the Act:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;None</span></div><div style="margin-bottom:2pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act of 1933.&#160;&#160;Yes &#9744;&#160;&#160;<ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xL2ZyYWc6ODMzN2RkMDhiM2IzNDVhN2ExNDdkZDVlNzUwNTA1NzMvdGV4dHJlZ2lvbjo4MzM3ZGQwOGIzYjM0NWE3YTE0N2RkNWU3NTA1MDU3M180NzI_39efe224-f399-4252-b081-7d07c1787513">No</ix:nonNumeric> &#9745;</span></div><div style="margin-bottom:2pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Securities Exchange Act of 1934.&#160;&#160;&#160;Yes &#9744;&#160;&#160;<ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xL2ZyYWc6ODMzN2RkMDhiM2IzNDVhN2ExNDdkZDVlNzUwNTA1NzMvdGV4dHJlZ2lvbjo4MzM3ZGQwOGIzYjM0NWE3YTE0N2RkNWU3NTA1MDU3M182Mzk_a48a486f-90df-40ba-9de9-fd914a9c6acc">No</ix:nonNumeric> &#9745;</span></div><div style="margin-bottom:2pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;<ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xL2ZyYWc6ODMzN2RkMDhiM2IzNDVhN2ExNDdkZDVlNzUwNTA1NzMvdGV4dHJlZ2lvbjo4MzM3ZGQwOGIzYjM0NWE3YTE0N2RkNWU3NTA1MDU3M185OTA_1a61a59d-953b-43f4-b642-c84e7031ec24">Yes</ix:nonNumeric> &#9745; No &#9744;</span></div><div style="margin-bottom:2pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&#160;&#160;&#160;<ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xL2ZyYWc6ODMzN2RkMDhiM2IzNDVhN2ExNDdkZDVlNzUwNTA1NzMvdGV4dHJlZ2lvbjo4MzM3ZGQwOGIzYjM0NWE3YTE0N2RkNWU3NTA1MDU3M18xMjkz_030e8f5e-00b9-4801-a895-0ea8f75aeb28">Yes</ix:nonNumeric> &#9745; No &#9744;</span></div><div style="margin-bottom:2pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company.&#160;&#160;See definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Securities Exchange Act of 1934.&#160;&#160;(check one):&#160;&#160;Large accelerated filer &#160;&#9744;&#160;&#160;<ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xL2ZyYWc6ODMzN2RkMDhiM2IzNDVhN2ExNDdkZDVlNzUwNTA1NzMvdGV4dHJlZ2lvbjo4MzM3ZGQwOGIzYjM0NWE3YTE0N2RkNWU3NTA1MDU3M18xNzA4_f1b619aa-01e9-4f5e-b45d-ca4a08262900">Accelerated filer</ix:nonNumeric>&#160;&#160;&#9744;</span><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-accelerated filer &#9745;&#160;&#160;&#160;Smaller reporting company <ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xL2ZyYWc6ODMzN2RkMDhiM2IzNDVhN2ExNDdkZDVlNzUwNTA1NzMvdGV4dHJlZ2lvbjo4MzM3ZGQwOGIzYjM0NWE3YTE0N2RkNWU3NTA1MDU3M18zNDQ3_659e23c8-07a5-4fc2-bf84-286d73cf69c3">&#9745;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Emerging growth company <ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xL2ZyYWc6ODMzN2RkMDhiM2IzNDVhN2ExNDdkZDVlNzUwNTA1NzMvdGV4dHJlZ2lvbjo4MzM3ZGQwOGIzYjM0NWE3YTE0N2RkNWU3NTA1MDU3M18xNzky_c2e99485-3f2f-4028-bb31-2bdce9c0cec8">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:2pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Securities Exchange Act of 1934. &#9744;</span></div><div style="margin-bottom:2pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  <ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xL2ZyYWc6ODMzN2RkMDhiM2IzNDVhN2ExNDdkZDVlNzUwNTA1NzMvdGV4dHJlZ2lvbjo4MzM3ZGQwOGIzYjM0NWE3YTE0N2RkNWU3NTA1MDU3M18zNDQ4_bbd5ad2b-4eee-4006-85a5-5dbec16f68fc">&#9745;</ix:nonNumeric></span></div><div style="margin-bottom:2pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Securities Exchange Act of 1934).&#160;&#160;&#160;Yes <ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xL2ZyYWc6ODMzN2RkMDhiM2IzNDVhN2ExNDdkZDVlNzUwNTA1NzMvdGV4dHJlZ2lvbjo4MzM3ZGQwOGIzYjM0NWE3YTE0N2RkNWU3NTA1MDU3M18yNTQz_09105619-3530-48a2-bd21-41769bd59760">&#9744;</ix:nonNumeric> No&#160;&#9745;</span></div><div style="margin-bottom:2pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The aggregate market value of voting stock held by non-affiliates of the registrant as of the last day of the registrant&#8217;s most recently completed second quarter was approximately $<ix:nonFraction unitRef="usd" contextRef="icf43ab9deda34d99b2dc4e7beae89d69_I20220630" decimals="-3" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xL2ZyYWc6ODMzN2RkMDhiM2IzNDVhN2ExNDdkZDVlNzUwNTA1NzMvdGV4dHJlZ2lvbjo4MzM3ZGQwOGIzYjM0NWE3YTE0N2RkNWU3NTA1MDU3M18yNzMx_60e2b2bc-b215-43a5-b51d-e275cc7d22bb">134.4</ix:nonFraction> million, based on the closing price of the common stock on the Nasdaq Global Select Market on June&#160;30, 2022 of $1.86 per share.&#160;&#160;For purposes of the preceding sentence only, our directors, executive officers and controlling stockholders are assumed to be affiliates.&#160;&#160;As of March 1, 2023, <ix:nonFraction unitRef="shares" contextRef="iba28186a17904066a6f7804d947264f5_I20230301" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xL2ZyYWc6ODMzN2RkMDhiM2IzNDVhN2ExNDdkZDVlNzUwNTA1NzMvdGV4dHJlZ2lvbjo4MzM3ZGQwOGIzYjM0NWE3YTE0N2RkNWU3NTA1MDU3M18xMDk5NTExNjMxNDA0_e163cafe-ead7-4921-b980-be464d84fe19">188,725,743</ix:nonFraction> shares of common stock were outstanding.</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Documents Incorporated by Reference</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xL2ZyYWc6ODMzN2RkMDhiM2IzNDVhN2ExNDdkZDVlNzUwNTA1NzMvdGV4dHJlZ2lvbjo4MzM3ZGQwOGIzYjM0NWE3YTE0N2RkNWU3NTA1MDU3M18zNDQ5_2f375968-bb89-4895-92c1-bcb4826093fe" escape="true">Certain sections of the registrant&#8217;s definitive proxy statement relating to the registrant&#8217;s 2023 annual meeting of stockholders, which proxy statement will be filed under the Securities Exchange Act of 1934 within 120 days of the end of the registrant&#8217;s fiscal year ended December&#160;31, 2022, are incorporated by reference into Part III of this annual report on Form 10-K.</ix:nonNumeric></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.926%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i122d3ae3d73245b585bd7f040afd795c_7"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lexicon Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.902%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.440%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Item</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i122d3ae3d73245b585bd7f040afd795c_13">Business</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i122d3ae3d73245b585bd7f040afd795c_13">1</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1A.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i122d3ae3d73245b585bd7f040afd795c_49">Risk Factors</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i122d3ae3d73245b585bd7f040afd795c_49">18</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1B.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i122d3ae3d73245b585bd7f040afd795c_52">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i122d3ae3d73245b585bd7f040afd795c_52">35</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i122d3ae3d73245b585bd7f040afd795c_55">Properties</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i122d3ae3d73245b585bd7f040afd795c_55">36</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i122d3ae3d73245b585bd7f040afd795c_58">Legal Proceedings</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i122d3ae3d73245b585bd7f040afd795c_58">36</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i122d3ae3d73245b585bd7f040afd795c_61">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i122d3ae3d73245b585bd7f040afd795c_61">36</a></span></div></td></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART II</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i122d3ae3d73245b585bd7f040afd795c_67">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i122d3ae3d73245b585bd7f040afd795c_67">37</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i122d3ae3d73245b585bd7f040afd795c_70">[Reserved]</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i122d3ae3d73245b585bd7f040afd795c_67">37</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i122d3ae3d73245b585bd7f040afd795c_73">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i122d3ae3d73245b585bd7f040afd795c_73">38</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7A.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i122d3ae3d73245b585bd7f040afd795c_76">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i122d3ae3d73245b585bd7f040afd795c_76">44</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i122d3ae3d73245b585bd7f040afd795c_79">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i122d3ae3d73245b585bd7f040afd795c_79">44</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i122d3ae3d73245b585bd7f040afd795c_82">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i122d3ae3d73245b585bd7f040afd795c_82">44</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9A.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i122d3ae3d73245b585bd7f040afd795c_85">Controls and Procedures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i122d3ae3d73245b585bd7f040afd795c_85">44</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9B.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i122d3ae3d73245b585bd7f040afd795c_91">Other Information</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i122d3ae3d73245b585bd7f040afd795c_91">47</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9C.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i122d3ae3d73245b585bd7f040afd795c_94">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i122d3ae3d73245b585bd7f040afd795c_94">47</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART III</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i122d3ae3d73245b585bd7f040afd795c_100">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i122d3ae3d73245b585bd7f040afd795c_100">48</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i122d3ae3d73245b585bd7f040afd795c_103">Executive Compensation</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i122d3ae3d73245b585bd7f040afd795c_103">48</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i122d3ae3d73245b585bd7f040afd795c_106">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i122d3ae3d73245b585bd7f040afd795c_106">48</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i122d3ae3d73245b585bd7f040afd795c_109">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i122d3ae3d73245b585bd7f040afd795c_109">48</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i122d3ae3d73245b585bd7f040afd795c_112">Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i122d3ae3d73245b585bd7f040afd795c_112">48</a></span></div></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART IV</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i122d3ae3d73245b585bd7f040afd795c_118">Exhibit and Financial Statement Schedules</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i122d3ae3d73245b585bd7f040afd795c_118">49</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i122d3ae3d73245b585bd7f040afd795c_121">Form 10-K Summary</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i122d3ae3d73245b585bd7f040afd795c_121">51</a></span></div></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i122d3ae3d73245b585bd7f040afd795c_124">Signatures</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i122d3ae3d73245b585bd7f040afd795c_124">52</a></span></div></td></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Lexicon name and logo are registered trademarks of Lexicon Pharmaceuticals, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________________________________</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In this annual report on Form 10-K, &#8220;Lexicon Pharmaceuticals,&#8221; &#8220;Lexicon,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Lexicon Pharmaceuticals, Inc. and its subsidiaries.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________________________________</span></div><div style="margin-bottom:9pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Factors Affecting Forward-Looking Statements</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This annual report on Form 10-K contains forward-looking statements.&#160;&#160;These statements relate to future events or our future financial performance.&#160;&#160;We have attempted to identify forward-looking statements by terminology including &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;can,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;should&#8221; or &#8220;will&#8221; or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including the risks outlined under &#8220;Item 1A.&#160;&#160;Risk Factors,&#8221; that may cause our or our industry&#8217;s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. We are not under any duty to update any of the forward-looking statements after the date of this annual report on Form 10-K to conform these statements to actual results, unless required by law.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i122d3ae3d73245b585bd7f040afd795c_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i122d3ae3d73245b585bd7f040afd795c_13"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i122d3ae3d73245b585bd7f040afd795c_16"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company with a mission of pioneering medicines that transform patients&#8217; lives.&#160;&#160;We are devoting most of our resources to the research, development and preparation for commercialization of our most advanced drug candidates:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:12.53pt">We have a pending New Drug Application, or NDA, for sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure.  The NDA is currently under review by the U.S. Food and Drug Administration, or FDA, and has been assigned a target action date of May 27, 2023 under the Prescription Drug User Fee Act VI, or PDUFA.  The NDA is supported by positive results from two Phase 3 clinical trials evaluating the effect of sotagliflozin on long-term outcomes related to cardiovascular death and heart failure in approximately 10,500 and 1,200 patients, respectively.  Under the NDA, we are seeking regulatory approval to market sotagliflozin to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure and in adults with type 2 diabetes mellitus, chronic kidney disease and other cardiovascular risk factors. We are now preparing for the anticipated commercial launch of sotagliflozin in the United States following approval.</span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have also engaged in the development of sotagliflozin in type 1 diabetes, which was the subject of a separate NDA.  That NDA was supported by positive results from three Phase 3 clinical trials evaluating the effect of sotagliflozin on type 1 diabetes in approximately 800, 800 and 1,400 patients, respectively. The FDA issued a complete response letter regarding our NDA for sotagliflozin in type 1 diabetes. At our request, the FDA has issued a public Notice of Opportunity for Hearing on whether there are grounds for denying approval of our NDA and the hearing process is ongoing.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are developing LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain. We have reported positive results from a Phase 2 clinical trial of LX9211 in diabetic peripheral neuropathic pain. We have reported top-line results from a separate Phase 2 clinical trial of LX9211 in post-herpetic neuralgia which demonstrated clear evidence of effect. LX9211 has received Fast Track designation from the FDA for development in diabetic peripheral neuropathic pain.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are conducting preclinical research and development and preparing to conduct clinical development of compounds from a number of additional drug programs originating from our internal drug discovery efforts.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160; Sotagliflozin and compounds from a number of additional drug programs originated from our own internal drug discovery efforts, and LX9211 originated from our collaborative neuroscience drug discovery efforts with Bristol-Myers Squibb.  Our efforts were driven by a systematic, target biology-driven approach in which we used gene knockout technologies and an integrated platform of advanced medical technologies to systematically study the physiological and behavioral functions of almost 5,000 genes in mice and assessed the utility of the proteins encoded by the corresponding human genes as potential drug targets.  We have identified and validated in living animals, or in vivo, more than 100 targets with promising profiles for drug discovery.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;We are working both independently and through collaborations and strategic alliances with third parties to capitalize on our drug target discoveries and drug discovery and development programs.  We seek to retain exclusive or co-exclusive rights to the benefits of certain drug discovery and development programs by developing and commercializing drug candidates from those programs internally, particularly in the United States for indications treated by specialist physicians.  We seek to collaborate with other pharmaceutical and biotechnology companies with respect to drug discovery or the development and commercialization of certain of our drug candidates, particularly with respect to commercialization in territories outside the United States or commercialization in the United States for indications treated by primary care physicians, or when the collaboration may otherwise provide us with access to expertise and resources that we do not possess internally or are complementary to our own.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated in Delaware in July 1995, commenced operations in September 1995 and were listed on The Nasdaq Global Select Market in April 2000.  Our corporate headquarters are located at 2445 Technology Forest Blvd., 11th Floor, The Woodlands, Texas 77381, and our telephone number is (281) 863-3000.  &#160;</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 are made available free of charge on our corporate website located at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.lexpharma.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as soon as reasonably practicable after the filing of those reports with the Securities and Exchange Commission, or the SEC.&#160;&#160;Information found on our website should not be considered part of this annual report on Form 10-K.  Alternatively, you may access these reports on the SEC&#8217;s website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.sec.gov</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i122d3ae3d73245b585bd7f040afd795c_19"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Drug Development Programs</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are devoting most of our resources to the research, development and preparation for commercialization of our most advanced drug candidates:  sotagliflozin, which we are developing as a treatment for heart failure and type 1 diabetes, and LX9211, which we are developing as a treatment for neuropathic pain.  We have also advanced a number of additional compounds into various stages of clinical and preclinical development.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sotagliflozin</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sotagliflozin is an orally-delivered small molecule compound for which we have a pending NDA for heart failure and that we have separately been developing for type 1 diabetes. Our scientists identified the targets of sotagliflozin, sodium-glucose cotransporter type&#160;1, or SGLT1, and sodium-glucose cotransporter type&#160;2, or SGLT2, in our target discovery efforts based on their discovery that mice lacking SGLT1, SGLT2 or both exhibited favorable phenotypes across multiple measures of glucose control and metabolism in preclinical models. Preclinical studies of sotagliflozin demonstrated that compounds inhibiting both targets had a favorable preclinical profile relative to compounds selective for SGLT2.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Heart Failure</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The FDA is currently reviewing our NDA for sotagliflozin in heart failure and has assigned a PDUFA target action date of May 27, 2023.  Under the NDA, we are seeking regulatory approval to market sotagliflozin to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure and in adults with type 2 diabetes mellitus, chronic kidney disease and other cardiovascular risk factors.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We have completed two Phase 3 clinical trials evaluating the safety and tolerability of sotagliflozin and its effects on long-term outcomes related to composite primary endpoints of total cardiovascular death, hospitalizations for heart failure and urgent visits for heart failure.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our SCORED Phase 3 clinical trial enrolled 10,584 patients with type 2 diabetes, chronic kidney disease with an estimated glomerular filtration rate, or eGFR, of 25 to 60 ml per minute per</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> 1.73 m</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> of body surface area and risks for cardiovascular disease in a randomized, double-blind, placebo-controlled study of sotagliflozin added to standard of care over a median treatment period of 16 months.  Patients were initiated on a</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> 200mg once daily dose of sotagliflozin, which was increased at the discretion of the investigator to 400mg if unacceptable side effects did not occur.  The primary efficacy endpoint under evaluation in the study was the total number of events comprised of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure in patients treated with sotagliflozin compared with placebo.  Data from the study showed that treatment with sotagliflozin </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">resulted in a significantly lower total number of cardiovascular deaths, heart failure hospitalizations and urgent visits as compared to placebo, meeting the study&#8217;s primary efficacy endpoint.  A total of 930 primary endpoint events occurred in the study, with 400 events in the sotagliflozin-treated group and 530 events in the placebo group.  There were 5.6 primary endpoint events per 100 patient-years in the sotagliflozin-treated group as compared to 7.5 events per 100 patient-years in the placebo group (HR=0.74; 95% CI=0.63 to 0.88; p&lt;0.001).  There were 2.2 events of cardiovascular death per 100 patient-years in the sotagliflozin-treated group as compared to 2.4 events per 100 patient-years in the placebo group (HR=0.90; 95% CI=0.73 to 1.12; p=0.35).  The data showed an average reduction in hemoglobin A1c, or A1C, of 0.56% in the sotagliflozin-treated group as compared to a reduction of 0.25% in the placebo group in patients with severe chronic kidney disease, defined as having an eGFR of less than 30 ml per minute per 1.73 m</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> of body surface area (p&lt;0.001).  In patients with moderate chronic kidney disease, defined as having an eGFR of greater than or equal to 30 ml per minute per 1.73 m</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">2  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">of body surface area, the data showed an average reduction in A1C of 0.60% in the sotagliflozin-treated group as compared to a reduction of 0.17% in the placebo group (p&lt;0.001).  Serious adverse events that led to discontinuation of study drug, as determined by investigators, occurred in 2.1% (n=112) of the patients in the sotagliflozin-treated group and in 1.8% (n=94) of the patients in the placebo group.  Based on investigator reported events, the most common adverse events of special interest included urinary tract infections (11.5% on sotagliflozin versus 11.1% on placebo), diarrhea (8.5% on  sotagliflozin versus 6.0% on placebo), volume depletion (5.3% on sotagliflozin versus 4.0% on placebo), bone fractures (2.1% on sotagliflozin versus 2.2% on placebo), and genital mycotic infections (2.4% on sotagliflozin versus 0.9% on placebo).  Among other adverse events of interest, diabetic ketoacidosis (0.6% on sotagliflozin vs. 0.3% on placebo) was more </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">common in the sotagliflozin-treated group and severe hypoglycemia (1.0% on sotagliflozin vs. 1.0% on placebo) was similar between treatment groups.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The SCORED clinical trial was originally designed with co-primary endpoints, assessed in time-to-event analyses, of the first occurrence of a major adverse cardiovascular, or MACE, event, defined as death from cardiovascular causes, non-fatal myocardial infarction or non-fatal stroke, and the first occurrence of death from cardiovascular causes or hospitalization from heart failure, as determined by independent adjudication.  The co-primary endpoints were modified in connection with the early close out of the study to include urgent heart failure visits and reflect the total number of events, as determined by investigators, in order to enhance the statistical power of the comparison.  The specification of the primary endpoint based on total events was implemented without any awareness of the study outcomes or study group assignments and without information from an interim analysis.  In a time-to-event analysis, applying the original co-primary endpoints based on investigator reported events, the results for both the first occurrence of a MACE event (HR=0.84; 95% CI=0.72 to 0.99; p=0.035) and the first occurrence of death from cardiovascular causes or hospitalization for heart failure (HR=0.78; 95% CI=0.66 to 0.91; p=0.001) were consistent with those of the modified primary endpoint.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our SOLOIST Phase 3 clinical trial enrolled 1,222 patients with type 2 diabetes who had recently been hospitalized with worsening heart failure in a randomized, double-blind, placebo-controlled study of sotagliflozin initiated either before or within three days of hospital discharge over a median treatment period of nine months.  Patients were initiated on a 200mg once daily dose of sotagliflozin, which was increased at the discretion of the investigator to 400mg if unacceptable side effects did not occur.  The primary efficacy endpoint under evaluation in the study was the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">total number of events comprised of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure in patients treated with sotagliflozin compared with placebo, with dosing initiated either before or within three days of hospital discharge.  The first dose of sotagliflozin or placebo was administered prior to hospital discharge in 48.8% of patients and a median of two days following discharge in 51.2% of patients, with the benefits of sotagliflozin being consistent between those prespecified patient subgroups.  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Data from the study showed that treatment with sotagliflozin </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">resulted in a significantly lower total number of cardiovascular deaths, heart failure hospitalizations and urgent visits as compared to placebo, meeting the study&#8217;s primary efficacy endpoint.  A total of 600 primary endpoint events occurred in the study, with 245 events in the sotagliflozin-treated group and 355 events in the placebo group.  There were 51.0 primary endpoint events per 100 patient-years in the sotagliflozin-treated group as compared to 76.3 events per 100 patient-years in the placebo group (HR=0.67; 95% CI=0.52 to 0.85; p&lt;0.001).  There were 10.6 events of cardiovascular death per 100 patient-years in the sotagliflozin-treated group as compared to 12.5 events per 100 patient-years in the placebo group (HR=0.84; 95% CI=0.58 to 1.22; p=0.36).  Effects on the primary endpoint were consistent among patients suffering from heart failure with reduced ejection fraction, or HFrEF, and heart failure with preserved ejection fraction, or HFpEF.  Serious adverse events that led to discontinuation of study drug, as determined by investigators, occurred in 3.0% (n=18) of the patients in the sotagliflozin-treated group and in 2.8% (n=17) of the patients in the placebo group.  The most common adverse events of special interest included hypotension (6.0% on sotagliflozin versus 4.6% on placebo), urinary tract infections (4.8% on sotagliflozin versus 5.1% on placebo), acute kidney injury (4.1% on sotagliflozin versus 4.4% on placebo), and diarrhea (6.1% on sotagliflozin versus 3.4% on placebo).  Among other adverse events of interest, genital mycotic infections (0.8% on sotagliflozin vs. 0.2% on placebo) were infrequent, severe hypoglycemia (1.5% on sotagliflozin vs. 0.3% on placebo) was more common in the sotagliflozin-treated group and diabetic ketoacidosis (0.3% on sotagliflozin vs. 0.7% on placebo) was similar between treatment groups.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The SOLOIST clinical trial was originally designed with a primary endpoint of the first occurrence of death from cardiovascular causes or hospitalization from heart failure, as determined by independent adjudication.  The primary endpoint were modified in connection with the early close out of the study to include urgent heart failure visits and reflect the total number of events, as determined by investigators, in order to enhance the statistical power of the comparison.  The specification of the primary endpoint based on total events was implemented without any awareness of the study outcomes or study group assignments and without information from an interim analysis.  Applying the original primary endpoint based on investigator reported events, the results for the first occurrence of death from cardiovascular causes or hospitalization for heart failure (HR=0.71; 95% CI=0.57 to 0.89; p=0.003) were consistent with those of the modified primary endpoint.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Results from both the SCORED and SOLOIST clinical trials were published in the New England Journal of Medicine in November 2020.  </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">  </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Type 1 Diabetes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We previously filed an NDA for sotagliflozin in type 1 diabetes, regarding which the FDA issued a complete response letter in March 2019 and confirmed that position in denying two appeals of the complete response letter in November 2019 and March 2020.  In November 2020, we requested an opportunity for an administrative hearing on whether there are grounds for denying approval of our NDA.  In response to such request, the FDA issued a public Notice of Opportunity for Hearing in March 2021 and the hearing process is ongoing.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2021, sotagliflozin was approved in the United Kingdom for use as an adjunct to insulin therapy to improve glycemic control in adults with type 1 diabetes and a body mass index </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">&gt;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> 27 kg/m</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, who could not achieve adequate glycemic control despite optimal insulin therapy.  We have not commercially launched sotagliflozin for the treatment of type 1 diabetes in the United Kingdom or any other region.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have completed three Phase 3 clinical trials evaluating the safety and tolerability of sotagliflozin and its effects on glycemic parameters associated with type 1 diabetes.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our pivotal inTandem1 Phase 3 clinical trial enrolled 793 patients with type 1 diabetes in the United States and Canada in a randomized, double-blind, placebo-controlled study of 200mg and 400mg once daily doses of sotagliflozin over a 24-week treatment period, followed by a 28-week extension.  Insulin therapy was optimized in patients over a 6-week period prior to dosing.  The primary efficacy endpoint under evaluation in the trial was the reduction of A1C versus placebo on optimized insulin treatment at 24 weeks, with secondary endpoints including percentage of patients achieving A1C levels of less than 7% without experiencing an event of severe hypoglycemia or diabetic ketoacidosis, or DKA, change in meal-time, or bolus, insulin use, body weight, fasting plasma glucose and patient-reported assessments.  Data from the study showed that patients treated with sotagliflozin experienced statistically significant reductions in A1C from baseline of 0.43% for the 200mg dose (p&lt;0.001) and 0.48% for the 400mg dose (p&lt;0.001), as compared to a reduction of 0.07% on placebo after 24 weeks of treatment, meeting the study&#8217;s primary efficacy endpoint at both dose levels.  The A1C benefit achieved with sotagliflozin was sustained with statistically significant results over the full 52-week duration of the study for both the 200mg and 400mg doses.  Benefits in all secondary efficacy endpoints were observed in both the 200mg and 400mg dose arms compared to placebo, with statistically significant improvements in all secondary efficacy endpoints observed in the 400mg dose arm and in the percentage of patients achieving A1C levels of less than 7% without any severe hypoglycemia or DKA events and weight loss observed in the 200mg dose arm and statistically significant improvements in all secondary efficacy endpoints observed in the 400mg dose arm.  Over the full 52-week treatment period, the incidences of treatment-emergent adverse events in the placebo, 200mg and 400mg dose arms were 80.6%, 81.7% and 79.8%, respectively; the incidences of serious adverse events were 7.5%, 10.3% and 11.1%, respectively; and the incidences of discontinuation due to adverse events were 4.1%, 4.9% and 6.5%, respectively.  Potential cases of severe hypoglycemia and DKA were reviewed by a blinded adjudication panel, which determined whether such cases met pre-established diagnostic criteria.  The number of patients with positively adjudicated severe hypoglycemic events during the full 52-week treatment period was 26 (9.7%), 17 (6.5%) and 17 (6.5%) in the placebo, 200mg and 400mg dose arms, respectively.  The number of patients with positively adjudicated DKA events during the full 52-week treatment period was 1 (0.4%), 9 (3.4%) and 11 (4.2%) in the placebo, 200mg and 400mg dose arms, respectively.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our pivotal inTandem2 Phase 3 clinical trial enrolled 782 patients with type 1 diabetes in Europe and Israel in a randomized, double-blind, placebo-controlled study of 200mg and 400mg once daily doses of sotagliflozin over a 24-week treatment period, followed by a 28-week extension.  Insulin therapy was optimized in patients over a 6-week period prior to dosing.  As with inTandem1, the primary efficacy endpoint under evaluation in the trial was the reduction of A1C versus placebo on optimized insulin treatment at 24 weeks, with secondary endpoints including percentage of patients achieving A1C levels of less than 7% without experiencing a severe hypoglycemia or DKA event, change in bolus insulin use, body weight, fasting plasma glucose and patient-reported assessments.  Data from the study showed that patients treated with sotagliflozin experienced statistically significant reductions in A1C from baseline of 0.39% for the 200mg dose (p&lt;0.001) and 0.37% for the 400mg dose (p&lt;0.001), as compared to a reduction of 0.02% on placebo after 24 weeks of treatment, meeting the study&#8217;s primary efficacy endpoint at both dose levels.  The A1C benefit achieved with sotagliflozin was sustained with statistically significant results over the full 52-week duration of the study for both the 200mg and 400mg doses.  Statistically significant improvements in all secondary efficacy endpoints were observed in both the 200mg and 400mg dose arms compared to placebo.  Over the full 52-week treatment period, the incidences of treatment-emergent adverse events in the placebo, 200mg and 400mg dose arms were 61.2%, 68.2% and 68.8%, respectively; the incidences of serious adverse events were 6.6%, 10.0% and 8.0%, respectively; and the incidences of discontinuation due to adverse events were 3.5%, 3.8% and 6.8%, respectively.  Potential cases of severe hypoglycemia and DKA were reviewed by a blinded adjudication panel, which determined whether such cases met pre-established diagnostic criteria.  The number of patients with positively adjudicated severe hypoglycemic events during the full 52-week treatment period was 13 (5.0%), 13 (5.0%) and 6 (2.3%) in the placebo, 200mg and 400mg dose arms, respectively.  The number of patients with positively adjudicated DKA events during the full 52-week treatment period was 0 (0.0%), 6 (2.3%) and 9 (3.4%) in the placebo, 200mg and 400mg dose arms, respectively.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have additionally reported pooled continuous glucose monitoring, or CGM, data from the inTandem1 and inTandem2 clinical trials.  The percentage of time during the initial 24-week treatment period spent inside the target range for CGM glucose (70-180 mg/dL) increased from 52.2% to 57.8% in patients treated with 200mg of sotagliflozin and from 50.7% to 64.1% in patients treated with 400mg of sotagliflozin, with no relevant change observed in patients receiving placebo.  The differences from placebo were clinically significant for both the 200mg and 400mg dose groups (p=0.026 and p&lt;0.001, respectively).  The increase in time spent in range by both sotagliflozin dose groups was a result of significantly reduced time </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">spent above 180 mg/dL, while the time spent below 70 mg/dL was not increased.  These results translate into an additional 1.41 hours and 3.02 hours that a patient would spend within the 70-180 mg/dL target range in a 24-hour period, for the 200mg and 400mg dose groups respectively.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inTandem3 Phase 3 clinical trial enrolled 1,405 patients with type 1 diabetes in the United States and Europe in a randomized, double-blind, placebo-controlled study of a 400mg once daily dose of sotagliflozin over a 24-week treatment period.  Insulin therapy was not optimized in patients and eligibility criteria included any background insulin therapy.  The primary efficacy endpoint under evaluation in the trial was the proportion of patients achieving A1C levels of less than 7% at 24 weeks without experiencing a severe hypoglycemic or DKA event, with secondary endpoints including the change from baseline in A1C, body weight, systolic blood pressure and bolus insulin use.  Data from the study showed statistically significant superiority of sotagliflozin (28.6%) compared to placebo (15.2%) in the proportion of patients achieving A1C levels of less than 7% without experiencing a severe hypoglycemic or DKA event (p&lt;0.001), meeting the study&#8217;s primary endpoint.  Patients treated with sotagliflozin also experienced statistically significant improvements in all secondary efficacy endpoints compared to placebo.  The incidences of treatment-emergent adverse events in the placebo and 400mg dose arms were 52.5% and 55.1%, respectively; the incidences of serious adverse events were 3.3% and 6.9%, respectively; and the incidences of discontinuation due to adverse events were 2.3% and 6.3%, respectively.  Potential cases of severe hypoglycemia and DKA were reviewed by a blinded adjudication panel, which determined whether such cases met pre-established diagnostic criteria.  The number of patients with positively adjudicated severe hypoglycemic events during the 24-week treatment period was 17 (2.4%) and 21 (3.0%) in the placebo and 400mg dose arms, respectively.  The number of patients with positively adjudicated DKA events during the 24-week treatment period was 4 (0.6%) and 21 (3.0%) in the placebo and 400mg dose arms, respectively.  Results from the inTandem3 trial were published in the New England Journal of Medicine in September 2017.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">LX9211</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LX9211 is an orally-delivered small molecule compound that we are developing as a treatment for neuropathic pain.  Our scientists identified the target of LX9211, adapter-associated kinase 1, or AAK1, in our target discovery efforts based on their discovery that mice lacking AAK1 exhibited increased resistance to induced neuropathic pain in preclinical models.  LX9211 and another development candidate were discovered by scientists working within our drug discovery alliance with Bristol-Myers Squibb from which we hold exclusive development and commercialization rights.  Preclinical studies of LX9211 demonstrated central nervous system penetration and reduction in pain behavior in models of neuropathic pain without affecting opiate pathways.  LX9211 has received Fast Track designation from the FDA for development in diabetic peripheral neuropathic pain, or DPN.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have completed two Phase 2 clinical trials evaluating LX9211 in neuropathic pain. The first trial, RELIEF-DPN-1, evaluated the safety and tolerability of LX9211 and its effects on DPN, and the second trial, RELIEF-PHN-1, evaluated the safety and tolerability of LX9211 and its effects on post-herpetic neuralgia, or PHN. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our RELIEF-DPN-1 clinical trial enrolled 319 patients experiencing DPN in a randomized, double-blind, placebo-controlled study of LX9211 evaluating three treatment groups receiving an initial loading dose of 100mg or 200mg of LX9211 or placebo, followed by once daily doses of 10mg or 20mg of LX9211 or placebo, respectively. The effects of LX9211 were assessed over an 11-week evaluation period, which included a 5-week placebo run-off period following the initial 6-week treatment period. The primary efficacy endpoint under evaluation in the study was the change from baseline to week 6 in average daily pain score, or ADPS, based on the 11-point numerical rating scale in patients treated with LX9211 compared with placebo. Data from the study showed a statistically significant reduction from baseline to week 6 in ADPS of 1.39 points in the low dose arm, compared to 0.72 in the placebo arm (p=0.007 versus placebo), meeting the study&#8217;s primary endpoint.  The high dose arm demonstrated a reduction from baseline to week 6 in ADPS of 1.27 points (p=0.030 versus placebo), narrowly missing statistical significance.  Consistent and statistically significant benefits in burning pain, pain interference with sleep and other measures of particular importance in DPN were also observed in both LX9211 treatment arms as compared to placebo during the initial 6-week treatment period.  During the blinded 5-week placebo run-off period, there was a gradual tapering of efficacy in both treatment arms with no evidence of rebound pain or withdrawal symptoms.  Adverse events were more frequent in the LX9211 treatment arms and at the higher dose during the initial 6-week treatment period, with the most common being dizziness, headache and nausea and nearly all being reported as mild or moderate.  There were no observed differences in drug-related treatment-emergent adverse events between the treatment and placebo arms during the run-off period, and no drug-related serious adverse events or deaths were reported in the study.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our RELIEF-PHN-1 clinical trial enrolled 79 patients experiencing PHN in a randomized, double-blind, placebo-controlled study of LX9211 evaluating two treatment groups receiving an initial loading dose of 200mg of LX9211 or placebo, followed by once daily doses of 20mg of LX9211 or placebo, respectively. The effects of LX9211 were assessed over an 11-week evaluation period, which included a 5-week placebo run-off period following the initial 6-week treatment period. The </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">primary efficacy endpoint under evaluation in the study was the change from baseline to week 6 in ADPS based on the 11-point numerical rating scale in patients treated with LX9211 compared with placebo. Topline data from the study showed a reduction from baseline to week 6 in ADPS of 2.42 points in the LX9211 arm, compared to a reduction of 1.62 points in the placebo arm (p=0.120 versus placebo), missing statistical significance in the study&#8217;s primary endpoint but demonstrating clear evidence of effect.  Separation of LX9211 from placebo on ADPS was observed at week 1 and maintained consistently thereafter, with an average placebo-adjusted reduction over the 6-week treatment period of 0.80 points (p=0.031 versus placebo).  Adverse events were consistent with those observed in our RELIEF-DPN-1 clinical trial, with dizziness as the most commonly reported and the most frequently associated with patient dropouts from the study. No drug-related serious adverse events or deaths were reported in the study.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Additional Drug Discovery and Development Programs</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are conducting preclinical research and development and preparing to conduct clinical development of compounds from a number of additional drug programs originating from our internal drug discovery efforts.  Those efforts were driven by a systematic, target biology-driven approach in which we used gene knockout technologies and an integrated platform of advanced medical technologies to systematically study the physiological and behavioral functions of almost 5,000 genes in mice and assessed the utility of the proteins encoded by the corresponding human genes as potential drug targets. We have identified and validated in living animals, or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, more than 100 targets with promising profiles for drug discovery.</span></div><div><span><br/></span></div><div id="i122d3ae3d73245b585bd7f040afd795c_22"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaborations and Strategic Alliances</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are working both independently and through collaborations and strategic alliances with third parties to capitalize on our drug target discoveries and drug discovery and development programs.  Consistent with this approach, we seek to retain exclusive rights to the benefits of certain drug discovery and development programs by developing and commercializing drug candidates from those programs internally, particularly in the United States for indications treated by specialist physicians.  We seek to collaborate with other pharmaceutical and biotechnology companies with respect to drug discovery or the development and commercialization of certain of our drug candidates, particularly with respect to commercialization in territories outside the United States or commercialization in the United States for indications treated by primary care physicians, or when the collaboration may provide us with access to expertise and resources that we do not possess internally or are complementary to our own.  We also seek to collaborate with other pharmaceutical and biotechnology companies, research institutes and academic institutions to capitalize on our drug target discoveries.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bristol-Myers Squibb</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We established a drug discovery alliance with Bristol-Myers Squibb Company in December 2003 to discover, develop and commercialize small molecule drugs in the neuroscience field.&#160;&#160;Bristol-Myers Squibb extended the target discovery term of the alliance in May 2006.&#160;&#160;We initiated the alliance with a number of neuroscience drug discovery programs at various stages of development and used our gene knockout technologies to identify additional drug targets with promise in the neuroscience field.&#160;&#160;For those targets that were selected for the alliance, we and Bristol-Myers Squibb worked together, on an exclusive basis, to identify, characterize and carry out the preclinical development of small molecule drugs.  Bristol-Myers Squibb has the first option to assume full responsibility for clinical development and commercialization of any drugs resulting from the alliance which enter clinical trials, other than LX9211 and additional compounds acting through AAK1, for which we hold exclusive development and commercialization rights under the alliance.  We received $86&#160;million in upfront payments and research funding under the agreement during the target discovery portion of the alliance, which expired in October 2009. &#160;In addition, we are entitled to receive clinical and regulatory milestone payments ranging, depending on the timing and extent of our efforts in the alliance, up to $76&#160;million for each drug developed by Bristol-Myers Squibb under the alliance.&#160;&#160;We will also earn royalties on sales of drugs commercialized by Bristol-Myers Squibb under the alliance.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LX9211 and another development compound acting through AAK1 were discovered by scientists working within our alliance with Bristol-Myers Squibb.  We have agreed to pay Bristol-Myers Squibb up to $34.5 million in clinical and regulatory milestones for the first indication and up to $16 million in clinical and regulatory milestones for each of the second and third indications, if applicable.  We have also agreed to pay single digit royalties on worldwide net sales and up to $40 million in commercial milestones.</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Genentech</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We established a drug discovery alliance with Genentech, Inc. in December 2002 to discover novel therapeutic proteins and antibody targets.&#160;&#160;We and Genentech expanded the alliance in November 2005 for the advanced research, development and commercialization of new biotherapeutic drugs.&#160;&#160;Under the original alliance agreement, we used our target </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">validation technologies to discover the functions of secreted proteins and potential antibody targets identified through Genentech&#8217;s internal drug discovery research.&#160;&#160;In the expanded alliance, we conducted additional, advanced research on a broad subset of those proteins and targets.&#160;&#160;We have exclusive rights to develop and commercialize biotherapeutic drugs for two of these targets, while Genentech has exclusive rights to develop and commercialize biotherapeutic drugs for the other targets.&#160;&#160;We retain certain other rights to discoveries made in the alliance, including non-exclusive rights, along with Genentech, for the development and commercialization of small molecule drugs addressing the targets included in the alliance.  We received $58&#160;million in upfront payments, research funding and research milestone payments under the agreement during the research collaboration term, which expired in November 2008.&#160;&#160;In addition, we are entitled to receive clinical and regulatory milestone payments ranging, depending on the extent of our efforts in the alliance, up to $25&#160;million for each drug target for which Genentech develops a biotherapeutic drug under the alliance.&#160;&#160;We will also earn royalties on sales of biotherapeutic drugs commercialized by Genentech under the alliance.&#160;&#160;Genentech is entitled to receive milestone payments and royalties on sales of biotherapeutic drugs which we develop or commercialize under the alliance.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Collaborations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established collaborations with a number of pharmaceutical and biotechnology companies, research institutes and academic institutions under which we have received fees in exchange for generating knockout mice for genes requested by the collaborator, providing phenotypic data with respect to such knockout mice or otherwise granting access to some of our technologies and discoveries.&#160;&#160;In some cases, we remain eligible to receive milestone or royalty payments on the sale of mice and phenotypic data or on products that our collaborators discover or develop using our technology.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i122d3ae3d73245b585bd7f040afd795c_25"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing and Product Supply</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not own or operate manufacturing or distribution facilities or resources for production and distribution of sotagliflozin, LX9211 or our other drug candidates.  Instead, we have multiple contractual agreements in place with third-party contract manufacturing organizations, or CMOs, who, on our behalf, manufacture&#160;supplies of sotagliflozin, LX9211 and our other drug candidates, and will continue to do so for the foreseeable future.  We have selected well-established and reputable global CMOs for our active pharmaceutical ingredient, or API, and drug product manufacturing that have good regulatory standing, large manufacturing capacities, and multiple manufacturing sites within their business footprint.  We employ highly skilled personnel with both technical and manufacturing experience to diligently manage the activities at our CMOs.  Our quality department audits these suppliers on a periodic basis.  We work closely with our third-party manufacturers to ensure compliance with current good manufacturing practices, or cGMP, and other stringent regulatory requirements enforced by the FDA and foreign regulatory agencies in other territories, as applicable.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Raw materials that are used to manufacture our API are sourced from multiple third-party suppliers in Asia and Europe.  Third-party API contract manufacturers in Asia and Europe stock sufficient quantities of these materials to ensure they can manufacture quantities of API sufficient to meet our requirements. We store API at third-party facilities in North America, and provide appropriate amounts to third-party drug product contract manufacturers in North America who then manufacture, package and label our specified quantities of finished goods for sotagliflozin, LX9211 and our other drug candidates.  Our third-party contract manufacturers also need to obtain materials such as excipients, components and reagents to manufacture our API and finished drug products.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within our supply chain, we have established safety stock amounts for both our API and drug products, and store those in multiple locations.  The quantities that we store are based on our business needs and take into account scenarios for demand, production lead times, potential supply interruptions and shelf life for our API and drug products.  In parallel, for business continuity reasons, we will evaluate the need to establish an additional or backup supplier for our API and drug product, as necessary.  </span></div><div><span><br/></span></div><div id="i122d3ae3d73245b585bd7f040afd795c_28"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology and pharmaceutical industries are highly competitive and characterized by rapid technological change.&#160;&#160;We face significant competition in each of the aspects of our business from other pharmaceutical and biotechnology companies, as well as academic research institutions, clinical reference laboratories and governmental agencies that are pursuing research or development activities similar to ours.  Many of our competitors have substantially greater research, development and commercialization capabilities and financial, scientific, marketing and human resources than we do.&#160;&#160;As a result, our competitors may succeed in developing products earlier than we do, obtaining approvals from the FDA or other regulatory agencies for those products more rapidly than we do, developing products that are more effective than those we develop or commercializing products more effectively and profitably than we do.&#160;&#160;Similarly, our collaborators face similar competition from other competitors who may succeed in developing products more quickly, developing products that are more </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">effective than those developed by our collaborators or commercialize products more effectively and profitably than our collaborators.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The competition for our drug candidates includes both marketed products and drug candidates that are being developed by others, including pharmaceutical products that are currently in a more advanced stage of clinical development or commercialization than are our own drug candidates.&#160;&#160;These competitive marketed products and drug candidates include compounds that employ different mechanisms of action in addressing diseases and conditions for which we are developing our own drug candidates and, in some cases such as sotagliflozin, that employ the same or similar mechanisms of action.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our ability to successfully compete with these potentially competitive drug candidates and other competitive products currently on the market will depend on, among other things:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the efficacy, safety and reliability of our products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability, and the ability of our collaborators, to complete preclinical and clinical development and obtain regulatory approvals for our drug candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and scope of regulatory approvals of our products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability, and the ability of our collaborators, to obtain product acceptance by physicians and other health care providers and secure coverage and adequate reimbursement for product use in approved indications;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability, and the ability of our collaborators, to manufacture and sell commercial quantities of our products;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the skills of our employees and our ability to recruit and retain skilled employees;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">protection of our intellectual property; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of substantial capital resources to fund development and commercialization activities.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our principal competition for sotagliflozin for the treatment of heart failure would include selective SGLT2 inhibitors which have gained or may gain regulatory approval for the treatment of heart failure.  Such selective SGLT2 inhibitors include dapagliflozin and empagliflozin, currently marketed for the treatment of heart failure by AstraZeneca and through an alliance between Boehringer Ingelheim and Eli Lilly, respectively.  We expect that such competition would also include, to some extent, other classes of drugs used in the treatment of heart failure, such as the combination drug sacubitril/valsartan, currently marketed for the treatment of heart failure by Novartis, and vericiguat, currently marketed for the treatment of heart failure by Merck.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our principal competition for sotagliflozin in the treatment of type 1 diabetes would include established insulin therapies, as well as selective SGLT2 inhibitors currently being prescribed off-label.  Such selective SGLT2 inhibitors include dapagliflozin, empagliflozin and canagliflozin, currently marketed for the treatment of type 2 diabetes by AstraZeneca, through an alliance between Boehringer Ingelheim and Eli Lilly, and by Janssen (a subsidiary of Johnson &amp; Johnson), respectively.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our principal competition for LX9211 for the treatment of DPN would include duloxetine and pregabalin, which are currently marketed for the treatment of DPN by Eli Lilly and Pfizer, respectively, and are also available as generics.  We also expect that we would experience competition from gabapentin, which is available as a generic and is frequently prescribed off-label for the treatment of DPN.  We expect that our principal competition for LX9211 for the treatment of PHN would include gabapentin and pregabalin, both of which are currently marketed for the treatment of PHN by Pfizer and also available as generics.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i122d3ae3d73245b585bd7f040afd795c_31"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development, manufacture and sale of pharmaceutical products are subject to extensive regulation by United States and foreign governmental authorities, including federal, state and local authorities.&#160;&#160;In the United States, new drugs are subject to regulation under the Federal Food, Drug and Cosmetic Act and the regulations promulgated thereunder, or the FDC Act.&#160;&#160;The FDA and comparable governmental authorities regulate, among other things, research and development activities and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the testing, manufacture, quality control, safety, efficacy, record keeping, reporting, labeling, storage, approval, advertising, promotion, sale, distribution, export and import of pharmaceutical products.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The standard process required by the FDA before a drug candidate may be marketed in the United States generally includes the following:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preclinical laboratory and animal tests performed under current good laboratory practices, or cGLP;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">submission of an IND, which must become effective before human clinical trials may commence;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adequate and well-controlled human clinical trials to establish the safety and efficacy of the drug candidate for its intended use;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">submission of an NDA, for approval of commercial marketing and sale, or of an NDA supplement, or sNDA, for approval of a new indication if the product is already approved for another indication;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pre-approval inspection of manufacturing facilities and selected clinical investigators for their compliance with cGMP and current good clinical practices, or cGCP;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if the FDA convenes an advisory committee, satisfactory completion of the advisory committee review; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">FDA approval of the NDA or sNDA.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This process for the testing and approval of drug candidates requires substantial time, effort and financial resources.&#160;&#160;Preclinical development of a drug candidate can take from one to several years to complete, with no guarantee that an IND based on those studies will become effective to even permit clinical testing to begin.&#160;&#160;Before commencing the first clinical trial of a drug candidate in the United States, we must submit an IND to the FDA.&#160;&#160;The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises concerns or questions about the conduct of the clinical trial.&#160;&#160;In such a case, we and the FDA must resolve any outstanding concerns before the clinical trial may begin.&#160;&#160;Submission of an IND may not result in FDA authorization to commence a clinical trial.  A separate submission to the existing IND must be made for each successive clinical trial conducted during product development, and the FDA must grant permission for each clinical trial to start and continue.&#160;&#160;Further, an independent institutional review board for each medical center proposing to participate in the clinical trial must review and approve the plan for any clinical trial before it commences at that center.&#160;&#160;Regulatory authorities or an institutional review board or we may suspend a clinical trial at any time on various grounds, including a finding that the subjects or patients are being exposed to an unacceptable health risk.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of NDA approval, human clinical trials are typically conducted in three sequential phases that may overlap.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 1 clinical trials are conducted in a limited number of healthy human volunteers or, in some cases, patients, to evaluate the safety, dosage tolerance, absorption, metabolism, distribution and excretion of the drug candidate;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 2 clinical trials are conducted in groups of patients afflicted with a specified disease or condition to obtain preliminary data regarding efficacy as well as to further evaluate safety and optimize dosing of the drug candidate.  Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 3 clinical trials are conducted in larger patient populations at multiple clinical trial sites to obtain statistically significant evidence of the efficacy of the drug candidate for its intended use and to further test for safety in an expanded patient population.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the FDA may require, or companies may pursue, additional clinical trials after a product is approved.&#160;&#160;These so-called Phase&#160;4 studies may be made a condition to be satisfied after a drug receives approval.  Failure to satisfy such post-marketing commitments can result in FDA enforcement action, up and to including withdrawal of NDA approval.  The results of Phase 4 studies can confirm the effectiveness of a drug candidate and can provide important safety information to augment the FDA&#8217;s adverse drug reaction reporting system.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After completion of clinical trials, FDA approval of an NDA must be obtained before a new drug may be marketed in the United States.&#160;&#160;The submission of an NDA requires payment of a substantial user fee to the FDA.  An NDA must contain, among other things, information on chemistry, manufacturing controls and potency and purity, non-clinical pharmacology and toxicology, human pharmacokinetics and bioavailability and clinical data.&#160;&#160;There can be no assurance that the FDA will accept </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an NDA for filing and, even if accepted for filing, that approval will be granted.&#160;&#160;The FDA may convene an advisory committee to provide clinical insight on NDA review questions.  Although the FDA is not required to follow the recommendations of an advisory committee, the agency typically does so.  Among other things, the FDA reviews an NDA to determine whether a product is safe and effective for its intended use and whether the facility in which it is manufactured, processed, packed, or held meets standards designed to assure the product&#8217;s continued safety, purity and potency.&#160;&#160;The FDA may deny approval of an NDA by way of a complete response letter if the applicable regulatory criteria are not satisfied, or it may require additional clinical data or an additional pivotal Phase 3 clinical trial.&#160;&#160;Even if such data are submitted, the FDA may ultimately decide that the NDA does not satisfy the criteria for approval.&#160;&#160;An NDA may be approved with significant restrictions on its labeling, marketing and distribution under a Risk Evaluation and Mitigation Strategy or otherwise that could restrict the commercial applications of a product or impose costly procedures in connection with the commercialization or use of the product.  Once issued, the FDA may withdraw product approval if ongoing regulatory standards are not met or if safety problems occur after the product reaches the market.&#160;&#160;In addition, the FDA may require testing and surveillance programs to monitor the effect of approved products which have been commercialized, and the FDA has the power to prevent or limit further marketing of a product based on the results of these post-marketing programs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to obtaining FDA approval for each product, each drug manufacturing establishment must be inspected and approved by the FDA.&#160;&#160;All manufacturing establishments are subject to inspections by the FDA and by other federal, state and local agencies and must comply with current Good Manufacturing Practices requirements.&#160;&#160;Non-compliance with these requirements can result in, among other things, total or partial suspension of production, failure of the government to grant approval for marketing and withdrawal, suspension or revocation of marketing approvals.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Satisfaction of FDA requirements or similar requirements of state, local and foreign regulatory agencies typically takes many years, with the actual time required varying substantially based on, among other things, the nature, novelty and complexity of the drug candidate and of the disease or condition.&#160;&#160;Government regulation may delay or prevent marketing of drug candidates or new diseases for a considerable period of time and impose costly procedures upon our activities.  The FDA or any other regulatory agency may not grant approvals for new indications for our product candidates on a timely basis, if at all.  Success in earlier-stage clinical trials does not ensure success in later-stage clinical trials.&#160;&#160;Targets and pathways identified in vitro may be determined to be less relevant in clinical studies and results in animal model studies may not be predictive of human clinical results.  Furthermore, data obtained from clinical activities is not always conclusive and may be susceptible to varying interpretations, which could delay, limit or prevent regulatory approval.  Even if a drug candidate receives regulatory approval, the approval may be significantly limited to specific disease states, patient populations and dosages.  Further, even after regulatory approval is obtained, later discovery of previously unknown problems with a product may result in restrictions on the product or even complete withdrawal of the product from the market.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once the FDA approves a product, a manufacturer must provide certain updated safety and efficacy information.&#160;&#160;Product changes as well as certain changes in a manufacturing process or facility would necessitate additional FDA review and approval.&#160;&#160;Other post-approval changes may also necessitate further FDA review and approval.&#160;&#160;Additionally, a manufacturer must meet other requirements including those related to adverse event reporting and record keeping.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products manufactured or distributed by us pursuant to FDA approvals are subject to continuing regulation by the FDA, including record-keeping requirements and reporting of adverse experiences with the drug.  Drug manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP, which impose certain procedural and documentation requirements upon us and our third-party manufacturers.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA closely regulates the marketing and promotion of drugs, including restricting the promotion of uses for which a drug is not approved by the agency.&#160;&#160;Not only must a company have appropriate substantiation to support claims made about a drug, under the FDA&#8217;s current interpretation of relevant laws, a company can make only those claims relating to safety and efficacy that are for indications for which the FDA has approved the drug and are otherwise consistent with the FDA-approved label for the drug.&#160;&#160;Failure to comply with these requirements can result in adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties.  Physicians may, in their independent medical judgment, prescribe legally available drugs for uses that are not described in the product&#8217;s labeling and that differ from those tested by us and approved by the FDA.  Such off-label uses are common across medical specialties.  Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances.  The FDA does not regulate the behavior of physicians in their choice of treatments.  The FDA does, however, restrict manufacturers&#8217; communications on the subject of off-label use.  Additionally, a significant number of pharmaceutical companies have been the target of inquiries and investigations by various United States federal and state regulatory, investigative, prosecutorial and administrative entities in connection with the promotion of products for off-label uses and other sales practices. These investigations have alleged violations of various United States federal and state laws and regulations, including claims asserting antitrust violations, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">violations of the FDC Act, false claims laws, the Prescription Drug Marketing Act, anti-kickback laws, and other alleged violations in connection with the promotion of products for unapproved uses, pricing and Medicare and/or Medicaid reimbursement.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United States Orphan Drug Act is intended to incentivize the development of products for rare diseases or conditions that affect fewer than 200,000 people in the United States.  If a drug is being developed for a rare disease or condition, to be eligible for designation as an orphan drug, the FDA must not have previously approved a drug considered the &#8220;same drug&#8221; for the same orphan indication.  If the FDA has previously approved another same drug for the same indication, the sponsor of the subsequent drug would be required to provide a plausible hypotheses of clinical superiority over the previously approved drug to obtain an orphan designation.  Upon FDA receipt of orphan drug designation, the sponsor is eligible for tax credits of up to 25% for qualified clinical trial expenses, the ability to apply for annual grant funding and waiver of PDUFA application fee.  In addition, upon marketing approval, an orphan-designated drug could be eligible for seven years of market exclusivity for the approved orphan-designated indication.  Such orphan drug exclusivity, if awarded, would only block the approval of any drug considered the same drug for the same orphan indication.  Moreover, a subsequent same drug could break a previously approved drug&#8217;s orphan exclusivity through a demonstration of clinical superiority over the previously approved drug.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has various programs, including Fast Track, priority review and accelerated approval, which are intended to expedite or simplify the process for developing and reviewing promising drugs, or to provide for the approval of a drug on the basis of a surrogate endpoint.  Generally, drugs that are eligible for these programs are those for serious or life-threatening conditions, those with the potential to address unmet medical needs and those that offer meaningful benefits over existing treatments.  For example, Fast Track is a process designed to facilitate the development and expedite the review of drugs to treat serious or life-threatening diseases or conditions and fill unmet medical needs.  Priority review is designed to give drugs that treat serious conditions and offer major advances in treatment or provide a treatment where no adequate therapy exists an initial review within six months of NDA filing as compared to a standard review time of 10 months from NDA filing.  Certain other types of drug applications are also eligible for priority review.  Although Fast Track and priority review do not affect the standards for approval, the FDA will attempt to facilitate early and frequent meetings with a sponsor of a Fast Track-designated drug and expedite review of the application for a drug designated for priority review.  Accelerated approval provides for an earlier approval for a new drug that is intended to treat a serious or life-threatening disease or condition and that fills an unmet medical need based on a surrogate endpoint.  As a condition of approval, the FDA may require that a sponsor of a product candidate receiving accelerated approval perform post-marketing clinical trials to confirm the clinically meaningful outcome as predicted by the surrogate marker trial.  In addition to the Fast Track, accelerated approval and priority review programs, the FDA also designates Breakthrough Therapy status to drugs that are intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development.  Drugs designated as breakthrough therapies are also eligible for accelerated approval.  The FDA will seek to ensure the sponsor of a breakthrough therapy product candidate receives intensive guidance on an efficient drug development program, intensive involvement of senior managers and experienced staff on a proactive, collaborative and cross-disciplinary review and rolling review.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional programs intended to expedite the development of drug products were included in the 21st Century Cures Act, or the Cures Act.  The Cures Act includes various provisions to accelerate the development and delivery of new treatments, such as those intended to expand the types of evidence manufacturers may bring to the FDA to support drug approval, to encourage patient-centered drug development, to liberalize the communication of healthcare economic information to payers, and to create greater transparency with regard to manufacturer expanded access programs.  Central to the Cures Act are provisions that enhance and accelerate the FDA&#8217;s processes for reviewing and approving new drugs and supplements to approved NDAs, including provisions that:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require the FDA to establish a program to evaluate the potential use of real world evidence to help support the approval of a new indication for an approved drug and to help support or satisfy post-approval study requirements;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide that the FDA may rely upon qualified data summaries to support the approval of a supplemental application with respect to a qualified indication for an already approved drug;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require the FDA to issue guidance for purposes of assisting sponsors in incorporating complex adaptive and other novel trial designs into proposed clinical protocols and applications for new drugs; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require the FDA to establish a process for the qualification of drug development tools for use in supporting or obtaining FDA approval for or investigational use of a drug.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Cures Act amends Section 114 of the Food and Drug Administration Modernization Act of 1997 to help clarify and facilitate the dissemination of healthcare economic information, including by broadening the definition of healthcare economic information, expressly extending the dissemination of healthcare economic information to payors, and clarifying that healthcare economic information must only relate to an FDA-approved indication rather than directly relate to the indication.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulation Outside of the United States</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to regulations in the United States, we are subject to the regulations of other countries governing clinical trials and the manufacturing, commercial sales and distribution of our products outside of the United States.  Whether or not we obtain FDA approval for a product, we must obtain approval by the comparable regulatory authorities of countries outside of the United States before we can commence clinical trials in such countries and approval of the regulators of such countries or economic areas, such as the European Union, before we may market products in those countries or areas.  The approval process and requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from place to place, and the time may be longer or shorter than that required for FDA approval.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under European Union regulatory systems, a company may submit marketing authorization applications, or MAAs, either under a centralized or decentralized procedure. Under the centralized procedure, MAAs are submitted to the European Medicines Agency, or EMA, whose Committee for Medicinal Products for Human Use reviews the application and issues an opinion on it.  The opinion is considered by the European Commission which is responsible for deciding applications.  If the application is approved, the European Commission grants a single marketing authorization that is valid for all European Union member states as well as Iceland, Liechtenstein and Norway, or the EEA.  The national authorization procedures, the decentralized and mutual recognition procedures, as well as national applications, are available for products for which the centralized procedure is not compulsory.  The mutual recognition procedure provides for the European Union member states selected by the applicant to mutually recognize a national marketing authorization that has already been granted by the competent authority of another member state, referred to as the Reference Member State, or RMS.  The decentralized procedure is used when the product in question has yet to be granted a marketing authorization in any member state.  Under this procedure the applicant can select the member state that will act as the RMS.  In both the mutual recognition and decentralized procedures, the RMS reviews the application and submits its assessment of the application to the member states where marketing authorizations are being sought, referred to as Concerned Member States or CMS.  Within 90 days of receiving the application and assessment report, each CMS must decide whether to recognize the RMS assessment.  If a member state does not agree with the assessment and the disputed points cannot be resolved, the matter is eventually referred to the European Commission, whose decision is binding on all member states.  If the application is successful, national marketing authorizations will be granted by the competent authorities in each of the member states chosen by the applicant.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conditional marketing authorizations may be granted for a limited number of medicinal products for human use referenced in European Union law applicable to conditional marketing authorizations where the clinical dataset is not comprehensive, if the risk-benefit balance of the product is positive, it is likely that the applicant will be in a position to provide the required comprehensive clinical trial data, unmet medical needs will be fulfilled and the benefit to public health of the immediate availability on the market of the medicinal product outweighs the risk inherent in the fact that additional data are still required.  Specific obligations, such as the completion of ongoing or new studies and obligations relating to the collection of pharmacovigilance data, may be amongst the conditions stipulated in the marketing authorization.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As in the United States, we may apply for designation of a product as an Orphan drug for the treatment of a specific indication in the European Union before the application for marketing authorization is made. In the European Union, orphan designation is available for products in development which are either intended for the diagnosis, prevention or treatment of life-threatening or chronically debilitating conditions affecting not more than 5 in 10,000 persons in the European Union, or intended for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition in the community and when, without incentives, it is unlikely that sales of the drug in the European Union would be sufficient to justify the necessary investment in developing the medicinal product.  Additionally, the sponsor of an application for orphan drug designation must establish that there exists no satisfactory authorized method of diagnosis, prevention, or treatment of the condition or even if such treatment exists, the product will be of significant benefit to those affected by that condition.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Orphan drugs in the European Union enjoy economic and marketing benefits, including up to ten years of market exclusivity for the approved indication unless another applicant can show that its product is safer, more effective or otherwise clinically superior to the orphan-designated product.  The period of market exclusivity may be reduced to six years if at the end of the fifth year it is established that the criteria for orphan designation are no longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare Regulation</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal and state healthcare laws, including fraud and abuse and health information privacy and security laws, also apply to our business.  If we fail to comply with those laws, we could face substantial penalties and our business, results of operations, financial condition and prospects could be adversely affected.  The laws that may affect our ability to operate include, but are not limited to: the federal Anti-Kickback Statute, which prohibits. among other things, soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce, or in return for, the purchase or recommendation of an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs; and federal civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payers that are false or fraudulent.  Additionally, we are subject to state law equivalents of each of the above federal laws, which may be broader in scope and apply regardless of whether the payer is a federal healthcare program, and many of which differ from each other in significant ways and may not have the same effect, further complicate compliance efforts.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerous federal and state laws, including state security breach notification laws, state health information privacy laws and federal and state consumer protection laws, govern the collection, use and disclosure of personal information.  Other countries also have, or are developing, laws governing the collection, use and transmission of personal information.  In addition, most healthcare providers who are expected to prescribe our products and from whom we obtain patient health information, are subject to privacy and security requirements under the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology and Clinical Health Act, or HIPAA.  Although we are not directly subject to HIPAA, we could be subject to criminal penalties if we knowingly obtain individually identifiable health information from a HIPAA-covered entity, including healthcare providers, in a manner that is not authorized or permitted by HIPAA.  The legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing amount of focus on privacy and data protection issues with the potential to affect our business, including recently enacted laws in a majority of states requiring security breach notification.  These laws could create liability for us or increase our cost of doing business. International laws, such as the EU Data Privacy Directive and Swiss Federal Act on Data Protection, regulate the processing of personal data within the European Union and between countries in the European Union and countries outside of the European Union, including the United States.  Failure to provide adequate privacy protections and maintain compliance with safe harbor mechanisms could jeopardize business transactions across borders and result in significant penalties.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Physician Payments Sunshine Act, enacted as part of the Patient Protection and Affordable Care Act of 2010, or the ACA, created a federal requirement under the federal Open Payments program, that requires certain manufacturers to track and report to the Centers for Medicare and Medicaid Services, or CMS, annually certain payments and other transfers of value provided to physicians and certain advanced non-physician health care practitioners and teaching hospitals made in the previous calendar year, as well as ownership and investment interests held by physicians and their immediate family members.  In addition, there are also an increasing number of state laws that require manufacturers to make reports to states on pricing and marketing information.  These laws may affect our sales, marketing, and other promotional activities by imposing administrative and compliance burdens on us.  In addition, given the lack of clarity with respect to these laws and their implementation, our reporting actions could be subject to the penalty provisions of the pertinent state and federal authorities.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For those marketed products which are covered in the United States by the Medicaid program, we have various obligations, including government price reporting and rebate requirements, which generally require products be offered at substantial rebates/discounts to Medicaid and certain purchasers.  We are also required to discount such products to authorized users of the Federal Supply Schedule of the General Services Administration, under which additional laws and requirements apply.  These programs require submission of pricing data and calculation of discounts and rebates pursuant to complex statutory formulas, as well as the entry into government procurement contracts governed by the Federal Acquisition Regulations, and the guidance governing such calculations is not always clear.  Compliance with such requirements can require significant investment in personnel, systems and resources, but failure to properly calculate our prices, or offer required discounts or rebates could subject us to substantial penalties.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare Reform</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of pharmaceutical products, restrict or regulate post-approval activities, and affect the ability to profitably sell pharmaceutical products that obtain marketing approval.  The FDA&#8217;s and other regulatory authorities&#8217; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of drug candidates.  Moreover, among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, the ACA has had a significant impact on the health care industry in the United States.  The ACA was designed to expand coverage for the uninsured while at the same time contain overall healthcare costs.  With regard to biopharmaceutical products, the ACA, among other things, addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extended the rebate program to individuals enrolled in Medicaid managed care organizations, established annual fees on manufacturers of certain branded prescription drugs, and created a new Medicare Part D coverage gap discount program. Additionally, the Creating and Restoring Equal Access to Equivalent Samples Act of 2019, or the CREATES Act, aims to address the concern articulated by both the FDA and others in the industry that some brand manufacturers have improperly restricted the distribution of their products, including by invoking the existence of a risk evaluation and mitigation strategies, or REMS, program for certain products, to deny generic product developers access to samples of brand products.  Because generic product developers need samples to conduct certain comparative testing required by the FDA, some have attributed the inability to timely obtain samples as a cause of delay in the entry of generic products.  To remedy this concern, the CREATES Act established a private cause of action that permits a generic product developer to sue the brand manufacturer to compel it to furnish the necessary samples on &#8220;commercially reasonable, market-based terms.&#8221;  Whether and how generic product developments will use this new pathway, as well as the likely outcome of any legal challenges to provisions of the CREATES Act, remain highly uncertain and its potential effects on future competition are unknown.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its enactment, there have been executive, judicial and Congressional challenges to certain aspects of the ACA and we expect there will be additional challenges and amendments to the ACA in the future.  Members of the United States Congress have indicated that they may continue to seek to modify, repeal or otherwise invalidate all, or certain provisions of, the ACA.  For example, the Tax Cuts and Jobs Act, among other things, removed penalties for not complying with the ACA&#8217;s individual mandate to carry health insurance, commonly referred to as the &#8220;individual mandate.&#8221;  It is unclear how this and other efforts to repeal and replace the ACA will impact the implementation of the ACA, the pharmaceutical industry more generally, and our business.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Inflation Reduction Act of 2022, or the Inflation Reduction Act, imposed significant changes to how drugs are covered and paid for under the Medicare program, including the creation of financial penalties for drugs whose prices rise faster than the rate of inflation, redesign of the Medicare Part D program to require manufacturers to bear more of the liability for certain drug benefits, and government price-setting for certain Medicare Part D drugs, starting in 2026, and Medicare Part B drugs starting in 2028.  The long-term implications of the Inflation Reduction Act remain uncertain and subject to various factors, including the manner in which the Department of Health and Human Services, or DHHS, decides to implement the statute.  Many experts and analysts, both within the industry and outside, have predicted that the law will harm innovation in the pharmaceutical industry and result in fewer new treatments being developed and approved over time.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As another example, the 2021 Consolidated Appropriations Act incorporated extensive healthcare provisions and amendments to existing laws, including a requirement that all manufacturers of drugs and biological products covered under Medicare Part B report the product&#8217;s average sales price to the DHHS, subject to enforcement via civil money penalties.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products.  DHHS has solicited feedback on some of various measures intended to lower drug prices and reduce the out of pocket costs of drugs and implemented others under its existing authority.  Congress and the executive branch have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs, making this area subject to ongoing uncertainty.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Individual states in the United States have also increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.  In December 2020, the United States Supreme Court held unanimously that federal law does not preempt the states&#8217; ability to regulate pharmaceutical benefit managers and other members of the health care and pharmaceutical supply chain, an important decision that may lead to further and more aggressive efforts by states in this area.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. We expect that additional state and federal healthcare </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Environmental and Worker Safety Matters</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to the foregoing, our business is subject to regulation under various state and federal environmental and worker safety laws, including the Occupational Safety and Health Act, the Resource Conservation and Recovery Act, the Comprehensive Environmental Response, Compensation and Liability Act and the Toxic Substances Control Act, each as amended from time to time.&#160;&#160;These and other laws and their implementing regulations govern our manufacture, use, storage, handling, transport and disposal of various biological, chemical, radioactive and other hazardous substances used in our operations and the wastes generated by those activities.  We cannot eliminate the risk of accidental contamination or discharge and any resultant injury from these substances.  We may face liability for any injury or contamination that results from our use or the use by third parties of those substances, and such liability may exceed our insurance coverage and our total assets.  Historically, our environmental and worker safety compliance costs have not had a material adverse effect on our results of operations, but there can be no assurance that such costs will not be material in the future or that such future compliance will not have a material adverse effect on our business and operational results.  The trend in environmental and occupational health and safety laws and regulations is to typically place more restrictions and limitations on activities that may adversely affect the environment or expose workers to injury.  If existing regulatory requirements or enforcement policies change or new regulatory or enforcement initiatives are developed and implemented in the future, we may be required to make significant, unanticipated capital and operating expenditures.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i122d3ae3d73245b585bd7f040afd795c_34"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patents and Proprietary Rights</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We can protect our proprietary rights from unauthorized use by third parties only to the extent that those rights are covered by valid and enforceable patents or are effectively maintained as trade secrets.  Accordingly, patents and other proprietary rights are an essential element of our business.&#160;&#160;We own or exclusively license patents and patent applications throughout the world that claim our products and drug candidates, including:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issued patents and pending patent applications in Europe, the United States, and other countries throughout the world, including Australia, Argentina, Brazil, Canada, China, Europe, India, Israel, Japan, Mexico, New Zealand, South Africa, and South Korea, that claim sotagliflozin, crystalline forms of sotagliflozin, pharmaceutical compositions comprising sotagliflozin, and methods of its manufacture and use; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issued patents and pending patent applications in Europe, the United States, and other countries throughout the world, including Australia, Brazil, Canada, China, Europe, India, Israel, Japan, Mexico, New Zealand, South Africa, and South Korea, that claim LX9211, pharmaceutical compositions comprising LX9211, and methods of its use.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Patents extend for varying periods according to the date of patent filing or grant and the legal term of patents in the various countries where patent protection is obtained. The actual protection afforded by a patent, which can vary from country to country, depends on the type of patent, the scope of its coverage and the availability of legal remedies in the country.  We have filed patent applications and hold issued patents covering each of our drug candidates.  None of our United States patents that claim one of our drug candidates has a normal expiration date earlier than 2028.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our employees, consultants and advisors are required to execute a proprietary information agreement upon the commencement of employment or consultation. In general, the agreement provides that all inventions conceived by the employee or consultant, and all confidential information developed or made known to the individual during the term of the agreement, shall be our exclusive property and shall be kept confidential, with disclosure to third parties allowed only in specified circumstances. We cannot assure you, however, that these agreements will provide useful protection of our proprietary information in the event of unauthorized use or disclosure of such information.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our patent and intellectual property rights are subject to certain rights and uncertainties.  See &#8220;Risks Related to Our Intellectual Property&#8221; under &#8220;Item 1A.&#160;Risk Factors.&#8221;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="i122d3ae3d73245b585bd7f040afd795c_37"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Executive Officers</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our executive officers and their ages and positions are listed below.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:27.025%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:63.781%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Name</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Age</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Position with the Company</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lonnel Coats</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and Director</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeffrey L. Wade</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Financial Officer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brian T. Crum</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and General Counsel</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Craig B. Granowitz, M.D., Ph.D.</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and Chief Medical Officer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kenneth B. Kassler-Taub, M.D.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President, Regulatory and Quality Assurance</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alan J. Main, Ph.D.</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Innovation and Chemical Sciences</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wendy E. McDermott</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vice President, Human Resources</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kiernan A. Seth, Ph.D.</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vice President and Chief Commercial Officer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristen L. Alexander</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vice President, Finance and Accounting</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Lonnel Coats</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> has been our chief executive officer and a director since July 2014.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Mr. Coats previously served in a series of executive leadership positions at Eisai Inc. and Eisai Corporation of North America, where he worked for 18 years before joining our company, most recently as chief executive officer from 2010 to 2014.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Prior to joining Eisai, Mr. Coats spent eight years with Janssen Pharmaceuticals, Inc., a division of Johnson &amp; Johnson, where he held a variety of management and sales positions. Mr. Coats serves as a director of Blueprint Medicines Corporation and Verve Therapeutics, Inc., and holds a B.S. from Oakland University.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Jeffrey L. Wade</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has been our president and chief financial officer since October 2021, having previously served in a series of finance, corporate development, administrative and legal leadership positions since joining our company in 1999.&#160;&#160;Before joining Lexicon, Mr.&#160;Wade was a partner with the law firm of Andrews&#160;&amp; Kurth&#160;L.L.P., where he represented companies in the biotechnology, information technology and energy industries in venture capital financings, public offerings and private placements, mergers and acquisitions, collaborations and licensing, and other corporate matters.&#160;&#160;Mr.&#160;Wade is a member of the boards of directors of the Texas Healthcare and Bioscience Institute and BioHouston.&#160;&#160;He received his B.A. and J.D. from the University of Texas.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Brian T. Crum</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> has been our senior vice president and general counsel since October 2021 and previously served in a series of legal leadership positions since joining our company in 2001.  Mr. Crum was previously a corporate securities attorney with the law firms of Brobeck, Phleger &amp; Harrison LLP and Andrews &amp; Kurth L.L.P., where he represented companies in the energy and information technology industries.  Mr. Crum received his B.B.A. and J.D. from the University of Texas.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Craig B. Granowitz, M.D., Ph.D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> has been our senior vice president and chief medical officer since August 2021.  Dr. Granowitz previously served as chief medical officer of Amarin Corporation plc since 2016.  Prior to joining Amarin, Dr. Granowitz served as senior vice president and head of global medical affairs, global human health of Merck &amp; Co., Inc. and in a variety of medical and commercial management positions for Schering-Plough Corporation. Dr. Granowitz received his B.A. from Dartmouth College and his M.D. and Ph.D. from Columbia University.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Kenneth B. Kassler-Taub, M.D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> has been our senior vice president, regulatory affairs and quality assurance since October 2021 and previously served as vice president, clinical operations and in other senior capacities since joining our company in 2014.  Dr. Kassler-Taub previously served in various senior clinical and medical leadership positions at Becton Dickinson and Company, where he worked for 12 years, most recently as vice president, corporate clinical development.  Prior to joining Becton Dickinson, Dr. Kassler-Taub spent 14 years with Bristol-Myers Squibb Company Pharmaceutical Research Institute, where he held a variety of clinical and drug safety positions.  Dr. Kassler-Taub received his B.A. from Amherst College and M.D. from the Boston University School of Medicine.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Alan J. Main, Ph.D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. has been our executive vice president of innovation and chemical sciences since September 2020 and previously served in a series of manufacturing and scientific leadership positions since joining our company in 2001.&#160;&#160;Dr.&#160;Main was president and chief executive officer of Coelacanth Corporation, a leader in using proprietary chemistry technologies to rapidly discover new chemical entities for drug development, until our acquisition of Coelacanth in 2001.&#160;&#160;Dr.&#160;Main was formerly senior vice president, U.S.&#160;Research at Novartis Pharmaceuticals Corporation, where he worked for 20&#160;years before joining Coelacanth.&#160;&#160;Dr.&#160;Main holds a B.S. from the University of Aberdeen, Scotland and a Ph.D. in organic chemistry from the University of Liverpool, England and completed postdoctoral studies at the Woodward Research Institute.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Wendy E. McDermott</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has been our vice president, human resources since January 2022.  Ms. McDermott previously served as chief people officer of Rafael Pharmaceuticals, Inc. since 2019, vice president, human resources of Sanofi from 2017 to 2019 and in a variety of human resources positions with Sanofi, Schering-Plough Corporation and other companies in the tobacco, media and talent and event management industries.  Ms. McDermott received her B.A. from State University of New York at Plattsburgh.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Kiernan A. Seth, Ph.D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has been our vice president and chief commercial officer since October 2021 and previously served in a series of commercial and medical leadership positions since joining our company in 2014.  Dr. Seth previously served as executive director and head of the oncology business unit with Eisai, Inc. and in a series of marketing roles with Bristol-Myers Squibb Company, Pfizer Inc. and Schering Plough Corporation.  Dr. Seth received his B.S. from Norfolk State University, his M.B.A. from St. Joseph&#8217;s University and his Ph.D. from Meharry Medical College.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Kristen L. Alexander</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has been our vice president of finance and accounting and principal accounting officer since September 2021 and previously served as controller since joining our company in 2017.  Ms. Alexander previously served as controller of Johnson Specialty Tools, LLC and in a variety of finance and accounting management positions for Trican Well Services, L.P., Nabors Industries Ltd. and Ernst &amp; Young, LLP.  Ms. Alexander is a certified public accountant and received her B.B.A. from the University of Oklahoma.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i122d3ae3d73245b585bd7f040afd795c_40"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Shareholders</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have valuable relationships with Invus, L.P. and its affiliates, which we collectively refer to as Invus.  Invus currently owns approximately 50.5% of the outstanding shares of our common stock.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i122d3ae3d73245b585bd7f040afd795c_43"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital Resources</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February&#160;28, 2023, we employed 135 persons, of whom 18 hold M.D. or Ph.D. degrees and another 47 hold other advanced degrees.&#160;&#160;All of our employees are located in the United States.  None of our employees are represented by a labor union and we believe that our relationship with our employees is good.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our company culture is supported by our five core values: innovation, transparency, ownership, respect and integrity.  We value a diverse workforce and proudly reflect a company culture developed with a variety of ethnic backgrounds, nationalities, races, religions, military service, sexual preferences and abilities.  We are committed to promoting and maintaining an inclusive, high-performing environment where all team members embrace and leverage each other&#8217;s talents and backgrounds and nourish innovative thinking in order to achieve their full potential and contribute to our success.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our most valued resource is the collective talent and time that our employees dedicate to support and advance our mission.  Accordingly, we offer our employees a comprehensive compensation and benefits package that is competitive within the industry and make investing in the growth and development of our employees an important priority.  Employee development is advanced through talent management, promotions, mentoring, stretch assignments, internships, formal training, speaker series, conferences, continuing education and educational reimbursement.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i122d3ae3d73245b585bd7f040afd795c_46"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, 2021 and 2020, respectively, we incurred expenses of $52.8&#160;million, $55.0&#160;million and $153.6&#160;million in company-sponsored as well as collaborative research and development activities, including $4.3&#160;million, $4.3&#160;million and $6.4&#160;million of stock-based compensation expense in 2022, 2021 and 2020, respectively.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><div id="i122d3ae3d73245b585bd7f040afd795c_49"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risk Factors </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following risks and uncertainties are important factors that could cause actual results or events to differ materially from those indicated by forward-looking statements.&#160;&#160;The factors described below are not the only ones we face and additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risk Factor Summary</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of the material risks to our business, operations and the investment in our common stock. This summary does not include all of the risks we face and you should carefully review and consider the full discussion of our risk factors below, together with the other information in this annual report on Form 10-K.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Risks Related to Our Business and Industry</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We depend heavily on our ability to obtain regulatory approval in the United States for sotagliflozin in heart failure. If we fail to obtain such regulatory approval, our business will suffer and our stock price will likely decline.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If approved, we will depend heavily on the commercial success of sotagliflozin in heart failure. If we do not achieve commercial success with sotagliflozin, our business will suffer and our stock price will likely decline.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clinical testing of our drug candidates in humans is an inherently risky and time-consuming process that may fail to demonstrate safety and efficacy, which could result in the delay, limitation or prevention of regulatory approval.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our drug candidates are subject to a lengthy and uncertain regulatory process that may not result in the necessary regulatory approvals, which could adversely affect our and our collaborators&#8217; ability to commercialize products.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are subject to certain healthcare laws, regulation and enforcement; our failure to comply with those laws could have a material adverse effect on our results of operations and financial condition.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our competitors may develop products that impair the value of any products that we or our collaborators may develop.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Risks Related to Our Capital Requirements and Financial Results</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We will need additional capital in the future and, if it is unavailable, we will be forced to delay, reduce or eliminate our research and development programs. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We do not have sufficient capital to support a full Phase 3 development program for LX9211 in neuropathic pain.  If we are unable to establish a strategic collaboration or other arrangement for that purpose, our capital needs will be substantially higher and we may be unable to obtain financing sufficient to fund Phase 3 development of LX9211 in neuropathic pain on acceptable terms, or at all, or may be required to reduce the scope of any such Phase 3 development program.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We have a history of net losses, and we expect to continue to incur net losses and may not achieve or maintain profitability.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Risks Related to Our Relationships with Third Parties</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We depend on our ability to establish collaborations with pharmaceutical and biotechnology companies for the development and commercialization of our other drug candidates. If we are unable to establish such collaborations, or if pharmaceutical products are not successfully and timely developed and commercialized under such collaborations, our opportunities to generate revenues from our other drug candidates will be greatly reduced.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Risks Related to Our Intellectual Property</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">If we are unable to adequately protect our intellectual property, third parties may be able to use our products and technologies, which could adversely affect our ability to compete in the market.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Risks Related to Our Employees and Facilities</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The loss of key personnel or the inability to attract and retain additional personnel could impair our ability to operate and expand our operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Risks Related to Environmental and Product Liability</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Our business has a substantial risk of product liability and we face potential product liability exposure far in excess of our limited insurance coverage.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Risks Related to Our Common Stock</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Invus, L.P. and its affiliates own a controlling interest in our outstanding common stock and may have interests which conflict with those of our other stockholders.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Invus has additional rights under its stockholders&#8217; agreement relating to the membership of our board of directors and under our certificate of incorporation relating to preemptive and consent rights, which provide Invus with substantial influence over significant corporate matters.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Risks Related to Our Business and Industry</span></div><div style="margin-bottom:11pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We depend heavily on our ability to obtain regulatory approval in the United States for sotagliflozin in heart failure. If we fail to obtain such regulatory approval, our business will suffer and our stock price will likely decline.</span></div><div style="margin-bottom:11pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our NDA for sotagliflozin in heart failure is currently under review by the FDA and has been assigned a PDUFA target action date of May 27, 2023. We cannot offer any assurances that the FDA will grant marketing approval for sotagliflozin in heart failure, on acceptable timelines or at all. Furthermore, regulatory approval in the United States for sotagliflozin, even if obtained, may limit the type of patients in which sotagliflozin may be used or otherwise require specific warning or labeling language, any of which may reduce the commercial potential of sotagliflozin in heart failure. Should we fail to obtain regulatory approval in the United States or obtain regulatory approval with limits that disadvantage us as compared to competitive products, our business and financial condition could be materially harmed and we may be more heavily dependent on the success of our other drug programs.</span></div><div style="margin-bottom:11pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If approved, we will depend heavily on the commercial success of sotagliflozin in heart failure. If we do not achieve commercial success with sotagliflozin, our business will suffer and our stock price will likely decline.</span></div><div style="margin-bottom:11pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If approved, we expect that a significant portion of our total revenues will be attributable to sales of sotagliflozin for heart failure in the United States, but we cannot be certain that sotagliflozin will be commercially successful. If approved, our future sales of sotagliflozin will depend on numerous factors, including:</span></div><div style="margin-bottom:11pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the specific indication, warnings and other labeling language approved by the FDA;</span></div><div style="margin-bottom:11pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of patients suffering from heart failure;</span></div><div style="margin-bottom:11pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competition from dapagliflozin, empagliflozin and, to some extent, other classes of drugs used in the treatment of heart failure, such as the combination drug sacubitril/valsartan;</span></div><div style="margin-bottom:11pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the safety profile of sotagliflozin, including whether previously unknown side effects or increased incidence or severity of known side effects as compared to those seen during development are identified with the commercial use of sotagliflozin;</span></div><div style="margin-bottom:11pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effectiveness of our commercial strategy for marketing sotagliflozin and our execution of that strategy, including our pricing strategy and the effectiveness of our efforts to obtain and maintain adequate third-party reimbursement;</span></div><div style="margin-bottom:11pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the acceptance of sotagliflozin by patients, the medical community and third-party payers; and</span></div><div style="margin-bottom:11pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to meet the demand for commercial supplies of sotagliflozin and to maintain and successfully monitor commercial manufacturing arrangements for sotagliflozin with third-party manufacturers to ensure they meet our standards and those of the FDA, which extensively regulates and monitors pharmaceutical manufacturing facilities.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:11pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we believe that sotagliflozin, if approved, will have a competitive commercial profile, our current estimates of the revenues that sotagliflozin could generate in future periods may change based upon the above factors, and could prove to be incorrect. If our revenues, market share or other indicators of market acceptance of sotagliflozin fail to meet the expectations of investors or public market analysts, the market price of our common stock could decline. In addition, if one or more of the factors above negatively affects sotagliflozin sales, our business and financial condition could be materially harmed and we may be more heavily dependent on the success of our other drug programs.</span></div><div style="margin-bottom:11pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical testing of our drug candidates in humans is an inherently risky and time-consuming process that may fail to demonstrate safety and efficacy, which could result in the delay, limitation or prevention of regulatory approval.</span></div><div style="margin-bottom:11pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to obtain regulatory approvals for the commercial sale of any products that we or our collaborators may develop, we or our collaborators are required to complete extensive clinical trials in humans to demonstrate the safety and efficacy of our drug candidates.&#160;&#160;We or our collaborators may not be able to obtain authority from the FDA, or other equivalent foreign regulatory agencies, to initiate or complete any clinical trials.&#160;&#160;In addition, we have limited internal resources for making regulatory filings and interacting with regulatory authorities.</span></div><div style="margin-bottom:11pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials are inherently risky and the results from nonclinical testing of a drug candidate that is under development may not be predictive of results that will be obtained in human clinical trials.&#160;&#160;In addition, the results of early human clinical trials may not be predictive of results that will be obtained in larger-scale, advanced stage clinical trials.&#160;&#160;A number of companies in the pharmaceutical industry have suffered significant setbacks in advanced clinical trials, even after achieving positive results in earlier trials. Negative or inconclusive results from a nonclinical study or a clinical trial could cause us, our collaborators or the FDA or other equivalent foreign regulatory agencies to terminate a nonclinical study or clinical trial or require that we or our collaborators repeat or modify it.&#160;&#160;Furthermore, we, one of our collaborators or a regulatory agency with jurisdiction over the trials may suspend clinical trials at any time if the subjects or patients participating in such trials are being exposed to unacceptable health risks or for other reasons.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any nonclinical or clinical test may fail to produce results satisfactory to the FDA or foreign regulatory authorities.&#160;&#160;Nonclinical and clinical data can be interpreted in different ways, which could delay, limit or prevent regulatory approval.  The FDA or institutional review boards at the medical institutions and healthcare facilities where we or our collaborators sponsor clinical trials may suspend any trial indefinitely if they find deficiencies in the conduct of these trials.&#160;&#160;Clinical trials must be conducted in accordance with the FDA&#8217;s current Good Clinical Practices.&#160;&#160;The FDA and these institutional review boards have authority to oversee our and our collaborators&#8217; clinical trials, and the FDA may require large numbers of subjects or patients.&#160;&#160;In addition, we or our collaborators must manufacture, or contract for the manufacture of, the drug candidates that we use in our clinical trials under the FDA&#8217;s current Good Manufacturing Practices.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rate of completion of clinical trials is dependent, in part, upon the rate of enrollment of patients.&#160;&#160;Patient accrual is a function of many factors, including the size of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the study, the nature of the study, the existence of competitive clinical trials and the availability of alternative treatments.&#160;&#160;Delays in planned patient enrollment may result in increased costs and prolonged clinical development, which in turn could allow our competitors to bring products to market before we do and impair our ability to commercialize our products or potential products.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our collaborators may not be able to successfully complete any clinical trial of a drug candidate within any specified time period.&#160;&#160;In some cases, we or our collaborators may not be able to complete the trial at all. Moreover, clinical trials may not show our drug candidates to be both safe and effective.&#160;&#160;Thus, the FDA and other regulatory authorities may not approve any drug candidates that we develop for any indication or may limit the approved indications or impose other conditions.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our drug candidates are subject to a lengthy and uncertain regulatory process that may not result in the necessary regulatory approvals, which could adversely affect our and our collaborators&#8217; ability to commercialize products.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our drug candidates, as well as the activities associated with their research, development and commercialization, are subject to extensive regulation by the FDA and other regulatory agencies in the United States and by comparable authorities in other countries.&#160;&#160;Failure to obtain regulatory approval for any drug candidate would prevent us from commercializing that drug candidate.&#160;&#160;The process of obtaining regulatory approvals is expensive, and often takes many years, if approval is obtained at all, and can vary substantially based upon the type, complexity and novelty of the drug candidates involved.&#160;&#160;Before a new drug application can be filed with the FDA, the drug candidate must undergo extensive clinical trials, which can take many years and may require substantial expenditures.&#160;&#160;Any clinical trial may fail to produce results satisfactory to the FDA.&#160;&#160;For example, the FDA could determine that the design of a clinical trial is inadequate to produce reliable results.&#160;&#160;Furthermore, prior to approving </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a new drug, the FDA typically requires that the efficacy of the drug be demonstrated in two double-blind, controlled studies.  The regulatory process also requires nonclinical testing, and data obtained from nonclinical and clinical activities are susceptible to varying interpretations, which could delay, limit or prevent regulatory approval.&#160;&#160;In addition, delays or rejections may be encountered based upon changes in regulatory policy for product approval during the period of product development and regulatory agency review.&#160;&#160;Changes in regulatory approval policy, regulations or statutes or the process for regulatory review during the development or approval periods of our drug candidates may cause delays in the approval or rejection of an application.  Even if the FDA or a comparable authority in another country approves a drug candidate, the approval may impose significant restrictions on the indicated uses, conditions for use, labeling, advertising, promotion, marketing and/or production of such product and may impose ongoing requirements for post-approval studies, including additional research and development and clinical trials.&#160;&#160;These agencies also may impose various civil or criminal sanctions for failure to comply with regulatory requirements, including withdrawal of product approval.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The commercial success of any products that we or our collaborators may develop will depend upon the degree of market acceptance among physicians, patients, health care payers and the medical community.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our or our collaborators&#8217; ability to commercialize any products that we or they may develop will be highly dependent upon the extent to which such products gain market acceptance among physicians, patients, health care payers, such as commercial health insurers, Medicare and Medicaid, and the medical community.&#160;&#160;If such products do not achieve an adequate level of acceptance, we may not generate adequate product revenues and we may not become profitable.&#160;&#160;The degree of market acceptance of such products will depend upon a number of factors, including:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effectiveness, or perceived effectiveness, of our products in comparison to competing products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the existence of any significant side effects, as well as their severity in comparison to any competing products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential advantages or disadvantages in relation to alternative treatments;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">current and future indications for which our products may be approved;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability to offer our products for sale at competitive prices;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">relative convenience and ease of administration;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the strength of marketing and distribution support; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sufficient third-party coverage or reimbursement.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we are unable to establish an effective sales force, marketing infrastructure and distribution capabilities, we will not be able to successfully commercialize any products that we or our collaborators may develop.</span></div><div style="margin-bottom:11pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to successfully commercialize any product that we or our collaborators may develop, we or they must establish or maintain an effective commercialization infrastructure supporting such product, including sales force, marketing organization and distribution capabilities.  Factors that may hinder efforts to effectively establish, manage and maintain such infrastructure for products that we or our collaborators may develop include:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to recruit, retain and effectively manage adequate numbers of effective sales and marketing personnel;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to maintain relationships with third-party logistics providers, pharmacies, third-party manufacturers and other third parties instrumental in the commercial manufacture and distribution of such products;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to establish or implement internal controls and procedures required in connection with sales of such products;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability of sales personnel to obtain access to or convince adequate numbers of physicians to prescribe such products; and</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential lack of complementary products to be offered by sales personnel, which may put us or our collaborators at a competitive disadvantage relative to companies with more extensive product lines.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:11pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our collaborators are unable to sustain our or their sales force, marketing infrastructure and distribution capability for such products, we may not be able to generate any product revenue, may generate increased expenses and may never become profitable.</span></div><div style="margin-bottom:11pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our collaborators will need to expend significant time and resources to train our sales forces to be credible, persuasive and compliant in discussing such products with the physicians treating the patients indicated under the label.  We or our collaborators will also need to continue to train our sales forces to ensure that a consistent and appropriate message about such products is being delivered to potential customers.  If we or our collaborators are unable to effectively train our sales forces and equip them with effective materials, including medical and sales literature to help them inform and educate potential customers about the benefits and risks of such products and their proper administration, our and their ability to successfully commercialize such products could be diminished, which could have a material adverse effect on our financial condition, stock price and operations.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we are unable to maintain adequate coverage and reimbursement from third-party payers for any products that we or our collaborators may develop, our revenues and prospects for profitability will suffer.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to successfully commercialize any products that we or our collaborators may develop is highly dependent on the extent to which coverage and reimbursement for such products are available from third-party payers, including governmental payers, such as Medicare and Medicaid, and private health insurers, including managed care organizations and group purchasing organizations.&#160;&#160;Many patients are not capable of paying themselves for the products that we or our collaborators may develop, and rely on third-party payers to pay for, or subsidize, their medical needs.&#160;&#160;If third-party payers do not provide coverage or reimbursement for such products, our revenues and prospects for profitability will suffer.&#160;&#160;In addition, even if third-party payers provide some coverage or reimbursement for such products, the availability of such coverage or reimbursement for prescription drugs under private health insurance and managed care plans often varies based on the type of contract or plan purchased.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in some foreign countries, particularly the countries in the European Union, the pricing of prescription pharmaceuticals is subject to governmental control.&#160;&#160;In these countries, price negotiations with governmental authorities can take six to 12&#160;months or longer after the receipt of regulatory marketing approval for a product.&#160;&#160;To obtain reimbursement and/or pricing approval in some countries, we or our collaborators may be required to conduct a clinical trial that compares the cost effectiveness of our drug candidates or products to other available therapies.&#160;&#160;The conduct of such a clinical trial could be expensive and result in delays in the commercialization of our drug candidates.&#160;&#160;Third-party payers are challenging the prices charged for medical products and services, and many third-party payers limit reimbursement for newly approved health care products.&#160;&#160;In particular, third-party payers may limit the indications for which they will reimburse patients who use any products that we or our collaborators may develop.&#160;&#160;Cost-control initiatives could decrease prices we or our collaborators might establish for products that may be developed, which would result in lower product revenues to us.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">We may not be able to manufacture products that we or our collaborators may develop in commercial quantities, which would impair our ability to commercialize such products.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our drug candidates have been manufactured in relatively small quantities for nonclinical and clinical trials.&#160;&#160;If any of these drug candidates, including sotagliflozin, are approved by the FDA or other regulatory agencies for commercial sale, we or our collaborators will need to manufacture them in larger quantities.  We may not be able to successfully increase the manufacturing capacity, whether in collaboration with third-party manufacturers or on our own, for any approved product in a timely or economic manner, or at all.&#160;&#160;Significant scale-up of manufacturing may require additional validation studies, which the FDA must review and approve.&#160;&#160;If we or our collaborators are unable to successfully increase the manufacturing capacity for any such product, the regulatory approval or commercial launch of that product may be delayed or there may be a shortage in supply.&#160;&#160;Pharmaceutical products typically require precise, high-quality manufacturing.&#160;&#160;The failure to achieve and maintain these high manufacturing standards, including the incidence of manufacturing errors, could result in patient injury or death, product recalls or withdrawals, delays or failures in product testing or delivery, cost overruns or other problems that could seriously hurt our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We and our collaborators are subject to extensive and rigorous ongoing regulation relating to any products that we or our collaborators may develop.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our collaborators are subject to extensive and rigorous ongoing domestic and foreign government regulation of, among other things, the research, development, testing, manufacture, labeling, promotion, advertising, distribution and marketing of any products which receive regulatory approvals from the FDA or foreign regulatory authorities.&#160;&#160;The failure to comply with these requirements or the identification of safety problems during commercial marketing could lead to the need for product marketing restrictions, product withdrawal or recall or other voluntary or regulatory action, which could delay further </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">marketing until the product is brought into compliance.&#160;&#160;The failure to comply with these requirements may also subject us or our collaborators to stringent penalties.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We are subject to certain healthcare laws, regulation and enforcement; our failure to comply with those laws could have a material adverse effect on our results of operations and financial condition.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to certain healthcare laws and regulations and enforcement by the federal government and the states in which we conduct our business. The laws that may affect our ability to operate include, without limitation:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Anti-Kickback Statute, which constrains our marketing practices, educational programs, pricing policies, relationships with healthcare providers or other entities, and other business activities, by prohibiting, among other things, persons and entities from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual for, or the purchase, order or recommendation of, any good or service for which payment may be made under federal healthcare programs such as the Medicare and Medicaid programs;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payers that are false or fraudulent;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal criminal laws that prohibit executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payer, including commercial insurers, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Foreign Corrupt Practices Act, a United States law which regulates certain financial relationships with foreign government officials (which could include, for example, certain medical professionals);</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal and state consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state and federal government price reporting laws that require us to calculate and report complex pricing metrics to government programs, where such reported price may be used in the calculation of reimbursement and/or discounts on our marketed drugs (participation in these programs and compliance with the applicable requirements may subject us to potentially significant discounts on our products, increased infrastructure costs, and potentially limit our ability to offer certain marketplace discounts); and</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state and federal expenditure tracking and reporting laws, which generally require certain types of expenditures in the United States to be tracked and reported.  For example, the Physician Payments Sunshine Act, among other things, imposes reporting requirements on certain manufacturers to annually report to CMS information related to payments and other transfers of value to physicians and certain advanced non-physician health care practitioners and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members.  Compliance with such requirements may require investment in infrastructure to ensure that tracking is performed properly, and some of these laws result in the public disclosure of various types of payments and relationships, which could potentially have a negative effect on our business and/or increase enforcement scrutiny of our activities.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, certain marketing practices, including off-label promotion, may also violate certain federal and state health regulatory fraud and abuse laws as well as false claims laws, including the civil False Claims Act.  Suits filed under the civil False Claims Act, known as &#8220;qui tam&#8221; actions, can be brought by any individual on behalf of the government and such individuals, commonly known as &#8220;whistleblowers,&#8221; may share in any amounts paid by the entity to the government in fines or settlement.  The filing of&#160;qui tam&#160;actions has caused a number of pharmaceutical, medical device and other healthcare companies to defend a civil False Claims Act action.  When an entity is determined to have violated the civil False Claims Act, it may be required to pay up to three times the actual damages sustained by the government, plus civil penalties for each separate false claim.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we, or our officers or employees, may be subject to penalties, including administrative civil and criminal penalties, damages, fines, withdrawal of regulatory approval, the curtailment or restructuring of our operations, the exclusion from participation in Medicare, Medicaid and other federal and state healthcare programs, individual imprisonment, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, any of which could adversely affect our ability to sell our products or operate our business and also adversely affect our financial results.  Defending against any such actions can be costly, time-consuming and may require significant financial and personnel resources.  Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerous federal and state laws, including state security breach notification laws, state health information privacy laws and federal and state consumer protection laws, govern the collection, use and disclosure of personal information. Other countries also have, or are developing, laws governing the collection, use and transmission of personal information. In addition, most healthcare providers who may be expected to prescribe our products and from whom we may obtain patient health information are subject to privacy and security requirements under the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA.  Although we are not directly subject to HIPAA, we could be subject to criminal penalties if we knowingly obtain individually identifiable health information from a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA.  The legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing amount of focus on privacy and data protection issues with the potential to affect our business, including recently enacted laws in a majority of states requiring security breach notification.  These laws could create liability for us or increase our cost of doing business.  International laws, such as the EU Data Privacy Directive and Swiss Federal Act on Data Protection, regulate the processing of personal data within Europe and between European countries and the United States.  Failure to provide adequate privacy protections and maintain compliance with safe harbor mechanisms could jeopardize business transactions across borders and result in significant penalties.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Current healthcare laws and regulations and future legislative or regulatory reforms to the healthcare system may negatively affect our revenues and prospects for profitability.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and some foreign countries, there have been, and continue to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of pharmaceutical products, restrict or regulate post-approval activities, and affect the ability to profitably sell pharmaceutical products that obtain marketing approval.  The FDA&#8217;s and other regulatory authorities&#8217; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of drug candidates.  If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we otherwise may have obtained and we may not achieve or sustain profitability.  Moreover, complying with any new legislation or regulatory changes could be time-intensive and expensive, resulting in a material adverse effect on our business.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, the Inflation Reduction Act imposed significant changes to how drugs are covered and paid for under the Medicare program, including the creation of financial penalties for drugs whose prices rise faster than the rate of inflation, redesign of the Medicare Part D program to require manufacturers to bear more of the liability for certain drug benefits, and government price-setting for certain Medicare Part D drugs, starting in 2026, and Medicare Part B drugs starting in 2028.  The long-term implications of the Inflation Reduction Act remain uncertain and subject to various factors, including the manner in which the DHHS decides to implement the statute.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A primary trend in the United States and some foreign countries is toward reform and cost containment in the health care industry.&#160;&#160;The United States and some foreign jurisdictions are considering or have enacted a number of legislative and regulatory proposals, such as the Inflation Reduction Act, that may have the effect of reducing the prices that we are able to charge for products we or our collaborators may develop.  Healthcare reform measures which may be adopted in the future in the United States and foreign jurisdictions may result in more rigorous coverage criteria and significant downward pressure on the prices drug manufacturers may charge.  As a result, our revenues and prospects for profitability could be significantly harmed.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the overall trend towards cost-effectiveness criteria and managed healthcare in the United States, third-party payers are increasingly attempting to contain healthcare costs by limiting both coverage and the level of reimbursement of new drugs. They may use tiered reimbursement and may adversely affect demand for products we or our collaborators may develop by placing them in an expensive tier.  They may also refuse to provide any coverage of uses of approved products for medical indications other than those for which the FDA has granted market approvals.  As a result, significant uncertainty exists </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as to whether and how much third-party payers will reimburse for newly approved drugs, which in turn will put pressure on the pricing of drugs.  Further, we do not have experience in ensuring approval by applicable third-party payers outside of the United States for coverage and reimbursement of pharmaceutical products.  We also anticipate pricing pressures in connection with the sale of products we or our collaborators may develop due to the increasing influence of health maintenance organizations and additional legislative proposals.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our competitors may develop products that impair the value of any products that we or our collaborators may develop.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pharmaceutical and biotechnology industries are highly diversified and are characterized by rapid technological change.&#160;&#160;We and our collaborators face, and will continue to face, intense competition from biotechnology and pharmaceutical companies, as well as academic research institutions, clinical reference laboratories and government agencies that are pursuing research and development activities similar to ours.&#160;&#160;In addition, significant delays in the development of our drug candidates could allow our competitors to bring products to market before us, which would impair our or our collaborators&#8217; ability to commercialize our drug candidates.&#160;&#160;Any products that we or our collaborators develop will compete in highly competitive markets.&#160;&#160;Further, our competitors may be more effective at using their technologies to develop commercial products.&#160;&#160;Many of the organizations competing with us have greater capital resources, larger research and development staff and facilities, more experience in obtaining regulatory approvals and more extensive product manufacturing and marketing capabilities.&#160;&#160;As a result, our competitors may be able to more easily develop products that would render any products that we or our collaborators develop obsolete and noncompetitive.&#160;&#160;For example, dapagliflozin and empagliflozin are currently being marketed by AstraZeneca and through an alliance between Boehringer Ingelheim and Eli Lilly, respectively, for the treatment of heart failure and certain other indications.  Each of those products act through SGLT2, one of the targets of sotagliflozin. We expect that our principal competition for sotagliflozin for the treatment of heart failure would include such selective SGLT2 inhibitors which have already received or may gain regulatory approval for the treatment of heart failure, as well as other classes of drugs used in the treatment of heart failure, such as the combination drug sacubitril/valsartan, currently marketed for the treatment of heart failure by Novartis, and vericiguat, currently marketed for the treatment of heart failure by Merck.  In addition, there may be drug candidates of which we are not aware at an earlier stage of development that may compete with our drug candidates.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">The outbreak of the novel coronavirus, or COVID-19, has had an adverse impact on our business operations and clinical trials and it could continue to adversely affect our business in the future.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:107%">  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business was disrupted and could continue to be materially adversely affected by the COVID-19 pandemic. In response to the pandemic and resulting state and local restrictions, we implemented mandatory work-from-home policies for the majority of our employees. Although the majority of our employees have now returned to the office, the emergence of any new, more virulent SARS-CoV-2 variants could negatively affect the health and availability of our workforce and cause new disruptions to our business operations.  Any such disruptions could negatively impact productivity and delay our ongoing commercialization plans and research and development efforts.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The emergence of new, more infectious and virulent variants may also negatively impact future clinical trials by impeding our ability to effectively recruit and retain patients, principal investigators and site staff due to concerns for patient safety and prioritization of healthcare resources toward the COVID-19 pandemic.  In addition, significant disruption in the operations of third party manufacturers and research and development organizations upon whom we rely may occur and, as a result, our business operations could be severely impacted. These and similar, and perhaps more severe, disruptions in our operations due to a resurgence of the COVID-19 pandemic could negatively impact our business, operating results and financial condition.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the potential economic impact brought by, and the duration of, the COVID-19 pandemic may be difficult to assess or predict, the pandemic has also resulted in disruption of global financial markets and supply chains. This disruption, if sustained or recurrent, could make it more difficult for us to access capital, which could in the future negatively affect our liquidity, and effectively manage the clinical and commercial supply of our products. In addition, a recession or market correction resulting from the spread of COVID-19 could materially affect our business and the value of our common stock. The global COVID-19 pandemic continues to evolve. The ultimate impact of the COVID-19 pandemic or a similar health pandemic or epidemic is highly uncertain and subject to change. We do not yet know the full extent of potential delays or impacts on our business, our clinical trials, healthcare systems or the global economy as a whole. These effects could have a material impact on our operations.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Our Capital Requirements and Financial Results</span></div><div style="margin-bottom:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We will need additional capital in the future and, if it is unavailable, we will be forced to delay, reduce or eliminate our research and development programs.&#160;&#160;If additional capital is not available on reasonable terms, we will be forced to obtain funds, if at all, by entering into financing agreements on unattractive terms.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had $138.4&#160;million in cash, cash equivalents and investments.&#160;&#160;We anticipate that our existing capital resources and the cash and revenues we expect to derive from collaborations and other sources will enable us to fund our currently planned operations for at least the next 12 months from the date of this report.  However, we caution you that we may generate less cash and revenues or incur expenses more rapidly than we currently anticipate.  Our currently planned operations for the next twelve months include the commercial launch of sotagliflozin in the United States for the treatment of heart failure, if approved, and the continued nonclinical and clinical development of sotagliflozin, LX9211 and our other drug candidates.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although difficult to accurately predict, the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> amount of our future capital requirements will be substantial and will depend on many factors, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of our commercial launch of sotagliflozin in the United States for the treatment of heart failure, if approved;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, progress and results of our clinical trials of sotagliflozin, LX9211 and our other drug candidates and our ability to obtain necessary regulatory approvals based on such clinical trials, including for sotagliflozin for the treatment of heart failure;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our success in establishing new collaborations and licenses;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the amount and timing of our research, development and commercialization expenditures;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of competing programs and products, and of technological and market developments; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the filing, maintenance, prosecution, defense and enforcement of patent claims and other intellectual property rights.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If our capital resources are insufficient to meet future capital requirements, we will need to raise additional funds to continue our currently planned operations.&#160;&#160;Our ability to raise additional capital is dependent on a number of factors, including the market demand for our securities, which itself is subject to a number of pharmaceutical development and business risks and uncertainties, as well as uncertainty that we would be able to raise such additional capital at a price or on terms that are favorable to us.  If we raise additional capital by issuing equity securities, our then-existing stockholders will experience dilution and the terms of any new equity securities may have preferences over our common stock.  The affirmative and restrictive covenants and the pledge of all of our assets as collateral under our existing term loans with Oxford Finance LLC, or the Oxford Term Loans, restrict our ability to raise additional capital by issuing debt securities.  We cannot be certain that additional financing, whether debt or equity, will be available in amounts or on terms acceptable to us, if at all.&#160;&#160;We may be unable to raise sufficient additional capital on reasonable terms, and if so, we will be forced to delay, reduce or eliminate our clinical development programs or commercialization efforts or obtain funds, if at all, by entering into financing agreements on unattractive terms.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">We do not have sufficient capital to support a full Phase 3 development program for LX9211 in neuropathic pain.  If we are unable to establish a strategic collaboration or other arrangement for that purpose, our capital needs will be substantially higher and we may be unable to obtain financing sufficient to fund Phase 3 development of LX9211 in neuropathic pain on acceptable terms, or at all, and may be required to reduce the scope of any such Phase 3 development program.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our existing resources are insufficient to support a full Phase 3 development program for LX9211 in neuropathic pain. Although we seek to collaborate with another pharmaceutical or biotechnology company or strategic partner under terms which would enable reliance on their resources, in whole or in part, and provide additional funding for such Phase 3 development program, we may be unable to successfully enter into any such collaboration or other arrangement on reasonable terms, or at all.  In such event, our capital needs will be substantially higher and we will be reliant on obtaining financing in support of any such Phase 3 development program from alternative sources.  We cannot be certain that such financing will be available in amounts or on terms acceptable to us, if at all.  If we are unable to secure such financing, we may be required to reduce the scope of any such Phase 3 development program.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We have a history of net losses, and we expect to continue to incur net losses and may not achieve or maintain profitability.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred aggregate net losses since our inception, including an aggregate net loss of $248.3 million for the three years </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ended December&#160;31, 2022.&#160;&#160;As o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f December&#160;31, 2022, we had an accumulated deficit of $1.6&#160;billion.&#160;&#160;Because of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the numerous risks and uncertainties associated with successfully developing and commercializing drug products, we are unable to predict the extent of any future losses or whether or when we will become profitable, if at all.&#160;&#160;The size of our net losses will depend, in part, on the rate of decline or growth in our revenues and on the amount of our expenses.  We expect to continue to incur significant expenses over the next several years as we expect to make significant investments in the commercial launch of sotagliflozin in the United States for the treatment of heart failure, if approved, and the continued nonclinical and clinical development of sotagliflozin, LX9211 and our other drug candidates.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have derived a substantial portion of our revenues from strategic collaborations and other research and development collaborations and technology licenses.  Future revenues from our existing collaborations are uncertain because they depend, to a large degree, on the achievement of milestones and payment of royalties we earn from any products developed or commercialized under the collaborations.  Our ability to secure future revenue-generating agreements will depend upon our ability to address the needs of our potential future collaborators and licensees, and to negotiate agreements that we believe are in our long-term best interests.&#160;&#160;We may determine that our interests are better served by retaining rights to our discoveries and advancing our therapeutic programs to a later stage, which could limit our near-term revenues and increase expenses.&#160;&#160;Because of these and other factors, our operating results have fluctuated in the past and are likely to do so in the future, and we do not believe that period-to-period comparisons of our operating results are a good indication of our future performance.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to spend significant amounts to fund our planned commercial launch of sotagliflozin in the United States for the treatment of heart failure, if approved, and nonclinical and clinical development of sotagliflozin, LX9211 and our other drug candidates.  As a result, we will need to generate substantial additional revenues to achieve profitability in future periods.&#160;&#160;Even if we do achieve profitability in future periods, we may not be able to sustain or increase such profitability on a quarterly or annual basis.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our operating results have fluctuated and likely will continue to fluctuate, and we believe that period-to-period comparisons of our operating results are not a good indication of our future performance.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating results have fluctuated in the past and are likely to fluctuate in the future.  A number of factors, many of which we cannot control, could subject our operating results to volatility, including:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of our commercial launch of sotagliflozin in the United States for the treatment of heart failure, if approved;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of our ongoing nonclinical and clinical development efforts and our ability to obtain regulatory approval of our drug candidates as a result of such efforts, including for sotagliflozin for the treatment of heart failure;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and amount of expenses incurred with respect to our nonclinical and clinical development and commercialization efforts;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our success in establishing new collaborations and technology licenses and the timing and financial terms of such arrangements;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and willingness of our collaborators to commercialize pharmaceutical products that would result in milestone payments and royalties;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our products and technologies; and</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general and industry-specific economic conditions, which may affect our and our collaborators&#8217; research and development expenditures.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of these and other factors, including the risks and uncertainties described in this section, our operating results have fluctuated in the past and are likely to do so in the future.&#160;&#160;Due to the likelihood of fluctuations in our revenues and expenses, we believe that period-to-period comparisons of our operating results are not a good indication of our future performance.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We have substantial indebtedness that may limit cash flow available to invest in the ongoing needs of our business.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have incurred</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> $48.9 milli</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">on of indebtedness. Although the affirmative and restrictive covenants and the pledge of substantially all of our assets as collateral under the Oxford Term Loans restrict our ability to obtain additional debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13.5pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">financing, we could in the future incur additional indebtedness beyond such amount. Our substantial debt combined with our other financial obligations and contractual commitments could have significant adverse consequences, including:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:12.53pt">requiring us to dedicate a substantial portion of cash flow from operations to the payment of interest on, and principal of, our debt, which will reduce the amounts available to fund working capital, capital expenditures, product commercialization and development efforts and other general corporate purposes;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:12.53pt">increasing our vulnerability to adverse changes in general economic, industry and market conditions;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:12.53pt">limiting our flexibility in planning for, or reacting to, changes in our business and the industry in which we compete; and</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:12.53pt">placing us at a competitive disadvantage compared to our competitors that have less debt or better debt servicing options.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We intend to satisfy our current and future debt service obligations with our existing cash and cash equivalents and marketable securities and funds from external sources. However, we may not have sufficient funds or may be unable to arrange for additional financing to pay the amounts due under our existing debt. Funds from external sources may not be available on acceptable terms, if at all. In addition, a failure to comply with the covenants under our existing debt instruments could result in an event of default under those instruments. In the event of an acceleration of amounts due under our debt instruments as a result of an event of default, including upon the occurrence of an event that would reasonably be expected to have a material adverse effect on our business, operations, properties, assets or condition or a failure to pay any amount due, we may not have sufficient funds or may be unable to arrange for additional financing to repay our indebtedness or to make any accelerated payments, and the lenders could seek to enforce their security interests in the collateral securing such indebtedness.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we do not effectively manage our affirmative and restrictive covenants under the Oxford Term Loans, our financial condition and results of operations could be adversely affected.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Our obligations under the Oxford Term Loans are secured by a first lien security interest in substantially all of our assets. In addition, the Oxford Term Loans require that we comply with certain affirmative and restrictive covenants, including a financial covenant relating to net sales of sotagliflozin following regulatory approval and additional covenants restricting dispositions, fundamental changes in our business, mergers or acquisitions, indebtedness, encumbrances, distributions, investments, transactions with affiliates and subordinated debt, any of which could restrict our business and operations, particularly our ability to respond to changes in our business or to take specified actions to take advantage of certain business opportunities that may be presented to us. Our failure to comply with any of these covenants could result in a default under the Oxford Term Loans, which could permit the lenders to declare all or part of any outstanding borrowings to be immediately due and payable. If we are unable to repay those amounts, the lenders could enforce the security interest granted to them to secure that debt, which would seriously harm our business.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Risks Related to Our Relationships with Third Parties</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We depend on our ability to establish collaborations with pharmaceutical and biotechnology companies for the development and commercialization of our other drug candidates. If we are unable to establish such collaborations, or if pharmaceutical products are not successfully and timely developed and commercialized under such collaborations, our opportunities to generate revenues from our other drug candidates will be greatly reduced.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We have derived a substantial majority of our revenues to date from collaborative arrangements with other pharmaceutical and biotechnology companies for the research, development and commercialization of our drug candidates and other research and development collaborations and technology licenses.  Future revenues from our existing and future collaborations depend upon the achievement of milestones and payment of royalties we earn from any future products developed under those arrangements.&#160;&#160;If our relationship terminates with any collaborator, our reputation in the business and scientific community may suffer and revenues will be negatively impacted to the extent such losses are not offset by additional collaborations or strategic alliances.&#160;&#160;If milestones are not achieved or our collaborators are unable to successfully develop and commercialize products from which milestones and royalties are payable, we will not earn the revenues contemplated by those arrangements.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have limited or no control over the resources that any third party may devote to the development and commercialization of products under our collaborations.&#160;&#160;Any of our present or future collaborators may not perform their obligations as expected.&#160;Our collaborators may breach or terminate their agreements with us or otherwise fail to conduct research, development or commercialization activities successfully or in a timely manner.&#160;&#160;Further, our collaborators may elect not to develop pharmaceutical products arising out of our arrangements or may not devote sufficient resources to the development, regulatory approval, manufacture, marketing or sale of these products.&#160;&#160;If any of these events occurs, we may not receive revenue or otherwise realize anticipated benefits from such collaborations, our product development efforts may be delayed and our business, operating results and financial condition could be adversely affected.</span></div><div><span><br/></span></div><div style="margin-bottom:11pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Conflicts with our collaborators could jeopardize the success of our collaborative agreements and harm our product development efforts.</span></div><div style="margin-bottom:11pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may pursue opportunities in specific disease and therapeutic modality fields that could result in conflicts with our collaborators, if any of our collaborators takes the position that our internal activities overlap with those activities that are exclusive to our collaboration.&#160;&#160;Moreover, disagreements could arise with our collaborators over rights to our intellectual property or our rights to share in any of the future revenues of compounds or therapeutic approaches developed by our collaborators.&#160;&#160;Any conflict with or among our collaborators could result in the termination of our collaborative agreements, delay collaborative research or development activities, impair our ability to renew or obtain future collaborative agreements or lead to costly and time consuming litigation.&#160;&#160;Conflicts with our collaborators could also have a negative impact on our relationship with existing collaborators, materially impairing our business and revenues.&#160;&#160;Some of our collaborators are also potential competitors or may become competitors in the future.&#160;&#160;Our collaborators could develop competing products, preclude us from entering into collaborations with their competitors or terminate their agreements with us prematurely.&#160;&#160;Any of these events could harm our product development efforts.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">We rely on third parties to carry out our nonclinical studies and clinical trials, which may harm or delay our research and development efforts.</span></div><div><span><br/></span></div><div style="margin-bottom:11pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on clinical research organizations and other third-party contractors to carry out many of our drug development activities, including the performance of nonclinical laboratory and animal tests under the FDA&#8217;s current Good Laboratory Practices regulations and the conduct of clinical trials of our drug candidates in accordance with protocols we establish.&#160;&#160;If these third parties do not successfully carry out their contractual duties or regulatory obligations or meet expected deadlines, our drug development activities may be delayed, suspended or terminated.&#160;&#160;Such a failure by these third parties could significantly impair our ability to develop and commercialize the affected drug candidates.</span></div><div style="margin-bottom:11pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We lack the capability to manufacture materials for nonclinical studies and clinical trials and commercial supplies for any products which gain regulatory approval. Our reliance on third parties to manufacture our drug candidates may harm or delay our research, development and commercialization efforts.</span></div><div style="margin-bottom:11pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently do not have the manufacturing capabilities or experience necessary to produce materials for nonclinical studies or clinical trials or commercial supplies for any products which gain regulatory approval and intend in the future to continue to rely on collaborators and third-party contractors to produce such materials.&#160;&#160;We will rely on selected manufacturers to deliver materials on a timely basis and to comply with applicable regulatory requirements, including the current Good Manufacturing Practices of the FDA, which relate to manufacturing and quality control activities.&#160;&#160;These manufacturers may not be able to produce material on a timely basis or manufacture material at the quality level or in the quantity required to meet our development and commercialization timelines and applicable regulatory requirements.&#160;&#160;In addition, there are a limited number of manufacturers that operate under the FDA&#8217;s current Good Manufacturing Practices and that are capable of producing such materials, and we may experience difficulty finding manufacturers with adequate capacity for our needs.&#160;&#160;If we are unable to contract for the production of sufficient quantity and quality of materials on acceptable terms, our product development or commercialization efforts may be delayed.&#160;&#160;Moreover, noncompliance with the FDA&#8217;s current Good Manufacturing Practices can result in, among other things, fines, injunctions, civil and criminal penalties, product recalls or seizures, suspension of production, failure to obtain marketing approval and withdrawal, suspension or revocation of marketing approvals.</span></div><div style="margin-bottom:11pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="margin-bottom:11pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we are unable to adequately protect our intellectual property, third parties may be able to use our products and technologies, which could adversely affect our ability to compete in the market.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our commercial success will depend in part upon our ability to obtain patents and maintain adequate protection of the intellectual property related to our products and technologies.&#160;&#160;The patent positions of biotechnology and pharmaceutical companies, including our patent position, are generally uncertain and involve complex legal and factual questions.&#160;&#160;We will be </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">able to protect our intellectual property rights from unauthorized use by third parties only to the extent that our products and technologies are covered by valid and enforceable patents or other intellectual property rights, or are effectively maintained as trade secrets or otherwise protected from disclosure by non-disclosure agreements.&#160;&#160;We will continue to apply for patents covering our products and technologies as, where and when we deem appropriate.  However, pending patent applications do not provide protection against competitors because they are not enforceable until they issue as patents.&#160;&#160;Further, the disclosures contained in our current and future patent applications may not be sufficient to meet statutory requirements for patentability and our applications may fail to result in issued patents.&#160;&#160;Once issued, patents still may not provide commercially meaningful protection.&#160;&#160;Our existing patents and any future patents we obtain may not be sufficiently broad to prevent others from developing competing products and technologies.&#160;&#160;Furthermore, others may independently develop similar or alternative products or technologies or design around our patents.&#160;&#160;If anyone infringes upon our or our collaborators&#8217; patent rights, enforcing these rights may be difficult, costly and time-consuming and, as a result, it may not be cost-effective or otherwise expedient to pursue litigation to enforce those patent rights.  Further, as we customarily assess whether to apply for new patents based on our ongoing research and development activities, this assessment and the filing for additional patent protection may require significant expenditures and therefore may not be commercially practicable.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our patents and other intellectual property rights may be challenged by third parties and may be invalidated, cancelled or held unenforceable under U.S. or foreign laws, or they may be infringed or misappropriated by third parties.  As a result, we may be involved in the defense and enforcement of our patent or other intellectual property rights in a court of law, U.S. Patent and Trademark Office inter partes review or reexamination proceeding, foreign opposition proceeding or related legal and administrative proceeding in the United States and elsewhere.  The costs of defending our patents or enforcing our other intellectual property rights, such as trademarks and trade secrets, in post-issuance administrative proceedings and litigation may be substantial and the outcome can be uncertain.  An adverse outcome may allow third parties to use our intellectual property without a license and negatively impact our business.</span></div><div style="margin-bottom:11pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, because patent applications can take many years to issue, third parties may have pending applications, unknown to us, which may later result in issued patents that cover the production, manufacture, commercialization or use of our products and drug candidates.&#160;&#160;&#160;If any such patents are issued to other entities, we may be unable to obtain patent protection for the same or similar discoveries that we make relating to our products and drug candidates.&#160;&#160;Moreover, we may be blocked from using our drug targets or drug candidates or developing or commercializing our products and other drug candidates, or may be required to obtain a license from a third party that may not be available on reasonable terms, if at all.&#160;&#160;Further, others may discover uses for our products and technology other than those covered in or claimed by our issued or pending patents, such as other uses for our drug targets and drug candidates, and these other uses may be separately patentable.&#160;&#160;Even if we have a patent claim on a particular technology or product, the holder of a patent covering the use of a similar technology or product could exclude us from selling a product that is based on the same use of that product.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the United States, and many companies have encountered significant problems in protecting and defending such rights in foreign jurisdictions.&#160;&#160;Many countries, including certain countries in Europe, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties (for example, if the patent owner has failed to &#8220;work&#8221; the invention in that country or the third party has patented improvements).&#160;&#160;In addition, many countries limit the enforceability of patents against government agencies or government contractors.&#160;&#160;In these countries, the patent owner may have limited remedies, which could materially diminish the value of the patent.&#160;&#160;Compulsory licensing of life-saving drugs is also becoming increasingly popular in developing countries either through direct legislation or international initiatives.&#160;&#160;Such compulsory licenses could be extended to include some of our products and drug candidates, which could limit our potential revenue opportunities.  Moreover, the legal systems of certain countries, particularly certain developing countries, do not favor the aggressive enforcement of patent and other intellectual property protection, which makes it difficult to stop infringement and misappropriation.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We rely on trade secret protection for some of our confidential and proprietary information.&#160;&#160;We have taken security measures to protect our proprietary information and trade secrets, but these measures may not provide adequate protection.&#160;&#160;While we seek to protect our proprietary information by entering into confidentiality agreements with employees, collaborators and consultants, we cannot assure you that our proprietary information will not be disclosed, or that we can meaningfully protect our trade secrets.&#160;&#160;In addition, our competitors may independently develop or duplicate substantially equivalent proprietary information or may otherwise gain access to or misappropriate our trade secrets.  For example, publicly available information, such as information in issued patents, published patent applications and scientific literature, can be used by third parties to independently develop technology and we cannot provide assurance that any such independently developed technology will not be equivalent or superior to our proprietary technology.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We rely on registered trademarks to protect our investment in our brand and goodwill.  However, competitors may challenge the validity of those trademarks and other brand names in which we have invested or may invest. Such challenges can be expensive and may adversely affect our ability to maintain the goodwill gained in connection with a particular trademark. </span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We may be involved in patent litigation and other disputes regarding intellectual property rights and may require licenses from third parties for our planned nonclinical and clinical development and commercialization activities.&#160;&#160;We may not prevail in any such litigation or other dispute or be able to obtain required licenses.</span></div><div style="margin-bottom:11pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products and those of our collaborators, as well as our nonclinical and clinical development efforts, may give rise to claims that they infringe or misappropriate the patents or other intellectual property rights of others.&#160;&#160;We are aware that other companies and institutions are developing products acting through the same drug targets through which some of our drug candidates currently in clinical development act, have conducted research on many of the same targets that we have identified and have filed patent applications potentially covering drug targets that we have identified and certain therapeutic products addressing such targets.&#160;&#160;In some cases, patents have issued, and may issue in the future, from these applications.&#160;&#160;In addition, many companies and institutions have well-established patent portfolios directed to common techniques, methods and means of developing, producing and manufacturing pharmaceutical products.&#160;&#160;These or other companies or institutions could bring legal actions against us or our collaborators for damages or to stop us or our collaborators from engaging in certain nonclinical or clinical development activities or from manufacturing and marketing therapeutic products that allegedly infringe their patent rights.&#160;&#160;If any of these actions are successful, in addition to our potential liability for damages, these entities may require us or our collaborators to obtain a license in order to continue engaging in the infringing activities or to manufacture or market the infringing therapeutic products or may force us to terminate such activities or manufacturing and marketing efforts.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may deem it advisable to pursue litigation or other dispute resolution proceedings against others to enforce our patents and intellectual property rights and may be the subject of litigation brought by third parties to enforce their patent and intellectual property rights.&#160;&#160;In addition, we may become involved in litigation or other dispute resolution proceedings based on intellectual property indemnification undertakings that we have given to certain of our collaborators.&#160;&#160;Patent and other intellectual property litigation is expensive and requires substantial amounts of management attention.&#160;&#160;The eventual outcome of any such litigation or dispute resolution proceedings is uncertain and involves substantial risks.  If we are sued for infringement or misappropriation and lose, we could be required to pay substantial damages and/or be enjoined from using or selling the allegedly infringing or misappropriation products or technology. The results or costs of any such litigation or dispute resolution proceedings may have an adverse effect on our business, operating results and financial condition.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:11pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that there will continue to be significant litigation in our industry regarding patent and other intellectual property rights.&#160;&#160;We have expended and many of our competitors have expended and are continuing to expend significant amounts of time, money and management resources on intellectual property litigation.&#160;&#160;If we become involved in future intellectual property litigation, it could consume a substantial portion of our resources and could negatively affect our results of operations.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Data breaches and cyber-attacks could compromise our intellectual property or other sensitive information and cause significant damage to our business, reputational harm and financial loss.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we collect, maintain and transmit sensitive data on our networks and systems, including our intellectual property and proprietary or confidential business information (such as research data and personal information) and confidential information with respect to our customers, clinical trial patients and our business partners.  We have also outsourced significant elements of our information technology infrastructure and, as a result, third parties may or could have access to our confidential information and personal data.  The secure maintenance of this information is critical to our business and reputation.  We believe that companies have been increasingly subject to a wide variety of security incidents, cyber-attacks and other attempts to gain unauthorized access and unintentional breaches.  These threats can come from a variety of sources, ranging in sophistication from an individual hacker to a state-sponsored attack and motive (including corporate espionage).  Cyber threats may be generic, or they may be custom-crafted against our information systems.  Our network and storage applications and those of our vendors may be subject to unauthorized access by hackers or information security breaches due to operator error, malfeasance or other system disruptions.  It is often difficult to anticipate or immediately detect such incidents and the damage caused by such incidents, particularly for cyber incidents such as advanced persistent threats.  These data breaches and any unauthorized access or disclosure of our information or intellectual property could compromise our intellectual property and expose sensitive business information.  A data security breach could also lead to public exposure of personal information of our clinical trial patients, customers and others.  Cyber-attacks and information security breaches could cause us to incur significant remediation costs, result in product development delays, disrupt key business operations and divert attention of management and key information technology resources.  Our network security and data recovery measures and those of our vendors may not be able to detect or prevent every attempted breach and may not permit us to respond effectively to every breach.  These incidents could also subject us to liability, expose us to significant expense and cause </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">significant harm to our reputation and business.  Reputational harm resulting from a significant cyber incident may cause unquantifiable damage to our established goodwill. Moreover, as cyber incidents continue to evolve, we will likely be required to expend additional resources to enhance our security posture and cybersecurity defenses or to investigate and remediate any vulnerability to or consequences of cyber incidents. Our insurance coverage may not be sufficient to prevent or recover from cyberattacks, including coverage of applicable resulting losses arising from the incident.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Further, each foreign jurisdiction and U.S. state in which we operate may have laws governing how we must respond to a cyber incident that results in the unauthorized access, disclosure, or loss of personal information.  Additionally, new laws and regulations governing data privacy and unauthorized disclosure of confidential information, including recent California legislation providing for a private right of action, pose increasingly complex compliance challenges and could potentially elevate our costs over time.  As legislation continues to develop and cyber incidents continue to evolve, we will likely be required to expend significant resources to continue to modify or enhance our protective measures to comply with such legislation and to detect, investigate and remediate vulnerabilities to cyber incidents.  Any failure by us to comply with such laws and regulations could result in reputational harm, loss of goodwill, penalties, liabilities and/or mandated changes in our business practices.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We may be subject to damages resulting from claims that we, our employees or independent contractors have wrongfully used or disclosed alleged trade secrets of their former employers.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our employees and independent contractors were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors.&#160;&#160;We may be subject to claims that these employees, independent contractors or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers.&#160;&#160;Litigation or other dispute resolution proceedings may be necessary to defend against these claims.&#160;&#160;Even if we are successful in defending against these claims, litigation or other dispute resolution proceedings could result in substantial costs and divert management&#8217;s attention.&#160;&#160;If we fail in defending such claims, in addition to paying money claims, we may lose valuable intellectual property rights or personnel.&#160;&#160;A loss of key research personnel and/or their work product could hamper or prevent our ability to commercialize certain drug candidates, which could severely harm our business.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Our Employees and Facilities</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we are unable to manage our growth, our business, financial condition, results of operations and prospects may be adversely affected.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect substantial growth in the number of our employees and in the scope of our operations as a result of our planned commercial launch of sotagliflozin in the Untied States for heart failure, if approved.  This growth would place significant demands on our management, operational and financial resources, and our current and planned personnel, systems, procedures and controls may not be adequate to support our growth.  To effectively manage our expected growth, we must continue to improve existing, and implement new, operational and financial systems, procedures and controls and must expand, train and manage our growing employee base, and there can be no assurance that we will effectively manage our growth without experiencing operating inefficiencies or control deficiencies.  We will need to increase our commercial, medical, clinical, and other personnel, and recruiting and retaining qualified individuals is difficult.  If we are unable to manage our growth effectively, or are unsuccessful in recruiting qualified personnel when advisable, our business, financial condition, results of operations and prospects may be adversely affected.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The loss of key personnel or the inability to attract and retain additional personnel could impair our ability to operate and expand our operations.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent upon the principal members of our management, as well as medical and clinical staff, the loss of whose services might adversely impact the achievement of our objectives.&#160;&#160;Retaining and, where advisable, recruiting qualified commercial, medical and clinical personnel will be critical to commercially launching sotagliflozin for heart failure, if approved, and advancing our nonclinical and clinical development programs for sotagliflozin, LX9211 and our other drug candidates.&#160;&#160;Competition is intense for experienced commercial, medical and clinical personnel, and we may be unable to retain or recruit such personnel with the expertise or experience necessary to allow us to successfully develop and commercialize our products.&#160;&#160;Further, all of our employees are employed &#8220;at will&#8221; and, therefore, may leave our employment at any time.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our facilities are located near coastal zones, and the occurrence of a hurricane or other disaster could damage our facilities and equipment, which could harm our operations.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our facilities are located in The Woodlands, Texas and Bridgewater, New Jersey, and therefore our facilities are vulnerable to damage from hurricanes.  We are also vulnerable to damage from other types of disasters, including fire, floods, power loss, communications failures, terrorism and similar events and any insurance we may maintain may not be adequate to cover our losses.  If any disaster were to occur, our ability to operate our business at our facilities could be seriously, or potentially completely, impaired.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Environmental and Product Liability</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We have used hazardous chemicals and radioactive and biological substances in our business. Any claims relating to improper handling, storage or disposal of these substances could be time consuming and costly.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our research and development processes have historically involved the controlled use of hazardous substances, including chemicals and radioactive and biological materials, and our operations have produced hazardous waste products.&#160;&#160;See &#8220;Part I, Item 1. Business &#8211; Government Regulation &#8211; Environmental and Worker Safety Matters&#8221; for more discussion on these and other environmental matters.  Compliance with environmental laws and regulations may be expensive, and current or future environmental regulations may impair our research, development and production efforts.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our collaborators may use hazardous materials in connection with our collaborative efforts. In the event of a lawsuit or investigation, we could be held responsible for any injury caused to persons or property by exposure to, or release of, these hazardous materials used by these parties.&#160;&#160;Further, we may be required to indemnify our collaborators against all damages and other liabilities arising out of our development activities or products produced in connection with these collaborations.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business has a substantial risk of product liability and we face potential product liability exposure far in excess of our limited insurance coverage.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be held liable if any product that we or our collaborators develop or commercialize, or any product that is made with the use or incorporation of any of our technologies, causes injury or is found otherwise unsuitable during product testing, manufacturing, marketing or sale.&#160;&#160;Regardless of merit or eventual outcome, product liability claims could result in decreased demand for our products and product candidates, injury to our reputation, withdrawal of patients from our clinical trials, product recall, substantial monetary awards to third parties and the inability to commercialize any products that we may develop.  These claims might be made directly by consumers, health care providers, pharmaceutical companies or others selling or testing our products.  We have obtained limited product liability insurance coverage for our clinical trials.  However, our insurance may not reimburse us or may not be sufficient to reimburse us for expenses or losses we may suffer.  Moreover, if insurance coverage becomes more expensive, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability.  On occasion, juries have awarded large judgments in class action lawsuits for claims based on drugs that had unanticipated side effects.  In addition, the pharmaceutical and biotechnology industries, in general, have been subject to significant medical malpractice litigation.  A successful product liability claim or series of claims brought against us could harm our reputation and business.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Our Common Stock</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Invus, L.P. and its affiliates own a controlling interest in our outstanding common stock and may have interests which conflict with those of our other stockholders.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Invus, L.P. and its affiliates, which we collectively refer to as Invus, currently own approximately 50.5% of the outstanding shares of our common stock and are thereby able to control the election and removal of our directors and determine our corporate and management policies, including potential mergers or acquisitions, asset sales, the amendment of our articles of incorporation or bylaws and other significant corporate transactions.  This concentration of ownership may delay or deter possible changes in control of our company, which may reduce the value of an investment in our common stock.  The interests of Invus and its affiliates may not be aligned with the interests of other holders of our common stock.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Invus has additional rights under its stockholders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> agreement relating to the membership of our board of directors and under our certificate of incorporation relating to preemptive and consent rights, which provide Invus with substantial influence over significant corporate matters. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under its stockholders&#8217; agreement, Invus has the right to designate a number of directors equal to the percentage of all the outstanding shares of our common stock owned by Invus and its affiliates, rounded up to the nearest whole number of directors.  Invus has designated three of the nine current members of our board of directors.  While Invus has not presently exercised its director designation rights in full, it may exercise them at any time in the future in its sole discretion.  To facilitate the exercise of such rights, we have agreed, upon written request from Invus, to take all necessary steps in accordance with our obligations under the stockholders&#8217; agreement to (1) increase the number of directors to the number specified by Invus (which number shall be no greater than reasonably necessary for the exercise of Invus&#8217; director designation rights under the stockholders&#8217; agreement) and (2) cause the appointment to the newly created directorships of directors so designated by Invus pursuant to its rights under the stockholders&#8217; agreement.  Invus also has the right to require proportionate representation of Invus-appointed directors on the audit, compensation and corporate governance committees of our board of directors, subject to certain restrictions.  Invus-designated directors currently serve as one of the three members of each of the compensation committee and the corporate governance committee of our board of directors, and no Invus-designated directors currently serve on the audit committee of our board of directors.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our fifth amended and restated certificate of incorporation also grants holders of 20% or more of our issued and outstanding common stock customary preemptive rights and consent rights prior to us taking any of the following actions: (1) creating or issuing any new class or series of shares of capital stock (or securities convertible into or exercisable for shares of capital stock) having rights, preferences or privileges senior to or on parity with the common stock, (2) subject to certain exceptions, repurchasing, retiring, redeeming or otherwise acquiring any equity securities (or securities convertible into or exchangeable for equity securities) or any subsidiary and (3) adopting, or proposing to adopt, or maintaining any shareholders&#8217; rights plan, &#8220;poison pill&#8221; or other similar plan or agreement, unless such stockholder is exempt from such plan or agreement.  Invus currently has such preemptive and consent rights as a result of its ownership position in our issued and outstanding common stock.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of these rights provide Invus with substantial influence over significant corporate matters and Invus&#8217; interest in those matters may not be aligned with the interests of other holders of our common stock.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our stock price may be extremely volatile.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading price of our common stock has been highly volatile, and we believe the trading price of our common stock will remain highly volatile and may fluctuate substantially due to factors such as the following, many of which we cannot control:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:11pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">results or delays in our or our collaborators&#8217; clinical trials;</span></div><div style="margin-bottom:11pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the announcement of FDA approval or non-approval, or delays in the FDA review process, of our or our collaborators&#8217; drug candidates or those of our competitors or actions taken by regulatory agencies with respect to our, our collaborators&#8217; or our competitors&#8217; clinical trials;</span></div><div style="margin-bottom:11pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actions taken by regulatory agencies with respect to sotagliflozin, LX9211 and our other drug candidates;</span></div><div style="margin-bottom:11pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the announcement of new products by our competitors;</span></div><div style="margin-bottom:11pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">quarterly variations in our or our competitors&#8217; results of operations;</span></div><div style="margin-bottom:11pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments in our relationships with our collaborators, including conflicts, litigation or the termination or modification of our agreements;</span></div><div style="margin-bottom:11pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the announcement of an in-licensed drug candidate or strategic acquisition;</span></div><div style="margin-bottom:11pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">litigation, including intellectual property infringement and misappropriation, and product liability lawsuits, involving us;</span></div><div style="margin-bottom:11pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to achieve operating results projected by securities analysts;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:11pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in earnings estimates or recommendations by securities analysts;</span></div><div style="margin-bottom:11pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the satisfaction of outstanding debt obligations or entry into new financing arrangements;</span></div><div style="margin-bottom:11pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments in the biotechnology or pharmaceutical industry;</span></div><div style="margin-bottom:11pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of large blocks of our common stock or sales of our common stock by our executive officers, directors and significant stockholders;</span></div><div style="margin-bottom:11pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">departures of key personnel or board members;</span></div><div style="margin-bottom:11pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">FDA or international regulatory actions;</span></div><div style="margin-bottom:11pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">third-party coverage and reimbursement policies;</span></div><div style="margin-bottom:11pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disposition of any of our drug programs or other technologies; and</span></div><div style="margin-bottom:11pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other factors, including general market, economic and political conditions and other factors unrelated to our operating performance or the operatin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">g</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> performance of our competitors.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These factors may materially adversely affect the market price of our common stock.  In addition, the stock markets in general, and the markets for biotechnology and pharmaceutical stocks in particular, have historically experienced significant volatility that has often been unrelated or disproportionate to the operating performance of particular companies.  For example, negative publicity regarding drug pricing and price increases by pharmaceutical companies has negatively impacted, and may continue to negatively impact, the markets for biotechnology and pharmaceutical stocks.  Likewise, the broader financial markets could experience significant volatility that could also negatively impact the markets for biotechnology and pharmaceutical stocks.  These broad market fluctuations have adversely affected and may in the future adversely affect the trading price of our common stock.  Excessive volatility may continue for an extended period of time.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past, following periods of volatility in the market price of a company&#8217;s securities, securities class action litigation has often been instituted.&#160;&#160;A securities class action suit against us could result in substantial costs and divert management&#8217;s attention and resources, which could have a material and adverse effect on our business.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Future issuances or sales of our common stock, or the perception that such issuances or sales may occur, may depress our stock price.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A substantial number of shares of our common stock is reserved for issuance upon the exercise of stock options and vesting of restricted stock units.  If we or our stockholders issue or sell substantial amounts of our common stock (including shares issued upon the exercise of stock options or vesting of restricted stock units) in the public market, or if the market perceives that such sales may occur, the market price of our common stock could fall and it may become more difficult for us to sell equity or equity-related securities in the future at a time and price that we deem appropriate.&#160;&#160;In addition, any such issuance or sale of our common stock will dilute the ownership interests of existing stockholders and may cause the market price of our common stock to decline.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business.&#160;&#160;If one or more of the analysts who cover us downgrade our stock or publish inaccurate or unfavorable research about our business, our stock price would likely decline.&#160;&#160;If one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, demand for our common stock could decrease, which might cause our stock price and trading volume to decline.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i122d3ae3d73245b585bd7f040afd795c_52"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1B. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unresolved Staff Comments</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><div id="i122d3ae3d73245b585bd7f040afd795c_55"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.&#160; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Properties</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, we leased a 25,000 square-foot office space in The Woodlands, Texas.  The term of the sublease extends from March 2021 through August 2025, and provides for escalating yearly base rent payments starting at $506,000 and increasing to $557,000 in the final year of the lease.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, our subsidiary, Lexicon Pharmaceuticals (New Jersey), Inc. leased a 22,000 square-foot office space in Bridgewater, New Jersey. The term of the lease extends from February 2023 through January 2034 and provides for escalating yearly base rent payments starting at $820,000 and increasing to $986,000 in the final year of the lease.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our facilities are well-maintained, in good operating condition and acceptable for our current operations.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i122d3ae3d73245b585bd7f040afd795c_58"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are from time to time party to claims and legal proceedings that arise in the normal course of our business and that we believe will not have, individually or in the aggregate, a material adverse effect on our results of operations, financial condition or liquidity.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i122d3ae3d73245b585bd7f040afd795c_61"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mine Safety Disclosures</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><div id="i122d3ae3d73245b585bd7f040afd795c_64"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i122d3ae3d73245b585bd7f040afd795c_67"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is quoted on The Nasdaq Global Select Market under the symbol &#8220;LXRX.&#8221;  As of February&#160;27, 2023, there were approximately 257 holders of record of our common stock.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never paid cash dividends on our common stock. We anticipate that we will retain all of our future earnings, if any, for use in the expansion and operation of our business and do not anticipate paying cash dividends in the foreseeable future.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Graph</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following performance graph compares the performance of our common stock to the Nasdaq Composite Index and the Nasdaq Biotechnology Index for the period beginning December&#160;31, 2017 and ending December&#160;31, 2022. The graph assumes that the value of the investment in our common stock and each index was $100 at December&#160;31, 2017, and that all dividends were reinvested.  The stock performance shown on the graph below represents historical performance and is not necessarily indicative of future stock price performance.</span></div><div><img src="lxrx-20221231_g1.jpg" alt="lxrx-20221231_g1.jpg" style="height:226px;margin-bottom:5pt;vertical-align:text-bottom;width:682px"/><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.702%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2017</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lexicon Pharmaceuticals, Inc.</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nasdaq Composite Index</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nasdaq Biotechnology Index</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing stock price performance comparisons shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference by any general statement incorporating by reference this annual report on Form 10-K into any filing under the Securities Act of 1933 or under the Securities Exchange Act of 1934, except to the extent that we specifically incorporate such comparisons by reference.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i122d3ae3d73245b585bd7f040afd795c_70"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">[Reserved]</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><div id="i122d3ae3d73245b585bd7f040afd795c_73"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">The following discussion and analysis should be read with our financial statements and notes included elsewhere in this annual report on Form 10-K.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company with a mission of pioneering medicines that transform patients&#8217; lives.&#160;&#160;We are devoting most of our resources to the research, development and preparation for commercialization of our most advanced drug candidates:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:12.53pt">We have a pending NDA for sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure.  The NDA is currently under review by the FDA and has been assigned a PDUFA target action date of May 27, 2023.  The NDA is supported by positive results from two Phase 3 clinical trials evaluating the effect of sotagliflozin on long-term outcomes related to cardiovascular death and heart failure in approximately 10,500 and 1,200 patients, respectively.  Under the NDA, we are seeking regulatory approval to market sotagliflozin to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure and in adults with type 2 diabetes mellitus, chronic kidney disease and other cardiovascular risk factors. We are now preparing for the anticipated commercial launch of sotagliflozin in the United States following approval.</span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have also engaged in the development of sotagliflozin in type 1 diabetes, which was the subject of a separate NDA.  That NDA was supported by positive results from three Phase 3 clinical trials evaluating the effect of sotagliflozin on type 1 diabetes in approximately 800, 800 and 1,400 patients, respectively. The FDA issued a complete response letter regarding our NDA for sotagliflozin in type 1 diabetes. At our request, the FDA has issued a public Notice of Opportunity for Hearing on whether there are grounds for denying approval of our NDA and the hearing process is ongoing.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are developing LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain. We have reported positive results from a Phase 2 clinical trial of LX9211 in diabetic peripheral neuropathic pain. We have reported top-line results from a separate Phase 2 clinical trial of LX9211 in post-herpetic neuralgia which demonstrated clear evidence of effect. LX9211 has received Fast Track designation from the FDA for development in diabetic peripheral neuropathic pain.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are conducting preclinical research and development and preparing to conduct clinical development of compounds from a number of additional drug programs originating from our internal drug discovery efforts.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Sotagliflozin and compounds from a number of additional drug programs originated from our own internal drug discovery efforts, and LX9211 originated from our collaborative neuroscience drug discovery efforts with Bristol-Myers Squibb.  Our efforts were driven by a systematic, target biology-driven approach in which we used gene knockout technologies and an integrated platform of advanced medical technologies to systematically study the physiological and behavioral functions of almost 5,000 genes in mice and assessed the utility of the proteins encoded by the corresponding human genes as potential drug targets.  We have identified and validated in living animals, or in vivo, more than 100 targets with promising profiles for drug discovery.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;We are working both independently and through collaborations and strategic alliances with third parties to capitalize on our drug target discoveries and drug discovery and development programs.  We seek to retain exclusive or co-exclusive rights to the benefits of certain drug discovery and development programs by developing and commercializing drug candidates from those programs internally, particularly in the United States for indications treated by specialist physicians.  We seek to collaborate with other pharmaceutical and biotechnology companies with respect to drug discovery or the development and commercialization of certain of our drug candidates, particularly with respect to commercialization in territories outside the United States or commercialization in the United States for indications treated by primary care physicians, or when the collaboration may otherwise provide us with access to expertise and resources that we do not possess internally or are complementary to our own.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have derived substantially all of our revenues from strategic collaborations and other research and development collaborations and technology licenses, as well as from commercial sales of our XERMELO product following its commercial launch in February 2017 until our sale of XERMELO and related assets to TerSera Therapeutics, LLC in September 2020.  To date, we have generated a substantial portion of our revenues from a limited number of sources.  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating results and, in particular, our ability to generate additional revenues are dependent on many factors, including the success of our planned commercial launch of sotagliflozin in the United States for heart failure, if approved; the success of our ongoing nonclinical and clinical development efforts and the ability to obtain necessary regulatory approvals of the drug candidates which are the subject of such efforts; our success in establishing new collaborations and licenses and our receipt of milestones, royalties and other payments under such arrangements; and general and industry-specific economic conditions which may affect research, development and commercialization expenditures.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to secure future revenue-generating agreements will depend upon our ability to address the needs of our potential future collaborators and licensees, and to negotiate agreements that we believe are in our long-term best interests.&#160;&#160;We may determine, as we have with certain of our drug candidates, that our interests are better served by retaining rights to our discoveries and advancing our therapeutic programs to a later stage, which could limit our near-term revenues and increase expenses.&#160;&#160;Because of these and other factors, our operating results have fluctuated in the past and are likely to do so in the future, and we do not believe that period-to-period comparisons of our operating results are a good indication of our future performance.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have incurred significant losses and, as of December&#160;31, 2022, we had an accumulated deficit of $1.6 billion. Our losses have resulted principally from costs incurred in research and development, selling, general and administrative costs associated with our operations, and non-cash stock-based compensation expenses associated with stock options and restricted stock units granted to employees and consultants.&#160;&#160;Research and development expenses consist primarily of salaries and related personnel costs, external research costs related to our nonclinical and clinical efforts, material costs, facility costs, depreciation on property and equipment, and other expenses related to our drug discovery and development programs. Selling, general and administrative expenses consist primarily of salaries and related expenses for executive, sales and marketing, and administrative personnel, professional fees and other corporate expenses, including information technology, facilities costs and general legal activities.&#160;&#160;We expect to continue to incur significant research and development costs in connection with the continuing research and development of our drug candidates.  As a result, we will need to generate significantly higher revenues to achieve profitability.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Consolidated Financial Statements included in this Annual Report on Form 10-K have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP"), which require that we make numerous estimates and assumptions. Actual results could differ from those estimates and assumptions, thus impacting our reported results of operations and financial position. The critical accounting policies and estimates described in this section are those that are most important to the depiction of our financial condition and results of operations and the application of which requires our most subjective judgments in making estimates about the effect of matters that are inherently uncertain. We describe our significant accounting policies more fully in Note 2, "Summary of Significant Accounting Policies," to the Consolidated Financial Statements included in this Annual Report on Form 10-K.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of costs incurred for research and development activities solely sponsored by us as well as collaborative research and development activities.&#160;&#160;These costs include direct and research-related overhead expenses and are expensed as incurred.&#160;&#160;Technology license fees for technologies that are utilized in research and development and have no alternative future use are expensed when incurred.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are presently devoting most of our resources to the research and development of our most advanced drug candidates:</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Sotagliflozin, an orally-delivered small molecule drug candidate that we are developing as a treatment for heart failure and type&#160;1 diabetes; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">LX9211, an orally-delivered small molecule drug candidate that we are developing as a treatment for neuropathic pain.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LX9211 originated from our collaborative neuroscience drug discovery efforts with Bristol-Myers Squibb, and sotagliflozin and compounds from a number of additional drug programs originated from our own internal drug discovery efforts.  Those efforts were driven by a systematic, target biology-driven approach in which we used gene knockout technologies and an integrated platform of advanced medical technologies to systematically study the physiological and behavioral functions of almost 5,000 genes in mice and assessed the utility of the proteins encoded by the corresponding human </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">genes as potential drug targets.  We have identified and validated in living animals, or in vivo, more than 100 targets with promising profiles for drug discovery.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The drug development process takes many years to complete.&#160;&#160;The cost and length of time varies due to many factors including the type, complexity and intended use of the drug candidate.&#160;&#160;We estimate that drug development activities are typically completed over the following periods:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:60.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.015%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Phase</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Completion Period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preclinical development</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1-2 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 1 clinical trials</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1-2 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2 clinical trials</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1-2 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 3 clinical trials</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2-4 years</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect research and development costs to remain substantial in the future as we continue to fund our nonclinical and clinical development efforts and advance new drug candidates into clinical development.&#160;&#160;Due to the variability in the length of time necessary for drug development, the uncertainties related to the cost of these activities and ultimate ability to obtain regulatory approval for commercialization, accurate and meaningful estimates of the ultimate costs to bring our drug candidates to market are not available. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record significant accrued liabilities related to unbilled expenses for products or services that we have received from service providers, specifically related to ongoing nonclinical studies and clinical trials.&#160;&#160;These costs primarily relate to clinical study management, monitoring, laboratory and analysis costs, drug supplies, toxicology studies and investigator grants.&#160;&#160;We may have multiple drugs in concurrent nonclinical studies and clinical trials at clinical sites throughout the world.&#160;&#160;In order to ensure that we have adequately provided for ongoing nonclinical and clinical development costs during the period in which we incur such costs, we maintain accruals to cover these expenses.&#160;&#160;Substantial portions of our nonclinical studies and clinical trials are performed by third party laboratories, medical centers, contract research organizations and other vendors.  For nonclinical studies, we accrue expenses based upon estimated percentage of work completed and the contract milestones remaining.  For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study.  We monitor patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to us by the vendors and clinical site visits.  Our estimates depend on the timeliness and accuracy of the data provided by our vendors regarding the status of each program and total program spending.  We periodically evaluate the estimates to determine if adjustments are necessary or appropriate based on information we receive.&#160;&#160;Although we use consistent milestones or subject or patient enrollment to drive expense recognition, the assessment of these costs is a subjective process that requires judgment.&#160;&#160;Upon settlement, these costs may differ materially from the amounts accrued in our consolidated financial statements.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial terms of these agreements are subject to negotiation and vary from contract to contract. In accruing the relevant costs, we estimated the time period over which services were to be performed and the level of effort required to complete or wind down each study.  Upon completion and settlement, these costs may differ materially from the amounts accrued in our consolidated financial statements.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record our research and development costs by type or category, rather than by project.&#160;&#160;Significant categories of costs include personnel, facilities and equipment costs and third-party and other services.&#160;&#160;In addition, a significant portion of our research and development expenses is not tracked by project as it benefits multiple projects. Consequently, fully-loaded research and development cost summaries by project are not available.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our long-lived assets include property, plant and equipment, right-of-use assets for leases and goodwill.  We regularly review long-lived assets for impairment.  The recoverability of long-lived assets, other than goodwill, is measured by comparing the assets carrying amount to the expected undiscounted future cash flows that the asset is expected to generate.  Determining whether an impairment has occurred typically requires various estimates and assumptions, including determining which cash flows are directly related to the potentially impaired asset, the useful life over which cash flows will occur, their amount, and the asset&#8217;s residual value, if any.  We use internal cash flow estimates, quoted market prices when available and independent appraisals as appropriate to determine fair value.  We derive the required cash flow estimates from our historical experience and our internal business plans and apply an appropriate discount rate.  In 2020, we recognized an impairment loss of $1.6 million to reduce the carrying value of the assets comprising our campus in The Woodlands, Texas, which were sold in December 2020, to an estimated fair value, less estimated selling costs. There were no significant impairments of long-lived assets in 2022 or 2021. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is not amortized, but is tested at least annually for impairment at the reporting unit level.&#160;&#160;We have determined that the reporting unit is the single operating segment disclosed in our current financial statements.&#160;&#160;Impairment is the condition that exists when the carrying amount of goodwill exceeds its implied fair value.&#160;&#160;The first step in the impairment process is to determine the fair value of the reporting unit and then compare it to the carrying value, including goodwill.&#160;&#160;We determined that the market capitalization approach is the most appropriate method of measuring fair value of the reporting unit.&#160;&#160;Under this approach, fair value is calculated as the average closing price of our common stock for the 30 days preceding the date that the annual impairment test is performed, multiplied by the number of outstanding shares on that date.&#160;&#160;A control premium, which is representative of premiums paid in the marketplace to acquire a controlling interest in a company, is then added to the market capitalization to determine the fair value of the reporting unit.&#160;&#160;If the fair value exceeds the carrying value, no further action is required and no impairment loss is recognized.&#160;&#160;Additional impairment assessments may be performed on an interim basis if we encounter events or changes in circumstances that would indicate that, more likely than not, the carrying value of goodwill has been impaired.&#160;&#160;There was no impairment of goodwill in 2022, 2021 and 2020.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 3, Recent Accounting Pronouncements, of the Notes to Consolidated Financial Statements, for a discussion of the impact of new accounting standards on our consolidated financial statements.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations &#8211; Comparison of Years Ended December&#160;31, 2022, 2021 and 2020 </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis should be read with &#8220;Results of Operations&#8221; and our financial statements and notes included in our annual report on Form 10-K for the year ended December&#160;31, 2021.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties and other revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Revenues from royalties and other revenue decreased to $0.1 million in 2022 from $0.3 million in 2021. In 2022, one company represented 100% of revenues.  In 2021, two companies represented 76% and 24% of revenues, respectively.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses and dollar and percentage changes as compared to the prior year are as follows (dollar amounts are presented in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:56.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dollar decrease</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage decrease</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of third-party and other services principally related to nonclinical and clinical development activities, salaries and other personnel-related expenses, facility and equipment costs and stock-based compensation.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Years Ended December&#160;31, 2022 and 2021 </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Third-party and other services &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Third-party and other services decreased 14% in 2022 to $29.9 million, primarily due to decreases in professional and consulting fees relating to preparations for the submission of our application for regulatory approval to market sotagliflozin in the United States for heart failure. Third-party and other services relate principally to our clinical trial and related development activities, such as nonclinical and clinical studies and contract manufacturing.&#160;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Personnel &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Personnel costs increased 25% in 2022 to $13.5 million, primarily due to higher employee salaries and benefit costs as a result of increasing headcount during 2022 in preparation for commercialization of sotagliflozin.  Salaries, bonuses, employee benefits, payroll taxes, recruiting and relocation costs are included in personnel costs.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Stock-based compensation &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Stock-based compensation expense was $4.3 million in 2022 and 2021. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Facilities and equipment &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Facilities and equipment costs was $1.6 million and $1.5 million in 2022 and 2021, respectively.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Other &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Other costs was $3.6 million and $3.5 million in 2022 and 2021, respectively.  Other costs primarily include travel, training, software licenses and insurance costs.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses and dollar and percentage changes as compared to the prior year are as follows (dollar amounts are presented in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:56.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total selling, general and administrative expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dollar increase (decrease)</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage increase (decrease)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses consist primarily of personnel costs to support the commercialization of sotagliflozin and activities from research and development; professional and consulting fees, stock-based compensation expense, and facility and equipment costs.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Years Ended December&#160;31, 2022 and 2021  </span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Personnel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Personnel costs increased 75% in 2022 to $18.8 million, primarily due to higher employee salaries and benefit costs as a result of increasing headcount during 2022 in preparation for commercialization of sotagliflozin.  Salaries, bonuses, employee benefits, payroll taxes, recruiting and relocation costs are included in personnel costs.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Professional and consulting fees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Professional and consulting fees increased 50% in 2022 to $16.3 million, primarily as a result of higher marketing and professional and consulting fees, partially offset by lower legal fees. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Stock-based compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Stock-based compensation expense increased 15% in 2022 to $7.3 million, primarily due to increasing headcount in the current year. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Facilities and equipment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Facilities and equipment costs was $1.4 million in 2022 and 2021.  </span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Other &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Other costs increased 39% in 2022 to $4.3 million, primarily due to increases in travel, training and software license expenses in 2022.</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense and Interest and Other Income, Net</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;&#160;Interest expense increased to $2.8 million in 2022 from $0.8 million in 2021, primarily due to the Oxford debt financings during March and December of 2022.  </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest and Other Income (Expense), Net.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;Interest and other income, net was $1.6 million and $0.1 million in the years ended December&#160;31, 2022 and 2021, respectively.&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:11pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss and Net Loss&#160;per Common Share </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss was $101.9 million, or a loss of $0.62 per share, in 2022, as compared to a net loss of $87.8 million, or $0.60 per share in 2021.&#160;&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have financed our operations from inception primarily through sales of common and preferred stock, contract and milestone payments we received under our collaborations and strategic licenses, target validation, database subscription and technology license agreements, product sales, government grants and contracts, and financing under debt, lease and other </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">project financing arrangements, as well as from commercial sales of our XERMELO product following its commercial launch in February 2017 until our sale of XERMELO and related assets to TerSera Therapeutics, LLC in September 2020. In March 2022, we entered into a loan and security agreement with Oxford Finance LLC that provides up to $150 million in borrowing capacity, available in four tranches, under which $50 million has been funded.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2022, we had $138.4 million in cash, cash equivalents and short-term investments. &#160;As of December&#160;31, 2021, we had $86.7 million in cash, cash equivalents and short-term investments.&#160;&#160;We used cash of $88.9 million in our operations in 2022. This consisted primarily of the net loss for the year of $101.9&#160;million, partially offset by a net decrease in operating assets net of liabilities of $0.4&#160;million and non-cash charges of $12.7&#160;million primarily related to stock-based compensation expense.  Investing activities used cash of $71.1&#160;million in 2022, primarily due to $69.8&#160;million net purchases of investments and $1.3&#160;million of asset purchases.  Financing activities provided cash of $142.2&#160;million, primarily as a result of $94.2&#160;million net proceeds from the issuance of common stock and $48.9&#160;million of net proceeds from the Oxford debt financing, which were partially offset by $0.9&#160;million used to repurchase common stock by retaining shares in substitution of the tax withholding obligations of recipients of restricted stock units granted under our 2017 Equity Incentive Plan with respect to the vesting of such restricted stock units.  </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Other commitments. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2021, sotagliflozin was approved in the United Kingdom for use as an adjunct to insulin therapy to improve glycemic control in adults with type 1 diabetes and a body mass index &#8805; 27 kg/m2, who could not achieve adequate glycemic control despite optimal insulin therapy. Upon the achievement of certain European regulatory approvals, we will be required to make certain royalty payments, totaling $4.5 million, in three equal annual installments of $1.5 million.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Under our drug discovery alliance with Bristol-Myers Squibb, we will be required to make a royalty payment of $5 million upon dosing of the first patient in a Phase 3 clinical trial of LX9211</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Facilities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;In February 2021, we leased a 25,000 square-foot office space in The Woodlands, Texas.  The term of the sublease extends from March 1, 2021 through August 31, 2025, and provides for escalating yearly base rent payments starting at $506,000 and increasing to $557,000 in the final year of the lease.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, our subsidiary, Lexicon Pharmaceuticals (New Jersey), Inc. leased a 22,000 square-foot office space in Bridgewater, New Jersey. The term of the lease extends from February 2023 through January 2034 and provides for escalating yearly base rent payments starting at $820,000 and increasing to $986,000 in the final year of the lease.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future capital requirements will be substantial and will depend on many factors, including the success of our planned commercial launch of sotagliflozin in heart failure, if approved,; the success of our ongoing nonclinical and clinical development efforts and the ability to obtain necessary regulatory approvals of the drug candidates which are the subject of such efforts; our success in establishing new collaborations and licenses and our receipt of milestones, royalties and other payments under such arrangements; the amount and timing of our research, development and commercialization expenditures; the resources we devote to developing and supporting our products and other factors.&#160;&#160;Our capital requirements will also be affected by any expenditures we make in connection with license agreements and acquisitions of and investments in complementary technologies and businesses.&#160;&#160;We expect to continue to devote substantial capital resources to prepare for the commercialization of sotagliflozin, if approved; to successfully complete our nonclinical and clinical development efforts with respect to sotagliflozin, LX9211 and our other drug candidates; and for other general corporate activities.&#160;&#160;We believe that our current unrestricted cash and investment balances and cash and revenues we expect to derive from strategic and other collaborations and other sources will be sufficient to fund our currently planned operations for at least the next 12 months from the date of this report.&#160;&#160;During or after this period, if cash generated by operations is insufficient to satisfy our liquidity requirements, we will need to sell additional equity or debt securities or obtain additional credit arrangements.&#160;&#160;If we are unable to obtain adequate financing when needed, we may have to delay or reduce the scope of one or more of our clinical trials, or research and development programs. Additional financing may not be available on terms acceptable to us or at all. The sale of additional equity or convertible debt securities may result in additional dilution to our stockholders.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, our board of directors may authorize us to repurchase shares of our common stock. If and when our board of directors should determine to authorize any such action, it would be on terms and under market conditions that our board of directors determines are in the best interest of us and our stockholders.  Any such actions could deplete significant amounts of our cash resources and/or result in additional dilution to our stockholders.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disclosure about Market Risk</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to limited market and credit risk on our cash equivalents which have maturities of three months or less at the time of purchase.&#160;&#160;We maintain a short-term investment portfolio which consists of U.S. Treasury bills and corporate debt </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">securities that mature three to 12 months from the time of purchase, which we believe are subject to limited market and credit risk.&#160;&#160;We currently do not hedge interest rate exposure or hold any derivative financial instruments in our investment portfolio.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had approximately $138.4 million in cash and cash equivalents and short-term investments as of&#160;December&#160;31, 2022.  We believe that t</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he working capital available to us will be sufficient to meet our cash requirements for at least the next 12&#160;months. We are subject to interest rate sensitivity on our outstanding Oxford Term Loans which </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">bear interest at a floating rate equal to the 30-day U.S. Dollar LIBOR plus 7.90%, but not less than 8.01%, subject to additional interest if an event of default occurs and is continuing.  As of December&#160;31, 2022, the interest rate was 12.04%.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have operated primarily in the United States and substantially all sales to date have been made in U.S. dollars. Accordingly, we have not had any material exposure to foreign currency rate fluctuations.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160; </span></div><div id="i122d3ae3d73245b585bd7f040afd795c_76"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7A.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;Disclosure about Market Risk&#8221; under &#8220;Item 7. Management&#8217;s Discussion and Analysis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of Financial Condition and Results of Operations&#8221; for quantitative and qualitative disclosures about market risk.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i122d3ae3d73245b585bd7f040afd795c_79"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8.&#160; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Statements and Supplementary Data</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements required by this Item are incorporated under Item 15 in Part IV of this report.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i122d3ae3d73245b585bd7f040afd795c_82"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i122d3ae3d73245b585bd7f040afd795c_85"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9A.&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Controls and Procedures</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) as of the end of the period covered by this report. Based on that evaluation, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures were effective as of December&#160;31, 2022 to ensure that the information required to be disclosed by us in the reports we file under the Securities Exchange Act is gathered, analyzed and disclosed with adequate timeliness, accuracy and completeness.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Report on Internal Control over Financial Reporting</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act).</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.&#160;&#160;Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management assessed the effectiveness of our internal control over financial reporting as of December&#160;31, 2022.&#160;&#160;In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control-Integrated Framework </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2013 Framework)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on such assessment using those criteria, management concluded that, as of December&#160;31, 2022, our internal control over financial reporting was effective.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our independent registered public accounting firm, <ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y184NS9mcmFnOmUwZDEzMTA1Zjk3OTRjY2I5NGM3NzZhNmZiMDJiNWFjL3RleHRyZWdpb246ZTBkMTMxMDVmOTc5NGNjYjk0Yzc3NmE2ZmIwMmI1YWNfMjU0NA_0d20f740-20f4-4348-bf42-9893788a6da7">Ernst &amp; Young LLP</ix:nonNumeric>, <ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y184NS9mcmFnOmUwZDEzMTA1Zjk3OTRjY2I5NGM3NzZhNmZiMDJiNWFjL3RleHRyZWdpb246ZTBkMTMxMDVmOTc5NGNjYjk0Yzc3NmE2ZmIwMmI1YWNfMjU0NQ_f68411df-fee5-445c-9a89-be02c4eb9c9c">Houston, Texas</ix:nonNumeric>, PCAOB ID: <ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y184NS9mcmFnOmUwZDEzMTA1Zjk3OTRjY2I5NGM3NzZhNmZiMDJiNWFjL3RleHRyZWdpb246ZTBkMTMxMDVmOTc5NGNjYjk0Yzc3NmE2ZmIwMmI1YWNfMjU0Ng_dce591cb-5fce-4301-a7c0-d1b8076d68fc">42</ix:nonNumeric>, has audited the financial statements included in this Annual Report and has issued a report on the effectiveness of our internal control over financial reporting.  The report of Ernst &amp; Young LLP is included below.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to our evaluation described above, there were no significant changes in internal controls or other factors during the fiscal quarter ended December&#160;31, 2022 that could significantly affect internal controls, including any corrective actions with regard to significant deficiencies and material weaknesses.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="i122d3ae3d73245b585bd7f040afd795c_88"></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Shareholders and the Board of Directors of Lexicon Pharmaceuticals, Inc.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on Internal Control Over Financial Reporting</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have audited Lexicon Pharmaceuticals, Inc. internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Lexicon Pharmaceuticals, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2022, based on the COSO criteria.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2022 and 2021, the related consolidated statements of comprehensive loss, stockholders&#8217; equity and cash flows for each of the three years in the period ended December 31, 2022, and the related notes and our report dated March 3, 2023 expressed an unqualified opinion thereon.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control Over Financial Reporting </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Ernst &amp; Young LLP</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Houston, Texas</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;3, 2023</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><div id="i122d3ae3d73245b585bd7f040afd795c_91"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9B.&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Information</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div id="i122d3ae3d73245b585bd7f040afd795c_94"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9C.&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i122d3ae3d73245b585bd7f040afd795c_97"></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i122d3ae3d73245b585bd7f040afd795c_100"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 10.&#160; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Directors, Executive Officers and Corporate Governance</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is hereby incorporated by reference from (a) the information appearing under the captions &#8220;Election of Directors,&#8221; &#8220;Stock Ownership of Certain Beneficial Owners and Management,&#8221; &#8220;Corporate Governance&#8221; and &#8220;Executive and Director Compensation&#8221; in our definitive proxy statement which involves the election of directors and is to be filed with the SEC pursuant to the Securities Exchange Act of 1934 within 120 days of the end of our fiscal year on December&#160;31, 2022 and (b)&#160;the information appearing under Item&#160;1 in Part&#160;I</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of this report.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i122d3ae3d73245b585bd7f040afd795c_103"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 11.&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Executive Compensation</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is hereby incorporated by reference from the information appearing under the captions &#8220;Corporate Governance&#8221; and &#8220;Executive and Director Compensation&#8221; in our definitive proxy statement which involves the election of directors and is to be filed with the Commission pursuant to the Securities Exchange Act of 1934 within 120 days of the end of our fiscal year on December&#160;31, 2022. Notwithstanding the foregoing, in accordance with the instructions to Item 407(e)(5) of Regulation S-K, the information contained in our proxy statement under the sub-heading &#8220;Compensation Committee Report&#8221; shall not be deemed to be filed as part of or incorporated by reference into this annual report on Form 10-K.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i122d3ae3d73245b585bd7f040afd795c_106"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 12.&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is hereby incorporated by reference from the information appearing under the captions &#8220;Stock Ownership of Certain Beneficial Owners and Management&#8221; and &#8220;Equity Compensation Plan Information&#8221; in our definitive proxy statement which involves the election of directors and is to be filed with the Commission pursuant to the Securities Exchange Act of 1934 within 120 days of the end of our fiscal year on December&#160;31, 2022.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i122d3ae3d73245b585bd7f040afd795c_109"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 13.&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Certain Relationships and Related Transactions, and Director Independence</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is hereby incorporated by reference from the information appearing under the captions &#8220;Corporate Governance&#8221; and &#8220;Transactions with Related Persons&#8221; in our definitive proxy statement which involves the election of directors and is to be filed with the Commission pursuant to the Securities Exchange Act of 1934 within 120 days of the end of our fiscal year on December&#160;31, 2022.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i122d3ae3d73245b585bd7f040afd795c_112"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 14.&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principal Accountant Fees and Services</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item as to the fees we pay our principal accountant is hereby incorporated by reference from the information appearing under the caption &#8220;Ratification and Approval of Independent Auditors&#8221; in our definitive proxy statement which involves the election of directors and is to be filed with the Commission pursuant to the Securities Exchange Act of 1934 within 120 days of the end of our fiscal year on December&#160;31, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><div id="i122d3ae3d73245b585bd7f040afd795c_115"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div style="text-align:justify"><span><br/></span></div><div id="i122d3ae3d73245b585bd7f040afd795c_118"></div><div style="-sec-extract:summary;margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 15.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exhibit and Financial Statement Schedules</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Documents filed as a part of this report:</span></div><div style="margin-bottom:6pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Consolidated Financial Statements</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.713%"><tr><td style="width:1.0%"></td><td style="width:88.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i122d3ae3d73245b585bd7f040afd795c_130">Report of Independent Registered Public Accounting Firm</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (PCAOB ID: 42)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i122d3ae3d73245b585bd7f040afd795c_130">F-1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i122d3ae3d73245b585bd7f040afd795c_133">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i122d3ae3d73245b585bd7f040afd795c_133">F-3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i122d3ae3d73245b585bd7f040afd795c_136">Consolidated Statements of Comprehensive </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i122d3ae3d73245b585bd7f040afd795c_136">Loss</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i122d3ae3d73245b585bd7f040afd795c_136">F-4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i122d3ae3d73245b585bd7f040afd795c_139">Consolidated Statements of Stockholders&#8217; Equity </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i122d3ae3d73245b585bd7f040afd795c_139">F-5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i122d3ae3d73245b585bd7f040afd795c_142">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i122d3ae3d73245b585bd7f040afd795c_142">F-6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i122d3ae3d73245b585bd7f040afd795c_145">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i122d3ae3d73245b585bd7f040afd795c_145">F-7</a></span></div></td></tr></table></div><div style="margin-bottom:6pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Financial Statement Schedules&#160;</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All other financial statement schedules are omitted because they are not applicable or not required, or because the required information is included in the financial statements or notes thereto.</span></div><div style="margin-bottom:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Exhibits</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"></td><td style="width:11.191%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.086%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.423%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282222000024/exh31-fifthamendedandresta.htm">Fifth Amended and Restated Certificate of Incorporation </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(filed as Exhibit 3.1 to the Company&#8217;s Current Report on Form&#160;8&#8209;K dated May 20, 2022 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282212000016/exh32secondamendedandresta.htm">Second Amended and Restated Bylaws </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(filed as Exhibit 3.2 to the Company&#8217;s Current Report on Form&#160;8&#8209;K dated April 26, 2012 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1062822/000095013407013586/h47609cexv10w1.htm">Securities Purchase Agreement</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, dated June 17, 2007, with Invus, L.P. (filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K dated June 17, 2007 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282209000118/exh10_1.htm">Amendment</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, dated October 7, 2009, to Securities Purchase Agreement, dated June&#160;17, 2007, with Invus, L.P. (filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K dated October 7, 2009 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1062822/000095013407013586/h47609cexv10w3.htm">Registration Rights Agreement</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, dated June 17, 2007, with Invus, L.P. (filed as Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K dated June 17, 2007 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1062822/000095013407013586/h47609cexv10w4.htm">Stockholders&#8217; Agreement</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, dated June 17, 2007, with Invus, L.P. (filed as Exhibit 10.4 to the Company&#8217;s Current Report on Form 8-K dated June 17, 2007 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1062822/000095012310024973/h70210exv10w1.htm">Supplement to Transaction Agreements</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, dated March 15, 2010, with Invus, L.P. and Invus C.V. (filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K dated March 15, 2010 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282212000005/exhibit101.htm">Supplement No. 2 to Transaction Agreements</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, dated February 23, 2012, with Invus, L.P. and Invus C.V. (filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K dated February 23, 2012 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1062822/000119312520321518/d87169dex101.htm">Supplement No. 3 to the Transaction Agreements</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, dated December 16, 2020, with Invus, L.P. and Invus C.V. (filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K dated December 16, 2020 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282222000005/exh48descriptionofcommonst.htm">Description of Common Stock</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  (filed as Exhibit 4.8 to the Company&#8217;s Annual Report on Form 10-K for the period ended December 31, 2021 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282219000007/exh101coatsofferletteramen.htm">Offer Letter</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, dated July 1, 2014, with Lonnel Coats, as amended (filed as Exhibit 10.1 to the Company&#8217;s Annual Report on Form 10-K for the period ended December 31, 2018 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1062822/000095012900000465/0000950129-00-000465.txt">Employment Agreement</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, dated January 1, 1999, with Jeffrey L. Wade (filed as Exhibit 10.3 to the Company&#8217;s Registration Statement on Form S-1 (Registration No. 333-96469) and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282222000005/exh103offerlettergranowitz.htm">Offer Letter</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, dated July 27, 2021, with Craig B. Granowitz, M.D., Ph.D. (filed as Exhibit 10.3 to the Company&#8217;s Annual Report on Form 10-K for the period ended December 31, 2021 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1062822/000095012901504054/h92253ex10-1.txt">Employment Agreement</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, dated July 12, 2001, with Alan J. Main, Ph.D. (filed as Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q for the period ended September 30, 2001 and incorporated by reference herein).</span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"></td><td style="width:11.191%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.086%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.423%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1062822/000095012900000465/0000950129-00-000465.txt">Form of Indemnification Agreement with Officers and Directors</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (filed as Exhibit 10.6 to the Company&#8217;s Registration Statement on Form S-1 (Registration No. 333-96469) and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282219000017/exh101proposedsummaryofnon.htm">Summary of Non-Employee Director Compensation</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (filed as Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q for the period ended March 31, 2019 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001062822/000106282220000025/exh1012017equityincent.htm">2017 Equity Incentive Plan, as amended</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K dated April 23, 2020 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282221000029/exh101-2017nonxemployeedir.htm">2017 Non-Employee Directors&#8217; Equity Incentive Plan</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282221000029/exh101-2017nonxemployeedir.htm">,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282221000029/exh101-2017nonxemployeedir.htm"> as amended</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (filed as Exhibit 10.1 to the Company's Current Report on Form 8-K dated April 29, 2021 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1062822/000106282218000008/exh1011officerstockoptiona.htm">Form of Stock Option Agreement with Officers</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> under the 2017 Equity Incentive Plan (filed as Exhibit 10.11 to the Company&#8217;s Annual Report on Form 10-K for the period ended December 31, 2017 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.10</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exh1010officerrestrictedst.htm">Form of Restricted Stock Unit Agreement</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> with Officers under the 2017 Equity Incentive Plan </span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282219000017/exh102non-employeedirector.htm">Form of Notice of Stock Option Grant to Directors</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> under the 2017 Non-Employee Directors&#8217; Equity Incentive Plan (filed as Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q for the period ended March 31, 2019 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1062822/000106282219000017/exh103non-employeedirector.htm">Form of Notice of Restricted Stock Unit Grant to Directors</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> under the 2017 Non-Employee Directors&#8217; Equity Incentive Plan (filed as Exhibit 10.3 to the Company&#8217;s Quarterly Report on Form 10-Q for the period ended March 31, 2019 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282215000025/exh102bmsagreement.htm">Collaboration and License Agreement</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, dated December&#160;17, 2003, with Bristol-Myers Squibb Company (filed as Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q for the period ended March 31, 2015 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282215000025/exh103bmsagreeementamendme.htm">First Amendment</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, dated May 30, 2006, to Collaboration and License Agreement, dated December&#160;17, 2003, with Bristol-Myers Squibb Company (filed as Exhibit 10.3 to the Company&#8217;s Quarterly Report on Form 10-Q for the period ended March 31, 2015 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;10.15</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282216000081/secondamendmenttocollabora.htm">Second Amendment,</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> dated November 2, 2016, to Collaboration and License Agreement, dated December 17, 2003, with Bristol-Myers Squibb Company (filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K dated November 2, 2016 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;10.16</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1062822/000095012906002238/h33572exv10w22.txt">Second Amended and Restated Collaboration and License Agreement</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, dated November 30, 2005, with Genentech, Inc. (filed as Exhibit 10.22 to the Company&#8217;s Annual Report on Form 10-K for the period ended December 31, 2005 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282209000109/exh10_1.htm">Amendment</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, dated June 8, 2009, to Second Amended and Restated Collaboration and License Agreement, dated November 30, 2005, with Genentech, Inc. (filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K/A dated June 8, 2009 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282221000005/subleaseagreementlexicon-r.htm">Sublease Agreement</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, dated February 8, 2021, with Repsol Oil &amp; Gas USA, LLC (filed as Exhibit 10.1 to the  Company&#8217;s Current Report on Form 8-K dated February 8, 2021 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282222000022/exh101oxfordloanandsecurit.htm">Loan and Security Agreement</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, dated March 17, 2022,  with Oxford Finance, LLC (filed as Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q for the period ended March 31, 2022 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282222000037/firstamendmenttooxfordloan.htm">First Amendment to Loan and Security Agreement</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, dated August 29, 2022, with Oxford Finance, LLC  (filed as Exhibit 10.1 to the Company's Current Report on Form 8-K dated August 29, 2022 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282222000005/exh211subsidiaries.htm">Subsidiaries</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (filed as Exhibit 21.1 to the Company&#8217;s Annual Report on Form 10-K for the period ended December 31, 2021 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*23.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exh231ernstyoungconsent2022.htm">Consent of Independent Registered Public Accounting Firm</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*24.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i122d3ae3d73245b585bd7f040afd795c_124">Power of Attorney</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (contained in signature page).</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*31.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exh311certificationofprinc.htm">Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*31.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exh312certificationofprinc.htm">Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*32.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exh321certificationofprinc.htm">Certification of Principal Executive and Principal Financial Officers Pursuant to Section 906 of the Sarbanes-Oxley Act of 20</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exh321certificationofprinc.htm">02</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*101.INS</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"></td><td style="width:11.191%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.086%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.423%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:0.1%"></td><td style="width:1.996%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.704%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Confidential treatment has been requested for portions of this exhibit (indicated by &#8220;[**]&#8221;).&#160;&#160;The confidential portions of this exhibit have been omitted and filed separately with the Securities and Exchange Commission.</span></td></tr></table></div><div><span><br/></span></div><div id="i122d3ae3d73245b585bd7f040afd795c_121"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 16.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Form 10-K Summary</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><div id="i122d3ae3d73245b585bd7f040afd795c_124"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Signatures</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.317%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.995%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.678%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lexicon Pharmaceuticals, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 3, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">LONNEL COATS</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lonnel Coats</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 3, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JEFFREY L. WADE</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeffrey L. Wade</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">President and Chief Financial Officer</span></td></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Power of Attorney</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Lonnel Coats and Jeffrey L. Wade, or either of them, each with the power of substitution, his or her attorney-in-fact, to sign any amendments to this Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, here ratifying and confirming all that each of said attorneys-in-fact, or his or her substitute or substitutes, may do or cause to be done by virtue hereof.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:28.036%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.451%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Date</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">/s/ LONNEL COATS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Chief Executive Officer and Director<br/>(Principal Executive Officer)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 3, 2023</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Lonnel Coats</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">/s/ JEFFREY L. WADE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">President and Chief Financial Officer (Principal Financial Officer)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 3, 2023</span></td></tr><tr style="height:17pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Jeffrey L. Wade</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">/s/ KRISTEN L. ALEXANDER</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Vice President, Finance and Accounting<br/>(Principal Accounting Officer)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 3, 2023</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Kristen L. Alexander</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">/s/ RAYMOND DEBBANE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Chairman of the Board of Directors</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 3, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Raymond Debbane</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">/s/ PHILIPPE J. AMOUYAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 3, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Philippe J. Amouyal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">/s/ SAMUEL L. BARKER</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 3, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Samuel L. Barker, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">/s/ ROBERT J. LEFKOWITZ</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 3, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Robert J. Lefkowitz, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">/s/ ALAN S. NIES</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 3, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Alan S. Nies, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">/s/ FRANK P. PALANTONI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 3, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Frank P. Palantoni</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">/s/ CHRISTOPHER J. SOBECKI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 3, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Christopher J. Sobecki</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">/s/ JUDITH L. SWAIN</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 3, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Judith L. Swain, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><div id="i122d3ae3d73245b585bd7f040afd795c_127"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="i122d3ae3d73245b585bd7f040afd795c_130"></div><div style="margin-bottom:8pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To the Shareholders and the Board of Directors of Lexicon Pharmaceuticals, Inc.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Opinion on the Financial Statements</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have audited the accompanying consolidated balance sheets of Lexicon Pharmaceuticals, Inc. (the Company) as of December 31, 2022 and 2021, the related consolidated statements of comprehensive loss</span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">,</span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> stockholders&#8217; equity and cash flows for each of the three years in the period ended December 31, 2022, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2022, in conformity with U.S. generally accepted accounting principles.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated March 3, 2023 expressed an unqualified opinion thereon.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Basis for Opinion</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Critical Audit Matter</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated</span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%"> </span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:14.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.017%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:14.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.017%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Accrued research and development expenses</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Description of the Matter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As described in Note 2 to the consolidated financial statements, the Company records accruals for estimated costs of research and development activities that include contract services for clinical trials. Clinical trial activities performed by third parties are accrued and expensed based upon estimates of the proportion of work completed over the life of the individual clinical trial in accordance with agreements established with contract research organizations ("CROs"), clinical trial sites and other third parties. Estimates are determined by reviewing contracts, vendor agreements, purchase orders, change orders and trial budgets, as well as through discussions with internal clinical personnel and external service providers as to the progress or stage of completion of trials or services and the agreed-upon fee to be paid for such services.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Auditing management&#8217;s accounting for accrued third-party clinical trial research and development expenses is especially challenging because of the judgment applied by management to determine the progress or stage of completion of the activities under the Company&#8217;s research and development agreements and the cost and extent of work performed during the reporting period for services not yet billed by contracted third-party vendors.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the Company&#8217;s accounting for accrued research and development expenses process, including controls over management&#8217;s review of clinical trial activity progress in comparison to budgets and invoices received from third parties. <br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our audit procedures included, among others, testing the accuracy and completeness of the underlying inputs used in management&#8217;s analysis to determine costs incurred. We compared expenses incurred to budgeted amounts per executed vendor contracts and to expenses incurred in prior periods and obtained an understanding of the reasons for changes. We inspected the terms and conditions of vendor contracts, change orders and trial budgets, and clerically tested the cost models to track progress against trial budgets. We evaluated estimated services incurred by third parties by understanding the terms and timeline of significant projects, evaluating management&#8217;s estimate of work performed and costs incurred by meeting with members of the Company&#8217;s clinical operations team, and obtaining external confirmation of key inputs to the accrual calculation, such as total approved trial budgets and amounts invoiced, and number and timing of patients enrolled in clinical studies. Further, we inspected invoices received from third parties during the year as well as after the balance sheet date and performed a lookback analysis to evaluate the completeness of accrued research and development expenses.</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ Ernst &amp; Young LLP  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have served as the Company&#8217;s auditor since 2002.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Houston, Texas</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March&#160;3, 2023</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-2</span></div></div></div><div id="i122d3ae3d73245b585bd7f040afd795c_133"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lexicon Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except par value)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:76.465%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.897%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.605%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzQtMS0xLTEtMzMyMDM_925732dc-9b01-492f-ac38-54ac5a55da6a">46,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzQtMy0xLTEtMzMyMDM_eab74309-30fc-4fc0-a30e-467a686670ce">64,065</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzUtMS0xLTEtMzMyMDM_fb2e20e7-5337-4a75-b4fe-81e7990058fd">92,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzUtMy0xLTEtMzMyMDM_0e11d4e2-cc5e-4110-a8d3-045fd7371ce7">22,678</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzYtMS0xLTEtMzMyMDM_5aa20657-5203-497a-990b-c834f8b40e4c">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzYtMy0xLTEtMzMyMDM_0623ae8b-43fb-4754-a021-b16b1dc21790">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzktMS0xLTEtMzMyMDM_667c7a4d-734e-41c7-8e69-a6840404ac45">2,481</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzktMy0xLTEtMzMyMDM_4636498f-2bb9-417b-9a12-eef73715903c">2,164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzEwLTEtMS0xLTMzMjAz_643b7a53-39d8-4636-bb6a-973da986fdb4">140,866</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzEwLTMtMS0xLTMzMjAz_ba31cd7f-3f95-4504-9129-59693a9f5273">88,921</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net of accumulated depreciation and amortization of $<ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzExLTAtMS0xLTMzMjAzL3RleHRyZWdpb246YzA2NmM4MjhiYWVkNGU1YWJkMTM1MzgyMDcyOGExNzFfODA_9a7fe9a6-6adb-48c8-9b0a-de234559aa6d">3,984</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzExLTAtMS0xLTMzMjAzL3RleHRyZWdpb246YzA2NmM4MjhiYWVkNGU1YWJkMTM1MzgyMDcyOGExNzFfODc_6b02c76c-5b60-4b76-9b31-9b53196b0974">4,853</ix:nonFraction>, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzExLTEtMS0xLTMzMjAz_e061369a-962b-4881-be2e-9233b3ff18b3">2,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzExLTMtMS0xLTMzMjAz_0b30fe86-21dd-4e74-87b7-6dc81a99cc64">1,176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzEyLTEtMS0xLTMzMjAz_876a854f-45a6-48cc-8609-2080732b34d7">44,543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzEyLTMtMS0xLTMzMjAz_9154821e-478b-4234-bf22-49eb02a3a7e2">44,543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use-assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzE0LTEtMS0xLTMzMjAz_4230a92b-dd44-444f-b0b4-0e2fa25fd36f">6,819</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231" decimals="-3" name="us-gaap:OtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzE0LTMtMS0xLTMzMjAz_ff06db99-f4dd-4b47-85f4-0895c8f44278">2,269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzE1LTEtMS0xLTMzMjAz_3ecc51a9-241e-49e9-8ec5-92cbae817530">194,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzE1LTMtMS0xLTMzMjAz_e4a6827c-071b-46e7-bd99-53b5f5102c8a">136,909</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzE4LTEtMS0xLTMzMjAz_afa964c3-8b7e-43f8-a7b6-30f4984f3a84">10,395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzE4LTMtMS0xLTMzMjAz_0a72f02b-ff69-4825-bcb1-046d1ae76d85">9,152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzE5LTEtMS0xLTMzMjAz_6f99c203-71a5-4e6a-8650-badb3f80af9b">12,777</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzE5LTMtMS0xLTMzMjAz_9f88ea08-d338-4e6e-971e-876362297635">12,972</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzIyLTEtMS0xLTMzMjAz_54579009-3d17-4da5-8159-9aece3367c6b">23,172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzIyLTMtMS0xLTMzMjAz_83e21b3c-9263-42da-adee-3895033111c4">22,124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" sign="-" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzI0LTEtMS0xLTMzMjAz_4613baca-314d-4cbc-bf0f-972f6cec7d74">48,579</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzI0LTMtMS0xLTMzMjAz_37a56631-5208-4b3a-999b-946eabf5e7bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzI2LTEtMS0xLTMzMjAz_f5d826d5-25f6-4107-8dcf-65a0a4c985a0">5,424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzI2LTMtMS0xLTMzMjAz_973bd826-6b1c-42f4-a2e4-6dc9c1b70ed4">1,190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzI3LTEtMS0xLTMzMjAz_a9fc19b7-f867-40ac-85e4-ec1ba2ea1ae9">77,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzI3LTMtMS0xLTMzMjAz_489d2c69-b613-41ab-a5ac-80ab1c82a7ba">23,314</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzI4LTEtMS0xLTMzMjAz_d0cfd92e-6552-480b-87d9-6ff6963716bb"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzI4LTMtMS0xLTMzMjAz_5a55192b-7aba-4f66-8c3a-a60fa722efef"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders' Equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231" decimals="2" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzMwLTAtMS0xLTMzMjAzL3RleHRyZWdpb246OGNhNjAwODZlZDY1NDQ0MmIzZjBmNzAzZWQxOGY0OThfMjE_8944aa3b-70bd-4ecb-94b1-231e2fb59d3f"><ix:nonFraction unitRef="usdPerShare" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="2" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzMwLTAtMS0xLTMzMjAzL3RleHRyZWdpb246OGNhNjAwODZlZDY1NDQ0MmIzZjBmNzAzZWQxOGY0OThfMjE_f40ea794-2900-471e-968a-b0da17137904">0.01</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzMwLTAtMS0xLTMzMjAzL3RleHRyZWdpb246OGNhNjAwODZlZDY1NDQ0MmIzZjBmNzAzZWQxOGY0OThfMzU_4cfcbc8d-32b4-4c08-b63c-5c7298b46a1f"><ix:nonFraction unitRef="shares" contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231" decimals="-3" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzMwLTAtMS0xLTMzMjAzL3RleHRyZWdpb246OGNhNjAwODZlZDY1NDQ0MmIzZjBmNzAzZWQxOGY0OThfMzU_8ff54584-a513-4b4d-b2e4-0fbe77abe331">5,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzMwLTAtMS0xLTMzMjAzL3RleHRyZWdpb246OGNhNjAwODZlZDY1NDQ0MmIzZjBmNzAzZWQxOGY0OThfNTc_0f89c543-e7f7-42f5-afd6-bad6c5c8d1a8"><ix:nonFraction unitRef="shares" contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzMwLTAtMS0xLTMzMjAzL3RleHRyZWdpb246OGNhNjAwODZlZDY1NDQ0MmIzZjBmNzAzZWQxOGY0OThfNTc_a625297b-9277-4952-ba75-32246c8a4dd1"><ix:nonFraction unitRef="shares" contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231" decimals="-3" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzMwLTAtMS0xLTMzMjAzL3RleHRyZWdpb246OGNhNjAwODZlZDY1NDQ0MmIzZjBmNzAzZWQxOGY0OThfNTc_ac3520a6-e374-4e5a-a909-91bc7da25120"><ix:nonFraction unitRef="shares" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzMwLTAtMS0xLTMzMjAzL3RleHRyZWdpb246OGNhNjAwODZlZDY1NDQ0MmIzZjBmNzAzZWQxOGY0OThfNTc_f19a8ffd-2659-4dc7-9772-ca27974fa792">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzMwLTEtMS0xLTMzMjAz_b5da95ab-758d-425b-9bb2-e4c6cb44b316">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzMwLTMtMS0xLTMzMjAz_f4a4ccf5-2077-423f-9cf6-22ffb87089aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231" decimals="3" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzMxLTAtMS0xLTMzMjAzL3RleHRyZWdpb246MGViODExNzAyYmI2NGI1Y2I0ODU0ZTEzMjUwMGVkYmJfMTg_20a064d6-4b87-4d13-8ad3-44a677d67bb8"><ix:nonFraction unitRef="usdPerShare" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="3" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzMxLTAtMS0xLTMzMjAzL3RleHRyZWdpb246MGViODExNzAyYmI2NGI1Y2I0ODU0ZTEzMjUwMGVkYmJfMTg_f34d9112-53e9-4df1-a9ab-75220106aa1a">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzMxLTAtMS0xLTMzMjAzL3RleHRyZWdpb246MGViODExNzAyYmI2NGI1Y2I0ODU0ZTEzMjUwMGVkYmJfMzI_56e5b451-4fb5-42a5-b1e1-07dc659c525e"><ix:nonFraction unitRef="shares" contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231" decimals="-3" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzMxLTAtMS0xLTMzMjAzL3RleHRyZWdpb246MGViODExNzAyYmI2NGI1Y2I0ODU0ZTEzMjUwMGVkYmJfMzI_f30188f5-85a1-47b4-972c-20761336dd45">300,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i55a81403781f47ae9d02222240bdb36d_I20221231" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzMxLTAtMS0xLTMzMjAzL3RleHRyZWdpb246MGViODExNzAyYmI2NGI1Y2I0ODU0ZTEzMjUwMGVkYmJfNTQ_1ff92a5a-0d47-47ec-b688-42ef1da84c50">189,214</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i940ed9833e654f3e88d67e4c166a14f2_I20211231" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzMxLTAtMS0xLTMzMjAzL3RleHRyZWdpb246MGViODExNzAyYmI2NGI1Y2I0ODU0ZTEzMjUwMGVkYmJfNjE_89746655-8b90-4ab5-b1cd-bc120b681a3d">150,082</ix:nonFraction> shares issued, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzMxLTEtMS0xLTMzMjAz_975cc197-ee66-4f89-babd-7adb2c8d66fc">189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzMxLTMtMS0xLTMzMjAz_4914c01b-d80a-42a6-a9f3-d6a77094e680">150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzMyLTEtMS0xLTMzMjAz_f34125f0-3459-4d39-a5f9-13888504bcbb">1,709,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzMyLTMtMS0xLTMzMjAz_52a93dc2-b1ae-4691-893d-1f032547f655">1,608,749</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzMzLTEtMS0xLTMzMjAz_bf360594-2d88-4cd1-8fe1-691784c6a3bb">1,589,720</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzMzLTMtMS0xLTMzMjAz_3a345e15-54c6-4ca2-a57c-ae1572208f15">1,487,776</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzM0LTEtMS0xLTMzMjAz_5a7d013d-9e37-4c1a-ab29-8b33f02de10d">428</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzM0LTMtMS0xLTMzMjAz_8c85c817-cc59-4080-8ecb-befdf2490c73">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury stock, at cost, <ix:nonFraction unitRef="shares" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="us-gaap:TreasuryStockShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzM1LTAtMS0xLTMzMjAzL3RleHRyZWdpb246MTRlMjU1OGVlNmM3NGQwOWFiNDcyZmRhYTU4YmY3ZmRfMjk_71b6dba2-bc99-40d9-8383-8fa2b9e3226c">488</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231" decimals="-3" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzM1LTAtMS0xLTMzMjAzL3RleHRyZWdpb246MTRlMjU1OGVlNmM3NGQwOWFiNDcyZmRhYTU4YmY3ZmRfMzY_ffa3f60e-7304-43ce-82c1-0e0d7209442d">1,165</ix:nonFraction> shares, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzM1LTEtMS0xLTMzMjAz_1b1d86ac-ee08-4a9e-aa74-b429d3198ed8">2,061</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231" decimals="-3" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzM1LTMtMS0xLTMzMjAz_21d93460-9ad5-4bce-9a5e-2461fcd4715d">7,518</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders' equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzM2LTEtMS0xLTMzMjAz_cf112a64-e530-4523-b220-c1557ce6ab99">117,124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzM2LTMtMS0xLTMzMjAz_09a74a3f-7a3e-4fbe-bb73-d5e3180e337f">113,595</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzM3LTEtMS0xLTMzMjAz_45ada8df-b9b5-4a82-b17f-fa5d9850e8a0">194,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzM3LTMtMS0xLTMzMjAz_8b16f056-1e4e-4e42-85fd-0d37d1c2c082">136,909</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-3</span></div></div></div><div id="i122d3ae3d73245b585bd7f040afd795c_136"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lexicon Pharmaceuticals, Inc.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share amounts)</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzMtMS0xLTEtMzMyMDM_3147083f-5f86-4e02-b1eb-2cec4ef07906">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzMtMy0xLTEtMzMyMDM_ddf79040-d624-4cef-be72-77f570bfef78">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzMtNS0xLTEtMzMyMDM_8c5152f3-c2ea-42e0-9872-7b103b4624f0">23,404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaborative agreements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzQtMS0xLTEtMzMyMDM_cad085b4-8214-45f3-9380-16015d2a9f4b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzQtMy0xLTEtMzMyMDM_dfa06747-5d8b-4fc5-85db-2039ce4b6ef3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzQtNS0xLTEtMzMyMDM_8dcad617-139a-42fa-a515-d13de0a7d6f1">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties and other revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" name="us-gaap:RoyaltyIncomeNonoperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzUtMS0xLTEtMzMyMDM_e3a384a5-6dc3-4460-91a8-1a0015b26c02">139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="-3" name="us-gaap:RoyaltyIncomeNonoperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzUtMy0xLTEtMzMyMDM_c61e382e-ebdd-4674-8bbb-535198bed173">298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-3" name="us-gaap:RoyaltyIncomeNonoperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzUtNS0xLTEtMzMyMDM_43a801c7-8e35-4b01-9e21-9ecc4e845c94">558</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzYtMS0xLTEtMzMyMDM_771262d0-10db-41d0-b69c-b3137046f09c">139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzYtMy0xLTEtMzMyMDM_7de636c8-be35-498d-8516-ba30a7a80847">298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzYtNS0xLTEtMzMyMDM_33c336c9-851b-4831-8bd9-22fecae276e9">23,995</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales (including finite-lived intangible asset amortization)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzgtMS0xLTEtMzMyMDM_054f5d46-c8c4-4e2e-a53d-b257c59a4ad8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzgtMy0xLTEtMzMyMDM_1fdb649b-bbaf-4955-8106-459122d2d444">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzgtNS0xLTEtMzMyMDM_9ae55a43-6829-4be8-987b-fb6063cf1e27">1,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development, including stock-based compensation of $<ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" name="lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzktMC0xLTEtMzMyMDMvdGV4dHJlZ2lvbjpiODc4YjdiZTdjM2I0NjgzOTFkMDM2Y2I0OWRiMWFmOF82OA_a6b7e64c-16b3-46dc-9c29-786934093e85">4,253</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="-3" name="lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzktMC0xLTEtMzMyMDMvdGV4dHJlZ2lvbjpiODc4YjdiZTdjM2I0NjgzOTFkMDM2Y2I0OWRiMWFmOF83Mg_9adb9afe-9d13-42d0-9079-281946780e17">4,284</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-3" name="lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzktMC0xLTEtMzMyMDMvdGV4dHJlZ2lvbjpiODc4YjdiZTdjM2I0NjgzOTFkMDM2Y2I0OWRiMWFmOF83OQ_176794b1-9989-4c4f-94d7-1f8bb4c62f26">6,376</ix:nonFraction> respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzktMS0xLTEtMzMyMDM_193204c8-bc1f-4674-a155-e577311b0c93">52,816</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzktMy0xLTEtMzMyMDM_67d68ec8-d8f3-4a29-8b4c-4c0e57df96f1">55,046</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzktNS0xLTEtMzMyMDM_c34938fb-852a-4869-a8ab-464441fb41eb">153,621</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative, including stock-based compensation of $<ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" name="lxrx:StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzExLTAtMS0xLTMzMjAzL3RleHRyZWdpb246N2U1OGRhZmJmYTY0NDQwN2JjNjA5MjZlMWI5ZDllYTZfNzk_2bf5c633-a75a-4cde-bd83-e6d117ec7f3d">7,267</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="-3" name="lxrx:StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzExLTAtMS0xLTMzMjAzL3RleHRyZWdpb246N2U1OGRhZmJmYTY0NDQwN2JjNjA5MjZlMWI5ZDllYTZfODM_bd422360-6018-4990-87ab-35f59cbd049d">6,293</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-3" name="lxrx:StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzExLTAtMS0xLTMzMjAzL3RleHRyZWdpb246N2U1OGRhZmJmYTY0NDQwN2JjNjA5MjZlMWI5ZDllYTZfOTA_07889794-51c6-4fee-a289-e34574abd61d">6,898</ix:nonFraction>, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzExLTEtMS0xLTMzMjAz_f9d1b5fd-d98f-4eb0-80ac-e3f974e56f2b">48,083</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzExLTMtMS0xLTMzMjAz_ec50baba-81ed-4a76-928b-ef13d8df3af8">32,342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzExLTUtMS0xLTMzMjAz_8799b324-784e-4734-b129-9abdff7c711e">47,230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment loss on buildings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzEyLTEtMS0xLTMzMjAz_8336170e-b3fa-4193-b274-f8e024e04524">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzEyLTMtMS0xLTMzMjAz_5393f314-a9c0-469b-ab62-7c395a615449">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzEyLTUtMS0xLTMzMjAz_0fd3b24b-cb5c-4dcf-bb13-4e8da4a5ce67">1,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzE0LTEtMS0xLTMzMjAz_7d59db53-a5b7-4ad3-822b-a9cc1ddaa7fa">100,899</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzE0LTMtMS0xLTMzMjAz_a86a0adf-35c0-4b86-98cb-c2a93d2c14ff">87,388</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzE0LTUtMS0xLTMzMjAz_78aba307-5235-4f78-980b-4f5b7e8c8b39">204,380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of XERMELO</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" name="lxrx:GainOnSaleOfNonFinancialAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzE2LTEtMS0xLTMzMjAz_29624906-d38c-4f2d-b088-4c50ae946472">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="-3" name="lxrx:GainOnSaleOfNonFinancialAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzE2LTMtMS0xLTMzMjAz_dbd426a8-c799-4e65-9cb3-0b7c82d0aa77">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-3" name="us-gaap:GainLossOnSaleOfProvedProperty" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzE2LTUtMS0xLTMzMjAz_6318db77-247d-4318-b10d-eb4f8a7072b0">132,585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzE3LTEtMS0xLTMzMjAz_f5f8d9bb-5e9a-4d17-936d-ef6b3678c900">100,760</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzE3LTMtMS0xLTMzMjAz_4aadfe98-7ded-443f-be18-07f3f776b5f2">87,090</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzE3LTUtMS0xLTMzMjAz_5dc77a7d-a163-4589-8977-f8c1cf54d30a">47,800</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on debt extinguishments, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzIwLTEtMS0xLTMzMjAz_b44b8a3d-5a83-4963-9681-3ac8ee688c81">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzIwLTMtMS0xLTMzMjAz_9ba2b3c9-8bff-4776-9a1b-4d6c98ee73dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzIwLTUtMS0xLTMzMjAz_4e2e0cb9-93d1-4992-af8e-8a0f2c8fd876">1,003</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzIxLTEtMS0xLTMzMjAz_df845922-e024-4389-9b2e-46bcd834c11c">2,780</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzIxLTMtMS0xLTMzMjAz_74948de9-efc9-45a2-b843-d6289d9f4a9c">802</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzIxLTUtMS0xLTMzMjAz_095f42f4-bb8e-4338-a2c3-e71095e70358">14,544</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzIyLTEtMS0xLTMzMjAz_4a575f2e-b725-4525-8521-c56fc63b7fa4">1,596</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzIyLTMtMS0xLTMzMjAz_0cfcc080-d176-48f9-b34a-360947ef6db9">134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzIyLTUtMS0xLTMzMjAz_8c2356fc-ff97-4b73-8158-fbd167352ada">2,767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzI1LTEtMS0xLTMzMjAz_181bb79d-8c2e-4c9b-a0b0-d6590c32dc62">101,944</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzI1LTMtMS0xLTMzMjAz_444e4420-d5d2-43f3-9e7c-65410142aceb">87,758</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzI1LTUtMS0xLTMzMjAz_258a3d81-1248-4b46-b727-916835a3b10b">58,574</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share, basic and diluted</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzI2LTEtMS0xLTMzMjAz_91269c32-a4e3-42a1-8051-c4bfb352b355">0.62</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzI2LTMtMS0xLTMzMjAz_2b8b52b6-91aa-4cb9-bdbe-332b98ad1289">0.60</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzI2LTUtMS0xLTMzMjAz_f2a1b3dc-1a9e-4a76-901f-d7fae3e99b5b">0.53</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in computing net loss per common share, basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzI4LTEtMS0xLTMzMjAz_978584a9-79ea-4b3a-8b7d-23a9f5a1379e">165,733</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzI4LTMtMS0xLTMzMjAz_9d7031b3-5fd8-4ab5-93ca-f872211df33d">145,652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzI4LTUtMS0xLTMzMjAz_1f9e95af-ad05-4ade-b2bc-96158490f607">110,841</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzMyLTEtMS0xLTMzMjAz_8b3c674d-2890-47f8-8795-73733a8391ba">418</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzMyLTMtMS0xLTMzMjAz_86b05dbf-a64e-4fe6-ad57-f547aed16077">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzMyLTUtMS0xLTMzMjAz_2d7753f2-c789-4ea0-b656-8be740454e23">90</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzMzLTEtMS0xLTMzMjAz_8a2a436f-00d9-4968-a10e-7750756fbcb7">102,362</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzMzLTMtMS0xLTMzMjAz_1e7aa44d-c337-4c5c-9e34-ac799409e984">87,762</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzMzLTUtMS0xLTMzMjAz_bb79d626-89d6-4ae5-b7ed-c4b10126a6bb">58,664</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-4</span></div></div></div><div id="i122d3ae3d73245b585bd7f040afd795c_139"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lexicon Pharmaceuticals, Inc.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Stockholders&#8217; Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.444%"><tr><td style="width:1.0%"></td><td style="width:32.000%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.498%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.140%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.498%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.978%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.498%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.514%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.498%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.330%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.498%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.162%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.498%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.285%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Paid-In</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Comprehensive</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Par Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gain (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i26b899de75ec4971bee2701c59fba66c_I20191231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzI1LTEtMS0xLTMzMjAz_13610d78-a1f3-4880-adfb-b9dcd18826df">106,679</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26b899de75ec4971bee2701c59fba66c_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzI1LTMtMS0xLTMzMjAz_4ae32ec8-0c6d-4275-9f09-28144ff76c26">106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25c577e3042140158482c3aaff32919b_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzI1LTUtMS0xLTMzMjAz_33d1073f-3e2f-4093-b039-96a6fe6b703f">1,462,172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d199e0bcee94bea905035d961fbf255_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzI1LTctMS0xLTMzMjAz_a0acb733-4723-4bc3-b32a-25c78569dbd3">1,341,444</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0476085741da4ed6ae45811b14d11523_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzI1LTktMS0xLTMzMjAz_e159e96e-efa7-4432-a126-15c061517157">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45c9e62c4e06465f8dea40fec66356eb_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzI1LTExLTEtMS0zMzIwMw_9845805a-9bd7-4fbb-9719-8e770a24e9fe">3,817</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9edf2464575242e584cd5272e2783ba2_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzI1LTEzLTEtMS0zMzIwMw_d444a61a-7305-41c2-a957-afd6d2b09a4b">117,101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica463ea57f7c4e77aece9c9b75812753_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzI3LTMtMS0xLTMzMjAz_841fc3fd-f736-449d-9228-848ebff69d4e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e407eae82ed45778d1645f5a4b283c9_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzI3LTUtMS0xLTMzMjAz_03d61324-f8af-4f05-8e69-c8668d237780">13,274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb1c532e55244fa7aaed402560483d25_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzI3LTctMS0xLTMzMjAz_dde5caaa-1287-4b10-9e5e-6009eba229b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08c5d241fccc478597d48a4e079af792_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzI3LTktMS0xLTMzMjAz_2d35d5cf-5e42-4bb7-ae49-3ae65de8ca6a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f65a415e8d8463d8ca0eb8a49eab0a1_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzI3LTExLTEtMS0zMzIwMw_5dd96bd5-db1b-4521-9e22-1d3641d843cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzI3LTEzLTEtMS0zMzIwMw_8756fa4c-34a0-44b9-8592-bfa3a6b3741d">13,274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under an Open Market Sale Agreement, net of issuance fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ica463ea57f7c4e77aece9c9b75812753_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzI5LTEtMS0xLTMzMjAz_b9042cde-38a8-4f06-8abf-07799ac96c54">3,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica463ea57f7c4e77aece9c9b75812753_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzI5LTMtMS0xLTMzMjAz_458862b5-30ca-4781-88b8-300160580ad7">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e407eae82ed45778d1645f5a4b283c9_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzI5LTUtMS0xLTMzMjAz_72d13295-6797-44a0-9ed1-9743967441c4">6,959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb1c532e55244fa7aaed402560483d25_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzI5LTctMS0xLTMzMjAz_f924cb6f-7060-4ea3-8d03-1cb846b5b7f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08c5d241fccc478597d48a4e079af792_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzI5LTktMS0xLTMzMjAz_25b367e0-1b6f-44d0-b671-b787f5f3c977">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f65a415e8d8463d8ca0eb8a49eab0a1_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzI5LTExLTEtMS0zMzIwMw_9f4257c8-303b-4bc9-96c1-4ce3bce17888">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzI5LTEzLTEtMS0zMzIwMw_ffc5910d-7693-4635-9c55-609053c1b049">6,963</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock upon private placement, net of issuance fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ica463ea57f7c4e77aece9c9b75812753_D20200101-20201231" decimals="-3" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzMwLTEtMS0xLTMzMjAz_a75e67e3-bc28-4f32-84d4-f53ea27f7696">20,313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica463ea57f7c4e77aece9c9b75812753_D20200101-20201231" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzMwLTMtMS0xLTMzMjAz_610f3a59-23b9-4ce3-a1d6-b0ace6f00624">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e407eae82ed45778d1645f5a4b283c9_D20200101-20201231" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzMwLTUtMS0xLTMzMjAz_1bfcfc82-672c-48ac-8b31-d7005b3806f9">62,987</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb1c532e55244fa7aaed402560483d25_D20200101-20201231" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzMwLTctMS0xLTMzMjAz_6e231fa1-d0f3-46d4-a9cc-9a621c165a5b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08c5d241fccc478597d48a4e079af792_D20200101-20201231" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzMwLTktMS0xLTMzMjAz_569b6aac-779b-4097-aeec-d647f4050786">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f65a415e8d8463d8ca0eb8a49eab0a1_D20200101-20201231" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzMwLTExLTEtMS0zMzIwMw_e84d8a38-1fad-42cd-8571-1e368f0f1d93">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzMwLTEzLTEtMS0zMzIwMw_1f85ed56-5956-4ae3-9d7c-b87243218a67">63,007</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock in settlement of convertible notes, net of issuance fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ica463ea57f7c4e77aece9c9b75812753_D20200101-20201231" decimals="-3" name="us-gaap:ConversionOfStockSharesIssued1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzMxLTEtMS0xLTMzMjAz_c5a5cbfe-3d3a-4e71-a75f-ceecb3248e6f">10,369</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica463ea57f7c4e77aece9c9b75812753_D20200101-20201231" decimals="-3" name="us-gaap:ConversionOfStockAmountIssued1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzMxLTMtMS0xLTMzMjAz_4bd92f4c-7a01-4cf0-8d5d-d78d56963c04">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e407eae82ed45778d1645f5a4b283c9_D20200101-20201231" decimals="-3" name="us-gaap:ConversionOfStockAmountIssued1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzMxLTUtMS0xLTMzMjAz_9e397a3f-cb11-4cc3-9a0f-fb4251465fde">15,704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb1c532e55244fa7aaed402560483d25_D20200101-20201231" decimals="-3" name="us-gaap:ConversionOfStockAmountIssued1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzMxLTctMS0xLTMzMjAz_d25442a9-5f7d-4979-b300-116bfde1c403">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08c5d241fccc478597d48a4e079af792_D20200101-20201231" decimals="-3" name="us-gaap:ConversionOfStockAmountIssued1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzMxLTktMS0xLTMzMjAz_a5a97a01-6385-4d20-bc7e-b29bd115ba3b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f65a415e8d8463d8ca0eb8a49eab0a1_D20200101-20201231" decimals="-3" name="us-gaap:ConversionOfStockAmountIssued1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzMxLTExLTEtMS0zMzIwMw_5fd726b3-9126-430a-8da1-c8ebc60f8fde">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-3" name="us-gaap:ConversionOfStockAmountIssued1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzMxLTEzLTEtMS0zMzIwMw_75b23632-eb3d-4b25-b969-da10161c29e7">15,714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under Equity Incentive Plans</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ica463ea57f7c4e77aece9c9b75812753_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzMyLTEtMS0xLTMzMjAz_bdaafe60-7743-4c5f-802c-bf4c81f62442">1,219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica463ea57f7c4e77aece9c9b75812753_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzMyLTMtMS0xLTMzMjAz_97209685-29d1-407d-87d8-ac2f366a91fc">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e407eae82ed45778d1645f5a4b283c9_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzMyLTUtMS0xLTMzMjAz_7eceae64-037f-44a7-aac7-13adf5a1ca13">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb1c532e55244fa7aaed402560483d25_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzMyLTctMS0xLTMzMjAz_bfcf1bff-f2a6-4657-832e-9b239eb100a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08c5d241fccc478597d48a4e079af792_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzMyLTktMS0xLTMzMjAz_74520e15-92c9-4b92-b28c-7cbe005979be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f65a415e8d8463d8ca0eb8a49eab0a1_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzMyLTExLTEtMS0zMzIwMw_caa7299a-762b-4ee5-b12b-08ec3f8436ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzMyLTEzLTEtMS0zMzIwMw_6bfbbd9b-c28c-4aba-a420-91e964cee5ec">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica463ea57f7c4e77aece9c9b75812753_D20200101-20201231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzM1LTMtMS0xLTMzMjAz_efc9207f-6281-45be-a14f-fae93c1cb2eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e407eae82ed45778d1645f5a4b283c9_D20200101-20201231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzM1LTUtMS0xLTMzMjAz_d0f1cc46-07c8-48ad-ac7e-4935a5438a08">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb1c532e55244fa7aaed402560483d25_D20200101-20201231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzM1LTctMS0xLTMzMjAz_730c099a-1c26-4796-bc4c-6975fb6a66e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08c5d241fccc478597d48a4e079af792_D20200101-20201231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzM1LTktMS0xLTMzMjAz_65c9abb0-8cce-413e-b05e-496e027179ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f65a415e8d8463d8ca0eb8a49eab0a1_D20200101-20201231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzM1LTExLTEtMS0zMzIwMw_ef862e1f-3062-4650-b9fb-ec527fa24f51">1,026</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzM1LTEzLTEtMS0zMzIwMw_698ec997-6cc5-45b1-8b37-4805a19ee854">1,026</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica463ea57f7c4e77aece9c9b75812753_D20200101-20201231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzM2LTMtMS0xLTMzMjAz_657284d5-3bf4-4976-ad0c-a0be456629cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e407eae82ed45778d1645f5a4b283c9_D20200101-20201231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzM2LTUtMS0xLTMzMjAz_d8455f85-3494-4d79-839d-be4b32ed03fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb1c532e55244fa7aaed402560483d25_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzM2LTctMS0xLTMzMjAz_29c5e71d-a168-4205-adc8-e07218bc5618">58,574</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08c5d241fccc478597d48a4e079af792_D20200101-20201231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzM2LTktMS0xLTMzMjAz_33994f92-2fd9-41bf-8d30-2adcca42835a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f65a415e8d8463d8ca0eb8a49eab0a1_D20200101-20201231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzM2LTExLTEtMS0zMzIwMw_c9bd8799-1bca-4bb9-879a-bfd9cdc15ec5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzM2LTEzLTEtMS0zMzIwMw_6aa755f6-66e2-44a2-bef3-cfafcd66a9e6">58,574</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica463ea57f7c4e77aece9c9b75812753_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzM3LTMtMS0xLTMzMjAz_f89a591b-7e10-442d-bef7-1b42423c8ba1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e407eae82ed45778d1645f5a4b283c9_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzM3LTUtMS0xLTMzMjAz_9177560b-3f60-40e5-acd3-34e7a35112bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb1c532e55244fa7aaed402560483d25_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzM3LTctMS0xLTMzMjAz_38e3097f-cc7c-4d02-9853-56eee4d6c303">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i08c5d241fccc478597d48a4e079af792_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzM3LTktMS0xLTMzMjAz_733153d5-d505-49c0-b40d-af770ad61fe4">90</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f65a415e8d8463d8ca0eb8a49eab0a1_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzM3LTExLTEtMS0zMzIwMw_423b9502-6957-4ece-8a68-baadb4fc327c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzM3LTEzLTEtMS0zMzIwMw_667f03b5-725f-4296-a600-905e3e57b03a">90</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic9c28386ac3f4264b971d6c2d1d20518_I20201231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzM5LTEtMS0xLTMzMjAz_2bd533e2-6664-4eb8-8135-5facf8e0cbb9">142,289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9c28386ac3f4264b971d6c2d1d20518_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzM5LTMtMS0xLTMzMjAz_095177ba-4f5a-4581-9614-7da6739917f6">142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie40de31d8a53466dbe16c3026141f0bf_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzM5LTUtMS0xLTMzMjAz_6aa76457-bb75-4c52-9503-e2e7102326a1">1,561,096</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i127c83dde28a497289a43680bd2d274e_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzM5LTctMS0xLTMzMjAz_858d53de-ef88-46f4-9723-6c4171585193">1,400,018</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i811c34b23fae41e08987de7c90d2a75f_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzM5LTktMS0xLTMzMjAz_02dccbe5-e553-4b82-ac89-edd9a867efeb">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9a9aae42bd8341688cde38a2a191ea99_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzM5LTExLTEtMS0zMzIwMw_00434b29-4509-431c-9762-0d68bd5ea5e1">4,843</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief9b221acfd5465cb83500067a09fff2_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzM5LTEzLTEtMS0zMzIwMw_09ab450b-0b52-4024-97f6-1b5fa2185115">156,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99a04acc720b46cabd4ee3c5a2dd0674_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQwLTMtMS0xLTMzMjAz_e7cf471f-6869-409b-8888-7889f6bdefc7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib42da41ca5a14b988815a9effcc674cd_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQwLTUtMS0xLTMzMjAz_b9a23847-a21d-473e-a04c-fe5bcdfcc193">10,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d1bda838f674f4eaaa6f31e5ff61ec4_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQwLTctMS0xLTMzMjAz_e67e3549-510c-44a8-8ba0-c20f9e494433">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1922c7bd454f43a4af07205eb1f1b25a_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQwLTktMS0xLTMzMjAz_df4eb40a-23f2-4f01-91d0-d0c81a674c89">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbbc5e8a454e4cb5bff0e55c593bf0bd_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQwLTExLTEtMS0zMzIwMw_9f0e9464-6706-44cb-9e41-08df20892973">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQwLTEzLTEtMS0zMzIwMw_3f49aab9-39d7-4ef8-a778-f03cfb733531">10,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under an Open Market Sale Agreement, net of issuance fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i99a04acc720b46cabd4ee3c5a2dd0674_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQxLTEtMS0xLTMzMjAz_68ab35fe-cea9-40bb-b223-1f2d89309640">6,177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99a04acc720b46cabd4ee3c5a2dd0674_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQxLTMtMS0xLTMzMjAz_87ad03fb-f927-47a4-af5e-0ecb844385bf">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib42da41ca5a14b988815a9effcc674cd_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQxLTUtMS0xLTMzMjAz_d7532a6a-839c-4729-9bee-1a4a9b71f2e4">35,485</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d1bda838f674f4eaaa6f31e5ff61ec4_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQxLTctMS0xLTMzMjAz_c4d427ff-c598-4975-b7e0-6e036388b165">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1922c7bd454f43a4af07205eb1f1b25a_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQxLTktMS0xLTMzMjAz_7e32113d-d97a-4b22-bd00-4dde009f6444">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbbc5e8a454e4cb5bff0e55c593bf0bd_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQxLTExLTEtMS0zMzIwMw_12bd5394-ad11-4a33-aeb1-5e128bbe2265">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQxLTEzLTEtMS0zMzIwMw_bd9a21b3-a952-4ebd-a57b-204f9de0f427">35,491</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under Equity Incentive Plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i99a04acc720b46cabd4ee3c5a2dd0674_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQyLTEtMS0xLTMzMjAz_276006ad-51ac-4aac-9840-b23ea2c3e177">1,616</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99a04acc720b46cabd4ee3c5a2dd0674_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQyLTMtMS0xLTMzMjAz_dddcc4ed-82fe-487c-b73a-6ca6a062ef3c">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib42da41ca5a14b988815a9effcc674cd_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQyLTUtMS0xLTMzMjAz_9735978d-6551-41cc-9ef1-9f210502284c">1,591</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d1bda838f674f4eaaa6f31e5ff61ec4_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQyLTctMS0xLTMzMjAz_c309f5bf-a58c-43bd-9b9e-24c564a99653">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1922c7bd454f43a4af07205eb1f1b25a_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQyLTktMS0xLTMzMjAz_dee276d5-a989-4421-853b-ebb10c3d056c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbbc5e8a454e4cb5bff0e55c593bf0bd_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQyLTExLTEtMS0zMzIwMw_7f9c2c53-8a87-4885-9cd6-9c1bae1b6e9b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQyLTEzLTEtMS0zMzIwMw_c3030faa-23ce-41c6-b09d-971da40320cf">1,593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99a04acc720b46cabd4ee3c5a2dd0674_D20210101-20211231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQzLTMtMS0xLTMzMjAz_2b63c9a9-5daa-40bc-b307-c60c3a943309">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib42da41ca5a14b988815a9effcc674cd_D20210101-20211231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQzLTUtMS0xLTMzMjAz_9f187c0e-bc84-4ea5-9cf8-fd437a1198ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d1bda838f674f4eaaa6f31e5ff61ec4_D20210101-20211231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQzLTctMS0xLTMzMjAz_4fb1a803-3170-4815-82b8-a871cca06f02">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1922c7bd454f43a4af07205eb1f1b25a_D20210101-20211231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQzLTktMS0xLTMzMjAz_7027817c-3c8e-4c71-bba7-3cc843bbde63">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idbbc5e8a454e4cb5bff0e55c593bf0bd_D20210101-20211231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQzLTExLTEtMS0zMzIwMw_34bff38b-8900-4d5e-8a23-b72f4f4dd701">2,675</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQzLTEzLTEtMS0zMzIwMw_f3d0e58c-b02a-488a-9c4e-6e63a3cae920">2,675</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99a04acc720b46cabd4ee3c5a2dd0674_D20210101-20211231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ0LTMtMS0xLTMzMjAz_33d984ea-9a81-4468-8b0b-26cc5c333f74">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib42da41ca5a14b988815a9effcc674cd_D20210101-20211231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ0LTUtMS0xLTMzMjAz_296b010d-8098-4816-bcc7-56a8e4980611">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d1bda838f674f4eaaa6f31e5ff61ec4_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ0LTctMS0xLTMzMjAz_117b8b0c-2d46-4223-bbb8-91c71c4331b7">87,758</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1922c7bd454f43a4af07205eb1f1b25a_D20210101-20211231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ0LTktMS0xLTMzMjAz_2c26ca00-9690-41e6-b699-ace78e0dee99">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbbc5e8a454e4cb5bff0e55c593bf0bd_D20210101-20211231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ0LTExLTEtMS0zMzIwMw_3d173a4a-ba55-411c-8247-425d6fce72e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ0LTEzLTEtMS0zMzIwMw_def718d5-e942-4fb4-8185-cc5aaa3ceec1">87,758</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99a04acc720b46cabd4ee3c5a2dd0674_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ1LTMtMS0xLTMzMjAz_5101a6ee-c8c2-47d2-887e-6608d13adef7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib42da41ca5a14b988815a9effcc674cd_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ1LTUtMS0xLTMzMjAz_11af6875-ea57-4ecd-8b0a-8739ed6757d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d1bda838f674f4eaaa6f31e5ff61ec4_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ1LTctMS0xLTMzMjAz_6a7d8c03-b6d3-492e-9cad-3459ad47faf0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1922c7bd454f43a4af07205eb1f1b25a_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ1LTktMS0xLTMzMjAz_6731f3fd-c971-4720-b78e-d4b4f5f6e8c2">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbbc5e8a454e4cb5bff0e55c593bf0bd_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ1LTExLTEtMS0zMzIwMw_9402b2b0-3d57-4e5c-91bb-26f6b955dfcf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ1LTEzLTEtMS0zMzIwMw_087c47c9-b60f-4539-84d3-771b0d19851e">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i940ed9833e654f3e88d67e4c166a14f2_I20211231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ2LTEtMS0xLTMzMjAz_444b76c0-21de-4255-bc1b-8f52d70df885">150,082</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i940ed9833e654f3e88d67e4c166a14f2_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ2LTMtMS0xLTMzMjAz_179ef32f-757c-44e0-ba87-1d29cfc144f4">150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4acd250f6fd84660b1b2a85f4f5e4a20_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ2LTUtMS0xLTMzMjAz_54715ad0-016b-4895-8205-787095e77832">1,608,749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i325272f405d94467a8e21c4ffc1fe333_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ2LTctMS0xLTMzMjAz_d4e13a9c-0828-45e6-97bc-72a9b8631254">1,487,776</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9a0a6b3dd9e245ab82da25e46d931740_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ2LTktMS0xLTMzMjAz_b669c9ab-12db-4e9d-b54c-5a8e2ce66488">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d9d5924ae0a4ce3964a5ae029dd6486_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ2LTExLTEtMS0zMzIwMw_c9a055f8-e308-4878-8124-2b6b39820a1e">7,518</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ2LTEzLTEtMS0zMzIwMw_a11d6b36-6133-4624-a221-aa63fe18888a">113,595</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1198e2c5aacd45858d7c4371b727d5b2_D20220101-20221231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ3LTMtMS0xLTM5NzA4_d5823c2a-3aba-48b3-8545-83fd8fcc3e96">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56c0cc327a1d4ed19387c28bde2e3ffb_D20220101-20221231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ3LTUtMS0xLTM5NzA4_e36bc658-7f24-4ec8-b233-e9ae20ba5327">11,520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd14ef30697244ac8b81d3b8376f5d6b_D20220101-20221231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ3LTctMS0xLTM5NzA4_548c2dc8-c7aa-4bc2-973f-b5013868f930">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9a66cc8a08d4b5d95fc1a3de8f017a0_D20220101-20221231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ3LTktMS0xLTM5NzA4_24883f3a-e20d-4016-9de2-03abf2682d7f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4961ca3cf71d48c3a2dc88cfab3d52f8_D20220101-20221231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ3LTExLTEtMS0zOTcwOA_d6a5775a-0351-453a-98cc-a754109b50d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ3LTEzLTEtMS0zOTcwOA_0a2c8871-8b0c-47af-96be-046f3542c2a1">11,520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under Equity Incentive Plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1198e2c5aacd45858d7c4371b727d5b2_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ4LTEtMS0xLTM5NzE4_79cd1f94-5a68-4be3-8cdc-562d307cb00c">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1198e2c5aacd45858d7c4371b727d5b2_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ4LTMtMS0xLTM5NzE4_1910794c-256e-4e9a-9232-eb3342676b2c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56c0cc327a1d4ed19387c28bde2e3ffb_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ4LTUtMS0xLTM5NzE4_96564e4b-f329-466b-a361-541db15aebea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd14ef30697244ac8b81d3b8376f5d6b_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ4LTctMS0xLTM5NzE4_764bbc64-19bf-4d7e-a313-4c2e52a25916">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9a66cc8a08d4b5d95fc1a3de8f017a0_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ4LTktMS0xLTM5NzE4_83a78deb-9191-4ba7-a29d-efbd00e0af7e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4961ca3cf71d48c3a2dc88cfab3d52f8_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ4LTExLTEtMS0zOTcxOA_39107c73-ae97-4b1a-8235-6d0e2df12558">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ4LTEzLTEtMS0zOTcxOA_1bab1241-760e-4626-b856-7d305936c09d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock, net of issuance fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1198e2c5aacd45858d7c4371b727d5b2_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ5LTEtMS0xLTM5NzEw_be19456e-f0f2-4d87-bb29-3caa85f79a28">39,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1198e2c5aacd45858d7c4371b727d5b2_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ5LTMtMS0xLTM5NzEw_9620cebf-b7c4-4163-8fc9-1badb5856339">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56c0cc327a1d4ed19387c28bde2e3ffb_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ5LTUtMS0xLTM5NzEw_fc9f370d-0d11-4300-904b-84c6be3d9a7f">94,166</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd14ef30697244ac8b81d3b8376f5d6b_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ5LTctMS0xLTM5NzEw_3142d6c1-2901-40a9-9e0d-576f3a3bd8e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9a66cc8a08d4b5d95fc1a3de8f017a0_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ5LTktMS0xLTM5NzEw_3bdcd14a-2c7d-4d7e-9c03-6ccf0f5f4f64">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4961ca3cf71d48c3a2dc88cfab3d52f8_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ5LTExLTEtMS0zOTcxMA_05ad6785-3be1-46d0-a273-f58ef971ed5e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ5LTEzLTEtMS0zOTcxMA_07d35f07-e47d-4518-9253-7353d64d9397">94,205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of equity classified warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1198e2c5aacd45858d7c4371b727d5b2_D20220101-20221231" decimals="-3" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzUwLTMtMS0xLTM5NzE2_e2dcad44-0a41-44eb-b677-200bd9a52a09">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56c0cc327a1d4ed19387c28bde2e3ffb_D20220101-20221231" decimals="-3" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzUwLTUtMS0xLTM5NzE2_40a7f883-0d67-47bb-9f75-908230acf6c6">1,030</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd14ef30697244ac8b81d3b8376f5d6b_D20220101-20221231" decimals="-3" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzUwLTctMS0xLTM5NzE2_675b2b87-5d03-4745-9caa-bf7ec87c71bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9a66cc8a08d4b5d95fc1a3de8f017a0_D20220101-20221231" decimals="-3" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzUwLTktMS0xLTM5NzE2_ee96264a-da11-405e-b287-ed64a7a16648">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4961ca3cf71d48c3a2dc88cfab3d52f8_D20220101-20221231" decimals="-3" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzUwLTExLTEtMS0zOTcxNg_dbe522c4-58b2-4216-b1c2-f1432df15ace">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzUwLTEzLTEtMS0zOTcxNg_51d48a3b-196f-4649-b76e-ccc9b00322ac">1,030</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of treasury stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1198e2c5aacd45858d7c4371b727d5b2_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzUxLTEtMS0xLTM5NzE2_6642bbe3-8b27-411e-8fe9-69aaa3d5d5c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1198e2c5aacd45858d7c4371b727d5b2_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzUxLTMtMS0xLTM5NzE2_502b5c76-43cc-4cc4-bd44-18921ec9fd16">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56c0cc327a1d4ed19387c28bde2e3ffb_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzUxLTUtMS0xLTM5NzE2_cd2b0ec8-8d1a-425a-b5fd-3aa89fdbf6ff">6,321</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd14ef30697244ac8b81d3b8376f5d6b_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzUxLTctMS0xLTM5NzE2_5877b19d-bbd5-4edf-ac4d-fe69f6a17596">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9a66cc8a08d4b5d95fc1a3de8f017a0_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzUxLTktMS0xLTM5NzE2_f8076bf9-3f15-4ad4-8f0e-8c79dacee8fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4961ca3cf71d48c3a2dc88cfab3d52f8_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzUxLTExLTEtMS0zOTcxNg_4dd5d289-cdf1-4141-89c6-499f502718ef">6,321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzUxLTEzLTEtMS0zOTcxNg_12787b36-9209-42b6-92e1-603c3f0418ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1198e2c5aacd45858d7c4371b727d5b2_D20220101-20221231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzUyLTMtMS0xLTM5NzEy_b24bd6b2-82e9-4fb5-9ad1-22e020e771f5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56c0cc327a1d4ed19387c28bde2e3ffb_D20220101-20221231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzUyLTUtMS0xLTM5NzEy_b3f80840-0553-4873-aad2-5d646765b27d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd14ef30697244ac8b81d3b8376f5d6b_D20220101-20221231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzUyLTctMS0xLTM5NzEy_6d5e2bef-6226-4d93-a046-b1c2e974ba48">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9a66cc8a08d4b5d95fc1a3de8f017a0_D20220101-20221231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzUyLTktMS0xLTM5NzEy_5fe245d2-ebb4-4da6-9895-fa145d4019a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4961ca3cf71d48c3a2dc88cfab3d52f8_D20220101-20221231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzUyLTExLTEtMS0zOTcxMg_737c0e84-3c71-456f-835d-1bded4355e5f">864</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzUyLTEzLTEtMS0zOTcxMg_175b06d1-1c71-46e6-a98b-8d92531a5f0e">864</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1198e2c5aacd45858d7c4371b727d5b2_D20220101-20221231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzUzLTMtMS0xLTM5NzEy_31d5d7aa-f537-4aa8-a186-39053689608f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56c0cc327a1d4ed19387c28bde2e3ffb_D20220101-20221231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzUzLTUtMS0xLTM5NzEy_0f102ad9-c5e0-47bf-a53a-114081c45833">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd14ef30697244ac8b81d3b8376f5d6b_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzUzLTctMS0xLTM5NzEy_a1325d65-42a2-4306-9221-9f03588cb0b6">101,944</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9a66cc8a08d4b5d95fc1a3de8f017a0_D20220101-20221231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzUzLTktMS0xLTM5NzEy_edb59a51-ec64-4e51-8cd2-3c165e64e632">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4961ca3cf71d48c3a2dc88cfab3d52f8_D20220101-20221231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzUzLTExLTEtMS0zOTcxMg_6f33566e-c57a-412f-8881-e82e4dba6e39">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzUzLTEzLTEtMS0zOTcxMg_f1873106-934e-43e7-b098-15c541bc9970">101,944</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1198e2c5aacd45858d7c4371b727d5b2_D20220101-20221231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzU0LTMtMS0xLTM5NzEy_510a9d41-29f1-4261-bb5d-e1651c2d5ae1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56c0cc327a1d4ed19387c28bde2e3ffb_D20220101-20221231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzU0LTUtMS0xLTM5NzEy_40b3f02f-ebda-470c-aeb5-86094cbe24e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd14ef30697244ac8b81d3b8376f5d6b_D20220101-20221231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzU0LTctMS0xLTM5NzEy_a303d11f-2e25-4957-8a4a-e18d9a00d4e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9a66cc8a08d4b5d95fc1a3de8f017a0_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzU0LTktMS0xLTM5NzEy_2f8cd24c-59c5-4e82-a90c-80bf8e70734b">418</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4961ca3cf71d48c3a2dc88cfab3d52f8_D20220101-20221231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzU0LTExLTEtMS0zOTcxMg_0edd965c-0e49-491f-95e2-78373b853940">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzU0LTEzLTEtMS0zOTcxMg_8b52d143-7670-4bcc-9257-3202bf8518b2">418</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i55a81403781f47ae9d02222240bdb36d_I20221231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzU1LTEtMS0xLTM5NzE0_e3c7fe0d-0ca8-458c-953e-91e1eabb5ca9">189,214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55a81403781f47ae9d02222240bdb36d_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzU1LTMtMS0xLTM5NzE0_e714cd89-fc32-4528-a197-5faae45187b9">189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f6ebc10d76e49c0bef5f073adb72d4b_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzU1LTUtMS0xLTM5NzE0_6bd20451-ee76-4a34-9488-036fed64e536">1,709,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i959cffadb372413d8e83d72e239e6ded_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzU1LTctMS0xLTM5NzE0_0d28fc3f-1306-43ad-b5d0-a2750c82dfd9">1,589,720</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2fcd93af513045eba562f9ff41a202ac_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzU1LTktMS0xLTM5NzE0_17b39ad8-672b-4389-a9d8-a516d8419241">428</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib1e8bc9bcf1a4a439d70f50e536be574_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzU1LTExLTEtMS0zOTcxNA_74c56366-77c1-43dd-b7ff-ecf075637955">2,061</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzU1LTEzLTEtMS0zOTcxNA_d1540253-48ce-485b-964f-843dd787e15c">117,124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-5</span></div></div></div><div id="i122d3ae3d73245b585bd7f040afd795c_142"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lexicon Pharmaceuticals, Inc.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands) </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.594%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.594%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzMtMS0xLTEtMzMyMDM_ec0a8c0b-9eef-4918-9eff-f05b6add70d1">101,944</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzMtMy0xLTEtMzMyMDM_5fb61578-349b-4168-8600-0d8fe529a382">87,758</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzMtNS0xLTEtMzMyMDM_59e2013f-02c4-4b6d-81f2-5bfefe8998f6">58,574</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzUtMS0xLTEtMzMyMDM_c5578ce1-74f8-402e-ba6f-4febdd8057fe">427</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzUtMy0xLTEtMzMyMDM_11d1f6d5-bbdb-4405-bb62-31db24ee5c17">292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzUtNS0xLTEtMzMyMDM_841b681d-87ee-4c86-a60b-10798e59ea85">2,934</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzYtMS0xLTEtMzMyMDM_833e7de3-65ac-40b7-a86d-565d0c3877f4">11,520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzYtMy0xLTEtMzMyMDM_df5360cf-1654-492f-b681-963c73761978">10,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzYtNS0xLTEtMzMyMDM_2677e1a4-1eb8-45c6-b1b1-119952913d27">13,274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzctMS0xLTEtMzMyMDM_d4c04083-b1b5-49a1-92ad-f9efa1d13e93">741</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzctMy0xLTEtMzMyMDM_ca9f9ce2-60b8-459c-a4cf-edfb47bdc8c8">54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzctNS0xLTEtMzMyMDM_fa2fb441-7f72-45bb-a5cc-2c87f3ebf191">1,013</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of XERMELO</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" name="lxrx:GainOnSaleOfNonFinancialAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzktMS0xLTEtMzMyMDM_b7312896-5ed3-4264-b7a3-8078eef1c5aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="-3" name="lxrx:GainOnSaleOfNonFinancialAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzktMy0xLTEtMzMyMDM_311098f2-5383-402d-bcf5-4156ac5e6129">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-3" name="lxrx:GainOnSaleOfNonFinancialAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzktNS0xLTEtMzMyMDM_6c3e1dc4-6bc0-440a-a533-407176a5a0e1">132,585</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment loss on building</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" name="us-gaap:ImpairmentOfRealEstate" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzEwLTEtMS0xLTMzMjAz_9591ab1c-d61c-44df-8092-6bf4e7183a07">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="-3" name="us-gaap:ImpairmentOfRealEstate" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzEwLTMtMS0xLTMzMjAz_91a1a945-fc46-4ff8-b68e-1661fe2ca9a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-3" name="us-gaap:ImpairmentOfRealEstate" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzEwLTUtMS0xLTMzMjAz_f5b53255-259f-4dc4-8ad0-77f363d189c0">1,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on debt extinguishments, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzEzLTEtMS0xLTMzMjAz_4f1e0640-52f3-4899-af53-69b7d057c58e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzEzLTMtMS0xLTMzMjAz_dbfc7909-d2b4-4cd8-a77c-560e9bc4bf75">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ExtinguishmentOfDebtGainLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzEzLTUtMS0xLTMzMjAz_d60a0fc5-ed1c-4772-bd02-8ee43d45c741">1,003</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss (gain) on disposal of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:GainLossOnDispositionOfAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzE0LTEtMS0xLTMzMjAz_9333a362-7c3f-4ed4-b434-d8157d720ea6">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:GainLossOnDispositionOfAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzE0LTMtMS0xLTMzMjAz_afab56bf-9996-4ea1-826f-36f16c62b575">49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-3" name="us-gaap:GainLossOnDispositionOfAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzE0LTUtMS0xLTMzMjAz_888baf9a-0b21-4a3f-ba17-9a491179fa48">707</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Increase) decrease in accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzE2LTEtMS0xLTMzMjAz_2679ed4f-688b-485d-997f-4a4198678c6c">14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzE2LTMtMS0xLTMzMjAz_2343c03f-86df-4ceb-92d5-88e0ce79b2ec">381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzE2LTUtMS0xLTMzMjAz_c0d348da-77b3-4652-82b6-f74bf0bb1c14">53,227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzE3LTEtMS0xLTMzMjAz_e3be3928-e6f9-486e-aab7-57f575cf60d8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzE3LTMtMS0xLTMzMjAz_62cd3dcf-e652-41a0-b839-9f10df0a9df3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzE3LTUtMS0xLTMzMjAz_f98c1b8a-ec63-4b7d-a41f-b54ad4cdd589">345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Increase) decrease in prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzE4LTEtMS0xLTMzMjAz_79bae6f2-df7b-434d-83ba-0790cea0faf1">316</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzE4LTMtMS0xLTMzMjAz_4b2641dc-a44a-419a-9462-d02c28ed4cc4">2,885</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzE4LTUtMS0xLTMzMjAz_2094a957-cb93-48de-ba5b-993e800ce0dc">1,948</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzE5LTEtMS0xLTMzMjAz_9d02eee3-c43e-45ae-9fa1-820f3c143c81">656</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzE5LTMtMS0xLTMzMjAz_ddffe301-d97e-4e97-a75d-80a81e6f47eb">661</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzE5LTUtMS0xLTMzMjAz_aa711a8b-e8b2-4fa0-9cac-5b0ac52b92b7">424</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase (decrease) in accounts payable and other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzIwLTEtMS0xLTMzMjAz_99cfcdc2-a708-45e9-8615-b0607187adfa">76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzIwLTMtMS0xLTMzMjAz_13e860f3-4be3-460b-9341-e1825466c424">14,158</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzIwLTUtMS0xLTMzMjAz_892fc4d3-fdf5-4bcd-a843-976acc469693">20,969</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzIyLTEtMS0xLTMzMjAz_b00cb19a-eb8a-49fe-83c7-8706bcfeb6a4">88,851</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzIyLTMtMS0xLTMzMjAz_19fdd8a7-702a-4160-865c-877c72f85749">87,017</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzIyLTUtMS0xLTMzMjAz_ddf34341-ffd8-4633-8f87-628b10117fb7">142,969</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzI0LTEtMS0xLTMzMjAz_a13deab8-788b-49e9-a5bd-84bdd873c5e6">1,326</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzI0LTMtMS0xLTMzMjAz_b8a53f66-2c63-438b-916f-31ee31401f57">1,221</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzI0LTUtMS0xLTMzMjAz_db795a05-1f7f-4fd5-ae0c-851ead558f9d">87</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from XERMELO sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromSaleOfProductiveAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzI1LTEtMS0xLTMzMjAz_c7f60108-6a9e-41ef-b11d-110e97e680b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromSaleOfProductiveAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzI1LTMtMS0xLTMzMjAz_ee3f74a3-8f02-4f8a-9342-97be64653fd5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromSaleOfProductiveAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzI1LTUtMS0xLTMzMjAz_a9626978-bb2a-477e-8c3c-61c28ab46549">160,385</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from disposal of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzI2LTEtMS0xLTMzMjAz_d59ed7a3-134a-4e2d-bbaf-1c6cc722d621">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzI2LTMtMS0xLTMzMjAz_2aa4c879-8535-499f-b943-92faa0a12b36">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromSaleOfBuildings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzI2LTUtMS0xLTMzMjAz_af124a5f-903f-4b3d-bfa9-eee7d5336ab9">11,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzI3LTEtMS0xLTMzMjAz_07103564-6b32-48ad-a24e-f8f8402c54e5">133,949</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzI3LTMtMS0xLTMzMjAz_f8df386c-389e-4aa6-95be-5a4759b45e77">34,261</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzI3LTUtMS0xLTMzMjAz_c8b5dc54-a93c-437c-a8ac-efcec5b7014b">58,555</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities of investments&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzI4LTEtMS0xLTMzMjAz_35b0c3d9-98b3-4cbd-b0cc-a3ac23745f89">64,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzI4LTMtMS0xLTMzMjAz_0f313816-eec6-4126-a5b9-40aa8eafe8ad">37,592</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzI4LTUtMS0xLTMzMjAz_f5c6a315-1c45-434c-a05d-62ad8690c451">268,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzI5LTEtMS0xLTMzMjAz_881ccc1a-c6de-4a76-bb4c-8f1bea9e481e">71,078</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzI5LTMtMS0xLTMzMjAz_01bab126-153f-4190-bd7c-e285c9994e67">2,110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzI5LTUtMS0xLTMzMjAz_3c546691-9b85-46c1-b724-47cc626dad52">380,756</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock, net of fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzMxLTEtMS0xLTMzMjAz_47c1e526-677b-45af-9459-31e53ed0fb5c">94,205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzMxLTMtMS0xLTMzMjAz_2da0dc62-191c-4634-8f28-3e8fdc463e9f">37,084</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzMxLTUtMS0xLTMzMjAz_9463e4f8-3f86-4fe2-9ea8-b448bd9405fb">69,970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzMyLTEtMS0xLTMzMjAz_57e3dc4a-1489-492a-85ea-0630a5bfc958">864</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzMyLTMtMS0xLTMzMjAz_eb508a37-d34a-4daa-bf1e-4006d162775d">2,675</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzMyLTUtMS0xLTMzMjAz_d7845178-070f-43a2-a5fa-618a38280b68">1,026</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds (repayment) of debt borrowings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzM0LTEtMS0xLTMzMjAz_6498653f-0b42-42a3-bd9f-f9584a69b479">48,868</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzM0LTMtMS0xLTMzMjAz_060432c0-edde-4193-a3c9-66e4684ed167">11,700</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzM0LTUtMS0xLTMzMjAz_bf3193e6-8de7-44a0-aff0-0ec48c8607e9">216,580</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzM2LTEtMS0xLTMzMjAz_9e39a87d-9bc8-4c1f-8d65-310394229b7c">142,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzM2LTMtMS0xLTMzMjAz_a1e34ef0-ea2c-4508-801c-f4b928942a37">22,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzM2LTUtMS0xLTMzMjAz_5ee5ab59-5488-4f6e-93e8-6be46db08957">147,636</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (decrease) increase in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzM3LTEtMS0xLTMzMjAz_454eafa9-06fc-4738-b66c-20078b54faa6">17,720</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzM3LTMtMS0xLTMzMjAz_edb62856-8981-4d2d-9983-1cf7a271b01d">62,198</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzM3LTUtMS0xLTMzMjAz_f39cefb8-4e33-43fd-81ec-37c335dd3dcf">90,151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of year&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzM4LTEtMS0xLTMzMjAz_d978472c-6d33-44e9-8143-d0bddcdf1e1c">64,065</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief9b221acfd5465cb83500067a09fff2_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzM4LTMtMS0xLTMzMjAz_1550191a-105c-43b6-9131-817f0d39e370">126,263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9edf2464575242e584cd5272e2783ba2_I20191231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzM4LTUtMS0xLTMzMjAz_8390eb01-a7e2-4cf0-a13e-35b8fd60ea8b">36,112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of year&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzM5LTEtMS0xLTMzMjAz_d531e1da-059b-4890-a284-153c608b9d41">46,345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzM5LTMtMS0xLTMzMjAz_c3d23364-d353-4a84-9111-0b303d4bf023">64,065</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief9b221acfd5465cb83500067a09fff2_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzM5LTUtMS0xLTMzMjAz_d112633a-1bc2-42da-a0de-7743b0958f1a">126,263</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzQyLTEtMS0xLTMzMjAz_e6c284e6-6c67-4050-a659-628baf11a5ba">2,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzQyLTMtMS0xLTMzMjAz_7b88e369-1acf-479a-a914-9b2f3c5effd2">799</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzQyLTUtMS0xLTMzMjAz_009e3924-6b63-4484-8da1-f888ae05a8ca">17,353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosure of noncash investing and financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzQ4LTEtMS0xLTMzMjAz_5d2f8503-c88e-4fd1-b158-5e4b8c84f9e5">5,206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzQ4LTMtMS0xLTMzMjAz_b94488fa-db84-43f7-9cc1-eaedce685a26">1,704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief9b221acfd5465cb83500067a09fff2_I20201231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzQ4LTUtMS0xLTMzMjAz_c5fd7156-c691-4826-b5c9-0601252af93d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of equity classified warrants</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="0" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzQ5LTEtMS0xLTM5NzIw_22fb7e5c-ecb5-49df-85a6-faa2a9213992">1,030</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="0" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzQ5LTMtMS0xLTM5NzIy_475d2106-0d1d-4e9b-8b48-032ce136d4bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="0" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzQ5LTUtMS0xLTM5NzI0_915575b3-f6ff-49c2-8923-e7fd76923492">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of treasury stock</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="0" name="us-gaap:TreasuryStockCarryingBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzUwLTEtMS0xLTM5NzIw_e8c88eaf-a220-4cd0-90f6-2f6897f563af">6,321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzUwLTMtMS0xLTM5NzIy_b7adc09c-a5f6-4475-8575-3b16ae4ca312">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzUwLTUtMS0xLTM5NzI0_de9acce8-5c51-497c-8fb1-11947351a7cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of exit fee liability related to debt borrowings</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="0" name="us-gaap:BusinessExitCosts1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzUxLTEtMS0xLTM5NzIw_3d9ea378-597d-43e9-8ddf-aad887584e5c">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="0" name="us-gaap:BusinessExitCosts1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzUxLTMtMS0xLTM5NzIy_7100f97b-24cd-490e-babf-518a4bc0bc14">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="0" name="us-gaap:BusinessExitCosts1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzUxLTUtMS0xLTM5NzI0_67ff4de2-51f4-4d9f-9b66-e441da7b07a2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities assumed by TerSera from the XERMELO sale</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzQ5LTEtMS0xLTMzMjAz_a7bf0272-6af5-49b5-88eb-c9450a33364b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzQ5LTMtMS0xLTMzMjAz_1c207315-b78f-4fe0-b8b0-81702e0725e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief9b221acfd5465cb83500067a09fff2_I20201231" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzQ5LTUtMS0xLTMzMjAz_66550881-1b49-400b-a01f-1b215d590a93">3,437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock issued in satisfaction of convertible debt exchanges</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzUwLTEtMS0xLTMzMjAz_e317e693-3e6f-4251-a197-336f5534a4c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzUwLTMtMS0xLTMzMjAz_fa58c453-4241-4fb3-b556-5bf81fefac07">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzUwLTUtMS0xLTMzMjAz_d7f3b008-3765-4e0c-96c1-919aa8a5c9ad">15,714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-6</span></div></div></div><div id="i122d3ae3d73245b585bd7f040afd795c_145"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lexicon Pharmaceuticals, Inc.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2022 </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i122d3ae3d73245b585bd7f040afd795c_148"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDgvZnJhZzpjZDNkNmMyMmIwNzc0M2U1YmQ2ZDgwNWQ4ZWRjZGZhMy90ZXh0cmVnaW9uOmNkM2Q2YzIyYjA3NzQzZTViZDZkODA1ZDhlZGNkZmEzXzE4MDg_5faaeedc-1e22-4b87-acca-008cd1a01c3f" continuedAt="ia22d0dc8ecad4ea58b2c5560556cc8fe" escape="true">Organization and Operations</ix:nonNumeric></span></div><ix:continuation id="ia22d0dc8ecad4ea58b2c5560556cc8fe"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lexicon Pharmaceuticals, Inc. (&#8220;Lexicon&#8221; or the &#8220;Company&#8221;) is a Delaware corporation incorporated on July&#160;7, 1995. Lexicon was organized to discover the functions and pharmaceutical utility of genes and use those gene function discoveries in the discovery and development of pharmaceutical products for the treatment of human disease.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lexicon has financed its operations from inception primarily through sales of common and preferred stock, contract and milestone payments to it under strategic collaborations and other research and development collaborations, target validation, database subscription and technology license agreements, product sales, government grants and contracts and financing under debt and lease arrangements. The Company&#8217;s future success is dependent upon many factors, including, but not limited to, the success of its commercialization efforts for any approved products; ongoing nonclinical and clinical development efforts and its ability to obtain necessary regulatory approvals of the drug candidates which are the subject of such efforts; its success in establishing new collaborations and licenses and its receipt of milestones, royalties and other payments under such arrangements; the amount and timing of research, development and commercialization expenditures; its resources devoted to developing and supporting its products; general and industry-specific economic conditions which may affect research, development and commercialization expenditures; and its ability to obtain and enforce patents and other proprietary rights in its discoveries, comply with federal and state regulations, and maintain sufficient capital to fund its activities.&#160;&#160;As a result of the aforementioned factors and the related uncertainties, there can be no assurance of the Company&#8217;s future success.</span></div></ix:continuation><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i122d3ae3d73245b585bd7f040afd795c_151"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzIzMDg4_43d49930-2031-4103-8ae4-a622ae328f28" continuedAt="i3444d5d5a61e4deba6f6b4d39322c710" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i3444d5d5a61e4deba6f6b4d39322c710" continuedAt="i68a04affa29d4a07b267ac54a03757d8"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%"><ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzIzMDE0_edbf7b9a-eb87-4a54-b928-886e8dd9be32" continuedAt="ice92a85639f04a74adb90be6071c3344" escape="true">Basis of Presentation:</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"><ix:continuation id="ice92a85639f04a74adb90be6071c3344"> The accompanying consolidated financial statements include the accounts of Lexicon and its wholly-owned subsidiaries.  Intercompany transactions and balances are eliminated in consolidation.</ix:continuation>    </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzIzMDYy_c7027eb2-c2b5-4f25-82ad-d26e176e5045" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The preparation of financial statements in conformity with U. S. generally accepted accounting principles (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</span></ix:nonNumeric></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzIzMDUz_fe3d4e22-a004-454d-a745-469a9865f6eb" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash, Cash Equivalents and Short-Term Investments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lexicon considers all highly-liquid investments with original maturities of three months or less to be cash equivalents.&#160;&#160;As of December&#160;31, 2022 and 2021, short-term investments consist of U.S. treasury bills and corporate debt securities.  The Company&#8217;s short-term investments are classified as available-for-sale securities and are carried at fair value, based on quoted market prices of the securities.&#160;&#160;The Company views its available-for-sale securities as available for use in current operations regardless of the stated maturity date of the security.&#160; The Company does not intend to sell any of its available-for-sale securities prior to their maturity dates. Unrealized gains and losses on such securities are reported as a separate component of stockholders&#8217; equity.&#160;&#160;Net realized gains and losses, interest and dividends are included in interest income.&#160;&#160;The cost of securities sold is based on the specific identification method.</span></ix:nonNumeric></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzIzMDY3_a150e800-a41a-4d12-96d1-010f229272a6" continuedAt="i002acaa0234c439f808ce384d3d6b8e3" escape="true">Accounts Receivable:</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i002acaa0234c439f808ce384d3d6b8e3">&#160;&#160;Lexicon records trade accounts receivable in the normal course of business related to the sale of products or services, net of an allowance for expected credit losses.</ix:continuation>&#160;&#160;&#160;</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="us-gaap:ConcentrationRiskDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzIzMDM5_69164596-9241-4812-9a52-43dc3dcd807d" continuedAt="id222eee27a164409b7da5b67ded73880" escape="true">Concentration of Credit Risk:</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id222eee27a164409b7da5b67ded73880"> Lexicon&#8217;s cash equivalents, investments and accounts receivable represent potential concentrations of credit risk. The Company attempts to minimize potential concentrations of risk in cash equivalents and investments by placing investments in high-quality financial instruments. The Company has not experienced any realized losses on its cash equivalents or short-term investments.  The Company&#8217;s accounts receivable are unsecured and are concentrated in pharmaceutical and biotechnology companies located in the United States.&#160;&#160;The Company has not experienced any significant credit losses to date.  In 2022, one customer in the United States represented <ix:nonFraction unitRef="number" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="2" name="lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzEwOTk1MTE2NTIxNjA_2984eac8-c625-4f6f-acdc-0c3981953301">100</ix:nonFraction>% of revenue.</ix:continuation>&#160;&#160; In 2021, customers in Switzerland and the United States represented <ix:nonFraction unitRef="number" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="2" name="lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzI0NjM_126449e4-27af-4979-924a-da8f4200fe9b">76</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="2" name="lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzI0NzA_e89ec413-e1af-4e46-9d31-49d63a6e6827">24</ix:nonFraction>% of revenue, respectively.&#160;In 2020, customers in the United States represented <ix:nonFraction unitRef="number" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="2" name="lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzI1NDk_96dcddcc-a927-4a0d-89d1-71ea20af0f2b">98</ix:nonFraction>% of revenue.&#160;At December&#160;31, 2022, management believes that the Company has no significant concentrations of credit risk.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzIzMDA3_5cc3ec0b-c30b-46a2-8b43-cb740d42fee6" continuedAt="ic9003136e7174e7e995df47bf24a0cac" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Information and Significant Customers:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lexicon operates in <ix:nonFraction unitRef="segment" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzI4Mjk_98aeccdf-9605-417b-9f49-60e73cbe20f0">one</ix:nonFraction> business segment, which primarily focuses on the discovery, development and commercialization of pharmaceutical products for the treatment of human disease. </span></ix:nonNumeric></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i68a04affa29d4a07b267ac54a03757d8" continuedAt="ia88c6a7bc6b54fe09dc58cfeaa0a7201"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic9003136e7174e7e995df47bf24a0cac">Substantially all of the Company&#8217;s revenues have been derived from drug discovery alliances, target validation collaborations for the development and, in some cases, analysis of the physiological effects of genes altered in knockout mice, technology licenses, subscriptions to its databases, product sales, government grants and contracts and compound library sales.  In 2022, one customer represented <ix:nonFraction unitRef="number" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="2" name="lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzEwOTk1MTE2NTIyMzY_2984eac8-c625-4f6f-acdc-0c3981953301">100</ix:nonFraction>% of revenue.</ix:continuation>  In 2021, one customer represented <ix:nonFraction unitRef="number" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="2" name="lxrx:LXRXBiologicscustomerconcentration" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzMzOTU_499d72bd-ec4f-469b-a759-82b259a8f856">76</ix:nonFraction>% of revenues and another customer represented <ix:nonFraction unitRef="number" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="2" name="lxrx:LXRXDiplomatcustomerconcentration" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzM0NDY_eeef8488-367b-454c-abeb-65882d4f6ee3">24</ix:nonFraction>% of revenues, respectively.  In 2020, two customers represented <ix:nonFraction unitRef="number" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="INF" name="lxrx:LXRXBiologicscustomerconcentration" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzM1NjE_e927ae28-eb7c-49d5-8843-ca8952ed552c">65</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="INF" name="lxrx:LXRXDiplomatcustomerconcentration" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzM1Njg_8a6788a5-cc0e-4a7d-94be-c70fb5565e33">22</ix:nonFraction>% of revenues, respectively.   </span></div><div style="text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzIzMDg5_22c908fc-887d-4bf4-a0be-dbc513debd79" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property and Equipment:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Property and equipment that is held and used is carried at cost and depreciated using the straight-line method over the estimated useful life of the assets which ranges from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzM5MTE_558fa410-9f8f-4ae0-80f8-17c88e115072">three</span> to <ix:nonNumeric contextRef="ief3a42398bf74858b5aa075d327d0116_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzM5MTc_e5d5dc12-42dc-49a9-860a-ffce31534b2c">40</ix:nonNumeric> years.&#160;&#160;Maintenance, repairs and minor replacements are charged to expense as incurred.&#160;&#160;Leasehold improvements are amortized over the shorter of the estimated useful life or the remaining lease term.&#160;&#160;Significant renewals and betterments are capitalized.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued liabilities: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Accrued liabilities consisted of the following:</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.163%"><tr><td style="width:1.0%"></td><td style="width:52.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.788%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="lxrx:AccruedResearchAndDevelopmentServicesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90YWJsZTo3MDMzYmY0N2YzNGU0NGYxOTJlMTEwOTJiMTlmMTAzYy90YWJsZXJhbmdlOjcwMzNiZjQ3ZjM0ZTQ0ZjE5MmUxMTA5MmIxOWYxMDNjXzMtMi0xLTEtMzMyMDM_ce7d3ef0-6043-4613-b384-32f3813c118c">3,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231" decimals="-3" name="lxrx:AccruedResearchAndDevelopmentServicesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90YWJsZTo3MDMzYmY0N2YzNGU0NGYxOTJlMTEwOTJiMTlmMTAzYy90YWJsZXJhbmdlOjcwMzNiZjQ3ZjM0ZTQ0ZjE5MmUxMTA5MmIxOWYxMDNjXzMtNC0xLTEtMzMyMDM_db7c3e25-9376-4e49-8b92-a18f2ef7da75">3,669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="lxrx:AccruedCompensationAndBenefitsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90YWJsZTo3MDMzYmY0N2YzNGU0NGYxOTJlMTEwOTJiMTlmMTAzYy90YWJsZXJhbmdlOjcwMzNiZjQ3ZjM0ZTQ0ZjE5MmUxMTA5MmIxOWYxMDNjXzQtMi0xLTEtMzMyMDM_f572b939-3e4e-41a0-86cc-33e3c6bf2543">7,830</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231" decimals="-3" name="lxrx:AccruedCompensationAndBenefitsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90YWJsZTo3MDMzYmY0N2YzNGU0NGYxOTJlMTEwOTJiMTlmMTAzYy90YWJsZXJhbmdlOjcwMzNiZjQ3ZjM0ZTQ0ZjE5MmUxMTA5MmIxOWYxMDNjXzQtNC0xLTEtMzMyMDM_9cb3e3c4-f026-4f9c-9103-064e890eda60">5,711</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short term lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90YWJsZTo3MDMzYmY0N2YzNGU0NGYxOTJlMTEwOTJiMTlmMTAzYy90YWJsZXJhbmdlOjcwMzNiZjQ3ZjM0ZTQ0ZjE5MmUxMTA5MmIxOWYxMDNjXzUtMi0xLTEtMzMyMDM_b071f5dd-7337-4f78-af25-5314a0bae291">1,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90YWJsZTo3MDMzYmY0N2YzNGU0NGYxOTJlMTEwOTJiMTlmMTAzYy90YWJsZXJhbmdlOjcwMzNiZjQ3ZjM0ZTQ0ZjE5MmUxMTA5MmIxOWYxMDNjXzUtNC0xLTEtMzMyMDM_8633b4ee-fde4-4697-adeb-cf350de80fb0">1,089</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90YWJsZTo3MDMzYmY0N2YzNGU0NGYxOTJlMTEwOTJiMTlmMTAzYy90YWJsZXJhbmdlOjcwMzNiZjQ3ZjM0ZTQ0ZjE5MmUxMTA5MmIxOWYxMDNjXzYtMi0xLTEtMzMyMDM_8076cfec-6e70-4000-8407-4bb86a19ebcd">404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90YWJsZTo3MDMzYmY0N2YzNGU0NGYxOTJlMTEwOTJiMTlmMTAzYy90YWJsZXJhbmdlOjcwMzNiZjQ3ZjM0ZTQ0ZjE5MmUxMTA5MmIxOWYxMDNjXzYtNC0xLTEtMzMyMDM_529a50d7-3c50-44c0-84c8-865b2455d8f7">2,503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90YWJsZTo3MDMzYmY0N2YzNGU0NGYxOTJlMTEwOTJiMTlmMTAzYy90YWJsZXJhbmdlOjcwMzNiZjQ3ZjM0ZTQ0ZjE5MmUxMTA5MmIxOWYxMDNjXzctMi0xLTEtMzMyMDM_889e74e0-1315-4d94-b003-9cb9ff831083">12,777</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90YWJsZTo3MDMzYmY0N2YzNGU0NGYxOTJlMTEwOTJiMTlmMTAzYy90YWJsZXJhbmdlOjcwMzNiZjQ3ZjM0ZTQ0ZjE5MmUxMTA5MmIxOWYxMDNjXzctNC0xLTEtMzMyMDM_5542e6fc-3955-4e13-b63f-1d3b7c3858bb">12,972</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzIzMDg3_27d1b8f4-534d-4400-a9b1-45e6a42c609e" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impairment of Long-Lived Assets:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;Long-lived assets and right-of-use assets for leases are reviewed for impairment when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable.  Recoverability of assets to be held and used is measured by comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount that the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. In 2020, the Company recognized an impairment loss of $<ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzEwOTk1MTE2NTA5MDA_0fd3b24b-cb5c-4dcf-bb13-4e8da4a5ce67">1.6</ix:nonFraction> million to reduce the carrying value of the assets comprising our campus in The Woodlands, Texas, which were sold in December 2020, to an estimated fair value, less estimated selling costs.  There were <ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzUyMTQ_0c846189-acad-4c5c-9ef3-b59101e6c5c0"><ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzUyMTQ_f5551571-421c-4969-b7f8-78f978ab9b77">no</ix:nonFraction></ix:nonFraction> impairments of long-lived assets, in 2022 or 2021.</span></ix:nonNumeric></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzIzMDUx_22694926-406c-4732-bb59-ddbad140a974" continuedAt="i66982fab6db8433e9725cae5447a4421" escape="true">Goodwill Impairment:</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i66982fab6db8433e9725cae5447a4421">&#160;&#160;Goodwill is not amortized, but is tested at least annually for impairment at the reporting unit level.&#160;&#160;The Company has determined that the reporting unit is the single operating segment disclosed in its current financial statements. Impairment is the condition that exists when the carrying amount of goodwill exceeds its implied fair value.&#160;&#160;The first step in the impairment process is to determine the fair value of the reporting unit and then compare it to the carrying value, including goodwill.&#160;&#160;If the fair value exceeds the carrying value, no further action is required and no impairment loss is recognized.&#160;&#160;Additional impairment assessments may be performed on an interim basis if the Company encounters events or changes in circumstances that would indicate that, more likely than not, the carrying value of goodwill has been impaired.</ix:continuation>&#160;&#160;There was no impairment of goodwill in 2022, 2021 or 2020.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lexicon determines if a contract is or contains a lease at inception or upon modification of the contract. A contract is or contains a lease if it conveys the right to control the use of an identified asset for a period in exchange for consideration. Control over the use of the identified asset means the lessee has both (a) the right to obtain substantially all of the economic benefits from the use of the asset and (b) the right to direct the use of the asset. Lexicon does not apply this accounting to those leases with terms of twelve (12) months or less. Operating lease right-of-use assets and associated lease liabilities are recorded in the balance sheet at the lease commencement date based on the present value of future lease payments to be made over the expected lease term. As the implicit rate is not determinable in its leases, Lexicon used a borrowing rate ranging between 9% and 9.7% at the commencement date in determining the present value of future payments.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ia88c6a7bc6b54fe09dc58cfeaa0a7201" continuedAt="i5108ad505c1a4f33826f3371b612b51f"><ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzIzMDMx_5c00d881-9aeb-48a5-bf95-3400124378a2" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Product Revenues</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Company&#8217;s sale of XERMELO and related assets to TerSera Therapeutics, LLC (&#8220;TerSera&#8221;) in September 2020, product revenues consisted of commercial sales of XERMELO in the United States and sales of bulk tablets of XERMELO to Ipsen.  Product revenues were recognized when the customer obtained control of the Company&#8217;s product, which occured upon delivery to the customer.  The Company recognized product revenue net of applicable reserves for variable consideration, including allowances for customer credits, estimated rebates, chargebacks, discounts, returns, distribution service fees, and government rebates, such as Medicare Part D coverage gap reimbursements in the United States, as discussed below.  These estimates were based on the most likely amount method for relevant factors such as current contractual and statutory requirements, industry data and forecasted customer buying and payment patterns. Product shipping and handling costs were considered a fulfillment activity when control transfers to the Company&#8217;s customers and such costs were included in cost of sales.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer Credits:  The Company&#8217;s customers were offered various forms of consideration, including allowances, service fees and prompt payment discounts.  The Company expected that its customers would earn prompt payment discounts.  As a result, the Company deducted the full amount of those discounts from total product sales when revenues were recognized.  Service fees were also deducted from product sales as they were earned.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rebates:  Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program.  Rebate amounts are based upon contractual agreements or legal requirements with public sector (e.g., Medicaid) benefit providers.  Rebates are amounts owed after the final dispensing of the product to a benefit plan participant and are based upon contractual agreements or legal requirements with public sector benefit providers.  The allowance for rebates is based on statutory discount rates and expected utilization.  The Company&#8217;s estimates for expected utilization of rebates were based on third party market research data and data received from the specialty pharmacies dispensing XERMELO.  Rebates were generally invoiced and paid in arrears so that the accrual balance consisted of an estimate of the amount expected to be incurred for the current quarter&#8217;s activity, plus an accrual balance for known unpaid rebates from the prior quarter.  If actual future rebates varied from estimates, the Company adjusted prior period accruals, which affected revenue in the period of adjustment.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks:  Chargebacks are discounts that occur when contracted customers purchase directly from a specialty pharmacy or distributor, who acts as a retailer.  Contracted customers, which consisted primarily of Public Health Service Institutions, non-profit clinics, and federal government entities purchasing via the Federal Supply Schedule, generally purchased XERMELO at a discounted price.  The specialty pharmacy or distributor, in turn, charged back to Lexicon the difference between the price paid by the specialty pharmacy or distributor and the discounted price paid to the specialty pharmacy or distributor by the customer.  The allowance for chargeback was based on known sales to contracted customers.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare Part D Coverage Gap:  The Medicare Part D prescription drug benefit mandates manufacturers to fund a portion of the Medicare Part D insurance coverage gap for prescription drugs sold to eligible patients.  The Company&#8217;s estimates for the expected Medicare Part D coverage gap were based on data received from the specialty pharmacies dispensing XERMELO and projections based on historical data.  Funding of the coverage gap was generally invoiced and paid in arrears so that the accrual balance consisted of an estimate of the amount expected to be incurred for the current quarter&#8217;s activity, plus an accrual balance for known prior quarters.  If actual future funding varied from estimates, the Company adjusted prior period accruals, which affected revenues in the period of adjustment.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Co-payment assistance:  Patients with commercial insurance who met certain eligibility requirements were eligible to receive co-payment assistance.  The Company accrued a liability for co-payment assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Collaborative Agreements</span></div></ix:nonNumeric><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under collaborative agreements include both license revenue and contract research revenue.  The Company performs the following five steps in determining the amount of revenue to recognize as it fulfills its performance obligations under each of its collaborative agreements:  (i) identify the contract(s) with a customer; (ii) identify the performance obligation in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligation.  The Company applies this five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.  At contract inception, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i5108ad505c1a4f33826f3371b612b51f" continuedAt="i6444f8fc56c746049b3b0e5549e82bf7"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">service is distinct.  The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.  The Company develops assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, the Company evaluates whether development milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method.  If it is probable that a significant revenue reversal will not occur, the associated development milestone value is included in the transaction price.  Development milestones that are not within the control of the Company or the licensee, including those requiring regulatory approval, are not considered probable of being achieved until those approvals are received.  The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue when (or as) the performance obligation is satisfied.  At the end of each reporting period, the Company re-evaluates the probability of achievement of the development milestones and any related constraint, and if necessary, adjusts its estimates of the overall transaction price.  Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues in the period of adjustment.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In agreements in which a license to the Company&#8217;s intellectual property is determined distinct from other performance obligations identified in the agreement, the Company recognizes revenue when the license is transferred to the licensee and the licensee is able to use and benefit from the license.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For agreements that include sales-based royalties, including milestones based on a level of sales, the license is deemed to be the predominant item to which the royalties relate and the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may receive payments from its licensees based on billing schedules established in each contract.  Upfront payments and fees are recorded as deferred revenue upon receipt or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under these agreements.  Amounts are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="us-gaap:CostOfSalesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzIzMDMy_65614d83-3760-47c7-899d-7e00f181f2ea" continuedAt="ia43d1405755c4570b25d8e26047dfb16" escape="true">Cost of Sales: </ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia43d1405755c4570b25d8e26047dfb16"> Cost of sales consisted of third-party manufacturing costs, freight and indirect overhead costs associated with sales of XERMELO.  Product shipping and handling costs were included in cost of sales. Cost of sales also included the amortization of the intangible asset for XERMELO using the straight-line method over the estimated useful life of <ix:nonNumeric contextRef="i0126e8a6d33142d5912c3766ac53314e_D20200101-20201231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzE2MjE2_1bea4d4a-ab9a-4e24-b15c-c9036a7b3a74">14</ix:nonNumeric> years.</ix:continuation> </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzIzMDE1_1a985477-ebdb-4b71-8f6e-ea3a427e3be0" continuedAt="i44ebc0e445764198800c03b1bdf83171" escape="true">Research and Development Expenses:</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i44ebc0e445764198800c03b1bdf83171"> Research and development expenses consist of costs incurred for company-sponsored as well as collaborative research and development activities. These costs include direct and research-related overhead expenses and are expensed as incurred.&#160;&#160;Technology license fees for technologies that are utilized in research and development and have no alternative future use are expensed when incurred.  Substantial portions of the Company&#8217;s preclinical and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors.  For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining.  For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study.  The Company monitors patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to the Company by the vendors and clinical site visits.  The Company&#8217;s estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each program and total program spending.  The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives.</ix:continuation> </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzIzMDQ0_cee28f99-f760-4d9b-8b7d-b3bceaf0d5ae" continuedAt="ib7aa4214ca9142f1aa7f5f93f1da095c" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;The Company recognizes compensation expense in its statements of comprehensive loss for share-based payments, including stock options and restricted stock units issued to employees, based on their fair values on the date of the grant, with the compensation expense recognized over the period in which an employee is required to provide service in exchange for the stock award.&#160;&#160;Stock-based compensation expense for awards without performance conditions is recognized based on the terms of vesting, which is typically on a straight-line basis.  Stock-based compensation expense for awards with performance conditions is recognized over the period from the date the performance condition is determined to be probable of occurring through the time the applicable condition is met.&#160;&#160;As of December&#160;31, 2022, future stock-based compensation cost for all outstanding unvested stock options and restricted stock units was $<ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzE4OTQ3_57565856-ee0d-4471-bcce-44b7a40432e0">21.0</ix:nonFraction> million, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzE5MDIw_c8ae7b40-c74a-4526-93a5-e244a39ab2c1">1.3</ix:nonNumeric>&#160;years.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options is estimated at the date of grant using the Black-Scholes method.&#160;&#160;The Black-Scholes option-pricing model requires the input of subjective assumptions.&#160;&#160;Because the Company&#8217;s employee stock options have </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i6444f8fc56c746049b3b0e5549e82bf7"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib7aa4214ca9142f1aa7f5f93f1da095c">characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&#8217;s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options.&#160;&#160;For purposes of determining the fair value of stock options, the Company segregates its options into two homogeneous groups, based on exercise and post-vesting employment termination behaviors, resulting in different assumptions used for expected option lives.&#160;&#160;Historical data is used to estimate the expected option life for each group.  Expected volatility is based on the historical volatility in the Company&#8217;s stock price.</ix:continuation>&#160;&#160;The following weighted-average assumptions were used for stock options granted in the years ended December&#160;31, 2022, 2021 and 2020, respectively:</span></div><div><ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzIzMDY1_6b25bc2c-d6b7-46d5-ab5c-a82c604af7bb" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expected Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Risk-free Interest Rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expected Term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Dividend<br/>Rate</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if1ed3c23317249048fd1e594aaae930b_D20220101-20221231" decimals="2" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90YWJsZTpmZDkwNGE5Y2QwYjA0YzhjOGI1ZTY0ZTc2ODEyODg2YS90YWJsZXJhbmdlOmZkOTA0YTljZDBiMDRjOGM4YjVlNjRlNzY4MTI4ODZhXzItMS0xLTEtMzMyMDM_5851ec66-243a-4ae1-8f46-afc5d9edad67">109</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if1ed3c23317249048fd1e594aaae930b_D20220101-20221231" decimals="3" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90YWJsZTpmZDkwNGE5Y2QwYjA0YzhjOGI1ZTY0ZTc2ODEyODg2YS90YWJsZXJhbmdlOmZkOTA0YTljZDBiMDRjOGM4YjVlNjRlNzY4MTI4ODZhXzItMy0xLTEtMzMyMDM_a7f4ae83-d24e-444e-a5d2-07d4cfe58f20">2.8</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if1ed3c23317249048fd1e594aaae930b_D20220101-20221231" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90YWJsZTpmZDkwNGE5Y2QwYjA0YzhjOGI1ZTY0ZTc2ODEyODg2YS90YWJsZXJhbmdlOmZkOTA0YTljZDBiMDRjOGM4YjVlNjRlNzY4MTI4ODZhXzItNS0xLTEtMzMyMDM_6e9ab1c5-2ce8-410c-988c-ed83b0007715">4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if1ed3c23317249048fd1e594aaae930b_D20220101-20221231" decimals="0" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90YWJsZTpmZDkwNGE5Y2QwYjA0YzhjOGI1ZTY0ZTc2ODEyODg2YS90YWJsZXJhbmdlOmZkOTA0YTljZDBiMDRjOGM4YjVlNjRlNzY4MTI4ODZhXzItNy0xLTEtMzMyMDM_21c3aa43-5177-45df-9640-755db0014bdf">0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Officers and non-employee directors</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if1ed3c23317249048fd1e594aaae930b_D20220101-20221231" decimals="2" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90YWJsZTpmZDkwNGE5Y2QwYjA0YzhjOGI1ZTY0ZTc2ODEyODg2YS90YWJsZXJhbmdlOmZkOTA0YTljZDBiMDRjOGM4YjVlNjRlNzY4MTI4ODZhXzMtMS0xLTEtMzMyMDM_542516f4-e99a-4487-8186-f22038dbc7e2">91</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if1ed3c23317249048fd1e594aaae930b_D20220101-20221231" decimals="3" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90YWJsZTpmZDkwNGE5Y2QwYjA0YzhjOGI1ZTY0ZTc2ODEyODg2YS90YWJsZXJhbmdlOmZkOTA0YTljZDBiMDRjOGM4YjVlNjRlNzY4MTI4ODZhXzMtMy0xLTEtMzMyMDM_75e9dd7a-7c5d-4df6-8d48-2d72580d594a">1.9</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if1ed3c23317249048fd1e594aaae930b_D20220101-20221231" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90YWJsZTpmZDkwNGE5Y2QwYjA0YzhjOGI1ZTY0ZTc2ODEyODg2YS90YWJsZXJhbmdlOmZkOTA0YTljZDBiMDRjOGM4YjVlNjRlNzY4MTI4ODZhXzMtNS0xLTEtMzMyMDM_8a3dd602-56ba-40a5-9b23-914843fafc04">7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if1ed3c23317249048fd1e594aaae930b_D20220101-20221231" decimals="0" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90YWJsZTpmZDkwNGE5Y2QwYjA0YzhjOGI1ZTY0ZTc2ODEyODg2YS90YWJsZXJhbmdlOmZkOTA0YTljZDBiMDRjOGM4YjVlNjRlNzY4MTI4ODZhXzMtNy0xLTEtMzMyMDM_54b0fa34-8fff-4041-9ce8-a6ba9ce12a77">0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic47b53ad6bac40f099489e67c81c19de_D20210101-20211231" decimals="2" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90YWJsZTpmZDkwNGE5Y2QwYjA0YzhjOGI1ZTY0ZTc2ODEyODg2YS90YWJsZXJhbmdlOmZkOTA0YTljZDBiMDRjOGM4YjVlNjRlNzY4MTI4ODZhXzUtMS0xLTEtMzMyMDM_2fb0b072-ca6f-4888-b0c5-3652fb7011fc">104</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic47b53ad6bac40f099489e67c81c19de_D20210101-20211231" decimals="3" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90YWJsZTpmZDkwNGE5Y2QwYjA0YzhjOGI1ZTY0ZTc2ODEyODg2YS90YWJsZXJhbmdlOmZkOTA0YTljZDBiMDRjOGM4YjVlNjRlNzY4MTI4ODZhXzUtMy0xLTEtMzMyMDM_983f9178-2282-408a-8938-17bd3efdc13a">0.7</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic47b53ad6bac40f099489e67c81c19de_D20210101-20211231" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90YWJsZTpmZDkwNGE5Y2QwYjA0YzhjOGI1ZTY0ZTc2ODEyODg2YS90YWJsZXJhbmdlOmZkOTA0YTljZDBiMDRjOGM4YjVlNjRlNzY4MTI4ODZhXzUtNS0xLTEtMzMyMDM_2fad9141-70d5-4a17-8f20-78205605dba4">4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic47b53ad6bac40f099489e67c81c19de_D20210101-20211231" decimals="0" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90YWJsZTpmZDkwNGE5Y2QwYjA0YzhjOGI1ZTY0ZTc2ODEyODg2YS90YWJsZXJhbmdlOmZkOTA0YTljZDBiMDRjOGM4YjVlNjRlNzY4MTI4ODZhXzUtNy0xLTEtMzMyMDM_ab152c4d-881b-4378-9c4a-931755ab2737">0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Officers and non-employee directors</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic47b53ad6bac40f099489e67c81c19de_D20210101-20211231" decimals="2" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90YWJsZTpmZDkwNGE5Y2QwYjA0YzhjOGI1ZTY0ZTc2ODEyODg2YS90YWJsZXJhbmdlOmZkOTA0YTljZDBiMDRjOGM4YjVlNjRlNzY4MTI4ODZhXzYtMS0xLTEtMzMyMDM_32e3dcf0-0685-44bf-acb5-a2a71a88d059">90</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic47b53ad6bac40f099489e67c81c19de_D20210101-20211231" decimals="3" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90YWJsZTpmZDkwNGE5Y2QwYjA0YzhjOGI1ZTY0ZTc2ODEyODg2YS90YWJsZXJhbmdlOmZkOTA0YTljZDBiMDRjOGM4YjVlNjRlNzY4MTI4ODZhXzYtMy0xLTEtMzMyMDM_dcd10521-1b52-4fa6-93c9-ca298ace1bd7">1.0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic47b53ad6bac40f099489e67c81c19de_D20210101-20211231" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90YWJsZTpmZDkwNGE5Y2QwYjA0YzhjOGI1ZTY0ZTc2ODEyODg2YS90YWJsZXJhbmdlOmZkOTA0YTljZDBiMDRjOGM4YjVlNjRlNzY4MTI4ODZhXzYtNS0xLTEtMzMyMDM_1537773b-fc4e-48dd-921c-f44970f73431">6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic47b53ad6bac40f099489e67c81c19de_D20210101-20211231" decimals="0" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90YWJsZTpmZDkwNGE5Y2QwYjA0YzhjOGI1ZTY0ZTc2ODEyODg2YS90YWJsZXJhbmdlOmZkOTA0YTljZDBiMDRjOGM4YjVlNjRlNzY4MTI4ODZhXzYtNy0xLTEtMzMyMDM_f4390936-a36d-46da-8a87-86f1f90f2208">0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9f10e15a388c4c8a99f1402fbd71ee00_D20200101-20201231" decimals="2" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90YWJsZTpmZDkwNGE5Y2QwYjA0YzhjOGI1ZTY0ZTc2ODEyODg2YS90YWJsZXJhbmdlOmZkOTA0YTljZDBiMDRjOGM4YjVlNjRlNzY4MTI4ODZhXzgtMS0xLTEtMzMyMDM_12967f28-8cfb-43ee-ad1b-bf5e48e39f1a">98</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9f10e15a388c4c8a99f1402fbd71ee00_D20200101-20201231" decimals="3" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90YWJsZTpmZDkwNGE5Y2QwYjA0YzhjOGI1ZTY0ZTc2ODEyODg2YS90YWJsZXJhbmdlOmZkOTA0YTljZDBiMDRjOGM4YjVlNjRlNzY4MTI4ODZhXzgtMy0xLTEtMzMyMDM_b36c35f4-aeac-40e0-9429-5ed451a5b8f3">1.3</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9f10e15a388c4c8a99f1402fbd71ee00_D20200101-20201231" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90YWJsZTpmZDkwNGE5Y2QwYjA0YzhjOGI1ZTY0ZTc2ODEyODg2YS90YWJsZXJhbmdlOmZkOTA0YTljZDBiMDRjOGM4YjVlNjRlNzY4MTI4ODZhXzgtNS0xLTEtMzMyMDM_1db923c8-43ad-4794-a02a-d8fe616a499a">4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9f10e15a388c4c8a99f1402fbd71ee00_D20200101-20201231" decimals="0" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90YWJsZTpmZDkwNGE5Y2QwYjA0YzhjOGI1ZTY0ZTc2ODEyODg2YS90YWJsZXJhbmdlOmZkOTA0YTljZDBiMDRjOGM4YjVlNjRlNzY4MTI4ODZhXzgtNy0xLTEtMzMyMDM_d17fc1e2-b7a2-437b-a02f-1ce1028b5ca4">0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Officers and non-employee directors</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9f10e15a388c4c8a99f1402fbd71ee00_D20200101-20201231" decimals="2" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90YWJsZTpmZDkwNGE5Y2QwYjA0YzhjOGI1ZTY0ZTc2ODEyODg2YS90YWJsZXJhbmdlOmZkOTA0YTljZDBiMDRjOGM4YjVlNjRlNzY4MTI4ODZhXzktMS0xLTEtMzMyMDM_9b4bb40d-9b86-45b2-adcc-fa6ca9a228d4">85</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9f10e15a388c4c8a99f1402fbd71ee00_D20200101-20201231" decimals="3" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90YWJsZTpmZDkwNGE5Y2QwYjA0YzhjOGI1ZTY0ZTc2ODEyODg2YS90YWJsZXJhbmdlOmZkOTA0YTljZDBiMDRjOGM4YjVlNjRlNzY4MTI4ODZhXzktMy0xLTEtMzMyMDM_2bbb39a0-4630-4da6-ac3c-4e5e317eaf04">1.4</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9f10e15a388c4c8a99f1402fbd71ee00_D20200101-20201231" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90YWJsZTpmZDkwNGE5Y2QwYjA0YzhjOGI1ZTY0ZTc2ODEyODg2YS90YWJsZXJhbmdlOmZkOTA0YTljZDBiMDRjOGM4YjVlNjRlNzY4MTI4ODZhXzktNS0xLTEtMzMyMDM_6184e6db-e4c7-41d6-baa0-a551bddd6d01">7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9f10e15a388c4c8a99f1402fbd71ee00_D20200101-20201231" decimals="0" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90YWJsZTpmZDkwNGE5Y2QwYjA0YzhjOGI1ZTY0ZTc2ODEyODg2YS90YWJsZXJhbmdlOmZkOTA0YTljZDBiMDRjOGM4YjVlNjRlNzY4MTI4ODZhXzktNy0xLTEtMzMyMDM_ae2ece78-979a-4c76-9c48-1f3f88bfc34c">0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:nonNumeric></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzIzMDE3_31931784-2ed8-4bdc-9abd-34a033935fd4" continuedAt="i9f897edc8d244a0eb415afdc5904b013" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been recognized differently in the financial statements and tax returns. The Company uses the liability method in accounting for income taxes. Under this method, deferred tax liabilities and assets are determined based on the difference between the financial statement carrying amounts and tax bases of liabilities and assets using enacted tax rates and laws in effect in the years in which the differences are expected to reverse. Deferred tax assets are evaluated for realization based on a more-likely-than-not criteria in determining if a valuation allowance should be provided.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a valuation allowance on net operating losses and other deferred tax assets. Accordingly, the Company has not reported any tax benefit relating to the remaining net operating loss carryforwards and income tax credit carryforwards that are available for utilization in future periods. On a periodic basis, the valuation allowance is reassessed on deferred income tax assets, weighing positive and negative evidence to assess the recoverability of the deferred tax assets. In 2022, the Company reassessed the valuation allowance and considered negative evidence, including the cumulative losses over the three years ended December&#160;31, 2022 and positive evidence including the projections of future income. After assessing both the negative and the positive evidence, the Company concluded that it should continue to maintain the valuation allowance on net operating losses and other deferred tax assets as of December&#160;31, 2022 given the significance of the weight of the negative evidence. Based on recent financial performance and future projections, the Company could record a reversal of all, or a portion of the valuation allowance associated with U.S. deferred tax assets in future periods. However, any such change is subject to actual performance and other considerations that may present positive or negative evidence at the time of the assessment. The total gross deferred tax asset balance subject to the valuation allowance assessment was approximately $<ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzIyMzE5_a71a53da-9e0a-4f18-beee-4f45922d8beb">347.1</ix:nonFraction>&#160;million at December&#160;31, 2022. </span></div></ix:nonNumeric><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9f897edc8d244a0eb415afdc5904b013">Significant judgment is required in making these assessments to maintain or reverse valuation allowances and, to the extent future expectations change the Company would have to assess the recoverability of these deferred tax assets at that time.</ix:continuation> </span></div><div><span><br/></span></div><div style="text-indent:36pt"><ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzIzMDU1_2b7dac93-f99d-4a7f-8d67-9a960d88ecc8" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Loss per Common Share:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Net loss per common share is computed using the weighted average number of shares of common stock outstanding. Shares associated with warrants, stock options and restricted stock units that could potentially dilute earnings per share in the future are not included in the computation of diluted earnings per share because they are antidilutive.</span></ix:nonNumeric></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div id="i122d3ae3d73245b585bd7f040afd795c_154"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTQvZnJhZzoxN2E5YTZmMTg0ZTc0YzU1YjY2NTliMjc4OTE2MDVjYi90ZXh0cmVnaW9uOjE3YTlhNmYxODRlNzRjNTViNjY1OWIyNzg5MTYwNWNiXzI0NjE_d6afad73-7136-4441-9de4-e024a7a852b8" continuedAt="i4646b6ce4e6640fa8bffabc17e29a5ce" escape="true">Recent Accounting Pronouncements</ix:nonNumeric></span></div><ix:continuation id="i4646b6ce4e6640fa8bffabc17e29a5ce"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity (Subtopic 815-40), which removes the separation models for convertible debt with cash conversion or beneficial conversion features. ASU 2020-06 also requires the application of the if-converted method for calculating earnings per diluted share, as the treasury stock method will no longer be permitted for convertible instruments. The adoption of ASU 2020-06 during the first quarter of 2022 did not have a material impact on the consolidated financial statements.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="i122d3ae3d73245b585bd7f040afd795c_160"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.  <ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="us-gaap:CashAndCashEquivalentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90ZXh0cmVnaW9uOjUyMThlODA3YWMwNjQwODViZjY2MGMxZGM4MGFhZGYxXzIzMw_54f4bd65-ff85-4b77-81f3-844c4e5fb1bc" continuedAt="ia4e00f989e1d4b5aaff386178a398077" escape="true">Cash, Cash Equivalents and Investments</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ia4e00f989e1d4b5aaff386178a398077" continuedAt="if81636efc4f1419ba88a7d421fca27a5"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of cash and cash equivalents and investments held at December&#160;31, 2022 and 2021 are as follows:</span></div><div style="text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90ZXh0cmVnaW9uOjUyMThlODA3YWMwNjQwODViZjY2MGMxZGM4MGFhZGYxXzI0MA_3e9e4eaf-5323-494c-8218-e2e3deb8ee75" escape="true"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"></td><td style="width:42.727%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.485%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i841f2e01285341bc84e68db28065de33_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZTo2M2FkYmVkMWFkZGU0M2Q1OTRjMDAzMzhmZmEzYzNhNy90YWJsZXJhbmdlOjYzYWRiZWQxYWRkZTQzZDU5NGMwMDMzOGZmYTNjM2E3XzMtMS0xLTEtMzMyMDM_378cc64e-dd13-4a78-b289-9bd8fab37332">46,345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i841f2e01285341bc84e68db28065de33_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZTo2M2FkYmVkMWFkZGU0M2Q1OTRjMDAzMzhmZmEzYzNhNy90YWJsZXJhbmdlOjYzYWRiZWQxYWRkZTQzZDU5NGMwMDMzOGZmYTNjM2E3XzMtMy0xLTEtMzMyMDM_a3e71e60-ebfd-4a4a-867d-b7d2f378af97">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i841f2e01285341bc84e68db28065de33_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZTo2M2FkYmVkMWFkZGU0M2Q1OTRjMDAzMzhmZmEzYzNhNy90YWJsZXJhbmdlOjYzYWRiZWQxYWRkZTQzZDU5NGMwMDMzOGZmYTNjM2E3XzMtNS0xLTEtMzMyMDM_e44626b2-ea03-4e8a-b8bd-5987d099f9f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i841f2e01285341bc84e68db28065de33_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZTo2M2FkYmVkMWFkZGU0M2Q1OTRjMDAzMzhmZmEzYzNhNy90YWJsZXJhbmdlOjYzYWRiZWQxYWRkZTQzZDU5NGMwMDMzOGZmYTNjM2E3XzMtNy0xLTEtMzMyMDM_b55435df-b26c-4718-bea3-93b161d2825e">46,345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities maturing within one year:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05102cf0094245939ba4bd0df2517905_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZTo2M2FkYmVkMWFkZGU0M2Q1OTRjMDAzMzhmZmEzYzNhNy90YWJsZXJhbmdlOjYzYWRiZWQxYWRkZTQzZDU5NGMwMDMzOGZmYTNjM2E3XzUtMS0xLTEtMzMyMDM_7160f422-ff0f-49ea-a7b8-0d55fb55151f">74,022</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05102cf0094245939ba4bd0df2517905_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZTo2M2FkYmVkMWFkZGU0M2Q1OTRjMDAzMzhmZmEzYzNhNy90YWJsZXJhbmdlOjYzYWRiZWQxYWRkZTQzZDU5NGMwMDMzOGZmYTNjM2E3XzUtMy0xLTEtMzMyMDM_e2a47d13-fe66-420d-9785-2b5c3ea6febd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i05102cf0094245939ba4bd0df2517905_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZTo2M2FkYmVkMWFkZGU0M2Q1OTRjMDAzMzhmZmEzYzNhNy90YWJsZXJhbmdlOjYzYWRiZWQxYWRkZTQzZDU5NGMwMDMzOGZmYTNjM2E3XzUtNS0xLTEtMzMyMDM_9ca91b25-6deb-45eb-94ac-93343227f03a">342</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05102cf0094245939ba4bd0df2517905_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZTo2M2FkYmVkMWFkZGU0M2Q1OTRjMDAzMzhmZmEzYzNhNy90YWJsZXJhbmdlOjYzYWRiZWQxYWRkZTQzZDU5NGMwMDMzOGZmYTNjM2E3XzUtNy0xLTEtMzMyMDM_2ed57356-53b5-44cc-af99-2330d62a0d10">73,680</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZTo2M2FkYmVkMWFkZGU0M2Q1OTRjMDAzMzhmZmEzYzNhNy90YWJsZXJhbmdlOjYzYWRiZWQxYWRkZTQzZDU5NGMwMDMzOGZmYTNjM2E3XzYtMS0xLTEtMzMyMDM_393a9df8-faf6-4174-8c98-30d3230bebf8">18,418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZTo2M2FkYmVkMWFkZGU0M2Q1OTRjMDAzMzhmZmEzYzNhNy90YWJsZXJhbmdlOjYzYWRiZWQxYWRkZTQzZDU5NGMwMDMzOGZmYTNjM2E3XzYtMy0xLTEtMzMyMDM_c1278168-6c6e-4a13-a653-a4711563273e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZTo2M2FkYmVkMWFkZGU0M2Q1OTRjMDAzMzhmZmEzYzNhNy90YWJsZXJhbmdlOjYzYWRiZWQxYWRkZTQzZDU5NGMwMDMzOGZmYTNjM2E3XzYtNS0xLTEtMzMyMDM_d39309f2-df5f-4a8a-8242-c834715b244d">86</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZTo2M2FkYmVkMWFkZGU0M2Q1OTRjMDAzMzhmZmEzYzNhNy90YWJsZXJhbmdlOjYzYWRiZWQxYWRkZTQzZDU5NGMwMDMzOGZmYTNjM2E3XzYtNy0xLTEtMzMyMDM_3e272602-dbb6-4340-8136-1490c69f2f8c">18,332</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib86823c5a00d40e98853633ef7fadf56_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZTo2M2FkYmVkMWFkZGU0M2Q1OTRjMDAzMzhmZmEzYzNhNy90YWJsZXJhbmdlOjYzYWRiZWQxYWRkZTQzZDU5NGMwMDMzOGZmYTNjM2E3XzctMS0xLTEtMzMyMDM_010a7e03-a771-4e4d-8d65-90a9c74e828f">92,440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib86823c5a00d40e98853633ef7fadf56_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZTo2M2FkYmVkMWFkZGU0M2Q1OTRjMDAzMzhmZmEzYzNhNy90YWJsZXJhbmdlOjYzYWRiZWQxYWRkZTQzZDU5NGMwMDMzOGZmYTNjM2E3XzctMy0xLTEtMzMyMDM_aed68f04-fe0b-4c29-b68b-f9dba265e27a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib86823c5a00d40e98853633ef7fadf56_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZTo2M2FkYmVkMWFkZGU0M2Q1OTRjMDAzMzhmZmEzYzNhNy90YWJsZXJhbmdlOjYzYWRiZWQxYWRkZTQzZDU5NGMwMDMzOGZmYTNjM2E3XzctNS0xLTEtMzMyMDM_1b159653-c78e-4a16-9af5-31655cacfbb2">428</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib86823c5a00d40e98853633ef7fadf56_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZTo2M2FkYmVkMWFkZGU0M2Q1OTRjMDAzMzhmZmEzYzNhNy90YWJsZXJhbmdlOjYzYWRiZWQxYWRkZTQzZDU5NGMwMDMzOGZmYTNjM2E3XzctNy0xLTEtMzMyMDM_c46cf538-1794-4a23-b402-5f58dc25e497">92,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5904a39d50aa48738bfa16090d0521a4_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZTo2M2FkYmVkMWFkZGU0M2Q1OTRjMDAzMzhmZmEzYzNhNy90YWJsZXJhbmdlOjYzYWRiZWQxYWRkZTQzZDU5NGMwMDMzOGZmYTNjM2E3XzgtMS0xLTEtMzMyMDM_3d2e9ffb-c345-463e-a301-8d6f261e2fc1">138,785</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5904a39d50aa48738bfa16090d0521a4_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZTo2M2FkYmVkMWFkZGU0M2Q1OTRjMDAzMzhmZmEzYzNhNy90YWJsZXJhbmdlOjYzYWRiZWQxYWRkZTQzZDU5NGMwMDMzOGZmYTNjM2E3XzgtMy0xLTEtMzMyMDM_c79b24b3-3c36-47e1-93d1-9900bfa7513e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5904a39d50aa48738bfa16090d0521a4_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZTo2M2FkYmVkMWFkZGU0M2Q1OTRjMDAzMzhmZmEzYzNhNy90YWJsZXJhbmdlOjYzYWRiZWQxYWRkZTQzZDU5NGMwMDMzOGZmYTNjM2E3XzgtNS0xLTEtMzMyMDM_71fe2101-89f4-438f-82ac-480583d6a3cf">428</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5904a39d50aa48738bfa16090d0521a4_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZTo2M2FkYmVkMWFkZGU0M2Q1OTRjMDAzMzhmZmEzYzNhNy90YWJsZXJhbmdlOjYzYWRiZWQxYWRkZTQzZDU5NGMwMDMzOGZmYTNjM2E3XzgtNy0xLTEtMzMyMDM_6b00a9a7-234e-4ff2-9d08-eb74d26c5915">138,357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"></td><td style="width:42.881%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idde6749a549b4ccc8f95351b92d40bce_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZToxZTAwZmE1Nzk0NmI0ZTc4Yjc1YjY0YTUwYzg4MzU4Zi90YWJsZXJhbmdlOjFlMDBmYTU3OTQ2YjRlNzhiNzViNjRhNTBjODgzNThmXzMtMS0xLTEtMzMyMDM_4e3f30bc-1509-4806-8710-6301e6115811">64,066</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idde6749a549b4ccc8f95351b92d40bce_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZToxZTAwZmE1Nzk0NmI0ZTc4Yjc1YjY0YTUwYzg4MzU4Zi90YWJsZXJhbmdlOjFlMDBmYTU3OTQ2YjRlNzhiNzViNjRhNTBjODgzNThmXzMtMy0xLTEtMzMyMDM_289a6fa7-0eb5-4045-9f2f-a077447223f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idde6749a549b4ccc8f95351b92d40bce_I20211231" decimals="-3" sign="-" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZToxZTAwZmE1Nzk0NmI0ZTc4Yjc1YjY0YTUwYzg4MzU4Zi90YWJsZXJhbmdlOjFlMDBmYTU3OTQ2YjRlNzhiNzViNjRhNTBjODgzNThmXzMtNS0xLTEtMzMyMDM_52999812-9085-4cd7-a59f-c8d766155219">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idde6749a549b4ccc8f95351b92d40bce_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZToxZTAwZmE1Nzk0NmI0ZTc4Yjc1YjY0YTUwYzg4MzU4Zi90YWJsZXJhbmdlOjFlMDBmYTU3OTQ2YjRlNzhiNzViNjRhNTBjODgzNThmXzMtNy0xLTEtMzMyMDM_fcdb8a68-f4d3-47a3-abad-22807d55c381">64,065</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities maturing within one year:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZToxZTAwZmE1Nzk0NmI0ZTc4Yjc1YjY0YTUwYzg4MzU4Zi90YWJsZXJhbmdlOjFlMDBmYTU3OTQ2YjRlNzhiNzViNjRhNTBjODgzNThmXzUtMS0xLTEtMzk3MjY_ef4f6308-8a83-46ce-962e-a04349f1e705">26,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZToxZTAwZmE1Nzk0NmI0ZTc4Yjc1YjY0YTUwYzg4MzU4Zi90YWJsZXJhbmdlOjFlMDBmYTU3OTQ2YjRlNzhiNzViNjRhNTBjODgzNThmXzUtMy0xLTEtMzk3MjY_f8c20521-b059-4073-8fba-7ba4de5d7d32">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZToxZTAwZmE1Nzk0NmI0ZTc4Yjc1YjY0YTUwYzg4MzU4Zi90YWJsZXJhbmdlOjFlMDBmYTU3OTQ2YjRlNzhiNzViNjRhNTBjODgzNThmXzUtNS0xLTEtMzk3MjY_68ea5ab6-0b6b-47af-bc1e-f858d68aafc5">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZToxZTAwZmE1Nzk0NmI0ZTc4Yjc1YjY0YTUwYzg4MzU4Zi90YWJsZXJhbmdlOjFlMDBmYTU3OTQ2YjRlNzhiNzViNjRhNTBjODgzNThmXzUtNy0xLTEtMzMyMDM_ec0c2f4f-fa14-47f8-b006-fb1bc68e1026">26,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45721c6af18946ed9ca1743c070424b5_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZToxZTAwZmE1Nzk0NmI0ZTc4Yjc1YjY0YTUwYzg4MzU4Zi90YWJsZXJhbmdlOjFlMDBmYTU3OTQ2YjRlNzhiNzViNjRhNTBjODgzNThmXzctMS0xLTEtMzMyMDM_b9bcf509-f923-4e14-96aa-291a8741d8dc">26,018</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45721c6af18946ed9ca1743c070424b5_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZToxZTAwZmE1Nzk0NmI0ZTc4Yjc1YjY0YTUwYzg4MzU4Zi90YWJsZXJhbmdlOjFlMDBmYTU3OTQ2YjRlNzhiNzViNjRhNTBjODgzNThmXzctMy0xLTEtMzMyMDM_0cd11a19-adf6-47f2-bf78-98e7848ec360">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45721c6af18946ed9ca1743c070424b5_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZToxZTAwZmE1Nzk0NmI0ZTc4Yjc1YjY0YTUwYzg4MzU4Zi90YWJsZXJhbmdlOjFlMDBmYTU3OTQ2YjRlNzhiNzViNjRhNTBjODgzNThmXzctNS0xLTEtMzMyMDM_be5bea61-c3de-4f6e-ae0d-2a619d52caab">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45721c6af18946ed9ca1743c070424b5_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZToxZTAwZmE1Nzk0NmI0ZTc4Yjc1YjY0YTUwYzg4MzU4Zi90YWJsZXJhbmdlOjFlMDBmYTU3OTQ2YjRlNzhiNzViNjRhNTBjODgzNThmXzctNy0xLTEtMzMyMDM_43f44c9a-d5d3-4557-93cf-2b27cbd069f7">26,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i512fe0c004b04e38b6d7b9742c09feab_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZToxZTAwZmE1Nzk0NmI0ZTc4Yjc1YjY0YTUwYzg4MzU4Zi90YWJsZXJhbmdlOjFlMDBmYTU3OTQ2YjRlNzhiNzViNjRhNTBjODgzNThmXzgtMS0xLTEtMzMyMDM_fcbe10fe-8c6d-46e0-ade5-1739036bcf33">90,084</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i512fe0c004b04e38b6d7b9742c09feab_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZToxZTAwZmE1Nzk0NmI0ZTc4Yjc1YjY0YTUwYzg4MzU4Zi90YWJsZXJhbmdlOjFlMDBmYTU3OTQ2YjRlNzhiNzViNjRhNTBjODgzNThmXzgtMy0xLTEtMzMyMDM_914dbb0b-73c8-435c-85b7-bb09de73e45c">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i512fe0c004b04e38b6d7b9742c09feab_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZToxZTAwZmE1Nzk0NmI0ZTc4Yjc1YjY0YTUwYzg4MzU4Zi90YWJsZXJhbmdlOjFlMDBmYTU3OTQ2YjRlNzhiNzViNjRhNTBjODgzNThmXzgtNS0xLTEtMzMyMDM_b36ad272-e59f-4a52-8283-c89b293efd12">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i512fe0c004b04e38b6d7b9742c09feab_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZToxZTAwZmE1Nzk0NmI0ZTc4Yjc1YjY0YTUwYzg4MzU4Zi90YWJsZXJhbmdlOjFlMDBmYTU3OTQ2YjRlNzhiNzViNjRhNTBjODgzNThmXzgtNy0xLTEtMzMyMDM_7fbef510-ba95-4877-86cf-b16cc7fcbd6e">90,077</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if81636efc4f1419ba88a7d421fca27a5">There were <ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" name="us-gaap:RealizedInvestmentGainsLosses" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90ZXh0cmVnaW9uOjUyMThlODA3YWMwNjQwODViZjY2MGMxZGM4MGFhZGYxXzE2MQ_34b74050-5934-47c7-9489-cd2bf81f92b3">no</ix:nonFraction> realized gains or losses for the years ended December&#160;31, 2022, 2021, and 2020.</ix:continuation>  </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div id="i122d3ae3d73245b585bd7f040afd795c_163"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjMvZnJhZzo4N2U5MWY4YzgwYTk0YTUwOTEzMjkxNzBlYTY5NjMzNC90ZXh0cmVnaW9uOjg3ZTkxZjhjODBhOTRhNTA5MTMyOTE3MGVhNjk2MzM0XzE0NzY_f0aeb314-206d-4845-b25a-f3318cf63165" continuedAt="i31596ceea0644d4c8a10483b9a086c04" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="i31596ceea0644d4c8a10483b9a086c04" continuedAt="i0992bb2036cd4999b2aa3c3a96465d43"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis.&#160;&#160;Assets and liabilities recorded at fair value in the consolidated balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value.&#160;&#160;The following levels are directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 &#8211; quoted prices in active markets for identical assets, which include U.S. treasury securities</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 &#8211; other significant observable inputs (including quoted prices for similar investments, market corroborated inputs, etc.), which include corporate debt securities</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 &#8211; significant unobservable inputs </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;The inputs or methodology used for valuing securities are not necessarily an indication of the credit risk associated with investing in those securities.&#160;&#160;The following tables provide the fair value measurements of applicable Company assets and liabilities that are measured at fair value on a recurring basis according to the fair value levels defined above as of December&#160;31, 2022 and 2021.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0992bb2036cd4999b2aa3c3a96465d43" continuedAt="ib4e5d0827c5b4c14bd18e3da5f685957">&#160;</ix:continuation></span></div><ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="us-gaap:FairValueByBalanceSheetGroupingTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjMvZnJhZzo4N2U5MWY4YzgwYTk0YTUwOTEzMjkxNzBlYTY5NjMzNC90ZXh0cmVnaW9uOjg3ZTkxZjhjODBhOTRhNTA5MTMyOTE3MGVhNjk2MzM0XzE0ODA_04914d6e-1b01-4d30-98d8-5a07298fb3ff" continuedAt="i7d63b319aea84aaabdcdb79eac457918" escape="true"></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ib4e5d0827c5b4c14bd18e3da5f685957"><ix:continuation id="i7d63b319aea84aaabdcdb79eac457918"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets and Liabilities at Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="21" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfe8c84430c424597db1dafc1f3fd2e_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjMvZnJhZzo4N2U5MWY4YzgwYTk0YTUwOTEzMjkxNzBlYTY5NjMzNC90YWJsZTo1NGNhNTgwNmRmMTU0YzEzYTU4ZTFkZjVhMDFlMGU0YS90YWJsZXJhbmdlOjU0Y2E1ODA2ZGYxNTRjMTNhNThlMWRmNWEwMWUwZTRhXzUtMS0xLTEtMzMyMDM_d2b00575-7e32-4602-b2e8-a2be6a50b859">46,345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70df917b1e21470f80121f484c414360_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjMvZnJhZzo4N2U5MWY4YzgwYTk0YTUwOTEzMjkxNzBlYTY5NjMzNC90YWJsZTo1NGNhNTgwNmRmMTU0YzEzYTU4ZTFkZjVhMDFlMGU0YS90YWJsZXJhbmdlOjU0Y2E1ODA2ZGYxNTRjMTNhNThlMWRmNWEwMWUwZTRhXzUtMy0xLTEtMzMyMDM_7ff1b94d-af0b-4503-9a5a-ed5819c65477">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4663c2e38d1a45debc09ce327eed516d_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjMvZnJhZzo4N2U5MWY4YzgwYTk0YTUwOTEzMjkxNzBlYTY5NjMzNC90YWJsZTo1NGNhNTgwNmRmMTU0YzEzYTU4ZTFkZjVhMDFlMGU0YS90YWJsZXJhbmdlOjU0Y2E1ODA2ZGYxNTRjMTNhNThlMWRmNWEwMWUwZTRhXzUtNS0xLTEtMzMyMDM_ba0a0255-21a9-4012-852d-9e34c8a74290">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjMvZnJhZzo4N2U5MWY4YzgwYTk0YTUwOTEzMjkxNzBlYTY5NjMzNC90YWJsZTo1NGNhNTgwNmRmMTU0YzEzYTU4ZTFkZjVhMDFlMGU0YS90YWJsZXJhbmdlOjU0Y2E1ODA2ZGYxNTRjMTNhNThlMWRmNWEwMWUwZTRhXzUtNy0xLTEtMzMyMDM_ac85ceea-72f9-48c5-a611-5b1b3cae5cb9">46,345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfe8c84430c424597db1dafc1f3fd2e_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjMvZnJhZzo4N2U5MWY4YzgwYTk0YTUwOTEzMjkxNzBlYTY5NjMzNC90YWJsZTo1NGNhNTgwNmRmMTU0YzEzYTU4ZTFkZjVhMDFlMGU0YS90YWJsZXJhbmdlOjU0Y2E1ODA2ZGYxNTRjMTNhNThlMWRmNWEwMWUwZTRhXzYtMS0xLTEtMzMyMDM_b1677e03-e80b-4cde-86e6-b7dd62c510d8">73,680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70df917b1e21470f80121f484c414360_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjMvZnJhZzo4N2U5MWY4YzgwYTk0YTUwOTEzMjkxNzBlYTY5NjMzNC90YWJsZTo1NGNhNTgwNmRmMTU0YzEzYTU4ZTFkZjVhMDFlMGU0YS90YWJsZXJhbmdlOjU0Y2E1ODA2ZGYxNTRjMTNhNThlMWRmNWEwMWUwZTRhXzYtMy0xLTEtMzMyMDM_82ecd5bc-b87f-48fe-90af-3a245fc32721">18,332</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4663c2e38d1a45debc09ce327eed516d_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjMvZnJhZzo4N2U5MWY4YzgwYTk0YTUwOTEzMjkxNzBlYTY5NjMzNC90YWJsZTo1NGNhNTgwNmRmMTU0YzEzYTU4ZTFkZjVhMDFlMGU0YS90YWJsZXJhbmdlOjU0Y2E1ODA2ZGYxNTRjMTNhNThlMWRmNWEwMWUwZTRhXzYtNS0xLTEtMzMyMDM_006e3828-0b8a-46f9-991a-79af74e5d7bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjMvZnJhZzo4N2U5MWY4YzgwYTk0YTUwOTEzMjkxNzBlYTY5NjMzNC90YWJsZTo1NGNhNTgwNmRmMTU0YzEzYTU4ZTFkZjVhMDFlMGU0YS90YWJsZXJhbmdlOjU0Y2E1ODA2ZGYxNTRjMTNhNThlMWRmNWEwMWUwZTRhXzYtNy0xLTEtMzMyMDM_26f5f09b-856f-4d23-9db4-37475ecbde83">92,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfe8c84430c424597db1dafc1f3fd2e_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjMvZnJhZzo4N2U5MWY4YzgwYTk0YTUwOTEzMjkxNzBlYTY5NjMzNC90YWJsZTo1NGNhNTgwNmRmMTU0YzEzYTU4ZTFkZjVhMDFlMGU0YS90YWJsZXJhbmdlOjU0Y2E1ODA2ZGYxNTRjMTNhNThlMWRmNWEwMWUwZTRhXzctMS0xLTEtMzMyMDM_9ca6843c-d985-46ae-b917-b097a33a8260">120,025</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70df917b1e21470f80121f484c414360_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjMvZnJhZzo4N2U5MWY4YzgwYTk0YTUwOTEzMjkxNzBlYTY5NjMzNC90YWJsZTo1NGNhNTgwNmRmMTU0YzEzYTU4ZTFkZjVhMDFlMGU0YS90YWJsZXJhbmdlOjU0Y2E1ODA2ZGYxNTRjMTNhNThlMWRmNWEwMWUwZTRhXzctMy0xLTEtMzMyMDM_54d199d2-69cf-40fc-9edc-4e049f4e7bc3">18,332</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4663c2e38d1a45debc09ce327eed516d_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjMvZnJhZzo4N2U5MWY4YzgwYTk0YTUwOTEzMjkxNzBlYTY5NjMzNC90YWJsZTo1NGNhNTgwNmRmMTU0YzEzYTU4ZTFkZjVhMDFlMGU0YS90YWJsZXJhbmdlOjU0Y2E1ODA2ZGYxNTRjMTNhNThlMWRmNWEwMWUwZTRhXzctNS0xLTEtMzMyMDM_0e702326-ec80-4970-bc56-8320a58dddec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjMvZnJhZzo4N2U5MWY4YzgwYTk0YTUwOTEzMjkxNzBlYTY5NjMzNC90YWJsZTo1NGNhNTgwNmRmMTU0YzEzYTU4ZTFkZjVhMDFlMGU0YS90YWJsZXJhbmdlOjU0Y2E1ODA2ZGYxNTRjMTNhNThlMWRmNWEwMWUwZTRhXzctNy0xLTEtMzMyMDM_f7ac4ee6-da17-497c-93fb-e4ea48f44899">138,357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets and Liabilities at Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="21" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i116622a8a31c498b8b13d9c3ba470fd3_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjMvZnJhZzo4N2U5MWY4YzgwYTk0YTUwOTEzMjkxNzBlYTY5NjMzNC90YWJsZTozOGFiZWY3ZTEyZmE0ODAwYjBjMWFiMDJkZTFiMjI2MS90YWJsZXJhbmdlOjM4YWJlZjdlMTJmYTQ4MDBiMGMxYWIwMmRlMWIyMjYxXzUtMS0xLTEtMzMyMDM_007165ee-0e77-49c6-aa3f-c6c376bad777">64,065</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d9a3d2b722d442a81512dcfc7684e90_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjMvZnJhZzo4N2U5MWY4YzgwYTk0YTUwOTEzMjkxNzBlYTY5NjMzNC90YWJsZTozOGFiZWY3ZTEyZmE0ODAwYjBjMWFiMDJkZTFiMjI2MS90YWJsZXJhbmdlOjM4YWJlZjdlMTJmYTQ4MDBiMGMxYWIwMmRlMWIyMjYxXzUtMy0xLTEtMzMyMDM_bc7743f9-8ae6-460b-8785-c232749d59aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80407335c811483eb7ec1795e3a17f08_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjMvZnJhZzo4N2U5MWY4YzgwYTk0YTUwOTEzMjkxNzBlYTY5NjMzNC90YWJsZTozOGFiZWY3ZTEyZmE0ODAwYjBjMWFiMDJkZTFiMjI2MS90YWJsZXJhbmdlOjM4YWJlZjdlMTJmYTQ4MDBiMGMxYWIwMmRlMWIyMjYxXzUtNS0xLTEtMzMyMDM_27e89480-b39f-4f01-910e-cf072c3e1148">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjMvZnJhZzo4N2U5MWY4YzgwYTk0YTUwOTEzMjkxNzBlYTY5NjMzNC90YWJsZTozOGFiZWY3ZTEyZmE0ODAwYjBjMWFiMDJkZTFiMjI2MS90YWJsZXJhbmdlOjM4YWJlZjdlMTJmYTQ4MDBiMGMxYWIwMmRlMWIyMjYxXzUtNy0xLTEtMzMyMDM_cfce145b-cc60-4945-a119-448f3bd27539">64,065</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i116622a8a31c498b8b13d9c3ba470fd3_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjMvZnJhZzo4N2U5MWY4YzgwYTk0YTUwOTEzMjkxNzBlYTY5NjMzNC90YWJsZTozOGFiZWY3ZTEyZmE0ODAwYjBjMWFiMDJkZTFiMjI2MS90YWJsZXJhbmdlOjM4YWJlZjdlMTJmYTQ4MDBiMGMxYWIwMmRlMWIyMjYxXzYtMS0xLTEtMzMyMDM_a2520a23-ef0b-479b-af0d-348ce3422b5e">7,561</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d9a3d2b722d442a81512dcfc7684e90_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjMvZnJhZzo4N2U5MWY4YzgwYTk0YTUwOTEzMjkxNzBlYTY5NjMzNC90YWJsZTozOGFiZWY3ZTEyZmE0ODAwYjBjMWFiMDJkZTFiMjI2MS90YWJsZXJhbmdlOjM4YWJlZjdlMTJmYTQ4MDBiMGMxYWIwMmRlMWIyMjYxXzYtMy0xLTEtMzMyMDM_91bffe4b-39f8-480e-aac1-284f2f7452ff">15,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80407335c811483eb7ec1795e3a17f08_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjMvZnJhZzo4N2U5MWY4YzgwYTk0YTUwOTEzMjkxNzBlYTY5NjMzNC90YWJsZTozOGFiZWY3ZTEyZmE0ODAwYjBjMWFiMDJkZTFiMjI2MS90YWJsZXJhbmdlOjM4YWJlZjdlMTJmYTQ4MDBiMGMxYWIwMmRlMWIyMjYxXzYtNS0xLTEtMzMyMDM_2b5f28e4-96cc-4110-ae27-217c81243804">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjMvZnJhZzo4N2U5MWY4YzgwYTk0YTUwOTEzMjkxNzBlYTY5NjMzNC90YWJsZTozOGFiZWY3ZTEyZmE0ODAwYjBjMWFiMDJkZTFiMjI2MS90YWJsZXJhbmdlOjM4YWJlZjdlMTJmYTQ4MDBiMGMxYWIwMmRlMWIyMjYxXzYtNy0xLTEtMzMyMDM_b439f2ac-3694-4eee-ad5d-316c89fa0436">22,678</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i116622a8a31c498b8b13d9c3ba470fd3_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjMvZnJhZzo4N2U5MWY4YzgwYTk0YTUwOTEzMjkxNzBlYTY5NjMzNC90YWJsZTozOGFiZWY3ZTEyZmE0ODAwYjBjMWFiMDJkZTFiMjI2MS90YWJsZXJhbmdlOjM4YWJlZjdlMTJmYTQ4MDBiMGMxYWIwMmRlMWIyMjYxXzctMS0xLTEtMzMyMDM_d5f68d0c-75d4-4418-9ce1-8b4d7c69e66d">71,626</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d9a3d2b722d442a81512dcfc7684e90_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjMvZnJhZzo4N2U5MWY4YzgwYTk0YTUwOTEzMjkxNzBlYTY5NjMzNC90YWJsZTozOGFiZWY3ZTEyZmE0ODAwYjBjMWFiMDJkZTFiMjI2MS90YWJsZXJhbmdlOjM4YWJlZjdlMTJmYTQ4MDBiMGMxYWIwMmRlMWIyMjYxXzctMy0xLTEtMzMyMDM_79e96bbf-b06e-4cd7-b18f-afb3115bdc41">15,117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80407335c811483eb7ec1795e3a17f08_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjMvZnJhZzo4N2U5MWY4YzgwYTk0YTUwOTEzMjkxNzBlYTY5NjMzNC90YWJsZTozOGFiZWY3ZTEyZmE0ODAwYjBjMWFiMDJkZTFiMjI2MS90YWJsZXJhbmdlOjM4YWJlZjdlMTJmYTQ4MDBiMGMxYWIwMmRlMWIyMjYxXzctNS0xLTEtMzMyMDM_7046c03a-4cde-46ec-946d-32d3f29b8c1c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjMvZnJhZzo4N2U5MWY4YzgwYTk0YTUwOTEzMjkxNzBlYTY5NjMzNC90YWJsZTozOGFiZWY3ZTEyZmE0ODAwYjBjMWFiMDJkZTFiMjI2MS90YWJsZXJhbmdlOjM4YWJlZjdlMTJmYTQ4MDBiMGMxYWIwMmRlMWIyMjYxXzctNy0xLTEtMzMyMDM_f6d3ea37-b24e-43d1-b417-03bc8e18efd6">86,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have any Level 3 assets or liabilities at December&#160;31, 2022 or 2021. Transfers between levels are recognized at the actual date of circumstance that caused the transfer.  There were no transfers between Level 1 and Level 2 during the periods presented.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 9, Debt Obligations, for fair value measurements of debt obligations.</span></div></ix:continuation><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i122d3ae3d73245b585bd7f040afd795c_166"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjYvZnJhZzo4NGM3ZmQwYTRhOGI0ZjY0YmQ3MDIxNjBmZDNmODhmYi90ZXh0cmVnaW9uOjg0YzdmZDBhNGE4YjRmNjRiZDcwMjE2MGZkM2Y4OGZiXzEwNDc_516cba84-f106-4ed0-a1e5-d46dc7076c9a" continuedAt="i893f2f1f98b44200a879c225bee9a9b1" escape="true">Property and Equipment</ix:nonNumeric></span></div><ix:continuation id="i893f2f1f98b44200a879c225bee9a9b1"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment at December&#160;31, 2022 and 2021 are as follows:</span><ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjYvZnJhZzo4NGM3ZmQwYTRhOGI0ZjY0YmQ3MDIxNjBmZDNmODhmYi90ZXh0cmVnaW9uOjg0YzdmZDBhNGE4YjRmNjRiZDcwMjE2MGZkM2Y4OGZiXzEwNDI_e1f517b8-905e-4682-83a6-b776a6aa0cf1" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:56.231%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.178%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.272%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.178%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.539%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Useful Lives</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">In Years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computers and software</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iada15b389ba44ae5ad53399ba96f0121_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjYvZnJhZzo4NGM3ZmQwYTRhOGI0ZjY0YmQ3MDIxNjBmZDNmODhmYi90YWJsZTpkNjQ2NzQ5YTY3Yzc0ZGUxOWE4NjAzNDc2ODAyYTg1OS90YWJsZXJhbmdlOmQ2NDY3NDlhNjdjNzRkZTE5YTg2MDM0NzY4MDJhODU5XzMtMS0xLTEtMzMyMDMvdGV4dHJlZ2lvbjplZWVhYTFkY2FjM2Q0ZTFkOWYyOWE2ZGQyOTFhMzM5M180_ca409140-de0e-4c4c-9889-86255d2cc825">3</ix:nonNumeric>-<ix:nonNumeric contextRef="ifaa3a61f9810465ab321c51897417ed6_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjYvZnJhZzo4NGM3ZmQwYTRhOGI0ZjY0YmQ3MDIxNjBmZDNmODhmYi90YWJsZTpkNjQ2NzQ5YTY3Yzc0ZGUxOWE4NjAzNDc2ODAyYTg1OS90YWJsZXJhbmdlOmQ2NDY3NDlhNjdjNzRkZTE5YTg2MDM0NzY4MDJhODU5XzMtMS0xLTEtMzMyMDMvdGV4dHJlZ2lvbjplZWVhYTFkY2FjM2Q0ZTFkOWYyOWE2ZGQyOTFhMzM5M183_49d3ee6b-ee53-4120-bdb1-09e13a86bb0c">5</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3c76eaf4e9546efa476fcd01ad729ac_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjYvZnJhZzo4NGM3ZmQwYTRhOGI0ZjY0YmQ3MDIxNjBmZDNmODhmYi90YWJsZTpkNjQ2NzQ5YTY3Yzc0ZGUxOWE4NjAzNDc2ODAyYTg1OS90YWJsZXJhbmdlOmQ2NDY3NDlhNjdjNzRkZTE5YTg2MDM0NzY4MDJhODU5XzMtNS0xLTEtMzMyMDM_9624ffdb-d0d7-48e6-84f8-88bf3e0cb828">2,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i152a1c1f46d945e2acc800b6dd644332_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjYvZnJhZzo4NGM3ZmQwYTRhOGI0ZjY0YmQ3MDIxNjBmZDNmODhmYi90YWJsZTpkNjQ2NzQ5YTY3Yzc0ZGUxOWE4NjAzNDc2ODAyYTg1OS90YWJsZXJhbmdlOmQ2NDY3NDlhNjdjNzRkZTE5YTg2MDM0NzY4MDJhODU5XzMtNy0xLTEtMzMyMDM_babc2001-84f6-4038-8d69-89071bd27f0f">3,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib432f651cb92444fa72128093d268fb8_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjYvZnJhZzo4NGM3ZmQwYTRhOGI0ZjY0YmQ3MDIxNjBmZDNmODhmYi90YWJsZTpkNjQ2NzQ5YTY3Yzc0ZGUxOWE4NjAzNDc2ODAyYTg1OS90YWJsZXJhbmdlOmQ2NDY3NDlhNjdjNzRkZTE5YTg2MDM0NzY4MDJhODU5XzQtMS0xLTEtMzMyMDMvdGV4dHJlZ2lvbjpkMjk0ZjE1ZTY5ODA0YzA3OTAzYTRlOWY2MGRjMzkxNl80_207d204b-ecfb-4f58-82de-9995eaf8a506">5</ix:nonNumeric>-<ix:nonNumeric contextRef="ib2362482683d4d88854d2053c48290a6_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjYvZnJhZzo4NGM3ZmQwYTRhOGI0ZjY0YmQ3MDIxNjBmZDNmODhmYi90YWJsZTpkNjQ2NzQ5YTY3Yzc0ZGUxOWE4NjAzNDc2ODAyYTg1OS90YWJsZXJhbmdlOmQ2NDY3NDlhNjdjNzRkZTE5YTg2MDM0NzY4MDJhODU5XzQtMS0xLTEtMzMyMDMvdGV4dHJlZ2lvbjpkMjk0ZjE1ZTY5ODA0YzA3OTAzYTRlOWY2MGRjMzkxNl83_da8ffb3c-b4db-4878-8b00-64813e082728">7</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1b08918d03a41e9ba2aa7258f976949_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjYvZnJhZzo4NGM3ZmQwYTRhOGI0ZjY0YmQ3MDIxNjBmZDNmODhmYi90YWJsZTpkNjQ2NzQ5YTY3Yzc0ZGUxOWE4NjAzNDc2ODAyYTg1OS90YWJsZXJhbmdlOmQ2NDY3NDlhNjdjNzRkZTE5YTg2MDM0NzY4MDJhODU5XzQtNS0xLTEtMzMyMDM_be2ee978-dc9d-4342-8496-0dc315662012">1,794</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c2e209ef7da4beea635d107d3eae5eb_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjYvZnJhZzo4NGM3ZmQwYTRhOGI0ZjY0YmQ3MDIxNjBmZDNmODhmYi90YWJsZTpkNjQ2NzQ5YTY3Yzc0ZGUxOWE4NjAzNDc2ODAyYTg1OS90YWJsZXJhbmdlOmQ2NDY3NDlhNjdjNzRkZTE5YTg2MDM0NzY4MDJhODU5XzQtNy0xLTEtMzMyMDM_a2f35a8a-0fe9-4068-b442-260f12329f0f">1,692</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie3fa401e333b4caead7644933a30b5df_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjYvZnJhZzo4NGM3ZmQwYTRhOGI0ZjY0YmQ3MDIxNjBmZDNmODhmYi90YWJsZTpkNjQ2NzQ5YTY3Yzc0ZGUxOWE4NjAzNDc2ODAyYTg1OS90YWJsZXJhbmdlOmQ2NDY3NDlhNjdjNzRkZTE5YTg2MDM0NzY4MDJhODU5XzYtMS0xLTEtMzMyMDMvdGV4dHJlZ2lvbjphYTQwMjY0YmM3ZmE0OWMzODNjNjJhZWZmZjE4NjI2MF80_975b155b-7182-42f7-8614-e49417f27df4">3</ix:nonNumeric>-<ix:nonNumeric contextRef="i572e39a39bbe428abb0ea4530d55ece2_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjYvZnJhZzo4NGM3ZmQwYTRhOGI0ZjY0YmQ3MDIxNjBmZDNmODhmYi90YWJsZTpkNjQ2NzQ5YTY3Yzc0ZGUxOWE4NjAzNDc2ODAyYTg1OS90YWJsZXJhbmdlOmQ2NDY3NDlhNjdjNzRkZTE5YTg2MDM0NzY4MDJhODU5XzYtMS0xLTEtMzMyMDMvdGV4dHJlZ2lvbjphYTQwMjY0YmM3ZmE0OWMzODNjNjJhZWZmZjE4NjI2MF83_431ba652-94d6-41aa-bc26-4bfc44e4119c">7</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7709100c2ea472b8bf3b0dacf1d3df5_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjYvZnJhZzo4NGM3ZmQwYTRhOGI0ZjY0YmQ3MDIxNjBmZDNmODhmYi90YWJsZTpkNjQ2NzQ5YTY3Yzc0ZGUxOWE4NjAzNDc2ODAyYTg1OS90YWJsZXJhbmdlOmQ2NDY3NDlhNjdjNzRkZTE5YTg2MDM0NzY4MDJhODU5XzYtNS0xLTEtMzMyMDM_1406041d-7f4e-4572-a138-6ccdb83c9245">2,052</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e34aff763f34fe18a41ebd0245a5197_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjYvZnJhZzo4NGM3ZmQwYTRhOGI0ZjY0YmQ3MDIxNjBmZDNmODhmYi90YWJsZTpkNjQ2NzQ5YTY3Yzc0ZGUxOWE4NjAzNDc2ODAyYTg1OS90YWJsZXJhbmdlOmQ2NDY3NDlhNjdjNzRkZTE5YTg2MDM0NzY4MDJhODU5XzYtNy0xLTEtMzMyMDM_f5ebe080-1ebc-44cd-8b2a-0281145baade">1,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjYvZnJhZzo4NGM3ZmQwYTRhOGI0ZjY0YmQ3MDIxNjBmZDNmODhmYi90YWJsZTpkNjQ2NzQ5YTY3Yzc0ZGUxOWE4NjAzNDc2ODAyYTg1OS90YWJsZXJhbmdlOmQ2NDY3NDlhNjdjNzRkZTE5YTg2MDM0NzY4MDJhODU5XzktNS0xLTEtMzMyMDM_f0d8ab2a-1332-4179-9aeb-10575f283fab">6,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjYvZnJhZzo4NGM3ZmQwYTRhOGI0ZjY0YmQ3MDIxNjBmZDNmODhmYi90YWJsZTpkNjQ2NzQ5YTY3Yzc0ZGUxOWE4NjAzNDc2ODAyYTg1OS90YWJsZXJhbmdlOmQ2NDY3NDlhNjdjNzRkZTE5YTg2MDM0NzY4MDJhODU5XzktNy0xLTEtMzMyMDM_fb6f7e6f-c9ce-4889-8f0c-1c18185c53a3">6,029</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjYvZnJhZzo4NGM3ZmQwYTRhOGI0ZjY0YmQ3MDIxNjBmZDNmODhmYi90YWJsZTpkNjQ2NzQ5YTY3Yzc0ZGUxOWE4NjAzNDc2ODAyYTg1OS90YWJsZXJhbmdlOmQ2NDY3NDlhNjdjNzRkZTE5YTg2MDM0NzY4MDJhODU5XzEwLTUtMS0xLTMzMjAz_b72d0c82-b2a3-42e6-82f6-bed768eea293">3,984</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjYvZnJhZzo4NGM3ZmQwYTRhOGI0ZjY0YmQ3MDIxNjBmZDNmODhmYi90YWJsZTpkNjQ2NzQ5YTY3Yzc0ZGUxOWE4NjAzNDc2ODAyYTg1OS90YWJsZXJhbmdlOmQ2NDY3NDlhNjdjNzRkZTE5YTg2MDM0NzY4MDJhODU5XzEwLTctMS0xLTMzMjAz_14ff725f-62cf-4986-9b44-b9f5f801957c">4,853</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjYvZnJhZzo4NGM3ZmQwYTRhOGI0ZjY0YmQ3MDIxNjBmZDNmODhmYi90YWJsZTpkNjQ2NzQ5YTY3Yzc0ZGUxOWE4NjAzNDc2ODAyYTg1OS90YWJsZXJhbmdlOmQ2NDY3NDlhNjdjNzRkZTE5YTg2MDM0NzY4MDJhODU5XzExLTUtMS0xLTMzMjAz_7a1ba291-3bed-4ccc-aae6-32b48fb3d298">2,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjYvZnJhZzo4NGM3ZmQwYTRhOGI0ZjY0YmQ3MDIxNjBmZDNmODhmYi90YWJsZTpkNjQ2NzQ5YTY3Yzc0ZGUxOWE4NjAzNDc2ODAyYTg1OS90YWJsZXJhbmdlOmQ2NDY3NDlhNjdjNzRkZTE5YTg2MDM0NzY4MDJhODU5XzExLTctMS0xLTMzMjAz_cd68b4f8-cf51-4111-830d-7726267bbac8">1,176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During each of the years ended December 31, 2022 and 2021, the Company retired $<ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="6" name="us-gaap:NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjYvZnJhZzo4NGM3ZmQwYTRhOGI0ZjY0YmQ3MDIxNjBmZDNmODhmYi90ZXh0cmVnaW9uOjg0YzdmZDBhNGE4YjRmNjRiZDcwMjE2MGZkM2Y4OGZiXzcyNw_2c61b886-7754-41c5-a5fe-8b094d3d3573">1.3</ix:nonFraction>&#160;million of computers and software and furniture and fixtures, which had been fully depreciated. During each of the years ended December 31, 2022 and 2021, the Company purchased $<ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjYvZnJhZzo4NGM3ZmQwYTRhOGI0ZjY0YmQ3MDIxNjBmZDNmODhmYi90ZXh0cmVnaW9uOjg0YzdmZDBhNGE4YjRmNjRiZDcwMjE2MGZkM2Y4OGZiXzEwOTk1MTE2Mjg4ODI_bfaa7505-6926-45b7-b170-84b4565f7ed0">1.3</ix:nonFraction> million of assets comprised of leasehold improvements, computers and software and furniture. The leasehold improvements are being amortized over the applicable lease term.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div id="i122d3ae3d73245b585bd7f040afd795c_169"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90ZXh0cmVnaW9uOmU0YTg4MTBjYTNiZTRjNmFiOGQ2ZmVlMDhiODU4MjhkXzQzMTU_46ab9dfd-2927-4d0d-a552-3b897d34681f" continuedAt="ie308730391e845d7943eeed13dd3c319" escape="true">Income Taxes </ix:nonNumeric></span></div><ix:continuation id="ie308730391e845d7943eeed13dd3c319" continuedAt="i72a749e65dcc494d89e59f45c73dd997"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Coronavirus Aid, Relief and Economic Security Act (&#8220;CARES Act&#8221;) was enacted on March 27, 2020 </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the United States to provide emergency assistance to individuals and businesses affected by the COVID-19 pandemic. The CARES Act includes temporary changes to both income and non-income based tax laws.  Future regulatory guidance under the CARES Act or additional legislation enacted by Congress in connection with the COVID-19 pandemic could impact our tax provision in future periods.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lexicon recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been recognized differently in the financial statements and tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between the financial statement carrying amounts and tax bases of liabilities and assets using enacted tax rates and laws in effect in the years in which the differences are expected to reverse. Deferred tax assets are evaluated for realization based on a more-likely-than-not criteria in determining if a valuation allowance should be provided.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of Lexicon&#8217;s deferred tax assets (liabilities) at December&#160;31, 2022 and 2021 are as follows:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span><ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90ZXh0cmVnaW9uOmU0YTg4MTBjYTNiZTRjNmFiOGQ2ZmVlMDhiODU4MjhkXzQzMTk_210920f7-a5e5-44db-870d-aae68febe15b" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTo3NTRlNjQ0ZmFhZDA0ODI3YWI1MjI3NDg2MDc5NzRjZC90YWJsZXJhbmdlOjc1NGU2NDRmYWFkMDQ4MjdhYjUyMjc0ODYwNzk3NGNkXzQtMS0xLTEtMzMyMDM_616b4ec7-e07e-4525-9915-4d992f3d26f8">251,331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTo3NTRlNjQ0ZmFhZDA0ODI3YWI1MjI3NDg2MDc5NzRjZC90YWJsZXJhbmdlOjc1NGU2NDRmYWFkMDQ4MjdhYjUyMjc0ODYwNzk3NGNkXzQtMy0xLTEtMzMyMDM_0d0a3272-6f5c-4d5e-a92b-f1130e118b36">229,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTo3NTRlNjQ0ZmFhZDA0ODI3YWI1MjI3NDg2MDc5NzRjZC90YWJsZXJhbmdlOjc1NGU2NDRmYWFkMDQ4MjdhYjUyMjc0ODYwNzk3NGNkXzUtMS0xLTEtMzMyMDM_61acee36-33d2-432a-8e15-2ff2f52ba10f">29,290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTo3NTRlNjQ0ZmFhZDA0ODI3YWI1MjI3NDg2MDc5NzRjZC90YWJsZXJhbmdlOjc1NGU2NDRmYWFkMDQ4MjdhYjUyMjc0ODYwNzk3NGNkXzUtMy0xLTEtMzMyMDM_5bf26494-638f-4828-96c9-ab53360412ff">29,290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Orphan drug credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="lxrx:DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTo3NTRlNjQ0ZmFhZDA0ODI3YWI1MjI3NDg2MDc5NzRjZC90YWJsZXJhbmdlOjc1NGU2NDRmYWFkMDQ4MjdhYjUyMjc0ODYwNzk3NGNkXzYtMS0xLTEtMzMyMDM_9a9d561c-f47e-4fd2-acd1-f73b3dd56946">24,524</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231" decimals="-3" name="lxrx:DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTo3NTRlNjQ0ZmFhZDA0ODI3YWI1MjI3NDg2MDc5NzRjZC90YWJsZXJhbmdlOjc1NGU2NDRmYWFkMDQ4MjdhYjUyMjc0ODYwNzk3NGNkXzYtMy0xLTEtMzMyMDM_15e20af5-7537-4c22-8ca5-c3cfd19a5084">24,524</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTo3NTRlNjQ0ZmFhZDA0ODI3YWI1MjI3NDg2MDc5NzRjZC90YWJsZXJhbmdlOjc1NGU2NDRmYWFkMDQ4MjdhYjUyMjc0ODYwNzk3NGNkXzctMS0xLTEtMzMyMDM_92c1cc88-63d8-469c-adb4-e203ac12d0bd">33,813</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTo3NTRlNjQ0ZmFhZDA0ODI3YWI1MjI3NDg2MDc5NzRjZC90YWJsZXJhbmdlOjc1NGU2NDRmYWFkMDQ4MjdhYjUyMjc0ODYwNzk3NGNkXzctMy0xLTEtMzMyMDM_d841a8d5-b5ce-4e78-9c6d-9e046224d378">36,770</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTo3NTRlNjQ0ZmFhZDA0ODI3YWI1MjI3NDg2MDc5NzRjZC90YWJsZXJhbmdlOjc1NGU2NDRmYWFkMDQ4MjdhYjUyMjc0ODYwNzk3NGNkXzgtMS0xLTEtMzMyMDM_e372100a-d0f0-4131-bf0f-166cf89d5962">5,445</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTo3NTRlNjQ0ZmFhZDA0ODI3YWI1MjI3NDg2MDc5NzRjZC90YWJsZXJhbmdlOjc1NGU2NDRmYWFkMDQ4MjdhYjUyMjc0ODYwNzk3NGNkXzgtMy0xLTEtMzMyMDM_67ae60cb-3df2-4b25-8f9f-36ec8fd356bb">5,163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="lxrx:DeferredTaxAssetsSection163j_LXRX" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTo3NTRlNjQ0ZmFhZDA0ODI3YWI1MjI3NDg2MDc5NzRjZC90YWJsZXJhbmdlOjc1NGU2NDRmYWFkMDQ4MjdhYjUyMjc0ODYwNzk3NGNkXzEwLTEtMS0xLTMzMjAz_64625095-e5de-4d2b-bdc1-fbbedeaa76a5">398</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231" decimals="-3" name="lxrx:DeferredTaxAssetsSection163j_LXRX" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTo3NTRlNjQ0ZmFhZDA0ODI3YWI1MjI3NDg2MDc5NzRjZC90YWJsZXJhbmdlOjc1NGU2NDRmYWFkMDQ4MjdhYjUyMjc0ODYwNzk3NGNkXzEwLTMtMS0xLTMzMjAz_3beb7834-6a4b-4b2c-a367-399b03995e2b">148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTo3NTRlNjQ0ZmFhZDA0ODI3YWI1MjI3NDg2MDc5NzRjZC90YWJsZXJhbmdlOjc1NGU2NDRmYWFkMDQ4MjdhYjUyMjc0ODYwNzk3NGNkXzExLTEtMS0xLTMzMjAz_9270bc00-0311-4275-84f9-fde3ffc5ac9d">2,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTo3NTRlNjQ0ZmFhZDA0ODI3YWI1MjI3NDg2MDc5NzRjZC90YWJsZXJhbmdlOjc1NGU2NDRmYWFkMDQ4MjdhYjUyMjc0ODYwNzk3NGNkXzExLTMtMS0xLTMzMjAz_87ba7b32-3e37-4752-a973-90e753e09c6e">1,308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTo3NTRlNjQ0ZmFhZDA0ODI3YWI1MjI3NDg2MDc5NzRjZC90YWJsZXJhbmdlOjc1NGU2NDRmYWFkMDQ4MjdhYjUyMjc0ODYwNzk3NGNkXzEyLTEtMS0xLTMzMjAz_59ceeebd-ea9b-4af9-b626-3942ef405a31">347,056</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTo3NTRlNjQ0ZmFhZDA0ODI3YWI1MjI3NDg2MDc5NzRjZC90YWJsZXJhbmdlOjc1NGU2NDRmYWFkMDQ4MjdhYjUyMjc0ODYwNzk3NGNkXzEyLTMtMS0xLTMzMjAz_77c578cd-de98-4de3-8efc-a0930cfa2233">326,630</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTo3NTRlNjQ0ZmFhZDA0ODI3YWI1MjI3NDg2MDc5NzRjZC90YWJsZXJhbmdlOjc1NGU2NDRmYWFkMDQ4MjdhYjUyMjc0ODYwNzk3NGNkXzE1LTEtMS0xLTMzMjAz_909686fb-0439-4f62-b7f2-9b9ddf9c995b">1,295</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTo3NTRlNjQ0ZmFhZDA0ODI3YWI1MjI3NDg2MDc5NzRjZC90YWJsZXJhbmdlOjc1NGU2NDRmYWFkMDQ4MjdhYjUyMjc0ODYwNzk3NGNkXzE1LTMtMS0xLTMzMjAz_bfd7cdd6-6a26-41c7-bb0c-e8a49cdf9121">412</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTo3NTRlNjQ0ZmFhZDA0ODI3YWI1MjI3NDg2MDc5NzRjZC90YWJsZXJhbmdlOjc1NGU2NDRmYWFkMDQ4MjdhYjUyMjc0ODYwNzk3NGNkXzE2LTEtMS0xLTMzMjAz_b6063e2d-e0b0-4d19-a4ab-cf3b292bbd70">1,295</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTo3NTRlNjQ0ZmFhZDA0ODI3YWI1MjI3NDg2MDc5NzRjZC90YWJsZXJhbmdlOjc1NGU2NDRmYWFkMDQ4MjdhYjUyMjc0ODYwNzk3NGNkXzE2LTMtMS0xLTMzMjAz_5cee8e36-6eb9-483e-be74-2698357321df">412</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTo3NTRlNjQ0ZmFhZDA0ODI3YWI1MjI3NDg2MDc5NzRjZC90YWJsZXJhbmdlOjc1NGU2NDRmYWFkMDQ4MjdhYjUyMjc0ODYwNzk3NGNkXzE3LTEtMS0xLTMzMjAz_44898143-da27-45ea-9509-3d24cf6ddeaf">345,761</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTo3NTRlNjQ0ZmFhZDA0ODI3YWI1MjI3NDg2MDc5NzRjZC90YWJsZXJhbmdlOjc1NGU2NDRmYWFkMDQ4MjdhYjUyMjc0ODYwNzk3NGNkXzE3LTMtMS0xLTMzMjAz_5e3242fe-7716-480e-86bf-0434bee118f1">326,218</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTo3NTRlNjQ0ZmFhZDA0ODI3YWI1MjI3NDg2MDc5NzRjZC90YWJsZXJhbmdlOjc1NGU2NDRmYWFkMDQ4MjdhYjUyMjc0ODYwNzk3NGNkXzE4LTEtMS0xLTMzMjAz_83c8982d-c9d9-4b30-b654-6604e1a6c769">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTo3NTRlNjQ0ZmFhZDA0ODI3YWI1MjI3NDg2MDc5NzRjZC90YWJsZXJhbmdlOjc1NGU2NDRmYWFkMDQ4MjdhYjUyMjc0ODYwNzk3NGNkXzE4LTMtMS0xLTMzMjAz_750e2c46-03bc-4a8f-b4b7-0712fd5eb897">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i72a749e65dcc494d89e59f45c73dd997"><ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90ZXh0cmVnaW9uOmU0YTg4MTBjYTNiZTRjNmFiOGQ2ZmVlMDhiODU4MjhkXzQzMTQ_a145305e-2b6e-4bcf-b789-2882a1dd4a85" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the statutory tax rate to the effective tax rate for the years ended December&#160;31, 2022, 2021 and 2020 consists of the following:</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"></td><td style="width:51.921%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.739%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.437%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.139%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected income tax expense (benefit) at <ix:nonFraction unitRef="number" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTowZDI2YzMxNjZmODc0NzQzOGZlYjZlN2E0ZWM2ZTFmNy90YWJsZXJhbmdlOjBkMjZjMzE2NmY4NzQ3NDM4ZmViNmU3YTRlYzZlMWY3XzMtMC0xLTEtMzMyMDMvdGV4dHJlZ2lvbjoyMGZhM2U3ZGRiMzQ0NzRhYTdhM2IzNThhOTM3MzU0ZF80NQ_4ad31183-524e-431d-ba01-90c8149619c5">21</ix:nonFraction>%</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTowZDI2YzMxNjZmODc0NzQzOGZlYjZlN2E0ZWM2ZTFmNy90YWJsZXJhbmdlOjBkMjZjMzE2NmY4NzQ3NDM4ZmViNmU3YTRlYzZlMWY3XzMtMS0xLTEtMzMyMDM_3e6d47fc-b21a-4c85-ae86-25f067a32110">21,408</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTowZDI2YzMxNjZmODc0NzQzOGZlYjZlN2E0ZWM2ZTFmNy90YWJsZXJhbmdlOjBkMjZjMzE2NmY4NzQ3NDM4ZmViNmU3YTRlYzZlMWY3XzMtMy0xLTEtMzMyMDM_00339b9c-9af3-4734-8e6b-7d9b36848642">18,429</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTowZDI2YzMxNjZmODc0NzQzOGZlYjZlN2E0ZWM2ZTFmNy90YWJsZXJhbmdlOjBkMjZjMzE2NmY4NzQ3NDM4ZmViNmU3YTRlYzZlMWY3XzMtNS0xLTEtMzMyMDM_f38a50e2-fc51-4719-91a6-4d8aad0a0a04">12,300</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTowZDI2YzMxNjZmODc0NzQzOGZlYjZlN2E0ZWM2ZTFmNy90YWJsZXJhbmdlOjBkMjZjMzE2NmY4NzQ3NDM4ZmViNmU3YTRlYzZlMWY3XzQtMS0xLTEtMzMyMDM_d5a3d8c1-2e76-4d48-89ee-7d253e859edf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTowZDI2YzMxNjZmODc0NzQzOGZlYjZlN2E0ZWM2ZTFmNy90YWJsZXJhbmdlOjBkMjZjMzE2NmY4NzQ3NDM4ZmViNmU3YTRlYzZlMWY3XzQtMy0xLTEtMzMyMDM_d1768f66-5085-423b-a1f2-de1fcef9d1b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTowZDI2YzMxNjZmODc0NzQzOGZlYjZlN2E0ZWM2ZTFmNy90YWJsZXJhbmdlOjBkMjZjMzE2NmY4NzQ3NDM4ZmViNmU3YTRlYzZlMWY3XzQtNS0xLTEtMzMyMDM_376cf674-348a-4285-90a8-58f75decbefd">269</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTowZDI2YzMxNjZmODc0NzQzOGZlYjZlN2E0ZWM2ZTFmNy90YWJsZXJhbmdlOjBkMjZjMzE2NmY4NzQ3NDM4ZmViNmU3YTRlYzZlMWY3XzUtMS0xLTEtMzMyMDM_d31c5666-c035-4c74-b8c3-c3e9dd423074">1,627</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="-3" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTowZDI2YzMxNjZmODc0NzQzOGZlYjZlN2E0ZWM2ZTFmNy90YWJsZXJhbmdlOjBkMjZjMzE2NmY4NzQ3NDM4ZmViNmU3YTRlYzZlMWY3XzUtMy0xLTEtMzMyMDM_c62ea3e1-8387-4052-ad00-b85d06cb97ca">851</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-3" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTowZDI2YzMxNjZmODc0NzQzOGZlYjZlN2E0ZWM2ZTFmNy90YWJsZXJhbmdlOjBkMjZjMzE2NmY4NzQ3NDM4ZmViNmU3YTRlYzZlMWY3XzUtNS0xLTEtMzMyMDM_ab34a106-b921-4ee9-bdde-3564926bb6c6">1,777</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write off of credit carryover due to 382 study</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" name="lxrx:WriteOffOfTaxCredits" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTowZDI2YzMxNjZmODc0NzQzOGZlYjZlN2E0ZWM2ZTFmNy90YWJsZXJhbmdlOjBkMjZjMzE2NmY4NzQ3NDM4ZmViNmU3YTRlYzZlMWY3XzExLTEtMS0xLTMzMjAz_dfa78ff0-5174-42c1-b991-fd6a854b977f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="-3" name="lxrx:WriteOffOfTaxCredits" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTowZDI2YzMxNjZmODc0NzQzOGZlYjZlN2E0ZWM2ZTFmNy90YWJsZXJhbmdlOjBkMjZjMzE2NmY4NzQ3NDM4ZmViNmU3YTRlYzZlMWY3XzExLTMtMS0xLTMzMjAz_c249e9c1-b734-4282-bba9-208c44f7824e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-3" name="lxrx:WriteOffOfTaxCredits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTowZDI2YzMxNjZmODc0NzQzOGZlYjZlN2E0ZWM2ZTFmNy90YWJsZXJhbmdlOjBkMjZjMzE2NmY4NzQ3NDM4ZmViNmU3YTRlYzZlMWY3XzExLTUtMS0xLTMzMjAz_e86aeb43-4026-4598-b288-32a3125b47d3">31,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTowZDI2YzMxNjZmODc0NzQzOGZlYjZlN2E0ZWM2ZTFmNy90YWJsZXJhbmdlOjBkMjZjMzE2NmY4NzQ3NDM4ZmViNmU3YTRlYzZlMWY3XzEyLTEtMS0xLTMzMjAz_6662d7bd-4c02-497c-8cc6-d79809b7df50">19,543</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTowZDI2YzMxNjZmODc0NzQzOGZlYjZlN2E0ZWM2ZTFmNy90YWJsZXJhbmdlOjBkMjZjMzE2NmY4NzQ3NDM4ZmViNmU3YTRlYzZlMWY3XzEyLTMtMS0xLTMzMjAz_bb7784b8-7dc3-421a-8b80-b0745b247ee5">17,210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTowZDI2YzMxNjZmODc0NzQzOGZlYjZlN2E0ZWM2ZTFmNy90YWJsZXJhbmdlOjBkMjZjMzE2NmY4NzQ3NDM4ZmViNmU3YTRlYzZlMWY3XzEyLTUtMS0xLTMzMjAz_d2c993e7-16f5-4d1d-b0b9-9004a7f9e612">20,418</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTowZDI2YzMxNjZmODc0NzQzOGZlYjZlN2E0ZWM2ZTFmNy90YWJsZXJhbmdlOjBkMjZjMzE2NmY4NzQ3NDM4ZmViNmU3YTRlYzZlMWY3XzEzLTEtMS0xLTMzMjAz_dff300ac-ba77-4a0d-b815-08941607ffc7">238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTowZDI2YzMxNjZmODc0NzQzOGZlYjZlN2E0ZWM2ZTFmNy90YWJsZXJhbmdlOjBkMjZjMzE2NmY4NzQ3NDM4ZmViNmU3YTRlYzZlMWY3XzEzLTMtMS0xLTMzMjAz_3c694516-e8ca-4c61-bf82-3375fb1faa49">368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTowZDI2YzMxNjZmODc0NzQzOGZlYjZlN2E0ZWM2ZTFmNy90YWJsZXJhbmdlOjBkMjZjMzE2NmY4NzQ3NDM4ZmViNmU3YTRlYzZlMWY3XzEzLTUtMS0xLTMzMjAz_de23c51e-96af-4c39-8a55-045e29815219">157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTowZDI2YzMxNjZmODc0NzQzOGZlYjZlN2E0ZWM2ZTFmNy90YWJsZXJhbmdlOjBkMjZjMzE2NmY4NzQ3NDM4ZmViNmU3YTRlYzZlMWY3XzE0LTEtMS0xLTMzMjAz_16956b0f-4b5a-4396-97f3-a763280a164c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTowZDI2YzMxNjZmODc0NzQzOGZlYjZlN2E0ZWM2ZTFmNy90YWJsZXJhbmdlOjBkMjZjMzE2NmY4NzQ3NDM4ZmViNmU3YTRlYzZlMWY3XzE0LTMtMS0xLTMzMjAz_924a7dc3-5676-44d3-8217-e64923009dec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTowZDI2YzMxNjZmODc0NzQzOGZlYjZlN2E0ZWM2ZTFmNy90YWJsZXJhbmdlOjBkMjZjMzE2NmY4NzQ3NDM4ZmViNmU3YTRlYzZlMWY3XzE0LTUtMS0xLTMzMjAz_68abb239-8998-494b-b50a-f6e783bf7897">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Other is primarily comprised of expiring Research and Development credits for the year ended December&#160;31, 2020 and nondeductible expenses for the years ended December&#160;31, 2022 and 2021.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 382 of the Internal Revenue Code of 1986, contains rules that limit the ability of a company that undergoes an &#8220;ownership change&#8221; to utilize its net operating loss and tax credit carryovers and certain built-in losses recognized in years after the &#8220;ownership change.&#8221; An &#8220;ownership change&#8221; is generally defined as any change in ownership of more than 50% of a corporation&#8217;s stock over a rolling three-year period by stockholders that own (directly or indirectly) 5% or more of the stock of a corporation, or arising from a new issuance of stock by a corporation. If an ownership change occurs, Section 382 generally imposes an annual limitation on the use of pre-ownership change net operating loss carryovers to offset taxable income earned after the ownership change. The Company completed a Section 382 study and determined that historical ownership changes occurred. The Section 382 annual limitation related to historical ownership changes impacts our ability to utilize our tax attributes. In 2020, the federal deferred tax assets and valuation allowance decreased due to the write-off of attributes that will expire still subject to limitation.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">At December&#160;31, 2022, Lexicon had both federal and state NOL carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90ZXh0cmVnaW9uOmU0YTg4MTBjYTNiZTRjNmFiOGQ2ZmVlMDhiODU4MjhkXzI4ODQ_3712e3c7-cc9d-4bf8-950e-19522fcd3ce9">1.2</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90ZXh0cmVnaW9uOmU0YTg4MTBjYTNiZTRjNmFiOGQ2ZmVlMDhiODU4MjhkXzI4OTE_6fd9dc84-d07f-48a5-97f2-c340d461bf29">86.9</ix:nonFraction> million, respectively.&#160;&#160;In 2022, federal NOLs increased by $<ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-5" name="lxrx:A2020FederalNOLIncrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90ZXh0cmVnaW9uOmU0YTg4MTBjYTNiZTRjNmFiOGQ2ZmVlMDhiODU4MjhkXzI5NDU_cd78e867-346d-45d8-b524-c65f8dff6789">104.0</ix:nonFraction> million related to a current year NOL. The Company had $<ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90ZXh0cmVnaW9uOmU0YTg4MTBjYTNiZTRjNmFiOGQ2ZmVlMDhiODU4MjhkXzI5OTU_c24b5736-dfca-4e83-b884-b93efb8c043e">446.3</ix:nonFraction> million of U.S. federal NOL carryforwards as of December 31, 2022, which can be carried forward indefinitely. The remaining federal and state NOL carryforwards will begin to expire in 2022.&#160;Based on the federal tax law limits and the Company&#8217;s cumulative loss position, the Company concluded it was appropriate to establish a full valuation allowance for its net deferred tax assets until an appropriate level of profitability is sustained.&#160;&#160;During the year ended December&#160;31, 2022, the valuation allowance increased $<ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90ZXh0cmVnaW9uOmU0YTg4MTBjYTNiZTRjNmFiOGQ2ZmVlMDhiODU4MjhkXzM0OTI_d1a0bd93-2e24-413c-b49f-9cca811d42d2">19.5</ix:nonFraction> million, primarily due to NOLs generated partially offset by decreases in deferred tax assets associated with capitalized research and development expenses.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of December&#160;31, 2022 and 2021, the Company did not have any unrecognized tax benefits.  Any interest and penalties related to uncertain tax positions will be reflected as a component of income tax expense.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is primarily subject to U.S. federal and New Jersey and Texas state income taxes.&#160;&#160;The tax years 1999 to current remain open to examination by U.S. federal authorities and 2012 to current remain open to examination by state authorities.&#160;&#160;The Company&#8217;s policy is to recognize interest and penalties related to income tax matters in income tax expense.&#160;&#160;As of December&#160;31, 2022 and 2021, the Company had <ix:nonFraction unitRef="usd" contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90ZXh0cmVnaW9uOmU0YTg4MTBjYTNiZTRjNmFiOGQ2ZmVlMDhiODU4MjhkXzQyMzU_1b4d282b-6a8b-468c-ac84-b3ca7d2ff347"><ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90ZXh0cmVnaW9uOmU0YTg4MTBjYTNiZTRjNmFiOGQ2ZmVlMDhiODU4MjhkXzQyMzU_b800fa70-0b08-4fe9-b23b-f2aafb2e8820">no</ix:nonFraction></ix:nonFraction> accruals for interest or penalties related to income tax matters.</span></div></ix:continuation><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i122d3ae3d73245b585bd7f040afd795c_172"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzIvZnJhZzphYjZmYzU0N2FmMGQ0ZmM5YTc0NmY5ZGQ2M2U2NTVjNC90ZXh0cmVnaW9uOmFiNmZjNTQ3YWYwZDRmYzlhNzQ2ZjlkZDYzZTY1NWM0XzEzMTM_ae944d30-5f24-45d0-8cbb-1bf98f622942" continuedAt="i3127749691f940bebf16afe1b9f557a5" escape="true">Goodwill</ix:nonNumeric></span></div><ix:continuation id="i3127749691f940bebf16afe1b9f557a5" continuedAt="i63e6969c957740a2af6d1bb58edc3836"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2001, Lexicon completed the acquisition of Coelacanth Corporation in a merger. Coelacanth, now Lexicon Pharmaceuticals (New Jersey), Inc., formed the core of the Company&#8217;s division responsible for small molecule compound discovery.&#160;&#160;The results of Lexicon Pharmaceuticals (New Jersey), Inc. are included in the Company&#8217;s results of operations for the period subsequent to the acquisition.  Goodwill associated with the acquisition of $<ix:nonFraction unitRef="usd" contextRef="i5c4b46c8c9cd4829a9a8f58250be63e9_I20010712" decimals="-5" name="lxrx:CoelacanthGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzIvZnJhZzphYjZmYzU0N2FmMGQ0ZmM5YTc0NmY5ZGQ2M2U2NTVjNC90ZXh0cmVnaW9uOmFiNmZjNTQ3YWYwZDRmYzlhNzQ2ZjlkZDYzZTY1NWM0XzQ2NQ_da82dd58-c803-42da-9d82-663789dd9135">25.8</ix:nonFraction> million, which represents the excess of the $<ix:nonFraction unitRef="usd" contextRef="i5c4b46c8c9cd4829a9a8f58250be63e9_I20010712" decimals="-5" name="lxrx:CoelacanthPurchasePrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzIvZnJhZzphYjZmYzU0N2FmMGQ0ZmM5YTc0NmY5ZGQ2M2U2NTVjNC90ZXh0cmVnaW9uOmFiNmZjNTQ3YWYwZDRmYzlhNzQ2ZjlkZDYzZTY1NWM0XzUwNA_ca019c35-8f7a-4aa9-98af-831f1b872d63">36.0</ix:nonFraction> million purchase price over the fair value of the underlying net identifiable assets, was assigned to the consolidated entity, Lexicon.&#160;&#160;</span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i63e6969c957740a2af6d1bb58edc3836"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2007, Lexicon entered into an arrangement providing for the financing of the clinical development of certain of its drug candidates.  Under the arrangement, Lexicon licensed to Symphony Icon, Inc. its intellectual property rights relating to the drug candidates and obtained an exclusive purchase option that gave Lexicon the right to acquire all the equity of Symphony Icon.  In July 2010, Lexicon exercised its purchase option and completed the acquisition of Symphony Icon.  Goodwill associated with the acquisition of $<ix:nonFraction unitRef="usd" contextRef="i7ca5f952951f4661bc87adf40c2f03b1_I20100730" decimals="-5" name="lxrx:SymphonyIconGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzIvZnJhZzphYjZmYzU0N2FmMGQ0ZmM5YTc0NmY5ZGQ2M2U2NTVjNC90ZXh0cmVnaW9uOmFiNmZjNTQ3YWYwZDRmYzlhNzQ2ZjlkZDYzZTY1NWM0Xzc5Mg_090dfcd8-5d7e-4e2c-813a-9114adab5b1a">18.7</ix:nonFraction> million, which represents the assets recognized in connection with the deferred tax liability acquired and did not result from excess purchase price, was assigned to the consolidated entity, Lexicon.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is not subject to amortization, but is tested at least annually for impairment at the reporting unit level, which is the Company&#8217;s single operating segment.&#160;&#160;The Company performed an impairment test of goodwill on its annual impairment assessment date.&#160;&#160;This test did not result in an impairment of goodwill.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i122d3ae3d73245b585bd7f040afd795c_175"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzQwOTA_87320180-6997-4b94-bdaa-c7441f206c58" continuedAt="ibaa798540a1543d68769bf2b37516da5" escape="true">Debt Obligations</ix:nonNumeric></span></div><ix:continuation id="ibaa798540a1543d68769bf2b37516da5" continuedAt="iba080fe3cdab4450b54ef91b88ce4d21"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Oxford Term Loans.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 17, 2022, Lexicon and one of its subsidiaries entered into a loan and security agreement with Oxford Finance LLC (&#8220;Oxford&#8221;) that provides up to $<ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="lxrx:OxfordLoanFacility" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2MzIwMzI_f9735c40-60f9-40fc-ace9-b8caca9aab4d">150</ix:nonFraction>&#160;million in borrowing capacity (the &#8220;Oxford Term Loans&#8221;) available in four tranches, each maturing in March 2027. Monthly interest-only payments are due during an initial 36-month period, which may be extended at Lexicon&#8217;s option to 48 months if Lexicon maintains compliance with a financial covenant relating to net sales of sotagliflozin following regulatory approval. The interest-only period will be followed by an amortization period extending through the maturity date.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 29, 2022, the Company entered into a first amendment to the loan and security agreement modifying the period during which the second $25 million tranche under the facility would be available for draw in exchange for $<ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="lxrx:OxfordAmendmentFee" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzQ5NDc4MDIzMzgyNzE_1f86aaeb-7231-4194-8ab4-268682b7f9c0">0.3</ix:nonFraction>&#160;million of cash consideration.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first $<ix:nonFraction unitRef="usd" contextRef="i2e6700e3a4984b19b27e50bda5764ecb_I20220331" decimals="-3" name="lxrx:TermLoanA" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2MzI2NjM_cd843c7c-84a8-4a15-9be0-df50e3eba87e">25</ix:nonFraction>&#160;million tranche was funded at closing. The second $<ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="lxrx:TermLoanB" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2MzI3MDk_52599d30-4dc9-4f78-b153-8f929d6224c4">25</ix:nonFraction>&#160;million tranche was funded on December 30, 2022.  The third $<ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="lxrx:TermLoanC" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2MzI4MTY_4daf8a93-b70f-453f-8ead-b321d81cecfb">50</ix:nonFraction>&#160;million tranche is available for draw at Lexicon&#8217;s option prior to June 30, 2023, but within 60 days of U.S. regulatory approval of sotagliflozin for heart failure. The fourth $<ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="lxrx:TermLoanD" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2MzI5ODg_0859246d-f1c5-4840-ae70-3dbeefbf64e7">50</ix:nonFraction>&#160;million tranche is available for draw at Lexicon&#8217;s option, subject to Oxford&#8217;s consent, at any time prior to the expiration of the interest-only payment period.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Principal payments of $<ix:nonFraction unitRef="usd" contextRef="i5082f56c08c74c63a4b9fbd86c1e2db5_D20250101-20251231" decimals="-3" name="lxrx:A2025OxfordPrincipalPaymentA" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzQ5NDc4MDIzMzc0MzI_d05d779b-b10d-455b-b9ec-ad320f8797d9">8.7</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="ic2f7712d90c8455ebf945f797fd6c4c5_D20260101-20261231" decimals="-3" name="lxrx:A2026OxfordPrincipalPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzQ5NDc4MDIzMzc0Mzc_307a4818-96f9-4395-b9bd-39f73b7e1df9">13.0</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="i58efde7a50b54415affc844b791d1774_D20270101-20271231" decimals="-3" name="lxrx:A2027OxfordPrincipalPaymentsA" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzQ5NDc4MDIzMzc0NDY_5e469e44-f9aa-4600-b9d8-260b7b0ada69">4.8</ix:nonFraction>&#160;million will be due during the fiscal years ended December 31, 2025, December 31, 2026 and December 31, 2027, respectively, with respect to the first tranche.  Principal payments of $<ix:nonFraction unitRef="usd" contextRef="i5082f56c08c74c63a4b9fbd86c1e2db5_D20250101-20251231" decimals="-3" name="lxrx:A2025OxfordPrincipalPaymentsB" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2NDIyODc_112772ce-58ab-4edb-8b8d-31c687f888c8">8.7</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="ic2f7712d90c8455ebf945f797fd6c4c5_D20260101-20261231" decimals="-3" name="lxrx:A2026OxfordPrincipalPaymentsB" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2NDIyOTY_aa928d34-b01b-445d-9d48-4850a57b9107">13.0</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="i58efde7a50b54415affc844b791d1774_D20270101-20271231" decimals="-3" name="lxrx:A2027OxfordPrincipalPaymentsB" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2NDIzMDQ_4c2275bf-7c09-4cd8-80ea-2760f13f588a">4.8</ix:nonFraction>&#160;million will be due during the fiscal years ended December 31, 2025, December 31, 2026 and December 31, 2027, respectively, with respect to the second tranche.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The loan and security agreement provides that, upon funding of the first three tranches, Lexicon will grant Oxford a warrant to purchase shares of its common stock having a value equal to <ix:nonFraction unitRef="number" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="INF" name="lxrx:TermLoanABWarrant" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2MzMzMzQ_6f15df05-2b64-4fb2-bdf2-7a61d7f5f4ac">3.50</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="INF" name="lxrx:TermLoanCWarrant" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2MzMzMzk_85b8e8f6-6dd3-4530-bb5f-870bfcf81c08">1.75</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="INF" name="lxrx:TermLoanDWarrant" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2MzMzNDc_d44f7ed7-7c35-4ca0-9ccb-c4d5e1d69b1a">0.875</ix:nonFraction>%, respectively, of each such tranche, as determined by reference to a 10-day average closing price of the shares. Each warrant will have an exercise price equal to such average closing price, be exercisable for a five-year period from the date of issuance and feature a net cashless exercise provision. Concurrent with the funding of the first tranche, Lexicon granted Oxford a warrant to purchase <ix:nonFraction unitRef="shares" contextRef="icf43ab9deda34d99b2dc4e7beae89d69_I20220630" decimals="0" name="lxrx:TermLoanAWarrantsNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2MzM3NDg_3a0aecbf-5308-4d04-8f13-a7949c449f6d">420,673</ix:nonFraction> shares of Lexicon&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="icf43ab9deda34d99b2dc4e7beae89d69_I20220630" decimals="2" name="lxrx:TermLoanAWarrantExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2MzM4MDk_5f3ce998-1624-4c8f-a18c-f19d978f56f0">2.08</ix:nonFraction> per share.  Concurrent with the funding of the second tranche, Lexicon granted Oxford a warrant to purchase <ix:nonFraction unitRef="shares" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="0" name="lxrx:TermLoanAWarrantsNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2Mzc1OTU_9442eea9-11d0-40c3-a514-5d8d5a92f2e1">224,128</ix:nonFraction> shares of Lexicon&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="2" name="lxrx:TermLoanAWarrantExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2Mzc2MDU_9c1a9572-c320-4581-942d-e272bd24176c">1.95</ix:nonFraction> per share. The warrants are exercisable for five years from their respective grant dates and are classified as equity instruments.  The Company allocated the proceeds from each tranche to the corresponding warrant using the relative fair value method and used the Black-Scholes model to calculate the fair value of the warrants.  The fair value of the first tranche warrant of $<ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2MzQxMzk_4446c9b6-fe4b-4dc4-8b28-cc290c0132cb">0.7</ix:nonFraction>&#160;million was recognized as equity with a corresponding debt discount of $<ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2MzQyMDY_4446c9b6-fe4b-4dc4-8b28-cc290c0132cb">0.7</ix:nonFraction>&#160;million. The fair value of the second tranche warrant of $<ix:nonFraction unitRef="usd" contextRef="if284e805242a400b99ebf80651bc00de_D20221001-20221231" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2Mzc4ODM_a3f4511e-6cc0-457b-a34b-9a451a1a124a">0.3</ix:nonFraction>&#160;million was recognized as equity with a corresponding debt discount of $<ix:nonFraction unitRef="usd" contextRef="if284e805242a400b99ebf80651bc00de_D20221001-20221231" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2Mzc4OTU_a3f4511e-6cc0-457b-a34b-9a451a1a124a">0.3</ix:nonFraction>&#160;million.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Oxford Term Loans bear interest at a floating rate equal to the 30-day U.S. Dollar LIBOR plus <ix:nonFraction unitRef="number" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2MzQzMTA_b48409a4-ce13-4513-8ad8-ee113800093c">7.90</ix:nonFraction>%, but not less than <ix:nonFraction unitRef="number" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="INF" name="us-gaap:LongTermDebtPercentageBearingFixedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2MzQzMzM_3f5156d3-c723-4074-8919-c3cfb1419351">8.01</ix:nonFraction>%, subject to additional interest if an event of default occurs and is continuing.  As of December&#160;31, 2022, the interest rate was <ix:nonFraction unitRef="number" contextRef="if284e805242a400b99ebf80651bc00de_D20221001-20221231" decimals="INF" name="us-gaap:SubordinatedBorrowingInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2Mzc5MDY_70490766-062e-490a-b64d-091c11591202">12.04</ix:nonFraction>%. If an event of default occurs and is continuing, Oxford may declare all amounts outstanding under the loan and security agreement to be immediately due and payable. Lexicon may prepay the Oxford Term Loans in whole at its option at any time. Any prepayment of the Oxford Term Loans is subject to prepayment fees for up to three years after the funding of each tranche of the loans.  A final payment exit fee equal to <ix:nonFraction unitRef="rate" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="INF" name="lxrx:FinalPaymentWithNoExtention" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2MzQ4NzQ_66f59108-a857-4b38-8d57-f1794337a237">6</ix:nonFraction>% of the amount funded under the Oxford Term Loans is due upon prepayment or maturity, which final payment will be adjusted to <ix:nonFraction unitRef="rate" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="INF" name="lxrx:FinalPaymentWithExtention" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2MzUwMDM_6acc3c27-229f-4d9c-bd4d-8588390b61f6">7</ix:nonFraction>% of the amount funded upon extension of the interest-only payment period.  The final payment exit fee of $<ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="lxrx:TermLoanAFinalPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2MzUxMTE_b58d62c3-c35c-4a9c-b5ba-409139e52060">1.5</ix:nonFraction>&#160;million was recorded once for each tranche as a debt discount on the funding date.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During March 2022, in connection with the first tranche of the loan and security agreement, the Company received cash proceeds of $<ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="lxrx:TermLoanANetCashReceipt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2MzUzMjA_840b195b-2d81-4500-8b8a-b75924a8956e">24.15</ix:nonFraction>&#160;million, net of debt issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="lxrx:TermLoanADebtIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2MzUzNTU_4f735794-62d4-45a6-adff-64b79bcc2970">0.35</ix:nonFraction>&#160;million and a facility fee of $<ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="lxrx:OxfordFacilityFee" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2MzUzODE_c1e4270f-ebcd-4109-9a04-ef7258ba1884">0.50</ix:nonFraction>&#160;million. The debt </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="iba080fe3cdab4450b54ef91b88ce4d21" continuedAt="i0a51bfc911fd4ddd8f43d66ad9cea552"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issuance costs and facility fee have been recorded as a debt discount on the consolidated balance sheet, which together with the final payment exit fee of $<ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="lxrx:TermLoanAFinalPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2MzU1NjA_b58d62c3-c35c-4a9c-b5ba-409139e52060">1.5</ix:nonFraction>&#160;million and warrant fair value of $<ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2MzU1OTA_4446c9b6-fe4b-4dc4-8b28-cc290c0132cb">0.7</ix:nonFraction>&#160;million are being amortized to interest expense throughout the life of the term loan using the effective interest rate method.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 30, 2022, in connection with the second tranche of the loan and security agreement, the Company received cash proceeds of $<ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="lxrx:TermLoanBNetCashReceipt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2Mzg1NzM_ed0ed99d-a7e3-4f95-9c67-e6d3e3a6ef06">24.96</ix:nonFraction>&#160;million, net of debt issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="lxrx:TermLoanBDebtDiscount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2Mzg1ODI_c9660de4-e3d0-4a4d-a4d3-a14aae101c01">0.04</ix:nonFraction>&#160;million. The debt issuance costs were recorded as a debt discount on the consolidated balance sheet, which together with the final payment exit fee of $<ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="lxrx:TermLoanAFinalPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2MzgzNzc_b58d62c3-c35c-4a9c-b5ba-409139e52060">1.5</ix:nonFraction>&#160;million and warrant fair value of $<ix:nonFraction unitRef="usd" contextRef="if284e805242a400b99ebf80651bc00de_D20221001-20221231" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2Mzg2NDQ_a3f4511e-6cc0-457b-a34b-9a451a1a124a">0.3</ix:nonFraction>&#160;million are being amortized to interest expense throughout the life of the term loan using the effective interest rate method. As of December&#160;31, 2022, the balance of the debt discount was $<ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="lxrx:TermLoanADebtDiscount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2Mzg2NTk_fe5b9522-0f91-468d-9ba5-d10c2d706ae8">4.4</ix:nonFraction>&#160;million. During the year ended December&#160;31, 2022, the Company recognized interest expense of $<ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" name="us-gaap:InterestExpenseInterestBearingLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2NDIzNDU_be52f0c8-4d69-4e57-a6e3-d9001d0e27f5">2.8</ix:nonFraction>&#160;million.  As of December&#160;31, 2022, the carrying value of the Oxford Term Loans was $<ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2NDIzMzc_43cc741a-b670-435e-a462-9714182c8506">48.6</ix:nonFraction>&#160;million.  The carrying value of the Oxford Term Loans approximates its fair value, as the loans bear interest at a rate that approximates prevailing market rates for instruments with similar characteristics. The fair value of the Oxford Term Loans is determined under Level 2 in the fair value hierarchy.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lexicon&#8217;s obligations under the Oxford Term Loans are secured by a first lien security interest in all of the assets of the Company and its subsidiaries. The loan and security agreement contains certain customary representations and warranties, affirmative and negative covenants and events of default applicable to Lexicon and its subsidiaries. In addition to the financial covenant, additional covenants include those restricting dispositions, fundamental changes to its business, mergers or acquisitions, indebtedness, encumbrances, distributions, investments, transactions with affiliates and subordinated debt. The Company was in compliance with its debt covenants as of December&#160;31, 2022.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Notes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In November 2014, Lexicon completed an offering of $<ix:nonFraction unitRef="usd" contextRef="ifaed8b1899ba47ddb389bc7180e9188b_D20141101-20141130" decimals="-5" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2Xzk4_4c233633-d318-4a82-871d-fa431c3802fd">87.5</ix:nonFraction> million in aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="4" name="lxrx:ConvertibleDebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEzNA_8008a6c8-b8b9-4254-9833-bb301a2784f0">5.25</ix:nonFraction>% Convertible Senior Notes due 2021 (the &#8220;Convertible Notes&#8221;).  The conversion feature did not meet the criteria for bifurcation as required by generally accepted accounting principles and the entire principal amount was recorded as long-term debt on the Company&#8217;s consolidated balance sheets.  The Convertible Notes were governed by an indenture between the Company and Wells Fargo Bank, N.A., as trustee.  The Convertible Notes bore interest at a rate of <ix:nonFraction unitRef="number" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="4" name="lxrx:ConvertibleDebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzU5Mg_8008a6c8-b8b9-4254-9833-bb301a2784f0">5.25</ix:nonFraction>%&#160;per year, which was payable semiannually in arrears on June&#160;1 and December&#160;1 of each year, beginning on June&#160;1, 2015.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, the Company entered into separate, privately negotiated exchange agreements to exchange $<ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzgwOQ_69dc93d3-7746-4b1c-97d8-5683a102d3dc">75.8</ix:nonFraction> million aggregate principal amount of the Convertible Notes for consideration valued at <ix:nonFraction unitRef="number" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="INF" name="lxrx:A2020ConvertibleDebtExchangePercentageOfPrincipal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2Xzg5Mg_ad6c539b-10c5-499d-a540-a4f18f56e0c9">85</ix:nonFraction>% of the principal amount of the Convertible Notes.  In September and October 2020, the Company issued <ix:nonFraction unitRef="shares" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="0" name="lxrx:A2020ConvertibleDebtExchangeSharePaymentTotal" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2Xzk3Mg_2a77d94f-9628-417f-ae2d-a6c1035d6eff">10,368,956</ix:nonFraction> shares of the Company&#8217;s common stock and paid $<ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-3" name="lxrx:ConvertibleDebtExchangeTotalCashConsideration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwMjE_27d1b1ef-b894-4bbf-886a-1d75e24d0b1f">50.0</ix:nonFraction> million in cash, which included $<ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-3" name="lxrx:A2020ConvertibleDebtExchangeAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwNDg_b46b5d46-1856-4e79-9ca4-755024fb9c62">1.3</ix:nonFraction> million of accrued interest, to exchange such Convertible Notes.  The Company recorded the exchanges under the accounting requirements for debt extinguishment of convertible instruments.  As a result, a debt extinguishment gain of $<ix:nonFraction unitRef="usd" contextRef="ief9b221acfd5465cb83500067a09fff2_I20201231" decimals="-3" name="lxrx:ConvertibleDebtExchange" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEyNzQ_cb31239b-27ea-48a8-bd00-f6655ec01e28">9.6</ix:nonFraction> million was recorded and is included in the accompanying consolidated statement of comprehensive loss for the year ended December 31, 2020.  In December 2021, the remaining balance of $<ix:nonFraction unitRef="usd" contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231" decimals="-3" name="us-gaap:ConvertibleDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzE1MTk_f3e8a292-f3c7-4fb4-a62a-483a69a97f1e">11.6</ix:nonFraction>&#160;million was repaid in cash.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mortgage Loan. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;In August 2018, a wholly owned subsidiary of Lexicon entered into a term loan and security agreement refinancing the previously existing mortgage on its facilities in The Woodlands, Texas (the &#8220;Property&#8221;).  The Company recorded the refinancing as a debt extinguishment, with <ix:nonFraction unitRef="usd" contextRef="idb9d77e7bb0d49ef814ea91873a8ee6f_D20180801-20180831" decimals="INF" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzIyNTU_5bf3c8dd-c475-4fef-bc71-028748d9bf14">no</ix:nonFraction> recognition of gain or loss on the transaction.  The loan agreement provided for a $<ix:nonFraction unitRef="usd" contextRef="i84cdb8b224f3426da99041ee143ab064_I20180830" decimals="-5" name="lxrx:MortgageDebtInstrument_Revere_LXRX" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzIzNDE_af1076ce-d391-4fc6-afdd-0efe7c1ec005">12.9</ix:nonFraction>&#160;million mortgage on the Property and had a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzIzNzk_9029d41a-c8aa-4619-a57b-c3c4b9a9cbad">two</span>-year term with a <ix:nonNumeric contextRef="idb9d77e7bb0d49ef814ea91873a8ee6f_D20180801-20180831" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzIzOTk_fb6a89f4-b3c7-47a5-95c4-b03e7fb2fc4f">10</ix:nonNumeric>-year amortization.  The mortgage loan bore interest at a rate per annum equal to the greater of (a) the 30-day LIBOR rate plus <ix:nonFraction unitRef="number" contextRef="i84cdb8b224f3426da99041ee143ab064_I20180830" decimals="INF" name="lxrx:MortgageDebtInterestRate_Base_Revere_LXRX" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzI1Mjg_1ad93c32-d19a-43e9-8608-09908634d6fe"><ix:nonFraction unitRef="number" contextRef="i84cdb8b224f3426da99041ee143ab064_I20180830" decimals="INF" name="lxrx:MortgageDebtInterestRate_Base_Revere_LXRX" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzI1Mjg_74973e68-5733-47a5-a377-897d19c1cd1b">5.5</ix:nonFraction></ix:nonFraction>% and (b) <ix:nonFraction unitRef="number" contextRef="i84cdb8b224f3426da99041ee143ab064_I20180830" decimals="INF" name="lxrx:MortgageDebtInterestRateBasePlus_Revere_LXRX" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzI1Mzg_81da859f-f7c3-4431-af39-8cbd7ba5936e"><ix:nonFraction unitRef="number" contextRef="i84cdb8b224f3426da99041ee143ab064_I20180830" decimals="INF" name="lxrx:MortgageDebtInterestRateBasePlus_Revere_LXRX" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzI1Mzg_e84df751-99bf-4a8c-ab75-eb14779d9701">7.5</ix:nonFraction></ix:nonFraction>% and provided for a balloon payment of $<ix:nonFraction unitRef="usd" contextRef="i84cdb8b224f3426da99041ee143ab064_I20180830" decimals="-5" name="lxrx:MortgageDebtBalloonPayment_LXRX" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzI1Nzk_30a507f1-d0c1-493c-858f-9a637bb13ded"><ix:nonFraction unitRef="usd" contextRef="i84cdb8b224f3426da99041ee143ab064_I20180830" decimals="-5" name="lxrx:MortgageDebtBalloonPayment_LXRX" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzI1Nzk_6bdcb825-1741-43fe-8038-a53f18a39b72">10.3</ix:nonFraction></ix:nonFraction>&#160;million, which was paid in full in August 2020.  </span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BioPharma Term Loan.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;In December 2017, Lexicon entered into a loan agreement with BioPharma Credit PLC and BioPharma Credit Investments IV Sub </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LP under which $<ix:nonFraction unitRef="usd" contextRef="i4d539018a70542119bc755c3276bee16_I20171218" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzI3ODQ_83e38d83-4507-4dd5-8b29-23ab346cad59">150</ix:nonFraction> million was funded in December 2017 (the &#8220;BioPharma Term Loan&#8221;).  The BioPharma Term Loan was scheduled to mature in December 2022, bore interest at <ix:nonFraction unitRef="number" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="2" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzI5Mjg_66f5342d-7917-49a9-b37b-34e768bf8c33">9</ix:nonFraction>% per year, subject to additional interest if an event of default occurred and was continuing, and was payable quarterly.   </span></div></ix:continuation><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0a51bfc911fd4ddd8f43d66ad9cea552">The BioPharma Term Loan was subject to mandatory prepayment provisions that required prepayment upon a change of control or receipt of proceeds from certain non-ordinary course transfers of assets.  The Company repaid the BioPharma Term Loan in whole, together with required prepayment and make-whole premiums, upon closing of the sale of XERMELO and related assets to TerSera Therapeutics LLC in September 2020.  The Company recorded the repayment under the accounting requirements for debt extinguishment and as a result, a loss of $8.6&#160;million was recognized and is included in the accompanying consolidated statement of comprehensive loss for the year ended December 31, 2020.</ix:continuation> </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-18</span></div></div></div><div id="i122d3ae3d73245b585bd7f040afd795c_178"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commitments and Contingencies</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Lease Obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;Lexicon&#8217;s operating leases include leases of office space in The Woodlands, Texas and Bridgewater, New Jersey that will expire in August 2025 and January 2034, respectively. In February 2021, the Company leased a 25,000 square-foot office space in The Woodlands, Texas and relocated the corporate offices. The term of the sublease extends from March 1, 2021 through August 31, 2025, and provides for escalating yearly base rent payments starting at $506,000 and increasing to $557,000 in the final year of the lease. In July 2022, the Company&#8217;s subsidiary, Lexicon Pharmaceuticals (New Jersey), Inc. leased a 22,000 square-foot office space in Bridgewater, New Jersey.  The lease agreement will expire January 2034 and provides for escalating yearly base rent payments starting at $820,000 and increasing to $986,000 in the final year of the lease.  Under its lease agreements, Lexicon is obligated to pay property taxes, insurance, and maintenance costs.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022 and 2021, the right-of-use assets for the office space leases had a balance of $<ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzgvZnJhZzplN2M4MTQ2M2ZkZWE0YWU5ODVmMWZmN2Q0YjI1ZTliNy90ZXh0cmVnaW9uOmU3YzgxNDYzZmRlYTRhZTk4NWYxZmY3ZDRiMjVlOWI3XzQzNQ_f5569e29-5635-473d-b4fb-869458329672">6.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzgvZnJhZzplN2M4MTQ2M2ZkZWE0YWU5ODVmMWZmN2Q0YjI1ZTliNy90ZXh0cmVnaW9uOmU3YzgxNDYzZmRlYTRhZTk4NWYxZmY3ZDRiMjVlOWI3XzEwOTk1MTE2MzM1NDc_0d2bf1c8-9549-4cf5-9837-4b7ff91047bb">2.3</ix:nonFraction>&#160;million, respectively, which are included in operating lease right-of-use-assets in the consolidated balance sheet. Current and long-term liabilities as of December&#160;31, 2022, relating to the leases were $<ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-5" name="us-gaap:ShortTermLeaseCommitmentAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzgvZnJhZzplN2M4MTQ2M2ZkZWE0YWU5ODVmMWZmN2Q0YjI1ZTliNy90ZXh0cmVnaW9uOmU3YzgxNDYzZmRlYTRhZTk4NWYxZmY3ZDRiMjVlOWI3XzU3Mg_c3bfff95-8fa9-4040-90c4-ca30790a2f4b">1.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzgvZnJhZzplN2M4MTQ2M2ZkZWE0YWU5ODVmMWZmN2Q0YjI1ZTliNy90ZXh0cmVnaW9uOmU3YzgxNDYzZmRlYTRhZTk4NWYxZmY3ZDRiMjVlOWI3XzU3OQ_5a966bdb-d8d5-4e7a-b8a9-6f3c47b4fa65">5.4</ix:nonFraction> million, respectively, which are included in accrued liabilities and long-term operating lease liabilities in the consolidated balance sheet, respectively.  Current and long-term liabilities as of December&#160;31, 2021, relating to the leases were $<ix:nonFraction unitRef="usd" contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231" decimals="-5" name="us-gaap:ShortTermLeaseCommitmentAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzgvZnJhZzplN2M4MTQ2M2ZkZWE0YWU5ODVmMWZmN2Q0YjI1ZTliNy90ZXh0cmVnaW9uOmU3YzgxNDYzZmRlYTRhZTk4NWYxZmY3ZDRiMjVlOWI3XzEwOTk1MTE2MzExMTY_1a3be916-b749-406c-ae73-3f459e3fb5c0">1.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzgvZnJhZzplN2M4MTQ2M2ZkZWE0YWU5ODVmMWZmN2Q0YjI1ZTliNy90ZXh0cmVnaW9uOmU3YzgxNDYzZmRlYTRhZTk4NWYxZmY3ZDRiMjVlOWI3XzEwOTk1MTE2MzExMjA_6d8d9d87-60f5-423f-9de0-58df7097b86a">1.2</ix:nonFraction>&#160;million, respectively, which are included in accrued liabilities and long-term operating lease liabilities in the consolidated balance sheet, respectively.  During the years ended December&#160;31, 2022 and 2021, the Company incurred lease expense of $<ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="-3" name="us-gaap:LeaseAndRentalExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzgvZnJhZzplN2M4MTQ2M2ZkZWE0YWU5ODVmMWZmN2Q0YjI1ZTliNy90ZXh0cmVnaW9uOmU3YzgxNDYzZmRlYTRhZTk4NWYxZmY3ZDRiMjVlOWI3XzEwOTk1MTE2MzQyOTg_78caed27-1a41-423f-b37e-f9420d4557c6">1.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" name="us-gaap:LeaseAndRentalExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzgvZnJhZzplN2M4MTQ2M2ZkZWE0YWU5ODVmMWZmN2Q0YjI1ZTliNy90ZXh0cmVnaW9uOmU3YzgxNDYzZmRlYTRhZTk4NWYxZmY3ZDRiMjVlOWI3XzEwOTk1MTE2MzM1MDE_7ba66f4c-2870-4b63-8719-b8876561ef11">1.7</ix:nonFraction>&#160;million, respectively. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2022 and 2021, the Company made cash payments for lease liabilities of $<ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsForRent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzgvZnJhZzplN2M4MTQ2M2ZkZWE0YWU5ODVmMWZmN2Q0YjI1ZTliNy90ZXh0cmVnaW9uOmU3YzgxNDYzZmRlYTRhZTk4NWYxZmY3ZDRiMjVlOWI3XzEwOTk1MTE2MzI4OTM_f71c11a5-5159-422a-ae87-c1af846852ec">1.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsForRent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzgvZnJhZzplN2M4MTQ2M2ZkZWE0YWU5ODVmMWZmN2Q0YjI1ZTliNy90ZXh0cmVnaW9uOmU3YzgxNDYzZmRlYTRhZTk4NWYxZmY3ZDRiMjVlOWI3XzEwOTk1MTE2MzI4OTY_91ebf393-189d-44a2-87a5-8a552ceb4d2d">0.8</ix:nonFraction> million, respectively. As of December&#160;31, 2022 and 2021, the weighted-average remaining lease terms were <ix:nonNumeric contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzgvZnJhZzplN2M4MTQ2M2ZkZWE0YWU5ODVmMWZmN2Q0YjI1ZTliNy90ZXh0cmVnaW9uOmU3YzgxNDYzZmRlYTRhZTk4NWYxZmY3ZDRiMjVlOWI3XzEwOTk1MTE2MzQyOTU_f130da7c-5f1b-4057-a5d0-0d70e5eda417">9.5</ix:nonNumeric> years and <ix:nonNumeric contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzgvZnJhZzplN2M4MTQ2M2ZkZWE0YWU5ODVmMWZmN2Q0YjI1ZTliNy90ZXh0cmVnaW9uOmU3YzgxNDYzZmRlYTRhZTk4NWYxZmY3ZDRiMjVlOWI3XzEwOTk1MTE2MzQyOTQ_6f8c0e31-5b56-4db0-90c4-c4a24f30843d">2.9</ix:nonNumeric> years, respectively, with weighted-average discount rates of <ix:nonFraction unitRef="number" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="INF" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzgvZnJhZzplN2M4MTQ2M2ZkZWE0YWU5ODVmMWZmN2Q0YjI1ZTliNy90ZXh0cmVnaW9uOmU3YzgxNDYzZmRlYTRhZTk4NWYxZmY3ZDRiMjVlOWI3XzEwOTk1MTE2MzMwNTE_d13332e8-8dbc-433b-abf8-9ff7432f74a6">9.6</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231" decimals="INF" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzgvZnJhZzplN2M4MTQ2M2ZkZWE0YWU5ODVmMWZmN2Q0YjI1ZTliNy90ZXh0cmVnaW9uOmU3YzgxNDYzZmRlYTRhZTk4NWYxZmY3ZDRiMjVlOWI3XzEwOTk1MTE2MzMwNDI_c6a87564-5a11-438f-b565-f993614af527">9.0</ix:nonFraction>%, respectively.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the undiscounted cash flows of the operating lease liability to the recorded lease liability at December&#160;31, 2022:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span><ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzgvZnJhZzplN2M4MTQ2M2ZkZWE0YWU5ODVmMWZmN2Q0YjI1ZTliNy90ZXh0cmVnaW9uOmU3YzgxNDYzZmRlYTRhZTk4NWYxZmY3ZDRiMjVlOWI3XzE4MDY_d46c4c40-0ee2-472b-876b-375282fdc522" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:80.744%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.056%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="0" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzgvZnJhZzplN2M4MTQ2M2ZkZWE0YWU5ODVmMWZmN2Q0YjI1ZTliNy90YWJsZTpjMzFlNGFiNDU2Zjc0YzMwODIxNTFiYmI0MDViYzY0NS90YWJsZXJhbmdlOmMzMWU0YWI0NTZmNzRjMzA4MjE1MWJiYjQwNWJjNjQ1XzItMS0xLTEtMzMyMDM_cf7a9c6d-284a-4b90-a225-ed03827bc27b">805</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="0" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzgvZnJhZzplN2M4MTQ2M2ZkZWE0YWU5ODVmMWZmN2Q0YjI1ZTliNy90YWJsZTpjMzFlNGFiNDU2Zjc0YzMwODIxNTFiYmI0MDViYzY0NS90YWJsZXJhbmdlOmMzMWU0YWI0NTZmNzRjMzA4MjE1MWJiYjQwNWJjNjQ1XzMtMS0xLTEtMzMyMDM_4f304515-8449-4a6d-9ed1-9b22507349ff">1,378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="0" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzgvZnJhZzplN2M4MTQ2M2ZkZWE0YWU5ODVmMWZmN2Q0YjI1ZTliNy90YWJsZTpjMzFlNGFiNDU2Zjc0YzMwODIxNTFiYmI0MDViYzY0NS90YWJsZXJhbmdlOmMzMWU0YWI0NTZmNzRjMzA4MjE1MWJiYjQwNWJjNjQ1XzQtMS0xLTEtMzMyMDM_9046b323-61b4-482b-9372-d127c9c21d94">1,220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="0" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzgvZnJhZzplN2M4MTQ2M2ZkZWE0YWU5ODVmMWZmN2Q0YjI1ZTliNy90YWJsZTpjMzFlNGFiNDU2Zjc0YzMwODIxNTFiYmI0MDViYzY0NS90YWJsZXJhbmdlOmMzMWU0YWI0NTZmNzRjMzA4MjE1MWJiYjQwNWJjNjQ1XzUtMS0xLTEtMzMyMDM_a4b9c57a-eff9-456b-88e0-bf9a332ad8ca">865</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="0" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzgvZnJhZzplN2M4MTQ2M2ZkZWE0YWU5ODVmMWZmN2Q0YjI1ZTliNy90YWJsZTpjMzFlNGFiNDU2Zjc0YzMwODIxNTFiYmI0MDViYzY0NS90YWJsZXJhbmdlOmMzMWU0YWI0NTZmNzRjMzA4MjE1MWJiYjQwNWJjNjQ1XzYtMS0xLTEtMzMyMDM_94a7b5b9-67dd-479f-9304-57b6b641b6f8">881</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="0" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzgvZnJhZzplN2M4MTQ2M2ZkZWE0YWU5ODVmMWZmN2Q0YjI1ZTliNy90YWJsZTpjMzFlNGFiNDU2Zjc0YzMwODIxNTFiYmI0MDViYzY0NS90YWJsZXJhbmdlOmMzMWU0YWI0NTZmNzRjMzA4MjE1MWJiYjQwNWJjNjQ1XzctMS0xLTEtMzMyMDM_a93c52f8-4948-4461-937f-82b8dd6b05b6">5,644</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted operating lease liability</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzgvZnJhZzplN2M4MTQ2M2ZkZWE0YWU5ODVmMWZmN2Q0YjI1ZTliNy90YWJsZTpjMzFlNGFiNDU2Zjc0YzMwODIxNTFiYmI0MDViYzY0NS90YWJsZXJhbmdlOmMzMWU0YWI0NTZmNzRjMzA4MjE1MWJiYjQwNWJjNjQ1XzgtMS0xLTEtMzMyMDM_77c7dce1-a418-4085-ba6f-59b276ab7906">10,793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: amount of lease payments representing interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" sign="-" name="lxrx:InterestOnLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzgvZnJhZzplN2M4MTQ2M2ZkZWE0YWU5ODVmMWZmN2Q0YjI1ZTliNy90YWJsZTpjMzFlNGFiNDU2Zjc0YzMwODIxNTFiYmI0MDViYzY0NS90YWJsZXJhbmdlOmMzMWU0YWI0NTZmNzRjMzA4MjE1MWJiYjQwNWJjNjQ1XzktMS0xLTEtMzMyMDM_0941fa98-8866-4d9d-81c4-7314353eae55">4,078</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of future lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="lxrx:PresentValueOfFutureLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzgvZnJhZzplN2M4MTQ2M2ZkZWE0YWU5ODVmMWZmN2Q0YjI1ZTliNy90YWJsZTpjMzFlNGFiNDU2Zjc0YzMwODIxNTFiYmI0MDViYzY0NS90YWJsZXJhbmdlOmMzMWU0YWI0NTZmNzRjMzA4MjE1MWJiYjQwNWJjNjQ1XzEwLTEtMS0xLTMzMjAz_6dddd8cf-dc91-433a-9aed-a15972dcd87b">6,715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: short-term operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="us-gaap:ShortTermLeaseCommitmentAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzgvZnJhZzplN2M4MTQ2M2ZkZWE0YWU5ODVmMWZmN2Q0YjI1ZTliNy90YWJsZTpjMzFlNGFiNDU2Zjc0YzMwODIxNTFiYmI0MDViYzY0NS90YWJsZXJhbmdlOmMzMWU0YWI0NTZmNzRjMzA4MjE1MWJiYjQwNWJjNjQ1XzExLTEtMS0xLTMzMjAz_9ee651be-02e3-4c75-8bca-9c2979b57e07">1,291</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liability</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzgvZnJhZzplN2M4MTQ2M2ZkZWE0YWU5ODVmMWZmN2Q0YjI1ZTliNy90YWJsZTpjMzFlNGFiNDU2Zjc0YzMwODIxNTFiYmI0MDViYzY0NS90YWJsZXJhbmdlOmMzMWU0YWI0NTZmNzRjMzA4MjE1MWJiYjQwNWJjNjQ1XzEyLTEtMS0xLTMzMjAz_b2f3510e-d727-4723-9f37-31ead70015aa">5,424</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employment Arrangements:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lexicon has entered into employment arrangements with certain of its corporate officers. Under the arrangements, each officer receives a base salary, subject to adjustment, with an annual discretionary bonus based upon specific objectives to be determined by the compensation committee. The employment arrangements are at-will and some contain non-competition agreements. Some of the arrangements also provide for certain severance payments for either <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzgvZnJhZzplN2M4MTQ2M2ZkZWE0YWU5ODVmMWZmN2Q0YjI1ZTliNy90ZXh0cmVnaW9uOmU3YzgxNDYzZmRlYTRhZTk4NWYxZmY3ZDRiMjVlOWI3XzEzMzM_0e763c45-71c7-4867-9a1b-bb54280dc662">six</span> or <ix:nonNumeric contextRef="ief3a42398bf74858b5aa075d327d0116_D20220101-20221231" name="lxrx:DeferredCompensationArrangementWithIndividualPaymentPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzgvZnJhZzplN2M4MTQ2M2ZkZWE0YWU5ODVmMWZmN2Q0YjI1ZTliNy90ZXh0cmVnaW9uOmU3YzgxNDYzZmRlYTRhZTk4NWYxZmY3ZDRiMjVlOWI3XzEzMzk_7d374a9c-ccca-41e2-9651-db47f57ee265">12</ix:nonNumeric> months and, in some cases, payment of a specified portion of the officer&#8217;s bonus target for such year, in the event of a specified termination of the officer&#8217;s employment.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;Lexicon is from time to time party to claims and legal proceedings that arise in the normal course of its business and that it believes will not have, individually or in the aggregate, a material adverse effect on its results of operations, financial condition or liquidity.&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-19</span></div></div></div><div id="i122d3ae3d73245b585bd7f040afd795c_181"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzQ3ODc_70fd6037-f7f0-418e-97aa-94a8ca2e1e57" continuedAt="i9c46ae9f55074d4d877e2f4181f0b15a" escape="true">Equity Incentive Awards</ix:nonNumeric></span></div><ix:continuation id="i9c46ae9f55074d4d877e2f4181f0b15a" continuedAt="i281311af3d6d4ffd97d4cd32967a6150"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Incentive Plans</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2017 Equity Incentive Plan:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;In September 1995, Lexicon adopted the 1995 Stock Option Plan, which was subsequently amended and renamed the 2017 Equity Incentive Plan (the &#8220;Equity Incentive Plan&#8221;).</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Equity Incentive Plan permits the grant of incentive stock options to employees and nonstatutory stock options to employees, directors and consultants of the Company. The plan also permits the grant of stock bonus awards, restricted stock awards, restricted stock unit awards, stock appreciation rights and performance stock awards. Incentive and nonstatutory stock options have an exercise price of <ix:nonFraction unitRef="number" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="2" name="lxrx:StockOptionExercisePriceAsPercentOfValueOfCommonStock" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzY2OQ_0dcbd528-4064-46c0-8223-a3775b001e03">100</ix:nonFraction>% or more of the fair market value of the Company&#8217;s common stock on the date of grant.&#160;&#160;Most stock options granted under the Equity Incentive Plan become vested and exercisable over a period of <ix:nonNumeric contextRef="i28b8859c0c154ed482c84e3ab218642d_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0Xzg2NA_16413875-7588-4ee1-bbfa-41a99b630cfb">four years</ix:nonNumeric>; however some have been granted with different vesting schedules.&#160;&#160;Stock options granted under the Equity Incentive Plan have a term of <ix:nonNumeric contextRef="i28b8859c0c154ed482c84e3ab218642d_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzEwMDM_a900bbf6-8b6c-45fc-b05c-2acf6fbb47b2">ten years</ix:nonNumeric> from the date of grant.  </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total number of shares of common stock that may be issued pursuant to stock awards under the Equity Incentive Plan shall not exceed in the aggregate <ix:nonFraction unitRef="shares" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="0" name="lxrx:TotalSharesThatMayBeIssuedEquityIncentivePlan" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzExODc_70a8ebe2-667d-4775-8014-930f2096d325">30,000,000</ix:nonFraction> shares at December&#160;31, 2022.&#160;&#160;As of December&#160;31, 2022, options to purchase <ix:nonFraction unitRef="shares" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="0" name="lxrx:OptionsOutstandingEquityIncentivePlan" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzEyMzU_7e8aff77-0b49-4fe7-a86b-9548126b4e75">11,847,723</ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="0" name="lxrx:RestrictedStockUnitsOutstandingEquityIncentivePlan" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzEyNDk_bf6c34e9-6512-4096-864e-8ca7909f5b6c">2,559,306</ix:nonFraction> restricted stock units were outstanding, <ix:nonFraction unitRef="shares" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="0" name="lxrx:StockOptionsExercisedEquityIncentivePlan" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzEyOTM_ff52d29d-a1c4-4ade-8338-46bd335eadf6">2,285,702</ix:nonFraction> shares had been issued upon the exercise of stock options, <ix:nonFraction unitRef="shares" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="0" name="lxrx:SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzEzNTU_49ec1c84-22e1-4248-8341-ca58f3abb020">5,294,942</ix:nonFraction> shares had been issued pursuant to restricted stock units and <ix:nonFraction unitRef="shares" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="0" name="lxrx:SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzE0MjA_7b9f9853-3fa7-4fac-be81-e3d5b97b5ff5">113,940</ix:nonFraction> shares had been issued pursuant to stock bonus awards or restricted stock awards granted under the Equity Incentive Plan.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2017 Non-Employee Directors&#8217; Equity Incentive Plan:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;In February 2000, Lexicon adopted the 2000 Non-Employee Directors&#8217; Stock Option Plan, which was subsequently amended and renamed the 2017 Non-Employee Directors&#8217; Equity Incentive Plan (the &#8220;Directors&#8217; Plan&#8221;).&#160;&#160;Under the Directors&#8217; Plan, non-employee directors may be granted awards under the plan with an aggregate grant date fair value of no more than $<ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="0" name="lxrx:Totalvalueofsharesbynonemployeeinayear" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzE5NTI_a10f5764-e89e-46a3-b628-ef6ed1b6b173">500,000</ix:nonFraction> during any calendar year, taken together with any cash fees paid to such non-employee director in compensation for service on Lexicon&#8217;s board of directors during such calendar year.&#160;Stock options granted under the Directors&#8217; Plan have an exercise price equal to the fair market value of the Company&#8217;s common stock on the date of grant and a term of <ix:nonNumeric contextRef="i28b8859c0c154ed482c84e3ab218642d_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzIzMDQ_298fdeee-48f4-4085-b9f9-f2e1477ae836">ten years</ix:nonNumeric> from the date of grant.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total number of shares of common stock that may be issued pursuant to stock awards under the Directors&#8217; Plan shall not exceed in the aggregate <ix:nonFraction unitRef="shares" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="0" name="lxrx:TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzI0ODA_1469bff7-9627-4bc8-b851-05feaf0e5aa9">1,200,000</ix:nonFraction> shares at December 31, 2022.&#160;&#160;As of December&#160;31, 2022, stock options to purchase <ix:nonFraction unitRef="shares" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="0" name="lxrx:OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzI1Mjg_31f498b9-52c2-4378-aed3-b581b5bbc652">501,224</ix:nonFraction> shares were outstanding, <ix:nonFraction unitRef="shares" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="lxrx:StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzI1NTY_698d5814-1de5-4661-842e-d25da6566d29">none</ix:nonFraction> had been issued upon the exercise of stock options, <ix:nonFraction unitRef="shares" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="0" name="lxrx:RestrictedStockUnitsOutstandingNonEmployeeDirectorsEquityIncentivePlan" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzI2MTE_9dc1bd14-b8be-44b5-813c-31e7d465be6e">74,416</ix:nonFraction> restricted stock units were outstanding and <ix:nonFraction unitRef="shares" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="0" name="lxrx:SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzI2NTg_8e8711b2-6521-48dd-bc6d-63d9ed341029">248,232</ix:nonFraction> shares had been issued pursuant to restricted stock and restricted stock unit awards granted under the Directors&#8217; Plan. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Option Activity:</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of stock option activity under Lexicon&#8217;s equity incentive plans:</span><ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzQ3OTU_1e932a84-646a-427f-87b7-cfd3aa52c50e" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:35.649%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.714%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands, except exercise price data)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8686f139ef8d4193a880a31b12d0ce30_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzItMi0xLTEtMzMyMDM_09382399-a669-4de2-b080-c3bc441077cd">8,367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8686f139ef8d4193a880a31b12d0ce30_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzItNC0xLTEtMzMyMDM_8f8b1636-d9fd-4251-bbc2-ca3c553dbac2">6.80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i038e4801d2d648b38d0de7b8dab0f316_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzItNi0xLTEtMzMyMDM_ad11bccf-dc53-435c-9335-804299b5b279">8,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i038e4801d2d648b38d0de7b8dab0f316_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzItOC0xLTEtMzMyMDM_8239faa0-30e3-48db-9c80-fe0ef4f91b99">7.12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib525d01afa1f498e883536f24362d124_I20191231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzItMTAtMS0xLTMzMjAz_6c048fd4-20a4-4323-a736-59772b6b5a39">7,695</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib525d01afa1f498e883536f24362d124_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzItMTItMS0xLTMzMjAz_6e1eb832-785c-487e-a734-eb063a7f9d12">8.95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i28b8859c0c154ed482c84e3ab218642d_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzMtMi0xLTEtMzMyMDM_2a5470af-b899-44da-bb36-bb9559b6c00e">5,099</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i28b8859c0c154ed482c84e3ab218642d_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzMtNC0xLTEtMzMyMDM_9f7b9ac2-b1c5-4b96-9e2b-36b50b0e8edb">2.97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1be397a2eed340ea9795e0c692981bed_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzMtNi0xLTEtMzMyMDM_b1c44db3-b38b-49f3-8ccc-99f633ddeb5c">1,808</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1be397a2eed340ea9795e0c692981bed_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzMtOC0xLTEtMzMyMDM_fdcd44c7-e862-493e-84d0-085eb51eff77">6.39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i94f2adcb200344b890fec8dc81de1ae6_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzMtMTAtMS0xLTMzMjAz_eb6a13df-5c60-4862-ac46-61ed42370315">3,495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i94f2adcb200344b890fec8dc81de1ae6_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzMtMTItMS0xLTMzMjAz_54c1ff1e-e63d-4c0e-9a03-1df2278876bd">3.24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i28b8859c0c154ed482c84e3ab218642d_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzQtMi0xLTEtMzMyMDM_2b059b94-f244-4e8e-8cc7-fc053d6d7c86">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i28b8859c0c154ed482c84e3ab218642d_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzQtNC0xLTEtMzMyMDM_fc6e1f16-88da-4990-94f2-348498560d3d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1be397a2eed340ea9795e0c692981bed_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzQtNi0xLTEtMzMyMDM_db29a242-ca37-4544-a339-de2bea089586">376</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1be397a2eed340ea9795e0c692981bed_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzQtOC0xLTEtMzMyMDM_7b217ca7-9ddd-436e-a877-fa94762ac496">4.37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i94f2adcb200344b890fec8dc81de1ae6_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzQtMTAtMS0xLTMzMjAz_a554c195-c21b-4bf8-80ee-82276f524567">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i94f2adcb200344b890fec8dc81de1ae6_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzQtMTItMS0xLTMzMjAz_97d16b67-4b16-4721-8607-4391d3c0a6e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i28b8859c0c154ed482c84e3ab218642d_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzUtMi0xLTEtMzMyMDM_33260959-d32f-4786-9e85-d0875ece08b7">163</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i28b8859c0c154ed482c84e3ab218642d_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzUtNC0xLTEtMzMyMDM_705715c7-be71-4bb8-a7da-ab2de676ffa8">12.50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1be397a2eed340ea9795e0c692981bed_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzUtNi0xLTEtMzMyMDM_4f9f0d56-8209-4d14-b843-81cae81919ea">191</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1be397a2eed340ea9795e0c692981bed_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzUtOC0xLTEtMzMyMDM_5f1d32fc-e9de-4348-b169-6018facd261f">12.50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i94f2adcb200344b890fec8dc81de1ae6_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzUtMTAtMS0xLTMzMjAz_e49b0c5e-a5b9-4437-baf1-179a723592ce">236</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i94f2adcb200344b890fec8dc81de1ae6_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzUtMTItMS0xLTMzMjAz_38532430-7996-4374-aa99-96187184d924">12.91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i28b8859c0c154ed482c84e3ab218642d_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzYtMi0xLTEtMzMyMDM_267875ca-85ce-4540-b8b8-4615878e0094">954</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i28b8859c0c154ed482c84e3ab218642d_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzYtNC0xLTEtMzMyMDM_11fec490-4366-405b-ad18-9ddc95a2f60f">7.41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1be397a2eed340ea9795e0c692981bed_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzYtNi0xLTEtMzMyMDM_cb908454-20ac-4232-875a-9f4764c56c60">1,271</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1be397a2eed340ea9795e0c692981bed_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzYtOC0xLTEtMzMyMDM_32a7df7d-47a8-412c-987c-ce0d6f3be685">8.17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i94f2adcb200344b890fec8dc81de1ae6_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzYtMTAtMS0xLTMzMjAz_a776072c-bd53-4027-8b13-af1891d60caa">2,557</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i94f2adcb200344b890fec8dc81de1ae6_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzYtMTItMS0xLTMzMjAz_7bec1555-10f4-4026-9c00-8ddda2e10ba3">6.78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1754ae6b09344ad1a9be3815a19dcd30_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzctMi0xLTEtMzMyMDM_300560f8-287d-4094-bd77-3f6872890b02">12,349</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1754ae6b09344ad1a9be3815a19dcd30_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzctNC0xLTEtMzMyMDM_adf08100-478c-4867-93e9-d54c7ca045a8">5.10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8686f139ef8d4193a880a31b12d0ce30_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzctNi0xLTEtMzMyMDM_e37aadac-8783-4130-8118-706a47ea8397">8,367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8686f139ef8d4193a880a31b12d0ce30_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzctOC0xLTEtMzMyMDM_4d30e464-c4ad-413d-8843-1d57359a4a69">6.80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i038e4801d2d648b38d0de7b8dab0f316_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzctMTAtMS0xLTMzMjAz_306ae95d-555b-4b33-8c1c-2784e735b287">8,397</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i038e4801d2d648b38d0de7b8dab0f316_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzctMTItMS0xLTMzMjAz_59d24c41-1473-4732-af1c-265bea4b0d94">7.12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at end of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1754ae6b09344ad1a9be3815a19dcd30_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzgtMi0xLTEtMzMyMDM_058ce809-6636-4578-b9fc-7ba8ed899301">5,747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1754ae6b09344ad1a9be3815a19dcd30_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzgtNC0xLTEtMzMyMDM_4958e93f-f0fc-4225-b6aa-bffef599b47b">7.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8686f139ef8d4193a880a31b12d0ce30_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzgtNi0xLTEtMzMyMDM_b4b7e9f3-d88b-48de-8a7d-f8aa0d0cf906">5,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8686f139ef8d4193a880a31b12d0ce30_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzgtOC0xLTEtMzMyMDM_cf2b38c0-3152-4eef-aed0-ffdbccfc7322">7.99</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i038e4801d2d648b38d0de7b8dab0f316_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzgtMTAtMS0xLTMzMjAz_2967d9b5-7b5d-46ba-b8b5-72d12dd7b9d5">4,684</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i038e4801d2d648b38d0de7b8dab0f316_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzgtMTItMS0xLTMzMjAz_f2ae6b26-9dde-439e-819c-ca7153c94d29">9.48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average estimated grant date fair value of stock options granted during the years ended December&#160;31, 2022, 2021 and 2020 were $<ix:nonFraction unitRef="usdPerShare" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzMwMjE_b7c1006f-0a6f-4ee6-bb08-639b2016c5cd">2.30</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzMwMjU_8c824552-d243-4745-8b63-a1264c046936">4.85</ix:nonFraction> and&#160;$<ix:nonFraction unitRef="usdPerShare" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzMwMzI_6c707046-9e02-47ea-b872-fb1640152fa3">2.35</ix:nonFraction>, respectively.&#160;&#160;The total intrinsic value of stock options exercised during the year ended December&#160;31, 2022 was $<ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzMxMzM_2d10d082-7559-4eca-aa82-68dac69b164a">0</ix:nonFraction>.&#160; The weighted average remaining contractual term of stock options outstanding and exercisable was <ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzMyMzU_ff4e3143-f9b1-4048-a007-e656b36181c8">7.2</ix:nonNumeric> and <ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzMyNDI_4bd2def6-f274-4421-808d-54eff7e36356">5.3</ix:nonNumeric> years, respectively, as of December&#160;31, 2022.&#160;&#160;At December&#160;31, 2022, the aggregate intrinsic value of the outstanding stock options was $<ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzMzNTE_7397a8fb-86fd-4ae4-8d2d-80c716764408">0.1</ix:nonFraction> million.  At December&#160;31, 2022, the intrinsic value of exercisable stock options was $<ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzM0MTY_2c394726-d216-4775-a8a4-5bd44813dde0">0</ix:nonFraction>. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><ix:continuation id="i281311af3d6d4ffd97d4cd32967a6150"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Bonus and Restricted Stock Unit Activity:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2022, 2021 and 2020, Lexicon granted its employees restricted stock units in lieu of or in addition to annual stock option awards. These restricted stock units vest in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzM2NTc_da5a4fdb-478f-48e1-83dd-2888411ee7f9">three</span> annual installments.  The total fair value of shares vested in 2022, 2021 and 2020 was $<ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzM3NDE_66bc099d-c85a-42f4-9c0a-8701a0183d7d">2.9</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzM3NDU_a840f37d-ded3-4254-ba11-27441f7ff4f9">8.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzM3NTI_fd11d2e3-bc96-4b23-98ca-445245cf1bbd">3.2</ix:nonFraction>&#160;million, respectively.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2022, 2021 and 2020, Lexicon granted its non-employee directors <ix:nonFraction unitRef="shares" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="0" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzEwOTk1MTE2MzI1ODc_d68241ad-979e-42a6-82d0-f0452d2919e3">74,416</ix:nonFraction>,  <ix:nonFraction unitRef="shares" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="0" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzM4NTI_4fadc2c3-80ad-4cc9-9a41-77877b287cbd">32,192</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="0" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzM4NTY_cc0e28c6-c055-4997-b1d4-faefac2b60ff">85,104</ix:nonFraction> restricted stock units, respectively. The restricted stock granted in 2022, 2021 and 2020 had weighted average grant date fair values of $<ix:nonFraction unitRef="usdPerShare" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="2" name="lxrx:SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzEwOTk1MTE2MzI2MTA_402fadfa-3a12-42dc-80b1-5b3d6d5e5dd4">1.77</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="2" name="lxrx:SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzM5OTc_dc10afeb-72b3-4e4f-9cd7-b759f85ae050">5.04</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="2" name="lxrx:SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzQwMDE_5ba8f9e2-c938-4f3d-94c2-c85e1aea26f7">1.86</ix:nonFraction> per share, respectively.  Vesting of restricted stock units occurs on the first anniversary of the grant date.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of restricted stock units activity under Lexicon&#8217;s stock-based compensation plans for the year ended December&#160;31, 2022:</span></div><div style="text-indent:36pt"><span><br/></span></div><div><ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzQ4MDE_7dac6ea3-6dc5-40d5-87f6-3284442f1678" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.103%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idba6d48abf934e46bb6d9906a7959407_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTpiMTYwM2Q5YWM4Zjk0MGRkYjU5Yjg3Zjc1ZmU0OGMyZS90YWJsZXJhbmdlOmIxNjAzZDlhYzhmOTQwZGRiNTliODdmNzVmZTQ4YzJlXzItMi0xLTEtMzMyMDM_5aa4964e-f213-42d6-a2fd-c20fed5e754f">1,854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idba6d48abf934e46bb6d9906a7959407_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTpiMTYwM2Q5YWM4Zjk0MGRkYjU5Yjg3Zjc1ZmU0OGMyZS90YWJsZXJhbmdlOmIxNjAzZDlhYzhmOTQwZGRiNTliODdmNzVmZTQ4YzJlXzItNC0xLTEtMzMyMDM_0be6f739-8ce5-4e44-8e76-275e772998b2">5.16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id0b2ee1a17b243b4a95803b356639783_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTpiMTYwM2Q5YWM4Zjk0MGRkYjU5Yjg3Zjc1ZmU0OGMyZS90YWJsZXJhbmdlOmIxNjAzZDlhYzhmOTQwZGRiNTliODdmNzVmZTQ4YzJlXzMtMi0xLTEtMzMyMDM_b5b7c7c9-928f-45a0-accc-d015eb74f19d">2,185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id0b2ee1a17b243b4a95803b356639783_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTpiMTYwM2Q5YWM4Zjk0MGRkYjU5Yjg3Zjc1ZmU0OGMyZS90YWJsZXJhbmdlOmIxNjAzZDlhYzhmOTQwZGRiNTliODdmNzVmZTQ4YzJlXzMtNC0xLTEtMzMyMDM_22d5d54d-5603-4eb3-b135-be8f5c29c615">3.15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="id0b2ee1a17b243b4a95803b356639783_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTpiMTYwM2Q5YWM4Zjk0MGRkYjU5Yjg3Zjc1ZmU0OGMyZS90YWJsZXJhbmdlOmIxNjAzZDlhYzhmOTQwZGRiNTliODdmNzVmZTQ4YzJlXzQtMi0xLTEtMzMyMDM_bfc2ff1a-4693-4aab-bf37-6d1f97bb28c9">1,012</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id0b2ee1a17b243b4a95803b356639783_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTpiMTYwM2Q5YWM4Zjk0MGRkYjU5Yjg3Zjc1ZmU0OGMyZS90YWJsZXJhbmdlOmIxNjAzZDlhYzhmOTQwZGRiNTliODdmNzVmZTQ4YzJlXzQtNC0xLTEtMzMyMDM_5106c131-9faf-461d-bab3-617f71abdf30">4.86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="id0b2ee1a17b243b4a95803b356639783_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTpiMTYwM2Q5YWM4Zjk0MGRkYjU5Yjg3Zjc1ZmU0OGMyZS90YWJsZXJhbmdlOmIxNjAzZDlhYzhmOTQwZGRiNTliODdmNzVmZTQ4YzJlXzUtMi0xLTEtMzMyMDM_10f79c71-3ec9-484c-a064-2279d2fb813b">279</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id0b2ee1a17b243b4a95803b356639783_D20220101-20221231" decimals="2" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTpiMTYwM2Q5YWM4Zjk0MGRkYjU5Yjg3Zjc1ZmU0OGMyZS90YWJsZXJhbmdlOmIxNjAzZDlhYzhmOTQwZGRiNTliODdmNzVmZTQ4YzJlXzUtNC0xLTEtMzMyMDM_e7a4299f-2b33-4078-a533-670514eb6d77">4.03</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idc54e15956a14d6a8516b3a8816e8281_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTpiMTYwM2Q5YWM4Zjk0MGRkYjU5Yjg3Zjc1ZmU0OGMyZS90YWJsZXJhbmdlOmIxNjAzZDlhYzhmOTQwZGRiNTliODdmNzVmZTQ4YzJlXzYtMi0xLTEtMzMyMDM_32a3bc8b-a4c8-4f34-ae2d-4a04059fa7b3">2,748</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idc54e15956a14d6a8516b3a8816e8281_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTpiMTYwM2Q5YWM4Zjk0MGRkYjU5Yjg3Zjc1ZmU0OGMyZS90YWJsZXJhbmdlOmIxNjAzZDlhYzhmOTQwZGRiNTliODdmNzVmZTQ4YzJlXzYtNC0xLTEtMzMyMDM_b0a33b0e-363e-4797-b3c1-e422517bfd36">3.78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2022, the Company issued $<ix:nonFraction unitRef="usd" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="-3" name="us-gaap:TreasuryStockPreferredValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzEwOTk1MTE2MzMwNTc_371d67bd-fe57-465b-8ba2-4987dcd05da0">6.3</ix:nonFraction>&#160;million of Treasury shares in lieu of issuing additional authorized common shares in order to satisfy the annual vesting of restricted stock units for its employees and officers.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Aggregate Shares Reserved for Issuance</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, an aggregate of <ix:nonFraction unitRef="shares" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzQzMjU_b0becdee-614a-48b7-95ea-480e0dd081e7">15,096,609</ix:nonFraction> shares of common stock were reserved for issuance upon exercise of outstanding stock options and vesting of outstanding restricted stock units and <ix:nonFraction unitRef="shares" contextRef="i024c9d1784a74539a536ca837e05f772_I20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzQ0NzU_71008da4-a86b-4db3-ad21-7afe34562bee">8,160,575</ix:nonFraction> additional shares were available for future grants under Lexicon&#8217;s equity incentive plans.&#160;&#160;The Company has a policy of using either authorized and unissued shares or treasury shares, including shares acquired by purchase in the open market or in private transactions, to satisfy equity award exercises.</span></div></ix:continuation><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i122d3ae3d73245b585bd7f040afd795c_184"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODQvZnJhZzowZTBjNjM1MmEyNTE0ODVmOGY2Y2M5YTUzZDA4YmUwYy90ZXh0cmVnaW9uOjBlMGM2MzUyYTI1MTQ4NWY4ZjZjYzlhNTNkMDhiZTBjXzY0NQ_6fec91d8-f7e1-46dc-8dc3-a0deecef6670" continuedAt="i1dd61ea846de49fab046d5c87d2b430f" escape="true">Benefit Plan</ix:nonNumeric></span></div><ix:continuation id="i1dd61ea846de49fab046d5c87d2b430f"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lexicon maintains a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code.&#160;&#160;The plan covers substantially all full-time employees.&#160;&#160;Participating employees may defer a portion of their pretax earnings, up to the Internal Revenue Service annual contribution limit.&#160;&#160;Beginning in 2000, the Company was required to match employee contributions according to a specified formula.&#160;&#160;The matching contributions totaled $<ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODQvZnJhZzowZTBjNjM1MmEyNTE0ODVmOGY2Y2M5YTUzZDA4YmUwYy90ZXh0cmVnaW9uOjBlMGM2MzUyYTI1MTQ4NWY4ZjZjYzlhNTNkMDhiZTBjXzQ2Ng_0ecd2d60-48b8-4b69-9959-fc91b17c9769">0.7</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODQvZnJhZzowZTBjNjM1MmEyNTE0ODVmOGY2Y2M5YTUzZDA4YmUwYy90ZXh0cmVnaW9uOjBlMGM2MzUyYTI1MTQ4NWY4ZjZjYzlhNTNkMDhiZTBjXzQ3MA_fd8b0733-cc48-438c-b343-5540c1b349b6">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODQvZnJhZzowZTBjNjM1MmEyNTE0ODVmOGY2Y2M5YTUzZDA4YmUwYy90ZXh0cmVnaW9uOjBlMGM2MzUyYTI1MTQ4NWY4ZjZjYzlhNTNkMDhiZTBjXzQ3Nw_8f175efa-d3cd-4ecf-8ab7-37cd0fbdd985">0.9</ix:nonFraction> million in the years ended December&#160;31, 2022, 2021 and 2020, respectively.&#160;&#160;Company contributions are vested based on the employee&#8217;s years of service, with full vesting after <ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="lxrx:DefinedContributionPlanRequisiteServicePeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODQvZnJhZzowZTBjNjM1MmEyNTE0ODVmOGY2Y2M5YTUzZDA4YmUwYy90ZXh0cmVnaW9uOjBlMGM2MzUyYTI1MTQ4NWY4ZjZjYzlhNTNkMDhiZTBjXzYyOA_a49907eb-4d5e-434a-99d2-a4a7a0f4ba0e">four years</ix:nonNumeric> of service.</span></div></ix:continuation><div id="i122d3ae3d73245b585bd7f040afd795c_1786"></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Asset Sale</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, the Company completed the sale of its XERMELO product and related assets (the &#8220;XERMELO sale&#8221;) to TerSera pursuant to an Asset Purchase and Sale Agreement entered into in July 2020.  The final consideration paid by TerSera was $<ix:nonFraction unitRef="usd" contextRef="ief9b221acfd5465cb83500067a09fff2_I20201231" decimals="-5" name="lxrx:FinalConsiderationIncludingAmountsReleasedToSettle" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzg2L2ZyYWc6MTkxMzYwNmNhYTc4NDBlNzkyYmY3ZDhlOTA0ODI1MDIvdGV4dHJlZ2lvbjoxOTEzNjA2Y2FhNzg0MGU3OTJiZjdkOGU5MDQ4MjUwMl81NDk3NTU4MTM5MTQ3_c6bc81ad-1a72-4cc4-b081-a2781eb5c44c">160.0</ix:nonFraction> million and the net gain recognized in connection with the XERMELO sale was $<ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-5" name="lxrx:GainOnSaleOfNonFinancialAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzg2L2ZyYWc6MTkxMzYwNmNhYTc4NDBlNzkyYmY3ZDhlOTA0ODI1MDIvdGV4dHJlZ2lvbjoxOTEzNjA2Y2FhNzg0MGU3OTJiZjdkOGU5MDQ4MjUwMl8xMDk5NTExNjI4ODY4_7275c45d-c702-4970-bbbe-04fe642ce7c8">132.6</ix:nonFraction>&#160;million.  The gain is reflected on the consolidated statement of comprehensive loss for the year ended December&#160;31, 2020. For the year ended December&#160;31, 2020, the pretax net loss on the consolidated statement of comprehensive loss for the Company&#8217;s XERMELO operations was $<ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzg2L2ZyYWc6MTkxMzYwNmNhYTc4NDBlNzkyYmY3ZDhlOTA0ODI1MDIvdGV4dHJlZ2lvbjoxOTEzNjA2Y2FhNzg0MGU3OTJiZjdkOGU5MDQ4MjUwMl81NDk3NTU4MTM5NDYw_c36b5206-29d9-4569-81a4-dbf0a94f8b4a">12.2</ix:nonFraction> million. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the XERMELO sale, the Company implemented a reduction in force which reduced its workforce by approximately fifty percent. The Company incurred and recognized severance charges of approximate $<ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-3" name="us-gaap:SeveranceCosts1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzg2L2ZyYWc6MTkxMzYwNmNhYTc4NDBlNzkyYmY3ZDhlOTA0ODI1MDIvdGV4dHJlZ2lvbjoxOTEzNjA2Y2FhNzg0MGU3OTJiZjdkOGU5MDQ4MjUwMl81NDk3NTU4MTM5Njc2_77708c85-b540-4531-8c48-7bf8ebd1a1cb">5.5</ix:nonFraction> million. Of this </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-21</span></div></div></div><hr style="page-break-after:always"/><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">charge, $<ix:nonFraction unitRef="usd" contextRef="i4aff0769c8dc406faa9ff4224da35cc9_D20200101-20201231" decimals="-3" name="us-gaap:SeveranceCosts1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzg2L2ZyYWc6MTkxMzYwNmNhYTc4NDBlNzkyYmY3ZDhlOTA0ODI1MDIvdGV4dHJlZ2lvbjoxOTEzNjA2Y2FhNzg0MGU3OTJiZjdkOGU5MDQ4MjUwMl81NDk3NTU4MTM5Njk3_9209a695-9c12-49f5-903f-3694860dc4d6">2.5</ix:nonFraction> million was recorded in research and development expense and $<ix:nonFraction unitRef="usd" contextRef="id9c84c90905348f0bcea48d159d00b8e_D20200101-20201231" decimals="-3" name="us-gaap:SeveranceCosts1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzg2L2ZyYWc6MTkxMzYwNmNhYTc4NDBlNzkyYmY3ZDhlOTA0ODI1MDIvdGV4dHJlZ2lvbjoxOTEzNjA2Y2FhNzg0MGU3OTJiZjdkOGU5MDQ4MjUwMl81NDk3NTU4MTM5NzU0_a86d334b-32b5-4c9c-8356-fa7676c7cfe7">3.0</ix:nonFraction> million was recorded in selling, general and administrative expense in the accompanying consolidated statement of comprehensive loss for the year ended December&#160;31, 2020.</span></div><div><span><br/></span></div><div id="i122d3ae3d73245b585bd7f040afd795c_187"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODcvZnJhZzo4YjU4NDQwZWMxYjM0ZWI0YWNlMTExOGQyMzEwNmFjOC90ZXh0cmVnaW9uOjhiNTg0NDBlYzFiMzRlYjRhY2UxMTE4ZDIzMTA2YWM4XzUxNTM_a5f2bfa4-ca02-4b92-8340-10e6eb177940" continuedAt="i53a88d21732b48c3871d52209b4b3101" escape="true">Collaboration and License Agreements</ix:nonNumeric></span></div><ix:continuation id="i53a88d21732b48c3871d52209b4b3101"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lexicon has derived substantially all of its revenues from drug discovery and development alliances, target validation collaborations for the development and, in some cases, analysis of the physiological effects of genes altered in knockout mice, product sales, government grants and contracts, technology licenses, subscriptions to its databases and compound library sales.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ipsen.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  In October 2014, Lexicon entered into a License and Collaboration Agreement, which was subsequently amended in March 2015 (collectively, the &#8220;Ipsen Agreement&#8221;), with Ipsen&#160;for the development and commercialization of XERMELO outside of the United States and Japan (the &#8220;Licensed Territory&#8221;).  Revenue for the year ended December&#160;31, 2020 included $<ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-5" name="lxrx:IpsenRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODcvZnJhZzo4YjU4NDQwZWMxYjM0ZWI0YWNlMTExOGQyMzEwNmFjOC90ZXh0cmVnaW9uOjhiNTg0NDBlYzFiMzRlYjRhY2UxMTE4ZDIzMTA2YWM4XzE5ODg_d53afa67-0a5d-4d94-b1aa-27543dff73e9">0.3</ix:nonFraction> million of royalties from Ipsen and $<ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-5" name="lxrx:Ipsenproductsales" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODcvZnJhZzo4YjU4NDQwZWMxYjM0ZWI0YWNlMTExOGQyMzEwNmFjOC90ZXh0cmVnaW9uOjhiNTg0NDBlYzFiMzRlYjRhY2UxMTE4ZDIzMTA2YWM4XzIwNTU_435a1941-2934-4c44-888a-dbdbe3b36c20">1.3</ix:nonFraction> million from sales of bulk tablets of XERMELO to Ipsen. The Ipsen Agreement was assigned to TerSera in September 2020 in connection with the XERMELO sale.</span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div id="i122d3ae3d73245b585bd7f040afd795c_193"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Capital Agreements</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  In December 2020, Lexicon sold <ix:nonFraction unitRef="shares" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="0" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xOTMvZnJhZzpiZWNkYTkwMDMzNTM0YTk3OGU1OTk2Yzk0OGYzN2FlYy90ZXh0cmVnaW9uOmJlY2RhOTAwMzM1MzRhOTc4ZTU5OTZjOTQ4ZjM3YWVjXzgy_7ed46289-38e4-4c1b-86c2-17a6ea15a931">20,312,500</ix:nonFraction> shares of its common stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ief9b221acfd5465cb83500067a09fff2_I20201231" decimals="2" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xOTMvZnJhZzpiZWNkYTkwMDMzNTM0YTk3OGU1OTk2Yzk0OGYzN2FlYy90ZXh0cmVnaW9uOmJlY2RhOTAwMzM1MzRhOTc4ZTU5OTZjOTQ4ZjM3YWVjXzEyNg_8f5b4327-40fd-4cee-8665-e2ff3fa2738e">3.20</ix:nonFraction> per share in a registered direct offering pursuant to an existing shelf registration statement.  Sale of the shares resulted in net proceeds of $<ix:nonFraction unitRef="usd" contextRef="ief9b221acfd5465cb83500067a09fff2_I20201231" decimals="-3" name="lxrx:ProceedsFromDecember2020CommonStockOffering" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xOTMvZnJhZzpiZWNkYTkwMDMzNTM0YTk3OGU1OTk2Yzk0OGYzN2FlYy90ZXh0cmVnaW9uOmJlY2RhOTAwMzM1MzRhOTc4ZTU5OTZjOTQ4ZjM3YWVjXzI3Mw_a1037295-7369-4039-aac5-99ddc3874587">63.0</ix:nonFraction>&#160;million, after deducting underwriting discounts and commissions of $<ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-3" name="lxrx:CommissionsFromDecember2020CommonStockOffering" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xOTMvZnJhZzpiZWNkYTkwMDMzNTM0YTk3OGU1OTk2Yzk0OGYzN2FlYy90ZXh0cmVnaW9uOmJlY2RhOTAwMzM1MzRhOTc4ZTU5OTZjOTQ4ZjM3YWVjXzMzNQ_d383aee6-91ac-408e-a974-3204d1213dab">1.8</ix:nonFraction>&#160;million and offering expenses of $<ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-5" name="lxrx:OfferingExpensesFromDecember20CommonStockOffering" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xOTMvZnJhZzpiZWNkYTkwMDMzNTM0YTk3OGU1OTk2Yzk0OGYzN2FlYy90ZXh0cmVnaW9uOmJlY2RhOTAwMzM1MzRhOTc4ZTU5OTZjOTQ4ZjM3YWVjXzM2Mw_0f14db88-e86a-4616-a719-63749618be1f">0.2</ix:nonFraction>&#160;million.  The investors in the offering were Artal International S.C.A., an affiliate of Invus, L.P., the Company&#8217;s largest stockholder, and BVF Partners L.P. and certain affiliates of BVF Partners L.P.  All of the net proceeds of the registered direct offering are reflected as issuance of common stock in the accompanying financial statements.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, Lexicon entered into an Open Market Sale Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;sales agreement&#8221;) with Jefferies LLC (&#8220;Jefferies&#8221;) relating to the shares of its common stock.  Under the sales agreement, Lexicon was able to offer and sell common stock having an aggregate sales price of up to $<ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" name="lxrx:ATMOffering2020Total" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xOTMvZnJhZzpiZWNkYTkwMDMzNTM0YTk3OGU1OTk2Yzk0OGYzN2FlYy90ZXh0cmVnaW9uOmJlY2RhOTAwMzM1MzRhOTc4ZTU5OTZjOTQ4ZjM3YWVjXzEwOTk1MTE2MzI0MTc_b9826152-f003-493d-986a-6bbdee00f54c">50.0</ix:nonFraction> million from time to time through Jefferies acting as its sales agent.  In November 2020, Lexicon sold <ix:nonFraction unitRef="shares" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="0" name="lxrx:SharesSoldInNov2020ATMOffering" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xOTMvZnJhZzpiZWNkYTkwMDMzNTM0YTk3OGU1OTk2Yzk0OGYzN2FlYy90ZXh0cmVnaW9uOmJlY2RhOTAwMzM1MzRhOTc4ZTU5OTZjOTQ4ZjM3YWVjXzEwOTk1MTE2MzA1NjA_002ef5ba-00b8-4ef9-abf7-d47b610e01c3">3,709,233</ix:nonFraction> shares of its common stock at a price of $<ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="3" name="lxrx:SharePriceInNovember20ATMOffering" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xOTMvZnJhZzpiZWNkYTkwMDMzNTM0YTk3OGU1OTk2Yzk0OGYzN2FlYy90ZXh0cmVnaW9uOmJlY2RhOTAwMzM1MzRhOTc4ZTU5OTZjOTQ4ZjM3YWVjXzEwOTk1MTE2MzA2MDU_be3aeba9-87ff-4667-97a4-693d32db8a29">1.992</ix:nonFraction> per share pursuant to the sales agreement, resulting in net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231" decimals="-3" name="lxrx:ProceedsFromNov2020ATMOffering" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xOTMvZnJhZzpiZWNkYTkwMDMzNTM0YTk3OGU1OTk2Yzk0OGYzN2FlYy90ZXh0cmVnaW9uOmJlY2RhOTAwMzM1MzRhOTc4ZTU5OTZjOTQ4ZjM3YWVjXzEwOTk1MTE2MzA2ODE_68d0a6ae-60db-437c-bfd4-e8e1f9c05b3d">7.0</ix:nonFraction>&#160;million.  In January 2021, Lexicon sold <ix:nonFraction unitRef="shares" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="0" name="lxrx:SharesSoldInJanuary2021ATMOffering" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xOTMvZnJhZzpiZWNkYTkwMDMzNTM0YTk3OGU1OTk2Yzk0OGYzN2FlYy90ZXh0cmVnaW9uOmJlY2RhOTAwMzM1MzRhOTc4ZTU5OTZjOTQ4ZjM3YWVjXzEwOTk1MTE2MzA3MTc_e47069a5-3461-4232-8d07-39a02ea5b4c0">2,000,000</ix:nonFraction> shares of its common stock at a price of $<ix:nonFraction unitRef="shares" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="3" name="lxrx:SharePriceInJanuary2021ATMOffering" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xOTMvZnJhZzpiZWNkYTkwMDMzNTM0YTk3OGU1OTk2Yzk0OGYzN2FlYy90ZXh0cmVnaW9uOmJlY2RhOTAwMzM1MzRhOTc4ZTU5OTZjOTQ4ZjM3YWVjXzEwOTk1MTE2MzA3NjI_0e1c429c-f440-4cdd-81a2-8b3b42a44bc7">8.463</ix:nonFraction> per share pursuant to the sales agreement, resulting in net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="-5" name="lxrx:ProceedsFromJanuary2021ATMOffering" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xOTMvZnJhZzpiZWNkYTkwMDMzNTM0YTk3OGU1OTk2Yzk0OGYzN2FlYy90ZXh0cmVnaW9uOmJlY2RhOTAwMzM1MzRhOTc4ZTU5OTZjOTQ4ZjM3YWVjXzEwOTk1MTE2MzA4Mzg_854b09d3-ecc5-493c-bddc-497e5e13412f">16.4</ix:nonFraction>&#160;million. In August and September 2021, Lexicon sold an aggregate of <ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="0" name="lxrx:SharesSoldInSeptember2021ATMOffering" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xOTMvZnJhZzpiZWNkYTkwMDMzNTM0YTk3OGU1OTk2Yzk0OGYzN2FlYy90ZXh0cmVnaW9uOmJlY2RhOTAwMzM1MzRhOTc4ZTU5OTZjOTQ4ZjM3YWVjXzEwOTk1MTE2MzA5MDI_71cc7521-3536-4403-8592-42fa7b931465">4,176,953</ix:nonFraction> shares of its common stock at a price of $<ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="3" name="lxrx:SharePriceInSeptember2021ATMOffering" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xOTMvZnJhZzpiZWNkYTkwMDMzNTM0YTk3OGU1OTk2Yzk0OGYzN2FlYy90ZXh0cmVnaW9uOmJlY2RhOTAwMzM1MzRhOTc4ZTU5OTZjOTQ4ZjM3YWVjXzEwOTk1MTE2MzA5NDc_97812d59-433d-427b-a29a-65ca6359f5cf">4.732</ix:nonFraction> per share pursuant to the sales agreement, resulting in net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231" decimals="-5" name="lxrx:ProceedsFromSeptember2021ATMOffering" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xOTMvZnJhZzpiZWNkYTkwMDMzNTM0YTk3OGU1OTk2Yzk0OGYzN2FlYy90ZXh0cmVnaW9uOmJlY2RhOTAwMzM1MzRhOTc4ZTU5OTZjOTQ4ZjM3YWVjXzEwOTk1MTE2MzEwMjM_d0460e22-21b8-46b4-95af-62da5e30d252">19.1</ix:nonFraction>&#160;million. The net proceeds from each of these sales are reflected as issuances of common stock in the accompanying financial statements.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, Lexicon sold an aggregate of <ix:nonFraction unitRef="shares" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" name="lxrx:SharesSoldInJuly2022Offering" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xOTMvZnJhZzpiZWNkYTkwMDMzNTM0YTk3OGU1OTk2Yzk0OGYzN2FlYy90ZXh0cmVnaW9uOmJlY2RhOTAwMzM1MzRhOTc4ZTU5OTZjOTQ4ZjM3YWVjXzEwOTk1MTE2Mjk5MTM_7615ec3d-a3d6-415a-a802-f3492bb32493">39,100,000</ix:nonFraction> shares of its common stock at a price of $<ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="2" name="lxrx:SharePriceInJuly2022Offering" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xOTMvZnJhZzpiZWNkYTkwMDMzNTM0YTk3OGU1OTk2Yzk0OGYzN2FlYy90ZXh0cmVnaW9uOmJlY2RhOTAwMzM1MzRhOTc4ZTU5OTZjOTQ4ZjM3YWVjXzEwOTk1MTE2Mjk5NTg_53a6a494-e691-49ed-a3ba-e6b22113e9b9">2.50</ix:nonFraction> per share in a public offering and concurrent private placement to two affiliates of Invus, L.P., resulting in net proceeds of $<ix:nonFraction unitRef="usd" contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231" decimals="-3" name="lxrx:ProceedsFromJuly2022Offering" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xOTMvZnJhZzpiZWNkYTkwMDMzNTM0YTk3OGU1OTk2Yzk0OGYzN2FlYy90ZXh0cmVnaW9uOmJlY2RhOTAwMzM1MzRhOTc4ZTU5OTZjOTQ4ZjM3YWVjXzEwOTk1MTE2MzAwODk_89595b1f-86c3-4670-861d-d1184615e9c7">94.2</ix:nonFraction>&#160;million, after deducting underwriting discounts and commissions and offering expenses.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.10
<SEQUENCE>2
<FILENAME>exh1010officerrestrictedst.htm
<DESCRIPTION>EX-10.10
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i623f508f92ca467c8fe3ff3250f9d63e_33"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Exhibit 10.10</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">RESTRICTED STOCK UNIT AGREEMENT</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">                                                      </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">(Officer Restricted Stock Unit)</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">            This Restricted Stock Unit Agreement (this &#8220;Agreement&#8221;), effective as of ____________ (the &#8220;Grant Date&#8221;), is by and between Lexicon Pharmaceuticals, Inc., a Delaware corporation (the &#8220;Company&#8221;), and _____________ (&#8220;Employee&#8221;).</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">To carry out the purposes of the Company&#8217;s 2017 Equity Incentive Plan (the &#8220;Plan&#8221;) and the determination of the compensation committee (the &#8220;Compensation Committee&#8221;) of the Company&#8217;s board of directors (the &#8220;Board&#8221;) to grant Employee a Restricted Stock Unit Award (as defined in the Plan) under the Plan, subject to the terms and conditions of this Agreement, of shares of the Company&#8217;s Common Stock, par value $0.001 per share (&#8220;Stock&#8221;), in order to provide Employee with incentives to exert maximum efforts for the Company&#8217;s success by providing Employee the opportunity to benefit from increases in the value of the Stock, and in consideration of the mutual agreements and other matters set forth herein and in the Plan, the Company and Employee hereby agree as follows&#58;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">            </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">1.         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Grant of Restricted Stock Unit Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.  Subject to the approval by the stockholders of the Company of an amendment to the Plan increasing the number of shares of Stock that may be issued thereunder from 30,000,000 shares to 55,000,000 shares, the Company hereby grants to Employee a Restricted Stock Unit Award, on the terms and conditions set forth in this Agreement and in the Plan, consisting of the right to receive an aggregate of _________ shares of Stock (the &#8220;Shares&#8221;) or, as provided in Section 4 below and in the sole discretion of the Board, a lump sum cash payment equal to the fair market value of the Shares on the date of vesting.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Vesting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.  (a) Subject to the terms and conditions set forth in this Agreement and the Plan, the right of Employee to receive the Shares shall vest with respect to one third of the total number of Shares on February 28 of each of the three years following the year of grant&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> that, if not already vested in accordance with the foregoing, the right of Employee to receive the Shares shall become vested upon (i) a termination of Employee&#8217;s Continuous Service (as defined in the Plan) by the Company without Cause (as defined below) or by Employee for Good Reason (as defined below) that occurs after the occurrence of a Change in Control (as defined below) or (ii) the termination of Employee&#8217;s Continuous Service as a result of Employee&#8217;s death or Disability (as defined in the Plan).</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">            (b)        For purposes of the foregoing&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(i)&#160;&#160;&#160;&#160;A &#8220;Change in Control&#8221; shall be deemed to have occurred if any of the following shall have taken place&#58; (A) any &#8220;person&#8221; (as such term is used in Sections 13(d) and 14(d)(2) of the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;)) other than Invus, L.P. and its affiliates (collectively, &#8220;Invus&#8221;) is or becomes the &#8220;beneficial owner&#8221; (as defined in Rule 13d-3 under the Exchange Act, or any successor provisions thereto), directly or indirectly, of securities of the Company representing 35% or more of the combined voting power of the Company&#8217;s then-outstanding voting securities&#59; (B) Invus becomes the &#8220;beneficial owner&#8221; (as defined in Rule 13d-3 under the Exchange Act, or any successor provisions thereto), directly or indirectly, of securities of the Company representing 50% or more of the combined voting power of the Company&#8217;s then-outstanding voting securities&#59; (C) the consummation of a reorganization, merger, or consolidation, in each case with respect to which persons who were stockholders of the Company immediately prior to such reorganization, merger or consolidation do not, immediately thereafter, own or control more than 50% of the combined voting power of the reorganized, merged or consolidated Company&#8217;s then-outstanding securities entitled to vote generally in the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">election of directors in substantially the same proportions as their ownership of the Company&#8217;s outstanding voting securities prior to such reorganization, merger or consolidation&#59; (D) a liquidation or dissolution of the Company or the sale of all or substantially all of the Company&#8217;s assets&#59; or (E) following the election or removal of directors, a majority of the Board consists of individuals who were not members of the Board two years before such election or removal, unless the election of each director who is not a director at the beginning of such two-year period has been approved in advance by directors representing at least a majority of the directors then in office who were directors at the beginning of the two-year period&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">, that notwithstanding the foregoing, neither the execution by the Company of the Securities Purchase Agreement and Stockholders&#8217; Agreement with Invus, L.P., each dated June 15, 2007 (as amended, supplemented or otherwise modified, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Invus Transaction Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;), nor the consummation of the transactions contemplated in the Invus Transaction Agreements, including, without limitation, the acquisition by Invus of the Initial Shares and the Rights Shares (as defined in the Invus Transaction Agreements), the election of any representatives of Invus to the board of directors of the Company, or the acquisition by Invus of additional shares of Stock, as permitted or contemplated under the Invus Transaction Agreements, will constitute a &#8220;Change in Control.&#8221;  The Compensation Committee, in its discretion, may deem any other corporate event affecting the Company to be a &#8220;Change in Control&#8221; hereunder.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(ii)&#160;&#160;&#160;&#160;&#8220;Cause&#8221; means a termination of Employee&#8217;s employment directly resulting from (A) Employee having engaged in intentional misconduct causing a material violation by the Company of any state or federal laws, (B) Employee having engaged in a theft of Company funds or Company assets or in a material act of fraud upon the Company, (C) an act of personal dishonesty taken by Employee that was intended to result in personal enrichment of Employee at the expense of the Company, (D) Employee&#8217;s final conviction (or the entry of any plea other than not guilty) in a court of competent jurisdiction of a felony, or (E) a breach by Employee of any contractual or fiduciary obligation to the Company, if such breach results in a material injury to the Company.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(iii)&#160;&#160;&#160;&#160;&#8220;Good Reason&#8221; means the occurrence of any of the following events without Employee&#8217;s express written consent&#58; (A) a material diminution in Employee&#8217;s base salary, (B) a material diminution in Employee&#8217;s authority, duties, or responsibilities, or (C) any other action or inaction that constitutes a material breach by the Company of any contractual obligation to Employee.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Forfeiture upon Termination of Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.  Simultaneously with termination of Employee&#8217;s Continuous Service for any reason other than as a result of Employee&#8217;s death or Disability (as defined in the Plan) prior to the vesting of Employee&#8217;s rights to receive the Shares in accordance with Section 2 of this Agreement, Employee shall automatically forfeit all rights to receive the Shares, unless and except to the extent otherwise agreed by the Company, in its sole discretion.  </font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Issuance of Shares upon Vesting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.  Subject to the provisions of Sections 3 and 6 of this Agreement, upon vesting of the Shares in accordance with Section 2 of this Agreement, the Company shall (a) provide Employee with prompt notice of such vesting event and (b) issue (i) the Shares to Employee for no additional consideration or (ii) in the sole discretion of the Board, to Employee a lump sum cash payment equal to the closing sale price of the Shares as of the last trading date immediately prior to the date of vesting multiplied by the number of Shares vesting on such date.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Non-Transferability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.  Employee&#8217;s rights under this Agreement, including with respect to any Shares as to which the interest of Employee has not vested in accordance with Section 2 of this Agreement, may not be transferred by Employee otherwise than by will or the laws of descent and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">distribution or pursuant to a qualified domestic relations order (as defined in Title I of the Employee Retirement Income Security Act of 1974, as amended, or the rules thereunder).</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Withholding of Tax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.   Employee shall be liable for any and all federal, state or local taxes, including withholding taxes, arising out of the grant or vesting of Shares hereunder.  Unless Employee elects otherwise as provided below, Employee shall satisfy such withholding tax obligation by withholding from any cash payment to the Employee or by forfeiting to the Company that number of Shares having a Fair Market Value (as defined in the Plan) equal to the Company&#8217;s withholding obligation relating to such grant or vesting of Shares hereunder.  Employee may alternatively elect to satisfy such withholding tax obligation by making a cash payment to the Company equal to the Company&#8217;s minimum withholding obligation, in which case Employee shall (a) provide the Company with written notice of such election and (b) pay to the Company in immediately available funds an amount equal to the Company&#8217;s minimum withholding obligation, in each case by no later than the date giving rise to such withholding tax obligation.  No Shares shall be issued to Employee unless and until Employee shall have paid or otherwise satisfied the withholding tax obligations with respect thereto.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Dividend Equivalents&#59; Voting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.  If the Board declares any dividends with respect to the Stock prior to the vesting of Employee&#8217;s rights to receive the Shares in accordance with Section 2 of this Agreement, dividend equivalents shall be credited to Employee in respect of the Shares and shall be converted into additional shares of Stock covered by this Agreement and such additional shares shall be subject to all of the terms and conditions of the underlying Shares.  Employee shall have no voting rights with respect to the Restricted Stock Unit Award or the Shares subject thereto until such time as the Shares are issued or the cash payment is made to Employee pursuant to Section 4 of this Agreement.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">No Right to Continued Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. Nothing in this Agreement or the Plan shall confer upon Employee any right to continue in the employ of the Company or shall interfere with or restrict in any way the right of the Company, which is hereby expressly reserved, to terminate Employee&#8217;s employment at any time for any reason whatsoever, with or without cause and with or without advance notice.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">2017 Equity Incentive Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.  The Plan, a copy of which is available for inspection by Employee at the Company&#8217;s principal executive office during business hours, is incorporated by reference in this Agreement.  This Agreement is subject to, and the Company and Employee agree to be bound by, all of the terms and conditions of the Plan. In the event of a conflict between this Agreement and the Plan, the terms of the Plan shall control.  Subject to the terms of the Plan, the administrator of the Plan shall have authority to construe the terms of this Agreement, and the determinations of the administrator of the Plan shall be final and binding on Employee and the Company.  </font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Binding Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.  This Agreement shall be binding upon and inure to the benefit of any successors to the Company and all persons lawfully claiming under Employee. </font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.  This Agreement and all actions taken hereunder shall be governed by and construed in accordance with the laws of the State of Delaware. </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">IN WITNESS WHEREOF, the Company has caused this Agreement to be duly executed and Employee has executed this Agreement effective for all purposes as of the Grant Date.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">LEXICON PHARMACEUTICALS, INC.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">                                                                           </font></div><div style="text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">            Lonnel Coats</font></div><div style="text-align:justify;text-indent:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">Chief Executive Officer</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">EMPLOYEE</font></div><div style="text-align:justify;text-indent:216pt"><font><br></font></div><div style="text-align:justify;text-indent:216pt"><font><br></font></div><div style="text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">                                                                               </font></div><div style="text-align:justify;text-indent:216pt"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:216pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>exh231ernstyoungconsent2022.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i69370867e9d6436781cd9ef79ae823bc_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consent to the incorporation by reference in the following Registration Statements&#58;</font></div><div><font><br></font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Registration Statements (Form S-8 Nos. 333-41532, 333-168678, 333-183020, 333-210145, 333-217873, 333-234569, 333-240169 and 333-258568) pertaining to the 2017 Equity Incentive Plan and to the 2017 Non-Employee Directors' Equity Incentive Plan of Lexicon Pharmaceuticals, Inc., and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Registration Statement (Form S-3 No. 333-258564) of Lexicon Pharmaceuticals, Inc.&#59;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of our reports dated March&#160;3, 2023, with respect to the consolidated financial statements of Lexicon Pharmaceuticals, Inc. and the effectiveness of internal control over financial reporting of Lexicon Pharmaceuticals, Inc., included in this Annual Report (Form 10-K) of Lexicon Pharmaceuticals, Inc. for the year ended December&#160;31, 2022.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Ernst &#38; Young LLP</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Houston, Texas</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;3, 2023 </font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>exh311certificationofprinc.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ic42a513252d041319e47511efab8b551_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Lonnel Coats, certify that&#58;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.935%"><tr><td style="width:1.0%"></td><td style="width:3.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.687%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.789%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I have reviewed this Annual Report on Form 10-K of Lexicon Pharmaceuticals, Inc.&#59;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">c)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">d)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions)</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; March&#160;3, 2023 </font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:53.219%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.581%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Lonnel Coats</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lonnel Coats</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>exh312certificationofprinc.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i30c742afd20c42c78b0a020f09800c08_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Jeffrey L. Wade, certify that&#58;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"></td><td style="width:3.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.569%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.099%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I have reviewed this Annual Report on Form 10-K of Lexicon Pharmaceuticals, Inc.&#59;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">c)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">d)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions)&#58;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; March&#160;3, 2023 </font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:53.219%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.581%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Jeffrey L. Wade</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeffrey L. Wade</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">President and Chief Financial Office</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">r</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>exh321certificationofprinc.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i95163843540b4e5fb9412ec0f2dfe04f_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350, as adopted), Lonnel Coats, Principal Executive Officer of Lexicon Pharmaceuticals, Inc. (&#8220;Lexicon&#8221;), and Jeffrey L. Wade, Principal Financial Officer of Lexicon, each hereby certify that&#58;</font></div><div style="text-align:justify;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.959%"><tr><td style="width:1.0%"></td><td style="width:6.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lexicon's Annual Report on Form 10-K for the year ended December 31, 2022, and to which this Certification is attached as Exhibit 32.1 (the &#8220;Periodic Report&#8221;), fully complies with the requirements of section 13(a) or section 15(d) of the Securities Exchange Act of 1934, and</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of Lexicon.</font></td></tr></table></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the undersigned have set their hands hereto as of the 3rd day of March, 2023.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:53.219%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.145%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.336%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Lonnel Coats</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lonnel Coats</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer</font></div></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:53.219%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.145%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.336%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Jeffrey L. Wade</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeffrey L. Wade</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">President and Chief Financial Officer</font></div></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>lxrx-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:379d89f1-f5df-4675-bf23-f82d2f2c7aaf,g:c8f45f50-51f6-43ab-b86a-02bdbec3750c-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:lxrx="http://www.lexpharma.com/20221231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.lexpharma.com/20221231">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/naics/2022" schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.lexpharma.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.lexpharma.com/role/ConsolidatedBalanceSheets">
        <link:definition>0000002 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetParentheticals" roleURI="http://www.lexpharma.com/role/BalanceSheetParentheticals">
        <link:definition>0000003 - Statement - Balance Sheet Parentheticals</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveLoss" roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss">
        <link:definition>0000004 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsofComprehensiveLossParentheticalsParentheticals" roleURI="http://www.lexpharma.com/role/StatementsofComprehensiveLossParentheticalsParentheticals">
        <link:definition>0000005 - Statement - Statements of Comprehensive Loss Parentheticals (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquity" roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity">
        <link:definition>0000006 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>0000007 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandOperations" roleURI="http://www.lexpharma.com/role/OrganizationandOperations">
        <link:definition>0000008 - Disclosure - Organization and Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000009 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RecentAccountingPronouncements" roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncements">
        <link:definition>0000010 - Disclosure - Recent Accounting Pronouncements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandCashEquivalentsandInvestments" roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments">
        <link:definition>0000011 - Disclosure - Cash and Cash Equivalents and Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.lexpharma.com/role/FairValueMeasurements">
        <link:definition>0000012 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipment" roleURI="http://www.lexpharma.com/role/PropertyandEquipment">
        <link:definition>0000013 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.lexpharma.com/role/IncomeTaxes">
        <link:definition>0000014 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Goodwill" roleURI="http://www.lexpharma.com/role/Goodwill">
        <link:definition>0000015 - Disclosure - Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtObligations" roleURI="http://www.lexpharma.com/role/DebtObligations">
        <link:definition>0000016 - Disclosure - Debt Obligations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.lexpharma.com/role/CommitmentsandContingencies">
        <link:definition>0000017 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentiveAwards" roleURI="http://www.lexpharma.com/role/EquityIncentiveAwards">
        <link:definition>0000018 - Disclosure - Equity Incentive Awards</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BenefitPlan" roleURI="http://www.lexpharma.com/role/BenefitPlan">
        <link:definition>0000019 - Disclosure - Benefit Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreements" roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreements">
        <link:definition>0000020 - Disclosure - Collaboration and License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShare" roleURI="http://www.lexpharma.com/role/EarningsPerShare">
        <link:definition>0000021 - Disclosure - Earnings Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SelectedQuarterlyFinancialDataUnaudited" roleURI="http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnaudited">
        <link:definition>0000022 - Disclosure - Selected Quarterly Financial Data (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetSale" roleURI="http://www.lexpharma.com/role/AssetSale">
        <link:definition>0000023 - Disclosure - Asset Sale</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherCapitalAgreements" roleURI="http://www.lexpharma.com/role/OtherCapitalAgreements">
        <link:definition>0000024 - Disclosure - Other Capital Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000025 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>0000026 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RecentAccountingPronouncementsTables" roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncementsTables">
        <link:definition>0000027 - Disclosure - Recent Accounting Pronouncements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandCashEquivalentsandInvestmentsTables" roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables">
        <link:definition>0000028 - Disclosure - Cash and Cash Equivalents and Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.lexpharma.com/role/FairValueMeasurementsTables">
        <link:definition>0000029 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentTables" roleURI="http://www.lexpharma.com/role/PropertyandEquipmentTables">
        <link:definition>0000030 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.lexpharma.com/role/IncomeTaxesTables">
        <link:definition>0000031 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillTables" roleURI="http://www.lexpharma.com/role/GoodwillTables">
        <link:definition>0000032 - Disclosure - Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtObligationsDebtObligationsTables" roleURI="http://www.lexpharma.com/role/DebtObligationsDebtObligationsTables">
        <link:definition>0000033 - Disclosure - Debt Obligations Debt Obligations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://www.lexpharma.com/role/CommitmentsandContingenciesTables">
        <link:definition>0000034 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentiveAwardsTables" roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsTables">
        <link:definition>0000035 - Disclosure - Equity Incentive Awards (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BenefitPlanTables" roleURI="http://www.lexpharma.com/role/BenefitPlanTables">
        <link:definition>0000036 - Disclosure - Benefit Plan (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareTables" roleURI="http://www.lexpharma.com/role/EarningsPerShareTables">
        <link:definition>0000037 - Disclosure - Earnings Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SelectedQuarterlyFinancialDataUnauditedTables" roleURI="http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedTables">
        <link:definition>0000038 - Disclosure - Selected Quarterly Financial Data (Unaudited) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetSaleTables" roleURI="http://www.lexpharma.com/role/AssetSaleTables">
        <link:definition>0000039 - Disclosure - Asset Sale (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesInventoryDetails" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails">
        <link:definition>0000040 - Disclosure - Summary of Significant Accounting Policies Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails">
        <link:definition>0000041 - Disclosure - Summary of Significant Accounting Policies Concentration of Credit Risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSegmentInformationandSignficantCustomersDetails" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationandSignficantCustomersDetails">
        <link:definition>0000042 - Disclosure - Summary of Significant Accounting Policies Segment Information and Signficant Customers (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesIntangibleassetDetails" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleassetDetails">
        <link:definition>0000043 - Disclosure - Summary of Significant Accounting Policies Intangible asset (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails">
        <link:definition>0000044 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesImpairmentofLongLivedAssetsDetails" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesImpairmentofLongLivedAssetsDetails">
        <link:definition>0000045 - Disclosure - Summary of Significant Accounting Policies Impairment of Long-Lived Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesGoodwillDetails" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesGoodwillDetails">
        <link:definition>0000046 - Disclosure - Summary of Significant Accounting Policies Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesCostofSalesDetails" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesCostofSalesDetails">
        <link:definition>0000047 - Disclosure - Summary of Significant Accounting Policies - Cost of Sales (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1">
        <link:definition>0000048 - Disclosure - Summary of Significant Accounting Policies Stock-Based Compensation (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesStockbasedCompensationDetails2" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationDetails2">
        <link:definition>0000049 - Disclosure - Summary of Significant Accounting Policies Stock-based Compensation (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RecentAccountingPronouncementsDetails" roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncementsDetails">
        <link:definition>0000050 - Disclosure - Recent Accounting Pronouncements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandCashEquivalentsandInvestmentsDetails" roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails">
        <link:definition>0000051 - Disclosure - Cash and Cash Equivalents and Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails1" roleURI="http://www.lexpharma.com/role/FairValueMeasurementsDetails1">
        <link:definition>0000052 - Disclosure - Fair Value Measurements (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails2" roleURI="http://www.lexpharma.com/role/FairValueMeasurementsDetails2">
        <link:definition>0000053 - Disclosure - Fair Value Measurements (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentDetails" roleURI="http://www.lexpharma.com/role/PropertyandEquipmentDetails">
        <link:definition>0000054 - Disclosure - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails1" roleURI="http://www.lexpharma.com/role/IncomeTaxesDetails1">
        <link:definition>0000055 - Disclosure - Income Taxes (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails2" roleURI="http://www.lexpharma.com/role/IncomeTaxesDetails2">
        <link:definition>0000056 - Disclosure - Income Taxes (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails3" roleURI="http://www.lexpharma.com/role/IncomeTaxesDetails3">
        <link:definition>0000057 - Disclosure - Income Taxes (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillDetails" roleURI="http://www.lexpharma.com/role/GoodwillDetails">
        <link:definition>0000058 - Disclosure - Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtObligationsNarrativeDetails" roleURI="http://www.lexpharma.com/role/DebtObligationsNarrativeDetails">
        <link:definition>0000059 - Disclosure - Debt Obligations - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtObligationsDetails1" roleURI="http://www.lexpharma.com/role/DebtObligationsDetails1">
        <link:definition>0000060 - Disclosure - Debt Obligations (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesNarrativeDetails" roleURI="http://www.lexpharma.com/role/CommitmentsandContingenciesNarrativeDetails">
        <link:definition>0000061 - Disclosure - Commitments and Contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails2" roleURI="http://www.lexpharma.com/role/CommitmentsandContingenciesDetails2">
        <link:definition>0000062 - Disclosure - Commitments and Contingencies (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://www.lexpharma.com/role/CommitmentsandContingenciesDetails">
        <link:definition>0000063 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentiveAwardsNarrativeDetails" roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails">
        <link:definition>0000064 - Disclosure - Equity Incentive Awards - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentiveAwardsDetails2" roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2">
        <link:definition>0000065 - Disclosure - Equity Incentive Awards (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentiveAwardsDetails3" roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3">
        <link:definition>0000066 - Disclosure - Equity Incentive Awards (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentiveAwardsDetails4" roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4">
        <link:definition>0000067 - Disclosure - Equity Incentive Awards (Details 4)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BenefitPlanDetails" roleURI="http://www.lexpharma.com/role/BenefitPlanDetails">
        <link:definition>0000068 - Disclosure - Benefit Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsDetails" roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails">
        <link:definition>0000069 - Disclosure - Collaboration and License Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareDetails" roleURI="http://www.lexpharma.com/role/EarningsPerShareDetails">
        <link:definition>0000070 - Disclosure - Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SelectedQuarterlyFinancialDataUnauditedQuarterlyFinancialInformationDetails" roleURI="http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedQuarterlyFinancialInformationDetails">
        <link:definition>0000071 - Disclosure - Selected Quarterly Financial Data (Unaudited) - Quarterly Financial Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetSaleDetails" roleURI="http://www.lexpharma.com/role/AssetSaleDetails">
        <link:definition>0000072 - Disclosure - Asset Sale (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherCapitalAgreementsDetails" roleURI="http://www.lexpharma.com/role/OtherCapitalAgreementsDetails">
        <link:definition>0000073 - Disclosure - Other Capital Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="lxrx_A2026OxfordPrincipalPaymentsB" abstract="false" name="A2026OxfordPrincipalPaymentsB" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_A2026OxfordPrincipalPayments" abstract="false" name="A2026OxfordPrincipalPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SanofiDevelopmentMilestones" abstract="false" name="SanofiDevelopmentMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SanofiRevenueRecognized" abstract="false" name="SanofiRevenueRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lxrx_TermLoanDWarrant" abstract="false" name="TermLoanDWarrant" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lxrx_GainOnSaleOfNonFinancialAssets" abstract="false" name="GainOnSaleOfNonFinancialAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfRegulatoryMilestones" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfRegulatoryMilestones" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lxrx_SanofiRevenueAllocatedtoFundingDeliverable" abstract="false" name="SanofiRevenueAllocatedtoFundingDeliverable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_TermLoanAWarrantsNumber" abstract="false" name="TermLoanAWarrantsNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan" abstract="false" name="StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_CollaborationAndLicenseAgreementsAbstract" abstract="true" name="CollaborationAndLicenseAgreementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfDevelopmentMilestones" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfDevelopmentMilestones" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" abstract="true" name="CashAndCashEquivalentsAndInvestmentsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_IpsenRevenueAllocatedtoLicenseDeliverable" abstract="false" name="IpsenRevenueAllocatedtoLicenseDeliverable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan" abstract="false" name="SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_AccruedCompensationAndBenefitsCurrent" abstract="false" name="AccruedCompensationAndBenefitsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_A2020ConvertibleDebtExchangePercentageOfPrincipal" abstract="false" name="A2020ConvertibleDebtExchangePercentageOfPrincipal" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lxrx_SanofiSalesMilestonePayments" abstract="false" name="SanofiSalesMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SymphonyIconGoodwill" abstract="false" name="SymphonyIconGoodwill" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX" abstract="false" name="MortgageDebtInterestRateBasePlus_Revere_LXRX" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lxrx_A2027OxfordPrincipalPaymentsA" abstract="false" name="A2027OxfordPrincipalPaymentsA" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_TermLoanADebtIssuanceCosts" abstract="false" name="TermLoanADebtIssuanceCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_FinalPaymentWithExtention" abstract="false" name="FinalPaymentWithExtention" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lxrx_TermLoanA" abstract="false" name="TermLoanA" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_FinalConsiderationIncludingAmountsReleasedToSettle" abstract="false" name="FinalConsiderationIncludingAmountsReleasedToSettle" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SharePriceInNovember20ATMOffering" abstract="false" name="SharePriceInNovember20ATMOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_TermLoanAWarrantExercisePrice" abstract="false" name="TermLoanAWarrantExercisePrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="lxrx_FairValueMeasurementsAbstract" abstract="true" name="FairValueMeasurementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_OxfordAmendmentFee" abstract="false" name="OxfordAmendmentFee" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lxrx_A2020ConvertibleDebtExchangeAccruedInterest" abstract="false" name="A2020ConvertibleDebtExchangeAccruedInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_EntityWideRevenueSanofiPercentage" abstract="false" name="EntityWideRevenueSanofiPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lxrx_PresentValueOfFutureLeasePayments" abstract="false" name="PresentValueOfFutureLeasePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan" abstract="false" name="SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_IpsenTotalUpfrontPayments" abstract="false" name="IpsenTotalUpfrontPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SanofiRegulatoryMilestones" abstract="false" name="SanofiRegulatoryMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SharesSoldInJanuary2021ATMOffering" abstract="false" name="SharesSoldInJanuary2021ATMOffering" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_StockOptionsExercisedEquityIncentivePlan" abstract="false" name="StockOptionsExercisedEquityIncentivePlan" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_TermLoanBDebtDiscount" abstract="false" name="TermLoanBDebtDiscount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SharesSoldInJuly2022Offering" abstract="false" name="SharesSoldInJuly2022Offering" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_ConsolidatedBalanceSheetsAbstract" abstract="true" name="ConsolidatedBalanceSheetsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_WriteOffOfTaxCredits" abstract="false" name="WriteOffOfTaxCredits" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ConsolidatedStatementsOfOperationsAbstract" abstract="true" name="ConsolidatedStatementsOfOperationsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_OrganizationAndOperationsAbstract" abstract="true" name="OrganizationAndOperationsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_SanofiCommercializationCostsFundedbyLexiconMaximumAmount" abstract="false" name="SanofiCommercializationCostsFundedbyLexiconMaximumAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ConsolidatedStatementsOfCashFlowsAbstract" abstract="true" name="ConsolidatedStatementsOfCashFlowsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_IpsenMilestonePaymentReceived" abstract="false" name="IpsenMilestonePaymentReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_DeferredCompensationArrangementWithIndividualPaymentPeriod" abstract="false" name="DeferredCompensationArrangementWithIndividualPaymentPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lxrx_OfferingExpensesFromDecember20CommonStockOffering" abstract="false" name="OfferingExpensesFromDecember20CommonStockOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_CommissionsFromDecember2020CommonStockOffering" abstract="false" name="CommissionsFromDecember2020CommonStockOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_OxfordFacilityFee" abstract="false" name="OxfordFacilityFee" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_TermLoanANetCashReceipt" abstract="false" name="TermLoanANetCashReceipt" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialCostsFundedPercentage" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialCostsFundedPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lxrx_ATMOfferingTotal" abstract="false" name="ATMOfferingTotal" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SanofiUpfrontPayment" abstract="false" name="SanofiUpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lxrx_GoodwillAbstract" abstract="true" name="GoodwillAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_ProceedsFromJanuary2021ATMOffering" abstract="false" name="ProceedsFromJanuary2021ATMOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan" abstract="false" name="RestrictedStockUnitsOutstandingEquityIncentivePlan" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lxrx_IpsenMaximumSalesMilestones" abstract="false" name="IpsenMaximumSalesMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense" abstract="false" name="StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ATMOffering2020Total" abstract="false" name="ATMOffering2020Total" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SanofiTerminationAgreement" abstract="false" name="SanofiTerminationAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_RDSeveranceCostsMember" abstract="true" name="RDSeveranceCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentCostsPeriod" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentCostsPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lxrx_DebtObligationsAbstract" abstract="true" name="DebtObligationsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_IpsenMaximumRegulatoryAndCommercialMilestones" abstract="false" name="IpsenMaximumRegulatoryAndCommercialMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable" abstract="false" name="IpsenRevenueAllocatedtoDevelopmentDeliverable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SharesSoldInNov2020ATMOffering" abstract="false" name="SharesSoldInNov2020ATMOffering" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_PropertyAndEquipmentAbstract" abstract="true" name="PropertyAndEquipmentAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_ProceedsFromJuly2022Offering" abstract="false" name="ProceedsFromJuly2022Offering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_LexiconBorrowingRate" abstract="false" name="LexiconBorrowingRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lxrx_MortgageDebtBalloonPayment_LXRX" abstract="false" name="MortgageDebtBalloonPayment_LXRX" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SharePriceInJanuary2021ATMOffering" abstract="false" name="SharePriceInJanuary2021ATMOffering" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_SanofiDeferredRevenueFromTermination" abstract="false" name="SanofiDeferredRevenueFromTermination" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lxrx_MortgageDebtInterestRate_Base_Revere_LXRX" abstract="false" name="MortgageDebtInterestRate_Base_Revere_LXRX" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lxrx_A2027OxfordPrincipalPayments" abstract="false" name="A2027OxfordPrincipalPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SaleOfNonFinancialAssetsTextBlock" abstract="false" name="SaleOfNonFinancialAssetsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="lxrx_TermLoanC" abstract="false" name="TermLoanC" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_IpsenTotalPaymentsToDate" abstract="false" name="IpsenTotalPaymentsToDate" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_OxfordLoanFacility" abstract="false" name="OxfordLoanFacility" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug" abstract="false" name="DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_RecentAccountingPronouncementsAbstract" abstract="true" name="RecentAccountingPronouncementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_RDTaxCreditDecrease" abstract="false" name="RDTaxCreditDecrease" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_Lxrx_Sanofiterminationcashpayment" abstract="false" name="Lxrx_Sanofiterminationcashpayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_CommitmentsAndContingenciesAbstract" abstract="true" name="CommitmentsAndContingenciesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_CoelacanthGoodwill" abstract="false" name="CoelacanthGoodwill" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_DefinedContributionPlanRequisiteServicePeriod" abstract="false" name="DefinedContributionPlanRequisiteServicePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" abstract="false" name="StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan" abstract="false" name="SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_MortgageDebtInstrument_Revere_LXRX" abstract="false" name="MortgageDebtInstrument_Revere_LXRX" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ProceedsFromSeptember2021ATMOffering" abstract="false" name="ProceedsFromSeptember2021ATMOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_TermLoanABWarrant" abstract="false" name="TermLoanABWarrant" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lxrx_ProceedsFromDecember2020CommonStockOffering" abstract="false" name="ProceedsFromDecember2020CommonStockOffering" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_PrincipalAmountOfConvertibleNotes" abstract="false" name="PrincipalAmountOfConvertibleNotes" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan" abstract="false" name="TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_ConvertibleDebtExchangeTotalCashConsideration" abstract="false" name="ConvertibleDebtExchangeTotalCashConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_EquityIncentiveAwardsAbstract" abstract="true" name="EquityIncentiveAwardsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones" abstract="false" name="TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ConvertibleDebtExchange" abstract="false" name="ConvertibleDebtExchange" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_LXRXDiplomatcustomerconcentration" abstract="false" name="LXRXDiplomatcustomerconcentration" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lxrx_FinalPaymentWithNoExtention" abstract="false" name="FinalPaymentWithNoExtention" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfCommercialMilestones" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfCommercialMilestones" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lxrx_CoelacanthPurchasePrice" abstract="false" name="CoelacanthPurchasePrice" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_A2020ConvertibleDebtExchangeSharePaymentTotal" abstract="false" name="A2020ConvertibleDebtExchangeSharePaymentTotal" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_SharesSoldInSeptember2021ATMOffering" abstract="false" name="SharesSoldInSeptember2021ATMOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage" abstract="false" name="ConvertibleDebtInstrumentInterestRateStatedPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lxrx_ConsolidatedStatementsOfOperationsParentheticalsAbstract" abstract="true" name="ConsolidatedStatementsOfOperationsParentheticalsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_RestrictedStockUnitsOutstandingNonEmployeeDirectorsEquityIncentivePlan" abstract="false" name="RestrictedStockUnitsOutstandingNonEmployeeDirectorsEquityIncentivePlan" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_LXRXBiologicscustomerconcentration" abstract="false" name="LXRXBiologicscustomerconcentration" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany" abstract="false" name="DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lxrx_SanofiOutcomesStudyMilestone" abstract="false" name="SanofiOutcomesStudyMilestone" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_InterestOnLeasePayments" abstract="false" name="InterestOnLeasePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_TermLoanBNetCashReceipt" abstract="false" name="TermLoanBNetCashReceipt" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon" abstract="false" name="DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_TermLoanADebtDiscount" abstract="false" name="TermLoanADebtDiscount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltiesPercentage" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltiesPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lxrx_SanofiRevenueAllocatedtoLicenseDeliverable" abstract="false" name="SanofiRevenueAllocatedtoLicenseDeliverable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable" abstract="false" name="SanofiRevenueAllocatedtoDevelopmentDeliverable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SettlementPaymentFromTermination" abstract="false" name="SettlementPaymentFromTermination" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_TermLoanD" abstract="false" name="TermLoanD" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_A2025OxfordPrincipalPaymentsB" abstract="false" name="A2025OxfordPrincipalPaymentsB" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_IpsenRevenueRecognized" abstract="false" name="IpsenRevenueRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_OptionsOutstandingEquityIncentivePlan" abstract="false" name="OptionsOutstandingEquityIncentivePlan" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_TermLoanCWarrant" abstract="false" name="TermLoanCWarrant" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lxrx_A2027OxfordPrincipalPaymentsB" abstract="false" name="A2027OxfordPrincipalPaymentsB" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_BenefitPlanAbstract" abstract="true" name="BenefitPlanAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_A2025OxfordPrincipalPaymentA" abstract="false" name="A2025OxfordPrincipalPaymentA" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock" abstract="false" name="StockOptionExercisePriceAsPercentOfValueOfCommonStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lxrx_SharePriceInJuly2022Offering" abstract="false" name="SharePriceInJuly2022Offering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_TermLoanB" abstract="false" name="TermLoanB" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan" abstract="false" name="OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lxrx_SharePriceInSeptember2021ATMOffering" abstract="false" name="SharePriceInSeptember2021ATMOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan" abstract="false" name="TotalSharesThatMayBeIssuedEquityIncentivePlan" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent" abstract="false" name="DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lxrx_DeferredTaxAssetsSection163j_LXRX" abstract="false" name="DeferredTaxAssetsSection163j_LXRX" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_DebtInstrumentRepurchasePercentage" abstract="false" name="DebtInstrumentRepurchasePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lxrx_BalanceSheetParentheticalsAbstract" abstract="true" name="BalanceSheetParentheticalsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_TermLoanAFinalPayment" abstract="false" name="TermLoanAFinalPayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_DecreaseInNOLs" abstract="false" name="DecreaseInNOLs" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_OtherCapitalAgreementsTextBlock" abstract="false" name="OtherCapitalAgreementsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="lxrx_ProceedsFromNov2020ATMOffering" abstract="false" name="ProceedsFromNov2020ATMOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable" abstract="false" name="IpsenRevenueAllocatedtoCommitteeDeliverable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_AccruedResearchAndDevelopmentServicesCurrent" abstract="false" name="AccruedResearchAndDevelopmentServicesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract" abstract="true" name="ConsolidatedStatementsOfStockholdersEquityAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_Ipsenproductsales" abstract="false" name="Ipsenproductsales" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lxrx_A2020FederalNOLIncrease" abstract="false" name="A2020FederalNOLIncrease" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_Totalvalueofsharesbynonemployeeinayear" abstract="false" name="Totalvalueofsharesbynonemployeeinayear" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>lxrx-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:379d89f1-f5df-4675-bf23-f82d2f2c7aaf,g:c8f45f50-51f6-43ab-b86a-02bdbec3750c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="lxrx-20221231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_63dc7197-dd37-4d59-bef8-cfdb1fec78c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d79afa21-865c-4923-8164-ba8a3663731c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_63dc7197-dd37-4d59-bef8-cfdb1fec78c4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d79afa21-865c-4923-8164-ba8a3663731c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_3a2503f7-6602-434e-b87a-6b65cd9be67b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_63dc7197-dd37-4d59-bef8-cfdb1fec78c4" xlink:to="loc_us-gaap_ShortTermInvestments_3a2503f7-6602-434e-b87a-6b65cd9be67b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_3b44a19a-24ea-44e6-b11c-8e40799e1f96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_63dc7197-dd37-4d59-bef8-cfdb1fec78c4" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_3b44a19a-24ea-44e6-b11c-8e40799e1f96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_b3d7a5f2-deed-41bf-ac36-d42b98f5d8fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_63dc7197-dd37-4d59-bef8-cfdb1fec78c4" xlink:to="loc_us-gaap_InventoryNet_b3d7a5f2-deed-41bf-ac36-d42b98f5d8fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_80d942cd-038d-4cb2-9366-96420ff8fc46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_63dc7197-dd37-4d59-bef8-cfdb1fec78c4" xlink:to="loc_us-gaap_OtherAssetsCurrent_80d942cd-038d-4cb2-9366-96420ff8fc46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_b41cff90-04b1-421a-9d6e-8023cb15c168" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d1f27303-3ecd-4fc4-b426-cd18743ce90a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_b41cff90-04b1-421a-9d6e-8023cb15c168" xlink:to="loc_us-gaap_LiabilitiesCurrent_d1f27303-3ecd-4fc4-b426-cd18743ce90a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_48d1ad28-386a-4a6a-8555-24f4c814fe1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_b41cff90-04b1-421a-9d6e-8023cb15c168" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_48d1ad28-386a-4a6a-8555-24f4c814fe1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_81b12cc0-0b2d-41ad-92d6-4edb9bb6893a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_b41cff90-04b1-421a-9d6e-8023cb15c168" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_81b12cc0-0b2d-41ad-92d6-4edb9bb6893a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_58541071-002c-4c17-9e41-1bb7e3d3a2a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_234530f2-6164-4316-acdd-24fec25402f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_58541071-002c-4c17-9e41-1bb7e3d3a2a3" xlink:to="loc_us-gaap_PreferredStockValue_234530f2-6164-4316-acdd-24fec25402f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_534bd4af-5d73-47a4-b16e-1f3796a24250" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_58541071-002c-4c17-9e41-1bb7e3d3a2a3" xlink:to="loc_us-gaap_CommonStockValue_534bd4af-5d73-47a4-b16e-1f3796a24250" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_ee92a4e9-218c-4658-b2fc-b31593c27c02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_58541071-002c-4c17-9e41-1bb7e3d3a2a3" xlink:to="loc_us-gaap_AdditionalPaidInCapital_ee92a4e9-218c-4658-b2fc-b31593c27c02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_13e711a6-4786-451b-aaec-18769287362c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_58541071-002c-4c17-9e41-1bb7e3d3a2a3" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_13e711a6-4786-451b-aaec-18769287362c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6eb44adf-aa1e-4a00-bd42-08d6766407d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_58541071-002c-4c17-9e41-1bb7e3d3a2a3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6eb44adf-aa1e-4a00-bd42-08d6766407d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_1f61d4b5-3e1e-4d7d-bc01-2c7b763dd252" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_58541071-002c-4c17-9e41-1bb7e3d3a2a3" xlink:to="loc_us-gaap_TreasuryStockValue_1f61d4b5-3e1e-4d7d-bc01-2c7b763dd252" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_99e7deb5-e0b7-4554-ae66-79e5c53c4dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_a0b3963a-318d-4698-b366-430ea23423ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_99e7deb5-e0b7-4554-ae66-79e5c53c4dbb" xlink:to="loc_us-gaap_AccountsPayableCurrent_a0b3963a-318d-4698-b366-430ea23423ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_32e7c25f-3344-4e44-871b-7c5ce0a36844" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_99e7deb5-e0b7-4554-ae66-79e5c53c4dbb" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_32e7c25f-3344-4e44-871b-7c5ce0a36844" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_77e5153b-9017-4427-ad67-8767e8589f22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_99e7deb5-e0b7-4554-ae66-79e5c53c4dbb" xlink:to="loc_us-gaap_LongTermDebtCurrent_77e5153b-9017-4427-ad67-8767e8589f22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_e0c37a80-1b73-45c0-991a-766aafd2fb4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_df6fd300-9d41-4294-8beb-6889e9d5dac5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e0c37a80-1b73-45c0-991a-766aafd2fb4d" xlink:to="loc_us-gaap_AssetsCurrent_df6fd300-9d41-4294-8beb-6889e9d5dac5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_920b1f25-e5e7-4377-a871-c202d67b9b41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e0c37a80-1b73-45c0-991a-766aafd2fb4d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_920b1f25-e5e7-4377-a871-c202d67b9b41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f5ee6e81-e231-410e-a68b-da9e5258a023" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e0c37a80-1b73-45c0-991a-766aafd2fb4d" xlink:to="loc_us-gaap_Goodwill_f5ee6e81-e231-410e-a68b-da9e5258a023" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsNet_bf6c30ed-635c-4bd0-b092-718ccf25e6bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e0c37a80-1b73-45c0-991a-766aafd2fb4d" xlink:to="loc_us-gaap_OtherIntangibleAssetsNet_bf6c30ed-635c-4bd0-b092-718ccf25e6bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_23ef494a-94ba-4ea7-8b3e-ce1496350336" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e0c37a80-1b73-45c0-991a-766aafd2fb4d" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_23ef494a-94ba-4ea7-8b3e-ce1496350336" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_46ed803a-3e23-4790-8dfd-af4b32240535" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3fc70913-e093-4ff9-a473-7658803c71d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_46ed803a-3e23-4790-8dfd-af4b32240535" xlink:to="loc_us-gaap_StockholdersEquity_3fc70913-e093-4ff9-a473-7658803c71d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_f770ae4a-b7df-4160-b749-75f70f9b8062" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_46ed803a-3e23-4790-8dfd-af4b32240535" xlink:to="loc_us-gaap_Liabilities_f770ae4a-b7df-4160-b749-75f70f9b8062" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="lxrx-20221231.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_92bef3fd-df6d-4223-8300-d8074cf60c13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_c5c3a1ea-37ed-42e9-8196-2bc8051795fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_92bef3fd-df6d-4223-8300-d8074cf60c13" xlink:to="loc_us-gaap_Revenues_c5c3a1ea-37ed-42e9-8196-2bc8051795fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_aa0b6923-8048-47c1-8a01-c18e46fdf2c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_92bef3fd-df6d-4223-8300-d8074cf60c13" xlink:to="loc_us-gaap_OperatingExpenses_aa0b6923-8048-47c1-8a01-c18e46fdf2c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_GainOnSaleOfNonFinancialAssets_0a06a4e8-335d-46fa-a6d7-4a362a19aab3" xlink:href="lxrx-20221231.xsd#lxrx_GainOnSaleOfNonFinancialAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_92bef3fd-df6d-4223-8300-d8074cf60c13" xlink:to="loc_lxrx_GainOnSaleOfNonFinancialAssets_0a06a4e8-335d-46fa-a6d7-4a362a19aab3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_505fff36-ee99-46cc-8e91-ca8fa1d0721e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_cd4e8b45-c647-4515-beea-2327a98948a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_505fff36-ee99-46cc-8e91-ca8fa1d0721e" xlink:to="loc_us-gaap_OperatingIncomeLoss_cd4e8b45-c647-4515-beea-2327a98948a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_0b4c3cad-c974-4f0f-bc21-1c96c6dfbe29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_505fff36-ee99-46cc-8e91-ca8fa1d0721e" xlink:to="loc_us-gaap_InterestExpense_0b4c3cad-c974-4f0f-bc21-1c96c6dfbe29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_a8cbf16f-a391-412b-a520-b0cc7dd8a528" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_505fff36-ee99-46cc-8e91-ca8fa1d0721e" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_a8cbf16f-a391-412b-a520-b0cc7dd8a528" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_0285328e-744e-4b6d-9f5b-a59097783b07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_505fff36-ee99-46cc-8e91-ca8fa1d0721e" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_0285328e-744e-4b6d-9f5b-a59097783b07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_f2e75ec6-a573-45d6-85ae-93d02cf3b47a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b6179f23-b567-4739-b3f9-0209704de282" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_f2e75ec6-a573-45d6-85ae-93d02cf3b47a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b6179f23-b567-4739-b3f9-0209704de282" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_94a33911-3527-4493-b927-3f6df7c9b3be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_f2e75ec6-a573-45d6-85ae-93d02cf3b47a" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_94a33911-3527-4493-b927-3f6df7c9b3be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_933b2206-8033-45eb-8bad-95fa92adcaa8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_f2e75ec6-a573-45d6-85ae-93d02cf3b47a" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_933b2206-8033-45eb-8bad-95fa92adcaa8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_cb81179a-9f77-4079-a87e-b40e65bf9589" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_f2e75ec6-a573-45d6-85ae-93d02cf3b47a" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_cb81179a-9f77-4079-a87e-b40e65bf9589" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_bdb4675a-221c-4e9d-84cb-ace5d53fa349" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_f2e75ec6-a573-45d6-85ae-93d02cf3b47a" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_bdb4675a-221c-4e9d-84cb-ace5d53fa349" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_39355719-1a84-4c59-9d24-0f2168ad357d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6112e66c-7d8d-41f2-9a11-b45852b96391" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_39355719-1a84-4c59-9d24-0f2168ad357d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6112e66c-7d8d-41f2-9a11-b45852b96391" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_48799b76-388b-4ba4-913b-122f166ac29d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_39355719-1a84-4c59-9d24-0f2168ad357d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_48799b76-388b-4ba4-913b-122f166ac29d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyIncomeNonoperating_91ead0d2-73ab-40ac-8cc7-cff4aa0d6642" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyIncomeNonoperating"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_39355719-1a84-4c59-9d24-0f2168ad357d" xlink:to="loc_us-gaap_RoyaltyIncomeNonoperating_91ead0d2-73ab-40ac-8cc7-cff4aa0d6642" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_53e015c0-dbcc-4c62-a1fe-779df2170f05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_25f03862-a743-4b76-b341-bac07885e040" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_53e015c0-dbcc-4c62-a1fe-779df2170f05" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_25f03862-a743-4b76-b341-bac07885e040" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_86265d9b-41cf-4168-ae75-7194aab0e4ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_53e015c0-dbcc-4c62-a1fe-779df2170f05" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_86265d9b-41cf-4168-ae75-7194aab0e4ab" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="lxrx-20221231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_7a23339d-3000-4a46-9b90-53276da75b35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e23de171-17e2-4c9e-a04c-c6923734378f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_7a23339d-3000-4a46-9b90-53276da75b35" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e23de171-17e2-4c9e-a04c-c6923734378f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0557fa3b-1503-4056-96d5-e6d3e7c13479" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_7a23339d-3000-4a46-9b90-53276da75b35" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0557fa3b-1503-4056-96d5-e6d3e7c13479" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ff6b1f63-c2ae-40bb-bcdc-5aa70aed5900" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_7a23339d-3000-4a46-9b90-53276da75b35" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ff6b1f63-c2ae-40bb-bcdc-5aa70aed5900" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f61b688-25c4-4f07-90d9-c6265cfffca9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3a4cc82c-17fc-4dd1-89e0-a7694d5a93fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f61b688-25c4-4f07-90d9-c6265cfffca9" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3a4cc82c-17fc-4dd1-89e0-a7694d5a93fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_b0b48258-e562-4cc5-851b-4a916e194bed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f61b688-25c4-4f07-90d9-c6265cfffca9" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_b0b48258-e562-4cc5-851b-4a916e194bed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_873465ed-60b1-41e3-bec4-77d6aa95b057" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f61b688-25c4-4f07-90d9-c6265cfffca9" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_873465ed-60b1-41e3-bec4-77d6aa95b057" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_d5105863-94c8-4475-8414-448cf01c53ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f61b688-25c4-4f07-90d9-c6265cfffca9" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_d5105863-94c8-4475-8414-448cf01c53ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_0b0d136a-32e5-4f01-b095-e256b9890d8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f61b688-25c4-4f07-90d9-c6265cfffca9" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_0b0d136a-32e5-4f01-b095-e256b9890d8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7a9d8f2f-93af-40f0-b23b-7bed788f5259" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_49fd8954-351f-43af-bfc3-0a64945d98fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7a9d8f2f-93af-40f0-b23b-7bed788f5259" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_49fd8954-351f-43af-bfc3-0a64945d98fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_cf5e08e6-23dd-49f9-814b-02b084b042d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7a9d8f2f-93af-40f0-b23b-7bed788f5259" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_cf5e08e6-23dd-49f9-814b-02b084b042d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_28e3055b-087e-4e86-a469-35bbeb39d49b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7a9d8f2f-93af-40f0-b23b-7bed788f5259" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_28e3055b-087e-4e86-a469-35bbeb39d49b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_1abb84e4-1db3-4bef-b7d6-18a39a1636f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7a9d8f2f-93af-40f0-b23b-7bed788f5259" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_1abb84e4-1db3-4bef-b7d6-18a39a1636f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5b6b8cdd-87ac-4f6e-a853-c46845e0ecf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_e09b5293-3bd8-4feb-ab48-d98583255869" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5b6b8cdd-87ac-4f6e-a853-c46845e0ecf8" xlink:to="loc_us-gaap_ProfitLoss_e09b5293-3bd8-4feb-ab48-d98583255869" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_d9910389-5c3d-453d-9d9f-d09f3fdb5e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5b6b8cdd-87ac-4f6e-a853-c46845e0ecf8" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_d9910389-5c3d-453d-9d9f-d09f3fdb5e8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_f26d02ed-8af3-4b70-b74e-ebcf28cd03fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5b6b8cdd-87ac-4f6e-a853-c46845e0ecf8" xlink:to="loc_us-gaap_ShareBasedCompensation_f26d02ed-8af3-4b70-b74e-ebcf28cd03fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_dbc31bf8-a35e-4976-b3a0-dc8f6b1d0bf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5b6b8cdd-87ac-4f6e-a853-c46845e0ecf8" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_dbc31bf8-a35e-4976-b3a0-dc8f6b1d0bf0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3f6efa0f-3325-4f85-8a5e-1acd7c3a16a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5b6b8cdd-87ac-4f6e-a853-c46845e0ecf8" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3f6efa0f-3325-4f85-8a5e-1acd7c3a16a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_4e5de52c-707d-4e30-8246-2499d22c5152" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5b6b8cdd-87ac-4f6e-a853-c46845e0ecf8" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_4e5de52c-707d-4e30-8246-2499d22c5152" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1e59ed85-4894-4afe-9001-4c5262b8a10a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5b6b8cdd-87ac-4f6e-a853-c46845e0ecf8" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1e59ed85-4894-4afe-9001-4c5262b8a10a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_9b0e4e60-1f3a-42ac-bec8-2173c826c8a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5b6b8cdd-87ac-4f6e-a853-c46845e0ecf8" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_9b0e4e60-1f3a-42ac-bec8-2173c826c8a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_9454b756-f877-4283-ad7d-55b8742a2267" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5b6b8cdd-87ac-4f6e-a853-c46845e0ecf8" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_9454b756-f877-4283-ad7d-55b8742a2267" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_545edddd-b93f-41cd-b52f-702403d96fa3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5b6b8cdd-87ac-4f6e-a853-c46845e0ecf8" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_545edddd-b93f-41cd-b52f-702403d96fa3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_f6676f6a-a59b-4aa1-8780-b5f1a04e4205" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5b6b8cdd-87ac-4f6e-a853-c46845e0ecf8" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_f6676f6a-a59b-4aa1-8780-b5f1a04e4205" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/IncomeTaxesDetails1" xlink:type="simple" xlink:href="lxrx-20221231.xsd#IncomeTaxesDetails1"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/IncomeTaxesDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_0541175d-9db6-4b4b-b92a-6ec34aa18892" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_cb582b24-c7d5-454f-8fc0-25953d431efa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_0541175d-9db6-4b4b-b92a-6ec34aa18892" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_cb582b24-c7d5-454f-8fc0-25953d431efa" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>lxrx-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:379d89f1-f5df-4675-bf23-f82d2f2c7aaf,g:c8f45f50-51f6-43ab-b86a-02bdbec3750c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CoverPage" xlink:type="simple" xlink:href="lxrx-20221231.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/CoverPage" xlink:type="extended" id="i2cefb51dede8432ab5ae509c689f8760_CoverPage">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_f550677d-450a-41ea-a7c5-0b65d0d79227" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_ce9dd1a5-f907-45b2-a9cc-e98be3401cc5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f550677d-450a-41ea-a7c5-0b65d0d79227" xlink:to="loc_dei_IcfrAuditorAttestationFlag_ce9dd1a5-f907-45b2-a9cc-e98be3401cc5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_e6297923-6c41-4b6a-b9fd-cec8966632ef" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f550677d-450a-41ea-a7c5-0b65d0d79227" xlink:to="loc_dei_CurrentFiscalYearEndDate_e6297923-6c41-4b6a-b9fd-cec8966632ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_04a10b75-9734-4371-8982-47bdc23e88ad" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f550677d-450a-41ea-a7c5-0b65d0d79227" xlink:to="loc_dei_AuditorName_04a10b75-9734-4371-8982-47bdc23e88ad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_93e1cebc-c09e-46c6-93ba-b4b39ec9738d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f550677d-450a-41ea-a7c5-0b65d0d79227" xlink:to="loc_dei_AuditorLocation_93e1cebc-c09e-46c6-93ba-b4b39ec9738d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_284a684a-652a-4861-9f97-a19ba7587f07" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f550677d-450a-41ea-a7c5-0b65d0d79227" xlink:to="loc_dei_AuditorFirmId_284a684a-652a-4861-9f97-a19ba7587f07" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_077e24fe-bb52-4396-96ca-bbc537199fd7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f550677d-450a-41ea-a7c5-0b65d0d79227" xlink:to="loc_dei_EntityAddressCityOrTown_077e24fe-bb52-4396-96ca-bbc537199fd7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_cfe1a574-a7f4-4908-9303-95cdd6f894c9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f550677d-450a-41ea-a7c5-0b65d0d79227" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_cfe1a574-a7f4-4908-9303-95cdd6f894c9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_0ca2913a-b83f-450b-9948-0a3c79f0bde4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_f550677d-450a-41ea-a7c5-0b65d0d79227" xlink:to="loc_dei_DocumentInformationTable_0ca2913a-b83f-450b-9948-0a3c79f0bde4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_25a20e50-cc67-4574-abc9-0509ad214c06" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_0ca2913a-b83f-450b-9948-0a3c79f0bde4" xlink:to="loc_srt_RestatementAxis_25a20e50-cc67-4574-abc9-0509ad214c06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_25a20e50-cc67-4574-abc9-0509ad214c06_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_25a20e50-cc67-4574-abc9-0509ad214c06" xlink:to="loc_srt_RestatementDomain_25a20e50-cc67-4574-abc9-0509ad214c06_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_27a8002a-59fa-48c5-aa1d-45c64a625e23" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_25a20e50-cc67-4574-abc9-0509ad214c06" xlink:to="loc_srt_RestatementDomain_27a8002a-59fa-48c5-aa1d-45c64a625e23" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="lxrx-20221231.xsd#ConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/ConsolidatedBalanceSheets" xlink:type="extended" id="i441ada19822b4088bb96ca2f2ef51fe1_ConsolidatedBalanceSheets">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b0a0f4de-f483-42cb-8b0c-fda922d5bd87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_e11012ec-0c79-496b-83a3-62fdec2b0667" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b0a0f4de-f483-42cb-8b0c-fda922d5bd87" xlink:to="loc_us-gaap_AssetsCurrentAbstract_e11012ec-0c79-496b-83a3-62fdec2b0667" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6809a171-0654-4aa0-a5b7-7d3703f459f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e11012ec-0c79-496b-83a3-62fdec2b0667" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6809a171-0654-4aa0-a5b7-7d3703f459f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_ac459104-bb00-467c-8bfa-76d50666e28b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e11012ec-0c79-496b-83a3-62fdec2b0667" xlink:to="loc_us-gaap_ShortTermInvestments_ac459104-bb00-467c-8bfa-76d50666e28b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_314ddc81-8141-4c5a-839b-90b58f619e39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e11012ec-0c79-496b-83a3-62fdec2b0667" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_314ddc81-8141-4c5a-839b-90b58f619e39" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_4065e7b2-5f76-456c-9b08-b806a10ece41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e11012ec-0c79-496b-83a3-62fdec2b0667" xlink:to="loc_us-gaap_InventoryNet_4065e7b2-5f76-456c-9b08-b806a10ece41" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_c1f2dd46-3b80-447f-9cce-773bad2ddbda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e11012ec-0c79-496b-83a3-62fdec2b0667" xlink:to="loc_us-gaap_OtherAssetsCurrent_c1f2dd46-3b80-447f-9cce-773bad2ddbda" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_8f05b1d1-7f1e-4b2d-94ad-aed66d1d2310" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e11012ec-0c79-496b-83a3-62fdec2b0667" xlink:to="loc_us-gaap_AssetsCurrent_8f05b1d1-7f1e-4b2d-94ad-aed66d1d2310" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f41807d6-024f-4299-9020-af2853a0cb9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b0a0f4de-f483-42cb-8b0c-fda922d5bd87" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f41807d6-024f-4299-9020-af2853a0cb9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_2d90b54d-2a05-4d44-84f8-40b12ad06184" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b0a0f4de-f483-42cb-8b0c-fda922d5bd87" xlink:to="loc_us-gaap_Goodwill_2d90b54d-2a05-4d44-84f8-40b12ad06184" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsNet_73722ee9-6a5b-4f43-8c13-1e3762d0404f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b0a0f4de-f483-42cb-8b0c-fda922d5bd87" xlink:to="loc_us-gaap_OtherIntangibleAssetsNet_73722ee9-6a5b-4f43-8c13-1e3762d0404f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_9eceafda-bf8e-4888-966a-98484c3e4b15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b0a0f4de-f483-42cb-8b0c-fda922d5bd87" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_9eceafda-bf8e-4888-966a-98484c3e4b15" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_66b7c147-4347-447d-8b6a-44df69a5d0aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b0a0f4de-f483-42cb-8b0c-fda922d5bd87" xlink:to="loc_us-gaap_Assets_66b7c147-4347-447d-8b6a-44df69a5d0aa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_a8551e32-ab69-4b40-8b4b-8b935ac82379" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b0a0f4de-f483-42cb-8b0c-fda922d5bd87" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_a8551e32-ab69-4b40-8b4b-8b935ac82379" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_079e66e4-e90c-4612-aa6c-a1626ae5cc67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a8551e32-ab69-4b40-8b4b-8b935ac82379" xlink:to="loc_us-gaap_AccountsPayableCurrent_079e66e4-e90c-4612-aa6c-a1626ae5cc67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_7893fc39-6c9f-4511-b46b-eb6ad916a370" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a8551e32-ab69-4b40-8b4b-8b935ac82379" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_7893fc39-6c9f-4511-b46b-eb6ad916a370" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_fe4d3f89-ae46-40c0-9b1f-ca8042d33e12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a8551e32-ab69-4b40-8b4b-8b935ac82379" xlink:to="loc_us-gaap_LongTermDebtCurrent_fe4d3f89-ae46-40c0-9b1f-ca8042d33e12" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_373370ec-1d77-493d-9703-25db841e8631" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a8551e32-ab69-4b40-8b4b-8b935ac82379" xlink:to="loc_us-gaap_LiabilitiesCurrent_373370ec-1d77-493d-9703-25db841e8631" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_940a6417-46fb-41d7-ad58-60f4778d0126" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b0a0f4de-f483-42cb-8b0c-fda922d5bd87" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_940a6417-46fb-41d7-ad58-60f4778d0126" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_ec4511f6-dfc8-4408-b5d7-47425044eb91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b0a0f4de-f483-42cb-8b0c-fda922d5bd87" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_ec4511f6-dfc8-4408-b5d7-47425044eb91" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_ba734641-19b5-4128-82e0-77105d0da14e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b0a0f4de-f483-42cb-8b0c-fda922d5bd87" xlink:to="loc_us-gaap_Liabilities_ba734641-19b5-4128-82e0-77105d0da14e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_62d8e39e-9eba-40ce-8788-d2b029faf3ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b0a0f4de-f483-42cb-8b0c-fda922d5bd87" xlink:to="loc_us-gaap_CommitmentsAndContingencies_62d8e39e-9eba-40ce-8788-d2b029faf3ea" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_bc7f3975-4f5f-4b0d-948b-88f4d904d4b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b0a0f4de-f483-42cb-8b0c-fda922d5bd87" xlink:to="loc_us-gaap_EquityAbstract_bc7f3975-4f5f-4b0d-948b-88f4d904d4b3" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_5cfb3b87-9abe-49dc-97d7-fc54c69a654e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_bc7f3975-4f5f-4b0d-948b-88f4d904d4b3" xlink:to="loc_us-gaap_PreferredStockValue_5cfb3b87-9abe-49dc-97d7-fc54c69a654e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_99c9c9c4-0c39-48c7-b6c2-cd9752f839f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_bc7f3975-4f5f-4b0d-948b-88f4d904d4b3" xlink:to="loc_us-gaap_CommonStockValue_99c9c9c4-0c39-48c7-b6c2-cd9752f839f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_405a1f58-a353-47ff-940d-1b769838cb98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_bc7f3975-4f5f-4b0d-948b-88f4d904d4b3" xlink:to="loc_us-gaap_AdditionalPaidInCapital_405a1f58-a353-47ff-940d-1b769838cb98" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c5dce900-26ca-4440-83b1-07091ef5ec3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_bc7f3975-4f5f-4b0d-948b-88f4d904d4b3" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c5dce900-26ca-4440-83b1-07091ef5ec3f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_918607d0-06b7-4e86-a745-56f9a99f2993" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_bc7f3975-4f5f-4b0d-948b-88f4d904d4b3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_918607d0-06b7-4e86-a745-56f9a99f2993" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_911cf203-743b-4f7d-b159-c9d54b3304fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_bc7f3975-4f5f-4b0d-948b-88f4d904d4b3" xlink:to="loc_us-gaap_TreasuryStockValue_911cf203-743b-4f7d-b159-c9d54b3304fd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b7c11765-23e7-4461-b509-ba535840d44f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_bc7f3975-4f5f-4b0d-948b-88f4d904d4b3" xlink:to="loc_us-gaap_StockholdersEquity_b7c11765-23e7-4461-b509-ba535840d44f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_64c3b843-2ad2-4f77-99ec-f4ad2364e2f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b0a0f4de-f483-42cb-8b0c-fda922d5bd87" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_64c3b843-2ad2-4f77-99ec-f4ad2364e2f2" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_d0c8e92c-2e7c-4958-a4ea-bd3eac5e2b55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b0a0f4de-f483-42cb-8b0c-fda922d5bd87" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_d0c8e92c-2e7c-4958-a4ea-bd3eac5e2b55" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_b59b2c1d-59e1-431a-9dd9-375a21aaa9bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b0a0f4de-f483-42cb-8b0c-fda922d5bd87" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_b59b2c1d-59e1-431a-9dd9-375a21aaa9bb" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_d2906b3a-a303-4129-b875-57c3240a6f7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b0a0f4de-f483-42cb-8b0c-fda922d5bd87" xlink:to="loc_us-gaap_PreferredStockSharesIssued_d2906b3a-a303-4129-b875-57c3240a6f7a" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_365bcaa0-0fc4-4736-a763-07e9333d141f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b0a0f4de-f483-42cb-8b0c-fda922d5bd87" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_365bcaa0-0fc4-4736-a763-07e9333d141f" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_d9c13963-7b33-4268-be37-3d7b964c9a14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b0a0f4de-f483-42cb-8b0c-fda922d5bd87" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_d9c13963-7b33-4268-be37-3d7b964c9a14" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_3a981f56-0edf-4fa5-a3b6-a6a7068df42f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b0a0f4de-f483-42cb-8b0c-fda922d5bd87" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_3a981f56-0edf-4fa5-a3b6-a6a7068df42f" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2999afb3-e374-420f-a149-a0fbc207669c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_b0a0f4de-f483-42cb-8b0c-fda922d5bd87" xlink:to="loc_us-gaap_StatementTable_2999afb3-e374-420f-a149-a0fbc207669c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_63306f6b-2c23-4bf2-b3c8-40c3e7420b32" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2999afb3-e374-420f-a149-a0fbc207669c" xlink:to="loc_srt_StatementScenarioAxis_63306f6b-2c23-4bf2-b3c8-40c3e7420b32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_63306f6b-2c23-4bf2-b3c8-40c3e7420b32_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_63306f6b-2c23-4bf2-b3c8-40c3e7420b32" xlink:to="loc_srt_ScenarioUnspecifiedDomain_63306f6b-2c23-4bf2-b3c8-40c3e7420b32_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_a3d64b4a-b31a-433a-b740-7d65374a06f9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_63306f6b-2c23-4bf2-b3c8-40c3e7420b32" xlink:to="loc_srt_ScenarioUnspecifiedDomain_a3d64b4a-b31a-433a-b740-7d65374a06f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_b5518901-e4c4-4a4e-81c2-cc3876c1e2ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2999afb3-e374-420f-a149-a0fbc207669c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_b5518901-e4c4-4a4e-81c2-cc3876c1e2ca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b5518901-e4c4-4a4e-81c2-cc3876c1e2ca_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b5518901-e4c4-4a4e-81c2-cc3876c1e2ca" xlink:to="loc_us-gaap_ClassOfStockDomain_b5518901-e4c4-4a4e-81c2-cc3876c1e2ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3ae5509c-59b6-48ca-a5a4-c337e0c946a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b5518901-e4c4-4a4e-81c2-cc3876c1e2ca" xlink:to="loc_us-gaap_ClassOfStockDomain_3ae5509c-59b6-48ca-a5a4-c337e0c946a3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/BalanceSheetParentheticals" xlink:type="simple" xlink:href="lxrx-20221231.xsd#BalanceSheetParentheticals"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/BalanceSheetParentheticals" xlink:type="extended" id="ic9970be27a0748b8acc0bdb018dc0a35_BalanceSheetParentheticals">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_5593bed0-4944-46bf-9f3e-10f0562d9407" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a3424c15-d0f8-466c-8392-6e4a07a310ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5593bed0-4944-46bf-9f3e-10f0562d9407" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a3424c15-d0f8-466c-8392-6e4a07a310ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6d071717-2e59-4130-ad82-1d85e757d2ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5593bed0-4944-46bf-9f3e-10f0562d9407" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6d071717-2e59-4130-ad82-1d85e757d2ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_dc4a4df5-d0d0-414a-9be9-12faa5287217" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5593bed0-4944-46bf-9f3e-10f0562d9407" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_dc4a4df5-d0d0-414a-9be9-12faa5287217" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_8ef686a5-5bbe-4523-a0ae-46a64f4f0d3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5593bed0-4944-46bf-9f3e-10f0562d9407" xlink:to="loc_us-gaap_PreferredStockSharesIssued_8ef686a5-5bbe-4523-a0ae-46a64f4f0d3a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_07e53e6b-a6f8-43bd-9cb5-75dafda14077" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5593bed0-4944-46bf-9f3e-10f0562d9407" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_07e53e6b-a6f8-43bd-9cb5-75dafda14077" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_8493a36e-e7cf-4643-aa22-ff906301f036" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5593bed0-4944-46bf-9f3e-10f0562d9407" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_8493a36e-e7cf-4643-aa22-ff906301f036" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_04ecff6b-efae-4920-8a5f-cac0aa9beff6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5593bed0-4944-46bf-9f3e-10f0562d9407" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_04ecff6b-efae-4920-8a5f-cac0aa9beff6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_48661cb5-1feb-4f2b-b731-603c872b039f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5593bed0-4944-46bf-9f3e-10f0562d9407" xlink:to="loc_us-gaap_CommonStockSharesIssued_48661cb5-1feb-4f2b-b731-603c872b039f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_fd309589-2afa-40ce-813e-3e28fc33682f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5593bed0-4944-46bf-9f3e-10f0562d9407" xlink:to="loc_us-gaap_TreasuryStockShares_fd309589-2afa-40ce-813e-3e28fc33682f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b3969aea-5a2e-499e-b8fc-2cceaad35587" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_5593bed0-4944-46bf-9f3e-10f0562d9407" xlink:to="loc_us-gaap_StatementTable_b3969aea-5a2e-499e-b8fc-2cceaad35587" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d3cc5138-a9ad-4248-8021-24254424ca36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_b3969aea-5a2e-499e-b8fc-2cceaad35587" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d3cc5138-a9ad-4248-8021-24254424ca36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d3cc5138-a9ad-4248-8021-24254424ca36_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d3cc5138-a9ad-4248-8021-24254424ca36" xlink:to="loc_us-gaap_EquityComponentDomain_d3cc5138-a9ad-4248-8021-24254424ca36_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5d9bd378-8bb2-47ba-aaa9-2719bb3ce405" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d3cc5138-a9ad-4248-8021-24254424ca36" xlink:to="loc_us-gaap_EquityComponentDomain_5d9bd378-8bb2-47ba-aaa9-2719bb3ce405" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_90e6a267-2c4c-468e-a87e-6fc807471fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5d9bd378-8bb2-47ba-aaa9-2719bb3ce405" xlink:to="loc_us-gaap_CommonStockMember_90e6a267-2c4c-468e-a87e-6fc807471fc6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_31873368-86de-4de1-b14e-7007bd0fde4a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_b3969aea-5a2e-499e-b8fc-2cceaad35587" xlink:to="loc_srt_StatementScenarioAxis_31873368-86de-4de1-b14e-7007bd0fde4a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_31873368-86de-4de1-b14e-7007bd0fde4a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_31873368-86de-4de1-b14e-7007bd0fde4a" xlink:to="loc_srt_ScenarioUnspecifiedDomain_31873368-86de-4de1-b14e-7007bd0fde4a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_0e710e06-4364-4b2b-9d6d-ef4cbb35d438" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_31873368-86de-4de1-b14e-7007bd0fde4a" xlink:to="loc_srt_ScenarioUnspecifiedDomain_0e710e06-4364-4b2b-9d6d-ef4cbb35d438" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_221d5524-e4be-48a6-9296-6b2ad5cae2bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_b3969aea-5a2e-499e-b8fc-2cceaad35587" xlink:to="loc_us-gaap_StatementClassOfStockAxis_221d5524-e4be-48a6-9296-6b2ad5cae2bf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_221d5524-e4be-48a6-9296-6b2ad5cae2bf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_221d5524-e4be-48a6-9296-6b2ad5cae2bf" xlink:to="loc_us-gaap_ClassOfStockDomain_221d5524-e4be-48a6-9296-6b2ad5cae2bf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_c6d3a6c7-4b09-410e-9b51-92370a2bebe3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_221d5524-e4be-48a6-9296-6b2ad5cae2bf" xlink:to="loc_us-gaap_ClassOfStockDomain_c6d3a6c7-4b09-410e-9b51-92370a2bebe3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="lxrx-20221231.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended" id="i90a3c36b0cfa40ad9fa0d41e9f9879c5_ConsolidatedStatementsofComprehensiveLoss">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_17fad38d-726e-4ab3-af8c-2e2172fbd9a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_e1a9b0ee-aec7-4f3c-9118-383f6557118f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_17fad38d-726e-4ab3-af8c-2e2172fbd9a7" xlink:to="loc_us-gaap_RevenuesAbstract_e1a9b0ee-aec7-4f3c-9118-383f6557118f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b2267bf1-137e-4fc3-a84c-5ac915ad18bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_e1a9b0ee-aec7-4f3c-9118-383f6557118f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b2267bf1-137e-4fc3-a84c-5ac915ad18bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_2c491f5a-2a27-4c3d-966d-7775320b013e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_e1a9b0ee-aec7-4f3c-9118-383f6557118f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_2c491f5a-2a27-4c3d-966d-7775320b013e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyIncomeNonoperating_1735dcb8-0741-4a68-8bbf-1afe3d070760" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyIncomeNonoperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_e1a9b0ee-aec7-4f3c-9118-383f6557118f" xlink:to="loc_us-gaap_RoyaltyIncomeNonoperating_1735dcb8-0741-4a68-8bbf-1afe3d070760" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_0814891b-250a-40ef-a8cc-90aea73f790d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_e1a9b0ee-aec7-4f3c-9118-383f6557118f" xlink:to="loc_us-gaap_Revenues_0814891b-250a-40ef-a8cc-90aea73f790d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_b245279d-5a10-475c-b59e-d796cdd49f67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_17fad38d-726e-4ab3-af8c-2e2172fbd9a7" xlink:to="loc_us-gaap_OperatingExpensesAbstract_b245279d-5a10-475c-b59e-d796cdd49f67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_5395dc1b-67af-47ba-9f2b-fb98df9f4d86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b245279d-5a10-475c-b59e-d796cdd49f67" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_5395dc1b-67af-47ba-9f2b-fb98df9f4d86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_253aa50b-c841-42ba-a1df-ef6fe95a2b38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b245279d-5a10-475c-b59e-d796cdd49f67" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_253aa50b-c841-42ba-a1df-ef6fe95a2b38" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_fda0d979-fdd2-410f-8de3-cc52ee5d5c3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b245279d-5a10-475c-b59e-d796cdd49f67" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_fda0d979-fdd2-410f-8de3-cc52ee5d5c3e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_604f9c65-4c0b-478f-91af-b43f3c6f4bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b245279d-5a10-475c-b59e-d796cdd49f67" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_604f9c65-4c0b-478f-91af-b43f3c6f4bbd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_d3845c99-943c-4ca1-b0ad-fe705de59ac3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b245279d-5a10-475c-b59e-d796cdd49f67" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_d3845c99-943c-4ca1-b0ad-fe705de59ac3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_191ac4dd-3860-49fc-8258-dcdd9c73a510" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b245279d-5a10-475c-b59e-d796cdd49f67" xlink:to="loc_us-gaap_OperatingExpenses_191ac4dd-3860-49fc-8258-dcdd9c73a510" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_GainOnSaleOfNonFinancialAssets_9469aa23-d0c5-4e30-a0fd-3148d65e2cf5" xlink:href="lxrx-20221231.xsd#lxrx_GainOnSaleOfNonFinancialAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b245279d-5a10-475c-b59e-d796cdd49f67" xlink:to="loc_lxrx_GainOnSaleOfNonFinancialAssets_9469aa23-d0c5-4e30-a0fd-3148d65e2cf5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_87d1e3ea-9405-4d4a-a86d-2e2358f8083f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_17fad38d-726e-4ab3-af8c-2e2172fbd9a7" xlink:to="loc_us-gaap_OperatingIncomeLoss_87d1e3ea-9405-4d4a-a86d-2e2358f8083f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_464bd45a-23f3-4112-8e7d-955812d2904b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_17fad38d-726e-4ab3-af8c-2e2172fbd9a7" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_464bd45a-23f3-4112-8e7d-955812d2904b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_0eac742e-c2a3-4f2b-ba3f-eabe1eef0a1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_17fad38d-726e-4ab3-af8c-2e2172fbd9a7" xlink:to="loc_us-gaap_InterestExpense_0eac742e-c2a3-4f2b-ba3f-eabe1eef0a1b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_35956bed-a3d7-4a21-9b37-c53808cb6c69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_17fad38d-726e-4ab3-af8c-2e2172fbd9a7" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_35956bed-a3d7-4a21-9b37-c53808cb6c69" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_da1cd30f-d06f-44fc-8a49-aa2748109dd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_17fad38d-726e-4ab3-af8c-2e2172fbd9a7" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_da1cd30f-d06f-44fc-8a49-aa2748109dd2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_a8d87c9b-842e-4f2e-9563-818bf65de18d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_17fad38d-726e-4ab3-af8c-2e2172fbd9a7" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_a8d87c9b-842e-4f2e-9563-818bf65de18d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4d87ae21-4c3a-4469-8ed3-378c9df1b356" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_17fad38d-726e-4ab3-af8c-2e2172fbd9a7" xlink:to="loc_us-gaap_NetIncomeLoss_4d87ae21-4c3a-4469-8ed3-378c9df1b356" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_7c9e4ed4-ccc8-4870-85e3-35157a7df052" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_17fad38d-726e-4ab3-af8c-2e2172fbd9a7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_7c9e4ed4-ccc8-4870-85e3-35157a7df052" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_12488dca-c4bb-446d-ae9d-f44bb3d6b1d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_7c9e4ed4-ccc8-4870-85e3-35157a7df052" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_12488dca-c4bb-446d-ae9d-f44bb3d6b1d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_cb714d6c-2af1-4a98-95aa-fe3ea3d47211" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_7c9e4ed4-ccc8-4870-85e3-35157a7df052" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_cb714d6c-2af1-4a98-95aa-fe3ea3d47211" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_70efa4f3-ee8b-46e9-b5af-d3522d32240c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_17fad38d-726e-4ab3-af8c-2e2172fbd9a7" xlink:to="loc_us-gaap_EarningsPerShareBasic_70efa4f3-ee8b-46e9-b5af-d3522d32240c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1c0f0a7f-0fb8-440b-8f92-bcbc2069cbcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_17fad38d-726e-4ab3-af8c-2e2172fbd9a7" xlink:to="loc_us-gaap_EarningsPerShareDiluted_1c0f0a7f-0fb8-440b-8f92-bcbc2069cbcd" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fdcee667-a8d6-4e3c-a618-5ee7f0c00e46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_17fad38d-726e-4ab3-af8c-2e2172fbd9a7" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fdcee667-a8d6-4e3c-a618-5ee7f0c00e46" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_b1ebb179-fa51-4c44-8e93-4ebc5231b25a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_17fad38d-726e-4ab3-af8c-2e2172fbd9a7" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_b1ebb179-fa51-4c44-8e93-4ebc5231b25a" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_7147de36-2899-48f9-94d6-abe543f7462a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_17fad38d-726e-4ab3-af8c-2e2172fbd9a7" xlink:to="loc_us-gaap_StatementTable_7147de36-2899-48f9-94d6-abe543f7462a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_2f177d9e-59ab-42c7-ad04-708fb5a890c1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_7147de36-2899-48f9-94d6-abe543f7462a" xlink:to="loc_srt_StatementScenarioAxis_2f177d9e-59ab-42c7-ad04-708fb5a890c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_2f177d9e-59ab-42c7-ad04-708fb5a890c1_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_2f177d9e-59ab-42c7-ad04-708fb5a890c1" xlink:to="loc_srt_ScenarioUnspecifiedDomain_2f177d9e-59ab-42c7-ad04-708fb5a890c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_fdf6d515-0045-400f-90fe-4ef6edb6bff7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_2f177d9e-59ab-42c7-ad04-708fb5a890c1" xlink:to="loc_srt_ScenarioUnspecifiedDomain_fdf6d515-0045-400f-90fe-4ef6edb6bff7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/StatementsofComprehensiveLossParentheticalsParentheticals" xlink:type="simple" xlink:href="lxrx-20221231.xsd#StatementsofComprehensiveLossParentheticalsParentheticals"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/StatementsofComprehensiveLossParentheticalsParentheticals" xlink:type="extended" id="ifb1d903bf6f548c8b072f8e5e8852886_StatementsofComprehensiveLossParentheticalsParentheticals">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4efcf08e-2bf9-4411-a8fe-f9a0beee4a31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_bf1544fe-fe8c-49e4-b023-2833f137c776" xlink:href="lxrx-20221231.xsd#lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4efcf08e-2bf9-4411-a8fe-f9a0beee4a31" xlink:to="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_bf1544fe-fe8c-49e4-b023-2833f137c776" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense_3f457a83-a78f-4985-9f85-4bd8fb6fa94f" xlink:href="lxrx-20221231.xsd#lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4efcf08e-2bf9-4411-a8fe-f9a0beee4a31" xlink:to="loc_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense_3f457a83-a78f-4985-9f85-4bd8fb6fa94f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_556c4ae9-2a6b-4975-99d4-bd9372f201d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_4efcf08e-2bf9-4411-a8fe-f9a0beee4a31" xlink:to="loc_us-gaap_StatementTable_556c4ae9-2a6b-4975-99d4-bd9372f201d4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_2e77d1f8-ba8a-4eb2-b973-df4ec5a94551" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_556c4ae9-2a6b-4975-99d4-bd9372f201d4" xlink:to="loc_srt_StatementScenarioAxis_2e77d1f8-ba8a-4eb2-b973-df4ec5a94551" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_2e77d1f8-ba8a-4eb2-b973-df4ec5a94551_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_2e77d1f8-ba8a-4eb2-b973-df4ec5a94551" xlink:to="loc_srt_ScenarioUnspecifiedDomain_2e77d1f8-ba8a-4eb2-b973-df4ec5a94551_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_dc4e60b9-9356-4511-b08b-94c4341da3f6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_2e77d1f8-ba8a-4eb2-b973-df4ec5a94551" xlink:to="loc_srt_ScenarioUnspecifiedDomain_dc4e60b9-9356-4511-b08b-94c4341da3f6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="lxrx-20221231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="i2698f11ad3a0443189e3cf7b59d277db_ConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_456d2144-b7d2-46d1-9ebc-93fe29942259" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_c94a4650-2da6-41e1-9925-6a9712ed6d8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_456d2144-b7d2-46d1-9ebc-93fe29942259" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_c94a4650-2da6-41e1-9925-6a9712ed6d8e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_dacec129-5821-4477-8d40-6796bcf58197" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_456d2144-b7d2-46d1-9ebc-93fe29942259" xlink:to="loc_us-gaap_StockholdersEquity_dacec129-5821-4477-8d40-6796bcf58197" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_a975f59b-b23f-4127-9784-723e389b6d39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_456d2144-b7d2-46d1-9ebc-93fe29942259" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_a975f59b-b23f-4127-9784-723e389b6d39" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_62bfb930-ea8b-48f5-ac8e-7843bb7b7390" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_456d2144-b7d2-46d1-9ebc-93fe29942259" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_62bfb930-ea8b-48f5-ac8e-7843bb7b7390" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_112ef092-45bf-4142-a579-24b5ed9cffab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_456d2144-b7d2-46d1-9ebc-93fe29942259" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_112ef092-45bf-4142-a579-24b5ed9cffab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_d754cde1-891b-49a8-9076-8f6bdfd77f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_456d2144-b7d2-46d1-9ebc-93fe29942259" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_d754cde1-891b-49a8-9076-8f6bdfd77f6d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_4fd75b66-1f1f-4b04-8424-4e0fd3a68d31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_456d2144-b7d2-46d1-9ebc-93fe29942259" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_4fd75b66-1f1f-4b04-8424-4e0fd3a68d31" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_9b158e8c-c756-4062-ad0e-e17101a22583" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_456d2144-b7d2-46d1-9ebc-93fe29942259" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_9b158e8c-c756-4062-ad0e-e17101a22583" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_683e53aa-4d4c-4968-b40f-bf9232bea1b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_456d2144-b7d2-46d1-9ebc-93fe29942259" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_683e53aa-4d4c-4968-b40f-bf9232bea1b5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_9fc290c0-69b1-41f0-8bde-c0245ff39ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_456d2144-b7d2-46d1-9ebc-93fe29942259" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_9fc290c0-69b1-41f0-8bde-c0245ff39ae2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_e5561d61-10b6-4829-8f82-a5a540ee75fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_456d2144-b7d2-46d1-9ebc-93fe29942259" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_e5561d61-10b6-4829-8f82-a5a540ee75fa" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2df374d6-c572-4a76-82c7-4c924e2ec184" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_456d2144-b7d2-46d1-9ebc-93fe29942259" xlink:to="loc_us-gaap_NetIncomeLoss_2df374d6-c572-4a76-82c7-4c924e2ec184" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_b3b2ad26-6464-4f3d-83b3-2d331e104ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_456d2144-b7d2-46d1-9ebc-93fe29942259" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_b3b2ad26-6464-4f3d-83b3-2d331e104ac5" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_c2ca2259-7ff1-48e8-be65-cb1d35e456f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d5f290ce-165b-454f-b086-4520022a01cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustment_8d6355ea-371f-4820-ad88-101956d21995" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_456d2144-b7d2-46d1-9ebc-93fe29942259" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustment_8d6355ea-371f-4820-ad88-101956d21995" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification_4e95db74-7a4c-4a47-a0e5-3b69009a47e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_456d2144-b7d2-46d1-9ebc-93fe29942259" xlink:to="loc_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification_4e95db74-7a4c-4a47-a0e5-3b69009a47e5" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_b575fb8f-370e-433e-a1a8-47e3ea0820eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_456d2144-b7d2-46d1-9ebc-93fe29942259" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_b575fb8f-370e-433e-a1a8-47e3ea0820eb" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountIssued1_a1233559-a650-4545-a64c-36f55517565a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockAmountIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_456d2144-b7d2-46d1-9ebc-93fe29942259" xlink:to="loc_us-gaap_ConversionOfStockAmountIssued1_a1233559-a650-4545-a64c-36f55517565a" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_357e3524-c4bd-49a4-85a3-f3284fc77972" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_456d2144-b7d2-46d1-9ebc-93fe29942259" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_357e3524-c4bd-49a4-85a3-f3284fc77972" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ProceedsFromDecember2020CommonStockOffering_dfcd6632-420a-42fa-9318-ae80c54af39c" xlink:href="lxrx-20221231.xsd#lxrx_ProceedsFromDecember2020CommonStockOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_456d2144-b7d2-46d1-9ebc-93fe29942259" xlink:to="loc_lxrx_ProceedsFromDecember2020CommonStockOffering_dfcd6632-420a-42fa-9318-ae80c54af39c" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesSoldInJanuary2021ATMOffering_a71cd40c-e62e-4813-bb2b-09fae7fa125d" xlink:href="lxrx-20221231.xsd#lxrx_SharesSoldInJanuary2021ATMOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_456d2144-b7d2-46d1-9ebc-93fe29942259" xlink:to="loc_lxrx_SharesSoldInJanuary2021ATMOffering_a71cd40c-e62e-4813-bb2b-09fae7fa125d" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ProceedsFromJanuary2021ATMOffering_2184dc1a-e733-42dc-88c8-1f9ef7d7a94a" xlink:href="lxrx-20221231.xsd#lxrx_ProceedsFromJanuary2021ATMOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_456d2144-b7d2-46d1-9ebc-93fe29942259" xlink:to="loc_lxrx_ProceedsFromJanuary2021ATMOffering_2184dc1a-e733-42dc-88c8-1f9ef7d7a94a" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharePriceInNovember20ATMOffering_041116ca-c4e0-45cd-80c8-27faacd3e839" xlink:href="lxrx-20221231.xsd#lxrx_SharePriceInNovember20ATMOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_456d2144-b7d2-46d1-9ebc-93fe29942259" xlink:to="loc_lxrx_SharePriceInNovember20ATMOffering_041116ca-c4e0-45cd-80c8-27faacd3e839" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ProceedsFromNov2020ATMOffering_4eda881f-9a45-459e-bdbb-5073c29487c9" xlink:href="lxrx-20221231.xsd#lxrx_ProceedsFromNov2020ATMOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_456d2144-b7d2-46d1-9ebc-93fe29942259" xlink:to="loc_lxrx_ProceedsFromNov2020ATMOffering_4eda881f-9a45-459e-bdbb-5073c29487c9" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CommissionsFromDecember2020CommonStockOffering_fc3b6078-82e5-44c3-b58b-c3cbacb75d32" xlink:href="lxrx-20221231.xsd#lxrx_CommissionsFromDecember2020CommonStockOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_456d2144-b7d2-46d1-9ebc-93fe29942259" xlink:to="loc_lxrx_CommissionsFromDecember2020CommonStockOffering_fc3b6078-82e5-44c3-b58b-c3cbacb75d32" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OfferingExpensesFromDecember20CommonStockOffering_28a5ec84-bf00-4358-b8f5-0ed462c51447" xlink:href="lxrx-20221231.xsd#lxrx_OfferingExpensesFromDecember20CommonStockOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_456d2144-b7d2-46d1-9ebc-93fe29942259" xlink:to="loc_lxrx_OfferingExpensesFromDecember20CommonStockOffering_28a5ec84-bf00-4358-b8f5-0ed462c51447" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ATMOfferingTotal_e1280569-3901-457a-b850-5b82c7e77d62" xlink:href="lxrx-20221231.xsd#lxrx_ATMOfferingTotal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_456d2144-b7d2-46d1-9ebc-93fe29942259" xlink:to="loc_lxrx_ATMOfferingTotal_e1280569-3901-457a-b850-5b82c7e77d62" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OtherCapitalAgreementsTextBlock_008b0df4-7b43-4c98-a615-4627ef802bf7" xlink:href="lxrx-20221231.xsd#lxrx_OtherCapitalAgreementsTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_456d2144-b7d2-46d1-9ebc-93fe29942259" xlink:to="loc_lxrx_OtherCapitalAgreementsTextBlock_008b0df4-7b43-4c98-a615-4627ef802bf7" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtInstrument_Revere_LXRX_0838f71f-8360-4f49-ae31-7d69e0fc733d" xlink:href="lxrx-20221231.xsd#lxrx_MortgageDebtInstrument_Revere_LXRX"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_456d2144-b7d2-46d1-9ebc-93fe29942259" xlink:to="loc_lxrx_MortgageDebtInstrument_Revere_LXRX_0838f71f-8360-4f49-ae31-7d69e0fc733d" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_5a40788c-bbda-4f41-8dd6-ee908409c5e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_456d2144-b7d2-46d1-9ebc-93fe29942259" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_5a40788c-bbda-4f41-8dd6-ee908409c5e5" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_6f7bac2f-67e6-4757-88bc-f7cf6d88ec3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_456d2144-b7d2-46d1-9ebc-93fe29942259" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_6f7bac2f-67e6-4757-88bc-f7cf6d88ec3e" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6a56cbaa-aec8-471a-86b0-7c2ce50d921b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_456d2144-b7d2-46d1-9ebc-93fe29942259" xlink:to="loc_us-gaap_StatementTable_6a56cbaa-aec8-471a-86b0-7c2ce50d921b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f077fec7-77de-4dbd-b891-b5d200d7d370" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_6a56cbaa-aec8-471a-86b0-7c2ce50d921b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f077fec7-77de-4dbd-b891-b5d200d7d370" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f077fec7-77de-4dbd-b891-b5d200d7d370_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f077fec7-77de-4dbd-b891-b5d200d7d370" xlink:to="loc_us-gaap_EquityComponentDomain_f077fec7-77de-4dbd-b891-b5d200d7d370_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3323358c-003f-4254-b834-a7ef7bb32d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f077fec7-77de-4dbd-b891-b5d200d7d370" xlink:to="loc_us-gaap_EquityComponentDomain_3323358c-003f-4254-b834-a7ef7bb32d6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_8a129a23-7f17-4ba3-af9b-a2b9f4d97617" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3323358c-003f-4254-b834-a7ef7bb32d6e" xlink:to="loc_us-gaap_CommonStockMember_8a129a23-7f17-4ba3-af9b-a2b9f4d97617" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_6ab42cb6-8a24-4066-b21a-d919ae2dae88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3323358c-003f-4254-b834-a7ef7bb32d6e" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_6ab42cb6-8a24-4066-b21a-d919ae2dae88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_75055d8e-8dee-409c-942a-bd4902c3735a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3323358c-003f-4254-b834-a7ef7bb32d6e" xlink:to="loc_us-gaap_RetainedEarningsMember_75055d8e-8dee-409c-942a-bd4902c3735a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c476fb3d-b526-4493-b5e8-c0ad4f72bc87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3323358c-003f-4254-b834-a7ef7bb32d6e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c476fb3d-b526-4493-b5e8-c0ad4f72bc87" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_c76d9bca-7f3c-494b-ba74-ac1806962095" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3323358c-003f-4254-b834-a7ef7bb32d6e" xlink:to="loc_us-gaap_TreasuryStockMember_c76d9bca-7f3c-494b-ba74-ac1806962095" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="lxrx-20221231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended" id="i0780506eb9474d53acb594c80798cdb6_ConsolidatedStatementsofCashFlows">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0a373d8b-18d4-4524-bd71-61f3966d6ec3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e7d47488-71ff-4e1f-9fe6-2e7e61085f58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0a373d8b-18d4-4524-bd71-61f3966d6ec3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e7d47488-71ff-4e1f-9fe6-2e7e61085f58" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_9d4656b2-4058-45be-884d-24819c4b1341" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e7d47488-71ff-4e1f-9fe6-2e7e61085f58" xlink:to="loc_us-gaap_ProfitLoss_9d4656b2-4058-45be-884d-24819c4b1341" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_da8a9432-5982-4211-aee9-b4eb684977cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e7d47488-71ff-4e1f-9fe6-2e7e61085f58" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_da8a9432-5982-4211-aee9-b4eb684977cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_cb603d9f-24c8-4db3-81db-5ea78cc26da4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_da8a9432-5982-4211-aee9-b4eb684977cb" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_cb603d9f-24c8-4db3-81db-5ea78cc26da4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_b1bad366-f49c-49f4-a4a5-ab7eb80f7cad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_da8a9432-5982-4211-aee9-b4eb684977cb" xlink:to="loc_us-gaap_ShareBasedCompensation_b1bad366-f49c-49f4-a4a5-ab7eb80f7cad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_3b1482de-bf5d-490a-bd28-429084bea4f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_da8a9432-5982-4211-aee9-b4eb684977cb" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_3b1482de-bf5d-490a-bd28-429084bea4f1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_620db6ce-e6fd-4823-b2b5-4215a79d249a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_da8a9432-5982-4211-aee9-b4eb684977cb" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_620db6ce-e6fd-4823-b2b5-4215a79d249a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ae6aba0d-04d0-49f3-958a-c86d8b1e8487" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_da8a9432-5982-4211-aee9-b4eb684977cb" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ae6aba0d-04d0-49f3-958a-c86d8b1e8487" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_400a692d-07ec-438b-906f-067b056c8ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ae6aba0d-04d0-49f3-958a-c86d8b1e8487" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_400a692d-07ec-438b-906f-067b056c8ef1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_346bc604-1455-42dd-9a1f-5bb40152b7fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ae6aba0d-04d0-49f3-958a-c86d8b1e8487" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_346bc604-1455-42dd-9a1f-5bb40152b7fc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_dfd405e5-64f9-4674-9446-e5760819c745" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ae6aba0d-04d0-49f3-958a-c86d8b1e8487" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_dfd405e5-64f9-4674-9446-e5760819c745" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_6bb38fee-03fd-4787-ae0a-c0784add80fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ae6aba0d-04d0-49f3-958a-c86d8b1e8487" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_6bb38fee-03fd-4787-ae0a-c0784add80fb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_040348c1-f131-484a-b9db-9574739a4340" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ae6aba0d-04d0-49f3-958a-c86d8b1e8487" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_040348c1-f131-484a-b9db-9574739a4340" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_8d91ade7-fa94-4861-a632-466bd04dcb49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ae6aba0d-04d0-49f3-958a-c86d8b1e8487" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_8d91ade7-fa94-4861-a632-466bd04dcb49" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_91f255e1-825e-467e-91f7-c501541bbe23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e7d47488-71ff-4e1f-9fe6-2e7e61085f58" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_91f255e1-825e-467e-91f7-c501541bbe23" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6bbf8898-f7e8-4ea0-8952-274d10fa02e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0a373d8b-18d4-4524-bd71-61f3966d6ec3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6bbf8898-f7e8-4ea0-8952-274d10fa02e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4f865550-c3da-4de6-ac03-b971c0191829" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6bbf8898-f7e8-4ea0-8952-274d10fa02e0" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4f865550-c3da-4de6-ac03-b971c0191829" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_495186a0-bdf0-4c66-bda4-138e1b5ab334" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6bbf8898-f7e8-4ea0-8952-274d10fa02e0" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_495186a0-bdf0-4c66-bda4-138e1b5ab334" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_99fe16b3-57ed-4cf3-88db-c81d5feaa46a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6bbf8898-f7e8-4ea0-8952-274d10fa02e0" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_99fe16b3-57ed-4cf3-88db-c81d5feaa46a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_1718bac5-92a7-4923-bdc7-bba552f8884c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6bbf8898-f7e8-4ea0-8952-274d10fa02e0" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_1718bac5-92a7-4923-bdc7-bba552f8884c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_3b7ff2f9-5eb8-4d51-97ec-f5707f5a47ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6bbf8898-f7e8-4ea0-8952-274d10fa02e0" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_3b7ff2f9-5eb8-4d51-97ec-f5707f5a47ce" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_91e06fcf-db27-40b2-9467-4dd650de2eb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6bbf8898-f7e8-4ea0-8952-274d10fa02e0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_91e06fcf-db27-40b2-9467-4dd650de2eb5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e56edba6-2e9f-413f-9450-3f3813af4789" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0a373d8b-18d4-4524-bd71-61f3966d6ec3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e56edba6-2e9f-413f-9450-3f3813af4789" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_28b880b9-450e-4338-8a5f-85963dff3033" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e56edba6-2e9f-413f-9450-3f3813af4789" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_28b880b9-450e-4338-8a5f-85963dff3033" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_9719e288-8795-41d2-8a25-57ff3cd53f86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e56edba6-2e9f-413f-9450-3f3813af4789" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_9719e288-8795-41d2-8a25-57ff3cd53f86" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_1d8ba0ac-a4a6-4391-9eb9-032be0463820" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e56edba6-2e9f-413f-9450-3f3813af4789" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_1d8ba0ac-a4a6-4391-9eb9-032be0463820" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_1d12a33e-bb6d-418e-b9fe-0d7d89f68900" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e56edba6-2e9f-413f-9450-3f3813af4789" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_1d12a33e-bb6d-418e-b9fe-0d7d89f68900" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6c60093c-d301-45b1-8320-ccaadb64d7f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e56edba6-2e9f-413f-9450-3f3813af4789" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6c60093c-d301-45b1-8320-ccaadb64d7f3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_93b02451-e5c9-4a09-98bc-8c65698b1287" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0a373d8b-18d4-4524-bd71-61f3966d6ec3" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_93b02451-e5c9-4a09-98bc-8c65698b1287" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a8cec397-bcef-445c-85a9-8dabd9c702aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0a373d8b-18d4-4524-bd71-61f3966d6ec3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a8cec397-bcef-445c-85a9-8dabd9c702aa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5e3733ce-cee4-441e-9e50-d33b799b7bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_06d32f88-97dc-4d44-831c-421d61e779bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0a373d8b-18d4-4524-bd71-61f3966d6ec3" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_06d32f88-97dc-4d44-831c-421d61e779bc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_d71856fe-0fac-4a97-ba38-4192ff8916ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_06d32f88-97dc-4d44-831c-421d61e779bc" xlink:to="loc_us-gaap_InterestPaidNet_d71856fe-0fac-4a97-ba38-4192ff8916ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_a6364186-a0a7-460a-a124-3ec3bed95600" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0a373d8b-18d4-4524-bd71-61f3966d6ec3" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_a6364186-a0a7-460a-a124-3ec3bed95600" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_62a2a5fb-a2f4-4608-a5eb-1371c2e31c16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0a373d8b-18d4-4524-bd71-61f3966d6ec3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_62a2a5fb-a2f4-4608-a5eb-1371c2e31c16" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_98077c16-0bfe-4ba3-8ec4-93200cbe8b62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0a373d8b-18d4-4524-bd71-61f3966d6ec3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_98077c16-0bfe-4ba3-8ec4-93200cbe8b62" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_c0437934-fed8-43c2-a191-85f7eb35f74e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0a373d8b-18d4-4524-bd71-61f3966d6ec3" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_c0437934-fed8-43c2-a191-85f7eb35f74e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_GainOnSaleOfNonFinancialAssets_816a39db-f4e5-4b84-981d-dc80e021098b" xlink:href="lxrx-20221231.xsd#lxrx_GainOnSaleOfNonFinancialAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0a373d8b-18d4-4524-bd71-61f3966d6ec3" xlink:to="loc_lxrx_GainOnSaleOfNonFinancialAssets_816a39db-f4e5-4b84-981d-dc80e021098b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfRealEstate_ea41db48-16db-4aef-8294-4850ec534c50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfRealEstate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0a373d8b-18d4-4524-bd71-61f3966d6ec3" xlink:to="loc_us-gaap_ImpairmentOfRealEstate_ea41db48-16db-4aef-8294-4850ec534c50" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_73c07481-007a-4041-8608-1bd09a2fd737" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0a373d8b-18d4-4524-bd71-61f3966d6ec3" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_73c07481-007a-4041-8608-1bd09a2fd737" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_eda47b2d-a649-4edb-bd27-79c0f573bede" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0a373d8b-18d4-4524-bd71-61f3966d6ec3" xlink:to="loc_us-gaap_AssetImpairmentCharges_eda47b2d-a649-4edb-bd27-79c0f573bede" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_8085a649-4b8f-4e1b-bbe9-1f449cd3e455" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0a373d8b-18d4-4524-bd71-61f3966d6ec3" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_8085a649-4b8f-4e1b-bbe9-1f449cd3e455" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfBuildings_3579156a-0a85-4708-9bb8-1e1950609c2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfBuildings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0a373d8b-18d4-4524-bd71-61f3966d6ec3" xlink:to="loc_us-gaap_ProceedsFromSaleOfBuildings_3579156a-0a85-4708-9bb8-1e1950609c2e" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_d86539d8-d5fc-4b79-bb1d-25a1b768450f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0a373d8b-18d4-4524-bd71-61f3966d6ec3" xlink:to="loc_us-gaap_SeveranceCosts1_d86539d8-d5fc-4b79-bb1d-25a1b768450f" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_489a7431-215a-4a04-a874-4d763e1d0f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0a373d8b-18d4-4524-bd71-61f3966d6ec3" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_489a7431-215a-4a04-a874-4d763e1d0f9c" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_49a22e7f-af7e-470e-8658-e2982eab3b64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0a373d8b-18d4-4524-bd71-61f3966d6ec3" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_49a22e7f-af7e-470e-8658-e2982eab3b64" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_485a5f5b-4bd0-42a3-bb12-408d5bcbb808" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0a373d8b-18d4-4524-bd71-61f3966d6ec3" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_485a5f5b-4bd0-42a3-bb12-408d5bcbb808" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCarryingBasis_39553004-624d-45b6-9a42-5cfae25caa6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCarryingBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0a373d8b-18d4-4524-bd71-61f3966d6ec3" xlink:to="loc_us-gaap_TreasuryStockCarryingBasis_39553004-624d-45b6-9a42-5cfae25caa6b" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_371766fd-a524-4469-9d77-6f9ba4cc54b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0a373d8b-18d4-4524-bd71-61f3966d6ec3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_371766fd-a524-4469-9d77-6f9ba4cc54b7" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessExitCosts1_8f5ec01a-0d28-4dc2-ad43-c94867efd03e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessExitCosts1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0a373d8b-18d4-4524-bd71-61f3966d6ec3" xlink:to="loc_us-gaap_BusinessExitCosts1_8f5ec01a-0d28-4dc2-ad43-c94867efd03e" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtGainLossNetOfTax_2b00bb17-36fe-45a5-b814-345eeb969abf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExtinguishmentOfDebtGainLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0a373d8b-18d4-4524-bd71-61f3966d6ec3" xlink:to="loc_us-gaap_ExtinguishmentOfDebtGainLossNetOfTax_2b00bb17-36fe-45a5-b814-345eeb969abf" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_349c0e97-ceea-4d2c-84e2-1d1fb3196ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0a373d8b-18d4-4524-bd71-61f3966d6ec3" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_349c0e97-ceea-4d2c-84e2-1d1fb3196ab6" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_50fe6e08-e81b-47bd-8837-5ad316139cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0a373d8b-18d4-4524-bd71-61f3966d6ec3" xlink:to="loc_us-gaap_StatementTable_50fe6e08-e81b-47bd-8837-5ad316139cf1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_4e65da16-9e15-404f-9bcc-dd8a9e5098f4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_50fe6e08-e81b-47bd-8837-5ad316139cf1" xlink:to="loc_srt_StatementScenarioAxis_4e65da16-9e15-404f-9bcc-dd8a9e5098f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_4e65da16-9e15-404f-9bcc-dd8a9e5098f4_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_4e65da16-9e15-404f-9bcc-dd8a9e5098f4" xlink:to="loc_srt_ScenarioUnspecifiedDomain_4e65da16-9e15-404f-9bcc-dd8a9e5098f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_64ebe54b-75b7-4408-a905-7494ac3aae68" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_4e65da16-9e15-404f-9bcc-dd8a9e5098f4" xlink:to="loc_srt_ScenarioUnspecifiedDomain_64ebe54b-75b7-4408-a905-7494ac3aae68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_c6b79841-df67-4499-83a3-bc76909339b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_50fe6e08-e81b-47bd-8837-5ad316139cf1" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_c6b79841-df67-4499-83a3-bc76909339b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_c6b79841-df67-4499-83a3-bc76909339b3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_c6b79841-df67-4499-83a3-bc76909339b3" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_c6b79841-df67-4499-83a3-bc76909339b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_3262e19b-6dac-4a27-ac64-3cd9fcd39cdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_c6b79841-df67-4499-83a3-bc76909339b3" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_3262e19b-6dac-4a27-ac64-3cd9fcd39cdb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_RDSeveranceCostsMember_37688626-77fb-4fac-8aaa-3c4b46a26e90" xlink:href="lxrx-20221231.xsd#lxrx_RDSeveranceCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_3262e19b-6dac-4a27-ac64-3cd9fcd39cdb" xlink:to="loc_lxrx_RDSeveranceCostsMember_37688626-77fb-4fac-8aaa-3c4b46a26e90" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleassetDetails" xlink:type="simple" xlink:href="lxrx-20221231.xsd#SummaryofSignificantAccountingPoliciesIntangibleassetDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleassetDetails" xlink:type="extended" id="i7be72d4af72141d49a7ffeab35774748_SummaryofSignificantAccountingPoliciesIntangibleassetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_efb21559-7eb3-439a-99e3-f5f70307dca8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsNet_ed917da3-0f1d-41d6-9318-6f2d1dd395ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_efb21559-7eb3-439a-99e3-f5f70307dca8" xlink:to="loc_us-gaap_OtherIntangibleAssetsNet_ed917da3-0f1d-41d6-9318-6f2d1dd395ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_3a7db3e8-1304-4fa8-a0a8-ef3d73bfcb49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_efb21559-7eb3-439a-99e3-f5f70307dca8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_3a7db3e8-1304-4fa8-a0a8-ef3d73bfcb49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_e16e841b-906a-41d6-a7d4-33709d7db60c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_efb21559-7eb3-439a-99e3-f5f70307dca8" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_e16e841b-906a-41d6-a7d4-33709d7db60c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_264b008b-c6cf-43aa-ba32-04d13e6d4865" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_efb21559-7eb3-439a-99e3-f5f70307dca8" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_264b008b-c6cf-43aa-ba32-04d13e6d4865" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a2cd5b12-0b35-4a4b-a4c9-672356528f75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_264b008b-c6cf-43aa-ba32-04d13e6d4865" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a2cd5b12-0b35-4a4b-a4c9-672356528f75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a2cd5b12-0b35-4a4b-a4c9-672356528f75_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a2cd5b12-0b35-4a4b-a4c9-672356528f75" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a2cd5b12-0b35-4a4b-a4c9-672356528f75_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_65f94029-3942-4baf-afc9-d30c13cce312" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a2cd5b12-0b35-4a4b-a4c9-672356528f75" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_65f94029-3942-4baf-afc9-d30c13cce312" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" xlink:type="simple" xlink:href="lxrx-20221231.xsd#SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" xlink:type="extended" id="i4f84b4fb6eae4c968791cff27b9ecf55_SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c4cf1834-d978-4661-90c9-3947bf06fc72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_908376d6-4ddf-4be2-b50a-3c6a2671c09a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c4cf1834-d978-4661-90c9-3947bf06fc72" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_908376d6-4ddf-4be2-b50a-3c6a2671c09a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedResearchAndDevelopmentServicesCurrent_3b95f20b-5f37-49ec-a7ba-5a7756f0e664" xlink:href="lxrx-20221231.xsd#lxrx_AccruedResearchAndDevelopmentServicesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c4cf1834-d978-4661-90c9-3947bf06fc72" xlink:to="loc_lxrx_AccruedResearchAndDevelopmentServicesCurrent_3b95f20b-5f37-49ec-a7ba-5a7756f0e664" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedCompensationAndBenefitsCurrent_bc8d8f4a-e24d-4d09-afec-5874a8163983" xlink:href="lxrx-20221231.xsd#lxrx_AccruedCompensationAndBenefitsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c4cf1834-d978-4661-90c9-3947bf06fc72" xlink:to="loc_lxrx_AccruedCompensationAndBenefitsCurrent_bc8d8f4a-e24d-4d09-afec-5874a8163983" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_1a035cae-f3de-40d3-acc6-cc1848670ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c4cf1834-d978-4661-90c9-3947bf06fc72" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_1a035cae-f3de-40d3-acc6-cc1848670ca3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_0df9749d-dabe-4d9a-930f-d280bfc43843" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c4cf1834-d978-4661-90c9-3947bf06fc72" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_0df9749d-dabe-4d9a-930f-d280bfc43843" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_e72da749-a930-4e44-87c4-6f8b82caa6c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c4cf1834-d978-4661-90c9-3947bf06fc72" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_e72da749-a930-4e44-87c4-6f8b82caa6c3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_952c7ed1-d74e-45ae-badd-9fb79230fb5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c4cf1834-d978-4661-90c9-3947bf06fc72" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_952c7ed1-d74e-45ae-badd-9fb79230fb5a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d5469a46-2873-4515-b64b-f4673ec8518a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_952c7ed1-d74e-45ae-badd-9fb79230fb5a" xlink:to="loc_srt_RangeAxis_d5469a46-2873-4515-b64b-f4673ec8518a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d5469a46-2873-4515-b64b-f4673ec8518a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d5469a46-2873-4515-b64b-f4673ec8518a" xlink:to="loc_srt_RangeMember_d5469a46-2873-4515-b64b-f4673ec8518a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_082642eb-7920-4992-9db3-2f0f9f683f9b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d5469a46-2873-4515-b64b-f4673ec8518a" xlink:to="loc_srt_RangeMember_082642eb-7920-4992-9db3-2f0f9f683f9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1d5591e7-3495-4986-bf0b-59bbcc554716" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_082642eb-7920-4992-9db3-2f0f9f683f9b" xlink:to="loc_srt_MinimumMember_1d5591e7-3495-4986-bf0b-59bbcc554716" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8b40d75a-228e-4853-9673-038eb02f1965" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_082642eb-7920-4992-9db3-2f0f9f683f9b" xlink:to="loc_srt_MaximumMember_8b40d75a-228e-4853-9673-038eb02f1965" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesCostofSalesDetails" xlink:type="simple" xlink:href="lxrx-20221231.xsd#SummaryofSignificantAccountingPoliciesCostofSalesDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesCostofSalesDetails" xlink:type="extended" id="i345b0580253c49a8abb88fa94f32162a_SummaryofSignificantAccountingPoliciesCostofSalesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_54987666-8660-44cf-ac5f-dbdc9198d515" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_775154ba-79d5-424a-b3e5-bfa2a4a62603" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_54987666-8660-44cf-ac5f-dbdc9198d515" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_775154ba-79d5-424a-b3e5-bfa2a4a62603" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_47d28926-e9c6-4c40-b93c-5ec9d95fc1f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_54987666-8660-44cf-ac5f-dbdc9198d515" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_47d28926-e9c6-4c40-b93c-5ec9d95fc1f2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f4a101bb-3b21-4039-afd0-870b2c99c4a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_47d28926-e9c6-4c40-b93c-5ec9d95fc1f2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f4a101bb-3b21-4039-afd0-870b2c99c4a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f4a101bb-3b21-4039-afd0-870b2c99c4a4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f4a101bb-3b21-4039-afd0-870b2c99c4a4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f4a101bb-3b21-4039-afd0-870b2c99c4a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_304f3606-19fb-40e9-ade7-ed4a23a7c98a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f4a101bb-3b21-4039-afd0-870b2c99c4a4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_304f3606-19fb-40e9-ade7-ed4a23a7c98a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_e30504fe-bfb0-469e-9938-5f6aa0d1936e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_304f3606-19fb-40e9-ade7-ed4a23a7c98a" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_e30504fe-bfb0-469e-9938-5f6aa0d1936e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1" xlink:type="simple" xlink:href="lxrx-20221231.xsd#SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1" xlink:type="extended" id="iedd0f033f3534c0e8a14ac84f36a8535_SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80e93edf-1715-4bc0-a2cc-1e41e5f84f77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_b5f7de50-7525-49e0-8d9f-b64a457c29f7" xlink:href="lxrx-20221231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80e93edf-1715-4bc0-a2cc-1e41e5f84f77" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_b5f7de50-7525-49e0-8d9f-b64a457c29f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_6d6876e6-6fc0-476e-9333-3bb291d6748b" xlink:href="lxrx-20221231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80e93edf-1715-4bc0-a2cc-1e41e5f84f77" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_6d6876e6-6fc0-476e-9333-3bb291d6748b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_2fc964f7-3c94-4c72-83b7-ddda0763db32" xlink:href="lxrx-20221231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80e93edf-1715-4bc0-a2cc-1e41e5f84f77" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_2fc964f7-3c94-4c72-83b7-ddda0763db32" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_e9b94ac9-8d5e-40ce-871c-05f21ebff3d7" xlink:href="lxrx-20221231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80e93edf-1715-4bc0-a2cc-1e41e5f84f77" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_e9b94ac9-8d5e-40ce-871c-05f21ebff3d7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_add22b52-c213-471c-8a6d-409808a7b40c" xlink:href="lxrx-20221231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80e93edf-1715-4bc0-a2cc-1e41e5f84f77" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_add22b52-c213-471c-8a6d-409808a7b40c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_de72d354-397f-4f8b-86e6-0fd05e267866" xlink:href="lxrx-20221231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80e93edf-1715-4bc0-a2cc-1e41e5f84f77" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_de72d354-397f-4f8b-86e6-0fd05e267866" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_c3f9d0b2-9f6c-40c5-9282-db1bd86eec04" xlink:href="lxrx-20221231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80e93edf-1715-4bc0-a2cc-1e41e5f84f77" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_c3f9d0b2-9f6c-40c5-9282-db1bd86eec04" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_0b3a7281-9c38-4cdd-999d-eef6a99f3d89" xlink:href="lxrx-20221231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80e93edf-1715-4bc0-a2cc-1e41e5f84f77" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_0b3a7281-9c38-4cdd-999d-eef6a99f3d89" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_ea43676d-6c76-4082-bcbb-a59e0c83f562" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80e93edf-1715-4bc0-a2cc-1e41e5f84f77" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_ea43676d-6c76-4082-bcbb-a59e0c83f562" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3622e2e0-709e-45c7-965e-51547531a5a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80e93edf-1715-4bc0-a2cc-1e41e5f84f77" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3622e2e0-709e-45c7-965e-51547531a5a7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ff0f26c1-98c4-4059-92a3-b8bc9e841279" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3622e2e0-709e-45c7-965e-51547531a5a7" xlink:to="loc_us-gaap_AwardTypeAxis_ff0f26c1-98c4-4059-92a3-b8bc9e841279" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ff0f26c1-98c4-4059-92a3-b8bc9e841279_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_ff0f26c1-98c4-4059-92a3-b8bc9e841279" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ff0f26c1-98c4-4059-92a3-b8bc9e841279_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e6d34259-edfb-4c27-8bd5-c6f6e4083e16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_ff0f26c1-98c4-4059-92a3-b8bc9e841279" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e6d34259-edfb-4c27-8bd5-c6f6e4083e16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_3fac491a-ddb5-4843-bd12-7ffda9f94e03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e6d34259-edfb-4c27-8bd5-c6f6e4083e16" xlink:to="loc_us-gaap_StockOptionMember_3fac491a-ddb5-4843-bd12-7ffda9f94e03" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_0556503a-1d14-48c8-9266-3cf9148d35fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3622e2e0-709e-45c7-965e-51547531a5a7" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_0556503a-1d14-48c8-9266-3cf9148d35fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0556503a-1d14-48c8-9266-3cf9148d35fa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0556503a-1d14-48c8-9266-3cf9148d35fa" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0556503a-1d14-48c8-9266-3cf9148d35fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2cabb0db-e2f7-499c-b10e-b489b4f36970" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0556503a-1d14-48c8-9266-3cf9148d35fa" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2cabb0db-e2f7-499c-b10e-b489b4f36970" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncementsDetails" xlink:type="simple" xlink:href="lxrx-20221231.xsd#RecentAccountingPronouncementsDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/RecentAccountingPronouncementsDetails" xlink:type="extended" id="ib8758f7001424219b1e1ca68433bda89_RecentAccountingPronouncementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_7988e5f9-7edb-473b-80e7-f691348a10f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_cd7925dd-3fa6-48d4-8600-7cc62ba9c033" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_7988e5f9-7edb-473b-80e7-f691348a10f9" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_cd7925dd-3fa6-48d4-8600-7cc62ba9c033" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_76d57628-e328-4917-b6e7-c3174a07f786" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_7988e5f9-7edb-473b-80e7-f691348a10f9" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_76d57628-e328-4917-b6e7-c3174a07f786" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_414a8cb4-c4c0-4f5b-bcaf-b4d09dfa3deb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_76d57628-e328-4917-b6e7-c3174a07f786" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_414a8cb4-c4c0-4f5b-bcaf-b4d09dfa3deb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_414a8cb4-c4c0-4f5b-bcaf-b4d09dfa3deb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_414a8cb4-c4c0-4f5b-bcaf-b4d09dfa3deb" xlink:to="loc_us-gaap_TypeOfAdoptionMember_414a8cb4-c4c0-4f5b-bcaf-b4d09dfa3deb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_3ccbbf3b-ae2a-4c7e-b39c-e3c073848fb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_414a8cb4-c4c0-4f5b-bcaf-b4d09dfa3deb" xlink:to="loc_us-gaap_TypeOfAdoptionMember_3ccbbf3b-ae2a-4c7e-b39c-e3c073848fb1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails" xlink:type="simple" xlink:href="lxrx-20221231.xsd#CashandCashEquivalentsandInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails" xlink:type="extended" id="i81bc6c3010684899a958e9bbf879f751_CashandCashEquivalentsandInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_34a14486-e5a3-4c3a-9d28-fd2468c46a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_c726bd98-cbde-433b-b006-704dd9b56fc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_34a14486-e5a3-4c3a-9d28-fd2468c46a4b" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_c726bd98-cbde-433b-b006-704dd9b56fc7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_5f081191-df17-4f93-9ab5-6522d133f16f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_34a14486-e5a3-4c3a-9d28-fd2468c46a4b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_5f081191-df17-4f93-9ab5-6522d133f16f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_f7c0e747-fdc3-4d33-90ff-9b9fb35d5105" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_34a14486-e5a3-4c3a-9d28-fd2468c46a4b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_f7c0e747-fdc3-4d33-90ff-9b9fb35d5105" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2e9cbeb2-b3b4-4f04-92cf-0076a90dc974" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_34a14486-e5a3-4c3a-9d28-fd2468c46a4b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2e9cbeb2-b3b4-4f04-92cf-0076a90dc974" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_598e3880-68a0-40cf-8641-7c5c8bedab08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_34a14486-e5a3-4c3a-9d28-fd2468c46a4b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesCurrent_598e3880-68a0-40cf-8641-7c5c8bedab08" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_eca87e52-6bb1-47aa-becb-3e8f3f1aee2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_34a14486-e5a3-4c3a-9d28-fd2468c46a4b" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_eca87e52-6bb1-47aa-becb-3e8f3f1aee2e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_3eeaeb3b-becd-4abb-a09e-bc253c318628" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_eca87e52-6bb1-47aa-becb-3e8f3f1aee2e" xlink:to="loc_us-gaap_InvestmentTypeAxis_3eeaeb3b-becd-4abb-a09e-bc253c318628" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_3eeaeb3b-becd-4abb-a09e-bc253c318628_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_3eeaeb3b-becd-4abb-a09e-bc253c318628" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_3eeaeb3b-becd-4abb-a09e-bc253c318628_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_bffa5944-6f6e-48c6-b020-531bad76b851" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_3eeaeb3b-becd-4abb-a09e-bc253c318628" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_bffa5944-6f6e-48c6-b020-531bad76b851" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_5ef713ca-5e65-47e3-bc6a-3ad10f046ec4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_bffa5944-6f6e-48c6-b020-531bad76b851" xlink:to="loc_us-gaap_CashMember_5ef713ca-5e65-47e3-bc6a-3ad10f046ec4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_25344c89-35bf-4319-91e7-e0ba62110e82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_bffa5944-6f6e-48c6-b020-531bad76b851" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_25344c89-35bf-4319-91e7-e0ba62110e82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_98b07080-d362-41b9-ba9c-035e7be10cb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_bffa5944-6f6e-48c6-b020-531bad76b851" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_98b07080-d362-41b9-ba9c-035e7be10cb2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember_f9f01ad4-8ba7-4378-9880-cb2d5063501d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_bffa5944-6f6e-48c6-b020-531bad76b851" xlink:to="loc_us-gaap_InvestmentsMember_f9f01ad4-8ba7-4378-9880-cb2d5063501d" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurementsDetails1" xlink:type="simple" xlink:href="lxrx-20221231.xsd#FairValueMeasurementsDetails1"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurementsDetails1" xlink:type="extended" id="i32f499141bd64221b16165716584e15b_FairValueMeasurementsDetails1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_34c91335-1df8-4c50-bda8-fbbeba63c217" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_53aa2ca1-f0bf-4cba-8a18-3ea040f57313" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_34c91335-1df8-4c50-bda8-fbbeba63c217" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_53aa2ca1-f0bf-4cba-8a18-3ea040f57313" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecurities_dafd7639-04a4-4731-8f62-c3800b73205a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_34c91335-1df8-4c50-bda8-fbbeba63c217" xlink:to="loc_us-gaap_AvailableForSaleSecurities_dafd7639-04a4-4731-8f62-c3800b73205a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_1b8294bc-306f-4f12-9bef-eda89094e603" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_34c91335-1df8-4c50-bda8-fbbeba63c217" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_1b8294bc-306f-4f12-9bef-eda89094e603" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_70895b09-71e2-4f19-8728-864a0ff25977" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_34c91335-1df8-4c50-bda8-fbbeba63c217" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_70895b09-71e2-4f19-8728-864a0ff25977" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_eccf802d-be54-4253-9204-87f5023897e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_70895b09-71e2-4f19-8728-864a0ff25977" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_eccf802d-be54-4253-9204-87f5023897e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eccf802d-be54-4253-9204-87f5023897e6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_eccf802d-be54-4253-9204-87f5023897e6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eccf802d-be54-4253-9204-87f5023897e6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4910f0dc-1e90-42a6-8253-7d5fa4c292a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_eccf802d-be54-4253-9204-87f5023897e6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4910f0dc-1e90-42a6-8253-7d5fa4c292a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_bcb97d6b-fd73-49fb-9242-98379c3cda42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4910f0dc-1e90-42a6-8253-7d5fa4c292a7" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_bcb97d6b-fd73-49fb-9242-98379c3cda42" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_6ccf9883-257d-4abd-aa16-92349f2d001b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4910f0dc-1e90-42a6-8253-7d5fa4c292a7" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_6ccf9883-257d-4abd-aa16-92349f2d001b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_0f5acf20-8756-47cf-b1f6-ad9121339be1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4910f0dc-1e90-42a6-8253-7d5fa4c292a7" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_0f5acf20-8756-47cf-b1f6-ad9121339be1" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurementsDetails2" xlink:type="simple" xlink:href="lxrx-20221231.xsd#FairValueMeasurementsDetails2"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurementsDetails2" xlink:type="extended" id="i10220ec8dfe244b1901de6e971138edb_FairValueMeasurementsDetails2">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_541d1db1-98ab-4e0a-a08d-f11ef3dc62f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_79522d78-f51c-465f-909e-77b1452e18fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_541d1db1-98ab-4e0a-a08d-f11ef3dc62f4" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_79522d78-f51c-465f-909e-77b1452e18fd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_e4b51402-8d14-429e-9105-d8ec0b346915" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_79522d78-f51c-465f-909e-77b1452e18fd" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_e4b51402-8d14-429e-9105-d8ec0b346915" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_e4b51402-8d14-429e-9105-d8ec0b346915_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_e4b51402-8d14-429e-9105-d8ec0b346915" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_e4b51402-8d14-429e-9105-d8ec0b346915_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_46114cfc-c911-4be7-9b9b-1731f6ea6c52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_e4b51402-8d14-429e-9105-d8ec0b346915" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_46114cfc-c911-4be7-9b9b-1731f6ea6c52" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/PropertyandEquipmentDetails" xlink:type="simple" xlink:href="lxrx-20221231.xsd#PropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/PropertyandEquipmentDetails" xlink:type="extended" id="ib73c96f13ebd4bc89504605fd7f6ed5d_PropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_41129bd3-05fd-4117-a16b-16e066b62fbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_4856f9b7-238a-420c-a155-ee8524168de0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_41129bd3-05fd-4117-a16b-16e066b62fbb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_4856f9b7-238a-420c-a155-ee8524168de0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_58e03839-8bcd-425d-a701-9af90d9448ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_41129bd3-05fd-4117-a16b-16e066b62fbb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_58e03839-8bcd-425d-a701-9af90d9448ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2269ab6e-b131-4e94-b0c6-1e1ca21e9144" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_41129bd3-05fd-4117-a16b-16e066b62fbb" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2269ab6e-b131-4e94-b0c6-1e1ca21e9144" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_cc186f5a-d376-46f2-a210-4f8dda42a675" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_41129bd3-05fd-4117-a16b-16e066b62fbb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_cc186f5a-d376-46f2-a210-4f8dda42a675" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfBuildings_be83e85d-4821-4ab6-b56c-5d23924005df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfBuildings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_41129bd3-05fd-4117-a16b-16e066b62fbb" xlink:to="loc_us-gaap_ProceedsFromSaleOfBuildings_be83e85d-4821-4ab6-b56c-5d23924005df" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land_22b7573a-4567-41f8-b2be-57ab2969e4b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Land"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_41129bd3-05fd-4117-a16b-16e066b62fbb" xlink:to="loc_us-gaap_Land_22b7573a-4567-41f8-b2be-57ab2969e4b8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryBuildingsAndImprovements_0d6ac69d-33cf-4089-b1fd-02bd512ff76e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryBuildingsAndImprovements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_41129bd3-05fd-4117-a16b-16e066b62fbb" xlink:to="loc_us-gaap_InventoryBuildingsAndImprovements_0d6ac69d-33cf-4089-b1fd-02bd512ff76e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_25297537-a0d3-4daf-b7cd-c8086355d87c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_41129bd3-05fd-4117-a16b-16e066b62fbb" xlink:to="loc_us-gaap_AssetImpairmentCharges_25297537-a0d3-4daf-b7cd-c8086355d87c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1_de7a9c5c-2cd2-440e-b71b-c09cfb4d8d5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_41129bd3-05fd-4117-a16b-16e066b62fbb" xlink:to="loc_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1_de7a9c5c-2cd2-440e-b71b-c09cfb4d8d5b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment_de3f78ea-30d7-43b4-b0b7-d20a2669389d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_41129bd3-05fd-4117-a16b-16e066b62fbb" xlink:to="loc_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment_de3f78ea-30d7-43b4-b0b7-d20a2669389d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bd775083-de63-4528-a496-76393d1da289" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_41129bd3-05fd-4117-a16b-16e066b62fbb" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bd775083-de63-4528-a496-76393d1da289" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_97d376f9-2d4d-4b9d-9e60-ea1bf45ebb23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bd775083-de63-4528-a496-76393d1da289" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_97d376f9-2d4d-4b9d-9e60-ea1bf45ebb23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_97d376f9-2d4d-4b9d-9e60-ea1bf45ebb23_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_97d376f9-2d4d-4b9d-9e60-ea1bf45ebb23" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_97d376f9-2d4d-4b9d-9e60-ea1bf45ebb23_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6f1aed85-3662-4aec-b599-ad88ee06d709" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_97d376f9-2d4d-4b9d-9e60-ea1bf45ebb23" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6f1aed85-3662-4aec-b599-ad88ee06d709" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_e849ec1a-8b91-4133-9821-ea1d8a495faf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6f1aed85-3662-4aec-b599-ad88ee06d709" xlink:to="loc_us-gaap_ComputerEquipmentMember_e849ec1a-8b91-4133-9821-ea1d8a495faf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_519bc91e-3ce8-41f3-aefe-c34750f757b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6f1aed85-3662-4aec-b599-ad88ee06d709" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_519bc91e-3ce8-41f3-aefe-c34750f757b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_310900a7-67e1-4ba9-be97-013e1a15f608" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6f1aed85-3662-4aec-b599-ad88ee06d709" xlink:to="loc_us-gaap_EquipmentMember_310900a7-67e1-4ba9-be97-013e1a15f608" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_d73416ae-307f-4648-ac8f-139ebbcc55db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6f1aed85-3662-4aec-b599-ad88ee06d709" xlink:to="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_d73416ae-307f-4648-ac8f-139ebbcc55db" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_fb621a1b-af95-476b-90c3-30eda5cb1494" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6f1aed85-3662-4aec-b599-ad88ee06d709" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_fb621a1b-af95-476b-90c3-30eda5cb1494" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_ed11906b-87f5-48de-a94f-d29cf48cff1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6f1aed85-3662-4aec-b599-ad88ee06d709" xlink:to="loc_us-gaap_LandMember_ed11906b-87f5-48de-a94f-d29cf48cff1c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_74b9390c-ba3a-4ba4-b304-383b4535e3ad" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bd775083-de63-4528-a496-76393d1da289" xlink:to="loc_srt_RangeAxis_74b9390c-ba3a-4ba4-b304-383b4535e3ad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_74b9390c-ba3a-4ba4-b304-383b4535e3ad_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_74b9390c-ba3a-4ba4-b304-383b4535e3ad" xlink:to="loc_srt_RangeMember_74b9390c-ba3a-4ba4-b304-383b4535e3ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_54402456-895e-457e-8f89-9391be50ff16" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_74b9390c-ba3a-4ba4-b304-383b4535e3ad" xlink:to="loc_srt_RangeMember_54402456-895e-457e-8f89-9391be50ff16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ecda4509-90d3-4ec3-812a-368a80ccba41" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_54402456-895e-457e-8f89-9391be50ff16" xlink:to="loc_srt_MinimumMember_ecda4509-90d3-4ec3-812a-368a80ccba41" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1852587f-afdc-47f2-a662-da24d1cb5d30" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_54402456-895e-457e-8f89-9391be50ff16" xlink:to="loc_srt_MaximumMember_1852587f-afdc-47f2-a662-da24d1cb5d30" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/IncomeTaxesDetails1" xlink:type="simple" xlink:href="lxrx-20221231.xsd#IncomeTaxesDetails1"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/IncomeTaxesDetails1" xlink:type="extended" id="i75ff1233444b43b8a4bb196d34ee4a90_IncomeTaxesDetails1">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_b7c49bf1-ef97-4efe-9d74-5b77566cedfe" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_0682203b-172c-4a6d-9d6f-8aa3a642aa29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_b7c49bf1-ef97-4efe-9d74-5b77566cedfe" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_0682203b-172c-4a6d-9d6f-8aa3a642aa29" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_7833d345-85d3-4f52-87ba-803f84feae72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_b7c49bf1-ef97-4efe-9d74-5b77566cedfe" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_7833d345-85d3-4f52-87ba-803f84feae72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug_17795d9c-6b07-45bc-8b5d-38c1620e2314" xlink:href="lxrx-20221231.xsd#lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_b7c49bf1-ef97-4efe-9d74-5b77566cedfe" xlink:to="loc_lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug_17795d9c-6b07-45bc-8b5d-38c1620e2314" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_ca158f67-eeca-4529-9716-8669baa88624" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_b7c49bf1-ef97-4efe-9d74-5b77566cedfe" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_ca158f67-eeca-4529-9716-8669baa88624" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_b8a855f7-982a-4a24-b1bd-22119855725c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_b7c49bf1-ef97-4efe-9d74-5b77566cedfe" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_b8a855f7-982a-4a24-b1bd-22119855725c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_9ac699b6-0953-4fd2-bca1-b732f80b7635" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_b7c49bf1-ef97-4efe-9d74-5b77566cedfe" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_9ac699b6-0953-4fd2-bca1-b732f80b7635" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_5beecb00-bfcf-4e46-9c9d-c666984fd621" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_b7c49bf1-ef97-4efe-9d74-5b77566cedfe" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_5beecb00-bfcf-4e46-9c9d-c666984fd621" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_25d13c2f-bf00-4d07-80fb-8f5515a45930" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_b7c49bf1-ef97-4efe-9d74-5b77566cedfe" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_25d13c2f-bf00-4d07-80fb-8f5515a45930" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_8a30a100-7d06-4543-b869-a60317b74a46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_b7c49bf1-ef97-4efe-9d74-5b77566cedfe" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_8a30a100-7d06-4543-b869-a60317b74a46" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_511d3762-1f54-488d-8d7f-4f63da917f6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_b7c49bf1-ef97-4efe-9d74-5b77566cedfe" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_511d3762-1f54-488d-8d7f-4f63da917f6b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_06894330-6036-4f95-9ae2-69db50a41888" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_b7c49bf1-ef97-4efe-9d74-5b77566cedfe" xlink:to="loc_us-gaap_DeferredTaxLiabilities_06894330-6036-4f95-9ae2-69db50a41888" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_c4a70970-c976-4ea7-a47d-f421c82e58f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_b7c49bf1-ef97-4efe-9d74-5b77566cedfe" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_c4a70970-c976-4ea7-a47d-f421c82e58f7" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2020FederalNOLIncrease_21e6e40e-56c9-4912-8d08-f33ee9b9ef7f" xlink:href="lxrx-20221231.xsd#lxrx_A2020FederalNOLIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_b7c49bf1-ef97-4efe-9d74-5b77566cedfe" xlink:to="loc_lxrx_A2020FederalNOLIncrease_21e6e40e-56c9-4912-8d08-f33ee9b9ef7f" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DecreaseInNOLs_e1678b85-bd42-4de1-ae06-90e7cbec129c" xlink:href="lxrx-20221231.xsd#lxrx_DecreaseInNOLs"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_b7c49bf1-ef97-4efe-9d74-5b77566cedfe" xlink:to="loc_lxrx_DecreaseInNOLs_e1678b85-bd42-4de1-ae06-90e7cbec129c" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_RDTaxCreditDecrease_ce2a5d03-8202-44ba-8334-e8920ce6b205" xlink:href="lxrx-20221231.xsd#lxrx_RDTaxCreditDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_b7c49bf1-ef97-4efe-9d74-5b77566cedfe" xlink:to="loc_lxrx_RDTaxCreditDecrease_ce2a5d03-8202-44ba-8334-e8920ce6b205" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DeferredTaxAssetsSection163j_LXRX_1fd55078-c858-4d89-9555-55ec96b03361" xlink:href="lxrx-20221231.xsd#lxrx_DeferredTaxAssetsSection163j_LXRX"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_b7c49bf1-ef97-4efe-9d74-5b77566cedfe" xlink:to="loc_lxrx_DeferredTaxAssetsSection163j_LXRX_1fd55078-c858-4d89-9555-55ec96b03361" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_b05fc680-c454-40d3-9b74-97f7a9d6e4e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_b7c49bf1-ef97-4efe-9d74-5b77566cedfe" xlink:to="loc_us-gaap_OperatingLossCarryforwards_b05fc680-c454-40d3-9b74-97f7a9d6e4e6" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_fe07a1af-c952-415e-93b2-5f3f4e9cf620" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_b7c49bf1-ef97-4efe-9d74-5b77566cedfe" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_fe07a1af-c952-415e-93b2-5f3f4e9cf620" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalIncomeTaxNoteTable_fccdf682-e62a-42f2-aedc-f3fca9f5196c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalIncomeTaxNoteTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_b7c49bf1-ef97-4efe-9d74-5b77566cedfe" xlink:to="loc_us-gaap_FederalIncomeTaxNoteTable_fccdf682-e62a-42f2-aedc-f3fca9f5196c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_629d7120-c653-4268-addb-9c2778930c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FederalIncomeTaxNoteTable_fccdf682-e62a-42f2-aedc-f3fca9f5196c" xlink:to="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_629d7120-c653-4268-addb-9c2778930c4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetDomain_629d7120-c653-4268-addb-9c2778930c4b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_629d7120-c653-4268-addb-9c2778930c4b" xlink:to="loc_us-gaap_DeferredTaxAssetDomain_629d7120-c653-4268-addb-9c2778930c4b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetDomain_7aedfb2e-6bcf-4fcb-b22d-cff845944d68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_629d7120-c653-4268-addb-9c2778930c4b" xlink:to="loc_us-gaap_DeferredTaxAssetDomain_7aedfb2e-6bcf-4fcb-b22d-cff845944d68" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/IncomeTaxesDetails2" xlink:type="simple" xlink:href="lxrx-20221231.xsd#IncomeTaxesDetails2"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/IncomeTaxesDetails2" xlink:type="extended" id="i0084d412679547ceb8a6882ed646362f_IncomeTaxesDetails2">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems_4bbcc5c7-869c-4bd3-a003-3e38a210c8fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon_26c09425-a714-446b-9cfc-3d118e6ac43f" xlink:href="lxrx-20221231.xsd#lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems_4bbcc5c7-869c-4bd3-a003-3e38a210c8fd" xlink:to="loc_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon_26c09425-a714-446b-9cfc-3d118e6ac43f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_7d960bfb-e9d9-42dc-8fa3-ee9f2ae91b18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems_4bbcc5c7-869c-4bd3-a003-3e38a210c8fd" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_7d960bfb-e9d9-42dc-8fa3-ee9f2ae91b18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalIncomeTaxNoteTable_3e8d748a-bbd4-41ad-95e7-db5199d98d40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalIncomeTaxNoteTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems_4bbcc5c7-869c-4bd3-a003-3e38a210c8fd" xlink:to="loc_us-gaap_FederalIncomeTaxNoteTable_3e8d748a-bbd4-41ad-95e7-db5199d98d40" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_541f1b23-8bd1-480f-8c82-7110e53028dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FederalIncomeTaxNoteTable_3e8d748a-bbd4-41ad-95e7-db5199d98d40" xlink:to="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_541f1b23-8bd1-480f-8c82-7110e53028dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetDomain_541f1b23-8bd1-480f-8c82-7110e53028dc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_541f1b23-8bd1-480f-8c82-7110e53028dc" xlink:to="loc_us-gaap_DeferredTaxAssetDomain_541f1b23-8bd1-480f-8c82-7110e53028dc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetDomain_052dd116-b65c-4fa5-8314-0be9042611e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_541f1b23-8bd1-480f-8c82-7110e53028dc" xlink:to="loc_us-gaap_DeferredTaxAssetDomain_052dd116-b65c-4fa5-8314-0be9042611e8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligationsNarrativeDetails" xlink:type="simple" xlink:href="lxrx-20221231.xsd#DebtObligationsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/DebtObligationsNarrativeDetails" xlink:type="extended" id="ifc5c2fce5ac64f25ac2856345159259b_DebtObligationsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_0359dc68-3464-4eba-a98a-1438862f43d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_0359dc68-3464-4eba-a98a-1438862f43d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage_bc58fc79-a4e1-4e3f-996b-b0a9f6163756" xlink:href="lxrx-20221231.xsd#lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage_bc58fc79-a4e1-4e3f-996b-b0a9f6163756" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_748e6974-a25a-473c-9d5c-52f5634f9095" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_748e6974-a25a-473c-9d5c-52f5634f9095" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_84e34505-478c-4143-bdac-c8910224189d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_84e34505-478c-4143-bdac-c8910224189d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DebtInstrumentRepurchasePercentage_0ff5a473-78fa-4953-944b-798a3be75452" xlink:href="lxrx-20221231.xsd#lxrx_DebtInstrumentRepurchasePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_DebtInstrumentRepurchasePercentage_0ff5a473-78fa-4953-944b-798a3be75452" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_357ce453-71a9-43f4-9573-ae9997b53cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_357ce453-71a9-43f4-9573-ae9997b53cdf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_cf975795-5df1-464e-9a96-a021f512fad4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_us-gaap_DebtInstrumentTerm_cf975795-5df1-464e-9a96-a021f512fad4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_a8ee886c-67b9-4335-8cfd-f0df8df80ea6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_a8ee886c-67b9-4335-8cfd-f0df8df80ea6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_9ec20030-b93f-4c93-b388-b12a6d0bb9d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_us-gaap_DebtInstrumentFairValue_9ec20030-b93f-4c93-b388-b12a6d0bb9d4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_101fd7bd-be1f-4bb9-9667-70ba77430b0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_101fd7bd-be1f-4bb9-9667-70ba77430b0a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_828dec1a-1851-4294-a07d-786f95bc18f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_828dec1a-1851-4294-a07d-786f95bc18f3" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_15e1e589-81a4-4cca-b5ca-81ced38a8a75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_15e1e589-81a4-4cca-b5ca-81ced38a8a75" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageLoansOnRealEstate_8406ed8b-a5af-4895-916c-2c83d5d5d033" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MortgageLoansOnRealEstate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_us-gaap_MortgageLoansOnRealEstate_8406ed8b-a5af-4895-916c-2c83d5d5d033" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_78dbcf73-477d-493e-9c97-6693e143f0bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_78dbcf73-477d-493e-9c97-6693e143f0bc" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_9a80617b-7c09-412a-aa87-e73019bec04c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_9a80617b-7c09-412a-aa87-e73019bec04c" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_80611284-1a00-47b7-9187-71d6b02bcff3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_us-gaap_ConvertibleDebt_80611284-1a00-47b7-9187-71d6b02bcff3" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchangeTotalCashConsideration_41e1ba01-ccab-4d52-b410-5e8b94898696" xlink:href="lxrx-20221231.xsd#lxrx_ConvertibleDebtExchangeTotalCashConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_ConvertibleDebtExchangeTotalCashConsideration_41e1ba01-ccab-4d52-b410-5e8b94898696" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2020ConvertibleDebtExchangeSharePaymentTotal_6e324f46-2d04-4485-831d-04940bb15b57" xlink:href="lxrx-20221231.xsd#lxrx_A2020ConvertibleDebtExchangeSharePaymentTotal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_A2020ConvertibleDebtExchangeSharePaymentTotal_6e324f46-2d04-4485-831d-04940bb15b57" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2020ConvertibleDebtExchangePercentageOfPrincipal_1b8beeb3-277c-41e4-b242-b622ca67858e" xlink:href="lxrx-20221231.xsd#lxrx_A2020ConvertibleDebtExchangePercentageOfPrincipal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_A2020ConvertibleDebtExchangePercentageOfPrincipal_1b8beeb3-277c-41e4-b242-b622ca67858e" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2020ConvertibleDebtExchangeAccruedInterest_f7647928-151c-4d5d-9538-bcc70362261a" xlink:href="lxrx-20221231.xsd#lxrx_A2020ConvertibleDebtExchangeAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_A2020ConvertibleDebtExchangeAccruedInterest_f7647928-151c-4d5d-9538-bcc70362261a" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_PrincipalAmountOfConvertibleNotes_35a6a473-6efb-41f1-9996-00c9634d930e" xlink:href="lxrx-20221231.xsd#lxrx_PrincipalAmountOfConvertibleNotes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_PrincipalAmountOfConvertibleNotes_35a6a473-6efb-41f1-9996-00c9634d930e" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchange_b1937d6b-166d-497a-b777-31a38cee7dda" xlink:href="lxrx-20221231.xsd#lxrx_ConvertibleDebtExchange"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_ConvertibleDebtExchange_b1937d6b-166d-497a-b777-31a38cee7dda" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX_fd42d7a8-b6ea-4915-8046-4f547dad1a3f" xlink:href="lxrx-20221231.xsd#lxrx_MortgageDebtInterestRate_Base_Revere_LXRX"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX_fd42d7a8-b6ea-4915-8046-4f547dad1a3f" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX_e7b3fbf2-e55b-4182-9d1e-fd937afc14cd" xlink:href="lxrx-20221231.xsd#lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX_e7b3fbf2-e55b-4182-9d1e-fd937afc14cd" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtInstrument_Revere_LXRX_ddd05c07-4be2-49d9-9004-57e2bb644931" xlink:href="lxrx-20221231.xsd#lxrx_MortgageDebtInstrument_Revere_LXRX"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_MortgageDebtInstrument_Revere_LXRX_ddd05c07-4be2-49d9-9004-57e2bb644931" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtBalloonPayment_LXRX_61825986-84ee-4023-9058-15b000a4055f" xlink:href="lxrx-20221231.xsd#lxrx_MortgageDebtBalloonPayment_LXRX"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_MortgageDebtBalloonPayment_LXRX_61825986-84ee-4023-9058-15b000a4055f" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_9ae4f65b-74f7-4941-9611-b4f1934c588a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_9ae4f65b-74f7-4941-9611-b4f1934c588a" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanAWarrantExercisePrice_8ca60f7c-cd5e-43a2-83a1-3e6d36f8336c" xlink:href="lxrx-20221231.xsd#lxrx_TermLoanAWarrantExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_TermLoanAWarrantExercisePrice_8ca60f7c-cd5e-43a2-83a1-3e6d36f8336c" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubordinatedBorrowingInterestRate_8bd3529e-9a11-45d6-9b8b-9994336ee7f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubordinatedBorrowingInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_us-gaap_SubordinatedBorrowingInterestRate_8bd3529e-9a11-45d6-9b8b-9994336ee7f8" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanDWarrant_421d35a6-a5b4-4068-ad6b-ea0122a28dc0" xlink:href="lxrx-20221231.xsd#lxrx_TermLoanDWarrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_TermLoanDWarrant_421d35a6-a5b4-4068-ad6b-ea0122a28dc0" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanAFinalPayment_b50d59d7-42d4-4fd5-9cc3-46c620524826" xlink:href="lxrx-20221231.xsd#lxrx_TermLoanAFinalPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_TermLoanAFinalPayment_b50d59d7-42d4-4fd5-9cc3-46c620524826" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FinalPaymentWithExtention_8f110b8e-c584-4207-8e3d-3573306eb9e3" xlink:href="lxrx-20221231.xsd#lxrx_FinalPaymentWithExtention"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_FinalPaymentWithExtention_8f110b8e-c584-4207-8e3d-3573306eb9e3" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FinalPaymentWithNoExtention_89a07abd-8726-4eaa-8901-c0841125ea60" xlink:href="lxrx-20221231.xsd#lxrx_FinalPaymentWithNoExtention"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_FinalPaymentWithNoExtention_89a07abd-8726-4eaa-8901-c0841125ea60" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanADebtIssuanceCosts_02a1e7e2-4f51-46c9-9d58-19b1e02ddd71" xlink:href="lxrx-20221231.xsd#lxrx_TermLoanADebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_TermLoanADebtIssuanceCosts_02a1e7e2-4f51-46c9-9d58-19b1e02ddd71" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OxfordFacilityFee_bda89198-e452-4808-a451-3bab9844e4ef" xlink:href="lxrx-20221231.xsd#lxrx_OxfordFacilityFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_OxfordFacilityFee_bda89198-e452-4808-a451-3bab9844e4ef" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanANetCashReceipt_139359a0-84e6-4e27-a6a1-3668c06cac58" xlink:href="lxrx-20221231.xsd#lxrx_TermLoanANetCashReceipt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_TermLoanANetCashReceipt_139359a0-84e6-4e27-a6a1-3668c06cac58" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_11d3e722-3072-4748-aa2b-125849f01a29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_11d3e722-3072-4748-aa2b-125849f01a29" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_b7d653b3-3fa9-4b88-9ca5-2b821c9fe955" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_us-gaap_InterestExpense_b7d653b3-3fa9-4b88-9ca5-2b821c9fe955" xlink:type="arc" order="37"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanADebtDiscount_287e794c-0c50-4ac3-82a1-50f81d45c963" xlink:href="lxrx-20221231.xsd#lxrx_TermLoanADebtDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_TermLoanADebtDiscount_287e794c-0c50-4ac3-82a1-50f81d45c963" xlink:type="arc" order="38"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanCWarrant_43231ce7-89f0-4605-82b6-86366ea7eab2" xlink:href="lxrx-20221231.xsd#lxrx_TermLoanCWarrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_TermLoanCWarrant_43231ce7-89f0-4605-82b6-86366ea7eab2" xlink:type="arc" order="39"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanAWarrantsNumber_9064f285-2456-4351-af11-196e825717cb" xlink:href="lxrx-20221231.xsd#lxrx_TermLoanAWarrantsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_TermLoanAWarrantsNumber_9064f285-2456-4351-af11-196e825717cb" xlink:type="arc" order="40"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanABWarrant_3fd23613-de92-4fbb-8040-0fe4a661caf9" xlink:href="lxrx-20221231.xsd#lxrx_TermLoanABWarrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_TermLoanABWarrant_3fd23613-de92-4fbb-8040-0fe4a661caf9" xlink:type="arc" order="41"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanB_93bc7c20-d0d7-45e4-8b34-4b9154bcd937" xlink:href="lxrx-20221231.xsd#lxrx_TermLoanB"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_TermLoanB_93bc7c20-d0d7-45e4-8b34-4b9154bcd937" xlink:type="arc" order="42"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2026OxfordPrincipalPayments_370b34ab-63da-4685-862f-92e508a22e84" xlink:href="lxrx-20221231.xsd#lxrx_A2026OxfordPrincipalPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_A2026OxfordPrincipalPayments_370b34ab-63da-4685-862f-92e508a22e84" xlink:type="arc" order="43"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OxfordLoanFacility_fb824185-6e28-48b6-b526-f0c289fe4d68" xlink:href="lxrx-20221231.xsd#lxrx_OxfordLoanFacility"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_OxfordLoanFacility_fb824185-6e28-48b6-b526-f0c289fe4d68" xlink:type="arc" order="44"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OxfordAmendmentFee_b1a16606-5e0f-4d0e-97ba-495ce01f6188" xlink:href="lxrx-20221231.xsd#lxrx_OxfordAmendmentFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_OxfordAmendmentFee_b1a16606-5e0f-4d0e-97ba-495ce01f6188" xlink:type="arc" order="45"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanA_27cbd539-e6b7-45c5-afe9-4273171a6cc6" xlink:href="lxrx-20221231.xsd#lxrx_TermLoanA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_TermLoanA_27cbd539-e6b7-45c5-afe9-4273171a6cc6" xlink:type="arc" order="46"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanC_17353012-288c-4f14-b0c2-98cc76fdd255" xlink:href="lxrx-20221231.xsd#lxrx_TermLoanC"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_TermLoanC_17353012-288c-4f14-b0c2-98cc76fdd255" xlink:type="arc" order="47"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanD_ad90a0c6-e220-4382-82c2-a0f45d2f0ad7" xlink:href="lxrx-20221231.xsd#lxrx_TermLoanD"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_TermLoanD_ad90a0c6-e220-4382-82c2-a0f45d2f0ad7" xlink:type="arc" order="48"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2027OxfordPrincipalPayments_0f3be38a-86cd-475b-a989-89a9c5c071df" xlink:href="lxrx-20221231.xsd#lxrx_A2027OxfordPrincipalPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_A2027OxfordPrincipalPayments_0f3be38a-86cd-475b-a989-89a9c5c071df" xlink:type="arc" order="49"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_be2c07cf-2fc9-44b5-9051-8f28c94547b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_us-gaap_LongTermDebt_be2c07cf-2fc9-44b5-9051-8f28c94547b3" xlink:type="arc" order="50"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndDebtExpense_a4838f9e-b0af-4831-a8f0-33109a00a87b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndDebtExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_us-gaap_InterestAndDebtExpense_a4838f9e-b0af-4831-a8f0-33109a00a87b" xlink:type="arc" order="51"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_e3742a20-6862-40f1-a92f-0d7552dffb25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_e3742a20-6862-40f1-a92f-0d7552dffb25" xlink:type="arc" order="52"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2027OxfordPrincipalPaymentsA_f2551314-4586-4762-87cf-f8e948d2ef0c" xlink:href="lxrx-20221231.xsd#lxrx_A2027OxfordPrincipalPaymentsA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_A2027OxfordPrincipalPaymentsA_f2551314-4586-4762-87cf-f8e948d2ef0c" xlink:type="arc" order="53"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2025OxfordPrincipalPaymentA_c9bd011d-65e9-4ea1-9399-baec82126350" xlink:href="lxrx-20221231.xsd#lxrx_A2025OxfordPrincipalPaymentA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_A2025OxfordPrincipalPaymentA_c9bd011d-65e9-4ea1-9399-baec82126350" xlink:type="arc" order="54"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2025OxfordPrincipalPaymentsB_e2b0755a-fad5-4bad-9b13-4f844f24bf43" xlink:href="lxrx-20221231.xsd#lxrx_A2025OxfordPrincipalPaymentsB"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_A2025OxfordPrincipalPaymentsB_e2b0755a-fad5-4bad-9b13-4f844f24bf43" xlink:type="arc" order="55"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2026OxfordPrincipalPaymentsB_2d052f4d-c629-4c1a-8c4f-6491e97bcaa7" xlink:href="lxrx-20221231.xsd#lxrx_A2026OxfordPrincipalPaymentsB"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_A2026OxfordPrincipalPaymentsB_2d052f4d-c629-4c1a-8c4f-6491e97bcaa7" xlink:type="arc" order="56"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2027OxfordPrincipalPaymentsB_500e05c7-8a3c-42a6-bce8-1d3f15f0906e" xlink:href="lxrx-20221231.xsd#lxrx_A2027OxfordPrincipalPaymentsB"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_A2027OxfordPrincipalPaymentsB_500e05c7-8a3c-42a6-bce8-1d3f15f0906e" xlink:type="arc" order="57"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_ed452f11-2279-48e2-94d6-a310f377e717" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_ed452f11-2279-48e2-94d6-a310f377e717" xlink:type="arc" order="58"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanBNetCashReceipt_b71791b2-da42-4d40-854a-81740688b1db" xlink:href="lxrx-20221231.xsd#lxrx_TermLoanBNetCashReceipt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_TermLoanBNetCashReceipt_b71791b2-da42-4d40-854a-81740688b1db" xlink:type="arc" order="59"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanBDebtDiscount_575127e3-4235-43ec-a880-a6c6d08729ce" xlink:href="lxrx-20221231.xsd#lxrx_TermLoanBDebtDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_TermLoanBDebtDiscount_575127e3-4235-43ec-a880-a6c6d08729ce" xlink:type="arc" order="60"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseInterestBearingLiability_1db8bf6c-efb1-4894-b13f-693f7b342464" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseInterestBearingLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_us-gaap_InterestExpenseInterestBearingLiability_1db8bf6c-efb1-4894-b13f-693f7b342464" xlink:type="arc" order="61"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_78c53c5c-db23-407c-b939-3ace89adc561" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_us-gaap_DebtInstrumentTable_78c53c5c-db23-407c-b939-3ace89adc561" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_8b83fbe9-53d7-468b-a81c-3c4ddb085215" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_78c53c5c-db23-407c-b939-3ace89adc561" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_8b83fbe9-53d7-468b-a81c-3c4ddb085215" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_8b83fbe9-53d7-468b-a81c-3c4ddb085215_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8b83fbe9-53d7-468b-a81c-3c4ddb085215" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_8b83fbe9-53d7-468b-a81c-3c4ddb085215_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a30fe2f7-2347-46fc-873c-326ccbdffc88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8b83fbe9-53d7-468b-a81c-3c4ddb085215" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a30fe2f7-2347-46fc-873c-326ccbdffc88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c1d69617-2f56-4eb2-9e75-13a203936be6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_78c53c5c-db23-407c-b939-3ace89adc561" xlink:to="loc_us-gaap_DebtInstrumentAxis_c1d69617-2f56-4eb2-9e75-13a203936be6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c1d69617-2f56-4eb2-9e75-13a203936be6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_c1d69617-2f56-4eb2-9e75-13a203936be6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c1d69617-2f56-4eb2-9e75-13a203936be6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c358bf82-d1d0-40b4-a59d-f8bb11e332a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_c1d69617-2f56-4eb2-9e75-13a203936be6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c358bf82-d1d0-40b4-a59d-f8bb11e332a5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="lxrx-20221231.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended" id="iee92815a5faa4abea9d80618b8a81017_CommitmentsandContingenciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_be12f698-33fa-43da-ae1d-a2fd10ebc2af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DeferredCompensationArrangementWithIndividualPaymentPeriod_13fffa46-7619-41ee-a152-2c5c95e6f71d" xlink:href="lxrx-20221231.xsd#lxrx_DeferredCompensationArrangementWithIndividualPaymentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_be12f698-33fa-43da-ae1d-a2fd10ebc2af" xlink:to="loc_lxrx_DeferredCompensationArrangementWithIndividualPaymentPeriod_13fffa46-7619-41ee-a152-2c5c95e6f71d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_LexiconBorrowingRate_da44e518-4210-4f64-b350-22c16dc18e7b" xlink:href="lxrx-20221231.xsd#lxrx_LexiconBorrowingRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_be12f698-33fa-43da-ae1d-a2fd10ebc2af" xlink:to="loc_lxrx_LexiconBorrowingRate_da44e518-4210-4f64-b350-22c16dc18e7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Lxrx_Sanofiterminationcashpayment_bf96b7dc-c43b-4d8c-a902-0d34d2903b9a" xlink:href="lxrx-20221231.xsd#lxrx_Lxrx_Sanofiterminationcashpayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_be12f698-33fa-43da-ae1d-a2fd10ebc2af" xlink:to="loc_lxrx_Lxrx_Sanofiterminationcashpayment_bf96b7dc-c43b-4d8c-a902-0d34d2903b9a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_173c2343-6f7c-494c-a03a-ff75f558fb52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_be12f698-33fa-43da-ae1d-a2fd10ebc2af" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_173c2343-6f7c-494c-a03a-ff75f558fb52" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets_e977f1bb-6c9a-445f-b7ba-6325906dbd6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_be12f698-33fa-43da-ae1d-a2fd10ebc2af" xlink:to="loc_us-gaap_OtherAssets_e977f1bb-6c9a-445f-b7ba-6325906dbd6b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense_f69a843e-e8d4-4597-b1c3-84f06a4f7b85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_be12f698-33fa-43da-ae1d-a2fd10ebc2af" xlink:to="loc_us-gaap_LeaseAndRentalExpense_f69a843e-e8d4-4597-b1c3-84f06a4f7b85" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_1ab46492-36eb-44eb-aace-518053e14416" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_be12f698-33fa-43da-ae1d-a2fd10ebc2af" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_1ab46492-36eb-44eb-aace-518053e14416" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_e85bd5f2-8fc7-40ec-846f-56e219092cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_be12f698-33fa-43da-ae1d-a2fd10ebc2af" xlink:to="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_e85bd5f2-8fc7-40ec-846f-56e219092cc5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_00c64ba7-4a1a-4061-a577-6408f7169885" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_e85bd5f2-8fc7-40ec-846f-56e219092cc5" xlink:to="loc_srt_RangeAxis_00c64ba7-4a1a-4061-a577-6408f7169885" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_00c64ba7-4a1a-4061-a577-6408f7169885_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_00c64ba7-4a1a-4061-a577-6408f7169885" xlink:to="loc_srt_RangeMember_00c64ba7-4a1a-4061-a577-6408f7169885_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_140ac65e-bc1b-478b-aacf-fc394eef4ead" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_00c64ba7-4a1a-4061-a577-6408f7169885" xlink:to="loc_srt_RangeMember_140ac65e-bc1b-478b-aacf-fc394eef4ead" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_614bc33f-a0de-4563-9d1c-daf5561db0ba" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_140ac65e-bc1b-478b-aacf-fc394eef4ead" xlink:to="loc_srt_MinimumMember_614bc33f-a0de-4563-9d1c-daf5561db0ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_eb8bb29a-5da7-4d46-af1c-b881af89c114" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_140ac65e-bc1b-478b-aacf-fc394eef4ead" xlink:to="loc_srt_MaximumMember_eb8bb29a-5da7-4d46-af1c-b881af89c114" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_dad263ff-6922-4993-82f0-5de71c585033" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_e85bd5f2-8fc7-40ec-846f-56e219092cc5" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_dad263ff-6922-4993-82f0-5de71c585033" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_dad263ff-6922-4993-82f0-5de71c585033_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_dad263ff-6922-4993-82f0-5de71c585033" xlink:to="loc_us-gaap_ReceivableTypeDomain_dad263ff-6922-4993-82f0-5de71c585033_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_81b3df7f-df35-43cc-a456-a88aebccf901" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_dad263ff-6922-4993-82f0-5de71c585033" xlink:to="loc_us-gaap_ReceivableTypeDomain_81b3df7f-df35-43cc-a456-a88aebccf901" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_3d6f2bcb-44ff-4fe3-bcbb-6a46d42848ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_81b3df7f-df35-43cc-a456-a88aebccf901" xlink:to="loc_us-gaap_AccountsReceivableMember_3d6f2bcb-44ff-4fe3-bcbb-6a46d42848ff" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CommitmentsandContingenciesDetails2" xlink:type="simple" xlink:href="lxrx-20221231.xsd#CommitmentsandContingenciesDetails2"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/CommitmentsandContingenciesDetails2" xlink:type="extended" id="icfa84633a9574abc84183197856e737f_CommitmentsandContingenciesDetails2">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_8775c00c-a0d4-4e0d-be59-fd68a7b7a2ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense_09b7a080-c3d0-4c8f-96c9-8278f249c0fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_8775c00c-a0d4-4e0d-be59-fd68a7b7a2ee" xlink:to="loc_us-gaap_LeaseAndRentalExpense_09b7a080-c3d0-4c8f-96c9-8278f249c0fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_13293aa1-15e0-4230-874f-e463bd7f1849" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_8775c00c-a0d4-4e0d-be59-fd68a7b7a2ee" xlink:to="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_13293aa1-15e0-4230-874f-e463bd7f1849" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="lxrx-20221231.xsd#CommitmentsandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/CommitmentsandContingenciesDetails" xlink:type="extended" id="iac0003303b884d8f92ac1dc5b5323c2c_CommitmentsandContingenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_3242428b-b8d9-45c9-b954-1118267e2519" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_1ba09402-5e90-4608-8c11-03fd5af813f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_3242428b-b8d9-45c9-b954-1118267e2519" xlink:to="loc_us-gaap_OperatingLeaseExpense_1ba09402-5e90-4608-8c11-03fd5af813f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRent_f8ea218d-8161-4ba6-80a4-235ea704d03b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_3242428b-b8d9-45c9-b954-1118267e2519" xlink:to="loc_us-gaap_PaymentsForRent_f8ea218d-8161-4ba6-80a4-235ea704d03b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_4dba5223-ad4f-4d92-8577-193c9cb8d79c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_3242428b-b8d9-45c9-b954-1118267e2519" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_4dba5223-ad4f-4d92-8577-193c9cb8d79c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_64517ca4-02a3-4b8c-901a-22ecde91cd78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_3242428b-b8d9-45c9-b954-1118267e2519" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_64517ca4-02a3-4b8c-901a-22ecde91cd78" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_c4ab4fca-1700-4339-94ce-ae5277672ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_3242428b-b8d9-45c9-b954-1118267e2519" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_c4ab4fca-1700-4339-94ce-ae5277672ea3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_6b433019-1f03-4da6-841d-29558324b6ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_3242428b-b8d9-45c9-b954-1118267e2519" xlink:to="loc_us-gaap_OtherCommitmentsTable_6b433019-1f03-4da6-841d-29558324b6ec" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_bd3f3a62-7fac-4ce1-b007-3f11f2be035f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_6b433019-1f03-4da6-841d-29558324b6ec" xlink:to="loc_us-gaap_OtherCommitmentsAxis_bd3f3a62-7fac-4ce1-b007-3f11f2be035f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_bd3f3a62-7fac-4ce1-b007-3f11f2be035f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherCommitmentsAxis_bd3f3a62-7fac-4ce1-b007-3f11f2be035f" xlink:to="loc_us-gaap_OtherCommitmentsDomain_bd3f3a62-7fac-4ce1-b007-3f11f2be035f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_37526d88-b4ba-41fa-8ab5-e6cbeae7ec1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherCommitmentsAxis_bd3f3a62-7fac-4ce1-b007-3f11f2be035f" xlink:to="loc_us-gaap_OtherCommitmentsDomain_37526d88-b4ba-41fa-8ab5-e6cbeae7ec1f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails" xlink:type="simple" xlink:href="lxrx-20221231.xsd#EquityIncentiveAwardsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails" xlink:type="extended" id="i37154af2d7e040f19a2293e0c7a810d5_EquityIncentiveAwardsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8e11a2f-08ba-4185-97be-ca1a4f53e2a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock_825cf371-51b9-4d9c-b43f-0065aef6bd7f" xlink:href="lxrx-20221231.xsd#lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8e11a2f-08ba-4185-97be-ca1a4f53e2a7" xlink:to="loc_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock_825cf371-51b9-4d9c-b43f-0065aef6bd7f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_4511a75a-948e-4e73-908c-84b200babf1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8e11a2f-08ba-4185-97be-ca1a4f53e2a7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_4511a75a-948e-4e73-908c-84b200babf1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_0efb40bd-f33a-4d7e-be2d-76c860f98f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8e11a2f-08ba-4185-97be-ca1a4f53e2a7" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_0efb40bd-f33a-4d7e-be2d-76c860f98f9a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan_d754b8f4-7e96-4092-aa7d-711feb16381f" xlink:href="lxrx-20221231.xsd#lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8e11a2f-08ba-4185-97be-ca1a4f53e2a7" xlink:to="loc_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan_d754b8f4-7e96-4092-aa7d-711feb16381f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OptionsOutstandingEquityIncentivePlan_15d7f614-0f28-4b7c-bf60-9b3e7179b0cf" xlink:href="lxrx-20221231.xsd#lxrx_OptionsOutstandingEquityIncentivePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8e11a2f-08ba-4185-97be-ca1a4f53e2a7" xlink:to="loc_lxrx_OptionsOutstandingEquityIncentivePlan_15d7f614-0f28-4b7c-bf60-9b3e7179b0cf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan_75db9a3d-6d8a-4739-8f47-fbe377d025ba" xlink:href="lxrx-20221231.xsd#lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8e11a2f-08ba-4185-97be-ca1a4f53e2a7" xlink:to="loc_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan_75db9a3d-6d8a-4739-8f47-fbe377d025ba" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_StockOptionsExercisedEquityIncentivePlan_46a8d5fb-ddf4-4117-86f4-5b3b4ba45a87" xlink:href="lxrx-20221231.xsd#lxrx_StockOptionsExercisedEquityIncentivePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8e11a2f-08ba-4185-97be-ca1a4f53e2a7" xlink:to="loc_lxrx_StockOptionsExercisedEquityIncentivePlan_46a8d5fb-ddf4-4117-86f4-5b3b4ba45a87" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan_9d7f3457-edc4-4882-96ab-6eef4503e297" xlink:href="lxrx-20221231.xsd#lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8e11a2f-08ba-4185-97be-ca1a4f53e2a7" xlink:to="loc_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan_9d7f3457-edc4-4882-96ab-6eef4503e297" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan_7e9870e2-f33f-4825-9a2d-b96ae8226370" xlink:href="lxrx-20221231.xsd#lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8e11a2f-08ba-4185-97be-ca1a4f53e2a7" xlink:to="loc_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan_7e9870e2-f33f-4825-9a2d-b96ae8226370" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Totalvalueofsharesbynonemployeeinayear_60b55c96-fa5a-459b-ad46-df9557211d4c" xlink:href="lxrx-20221231.xsd#lxrx_Totalvalueofsharesbynonemployeeinayear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8e11a2f-08ba-4185-97be-ca1a4f53e2a7" xlink:to="loc_lxrx_Totalvalueofsharesbynonemployeeinayear_60b55c96-fa5a-459b-ad46-df9557211d4c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan_fd07b7e6-172b-4c45-b317-836fb9c8e9a5" xlink:href="lxrx-20221231.xsd#lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8e11a2f-08ba-4185-97be-ca1a4f53e2a7" xlink:to="loc_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan_fd07b7e6-172b-4c45-b317-836fb9c8e9a5" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan_381313ec-041f-4b58-8362-64c8c5eafa93" xlink:href="lxrx-20221231.xsd#lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8e11a2f-08ba-4185-97be-ca1a4f53e2a7" xlink:to="loc_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan_381313ec-041f-4b58-8362-64c8c5eafa93" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan_36ab9a22-6cfa-4b50-a61a-b5d98268ec03" xlink:href="lxrx-20221231.xsd#lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8e11a2f-08ba-4185-97be-ca1a4f53e2a7" xlink:to="loc_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan_36ab9a22-6cfa-4b50-a61a-b5d98268ec03" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan_feac0726-b292-4768-a351-557091762733" xlink:href="lxrx-20221231.xsd#lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8e11a2f-08ba-4185-97be-ca1a4f53e2a7" xlink:to="loc_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan_feac0726-b292-4768-a351-557091762733" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_e7e816f9-b9ff-47c0-bd8a-dcedfafecbfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8e11a2f-08ba-4185-97be-ca1a4f53e2a7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_e7e816f9-b9ff-47c0-bd8a-dcedfafecbfd" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2d204e11-bbfa-4d3e-881e-fd93ccba9320" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8e11a2f-08ba-4185-97be-ca1a4f53e2a7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2d204e11-bbfa-4d3e-881e-fd93ccba9320" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_RestrictedStockUnitsOutstandingNonEmployeeDirectorsEquityIncentivePlan_7e3a8312-f74b-4148-af31-7394a505a874" xlink:href="lxrx-20221231.xsd#lxrx_RestrictedStockUnitsOutstandingNonEmployeeDirectorsEquityIncentivePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8e11a2f-08ba-4185-97be-ca1a4f53e2a7" xlink:to="loc_lxrx_RestrictedStockUnitsOutstandingNonEmployeeDirectorsEquityIncentivePlan_7e3a8312-f74b-4148-af31-7394a505a874" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_96206c94-dfde-43b0-8ecc-e3a34a958570" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8e11a2f-08ba-4185-97be-ca1a4f53e2a7" xlink:to="loc_us-gaap_TreasuryStockValue_96206c94-dfde-43b0-8ecc-e3a34a958570" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCarryingBasis_f8b719a0-c78b-424e-add7-ed4371cffc1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCarryingBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8e11a2f-08ba-4185-97be-ca1a4f53e2a7" xlink:to="loc_us-gaap_TreasuryStockCarryingBasis_f8b719a0-c78b-424e-add7-ed4371cffc1a" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockPreferredValue_c798790d-328a-4c91-bdc6-34dd5f239114" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockPreferredValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8e11a2f-08ba-4185-97be-ca1a4f53e2a7" xlink:to="loc_us-gaap_TreasuryStockPreferredValue_c798790d-328a-4c91-bdc6-34dd5f239114" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f27d9a80-b360-4bde-bcf4-751d724766ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8e11a2f-08ba-4185-97be-ca1a4f53e2a7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f27d9a80-b360-4bde-bcf4-751d724766ba" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a98e8532-bd25-4453-8d98-d9e42116b7f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f27d9a80-b360-4bde-bcf4-751d724766ba" xlink:to="loc_us-gaap_AwardTypeAxis_a98e8532-bd25-4453-8d98-d9e42116b7f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a98e8532-bd25-4453-8d98-d9e42116b7f7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_a98e8532-bd25-4453-8d98-d9e42116b7f7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a98e8532-bd25-4453-8d98-d9e42116b7f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_280cf464-ce98-4162-ab5b-ce9f44c9913d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_a98e8532-bd25-4453-8d98-d9e42116b7f7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_280cf464-ce98-4162-ab5b-ce9f44c9913d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_68a9b8df-920a-4b3b-a342-ee2ad70dffe6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_280cf464-ce98-4162-ab5b-ce9f44c9913d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_68a9b8df-920a-4b3b-a342-ee2ad70dffe6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_226f84d6-2724-4409-8eb4-d53a22927bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_280cf464-ce98-4162-ab5b-ce9f44c9913d" xlink:to="loc_us-gaap_RestrictedStockMember_226f84d6-2724-4409-8eb4-d53a22927bf7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9cb8c437-ecc7-495e-8b55-04704b47db54" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f27d9a80-b360-4bde-bcf4-751d724766ba" xlink:to="loc_srt_RangeAxis_9cb8c437-ecc7-495e-8b55-04704b47db54" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9cb8c437-ecc7-495e-8b55-04704b47db54_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9cb8c437-ecc7-495e-8b55-04704b47db54" xlink:to="loc_srt_RangeMember_9cb8c437-ecc7-495e-8b55-04704b47db54_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1d5159f1-59ab-4674-96bf-e34ae568f0ba" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9cb8c437-ecc7-495e-8b55-04704b47db54" xlink:to="loc_srt_RangeMember_1d5159f1-59ab-4674-96bf-e34ae568f0ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_702e0aec-0727-4ddb-a98a-9c2e05d9c982" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1d5159f1-59ab-4674-96bf-e34ae568f0ba" xlink:to="loc_srt_MinimumMember_702e0aec-0727-4ddb-a98a-9c2e05d9c982" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_642b5258-0c48-4a82-865f-3f7f1bb59f3a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1d5159f1-59ab-4674-96bf-e34ae568f0ba" xlink:to="loc_srt_MaximumMember_642b5258-0c48-4a82-865f-3f7f1bb59f3a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2" xlink:type="simple" xlink:href="lxrx-20221231.xsd#EquityIncentiveAwardsDetails2"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2" xlink:type="extended" id="i1cc840b4d3e74d8aac9719271e756336_EquityIncentiveAwardsDetails2">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bddde39-e934-4730-b6e2-313054f86fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_feb3b738-0af3-4361-a3f3-d3747d910087" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bddde39-e934-4730-b6e2-313054f86fb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_feb3b738-0af3-4361-a3f3-d3747d910087" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ab13f6e7-66fc-485a-b9da-a59e753b2799" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bddde39-e934-4730-b6e2-313054f86fb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ab13f6e7-66fc-485a-b9da-a59e753b2799" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5aeedfba-d71f-4879-be56-b68883e93966" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bddde39-e934-4730-b6e2-313054f86fb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5aeedfba-d71f-4879-be56-b68883e93966" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5761f1f2-cf62-4e2e-8ad1-6ff849c15c32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bddde39-e934-4730-b6e2-313054f86fb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5761f1f2-cf62-4e2e-8ad1-6ff849c15c32" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2488bd54-1bc0-4e77-9114-51ddc7e3beb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bddde39-e934-4730-b6e2-313054f86fb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2488bd54-1bc0-4e77-9114-51ddc7e3beb1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_290dabae-a397-45e9-9d5f-1b51ccc354f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bddde39-e934-4730-b6e2-313054f86fb5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_290dabae-a397-45e9-9d5f-1b51ccc354f5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_7ef6a4c2-0474-4f2a-8e0d-71daf490a40a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bddde39-e934-4730-b6e2-313054f86fb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_7ef6a4c2-0474-4f2a-8e0d-71daf490a40a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_cba4799b-adb3-4f52-80ed-e0c18eae373b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bddde39-e934-4730-b6e2-313054f86fb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_cba4799b-adb3-4f52-80ed-e0c18eae373b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_78f58a6d-4d9d-4501-8e68-e7cf3bfb3f1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bddde39-e934-4730-b6e2-313054f86fb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_78f58a6d-4d9d-4501-8e68-e7cf3bfb3f1c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_16197044-226e-4ac2-b93b-f9eb4ffc6acf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bddde39-e934-4730-b6e2-313054f86fb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_16197044-226e-4ac2-b93b-f9eb4ffc6acf" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_53bc51e4-0f43-43bf-a482-934db99be796" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bddde39-e934-4730-b6e2-313054f86fb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_53bc51e4-0f43-43bf-a482-934db99be796" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_5cb21ae4-6c0f-4b34-9f6f-24a80ed6e6c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bddde39-e934-4730-b6e2-313054f86fb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_5cb21ae4-6c0f-4b34-9f6f-24a80ed6e6c9" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_aea615d0-f61e-4ae8-bab4-221805b1b13a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bddde39-e934-4730-b6e2-313054f86fb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_aea615d0-f61e-4ae8-bab4-221805b1b13a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1e3ac405-0e32-43dc-9568-032f730f4a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bddde39-e934-4730-b6e2-313054f86fb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1e3ac405-0e32-43dc-9568-032f730f4a1c" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_7eb48afb-27f3-4fa3-a345-944893f1b25f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bddde39-e934-4730-b6e2-313054f86fb5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_7eb48afb-27f3-4fa3-a345-944893f1b25f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_a045628b-9609-452d-ba6e-b71ffb15231a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bddde39-e934-4730-b6e2-313054f86fb5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_a045628b-9609-452d-ba6e-b71ffb15231a" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_19b59159-f8a2-415a-a267-b74954e36db5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bddde39-e934-4730-b6e2-313054f86fb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_19b59159-f8a2-415a-a267-b74954e36db5" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_42c40733-4ed5-4ec1-a72d-e33369bad4c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bddde39-e934-4730-b6e2-313054f86fb5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_42c40733-4ed5-4ec1-a72d-e33369bad4c1" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18c44579-92f4-406e-af57-a5d3a7314081" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bddde39-e934-4730-b6e2-313054f86fb5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18c44579-92f4-406e-af57-a5d3a7314081" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ff6c4e5c-6115-4030-a384-3e2c420d03bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18c44579-92f4-406e-af57-a5d3a7314081" xlink:to="loc_us-gaap_AwardTypeAxis_ff6c4e5c-6115-4030-a384-3e2c420d03bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ff6c4e5c-6115-4030-a384-3e2c420d03bd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_ff6c4e5c-6115-4030-a384-3e2c420d03bd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ff6c4e5c-6115-4030-a384-3e2c420d03bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3f0efd7a-119a-4a8e-bf0d-213365cb36e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_ff6c4e5c-6115-4030-a384-3e2c420d03bd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3f0efd7a-119a-4a8e-bf0d-213365cb36e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_3dc5369a-a54b-4c7a-99d2-6a03cb2da4d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3f0efd7a-119a-4a8e-bf0d-213365cb36e3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_3dc5369a-a54b-4c7a-99d2-6a03cb2da4d2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3" xlink:type="simple" xlink:href="lxrx-20221231.xsd#EquityIncentiveAwardsDetails3"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3" xlink:type="extended" id="if0269159a04947c494c111d56fdadf06_EquityIncentiveAwardsDetails3">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64d97b46-ebf5-436f-99ea-3ec97804d12f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod_dd111d5e-59d3-436f-ba4e-fb853ebed30c" xlink:href="lxrx-20221231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64d97b46-ebf5-436f-99ea-3ec97804d12f" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod_dd111d5e-59d3-436f-ba4e-fb853ebed30c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue_70eec4e6-94a6-4cd4-9dc9-2e299dccf515" xlink:href="lxrx-20221231.xsd#lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64d97b46-ebf5-436f-99ea-3ec97804d12f" xlink:to="loc_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue_70eec4e6-94a6-4cd4-9dc9-2e299dccf515" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_581ae7d2-b2db-464f-95d5-1bd30feb3936" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64d97b46-ebf5-436f-99ea-3ec97804d12f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_581ae7d2-b2db-464f-95d5-1bd30feb3936" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4d19698c-ce42-4cfe-811e-da8bc5957b4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64d97b46-ebf5-436f-99ea-3ec97804d12f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4d19698c-ce42-4cfe-811e-da8bc5957b4e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_65e1e75b-eb59-4b56-b0ec-fefdf25cb3df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4d19698c-ce42-4cfe-811e-da8bc5957b4e" xlink:to="loc_us-gaap_PlanNameAxis_65e1e75b-eb59-4b56-b0ec-fefdf25cb3df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_65e1e75b-eb59-4b56-b0ec-fefdf25cb3df_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_65e1e75b-eb59-4b56-b0ec-fefdf25cb3df" xlink:to="loc_us-gaap_PlanNameDomain_65e1e75b-eb59-4b56-b0ec-fefdf25cb3df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_cb5b1171-fd74-4178-a2d5-e1470aee98cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_65e1e75b-eb59-4b56-b0ec-fefdf25cb3df" xlink:to="loc_us-gaap_PlanNameDomain_cb5b1171-fd74-4178-a2d5-e1470aee98cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_cc5d6c49-e59e-45ec-b1f5-d03a17581452" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4d19698c-ce42-4cfe-811e-da8bc5957b4e" xlink:to="loc_us-gaap_AwardTypeAxis_cc5d6c49-e59e-45ec-b1f5-d03a17581452" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cc5d6c49-e59e-45ec-b1f5-d03a17581452_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_cc5d6c49-e59e-45ec-b1f5-d03a17581452" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cc5d6c49-e59e-45ec-b1f5-d03a17581452_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7d52d817-0862-4319-98ba-3b395917d5d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_cc5d6c49-e59e-45ec-b1f5-d03a17581452" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7d52d817-0862-4319-98ba-3b395917d5d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_bb16b5f6-3df5-4669-9a4a-1effa4cfed88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4d19698c-ce42-4cfe-811e-da8bc5957b4e" xlink:to="loc_us-gaap_StatementClassOfStockAxis_bb16b5f6-3df5-4669-9a4a-1effa4cfed88" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_bb16b5f6-3df5-4669-9a4a-1effa4cfed88_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_bb16b5f6-3df5-4669-9a4a-1effa4cfed88" xlink:to="loc_us-gaap_ClassOfStockDomain_bb16b5f6-3df5-4669-9a4a-1effa4cfed88_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_0352020d-8408-4223-a8c3-ae53fe14221f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_bb16b5f6-3df5-4669-9a4a-1effa4cfed88" xlink:to="loc_us-gaap_ClassOfStockDomain_0352020d-8408-4223-a8c3-ae53fe14221f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_601b07ca-bdcf-42aa-95c0-6dd89a65acce" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4d19698c-ce42-4cfe-811e-da8bc5957b4e" xlink:to="loc_srt_RangeAxis_601b07ca-bdcf-42aa-95c0-6dd89a65acce" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_601b07ca-bdcf-42aa-95c0-6dd89a65acce_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_601b07ca-bdcf-42aa-95c0-6dd89a65acce" xlink:to="loc_srt_RangeMember_601b07ca-bdcf-42aa-95c0-6dd89a65acce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_34e85db6-a0d4-402d-9958-dcbbcc683e6d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_601b07ca-bdcf-42aa-95c0-6dd89a65acce" xlink:to="loc_srt_RangeMember_34e85db6-a0d4-402d-9958-dcbbcc683e6d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4" xlink:type="simple" xlink:href="lxrx-20221231.xsd#EquityIncentiveAwardsDetails4"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4" xlink:type="extended" id="i96a9cb639a1546859aea56b942a964aa_EquityIncentiveAwardsDetails4">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5bb47aee-2a51-4cb7-b5e6-87723ce10ee8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_917f6537-0b19-4615-b66b-7c4712839b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5bb47aee-2a51-4cb7-b5e6-87723ce10ee8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_917f6537-0b19-4615-b66b-7c4712839b5f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9af4f65a-2a8a-47ab-ba9f-24f27d96ba8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5bb47aee-2a51-4cb7-b5e6-87723ce10ee8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9af4f65a-2a8a-47ab-ba9f-24f27d96ba8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7ca7ebb6-1a45-42b9-ab9a-a8e2214d86ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5bb47aee-2a51-4cb7-b5e6-87723ce10ee8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7ca7ebb6-1a45-42b9-ab9a-a8e2214d86ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9e6b320c-7037-46a8-a8d4-3522fcb6d5ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5bb47aee-2a51-4cb7-b5e6-87723ce10ee8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9e6b320c-7037-46a8-a8d4-3522fcb6d5ff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ae98cf42-82c6-40be-8bfd-ba4d8d850121" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5bb47aee-2a51-4cb7-b5e6-87723ce10ee8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ae98cf42-82c6-40be-8bfd-ba4d8d850121" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_afa7c29c-a993-4b8f-aba6-a4470bcd355d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5bb47aee-2a51-4cb7-b5e6-87723ce10ee8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_afa7c29c-a993-4b8f-aba6-a4470bcd355d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0ac788db-6396-48b1-92ba-cc2789ddc832" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5bb47aee-2a51-4cb7-b5e6-87723ce10ee8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0ac788db-6396-48b1-92ba-cc2789ddc832" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue_ede32df3-d4ba-4588-aee8-df37c70d0659" xlink:href="lxrx-20221231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5bb47aee-2a51-4cb7-b5e6-87723ce10ee8" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue_ede32df3-d4ba-4588-aee8-df37c70d0659" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f478f7a3-c577-42a3-85fa-958b68ea1698" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5bb47aee-2a51-4cb7-b5e6-87723ce10ee8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f478f7a3-c577-42a3-85fa-958b68ea1698" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0b0f239b-7f56-47a9-9e01-028acecde22e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f478f7a3-c577-42a3-85fa-958b68ea1698" xlink:to="loc_us-gaap_AwardTypeAxis_0b0f239b-7f56-47a9-9e01-028acecde22e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0b0f239b-7f56-47a9-9e01-028acecde22e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_0b0f239b-7f56-47a9-9e01-028acecde22e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0b0f239b-7f56-47a9-9e01-028acecde22e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6273c443-10df-47af-a2fb-b3df9b01414b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_0b0f239b-7f56-47a9-9e01-028acecde22e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6273c443-10df-47af-a2fb-b3df9b01414b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_49dffdc0-d705-46ba-974e-0f81080dacab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6273c443-10df-47af-a2fb-b3df9b01414b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_49dffdc0-d705-46ba-974e-0f81080dacab" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails" xlink:type="simple" xlink:href="lxrx-20221231.xsd#CollaborationandLicenseAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails" xlink:type="extended" id="i876549be14b8481cab7f98d714b02fac_CollaborationandLicenseAgreementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_ef2328f9-6c11-4fd0-81ec-ea033dcc3c53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SettlementPaymentFromTermination_5b06b00b-f0f2-4e6e-bcb0-cd4752139037" xlink:href="lxrx-20221231.xsd#lxrx_SettlementPaymentFromTermination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_ef2328f9-6c11-4fd0-81ec-ea033dcc3c53" xlink:to="loc_lxrx_SettlementPaymentFromTermination_5b06b00b-f0f2-4e6e-bcb0-cd4752139037" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalFees_7ee56daf-c898-49b4-8d12-b97890a760db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_ef2328f9-6c11-4fd0-81ec-ea033dcc3c53" xlink:to="loc_us-gaap_LegalFees_7ee56daf-c898-49b4-8d12-b97890a760db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_f5362767-3066-4bb2-9ede-1e70e8b99257" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_ef2328f9-6c11-4fd0-81ec-ea033dcc3c53" xlink:to="loc_us-gaap_SubsequentEventTable_f5362767-3066-4bb2-9ede-1e70e8b99257" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_f77e3908-4ae4-486f-9433-2cfd431f4215" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_f5362767-3066-4bb2-9ede-1e70e8b99257" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_f77e3908-4ae4-486f-9433-2cfd431f4215" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_f77e3908-4ae4-486f-9433-2cfd431f4215_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f77e3908-4ae4-486f-9433-2cfd431f4215" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_f77e3908-4ae4-486f-9433-2cfd431f4215_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2261c940-d78f-449d-b6f0-9da28ce67d16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f77e3908-4ae4-486f-9433-2cfd431f4215" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2261c940-d78f-449d-b6f0-9da28ce67d16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_a20a3b31-9e33-4541-b2b4-85d6104f6acd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_2261c940-d78f-449d-b6f0-9da28ce67d16" xlink:to="loc_us-gaap_SubsequentEventMember_a20a3b31-9e33-4541-b2b4-85d6104f6acd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedQuarterlyFinancialInformationDetails" xlink:type="simple" xlink:href="lxrx-20221231.xsd#SelectedQuarterlyFinancialDataUnauditedQuarterlyFinancialInformationDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedQuarterlyFinancialInformationDetails" xlink:type="extended" id="i73eda501250141f5bb5f1d3a779f4326_SelectedQuarterlyFinancialDataUnauditedQuarterlyFinancialInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems_ede0130d-39b7-48b6-8d58-327870f19cd9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_bbb3d5cf-067e-454d-ab9c-f540353372e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_ede0130d-39b7-48b6-8d58-327870f19cd9" xlink:to="loc_us-gaap_Revenues_bbb3d5cf-067e-454d-ab9c-f540353372e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_86d03593-7e4b-499a-bea1-9cad878f6ccf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_ede0130d-39b7-48b6-8d58-327870f19cd9" xlink:to="loc_us-gaap_OperatingIncomeLoss_86d03593-7e4b-499a-bea1-9cad878f6ccf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5cc836a6-fc05-4ded-b2a2-f7c31d9a596b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_ede0130d-39b7-48b6-8d58-327870f19cd9" xlink:to="loc_us-gaap_NetIncomeLoss_5cc836a6-fc05-4ded-b2a2-f7c31d9a596b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_cbdb6ca1-088f-499a-9cdd-1c5455247734" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_ede0130d-39b7-48b6-8d58-327870f19cd9" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_cbdb6ca1-088f-499a-9cdd-1c5455247734" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b746f979-694f-449c-850a-2ab3cb04ee05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_ede0130d-39b7-48b6-8d58-327870f19cd9" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b746f979-694f-449c-850a-2ab3cb04ee05" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_a13f611a-32ff-45af-950b-f08521ec6d44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_ede0130d-39b7-48b6-8d58-327870f19cd9" xlink:to="loc_us-gaap_EarningsPerShareDiluted_a13f611a-32ff-45af-950b-f08521ec6d44" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_84fbdb0b-e7f5-4eb1-b6dc-fb509a690b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_ede0130d-39b7-48b6-8d58-327870f19cd9" xlink:to="loc_us-gaap_EarningsPerShareBasic_84fbdb0b-e7f5-4eb1-b6dc-fb509a690b5f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable_f7b33525-080f-4295-a971-27b392a7d516" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_ede0130d-39b7-48b6-8d58-327870f19cd9" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTable_f7b33525-080f-4295-a971-27b392a7d516" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_e4998857-0ea8-475c-807c-4aaf9355bb8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_f7b33525-080f-4295-a971-27b392a7d516" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_e4998857-0ea8-475c-807c-4aaf9355bb8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e4998857-0ea8-475c-807c-4aaf9355bb8b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e4998857-0ea8-475c-807c-4aaf9355bb8b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e4998857-0ea8-475c-807c-4aaf9355bb8b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_679221eb-9701-411a-bf4c-e48e0d9d3297" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e4998857-0ea8-475c-807c-4aaf9355bb8b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_679221eb-9701-411a-bf4c-e48e0d9d3297" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/AssetSaleDetails" xlink:type="simple" xlink:href="lxrx-20221231.xsd#AssetSaleDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/AssetSaleDetails" xlink:type="extended" id="ib753c2372730490a9499bd1da70269d3_AssetSaleDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_bea8104e-5ec2-438c-ae31-8bdf5d420ef8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_dde3663b-632f-4fea-811a-9c27af25e0e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bea8104e-5ec2-438c-ae31-8bdf5d420ef8" xlink:to="loc_us-gaap_SeveranceCosts1_dde3663b-632f-4fea-811a-9c27af25e0e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_GainOnSaleOfNonFinancialAssets_f3adca55-4278-4db5-9093-edb7ca054820" xlink:href="lxrx-20221231.xsd#lxrx_GainOnSaleOfNonFinancialAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bea8104e-5ec2-438c-ae31-8bdf5d420ef8" xlink:to="loc_lxrx_GainOnSaleOfNonFinancialAssets_f3adca55-4278-4db5-9093-edb7ca054820" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones_4060659f-533a-411c-b768-a3069d0d6349" xlink:href="lxrx-20221231.xsd#lxrx_TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bea8104e-5ec2-438c-ae31-8bdf5d420ef8" xlink:to="loc_lxrx_TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones_4060659f-533a-411c-b768-a3069d0d6349" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FinalConsiderationIncludingAmountsReleasedToSettle_84223f6f-d718-4aff-a285-3adf5c81d683" xlink:href="lxrx-20221231.xsd#lxrx_FinalConsiderationIncludingAmountsReleasedToSettle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bea8104e-5ec2-438c-ae31-8bdf5d420ef8" xlink:to="loc_lxrx_FinalConsiderationIncludingAmountsReleasedToSettle_84223f6f-d718-4aff-a285-3adf5c81d683" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherAssets_20444eb6-bc2f-4821-9a06-9b5cfb74d48c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bea8104e-5ec2-438c-ae31-8bdf5d420ef8" xlink:to="loc_us-gaap_GainLossOnSaleOfOtherAssets_20444eb6-bc2f-4821-9a06-9b5cfb74d48c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_b9853dcb-2d7c-4487-945e-fb74162b72a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bea8104e-5ec2-438c-ae31-8bdf5d420ef8" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_b9853dcb-2d7c-4487-945e-fb74162b72a4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfProvedProperty_8664e824-71b0-483f-9299-4b4d2cae7a98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfProvedProperty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bea8104e-5ec2-438c-ae31-8bdf5d420ef8" xlink:to="loc_us-gaap_GainLossOnSaleOfProvedProperty_8664e824-71b0-483f-9299-4b4d2cae7a98" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_af4b616a-7ee1-4c6a-adda-f73d3fd4f711" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bea8104e-5ec2-438c-ae31-8bdf5d420ef8" xlink:to="loc_us-gaap_DebtInstrumentTable_af4b616a-7ee1-4c6a-adda-f73d3fd4f711" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_ec8606fc-a5ee-4572-a2e2-5d3308baa506" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_af4b616a-7ee1-4c6a-adda-f73d3fd4f711" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_ec8606fc-a5ee-4572-a2e2-5d3308baa506" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_ec8606fc-a5ee-4572-a2e2-5d3308baa506_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_ec8606fc-a5ee-4572-a2e2-5d3308baa506" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_ec8606fc-a5ee-4572-a2e2-5d3308baa506_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_25f7517f-639d-4e65-a566-96b8d4303a49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_ec8606fc-a5ee-4572-a2e2-5d3308baa506" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_25f7517f-639d-4e65-a566-96b8d4303a49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_naics_ZZ541713_19b08356-1c7a-4323-943d-0f61145caa2c" xlink:href="https://xbrl.sec.gov/naics/2022/naics-2022.xsd#naics_ZZ541713"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_25f7517f-639d-4e65-a566-96b8d4303a49" xlink:to="loc_naics_ZZ541713_19b08356-1c7a-4323-943d-0f61145caa2c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_db27e831-3553-44db-98a7-c77df5b750b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_25f7517f-639d-4e65-a566-96b8d4303a49" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_db27e831-3553-44db-98a7-c77df5b750b7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/OtherCapitalAgreementsDetails" xlink:type="simple" xlink:href="lxrx-20221231.xsd#OtherCapitalAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/OtherCapitalAgreementsDetails" xlink:type="extended" id="i36c0d405137340ffb5026c7ef2ee0b10_OtherCapitalAgreementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_8f64441e-c42c-45dd-b1d8-dfd43daacd85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ATMOffering2020Total_0725caff-6b3e-4905-bf4b-adce103ae2b2" xlink:href="lxrx-20221231.xsd#lxrx_ATMOffering2020Total"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_8f64441e-c42c-45dd-b1d8-dfd43daacd85" xlink:to="loc_lxrx_ATMOffering2020Total_0725caff-6b3e-4905-bf4b-adce103ae2b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_6262c035-757b-448b-9f4d-cd8fb99e8ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_8f64441e-c42c-45dd-b1d8-dfd43daacd85" xlink:to="loc_us-gaap_SubsequentEventTable_6262c035-757b-448b-9f4d-cd8fb99e8ec8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_b50380d4-9fd4-40b5-8afa-646c4524096a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_6262c035-757b-448b-9f4d-cd8fb99e8ec8" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_b50380d4-9fd4-40b5-8afa-646c4524096a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b50380d4-9fd4-40b5-8afa-646c4524096a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b50380d4-9fd4-40b5-8afa-646c4524096a" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b50380d4-9fd4-40b5-8afa-646c4524096a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_9ee720b0-24d8-4174-9ff3-639d56821080" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b50380d4-9fd4-40b5-8afa-646c4524096a" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_9ee720b0-24d8-4174-9ff3-639d56821080" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_6ecf7a29-f209-4908-8825-edd49bdd3679" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_9ee720b0-24d8-4174-9ff3-639d56821080" xlink:to="loc_us-gaap_SubsequentEventMember_6ecf7a29-f209-4908-8825-edd49bdd3679" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>lxrx-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:379d89f1-f5df-4675-bf23-f82d2f2c7aaf,g:c8f45f50-51f6-43ab-b86a-02bdbec3750c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_srt_RestatementAxis_c5554274-9b41-4e62-8022-7e9aec9c0251_terseLabel_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement [Axis]</link:label>
    <link:label id="lab_srt_RestatementAxis_label_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAxis" xlink:to="lab_srt_RestatementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_944147bf-04c2-4fd4-8fed-7eed8d5e522f_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_948ff8b0-95ad-4d1d-81a1-83c1defccb8b_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leaseholds and Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_2fb36151-a95a-4482-88d4-23e1748ea217_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_8803e3eb-ddb3-4059-8b80-b1e93cff6a15_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_DebtObligationsAbstract_0738b071-5435-41a3-8551-857191a476fa_terseLabel_en-US" xlink:label="lab_lxrx_DebtObligationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Obligations [Abstract]</link:label>
    <link:label id="lab_lxrx_DebtObligationsAbstract_label_en-US" xlink:label="lab_lxrx_DebtObligationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Obligations [Abstract]</link:label>
    <link:label id="lab_lxrx_DebtObligationsAbstract_documentation_en-US" xlink:label="lab_lxrx_DebtObligationsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Obligations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DebtObligationsAbstract" xlink:href="lxrx-20221231.xsd#lxrx_DebtObligationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_DebtObligationsAbstract" xlink:to="lab_lxrx_DebtObligationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessExitCosts1_858672aa-c465-4faf-8285-9f2777209966_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessExitCosts1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Exit Costs</link:label>
    <link:label id="lab_us-gaap_BusinessExitCosts1_label_en-US" xlink:label="lab_us-gaap_BusinessExitCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Exit Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessExitCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessExitCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessExitCosts1" xlink:to="lab_us-gaap_BusinessExitCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_375f957c-88fd-4400-bf7e-bdc6534a16bb_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockAmountIssued1_2a94db2c-cf77-4b4e-95b8-94d4f3cbb931_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock, Amount Issued</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockAmountIssued1_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock, Amount Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockAmountIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockAmountIssued1" xlink:to="lab_us-gaap_ConversionOfStockAmountIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_6c5e53fd-a763-4509-85d3-2a35886da5f3_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_d5a5d264-c722-4a9f-babb-257f4e6bf655_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_f1bf00d5-7953-403d-b854-47edaf123085_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_609bba18-f4d1-4c04-913d-1606b439f89b_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_label_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivableTypeDomain" xlink:to="lab_us-gaap_ReceivableTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_eff2282e-d8c0-46ed-9f19-13b49690a00f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_e44ecf7c-5d55-4595-9caf-e6722c47acf7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash, Cash Equivalents and Short-term Investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_A2026OxfordPrincipalPaymentsB_d81c6022-78a8-4a1a-894b-0f13656b6dd3_terseLabel_en-US" xlink:label="lab_lxrx_A2026OxfordPrincipalPaymentsB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026 Oxford Principal Payments B</link:label>
    <link:label id="lab_lxrx_A2026OxfordPrincipalPaymentsB_label_en-US" xlink:label="lab_lxrx_A2026OxfordPrincipalPaymentsB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026 Oxford Principal Payments B</link:label>
    <link:label id="lab_lxrx_A2026OxfordPrincipalPaymentsB_documentation_en-US" xlink:label="lab_lxrx_A2026OxfordPrincipalPaymentsB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026 Oxford Principal Payments B</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2026OxfordPrincipalPaymentsB" xlink:href="lxrx-20221231.xsd#lxrx_A2026OxfordPrincipalPaymentsB"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_A2026OxfordPrincipalPaymentsB" xlink:to="lab_lxrx_A2026OxfordPrincipalPaymentsB" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCommitmentAmount_fe04c0b6-88b4-43f4-8023-e22315a542a3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCommitmentAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Lease Commitment, Amount</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCommitmentAmount_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Lease Commitment, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCommitmentAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCommitmentAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCommitmentAmount" xlink:to="lab_us-gaap_ShortTermLeaseCommitmentAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_805c1002-73d7-48de-bc0d-f1ee4aec0a6d_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_FinalPaymentWithNoExtention_139b8317-ed8d-4a02-aa6b-9fa77fa763af_terseLabel_en-US" xlink:label="lab_lxrx_FinalPaymentWithNoExtention" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final Payment % with no extention</link:label>
    <link:label id="lab_lxrx_FinalPaymentWithNoExtention_label_en-US" xlink:label="lab_lxrx_FinalPaymentWithNoExtention" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final Payment % with no extention</link:label>
    <link:label id="lab_lxrx_FinalPaymentWithNoExtention_documentation_en-US" xlink:label="lab_lxrx_FinalPaymentWithNoExtention" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final Payment % with no extention</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FinalPaymentWithNoExtention" xlink:href="lxrx-20221231.xsd#lxrx_FinalPaymentWithNoExtention"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_FinalPaymentWithNoExtention" xlink:to="lab_lxrx_FinalPaymentWithNoExtention" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon_385bc703-c268-4e2d-b626-f9c6b3dce093_terseLabel_en-US" xlink:label="lab_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liability Related to Acquisition of Symphony Icon</link:label>
    <link:label id="lab_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon_label_en-US" xlink:label="lab_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liability Related to Acquisition of Symphony Icon</link:label>
    <link:label id="lab_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon_documentation_en-US" xlink:label="lab_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs. Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million and issued 13,237,519 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation. Lexicon also agreed to make up to $45 million in additional payments, which will consist of 50% of any consideration Lexicon receives pursuant to any licensing transaction under which Lexicon grants a third party rights to commercialize LX1032, LX1033 or other pharmaceutical compositions modulating the same target as those drug candidates. This represents the deferred tax liability relating to the tax impact of future amortization or possible impairments associated with intangible assets acquired with Symphony Icon, which are not deductible for tax purposes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon" xlink:href="lxrx-20221231.xsd#lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon" xlink:to="lab_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfDevelopmentMilestones_27d4efba-1d0d-417c-9bee-a5300ea5482d_terseLabel_en-US" xlink:label="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of development milestones</link:label>
    <link:label id="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfDevelopmentMilestones_label_en-US" xlink:label="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Number Of Development Milestones</link:label>
    <link:label id="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfDevelopmentMilestones_documentation_en-US" xlink:label="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Number Of Development Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfDevelopmentMilestones" xlink:href="lxrx-20221231.xsd#lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfDevelopmentMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfDevelopmentMilestones" xlink:to="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfDevelopmentMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_14e7d23c-57b5-41fe-aebb-8933aebbc7de_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_891233f1-e51f-4d0d-b629-3d2abf05d7fd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_02331cb8-a453-43dc-8f33-e18bb9c378da_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_8d33d4aa-75af-4c28-adc9-edcf88557d17_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_AccruedCompensationAndBenefitsCurrent_141e49ac-aa1e-4340-be79-0ac19afec2ba_terseLabel_en-US" xlink:label="lab_lxrx_AccruedCompensationAndBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and benefits current</link:label>
    <link:label id="lab_lxrx_AccruedCompensationAndBenefitsCurrent_label_en-US" xlink:label="lab_lxrx_AccruedCompensationAndBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and benefits current</link:label>
    <link:label id="lab_lxrx_AccruedCompensationAndBenefitsCurrent_documentation_en-US" xlink:label="lab_lxrx_AccruedCompensationAndBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and benefits current - due within 1 year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedCompensationAndBenefitsCurrent" xlink:href="lxrx-20221231.xsd#lxrx_AccruedCompensationAndBenefitsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_AccruedCompensationAndBenefitsCurrent" xlink:to="lab_lxrx_AccruedCompensationAndBenefitsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_5b7d9ead-8cb8-46ec-ae7f-65870c08fca8_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $.001 par value; 225,000 shares authorized; 106,679 and 106,162 shares issued, respectively</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfCommercialMilestones_4e565ed4-b4d3-42f4-aaba-bafbb08dc2a3_terseLabel_en-US" xlink:label="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of commercial milestones</link:label>
    <link:label id="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfCommercialMilestones_label_en-US" xlink:label="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Number Of Commercial Milestones</link:label>
    <link:label id="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfCommercialMilestones_documentation_en-US" xlink:label="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Number Of Commercial Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfCommercialMilestones" xlink:href="lxrx-20221231.xsd#lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfCommercialMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfCommercialMilestones" xlink:to="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfCommercialMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_TermLoanDWarrant_6aa87b26-a785-4ffe-9b7e-c811df3cccd0_terseLabel_en-US" xlink:label="lab_lxrx_TermLoanDWarrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan D Warrant %</link:label>
    <link:label id="lab_lxrx_TermLoanDWarrant_label_en-US" xlink:label="lab_lxrx_TermLoanDWarrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan D Warrant %</link:label>
    <link:label id="lab_lxrx_TermLoanDWarrant_documentation_en-US" xlink:label="lab_lxrx_TermLoanDWarrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan D Warrant %</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanDWarrant" xlink:href="lxrx-20221231.xsd#lxrx_TermLoanDWarrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TermLoanDWarrant" xlink:to="lab_lxrx_TermLoanDWarrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_490c52e4-87ee-43cb-a426-4b85386ab5f4_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_8618c715-38ad-4c64-a4d5-ee7131795b77_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_af9e6827-b736-43ae-8da5-84ba575690a2_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_38196148-2bc9-41d8-8af9-f09b67e84ac8_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_84fb59ff-9caa-4a8f-9c18-7faed0cbcd5c_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c2110097-49d4-4684-ae50-c92f65140d6a_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationLineItems_f54e71d7-f839-4315-815c-e99d9a803e0e_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_807472eb-f80d-4aba-b371-6284c3293cd7_verboseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan_9566e8dd-b8ae-4eb4-8694-d9824cdcae06_terseLabel_en-US" xlink:label="lab_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shares That May be Issued, Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan_label_en-US" xlink:label="lab_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shares That May be Issued, Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan_documentation_en-US" xlink:label="lab_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The total number of shares of common stock that may be issued pursuant to stock awards under the Equity Incentive Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan" xlink:href="lxrx-20221231.xsd#lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan" xlink:to="lab_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX_b282074b-0944-45c4-a598-fa44b471718f_terseLabel_en-US" xlink:label="lab_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Interest Rate BasePlus_Revere_LXRX</link:label>
    <link:label id="lab_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX_label_en-US" xlink:label="lab_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Interest Rate BasePlus_Revere_LXRX</link:label>
    <link:label id="lab_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX_documentation_en-US" xlink:label="lab_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Interest Rate BasePlus_Revere_LXRX - represents a base for the range of the interest rate that will be charged on the Revere loan. Interest charged will be greater of 30-day LIBOR plus 5.5% or 7.5%</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX" xlink:href="lxrx-20221231.xsd#lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX" xlink:to="lab_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_4f16828f-9eb7-4721-8a7e-f1c275aa5def_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_A2027OxfordPrincipalPayments_19b4ea0e-ac77-4542-bcf9-40f30d79d212_terseLabel_en-US" xlink:label="lab_lxrx_A2027OxfordPrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027 Oxford Principal Payments</link:label>
    <link:label id="lab_lxrx_A2027OxfordPrincipalPayments_label_en-US" xlink:label="lab_lxrx_A2027OxfordPrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027 Oxford Principal Payments</link:label>
    <link:label id="lab_lxrx_A2027OxfordPrincipalPayments_documentation_en-US" xlink:label="lab_lxrx_A2027OxfordPrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027 Oxford Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2027OxfordPrincipalPayments" xlink:href="lxrx-20221231.xsd#lxrx_A2027OxfordPrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_A2027OxfordPrincipalPayments" xlink:to="lab_lxrx_A2027OxfordPrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_bcf15a24-3e57-4201-8578-a4135d179d74_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_81ef0e95-7cdd-4efd-8c1c-db63e7fae582_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_ca45b101-6808-4f1b-a69d-e5855a950922_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">For officers and non-employee directors, the estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" xlink:href="lxrx-20221231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_6bde2fda-3d05-4261-ae06-1c10ef808822_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement, Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_56f4a79f-b8a1-4d9d-a210-e9e2257d47e1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_bff5ee80-4028-4d09-aa39-3a6b06f0e10c_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_e506616b-261d-4486-a94d-98e90dfa1691_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_9a4cefa3-789c-48fb-98a7-aca07daacabe_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_887db6a4-9913-4071-951e-be96fff5afab_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance by Deferred Tax Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance by Deferred Tax Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:to="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_7877a6e3-58cf-4cf9-9df8-4972dd432fa7_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_ab3b0325-65fb-4ea6-9ffc-fd22092b4417_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable_8dc06e28-0cfa-4c0c-860e-56a9cbd0f0db_terseLabel_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Revenue Allocated to License Deliverable</link:label>
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable_label_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Revenue Allocated to License Deliverable</link:label>
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable_documentation_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the amount of the upfront payment allocated to the license deliverable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable" xlink:href="lxrx-20221231.xsd#lxrx_IpsenRevenueAllocatedtoLicenseDeliverable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable" xlink:to="lab_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_e024fe80-8a14-4a10-883a-bd26bec4aeb9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, State</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_2f532552-0b75-4769-b675-4b66116babd0_terseLabel_en-US" xlink:label="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense associated with research and development expense</link:label>
    <link:label id="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense associated with research and development expense</link:label>
    <link:label id="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_documentation_en-US" xlink:label="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense included in research and development expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" xlink:href="lxrx-20221231.xsd#lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" xlink:to="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_42f04277-98f0-4aa1-99a3-067c07306d9f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_f8f00821-6577-42c4-893f-d24d8a0c3832_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_5f4f853a-1d9b-4028-9afd-60c0f1b47f94_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ProceedsFromJuly2022Offering_5e41087a-fe51-4a52-9d6e-df23bf136920_terseLabel_en-US" xlink:label="lab_lxrx_ProceedsFromJuly2022Offering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from July 2022 Offering</link:label>
    <link:label id="lab_lxrx_ProceedsFromJuly2022Offering_label_en-US" xlink:label="lab_lxrx_ProceedsFromJuly2022Offering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from July 2022 Offering</link:label>
    <link:label id="lab_lxrx_ProceedsFromJuly2022Offering_documentation_en-US" xlink:label="lab_lxrx_ProceedsFromJuly2022Offering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from July 2022 Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ProceedsFromJuly2022Offering" xlink:href="lxrx-20221231.xsd#lxrx_ProceedsFromJuly2022Offering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ProceedsFromJuly2022Offering" xlink:to="lab_lxrx_ProceedsFromJuly2022Offering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_2c381749-f83f-44ee-85c9-cb6149926bb1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_529afd2a-39e5-4229-9b12-4e6274a85520_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6ccf947b-5802-4eba-95a7-473ddbaaf0ac_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_d4567ef9-27d0-4675-8bf2-8ff97cce9587_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_label_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_155a2bf0-4648-4113-bf40-a02b910f914a_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_6bb3df05-d10b-4947-aa35-f14735910050_terseLabel_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities</link:label>
    <link:label id="lab_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_label_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xlink:to="lab_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_LXRXDiplomatcustomerconcentration_c2f0a909-459e-4bdb-b74c-c263b8bc5863_terseLabel_en-US" xlink:label="lab_lxrx_LXRXDiplomatcustomerconcentration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LXRX Diplomat customer concentration</link:label>
    <link:label id="lab_lxrx_LXRXDiplomatcustomerconcentration_label_en-US" xlink:label="lab_lxrx_LXRXDiplomatcustomerconcentration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LXRX Diplomat customer concentration</link:label>
    <link:label id="lab_lxrx_LXRXDiplomatcustomerconcentration_documentation_en-US" xlink:label="lab_lxrx_LXRXDiplomatcustomerconcentration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LXRX Diplomat customer concentration - represents the percent of revenue that Diplomat contributes to revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_LXRXDiplomatcustomerconcentration" xlink:href="lxrx-20221231.xsd#lxrx_LXRXDiplomatcustomerconcentration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_LXRXDiplomatcustomerconcentration" xlink:to="lab_lxrx_LXRXDiplomatcustomerconcentration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ab6ae4a6-17f1-4d25-a66e-7c7bb82e35bb_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_d7bc804b-f147-4d10-b724-a7c0464c9926_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_EntityWideRevenueSanofiPercentage_1a13f2e2-0278-425f-9011-15f8fb5a4fcb_terseLabel_en-US" xlink:label="lab_lxrx_EntityWideRevenueSanofiPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Wide Revenue Sanofi Percentage</link:label>
    <link:label id="lab_lxrx_EntityWideRevenueSanofiPercentage_label_en-US" xlink:label="lab_lxrx_EntityWideRevenueSanofiPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Wide Revenue Sanofi Percentage</link:label>
    <link:label id="lab_lxrx_EntityWideRevenueSanofiPercentage_documentation_en-US" xlink:label="lab_lxrx_EntityWideRevenueSanofiPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of revenue generated from Sanofi that accounts for 10 percent or more of an entity's revenues.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_EntityWideRevenueSanofiPercentage" xlink:href="lxrx-20221231.xsd#lxrx_EntityWideRevenueSanofiPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_EntityWideRevenueSanofiPercentage" xlink:to="lab_lxrx_EntityWideRevenueSanofiPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent_0cc8bc64-cdfe-4452-a9a0-1c2ab7ba32e8_terseLabel_en-US" xlink:label="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure on Geographic Areas, Revenue from External Customers Attributed to Entity's Country of Domicile, Percent</link:label>
    <link:label id="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent_label_en-US" xlink:label="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure on Geographic Areas, Revenue from External Customers Attributed to Entity's Country of Domicile, Percent</link:label>
    <link:label id="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent_documentation_en-US" xlink:label="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from external customers attributed to the entity's country of domicile as a percentage of total revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent" xlink:href="lxrx-20221231.xsd#lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent" xlink:to="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_8d745f55-1586-4d6f-9bf8-a8efd3b4ec91_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_3871a7bb-cde3-4dc3-ad83-d201f7501ec4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_f4b83179-7d23-4a45-8d64-3f7adb94db0a_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-Process Research and Development</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan_7bdfcd1f-d92a-4943-8851-09d9946c92d8_terseLabel_en-US" xlink:label="lab_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units Outstanding, Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan_label_en-US" xlink:label="lab_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units Outstanding, Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan_documentation_en-US" xlink:label="lab_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units outstanding under the Equity Incentive Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan" xlink:href="lxrx-20221231.xsd#lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan" xlink:to="lab_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenRevenueRecognized_b3ae9328-f463-468d-8bc0-603b55134c06_terseLabel_en-US" xlink:label="lab_lxrx_IpsenRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Revenue Recognized</link:label>
    <link:label id="lab_lxrx_IpsenRevenueRecognized_label_en-US" xlink:label="lab_lxrx_IpsenRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Revenue Recognized</link:label>
    <link:label id="lab_lxrx_IpsenRevenueRecognized_documentation_en-US" xlink:label="lab_lxrx_IpsenRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the revenue recognized in the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenRevenueRecognized" xlink:href="lxrx-20221231.xsd#lxrx_IpsenRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenRevenueRecognized" xlink:to="lab_lxrx_IpsenRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_92cb9d2e-6dc4-4092-9147-dff25f616586_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_3504b6fa-1d5d-4f9d-9a55-c662b66e212b_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Cost</link:label>
    <link:label id="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of Financing and Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_3254eb8f-8584-4526-ac93-98ec09acb7c8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsDomain" xlink:to="lab_us-gaap_OtherCommitmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_CommitmentsAndContingenciesAbstract_5040cd44-b1b5-428c-ac6b-612f18446c0f_terseLabel_en-US" xlink:label="lab_lxrx_CommitmentsAndContingenciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies [Abstract]</link:label>
    <link:label id="lab_lxrx_CommitmentsAndContingenciesAbstract_label_en-US" xlink:label="lab_lxrx_CommitmentsAndContingenciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies [Abstract]</link:label>
    <link:label id="lab_lxrx_CommitmentsAndContingenciesAbstract_documentation_en-US" xlink:label="lab_lxrx_CommitmentsAndContingenciesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CommitmentsAndContingenciesAbstract" xlink:href="lxrx-20221231.xsd#lxrx_CommitmentsAndContingenciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_CommitmentsAndContingenciesAbstract" xlink:to="lab_lxrx_CommitmentsAndContingenciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_12498232-d382-4f6f-924b-1c2c8a47e8eb_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_74ad048b-1072-4aa6-a806-a76a01c68ae3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_c02c15f1-be0a-4bed-b29e-653ad3b7a3a8_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_86282f30-042f-41be-80d3-f7c6fea3ac68_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_TermLoanAFinalPayment_963fc9dd-4b68-4e9f-a979-cdc7ba8b55df_terseLabel_en-US" xlink:label="lab_lxrx_TermLoanAFinalPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Final Payment</link:label>
    <link:label id="lab_lxrx_TermLoanAFinalPayment_label_en-US" xlink:label="lab_lxrx_TermLoanAFinalPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Final Payment</link:label>
    <link:label id="lab_lxrx_TermLoanAFinalPayment_documentation_en-US" xlink:label="lab_lxrx_TermLoanAFinalPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Final Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanAFinalPayment" xlink:href="lxrx-20221231.xsd#lxrx_TermLoanAFinalPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TermLoanAFinalPayment" xlink:to="lab_lxrx_TermLoanAFinalPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_d6100b9e-c0b0-4497-97d4-9784424e4b0b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_38a1bc5a-45b7-4cea-b79d-9cfb2fdde3e9_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease) (Deprecated 2022)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_563b4d74-4363-40ff-897f-25ffa9b7544f_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CondensedFinancialStatementsCaptionsLineItems_e2235fca-17f6-4a50-94f1-05140e7c0399_terseLabel_en-US" xlink:label="lab_srt_CondensedFinancialStatementsCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Financial Statements, Captions</link:label>
    <link:label id="lab_srt_CondensedFinancialStatementsCaptionsLineItems_label_en-US" xlink:label="lab_srt_CondensedFinancialStatementsCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Financial Statements, Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="lab_srt_CondensedFinancialStatementsCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_db2f5067-02df-44b5-8359-da031c2499bd_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Productive Assets</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:to="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e196f526-cb9d-4a28-ad6e-d4ff847cea8b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2a1ca1e-c971-4fec-8a0b-4f5f6be191a6_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0217ec5a-d463-4c6a-a351-165b79c63eb9_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_2132750c-abec-4d8e-b3c3-556972a976e9_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Issued, Basic</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Issued, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfCashFlowsAbstract_63d33386-34fe-48a2-9565-a167b0c2bce2_terseLabel_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Cash Flows [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfCashFlowsAbstract_label_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Cash Flows [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfCashFlowsAbstract_documentation_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedStatementsOfCashFlowsAbstract" xlink:href="lxrx-20221231.xsd#lxrx_ConsolidatedStatementsOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConsolidatedStatementsOfCashFlowsAbstract" xlink:to="lab_lxrx_ConsolidatedStatementsOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_bff6eaa2-07da-406b-92ad-b02431458d6e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SharePriceInJuly2022Offering_73347c88-cbae-43cb-a675-6525a3825e35_terseLabel_en-US" xlink:label="lab_lxrx_SharePriceInJuly2022Offering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price in July 2022 Offering</link:label>
    <link:label id="lab_lxrx_SharePriceInJuly2022Offering_label_en-US" xlink:label="lab_lxrx_SharePriceInJuly2022Offering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price in July 2022 Offering</link:label>
    <link:label id="lab_lxrx_SharePriceInJuly2022Offering_documentation_en-US" xlink:label="lab_lxrx_SharePriceInJuly2022Offering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price in July 2022 Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharePriceInJuly2022Offering" xlink:href="lxrx-20221231.xsd#lxrx_SharePriceInJuly2022Offering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SharePriceInJuly2022Offering" xlink:to="lab_lxrx_SharePriceInJuly2022Offering" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_7251927c-0e0e-4aa0-ba4c-670ac265b8c0_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_38c1a4b2-fef5-4917-85c0-a91f3170b25b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_74a7c4c7-a144-4f6f-b6f6-6b366e02fbc4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_94cc3686-3e6e-429f-a842-71b5e2212280_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_1ce349ad-ae52-40a7-9784-af4ba1db76f2_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_ce1a221c-22a0-4d55-a8cd-b54681dcb3b7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful life of assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_8961eade-5c13-4489-8809-2bba97896088_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Useful Lives</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1433ba31-a768-48ac-b43f-159e3f0f8ba0_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_e3529f35-630b-4ade-8fe0-3f4026f0730d_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeveranceCosts1_ed692379-3796-410f-a05c-2949f41d3178_terseLabel_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance Costs</link:label>
    <link:label id="lab_us-gaap_SeveranceCosts1_label_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1" xlink:to="lab_us-gaap_SeveranceCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_94e86f24-cd81-41e9-ac93-b2e7e34b7ece_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_84016196-cd67-4752-a562-08cc5ac03fa9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Obligations</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfBuildings_22efee66-8c97-44e2-9695-4153412fdc05_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfBuildings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Buildings</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfBuildings_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfBuildings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Buildings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfBuildings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfBuildings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfBuildings" xlink:to="lab_us-gaap_ProceedsFromSaleOfBuildings" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_da7c0a8b-a1be-4b32-85f7-96800a95d8e5_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_88666b52-215f-4fda-911c-837d00cc94cd_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_336756ea-9364-4c9a-b182-02f16b866957_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax benefit</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_29d5f5a4-8e28-49d7-a045-4feb654a07de_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Benefit</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_TermLoanABWarrant_3d625293-8a85-4412-bdc5-36ecd0f69ceb_terseLabel_en-US" xlink:label="lab_lxrx_TermLoanABWarrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A&amp;B Warrant %</link:label>
    <link:label id="lab_lxrx_TermLoanABWarrant_label_en-US" xlink:label="lab_lxrx_TermLoanABWarrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A&amp;B Warrant %</link:label>
    <link:label id="lab_lxrx_TermLoanABWarrant_documentation_en-US" xlink:label="lab_lxrx_TermLoanABWarrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A&amp;B Warrant %</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanABWarrant" xlink:href="lxrx-20221231.xsd#lxrx_TermLoanABWarrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TermLoanABWarrant" xlink:to="lab_lxrx_TermLoanABWarrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_246495ba-7a48-410f-9e56-dd18a9df5e75_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_A2025OxfordPrincipalPaymentsB_dc7dc1f0-2e6a-4e91-ad52-3c3ccdbe156c_terseLabel_en-US" xlink:label="lab_lxrx_A2025OxfordPrincipalPaymentsB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025 Oxford Principal Payments B</link:label>
    <link:label id="lab_lxrx_A2025OxfordPrincipalPaymentsB_label_en-US" xlink:label="lab_lxrx_A2025OxfordPrincipalPaymentsB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025 Oxford Principal Payments B</link:label>
    <link:label id="lab_lxrx_A2025OxfordPrincipalPaymentsB_documentation_en-US" xlink:label="lab_lxrx_A2025OxfordPrincipalPaymentsB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025 Oxford Principal Payments B</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2025OxfordPrincipalPaymentsB" xlink:href="lxrx-20221231.xsd#lxrx_A2025OxfordPrincipalPaymentsB"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_A2025OxfordPrincipalPaymentsB" xlink:to="lab_lxrx_A2025OxfordPrincipalPaymentsB" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_6c5a8ad7-94cf-4dbb-9ebd-b384a1311157_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Fair Value Disclosure</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-Sale Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_LexiconBorrowingRate_8085a786-e478-4545-a204-36e0fe02034a_terseLabel_en-US" xlink:label="lab_lxrx_LexiconBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lexicon borrowing rate</link:label>
    <link:label id="lab_lxrx_LexiconBorrowingRate_label_en-US" xlink:label="lab_lxrx_LexiconBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lexicon borrowing rate</link:label>
    <link:label id="lab_lxrx_LexiconBorrowingRate_documentation_en-US" xlink:label="lab_lxrx_LexiconBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lexicon borrowing rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_LexiconBorrowingRate" xlink:href="lxrx-20221231.xsd#lxrx_LexiconBorrowingRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_LexiconBorrowingRate" xlink:to="lab_lxrx_LexiconBorrowingRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_9057b1b3-2f66-44f5-aed6-f32c1418cf1f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_a1426c20-af37-486e-86be-b167d67fd6d8_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_Ipsenproductsales_2a2e51e5-738f-4b2b-a43c-2b1559705f48_terseLabel_en-US" xlink:label="lab_lxrx_Ipsenproductsales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen product sales</link:label>
    <link:label id="lab_lxrx_Ipsenproductsales_label_en-US" xlink:label="lab_lxrx_Ipsenproductsales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen product sales</link:label>
    <link:label id="lab_lxrx_Ipsenproductsales_documentation_en-US" xlink:label="lab_lxrx_Ipsenproductsales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl outside the United States and Japan. This represents the amount of product sales to Ipsen.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Ipsenproductsales" xlink:href="lxrx-20221231.xsd#lxrx_Ipsenproductsales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_Ipsenproductsales" xlink:to="lab_lxrx_Ipsenproductsales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_d6dfa99d-1ff6-46d5-80b0-e21880528f16_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_TermLoanBDebtDiscount_31a78b08-7f60-4938-9df6-a6835b7febc3_terseLabel_en-US" xlink:label="lab_lxrx_TermLoanBDebtDiscount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Debt Discount</link:label>
    <link:label id="lab_lxrx_TermLoanBDebtDiscount_label_en-US" xlink:label="lab_lxrx_TermLoanBDebtDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Debt Discount</link:label>
    <link:label id="lab_lxrx_TermLoanBDebtDiscount_documentation_en-US" xlink:label="lab_lxrx_TermLoanBDebtDiscount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Debt Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanBDebtDiscount" xlink:href="lxrx-20221231.xsd#lxrx_TermLoanBDebtDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TermLoanBDebtDiscount" xlink:to="lab_lxrx_TermLoanBDebtDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_02cb057b-ed0a-40b8-a04f-5418eb2520d5_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received Per Transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received Per Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_96106711-4f76-4587-ab57-2277cfdf60d7_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade and Other Accounts Receivable, Policy</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_7dd279d4-4dc4-4efa-9f82-76d25a9fb09d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_5a0f886d-bfcb-4c92-983a-63707b58e5b0_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information by Financial Statement Line Item [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_e9ee8a64-0b2b-439f-b8e7-80df58dc73df_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_TermLoanBNetCashReceipt_063e656c-ac8d-4555-8e31-74a35e3945a7_terseLabel_en-US" xlink:label="lab_lxrx_TermLoanBNetCashReceipt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Net Cash Receipt</link:label>
    <link:label id="lab_lxrx_TermLoanBNetCashReceipt_label_en-US" xlink:label="lab_lxrx_TermLoanBNetCashReceipt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Net Cash Receipt</link:label>
    <link:label id="lab_lxrx_TermLoanBNetCashReceipt_documentation_en-US" xlink:label="lab_lxrx_TermLoanBNetCashReceipt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Net Cash Receipt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanBNetCashReceipt" xlink:href="lxrx-20221231.xsd#lxrx_TermLoanBNetCashReceipt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TermLoanBNetCashReceipt" xlink:to="lab_lxrx_TermLoanBNetCashReceipt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_2d1e7c9e-116c-49ed-b244-ae5e8a51d752_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt, net of deferred issuance costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_6ab54517-f297-41f4-a3f4-cd079192d6c6_negatedLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_71ae2c9a-fa95-4bea-84f7-436f8186a294_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_653a9fd9-a59c-47a1-a0ca-7198b2db7b62_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_0189395d-4dbf-4584-a3af-5ef32c5209d4_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfBusiness_dd03afa7-bc4c-4a1b-b834-ea65f416b2c4_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Business</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfBusiness_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfBusiness" xlink:to="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_087728ba-6301-44a3-bad3-099bd6299914_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsAxis" xlink:to="lab_us-gaap_OtherCommitmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_389ebd46-4ba9-4244-b9b5-65f1495f83c8_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss before taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_ac489462-9e6a-42c5-b7d5-797ff4d238b1_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_140154a2-0fab-40ee-ae56-6c841d6d0db4_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_8581efac-3b13-484b-97d0-5030d6b9e4e2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenTotalPaymentsToDate_f59aa8cf-83af-43bc-89cb-cd58ae105e0e_terseLabel_en-US" xlink:label="lab_lxrx_IpsenTotalPaymentsToDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Total Payments To Date</link:label>
    <link:label id="lab_lxrx_IpsenTotalPaymentsToDate_label_en-US" xlink:label="lab_lxrx_IpsenTotalPaymentsToDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Total Payments To Date</link:label>
    <link:label id="lab_lxrx_IpsenTotalPaymentsToDate_documentation_en-US" xlink:label="lab_lxrx_IpsenTotalPaymentsToDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl outside the United States and Japan. This represents the total all payments under the agreement to date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenTotalPaymentsToDate" xlink:href="lxrx-20221231.xsd#lxrx_IpsenTotalPaymentsToDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenTotalPaymentsToDate" xlink:to="lab_lxrx_IpsenTotalPaymentsToDate" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_CoelacanthGoodwill_b2be20f2-8a57-461d-a754-7a6e23f63d5b_terseLabel_en-US" xlink:label="lab_lxrx_CoelacanthGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coelacanth Goodwill</link:label>
    <link:label id="lab_lxrx_CoelacanthGoodwill_label_en-US" xlink:label="lab_lxrx_CoelacanthGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coelacanth Goodwill</link:label>
    <link:label id="lab_lxrx_CoelacanthGoodwill_documentation_en-US" xlink:label="lab_lxrx_CoelacanthGoodwill" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">On July 12, 2001, Lexicon completed the acquisition of Coelacanth Corporation in a merger. Goodwill associated with the acquisition of $25.8 million, which represents the excess of the $36.0 million purchase price over the fair value of the underlying net identifiable assets, was assigned to the consolidated entity, Lexicon. This represents the goodwill.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CoelacanthGoodwill" xlink:href="lxrx-20221231.xsd#lxrx_CoelacanthGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_CoelacanthGoodwill" xlink:to="lab_lxrx_CoelacanthGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_a57b0893-92f3-4be9-bcce-eae66fa8d47a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_2f594169-1a82-4c04-bdc4-cbc02fedf9c7_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_c650f84a-bef5-4229-8696-aaa187d60361_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsMember" xlink:to="lab_us-gaap_ShortTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4eae58b1-796c-4c1d-b582-f9a929c45bd8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug_67ab15d8-ee0b-43da-96f6-3ed83e6532e1_terseLabel_en-US" xlink:label="lab_lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Orphan Drug</link:label>
    <link:label id="lab_lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug_label_en-US" xlink:label="lab_lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Orphan Drug</link:label>
    <link:label id="lab_lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug_documentation_en-US" xlink:label="lab_lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible orphan drug credit carryforwards.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug" xlink:href="lxrx-20221231.xsd#lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug" xlink:to="lab_lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_41536402-6579-412e-916a-ca5700d10dc0_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Outstanding, Weighted Average Remaining Vesting Period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_fe32c840-9d7f-4bf9-bfab-afb1bcd9f16f_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognition of gain or loss on extinguishment</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_095fa2d7-bdd8-4da9-bbca-a98c85e44860_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognition of gain or loss on extinguishment</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_df1e464d-1739-4d78-b26e-c22353f98d4b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable_bcf1acf0-fb0d-42b7-8a83-2edff9ac2408_terseLabel_en-US" xlink:label="lab_lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Revenue Allocated to Development Deliverable</link:label>
    <link:label id="lab_lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable_label_en-US" xlink:label="lab_lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Revenue Allocated to Development Deliverable</link:label>
    <link:label id="lab_lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable_documentation_en-US" xlink:label="lab_lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the amount of the upfront payment allocated to the development services deliverable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable" xlink:href="lxrx-20221231.xsd#lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable" xlink:to="lab_lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SanofiSalesMilestonePayments_8f333c06-5fa0-40f8-bbd0-f89e72e9b87e_terseLabel_en-US" xlink:label="lab_lxrx_SanofiSalesMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Sales Milestone Payments</link:label>
    <link:label id="lab_lxrx_SanofiSalesMilestonePayments_label_en-US" xlink:label="lab_lxrx_SanofiSalesMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Sales Milestone Payments</link:label>
    <link:label id="lab_lxrx_SanofiSalesMilestonePayments_documentation_en-US" xlink:label="lab_lxrx_SanofiSalesMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate satagliflozin. This represents the potential sales milestones payments under the agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiSalesMilestonePayments" xlink:href="lxrx-20221231.xsd#lxrx_SanofiSalesMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SanofiSalesMilestonePayments" xlink:to="lab_lxrx_SanofiSalesMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_c79ef786-5ad0-40cf-b8f6-99859ab9b3ac_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computers and Software</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesCurrent_aa1e2ad2-7076-48cb-9428-0efe049d3e84_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Current</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-Sale Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_19e41a1e-6419-41b1-bcb7-9430afc2aab4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_a46952e2-106d-4aed-ad3e-a119297e9cfb_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_TermLoanAWarrantsNumber_b5b57b57-cf24-4a85-b2fc-a8c9c9fceb52_terseLabel_en-US" xlink:label="lab_lxrx_TermLoanAWarrantsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Warrants Number</link:label>
    <link:label id="lab_lxrx_TermLoanAWarrantsNumber_label_en-US" xlink:label="lab_lxrx_TermLoanAWarrantsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Warrants Number</link:label>
    <link:label id="lab_lxrx_TermLoanAWarrantsNumber_documentation_en-US" xlink:label="lab_lxrx_TermLoanAWarrantsNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Warrants Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanAWarrantsNumber" xlink:href="lxrx-20221231.xsd#lxrx_TermLoanAWarrantsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TermLoanAWarrantsNumber" xlink:to="lab_lxrx_TermLoanAWarrantsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_d34af423-ee03-40a0-9d6d-10117e2b573c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative agreements</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_9106d0ef-1286-4310-86ae-8a46db397e7e_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_20ad97b6-7aa2-4f03-9bde-c1c744cc2fcb_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ATMOffering2020Total_14869ca9-0b08-4b45-9a9c-3b4192a53efc_terseLabel_en-US" xlink:label="lab_lxrx_ATMOffering2020Total" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Offering 2020 Total</link:label>
    <link:label id="lab_lxrx_ATMOffering2020Total_label_en-US" xlink:label="lab_lxrx_ATMOffering2020Total" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Offering 2020 Total</link:label>
    <link:label id="lab_lxrx_ATMOffering2020Total_documentation_en-US" xlink:label="lab_lxrx_ATMOffering2020Total" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Offering 2020 Total</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ATMOffering2020Total" xlink:href="lxrx-20221231.xsd#lxrx_ATMOffering2020Total"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ATMOffering2020Total" xlink:to="lab_lxrx_ATMOffering2020Total" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_TermLoanD_e8a7ceb8-7ebe-4854-9ce6-1ee79ba5bc76_terseLabel_en-US" xlink:label="lab_lxrx_TermLoanD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan D</link:label>
    <link:label id="lab_lxrx_TermLoanD_label_en-US" xlink:label="lab_lxrx_TermLoanD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan D</link:label>
    <link:label id="lab_lxrx_TermLoanD_documentation_en-US" xlink:label="lab_lxrx_TermLoanD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan D</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanD" xlink:href="lxrx-20221231.xsd#lxrx_TermLoanD"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TermLoanD" xlink:to="lab_lxrx_TermLoanD" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_TermLoanC_f6ee4cc8-6c22-47ed-befa-ede48c0822ed_terseLabel_en-US" xlink:label="lab_lxrx_TermLoanC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan C</link:label>
    <link:label id="lab_lxrx_TermLoanC_label_en-US" xlink:label="lab_lxrx_TermLoanC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan C</link:label>
    <link:label id="lab_lxrx_TermLoanC_documentation_en-US" xlink:label="lab_lxrx_TermLoanC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan C</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanC" xlink:href="lxrx-20221231.xsd#lxrx_TermLoanC"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TermLoanC" xlink:to="lab_lxrx_TermLoanC" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_TermLoanB_357371d6-b0d1-42e2-a772-2af34356430b_terseLabel_en-US" xlink:label="lab_lxrx_TermLoanB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B</link:label>
    <link:label id="lab_lxrx_TermLoanB_label_en-US" xlink:label="lab_lxrx_TermLoanB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B</link:label>
    <link:label id="lab_lxrx_TermLoanB_documentation_en-US" xlink:label="lab_lxrx_TermLoanB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanB" xlink:href="lxrx-20221231.xsd#lxrx_TermLoanB"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TermLoanB" xlink:to="lab_lxrx_TermLoanB" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_29159eac-ba90-4ad3-98c7-04bf68d3637f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_TermLoanA_853c11c3-984d-4755-9882-dbe5ad8ec77e_terseLabel_en-US" xlink:label="lab_lxrx_TermLoanA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A</link:label>
    <link:label id="lab_lxrx_TermLoanA_label_en-US" xlink:label="lab_lxrx_TermLoanA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A</link:label>
    <link:label id="lab_lxrx_TermLoanA_documentation_en-US" xlink:label="lab_lxrx_TermLoanA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanA" xlink:href="lxrx-20221231.xsd#lxrx_TermLoanA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TermLoanA" xlink:to="lab_lxrx_TermLoanA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_2068852f-9af1-47c6-8521-b07a145ef876_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit Plan</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_PresentValueOfFutureLeasePayments_4f4f9d42-081a-4eeb-b033-1ed9ed6552fc_terseLabel_en-US" xlink:label="lab_lxrx_PresentValueOfFutureLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present Value of Future Lease Payments</link:label>
    <link:label id="lab_lxrx_PresentValueOfFutureLeasePayments_label_en-US" xlink:label="lab_lxrx_PresentValueOfFutureLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present Value of Future Lease Payments</link:label>
    <link:label id="lab_lxrx_PresentValueOfFutureLeasePayments_documentation_en-US" xlink:label="lab_lxrx_PresentValueOfFutureLeasePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present Value of Future Lease Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_PresentValueOfFutureLeasePayments" xlink:href="lxrx-20221231.xsd#lxrx_PresentValueOfFutureLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_PresentValueOfFutureLeasePayments" xlink:to="lab_lxrx_PresentValueOfFutureLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_e8852a31-7fd9-4e7f-b261-d2ffcadd7bf7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_d9562d31-bcbc-4434-a211-6e3f19bc1bb6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_df864564-c5d1-4b92-b996-36b3ba02b85b_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_LXRXBiologicscustomerconcentration_3af70e14-44fe-44ff-bad6-d133dec45687_terseLabel_en-US" xlink:label="lab_lxrx_LXRXBiologicscustomerconcentration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biologics customer concentration</link:label>
    <link:label id="lab_lxrx_LXRXBiologicscustomerconcentration_label_en-US" xlink:label="lab_lxrx_LXRXBiologicscustomerconcentration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LXRX Biologics customer concentration</link:label>
    <link:label id="lab_lxrx_LXRXBiologicscustomerconcentration_documentation_en-US" xlink:label="lab_lxrx_LXRXBiologicscustomerconcentration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LXRX Biologics customer concentration - represents percent of revenue that Biologics contributes to total revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_LXRXBiologicscustomerconcentration" xlink:href="lxrx-20221231.xsd#lxrx_LXRXBiologicscustomerconcentration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_LXRXBiologicscustomerconcentration" xlink:to="lab_lxrx_LXRXBiologicscustomerconcentration" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_ea2c0564-0838-45d4-bc8d-7745807b4aff_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_be8a198d-c971-47ea-8cc0-828c6d64c480_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenTotalUpfrontPayments_29a686e2-dff0-4f88-bfc2-efe8e49013ef_terseLabel_en-US" xlink:label="lab_lxrx_IpsenTotalUpfrontPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Total Upfront Payments</link:label>
    <link:label id="lab_lxrx_IpsenTotalUpfrontPayments_label_en-US" xlink:label="lab_lxrx_IpsenTotalUpfrontPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Total Upfront Payments</link:label>
    <link:label id="lab_lxrx_IpsenTotalUpfrontPayments_documentation_en-US" xlink:label="lab_lxrx_IpsenTotalUpfrontPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the total of the upfront payments under the agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenTotalUpfrontPayments" xlink:href="lxrx-20221231.xsd#lxrx_IpsenTotalUpfrontPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenTotalUpfrontPayments" xlink:to="lab_lxrx_IpsenTotalUpfrontPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_e0574aef-dc7f-4231-ac8f-5f487bbd0882_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_9f747602-58b6-45f5-a52b-6d353e6da25a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value per share (usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_A2020ConvertibleDebtExchangeAccruedInterest_b3b725a3-fdfe-4776-8a35-4508db9c2faa_terseLabel_en-US" xlink:label="lab_lxrx_A2020ConvertibleDebtExchangeAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 convertible debt exchange - accrued interest</link:label>
    <link:label id="lab_lxrx_A2020ConvertibleDebtExchangeAccruedInterest_label_en-US" xlink:label="lab_lxrx_A2020ConvertibleDebtExchangeAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 convertible debt exchange - accrued interest</link:label>
    <link:label id="lab_lxrx_A2020ConvertibleDebtExchangeAccruedInterest_documentation_en-US" xlink:label="lab_lxrx_A2020ConvertibleDebtExchangeAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 convertible debt exchange - accrued interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2020ConvertibleDebtExchangeAccruedInterest" xlink:href="lxrx-20221231.xsd#lxrx_A2020ConvertibleDebtExchangeAccruedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_A2020ConvertibleDebtExchangeAccruedInterest" xlink:to="lab_lxrx_A2020ConvertibleDebtExchangeAccruedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseInterestBearingLiability_aa1bee8b-e658-45ac-a384-42b0d91f3e67_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseInterestBearingLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Interest-Bearing Liability</link:label>
    <link:label id="lab_us-gaap_InterestExpenseInterestBearingLiability_label_en-US" xlink:label="lab_us-gaap_InterestExpenseInterestBearingLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Interest-Bearing Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseInterestBearingLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseInterestBearingLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseInterestBearingLiability" xlink:to="lab_us-gaap_InterestExpenseInterestBearingLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_a01a4bce-8700-45fc-a54f-7bbde111d550_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_38bfdc63-543e-4dd3-8928-e5c499814497_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_ef855f06-f57f-499f-b43c-22f079d0f0d9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_6abec23a-d27d-452b-b35c-9d2858e4707e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Federal</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_5a2ca04d-08bd-4962-bb19-b36c5ce8a81a_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_7efe2293-c6c5-4c42-864d-89541da2964e_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SanofiCommercializationCostsFundedbyLexiconMaximumAmount_cc0c5d92-7626-48a8-af04-39272e680209_terseLabel_en-US" xlink:label="lab_lxrx_SanofiCommercializationCostsFundedbyLexiconMaximumAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Development Costs Funded by Lexicon Maximum Amount</link:label>
    <link:label id="lab_lxrx_SanofiCommercializationCostsFundedbyLexiconMaximumAmount_label_en-US" xlink:label="lab_lxrx_SanofiCommercializationCostsFundedbyLexiconMaximumAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Commercialization Costs Funded by Lexicon Maximum Amount</link:label>
    <link:label id="lab_lxrx_SanofiCommercializationCostsFundedbyLexiconMaximumAmount_documentation_en-US" xlink:label="lab_lxrx_SanofiCommercializationCostsFundedbyLexiconMaximumAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate satagliflozin. This represents the maximum amount that Lexicon will fund of the planned type 2 diabetes development costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiCommercializationCostsFundedbyLexiconMaximumAmount" xlink:href="lxrx-20221231.xsd#lxrx_SanofiCommercializationCostsFundedbyLexiconMaximumAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SanofiCommercializationCostsFundedbyLexiconMaximumAmount" xlink:to="lab_lxrx_SanofiCommercializationCostsFundedbyLexiconMaximumAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_29180719-8054-4cb6-a118-32b3bdec2dce_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development, including stock-based compensation of $4,253, $4,284 and $6,376 respectively</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ProceedsFromDecember2020CommonStockOffering_79dcb94b-ce05-45f0-a8c8-90cf59a3db32_terseLabel_en-US" xlink:label="lab_lxrx_ProceedsFromDecember2020CommonStockOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from December 2020 common stock offering</link:label>
    <link:label id="lab_lxrx_ProceedsFromDecember2020CommonStockOffering_label_en-US" xlink:label="lab_lxrx_ProceedsFromDecember2020CommonStockOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from December 2020 common stock offering</link:label>
    <link:label id="lab_lxrx_ProceedsFromDecember2020CommonStockOffering_documentation_en-US" xlink:label="lab_lxrx_ProceedsFromDecember2020CommonStockOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from December 2020 common stock offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ProceedsFromDecember2020CommonStockOffering" xlink:href="lxrx-20221231.xsd#lxrx_ProceedsFromDecember2020CommonStockOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ProceedsFromDecember2020CommonStockOffering" xlink:to="lab_lxrx_ProceedsFromDecember2020CommonStockOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_b1013dec-5b47-4793-8b27-7201ca84b527_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_d9c251f2-46ab-4979-9db0-7b42e7cdacf9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_e2e803ef-48a7-4be8-a0d1-6b1e516ed695_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Percentage Bearing Fixed Interest, Percentage Rate</link:label>
    <link:label id="lab_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_label_en-US" xlink:label="lab_us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Percentage Bearing Fixed Interest, Percentage Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:to="lab_us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_37bcdce0-20a5-4aaf-9cab-8cf77be5c2a4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_84833c69-f929-4e98-b2b5-2604e4561daf_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_b264bc34-2d47-4148-9451-f633d8dde69e_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Employees</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Employees</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the employees' option's term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" xlink:href="lxrx-20221231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_DecreaseInNOLs_b5e37a40-456e-4258-9a7c-dc13c11ae6c3_terseLabel_en-US" xlink:label="lab_lxrx_DecreaseInNOLs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in NOLs</link:label>
    <link:label id="lab_lxrx_DecreaseInNOLs_label_en-US" xlink:label="lab_lxrx_DecreaseInNOLs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in NOLs</link:label>
    <link:label id="lab_lxrx_DecreaseInNOLs_documentation_en-US" xlink:label="lab_lxrx_DecreaseInNOLs" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in NOLs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DecreaseInNOLs" xlink:href="lxrx-20221231.xsd#lxrx_DecreaseInNOLs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_DecreaseInNOLs" xlink:to="lab_lxrx_DecreaseInNOLs" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_WriteOffOfTaxCredits_66307e45-642f-4677-9d17-cece9af30e7c_terseLabel_en-US" xlink:label="lab_lxrx_WriteOffOfTaxCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write-off of tax credits</link:label>
    <link:label id="lab_lxrx_WriteOffOfTaxCredits_label_en-US" xlink:label="lab_lxrx_WriteOffOfTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write-off of tax credits</link:label>
    <link:label id="lab_lxrx_WriteOffOfTaxCredits_documentation_en-US" xlink:label="lab_lxrx_WriteOffOfTaxCredits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write-off of tax credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_WriteOffOfTaxCredits" xlink:href="lxrx-20221231.xsd#lxrx_WriteOffOfTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_WriteOffOfTaxCredits" xlink:to="lab_lxrx_WriteOffOfTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_1d4926ff-4138-4d77-8802-a70d358532d2_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ea543dbf-7df3-4efc-922e-7378ac93a439_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable_8afe32c8-1c4d-4a45-9e3d-3aedfa34ffbf_terseLabel_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Revenue Allocated to Development Deliverable</link:label>
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable_label_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Revenue Allocated to Development Deliverable</link:label>
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable_documentation_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the amount of the upfront payment allocated to the development services deliverable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable" xlink:href="lxrx-20221231.xsd#lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable" xlink:to="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfProvedProperty_3b1a2a9d-6ea7-4495-968f-523aca63595a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfProvedProperty" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Proved Property</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfProvedProperty_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfProvedProperty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Proved Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfProvedProperty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfProvedProperty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfProvedProperty" xlink:to="lab_us-gaap_GainLossOnSaleOfProvedProperty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockOptionMember_481d1628-d5f7-4572-9041-cfd419bc84a3_terseLabel_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:label id="lab_us-gaap_StockOptionMember_label_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember" xlink:to="lab_us-gaap_StockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterials_33358f3a-e657-4626-bbf5-cde184f97f25_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials" xlink:to="lab_us-gaap_InventoryRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_A2020FederalNOLIncrease_fbca14bc-1f70-4d99-bf93-f76261d228f1_terseLabel_en-US" xlink:label="lab_lxrx_A2020FederalNOLIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Federal NOL increase</link:label>
    <link:label id="lab_lxrx_A2020FederalNOLIncrease_label_en-US" xlink:label="lab_lxrx_A2020FederalNOLIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Federal NOL increase</link:label>
    <link:label id="lab_lxrx_A2020FederalNOLIncrease_documentation_en-US" xlink:label="lab_lxrx_A2020FederalNOLIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Federal NOL increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2020FederalNOLIncrease" xlink:href="lxrx-20221231.xsd#lxrx_A2020FederalNOLIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_A2020FederalNOLIncrease" xlink:to="lab_lxrx_A2020FederalNOLIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_1422ecab-0bb1-451c-bd43-afd0843c3f31_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_d5e305df-394e-4566-b4be-9d5790068a27_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_AccruedResearchAndDevelopmentServicesCurrent_4fb2b522-ed50-4ab5-8d93-b8eea24444b8_terseLabel_en-US" xlink:label="lab_lxrx_AccruedResearchAndDevelopmentServicesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development services current</link:label>
    <link:label id="lab_lxrx_AccruedResearchAndDevelopmentServicesCurrent_label_en-US" xlink:label="lab_lxrx_AccruedResearchAndDevelopmentServicesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development services current</link:label>
    <link:label id="lab_lxrx_AccruedResearchAndDevelopmentServicesCurrent_documentation_en-US" xlink:label="lab_lxrx_AccruedResearchAndDevelopmentServicesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development services current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedResearchAndDevelopmentServicesCurrent" xlink:href="lxrx-20221231.xsd#lxrx_AccruedResearchAndDevelopmentServicesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_AccruedResearchAndDevelopmentServicesCurrent" xlink:to="lab_lxrx_AccruedResearchAndDevelopmentServicesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SharesSoldInNov2020ATMOffering_9ca118f1-091a-4987-9ddb-18405e37105c_terseLabel_en-US" xlink:label="lab_lxrx_SharesSoldInNov2020ATMOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold in Nov 2020 ATM Offering</link:label>
    <link:label id="lab_lxrx_SharesSoldInNov2020ATMOffering_label_en-US" xlink:label="lab_lxrx_SharesSoldInNov2020ATMOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold in Nov 2020 ATM Offering</link:label>
    <link:label id="lab_lxrx_SharesSoldInNov2020ATMOffering_documentation_en-US" xlink:label="lab_lxrx_SharesSoldInNov2020ATMOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold in Nov 2020 ATM Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesSoldInNov2020ATMOffering" xlink:href="lxrx-20221231.xsd#lxrx_SharesSoldInNov2020ATMOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SharesSoldInNov2020ATMOffering" xlink:to="lab_lxrx_SharesSoldInNov2020ATMOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_dd7c9032-0d3d-4821-a392-d09ee8e4b40b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in accounts payable and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_71c2d69d-cf9f-48e4-9271-0287087cb5e5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtWeightedAverageInterestRate_d55db1b8-ecd3-4b4d-afde-8a6091401a5a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Weighted Average Interest Rate</link:label>
    <link:label id="lab_us-gaap_DebtWeightedAverageInterestRate_label_en-US" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Weighted Average Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtWeightedAverageInterestRate" xlink:to="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_abe17547-f080-4ec1-9c2a-3cc2551ff96a_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Gross Unrealized Gain Accumulated in Investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-Sale Securities, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfOtherAssets_b8112413-c26d-43c6-8fe6-9a6fd8555a27_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Other Assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfOtherAssets_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfOtherAssets" xlink:to="lab_us-gaap_GainLossOnSaleOfOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1_a3abdd23-b867-458d-b7a6-de16f7f628ad_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Divestiture, Amount of Consideration Received</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Divestiture, Amount of Consideration Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" xlink:to="lab_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_4f048846-5806-4b12-bd00-b6a1395a585d_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_b35e8861-4502-4c64-8b27-7891d96c50ac_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_A2026OxfordPrincipalPayments_a9c34ed1-dd64-4be5-ab7c-71c42c2b0581_terseLabel_en-US" xlink:label="lab_lxrx_A2026OxfordPrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026 Oxford Principal Payments</link:label>
    <link:label id="lab_lxrx_A2026OxfordPrincipalPayments_label_en-US" xlink:label="lab_lxrx_A2026OxfordPrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026 Oxford Principal Payments</link:label>
    <link:label id="lab_lxrx_A2026OxfordPrincipalPayments_documentation_en-US" xlink:label="lab_lxrx_A2026OxfordPrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026 Oxford Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2026OxfordPrincipalPayments" xlink:href="lxrx-20221231.xsd#lxrx_A2026OxfordPrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_A2026OxfordPrincipalPayments" xlink:to="lab_lxrx_A2026OxfordPrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_16e0631b-417f-419d-ad8f-0a99f6ac4719_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue_fdb97d88-b0fd-4b2f-aaaf-b20a3c6c74d2_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period, Weighted Average Fair Value</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period, Weighted Average Fair Value</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan that were forfeited during the reporting period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue" xlink:href="lxrx-20221231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_b2606406-29f4-4312-85fc-5c3356a36956_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SanofiOutcomesStudyMilestone_9676a407-a00f-402a-8c52-a619db544c2a_terseLabel_en-US" xlink:label="lab_lxrx_SanofiOutcomesStudyMilestone" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Outcomes Study Milestone</link:label>
    <link:label id="lab_lxrx_SanofiOutcomesStudyMilestone_label_en-US" xlink:label="lab_lxrx_SanofiOutcomesStudyMilestone" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Outcomes Study Milestone</link:label>
    <link:label id="lab_lxrx_SanofiOutcomesStudyMilestone_documentation_en-US" xlink:label="lab_lxrx_SanofiOutcomesStudyMilestone" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate satagliflozin. This represents the milestone based on the results of an outcomes study in type 2 diabetes patients the completion of which would likely occur after initial regulatory approval.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiOutcomesStudyMilestone" xlink:href="lxrx-20221231.xsd#lxrx_SanofiOutcomesStudyMilestone"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SanofiOutcomesStudyMilestone" xlink:to="lab_lxrx_SanofiOutcomesStudyMilestone" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FederalIncomeTaxNoteTable_324eb728-b3a2-4297-90f0-52408dca2647_terseLabel_en-US" xlink:label="lab_us-gaap_FederalIncomeTaxNoteTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Income Tax Note [Table]</link:label>
    <link:label id="lab_us-gaap_FederalIncomeTaxNoteTable_label_en-US" xlink:label="lab_us-gaap_FederalIncomeTaxNoteTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Income Tax Note [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalIncomeTaxNoteTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalIncomeTaxNoteTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalIncomeTaxNoteTable" xlink:to="lab_us-gaap_FederalIncomeTaxNoteTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_7fa9e772-24d6-4962-9a14-6dcf1d484e01_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_CollaborationAndLicenseAgreementsAbstract_b3e11059-3e0f-4e7f-8e32-ea39eedb3a1b_terseLabel_en-US" xlink:label="lab_lxrx_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License Agreements [Abstract]</link:label>
    <link:label id="lab_lxrx_CollaborationAndLicenseAgreementsAbstract_label_en-US" xlink:label="lab_lxrx_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License Agreements [Abstract]</link:label>
    <link:label id="lab_lxrx_CollaborationAndLicenseAgreementsAbstract_documentation_en-US" xlink:label="lab_lxrx_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License Agreements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CollaborationAndLicenseAgreementsAbstract" xlink:href="lxrx-20221231.xsd#lxrx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract" xlink:to="lab_lxrx_CollaborationAndLicenseAgreementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_90e4096c-0e9e-4f0e-8e12-55b2e41bc6f2_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1e7c3d28-2282-49f6-8774-8aed2ad37713_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-Sale Securities, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_5314d8c2-f3aa-4fa6-a548-78e6deebbe39_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_855be8f1-75b2-46b0-aa75-d1518bf6a83c_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, value</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_218f4ff1-bf85-4808-bad4-90b87d24cb96_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, value</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_44b55ee5-27b6-4540-8479-cb9aa6f6dd1d_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsMember_5d46f4c5-226e-424d-ac7c-98cfea6b3cad_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents and Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsMember_label_en-US" xlink:label="lab_us-gaap_InvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsMember" xlink:to="lab_us-gaap_InvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_77593d5c-4e84-43a5-9908-6ea1fe82abd2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_7584e302-5bb0-41de-8741-11b66d3a9a9b_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_TermLoanADebtDiscount_e5b2a595-d00f-4003-92f1-cc9a1acdd2a8_terseLabel_en-US" xlink:label="lab_lxrx_TermLoanADebtDiscount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Debt Discount</link:label>
    <link:label id="lab_lxrx_TermLoanADebtDiscount_label_en-US" xlink:label="lab_lxrx_TermLoanADebtDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Debt Discount</link:label>
    <link:label id="lab_lxrx_TermLoanADebtDiscount_documentation_en-US" xlink:label="lab_lxrx_TermLoanADebtDiscount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Debt Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanADebtDiscount" xlink:href="lxrx-20221231.xsd#lxrx_TermLoanADebtDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TermLoanADebtDiscount" xlink:to="lab_lxrx_TermLoanADebtDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1436e6d7-61ca-46a3-a037-699828b37d07_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_47f6f112-6dd1-4126-9c13-2db80458e2e0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetDomain_01aee134-1dac-4ccb-8eb4-c57b71219706_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetDomain_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetDomain" xlink:to="lab_us-gaap_DeferredTaxAssetDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_694f5d32-6261-4350-893f-5ee16be42013_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_3c4ecbaa-fd20-4eea-bbf0-31f2c55621bf_terseLabel_en-US" xlink:label="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents and Investments [Abstract]</link:label>
    <link:label id="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_label_en-US" xlink:label="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents and Investments [Abstract]</link:label>
    <link:label id="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_documentation_en-US" xlink:label="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents and Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" xlink:href="lxrx-20221231.xsd#lxrx_CashAndCashEquivalentsAndInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" xlink:to="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e0b20715-9bb3-47c1-a975-0207a361bce2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_30f34f12-65a7-49d6-90ca-2bc300800426_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryBuildingsAndImprovements_17a5f388-edeb-46f5-adaa-586f73398a3a_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryBuildingsAndImprovements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Buildings and Improvements</link:label>
    <link:label id="lab_us-gaap_InventoryBuildingsAndImprovements_label_en-US" xlink:label="lab_us-gaap_InventoryBuildingsAndImprovements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Buildings and Improvements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryBuildingsAndImprovements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryBuildingsAndImprovements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryBuildingsAndImprovements" xlink:to="lab_us-gaap_InventoryBuildingsAndImprovements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_1824dc25-6109-4e73-b83f-1dc159d6c284_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:to="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_CoelacanthPurchasePrice_cc207814-1e55-428f-a976-3c197df6502d_terseLabel_en-US" xlink:label="lab_lxrx_CoelacanthPurchasePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coelacanth Purchase Price</link:label>
    <link:label id="lab_lxrx_CoelacanthPurchasePrice_label_en-US" xlink:label="lab_lxrx_CoelacanthPurchasePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coelacanth Purchase Price</link:label>
    <link:label id="lab_lxrx_CoelacanthPurchasePrice_documentation_en-US" xlink:label="lab_lxrx_CoelacanthPurchasePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">On July 12, 2001, Lexicon completed the acquisition of Coelacanth Corporation in a merger. Goodwill associated with the acquisition of $25.8 million, which represents the excess of the $36.0 million purchase price over the fair value of the underlying net identifiable assets, was assigned to the consolidated entity, Lexicon. This represents the purchase price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CoelacanthPurchasePrice" xlink:href="lxrx-20221231.xsd#lxrx_CoelacanthPurchasePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_CoelacanthPurchasePrice" xlink:to="lab_lxrx_CoelacanthPurchasePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRent_3cbe61f4-8492-4b3e-ad75-7abaac83b05d_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Rent</link:label>
    <link:label id="lab_us-gaap_PaymentsForRent_label_en-US" xlink:label="lab_us-gaap_PaymentsForRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Rent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRent" xlink:to="lab_us-gaap_PaymentsForRent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_cfe06820-70b8-4698-a751-0adbd111d869_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SanofiRegulatoryMilestones_b4c2343b-43e1-4b4e-b55f-a5471362b5a1_terseLabel_en-US" xlink:label="lab_lxrx_SanofiRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Regulatory Milestones</link:label>
    <link:label id="lab_lxrx_SanofiRegulatoryMilestones_label_en-US" xlink:label="lab_lxrx_SanofiRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Regulatory Milestones</link:label>
    <link:label id="lab_lxrx_SanofiRegulatoryMilestones_documentation_en-US" xlink:label="lab_lxrx_SanofiRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the regulatory milestones relating to the first commercial sale following regulatory approval of sotagliflozin for type 1 and type 2 diabetes in each of the United States and Europe.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiRegulatoryMilestones" xlink:href="lxrx-20221231.xsd#lxrx_SanofiRegulatoryMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SanofiRegulatoryMilestones" xlink:to="lab_lxrx_SanofiRegulatoryMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_A2020ConvertibleDebtExchangeSharePaymentTotal_f6b6e33f-ac2b-40f6-94fe-37e912cca331_terseLabel_en-US" xlink:label="lab_lxrx_A2020ConvertibleDebtExchangeSharePaymentTotal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Convertible debt exchange - share payment total</link:label>
    <link:label id="lab_lxrx_A2020ConvertibleDebtExchangeSharePaymentTotal_label_en-US" xlink:label="lab_lxrx_A2020ConvertibleDebtExchangeSharePaymentTotal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Convertible debt exchange - share payment total</link:label>
    <link:label id="lab_lxrx_A2020ConvertibleDebtExchangeSharePaymentTotal_documentation_en-US" xlink:label="lab_lxrx_A2020ConvertibleDebtExchangeSharePaymentTotal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Convertible debt exchange - share payment total</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2020ConvertibleDebtExchangeSharePaymentTotal" xlink:href="lxrx-20221231.xsd#lxrx_A2020ConvertibleDebtExchangeSharePaymentTotal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_A2020ConvertibleDebtExchangeSharePaymentTotal" xlink:to="lab_lxrx_A2020ConvertibleDebtExchangeSharePaymentTotal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_6ec8bedb-d285-4589-8b46-f760f285d08c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_label_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_00a6d9b1-9c1f-4f55-8171-0f6e13447f13_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under Equity Incentive Plans, value</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_f780464c-d30f-4b68-8ee8-3f3dddc42726_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2347f394-31a8-47c4-bc79-19bb1504e131_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_f9058f95-3f80-43c2-b562-5d8ed64cfa25_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_6f300057-035e-4f6d-aa61-261fbe0ab953_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_2b5ad9ce-27be-45f9-add7-80238f4d2c28_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_8eb5897b-00bf-46d1-afaa-974cf6d8854b_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Policy</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_cea6c248-4a60-4732-8230-f7be1a7a55dc_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_7ff944de-a164-40d4-8e42-af7b84f5bb50_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MortgageLoansOnRealEstate_080354ac-0792-418b-9c26-f9244cf21454_terseLabel_en-US" xlink:label="lab_us-gaap_MortgageLoansOnRealEstate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate</link:label>
    <link:label id="lab_us-gaap_MortgageLoansOnRealEstate_label_en-US" xlink:label="lab_us-gaap_MortgageLoansOnRealEstate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageLoansOnRealEstate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MortgageLoansOnRealEstate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MortgageLoansOnRealEstate" xlink:to="lab_us-gaap_MortgageLoansOnRealEstate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_93f9e5c8-c1ca-4432-b30a-b8d38a0c05e0_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_173c8a7a-1251-4b6b-8e6a-be9ee21609ce_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones_16a3d7f5-eb69-491a-a268-25be22d54200_terseLabel_en-US" xlink:label="lab_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Maximum Regulatory And Commercial Milestones</link:label>
    <link:label id="lab_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones_label_en-US" xlink:label="lab_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Maximum Regulatory And Commercial Milestones</link:label>
    <link:label id="lab_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones_documentation_en-US" xlink:label="lab_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the maximum regulatory and commercial launch milestone payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones" xlink:href="lxrx-20221231.xsd#lxrx_IpsenMaximumRegulatoryAndCommercialMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones" xlink:to="lab_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_16999491-3b82-48a8-97cf-544c953e4443_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_73609ed1-ec14-4b06-8884-f13362840636_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="lab_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_d42f8e7b-321b-437b-a8fa-e313a9bbec80_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_RDTaxCreditDecrease_b4dfc2dd-b4dc-48e5-af1e-c8e826114673_terseLabel_en-US" xlink:label="lab_lxrx_RDTaxCreditDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R&amp;D Tax Credit Decrease</link:label>
    <link:label id="lab_lxrx_RDTaxCreditDecrease_label_en-US" xlink:label="lab_lxrx_RDTaxCreditDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R&amp;D Tax Credit Decrease</link:label>
    <link:label id="lab_lxrx_RDTaxCreditDecrease_documentation_en-US" xlink:label="lab_lxrx_RDTaxCreditDecrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R&amp;D Tax Credit Decrease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_RDTaxCreditDecrease" xlink:href="lxrx-20221231.xsd#lxrx_RDTaxCreditDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_RDTaxCreditDecrease" xlink:to="lab_lxrx_RDTaxCreditDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_ab7ded41-699b-4a0d-b383-9244445adbb9_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SharesSoldInJuly2022Offering_24039d6b-7a53-4ff1-bd1c-97c793b95bb7_terseLabel_en-US" xlink:label="lab_lxrx_SharesSoldInJuly2022Offering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold in July 2022 Offering</link:label>
    <link:label id="lab_lxrx_SharesSoldInJuly2022Offering_label_en-US" xlink:label="lab_lxrx_SharesSoldInJuly2022Offering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold in July 2022 Offering</link:label>
    <link:label id="lab_lxrx_SharesSoldInJuly2022Offering_documentation_en-US" xlink:label="lab_lxrx_SharesSoldInJuly2022Offering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold in July 2022 Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesSoldInJuly2022Offering" xlink:href="lxrx-20221231.xsd#lxrx_SharesSoldInJuly2022Offering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SharesSoldInJuly2022Offering" xlink:to="lab_lxrx_SharesSoldInJuly2022Offering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_72f23d56-58bb-4a33-83c4-a7deae92726d_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_DeferredCompensationArrangementWithIndividualPaymentPeriod_2db133e3-1ca8-4ae0-b79d-2b00054dda48_terseLabel_en-US" xlink:label="lab_lxrx_DeferredCompensationArrangementWithIndividualPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment period</link:label>
    <link:label id="lab_lxrx_DeferredCompensationArrangementWithIndividualPaymentPeriod_label_en-US" xlink:label="lab_lxrx_DeferredCompensationArrangementWithIndividualPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Arrangement With Individual, Payment Period</link:label>
    <link:label id="lab_lxrx_DeferredCompensationArrangementWithIndividualPaymentPeriod_documentation_en-US" xlink:label="lab_lxrx_DeferredCompensationArrangementWithIndividualPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Arrangement With Individual, Payment Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DeferredCompensationArrangementWithIndividualPaymentPeriod" xlink:href="lxrx-20221231.xsd#lxrx_DeferredCompensationArrangementWithIndividualPaymentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_DeferredCompensationArrangementWithIndividualPaymentPeriod" xlink:to="lab_lxrx_DeferredCompensationArrangementWithIndividualPaymentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_4f874e30-2211-4a7d-bf9e-f6c7c1867138_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_f3a03dab-cbae-4f34-a1ae-d68775563001_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net of allowances of $4</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_a3a0a74f-c7b1-49f7-b1cd-ee73224b8c09_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_ae4e13b8-74d5-4ef6-bdd6-1cfa6e3d7ca3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement, Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_854d40b8-1b0c-4b0a-8bfe-72b42ab07954_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_24917059-5f8d-404c-ab5c-676989321411_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ATMOfferingTotal_0ad1e8ec-21b8-418f-be25-2defc338fcbe_terseLabel_en-US" xlink:label="lab_lxrx_ATMOfferingTotal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Offering Total</link:label>
    <link:label id="lab_lxrx_ATMOfferingTotal_label_en-US" xlink:label="lab_lxrx_ATMOfferingTotal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Offering Total</link:label>
    <link:label id="lab_lxrx_ATMOfferingTotal_documentation_en-US" xlink:label="lab_lxrx_ATMOfferingTotal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Offering Total</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ATMOfferingTotal" xlink:href="lxrx-20221231.xsd#lxrx_ATMOfferingTotal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ATMOfferingTotal" xlink:to="lab_lxrx_ATMOfferingTotal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_f33c2017-29db-4fcf-8b7b-4e3409521123_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Five Years</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Five Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_6abed942-ee46-4165-94b2-ef00a2667445_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementDomain_f1e1c88c-867f-4fcd-80ec-da6f94720f4e_terseLabel_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement [Domain]</link:label>
    <link:label id="lab_srt_RestatementDomain_label_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementDomain" xlink:to="lab_srt_RestatementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_e8eeea73-2b32-4d66-9325-0e1e096a4c48_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan_34c28383-d652-48fa-a663-775d518134ce_terseLabel_en-US" xlink:label="lab_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Outstanding, Non-Employee Directors Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan_label_en-US" xlink:label="lab_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Outstanding, Non-Employee Directors Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan_documentation_en-US" xlink:label="lab_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase shares outstanding under the Non-Employee Directors Equity Incentive Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan" xlink:href="lxrx-20221231.xsd#lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan" xlink:to="lab_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_c3f50f60-1fd5-4b9c-81dd-d42dfcb3ae3f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1de0f9d1-66de-42bf-ae18-73fc7c58c420_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_6e8d9e81-02e4-4c9b-aba8-699db6a00263_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_A2020ConvertibleDebtExchangePercentageOfPrincipal_5ccfbf92-8254-46a4-b3a8-b719bf9e9251_terseLabel_en-US" xlink:label="lab_lxrx_A2020ConvertibleDebtExchangePercentageOfPrincipal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 convertible debt exchange - percentage of principal</link:label>
    <link:label id="lab_lxrx_A2020ConvertibleDebtExchangePercentageOfPrincipal_label_en-US" xlink:label="lab_lxrx_A2020ConvertibleDebtExchangePercentageOfPrincipal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 convertible debt exchange - percentage of principal</link:label>
    <link:label id="lab_lxrx_A2020ConvertibleDebtExchangePercentageOfPrincipal_documentation_en-US" xlink:label="lab_lxrx_A2020ConvertibleDebtExchangePercentageOfPrincipal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 convertible debt exchange - percentage of principal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2020ConvertibleDebtExchangePercentageOfPrincipal" xlink:href="lxrx-20221231.xsd#lxrx_A2020ConvertibleDebtExchangePercentageOfPrincipal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_A2020ConvertibleDebtExchangePercentageOfPrincipal" xlink:to="lab_lxrx_A2020ConvertibleDebtExchangePercentageOfPrincipal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5bee19bc-6c78-463b-9d4f-8d88cd416f7f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_9b6dc267-01a4-4093-a28b-186b208b481f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, In Process Research and Development</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_OptionsOutstandingEquityIncentivePlan_afe7180d-5746-4084-ab05-2863be2cc2f7_terseLabel_en-US" xlink:label="lab_lxrx_OptionsOutstandingEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Outstanding, Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_OptionsOutstandingEquityIncentivePlan_label_en-US" xlink:label="lab_lxrx_OptionsOutstandingEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Outstanding, Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_OptionsOutstandingEquityIncentivePlan_documentation_en-US" xlink:label="lab_lxrx_OptionsOutstandingEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase shares outstanding under the Equity Incentive Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OptionsOutstandingEquityIncentivePlan" xlink:href="lxrx-20221231.xsd#lxrx_OptionsOutstandingEquityIncentivePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_OptionsOutstandingEquityIncentivePlan" xlink:to="lab_lxrx_OptionsOutstandingEquityIncentivePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_4f831671-d923-4513-81a2-62429bb3c646_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_a2a30359-fa63-45f5-98d9-89e85c63852f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_70a40eb0-459b-4498-9229-6adcab20a16e_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements and Changes in Accounting Principles [Text Block]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_cb903635-cd4f-4034-9e56-bc530842fcaf_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_89d553ab-f4a4-45dd-9f9c-4e81da0f1d97_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Gain (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetRetirementObligationDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetRetirementObligationDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Retirement Obligation Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetRetirementObligationDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetRetirementObligationDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetRetirementObligationDisclosureAbstract" xlink:to="lab_us-gaap_AssetRetirementObligationDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_3b68e99a-9193-4ec4-8f8d-7538df00b03c_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_FinalPaymentWithExtention_2afe1a9e-1bc3-49a5-96a8-9d708b87496a_terseLabel_en-US" xlink:label="lab_lxrx_FinalPaymentWithExtention" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final Payment % with extention</link:label>
    <link:label id="lab_lxrx_FinalPaymentWithExtention_label_en-US" xlink:label="lab_lxrx_FinalPaymentWithExtention" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final Payment % with extention</link:label>
    <link:label id="lab_lxrx_FinalPaymentWithExtention_documentation_en-US" xlink:label="lab_lxrx_FinalPaymentWithExtention" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final Payment % with extention</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FinalPaymentWithExtention" xlink:href="lxrx-20221231.xsd#lxrx_FinalPaymentWithExtention"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_FinalPaymentWithExtention" xlink:to="lab_lxrx_FinalPaymentWithExtention" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_1db3fdd4-b7cb-45dc-b761-fc621b91d154_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_6296222d-79e8-4094-8cd7-ee9d2700ae33_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfOperationsParentheticalsAbstract_5cc7e78b-6bf4-409f-acd1-8744490491bf_terseLabel_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfOperationsParentheticalsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Operations Parentheticals [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfOperationsParentheticalsAbstract_label_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfOperationsParentheticalsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Operations Parentheticals [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfOperationsParentheticalsAbstract_documentation_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfOperationsParentheticalsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Operations Parentheticals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedStatementsOfOperationsParentheticalsAbstract" xlink:href="lxrx-20221231.xsd#lxrx_ConsolidatedStatementsOfOperationsParentheticalsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConsolidatedStatementsOfOperationsParentheticalsAbstract" xlink:to="lab_lxrx_ConsolidatedStatementsOfOperationsParentheticalsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_029cec74-2ce0-4bdd-b755-c96199c0bc24_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The risk-free interest rate assumption that is used in valuing an option on its own shares for officers and non-employee directors.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" xlink:href="lxrx-20221231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_1e7fcb87-9cc9-4a7b-9d5d-3ac52e6b21cc_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustment_0e1f6fe9-629d-4e65-867b-63ac0527b6e1_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for New Accounting Pronouncement</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustment_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Period Reclassification Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustment" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_7648755b-8d2a-436a-9eef-e50eafb38886_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_a2014645-bd45-41c3-82ab-fdf32193c43b_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue_95f6cece-6b4c-4db5-99d4-ca8bdf35188d_terseLabel_en-US" xlink:label="lab_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Stock Bonus and Restricted Stock to Consultants, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Stock Bonus and Restricted Stock to Consultants, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue_documentation_en-US" xlink:label="lab_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The weighted average grant date fair value for grants of stock bonus and restricted stock awards made to consultants during the period under equity incentive plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue" xlink:href="lxrx-20221231.xsd#lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract_1ddb93fd-16e4-4bbe-9126-9ac9304293b0_terseLabel_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Stockholders&#8217; Equity [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Stockholders&#8217; Equity [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract_documentation_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Stockholders&#8217; Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract" xlink:href="lxrx-20221231.xsd#lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract" xlink:to="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3c5b325f-a314-4fe9-a4c6-95037335d365_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation, Stock Options, Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_9ffdcbad-ede9-4a57-9741-bb2b89912844_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_fed6cf35-980a-4a63-85f9-a97117d6c013_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) From Operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_9094529b-97cb-41fb-a3b7-457f0a0873fb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SanofiRevenueAllocatedtoFundingDeliverable_44238172-4005-442c-bfb0-e7d9b115992d_terseLabel_en-US" xlink:label="lab_lxrx_SanofiRevenueAllocatedtoFundingDeliverable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Revenue Allocated to Funding Deliverable</link:label>
    <link:label id="lab_lxrx_SanofiRevenueAllocatedtoFundingDeliverable_label_en-US" xlink:label="lab_lxrx_SanofiRevenueAllocatedtoFundingDeliverable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Revenue Allocated to Funding Deliverable</link:label>
    <link:label id="lab_lxrx_SanofiRevenueAllocatedtoFundingDeliverable_documentation_en-US" xlink:label="lab_lxrx_SanofiRevenueAllocatedtoFundingDeliverable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the amount of the upfront payment allocated to the funding deliverable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiRevenueAllocatedtoFundingDeliverable" xlink:href="lxrx-20221231.xsd#lxrx_SanofiRevenueAllocatedtoFundingDeliverable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SanofiRevenueAllocatedtoFundingDeliverable" xlink:to="lab_lxrx_SanofiRevenueAllocatedtoFundingDeliverable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_42c1fe99-e016-49ec-8c79-f9beb0044334_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_612577d3-1408-4d9e-8451-0cda2a2b1395_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5335da39-a6eb-4c24-85ba-7ef5c0596253_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Increase) decrease in prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_47f9d0c6-f8b5-4078-be23-a58cc1b86ff4_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_TermLoanAWarrantExercisePrice_a9161f75-8490-46a2-bb98-b87993a3c860_terseLabel_en-US" xlink:label="lab_lxrx_TermLoanAWarrantExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Warrant Exercise Price</link:label>
    <link:label id="lab_lxrx_TermLoanAWarrantExercisePrice_label_en-US" xlink:label="lab_lxrx_TermLoanAWarrantExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Warrant Exercise Price</link:label>
    <link:label id="lab_lxrx_TermLoanAWarrantExercisePrice_documentation_en-US" xlink:label="lab_lxrx_TermLoanAWarrantExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Warrant Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanAWarrantExercisePrice" xlink:href="lxrx-20221231.xsd#lxrx_TermLoanAWarrantExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TermLoanAWarrantExercisePrice" xlink:to="lab_lxrx_TermLoanAWarrantExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_DeferredTaxAssetsSection163j_LXRX_a0fc1d32-9ae5-4759-8f3b-3f80451d69f6_terseLabel_en-US" xlink:label="lab_lxrx_DeferredTaxAssetsSection163j_LXRX" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Section 163j_LXRX</link:label>
    <link:label id="lab_lxrx_DeferredTaxAssetsSection163j_LXRX_label_en-US" xlink:label="lab_lxrx_DeferredTaxAssetsSection163j_LXRX" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Section 163j_LXRX</link:label>
    <link:label id="lab_lxrx_DeferredTaxAssetsSection163j_LXRX_documentation_en-US" xlink:label="lab_lxrx_DeferredTaxAssetsSection163j_LXRX" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Section 163j_LXRX - represents the disallowed interest expense deduction as a result of adoption of the Tax Act in 2017</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DeferredTaxAssetsSection163j_LXRX" xlink:href="lxrx-20221231.xsd#lxrx_DeferredTaxAssetsSection163j_LXRX"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_DeferredTaxAssetsSection163j_LXRX" xlink:to="lab_lxrx_DeferredTaxAssetsSection163j_LXRX" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_47fd33fb-b7d8-4603-b054-21e8403566f8_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, shares</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_ac7fce74-694c-4a28-aa30-9c92c3944579_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, shares</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_43016b95-b9e9-43c7-83d7-e36d09046f46_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetImpairment_b9c85aca-e9b7-403e-8be2-962b9858bef6_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Asset Impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetImpairment_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Asset Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable_5fa65e8c-3b93-4e4c-a62a-991fe96b8c4f_terseLabel_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Revenue Allocated to Committee Deliverable</link:label>
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable_label_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Revenue Allocated to Committee Deliverable</link:label>
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable_documentation_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This is the amount of the upfront payment allocated to the committee participation deliverable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable" xlink:href="lxrx-20221231.xsd#lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable" xlink:to="lab_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockShares_b0592813-43cf-409d-8585-a4a27e8057a5_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fa7bb745-7bf4-4aca-ab99-b6a6d88bd3da_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConvertibleDebtExchange_23884c08-fb24-4bb5-9dce-de3f92ee04d6_terseLabel_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchange" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange</link:label>
    <link:label id="lab_lxrx_ConvertibleDebtExchange_label_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchange" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange</link:label>
    <link:label id="lab_lxrx_ConvertibleDebtExchange_documentation_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchange" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchange" xlink:href="lxrx-20221231.xsd#lxrx_ConvertibleDebtExchange"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConvertibleDebtExchange" xlink:to="lab_lxrx_ConvertibleDebtExchange" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_fea6d336-c1d8-4249-960f-a8bda490941a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a587122f-40e5-474c-86dc-b0e933562f82_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile consolidated net loss to net cash provided by (used in) operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_ee2f41ec-956f-4ebc-9b61-2bbad46f18db_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_726d8afc-b22d-4b35-b1c5-f7b617727fbd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_4e7f22da-87da-438e-8462-d88164f78ccc_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_21a4f3c5-6a2e-4ba8-8367-8f79c0f5067e_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value per share (usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0d43b59f-9fa3-4469-ac37-09bc825392a6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_a7cd3b7c-c7e4-4173-b3e3-7123e9cf9aa9_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_08c4af3f-0ab8-4490-b0f2-08b25541ae84_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_GainOnSaleOfNonFinancialAssets_27c2df3a-47bd-4958-a8ce-f5782cd7bf3b_terseLabel_en-US" xlink:label="lab_lxrx_GainOnSaleOfNonFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of non-financial assets</link:label>
    <link:label id="lab_lxrx_GainOnSaleOfNonFinancialAssets_cf594eaa-8de1-4f2a-856b-1fcb01f39616_negatedTerseLabel_en-US" xlink:label="lab_lxrx_GainOnSaleOfNonFinancialAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of non-financial assets</link:label>
    <link:label id="lab_lxrx_GainOnSaleOfNonFinancialAssets_label_en-US" xlink:label="lab_lxrx_GainOnSaleOfNonFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of non-financial assets</link:label>
    <link:label id="lab_lxrx_GainOnSaleOfNonFinancialAssets_documentation_en-US" xlink:label="lab_lxrx_GainOnSaleOfNonFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of non-financial assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_GainOnSaleOfNonFinancialAssets" xlink:href="lxrx-20221231.xsd#lxrx_GainOnSaleOfNonFinancialAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_GainOnSaleOfNonFinancialAssets" xlink:to="lab_lxrx_GainOnSaleOfNonFinancialAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_StockOptionsExercisedEquityIncentivePlan_8cc11999-9c74-48a1-a4f2-9cba3052921f_terseLabel_en-US" xlink:label="lab_lxrx_StockOptionsExercisedEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options Exercised, Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_StockOptionsExercisedEquityIncentivePlan_label_en-US" xlink:label="lab_lxrx_StockOptionsExercisedEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options Exercised, Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_StockOptionsExercisedEquityIncentivePlan_documentation_en-US" xlink:label="lab_lxrx_StockOptionsExercisedEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued upon the exercise of stock options under the Equity Incentive Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_StockOptionsExercisedEquityIncentivePlan" xlink:href="lxrx-20221231.xsd#lxrx_StockOptionsExercisedEquityIncentivePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_StockOptionsExercisedEquityIncentivePlan" xlink:to="lab_lxrx_StockOptionsExercisedEquityIncentivePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_55733532-7753-45ce-94bd-9377bc8ed063_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_55f7e5d1-90a5-4637-9fd0-885ad19cf03b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Total Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_56940e8b-7513-4175-8f25-5498b7c3c852_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales (including finite-lived intangible asset amortization)</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_680853fb-6b1d-44f9-9768-91ede0e30ac9_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_a94600fe-d5be-46ff-b31b-ca9aedb27e52_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Disclosure</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="lab_us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_bb087e29-080c-4629-97f0-a03798bfdfae_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation and amortization, property and equipment</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_869397dd-6de0-4993-b1bb-f535051eb552_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_1d96c59c-fc05-4afb-9483-dc3d6720037b_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings</link:label>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_label_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building and Building Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:to="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_60fec9e5-f032-4064-836a-e7cb7350be98_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_a8992e87-0952-4a9f-b9d2-3459cad06e09_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_d16cb97b-381c-4bca-ad6f-8a04878d9138_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsGross" xlink:to="lab_us-gaap_DeferredFinanceCostsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_ee647512-44e1-4a2c-a935-4250e934b0ca_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due Thereafter</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due Thereafter</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage_e36c4fee-25ca-477d-8fa9-e3117cbf8a54_terseLabel_en-US" xlink:label="lab_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt Instrument Interest Rate Stated Percentage</link:label>
    <link:label id="lab_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt Instrument Interest Rate Stated Percentage</link:label>
    <link:label id="lab_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage_documentation_en-US" xlink:label="lab_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual interest rate for funds borrowed under convertible debt, under the debt agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage" xlink:href="lxrx-20221231.xsd#lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage" xlink:to="lab_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_98d28af8-0c69-4d6f-ba4a-e3d360587db0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $.001 par value; 225,000 shares authorized; 106,679 and 106,162 shares issued, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_56ef6a77-ec8e-476a-8b10-c48235d86262_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_e5742406-6b62-4d22-95e5-99e111c2f460_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Amortized Cost Basis</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-Sale Securities, Amortized Cost Basis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_FairValueMeasurementsAbstract_6df4b961-4243-4295-8582-4505ef840704_terseLabel_en-US" xlink:label="lab_lxrx_FairValueMeasurementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements [Abstract]</link:label>
    <link:label id="lab_lxrx_FairValueMeasurementsAbstract_label_en-US" xlink:label="lab_lxrx_FairValueMeasurementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements [Abstract]</link:label>
    <link:label id="lab_lxrx_FairValueMeasurementsAbstract_documentation_en-US" xlink:label="lab_lxrx_FairValueMeasurementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FairValueMeasurementsAbstract" xlink:href="lxrx-20221231.xsd#lxrx_FairValueMeasurementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_FairValueMeasurementsAbstract" xlink:to="lab_lxrx_FairValueMeasurementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_de27427b-0e08-4737-81dc-98968ed6a03d_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the officers' and non-employee directors' option's term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" xlink:href="lxrx-20221231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_51218300-1c5c-4ad7-b6f2-c1d5a46137fe_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_cf1dc8b7-62f0-4ae9-997f-e0d8356a0534_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_5ea24003-28d5-47d6-a365-8aeb7bd696af_terseLabel_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized Investment Gains (Losses)</link:label>
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_label_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized Investment Gains (Losses)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealizedInvestmentGainsLosses" xlink:to="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1985ad47-c337-4d14-8e6a-b627d1406141_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4a2161d4-3e42-4817-beb1-76e147cddba4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_61c32a6b-8af2-4bc0-a14d-42f5dae77418_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract_6663f67d-29d1-49e2-8769-82676940ec16_terseLabel_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Operations [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract_label_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Operations [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract_documentation_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedStatementsOfOperationsAbstract" xlink:href="lxrx-20221231.xsd#lxrx_ConsolidatedStatementsOfOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConsolidatedStatementsOfOperationsAbstract" xlink:to="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_DebtInstrumentRepurchasePercentage_08944afd-1b0d-4439-84d9-970a15c27865_terseLabel_en-US" xlink:label="lab_lxrx_DebtInstrumentRepurchasePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase price</link:label>
    <link:label id="lab_lxrx_DebtInstrumentRepurchasePercentage_label_en-US" xlink:label="lab_lxrx_DebtInstrumentRepurchasePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Percentage</link:label>
    <link:label id="lab_lxrx_DebtInstrumentRepurchasePercentage_documentation_en-US" xlink:label="lab_lxrx_DebtInstrumentRepurchasePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DebtInstrumentRepurchasePercentage" xlink:href="lxrx-20221231.xsd#lxrx_DebtInstrumentRepurchasePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_DebtInstrumentRepurchasePercentage" xlink:to="lab_lxrx_DebtInstrumentRepurchasePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany_78362d80-c7dc-4d53-ae11-c3aae32ee597_terseLabel_en-US" xlink:label="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure On Geographic Areas Revenue From External Customers Attributed to Germany</link:label>
    <link:label id="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany_label_en-US" xlink:label="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure On Geographic Areas Revenue From External Customers Attributed to Germany</link:label>
    <link:label id="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany_documentation_en-US" xlink:label="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure On Geographic Areas Revenue From External Customers Attributed to Germany</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany" xlink:href="lxrx-20221231.xsd#lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany" xlink:to="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan_c66962f6-b5c2-433b-9ad4-90ef5b53d8f1_terseLabel_en-US" xlink:label="lab_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shares That May Be Issued, Non-Employee Directors Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan_label_en-US" xlink:label="lab_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shares That May Be Issued, Non-Employee Directors Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan_documentation_en-US" xlink:label="lab_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The total number of shares of common stock that may be issued pursuant to stock awards under the Non-Employee Directors Equity Incentive Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan" xlink:href="lxrx-20221231.xsd#lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan" xlink:to="lab_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan_44f20051-126b-43f5-92ad-dbeb9d440815_terseLabel_en-US" xlink:label="lab_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued Pursuant to Stock Bonus Awards, Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan_label_en-US" xlink:label="lab_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued Pursuant to Stock Bonus Awards, Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan_documentation_en-US" xlink:label="lab_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued pursuant to stock bonus awards or restricted stock awards under the Equity Incentive Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan" xlink:href="lxrx-20221231.xsd#lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan" xlink:to="lab_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_20858803-7fd2-4878-a164-cad0ab0f02ed_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_e6be65c1-d782-43e0-a781-60b3929dfdad_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_7fd83183-d048-4127-83ff-b00bd5640e90_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_ca2ef958-aa47-4176-8809-32e7bf4e4c21_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from debt borrowings, net of fees</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_A2025OxfordPrincipalPaymentA_fad3fb9d-0cc7-4631-a855-ddb10c269633_terseLabel_en-US" xlink:label="lab_lxrx_A2025OxfordPrincipalPaymentA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025 Oxford Principal Payment A</link:label>
    <link:label id="lab_lxrx_A2025OxfordPrincipalPaymentA_label_en-US" xlink:label="lab_lxrx_A2025OxfordPrincipalPaymentA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025 Oxford Principal Payment A</link:label>
    <link:label id="lab_lxrx_A2025OxfordPrincipalPaymentA_documentation_en-US" xlink:label="lab_lxrx_A2025OxfordPrincipalPaymentA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025 Oxford Principal Payment A</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2025OxfordPrincipalPaymentA" xlink:href="lxrx-20221231.xsd#lxrx_A2025OxfordPrincipalPaymentA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_A2025OxfordPrincipalPaymentA" xlink:to="lab_lxrx_A2025OxfordPrincipalPaymentA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_8b18d465-e8a8-4e52-98ef-c3f823021255_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenMaximumSalesMilestones_7fcc02df-a531-456e-9f65-71f371cd8f4b_terseLabel_en-US" xlink:label="lab_lxrx_IpsenMaximumSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Maximum Sales Milestones</link:label>
    <link:label id="lab_lxrx_IpsenMaximumSalesMilestones_label_en-US" xlink:label="lab_lxrx_IpsenMaximumSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Maximum Sales Milestones</link:label>
    <link:label id="lab_lxrx_IpsenMaximumSalesMilestones_documentation_en-US" xlink:label="lab_lxrx_IpsenMaximumSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the maximum sales milestones payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenMaximumSalesMilestones" xlink:href="lxrx-20221231.xsd#lxrx_IpsenMaximumSalesMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenMaximumSalesMilestones" xlink:to="lab_lxrx_IpsenMaximumSalesMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_00de05a5-098d-4096-bbdc-92dc2a2017ee_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_CommissionsFromDecember2020CommonStockOffering_edc0470d-4d36-47fc-9d6c-04f205fcf0dd_terseLabel_en-US" xlink:label="lab_lxrx_CommissionsFromDecember2020CommonStockOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commissions from December 2020 Common Stock Offering</link:label>
    <link:label id="lab_lxrx_CommissionsFromDecember2020CommonStockOffering_label_en-US" xlink:label="lab_lxrx_CommissionsFromDecember2020CommonStockOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commissions from December 2020 Common Stock Offering</link:label>
    <link:label id="lab_lxrx_CommissionsFromDecember2020CommonStockOffering_documentation_en-US" xlink:label="lab_lxrx_CommissionsFromDecember2020CommonStockOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commissions from December 2020 Common Stock Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CommissionsFromDecember2020CommonStockOffering" xlink:href="lxrx-20221231.xsd#lxrx_CommissionsFromDecember2020CommonStockOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_CommissionsFromDecember2020CommonStockOffering" xlink:to="lab_lxrx_CommissionsFromDecember2020CommonStockOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_38fb6cff-ac19-4a10-ac65-c5778cea2bfe_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_e934a0e2-9dba-44ed-b906-0c07f4e2c2b6_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Statement Line Items with Differences in Reported Amount and Reporting Currency Denominated Amounts [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfRegulatoryMilestones_07c9c913-5b1a-488f-8e11-b82b6752ef79_terseLabel_en-US" xlink:label="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of regulatory milestones</link:label>
    <link:label id="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfRegulatoryMilestones_label_en-US" xlink:label="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Number Of Regulatory Milestones</link:label>
    <link:label id="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfRegulatoryMilestones_documentation_en-US" xlink:label="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Number Of Regulatory Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfRegulatoryMilestones" xlink:href="lxrx-20221231.xsd#lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfRegulatoryMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfRegulatoryMilestones" xlink:to="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfRegulatoryMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_a90c6de7-89c8-4b32-a7ce-f49ab119aec3_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_472d40c9-e89f-439f-8668-569d198cda30_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_e22eb041-925f-4d15-9157-cf6f66991e05_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_02476c20-3b9e-48e7-9432-2f26a217afdb_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_e67b9a84-97e9-450e-8d0c-86544f413ccf_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, If-converted Value in Excess of Principal</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, If-converted Value in Excess of Principal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" xlink:to="lab_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_07dae369-131d-4523-825b-a4723637d91c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_b676b68f-7c3a-4fc1-8bc5-b5ae02df0324_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_a063e9a4-9383-4e4f-9e51-829d062665d9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="lab_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_71676e1f-7b7c-411a-8aa3-e060fbe2db17_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_3dada984-c719-4adb-9df4-3cf2b0e5ddae_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_bfb3e5ad-c92d-46f1-8ff1-7d4b2190e4d9_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfRealEstate_01c59e80-9ce1-46b5-8169-62b2567f6aad_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfRealEstate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Real Estate</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfRealEstate_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfRealEstate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Real Estate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfRealEstate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfRealEstate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfRealEstate" xlink:to="lab_us-gaap_ImpairmentOfRealEstate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment_4a22744a-46c6-47e1-9bbb-99da080388e4_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Other Property, Plant, and Equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Other Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_3609f9bd-cdd8-456c-8861-ac33bd1cd4eb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use-assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebt_61b1cb98-57f6-4ada-a7c1-bf47d26e23fc_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebt" xlink:to="lab_us-gaap_ConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_82519018-da0b-4ea8-94df-107aca52fe8e_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Policy</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense_a414f44c-8036-4abb-8c25-78ded4e65188_terseLabel_en-US" xlink:label="lab_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense associated with general and administrative expense</link:label>
    <link:label id="lab_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense associated with general and administrative expense</link:label>
    <link:label id="lab_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense_documentation_en-US" xlink:label="lab_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense associated with general and administrative expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense" xlink:href="lxrx-20221231.xsd#lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense" xlink:to="lab_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_4e6380e7-cd7f-445a-8814-2dbff22f9520_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_e80df996-270e-4f4c-8093-d3ac470ad9cd_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The expected term assumption that is used in valuing an option on its own shares for officers and non-employee directors.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" xlink:href="lxrx-20221231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_f38e294d-aeaf-42cb-99dc-3b481ea4d635_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyIncomeNonoperating_52e72088-2056-4689-b53e-54d1a171fae1_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyIncomeNonoperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties and other revenue</link:label>
    <link:label id="lab_us-gaap_RoyaltyIncomeNonoperating_label_en-US" xlink:label="lab_us-gaap_RoyaltyIncomeNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Income, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyIncomeNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyIncomeNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyIncomeNonoperating" xlink:to="lab_us-gaap_RoyaltyIncomeNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_708bbffb-6274-44e4-9e21-3622b8f79e70_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Treasury Stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_a3dbf8d2-0e5a-439b-a0ec-975458a1c339_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Treasury Stock Reissued</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Treasury Stock Reissued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e8cceefc-dcf9-479b-af60-1f562f128400_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_a2e187ab-622b-4f61-a230-49517ec1e734_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_0ea2f865-53bf-4920-8287-3dbc6ff1dfab_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net of accumulated depreciation and amortization of $61,741 and $60,006, respectively</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_e0856c98-5102-4329-a108-29d7427d2494_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_517cec61-a32f-45b1-b449-bdcf6f33ae21_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of debt borrowings</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_3f838ec0-30d8-44e7-ab7e-4b98a7432290_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_002be0bb-dc7c-481c-8ad8-065ec25ff2d2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, at cost, 407 and 236 shares, respectively</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_b98ee114-faae-46bc-9ab0-cb084e92da8e_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod_a22348e8-eb23-49ac-a169-0bd268b6c13d_terseLabel_en-US" xlink:label="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration period</link:label>
    <link:label id="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod_label_en-US" xlink:label="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Expiration Period</link:label>
    <link:label id="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod_documentation_en-US" xlink:label="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod" xlink:href="lxrx-20221231.xsd#lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod" xlink:to="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d2c796d2-8b14-4537-8681-c2b582ae4c40_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_e0d38826-a14b-4a0d-983b-4b196b86726f_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_66d9cc73-bea8-4eb2-9aba-3668b30f6cf2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_eebf1ec6-a2ab-4f1a-9fd5-406df49931c5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_85f42230-570f-4197-a516-e76a10245792_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected VolatilityRate, Employees</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, ExpectedVolatilityRate, Employees</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">For employees, the estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" xlink:href="lxrx-20221231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_759a22ee-0e15-45df-a070-e37dd1b86556_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_95013c1d-a9c6-4491-834a-44f4e7d78856_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_Totalvalueofsharesbynonemployeeinayear_3e8d83a7-1342-4fa3-a397-3474e4c2917d_terseLabel_en-US" xlink:label="lab_lxrx_Totalvalueofsharesbynonemployeeinayear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total value of shares by nonemployee in a year</link:label>
    <link:label id="lab_lxrx_Totalvalueofsharesbynonemployeeinayear_label_en-US" xlink:label="lab_lxrx_Totalvalueofsharesbynonemployeeinayear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total value of shares by nonemployee in a year</link:label>
    <link:label id="lab_lxrx_Totalvalueofsharesbynonemployeeinayear_documentation_en-US" xlink:label="lab_lxrx_Totalvalueofsharesbynonemployeeinayear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total value of shares by nonemployee in a year - represents amounts under which non-employee director may be granted awards under the Non-Employee Directors Equity Incentive Plan such that the aggregate grant date fair value may not exceed $500,000 in any calendar year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Totalvalueofsharesbynonemployeeinayear" xlink:href="lxrx-20221231.xsd#lxrx_Totalvalueofsharesbynonemployeeinayear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_Totalvalueofsharesbynonemployeeinayear" xlink:to="lab_lxrx_Totalvalueofsharesbynonemployeeinayear" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_bc92b6e6-37b4-41b9-a5fc-5225899372f0_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8f8e6026-9462-4c2a-8659-a3bb10da0fae_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones_9bd0d6fb-15ca-43b6-9e3b-2d488a5160d0_terseLabel_en-US" xlink:label="lab_lxrx_TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TerSera Maximum Development, Regulatory and Commercial Milestones</link:label>
    <link:label id="lab_lxrx_TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones_label_en-US" xlink:label="lab_lxrx_TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TerSera Maximum Development, Regulatory and Commercial Milestones</link:label>
    <link:label id="lab_lxrx_TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones_documentation_en-US" xlink:label="lab_lxrx_TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TerSera Maximum Development, Regulatory and Commercial Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones" xlink:href="lxrx-20221231.xsd#lxrx_TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones" xlink:to="lab_lxrx_TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestAndDebtExpense_589cf4c3-7eda-4e04-a662-6782dc2e6f02_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestAndDebtExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and Debt Expense</link:label>
    <link:label id="lab_us-gaap_InterestAndDebtExpense_label_en-US" xlink:label="lab_us-gaap_InterestAndDebtExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and Debt Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndDebtExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndDebtExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestAndDebtExpense" xlink:to="lab_us-gaap_InterestAndDebtExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_31cd6adb-ca84-44b5-a8ab-b78012e0e453_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Rent Expense</link:label>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_label_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Rent Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseAndRentalExpense" xlink:to="lab_us-gaap_LeaseAndRentalExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_eaf43533-7dcf-4bb0-9c0e-3e8a04e1ce33_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_84818076-b453-4017-af3d-3c3ea4dbcb66_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of year</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0425f09d-b14d-442f-8aed-66b6a6b12c40_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of year</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_77ed8bf4-2285-4cb3-a098-1cc908531623_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_29b7ea8c-ff09-440d-8640-f4432cc47657_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SharePriceInJanuary2021ATMOffering_f91f5922-24a6-4c7a-9af7-0595588a66ef_terseLabel_en-US" xlink:label="lab_lxrx_SharePriceInJanuary2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price in January 2021 ATM Offering</link:label>
    <link:label id="lab_lxrx_SharePriceInJanuary2021ATMOffering_label_en-US" xlink:label="lab_lxrx_SharePriceInJanuary2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price in January 2021 ATM Offering</link:label>
    <link:label id="lab_lxrx_SharePriceInJanuary2021ATMOffering_documentation_en-US" xlink:label="lab_lxrx_SharePriceInJanuary2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price in January 2021 ATM Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharePriceInJanuary2021ATMOffering" xlink:href="lxrx-20221231.xsd#lxrx_SharePriceInJanuary2021ATMOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SharePriceInJanuary2021ATMOffering" xlink:to="lab_lxrx_SharePriceInJanuary2021ATMOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_d31fc212-72e2-4ffe-8085-a391099d8a88_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_a50b1c4c-0118-42ca-b7b6-c228634453c6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable" xlink:to="lab_us-gaap_OtherCommitmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_OxfordAmendmentFee_88a5f690-892b-45a6-914d-ca90d090e292_terseLabel_en-US" xlink:label="lab_lxrx_OxfordAmendmentFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Amendment Fee</link:label>
    <link:label id="lab_lxrx_OxfordAmendmentFee_label_en-US" xlink:label="lab_lxrx_OxfordAmendmentFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Amendment Fee</link:label>
    <link:label id="lab_lxrx_OxfordAmendmentFee_documentation_en-US" xlink:label="lab_lxrx_OxfordAmendmentFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Amendment Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OxfordAmendmentFee" xlink:href="lxrx-20221231.xsd#lxrx_OxfordAmendmentFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_OxfordAmendmentFee" xlink:to="lab_lxrx_OxfordAmendmentFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_63419cbc-4a5f-4013-91ce-f995260834c5_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_daa30c99-3f2d-4c49-b04e-e0f206006097_terseLabel_en-US" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Stock and Warrants for Services or Claims</link:label>
    <link:label id="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_label_en-US" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Stock and Warrants for Services or Claims</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_GoodwillAbstract_44efa89a-c148-469e-bf8b-0237686b4dc3_terseLabel_en-US" xlink:label="lab_lxrx_GoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Abstract]</link:label>
    <link:label id="lab_lxrx_GoodwillAbstract_label_en-US" xlink:label="lab_lxrx_GoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Abstract]</link:label>
    <link:label id="lab_lxrx_GoodwillAbstract_documentation_en-US" xlink:label="lab_lxrx_GoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_GoodwillAbstract" xlink:href="lxrx-20221231.xsd#lxrx_GoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_GoodwillAbstract" xlink:to="lab_lxrx_GoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_c40243f8-9d1d-4b48-82a2-39f5a0ae46c8_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales</link:label>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:to="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_d94d41f6-281d-417f-8076-9ec9d1a4cc5f_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SettlementPaymentFromTermination_1ea50177-5d04-4b2a-abe5-b2b5720871c8_terseLabel_en-US" xlink:label="lab_lxrx_SettlementPaymentFromTermination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Payment from Termination</link:label>
    <link:label id="lab_lxrx_SettlementPaymentFromTermination_label_en-US" xlink:label="lab_lxrx_SettlementPaymentFromTermination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Payment from Termination</link:label>
    <link:label id="lab_lxrx_SettlementPaymentFromTermination_documentation_en-US" xlink:label="lab_lxrx_SettlementPaymentFromTermination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Payment from Termination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SettlementPaymentFromTermination" xlink:href="lxrx-20221231.xsd#lxrx_SettlementPaymentFromTermination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SettlementPaymentFromTermination" xlink:to="lab_lxrx_SettlementPaymentFromTermination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_44b796b8-a07b-47e5-b5b6-ad08f408c7ba_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_745b8a1a-bbc1-4a7e-9c94-5b04a930cd5e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_d74c7162-7ba6-4557-a4e4-97cee366dcf4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_763738a9-c46b-4c6a-a7d9-a0f8d0559194_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:to="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_TermLoanANetCashReceipt_e2ca6cec-66b4-48fc-b454-a905af2fe48d_terseLabel_en-US" xlink:label="lab_lxrx_TermLoanANetCashReceipt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Net Cash Receipt</link:label>
    <link:label id="lab_lxrx_TermLoanANetCashReceipt_label_en-US" xlink:label="lab_lxrx_TermLoanANetCashReceipt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Net Cash Receipt</link:label>
    <link:label id="lab_lxrx_TermLoanANetCashReceipt_documentation_en-US" xlink:label="lab_lxrx_TermLoanANetCashReceipt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Net Cash Receipt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanANetCashReceipt" xlink:href="lxrx-20221231.xsd#lxrx_TermLoanANetCashReceipt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TermLoanANetCashReceipt" xlink:to="lab_lxrx_TermLoanANetCashReceipt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_eff137bd-c3a9-423e-8a01-ef491184a446_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_0c31e3e3-8df4-4136-a197-6b8ac8e9e681_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ProceedsFromJanuary2021ATMOffering_4ba4cbe8-c3ab-4136-8b7c-6dbba26f3d9a_terseLabel_en-US" xlink:label="lab_lxrx_ProceedsFromJanuary2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from January 2021 ATM Offering</link:label>
    <link:label id="lab_lxrx_ProceedsFromJanuary2021ATMOffering_label_en-US" xlink:label="lab_lxrx_ProceedsFromJanuary2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from January 2021 ATM Offering</link:label>
    <link:label id="lab_lxrx_ProceedsFromJanuary2021ATMOffering_documentation_en-US" xlink:label="lab_lxrx_ProceedsFromJanuary2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from January 2021 ATM Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ProceedsFromJanuary2021ATMOffering" xlink:href="lxrx-20221231.xsd#lxrx_ProceedsFromJanuary2021ATMOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ProceedsFromJanuary2021ATMOffering" xlink:to="lab_lxrx_ProceedsFromJanuary2021ATMOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_f86cd9bc-9fe0-44bc-a1e5-1e9820a2f98a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Increase) decrease in accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_8c0b9c1c-3930-491c-a933-ff44a9da4662_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_b08de3e8-9cda-4fc8-bc75-d33f5b6dd9b7_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Operations</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_0660d777-fbba-4b07-affc-a8fbce41ae62_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfCondensedFinancialStatementsTable_920b12c2-9512-47ce-ab98-5290eedeb021_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfCondensedFinancialStatementsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Condensed Financial Statements [Table]</link:label>
    <link:label id="lab_srt_ScheduleOfCondensedFinancialStatementsTable_label_en-US" xlink:label="lab_srt_ScheduleOfCondensedFinancialStatementsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Financial Statements [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="lab_srt_ScheduleOfCondensedFinancialStatementsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubordinatedBorrowingInterestRate_841c115e-630d-45bf-8b06-fc7e0f0cac14_terseLabel_en-US" xlink:label="lab_us-gaap_SubordinatedBorrowingInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subordinated Borrowing, Interest Rate</link:label>
    <link:label id="lab_us-gaap_SubordinatedBorrowingInterestRate_label_en-US" xlink:label="lab_us-gaap_SubordinatedBorrowingInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subordinated Borrowing, Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubordinatedBorrowingInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubordinatedBorrowingInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubordinatedBorrowingInterestRate" xlink:to="lab_us-gaap_SubordinatedBorrowingInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SharesSoldInSeptember2021ATMOffering_b576605c-94a9-4081-b6b5-8a094312e66a_terseLabel_en-US" xlink:label="lab_lxrx_SharesSoldInSeptember2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold in September 2021 ATM offering</link:label>
    <link:label id="lab_lxrx_SharesSoldInSeptember2021ATMOffering_label_en-US" xlink:label="lab_lxrx_SharesSoldInSeptember2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold in September 2021 ATM offering</link:label>
    <link:label id="lab_lxrx_SharesSoldInSeptember2021ATMOffering_documentation_en-US" xlink:label="lab_lxrx_SharesSoldInSeptember2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold in September 2021 ATM offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesSoldInSeptember2021ATMOffering" xlink:href="lxrx-20221231.xsd#lxrx_SharesSoldInSeptember2021ATMOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SharesSoldInSeptember2021ATMOffering" xlink:to="lab_lxrx_SharesSoldInSeptember2021ATMOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_ee626cfe-3f1c-47d8-a1e3-33440560ead7_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SanofiDeferredRevenueFromTermination_b1885e2d-00a8-4a87-81da-89e244633856_terseLabel_en-US" xlink:label="lab_lxrx_SanofiDeferredRevenueFromTermination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Deferred Revenue from Termination</link:label>
    <link:label id="lab_lxrx_SanofiDeferredRevenueFromTermination_label_en-US" xlink:label="lab_lxrx_SanofiDeferredRevenueFromTermination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Deferred Revenue from Termination</link:label>
    <link:label id="lab_lxrx_SanofiDeferredRevenueFromTermination_documentation_en-US" xlink:label="lab_lxrx_SanofiDeferredRevenueFromTermination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Deferred Revenue from Termination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiDeferredRevenueFromTermination" xlink:href="lxrx-20221231.xsd#lxrx_SanofiDeferredRevenueFromTermination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SanofiDeferredRevenueFromTermination" xlink:to="lab_lxrx_SanofiDeferredRevenueFromTermination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockSharesIssued1_ea1d9212-6a45-4d03-95b2-26de5d13e197_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockSharesIssued1_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesIssued1" xlink:to="lab_us-gaap_ConversionOfStockSharesIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_043e5b71-8cc7-4f8e-95ba-f8086c1165c0_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_62745bdb-4ef7-4fbc-aacf-8c5f7a34b87b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under Equity Incentive Plans, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_371d1a96-141a-4053-9612-8f9ac155df16_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConsolidatedBalanceSheetsAbstract_e92999b7-89cc-4684-b4eb-ea7d6904f4bf_terseLabel_en-US" xlink:label="lab_lxrx_ConsolidatedBalanceSheetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Balance Sheets [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedBalanceSheetsAbstract_label_en-US" xlink:label="lab_lxrx_ConsolidatedBalanceSheetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Balance Sheets [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedBalanceSheetsAbstract_documentation_en-US" xlink:label="lab_lxrx_ConsolidatedBalanceSheetsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Balance Sheets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedBalanceSheetsAbstract" xlink:href="lxrx-20221231.xsd#lxrx_ConsolidatedBalanceSheetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract" xlink:to="lab_lxrx_ConsolidatedBalanceSheetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SaleOfNonFinancialAssetsTextBlock_2a6ceabe-1359-494a-aefb-be5ac21a3fc2_terseLabel_en-US" xlink:label="lab_lxrx_SaleOfNonFinancialAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Non-Financial Assets</link:label>
    <link:label id="lab_lxrx_SaleOfNonFinancialAssetsTextBlock_label_en-US" xlink:label="lab_lxrx_SaleOfNonFinancialAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Non-Financial Assets [Text Block]</link:label>
    <link:label id="lab_lxrx_SaleOfNonFinancialAssetsTextBlock_documentation_en-US" xlink:label="lab_lxrx_SaleOfNonFinancialAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Non-Financial Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SaleOfNonFinancialAssetsTextBlock" xlink:href="lxrx-20221231.xsd#lxrx_SaleOfNonFinancialAssetsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SaleOfNonFinancialAssetsTextBlock" xlink:to="lab_lxrx_SaleOfNonFinancialAssetsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_3f557c3a-9362-4a1b-a7d9-9d746b794450_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Land_e387f8ed-b643-462c-b7dd-fdbf515a54db_terseLabel_en-US" xlink:label="lab_us-gaap_Land" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_Land_label_en-US" xlink:label="lab_us-gaap_Land" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Land"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Land" xlink:to="lab_us-gaap_Land" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_739b2ef2-258a-4d2c-ba77-5c5ed7cb0922_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SharePriceInSeptember2021ATMOffering_4979aabd-e69d-4878-9b46-c368a24e211a_terseLabel_en-US" xlink:label="lab_lxrx_SharePriceInSeptember2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price in September 2021 ATM Offering</link:label>
    <link:label id="lab_lxrx_SharePriceInSeptember2021ATMOffering_label_en-US" xlink:label="lab_lxrx_SharePriceInSeptember2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price in September 2021 ATM Offering</link:label>
    <link:label id="lab_lxrx_SharePriceInSeptember2021ATMOffering_documentation_en-US" xlink:label="lab_lxrx_SharePriceInSeptember2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price in September 2021 ATM Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharePriceInSeptember2021ATMOffering" xlink:href="lxrx-20221231.xsd#lxrx_SharePriceInSeptember2021ATMOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SharePriceInSeptember2021ATMOffering" xlink:to="lab_lxrx_SharePriceInSeptember2021ATMOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_d3f13102-ec31-4e63-867f-2cb6d1fb218d_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SharesSoldInJanuary2021ATMOffering_5970efb8-7106-4ec2-a9dd-e6256e19e2cd_terseLabel_en-US" xlink:label="lab_lxrx_SharesSoldInJanuary2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold in January 2021 ATM offering</link:label>
    <link:label id="lab_lxrx_SharesSoldInJanuary2021ATMOffering_label_en-US" xlink:label="lab_lxrx_SharesSoldInJanuary2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold in January 2021 ATM offering</link:label>
    <link:label id="lab_lxrx_SharesSoldInJanuary2021ATMOffering_documentation_en-US" xlink:label="lab_lxrx_SharesSoldInJanuary2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold in January 2021 ATM offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesSoldInJanuary2021ATMOffering" xlink:href="lxrx-20221231.xsd#lxrx_SharesSoldInJanuary2021ATMOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SharesSoldInJanuary2021ATMOffering" xlink:to="lab_lxrx_SharesSoldInJanuary2021ATMOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_35168d23-9689-455e-bb23-513e6a546290_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_9b73077d-c131-4fbe-95cd-407345f1eb54_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_61242591-42a9-49b0-83d5-c078c472fd2c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan_c2507775-0d03-4888-8114-72c4a5b9ff00_terseLabel_en-US" xlink:label="lab_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued Pursuant to Restricted Stock Awards, Non-Employee Directors Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan_label_en-US" xlink:label="lab_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued Pursuant to Restricted Stock Awards, Non-Employee Directors Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan_documentation_en-US" xlink:label="lab_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued pursuant to restricted stock awards under the Non-Employee Directors Equity Incentive Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan" xlink:href="lxrx-20221231.xsd#lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan" xlink:to="lab_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets_3c214754-fbb0-4e61-a3d7-fd5e5e726d6d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on disposal of property and equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_7db0eead-fb07-41ca-b691-6ff896ea4281_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_242ac151-d88b-409d-bea3-fe60f8da7513_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SanofiRevenueAllocatedtoLicenseDeliverable_22ad72ce-d9fc-4202-a1ec-bdb020c5b73e_terseLabel_en-US" xlink:label="lab_lxrx_SanofiRevenueAllocatedtoLicenseDeliverable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Revenue Allocated to License Deliverable</link:label>
    <link:label id="lab_lxrx_SanofiRevenueAllocatedtoLicenseDeliverable_label_en-US" xlink:label="lab_lxrx_SanofiRevenueAllocatedtoLicenseDeliverable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Revenue Allocated to License Deliverable</link:label>
    <link:label id="lab_lxrx_SanofiRevenueAllocatedtoLicenseDeliverable_documentation_en-US" xlink:label="lab_lxrx_SanofiRevenueAllocatedtoLicenseDeliverable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the amount of the upfront payment allocated to the license deliverable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiRevenueAllocatedtoLicenseDeliverable" xlink:href="lxrx-20221231.xsd#lxrx_SanofiRevenueAllocatedtoLicenseDeliverable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SanofiRevenueAllocatedtoLicenseDeliverable" xlink:to="lab_lxrx_SanofiRevenueAllocatedtoLicenseDeliverable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_b7a3b6b2-8a0a-4734-a05e-f897bca1150d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Increase) decrease in other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock_a372ecb3-e43c-464d-a21d-2033568e3658_terseLabel_en-US" xlink:label="lab_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option Exercise Price as Percent of Value of Common Stock</link:label>
    <link:label id="lab_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock_label_en-US" xlink:label="lab_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option Exercise Price as Percent of Value of Common Stock</link:label>
    <link:label id="lab_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock_documentation_en-US" xlink:label="lab_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive and nonstatutory stock options have an exercise price of 100% or more of the fair market value of common stock on the date of grant.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock" xlink:href="lxrx-20221231.xsd#lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock" xlink:to="lab_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_A2027OxfordPrincipalPaymentsB_b20561dd-1379-4c43-889d-e8b9f863deef_terseLabel_en-US" xlink:label="lab_lxrx_A2027OxfordPrincipalPaymentsB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027 Oxford Principal Payments B</link:label>
    <link:label id="lab_lxrx_A2027OxfordPrincipalPaymentsB_label_en-US" xlink:label="lab_lxrx_A2027OxfordPrincipalPaymentsB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027 Oxford Principal Payments B</link:label>
    <link:label id="lab_lxrx_A2027OxfordPrincipalPaymentsB_documentation_en-US" xlink:label="lab_lxrx_A2027OxfordPrincipalPaymentsB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027 Oxford Principal Payments B</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2027OxfordPrincipalPaymentsB" xlink:href="lxrx-20221231.xsd#lxrx_A2027OxfordPrincipalPaymentsB"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_A2027OxfordPrincipalPaymentsB" xlink:to="lab_lxrx_A2027OxfordPrincipalPaymentsB" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_b6abfa16-307d-41f5-930f-686a621c4e14_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_6bcfd41c-158d-4a4f-8ca8-80d51571450b_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_a68bff89-2c46-4575-9ebb-4f46c291910d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock, net of fees</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_d7151c05-04bb-4b8b-bf8c-475e69d31047_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_a0690a72-eb6f-4d35-b052-f4055e6d46d9_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_914f8198-38ad-414f-b885-4f7d7131302c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_naics_ZZ541713_e548899e-254c-48d9-a777-14d20f04bf86_terseLabel_en-US" xlink:label="lab_naics_ZZ541713" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">541713 Research and Development in Nanotechnology</link:label>
    <link:label id="lab_naics_ZZ541713_label_en-US" xlink:label="lab_naics_ZZ541713" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">541713 Research and Development in Nanotechnology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_naics_ZZ541713" xlink:href="https://xbrl.sec.gov/naics/2022/naics-2022.xsd#naics_ZZ541713"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_naics_ZZ541713" xlink:to="lab_naics_ZZ541713" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan_fe36c62d-2da0-41a9-80b1-4989d6854239_terseLabel_en-US" xlink:label="lab_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options Exercised, Non-Employee Directors Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan_label_en-US" xlink:label="lab_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options Exercised, Non-Employee Directors Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan_documentation_en-US" xlink:label="lab_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued upon the exercise of stock options under the Non-Employee Directors Equity Incentive Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan" xlink:href="lxrx-20221231.xsd#lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan" xlink:to="lab_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SanofiUpfrontPayment_512c6849-2de8-429a-9c28-6a298f99a1b2_terseLabel_en-US" xlink:label="lab_lxrx_SanofiUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Upfront Payment</link:label>
    <link:label id="lab_lxrx_SanofiUpfrontPayment_label_en-US" xlink:label="lab_lxrx_SanofiUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Upfront Payment</link:label>
    <link:label id="lab_lxrx_SanofiUpfrontPayment_documentation_en-US" xlink:label="lab_lxrx_SanofiUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate satagliflozin. This represents the upfront payment under the agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiUpfrontPayment" xlink:href="lxrx-20221231.xsd#lxrx_SanofiUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SanofiUpfrontPayment" xlink:to="lab_lxrx_SanofiUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b159c16f-6de7-4428-b667-438f6a1de4f4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_abaa9a78-bc3f-4cce-a485-8781f138c4d1_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $.01 par value; 5,000 shares authorized; no shares issued and outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_MortgageDebtInstrument_Revere_LXRX_c36cb50c-d394-4f29-92a6-8f22008cd1cc_terseLabel_en-US" xlink:label="lab_lxrx_MortgageDebtInstrument_Revere_LXRX" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Instrument_Revere_LXRX</link:label>
    <link:label id="lab_lxrx_MortgageDebtInstrument_Revere_LXRX_label_en-US" xlink:label="lab_lxrx_MortgageDebtInstrument_Revere_LXRX" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Instrument_Revere_LXRX</link:label>
    <link:label id="lab_lxrx_MortgageDebtInstrument_Revere_LXRX_documentation_en-US" xlink:label="lab_lxrx_MortgageDebtInstrument_Revere_LXRX" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Instrument_Revere_LXRX - Principal loan amount borrowed, using Woodlands Campus as collateral</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtInstrument_Revere_LXRX" xlink:href="lxrx-20221231.xsd#lxrx_MortgageDebtInstrument_Revere_LXRX"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_MortgageDebtInstrument_Revere_LXRX" xlink:to="lab_lxrx_MortgageDebtInstrument_Revere_LXRX" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_OtherCapitalAgreementsTextBlock_d2459a20-2229-47b0-8f41-d8f83255ab46_terseLabel_en-US" xlink:label="lab_lxrx_OtherCapitalAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Capital Agreements</link:label>
    <link:label id="lab_lxrx_OtherCapitalAgreementsTextBlock_label_en-US" xlink:label="lab_lxrx_OtherCapitalAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Capital Agreements [Text Block]</link:label>
    <link:label id="lab_lxrx_OtherCapitalAgreementsTextBlock_documentation_en-US" xlink:label="lab_lxrx_OtherCapitalAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Capital Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OtherCapitalAgreementsTextBlock" xlink:href="lxrx-20221231.xsd#lxrx_OtherCapitalAgreementsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_OtherCapitalAgreementsTextBlock" xlink:to="lab_lxrx_OtherCapitalAgreementsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_7e615ef2-7629-4fd2-8f4d-3617ad562133_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_247cffab-f177-4836-bf16-95579cc61951_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_5e56d5c1-ca35-4bf6-b618-36a9d5befe61_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_092624d6-9b94-47db-88d5-a18ea2e2eddd_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_EquityIncentiveAwardsAbstract_8562e196-81b6-4185-a833-d2741f73bc2c_terseLabel_en-US" xlink:label="lab_lxrx_EquityIncentiveAwardsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Awards [Abstract]</link:label>
    <link:label id="lab_lxrx_EquityIncentiveAwardsAbstract_label_en-US" xlink:label="lab_lxrx_EquityIncentiveAwardsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Awards [Abstract]</link:label>
    <link:label id="lab_lxrx_EquityIncentiveAwardsAbstract_documentation_en-US" xlink:label="lab_lxrx_EquityIncentiveAwardsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Awards [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_EquityIncentiveAwardsAbstract" xlink:href="lxrx-20221231.xsd#lxrx_EquityIncentiveAwardsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_EquityIncentiveAwardsAbstract" xlink:to="lab_lxrx_EquityIncentiveAwardsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0e1fde0f-3e7c-4f6b-a665-022d55b5fca8_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_a9f4639f-3311-46cd-9153-03d117b15b78_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_7e206579-2847-4390-a978-4ec16eda1309_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Intangible Assets, Indefinite-Lived, Policy</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Intangible Assets, Indefinite-Lived, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_DefinedContributionPlanRequisiteServicePeriod_ecf1d848-7857-4bee-99fc-c3905b13e1f7_terseLabel_en-US" xlink:label="lab_lxrx_DefinedContributionPlanRequisiteServicePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Years of service</link:label>
    <link:label id="lab_lxrx_DefinedContributionPlanRequisiteServicePeriod_label_en-US" xlink:label="lab_lxrx_DefinedContributionPlanRequisiteServicePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Requisite Service Period</link:label>
    <link:label id="lab_lxrx_DefinedContributionPlanRequisiteServicePeriod_documentation_en-US" xlink:label="lab_lxrx_DefinedContributionPlanRequisiteServicePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Requisite Service Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DefinedContributionPlanRequisiteServicePeriod" xlink:href="lxrx-20221231.xsd#lxrx_DefinedContributionPlanRequisiteServicePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_DefinedContributionPlanRequisiteServicePeriod" xlink:to="lab_lxrx_DefinedContributionPlanRequisiteServicePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_1552004d-207d-4af1-9f3b-24d8f0ed42e7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_FinalConsiderationIncludingAmountsReleasedToSettle_d4b04e6f-acca-4869-aa22-d608c385ff65_terseLabel_en-US" xlink:label="lab_lxrx_FinalConsiderationIncludingAmountsReleasedToSettle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final Consideration including amounts released to settle</link:label>
    <link:label id="lab_lxrx_FinalConsiderationIncludingAmountsReleasedToSettle_label_en-US" xlink:label="lab_lxrx_FinalConsiderationIncludingAmountsReleasedToSettle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final Consideration including amounts released to settle</link:label>
    <link:label id="lab_lxrx_FinalConsiderationIncludingAmountsReleasedToSettle_documentation_en-US" xlink:label="lab_lxrx_FinalConsiderationIncludingAmountsReleasedToSettle" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final Consideration including amounts released to settle</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FinalConsiderationIncludingAmountsReleasedToSettle" xlink:href="lxrx-20221231.xsd#lxrx_FinalConsiderationIncludingAmountsReleasedToSettle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_FinalConsiderationIncludingAmountsReleasedToSettle" xlink:to="lab_lxrx_FinalConsiderationIncludingAmountsReleasedToSettle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_e18d0c32-98cc-405c-92d4-f82545c07a67_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_4442d742-a870-4dc3-a013-7e0bc1a0eaa0_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_2150f184-7e24-4b5e-afa0-e38cd6a3531a_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_d1f3b1db-2818-49e8-8d49-5b2c905f07da_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Awards</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssets_f6ae6f57-9991-4c09-976a-7cef86e6aa59_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets</link:label>
    <link:label id="lab_us-gaap_OtherAssets_label_en-US" xlink:label="lab_us-gaap_OtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssets" xlink:to="lab_us-gaap_OtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_56b07009-0584-43e5-b101-d5819e7038ae_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_BalanceSheetParentheticalsAbstract_49ae079f-3217-4b9a-aa1f-5ed08f1e699b_terseLabel_en-US" xlink:label="lab_lxrx_BalanceSheetParentheticalsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Parentheticals [Abstract]</link:label>
    <link:label id="lab_lxrx_BalanceSheetParentheticalsAbstract_label_en-US" xlink:label="lab_lxrx_BalanceSheetParentheticalsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Parentheticals [Abstract]</link:label>
    <link:label id="lab_lxrx_BalanceSheetParentheticalsAbstract_documentation_en-US" xlink:label="lab_lxrx_BalanceSheetParentheticalsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Parentheticals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_BalanceSheetParentheticalsAbstract" xlink:href="lxrx-20221231.xsd#lxrx_BalanceSheetParentheticalsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_BalanceSheetParentheticalsAbstract" xlink:to="lab_lxrx_BalanceSheetParentheticalsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_3eb8cf91-aafe-450f-b2bf-f97733248fa3_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification_e566c36f-4475-49c3-970d-3993f6e053f5_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification (Deprecated 2020)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification" xlink:to="lab_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_bdaf1641-e20f-4c94-b434-f63f63d05ad1_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_0280ed60-6fb6-48bf-b2a4-603ea6829920_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_70c2bbcd-4948-4463-932f-4524cda1c41e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_09cc6794-68c0-44ea-9130-a1ef57123fed_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_0bd67767-3ad2-4e20-8854-aa5e8cb15972_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Employees</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Employees</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The expected term assumption that is used in valuing an option on its own shares for employees.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" xlink:href="lxrx-20221231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_baee1739-33c9-42fa-bad0-c072fbd2f6ad_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandMember_f7a3fe10-eb95-4765-a00d-b96ea0a17dcb_terseLabel_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_LandMember_label_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandMember" xlink:to="lab_us-gaap_LandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_3d628e13-fff7-40e7-92f3-c21b17ccdd04_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialCostsFundedPercentage_ffe01269-e678-40d7-b9ca-e2fdafb79ed4_terseLabel_en-US" xlink:label="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialCostsFundedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funded commercialization costs</link:label>
    <link:label id="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialCostsFundedPercentage_label_en-US" xlink:label="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialCostsFundedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Commercial Costs, Funded Percentage</link:label>
    <link:label id="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialCostsFundedPercentage_documentation_en-US" xlink:label="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialCostsFundedPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Commercial Costs, Funded Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialCostsFundedPercentage" xlink:href="lxrx-20221231.xsd#lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialCostsFundedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialCostsFundedPercentage" xlink:to="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialCostsFundedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_1a3cf1c0-ace9-4f8e-a180-c53b331a4e34_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_1d810c58-13fb-4b5d-9a7b-3aa83f7207e3_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Treasury Stock Reissued</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Treasury Stock Reissued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_Lxrx_Sanofiterminationcashpayment_587947a2-a62c-4d53-a9db-39919c11cb7c_terseLabel_en-US" xlink:label="lab_lxrx_Lxrx_Sanofiterminationcashpayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">lxrx_Sanofi termination cash payment</link:label>
    <link:label id="lab_lxrx_Lxrx_Sanofiterminationcashpayment_label_en-US" xlink:label="lab_lxrx_Lxrx_Sanofiterminationcashpayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">lxrx_Sanofi termination cash payment</link:label>
    <link:label id="lab_lxrx_Lxrx_Sanofiterminationcashpayment_documentation_en-US" xlink:label="lab_lxrx_Lxrx_Sanofiterminationcashpayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">lxrx_Sanofi termination cash payment - represents the cash payment from Sanofi to terminate the collaboration alliance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Lxrx_Sanofiterminationcashpayment" xlink:href="lxrx-20221231.xsd#lxrx_Lxrx_Sanofiterminationcashpayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_Lxrx_Sanofiterminationcashpayment" xlink:to="lab_lxrx_Lxrx_Sanofiterminationcashpayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_e1e31188-d559-4abf-bcd2-6de8af84f106_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_bc5c0ab4-6e59-43c1-9166-69d6c6a2b86f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_ce5d54cd-83fa-482d-8492-94dc3cef821b_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_1d3f3794-3611-4449-9a8c-d86c71457957_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_59fd8fd3-f9b4-4063-9ee6-73570582fb67_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_439c68c8-c7d2-49b4-86e7-e064c3669d11_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SanofiTerminationAgreement_ed5c9261-44e6-4b8f-9e95-a97d1b564035_terseLabel_en-US" xlink:label="lab_lxrx_SanofiTerminationAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Termination Agreement</link:label>
    <link:label id="lab_lxrx_SanofiTerminationAgreement_label_en-US" xlink:label="lab_lxrx_SanofiTerminationAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Termination Agreement</link:label>
    <link:label id="lab_lxrx_SanofiTerminationAgreement_documentation_en-US" xlink:label="lab_lxrx_SanofiTerminationAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Termination Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiTerminationAgreement" xlink:href="lxrx-20221231.xsd#lxrx_SanofiTerminationAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SanofiTerminationAgreement" xlink:to="lab_lxrx_SanofiTerminationAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod_d9675a9b-2378-44f5-8eab-7ebf00604afd_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Stock Bonus and Restricted Stock, Grants in Period</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Stock Bonus And Restricted Stock Grants In Period</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The number of grants of stock bonus and restricted stock awards made during the period under equity incentive plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod" xlink:href="lxrx-20221231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_b9f0cfbb-7e06-4e19-96f7-84c4fcf9795e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltiesPercentage_d31cc09e-c4d1-456d-b91f-cedc9b9646c1_terseLabel_en-US" xlink:label="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltiesPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties percentage</link:label>
    <link:label id="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltiesPercentage_label_en-US" xlink:label="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltiesPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Royalties Percentage</link:label>
    <link:label id="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltiesPercentage_documentation_en-US" xlink:label="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltiesPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Royalties Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltiesPercentage" xlink:href="lxrx-20221231.xsd#lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltiesPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltiesPercentage" xlink:to="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltiesPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_fed903b1-c45e-4e24-8139-c30ec89be10a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_BenefitPlanAbstract_24837cff-233e-4713-92f6-a1440bec36a2_terseLabel_en-US" xlink:label="lab_lxrx_BenefitPlanAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit Plan [Abstract]</link:label>
    <link:label id="lab_lxrx_BenefitPlanAbstract_label_en-US" xlink:label="lab_lxrx_BenefitPlanAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit Plan [Abstract]</link:label>
    <link:label id="lab_lxrx_BenefitPlanAbstract_documentation_en-US" xlink:label="lab_lxrx_BenefitPlanAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit Plan [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_BenefitPlanAbstract" xlink:href="lxrx-20221231.xsd#lxrx_BenefitPlanAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_BenefitPlanAbstract" xlink:to="lab_lxrx_BenefitPlanAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b8beecd8-9d80-4b2c-a1ec-afb36c0a5bce_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_PrincipalAmountOfConvertibleNotes_bab7bed7-e0c0-4e20-b44e-b68341e0c8e9_terseLabel_en-US" xlink:label="lab_lxrx_PrincipalAmountOfConvertibleNotes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount of convertible notes</link:label>
    <link:label id="lab_lxrx_PrincipalAmountOfConvertibleNotes_label_en-US" xlink:label="lab_lxrx_PrincipalAmountOfConvertibleNotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount of convertible notes</link:label>
    <link:label id="lab_lxrx_PrincipalAmountOfConvertibleNotes_documentation_en-US" xlink:label="lab_lxrx_PrincipalAmountOfConvertibleNotes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount of convertible notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_PrincipalAmountOfConvertibleNotes" xlink:href="lxrx-20221231.xsd#lxrx_PrincipalAmountOfConvertibleNotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_PrincipalAmountOfConvertibleNotes" xlink:to="lab_lxrx_PrincipalAmountOfConvertibleNotes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_f6314028-11e5-4dfe-85b6-2f31d6a9aaeb_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived Intangible Assets, Fair Value Disclosure</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ProceedsFromSeptember2021ATMOffering_ecc36c35-b617-4aea-92c7-502226b9e751_terseLabel_en-US" xlink:label="lab_lxrx_ProceedsFromSeptember2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from September 2021 ATM Offering</link:label>
    <link:label id="lab_lxrx_ProceedsFromSeptember2021ATMOffering_label_en-US" xlink:label="lab_lxrx_ProceedsFromSeptember2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from September 2021 ATM Offering</link:label>
    <link:label id="lab_lxrx_ProceedsFromSeptember2021ATMOffering_documentation_en-US" xlink:label="lab_lxrx_ProceedsFromSeptember2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from September 2021 ATM Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ProceedsFromSeptember2021ATMOffering" xlink:href="lxrx-20221231.xsd#lxrx_ProceedsFromSeptember2021ATMOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ProceedsFromSeptember2021ATMOffering" xlink:to="lab_lxrx_ProceedsFromSeptember2021ATMOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_060cf358-752c-46e8-afc5-8b2d13dabc98_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_49e6e0ce-353f-4765-8a0c-3eef1313316d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX_19062e8b-957b-4d87-a029-374bab234dde_terseLabel_en-US" xlink:label="lab_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Interest Rate_Base_Revere_LXRX</link:label>
    <link:label id="lab_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX_label_en-US" xlink:label="lab_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Interest Rate_Base_Revere_LXRX</link:label>
    <link:label id="lab_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX_documentation_en-US" xlink:label="lab_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Interest Rate_Base_Revere_LXRX - interest rate in Revere loan agreement is 30-day LIBOR plus 5.5% as base rate. Interest charged is the greater of base or 7.5%</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX" xlink:href="lxrx-20221231.xsd#lxrx_MortgageDebtInterestRate_Base_Revere_LXRX"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX" xlink:to="lab_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_A2027OxfordPrincipalPaymentsA_62b2ac7c-d01f-4d41-94f9-66a88afa134c_terseLabel_en-US" xlink:label="lab_lxrx_A2027OxfordPrincipalPaymentsA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027 Oxford Principal Payments A</link:label>
    <link:label id="lab_lxrx_A2027OxfordPrincipalPaymentsA_label_en-US" xlink:label="lab_lxrx_A2027OxfordPrincipalPaymentsA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027 Oxford Principal Payments A</link:label>
    <link:label id="lab_lxrx_A2027OxfordPrincipalPaymentsA_documentation_en-US" xlink:label="lab_lxrx_A2027OxfordPrincipalPaymentsA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027 Oxford Principal Payments A</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2027OxfordPrincipalPaymentsA" xlink:href="lxrx-20221231.xsd#lxrx_A2027OxfordPrincipalPaymentsA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_A2027OxfordPrincipalPaymentsA" xlink:to="lab_lxrx_A2027OxfordPrincipalPaymentsA" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_TermLoanCWarrant_a7dd7d23-767f-41e7-affb-118a8aa039ae_terseLabel_en-US" xlink:label="lab_lxrx_TermLoanCWarrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan C Warrant %</link:label>
    <link:label id="lab_lxrx_TermLoanCWarrant_label_en-US" xlink:label="lab_lxrx_TermLoanCWarrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan C Warrant %</link:label>
    <link:label id="lab_lxrx_TermLoanCWarrant_documentation_en-US" xlink:label="lab_lxrx_TermLoanCWarrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan C Warrant %</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanCWarrant" xlink:href="lxrx-20221231.xsd#lxrx_TermLoanCWarrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TermLoanCWarrant" xlink:to="lab_lxrx_TermLoanCWarrant" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan_53354be3-5175-41b1-a7ae-56f9d59e08e1_terseLabel_en-US" xlink:label="lab_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued Pursuant to Restricted Stock Units, Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan_label_en-US" xlink:label="lab_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued Pursuant to Restricted Stock Units, Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan_documentation_en-US" xlink:label="lab_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued pursuant to restricted stock units under the Equity Incentive Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan" xlink:href="lxrx-20221231.xsd#lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan" xlink:to="lab_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_492ad9dc-f8e3-4907-9620-0a35ceef3929_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_TermLoanADebtIssuanceCosts_b0456f09-68c4-4e09-95f2-5c38e0981b11_terseLabel_en-US" xlink:label="lab_lxrx_TermLoanADebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Debt Issuance Costs</link:label>
    <link:label id="lab_lxrx_TermLoanADebtIssuanceCosts_label_en-US" xlink:label="lab_lxrx_TermLoanADebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Debt Issuance Costs</link:label>
    <link:label id="lab_lxrx_TermLoanADebtIssuanceCosts_documentation_en-US" xlink:label="lab_lxrx_TermLoanADebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanADebtIssuanceCosts" xlink:href="lxrx-20221231.xsd#lxrx_TermLoanADebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TermLoanADebtIssuanceCosts" xlink:to="lab_lxrx_TermLoanADebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_fc63a729-2dc3-4a5b-8caf-017c07ee9689_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Employee</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Employee</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The risk-free interest rate assumption that is used in valuing an option on its own shares for employees.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" xlink:href="lxrx-20221231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_RecentAccountingPronouncementsAbstract_aa69d60f-2453-48fa-8b84-5ad3ffaf2760_terseLabel_en-US" xlink:label="lab_lxrx_RecentAccountingPronouncementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements [Abstract]</link:label>
    <link:label id="lab_lxrx_RecentAccountingPronouncementsAbstract_label_en-US" xlink:label="lab_lxrx_RecentAccountingPronouncementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements [Abstract]</link:label>
    <link:label id="lab_lxrx_RecentAccountingPronouncementsAbstract_documentation_en-US" xlink:label="lab_lxrx_RecentAccountingPronouncementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_RecentAccountingPronouncementsAbstract" xlink:href="lxrx-20221231.xsd#lxrx_RecentAccountingPronouncementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_RecentAccountingPronouncementsAbstract" xlink:to="lab_lxrx_RecentAccountingPronouncementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_8286a203-957e-4d79-98c6-e71f73fe5835_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenMilestonePaymentReceived_1e8cef86-411a-4bc2-866f-1357b15840e6_terseLabel_en-US" xlink:label="lab_lxrx_IpsenMilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Milestone Payment Received</link:label>
    <link:label id="lab_lxrx_IpsenMilestonePaymentReceived_label_en-US" xlink:label="lab_lxrx_IpsenMilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Milestone Payment Received</link:label>
    <link:label id="lab_lxrx_IpsenMilestonePaymentReceived_documentation_en-US" xlink:label="lab_lxrx_IpsenMilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl outside the United States and Japan. This represents the amount of milestone payments earned during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenMilestonePaymentReceived" xlink:href="lxrx-20221231.xsd#lxrx_IpsenMilestonePaymentReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenMilestonePaymentReceived" xlink:to="lab_lxrx_IpsenMilestonePaymentReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConvertibleDebtExchangeTotalCashConsideration_3e1da325-95c5-40d9-b054-daa3ad174318_terseLabel_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchangeTotalCashConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt Exchange - Total cash consideration</link:label>
    <link:label id="lab_lxrx_ConvertibleDebtExchangeTotalCashConsideration_label_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchangeTotalCashConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt Exchange - Total cash consideration</link:label>
    <link:label id="lab_lxrx_ConvertibleDebtExchangeTotalCashConsideration_documentation_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchangeTotalCashConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt Exchange - Total cash consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchangeTotalCashConsideration" xlink:href="lxrx-20221231.xsd#lxrx_ConvertibleDebtExchangeTotalCashConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConvertibleDebtExchangeTotalCashConsideration" xlink:to="lab_lxrx_ConvertibleDebtExchangeTotalCashConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_InterestOnLeasePayments_e7519b76-5ec4-47f3-8040-744c9ef48c0d_terseLabel_en-US" xlink:label="lab_lxrx_InterestOnLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest on Lease Payments</link:label>
    <link:label id="lab_lxrx_InterestOnLeasePayments_label_en-US" xlink:label="lab_lxrx_InterestOnLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest on Lease Payments</link:label>
    <link:label id="lab_lxrx_InterestOnLeasePayments_documentation_en-US" xlink:label="lab_lxrx_InterestOnLeasePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest on Lease Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_InterestOnLeasePayments" xlink:href="lxrx-20221231.xsd#lxrx_InterestOnLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_InterestOnLeasePayments" xlink:to="lab_lxrx_InterestOnLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_c067a870-d601-47f9-8eb7-217d7d2299a9_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SymphonyIconGoodwill_6b3550d5-720f-40fb-b9d4-ed7d515679d5_terseLabel_en-US" xlink:label="lab_lxrx_SymphonyIconGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Symphony Icon Goodwill</link:label>
    <link:label id="lab_lxrx_SymphonyIconGoodwill_label_en-US" xlink:label="lab_lxrx_SymphonyIconGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Symphony Icon Goodwill</link:label>
    <link:label id="lab_lxrx_SymphonyIconGoodwill_documentation_en-US" xlink:label="lab_lxrx_SymphonyIconGoodwill" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">On July 30, 2010, Lexicon exercised its Purchase Option and completed the acquisition of Symphony Icon. Goodwill associated with the acquisition of $18.7 million, which represents the assets recognized in connection with the deferred tax liability acquired and did not result from excess purchase price, was assigned to the consolidated entity, Lexicon.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SymphonyIconGoodwill" xlink:href="lxrx-20221231.xsd#lxrx_SymphonyIconGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SymphonyIconGoodwill" xlink:to="lab_lxrx_SymphonyIconGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_7fef254a-de8c-456e-943b-a0f7dbf9189a_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_RDSeveranceCostsMember_d6f9c707-6187-4d2d-bdcf-547d4c6810a8_terseLabel_en-US" xlink:label="lab_lxrx_RDSeveranceCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R&amp;D severance costs</link:label>
    <link:label id="lab_lxrx_RDSeveranceCostsMember_label_en-US" xlink:label="lab_lxrx_RDSeveranceCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R&amp;D severance costs [Member]</link:label>
    <link:label id="lab_lxrx_RDSeveranceCostsMember_documentation_en-US" xlink:label="lab_lxrx_RDSeveranceCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R&amp;D severance costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_RDSeveranceCostsMember" xlink:href="lxrx-20221231.xsd#lxrx_RDSeveranceCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_RDSeveranceCostsMember" xlink:to="lab_lxrx_RDSeveranceCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_9b70127c-e678-4bb4-8563-b4107a7f895a_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_OxfordLoanFacility_57fb2f05-c90b-45dc-baa9-e8b565a50c5a_terseLabel_en-US" xlink:label="lab_lxrx_OxfordLoanFacility" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Loan Facility</link:label>
    <link:label id="lab_lxrx_OxfordLoanFacility_label_en-US" xlink:label="lab_lxrx_OxfordLoanFacility" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Loan Facility</link:label>
    <link:label id="lab_lxrx_OxfordLoanFacility_documentation_en-US" xlink:label="lab_lxrx_OxfordLoanFacility" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Loan Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OxfordLoanFacility" xlink:href="lxrx-20221231.xsd#lxrx_OxfordLoanFacility"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_OxfordLoanFacility" xlink:to="lab_lxrx_OxfordLoanFacility" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_2af85264-fcbc-4e1c-a360-f20990fad82d_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Change in Amount</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_ecc11350-e4a4-466c-8235-ffc9d33475c0_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_58012cbd-ccd0-4519-88f4-85302694e0c9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_155e2be2-18b8-46e8-a33d-a65aa9c17d07_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockPreferredValue_a52248a4-5e50-4e65-82ff-7340bfbc6f8c_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockPreferredValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Preferred, Value</link:label>
    <link:label id="lab_us-gaap_TreasuryStockPreferredValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockPreferredValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Preferred, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockPreferredValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockPreferredValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockPreferredValue" xlink:to="lab_us-gaap_TreasuryStockPreferredValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_50c91274-8da1-44ad-8f9f-f188f49735a9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_e2fae28f-5ad2-4787-8f10-f18fc37a4ace_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Lease Obligation</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt and Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtGainLossNetOfTax_7d9ab6f9-b8b3-40da-a005-b84ae9a747d4_terseLabel_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtGainLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extinguishment of Debt, Gain (Loss), Net of Tax</link:label>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtGainLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtGainLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extinguishment of Debt, Gain (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtGainLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExtinguishmentOfDebtGainLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExtinguishmentOfDebtGainLossNetOfTax" xlink:to="lab_us-gaap_ExtinguishmentOfDebtGainLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_RestrictedStockUnitsOutstandingNonEmployeeDirectorsEquityIncentivePlan_aa25b827-d77c-484f-ac72-b1dd653ee0b0_terseLabel_en-US" xlink:label="lab_lxrx_RestrictedStockUnitsOutstandingNonEmployeeDirectorsEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units Outstanding, Non-Employee Directors Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_RestrictedStockUnitsOutstandingNonEmployeeDirectorsEquityIncentivePlan_label_en-US" xlink:label="lab_lxrx_RestrictedStockUnitsOutstandingNonEmployeeDirectorsEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units Outstanding, Non-Employee Directors Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_RestrictedStockUnitsOutstandingNonEmployeeDirectorsEquityIncentivePlan_documentation_en-US" xlink:label="lab_lxrx_RestrictedStockUnitsOutstandingNonEmployeeDirectorsEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units Outstanding, Non-Employee Directors Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_RestrictedStockUnitsOutstandingNonEmployeeDirectorsEquityIncentivePlan" xlink:href="lxrx-20221231.xsd#lxrx_RestrictedStockUnitsOutstandingNonEmployeeDirectorsEquityIncentivePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_RestrictedStockUnitsOutstandingNonEmployeeDirectorsEquityIncentivePlan" xlink:to="lab_lxrx_RestrictedStockUnitsOutstandingNonEmployeeDirectorsEquityIncentivePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_e05cb22e-140f-4520-bf8d-e05c54d31f3d_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity:</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_3e2a1ee2-c294-4792-8aa7-7899890c97fa_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_a3b4a51b-44d4-4dae-92e1-dd26c227c506_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_OxfordFacilityFee_2ac9a279-920f-4a81-ac59-34e63e4e1813_terseLabel_en-US" xlink:label="lab_lxrx_OxfordFacilityFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Facility Fee</link:label>
    <link:label id="lab_lxrx_OxfordFacilityFee_label_en-US" xlink:label="lab_lxrx_OxfordFacilityFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Facility Fee</link:label>
    <link:label id="lab_lxrx_OxfordFacilityFee_documentation_en-US" xlink:label="lab_lxrx_OxfordFacilityFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Facility Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OxfordFacilityFee" xlink:href="lxrx-20221231.xsd#lxrx_OxfordFacilityFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_OxfordFacilityFee" xlink:to="lab_lxrx_OxfordFacilityFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCarryingBasis_984fe2c1-cabb-423d-80b0-ac4acb5d1f14_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCarryingBasis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unearned ESOP Shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCarryingBasis_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCarryingBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Carrying Basis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCarryingBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCarryingBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCarryingBasis" xlink:to="lab_us-gaap_TreasuryStockCarryingBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_81d01268-d063-43ad-92fa-713f743e2ae2_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c8c9fdde-c266-4e8d-a22c-6430df4cc422_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnamortizedDebtIssuanceExpense_7a506c36-88fe-4ad5-9bbd-062747c89161_terseLabel_en-US" xlink:label="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized Debt Issuance Expense</link:label>
    <link:label id="lab_us-gaap_UnamortizedDebtIssuanceExpense_label_en-US" xlink:label="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized Debt Issuance Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnamortizedDebtIssuanceExpense" xlink:to="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_fe49af9d-807d-4371-9eb8-3fccd6c7cb35_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashMember_9fad24a3-289d-4220-9d05-447e666dbb81_terseLabel_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_CashMember_label_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashMember" xlink:to="lab_us-gaap_CashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_43b35554-b480-4f64-b0ef-b2333983390b_terseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_91868f5d-94f3-4acd-afbf-964e3ca01846_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentCostsPeriod_d8ed1f4d-5a11-40eb-80f8-cf412f16903c_terseLabel_en-US" xlink:label="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentCostsPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development costs period</link:label>
    <link:label id="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentCostsPeriod_label_en-US" xlink:label="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentCostsPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Development Costs Period</link:label>
    <link:label id="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentCostsPeriod_documentation_en-US" xlink:label="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentCostsPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Development Costs Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentCostsPeriod" xlink:href="lxrx-20221231.xsd#lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentCostsPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentCostsPeriod" xlink:to="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentCostsPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_625bd6e4-d2d0-42a6-84e5-8fb7a28944ae_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents and Investments</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_OrganizationAndOperationsAbstract_08dbc715-1917-45b8-a999-bc3c413cce2e_terseLabel_en-US" xlink:label="lab_lxrx_OrganizationAndOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Operations [Abstract]</link:label>
    <link:label id="lab_lxrx_OrganizationAndOperationsAbstract_label_en-US" xlink:label="lab_lxrx_OrganizationAndOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Operations [Abstract]</link:label>
    <link:label id="lab_lxrx_OrganizationAndOperationsAbstract_documentation_en-US" xlink:label="lab_lxrx_OrganizationAndOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OrganizationAndOperationsAbstract" xlink:href="lxrx-20221231.xsd#lxrx_OrganizationAndOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_OrganizationAndOperationsAbstract" xlink:to="lab_lxrx_OrganizationAndOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsNet_f024c958-7286-414d-ac3e-67b7383f22d0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsNet" xlink:to="lab_us-gaap_OtherIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_bcd9fec0-f4ca-4a00-bfcd-ce78ab75959b_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_cb039bdb-64f9-48fc-b1a9-dd6c481bf456_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f71928eb-3c0f-4469-9d42-0adce3efba6a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3d8811b4-3cb2-4d18-acfe-b78c069377b7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_1b573c95-5f30-4cb8-88bb-2109ff5b3ef2_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SharePriceInNovember20ATMOffering_d01e5fcd-f877-4cc2-be95-028a5d028cf3_terseLabel_en-US" xlink:label="lab_lxrx_SharePriceInNovember20ATMOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price in November 20 ATM Offering</link:label>
    <link:label id="lab_lxrx_SharePriceInNovember20ATMOffering_label_en-US" xlink:label="lab_lxrx_SharePriceInNovember20ATMOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price in November 20 ATM Offering</link:label>
    <link:label id="lab_lxrx_SharePriceInNovember20ATMOffering_documentation_en-US" xlink:label="lab_lxrx_SharePriceInNovember20ATMOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price in November 20 ATM Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharePriceInNovember20ATMOffering" xlink:href="lxrx-20221231.xsd#lxrx_SharePriceInNovember20ATMOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SharePriceInNovember20ATMOffering" xlink:to="lab_lxrx_SharePriceInNovember20ATMOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_e4ab8498-0c78-49a5-92cf-b9f61122c595_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_936dde3b-9497-44b5-a841-38d20fe03e16_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_5d31b7b7-376e-4ade-81bd-ee5fcddb97ec_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_266eb8c7-69ad-4242-b93a-3385cbdb7bb6_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative, including stock-based compensation of $7,267, $6,293 and $6,898, respectively</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalFees_66cbadff-b47c-423a-87f6-f06be2e40511_terseLabel_en-US" xlink:label="lab_us-gaap_LegalFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Fees</link:label>
    <link:label id="lab_us-gaap_LegalFees_label_en-US" xlink:label="lab_us-gaap_LegalFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalFees" xlink:to="lab_us-gaap_LegalFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_663c1792-7ab6-45f7-b0dc-3af5c99e2dde_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SanofiRevenueRecognized_d2ea138f-e824-4e08-b620-6570890ac36b_terseLabel_en-US" xlink:label="lab_lxrx_SanofiRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Revenue Recognized</link:label>
    <link:label id="lab_lxrx_SanofiRevenueRecognized_label_en-US" xlink:label="lab_lxrx_SanofiRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Revenue Recognized</link:label>
    <link:label id="lab_lxrx_SanofiRevenueRecognized_documentation_en-US" xlink:label="lab_lxrx_SanofiRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the revenue recognized in the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiRevenueRecognized" xlink:href="lxrx-20221231.xsd#lxrx_SanofiRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SanofiRevenueRecognized" xlink:to="lab_lxrx_SanofiRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_a6f3f9ca-897a-4ea5-84a9-c92cfa9e6c39_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_bd7280a9-7ce6-4e66-9686-3dbd18fd022f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsLineItems" xlink:to="lab_us-gaap_OtherCommitmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_3e77fefd-e99d-4696-835b-12f137bdf852_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dfc78ea5-9db4-4acf-8f70-4a7ea7c19f6b_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_OfferingExpensesFromDecember20CommonStockOffering_1d69e3cd-8844-44ac-85dc-2d5a8180ed7a_terseLabel_en-US" xlink:label="lab_lxrx_OfferingExpensesFromDecember20CommonStockOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering expenses from December 20 common stock offering</link:label>
    <link:label id="lab_lxrx_OfferingExpensesFromDecember20CommonStockOffering_label_en-US" xlink:label="lab_lxrx_OfferingExpensesFromDecember20CommonStockOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering expenses from December 20 common stock offering</link:label>
    <link:label id="lab_lxrx_OfferingExpensesFromDecember20CommonStockOffering_documentation_en-US" xlink:label="lab_lxrx_OfferingExpensesFromDecember20CommonStockOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering expenses from December 20 common stock offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OfferingExpensesFromDecember20CommonStockOffering" xlink:href="lxrx-20221231.xsd#lxrx_OfferingExpensesFromDecember20CommonStockOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_OfferingExpensesFromDecember20CommonStockOffering" xlink:to="lab_lxrx_OfferingExpensesFromDecember20CommonStockOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_0c1bfcdf-b7e7-4138-9299-94a13cb3ee3b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SanofiDevelopmentMilestones_a01da891-9fe6-45c1-830a-13d71a4205a8_terseLabel_en-US" xlink:label="lab_lxrx_SanofiDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Development Milestones</link:label>
    <link:label id="lab_lxrx_SanofiDevelopmentMilestones_label_en-US" xlink:label="lab_lxrx_SanofiDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Development Milestones</link:label>
    <link:label id="lab_lxrx_SanofiDevelopmentMilestones_documentation_en-US" xlink:label="lab_lxrx_SanofiDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate satagliflozin. This represents the development milestones relating to the achievement of positive results in certain Phase 3 clinical trials in type 2 diabetes patients.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiDevelopmentMilestones" xlink:href="lxrx-20221231.xsd#lxrx_SanofiDevelopmentMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SanofiDevelopmentMilestones" xlink:to="lab_lxrx_SanofiDevelopmentMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_feb6730b-38e6-4923-9f96-9fb75e5ffaa1_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of noncash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_feb81d27-b39f-49f6-befb-299366756c48_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ProceedsFromNov2020ATMOffering_838a74b8-7366-4143-a2cd-0fb61112248c_terseLabel_en-US" xlink:label="lab_lxrx_ProceedsFromNov2020ATMOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Nov 2020 ATM Offering</link:label>
    <link:label id="lab_lxrx_ProceedsFromNov2020ATMOffering_label_en-US" xlink:label="lab_lxrx_ProceedsFromNov2020ATMOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Nov 2020 ATM Offering</link:label>
    <link:label id="lab_lxrx_ProceedsFromNov2020ATMOffering_documentation_en-US" xlink:label="lab_lxrx_ProceedsFromNov2020ATMOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Nov 2020 ATM Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ProceedsFromNov2020ATMOffering" xlink:href="lxrx-20221231.xsd#lxrx_ProceedsFromNov2020ATMOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ProceedsFromNov2020ATMOffering" xlink:to="lab_lxrx_ProceedsFromNov2020ATMOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_42b2f057-be0c-4d02-aed4-3488f0a9fef5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_748de125-50a3-40d7-adfd-33c03d6daeeb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems_d66c6e0a-d86b-4e1e-9bc1-1f2d6ba4033b_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Owned, Federal Income Tax Note [Line Items]</link:label>
    <link:label id="lab_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems_label_en-US" xlink:label="lab_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Owned, Federal Income Tax Note [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems" xlink:to="lab_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_40a4fb14-a694-4c61-8a46-9c933e57f60d_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0e7a695f-ed9e-432f-bdd3-045de26db0d2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_PropertyAndEquipmentAbstract_0551e4e3-fab0-4fe9-9fb9-48dddcf3371a_terseLabel_en-US" xlink:label="lab_lxrx_PropertyAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment [Abstract]</link:label>
    <link:label id="lab_lxrx_PropertyAndEquipmentAbstract_label_en-US" xlink:label="lab_lxrx_PropertyAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment [Abstract]</link:label>
    <link:label id="lab_lxrx_PropertyAndEquipmentAbstract_documentation_en-US" xlink:label="lab_lxrx_PropertyAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_PropertyAndEquipmentAbstract" xlink:href="lxrx-20221231.xsd#lxrx_PropertyAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_PropertyAndEquipmentAbstract" xlink:to="lab_lxrx_PropertyAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_MortgageDebtBalloonPayment_LXRX_cddd03e9-df2b-40c5-b348-a9aedb530e3a_terseLabel_en-US" xlink:label="lab_lxrx_MortgageDebtBalloonPayment_LXRX" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Balloon Payment_LXRX</link:label>
    <link:label id="lab_lxrx_MortgageDebtBalloonPayment_LXRX_label_en-US" xlink:label="lab_lxrx_MortgageDebtBalloonPayment_LXRX" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Balloon Payment_LXRX</link:label>
    <link:label id="lab_lxrx_MortgageDebtBalloonPayment_LXRX_documentation_en-US" xlink:label="lab_lxrx_MortgageDebtBalloonPayment_LXRX" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Balloon Payment_LXRX - Balloon payment due at the end of the 2-year maturity date of mortgage loan with Revere.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtBalloonPayment_LXRX" xlink:href="lxrx-20221231.xsd#lxrx_MortgageDebtBalloonPayment_LXRX"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_MortgageDebtBalloonPayment_LXRX" xlink:to="lab_lxrx_MortgageDebtBalloonPayment_LXRX" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_c603174a-1173-4efe-9a9a-be452b7564a9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_6d29fb1e-d047-41eb-823f-8180a99c786b_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_e862293c-2d46-4e4b-a5fb-497ff0b0d66e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>lxrx-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:379d89f1-f5df-4675-bf23-f82d2f2c7aaf,g:c8f45f50-51f6-43ab-b86a-02bdbec3750c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.lexpharma.com/role/CoverPage" xlink:type="simple" xlink:href="lxrx-20221231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_e44a6c18-188f-48ab-a64b-a6a11815b315" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_a621f190-2de0-49bb-928f-a6fd2a118b91" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e44a6c18-188f-48ab-a64b-a6a11815b315" xlink:to="loc_dei_DocumentType_a621f190-2de0-49bb-928f-a6fd2a118b91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_2cf05fd0-8069-42c3-a362-ad24faf9e9f9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e44a6c18-188f-48ab-a64b-a6a11815b315" xlink:to="loc_dei_DocumentAnnualReport_2cf05fd0-8069-42c3-a362-ad24faf9e9f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_cde5b62f-b047-4503-a4d7-9e33344fe87d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e44a6c18-188f-48ab-a64b-a6a11815b315" xlink:to="loc_dei_DocumentPeriodEndDate_cde5b62f-b047-4503-a4d7-9e33344fe87d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_4388d35d-e844-4342-ade3-96ff71e46a18" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e44a6c18-188f-48ab-a64b-a6a11815b315" xlink:to="loc_dei_DocumentTransitionReport_4388d35d-e844-4342-ade3-96ff71e46a18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_874ef05b-909e-4352-8dec-ce67760cc550" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e44a6c18-188f-48ab-a64b-a6a11815b315" xlink:to="loc_dei_EntityFileNumber_874ef05b-909e-4352-8dec-ce67760cc550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_87beda87-5614-45ca-92f8-ca8973b7c579" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e44a6c18-188f-48ab-a64b-a6a11815b315" xlink:to="loc_dei_EntityIncorporationStateCountryCode_87beda87-5614-45ca-92f8-ca8973b7c579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_111d90c8-4bb8-481d-90a1-79f0162ce70c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e44a6c18-188f-48ab-a64b-a6a11815b315" xlink:to="loc_dei_EntityTaxIdentificationNumber_111d90c8-4bb8-481d-90a1-79f0162ce70c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_4e52f7ec-954f-4c73-a081-52f4e99dc666" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e44a6c18-188f-48ab-a64b-a6a11815b315" xlink:to="loc_dei_EntityAddressAddressLine1_4e52f7ec-954f-4c73-a081-52f4e99dc666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_048b7660-2420-429f-9441-2a1926b5db7e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e44a6c18-188f-48ab-a64b-a6a11815b315" xlink:to="loc_dei_CityAreaCode_048b7660-2420-429f-9441-2a1926b5db7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_e66b3632-e225-499d-adfc-8a72d5d68a7a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e44a6c18-188f-48ab-a64b-a6a11815b315" xlink:to="loc_dei_LocalPhoneNumber_e66b3632-e225-499d-adfc-8a72d5d68a7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_c73e8288-bdfd-465b-8d7b-dcf56a8b7620" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e44a6c18-188f-48ab-a64b-a6a11815b315" xlink:to="loc_dei_EntityAddressCityOrTown_c73e8288-bdfd-465b-8d7b-dcf56a8b7620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_f42198b8-ea7c-41e0-87f6-7d0d93facd0e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e44a6c18-188f-48ab-a64b-a6a11815b315" xlink:to="loc_dei_EntityAddressStateOrProvince_f42198b8-ea7c-41e0-87f6-7d0d93facd0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_a524f6d4-f8f3-43a0-9935-fee01aaf1a00" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e44a6c18-188f-48ab-a64b-a6a11815b315" xlink:to="loc_dei_EntityAddressPostalZipCode_a524f6d4-f8f3-43a0-9935-fee01aaf1a00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_8ace0e7f-dc3c-4882-9172-f0d1f9ab4207" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e44a6c18-188f-48ab-a64b-a6a11815b315" xlink:to="loc_dei_Security12bTitle_8ace0e7f-dc3c-4882-9172-f0d1f9ab4207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_623173d2-f2ba-427e-bbbc-d75fe28c9cab" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e44a6c18-188f-48ab-a64b-a6a11815b315" xlink:to="loc_dei_SecurityExchangeName_623173d2-f2ba-427e-bbbc-d75fe28c9cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_ff83d2fc-96cb-4789-ac91-9ceffcf90f98" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e44a6c18-188f-48ab-a64b-a6a11815b315" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_ff83d2fc-96cb-4789-ac91-9ceffcf90f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_4787b3f4-ad9b-4f5a-bf8f-460af76b784b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e44a6c18-188f-48ab-a64b-a6a11815b315" xlink:to="loc_dei_EntityVoluntaryFilers_4787b3f4-ad9b-4f5a-bf8f-460af76b784b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_f3e2de47-aa5d-4951-b036-60a78060853f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e44a6c18-188f-48ab-a64b-a6a11815b315" xlink:to="loc_dei_EntityCurrentReportingStatus_f3e2de47-aa5d-4951-b036-60a78060853f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_92e1ee36-b372-4555-9fc6-393f3143f4af" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e44a6c18-188f-48ab-a64b-a6a11815b315" xlink:to="loc_dei_EntityInteractiveDataCurrent_92e1ee36-b372-4555-9fc6-393f3143f4af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_0d3ed839-cc73-4144-8522-e0f1c91b3888" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e44a6c18-188f-48ab-a64b-a6a11815b315" xlink:to="loc_dei_EntityFilerCategory_0d3ed839-cc73-4144-8522-e0f1c91b3888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_ad6bce43-1d35-48fc-9d7f-5e34bc862664" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e44a6c18-188f-48ab-a64b-a6a11815b315" xlink:to="loc_dei_EntitySmallBusiness_ad6bce43-1d35-48fc-9d7f-5e34bc862664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_8a044bc5-27eb-4b91-a8eb-65f6b880d9e3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e44a6c18-188f-48ab-a64b-a6a11815b315" xlink:to="loc_dei_EntityEmergingGrowthCompany_8a044bc5-27eb-4b91-a8eb-65f6b880d9e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_a583a5a0-48fe-4fd5-b0c7-1c6d46df2225" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e44a6c18-188f-48ab-a64b-a6a11815b315" xlink:to="loc_dei_EntityShellCompany_a583a5a0-48fe-4fd5-b0c7-1c6d46df2225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_24ad590b-dbb5-4093-b736-d26a2899575f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e44a6c18-188f-48ab-a64b-a6a11815b315" xlink:to="loc_dei_EntityPublicFloat_24ad590b-dbb5-4093-b736-d26a2899575f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_ae445a08-47d2-4ebc-8a62-f3125e466cd9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e44a6c18-188f-48ab-a64b-a6a11815b315" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_ae445a08-47d2-4ebc-8a62-f3125e466cd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_f33fa608-35be-4fed-a859-f8e2d61f9cae" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e44a6c18-188f-48ab-a64b-a6a11815b315" xlink:to="loc_dei_EntityRegistrantName_f33fa608-35be-4fed-a859-f8e2d61f9cae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_5ae19c67-aff0-45e2-bd24-11bcfe1748ea" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e44a6c18-188f-48ab-a64b-a6a11815b315" xlink:to="loc_dei_EntityCentralIndexKey_5ae19c67-aff0-45e2-bd24-11bcfe1748ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_136c3b6f-06ce-4e6d-aa34-0b36b3b7106a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e44a6c18-188f-48ab-a64b-a6a11815b315" xlink:to="loc_dei_CurrentFiscalYearEndDate_136c3b6f-06ce-4e6d-aa34-0b36b3b7106a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_cb8c4768-623a-453c-9a2c-517c4e29e637" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e44a6c18-188f-48ab-a64b-a6a11815b315" xlink:to="loc_dei_DocumentFiscalYearFocus_cb8c4768-623a-453c-9a2c-517c4e29e637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_4495637f-786f-4393-9997-ce3e031c3575" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e44a6c18-188f-48ab-a64b-a6a11815b315" xlink:to="loc_dei_DocumentFiscalPeriodFocus_4495637f-786f-4393-9997-ce3e031c3575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_fcce4229-9850-4cee-a3a2-e3fd21bf83ac" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e44a6c18-188f-48ab-a64b-a6a11815b315" xlink:to="loc_dei_AmendmentFlag_fcce4229-9850-4cee-a3a2-e3fd21bf83ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_a051919c-9a95-46b4-9ed6-7074008d4e0b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e44a6c18-188f-48ab-a64b-a6a11815b315" xlink:to="loc_dei_TradingSymbol_a051919c-9a95-46b4-9ed6-7074008d4e0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_a0b1c89c-4755-4f52-8fbd-fa94908194f3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e44a6c18-188f-48ab-a64b-a6a11815b315" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_a0b1c89c-4755-4f52-8fbd-fa94908194f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_9ebe5e64-565e-4d77-adec-9d23d4f7c686" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e44a6c18-188f-48ab-a64b-a6a11815b315" xlink:to="loc_dei_IcfrAuditorAttestationFlag_9ebe5e64-565e-4d77-adec-9d23d4f7c686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_0ca2913a-b83f-450b-9948-0a3c79f0bde4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e44a6c18-188f-48ab-a64b-a6a11815b315" xlink:to="loc_dei_DocumentInformationTable_0ca2913a-b83f-450b-9948-0a3c79f0bde4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_25a20e50-cc67-4574-abc9-0509ad214c06" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_0ca2913a-b83f-450b-9948-0a3c79f0bde4" xlink:to="loc_srt_RestatementAxis_25a20e50-cc67-4574-abc9-0509ad214c06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_27a8002a-59fa-48c5-aa1d-45c64a625e23" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_25a20e50-cc67-4574-abc9-0509ad214c06" xlink:to="loc_srt_RestatementDomain_27a8002a-59fa-48c5-aa1d-45c64a625e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_f550677d-450a-41ea-a7c5-0b65d0d79227" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_0ca2913a-b83f-450b-9948-0a3c79f0bde4" xlink:to="loc_dei_DocumentInformationLineItems_f550677d-450a-41ea-a7c5-0b65d0d79227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_ce9dd1a5-f907-45b2-a9cc-e98be3401cc5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f550677d-450a-41ea-a7c5-0b65d0d79227" xlink:to="loc_dei_IcfrAuditorAttestationFlag_ce9dd1a5-f907-45b2-a9cc-e98be3401cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_e6297923-6c41-4b6a-b9fd-cec8966632ef" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f550677d-450a-41ea-a7c5-0b65d0d79227" xlink:to="loc_dei_CurrentFiscalYearEndDate_e6297923-6c41-4b6a-b9fd-cec8966632ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_04a10b75-9734-4371-8982-47bdc23e88ad" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f550677d-450a-41ea-a7c5-0b65d0d79227" xlink:to="loc_dei_AuditorName_04a10b75-9734-4371-8982-47bdc23e88ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_93e1cebc-c09e-46c6-93ba-b4b39ec9738d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f550677d-450a-41ea-a7c5-0b65d0d79227" xlink:to="loc_dei_AuditorLocation_93e1cebc-c09e-46c6-93ba-b4b39ec9738d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_284a684a-652a-4861-9f97-a19ba7587f07" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f550677d-450a-41ea-a7c5-0b65d0d79227" xlink:to="loc_dei_AuditorFirmId_284a684a-652a-4861-9f97-a19ba7587f07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_077e24fe-bb52-4396-96ca-bbc537199fd7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f550677d-450a-41ea-a7c5-0b65d0d79227" xlink:to="loc_dei_EntityAddressCityOrTown_077e24fe-bb52-4396-96ca-bbc537199fd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_cfe1a574-a7f4-4908-9303-95cdd6f894c9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f550677d-450a-41ea-a7c5-0b65d0d79227" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_cfe1a574-a7f4-4908-9303-95cdd6f894c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="lxrx-20221231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedBalanceSheetsAbstract_9e93b990-dc3f-498f-9a62-96cd906f71ce" xlink:href="lxrx-20221231.xsd#lxrx_ConsolidatedBalanceSheetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2999afb3-e374-420f-a149-a0fbc207669c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract_9e93b990-dc3f-498f-9a62-96cd906f71ce" xlink:to="loc_us-gaap_StatementTable_2999afb3-e374-420f-a149-a0fbc207669c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_63306f6b-2c23-4bf2-b3c8-40c3e7420b32" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2999afb3-e374-420f-a149-a0fbc207669c" xlink:to="loc_srt_StatementScenarioAxis_63306f6b-2c23-4bf2-b3c8-40c3e7420b32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_a3d64b4a-b31a-433a-b740-7d65374a06f9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_63306f6b-2c23-4bf2-b3c8-40c3e7420b32" xlink:to="loc_srt_ScenarioUnspecifiedDomain_a3d64b4a-b31a-433a-b740-7d65374a06f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_b5518901-e4c4-4a4e-81c2-cc3876c1e2ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2999afb3-e374-420f-a149-a0fbc207669c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_b5518901-e4c4-4a4e-81c2-cc3876c1e2ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3ae5509c-59b6-48ca-a5a4-c337e0c946a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b5518901-e4c4-4a4e-81c2-cc3876c1e2ca" xlink:to="loc_us-gaap_ClassOfStockDomain_3ae5509c-59b6-48ca-a5a4-c337e0c946a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b0a0f4de-f483-42cb-8b0c-fda922d5bd87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2999afb3-e374-420f-a149-a0fbc207669c" xlink:to="loc_us-gaap_StatementLineItems_b0a0f4de-f483-42cb-8b0c-fda922d5bd87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_e11012ec-0c79-496b-83a3-62fdec2b0667" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b0a0f4de-f483-42cb-8b0c-fda922d5bd87" xlink:to="loc_us-gaap_AssetsCurrentAbstract_e11012ec-0c79-496b-83a3-62fdec2b0667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6809a171-0654-4aa0-a5b7-7d3703f459f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e11012ec-0c79-496b-83a3-62fdec2b0667" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6809a171-0654-4aa0-a5b7-7d3703f459f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_ac459104-bb00-467c-8bfa-76d50666e28b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e11012ec-0c79-496b-83a3-62fdec2b0667" xlink:to="loc_us-gaap_ShortTermInvestments_ac459104-bb00-467c-8bfa-76d50666e28b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_314ddc81-8141-4c5a-839b-90b58f619e39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e11012ec-0c79-496b-83a3-62fdec2b0667" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_314ddc81-8141-4c5a-839b-90b58f619e39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_4065e7b2-5f76-456c-9b08-b806a10ece41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e11012ec-0c79-496b-83a3-62fdec2b0667" xlink:to="loc_us-gaap_InventoryNet_4065e7b2-5f76-456c-9b08-b806a10ece41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_c1f2dd46-3b80-447f-9cce-773bad2ddbda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e11012ec-0c79-496b-83a3-62fdec2b0667" xlink:to="loc_us-gaap_OtherAssetsCurrent_c1f2dd46-3b80-447f-9cce-773bad2ddbda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_8f05b1d1-7f1e-4b2d-94ad-aed66d1d2310" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e11012ec-0c79-496b-83a3-62fdec2b0667" xlink:to="loc_us-gaap_AssetsCurrent_8f05b1d1-7f1e-4b2d-94ad-aed66d1d2310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f41807d6-024f-4299-9020-af2853a0cb9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b0a0f4de-f483-42cb-8b0c-fda922d5bd87" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f41807d6-024f-4299-9020-af2853a0cb9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_2d90b54d-2a05-4d44-84f8-40b12ad06184" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b0a0f4de-f483-42cb-8b0c-fda922d5bd87" xlink:to="loc_us-gaap_Goodwill_2d90b54d-2a05-4d44-84f8-40b12ad06184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsNet_73722ee9-6a5b-4f43-8c13-1e3762d0404f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b0a0f4de-f483-42cb-8b0c-fda922d5bd87" xlink:to="loc_us-gaap_OtherIntangibleAssetsNet_73722ee9-6a5b-4f43-8c13-1e3762d0404f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_9eceafda-bf8e-4888-966a-98484c3e4b15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b0a0f4de-f483-42cb-8b0c-fda922d5bd87" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_9eceafda-bf8e-4888-966a-98484c3e4b15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_66b7c147-4347-447d-8b6a-44df69a5d0aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b0a0f4de-f483-42cb-8b0c-fda922d5bd87" xlink:to="loc_us-gaap_Assets_66b7c147-4347-447d-8b6a-44df69a5d0aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_a8551e32-ab69-4b40-8b4b-8b935ac82379" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b0a0f4de-f483-42cb-8b0c-fda922d5bd87" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_a8551e32-ab69-4b40-8b4b-8b935ac82379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_079e66e4-e90c-4612-aa6c-a1626ae5cc67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a8551e32-ab69-4b40-8b4b-8b935ac82379" xlink:to="loc_us-gaap_AccountsPayableCurrent_079e66e4-e90c-4612-aa6c-a1626ae5cc67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_7893fc39-6c9f-4511-b46b-eb6ad916a370" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a8551e32-ab69-4b40-8b4b-8b935ac82379" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_7893fc39-6c9f-4511-b46b-eb6ad916a370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_fe4d3f89-ae46-40c0-9b1f-ca8042d33e12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a8551e32-ab69-4b40-8b4b-8b935ac82379" xlink:to="loc_us-gaap_LongTermDebtCurrent_fe4d3f89-ae46-40c0-9b1f-ca8042d33e12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_373370ec-1d77-493d-9703-25db841e8631" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a8551e32-ab69-4b40-8b4b-8b935ac82379" xlink:to="loc_us-gaap_LiabilitiesCurrent_373370ec-1d77-493d-9703-25db841e8631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_940a6417-46fb-41d7-ad58-60f4778d0126" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b0a0f4de-f483-42cb-8b0c-fda922d5bd87" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_940a6417-46fb-41d7-ad58-60f4778d0126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_ec4511f6-dfc8-4408-b5d7-47425044eb91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b0a0f4de-f483-42cb-8b0c-fda922d5bd87" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_ec4511f6-dfc8-4408-b5d7-47425044eb91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_ba734641-19b5-4128-82e0-77105d0da14e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b0a0f4de-f483-42cb-8b0c-fda922d5bd87" xlink:to="loc_us-gaap_Liabilities_ba734641-19b5-4128-82e0-77105d0da14e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_62d8e39e-9eba-40ce-8788-d2b029faf3ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b0a0f4de-f483-42cb-8b0c-fda922d5bd87" xlink:to="loc_us-gaap_CommitmentsAndContingencies_62d8e39e-9eba-40ce-8788-d2b029faf3ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_bc7f3975-4f5f-4b0d-948b-88f4d904d4b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b0a0f4de-f483-42cb-8b0c-fda922d5bd87" xlink:to="loc_us-gaap_EquityAbstract_bc7f3975-4f5f-4b0d-948b-88f4d904d4b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_5cfb3b87-9abe-49dc-97d7-fc54c69a654e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_bc7f3975-4f5f-4b0d-948b-88f4d904d4b3" xlink:to="loc_us-gaap_PreferredStockValue_5cfb3b87-9abe-49dc-97d7-fc54c69a654e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_99c9c9c4-0c39-48c7-b6c2-cd9752f839f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_bc7f3975-4f5f-4b0d-948b-88f4d904d4b3" xlink:to="loc_us-gaap_CommonStockValue_99c9c9c4-0c39-48c7-b6c2-cd9752f839f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_405a1f58-a353-47ff-940d-1b769838cb98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_bc7f3975-4f5f-4b0d-948b-88f4d904d4b3" xlink:to="loc_us-gaap_AdditionalPaidInCapital_405a1f58-a353-47ff-940d-1b769838cb98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c5dce900-26ca-4440-83b1-07091ef5ec3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_bc7f3975-4f5f-4b0d-948b-88f4d904d4b3" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c5dce900-26ca-4440-83b1-07091ef5ec3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_918607d0-06b7-4e86-a745-56f9a99f2993" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_bc7f3975-4f5f-4b0d-948b-88f4d904d4b3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_918607d0-06b7-4e86-a745-56f9a99f2993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_911cf203-743b-4f7d-b159-c9d54b3304fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_bc7f3975-4f5f-4b0d-948b-88f4d904d4b3" xlink:to="loc_us-gaap_TreasuryStockValue_911cf203-743b-4f7d-b159-c9d54b3304fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b7c11765-23e7-4461-b509-ba535840d44f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_bc7f3975-4f5f-4b0d-948b-88f4d904d4b3" xlink:to="loc_us-gaap_StockholdersEquity_b7c11765-23e7-4461-b509-ba535840d44f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_64c3b843-2ad2-4f77-99ec-f4ad2364e2f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b0a0f4de-f483-42cb-8b0c-fda922d5bd87" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_64c3b843-2ad2-4f77-99ec-f4ad2364e2f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_d0c8e92c-2e7c-4958-a4ea-bd3eac5e2b55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b0a0f4de-f483-42cb-8b0c-fda922d5bd87" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_d0c8e92c-2e7c-4958-a4ea-bd3eac5e2b55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_b59b2c1d-59e1-431a-9dd9-375a21aaa9bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b0a0f4de-f483-42cb-8b0c-fda922d5bd87" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_b59b2c1d-59e1-431a-9dd9-375a21aaa9bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_d2906b3a-a303-4129-b875-57c3240a6f7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b0a0f4de-f483-42cb-8b0c-fda922d5bd87" xlink:to="loc_us-gaap_PreferredStockSharesIssued_d2906b3a-a303-4129-b875-57c3240a6f7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_365bcaa0-0fc4-4736-a763-07e9333d141f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b0a0f4de-f483-42cb-8b0c-fda922d5bd87" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_365bcaa0-0fc4-4736-a763-07e9333d141f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_d9c13963-7b33-4268-be37-3d7b964c9a14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b0a0f4de-f483-42cb-8b0c-fda922d5bd87" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_d9c13963-7b33-4268-be37-3d7b964c9a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_3a981f56-0edf-4fa5-a3b6-a6a7068df42f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b0a0f4de-f483-42cb-8b0c-fda922d5bd87" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_3a981f56-0edf-4fa5-a3b6-a6a7068df42f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/BalanceSheetParentheticals" xlink:type="simple" xlink:href="lxrx-20221231.xsd#BalanceSheetParentheticals"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/BalanceSheetParentheticals" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_BalanceSheetParentheticalsAbstract_8b3d0502-66ad-4ee5-ad53-fb32e7d9fe22" xlink:href="lxrx-20221231.xsd#lxrx_BalanceSheetParentheticalsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b3969aea-5a2e-499e-b8fc-2cceaad35587" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_BalanceSheetParentheticalsAbstract_8b3d0502-66ad-4ee5-ad53-fb32e7d9fe22" xlink:to="loc_us-gaap_StatementTable_b3969aea-5a2e-499e-b8fc-2cceaad35587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d3cc5138-a9ad-4248-8021-24254424ca36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b3969aea-5a2e-499e-b8fc-2cceaad35587" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d3cc5138-a9ad-4248-8021-24254424ca36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5d9bd378-8bb2-47ba-aaa9-2719bb3ce405" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d3cc5138-a9ad-4248-8021-24254424ca36" xlink:to="loc_us-gaap_EquityComponentDomain_5d9bd378-8bb2-47ba-aaa9-2719bb3ce405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_90e6a267-2c4c-468e-a87e-6fc807471fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5d9bd378-8bb2-47ba-aaa9-2719bb3ce405" xlink:to="loc_us-gaap_CommonStockMember_90e6a267-2c4c-468e-a87e-6fc807471fc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_31873368-86de-4de1-b14e-7007bd0fde4a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b3969aea-5a2e-499e-b8fc-2cceaad35587" xlink:to="loc_srt_StatementScenarioAxis_31873368-86de-4de1-b14e-7007bd0fde4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_0e710e06-4364-4b2b-9d6d-ef4cbb35d438" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_31873368-86de-4de1-b14e-7007bd0fde4a" xlink:to="loc_srt_ScenarioUnspecifiedDomain_0e710e06-4364-4b2b-9d6d-ef4cbb35d438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_221d5524-e4be-48a6-9296-6b2ad5cae2bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b3969aea-5a2e-499e-b8fc-2cceaad35587" xlink:to="loc_us-gaap_StatementClassOfStockAxis_221d5524-e4be-48a6-9296-6b2ad5cae2bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_c6d3a6c7-4b09-410e-9b51-92370a2bebe3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_221d5524-e4be-48a6-9296-6b2ad5cae2bf" xlink:to="loc_us-gaap_ClassOfStockDomain_c6d3a6c7-4b09-410e-9b51-92370a2bebe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_5593bed0-4944-46bf-9f3e-10f0562d9407" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b3969aea-5a2e-499e-b8fc-2cceaad35587" xlink:to="loc_us-gaap_StatementLineItems_5593bed0-4944-46bf-9f3e-10f0562d9407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a3424c15-d0f8-466c-8392-6e4a07a310ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5593bed0-4944-46bf-9f3e-10f0562d9407" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a3424c15-d0f8-466c-8392-6e4a07a310ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6d071717-2e59-4130-ad82-1d85e757d2ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5593bed0-4944-46bf-9f3e-10f0562d9407" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6d071717-2e59-4130-ad82-1d85e757d2ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_dc4a4df5-d0d0-414a-9be9-12faa5287217" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5593bed0-4944-46bf-9f3e-10f0562d9407" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_dc4a4df5-d0d0-414a-9be9-12faa5287217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_8ef686a5-5bbe-4523-a0ae-46a64f4f0d3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5593bed0-4944-46bf-9f3e-10f0562d9407" xlink:to="loc_us-gaap_PreferredStockSharesIssued_8ef686a5-5bbe-4523-a0ae-46a64f4f0d3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_07e53e6b-a6f8-43bd-9cb5-75dafda14077" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5593bed0-4944-46bf-9f3e-10f0562d9407" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_07e53e6b-a6f8-43bd-9cb5-75dafda14077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_8493a36e-e7cf-4643-aa22-ff906301f036" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5593bed0-4944-46bf-9f3e-10f0562d9407" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_8493a36e-e7cf-4643-aa22-ff906301f036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_04ecff6b-efae-4920-8a5f-cac0aa9beff6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5593bed0-4944-46bf-9f3e-10f0562d9407" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_04ecff6b-efae-4920-8a5f-cac0aa9beff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_48661cb5-1feb-4f2b-b731-603c872b039f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5593bed0-4944-46bf-9f3e-10f0562d9407" xlink:to="loc_us-gaap_CommonStockSharesIssued_48661cb5-1feb-4f2b-b731-603c872b039f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_fd309589-2afa-40ce-813e-3e28fc33682f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5593bed0-4944-46bf-9f3e-10f0562d9407" xlink:to="loc_us-gaap_TreasuryStockShares_fd309589-2afa-40ce-813e-3e28fc33682f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="lxrx-20221231.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedStatementsOfOperationsAbstract_a51de38a-20c3-42fd-881f-ecc72909a718" xlink:href="lxrx-20221231.xsd#lxrx_ConsolidatedStatementsOfOperationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_7147de36-2899-48f9-94d6-abe543f7462a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedStatementsOfOperationsAbstract_a51de38a-20c3-42fd-881f-ecc72909a718" xlink:to="loc_us-gaap_StatementTable_7147de36-2899-48f9-94d6-abe543f7462a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_2f177d9e-59ab-42c7-ad04-708fb5a890c1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_7147de36-2899-48f9-94d6-abe543f7462a" xlink:to="loc_srt_StatementScenarioAxis_2f177d9e-59ab-42c7-ad04-708fb5a890c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_fdf6d515-0045-400f-90fe-4ef6edb6bff7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_2f177d9e-59ab-42c7-ad04-708fb5a890c1" xlink:to="loc_srt_ScenarioUnspecifiedDomain_fdf6d515-0045-400f-90fe-4ef6edb6bff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_17fad38d-726e-4ab3-af8c-2e2172fbd9a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_7147de36-2899-48f9-94d6-abe543f7462a" xlink:to="loc_us-gaap_StatementLineItems_17fad38d-726e-4ab3-af8c-2e2172fbd9a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_e1a9b0ee-aec7-4f3c-9118-383f6557118f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_17fad38d-726e-4ab3-af8c-2e2172fbd9a7" xlink:to="loc_us-gaap_RevenuesAbstract_e1a9b0ee-aec7-4f3c-9118-383f6557118f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b2267bf1-137e-4fc3-a84c-5ac915ad18bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_e1a9b0ee-aec7-4f3c-9118-383f6557118f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b2267bf1-137e-4fc3-a84c-5ac915ad18bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_2c491f5a-2a27-4c3d-966d-7775320b013e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_e1a9b0ee-aec7-4f3c-9118-383f6557118f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_2c491f5a-2a27-4c3d-966d-7775320b013e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyIncomeNonoperating_1735dcb8-0741-4a68-8bbf-1afe3d070760" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyIncomeNonoperating"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_e1a9b0ee-aec7-4f3c-9118-383f6557118f" xlink:to="loc_us-gaap_RoyaltyIncomeNonoperating_1735dcb8-0741-4a68-8bbf-1afe3d070760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_0814891b-250a-40ef-a8cc-90aea73f790d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_e1a9b0ee-aec7-4f3c-9118-383f6557118f" xlink:to="loc_us-gaap_Revenues_0814891b-250a-40ef-a8cc-90aea73f790d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_b245279d-5a10-475c-b59e-d796cdd49f67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_17fad38d-726e-4ab3-af8c-2e2172fbd9a7" xlink:to="loc_us-gaap_OperatingExpensesAbstract_b245279d-5a10-475c-b59e-d796cdd49f67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_5395dc1b-67af-47ba-9f2b-fb98df9f4d86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b245279d-5a10-475c-b59e-d796cdd49f67" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_5395dc1b-67af-47ba-9f2b-fb98df9f4d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_253aa50b-c841-42ba-a1df-ef6fe95a2b38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b245279d-5a10-475c-b59e-d796cdd49f67" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_253aa50b-c841-42ba-a1df-ef6fe95a2b38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_fda0d979-fdd2-410f-8de3-cc52ee5d5c3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b245279d-5a10-475c-b59e-d796cdd49f67" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_fda0d979-fdd2-410f-8de3-cc52ee5d5c3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_604f9c65-4c0b-478f-91af-b43f3c6f4bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b245279d-5a10-475c-b59e-d796cdd49f67" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_604f9c65-4c0b-478f-91af-b43f3c6f4bbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_d3845c99-943c-4ca1-b0ad-fe705de59ac3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b245279d-5a10-475c-b59e-d796cdd49f67" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_d3845c99-943c-4ca1-b0ad-fe705de59ac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_191ac4dd-3860-49fc-8258-dcdd9c73a510" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b245279d-5a10-475c-b59e-d796cdd49f67" xlink:to="loc_us-gaap_OperatingExpenses_191ac4dd-3860-49fc-8258-dcdd9c73a510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_GainOnSaleOfNonFinancialAssets_9469aa23-d0c5-4e30-a0fd-3148d65e2cf5" xlink:href="lxrx-20221231.xsd#lxrx_GainOnSaleOfNonFinancialAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b245279d-5a10-475c-b59e-d796cdd49f67" xlink:to="loc_lxrx_GainOnSaleOfNonFinancialAssets_9469aa23-d0c5-4e30-a0fd-3148d65e2cf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_87d1e3ea-9405-4d4a-a86d-2e2358f8083f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_17fad38d-726e-4ab3-af8c-2e2172fbd9a7" xlink:to="loc_us-gaap_OperatingIncomeLoss_87d1e3ea-9405-4d4a-a86d-2e2358f8083f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_464bd45a-23f3-4112-8e7d-955812d2904b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_17fad38d-726e-4ab3-af8c-2e2172fbd9a7" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_464bd45a-23f3-4112-8e7d-955812d2904b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_0eac742e-c2a3-4f2b-ba3f-eabe1eef0a1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_17fad38d-726e-4ab3-af8c-2e2172fbd9a7" xlink:to="loc_us-gaap_InterestExpense_0eac742e-c2a3-4f2b-ba3f-eabe1eef0a1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_35956bed-a3d7-4a21-9b37-c53808cb6c69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_17fad38d-726e-4ab3-af8c-2e2172fbd9a7" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_35956bed-a3d7-4a21-9b37-c53808cb6c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_da1cd30f-d06f-44fc-8a49-aa2748109dd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_17fad38d-726e-4ab3-af8c-2e2172fbd9a7" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_da1cd30f-d06f-44fc-8a49-aa2748109dd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_a8d87c9b-842e-4f2e-9563-818bf65de18d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_17fad38d-726e-4ab3-af8c-2e2172fbd9a7" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_a8d87c9b-842e-4f2e-9563-818bf65de18d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4d87ae21-4c3a-4469-8ed3-378c9df1b356" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_17fad38d-726e-4ab3-af8c-2e2172fbd9a7" xlink:to="loc_us-gaap_NetIncomeLoss_4d87ae21-4c3a-4469-8ed3-378c9df1b356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_7c9e4ed4-ccc8-4870-85e3-35157a7df052" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_17fad38d-726e-4ab3-af8c-2e2172fbd9a7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_7c9e4ed4-ccc8-4870-85e3-35157a7df052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_12488dca-c4bb-446d-ae9d-f44bb3d6b1d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_7c9e4ed4-ccc8-4870-85e3-35157a7df052" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_12488dca-c4bb-446d-ae9d-f44bb3d6b1d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_cb714d6c-2af1-4a98-95aa-fe3ea3d47211" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_7c9e4ed4-ccc8-4870-85e3-35157a7df052" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_cb714d6c-2af1-4a98-95aa-fe3ea3d47211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_70efa4f3-ee8b-46e9-b5af-d3522d32240c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_17fad38d-726e-4ab3-af8c-2e2172fbd9a7" xlink:to="loc_us-gaap_EarningsPerShareBasic_70efa4f3-ee8b-46e9-b5af-d3522d32240c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1c0f0a7f-0fb8-440b-8f92-bcbc2069cbcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_17fad38d-726e-4ab3-af8c-2e2172fbd9a7" xlink:to="loc_us-gaap_EarningsPerShareDiluted_1c0f0a7f-0fb8-440b-8f92-bcbc2069cbcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fdcee667-a8d6-4e3c-a618-5ee7f0c00e46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_17fad38d-726e-4ab3-af8c-2e2172fbd9a7" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fdcee667-a8d6-4e3c-a618-5ee7f0c00e46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_b1ebb179-fa51-4c44-8e93-4ebc5231b25a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_17fad38d-726e-4ab3-af8c-2e2172fbd9a7" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_b1ebb179-fa51-4c44-8e93-4ebc5231b25a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/StatementsofComprehensiveLossParentheticalsParentheticals" xlink:type="simple" xlink:href="lxrx-20221231.xsd#StatementsofComprehensiveLossParentheticalsParentheticals"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/StatementsofComprehensiveLossParentheticalsParentheticals" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedStatementsOfOperationsParentheticalsAbstract_1d35c689-14e6-4ff3-8e0d-7548428c3a14" xlink:href="lxrx-20221231.xsd#lxrx_ConsolidatedStatementsOfOperationsParentheticalsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_556c4ae9-2a6b-4975-99d4-bd9372f201d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedStatementsOfOperationsParentheticalsAbstract_1d35c689-14e6-4ff3-8e0d-7548428c3a14" xlink:to="loc_us-gaap_StatementTable_556c4ae9-2a6b-4975-99d4-bd9372f201d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_2e77d1f8-ba8a-4eb2-b973-df4ec5a94551" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_556c4ae9-2a6b-4975-99d4-bd9372f201d4" xlink:to="loc_srt_StatementScenarioAxis_2e77d1f8-ba8a-4eb2-b973-df4ec5a94551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_dc4e60b9-9356-4511-b08b-94c4341da3f6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_2e77d1f8-ba8a-4eb2-b973-df4ec5a94551" xlink:to="loc_srt_ScenarioUnspecifiedDomain_dc4e60b9-9356-4511-b08b-94c4341da3f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4efcf08e-2bf9-4411-a8fe-f9a0beee4a31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_556c4ae9-2a6b-4975-99d4-bd9372f201d4" xlink:to="loc_us-gaap_StatementLineItems_4efcf08e-2bf9-4411-a8fe-f9a0beee4a31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_bf1544fe-fe8c-49e4-b023-2833f137c776" xlink:href="lxrx-20221231.xsd#lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4efcf08e-2bf9-4411-a8fe-f9a0beee4a31" xlink:to="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_bf1544fe-fe8c-49e4-b023-2833f137c776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense_3f457a83-a78f-4985-9f85-4bd8fb6fa94f" xlink:href="lxrx-20221231.xsd#lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4efcf08e-2bf9-4411-a8fe-f9a0beee4a31" xlink:to="loc_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense_3f457a83-a78f-4985-9f85-4bd8fb6fa94f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="lxrx-20221231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract_ff1403ae-696c-42f9-936f-8989c9b0c162" xlink:href="lxrx-20221231.xsd#lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6a56cbaa-aec8-471a-86b0-7c2ce50d921b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract_ff1403ae-696c-42f9-936f-8989c9b0c162" xlink:to="loc_us-gaap_StatementTable_6a56cbaa-aec8-471a-86b0-7c2ce50d921b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f077fec7-77de-4dbd-b891-b5d200d7d370" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6a56cbaa-aec8-471a-86b0-7c2ce50d921b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f077fec7-77de-4dbd-b891-b5d200d7d370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3323358c-003f-4254-b834-a7ef7bb32d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f077fec7-77de-4dbd-b891-b5d200d7d370" xlink:to="loc_us-gaap_EquityComponentDomain_3323358c-003f-4254-b834-a7ef7bb32d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_8a129a23-7f17-4ba3-af9b-a2b9f4d97617" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3323358c-003f-4254-b834-a7ef7bb32d6e" xlink:to="loc_us-gaap_CommonStockMember_8a129a23-7f17-4ba3-af9b-a2b9f4d97617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_6ab42cb6-8a24-4066-b21a-d919ae2dae88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3323358c-003f-4254-b834-a7ef7bb32d6e" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_6ab42cb6-8a24-4066-b21a-d919ae2dae88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_75055d8e-8dee-409c-942a-bd4902c3735a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3323358c-003f-4254-b834-a7ef7bb32d6e" xlink:to="loc_us-gaap_RetainedEarningsMember_75055d8e-8dee-409c-942a-bd4902c3735a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c476fb3d-b526-4493-b5e8-c0ad4f72bc87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3323358c-003f-4254-b834-a7ef7bb32d6e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c476fb3d-b526-4493-b5e8-c0ad4f72bc87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_c76d9bca-7f3c-494b-ba74-ac1806962095" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3323358c-003f-4254-b834-a7ef7bb32d6e" xlink:to="loc_us-gaap_TreasuryStockMember_c76d9bca-7f3c-494b-ba74-ac1806962095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_456d2144-b7d2-46d1-9ebc-93fe29942259" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6a56cbaa-aec8-471a-86b0-7c2ce50d921b" xlink:to="loc_us-gaap_StatementLineItems_456d2144-b7d2-46d1-9ebc-93fe29942259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_c94a4650-2da6-41e1-9925-6a9712ed6d8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_456d2144-b7d2-46d1-9ebc-93fe29942259" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_c94a4650-2da6-41e1-9925-6a9712ed6d8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_dacec129-5821-4477-8d40-6796bcf58197" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_456d2144-b7d2-46d1-9ebc-93fe29942259" xlink:to="loc_us-gaap_StockholdersEquity_dacec129-5821-4477-8d40-6796bcf58197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_a975f59b-b23f-4127-9784-723e389b6d39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_456d2144-b7d2-46d1-9ebc-93fe29942259" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_a975f59b-b23f-4127-9784-723e389b6d39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_62bfb930-ea8b-48f5-ac8e-7843bb7b7390" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_456d2144-b7d2-46d1-9ebc-93fe29942259" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_62bfb930-ea8b-48f5-ac8e-7843bb7b7390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_112ef092-45bf-4142-a579-24b5ed9cffab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_456d2144-b7d2-46d1-9ebc-93fe29942259" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_112ef092-45bf-4142-a579-24b5ed9cffab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_d754cde1-891b-49a8-9076-8f6bdfd77f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_456d2144-b7d2-46d1-9ebc-93fe29942259" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_d754cde1-891b-49a8-9076-8f6bdfd77f6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_4fd75b66-1f1f-4b04-8424-4e0fd3a68d31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_456d2144-b7d2-46d1-9ebc-93fe29942259" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_4fd75b66-1f1f-4b04-8424-4e0fd3a68d31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_9b158e8c-c756-4062-ad0e-e17101a22583" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_456d2144-b7d2-46d1-9ebc-93fe29942259" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_9b158e8c-c756-4062-ad0e-e17101a22583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_683e53aa-4d4c-4968-b40f-bf9232bea1b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_456d2144-b7d2-46d1-9ebc-93fe29942259" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_683e53aa-4d4c-4968-b40f-bf9232bea1b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_9fc290c0-69b1-41f0-8bde-c0245ff39ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_456d2144-b7d2-46d1-9ebc-93fe29942259" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_9fc290c0-69b1-41f0-8bde-c0245ff39ae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_e5561d61-10b6-4829-8f82-a5a540ee75fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_456d2144-b7d2-46d1-9ebc-93fe29942259" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_e5561d61-10b6-4829-8f82-a5a540ee75fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2df374d6-c572-4a76-82c7-4c924e2ec184" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_456d2144-b7d2-46d1-9ebc-93fe29942259" xlink:to="loc_us-gaap_NetIncomeLoss_2df374d6-c572-4a76-82c7-4c924e2ec184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_b3b2ad26-6464-4f3d-83b3-2d331e104ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_456d2144-b7d2-46d1-9ebc-93fe29942259" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_b3b2ad26-6464-4f3d-83b3-2d331e104ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_c2ca2259-7ff1-48e8-be65-cb1d35e456f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_456d2144-b7d2-46d1-9ebc-93fe29942259" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_c2ca2259-7ff1-48e8-be65-cb1d35e456f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d5f290ce-165b-454f-b086-4520022a01cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_456d2144-b7d2-46d1-9ebc-93fe29942259" xlink:to="loc_us-gaap_StockholdersEquity_d5f290ce-165b-454f-b086-4520022a01cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustment_8d6355ea-371f-4820-ad88-101956d21995" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustment"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_456d2144-b7d2-46d1-9ebc-93fe29942259" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustment_8d6355ea-371f-4820-ad88-101956d21995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification_4e95db74-7a4c-4a47-a0e5-3b69009a47e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_456d2144-b7d2-46d1-9ebc-93fe29942259" xlink:to="loc_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification_4e95db74-7a4c-4a47-a0e5-3b69009a47e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_b575fb8f-370e-433e-a1a8-47e3ea0820eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_456d2144-b7d2-46d1-9ebc-93fe29942259" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_b575fb8f-370e-433e-a1a8-47e3ea0820eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountIssued1_a1233559-a650-4545-a64c-36f55517565a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockAmountIssued1"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_456d2144-b7d2-46d1-9ebc-93fe29942259" xlink:to="loc_us-gaap_ConversionOfStockAmountIssued1_a1233559-a650-4545-a64c-36f55517565a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_357e3524-c4bd-49a4-85a3-f3284fc77972" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_456d2144-b7d2-46d1-9ebc-93fe29942259" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_357e3524-c4bd-49a4-85a3-f3284fc77972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ProceedsFromDecember2020CommonStockOffering_dfcd6632-420a-42fa-9318-ae80c54af39c" xlink:href="lxrx-20221231.xsd#lxrx_ProceedsFromDecember2020CommonStockOffering"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_456d2144-b7d2-46d1-9ebc-93fe29942259" xlink:to="loc_lxrx_ProceedsFromDecember2020CommonStockOffering_dfcd6632-420a-42fa-9318-ae80c54af39c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesSoldInJanuary2021ATMOffering_a71cd40c-e62e-4813-bb2b-09fae7fa125d" xlink:href="lxrx-20221231.xsd#lxrx_SharesSoldInJanuary2021ATMOffering"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_456d2144-b7d2-46d1-9ebc-93fe29942259" xlink:to="loc_lxrx_SharesSoldInJanuary2021ATMOffering_a71cd40c-e62e-4813-bb2b-09fae7fa125d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ProceedsFromJanuary2021ATMOffering_2184dc1a-e733-42dc-88c8-1f9ef7d7a94a" xlink:href="lxrx-20221231.xsd#lxrx_ProceedsFromJanuary2021ATMOffering"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_456d2144-b7d2-46d1-9ebc-93fe29942259" xlink:to="loc_lxrx_ProceedsFromJanuary2021ATMOffering_2184dc1a-e733-42dc-88c8-1f9ef7d7a94a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharePriceInNovember20ATMOffering_041116ca-c4e0-45cd-80c8-27faacd3e839" xlink:href="lxrx-20221231.xsd#lxrx_SharePriceInNovember20ATMOffering"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_456d2144-b7d2-46d1-9ebc-93fe29942259" xlink:to="loc_lxrx_SharePriceInNovember20ATMOffering_041116ca-c4e0-45cd-80c8-27faacd3e839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ProceedsFromNov2020ATMOffering_4eda881f-9a45-459e-bdbb-5073c29487c9" xlink:href="lxrx-20221231.xsd#lxrx_ProceedsFromNov2020ATMOffering"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_456d2144-b7d2-46d1-9ebc-93fe29942259" xlink:to="loc_lxrx_ProceedsFromNov2020ATMOffering_4eda881f-9a45-459e-bdbb-5073c29487c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CommissionsFromDecember2020CommonStockOffering_fc3b6078-82e5-44c3-b58b-c3cbacb75d32" xlink:href="lxrx-20221231.xsd#lxrx_CommissionsFromDecember2020CommonStockOffering"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_456d2144-b7d2-46d1-9ebc-93fe29942259" xlink:to="loc_lxrx_CommissionsFromDecember2020CommonStockOffering_fc3b6078-82e5-44c3-b58b-c3cbacb75d32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OfferingExpensesFromDecember20CommonStockOffering_28a5ec84-bf00-4358-b8f5-0ed462c51447" xlink:href="lxrx-20221231.xsd#lxrx_OfferingExpensesFromDecember20CommonStockOffering"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_456d2144-b7d2-46d1-9ebc-93fe29942259" xlink:to="loc_lxrx_OfferingExpensesFromDecember20CommonStockOffering_28a5ec84-bf00-4358-b8f5-0ed462c51447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ATMOfferingTotal_e1280569-3901-457a-b850-5b82c7e77d62" xlink:href="lxrx-20221231.xsd#lxrx_ATMOfferingTotal"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_456d2144-b7d2-46d1-9ebc-93fe29942259" xlink:to="loc_lxrx_ATMOfferingTotal_e1280569-3901-457a-b850-5b82c7e77d62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OtherCapitalAgreementsTextBlock_008b0df4-7b43-4c98-a615-4627ef802bf7" xlink:href="lxrx-20221231.xsd#lxrx_OtherCapitalAgreementsTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_456d2144-b7d2-46d1-9ebc-93fe29942259" xlink:to="loc_lxrx_OtherCapitalAgreementsTextBlock_008b0df4-7b43-4c98-a615-4627ef802bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtInstrument_Revere_LXRX_0838f71f-8360-4f49-ae31-7d69e0fc733d" xlink:href="lxrx-20221231.xsd#lxrx_MortgageDebtInstrument_Revere_LXRX"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_456d2144-b7d2-46d1-9ebc-93fe29942259" xlink:to="loc_lxrx_MortgageDebtInstrument_Revere_LXRX_0838f71f-8360-4f49-ae31-7d69e0fc733d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_5a40788c-bbda-4f41-8dd6-ee908409c5e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_456d2144-b7d2-46d1-9ebc-93fe29942259" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_5a40788c-bbda-4f41-8dd6-ee908409c5e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_6f7bac2f-67e6-4757-88bc-f7cf6d88ec3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_456d2144-b7d2-46d1-9ebc-93fe29942259" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_6f7bac2f-67e6-4757-88bc-f7cf6d88ec3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="lxrx-20221231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedStatementsOfCashFlowsAbstract_864a324b-7ab8-443c-b920-894ca9240a96" xlink:href="lxrx-20221231.xsd#lxrx_ConsolidatedStatementsOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_50fe6e08-e81b-47bd-8837-5ad316139cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedStatementsOfCashFlowsAbstract_864a324b-7ab8-443c-b920-894ca9240a96" xlink:to="loc_us-gaap_StatementTable_50fe6e08-e81b-47bd-8837-5ad316139cf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_4e65da16-9e15-404f-9bcc-dd8a9e5098f4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_50fe6e08-e81b-47bd-8837-5ad316139cf1" xlink:to="loc_srt_StatementScenarioAxis_4e65da16-9e15-404f-9bcc-dd8a9e5098f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_64ebe54b-75b7-4408-a905-7494ac3aae68" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_4e65da16-9e15-404f-9bcc-dd8a9e5098f4" xlink:to="loc_srt_ScenarioUnspecifiedDomain_64ebe54b-75b7-4408-a905-7494ac3aae68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_c6b79841-df67-4499-83a3-bc76909339b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_50fe6e08-e81b-47bd-8837-5ad316139cf1" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_c6b79841-df67-4499-83a3-bc76909339b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_3262e19b-6dac-4a27-ac64-3cd9fcd39cdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_c6b79841-df67-4499-83a3-bc76909339b3" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_3262e19b-6dac-4a27-ac64-3cd9fcd39cdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_RDSeveranceCostsMember_37688626-77fb-4fac-8aaa-3c4b46a26e90" xlink:href="lxrx-20221231.xsd#lxrx_RDSeveranceCostsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_3262e19b-6dac-4a27-ac64-3cd9fcd39cdb" xlink:to="loc_lxrx_RDSeveranceCostsMember_37688626-77fb-4fac-8aaa-3c4b46a26e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0a373d8b-18d4-4524-bd71-61f3966d6ec3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_50fe6e08-e81b-47bd-8837-5ad316139cf1" xlink:to="loc_us-gaap_StatementLineItems_0a373d8b-18d4-4524-bd71-61f3966d6ec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e7d47488-71ff-4e1f-9fe6-2e7e61085f58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0a373d8b-18d4-4524-bd71-61f3966d6ec3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e7d47488-71ff-4e1f-9fe6-2e7e61085f58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_9d4656b2-4058-45be-884d-24819c4b1341" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e7d47488-71ff-4e1f-9fe6-2e7e61085f58" xlink:to="loc_us-gaap_ProfitLoss_9d4656b2-4058-45be-884d-24819c4b1341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_da8a9432-5982-4211-aee9-b4eb684977cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e7d47488-71ff-4e1f-9fe6-2e7e61085f58" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_da8a9432-5982-4211-aee9-b4eb684977cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_cb603d9f-24c8-4db3-81db-5ea78cc26da4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_da8a9432-5982-4211-aee9-b4eb684977cb" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_cb603d9f-24c8-4db3-81db-5ea78cc26da4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_b1bad366-f49c-49f4-a4a5-ab7eb80f7cad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_da8a9432-5982-4211-aee9-b4eb684977cb" xlink:to="loc_us-gaap_ShareBasedCompensation_b1bad366-f49c-49f4-a4a5-ab7eb80f7cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_3b1482de-bf5d-490a-bd28-429084bea4f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_da8a9432-5982-4211-aee9-b4eb684977cb" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_3b1482de-bf5d-490a-bd28-429084bea4f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_620db6ce-e6fd-4823-b2b5-4215a79d249a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_da8a9432-5982-4211-aee9-b4eb684977cb" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_620db6ce-e6fd-4823-b2b5-4215a79d249a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ae6aba0d-04d0-49f3-958a-c86d8b1e8487" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_da8a9432-5982-4211-aee9-b4eb684977cb" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ae6aba0d-04d0-49f3-958a-c86d8b1e8487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_400a692d-07ec-438b-906f-067b056c8ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ae6aba0d-04d0-49f3-958a-c86d8b1e8487" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_400a692d-07ec-438b-906f-067b056c8ef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_346bc604-1455-42dd-9a1f-5bb40152b7fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ae6aba0d-04d0-49f3-958a-c86d8b1e8487" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_346bc604-1455-42dd-9a1f-5bb40152b7fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_dfd405e5-64f9-4674-9446-e5760819c745" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ae6aba0d-04d0-49f3-958a-c86d8b1e8487" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_dfd405e5-64f9-4674-9446-e5760819c745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_6bb38fee-03fd-4787-ae0a-c0784add80fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ae6aba0d-04d0-49f3-958a-c86d8b1e8487" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_6bb38fee-03fd-4787-ae0a-c0784add80fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_040348c1-f131-484a-b9db-9574739a4340" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ae6aba0d-04d0-49f3-958a-c86d8b1e8487" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_040348c1-f131-484a-b9db-9574739a4340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_8d91ade7-fa94-4861-a632-466bd04dcb49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ae6aba0d-04d0-49f3-958a-c86d8b1e8487" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_8d91ade7-fa94-4861-a632-466bd04dcb49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_91f255e1-825e-467e-91f7-c501541bbe23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e7d47488-71ff-4e1f-9fe6-2e7e61085f58" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_91f255e1-825e-467e-91f7-c501541bbe23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6bbf8898-f7e8-4ea0-8952-274d10fa02e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0a373d8b-18d4-4524-bd71-61f3966d6ec3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6bbf8898-f7e8-4ea0-8952-274d10fa02e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4f865550-c3da-4de6-ac03-b971c0191829" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6bbf8898-f7e8-4ea0-8952-274d10fa02e0" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4f865550-c3da-4de6-ac03-b971c0191829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_495186a0-bdf0-4c66-bda4-138e1b5ab334" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6bbf8898-f7e8-4ea0-8952-274d10fa02e0" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_495186a0-bdf0-4c66-bda4-138e1b5ab334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_99fe16b3-57ed-4cf3-88db-c81d5feaa46a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6bbf8898-f7e8-4ea0-8952-274d10fa02e0" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_99fe16b3-57ed-4cf3-88db-c81d5feaa46a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_1718bac5-92a7-4923-bdc7-bba552f8884c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6bbf8898-f7e8-4ea0-8952-274d10fa02e0" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_1718bac5-92a7-4923-bdc7-bba552f8884c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_3b7ff2f9-5eb8-4d51-97ec-f5707f5a47ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6bbf8898-f7e8-4ea0-8952-274d10fa02e0" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_3b7ff2f9-5eb8-4d51-97ec-f5707f5a47ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_91e06fcf-db27-40b2-9467-4dd650de2eb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6bbf8898-f7e8-4ea0-8952-274d10fa02e0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_91e06fcf-db27-40b2-9467-4dd650de2eb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e56edba6-2e9f-413f-9450-3f3813af4789" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0a373d8b-18d4-4524-bd71-61f3966d6ec3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e56edba6-2e9f-413f-9450-3f3813af4789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_28b880b9-450e-4338-8a5f-85963dff3033" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e56edba6-2e9f-413f-9450-3f3813af4789" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_28b880b9-450e-4338-8a5f-85963dff3033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_9719e288-8795-41d2-8a25-57ff3cd53f86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e56edba6-2e9f-413f-9450-3f3813af4789" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_9719e288-8795-41d2-8a25-57ff3cd53f86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_1d8ba0ac-a4a6-4391-9eb9-032be0463820" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e56edba6-2e9f-413f-9450-3f3813af4789" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_1d8ba0ac-a4a6-4391-9eb9-032be0463820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_1d12a33e-bb6d-418e-b9fe-0d7d89f68900" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e56edba6-2e9f-413f-9450-3f3813af4789" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_1d12a33e-bb6d-418e-b9fe-0d7d89f68900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6c60093c-d301-45b1-8320-ccaadb64d7f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e56edba6-2e9f-413f-9450-3f3813af4789" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6c60093c-d301-45b1-8320-ccaadb64d7f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_93b02451-e5c9-4a09-98bc-8c65698b1287" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0a373d8b-18d4-4524-bd71-61f3966d6ec3" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_93b02451-e5c9-4a09-98bc-8c65698b1287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a8cec397-bcef-445c-85a9-8dabd9c702aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0a373d8b-18d4-4524-bd71-61f3966d6ec3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a8cec397-bcef-445c-85a9-8dabd9c702aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5e3733ce-cee4-441e-9e50-d33b799b7bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0a373d8b-18d4-4524-bd71-61f3966d6ec3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5e3733ce-cee4-441e-9e50-d33b799b7bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_06d32f88-97dc-4d44-831c-421d61e779bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0a373d8b-18d4-4524-bd71-61f3966d6ec3" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_06d32f88-97dc-4d44-831c-421d61e779bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_d71856fe-0fac-4a97-ba38-4192ff8916ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_06d32f88-97dc-4d44-831c-421d61e779bc" xlink:to="loc_us-gaap_InterestPaidNet_d71856fe-0fac-4a97-ba38-4192ff8916ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_a6364186-a0a7-460a-a124-3ec3bed95600" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0a373d8b-18d4-4524-bd71-61f3966d6ec3" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_a6364186-a0a7-460a-a124-3ec3bed95600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_62a2a5fb-a2f4-4608-a5eb-1371c2e31c16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0a373d8b-18d4-4524-bd71-61f3966d6ec3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_62a2a5fb-a2f4-4608-a5eb-1371c2e31c16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_98077c16-0bfe-4ba3-8ec4-93200cbe8b62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0a373d8b-18d4-4524-bd71-61f3966d6ec3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_98077c16-0bfe-4ba3-8ec4-93200cbe8b62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_c0437934-fed8-43c2-a191-85f7eb35f74e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0a373d8b-18d4-4524-bd71-61f3966d6ec3" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_c0437934-fed8-43c2-a191-85f7eb35f74e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_GainOnSaleOfNonFinancialAssets_816a39db-f4e5-4b84-981d-dc80e021098b" xlink:href="lxrx-20221231.xsd#lxrx_GainOnSaleOfNonFinancialAssets"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0a373d8b-18d4-4524-bd71-61f3966d6ec3" xlink:to="loc_lxrx_GainOnSaleOfNonFinancialAssets_816a39db-f4e5-4b84-981d-dc80e021098b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfRealEstate_ea41db48-16db-4aef-8294-4850ec534c50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfRealEstate"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0a373d8b-18d4-4524-bd71-61f3966d6ec3" xlink:to="loc_us-gaap_ImpairmentOfRealEstate_ea41db48-16db-4aef-8294-4850ec534c50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_73c07481-007a-4041-8608-1bd09a2fd737" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0a373d8b-18d4-4524-bd71-61f3966d6ec3" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_73c07481-007a-4041-8608-1bd09a2fd737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_eda47b2d-a649-4edb-bd27-79c0f573bede" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0a373d8b-18d4-4524-bd71-61f3966d6ec3" xlink:to="loc_us-gaap_AssetImpairmentCharges_eda47b2d-a649-4edb-bd27-79c0f573bede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_8085a649-4b8f-4e1b-bbe9-1f449cd3e455" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0a373d8b-18d4-4524-bd71-61f3966d6ec3" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_8085a649-4b8f-4e1b-bbe9-1f449cd3e455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfBuildings_3579156a-0a85-4708-9bb8-1e1950609c2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfBuildings"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0a373d8b-18d4-4524-bd71-61f3966d6ec3" xlink:to="loc_us-gaap_ProceedsFromSaleOfBuildings_3579156a-0a85-4708-9bb8-1e1950609c2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_d86539d8-d5fc-4b79-bb1d-25a1b768450f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0a373d8b-18d4-4524-bd71-61f3966d6ec3" xlink:to="loc_us-gaap_SeveranceCosts1_d86539d8-d5fc-4b79-bb1d-25a1b768450f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_489a7431-215a-4a04-a874-4d763e1d0f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0a373d8b-18d4-4524-bd71-61f3966d6ec3" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_489a7431-215a-4a04-a874-4d763e1d0f9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_49a22e7f-af7e-470e-8658-e2982eab3b64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0a373d8b-18d4-4524-bd71-61f3966d6ec3" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_49a22e7f-af7e-470e-8658-e2982eab3b64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_485a5f5b-4bd0-42a3-bb12-408d5bcbb808" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0a373d8b-18d4-4524-bd71-61f3966d6ec3" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_485a5f5b-4bd0-42a3-bb12-408d5bcbb808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCarryingBasis_39553004-624d-45b6-9a42-5cfae25caa6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCarryingBasis"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0a373d8b-18d4-4524-bd71-61f3966d6ec3" xlink:to="loc_us-gaap_TreasuryStockCarryingBasis_39553004-624d-45b6-9a42-5cfae25caa6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_371766fd-a524-4469-9d77-6f9ba4cc54b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0a373d8b-18d4-4524-bd71-61f3966d6ec3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_371766fd-a524-4469-9d77-6f9ba4cc54b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessExitCosts1_8f5ec01a-0d28-4dc2-ad43-c94867efd03e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessExitCosts1"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0a373d8b-18d4-4524-bd71-61f3966d6ec3" xlink:to="loc_us-gaap_BusinessExitCosts1_8f5ec01a-0d28-4dc2-ad43-c94867efd03e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtGainLossNetOfTax_2b00bb17-36fe-45a5-b814-345eeb969abf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExtinguishmentOfDebtGainLossNetOfTax"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0a373d8b-18d4-4524-bd71-61f3966d6ec3" xlink:to="loc_us-gaap_ExtinguishmentOfDebtGainLossNetOfTax_2b00bb17-36fe-45a5-b814-345eeb969abf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_349c0e97-ceea-4d2c-84e2-1d1fb3196ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0a373d8b-18d4-4524-bd71-61f3966d6ec3" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_349c0e97-ceea-4d2c-84e2-1d1fb3196ab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/OrganizationandOperations" xlink:type="simple" xlink:href="lxrx-20221231.xsd#OrganizationandOperations"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/OrganizationandOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OrganizationAndOperationsAbstract_e2aa299d-59f2-462e-aed7-d8a991af803a" xlink:href="lxrx-20221231.xsd#lxrx_OrganizationAndOperationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_223f6bec-c514-4047-99c2-d7ae6bd45b70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_OrganizationAndOperationsAbstract_e2aa299d-59f2-462e-aed7-d8a991af803a" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_223f6bec-c514-4047-99c2-d7ae6bd45b70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="lxrx-20221231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9348365b-744e-4e41-9925-3bc755783bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_453a12ba-fd2f-46e4-ad34-e03342578217" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9348365b-744e-4e41-9925-3bc755783bbd" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_453a12ba-fd2f-46e4-ad34-e03342578217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncements" xlink:type="simple" xlink:href="lxrx-20221231.xsd#RecentAccountingPronouncements"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/RecentAccountingPronouncements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_RecentAccountingPronouncementsAbstract_c13ef0e7-22a3-4b79-9106-3b51549f87dc" xlink:href="lxrx-20221231.xsd#lxrx_RecentAccountingPronouncementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_7337a143-20ea-408b-ae0e-94d65934266f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_RecentAccountingPronouncementsAbstract_c13ef0e7-22a3-4b79-9106-3b51549f87dc" xlink:to="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_7337a143-20ea-408b-ae0e-94d65934266f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments" xlink:type="simple" xlink:href="lxrx-20221231.xsd#CashandCashEquivalentsandInvestments"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_cc38aea5-75c4-4208-97dc-5c3d7da9fef6" xlink:href="lxrx-20221231.xsd#lxrx_CashAndCashEquivalentsAndInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_5bbeb49b-6acb-4ca0-ad18-a10cd3e08763" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_cc38aea5-75c4-4208-97dc-5c3d7da9fef6" xlink:to="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_5bbeb49b-6acb-4ca0-ad18-a10cd3e08763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="lxrx-20221231.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FairValueMeasurementsAbstract_efe82bb2-29d5-4b25-b9fb-0f1abb6d04d8" xlink:href="lxrx-20221231.xsd#lxrx_FairValueMeasurementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_c6c0fabb-8a23-46b7-8d8a-8b238fd69bf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_FairValueMeasurementsAbstract_efe82bb2-29d5-4b25-b9fb-0f1abb6d04d8" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_c6c0fabb-8a23-46b7-8d8a-8b238fd69bf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="lxrx-20221231.xsd#PropertyandEquipment"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/PropertyandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_PropertyAndEquipmentAbstract_806d9233-f3b5-4689-86d5-f908a0125e0e" xlink:href="lxrx-20221231.xsd#lxrx_PropertyAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2293eb5e-48b0-40da-bf10-cb6eabc163b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_PropertyAndEquipmentAbstract_806d9233-f3b5-4689-86d5-f908a0125e0e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2293eb5e-48b0-40da-bf10-cb6eabc163b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/IncomeTaxes" xlink:type="simple" xlink:href="lxrx-20221231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_bea01450-a239-4e98-9a28-45ac3a8fe9f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_1cc2a74b-2f30-458a-a0c3-72020c244251" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bea01450-a239-4e98-9a28-45ac3a8fe9f3" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_1cc2a74b-2f30-458a-a0c3-72020c244251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/Goodwill" xlink:type="simple" xlink:href="lxrx-20221231.xsd#Goodwill"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/Goodwill" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_GoodwillAbstract_310847ab-01f5-4f56-911e-b8397f0668e7" xlink:href="lxrx-20221231.xsd#lxrx_GoodwillAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_01f23cce-5f87-47f1-85c0-74c4e9fff6ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_GoodwillAbstract_310847ab-01f5-4f56-911e-b8397f0668e7" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_01f23cce-5f87-47f1-85c0-74c4e9fff6ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligations" xlink:type="simple" xlink:href="lxrx-20221231.xsd#DebtObligations"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/DebtObligations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DebtObligationsAbstract_f298fecd-7aca-40fc-9479-91f59a6b927e" xlink:href="lxrx-20221231.xsd#lxrx_DebtObligationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_68627ae0-88ea-416b-b735-f0a6a3cc73b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_DebtObligationsAbstract_f298fecd-7aca-40fc-9479-91f59a6b927e" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_68627ae0-88ea-416b-b735-f0a6a3cc73b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="lxrx-20221231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CommitmentsAndContingenciesAbstract_931e74c0-8071-4017-85a9-8ba6ec6bbea9" xlink:href="lxrx-20221231.xsd#lxrx_CommitmentsAndContingenciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_28bf4101-8ae3-446f-a539-fbdd4e6ed1d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CommitmentsAndContingenciesAbstract_931e74c0-8071-4017-85a9-8ba6ec6bbea9" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_28bf4101-8ae3-446f-a539-fbdd4e6ed1d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwards" xlink:type="simple" xlink:href="lxrx-20221231.xsd#EquityIncentiveAwards"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwards" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_EquityIncentiveAwardsAbstract_d8c178f0-8a2c-45a6-9461-d796158897c3" xlink:href="lxrx-20221231.xsd#lxrx_EquityIncentiveAwardsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_3d36069c-a3a4-4c20-8731-18c061a67843" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_EquityIncentiveAwardsAbstract_d8c178f0-8a2c-45a6-9461-d796158897c3" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_3d36069c-a3a4-4c20-8731-18c061a67843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/BenefitPlan" xlink:type="simple" xlink:href="lxrx-20221231.xsd#BenefitPlan"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/BenefitPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_BenefitPlanAbstract_0e0cb6a0-0fa9-4b15-a094-594526e79ee1" xlink:href="lxrx-20221231.xsd#lxrx_BenefitPlanAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_44fa7a3f-2169-4c71-8dbb-47a04ee96002" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_BenefitPlanAbstract_0e0cb6a0-0fa9-4b15-a094-594526e79ee1" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_44fa7a3f-2169-4c71-8dbb-47a04ee96002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreements" xlink:type="simple" xlink:href="lxrx-20221231.xsd#CollaborationandLicenseAgreements"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CollaborationandLicenseAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_99882dd0-1773-4fb2-9edb-dccdb7037e1d" xlink:href="lxrx-20221231.xsd#lxrx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_50b941c1-b56a-4efd-a374-1b59c8132793" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_99882dd0-1773-4fb2-9edb-dccdb7037e1d" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_50b941c1-b56a-4efd-a374-1b59c8132793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/EarningsPerShare" xlink:type="simple" xlink:href="lxrx-20221231.xsd#EarningsPerShare"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/EarningsPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0555ac22-2770-4378-bba7-4e6a8a25c6fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_17a341e3-0880-405c-a9ac-62644f190107" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0555ac22-2770-4378-bba7-4e6a8a25c6fb" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_17a341e3-0880-405c-a9ac-62644f190107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnaudited" xlink:type="simple" xlink:href="lxrx-20221231.xsd#SelectedQuarterlyFinancialDataUnaudited"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_521880fa-9408-4803-beae-0e9d5201ecbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/AssetSale" xlink:type="simple" xlink:href="lxrx-20221231.xsd#AssetSale"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/AssetSale" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetRetirementObligationDisclosureAbstract_bd061d73-e48b-4884-bad2-0a87db4c6420" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetRetirementObligationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SaleOfNonFinancialAssetsTextBlock_efb3efc8-0b09-42e6-b3a9-4697bb890f49" xlink:href="lxrx-20221231.xsd#lxrx_SaleOfNonFinancialAssetsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetRetirementObligationDisclosureAbstract_bd061d73-e48b-4884-bad2-0a87db4c6420" xlink:to="loc_lxrx_SaleOfNonFinancialAssetsTextBlock_efb3efc8-0b09-42e6-b3a9-4697bb890f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/OtherCapitalAgreements" xlink:type="simple" xlink:href="lxrx-20221231.xsd#OtherCapitalAgreements"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/OtherCapitalAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_81bb8016-0d31-4bc4-8563-5dcf6a736671" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OtherCapitalAgreementsTextBlock_4070ffe3-9637-46f7-aacd-f36d53f5110d" xlink:href="lxrx-20221231.xsd#lxrx_OtherCapitalAgreementsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_81bb8016-0d31-4bc4-8563-5dcf6a736671" xlink:to="loc_lxrx_OtherCapitalAgreementsTextBlock_4070ffe3-9637-46f7-aacd-f36d53f5110d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="lxrx-20221231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_54995678-5167-4bef-bbcf-d9c62dd259d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_6a2d2dfa-2362-42f5-b15b-66b7fa626750" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_54995678-5167-4bef-bbcf-d9c62dd259d3" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_6a2d2dfa-2362-42f5-b15b-66b7fa626750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_5aa16f58-5cc9-4250-9c10-3cd0108d2fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_54995678-5167-4bef-bbcf-d9c62dd259d3" xlink:to="loc_us-gaap_UseOfEstimates_5aa16f58-5cc9-4250-9c10-3cd0108d2fe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_fc91532f-c361-4407-8668-f39d146ae910" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_54995678-5167-4bef-bbcf-d9c62dd259d3" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_fc91532f-c361-4407-8668-f39d146ae910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_bbd90379-cbe9-47ae-a673-a92fed1a08e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_54995678-5167-4bef-bbcf-d9c62dd259d3" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_bbd90379-cbe9-47ae-a673-a92fed1a08e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_c589495e-5a89-447e-aa96-b788417ac87f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_54995678-5167-4bef-bbcf-d9c62dd259d3" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_c589495e-5a89-447e-aa96-b788417ac87f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskDisclosureTextBlock_8f4b2aa5-67ec-4a9b-be86-7df04975a1c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_54995678-5167-4bef-bbcf-d9c62dd259d3" xlink:to="loc_us-gaap_ConcentrationRiskDisclosureTextBlock_8f4b2aa5-67ec-4a9b-be86-7df04975a1c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_060293ba-5ea3-4a8e-8726-511b130f5324" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_54995678-5167-4bef-bbcf-d9c62dd259d3" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_060293ba-5ea3-4a8e-8726-511b130f5324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_5d1fd763-b4d4-4ee4-9b2b-e994a0a37d02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_54995678-5167-4bef-bbcf-d9c62dd259d3" xlink:to="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_5d1fd763-b4d4-4ee4-9b2b-e994a0a37d02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_82acf9c5-e4d1-463e-a2f7-46b53bd35032" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_54995678-5167-4bef-bbcf-d9c62dd259d3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_82acf9c5-e4d1-463e-a2f7-46b53bd35032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_541c357f-9af6-450e-b233-fd45b3e039c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_54995678-5167-4bef-bbcf-d9c62dd259d3" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_541c357f-9af6-450e-b233-fd45b3e039c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_3d9ac05d-6325-4575-9700-a2d12d47d838" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_54995678-5167-4bef-bbcf-d9c62dd259d3" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_3d9ac05d-6325-4575-9700-a2d12d47d838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_d039d0d7-8c75-46a4-a9a5-13f8ec01b4c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_54995678-5167-4bef-bbcf-d9c62dd259d3" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_d039d0d7-8c75-46a4-a9a5-13f8ec01b4c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock_d5a36844-96e1-4acc-b060-34e0ce699945" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_54995678-5167-4bef-bbcf-d9c62dd259d3" xlink:to="loc_us-gaap_CostOfSalesPolicyTextBlock_d5a36844-96e1-4acc-b060-34e0ce699945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_5004d500-86cb-447a-baab-bf796cfd66f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_54995678-5167-4bef-bbcf-d9c62dd259d3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_5004d500-86cb-447a-baab-bf796cfd66f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_48bf75fb-ae4a-4c78-8b5b-2c31235f3184" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_54995678-5167-4bef-bbcf-d9c62dd259d3" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_48bf75fb-ae4a-4c78-8b5b-2c31235f3184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_aed567c0-4555-411d-8e69-e33c80d332fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_54995678-5167-4bef-bbcf-d9c62dd259d3" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_aed567c0-4555-411d-8e69-e33c80d332fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_b13966c4-9997-4948-babd-a08047dc8b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_54995678-5167-4bef-bbcf-d9c62dd259d3" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_b13966c4-9997-4948-babd-a08047dc8b9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_e6c8777c-a163-480c-a65c-875ff3fa541b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_54995678-5167-4bef-bbcf-d9c62dd259d3" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_e6c8777c-a163-480c-a65c-875ff3fa541b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="lxrx-20221231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_42eec4a3-68ae-41c5-9a47-256372622867" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_ae209652-e8bc-4da6-a062-719e75410820" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_42eec4a3-68ae-41c5-9a47-256372622867" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_ae209652-e8bc-4da6-a062-719e75410820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncementsTables" xlink:type="simple" xlink:href="lxrx-20221231.xsd#RecentAccountingPronouncementsTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/RecentAccountingPronouncementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables" xlink:type="simple" xlink:href="lxrx-20221231.xsd#CashandCashEquivalentsandInvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_7fd62534-12fd-45dd-b14c-f3298191f251" xlink:href="lxrx-20221231.xsd#lxrx_CashAndCashEquivalentsAndInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_2e44915d-7895-4c50-914f-26d7c244227f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_7fd62534-12fd-45dd-b14c-f3298191f251" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_2e44915d-7895-4c50-914f-26d7c244227f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="lxrx-20221231.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FairValueMeasurementsAbstract_fbd68208-3b88-4ca2-ba2a-1fcba3f7fe5b" xlink:href="lxrx-20221231.xsd#lxrx_FairValueMeasurementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_5fabd8b4-9c6f-4c83-a8bb-873efbbd981e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_FairValueMeasurementsAbstract_fbd68208-3b88-4ca2-ba2a-1fcba3f7fe5b" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_5fabd8b4-9c6f-4c83-a8bb-873efbbd981e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="lxrx-20221231.xsd#PropertyandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/PropertyandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_PropertyAndEquipmentAbstract_f162816a-4b2a-4ef5-8e22-5bb5946c0433" xlink:href="lxrx-20221231.xsd#lxrx_PropertyAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_b13e439f-00d5-43b1-bcda-55bec1b1b92a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_PropertyAndEquipmentAbstract_f162816a-4b2a-4ef5-8e22-5bb5946c0433" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_b13e439f-00d5-43b1-bcda-55bec1b1b92a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="lxrx-20221231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_31a04072-b05c-40d2-94a8-8e4dc9c1afcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_70a6cca4-3807-4d77-bb82-b5e34f148637" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_31a04072-b05c-40d2-94a8-8e4dc9c1afcf" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_70a6cca4-3807-4d77-bb82-b5e34f148637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_130a6c0f-86a0-4f7f-a30a-b109fe221fb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_31a04072-b05c-40d2-94a8-8e4dc9c1afcf" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_130a6c0f-86a0-4f7f-a30a-b109fe221fb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/GoodwillTables" xlink:type="simple" xlink:href="lxrx-20221231.xsd#GoodwillTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/GoodwillTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligationsDebtObligationsTables" xlink:type="simple" xlink:href="lxrx-20221231.xsd#DebtObligationsDebtObligationsTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/DebtObligationsDebtObligationsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DebtObligationsAbstract_153a46ac-2a6b-45cb-8251-5d50cd8e3f39" xlink:href="lxrx-20221231.xsd#lxrx_DebtObligationsAbstract"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="lxrx-20221231.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CommitmentsAndContingenciesAbstract_2b4db010-d8a7-4261-86e5-4dc83c382cab" xlink:href="lxrx-20221231.xsd#lxrx_CommitmentsAndContingenciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_89ace9fa-2f35-41f1-b3ed-26e460278883" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CommitmentsAndContingenciesAbstract_2b4db010-d8a7-4261-86e5-4dc83c382cab" xlink:to="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_89ace9fa-2f35-41f1-b3ed-26e460278883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsTables" xlink:type="simple" xlink:href="lxrx-20221231.xsd#EquityIncentiveAwardsTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwardsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_EquityIncentiveAwardsAbstract_b5db2b6c-151e-4784-a0fd-7b91918ea338" xlink:href="lxrx-20221231.xsd#lxrx_EquityIncentiveAwardsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_32ae385f-fa9f-45fa-bc5a-25f25592618f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_EquityIncentiveAwardsAbstract_b5db2b6c-151e-4784-a0fd-7b91918ea338" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_32ae385f-fa9f-45fa-bc5a-25f25592618f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_a10efbb0-f06f-4045-90a4-53f0e928e87a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_EquityIncentiveAwardsAbstract_b5db2b6c-151e-4784-a0fd-7b91918ea338" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_a10efbb0-f06f-4045-90a4-53f0e928e87a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/BenefitPlanTables" xlink:type="simple" xlink:href="lxrx-20221231.xsd#BenefitPlanTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/BenefitPlanTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/EarningsPerShareTables" xlink:type="simple" xlink:href="lxrx-20221231.xsd#EarningsPerShareTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/EarningsPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_be088248-5b0e-4bb7-add2-fb4806b3c809" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_fdb2f9de-4e68-4dbd-b2da-6e0c0aa7d4d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_be088248-5b0e-4bb7-add2-fb4806b3c809" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_fdb2f9de-4e68-4dbd-b2da-6e0c0aa7d4d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedTables" xlink:type="simple" xlink:href="lxrx-20221231.xsd#SelectedQuarterlyFinancialDataUnauditedTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_f5eaa003-3ac5-45b5-b940-cb309714251e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/AssetSaleTables" xlink:type="simple" xlink:href="lxrx-20221231.xsd#AssetSaleTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/AssetSaleTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetRetirementObligationDisclosureAbstract_ee51ae4d-c83c-4c5c-9099-880b096b9a63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetRetirementObligationDisclosureAbstract"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails" xlink:type="simple" xlink:href="lxrx-20221231.xsd#SummaryofSignificantAccountingPoliciesInventoryDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_39d06ba1-4570-4710-833f-47c8dbc9a0ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_c2949f86-e47d-47ca-91dc-bf05cc3f46e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_39d06ba1-4570-4710-833f-47c8dbc9a0ec" xlink:to="loc_us-gaap_InventoryWorkInProcess_c2949f86-e47d-47ca-91dc-bf05cc3f46e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_a3a9ba47-022f-4614-bd38-fc012a6e42b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_39d06ba1-4570-4710-833f-47c8dbc9a0ec" xlink:to="loc_us-gaap_InventoryFinishedGoods_a3a9ba47-022f-4614-bd38-fc012a6e42b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_6bb80976-7344-4b9e-b03b-97eb2cb2b6d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_39d06ba1-4570-4710-833f-47c8dbc9a0ec" xlink:to="loc_us-gaap_InventoryRawMaterials_6bb80976-7344-4b9e-b03b-97eb2cb2b6d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails" xlink:type="simple" xlink:href="lxrx-20221231.xsd#SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b3cba848-4f22-44a4-8c2d-5723af083c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent_d894ab47-77da-4fd4-962c-3d906de23609" xlink:href="lxrx-20221231.xsd#lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b3cba848-4f22-44a4-8c2d-5723af083c5f" xlink:to="loc_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent_d894ab47-77da-4fd4-962c-3d906de23609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany_a4653361-3475-4257-a2e5-4e77479d0666" xlink:href="lxrx-20221231.xsd#lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b3cba848-4f22-44a4-8c2d-5723af083c5f" xlink:to="loc_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany_a4653361-3475-4257-a2e5-4e77479d0666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationandSignficantCustomersDetails" xlink:type="simple" xlink:href="lxrx-20221231.xsd#SummaryofSignificantAccountingPoliciesSegmentInformationandSignficantCustomersDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationandSignficantCustomersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_572d2211-a08e-4db6-9bdf-214f76aaa4f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_442573c6-a146-48dd-ac15-5ffad06f906b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_572d2211-a08e-4db6-9bdf-214f76aaa4f4" xlink:to="loc_us-gaap_NumberOfOperatingSegments_442573c6-a146-48dd-ac15-5ffad06f906b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_EntityWideRevenueSanofiPercentage_41c4cc56-2853-46eb-a579-3d31bebe3cfc" xlink:href="lxrx-20221231.xsd#lxrx_EntityWideRevenueSanofiPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_572d2211-a08e-4db6-9bdf-214f76aaa4f4" xlink:to="loc_lxrx_EntityWideRevenueSanofiPercentage_41c4cc56-2853-46eb-a579-3d31bebe3cfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_LXRXDiplomatcustomerconcentration_5473483e-0873-4f8d-b568-910c4265dfe3" xlink:href="lxrx-20221231.xsd#lxrx_LXRXDiplomatcustomerconcentration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_572d2211-a08e-4db6-9bdf-214f76aaa4f4" xlink:to="loc_lxrx_LXRXDiplomatcustomerconcentration_5473483e-0873-4f8d-b568-910c4265dfe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_LXRXBiologicscustomerconcentration_0a140ce4-c011-4f49-b40e-48fcadb86d86" xlink:href="lxrx-20221231.xsd#lxrx_LXRXBiologicscustomerconcentration"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_572d2211-a08e-4db6-9bdf-214f76aaa4f4" xlink:to="loc_lxrx_LXRXBiologicscustomerconcentration_0a140ce4-c011-4f49-b40e-48fcadb86d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleassetDetails" xlink:type="simple" xlink:href="lxrx-20221231.xsd#SummaryofSignificantAccountingPoliciesIntangibleassetDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleassetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c29252bf-6218-4f66-9e6e-c260161662a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_264b008b-c6cf-43aa-ba32-04d13e6d4865" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c29252bf-6218-4f66-9e6e-c260161662a3" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_264b008b-c6cf-43aa-ba32-04d13e6d4865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a2cd5b12-0b35-4a4b-a4c9-672356528f75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_264b008b-c6cf-43aa-ba32-04d13e6d4865" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a2cd5b12-0b35-4a4b-a4c9-672356528f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_65f94029-3942-4baf-afc9-d30c13cce312" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a2cd5b12-0b35-4a4b-a4c9-672356528f75" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_65f94029-3942-4baf-afc9-d30c13cce312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_efb21559-7eb3-439a-99e3-f5f70307dca8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_264b008b-c6cf-43aa-ba32-04d13e6d4865" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_efb21559-7eb3-439a-99e3-f5f70307dca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsNet_ed917da3-0f1d-41d6-9318-6f2d1dd395ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_efb21559-7eb3-439a-99e3-f5f70307dca8" xlink:to="loc_us-gaap_OtherIntangibleAssetsNet_ed917da3-0f1d-41d6-9318-6f2d1dd395ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_3a7db3e8-1304-4fa8-a0a8-ef3d73bfcb49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_efb21559-7eb3-439a-99e3-f5f70307dca8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_3a7db3e8-1304-4fa8-a0a8-ef3d73bfcb49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_e16e841b-906a-41d6-a7d4-33709d7db60c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_efb21559-7eb3-439a-99e3-f5f70307dca8" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_e16e841b-906a-41d6-a7d4-33709d7db60c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" xlink:type="simple" xlink:href="lxrx-20221231.xsd#SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f42d2a54-e19a-4588-85cc-d0efd9732722" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_952c7ed1-d74e-45ae-badd-9fb79230fb5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f42d2a54-e19a-4588-85cc-d0efd9732722" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_952c7ed1-d74e-45ae-badd-9fb79230fb5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d5469a46-2873-4515-b64b-f4673ec8518a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_952c7ed1-d74e-45ae-badd-9fb79230fb5a" xlink:to="loc_srt_RangeAxis_d5469a46-2873-4515-b64b-f4673ec8518a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_082642eb-7920-4992-9db3-2f0f9f683f9b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d5469a46-2873-4515-b64b-f4673ec8518a" xlink:to="loc_srt_RangeMember_082642eb-7920-4992-9db3-2f0f9f683f9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1d5591e7-3495-4986-bf0b-59bbcc554716" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_082642eb-7920-4992-9db3-2f0f9f683f9b" xlink:to="loc_srt_MinimumMember_1d5591e7-3495-4986-bf0b-59bbcc554716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8b40d75a-228e-4853-9673-038eb02f1965" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_082642eb-7920-4992-9db3-2f0f9f683f9b" xlink:to="loc_srt_MaximumMember_8b40d75a-228e-4853-9673-038eb02f1965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c4cf1834-d978-4661-90c9-3947bf06fc72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_952c7ed1-d74e-45ae-badd-9fb79230fb5a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c4cf1834-d978-4661-90c9-3947bf06fc72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_908376d6-4ddf-4be2-b50a-3c6a2671c09a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c4cf1834-d978-4661-90c9-3947bf06fc72" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_908376d6-4ddf-4be2-b50a-3c6a2671c09a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedResearchAndDevelopmentServicesCurrent_3b95f20b-5f37-49ec-a7ba-5a7756f0e664" xlink:href="lxrx-20221231.xsd#lxrx_AccruedResearchAndDevelopmentServicesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c4cf1834-d978-4661-90c9-3947bf06fc72" xlink:to="loc_lxrx_AccruedResearchAndDevelopmentServicesCurrent_3b95f20b-5f37-49ec-a7ba-5a7756f0e664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedCompensationAndBenefitsCurrent_bc8d8f4a-e24d-4d09-afec-5874a8163983" xlink:href="lxrx-20221231.xsd#lxrx_AccruedCompensationAndBenefitsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c4cf1834-d978-4661-90c9-3947bf06fc72" xlink:to="loc_lxrx_AccruedCompensationAndBenefitsCurrent_bc8d8f4a-e24d-4d09-afec-5874a8163983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_1a035cae-f3de-40d3-acc6-cc1848670ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c4cf1834-d978-4661-90c9-3947bf06fc72" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_1a035cae-f3de-40d3-acc6-cc1848670ca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_0df9749d-dabe-4d9a-930f-d280bfc43843" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c4cf1834-d978-4661-90c9-3947bf06fc72" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_0df9749d-dabe-4d9a-930f-d280bfc43843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_e72da749-a930-4e44-87c4-6f8b82caa6c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c4cf1834-d978-4661-90c9-3947bf06fc72" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_e72da749-a930-4e44-87c4-6f8b82caa6c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesImpairmentofLongLivedAssetsDetails" xlink:type="simple" xlink:href="lxrx-20221231.xsd#SummaryofSignificantAccountingPoliciesImpairmentofLongLivedAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesImpairmentofLongLivedAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b1486f13-a509-477b-8159-2228ce87a2b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_8d0278cf-6f6d-4546-bf03-06fb35db6cb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b1486f13-a509-477b-8159-2228ce87a2b1" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_8d0278cf-6f6d-4546-bf03-06fb35db6cb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_849c0126-9003-4071-80b6-821b78ce276f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b1486f13-a509-477b-8159-2228ce87a2b1" xlink:to="loc_us-gaap_AssetImpairmentCharges_849c0126-9003-4071-80b6-821b78ce276f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_a93b2f9c-1b4b-411b-b377-014599b06111" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b1486f13-a509-477b-8159-2228ce87a2b1" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_a93b2f9c-1b4b-411b-b377-014599b06111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_55319e47-b9d3-4473-b8c7-818d1ff3a97c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesGoodwillDetails" xlink:type="simple" xlink:href="lxrx-20221231.xsd#SummaryofSignificantAccountingPoliciesGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_24406d7a-3a6a-4b4d-a103-a234e2fa2fb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_07549adc-066e-4aef-9bc4-d3978b05d8ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_24406d7a-3a6a-4b4d-a103-a234e2fa2fb4" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_07549adc-066e-4aef-9bc4-d3978b05d8ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesCostofSalesDetails" xlink:type="simple" xlink:href="lxrx-20221231.xsd#SummaryofSignificantAccountingPoliciesCostofSalesDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesCostofSalesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_fe4a2341-4d40-4977-b7bb-8615aa9a4f46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_47d28926-e9c6-4c40-b93c-5ec9d95fc1f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fe4a2341-4d40-4977-b7bb-8615aa9a4f46" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_47d28926-e9c6-4c40-b93c-5ec9d95fc1f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f4a101bb-3b21-4039-afd0-870b2c99c4a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_47d28926-e9c6-4c40-b93c-5ec9d95fc1f2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f4a101bb-3b21-4039-afd0-870b2c99c4a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_304f3606-19fb-40e9-ade7-ed4a23a7c98a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f4a101bb-3b21-4039-afd0-870b2c99c4a4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_304f3606-19fb-40e9-ade7-ed4a23a7c98a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_e30504fe-bfb0-469e-9938-5f6aa0d1936e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_304f3606-19fb-40e9-ade7-ed4a23a7c98a" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_e30504fe-bfb0-469e-9938-5f6aa0d1936e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_54987666-8660-44cf-ac5f-dbdc9198d515" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_47d28926-e9c6-4c40-b93c-5ec9d95fc1f2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_54987666-8660-44cf-ac5f-dbdc9198d515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_775154ba-79d5-424a-b3e5-bfa2a4a62603" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_54987666-8660-44cf-ac5f-dbdc9198d515" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_775154ba-79d5-424a-b3e5-bfa2a4a62603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1" xlink:type="simple" xlink:href="lxrx-20221231.xsd#SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0392e4c9-a7f2-44ad-9dac-871555aa2f0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3622e2e0-709e-45c7-965e-51547531a5a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0392e4c9-a7f2-44ad-9dac-871555aa2f0f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3622e2e0-709e-45c7-965e-51547531a5a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ff0f26c1-98c4-4059-92a3-b8bc9e841279" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3622e2e0-709e-45c7-965e-51547531a5a7" xlink:to="loc_us-gaap_AwardTypeAxis_ff0f26c1-98c4-4059-92a3-b8bc9e841279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e6d34259-edfb-4c27-8bd5-c6f6e4083e16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_ff0f26c1-98c4-4059-92a3-b8bc9e841279" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e6d34259-edfb-4c27-8bd5-c6f6e4083e16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_3fac491a-ddb5-4843-bd12-7ffda9f94e03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e6d34259-edfb-4c27-8bd5-c6f6e4083e16" xlink:to="loc_us-gaap_StockOptionMember_3fac491a-ddb5-4843-bd12-7ffda9f94e03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_0556503a-1d14-48c8-9266-3cf9148d35fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3622e2e0-709e-45c7-965e-51547531a5a7" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_0556503a-1d14-48c8-9266-3cf9148d35fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2cabb0db-e2f7-499c-b10e-b489b4f36970" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0556503a-1d14-48c8-9266-3cf9148d35fa" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2cabb0db-e2f7-499c-b10e-b489b4f36970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80e93edf-1715-4bc0-a2cc-1e41e5f84f77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3622e2e0-709e-45c7-965e-51547531a5a7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80e93edf-1715-4bc0-a2cc-1e41e5f84f77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_b5f7de50-7525-49e0-8d9f-b64a457c29f7" xlink:href="lxrx-20221231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80e93edf-1715-4bc0-a2cc-1e41e5f84f77" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_b5f7de50-7525-49e0-8d9f-b64a457c29f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_6d6876e6-6fc0-476e-9333-3bb291d6748b" xlink:href="lxrx-20221231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80e93edf-1715-4bc0-a2cc-1e41e5f84f77" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_6d6876e6-6fc0-476e-9333-3bb291d6748b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_2fc964f7-3c94-4c72-83b7-ddda0763db32" xlink:href="lxrx-20221231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80e93edf-1715-4bc0-a2cc-1e41e5f84f77" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_2fc964f7-3c94-4c72-83b7-ddda0763db32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_e9b94ac9-8d5e-40ce-871c-05f21ebff3d7" xlink:href="lxrx-20221231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80e93edf-1715-4bc0-a2cc-1e41e5f84f77" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_e9b94ac9-8d5e-40ce-871c-05f21ebff3d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_add22b52-c213-471c-8a6d-409808a7b40c" xlink:href="lxrx-20221231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80e93edf-1715-4bc0-a2cc-1e41e5f84f77" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_add22b52-c213-471c-8a6d-409808a7b40c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_de72d354-397f-4f8b-86e6-0fd05e267866" xlink:href="lxrx-20221231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80e93edf-1715-4bc0-a2cc-1e41e5f84f77" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_de72d354-397f-4f8b-86e6-0fd05e267866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_c3f9d0b2-9f6c-40c5-9282-db1bd86eec04" xlink:href="lxrx-20221231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80e93edf-1715-4bc0-a2cc-1e41e5f84f77" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_c3f9d0b2-9f6c-40c5-9282-db1bd86eec04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_0b3a7281-9c38-4cdd-999d-eef6a99f3d89" xlink:href="lxrx-20221231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80e93edf-1715-4bc0-a2cc-1e41e5f84f77" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_0b3a7281-9c38-4cdd-999d-eef6a99f3d89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_ea43676d-6c76-4082-bcbb-a59e0c83f562" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80e93edf-1715-4bc0-a2cc-1e41e5f84f77" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_ea43676d-6c76-4082-bcbb-a59e0c83f562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationDetails2" xlink:type="simple" xlink:href="lxrx-20221231.xsd#SummaryofSignificantAccountingPoliciesStockbasedCompensationDetails2"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationDetails2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_bcaad7b7-2bed-4b28-ad9f-3beaf4bd7f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_d5c9c65e-f380-4869-8d6d-c4309172c328" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bcaad7b7-2bed-4b28-ad9f-3beaf4bd7f6e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_d5c9c65e-f380-4869-8d6d-c4309172c328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7c125694-8160-407a-995b-5f429be7489f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bcaad7b7-2bed-4b28-ad9f-3beaf4bd7f6e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7c125694-8160-407a-995b-5f429be7489f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncementsDetails" xlink:type="simple" xlink:href="lxrx-20221231.xsd#RecentAccountingPronouncementsDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/RecentAccountingPronouncementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_RecentAccountingPronouncementsAbstract_11ad3210-2f60-421e-981a-937f67363972" xlink:href="lxrx-20221231.xsd#lxrx_RecentAccountingPronouncementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_76d57628-e328-4917-b6e7-c3174a07f786" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_RecentAccountingPronouncementsAbstract_11ad3210-2f60-421e-981a-937f67363972" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_76d57628-e328-4917-b6e7-c3174a07f786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_414a8cb4-c4c0-4f5b-bcaf-b4d09dfa3deb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_76d57628-e328-4917-b6e7-c3174a07f786" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_414a8cb4-c4c0-4f5b-bcaf-b4d09dfa3deb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_3ccbbf3b-ae2a-4c7e-b39c-e3c073848fb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_414a8cb4-c4c0-4f5b-bcaf-b4d09dfa3deb" xlink:to="loc_us-gaap_TypeOfAdoptionMember_3ccbbf3b-ae2a-4c7e-b39c-e3c073848fb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_7988e5f9-7edb-473b-80e7-f691348a10f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_76d57628-e328-4917-b6e7-c3174a07f786" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_7988e5f9-7edb-473b-80e7-f691348a10f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_cd7925dd-3fa6-48d4-8600-7cc62ba9c033" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_7988e5f9-7edb-473b-80e7-f691348a10f9" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_cd7925dd-3fa6-48d4-8600-7cc62ba9c033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails" xlink:type="simple" xlink:href="lxrx-20221231.xsd#CashandCashEquivalentsandInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_33cfd05e-ea68-4683-a15a-66939bd93bd5" xlink:href="lxrx-20221231.xsd#lxrx_CashAndCashEquivalentsAndInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_eca87e52-6bb1-47aa-becb-3e8f3f1aee2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_33cfd05e-ea68-4683-a15a-66939bd93bd5" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_eca87e52-6bb1-47aa-becb-3e8f3f1aee2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_3eeaeb3b-becd-4abb-a09e-bc253c318628" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_eca87e52-6bb1-47aa-becb-3e8f3f1aee2e" xlink:to="loc_us-gaap_InvestmentTypeAxis_3eeaeb3b-becd-4abb-a09e-bc253c318628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_bffa5944-6f6e-48c6-b020-531bad76b851" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_3eeaeb3b-becd-4abb-a09e-bc253c318628" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_bffa5944-6f6e-48c6-b020-531bad76b851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_5ef713ca-5e65-47e3-bc6a-3ad10f046ec4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_bffa5944-6f6e-48c6-b020-531bad76b851" xlink:to="loc_us-gaap_CashMember_5ef713ca-5e65-47e3-bc6a-3ad10f046ec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_25344c89-35bf-4319-91e7-e0ba62110e82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_bffa5944-6f6e-48c6-b020-531bad76b851" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_25344c89-35bf-4319-91e7-e0ba62110e82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_98b07080-d362-41b9-ba9c-035e7be10cb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_bffa5944-6f6e-48c6-b020-531bad76b851" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_98b07080-d362-41b9-ba9c-035e7be10cb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember_f9f01ad4-8ba7-4378-9880-cb2d5063501d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_bffa5944-6f6e-48c6-b020-531bad76b851" xlink:to="loc_us-gaap_InvestmentsMember_f9f01ad4-8ba7-4378-9880-cb2d5063501d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_34a14486-e5a3-4c3a-9d28-fd2468c46a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_eca87e52-6bb1-47aa-becb-3e8f3f1aee2e" xlink:to="loc_us-gaap_CashAndCashEquivalentsLineItems_34a14486-e5a3-4c3a-9d28-fd2468c46a4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_c726bd98-cbde-433b-b006-704dd9b56fc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_34a14486-e5a3-4c3a-9d28-fd2468c46a4b" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_c726bd98-cbde-433b-b006-704dd9b56fc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_5f081191-df17-4f93-9ab5-6522d133f16f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_34a14486-e5a3-4c3a-9d28-fd2468c46a4b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_5f081191-df17-4f93-9ab5-6522d133f16f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_f7c0e747-fdc3-4d33-90ff-9b9fb35d5105" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_34a14486-e5a3-4c3a-9d28-fd2468c46a4b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_f7c0e747-fdc3-4d33-90ff-9b9fb35d5105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2e9cbeb2-b3b4-4f04-92cf-0076a90dc974" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_34a14486-e5a3-4c3a-9d28-fd2468c46a4b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2e9cbeb2-b3b4-4f04-92cf-0076a90dc974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_598e3880-68a0-40cf-8641-7c5c8bedab08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_34a14486-e5a3-4c3a-9d28-fd2468c46a4b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesCurrent_598e3880-68a0-40cf-8641-7c5c8bedab08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurementsDetails1" xlink:type="simple" xlink:href="lxrx-20221231.xsd#FairValueMeasurementsDetails1"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurementsDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FairValueMeasurementsAbstract_51977a2f-6bb9-4fb8-8a42-eded449548ca" xlink:href="lxrx-20221231.xsd#lxrx_FairValueMeasurementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_70895b09-71e2-4f19-8728-864a0ff25977" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_FairValueMeasurementsAbstract_51977a2f-6bb9-4fb8-8a42-eded449548ca" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_70895b09-71e2-4f19-8728-864a0ff25977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_eccf802d-be54-4253-9204-87f5023897e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_70895b09-71e2-4f19-8728-864a0ff25977" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_eccf802d-be54-4253-9204-87f5023897e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4910f0dc-1e90-42a6-8253-7d5fa4c292a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_eccf802d-be54-4253-9204-87f5023897e6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4910f0dc-1e90-42a6-8253-7d5fa4c292a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_bcb97d6b-fd73-49fb-9242-98379c3cda42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4910f0dc-1e90-42a6-8253-7d5fa4c292a7" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_bcb97d6b-fd73-49fb-9242-98379c3cda42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_6ccf9883-257d-4abd-aa16-92349f2d001b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4910f0dc-1e90-42a6-8253-7d5fa4c292a7" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_6ccf9883-257d-4abd-aa16-92349f2d001b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_0f5acf20-8756-47cf-b1f6-ad9121339be1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4910f0dc-1e90-42a6-8253-7d5fa4c292a7" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_0f5acf20-8756-47cf-b1f6-ad9121339be1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_34c91335-1df8-4c50-bda8-fbbeba63c217" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_70895b09-71e2-4f19-8728-864a0ff25977" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_34c91335-1df8-4c50-bda8-fbbeba63c217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_53aa2ca1-f0bf-4cba-8a18-3ea040f57313" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_34c91335-1df8-4c50-bda8-fbbeba63c217" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_53aa2ca1-f0bf-4cba-8a18-3ea040f57313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecurities_dafd7639-04a4-4731-8f62-c3800b73205a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_34c91335-1df8-4c50-bda8-fbbeba63c217" xlink:to="loc_us-gaap_AvailableForSaleSecurities_dafd7639-04a4-4731-8f62-c3800b73205a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_1b8294bc-306f-4f12-9bef-eda89094e603" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_34c91335-1df8-4c50-bda8-fbbeba63c217" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_1b8294bc-306f-4f12-9bef-eda89094e603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurementsDetails2" xlink:type="simple" xlink:href="lxrx-20221231.xsd#FairValueMeasurementsDetails2"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurementsDetails2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FairValueMeasurementsAbstract_2e65cfd0-7e7a-4944-bd7b-35fa957fd384" xlink:href="lxrx-20221231.xsd#lxrx_FairValueMeasurementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_79522d78-f51c-465f-909e-77b1452e18fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_FairValueMeasurementsAbstract_2e65cfd0-7e7a-4944-bd7b-35fa957fd384" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_79522d78-f51c-465f-909e-77b1452e18fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_e4b51402-8d14-429e-9105-d8ec0b346915" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_79522d78-f51c-465f-909e-77b1452e18fd" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_e4b51402-8d14-429e-9105-d8ec0b346915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_46114cfc-c911-4be7-9b9b-1731f6ea6c52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_e4b51402-8d14-429e-9105-d8ec0b346915" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_46114cfc-c911-4be7-9b9b-1731f6ea6c52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_541d1db1-98ab-4e0a-a08d-f11ef3dc62f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_79522d78-f51c-465f-909e-77b1452e18fd" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_541d1db1-98ab-4e0a-a08d-f11ef3dc62f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/PropertyandEquipmentDetails" xlink:type="simple" xlink:href="lxrx-20221231.xsd#PropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/PropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_PropertyAndEquipmentAbstract_235a9020-4f1d-401d-93fc-1f3209c8ffb9" xlink:href="lxrx-20221231.xsd#lxrx_PropertyAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bd775083-de63-4528-a496-76393d1da289" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_PropertyAndEquipmentAbstract_235a9020-4f1d-401d-93fc-1f3209c8ffb9" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bd775083-de63-4528-a496-76393d1da289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_97d376f9-2d4d-4b9d-9e60-ea1bf45ebb23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bd775083-de63-4528-a496-76393d1da289" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_97d376f9-2d4d-4b9d-9e60-ea1bf45ebb23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6f1aed85-3662-4aec-b599-ad88ee06d709" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_97d376f9-2d4d-4b9d-9e60-ea1bf45ebb23" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6f1aed85-3662-4aec-b599-ad88ee06d709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_e849ec1a-8b91-4133-9821-ea1d8a495faf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6f1aed85-3662-4aec-b599-ad88ee06d709" xlink:to="loc_us-gaap_ComputerEquipmentMember_e849ec1a-8b91-4133-9821-ea1d8a495faf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_519bc91e-3ce8-41f3-aefe-c34750f757b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6f1aed85-3662-4aec-b599-ad88ee06d709" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_519bc91e-3ce8-41f3-aefe-c34750f757b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_310900a7-67e1-4ba9-be97-013e1a15f608" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6f1aed85-3662-4aec-b599-ad88ee06d709" xlink:to="loc_us-gaap_EquipmentMember_310900a7-67e1-4ba9-be97-013e1a15f608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_d73416ae-307f-4648-ac8f-139ebbcc55db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6f1aed85-3662-4aec-b599-ad88ee06d709" xlink:to="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_d73416ae-307f-4648-ac8f-139ebbcc55db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_fb621a1b-af95-476b-90c3-30eda5cb1494" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6f1aed85-3662-4aec-b599-ad88ee06d709" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_fb621a1b-af95-476b-90c3-30eda5cb1494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_ed11906b-87f5-48de-a94f-d29cf48cff1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6f1aed85-3662-4aec-b599-ad88ee06d709" xlink:to="loc_us-gaap_LandMember_ed11906b-87f5-48de-a94f-d29cf48cff1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_74b9390c-ba3a-4ba4-b304-383b4535e3ad" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bd775083-de63-4528-a496-76393d1da289" xlink:to="loc_srt_RangeAxis_74b9390c-ba3a-4ba4-b304-383b4535e3ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_54402456-895e-457e-8f89-9391be50ff16" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_74b9390c-ba3a-4ba4-b304-383b4535e3ad" xlink:to="loc_srt_RangeMember_54402456-895e-457e-8f89-9391be50ff16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ecda4509-90d3-4ec3-812a-368a80ccba41" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_54402456-895e-457e-8f89-9391be50ff16" xlink:to="loc_srt_MinimumMember_ecda4509-90d3-4ec3-812a-368a80ccba41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1852587f-afdc-47f2-a662-da24d1cb5d30" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_54402456-895e-457e-8f89-9391be50ff16" xlink:to="loc_srt_MaximumMember_1852587f-afdc-47f2-a662-da24d1cb5d30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_41129bd3-05fd-4117-a16b-16e066b62fbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bd775083-de63-4528-a496-76393d1da289" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_41129bd3-05fd-4117-a16b-16e066b62fbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_4856f9b7-238a-420c-a155-ee8524168de0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_41129bd3-05fd-4117-a16b-16e066b62fbb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_4856f9b7-238a-420c-a155-ee8524168de0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_58e03839-8bcd-425d-a701-9af90d9448ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_41129bd3-05fd-4117-a16b-16e066b62fbb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_58e03839-8bcd-425d-a701-9af90d9448ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2269ab6e-b131-4e94-b0c6-1e1ca21e9144" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_41129bd3-05fd-4117-a16b-16e066b62fbb" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2269ab6e-b131-4e94-b0c6-1e1ca21e9144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_cc186f5a-d376-46f2-a210-4f8dda42a675" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_41129bd3-05fd-4117-a16b-16e066b62fbb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_cc186f5a-d376-46f2-a210-4f8dda42a675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfBuildings_be83e85d-4821-4ab6-b56c-5d23924005df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfBuildings"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_41129bd3-05fd-4117-a16b-16e066b62fbb" xlink:to="loc_us-gaap_ProceedsFromSaleOfBuildings_be83e85d-4821-4ab6-b56c-5d23924005df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land_22b7573a-4567-41f8-b2be-57ab2969e4b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Land"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_41129bd3-05fd-4117-a16b-16e066b62fbb" xlink:to="loc_us-gaap_Land_22b7573a-4567-41f8-b2be-57ab2969e4b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryBuildingsAndImprovements_0d6ac69d-33cf-4089-b1fd-02bd512ff76e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryBuildingsAndImprovements"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_41129bd3-05fd-4117-a16b-16e066b62fbb" xlink:to="loc_us-gaap_InventoryBuildingsAndImprovements_0d6ac69d-33cf-4089-b1fd-02bd512ff76e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_25297537-a0d3-4daf-b7cd-c8086355d87c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_41129bd3-05fd-4117-a16b-16e066b62fbb" xlink:to="loc_us-gaap_AssetImpairmentCharges_25297537-a0d3-4daf-b7cd-c8086355d87c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1_de7a9c5c-2cd2-440e-b71b-c09cfb4d8d5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_41129bd3-05fd-4117-a16b-16e066b62fbb" xlink:to="loc_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1_de7a9c5c-2cd2-440e-b71b-c09cfb4d8d5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment_de3f78ea-30d7-43b4-b0b7-d20a2669389d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_41129bd3-05fd-4117-a16b-16e066b62fbb" xlink:to="loc_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment_de3f78ea-30d7-43b4-b0b7-d20a2669389d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/IncomeTaxesDetails1" xlink:type="simple" xlink:href="lxrx-20221231.xsd#IncomeTaxesDetails1"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/IncomeTaxesDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_94328293-7cd0-49fc-9833-2dc89725b5ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalIncomeTaxNoteTable_fccdf682-e62a-42f2-aedc-f3fca9f5196c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalIncomeTaxNoteTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_94328293-7cd0-49fc-9833-2dc89725b5ad" xlink:to="loc_us-gaap_FederalIncomeTaxNoteTable_fccdf682-e62a-42f2-aedc-f3fca9f5196c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_629d7120-c653-4268-addb-9c2778930c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FederalIncomeTaxNoteTable_fccdf682-e62a-42f2-aedc-f3fca9f5196c" xlink:to="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_629d7120-c653-4268-addb-9c2778930c4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetDomain_7aedfb2e-6bcf-4fcb-b22d-cff845944d68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_629d7120-c653-4268-addb-9c2778930c4b" xlink:to="loc_us-gaap_DeferredTaxAssetDomain_7aedfb2e-6bcf-4fcb-b22d-cff845944d68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_b7c49bf1-ef97-4efe-9d74-5b77566cedfe" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FederalIncomeTaxNoteTable_fccdf682-e62a-42f2-aedc-f3fca9f5196c" xlink:to="loc_dei_DocumentInformationLineItems_b7c49bf1-ef97-4efe-9d74-5b77566cedfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_0682203b-172c-4a6d-9d6f-8aa3a642aa29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_b7c49bf1-ef97-4efe-9d74-5b77566cedfe" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_0682203b-172c-4a6d-9d6f-8aa3a642aa29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_7833d345-85d3-4f52-87ba-803f84feae72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_b7c49bf1-ef97-4efe-9d74-5b77566cedfe" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_7833d345-85d3-4f52-87ba-803f84feae72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug_17795d9c-6b07-45bc-8b5d-38c1620e2314" xlink:href="lxrx-20221231.xsd#lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_b7c49bf1-ef97-4efe-9d74-5b77566cedfe" xlink:to="loc_lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug_17795d9c-6b07-45bc-8b5d-38c1620e2314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_ca158f67-eeca-4529-9716-8669baa88624" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_b7c49bf1-ef97-4efe-9d74-5b77566cedfe" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_ca158f67-eeca-4529-9716-8669baa88624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_b8a855f7-982a-4a24-b1bd-22119855725c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_b7c49bf1-ef97-4efe-9d74-5b77566cedfe" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_b8a855f7-982a-4a24-b1bd-22119855725c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_9ac699b6-0953-4fd2-bca1-b732f80b7635" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_b7c49bf1-ef97-4efe-9d74-5b77566cedfe" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_9ac699b6-0953-4fd2-bca1-b732f80b7635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_5beecb00-bfcf-4e46-9c9d-c666984fd621" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_b7c49bf1-ef97-4efe-9d74-5b77566cedfe" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_5beecb00-bfcf-4e46-9c9d-c666984fd621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_25d13c2f-bf00-4d07-80fb-8f5515a45930" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_b7c49bf1-ef97-4efe-9d74-5b77566cedfe" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_25d13c2f-bf00-4d07-80fb-8f5515a45930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_8a30a100-7d06-4543-b869-a60317b74a46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_b7c49bf1-ef97-4efe-9d74-5b77566cedfe" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_8a30a100-7d06-4543-b869-a60317b74a46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_511d3762-1f54-488d-8d7f-4f63da917f6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_b7c49bf1-ef97-4efe-9d74-5b77566cedfe" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_511d3762-1f54-488d-8d7f-4f63da917f6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_06894330-6036-4f95-9ae2-69db50a41888" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_b7c49bf1-ef97-4efe-9d74-5b77566cedfe" xlink:to="loc_us-gaap_DeferredTaxLiabilities_06894330-6036-4f95-9ae2-69db50a41888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_c4a70970-c976-4ea7-a47d-f421c82e58f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_b7c49bf1-ef97-4efe-9d74-5b77566cedfe" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_c4a70970-c976-4ea7-a47d-f421c82e58f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2020FederalNOLIncrease_21e6e40e-56c9-4912-8d08-f33ee9b9ef7f" xlink:href="lxrx-20221231.xsd#lxrx_A2020FederalNOLIncrease"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_b7c49bf1-ef97-4efe-9d74-5b77566cedfe" xlink:to="loc_lxrx_A2020FederalNOLIncrease_21e6e40e-56c9-4912-8d08-f33ee9b9ef7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DecreaseInNOLs_e1678b85-bd42-4de1-ae06-90e7cbec129c" xlink:href="lxrx-20221231.xsd#lxrx_DecreaseInNOLs"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_b7c49bf1-ef97-4efe-9d74-5b77566cedfe" xlink:to="loc_lxrx_DecreaseInNOLs_e1678b85-bd42-4de1-ae06-90e7cbec129c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_RDTaxCreditDecrease_ce2a5d03-8202-44ba-8334-e8920ce6b205" xlink:href="lxrx-20221231.xsd#lxrx_RDTaxCreditDecrease"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_b7c49bf1-ef97-4efe-9d74-5b77566cedfe" xlink:to="loc_lxrx_RDTaxCreditDecrease_ce2a5d03-8202-44ba-8334-e8920ce6b205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DeferredTaxAssetsSection163j_LXRX_1fd55078-c858-4d89-9555-55ec96b03361" xlink:href="lxrx-20221231.xsd#lxrx_DeferredTaxAssetsSection163j_LXRX"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_b7c49bf1-ef97-4efe-9d74-5b77566cedfe" xlink:to="loc_lxrx_DeferredTaxAssetsSection163j_LXRX_1fd55078-c858-4d89-9555-55ec96b03361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_b05fc680-c454-40d3-9b74-97f7a9d6e4e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_b7c49bf1-ef97-4efe-9d74-5b77566cedfe" xlink:to="loc_us-gaap_OperatingLossCarryforwards_b05fc680-c454-40d3-9b74-97f7a9d6e4e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_fe07a1af-c952-415e-93b2-5f3f4e9cf620" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_b7c49bf1-ef97-4efe-9d74-5b77566cedfe" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_fe07a1af-c952-415e-93b2-5f3f4e9cf620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/IncomeTaxesDetails2" xlink:type="simple" xlink:href="lxrx-20221231.xsd#IncomeTaxesDetails2"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/IncomeTaxesDetails2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_167d192d-c029-46fa-b9c2-00c5c384e6d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3ebe3355-0378-49ad-a2df-8bc2d482c3da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_167d192d-c029-46fa-b9c2-00c5c384e6d4" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3ebe3355-0378-49ad-a2df-8bc2d482c3da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_9b4d0caa-cf63-4a76-ae0f-d27f564cea52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_167d192d-c029-46fa-b9c2-00c5c384e6d4" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_9b4d0caa-cf63-4a76-ae0f-d27f564cea52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_c26835f4-9619-4725-b571-33bfc8fdb18a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_167d192d-c029-46fa-b9c2-00c5c384e6d4" xlink:to="loc_us-gaap_OperatingLossCarryforwards_c26835f4-9619-4725-b571-33bfc8fdb18a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_704fd97c-f4d7-44c3-bdb9-a8568806bb67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_167d192d-c029-46fa-b9c2-00c5c384e6d4" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_704fd97c-f4d7-44c3-bdb9-a8568806bb67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_40075640-ab2c-4989-a67c-043fb05f9311" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_167d192d-c029-46fa-b9c2-00c5c384e6d4" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_40075640-ab2c-4989-a67c-043fb05f9311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalIncomeTaxNoteTable_3e8d748a-bbd4-41ad-95e7-db5199d98d40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalIncomeTaxNoteTable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_167d192d-c029-46fa-b9c2-00c5c384e6d4" xlink:to="loc_us-gaap_FederalIncomeTaxNoteTable_3e8d748a-bbd4-41ad-95e7-db5199d98d40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_541f1b23-8bd1-480f-8c82-7110e53028dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FederalIncomeTaxNoteTable_3e8d748a-bbd4-41ad-95e7-db5199d98d40" xlink:to="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_541f1b23-8bd1-480f-8c82-7110e53028dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetDomain_052dd116-b65c-4fa5-8314-0be9042611e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_541f1b23-8bd1-480f-8c82-7110e53028dc" xlink:to="loc_us-gaap_DeferredTaxAssetDomain_052dd116-b65c-4fa5-8314-0be9042611e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems_4bbcc5c7-869c-4bd3-a003-3e38a210c8fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FederalIncomeTaxNoteTable_3e8d748a-bbd4-41ad-95e7-db5199d98d40" xlink:to="loc_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems_4bbcc5c7-869c-4bd3-a003-3e38a210c8fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon_26c09425-a714-446b-9cfc-3d118e6ac43f" xlink:href="lxrx-20221231.xsd#lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems_4bbcc5c7-869c-4bd3-a003-3e38a210c8fd" xlink:to="loc_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon_26c09425-a714-446b-9cfc-3d118e6ac43f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_7d960bfb-e9d9-42dc-8fa3-ee9f2ae91b18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems_4bbcc5c7-869c-4bd3-a003-3e38a210c8fd" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_7d960bfb-e9d9-42dc-8fa3-ee9f2ae91b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/IncomeTaxesDetails3" xlink:type="simple" xlink:href="lxrx-20221231.xsd#IncomeTaxesDetails3"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/IncomeTaxesDetails3" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_e38b8789-6ddb-462e-9ee1-c4fc13f2dc78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_f620f3cf-f47b-4cbd-a0f9-5fa4dacb3d31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e38b8789-6ddb-462e-9ee1-c4fc13f2dc78" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_f620f3cf-f47b-4cbd-a0f9-5fa4dacb3d31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_8b8d70da-687b-4534-b025-6c15ff5a6035" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e38b8789-6ddb-462e-9ee1-c4fc13f2dc78" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_8b8d70da-687b-4534-b025-6c15ff5a6035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_c3ab3f35-a6d4-446d-a99c-474e1445a7b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e38b8789-6ddb-462e-9ee1-c4fc13f2dc78" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_c3ab3f35-a6d4-446d-a99c-474e1445a7b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_359a73ad-4f10-497b-9934-66a65adbde99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e38b8789-6ddb-462e-9ee1-c4fc13f2dc78" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_359a73ad-4f10-497b-9934-66a65adbde99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_38dd3e0d-a4b3-46dc-ba0d-94f288517b38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e38b8789-6ddb-462e-9ee1-c4fc13f2dc78" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_38dd3e0d-a4b3-46dc-ba0d-94f288517b38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_WriteOffOfTaxCredits_f9b99fc6-6a4b-4878-8940-bd05c91e5722" xlink:href="lxrx-20221231.xsd#lxrx_WriteOffOfTaxCredits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e38b8789-6ddb-462e-9ee1-c4fc13f2dc78" xlink:to="loc_lxrx_WriteOffOfTaxCredits_f9b99fc6-6a4b-4878-8940-bd05c91e5722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_b09131c9-1d9c-415f-89db-cd187211ac4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e38b8789-6ddb-462e-9ee1-c4fc13f2dc78" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_b09131c9-1d9c-415f-89db-cd187211ac4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f174f709-775d-4b26-ad67-679b73985efc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e38b8789-6ddb-462e-9ee1-c4fc13f2dc78" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f174f709-775d-4b26-ad67-679b73985efc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_6f287cb7-0ef6-43bb-8650-d61e142d8060" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e38b8789-6ddb-462e-9ee1-c4fc13f2dc78" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_6f287cb7-0ef6-43bb-8650-d61e142d8060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/GoodwillDetails" xlink:type="simple" xlink:href="lxrx-20221231.xsd#GoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/GoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_GoodwillAbstract_78c7ed24-85a5-48fd-a86c-859d59984aea" xlink:href="lxrx-20221231.xsd#lxrx_GoodwillAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CoelacanthGoodwill_267117a9-e92f-4647-838d-1d4f892e2ae4" xlink:href="lxrx-20221231.xsd#lxrx_CoelacanthGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_GoodwillAbstract_78c7ed24-85a5-48fd-a86c-859d59984aea" xlink:to="loc_lxrx_CoelacanthGoodwill_267117a9-e92f-4647-838d-1d4f892e2ae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CoelacanthPurchasePrice_d946cb7c-1b86-424c-a1fa-639f3b5cedc1" xlink:href="lxrx-20221231.xsd#lxrx_CoelacanthPurchasePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_GoodwillAbstract_78c7ed24-85a5-48fd-a86c-859d59984aea" xlink:to="loc_lxrx_CoelacanthPurchasePrice_d946cb7c-1b86-424c-a1fa-639f3b5cedc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SymphonyIconGoodwill_9df64d18-2263-413b-8c2c-1de791931311" xlink:href="lxrx-20221231.xsd#lxrx_SymphonyIconGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_GoodwillAbstract_78c7ed24-85a5-48fd-a86c-859d59984aea" xlink:to="loc_lxrx_SymphonyIconGoodwill_9df64d18-2263-413b-8c2c-1de791931311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligationsNarrativeDetails" xlink:type="simple" xlink:href="lxrx-20221231.xsd#DebtObligationsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/DebtObligationsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DebtObligationsAbstract_b0002b83-bcbf-479f-aee6-0a5540baccef" xlink:href="lxrx-20221231.xsd#lxrx_DebtObligationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_78c53c5c-db23-407c-b939-3ace89adc561" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_DebtObligationsAbstract_b0002b83-bcbf-479f-aee6-0a5540baccef" xlink:to="loc_us-gaap_DebtInstrumentTable_78c53c5c-db23-407c-b939-3ace89adc561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_8b83fbe9-53d7-468b-a81c-3c4ddb085215" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_78c53c5c-db23-407c-b939-3ace89adc561" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_8b83fbe9-53d7-468b-a81c-3c4ddb085215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a30fe2f7-2347-46fc-873c-326ccbdffc88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8b83fbe9-53d7-468b-a81c-3c4ddb085215" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a30fe2f7-2347-46fc-873c-326ccbdffc88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c1d69617-2f56-4eb2-9e75-13a203936be6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_78c53c5c-db23-407c-b939-3ace89adc561" xlink:to="loc_us-gaap_DebtInstrumentAxis_c1d69617-2f56-4eb2-9e75-13a203936be6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c358bf82-d1d0-40b4-a59d-f8bb11e332a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_c1d69617-2f56-4eb2-9e75-13a203936be6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c358bf82-d1d0-40b4-a59d-f8bb11e332a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_78c53c5c-db23-407c-b939-3ace89adc561" xlink:to="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_0359dc68-3464-4eba-a98a-1438862f43d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_0359dc68-3464-4eba-a98a-1438862f43d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage_bc58fc79-a4e1-4e3f-996b-b0a9f6163756" xlink:href="lxrx-20221231.xsd#lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage_bc58fc79-a4e1-4e3f-996b-b0a9f6163756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_748e6974-a25a-473c-9d5c-52f5634f9095" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_748e6974-a25a-473c-9d5c-52f5634f9095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_84e34505-478c-4143-bdac-c8910224189d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_84e34505-478c-4143-bdac-c8910224189d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DebtInstrumentRepurchasePercentage_0ff5a473-78fa-4953-944b-798a3be75452" xlink:href="lxrx-20221231.xsd#lxrx_DebtInstrumentRepurchasePercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_DebtInstrumentRepurchasePercentage_0ff5a473-78fa-4953-944b-798a3be75452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_357ce453-71a9-43f4-9573-ae9997b53cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_357ce453-71a9-43f4-9573-ae9997b53cdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_cf975795-5df1-464e-9a96-a021f512fad4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_us-gaap_DebtInstrumentTerm_cf975795-5df1-464e-9a96-a021f512fad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_a8ee886c-67b9-4335-8cfd-f0df8df80ea6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_a8ee886c-67b9-4335-8cfd-f0df8df80ea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_9ec20030-b93f-4c93-b388-b12a6d0bb9d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_us-gaap_DebtInstrumentFairValue_9ec20030-b93f-4c93-b388-b12a6d0bb9d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_101fd7bd-be1f-4bb9-9667-70ba77430b0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_101fd7bd-be1f-4bb9-9667-70ba77430b0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_828dec1a-1851-4294-a07d-786f95bc18f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_828dec1a-1851-4294-a07d-786f95bc18f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_15e1e589-81a4-4cca-b5ca-81ced38a8a75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_15e1e589-81a4-4cca-b5ca-81ced38a8a75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageLoansOnRealEstate_8406ed8b-a5af-4895-916c-2c83d5d5d033" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MortgageLoansOnRealEstate"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_us-gaap_MortgageLoansOnRealEstate_8406ed8b-a5af-4895-916c-2c83d5d5d033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_78dbcf73-477d-493e-9c97-6693e143f0bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_78dbcf73-477d-493e-9c97-6693e143f0bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_9a80617b-7c09-412a-aa87-e73019bec04c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_9a80617b-7c09-412a-aa87-e73019bec04c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_80611284-1a00-47b7-9187-71d6b02bcff3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebt"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_us-gaap_ConvertibleDebt_80611284-1a00-47b7-9187-71d6b02bcff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchangeTotalCashConsideration_41e1ba01-ccab-4d52-b410-5e8b94898696" xlink:href="lxrx-20221231.xsd#lxrx_ConvertibleDebtExchangeTotalCashConsideration"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_ConvertibleDebtExchangeTotalCashConsideration_41e1ba01-ccab-4d52-b410-5e8b94898696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2020ConvertibleDebtExchangeSharePaymentTotal_6e324f46-2d04-4485-831d-04940bb15b57" xlink:href="lxrx-20221231.xsd#lxrx_A2020ConvertibleDebtExchangeSharePaymentTotal"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_A2020ConvertibleDebtExchangeSharePaymentTotal_6e324f46-2d04-4485-831d-04940bb15b57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2020ConvertibleDebtExchangePercentageOfPrincipal_1b8beeb3-277c-41e4-b242-b622ca67858e" xlink:href="lxrx-20221231.xsd#lxrx_A2020ConvertibleDebtExchangePercentageOfPrincipal"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_A2020ConvertibleDebtExchangePercentageOfPrincipal_1b8beeb3-277c-41e4-b242-b622ca67858e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2020ConvertibleDebtExchangeAccruedInterest_f7647928-151c-4d5d-9538-bcc70362261a" xlink:href="lxrx-20221231.xsd#lxrx_A2020ConvertibleDebtExchangeAccruedInterest"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_A2020ConvertibleDebtExchangeAccruedInterest_f7647928-151c-4d5d-9538-bcc70362261a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_PrincipalAmountOfConvertibleNotes_35a6a473-6efb-41f1-9996-00c9634d930e" xlink:href="lxrx-20221231.xsd#lxrx_PrincipalAmountOfConvertibleNotes"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_PrincipalAmountOfConvertibleNotes_35a6a473-6efb-41f1-9996-00c9634d930e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchange_b1937d6b-166d-497a-b777-31a38cee7dda" xlink:href="lxrx-20221231.xsd#lxrx_ConvertibleDebtExchange"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_ConvertibleDebtExchange_b1937d6b-166d-497a-b777-31a38cee7dda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX_fd42d7a8-b6ea-4915-8046-4f547dad1a3f" xlink:href="lxrx-20221231.xsd#lxrx_MortgageDebtInterestRate_Base_Revere_LXRX"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX_fd42d7a8-b6ea-4915-8046-4f547dad1a3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX_e7b3fbf2-e55b-4182-9d1e-fd937afc14cd" xlink:href="lxrx-20221231.xsd#lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX_e7b3fbf2-e55b-4182-9d1e-fd937afc14cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtInstrument_Revere_LXRX_ddd05c07-4be2-49d9-9004-57e2bb644931" xlink:href="lxrx-20221231.xsd#lxrx_MortgageDebtInstrument_Revere_LXRX"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_MortgageDebtInstrument_Revere_LXRX_ddd05c07-4be2-49d9-9004-57e2bb644931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtBalloonPayment_LXRX_61825986-84ee-4023-9058-15b000a4055f" xlink:href="lxrx-20221231.xsd#lxrx_MortgageDebtBalloonPayment_LXRX"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_MortgageDebtBalloonPayment_LXRX_61825986-84ee-4023-9058-15b000a4055f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_9ae4f65b-74f7-4941-9611-b4f1934c588a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_9ae4f65b-74f7-4941-9611-b4f1934c588a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanAWarrantExercisePrice_8ca60f7c-cd5e-43a2-83a1-3e6d36f8336c" xlink:href="lxrx-20221231.xsd#lxrx_TermLoanAWarrantExercisePrice"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_TermLoanAWarrantExercisePrice_8ca60f7c-cd5e-43a2-83a1-3e6d36f8336c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubordinatedBorrowingInterestRate_8bd3529e-9a11-45d6-9b8b-9994336ee7f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubordinatedBorrowingInterestRate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_us-gaap_SubordinatedBorrowingInterestRate_8bd3529e-9a11-45d6-9b8b-9994336ee7f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanDWarrant_421d35a6-a5b4-4068-ad6b-ea0122a28dc0" xlink:href="lxrx-20221231.xsd#lxrx_TermLoanDWarrant"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_TermLoanDWarrant_421d35a6-a5b4-4068-ad6b-ea0122a28dc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanAFinalPayment_b50d59d7-42d4-4fd5-9cc3-46c620524826" xlink:href="lxrx-20221231.xsd#lxrx_TermLoanAFinalPayment"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_TermLoanAFinalPayment_b50d59d7-42d4-4fd5-9cc3-46c620524826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FinalPaymentWithExtention_8f110b8e-c584-4207-8e3d-3573306eb9e3" xlink:href="lxrx-20221231.xsd#lxrx_FinalPaymentWithExtention"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_FinalPaymentWithExtention_8f110b8e-c584-4207-8e3d-3573306eb9e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FinalPaymentWithNoExtention_89a07abd-8726-4eaa-8901-c0841125ea60" xlink:href="lxrx-20221231.xsd#lxrx_FinalPaymentWithNoExtention"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_FinalPaymentWithNoExtention_89a07abd-8726-4eaa-8901-c0841125ea60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanADebtIssuanceCosts_02a1e7e2-4f51-46c9-9d58-19b1e02ddd71" xlink:href="lxrx-20221231.xsd#lxrx_TermLoanADebtIssuanceCosts"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_TermLoanADebtIssuanceCosts_02a1e7e2-4f51-46c9-9d58-19b1e02ddd71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OxfordFacilityFee_bda89198-e452-4808-a451-3bab9844e4ef" xlink:href="lxrx-20221231.xsd#lxrx_OxfordFacilityFee"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_OxfordFacilityFee_bda89198-e452-4808-a451-3bab9844e4ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanANetCashReceipt_139359a0-84e6-4e27-a6a1-3668c06cac58" xlink:href="lxrx-20221231.xsd#lxrx_TermLoanANetCashReceipt"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_TermLoanANetCashReceipt_139359a0-84e6-4e27-a6a1-3668c06cac58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_11d3e722-3072-4748-aa2b-125849f01a29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_11d3e722-3072-4748-aa2b-125849f01a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_b7d653b3-3fa9-4b88-9ca5-2b821c9fe955" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_us-gaap_InterestExpense_b7d653b3-3fa9-4b88-9ca5-2b821c9fe955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanADebtDiscount_287e794c-0c50-4ac3-82a1-50f81d45c963" xlink:href="lxrx-20221231.xsd#lxrx_TermLoanADebtDiscount"/>
    <link:presentationArc order="39" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_TermLoanADebtDiscount_287e794c-0c50-4ac3-82a1-50f81d45c963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanCWarrant_43231ce7-89f0-4605-82b6-86366ea7eab2" xlink:href="lxrx-20221231.xsd#lxrx_TermLoanCWarrant"/>
    <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_TermLoanCWarrant_43231ce7-89f0-4605-82b6-86366ea7eab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanAWarrantsNumber_9064f285-2456-4351-af11-196e825717cb" xlink:href="lxrx-20221231.xsd#lxrx_TermLoanAWarrantsNumber"/>
    <link:presentationArc order="41" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_TermLoanAWarrantsNumber_9064f285-2456-4351-af11-196e825717cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanABWarrant_3fd23613-de92-4fbb-8040-0fe4a661caf9" xlink:href="lxrx-20221231.xsd#lxrx_TermLoanABWarrant"/>
    <link:presentationArc order="42" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_TermLoanABWarrant_3fd23613-de92-4fbb-8040-0fe4a661caf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanB_93bc7c20-d0d7-45e4-8b34-4b9154bcd937" xlink:href="lxrx-20221231.xsd#lxrx_TermLoanB"/>
    <link:presentationArc order="43" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_TermLoanB_93bc7c20-d0d7-45e4-8b34-4b9154bcd937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2026OxfordPrincipalPayments_370b34ab-63da-4685-862f-92e508a22e84" xlink:href="lxrx-20221231.xsd#lxrx_A2026OxfordPrincipalPayments"/>
    <link:presentationArc order="44" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_A2026OxfordPrincipalPayments_370b34ab-63da-4685-862f-92e508a22e84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OxfordLoanFacility_fb824185-6e28-48b6-b526-f0c289fe4d68" xlink:href="lxrx-20221231.xsd#lxrx_OxfordLoanFacility"/>
    <link:presentationArc order="45" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_OxfordLoanFacility_fb824185-6e28-48b6-b526-f0c289fe4d68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OxfordAmendmentFee_b1a16606-5e0f-4d0e-97ba-495ce01f6188" xlink:href="lxrx-20221231.xsd#lxrx_OxfordAmendmentFee"/>
    <link:presentationArc order="46" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_OxfordAmendmentFee_b1a16606-5e0f-4d0e-97ba-495ce01f6188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanA_27cbd539-e6b7-45c5-afe9-4273171a6cc6" xlink:href="lxrx-20221231.xsd#lxrx_TermLoanA"/>
    <link:presentationArc order="47" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_TermLoanA_27cbd539-e6b7-45c5-afe9-4273171a6cc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanC_17353012-288c-4f14-b0c2-98cc76fdd255" xlink:href="lxrx-20221231.xsd#lxrx_TermLoanC"/>
    <link:presentationArc order="48" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_TermLoanC_17353012-288c-4f14-b0c2-98cc76fdd255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanD_ad90a0c6-e220-4382-82c2-a0f45d2f0ad7" xlink:href="lxrx-20221231.xsd#lxrx_TermLoanD"/>
    <link:presentationArc order="49" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_TermLoanD_ad90a0c6-e220-4382-82c2-a0f45d2f0ad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2027OxfordPrincipalPayments_0f3be38a-86cd-475b-a989-89a9c5c071df" xlink:href="lxrx-20221231.xsd#lxrx_A2027OxfordPrincipalPayments"/>
    <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_A2027OxfordPrincipalPayments_0f3be38a-86cd-475b-a989-89a9c5c071df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_be2c07cf-2fc9-44b5-9051-8f28c94547b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="51" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_us-gaap_LongTermDebt_be2c07cf-2fc9-44b5-9051-8f28c94547b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndDebtExpense_a4838f9e-b0af-4831-a8f0-33109a00a87b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndDebtExpense"/>
    <link:presentationArc order="52" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_us-gaap_InterestAndDebtExpense_a4838f9e-b0af-4831-a8f0-33109a00a87b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_e3742a20-6862-40f1-a92f-0d7552dffb25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="53" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_e3742a20-6862-40f1-a92f-0d7552dffb25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2027OxfordPrincipalPaymentsA_f2551314-4586-4762-87cf-f8e948d2ef0c" xlink:href="lxrx-20221231.xsd#lxrx_A2027OxfordPrincipalPaymentsA"/>
    <link:presentationArc order="54" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_A2027OxfordPrincipalPaymentsA_f2551314-4586-4762-87cf-f8e948d2ef0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2025OxfordPrincipalPaymentA_c9bd011d-65e9-4ea1-9399-baec82126350" xlink:href="lxrx-20221231.xsd#lxrx_A2025OxfordPrincipalPaymentA"/>
    <link:presentationArc order="55" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_A2025OxfordPrincipalPaymentA_c9bd011d-65e9-4ea1-9399-baec82126350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2025OxfordPrincipalPaymentsB_e2b0755a-fad5-4bad-9b13-4f844f24bf43" xlink:href="lxrx-20221231.xsd#lxrx_A2025OxfordPrincipalPaymentsB"/>
    <link:presentationArc order="56" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_A2025OxfordPrincipalPaymentsB_e2b0755a-fad5-4bad-9b13-4f844f24bf43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2026OxfordPrincipalPaymentsB_2d052f4d-c629-4c1a-8c4f-6491e97bcaa7" xlink:href="lxrx-20221231.xsd#lxrx_A2026OxfordPrincipalPaymentsB"/>
    <link:presentationArc order="57" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_A2026OxfordPrincipalPaymentsB_2d052f4d-c629-4c1a-8c4f-6491e97bcaa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2027OxfordPrincipalPaymentsB_500e05c7-8a3c-42a6-bce8-1d3f15f0906e" xlink:href="lxrx-20221231.xsd#lxrx_A2027OxfordPrincipalPaymentsB"/>
    <link:presentationArc order="58" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_A2027OxfordPrincipalPaymentsB_500e05c7-8a3c-42a6-bce8-1d3f15f0906e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_ed452f11-2279-48e2-94d6-a310f377e717" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:presentationArc order="59" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_ed452f11-2279-48e2-94d6-a310f377e717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanBNetCashReceipt_b71791b2-da42-4d40-854a-81740688b1db" xlink:href="lxrx-20221231.xsd#lxrx_TermLoanBNetCashReceipt"/>
    <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_TermLoanBNetCashReceipt_b71791b2-da42-4d40-854a-81740688b1db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanBDebtDiscount_575127e3-4235-43ec-a880-a6c6d08729ce" xlink:href="lxrx-20221231.xsd#lxrx_TermLoanBDebtDiscount"/>
    <link:presentationArc order="61" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_lxrx_TermLoanBDebtDiscount_575127e3-4235-43ec-a880-a6c6d08729ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseInterestBearingLiability_1db8bf6c-efb1-4894-b13f-693f7b342464" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseInterestBearingLiability"/>
    <link:presentationArc order="62" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09bb3816-ea70-4955-932f-3636fab5d0da" xlink:to="loc_us-gaap_InterestExpenseInterestBearingLiability_1db8bf6c-efb1-4894-b13f-693f7b342464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligationsDetails1" xlink:type="simple" xlink:href="lxrx-20221231.xsd#DebtObligationsDetails1"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/DebtObligationsDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DebtObligationsAbstract_7f73102e-cae0-4716-98d8-c6e0be65a435" xlink:href="lxrx-20221231.xsd#lxrx_DebtObligationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_7267337d-41b6-462d-bf10-bfed32662f83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_DebtObligationsAbstract_7f73102e-cae0-4716-98d8-c6e0be65a435" xlink:to="loc_us-gaap_LongTermDebtCurrent_7267337d-41b6-462d-bf10-bfed32662f83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_21190ae5-bc8f-49ca-988c-a7cba2a462ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_DebtObligationsAbstract_7f73102e-cae0-4716-98d8-c6e0be65a435" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_21190ae5-bc8f-49ca-988c-a7cba2a462ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="lxrx-20221231.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CommitmentsAndContingenciesAbstract_652fec6c-fbc7-4f46-ae24-c8b8f8d5708c" xlink:href="lxrx-20221231.xsd#lxrx_CommitmentsAndContingenciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_e85bd5f2-8fc7-40ec-846f-56e219092cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CommitmentsAndContingenciesAbstract_652fec6c-fbc7-4f46-ae24-c8b8f8d5708c" xlink:to="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_e85bd5f2-8fc7-40ec-846f-56e219092cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_00c64ba7-4a1a-4061-a577-6408f7169885" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_e85bd5f2-8fc7-40ec-846f-56e219092cc5" xlink:to="loc_srt_RangeAxis_00c64ba7-4a1a-4061-a577-6408f7169885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_140ac65e-bc1b-478b-aacf-fc394eef4ead" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_00c64ba7-4a1a-4061-a577-6408f7169885" xlink:to="loc_srt_RangeMember_140ac65e-bc1b-478b-aacf-fc394eef4ead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_614bc33f-a0de-4563-9d1c-daf5561db0ba" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_140ac65e-bc1b-478b-aacf-fc394eef4ead" xlink:to="loc_srt_MinimumMember_614bc33f-a0de-4563-9d1c-daf5561db0ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_eb8bb29a-5da7-4d46-af1c-b881af89c114" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_140ac65e-bc1b-478b-aacf-fc394eef4ead" xlink:to="loc_srt_MaximumMember_eb8bb29a-5da7-4d46-af1c-b881af89c114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_dad263ff-6922-4993-82f0-5de71c585033" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_e85bd5f2-8fc7-40ec-846f-56e219092cc5" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_dad263ff-6922-4993-82f0-5de71c585033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_81b3df7f-df35-43cc-a456-a88aebccf901" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_dad263ff-6922-4993-82f0-5de71c585033" xlink:to="loc_us-gaap_ReceivableTypeDomain_81b3df7f-df35-43cc-a456-a88aebccf901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_3d6f2bcb-44ff-4fe3-bcbb-6a46d42848ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_81b3df7f-df35-43cc-a456-a88aebccf901" xlink:to="loc_us-gaap_AccountsReceivableMember_3d6f2bcb-44ff-4fe3-bcbb-6a46d42848ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_be12f698-33fa-43da-ae1d-a2fd10ebc2af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_e85bd5f2-8fc7-40ec-846f-56e219092cc5" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_be12f698-33fa-43da-ae1d-a2fd10ebc2af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DeferredCompensationArrangementWithIndividualPaymentPeriod_13fffa46-7619-41ee-a152-2c5c95e6f71d" xlink:href="lxrx-20221231.xsd#lxrx_DeferredCompensationArrangementWithIndividualPaymentPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_be12f698-33fa-43da-ae1d-a2fd10ebc2af" xlink:to="loc_lxrx_DeferredCompensationArrangementWithIndividualPaymentPeriod_13fffa46-7619-41ee-a152-2c5c95e6f71d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_LexiconBorrowingRate_da44e518-4210-4f64-b350-22c16dc18e7b" xlink:href="lxrx-20221231.xsd#lxrx_LexiconBorrowingRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_be12f698-33fa-43da-ae1d-a2fd10ebc2af" xlink:to="loc_lxrx_LexiconBorrowingRate_da44e518-4210-4f64-b350-22c16dc18e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Lxrx_Sanofiterminationcashpayment_bf96b7dc-c43b-4d8c-a902-0d34d2903b9a" xlink:href="lxrx-20221231.xsd#lxrx_Lxrx_Sanofiterminationcashpayment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_be12f698-33fa-43da-ae1d-a2fd10ebc2af" xlink:to="loc_lxrx_Lxrx_Sanofiterminationcashpayment_bf96b7dc-c43b-4d8c-a902-0d34d2903b9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_173c2343-6f7c-494c-a03a-ff75f558fb52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_be12f698-33fa-43da-ae1d-a2fd10ebc2af" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_173c2343-6f7c-494c-a03a-ff75f558fb52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets_e977f1bb-6c9a-445f-b7ba-6325906dbd6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_be12f698-33fa-43da-ae1d-a2fd10ebc2af" xlink:to="loc_us-gaap_OtherAssets_e977f1bb-6c9a-445f-b7ba-6325906dbd6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense_f69a843e-e8d4-4597-b1c3-84f06a4f7b85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_be12f698-33fa-43da-ae1d-a2fd10ebc2af" xlink:to="loc_us-gaap_LeaseAndRentalExpense_f69a843e-e8d4-4597-b1c3-84f06a4f7b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_1ab46492-36eb-44eb-aace-518053e14416" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_be12f698-33fa-43da-ae1d-a2fd10ebc2af" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_1ab46492-36eb-44eb-aace-518053e14416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CommitmentsandContingenciesDetails2" xlink:type="simple" xlink:href="lxrx-20221231.xsd#CommitmentsandContingenciesDetails2"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CommitmentsandContingenciesDetails2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CommitmentsAndContingenciesAbstract_12705da4-a82a-4a68-8c02-8c5c270aa228" xlink:href="lxrx-20221231.xsd#lxrx_CommitmentsAndContingenciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_a160c0bf-309c-4583-b557-569f0d654d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CommitmentsAndContingenciesAbstract_12705da4-a82a-4a68-8c02-8c5c270aa228" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_a160c0bf-309c-4583-b557-569f0d654d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_872ad587-99d7-446c-b075-67bdf8f9d117" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CommitmentsAndContingenciesAbstract_12705da4-a82a-4a68-8c02-8c5c270aa228" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_872ad587-99d7-446c-b075-67bdf8f9d117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_bad903f9-7177-4a19-af4e-4368bf434618" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CommitmentsAndContingenciesAbstract_12705da4-a82a-4a68-8c02-8c5c270aa228" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_bad903f9-7177-4a19-af4e-4368bf434618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_9c82f14d-1f12-4e4b-b323-f88a48664f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CommitmentsAndContingenciesAbstract_12705da4-a82a-4a68-8c02-8c5c270aa228" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_9c82f14d-1f12-4e4b-b323-f88a48664f2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_782f0ecf-0513-45f9-9588-07126791ba41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CommitmentsAndContingenciesAbstract_12705da4-a82a-4a68-8c02-8c5c270aa228" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_782f0ecf-0513-45f9-9588-07126791ba41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_e197e2fb-ab1a-4407-87d3-0625debc9f84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CommitmentsAndContingenciesAbstract_12705da4-a82a-4a68-8c02-8c5c270aa228" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_e197e2fb-ab1a-4407-87d3-0625debc9f84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_37feb764-ceb1-4b5a-ab41-ecd6d786decc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CommitmentsAndContingenciesAbstract_12705da4-a82a-4a68-8c02-8c5c270aa228" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_37feb764-ceb1-4b5a-ab41-ecd6d786decc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_InterestOnLeasePayments_eecde2ff-8dff-4cd4-a730-441eb24c1343" xlink:href="lxrx-20221231.xsd#lxrx_InterestOnLeasePayments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CommitmentsAndContingenciesAbstract_12705da4-a82a-4a68-8c02-8c5c270aa228" xlink:to="loc_lxrx_InterestOnLeasePayments_eecde2ff-8dff-4cd4-a730-441eb24c1343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_PresentValueOfFutureLeasePayments_f2dc59f0-ed52-405b-89fe-80958b86fd67" xlink:href="lxrx-20221231.xsd#lxrx_PresentValueOfFutureLeasePayments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CommitmentsAndContingenciesAbstract_12705da4-a82a-4a68-8c02-8c5c270aa228" xlink:to="loc_lxrx_PresentValueOfFutureLeasePayments_f2dc59f0-ed52-405b-89fe-80958b86fd67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCommitmentAmount_806cf1aa-43d0-4b1b-838b-923654d561bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCommitmentAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CommitmentsAndContingenciesAbstract_12705da4-a82a-4a68-8c02-8c5c270aa228" xlink:to="loc_us-gaap_ShortTermLeaseCommitmentAmount_806cf1aa-43d0-4b1b-838b-923654d561bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_97bf4dd3-88ab-4b34-bdc4-6beb4ff9bca0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CommitmentsAndContingenciesAbstract_12705da4-a82a-4a68-8c02-8c5c270aa228" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_97bf4dd3-88ab-4b34-bdc4-6beb4ff9bca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_ae68d17e-7a83-4616-b0f8-b39d22f5c2c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CommitmentsAndContingenciesAbstract_12705da4-a82a-4a68-8c02-8c5c270aa228" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_ae68d17e-7a83-4616-b0f8-b39d22f5c2c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_13293aa1-15e0-4230-874f-e463bd7f1849" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CommitmentsAndContingenciesAbstract_12705da4-a82a-4a68-8c02-8c5c270aa228" xlink:to="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_13293aa1-15e0-4230-874f-e463bd7f1849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_8775c00c-a0d4-4e0d-be59-fd68a7b7a2ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_13293aa1-15e0-4230-874f-e463bd7f1849" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_8775c00c-a0d4-4e0d-be59-fd68a7b7a2ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense_09b7a080-c3d0-4c8f-96c9-8278f249c0fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_8775c00c-a0d4-4e0d-be59-fd68a7b7a2ee" xlink:to="loc_us-gaap_LeaseAndRentalExpense_09b7a080-c3d0-4c8f-96c9-8278f249c0fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="lxrx-20221231.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6f5dffec-3f1d-4940-b96c-614291adeec7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_6b433019-1f03-4da6-841d-29558324b6ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6f5dffec-3f1d-4940-b96c-614291adeec7" xlink:to="loc_us-gaap_OtherCommitmentsTable_6b433019-1f03-4da6-841d-29558324b6ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_bd3f3a62-7fac-4ce1-b007-3f11f2be035f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_6b433019-1f03-4da6-841d-29558324b6ec" xlink:to="loc_us-gaap_OtherCommitmentsAxis_bd3f3a62-7fac-4ce1-b007-3f11f2be035f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_37526d88-b4ba-41fa-8ab5-e6cbeae7ec1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAxis_bd3f3a62-7fac-4ce1-b007-3f11f2be035f" xlink:to="loc_us-gaap_OtherCommitmentsDomain_37526d88-b4ba-41fa-8ab5-e6cbeae7ec1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_3242428b-b8d9-45c9-b954-1118267e2519" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_6b433019-1f03-4da6-841d-29558324b6ec" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_3242428b-b8d9-45c9-b954-1118267e2519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_1ba09402-5e90-4608-8c11-03fd5af813f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_3242428b-b8d9-45c9-b954-1118267e2519" xlink:to="loc_us-gaap_OperatingLeaseExpense_1ba09402-5e90-4608-8c11-03fd5af813f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRent_f8ea218d-8161-4ba6-80a4-235ea704d03b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_3242428b-b8d9-45c9-b954-1118267e2519" xlink:to="loc_us-gaap_PaymentsForRent_f8ea218d-8161-4ba6-80a4-235ea704d03b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_4dba5223-ad4f-4d92-8577-193c9cb8d79c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_3242428b-b8d9-45c9-b954-1118267e2519" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_4dba5223-ad4f-4d92-8577-193c9cb8d79c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_64517ca4-02a3-4b8c-901a-22ecde91cd78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_3242428b-b8d9-45c9-b954-1118267e2519" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_64517ca4-02a3-4b8c-901a-22ecde91cd78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_c4ab4fca-1700-4339-94ce-ae5277672ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_3242428b-b8d9-45c9-b954-1118267e2519" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_c4ab4fca-1700-4339-94ce-ae5277672ea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails" xlink:type="simple" xlink:href="lxrx-20221231.xsd#EquityIncentiveAwardsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_EquityIncentiveAwardsAbstract_8264f71c-85d0-4702-98cf-46841421e745" xlink:href="lxrx-20221231.xsd#lxrx_EquityIncentiveAwardsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f27d9a80-b360-4bde-bcf4-751d724766ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_EquityIncentiveAwardsAbstract_8264f71c-85d0-4702-98cf-46841421e745" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f27d9a80-b360-4bde-bcf4-751d724766ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a98e8532-bd25-4453-8d98-d9e42116b7f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f27d9a80-b360-4bde-bcf4-751d724766ba" xlink:to="loc_us-gaap_AwardTypeAxis_a98e8532-bd25-4453-8d98-d9e42116b7f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_280cf464-ce98-4162-ab5b-ce9f44c9913d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_a98e8532-bd25-4453-8d98-d9e42116b7f7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_280cf464-ce98-4162-ab5b-ce9f44c9913d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_68a9b8df-920a-4b3b-a342-ee2ad70dffe6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_280cf464-ce98-4162-ab5b-ce9f44c9913d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_68a9b8df-920a-4b3b-a342-ee2ad70dffe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_226f84d6-2724-4409-8eb4-d53a22927bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_280cf464-ce98-4162-ab5b-ce9f44c9913d" xlink:to="loc_us-gaap_RestrictedStockMember_226f84d6-2724-4409-8eb4-d53a22927bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9cb8c437-ecc7-495e-8b55-04704b47db54" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f27d9a80-b360-4bde-bcf4-751d724766ba" xlink:to="loc_srt_RangeAxis_9cb8c437-ecc7-495e-8b55-04704b47db54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1d5159f1-59ab-4674-96bf-e34ae568f0ba" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9cb8c437-ecc7-495e-8b55-04704b47db54" xlink:to="loc_srt_RangeMember_1d5159f1-59ab-4674-96bf-e34ae568f0ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_702e0aec-0727-4ddb-a98a-9c2e05d9c982" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1d5159f1-59ab-4674-96bf-e34ae568f0ba" xlink:to="loc_srt_MinimumMember_702e0aec-0727-4ddb-a98a-9c2e05d9c982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_642b5258-0c48-4a82-865f-3f7f1bb59f3a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1d5159f1-59ab-4674-96bf-e34ae568f0ba" xlink:to="loc_srt_MaximumMember_642b5258-0c48-4a82-865f-3f7f1bb59f3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8e11a2f-08ba-4185-97be-ca1a4f53e2a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f27d9a80-b360-4bde-bcf4-751d724766ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8e11a2f-08ba-4185-97be-ca1a4f53e2a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock_825cf371-51b9-4d9c-b43f-0065aef6bd7f" xlink:href="lxrx-20221231.xsd#lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8e11a2f-08ba-4185-97be-ca1a4f53e2a7" xlink:to="loc_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock_825cf371-51b9-4d9c-b43f-0065aef6bd7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_4511a75a-948e-4e73-908c-84b200babf1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8e11a2f-08ba-4185-97be-ca1a4f53e2a7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_4511a75a-948e-4e73-908c-84b200babf1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_0efb40bd-f33a-4d7e-be2d-76c860f98f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8e11a2f-08ba-4185-97be-ca1a4f53e2a7" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_0efb40bd-f33a-4d7e-be2d-76c860f98f9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan_d754b8f4-7e96-4092-aa7d-711feb16381f" xlink:href="lxrx-20221231.xsd#lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8e11a2f-08ba-4185-97be-ca1a4f53e2a7" xlink:to="loc_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan_d754b8f4-7e96-4092-aa7d-711feb16381f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OptionsOutstandingEquityIncentivePlan_15d7f614-0f28-4b7c-bf60-9b3e7179b0cf" xlink:href="lxrx-20221231.xsd#lxrx_OptionsOutstandingEquityIncentivePlan"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8e11a2f-08ba-4185-97be-ca1a4f53e2a7" xlink:to="loc_lxrx_OptionsOutstandingEquityIncentivePlan_15d7f614-0f28-4b7c-bf60-9b3e7179b0cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan_75db9a3d-6d8a-4739-8f47-fbe377d025ba" xlink:href="lxrx-20221231.xsd#lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8e11a2f-08ba-4185-97be-ca1a4f53e2a7" xlink:to="loc_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan_75db9a3d-6d8a-4739-8f47-fbe377d025ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_StockOptionsExercisedEquityIncentivePlan_46a8d5fb-ddf4-4117-86f4-5b3b4ba45a87" xlink:href="lxrx-20221231.xsd#lxrx_StockOptionsExercisedEquityIncentivePlan"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8e11a2f-08ba-4185-97be-ca1a4f53e2a7" xlink:to="loc_lxrx_StockOptionsExercisedEquityIncentivePlan_46a8d5fb-ddf4-4117-86f4-5b3b4ba45a87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan_9d7f3457-edc4-4882-96ab-6eef4503e297" xlink:href="lxrx-20221231.xsd#lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8e11a2f-08ba-4185-97be-ca1a4f53e2a7" xlink:to="loc_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan_9d7f3457-edc4-4882-96ab-6eef4503e297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan_7e9870e2-f33f-4825-9a2d-b96ae8226370" xlink:href="lxrx-20221231.xsd#lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8e11a2f-08ba-4185-97be-ca1a4f53e2a7" xlink:to="loc_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan_7e9870e2-f33f-4825-9a2d-b96ae8226370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Totalvalueofsharesbynonemployeeinayear_60b55c96-fa5a-459b-ad46-df9557211d4c" xlink:href="lxrx-20221231.xsd#lxrx_Totalvalueofsharesbynonemployeeinayear"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8e11a2f-08ba-4185-97be-ca1a4f53e2a7" xlink:to="loc_lxrx_Totalvalueofsharesbynonemployeeinayear_60b55c96-fa5a-459b-ad46-df9557211d4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan_fd07b7e6-172b-4c45-b317-836fb9c8e9a5" xlink:href="lxrx-20221231.xsd#lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8e11a2f-08ba-4185-97be-ca1a4f53e2a7" xlink:to="loc_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan_fd07b7e6-172b-4c45-b317-836fb9c8e9a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan_381313ec-041f-4b58-8362-64c8c5eafa93" xlink:href="lxrx-20221231.xsd#lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8e11a2f-08ba-4185-97be-ca1a4f53e2a7" xlink:to="loc_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan_381313ec-041f-4b58-8362-64c8c5eafa93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan_36ab9a22-6cfa-4b50-a61a-b5d98268ec03" xlink:href="lxrx-20221231.xsd#lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8e11a2f-08ba-4185-97be-ca1a4f53e2a7" xlink:to="loc_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan_36ab9a22-6cfa-4b50-a61a-b5d98268ec03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan_feac0726-b292-4768-a351-557091762733" xlink:href="lxrx-20221231.xsd#lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8e11a2f-08ba-4185-97be-ca1a4f53e2a7" xlink:to="loc_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan_feac0726-b292-4768-a351-557091762733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_e7e816f9-b9ff-47c0-bd8a-dcedfafecbfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8e11a2f-08ba-4185-97be-ca1a4f53e2a7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_e7e816f9-b9ff-47c0-bd8a-dcedfafecbfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2d204e11-bbfa-4d3e-881e-fd93ccba9320" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8e11a2f-08ba-4185-97be-ca1a4f53e2a7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2d204e11-bbfa-4d3e-881e-fd93ccba9320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_RestrictedStockUnitsOutstandingNonEmployeeDirectorsEquityIncentivePlan_7e3a8312-f74b-4148-af31-7394a505a874" xlink:href="lxrx-20221231.xsd#lxrx_RestrictedStockUnitsOutstandingNonEmployeeDirectorsEquityIncentivePlan"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8e11a2f-08ba-4185-97be-ca1a4f53e2a7" xlink:to="loc_lxrx_RestrictedStockUnitsOutstandingNonEmployeeDirectorsEquityIncentivePlan_7e3a8312-f74b-4148-af31-7394a505a874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_96206c94-dfde-43b0-8ecc-e3a34a958570" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8e11a2f-08ba-4185-97be-ca1a4f53e2a7" xlink:to="loc_us-gaap_TreasuryStockValue_96206c94-dfde-43b0-8ecc-e3a34a958570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCarryingBasis_f8b719a0-c78b-424e-add7-ed4371cffc1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCarryingBasis"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8e11a2f-08ba-4185-97be-ca1a4f53e2a7" xlink:to="loc_us-gaap_TreasuryStockCarryingBasis_f8b719a0-c78b-424e-add7-ed4371cffc1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockPreferredValue_c798790d-328a-4c91-bdc6-34dd5f239114" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockPreferredValue"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8e11a2f-08ba-4185-97be-ca1a4f53e2a7" xlink:to="loc_us-gaap_TreasuryStockPreferredValue_c798790d-328a-4c91-bdc6-34dd5f239114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2" xlink:type="simple" xlink:href="lxrx-20221231.xsd#EquityIncentiveAwardsDetails2"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_EquityIncentiveAwardsAbstract_be71be3c-303d-45f4-9caa-914f24acab7f" xlink:href="lxrx-20221231.xsd#lxrx_EquityIncentiveAwardsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18c44579-92f4-406e-af57-a5d3a7314081" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_EquityIncentiveAwardsAbstract_be71be3c-303d-45f4-9caa-914f24acab7f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18c44579-92f4-406e-af57-a5d3a7314081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ff6c4e5c-6115-4030-a384-3e2c420d03bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18c44579-92f4-406e-af57-a5d3a7314081" xlink:to="loc_us-gaap_AwardTypeAxis_ff6c4e5c-6115-4030-a384-3e2c420d03bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3f0efd7a-119a-4a8e-bf0d-213365cb36e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_ff6c4e5c-6115-4030-a384-3e2c420d03bd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3f0efd7a-119a-4a8e-bf0d-213365cb36e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_3dc5369a-a54b-4c7a-99d2-6a03cb2da4d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3f0efd7a-119a-4a8e-bf0d-213365cb36e3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_3dc5369a-a54b-4c7a-99d2-6a03cb2da4d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bddde39-e934-4730-b6e2-313054f86fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18c44579-92f4-406e-af57-a5d3a7314081" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bddde39-e934-4730-b6e2-313054f86fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_feb3b738-0af3-4361-a3f3-d3747d910087" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bddde39-e934-4730-b6e2-313054f86fb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_feb3b738-0af3-4361-a3f3-d3747d910087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ab13f6e7-66fc-485a-b9da-a59e753b2799" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bddde39-e934-4730-b6e2-313054f86fb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ab13f6e7-66fc-485a-b9da-a59e753b2799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5aeedfba-d71f-4879-be56-b68883e93966" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bddde39-e934-4730-b6e2-313054f86fb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5aeedfba-d71f-4879-be56-b68883e93966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5761f1f2-cf62-4e2e-8ad1-6ff849c15c32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bddde39-e934-4730-b6e2-313054f86fb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5761f1f2-cf62-4e2e-8ad1-6ff849c15c32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2488bd54-1bc0-4e77-9114-51ddc7e3beb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bddde39-e934-4730-b6e2-313054f86fb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2488bd54-1bc0-4e77-9114-51ddc7e3beb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_290dabae-a397-45e9-9d5f-1b51ccc354f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bddde39-e934-4730-b6e2-313054f86fb5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_290dabae-a397-45e9-9d5f-1b51ccc354f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_7ef6a4c2-0474-4f2a-8e0d-71daf490a40a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bddde39-e934-4730-b6e2-313054f86fb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_7ef6a4c2-0474-4f2a-8e0d-71daf490a40a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_cba4799b-adb3-4f52-80ed-e0c18eae373b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bddde39-e934-4730-b6e2-313054f86fb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_cba4799b-adb3-4f52-80ed-e0c18eae373b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_78f58a6d-4d9d-4501-8e68-e7cf3bfb3f1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bddde39-e934-4730-b6e2-313054f86fb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_78f58a6d-4d9d-4501-8e68-e7cf3bfb3f1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_16197044-226e-4ac2-b93b-f9eb4ffc6acf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bddde39-e934-4730-b6e2-313054f86fb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_16197044-226e-4ac2-b93b-f9eb4ffc6acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_53bc51e4-0f43-43bf-a482-934db99be796" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bddde39-e934-4730-b6e2-313054f86fb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_53bc51e4-0f43-43bf-a482-934db99be796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_5cb21ae4-6c0f-4b34-9f6f-24a80ed6e6c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bddde39-e934-4730-b6e2-313054f86fb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_5cb21ae4-6c0f-4b34-9f6f-24a80ed6e6c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_aea615d0-f61e-4ae8-bab4-221805b1b13a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bddde39-e934-4730-b6e2-313054f86fb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_aea615d0-f61e-4ae8-bab4-221805b1b13a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1e3ac405-0e32-43dc-9568-032f730f4a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bddde39-e934-4730-b6e2-313054f86fb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1e3ac405-0e32-43dc-9568-032f730f4a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_7eb48afb-27f3-4fa3-a345-944893f1b25f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bddde39-e934-4730-b6e2-313054f86fb5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_7eb48afb-27f3-4fa3-a345-944893f1b25f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_a045628b-9609-452d-ba6e-b71ffb15231a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bddde39-e934-4730-b6e2-313054f86fb5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_a045628b-9609-452d-ba6e-b71ffb15231a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_19b59159-f8a2-415a-a267-b74954e36db5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bddde39-e934-4730-b6e2-313054f86fb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_19b59159-f8a2-415a-a267-b74954e36db5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_42c40733-4ed5-4ec1-a72d-e33369bad4c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bddde39-e934-4730-b6e2-313054f86fb5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_42c40733-4ed5-4ec1-a72d-e33369bad4c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3" xlink:type="simple" xlink:href="lxrx-20221231.xsd#EquityIncentiveAwardsDetails3"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_EquityIncentiveAwardsAbstract_e8f827da-3834-450d-a25f-179833dda4b4" xlink:href="lxrx-20221231.xsd#lxrx_EquityIncentiveAwardsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4d19698c-ce42-4cfe-811e-da8bc5957b4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_EquityIncentiveAwardsAbstract_e8f827da-3834-450d-a25f-179833dda4b4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4d19698c-ce42-4cfe-811e-da8bc5957b4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_65e1e75b-eb59-4b56-b0ec-fefdf25cb3df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4d19698c-ce42-4cfe-811e-da8bc5957b4e" xlink:to="loc_us-gaap_PlanNameAxis_65e1e75b-eb59-4b56-b0ec-fefdf25cb3df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_cb5b1171-fd74-4178-a2d5-e1470aee98cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_65e1e75b-eb59-4b56-b0ec-fefdf25cb3df" xlink:to="loc_us-gaap_PlanNameDomain_cb5b1171-fd74-4178-a2d5-e1470aee98cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_cc5d6c49-e59e-45ec-b1f5-d03a17581452" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4d19698c-ce42-4cfe-811e-da8bc5957b4e" xlink:to="loc_us-gaap_AwardTypeAxis_cc5d6c49-e59e-45ec-b1f5-d03a17581452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7d52d817-0862-4319-98ba-3b395917d5d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_cc5d6c49-e59e-45ec-b1f5-d03a17581452" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7d52d817-0862-4319-98ba-3b395917d5d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_bb16b5f6-3df5-4669-9a4a-1effa4cfed88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4d19698c-ce42-4cfe-811e-da8bc5957b4e" xlink:to="loc_us-gaap_StatementClassOfStockAxis_bb16b5f6-3df5-4669-9a4a-1effa4cfed88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_0352020d-8408-4223-a8c3-ae53fe14221f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_bb16b5f6-3df5-4669-9a4a-1effa4cfed88" xlink:to="loc_us-gaap_ClassOfStockDomain_0352020d-8408-4223-a8c3-ae53fe14221f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_601b07ca-bdcf-42aa-95c0-6dd89a65acce" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4d19698c-ce42-4cfe-811e-da8bc5957b4e" xlink:to="loc_srt_RangeAxis_601b07ca-bdcf-42aa-95c0-6dd89a65acce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_34e85db6-a0d4-402d-9958-dcbbcc683e6d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_601b07ca-bdcf-42aa-95c0-6dd89a65acce" xlink:to="loc_srt_RangeMember_34e85db6-a0d4-402d-9958-dcbbcc683e6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64d97b46-ebf5-436f-99ea-3ec97804d12f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4d19698c-ce42-4cfe-811e-da8bc5957b4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64d97b46-ebf5-436f-99ea-3ec97804d12f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod_dd111d5e-59d3-436f-ba4e-fb853ebed30c" xlink:href="lxrx-20221231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64d97b46-ebf5-436f-99ea-3ec97804d12f" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod_dd111d5e-59d3-436f-ba4e-fb853ebed30c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue_70eec4e6-94a6-4cd4-9dc9-2e299dccf515" xlink:href="lxrx-20221231.xsd#lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64d97b46-ebf5-436f-99ea-3ec97804d12f" xlink:to="loc_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue_70eec4e6-94a6-4cd4-9dc9-2e299dccf515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_581ae7d2-b2db-464f-95d5-1bd30feb3936" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64d97b46-ebf5-436f-99ea-3ec97804d12f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_581ae7d2-b2db-464f-95d5-1bd30feb3936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4" xlink:type="simple" xlink:href="lxrx-20221231.xsd#EquityIncentiveAwardsDetails4"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_EquityIncentiveAwardsAbstract_06ac7132-e680-4205-b9cf-551ce6a671a1" xlink:href="lxrx-20221231.xsd#lxrx_EquityIncentiveAwardsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f478f7a3-c577-42a3-85fa-958b68ea1698" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_EquityIncentiveAwardsAbstract_06ac7132-e680-4205-b9cf-551ce6a671a1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f478f7a3-c577-42a3-85fa-958b68ea1698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0b0f239b-7f56-47a9-9e01-028acecde22e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f478f7a3-c577-42a3-85fa-958b68ea1698" xlink:to="loc_us-gaap_AwardTypeAxis_0b0f239b-7f56-47a9-9e01-028acecde22e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6273c443-10df-47af-a2fb-b3df9b01414b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_0b0f239b-7f56-47a9-9e01-028acecde22e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6273c443-10df-47af-a2fb-b3df9b01414b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_49dffdc0-d705-46ba-974e-0f81080dacab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6273c443-10df-47af-a2fb-b3df9b01414b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_49dffdc0-d705-46ba-974e-0f81080dacab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5bb47aee-2a51-4cb7-b5e6-87723ce10ee8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f478f7a3-c577-42a3-85fa-958b68ea1698" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5bb47aee-2a51-4cb7-b5e6-87723ce10ee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_917f6537-0b19-4615-b66b-7c4712839b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5bb47aee-2a51-4cb7-b5e6-87723ce10ee8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_917f6537-0b19-4615-b66b-7c4712839b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9af4f65a-2a8a-47ab-ba9f-24f27d96ba8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5bb47aee-2a51-4cb7-b5e6-87723ce10ee8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9af4f65a-2a8a-47ab-ba9f-24f27d96ba8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7ca7ebb6-1a45-42b9-ab9a-a8e2214d86ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5bb47aee-2a51-4cb7-b5e6-87723ce10ee8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7ca7ebb6-1a45-42b9-ab9a-a8e2214d86ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9e6b320c-7037-46a8-a8d4-3522fcb6d5ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5bb47aee-2a51-4cb7-b5e6-87723ce10ee8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9e6b320c-7037-46a8-a8d4-3522fcb6d5ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ae98cf42-82c6-40be-8bfd-ba4d8d850121" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5bb47aee-2a51-4cb7-b5e6-87723ce10ee8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ae98cf42-82c6-40be-8bfd-ba4d8d850121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_afa7c29c-a993-4b8f-aba6-a4470bcd355d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5bb47aee-2a51-4cb7-b5e6-87723ce10ee8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_afa7c29c-a993-4b8f-aba6-a4470bcd355d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0ac788db-6396-48b1-92ba-cc2789ddc832" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5bb47aee-2a51-4cb7-b5e6-87723ce10ee8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0ac788db-6396-48b1-92ba-cc2789ddc832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue_ede32df3-d4ba-4588-aee8-df37c70d0659" xlink:href="lxrx-20221231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5bb47aee-2a51-4cb7-b5e6-87723ce10ee8" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue_ede32df3-d4ba-4588-aee8-df37c70d0659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/BenefitPlanDetails" xlink:type="simple" xlink:href="lxrx-20221231.xsd#BenefitPlanDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/BenefitPlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_BenefitPlanAbstract_525108d3-1492-4602-8f6f-35e82b003748" xlink:href="lxrx-20221231.xsd#lxrx_BenefitPlanAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_132161f2-4235-4830-bef5-0d3130de0696" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_BenefitPlanAbstract_525108d3-1492-4602-8f6f-35e82b003748" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_132161f2-4235-4830-bef5-0d3130de0696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DefinedContributionPlanRequisiteServicePeriod_ab9a4230-192d-4a2f-95df-600e9b2647ed" xlink:href="lxrx-20221231.xsd#lxrx_DefinedContributionPlanRequisiteServicePeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_BenefitPlanAbstract_525108d3-1492-4602-8f6f-35e82b003748" xlink:to="loc_lxrx_DefinedContributionPlanRequisiteServicePeriod_ab9a4230-192d-4a2f-95df-600e9b2647ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails" xlink:type="simple" xlink:href="lxrx-20221231.xsd#CollaborationandLicenseAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_62f65bcc-3a2d-4cd9-9bbd-f06cc3a287c7" xlink:href="lxrx-20221231.xsd#lxrx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiUpfrontPayment_8b201620-c71b-430a-b6e4-57e7c7d323e2" xlink:href="lxrx-20221231.xsd#lxrx_SanofiUpfrontPayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_62f65bcc-3a2d-4cd9-9bbd-f06cc3a287c7" xlink:to="loc_lxrx_SanofiUpfrontPayment_8b201620-c71b-430a-b6e4-57e7c7d323e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiDevelopmentMilestones_c19678e9-31e4-4e3b-a153-7dcd4cdf829a" xlink:href="lxrx-20221231.xsd#lxrx_SanofiDevelopmentMilestones"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_62f65bcc-3a2d-4cd9-9bbd-f06cc3a287c7" xlink:to="loc_lxrx_SanofiDevelopmentMilestones_c19678e9-31e4-4e3b-a153-7dcd4cdf829a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfDevelopmentMilestones_fab1b581-780c-449f-940f-e2fb1813bc30" xlink:href="lxrx-20221231.xsd#lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfDevelopmentMilestones"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_62f65bcc-3a2d-4cd9-9bbd-f06cc3a287c7" xlink:to="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfDevelopmentMilestones_fab1b581-780c-449f-940f-e2fb1813bc30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiRegulatoryMilestones_f0f3bcfb-dae3-441c-a902-ca90cdfa79d6" xlink:href="lxrx-20221231.xsd#lxrx_SanofiRegulatoryMilestones"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_62f65bcc-3a2d-4cd9-9bbd-f06cc3a287c7" xlink:to="loc_lxrx_SanofiRegulatoryMilestones_f0f3bcfb-dae3-441c-a902-ca90cdfa79d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfRegulatoryMilestones_2923089b-fcff-47b8-b062-f2a6e648c89b" xlink:href="lxrx-20221231.xsd#lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfRegulatoryMilestones"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_62f65bcc-3a2d-4cd9-9bbd-f06cc3a287c7" xlink:to="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfRegulatoryMilestones_2923089b-fcff-47b8-b062-f2a6e648c89b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiOutcomesStudyMilestone_315d52b5-dfec-4b7f-9213-c16714f74b8c" xlink:href="lxrx-20221231.xsd#lxrx_SanofiOutcomesStudyMilestone"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_62f65bcc-3a2d-4cd9-9bbd-f06cc3a287c7" xlink:to="loc_lxrx_SanofiOutcomesStudyMilestone_315d52b5-dfec-4b7f-9213-c16714f74b8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiSalesMilestonePayments_80718cd4-b132-4ab9-b993-525f995e52a8" xlink:href="lxrx-20221231.xsd#lxrx_SanofiSalesMilestonePayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_62f65bcc-3a2d-4cd9-9bbd-f06cc3a287c7" xlink:to="loc_lxrx_SanofiSalesMilestonePayments_80718cd4-b132-4ab9-b993-525f995e52a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfCommercialMilestones_ff6aabf2-2a04-44b6-b661-14569368cc4d" xlink:href="lxrx-20221231.xsd#lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfCommercialMilestones"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_62f65bcc-3a2d-4cd9-9bbd-f06cc3a287c7" xlink:to="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfCommercialMilestones_ff6aabf2-2a04-44b6-b661-14569368cc4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltiesPercentage_db8f5664-e443-4d7b-888a-f718aca272b0" xlink:href="lxrx-20221231.xsd#lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltiesPercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_62f65bcc-3a2d-4cd9-9bbd-f06cc3a287c7" xlink:to="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltiesPercentage_db8f5664-e443-4d7b-888a-f718aca272b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialCostsFundedPercentage_c988c069-f64a-449a-b1d6-59d93fb8f10c" xlink:href="lxrx-20221231.xsd#lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialCostsFundedPercentage"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_62f65bcc-3a2d-4cd9-9bbd-f06cc3a287c7" xlink:to="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialCostsFundedPercentage_c988c069-f64a-449a-b1d6-59d93fb8f10c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentCostsPeriod_70abd992-918a-4e15-99fd-4dcd9ac175f4" xlink:href="lxrx-20221231.xsd#lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentCostsPeriod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_62f65bcc-3a2d-4cd9-9bbd-f06cc3a287c7" xlink:to="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentCostsPeriod_70abd992-918a-4e15-99fd-4dcd9ac175f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiCommercializationCostsFundedbyLexiconMaximumAmount_2b5b311b-f752-4457-83bc-0ac85001c115" xlink:href="lxrx-20221231.xsd#lxrx_SanofiCommercializationCostsFundedbyLexiconMaximumAmount"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_62f65bcc-3a2d-4cd9-9bbd-f06cc3a287c7" xlink:to="loc_lxrx_SanofiCommercializationCostsFundedbyLexiconMaximumAmount_2b5b311b-f752-4457-83bc-0ac85001c115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod_35f276c4-398a-4bbd-baec-3f2fd7dcbecb" xlink:href="lxrx-20221231.xsd#lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_62f65bcc-3a2d-4cd9-9bbd-f06cc3a287c7" xlink:to="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod_35f276c4-398a-4bbd-baec-3f2fd7dcbecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable_5cb5db93-ab44-4833-8b54-d4a79d8b7733" xlink:href="lxrx-20221231.xsd#lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_62f65bcc-3a2d-4cd9-9bbd-f06cc3a287c7" xlink:to="loc_lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable_5cb5db93-ab44-4833-8b54-d4a79d8b7733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiRevenueAllocatedtoLicenseDeliverable_d130aab7-dea3-4fb0-aa6a-50342025959a" xlink:href="lxrx-20221231.xsd#lxrx_SanofiRevenueAllocatedtoLicenseDeliverable"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_62f65bcc-3a2d-4cd9-9bbd-f06cc3a287c7" xlink:to="loc_lxrx_SanofiRevenueAllocatedtoLicenseDeliverable_d130aab7-dea3-4fb0-aa6a-50342025959a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiRevenueRecognized_8685d4da-e278-4c49-abcf-432fad6be1fb" xlink:href="lxrx-20221231.xsd#lxrx_SanofiRevenueRecognized"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_62f65bcc-3a2d-4cd9-9bbd-f06cc3a287c7" xlink:to="loc_lxrx_SanofiRevenueRecognized_8685d4da-e278-4c49-abcf-432fad6be1fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiRevenueAllocatedtoFundingDeliverable_76a7de5f-5d5c-49d9-bdac-1576ff4f2f63" xlink:href="lxrx-20221231.xsd#lxrx_SanofiRevenueAllocatedtoFundingDeliverable"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_62f65bcc-3a2d-4cd9-9bbd-f06cc3a287c7" xlink:to="loc_lxrx_SanofiRevenueAllocatedtoFundingDeliverable_76a7de5f-5d5c-49d9-bdac-1576ff4f2f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenTotalPaymentsToDate_86735be6-658c-415d-b0b1-8601adb4efdf" xlink:href="lxrx-20221231.xsd#lxrx_IpsenTotalPaymentsToDate"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_62f65bcc-3a2d-4cd9-9bbd-f06cc3a287c7" xlink:to="loc_lxrx_IpsenTotalPaymentsToDate_86735be6-658c-415d-b0b1-8601adb4efdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenTotalUpfrontPayments_d7c73d39-4b19-4568-a04b-81542eaf9b94" xlink:href="lxrx-20221231.xsd#lxrx_IpsenTotalUpfrontPayments"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_62f65bcc-3a2d-4cd9-9bbd-f06cc3a287c7" xlink:to="loc_lxrx_IpsenTotalUpfrontPayments_d7c73d39-4b19-4568-a04b-81542eaf9b94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenMilestonePaymentReceived_3addf0cc-bff2-4b50-ba56-190ce9e0a3a5" xlink:href="lxrx-20221231.xsd#lxrx_IpsenMilestonePaymentReceived"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_62f65bcc-3a2d-4cd9-9bbd-f06cc3a287c7" xlink:to="loc_lxrx_IpsenMilestonePaymentReceived_3addf0cc-bff2-4b50-ba56-190ce9e0a3a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable_03613d67-1428-4625-9412-2b0ba9ca83ee" xlink:href="lxrx-20221231.xsd#lxrx_IpsenRevenueAllocatedtoLicenseDeliverable"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_62f65bcc-3a2d-4cd9-9bbd-f06cc3a287c7" xlink:to="loc_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable_03613d67-1428-4625-9412-2b0ba9ca83ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones_09ac93e8-9d7f-402c-9c9e-b4afa096ddf2" xlink:href="lxrx-20221231.xsd#lxrx_IpsenMaximumRegulatoryAndCommercialMilestones"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_62f65bcc-3a2d-4cd9-9bbd-f06cc3a287c7" xlink:to="loc_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones_09ac93e8-9d7f-402c-9c9e-b4afa096ddf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable_1e47222c-570d-4592-afa4-88d7d79209b7" xlink:href="lxrx-20221231.xsd#lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_62f65bcc-3a2d-4cd9-9bbd-f06cc3a287c7" xlink:to="loc_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable_1e47222c-570d-4592-afa4-88d7d79209b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable_7d8d756b-eecc-4d79-ba95-f04a0c99ff82" xlink:href="lxrx-20221231.xsd#lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_62f65bcc-3a2d-4cd9-9bbd-f06cc3a287c7" xlink:to="loc_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable_7d8d756b-eecc-4d79-ba95-f04a0c99ff82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenRevenueRecognized_0427b20e-4f63-454d-b3b7-d6b5c0d007e7" xlink:href="lxrx-20221231.xsd#lxrx_IpsenRevenueRecognized"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_62f65bcc-3a2d-4cd9-9bbd-f06cc3a287c7" xlink:to="loc_lxrx_IpsenRevenueRecognized_0427b20e-4f63-454d-b3b7-d6b5c0d007e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Ipsenproductsales_e68e71d6-292f-435c-8b2a-826b8a649a82" xlink:href="lxrx-20221231.xsd#lxrx_Ipsenproductsales"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_62f65bcc-3a2d-4cd9-9bbd-f06cc3a287c7" xlink:to="loc_lxrx_Ipsenproductsales_e68e71d6-292f-435c-8b2a-826b8a649a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenMaximumSalesMilestones_529a467d-4d43-4c2f-8415-e274b3d70f40" xlink:href="lxrx-20221231.xsd#lxrx_IpsenMaximumSalesMilestones"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_62f65bcc-3a2d-4cd9-9bbd-f06cc3a287c7" xlink:to="loc_lxrx_IpsenMaximumSalesMilestones_529a467d-4d43-4c2f-8415-e274b3d70f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SettlementPaymentFromTermination_b7c2c9db-f180-4935-814b-e17094a37d43" xlink:href="lxrx-20221231.xsd#lxrx_SettlementPaymentFromTermination"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_62f65bcc-3a2d-4cd9-9bbd-f06cc3a287c7" xlink:to="loc_lxrx_SettlementPaymentFromTermination_b7c2c9db-f180-4935-814b-e17094a37d43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiTerminationAgreement_d3864c2d-1b2b-4b3e-a4bf-c96cc4156927" xlink:href="lxrx-20221231.xsd#lxrx_SanofiTerminationAgreement"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_62f65bcc-3a2d-4cd9-9bbd-f06cc3a287c7" xlink:to="loc_lxrx_SanofiTerminationAgreement_d3864c2d-1b2b-4b3e-a4bf-c96cc4156927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiDeferredRevenueFromTermination_f33bfb79-ad66-4f90-9547-48cd0d892220" xlink:href="lxrx-20221231.xsd#lxrx_SanofiDeferredRevenueFromTermination"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_62f65bcc-3a2d-4cd9-9bbd-f06cc3a287c7" xlink:to="loc_lxrx_SanofiDeferredRevenueFromTermination_f33bfb79-ad66-4f90-9547-48cd0d892220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_f5362767-3066-4bb2-9ede-1e70e8b99257" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_62f65bcc-3a2d-4cd9-9bbd-f06cc3a287c7" xlink:to="loc_us-gaap_SubsequentEventTable_f5362767-3066-4bb2-9ede-1e70e8b99257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_f77e3908-4ae4-486f-9433-2cfd431f4215" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_f5362767-3066-4bb2-9ede-1e70e8b99257" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_f77e3908-4ae4-486f-9433-2cfd431f4215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2261c940-d78f-449d-b6f0-9da28ce67d16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f77e3908-4ae4-486f-9433-2cfd431f4215" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2261c940-d78f-449d-b6f0-9da28ce67d16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_a20a3b31-9e33-4541-b2b4-85d6104f6acd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_2261c940-d78f-449d-b6f0-9da28ce67d16" xlink:to="loc_us-gaap_SubsequentEventMember_a20a3b31-9e33-4541-b2b4-85d6104f6acd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_ef2328f9-6c11-4fd0-81ec-ea033dcc3c53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_f5362767-3066-4bb2-9ede-1e70e8b99257" xlink:to="loc_us-gaap_SubsequentEventLineItems_ef2328f9-6c11-4fd0-81ec-ea033dcc3c53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SettlementPaymentFromTermination_5b06b00b-f0f2-4e6e-bcb0-cd4752139037" xlink:href="lxrx-20221231.xsd#lxrx_SettlementPaymentFromTermination"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_ef2328f9-6c11-4fd0-81ec-ea033dcc3c53" xlink:to="loc_lxrx_SettlementPaymentFromTermination_5b06b00b-f0f2-4e6e-bcb0-cd4752139037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalFees_7ee56daf-c898-49b4-8d12-b97890a760db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalFees"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_ef2328f9-6c11-4fd0-81ec-ea033dcc3c53" xlink:to="loc_us-gaap_LegalFees_7ee56daf-c898-49b4-8d12-b97890a760db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/EarningsPerShareDetails" xlink:type="simple" xlink:href="lxrx-20221231.xsd#EarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_de5bf2c4-51cc-4ffe-8ed5-27c50900b787" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_98b55627-fe85-4953-82bc-ff0bf4821122" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_de5bf2c4-51cc-4ffe-8ed5-27c50900b787" xlink:to="loc_us-gaap_NetIncomeLoss_98b55627-fe85-4953-82bc-ff0bf4821122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_4458f71c-1a35-4147-bd85-b3654a797f89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_de5bf2c4-51cc-4ffe-8ed5-27c50900b787" xlink:to="loc_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_4458f71c-1a35-4147-bd85-b3654a797f89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_ff0a325e-50c5-4445-ab05-05c43c4ebc1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_de5bf2c4-51cc-4ffe-8ed5-27c50900b787" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_ff0a325e-50c5-4445-ab05-05c43c4ebc1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_76ad9204-2542-4596-beaf-7eda317d3e3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_de5bf2c4-51cc-4ffe-8ed5-27c50900b787" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_76ad9204-2542-4596-beaf-7eda317d3e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b93223e9-f1c2-4831-946d-f2e2a6718f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_de5bf2c4-51cc-4ffe-8ed5-27c50900b787" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b93223e9-f1c2-4831-946d-f2e2a6718f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_647f2eed-70ab-4384-9199-1829ff8d9385" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_de5bf2c4-51cc-4ffe-8ed5-27c50900b787" xlink:to="loc_us-gaap_EarningsPerShareBasic_647f2eed-70ab-4384-9199-1829ff8d9385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_4590c59d-45af-494d-a673-448c5de27496" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_de5bf2c4-51cc-4ffe-8ed5-27c50900b787" xlink:to="loc_us-gaap_EarningsPerShareDiluted_4590c59d-45af-494d-a673-448c5de27496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_273ef710-c595-42ed-a988-9962b45e0c37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_de5bf2c4-51cc-4ffe-8ed5-27c50900b787" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_273ef710-c595-42ed-a988-9962b45e0c37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_bd90d4e5-ebdd-4dcd-87d0-c52b12bbfc05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_de5bf2c4-51cc-4ffe-8ed5-27c50900b787" xlink:to="loc_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_bd90d4e5-ebdd-4dcd-87d0-c52b12bbfc05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_cc343540-701f-4791-b379-a1abbc71b7fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_de5bf2c4-51cc-4ffe-8ed5-27c50900b787" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_cc343540-701f-4791-b379-a1abbc71b7fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedQuarterlyFinancialInformationDetails" xlink:type="simple" xlink:href="lxrx-20221231.xsd#SelectedQuarterlyFinancialDataUnauditedQuarterlyFinancialInformationDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedQuarterlyFinancialInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_ce5a3b56-6301-4a84-b3d9-b4959c56341d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable_f7b33525-080f-4295-a971-27b392a7d516" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_ce5a3b56-6301-4a84-b3d9-b4959c56341d" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTable_f7b33525-080f-4295-a971-27b392a7d516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_e4998857-0ea8-475c-807c-4aaf9355bb8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_f7b33525-080f-4295-a971-27b392a7d516" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_e4998857-0ea8-475c-807c-4aaf9355bb8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_679221eb-9701-411a-bf4c-e48e0d9d3297" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e4998857-0ea8-475c-807c-4aaf9355bb8b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_679221eb-9701-411a-bf4c-e48e0d9d3297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems_ede0130d-39b7-48b6-8d58-327870f19cd9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_f7b33525-080f-4295-a971-27b392a7d516" xlink:to="loc_srt_CondensedFinancialStatementsCaptionsLineItems_ede0130d-39b7-48b6-8d58-327870f19cd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_bbb3d5cf-067e-454d-ab9c-f540353372e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_ede0130d-39b7-48b6-8d58-327870f19cd9" xlink:to="loc_us-gaap_Revenues_bbb3d5cf-067e-454d-ab9c-f540353372e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_86d03593-7e4b-499a-bea1-9cad878f6ccf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_ede0130d-39b7-48b6-8d58-327870f19cd9" xlink:to="loc_us-gaap_OperatingIncomeLoss_86d03593-7e4b-499a-bea1-9cad878f6ccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5cc836a6-fc05-4ded-b2a2-f7c31d9a596b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_ede0130d-39b7-48b6-8d58-327870f19cd9" xlink:to="loc_us-gaap_NetIncomeLoss_5cc836a6-fc05-4ded-b2a2-f7c31d9a596b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_cbdb6ca1-088f-499a-9cdd-1c5455247734" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_ede0130d-39b7-48b6-8d58-327870f19cd9" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_cbdb6ca1-088f-499a-9cdd-1c5455247734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b746f979-694f-449c-850a-2ab3cb04ee05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_ede0130d-39b7-48b6-8d58-327870f19cd9" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b746f979-694f-449c-850a-2ab3cb04ee05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_a13f611a-32ff-45af-950b-f08521ec6d44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_ede0130d-39b7-48b6-8d58-327870f19cd9" xlink:to="loc_us-gaap_EarningsPerShareDiluted_a13f611a-32ff-45af-950b-f08521ec6d44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_84fbdb0b-e7f5-4eb1-b6dc-fb509a690b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_ede0130d-39b7-48b6-8d58-327870f19cd9" xlink:to="loc_us-gaap_EarningsPerShareBasic_84fbdb0b-e7f5-4eb1-b6dc-fb509a690b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/AssetSaleDetails" xlink:type="simple" xlink:href="lxrx-20221231.xsd#AssetSaleDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/AssetSaleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetRetirementObligationDisclosureAbstract_3114a33e-0220-4b9a-a3d6-cb814ac663cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetRetirementObligationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_69877d11-4208-4665-8fc7-ca2a0a368f7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetRetirementObligationDisclosureAbstract_3114a33e-0220-4b9a-a3d6-cb814ac663cf" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_69877d11-4208-4665-8fc7-ca2a0a368f7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_5267bb57-15e9-4bb9-a6b7-2f33bd72785c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetRetirementObligationDisclosureAbstract_3114a33e-0220-4b9a-a3d6-cb814ac663cf" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_5267bb57-15e9-4bb9-a6b7-2f33bd72785c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_c2239020-4022-4c81-8569-683019dec9cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetRetirementObligationDisclosureAbstract_3114a33e-0220-4b9a-a3d6-cb814ac663cf" xlink:to="loc_us-gaap_SeveranceCosts1_c2239020-4022-4c81-8569-683019dec9cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_af4b616a-7ee1-4c6a-adda-f73d3fd4f711" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetRetirementObligationDisclosureAbstract_3114a33e-0220-4b9a-a3d6-cb814ac663cf" xlink:to="loc_us-gaap_DebtInstrumentTable_af4b616a-7ee1-4c6a-adda-f73d3fd4f711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_ec8606fc-a5ee-4572-a2e2-5d3308baa506" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_af4b616a-7ee1-4c6a-adda-f73d3fd4f711" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_ec8606fc-a5ee-4572-a2e2-5d3308baa506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_25f7517f-639d-4e65-a566-96b8d4303a49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_ec8606fc-a5ee-4572-a2e2-5d3308baa506" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_25f7517f-639d-4e65-a566-96b8d4303a49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_naics_ZZ541713_19b08356-1c7a-4323-943d-0f61145caa2c" xlink:href="https://xbrl.sec.gov/naics/2022/naics-2022.xsd#naics_ZZ541713"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_25f7517f-639d-4e65-a566-96b8d4303a49" xlink:to="loc_naics_ZZ541713_19b08356-1c7a-4323-943d-0f61145caa2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_db27e831-3553-44db-98a7-c77df5b750b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_25f7517f-639d-4e65-a566-96b8d4303a49" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_db27e831-3553-44db-98a7-c77df5b750b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_bea8104e-5ec2-438c-ae31-8bdf5d420ef8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_af4b616a-7ee1-4c6a-adda-f73d3fd4f711" xlink:to="loc_us-gaap_DebtInstrumentLineItems_bea8104e-5ec2-438c-ae31-8bdf5d420ef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_dde3663b-632f-4fea-811a-9c27af25e0e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bea8104e-5ec2-438c-ae31-8bdf5d420ef8" xlink:to="loc_us-gaap_SeveranceCosts1_dde3663b-632f-4fea-811a-9c27af25e0e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_GainOnSaleOfNonFinancialAssets_f3adca55-4278-4db5-9093-edb7ca054820" xlink:href="lxrx-20221231.xsd#lxrx_GainOnSaleOfNonFinancialAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bea8104e-5ec2-438c-ae31-8bdf5d420ef8" xlink:to="loc_lxrx_GainOnSaleOfNonFinancialAssets_f3adca55-4278-4db5-9093-edb7ca054820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones_4060659f-533a-411c-b768-a3069d0d6349" xlink:href="lxrx-20221231.xsd#lxrx_TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bea8104e-5ec2-438c-ae31-8bdf5d420ef8" xlink:to="loc_lxrx_TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones_4060659f-533a-411c-b768-a3069d0d6349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FinalConsiderationIncludingAmountsReleasedToSettle_84223f6f-d718-4aff-a285-3adf5c81d683" xlink:href="lxrx-20221231.xsd#lxrx_FinalConsiderationIncludingAmountsReleasedToSettle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bea8104e-5ec2-438c-ae31-8bdf5d420ef8" xlink:to="loc_lxrx_FinalConsiderationIncludingAmountsReleasedToSettle_84223f6f-d718-4aff-a285-3adf5c81d683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherAssets_20444eb6-bc2f-4821-9a06-9b5cfb74d48c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfOtherAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bea8104e-5ec2-438c-ae31-8bdf5d420ef8" xlink:to="loc_us-gaap_GainLossOnSaleOfOtherAssets_20444eb6-bc2f-4821-9a06-9b5cfb74d48c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_b9853dcb-2d7c-4487-945e-fb74162b72a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bea8104e-5ec2-438c-ae31-8bdf5d420ef8" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_b9853dcb-2d7c-4487-945e-fb74162b72a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfProvedProperty_8664e824-71b0-483f-9299-4b4d2cae7a98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfProvedProperty"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bea8104e-5ec2-438c-ae31-8bdf5d420ef8" xlink:to="loc_us-gaap_GainLossOnSaleOfProvedProperty_8664e824-71b0-483f-9299-4b4d2cae7a98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/OtherCapitalAgreementsDetails" xlink:type="simple" xlink:href="lxrx-20221231.xsd#OtherCapitalAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/OtherCapitalAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_6862365e-5235-4a03-82ee-d1ea87d72824" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_625da1b9-fd9d-4430-8672-32e63c3169a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6862365e-5235-4a03-82ee-d1ea87d72824" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_625da1b9-fd9d-4430-8672-32e63c3169a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_3b83097d-dd0f-4be8-b35e-f6bf6c44c3ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6862365e-5235-4a03-82ee-d1ea87d72824" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_3b83097d-dd0f-4be8-b35e-f6bf6c44c3ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ProceedsFromDecember2020CommonStockOffering_19a5db38-3125-4504-902a-bfbc68703a4e" xlink:href="lxrx-20221231.xsd#lxrx_ProceedsFromDecember2020CommonStockOffering"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6862365e-5235-4a03-82ee-d1ea87d72824" xlink:to="loc_lxrx_ProceedsFromDecember2020CommonStockOffering_19a5db38-3125-4504-902a-bfbc68703a4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CommissionsFromDecember2020CommonStockOffering_9efc1238-c5f4-47d2-9037-c04ab0beeb1c" xlink:href="lxrx-20221231.xsd#lxrx_CommissionsFromDecember2020CommonStockOffering"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6862365e-5235-4a03-82ee-d1ea87d72824" xlink:to="loc_lxrx_CommissionsFromDecember2020CommonStockOffering_9efc1238-c5f4-47d2-9037-c04ab0beeb1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OfferingExpensesFromDecember20CommonStockOffering_8ecc925f-5bcb-4f2d-bf27-136713be3280" xlink:href="lxrx-20221231.xsd#lxrx_OfferingExpensesFromDecember20CommonStockOffering"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6862365e-5235-4a03-82ee-d1ea87d72824" xlink:to="loc_lxrx_OfferingExpensesFromDecember20CommonStockOffering_8ecc925f-5bcb-4f2d-bf27-136713be3280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ATMOfferingTotal_851983f8-4942-4008-8a84-cf02dba18ecf" xlink:href="lxrx-20221231.xsd#lxrx_ATMOfferingTotal"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6862365e-5235-4a03-82ee-d1ea87d72824" xlink:to="loc_lxrx_ATMOfferingTotal_851983f8-4942-4008-8a84-cf02dba18ecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesSoldInNov2020ATMOffering_35214160-04df-4467-a87f-c3d47f9de18e" xlink:href="lxrx-20221231.xsd#lxrx_SharesSoldInNov2020ATMOffering"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6862365e-5235-4a03-82ee-d1ea87d72824" xlink:to="loc_lxrx_SharesSoldInNov2020ATMOffering_35214160-04df-4467-a87f-c3d47f9de18e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharePriceInNovember20ATMOffering_b453fb8a-cc5c-4f14-90b0-d964fc1b1925" xlink:href="lxrx-20221231.xsd#lxrx_SharePriceInNovember20ATMOffering"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6862365e-5235-4a03-82ee-d1ea87d72824" xlink:to="loc_lxrx_SharePriceInNovember20ATMOffering_b453fb8a-cc5c-4f14-90b0-d964fc1b1925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ProceedsFromNov2020ATMOffering_123b08fd-9c64-494f-a166-8b4e274dfe2f" xlink:href="lxrx-20221231.xsd#lxrx_ProceedsFromNov2020ATMOffering"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6862365e-5235-4a03-82ee-d1ea87d72824" xlink:to="loc_lxrx_ProceedsFromNov2020ATMOffering_123b08fd-9c64-494f-a166-8b4e274dfe2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesSoldInJanuary2021ATMOffering_7b44d7ad-ecdf-48f3-93db-4c832569cea1" xlink:href="lxrx-20221231.xsd#lxrx_SharesSoldInJanuary2021ATMOffering"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6862365e-5235-4a03-82ee-d1ea87d72824" xlink:to="loc_lxrx_SharesSoldInJanuary2021ATMOffering_7b44d7ad-ecdf-48f3-93db-4c832569cea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharePriceInJanuary2021ATMOffering_e574bcd2-cd75-42f0-b2e9-2065dd9012d3" xlink:href="lxrx-20221231.xsd#lxrx_SharePriceInJanuary2021ATMOffering"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6862365e-5235-4a03-82ee-d1ea87d72824" xlink:to="loc_lxrx_SharePriceInJanuary2021ATMOffering_e574bcd2-cd75-42f0-b2e9-2065dd9012d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ProceedsFromJanuary2021ATMOffering_9436dea2-a529-4af7-8cb4-0cd170c34589" xlink:href="lxrx-20221231.xsd#lxrx_ProceedsFromJanuary2021ATMOffering"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6862365e-5235-4a03-82ee-d1ea87d72824" xlink:to="loc_lxrx_ProceedsFromJanuary2021ATMOffering_9436dea2-a529-4af7-8cb4-0cd170c34589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharePriceInJanuary2021ATMOffering_e1da8a8a-3940-4708-87ae-3af2a1511efb" xlink:href="lxrx-20221231.xsd#lxrx_SharePriceInJanuary2021ATMOffering"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesSoldInJanuary2021ATMOffering_2a6f7e5b-7ab3-44ad-bbbe-2e56e5277c57" xlink:href="lxrx-20221231.xsd#lxrx_SharesSoldInJanuary2021ATMOffering"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ProceedsFromJanuary2021ATMOffering_795feb57-2789-4a48-acad-0b9f079a687b" xlink:href="lxrx-20221231.xsd#lxrx_ProceedsFromJanuary2021ATMOffering"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ATMOfferingTotal_6a963122-552e-4268-8ab2-b30639c26787" xlink:href="lxrx-20221231.xsd#lxrx_ATMOfferingTotal"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesSoldInSeptember2021ATMOffering_810b3c88-0588-465f-b16d-03e2a0bac43b" xlink:href="lxrx-20221231.xsd#lxrx_SharesSoldInSeptember2021ATMOffering"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6862365e-5235-4a03-82ee-d1ea87d72824" xlink:to="loc_lxrx_SharesSoldInSeptember2021ATMOffering_810b3c88-0588-465f-b16d-03e2a0bac43b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharePriceInSeptember2021ATMOffering_04038ca5-a165-4e28-95b9-6dfa09269222" xlink:href="lxrx-20221231.xsd#lxrx_SharePriceInSeptember2021ATMOffering"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6862365e-5235-4a03-82ee-d1ea87d72824" xlink:to="loc_lxrx_SharePriceInSeptember2021ATMOffering_04038ca5-a165-4e28-95b9-6dfa09269222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ProceedsFromSeptember2021ATMOffering_a2186880-d350-4b9e-bc09-c33be04a382f" xlink:href="lxrx-20221231.xsd#lxrx_ProceedsFromSeptember2021ATMOffering"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6862365e-5235-4a03-82ee-d1ea87d72824" xlink:to="loc_lxrx_ProceedsFromSeptember2021ATMOffering_a2186880-d350-4b9e-bc09-c33be04a382f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ProceedsFromJuly2022Offering_5da7257a-b2ba-4e6c-a859-a40a46687635" xlink:href="lxrx-20221231.xsd#lxrx_ProceedsFromJuly2022Offering"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6862365e-5235-4a03-82ee-d1ea87d72824" xlink:to="loc_lxrx_ProceedsFromJuly2022Offering_5da7257a-b2ba-4e6c-a859-a40a46687635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesSoldInJuly2022Offering_e740780b-f324-4dc3-81c2-20ccb6754c39" xlink:href="lxrx-20221231.xsd#lxrx_SharesSoldInJuly2022Offering"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6862365e-5235-4a03-82ee-d1ea87d72824" xlink:to="loc_lxrx_SharesSoldInJuly2022Offering_e740780b-f324-4dc3-81c2-20ccb6754c39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharePriceInJuly2022Offering_5ebc0714-4b29-41f6-9909-8ee83f54d12a" xlink:href="lxrx-20221231.xsd#lxrx_SharePriceInJuly2022Offering"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6862365e-5235-4a03-82ee-d1ea87d72824" xlink:to="loc_lxrx_SharePriceInJuly2022Offering_5ebc0714-4b29-41f6-9909-8ee83f54d12a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_6262c035-757b-448b-9f4d-cd8fb99e8ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6862365e-5235-4a03-82ee-d1ea87d72824" xlink:to="loc_us-gaap_SubsequentEventTable_6262c035-757b-448b-9f4d-cd8fb99e8ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_b50380d4-9fd4-40b5-8afa-646c4524096a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_6262c035-757b-448b-9f4d-cd8fb99e8ec8" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_b50380d4-9fd4-40b5-8afa-646c4524096a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_9ee720b0-24d8-4174-9ff3-639d56821080" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b50380d4-9fd4-40b5-8afa-646c4524096a" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_9ee720b0-24d8-4174-9ff3-639d56821080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_6ecf7a29-f209-4908-8825-edd49bdd3679" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_9ee720b0-24d8-4174-9ff3-639d56821080" xlink:to="loc_us-gaap_SubsequentEventMember_6ecf7a29-f209-4908-8825-edd49bdd3679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_8f64441e-c42c-45dd-b1d8-dfd43daacd85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_6262c035-757b-448b-9f4d-cd8fb99e8ec8" xlink:to="loc_us-gaap_SubsequentEventLineItems_8f64441e-c42c-45dd-b1d8-dfd43daacd85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ATMOffering2020Total_0725caff-6b3e-4905-bf4b-adce103ae2b2" xlink:href="lxrx-20221231.xsd#lxrx_ATMOffering2020Total"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8f64441e-c42c-45dd-b1d8-dfd43daacd85" xlink:to="loc_lxrx_ATMOffering2020Total_0725caff-6b3e-4905-bf4b-adce103ae2b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>lxrx-20221231_g1.jpg
<TEXT>
begin 644 lxrx-20221231_g1.jpg
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M6IQ=GLK6&'[+#)TEG>XD0[(HWDV?V_OV3?VN_BK^S-X>_99_X)\_%KP3\*]
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MC_C1]B\;_P#0;LO_  &/^-;%% &/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\
M 8_XUL44 <[?W'C'3[FUM9=7M6-U+Y:%;;@'&>>:M?8O&_\ T&[+_P !C_C1
MXE_Y"^C_ /7Z?_036Q0!C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^-;%
M% &/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XUL44 8_V+QO_ -!NR_\
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M_P!?LW_H5 !]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XUL44 8_V+QO\
M]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C6Q10!C_8O&_P#T&[+_ ,!C_C1]B\;_
M /0;LO\ P&/^-;%% &/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XUL44
M8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C6Q10!C_8O&_P#T&[+_ ,!C
M_C1]B\;_ /0;LO\ P&/^-;%% &/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P#
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M^1WO?^O*+^9K8K'LO^1WO?\ KRB_F:V* "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH Q_$O_(7T?_K]/_H)K8K'\2_\A?1_^OT_^@FMB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "L?P/\ \@B7_K]F_P#0JV*Q
M_ __ "")?^OV;_T*@#8HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "L?Q+_R%]'_ .OT_P#H)K8K'\2_\A?1_P#K]/\ Z": -BBBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_ >B7:P7]]K,C1VVC6EE.X(MYD>-'\Y@RI'#(661<QO\5_L@)^U)_P $H_\
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MX;N9P;F1BZ,N 2W3\* .KHK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI:
M-BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A
M)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$
MEU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%
M"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z
M%"]_[Z6C_A)=7_Z%"]_[Z6@#8K'\2_\ (7T?_K]/_H)H_P"$EU?_ *%"]_[Z
M6J5_JEYJ.LZ6MUHT]ILO/E,Q!W?*>F* .EHHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MUXFT?0M3OIM%\*Z9!!#-:6AT^":6.\N$>&UBEP!"CS3[A)%$DGQ9_P />_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MA+^RC?V$+_ZO4_&]Z+0+Z$VR_O"/HU4)/A=^UE\0&W?%7XY:GI5J_P#K-*\
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M 16_V7Z4?\,C^+/&_P"]^/'[2?BWQ&K<RZ9I,JZ58O\ [+10Y+#MG(->J_\
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M_P!"A>_]]+5*_P!4O-1UG2UNM&GM-EY\IF(.[Y3TQ0!TM%%% !1110 4444
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M_"NYGO=1NGPJM)(S_<CC"111@".**-$1550*_2VB@#Y1^,7_  3=\4_M5_\
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M]Q7\9\)\9<;XSBG 4/[3K/GK4HVG5JS@[SBK3CSKFC_-&ZNKJZN?Y]\$<?\
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MD>KY$>=_;W$7#ONYYA_:T5_S$8>,FDN]6A[U2'G*FZL>LN1'NU%<9\)/C_\
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MJ_4&IZA;:3IMQJMZQ6&U@>64@9(502>._ H ^,?V>?\ @IOXWT_]G?PIJ_\
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M%% !1110 51\3:9-K?AO4-&MG59+NQEAC9R=H9D*@G';FKU% 'Q9_P $U_\
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M<R"4VEC''O AR =H&>: />O^$Q\,?]!J#_OJC_A,?#'_ $&H/^^JN?V=I_\
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M_?5'_"8^&/\ H-0?]]5<_L[3_P#GQA_[]"C^SM/_ .?&'_OT* *?_"8^&/\
MH-0?]]4?\)CX8_Z#4'_?57/[.T__ )\8?^_0H_L[3_\ GQA_[]"@"G_PF/AC
M_H-0?]]4?\)CX8_Z#4'_ 'U5S^SM/_Y\8?\ OT*/[.T__GQA_P"_0H I_P#"
M8^&/^@U!_P!]4?\ "8^&/^@U!_WU5S^SM/\ ^?&'_OT*/[.T_P#Y\8?^_0H
MY^T\2Z"GBV[O7U2(1/:QJDF>"03D5J?\)CX8_P"@U!_WU52SLK,^,[V(VD6T
M6<9"^6, Y-:_]G:?_P ^,/\ WZ% %/\ X3'PQ_T&H/\ OJC_ (3'PQ_T&H/^
M^JN?V=I__/C#_P!^A1_9VG_\^,/_ 'Z% %/_ (3'PQ_T&H/^^J/^$Q\,?]!J
M#_OJKG]G:?\ \^,/_?H4?V=I_P#SXP_]^A0!3_X3'PQ_T&H/^^J/^$Q\,?\
M0:@_[ZK ^)WQB^"GP;LOMOQ)\7:3I9*[H[:4AIY1_L0H"[_@IKSG_A>?QL^+
MO^C_ +.W[/OV*PDX3Q7X]3[);X_OQVZYEE4]0PXXY%>!F'$^3Y?B/JSFZE;_
M )]TTZE3YQBFXK^]+ECW9\OFG&.095BOJDJCJXC_ )\THNK5^<()N*_O3Y8K
MK)'L4WC?PE;0M<7'B"VCC12SN[X"@=22>@KS#QI^W%\&=$U!O#?P_:_\;:UT
M73?"UJ9U4^KS'$:KZD%B.XJC9?L:S>.KE-8_:6^*VJ^,90P<:):?\2_2HSU
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MLM>[>"_VX_@WJ?P9TCXL?$36[+PY<:NLYB\/I?&\NAY=Q)"-J1H';=Y8.=@
MW8SQFO RCQ1X!SRM.GA,=%N$7.3E&=-**:3?-4C&.\DK7OKMN?+Y%XT>&/$=
M>I2P.91;IP=23G&I2BH)QBVY580CO**M>[OHM&>T5#?W]AI5G)J.IWL-M;PH
M6FGGD"(BCN6/ 'N:\4_X7;^TM\8?W/P*^"7_  CVF2?=\3_$!C!E3_%':)F1
MN.58DJ>,@5-8?L:V7C&\CU[]I/XGZWX^O$<.NGW$IL],A;_8M82!QTR3@XY%
M>E_K+B\QTR?"2JI_\O)WI4O5.2<YKLX4Y1?\R/7_ -;\=FONY#@IUT_^7M2]
M"AZJ4XNI-=G3I3B_YT6?$G[:7PY?5I/"GP;T+5OB%K2'!M/"]J9+>(]C+<D>
M6B?[2[@*H?\ "$_MB?&?Y_'WCZP^&VC2?>T?PIBYU)E_NO=M\L;?[47Y5[%X
M;\+^&O!VDQZ#X2\/V6F64(_=6EA:I#&OT50!5^C_ %?S/,M<VQDI1_Y]T;TJ
M?HY)NK+S_>1B^L.@?ZKYQF_O9YCY2B_^75"]"EZ2DI.O/S_>QA+K3L['G/PQ
M_93^"'PJO?[=T7PBNH:RS;Y=?UV4WE[(_P#?\R3.QO\ <"UZ-117OY?EF795
MA_88*C&G#M%)*_=VW;ZMZOJ?3Y7D^59)A?JV7T(4:>]H145?N[+5OJWJ^K"B
MBBNX](**** "BF7-S;65N]W>7"111J6DEE<*J@=22> *\=^*'_!0_P#8;^#7
MF1_$+]JGP5:SPY\VRM-;CO+E/K!;F20?]\UC7Q.'PT>:M-17FTOS/3RS)<XS
MJM['+L-4K3[4X2F_NBFSV6BODD_\%@?@UXUS%^S5^SU\8OBJ7X@O?"/P_N$L
MCZ%Y[GRO+7_:*GZ4?\-%_P#!63XI_+\*_P!@KP?X"MY/^/?4_BAX_6ZW#^\]
MKIZB6/\ W22:\_\ MO 3_@MU/\$927WI./WL^N_XAAQ=A]<PA3PBZ_6:U&A)
M?]PZDXU7Z1@WY'UM39)(X8VFFD5$1269C@ #J2:^2_\ AE[_ (*E?%+Y_B]_
MP4/T3P;:R?Z_1_A=X B.?9+R\;SDQZX/Z5RGQS_X)L?LB_"7X/\ B+X\?MF_
M&CXL_%33?#.E2ZAJ$?CGXB73Q2L@^6&*.W,(4N^U$3)^9E%14S''>S<X89QB
ME=N<HQ5EU]WG?WHZ,)P;PN\53PV(SF-6I.2BH86A5K3<I.RBO:K#4VVW9<M1
MKS/%_P#@MG_P5'O?A+\7?AS\*_V:_'%E>:AX3UN'Q/XHN-.O5EA>2-]L&G2M
M&2,,HE:6,\[7BKZQ\&?\%?\ _@G=XL\)Z7XEO/VF_#VDSZC80W$VEZE+(D]F
M[H&:&0;,!T)*G'&0<'%?SM^+-:M/$?BC4=?T_0;72K>]O99K?2[$$0V<;,2L
M*;B254$*"220,DDY-?IM_P &[WQR^%7BS4O$7['?Q?\ !'A_4[R57UKP;=ZM
MI,$TC@ "[M TBDD ;9E7T\\U^=9'Q9F..S^<.:,56:45)-I-+1*SB]?Q=M#^
MS?%/Z/G!O"OA%A<3["M5J9=&4JLJ4J=.I4C4DG4E/FA535-ZI+X8*7O-+7]"
M_P#AZ/\ \$\?^CP/ _\ X.%H_P"'H_\ P3Q_Z/ \#_\ @X6O1/\ AF7]F[_H
MWSP/_P"$G9__ !NC_AF7]F[_ *-\\#_^$G9__&Z_2.7//YZ?_@,O_DC^*/;^
M%G_/C&_^#J'_ ,H.#@_X*:?\$^KB(31_MB_#\ ]!)XCA4_DQ!%/_ .'EO_!/
MW_H\;X>?^%/;_P#Q5=A<?LF_LL7<IGNOV:/A_([?>>3P;8L3^)BIG_#(O[*'
M_1L/P\_\(JP_^-4<N>?S4_NE_P#)![7PL_Y]8W_P90_^5'+VO_!2']@*\8K#
M^V3\-QM&3YOBZUC_ /0G&:G_ .'B7[!/_1YGPP_\+>Q_^.UN77[&_P"R'>J%
MO?V5OAO,%.5$O@;3VQ^<-0_\,3_L9_\ 1H_PQ_\ ""T[_P",T6SSO3^Z7^8^
M?PL?V,:O^WJ#_P#;$94?_!0[]@N618E_;-^%X+' +>.;%1^),N!5K_AOC]A7
M_H]/X2_^'&TS_P"/U9E_8B_8OGC:&;]D/X7NC##*W@#3B"/0CR:K?\,#_L*_
M]&6?"7_PW.F?_&*?_"Y_T[_\F%?PL?3&KYT'^B#_ (;X_85_Z/3^$O\ X<;3
M/_C]68OVW?V+YXUFA_:\^%[HPRK+X_TX@CU!\ZJW_# _["O_ $99\)?_  W.
MF?\ QBJLG_!/']@N61I6_8R^%X+')"^!K%1^ $6!2_X7/^G?_DP[>%CZXU?*
M@_U1J_\ #;'[&?\ T=Q\,?\ PO=._P#CU36O[9'[(=ZI:R_:I^&\P4X8Q>.=
M/;'Y35A_\.[?V"?^C,_AA_X1%C_\:J"Z_P"";W[ 5XP:;]C;X;C:,#RO"-K'
M_P"@H,T7SSM3^^7^0N3PL?V\:O\ MV@__;T=1_PUU^RA_P!'/?#S_P +6P_^
M.T^W_:R_98NY1!:_M+_#^1V^ZD?C*Q8G\!+7'_\ #M+_ ()^_P#1G/P\_P#"
M8M__ (FF3_\ !,O_ ()]7$1AD_8Z^'X!ZF/PY"I_-0"*?-GG\M/[Y?\ R(_9
M>%G_ #]QO_@NA_\ +3O/^&FOV;O^C@_ _P#X5EG_ /'*/^&FOV;O^C@_ _\
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M5Z/]M>''_0GK?^%B_P#F8CV>,_Y^+_P'_P"V/P4_X.(_^"R_A[]IK]FKPO\
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MOBK3;8@0:=J%U,?+@MV5$2;RQ++-$K1-+^\9Z[?XC?\ !.GXV_";_@HOJO\
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M_G2?NE10;EPGE!$P >:_\$S?$NO^ _\ @MM^T1^SMX-^&FO?#7X=WOPL\/\
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M@&OT\\13>(K?1+F?PEIME>:DL>;.VU&^>V@D?T>5(I60>X1OI7Q#_P $PO\
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M!%W;W>E:1\/?"\MK=^)[VV(:TNM7NI@O$,JI.(+>-0\T<;.Y5"C^W?";X?\
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MFQTF*Q6VM)+B9[61X8D1%FEMVBGD(52TLSL0"QKZAH *^;O&?_!3;X0^$/\
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M&H/^^J -*BLW_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJ@#2HK-_X3'PQ_T&H/\
MOJL+Q5\?_@IX'1F\7?%#1=/91DQ7-\JR'Z)G<?P%88G%87!TG5Q$U"*ZR:2^
M]Z'-B\;@\OH.MBJD:<%O*344OFVD=?17A^H_M]?!JZE:T^&F@^*/&4X.T?\
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M_P %./"WR^-_^"57]HPI_K+[PK\7=-FW?[L$B!S^='_#T'Q[X;&/B=_P3/\
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M9<'\1XK)<?&U7#SE"79V>DE_=DK2B^J:84445UGSX4444 %%%% !17%_%_\
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M_',<LNF>$- N-2GM;<9FNWC0F.VB'.Z6639$B@$L\B@<FO O^"*__!0S7?\
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M-N.>,L]I>RQ^85JD/Y)5)<B790ORI>221#_9VG_\^,/_ 'Z%']G:?_SXP_\
M?H5-17<?*D/]G:?_ ,^,/_?H4?V=I_\ SXP_]^A4U% $/]G:?_SXP_\ ?H4?
MV=I__/C#_P!^A4U% $/]G:?_ ,^,/_?H4?V=I_\ SXP_]^A4U% $/]G:?_SX
MP_\ ?H4?V=I__/C#_P!^A4U% $/]G:?_ ,^,/_?H4?V=I_\ SXP_]^A4U% $
M/]G:?_SXP_\ ?H4?V=I__/C#_P!^A4U% &%XCLK--5TE4M(@&O"& C'(VFM?
M^SM/_P"?&'_OT*S?$O\ R%]'_P"OT_\ H)K8H A_L[3_ /GQA_[]"C^SM/\
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M&5!U&M-?>]M"]WK\*MMJ>+_\-V_![_H5_&O_ (25Q_A1_P -V_![_H5_&O\
MX25Q_A7M%%<?]G<7_P#0PI_^$[_^7'!_97'?_0TI?^$K_P#F@_/G_@H]\=O!
M_P :_P#A#?\ A$]+UJV_LS^T?M']L:1):[O,^S;=F\?-_JSG'3(]:^8:_0?_
M (*._L\?&'X]?\(;_P *G\(?VK_97]H_;_\ B86\'E>;]FV?ZZ1-V?+?IG&.
M<9%?,/\ P[R_;"_Z)!_Y<&G_ /R17\A>*/!_&N-XZQ=:.$JXA/V?[RG0J<DK
M4H+2W.M+<K]YZI[;+^#O&?@+Q#S'Q*QV(C@:^*4O9?O:6&JJG.U&FO=Y?:+W
M;<KM-^\GMLNU_P""</QV\'_!3_A,O^$LTO6KG^T_[.^S_P!CZ1)=;?+^T[M^
MP?+_ *P8SUP?2OI[_ANWX/?]"OXU_P#"2N/\*XK_ ()Q?L\?&'X"_P#"9?\
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MSF)XT$4GC_1$UR:60 8\XZ.Z11^8>I47P0-T&/EH \V_X+8_M/\ C;X,:?\
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M["/[,7Q.L?C'\#?@<VA>(].BFCL]17Q3JMP$26-HI 8Y[IXW!1F'S*<'!&"
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M10 4444 %8_B7_D+Z/\ ]?I_]!-;%8_B7_D+Z/\ ]?I_]!- &Q1110 4444
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M?F'M,7#XH)^C_1V_,^V_^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\ OJOB,K_P7[^
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M"A9:IIUQ#=6=Y!XYUQ9(+B-@Z2*1>\,K $'L17U9_P )CX8_Z#4'_?5?A/\
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M_P"^JN?V=I__ #XP_P#?H4?V=I__ #XP_P#?H4 4_P#A,?#'_0:@_P"^J/\
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M1:5@?NC;U-:G_"8^&/\ H-0?]]54\1V5FFJZ2J6D0#7A# 1CD;36O_9VG_\
M/C#_ -^A0!3_ .$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJKG]G:?_SXP_\ ?H4?
MV=I__/C#_P!^A0!3_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C#_WZ
M%']G:?\ \^,/_?H4 4_^$Q\,?]!J#_OJC_A,?#'_ $&H/^^JN?V=I_\ SXP_
M]^A1_9VG_P#/C#_WZ% %/_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZJY_9VG_\
M/C#_ -^A1_9VG_\ /C#_ -^A0!3_ .$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJK
MG]G:?_SXP_\ ?H4?V=I__/C#_P!^A0!3_P"$Q\,?]!J#_OJC_A,?#'_0:@_[
MZJY_9VG_ //C#_WZ%']G:?\ \^,/_?H4 4_^$Q\,?]!J#_OJC_A,?#'_ $&H
M/^^JN?V=I_\ SXP_]^A1_9VG_P#/C#_WZ% %/_A,?#'_ $&H/^^J/^$Q\,?]
M!J#_ +ZJY_9VG_\ /C#_ -^A1_9VG_\ /C#_ -^A0!3_ .$Q\,?]!J#_ +ZK
M+\)>)=!L=,DAN]4BC8W4K!6/8MP:Z#^SM/\ ^?&'_OT*R/!=E9RZ5(TMI$Q^
MV2C+1@\;J +?_"8^&/\ H-0?]]4?\)CX8_Z#4'_?57/[.T__ )\8?^_0H_L[
M3_\ GQA_[]"@"G_PF/AC_H-0?]]4?\)CX8_Z#4'_ 'U5S^SM/_Y\8?\ OT*/
M[.T__GQA_P"_0H I_P#"8^&/^@U!_P!]4?\ "8^&/^@U!_WU5S^SM/\ ^?&'
M_OT*/[.T_P#Y\8?^_0H I_\ "8^&/^@U!_WU1_PF/AC_ *#4'_?57/[.T_\
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MPY;7!DFEL;*3S%M%R[-^_G6==S-(+<%BE=7_ ,&NW_*"KX&?[OB7_P!2;5:
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M&7@3P/>6EUI]GX'\,36^K>+)[-UDLWU>\GVA4CECBF:.!-T[QJ))&4R+)L?
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M=U=7D$#(ENA=H;5(B5DDWO.X4*0#QC1_^5K'5O\ LQ1?_4MAK-_X)C)\-O\
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M1110 4444 %%%% !1110 4444 %>"_M<_P#)</@9_P!CW+_Z(KWJO!?VN?\
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MXE_Y"^C_ /7Z?_036Q6/XE_Y"^C_ /7Z?_030!L4444 %%%% !1110 4444
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\VI_P4\^!6J?\
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MH_X3'PQ_T&H/^^J -*BLW_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZH TJ*S?\
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M\$?3*MMK7[4E[I$[<>1JGP[UZ-@>X)%B5&.AYZTO^(4^)C5X9-B9?X:-2?\
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M_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G:?\
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M-\8_\BQ>_P#7 T 7-._Y!\'_ %Q7^0J:H=._Y!\'_7%?Y"IJ "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH Q[+_ )'>]_Z\HOYFMBL>R_Y'>]_Z
M\HOYFMB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,?Q+_ ,A?
M1_\ K]/_ *":V*Q_$O\ R%]'_P"OT_\ H)K8H **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ K'\#_\ ((E_Z_9O_0JV*Q_ _P#R")?^OV;_ -"H
M V**** "BBB@ HHHH **** "BBB@ HHHH **** ,[Q-X1\)^---;1O&/AC3M
M6LW^_::G91SQ-]5<$'\J\.^)7_!*'_@FE\6Q(_CC]ACX8332Y\V[L/"-M8W#
M^YFMECD)]]U?05%>KEN>YWDT^;+\54HOO3G*#_\ )6B)TJ53XXI^J/P7_P"#
MBS_@BC\!_P!E3]G7PW^TE^PW\%+W0M$T;7)X/B%I]IK=_?PP0W"QBWO-EU-+
MY")+&T;%-HS<1Y& ,?B_7]P&KZ1I/B#2;K0=>TNWOK&]MW@O+*\@66*>)U*O
M&Z,"&5E)!4@@@D&OCW7?^"%W_!)>T^*NF_$BW_8C\++J$^I&26U%S>?V>QQG
M'V#S_LFW/\'E;>V*_LKPB^EM2X3X7>5<54J^*JTW)TZT9*<Y*3YN6HZLXOW6
MVE).7NVCRKEU^=Q^0NO7YZ#44]UM]UCY1_X-$?V;?B7\,OV9/B5^T)XSTJYL
M='^(^NZ=!X7BNHRGVJ#3TNEDNT!ZQO)=-&&[FW;L!7Z\57TC2-)\/Z3:Z#H.
MEV]C8V5ND%G96<"Q101(H5(T10 JJH "@    58K^5O$;C3$^(?&V-XAKTU3
M>(DFHIWY8QC&$%>RNU",4W97=W97L>Y@\,L)AHT4[V_X<****^).D**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#
M\R/^"<FMZK\3/^#B7]N;QIXJE9[CPGX=\(>&]"BD.?LU@UKYC(F>BO) )2.A
M:0FG_LY^(M0\+?\ !U1^T'\/M"D:/2_%G[-NB:[K\,9PLM_93Z;:6\CCH66"
MXD4$\X8^]>H>)_V=_'/[%W_!6_Q1_P %"O!OP[U_Q/\ #GXV_#ZTT/XF6WA+
M2)=1U'0M>TTQK8ZA]C@#3W%K+:H8&$$<CQR@.PV,2-/]@+]DGXCW?[=GQY_X
M*C_'/P3>>%]5^*RZ9X>^'OA'52GV_2?#.GV\48FNU1F$4UY-$EP8-Q:%50/A
MRR( ?:-%%% '!_$']I[X ?"KQ&WA+XB?%32](U)(4E:SNY&#A&Y5N >#7SS^
MU9^U[^S1J7Q&^%7C?3_C%I$^E^&/%4M]KUW$[L+.W\G'F, NXC/&%!/M7U=J
MW@CP7KUX=0USPAI=[<%0IGN]/CD<@=!N92<5X)^UE\-?ATWQ;^#6CMX!T0VE
M_P"-98;ZU.E0^7<1_9F^21=N'7V.10 __A[=_P $Z/\ HZ31?_ "\_\ C-'_
M  ]N_P""='_1TFB_^ %Y_P#&:]3_ .&7_P!FG_HWCP+_ .$E9_\ QJC_ (9?
M_9I_Z-X\"_\ A)6?_P :H \L_P"'MW_!.C_HZ31?_ "\_P#C-'_#V[_@G1_T
M=)HO_@!>?_&:]3_X9?\ V:?^C>/ O_A)6?\ \:H_X9?_ &:?^C>/ O\ X25G
M_P#&J /+/^'MW_!.C_HZ31?_   O/_C-'_#V[_@G1_T=)HO_ ( 7G_QFO4_^
M&7_V:?\ HWCP+_X25G_\:H_X9?\ V:?^C>/ O_A)6?\ \:H \L_X>W?\$Z/^
MCI-%_P# "\_^,T?\/;O^"='_ $=)HO\ X 7G_P 9KU/_ (9?_9I_Z-X\"_\
MA)6?_P :H_X9?_9I_P"C>/ O_A)6?_QJ@#RS_A[=_P $Z/\ HZ31?_ "\_\
MC-'_  ]N_P""='_1TFB_^ %Y_P#&:]3_ .&7_P!FG_HWCP+_ .$E9_\ QJC_
M (9?_9I_Z-X\"_\ A)6?_P :H \L_P"'MW_!.C_HZ31?_ "\_P#C-'_#V[_@
MG1_T=)HO_@!>?_&:]3_X9?\ V:?^C>/ O_A)6?\ \:H_X9?_ &:?^C>/ O\
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M;QX%_P#"2L__ (U0!Y9_P]N_X)T?]'2:+_X 7G_QFC_A[=_P3H_Z.DT7_P
M+S_XS7J?_#+_ .S3_P!&\>!?_"2L_P#XU1_PR_\ LT_]&\>!?_"2L_\ XU0!
MY9_P]N_X)T?]'2:+_P" %Y_\9H_X>W?\$Z/^CI-%_P# "\_^,UZG_P ,O_LT
M_P#1O'@7_P )*S_^-4?\,O\ [-/_ $;QX%_\)*S_ /C5 'EG_#V[_@G1_P!'
M2:+_ . %Y_\ &:/^'MW_  3H_P"CI-%_\ +S_P",UZG_ ,,O_LT_]&\>!?\
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M4?\ #+_[-/\ T;QX%_\ "2L__C5 'EG_  ]N_P""='_1TFB_^ %Y_P#&:/\
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M%_\ "2L__C5 'EG_  ]N_P""='_1TFB_^ %Y_P#&:/\ A[=_P3H_Z.DT7_P
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M_1TFB_\ @!>?_&:/^'MW_!.C_HZ31?\ P O/_C->I_\ #+_[-/\ T;QX%_\
M"2L__C5'_#+_ .S3_P!&\>!?_"2L_P#XU0!Y9_P]N_X)T?\ 1TFB_P#@!>?_
M !FC_A[=_P $Z/\ HZ31?_ "\_\ C->I_P##+_[-/_1O'@7_ ,)*S_\ C5'_
M  R_^S3_ -&\>!?_  DK/_XU0!Y9_P /;O\ @G1_T=)HO_@!>?\ QFLKPC_P
M5B_X)XV6F217?[3NCQL;J5@K6%YT+<'_ %->T?\ #+_[-/\ T;QX%_\ "2L_
M_C5>*_L(_L__  &\1_![5+[Q#\$O"-_.GC75XDFO?#=K*ZQK<$*@+1DA0. .
M@H U_P#A[=_P3H_Z.DT7_P  +S_XS1_P]N_X)T?]'2:+_P" %Y_\9KU/_AE_
M]FG_ *-X\"_^$E9__&J/^&7_ -FG_HWCP+_X25G_ /&J /+/^'MW_!.C_HZ3
M1?\ P O/_C-'_#V[_@G1_P!'2:+_ . %Y_\ &:]3_P"&7_V:?^C>/ O_ (25
MG_\ &J/^&7_V:?\ HWCP+_X25G_\:H \L_X>W?\ !.C_ *.DT7_P O/_ (S1
M_P /;O\ @G1_T=)HO_@!>?\ QFO4_P#AE_\ 9I_Z-X\"_P#A)6?_ ,:H_P"&
M7_V:?^C>/ O_ (25G_\ &J /+/\ A[=_P3H_Z.DT7_P O/\ XS1_P]N_X)T?
M]'2:+_X 7G_QFO4_^&7_ -FG_HWCP+_X25G_ /&J/^&7_P!FG_HWCP+_ .$E
M9_\ QJ@#RS_A[=_P3H_Z.DT7_P  +S_XS1_P]N_X)T?]'2:+_P" %Y_\9KU/
M_AE_]FG_ *-X\"_^$E9__&J/^&7_ -FG_HWCP+_X25G_ /&J /+/^'MW_!.C
M_HZ31?\ P O/_C-'_#V[_@G1_P!'2:+_ . %Y_\ &:]3_P"&7_V:?^C>/ O_
M (25G_\ &J/^&7_V:?\ HWCP+_X25G_\:H \L_X>W?\ !.C_ *.DT7_P O/_
M (S1_P /;O\ @G1_T=)HO_@!>?\ QFO4_P#AE_\ 9I_Z-X\"_P#A)6?_ ,:H
M_P"&7_V:?^C>/ O_ (25G_\ &J /+/\ A[=_P3H_Z.DT7_P O/\ XS1_P]N_
MX)T?]'2:+_X 7G_QFO4_^&7_ -FG_HWCP+_X25G_ /&J/^&7_P!FG_HWCP+_
M .$E9_\ QJ@#RS_A[=_P3H_Z.DT7_P  +S_XS6KX"_;W_9!^/_CK2/"/P@^.
M>EZWJ7VT 6D,,\;$LI"@>9&H).#P/2N^_P"&7_V:?^C>/ O_ (25G_\ &J\D
M^/WPH^%OPY^.7P6N?A[\-= T&2Z\<.MS)HVC06K3*+9R QB5=P!)QGIF@#Z4
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BO#_VTOVWM%_9"TS1-&T+X)^-_BAXZ\5-<?\
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M &=O%/PH/Q;:2'X;:AXFO[*XCO;U8O/&EWGV:5_L&H/#ET@<NCE'193(OED
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MCXR_\$-_CMKVO0-<Z?X#L;>_TU+/POI#L 5A5I"6O+D(C7%R<$@)"@6.,F0
M\_\ ^"O?P#U+]DS_ ()\_L'?\$YV\0&_T@_'GP/X;\7WT9(BU+[.C"52#_RR
M>=VE5#T\I/[M>N?\'7?B'4/ '_!,WP]\8/#4K0^(/!'QN\,Z[X8NHB1)!?PO
M.(W0CD, S=.:[G]MS]F']J;_ (*L_P#!,G0_%GB+X.VGPQ^-OAGQK:_$#X;>
M"=6U$2G2[_3KJ46EE>W/RJ9;BU9PS*$2.2X0'(B+-4_;9^%GQ+_X+"2_!/\
M9ZF_9\\;^!O OAOXC:=XX^-=]X[T1M/$*V$,OE^'[;S.-0EGFFP]Q;;[9(X2
MPE9F5& /7?\ @MZ _P#P2&_:*W+_ ,TGU8X/;]P:U_V/?"GB'QY_P2$^%O@;
MPCJXT_5M9_9NT.QTN_+%?LUQ-H$,<<N1R-KLK9'/%9__  67T+QQ\0?^":_Q
M=^"OPL^&OB/Q9XK\<>"+[1O#NB^'-'EN7FN9DV R.H\N!!NW%I&4$ @9/%==
M_P $W9=>T7]@CX3>"_&_@/Q#X;UWP?\ #;0]#\1:)X@T6:VN;:]L]-MXIT56
M7$ZAU(62(NC= 200 #X._P"")O\ P4!_9K_9A_X)I0_L%?MM7\G@;XJ?!>WU
MS2/&OPRUK2IVU._L_M5U=+<VEK%&[WD#P38+PAURCL?D96;TC_@U(@\<0?\
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MM]-M%WR-::?!YCB.,;V)>2:0R32R.P!K_MW:KJ/BW_@Y-_8C^#6K.Q\.^&_
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M %4-<\+>'?$TVGS^(-&@O&TK4%OM/^T)N$%RJ.BRJ#QN =L'L3D<@$7Z\?\
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M\2^4<>?86\.HW\*/CJHN8489[CUK[1_:J\>_"[]DS]C3Q'?MX+AN-&T?PO\
MV+X:\&6%IYC:O<RQBTL-'MX1DR27$KPVZ(.ID&>,FOG[X8_LX^.?VE/^"L%W
M_P %2_B1\.=>\->#/AQ\*SX-^$FB>(-,>VU76+F::>>_UA[)QYUJGES-:Q0S
M*DTGS.8T&S?XYJ_[?7[=WB?]IN\^,OQ*_P"")'QY\1Z1X4OYH?A+HT<^FP6^
MEQ-&8I-6GC>5O,U&9&D0-G;;0.T463+/+, ?6/\ P1]_8O\ $/\ P3Y_X)N?
M"O\ 9.\9WT=QKWAS1)KCQ$T,@>./4+VZFOKF%&'#)'+<O$K#[PC#=Z\!_8!
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M6[F3S&GE"P?NX8(E6)1DNTC2MR@CPWT50 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?P;J_B%]3\#Z$=+CU&.'3S)-=WTJO-!"I.UY)%1Y9,D[1*W4 ^WJ*_._QO\
M\%\=3\#_ +)/@;]OJ]_X)Z_$2;X*ZWIVDW7C;QZ-;L(E\.?;I(H@(+25ENM1
M2.69(VF6**)F($;N.1]/_M6?MT_#S]FB^^&O@?3M%F\5>-?C)XD71?AKX9L;
MM(%U&3RA--=33L"(+2"$B264+(X#*$CD9@M 'N-%?']E_P %6]<\/_MYP?\
M!-[XH_L6>-U^(]YH]MKUGJ'@C7-+U/0GT":X6V;5#<WT]A<>7#*766)+5Y5\
MERBR  G[ H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140624938160864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 01, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">76-0474169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2445 Technology Forest Blvd., 11th Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(281)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">863-3000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">The Woodlands,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">77381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 134,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Certain sections of the registrant&#8217;s definitive proxy statement relating to the registrant&#8217;s 2023 annual meeting of stockholders, which proxy statement will be filed under the Securities Exchange Act of 1934 within 120 days of the end of the registrant&#8217;s fiscal year ended December&#160;31, 2022, are incorporated by reference into Part III of this annual report on Form 10-K.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Lexicon Pharmaceuticals, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001062822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LXRX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">188,725,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Houston, Texas<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">The Woodlands,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">188,725,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140624941670336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Assets, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 46,345<span></span>
</td>
<td class="nump">$ 64,065<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">92,012<span></span>
</td>
<td class="nump">22,678<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of allowances of $4</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,481<span></span>
</td>
<td class="nump">2,164<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">140,866<span></span>
</td>
<td class="nump">88,921<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation and amortization of $61,741 and $60,006, respectively</a></td>
<td class="nump">2,071<span></span>
</td>
<td class="nump">1,176<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">44,543<span></span>
</td>
<td class="nump">44,543<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Operating lease right-of-use-assets</a></td>
<td class="nump">6,819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">194,299<span></span>
</td>
<td class="nump">136,909<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">10,395<span></span>
</td>
<td class="nump">9,152<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">12,777<span></span>
</td>
<td class="nump">12,972<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">23,172<span></span>
</td>
<td class="nump">22,124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">5,424<span></span>
</td>
<td class="nump">1,190<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">77,175<span></span>
</td>
<td class="nump">23,314<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Stockholders' Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $.01 par value; 5,000 shares authorized; no shares issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $.001 par value; 225,000 shares authorized; 106,679 and 106,162 shares issued, respectively</a></td>
<td class="nump">189<span></span>
</td>
<td class="nump">150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,709,144<span></span>
</td>
<td class="nump">1,608,749<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,589,720)<span></span>
</td>
<td class="num">(1,487,776)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(428)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost, 407 and 236 shares, respectively</a></td>
<td class="num">(2,061)<span></span>
</td>
<td class="num">(7,518)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">117,124<span></span>
</td>
<td class="nump">113,595<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 194,299<span></span>
</td>
<td class="nump">$ 136,909<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value per share (usd per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share (usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140624937339136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Parentheticals - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization, property and equipment</a></td>
<td class="nump">$ 3,984<span></span>
</td>
<td class="nump">$ 4,853<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value per share (usd per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share (usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock, shares</a></td>
<td class="nump">488<span></span>
</td>
<td class="nump">1,165<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">189,214<span></span>
</td>
<td class="nump">150,082<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140624938293472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 23,404,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Collaborative agreements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">33,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyIncomeNonoperating', window );">Royalties and other revenue</a></td>
<td class="nump">139,000<span></span>
</td>
<td class="nump">298,000<span></span>
</td>
<td class="nump">558,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">139,000<span></span>
</td>
<td class="nump">298,000<span></span>
</td>
<td class="nump">23,995,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales (including finite-lived intangible asset amortization)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,929,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development, including stock-based compensation of $4,253, $4,284 and $6,376 respectively</a></td>
<td class="nump">52,816,000<span></span>
</td>
<td class="nump">55,046,000<span></span>
</td>
<td class="nump">153,621,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Selling, general and administrative, including stock-based compensation of $7,267, $6,293 and $6,898, respectively</a></td>
<td class="nump">48,083,000<span></span>
</td>
<td class="nump">32,342,000<span></span>
</td>
<td class="nump">47,230,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">100,899,000<span></span>
</td>
<td class="nump">87,388,000<span></span>
</td>
<td class="nump">204,380,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_GainOnSaleOfNonFinancialAssets', window );">Gain on sale of non-financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">132,585,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="num">(100,760,000)<span></span>
</td>
<td class="num">(87,090,000)<span></span>
</td>
<td class="num">(47,800,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Recognition of gain or loss on extinguishment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,003,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(2,780,000)<span></span>
</td>
<td class="num">(802,000)<span></span>
</td>
<td class="num">(14,544,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Interest and other income, net</a></td>
<td class="nump">1,596,000<span></span>
</td>
<td class="nump">134,000<span></span>
</td>
<td class="nump">2,767,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(101,944,000)<span></span>
</td>
<td class="num">(87,758,000)<span></span>
</td>
<td class="num">(58,574,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on investments</a></td>
<td class="num">(418,000)<span></span>
</td>
<td class="num">(4,000)<span></span>
</td>
<td class="num">(90,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (102,362,000)<span></span>
</td>
<td class="num">$ (87,762,000)<span></span>
</td>
<td class="num">$ (58,664,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings Per Share, Basic</a></td>
<td class="num">$ (0.62)<span></span>
</td>
<td class="num">$ (0.60)<span></span>
</td>
<td class="num">$ (0.53)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic', window );">Weighted Average Number of Shares Issued, Basic</a></td>
<td class="nump">165,733<span></span>
</td>
<td class="nump">145,652<span></span>
</td>
<td class="nump">110,841<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_GainOnSaleOfNonFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain on sale of non-financial assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_GainOnSaleOfNonFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyIncomeNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ancillary revenue earned during the period from the consideration paid to the entity for the use of its rights and property by another party. Examples include licensing the use of copyrighted materials and leasing the extraction of natural resources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyIncomeNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e2646-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesIssuedBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140624942931296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Comprehensive Loss Parentheticals (Parentheticals) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense', window );">Stock-based compensation expense associated with research and development expense</a></td>
<td class="nump">$ 4,253<span></span>
</td>
<td class="nump">$ 4,284<span></span>
</td>
<td class="nump">$ 6,376<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense', window );">Stock-based compensation expense associated with general and administrative expense</a></td>
<td class="nump">$ 7,267<span></span>
</td>
<td class="nump">$ 6,293<span></span>
</td>
<td class="nump">$ 6,898<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock-based compensation expense associated with general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock-based compensation expense included in research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140624936478144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Gain (Loss)</div></th>
<th class="th"><div>Treasury Stock</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,679,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, value at Dec. 31, 2019</a></td>
<td class="nump">$ 117,101,000<span></span>
</td>
<td class="nump">$ 106,000<span></span>
</td>
<td class="nump">$ 1,462,172,000<span></span>
</td>
<td class="num">$ (1,341,444,000)<span></span>
</td>
<td class="nump">$ 84,000<span></span>
</td>
<td class="num">$ (3,817,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">13,274,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,274,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="nump">6,963,000<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="nump">6,959,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,709,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Issuance of Stock and Warrants for Services or Claims</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Sale of Stock, Consideration Received Per Transaction</a></td>
<td class="nump">63,007,000<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">62,987,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,369,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Issuance of common stock under Equity Incentive Plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,219,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under Equity Incentive Plans, value</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="num">(1,026,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,026,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(58,574,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(58,574,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on investments</a></td>
<td class="num">(90,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(90,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,289,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, value at Dec. 31, 2020</a></td>
<td class="nump">$ 156,371,000<span></span>
</td>
<td class="nump">$ 142,000<span></span>
</td>
<td class="nump">1,561,096,000<span></span>
</td>
<td class="num">(1,400,018,000)<span></span>
</td>
<td class="num">(6,000)<span></span>
</td>
<td class="num">(4,843,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of Stock, Number of Shares Issued in Transaction</a></td>
<td class="nump">20,312,500<span></span>
</td>
<td class="nump">20,313,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountIssued1', window );">Conversion of Stock, Amount Issued</a></td>
<td class="nump">$ 15,714,000<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">15,704,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_SharePriceInNovember20ATMOffering', window );">Share price in November 20 ATM Offering</a></td>
<td class="nump">1.992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_ProceedsFromNov2020ATMOffering', window );">Proceeds from Nov 2020 ATM Offering</a></td>
<td class="nump">7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_CommissionsFromDecember2020CommonStockOffering', window );">Commissions from December 2020 Common Stock Offering</a></td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_OfferingExpensesFromDecember20CommonStockOffering', window );">Offering expenses from December 20 common stock offering</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of Treasury Stock</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="nump">$ 3.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_ProceedsFromDecember2020CommonStockOffering', window );">Proceeds from December 2020 common stock offering</a></td>
<td class="nump">$ 63,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">10,577,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,577,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="nump">35,491,000<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="nump">35,485,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,177,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Issuance of Stock and Warrants for Services or Claims</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Issuance of common stock under Equity Incentive Plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,616,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under Equity Incentive Plans, value</a></td>
<td class="nump">1,593,000<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">1,591,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="num">(2,675,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,675,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(87,758,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(87,758,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on investments</a></td>
<td class="num">(4,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,082,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, value at Dec. 31, 2021</a></td>
<td class="nump">$ 113,595,000<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="nump">1,608,749,000<span></span>
</td>
<td class="num">(1,487,776,000)<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
<td class="num">(7,518,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_SharesSoldInJanuary2021ATMOffering', window );">Shares sold in January 2021 ATM offering</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_ProceedsFromJanuary2021ATMOffering', window );">Proceeds from January 2021 ATM Offering</a></td>
<td class="nump">$ 16,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of Treasury Stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">11,520,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,520,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="nump">94,205,000<span></span>
</td>
<td class="nump">$ 39,000<span></span>
</td>
<td class="nump">94,166,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Issuance of Stock and Warrants for Services or Claims</a></td>
<td class="nump">1,030,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,030,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Issuance of common stock under Equity Incentive Plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under Equity Incentive Plans, value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="num">(864,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(864,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(101,944,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(101,944,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on investments</a></td>
<td class="num">(418,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(418,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">189,214,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, value at Dec. 31, 2022</a></td>
<td class="nump">117,124,000<span></span>
</td>
<td class="nump">$ 189,000<span></span>
</td>
<td class="nump">1,709,144,000<span></span>
</td>
<td class="num">(1,589,720,000)<span></span>
</td>
<td class="num">(428,000)<span></span>
</td>
<td class="num">(2,061,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Stock Issued During Period, Shares, Treasury Stock Reissued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of Treasury Stock</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (6,321,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (6,321,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_CommissionsFromDecember2020CommonStockOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commissions from December 2020 Common Stock Offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_CommissionsFromDecember2020CommonStockOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_OfferingExpensesFromDecember20CommonStockOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Offering expenses from December 20 common stock offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_OfferingExpensesFromDecember20CommonStockOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ProceedsFromDecember2020CommonStockOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from December 2020 common stock offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ProceedsFromDecember2020CommonStockOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ProceedsFromJanuary2021ATMOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from January 2021 ATM Offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ProceedsFromJanuary2021ATMOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ProceedsFromNov2020ATMOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Nov 2020 ATM Offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ProceedsFromNov2020ATMOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SharePriceInNovember20ATMOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share price in November 20 ATM Offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SharePriceInNovember20ATMOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SharesSoldInJanuary2021ATMOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares sold in January 2021 ATM offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SharesSoldInJanuary2021ATMOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedPerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140624936491280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (101,944,000)<span></span>
</td>
<td class="num">$ (87,758,000)<span></span>
</td>
<td class="num">$ (58,574,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile consolidated net loss to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">427,000<span></span>
</td>
<td class="nump">292,000<span></span>
</td>
<td class="nump">2,934,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">11,520,000<span></span>
</td>
<td class="nump">10,577,000<span></span>
</td>
<td class="nump">13,274,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Loss on disposal of property and equipment</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">49,000<span></span>
</td>
<td class="num">(707,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred tax benefit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">(Increase) decrease in accounts receivable</a></td>
<td class="num">(14,000)<span></span>
</td>
<td class="nump">381,000<span></span>
</td>
<td class="nump">53,227,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Increase in inventories</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">345,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">(Increase) decrease in prepaid expenses and other current assets</a></td>
<td class="num">(316,000)<span></span>
</td>
<td class="nump">2,885,000<span></span>
</td>
<td class="num">(1,948,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">(Increase) decrease in other assets</a></td>
<td class="nump">656,000<span></span>
</td>
<td class="nump">661,000<span></span>
</td>
<td class="nump">424,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Increase (decrease) in accounts payable and other liabilities</a></td>
<td class="nump">76,000<span></span>
</td>
<td class="num">(14,158,000)<span></span>
</td>
<td class="num">(20,969,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(88,851,000)<span></span>
</td>
<td class="num">(87,017,000)<span></span>
</td>
<td class="num">(142,969,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(1,326,000)<span></span>
</td>
<td class="num">(1,221,000)<span></span>
</td>
<td class="num">(87,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Proceeds from Sale of Productive Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">160,385,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from Sale of Property, Plant, and Equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(133,949,000)<span></span>
</td>
<td class="num">(34,261,000)<span></span>
</td>
<td class="num">(58,555,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Maturities of investments</a></td>
<td class="nump">64,197,000<span></span>
</td>
<td class="nump">37,592,000<span></span>
</td>
<td class="nump">268,000,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="num">(71,078,000)<span></span>
</td>
<td class="nump">2,110,000<span></span>
</td>
<td class="nump">380,756,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of fees</a></td>
<td class="nump">94,205,000<span></span>
</td>
<td class="nump">37,084,000<span></span>
</td>
<td class="nump">69,970,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common stock</a></td>
<td class="num">(864,000)<span></span>
</td>
<td class="num">(2,675,000)<span></span>
</td>
<td class="num">(1,026,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of debt borrowings</a></td>
<td class="nump">48,868,000<span></span>
</td>
<td class="num">(11,700,000)<span></span>
</td>
<td class="num">(216,580,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">142,209,000<span></span>
</td>
<td class="nump">22,709,000<span></span>
</td>
<td class="num">(147,636,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(17,720,000)<span></span>
</td>
<td class="num">(62,198,000)<span></span>
</td>
<td class="nump">90,151,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of year</a></td>
<td class="nump">64,065,000<span></span>
</td>
<td class="nump">126,263,000<span></span>
</td>
<td class="nump">36,112,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of year</a></td>
<td class="nump">46,345,000<span></span>
</td>
<td class="nump">64,065,000<span></span>
</td>
<td class="nump">126,263,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">2,289,000<span></span>
</td>
<td class="nump">799,000<span></span>
</td>
<td class="nump">17,353,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of noncash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Common stock, $.001 par value; 225,000 shares authorized; 106,679 and 106,162 shares issued, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">15,714,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,437,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">741,000<span></span>
</td>
<td class="nump">54,000<span></span>
</td>
<td class="nump">1,013,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_GainOnSaleOfNonFinancialAssets', window );">Gain on sale of non-financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(132,585,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfRealEstate', window );">Impairment of Real Estate</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of Intangible Assets (Excluding Goodwill)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Recognition of gain or loss on extinguishment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,003,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfBuildings', window );">Proceeds from Sale of Buildings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,013,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">6,800,000<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</a></td>
<td class="nump">5,206,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Issuance of Stock and Warrants for Services or Claims</a></td>
<td class="nump">1,030,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCarryingBasis', window );">Unearned ESOP Shares</a></td>
<td class="nump">6,321,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Stock Issued During Period, Value, Treasury Stock Reissued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessExitCosts1', window );">Business Exit Costs</a></td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtGainLossNetOfTax', window );">Extinguishment of Debt, Gain (Loss), Net of Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,003,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,704,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_GainOnSaleOfNonFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain on sale of non-financial assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_GainOnSaleOfNonFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessExitCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessExitCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtGainLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the reacquisition price and the net carrying amount of the extinguished debt recognized currently as a component of income in the period of extinguishment, net of tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtGainLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2443-110228<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfRealEstate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings in the period to reduce the carrying amount of real property to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfRealEstate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfBuildings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sale of buildings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfBuildings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCarryingBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost basis for treasury stock acquired for purposes other than retirement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCarryingBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140624938052064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_OrganizationAndOperationsAbstract', window );"><strong>Organization and Operations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Operations</a></td>
<td class="text">Organization and Operations<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lexicon Pharmaceuticals, Inc. (&#8220;Lexicon&#8221; or the &#8220;Company&#8221;) is a Delaware corporation incorporated on July&#160;7, 1995. Lexicon was organized to discover the functions and pharmaceutical utility of genes and use those gene function discoveries in the discovery and development of pharmaceutical products for the treatment of human disease.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lexicon has financed its operations from inception primarily through sales of common and preferred stock, contract and milestone payments to it under strategic collaborations and other research and development collaborations, target validation, database subscription and technology license agreements, product sales, government grants and contracts and financing under debt and lease arrangements. The Company&#8217;s future success is dependent upon many factors, including, but not limited to, the success of its commercialization efforts for any approved products; ongoing nonclinical and clinical development efforts and its ability to obtain necessary regulatory approvals of the drug candidates which are the subject of such efforts; its success in establishing new collaborations and licenses and its receipt of milestones, royalties and other payments under such arrangements; the amount and timing of research, development and commercialization expenditures; its resources devoted to developing and supporting its products; general and industry-specific economic conditions which may affect research, development and commercialization expenditures; and its ability to obtain and enforce patents and other proprietary rights in its discoveries, comply with federal and state regulations, and maintain sufficient capital to fund its activities.&#160;&#160;As a result of the aforementioned factors and the related uncertainties, there can be no assurance of the Company&#8217;s future success.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_OrganizationAndOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Organization and Operations [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_OrganizationAndOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140624939258992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Basis of Presentation:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> The accompanying consolidated financial statements include the accounts of Lexicon and its wholly-owned subsidiaries.  Intercompany transactions and balances are eliminated in consolidation.    </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The preparation of financial statements in conformity with U. S. generally accepted accounting principles (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash, Cash Equivalents and Short-Term Investments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lexicon considers all highly-liquid investments with original maturities of three months or less to be cash equivalents.&#160;&#160;As of December&#160;31, 2022 and 2021, short-term investments consist of U.S. treasury bills and corporate debt securities.  The Company&#8217;s short-term investments are classified as available-for-sale securities and are carried at fair value, based on quoted market prices of the securities.&#160;&#160;The Company views its available-for-sale securities as available for use in current operations regardless of the stated maturity date of the security.&#160; The Company does not intend to sell any of its available-for-sale securities prior to their maturity dates. Unrealized gains and losses on such securities are reported as a separate component of stockholders&#8217; equity.&#160;&#160;Net realized gains and losses, interest and dividends are included in interest income.&#160;&#160;The cost of securities sold is based on the specific identification method.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivable:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;Lexicon records trade accounts receivable in the normal course of business related to the sale of products or services, net of an allowance for expected credit losses.&#160;&#160;&#160;</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration of Credit Risk:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lexicon&#8217;s cash equivalents, investments and accounts receivable represent potential concentrations of credit risk. The Company attempts to minimize potential concentrations of risk in cash equivalents and investments by placing investments in high-quality financial instruments. The Company has not experienced any realized losses on its cash equivalents or short-term investments.  The Company&#8217;s accounts receivable are unsecured and are concentrated in pharmaceutical and biotechnology companies located in the United States.&#160;&#160;The Company has not experienced any significant credit losses to date.  In 2022, one customer in the United States represented 100% of revenue.&#160;&#160; In 2021, customers in Switzerland and the United States represented 76% and 24% of revenue, respectively.&#160;In 2020, customers in the United States represented 98% of revenue.&#160;At December&#160;31, 2022, management believes that the Company has no significant concentrations of credit risk.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Information and Significant Customers:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lexicon operates in one business segment, which primarily focuses on the discovery, development and commercialization of pharmaceutical products for the treatment of human disease. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of the Company&#8217;s revenues have been derived from drug discovery alliances, target validation collaborations for the development and, in some cases, analysis of the physiological effects of genes altered in knockout mice, technology licenses, subscriptions to its databases, product sales, government grants and contracts and compound library sales.  In 2022, one customer represented 100% of revenue.  In 2021, one customer represented 76% of revenues and another customer represented 24% of revenues, respectively.  In 2020, two customers represented 65% and 22% of revenues, respectively.   </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property and Equipment:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Property and equipment that is held and used is carried at cost and depreciated using the straight-line method over the estimated useful life of the assets which ranges from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzM5MTE_558fa410-9f8f-4ae0-80f8-17c88e115072">three</span> to 40 years.&#160;&#160;Maintenance, repairs and minor replacements are charged to expense as incurred.&#160;&#160;Leasehold improvements are amortized over the shorter of the estimated useful life or the remaining lease term.&#160;&#160;Significant renewals and betterments are capitalized.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued liabilities: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Accrued liabilities consisted of the following:</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.163%"><tr><td style="width:1.0%"/><td style="width:52.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.689%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.757%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.788%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,669&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short term lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,089&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,503&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,777&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,972&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impairment of Long-Lived Assets:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;Long-lived assets and right-of-use assets for leases are reviewed for impairment when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable.  Recoverability of assets to be held and used is measured by comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount that the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. In 2020, the Company recognized an impairment loss of $1.6 million to reduce the carrying value of the assets comprising our campus in The Woodlands, Texas, which were sold in December 2020, to an estimated fair value, less estimated selling costs.  There were no impairments of long-lived assets, in 2022 or 2021.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill Impairment:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;Goodwill is not amortized, but is tested at least annually for impairment at the reporting unit level.&#160;&#160;The Company has determined that the reporting unit is the single operating segment disclosed in its current financial statements. Impairment is the condition that exists when the carrying amount of goodwill exceeds its implied fair value.&#160;&#160;The first step in the impairment process is to determine the fair value of the reporting unit and then compare it to the carrying value, including goodwill.&#160;&#160;If the fair value exceeds the carrying value, no further action is required and no impairment loss is recognized.&#160;&#160;Additional impairment assessments may be performed on an interim basis if the Company encounters events or changes in circumstances that would indicate that, more likely than not, the carrying value of goodwill has been impaired.&#160;&#160;There was no impairment of goodwill in 2022, 2021 or 2020.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lexicon determines if a contract is or contains a lease at inception or upon modification of the contract. A contract is or contains a lease if it conveys the right to control the use of an identified asset for a period in exchange for consideration. Control over the use of the identified asset means the lessee has both (a) the right to obtain substantially all of the economic benefits from the use of the asset and (b) the right to direct the use of the asset. Lexicon does not apply this accounting to those leases with terms of twelve (12) months or less. Operating lease right-of-use assets and associated lease liabilities are recorded in the balance sheet at the lease commencement date based on the present value of future lease payments to be made over the expected lease term. As the implicit rate is not determinable in its leases, Lexicon used a borrowing rate ranging between 9% and 9.7% at the commencement date in determining the present value of future payments.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Product Revenues</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Company&#8217;s sale of XERMELO and related assets to TerSera Therapeutics, LLC (&#8220;TerSera&#8221;) in September 2020, product revenues consisted of commercial sales of XERMELO in the United States and sales of bulk tablets of XERMELO to Ipsen.  Product revenues were recognized when the customer obtained control of the Company&#8217;s product, which occured upon delivery to the customer.  The Company recognized product revenue net of applicable reserves for variable consideration, including allowances for customer credits, estimated rebates, chargebacks, discounts, returns, distribution service fees, and government rebates, such as Medicare Part D coverage gap reimbursements in the United States, as discussed below.  These estimates were based on the most likely amount method for relevant factors such as current contractual and statutory requirements, industry data and forecasted customer buying and payment patterns. Product shipping and handling costs were considered a fulfillment activity when control transfers to the Company&#8217;s customers and such costs were included in cost of sales.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer Credits:  The Company&#8217;s customers were offered various forms of consideration, including allowances, service fees and prompt payment discounts.  The Company expected that its customers would earn prompt payment discounts.  As a result, the Company deducted the full amount of those discounts from total product sales when revenues were recognized.  Service fees were also deducted from product sales as they were earned.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rebates:  Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program.  Rebate amounts are based upon contractual agreements or legal requirements with public sector (e.g., Medicaid) benefit providers.  Rebates are amounts owed after the final dispensing of the product to a benefit plan participant and are based upon contractual agreements or legal requirements with public sector benefit providers.  The allowance for rebates is based on statutory discount rates and expected utilization.  The Company&#8217;s estimates for expected utilization of rebates were based on third party market research data and data received from the specialty pharmacies dispensing XERMELO.  Rebates were generally invoiced and paid in arrears so that the accrual balance consisted of an estimate of the amount expected to be incurred for the current quarter&#8217;s activity, plus an accrual balance for known unpaid rebates from the prior quarter.  If actual future rebates varied from estimates, the Company adjusted prior period accruals, which affected revenue in the period of adjustment.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks:  Chargebacks are discounts that occur when contracted customers purchase directly from a specialty pharmacy or distributor, who acts as a retailer.  Contracted customers, which consisted primarily of Public Health Service Institutions, non-profit clinics, and federal government entities purchasing via the Federal Supply Schedule, generally purchased XERMELO at a discounted price.  The specialty pharmacy or distributor, in turn, charged back to Lexicon the difference between the price paid by the specialty pharmacy or distributor and the discounted price paid to the specialty pharmacy or distributor by the customer.  The allowance for chargeback was based on known sales to contracted customers.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare Part D Coverage Gap:  The Medicare Part D prescription drug benefit mandates manufacturers to fund a portion of the Medicare Part D insurance coverage gap for prescription drugs sold to eligible patients.  The Company&#8217;s estimates for the expected Medicare Part D coverage gap were based on data received from the specialty pharmacies dispensing XERMELO and projections based on historical data.  Funding of the coverage gap was generally invoiced and paid in arrears so that the accrual balance consisted of an estimate of the amount expected to be incurred for the current quarter&#8217;s activity, plus an accrual balance for known prior quarters.  If actual future funding varied from estimates, the Company adjusted prior period accruals, which affected revenues in the period of adjustment.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Co-payment assistance:  Patients with commercial insurance who met certain eligibility requirements were eligible to receive co-payment assistance.  The Company accrued a liability for co-payment assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Collaborative Agreements</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under collaborative agreements include both license revenue and contract research revenue.  The Company performs the following five steps in determining the amount of revenue to recognize as it fulfills its performance obligations under each of its collaborative agreements:  (i) identify the contract(s) with a customer; (ii) identify the performance obligation in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligation.  The Company applies this five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.  At contract inception, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">service is distinct.  The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.  The Company develops assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, the Company evaluates whether development milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method.  If it is probable that a significant revenue reversal will not occur, the associated development milestone value is included in the transaction price.  Development milestones that are not within the control of the Company or the licensee, including those requiring regulatory approval, are not considered probable of being achieved until those approvals are received.  The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue when (or as) the performance obligation is satisfied.  At the end of each reporting period, the Company re-evaluates the probability of achievement of the development milestones and any related constraint, and if necessary, adjusts its estimates of the overall transaction price.  Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues in the period of adjustment.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In agreements in which a license to the Company&#8217;s intellectual property is determined distinct from other performance obligations identified in the agreement, the Company recognizes revenue when the license is transferred to the licensee and the licensee is able to use and benefit from the license.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For agreements that include sales-based royalties, including milestones based on a level of sales, the license is deemed to be the predominant item to which the royalties relate and the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may receive payments from its licensees based on billing schedules established in each contract.  Upfront payments and fees are recorded as deferred revenue upon receipt or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under these agreements.  Amounts are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Sales: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Cost of sales consisted of third-party manufacturing costs, freight and indirect overhead costs associated with sales of XERMELO.  Product shipping and handling costs were included in cost of sales. Cost of sales also included the amortization of the intangible asset for XERMELO using the straight-line method over the estimated useful life of 14 years. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Research and development expenses consist of costs incurred for company-sponsored as well as collaborative research and development activities. These costs include direct and research-related overhead expenses and are expensed as incurred.&#160;&#160;Technology license fees for technologies that are utilized in research and development and have no alternative future use are expensed when incurred.  Substantial portions of the Company&#8217;s preclinical and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors.  For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining.  For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study.  The Company monitors patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to the Company by the vendors and clinical site visits.  The Company&#8217;s estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each program and total program spending.  The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives. </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;The Company recognizes compensation expense in its statements of comprehensive loss for share-based payments, including stock options and restricted stock units issued to employees, based on their fair values on the date of the grant, with the compensation expense recognized over the period in which an employee is required to provide service in exchange for the stock award.&#160;&#160;Stock-based compensation expense for awards without performance conditions is recognized based on the terms of vesting, which is typically on a straight-line basis.  Stock-based compensation expense for awards with performance conditions is recognized over the period from the date the performance condition is determined to be probable of occurring through the time the applicable condition is met.&#160;&#160;As of December&#160;31, 2022, future stock-based compensation cost for all outstanding unvested stock options and restricted stock units was $21.0 million, which is expected to be recognized over a weighted-average period of 1.3&#160;years.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options is estimated at the date of grant using the Black-Scholes method.&#160;&#160;The Black-Scholes option-pricing model requires the input of subjective assumptions.&#160;&#160;Because the Company&#8217;s employee stock options have </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&#8217;s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options.&#160;&#160;For purposes of determining the fair value of stock options, the Company segregates its options into two homogeneous groups, based on exercise and post-vesting employment termination behaviors, resulting in different assumptions used for expected option lives.&#160;&#160;Historical data is used to estimate the expected option life for each group.  Expected volatility is based on the historical volatility in the Company&#8217;s stock price.&#160;&#160;The following weighted-average assumptions were used for stock options granted in the years ended December&#160;31, 2022, 2021 and 2020, respectively:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expected Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Risk-free Interest Rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expected Term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Dividend<br/>Rate</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Officers and non-employee directors</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Officers and non-employee directors</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Officers and non-employee directors</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been recognized differently in the financial statements and tax returns. The Company uses the liability method in accounting for income taxes. Under this method, deferred tax liabilities and assets are determined based on the difference between the financial statement carrying amounts and tax bases of liabilities and assets using enacted tax rates and laws in effect in the years in which the differences are expected to reverse. Deferred tax assets are evaluated for realization based on a more-likely-than-not criteria in determining if a valuation allowance should be provided.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a valuation allowance on net operating losses and other deferred tax assets. Accordingly, the Company has not reported any tax benefit relating to the remaining net operating loss carryforwards and income tax credit carryforwards that are available for utilization in future periods. On a periodic basis, the valuation allowance is reassessed on deferred income tax assets, weighing positive and negative evidence to assess the recoverability of the deferred tax assets. In 2022, the Company reassessed the valuation allowance and considered negative evidence, including the cumulative losses over the three years ended December&#160;31, 2022 and positive evidence including the projections of future income. After assessing both the negative and the positive evidence, the Company concluded that it should continue to maintain the valuation allowance on net operating losses and other deferred tax assets as of December&#160;31, 2022 given the significance of the weight of the negative evidence. Based on recent financial performance and future projections, the Company could record a reversal of all, or a portion of the valuation allowance associated with U.S. deferred tax assets in future periods. However, any such change is subject to actual performance and other considerations that may present positive or negative evidence at the time of the assessment. The total gross deferred tax asset balance subject to the valuation allowance assessment was approximately $347.1&#160;million at December&#160;31, 2022. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant judgment is required in making these assessments to maintain or reverse valuation allowances and, to the extent future expectations change the Company would have to assess the recoverability of these deferred tax assets at that time. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Loss per Common Share:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Net loss per common share is computed using the weighted average number of shares of common stock outstanding. Shares associated with warrants, stock options and restricted stock units that could potentially dilute earnings per share in the future are not included in the computation of diluted earnings per share because they are antidilutive.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140624943694928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recent Accounting Pronouncements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_RecentAccountingPronouncementsAbstract', window );"><strong>Recent Accounting Pronouncements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">New Accounting Pronouncements and Changes in Accounting Principles [Text Block]</a></td>
<td class="text">Recent Accounting Pronouncements<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity (Subtopic 815-40), which removes the separation models for convertible debt with cash conversion or beneficial conversion features. ASU 2020-06 also requires the application of the if-converted method for calculating earnings per diluted share, as the treasury stock method will no longer be permitted for convertible instruments. The adoption of ASU 2020-06 during the first quarter of 2022 did not have a material impact on the consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_RecentAccountingPronouncementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recent Accounting Pronouncements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_RecentAccountingPronouncementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI https://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=d3e31137-122693<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL122150809-237846<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=SL108384541-122693<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140624939198160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash Equivalents and Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract', window );"><strong>Cash and Cash Equivalents and Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock', window );">Cash and Cash Equivalents and Investments</a></td>
<td class="text">Cash, Cash Equivalents and Investments<div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of cash and cash equivalents and investments held at December&#160;31, 2022 and 2021 are as follows:</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"/><td style="width:42.727%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.485%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities maturing within one year:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,022&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(342)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,418&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,332&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,440&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(428)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,012&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,785&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(428)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,357&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"/><td style="width:42.881%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.331%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities maturing within one year:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,012&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,018&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,012&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,084&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,077&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>There were no realized gains or losses for the years ended December&#160;31, 2022, 2021, and 2020.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash and Cash Equivalents and Investments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_CashAndCashEquivalentsAndInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140624939872992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_FairValueMeasurementsAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis.&#160;&#160;Assets and liabilities recorded at fair value in the consolidated balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value.&#160;&#160;The following levels are directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 &#8211; quoted prices in active markets for identical assets, which include U.S. treasury securities</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 &#8211; other significant observable inputs (including quoted prices for similar investments, market corroborated inputs, etc.), which include corporate debt securities</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 &#8211; significant unobservable inputs </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;The inputs or methodology used for valuing securities are not necessarily an indication of the credit risk associated with investing in those securities.&#160;&#160;The following tables provide the fair value measurements of applicable Company assets and liabilities that are measured at fair value on a recurring basis according to the fair value levels defined above as of December&#160;31, 2022 and 2021.</span></div>&#160;<div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.988%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets and Liabilities at Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,680&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,332&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,012&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,025&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,332&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,357&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.988%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets and Liabilities at Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,561&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,678&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,626&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,117&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,743&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have any Level 3 assets or liabilities at December&#160;31, 2022 or 2021. Transfers between levels are recognized at the actual date of circumstance that caused the transfer.  There were no transfers between Level 1 and Level 2 during the periods presented.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 9, Debt Obligations, for fair value measurements of debt obligations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_FairValueMeasurementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Measurements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_FairValueMeasurementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140625031261360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_PropertyAndEquipmentAbstract', window );"><strong>Property and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">Property and Equipment<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment at December&#160;31, 2022 and 2021 are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:56.231%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.178%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.272%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.178%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.539%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Useful Lives</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">In Years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computers and software</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-5</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,027&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5-7</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,794&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,692&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-7</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,052&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,310&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,055&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,029&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,984)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,853)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,071&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,176&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_PropertyAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Property and Equipment [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_PropertyAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140625031908832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Coronavirus Aid, Relief and Economic Security Act (&#8220;CARES Act&#8221;) was enacted on March 27, 2020 </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the United States to provide emergency assistance to individuals and businesses affected by the COVID-19 pandemic. The CARES Act includes temporary changes to both income and non-income based tax laws.  Future regulatory guidance under the CARES Act or additional legislation enacted by Congress in connection with the COVID-19 pandemic could impact our tax provision in future periods.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lexicon recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been recognized differently in the financial statements and tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between the financial statement carrying amounts and tax bases of liabilities and assets using enacted tax rates and laws in effect in the years in which the differences are expected to reverse. Deferred tax assets are evaluated for realization based on a more-likely-than-not criteria in determining if a valuation allowance should be provided.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of Lexicon&#8217;s deferred tax assets (liabilities) at December&#160;31, 2022 and 2021 are as follows:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251,331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,427&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Orphan drug credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,524&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,524&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,813&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,770&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,445&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,163&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347,056&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326,630&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,295)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(412)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,295)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(412)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(345,761)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(326,218)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the statutory tax rate to the effective tax rate for the years ended December&#160;31, 2022, 2021 and 2020 consists of the following:</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"/><td style="width:51.921%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.739%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.437%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.139%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected income tax expense (benefit) at 21%</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,408)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,429)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,300)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(269)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,627&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">851&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,777&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write off of credit carryover due to 382 study</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,053&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,543&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,418)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Other is primarily comprised of expiring Research and Development credits for the year ended December&#160;31, 2020 and nondeductible expenses for the years ended December&#160;31, 2022 and 2021.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 382 of the Internal Revenue Code of 1986, contains rules that limit the ability of a company that undergoes an &#8220;ownership change&#8221; to utilize its net operating loss and tax credit carryovers and certain built-in losses recognized in years after the &#8220;ownership change.&#8221; An &#8220;ownership change&#8221; is generally defined as any change in ownership of more than 50% of a corporation&#8217;s stock over a rolling three-year period by stockholders that own (directly or indirectly) 5% or more of the stock of a corporation, or arising from a new issuance of stock by a corporation. If an ownership change occurs, Section 382 generally imposes an annual limitation on the use of pre-ownership change net operating loss carryovers to offset taxable income earned after the ownership change. The Company completed a Section 382 study and determined that historical ownership changes occurred. The Section 382 annual limitation related to historical ownership changes impacts our ability to utilize our tax attributes. In 2020, the federal deferred tax assets and valuation allowance decreased due to the write-off of attributes that will expire still subject to limitation.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">At December&#160;31, 2022, Lexicon had both federal and state NOL carryforwards of approximately $1.2 billion and $86.9 million, respectively.&#160;&#160;In 2022, federal NOLs increased by $104.0 million related to a current year NOL. The Company had $446.3 million of U.S. federal NOL carryforwards as of December 31, 2022, which can be carried forward indefinitely. The remaining federal and state NOL carryforwards will begin to expire in 2022.&#160;Based on the federal tax law limits and the Company&#8217;s cumulative loss position, the Company concluded it was appropriate to establish a full valuation allowance for its net deferred tax assets until an appropriate level of profitability is sustained.&#160;&#160;During the year ended December&#160;31, 2022, the valuation allowance increased $19.5 million, primarily due to NOLs generated partially offset by decreases in deferred tax assets associated with capitalized research and development expenses.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of December&#160;31, 2022 and 2021, the Company did not have any unrecognized tax benefits.  Any interest and penalties related to uncertain tax positions will be reflected as a component of income tax expense.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is primarily subject to U.S. federal and New Jersey and Texas state income taxes.&#160;&#160;The tax years 1999 to current remain open to examination by U.S. federal authorities and 2012 to current remain open to examination by state authorities.&#160;&#160;The Company&#8217;s policy is to recognize interest and penalties related to income tax matters in income tax expense.&#160;&#160;As of December&#160;31, 2022 and 2021, the Company had no accruals for interest or penalties related to income tax matters.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140624939201680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_GoodwillAbstract', window );"><strong>Goodwill [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill</a></td>
<td class="text">Goodwill<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2001, Lexicon completed the acquisition of Coelacanth Corporation in a merger. Coelacanth, now Lexicon Pharmaceuticals (New Jersey), Inc., formed the core of the Company&#8217;s division responsible for small molecule compound discovery.&#160;&#160;The results of Lexicon Pharmaceuticals (New Jersey), Inc. are included in the Company&#8217;s results of operations for the period subsequent to the acquisition.  Goodwill associated with the acquisition of $25.8 million, which represents the excess of the $36.0 million purchase price over the fair value of the underlying net identifiable assets, was assigned to the consolidated entity, Lexicon.&#160;&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2007, Lexicon entered into an arrangement providing for the financing of the clinical development of certain of its drug candidates.  Under the arrangement, Lexicon licensed to Symphony Icon, Inc. its intellectual property rights relating to the drug candidates and obtained an exclusive purchase option that gave Lexicon the right to acquire all the equity of Symphony Icon.  In July 2010, Lexicon exercised its purchase option and completed the acquisition of Symphony Icon.  Goodwill associated with the acquisition of $18.7 million, which represents the assets recognized in connection with the deferred tax liability acquired and did not result from excess purchase price, was assigned to the consolidated entity, Lexicon.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is not subject to amortization, but is tested at least annually for impairment at the reporting unit level, which is the Company&#8217;s single operating segment.&#160;&#160;The Company performed an impairment test of goodwill on its annual impairment assessment date.&#160;&#160;This test did not result in an impairment of goodwill.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_GoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Goodwill [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_GoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI https://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140624939198160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Obligations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_DebtObligationsAbstract', window );"><strong>Debt Obligations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt Obligations</a></td>
<td class="text">Debt Obligations<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Oxford Term Loans.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 17, 2022, Lexicon and one of its subsidiaries entered into a loan and security agreement with Oxford Finance LLC (&#8220;Oxford&#8221;) that provides up to $150&#160;million in borrowing capacity (the &#8220;Oxford Term Loans&#8221;) available in four tranches, each maturing in March 2027. Monthly interest-only payments are due during an initial 36-month period, which may be extended at Lexicon&#8217;s option to 48 months if Lexicon maintains compliance with a financial covenant relating to net sales of sotagliflozin following regulatory approval. The interest-only period will be followed by an amortization period extending through the maturity date.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 29, 2022, the Company entered into a first amendment to the loan and security agreement modifying the period during which the second $25 million tranche under the facility would be available for draw in exchange for $0.3&#160;million of cash consideration.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first $25&#160;million tranche was funded at closing. The second $25&#160;million tranche was funded on December 30, 2022.  The third $50&#160;million tranche is available for draw at Lexicon&#8217;s option prior to June 30, 2023, but within 60 days of U.S. regulatory approval of sotagliflozin for heart failure. The fourth $50&#160;million tranche is available for draw at Lexicon&#8217;s option, subject to Oxford&#8217;s consent, at any time prior to the expiration of the interest-only payment period.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Principal payments of $8.7&#160;million, $13.0&#160;million, and $4.8&#160;million will be due during the fiscal years ended December 31, 2025, December 31, 2026 and December 31, 2027, respectively, with respect to the first tranche.  Principal payments of $8.7&#160;million, $13.0&#160;million, and $4.8&#160;million will be due during the fiscal years ended December 31, 2025, December 31, 2026 and December 31, 2027, respectively, with respect to the second tranche.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The loan and security agreement provides that, upon funding of the first three tranches, Lexicon will grant Oxford a warrant to purchase shares of its common stock having a value equal to 3.50%, 1.75% and 0.875%, respectively, of each such tranche, as determined by reference to a 10-day average closing price of the shares. Each warrant will have an exercise price equal to such average closing price, be exercisable for a five-year period from the date of issuance and feature a net cashless exercise provision. Concurrent with the funding of the first tranche, Lexicon granted Oxford a warrant to purchase 420,673 shares of Lexicon&#8217;s common stock at an exercise price of $2.08 per share.  Concurrent with the funding of the second tranche, Lexicon granted Oxford a warrant to purchase 224,128 shares of Lexicon&#8217;s common stock at an exercise price of $1.95 per share. The warrants are exercisable for five years from their respective grant dates and are classified as equity instruments.  The Company allocated the proceeds from each tranche to the corresponding warrant using the relative fair value method and used the Black-Scholes model to calculate the fair value of the warrants.  The fair value of the first tranche warrant of $0.7&#160;million was recognized as equity with a corresponding debt discount of $0.7&#160;million. The fair value of the second tranche warrant of $0.3&#160;million was recognized as equity with a corresponding debt discount of $0.3&#160;million.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Oxford Term Loans bear interest at a floating rate equal to the 30-day U.S. Dollar LIBOR plus 7.90%, but not less than 8.01%, subject to additional interest if an event of default occurs and is continuing.  As of December&#160;31, 2022, the interest rate was 12.04%. If an event of default occurs and is continuing, Oxford may declare all amounts outstanding under the loan and security agreement to be immediately due and payable. Lexicon may prepay the Oxford Term Loans in whole at its option at any time. Any prepayment of the Oxford Term Loans is subject to prepayment fees for up to three years after the funding of each tranche of the loans.  A final payment exit fee equal to 6% of the amount funded under the Oxford Term Loans is due upon prepayment or maturity, which final payment will be adjusted to 7% of the amount funded upon extension of the interest-only payment period.  The final payment exit fee of $1.5&#160;million was recorded once for each tranche as a debt discount on the funding date.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During March 2022, in connection with the first tranche of the loan and security agreement, the Company received cash proceeds of $24.15&#160;million, net of debt issuance costs of $0.35&#160;million and a facility fee of $0.50&#160;million. The debt </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issuance costs and facility fee have been recorded as a debt discount on the consolidated balance sheet, which together with the final payment exit fee of $1.5&#160;million and warrant fair value of $0.7&#160;million are being amortized to interest expense throughout the life of the term loan using the effective interest rate method.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 30, 2022, in connection with the second tranche of the loan and security agreement, the Company received cash proceeds of $24.96&#160;million, net of debt issuance costs of $0.04&#160;million. The debt issuance costs were recorded as a debt discount on the consolidated balance sheet, which together with the final payment exit fee of $1.5&#160;million and warrant fair value of $0.3&#160;million are being amortized to interest expense throughout the life of the term loan using the effective interest rate method. As of December&#160;31, 2022, the balance of the debt discount was $4.4&#160;million. During the year ended December&#160;31, 2022, the Company recognized interest expense of $2.8&#160;million.  As of December&#160;31, 2022, the carrying value of the Oxford Term Loans was $48.6&#160;million.  The carrying value of the Oxford Term Loans approximates its fair value, as the loans bear interest at a rate that approximates prevailing market rates for instruments with similar characteristics. The fair value of the Oxford Term Loans is determined under Level 2 in the fair value hierarchy.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lexicon&#8217;s obligations under the Oxford Term Loans are secured by a first lien security interest in all of the assets of the Company and its subsidiaries. The loan and security agreement contains certain customary representations and warranties, affirmative and negative covenants and events of default applicable to Lexicon and its subsidiaries. In addition to the financial covenant, additional covenants include those restricting dispositions, fundamental changes to its business, mergers or acquisitions, indebtedness, encumbrances, distributions, investments, transactions with affiliates and subordinated debt. The Company was in compliance with its debt covenants as of December&#160;31, 2022.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Notes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In November 2014, Lexicon completed an offering of $87.5 million in aggregate principal amount of 5.25% Convertible Senior Notes due 2021 (the &#8220;Convertible Notes&#8221;).  The conversion feature did not meet the criteria for bifurcation as required by generally accepted accounting principles and the entire principal amount was recorded as long-term debt on the Company&#8217;s consolidated balance sheets.  The Convertible Notes were governed by an indenture between the Company and Wells Fargo Bank, N.A., as trustee.  The Convertible Notes bore interest at a rate of 5.25%&#160;per year, which was payable semiannually in arrears on June&#160;1 and December&#160;1 of each year, beginning on June&#160;1, 2015.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, the Company entered into separate, privately negotiated exchange agreements to exchange $75.8 million aggregate principal amount of the Convertible Notes for consideration valued at 85% of the principal amount of the Convertible Notes.  In September and October 2020, the Company issued 10,368,956 shares of the Company&#8217;s common stock and paid $50.0 million in cash, which included $1.3 million of accrued interest, to exchange such Convertible Notes.  The Company recorded the exchanges under the accounting requirements for debt extinguishment of convertible instruments.  As a result, a debt extinguishment gain of $9.6 million was recorded and is included in the accompanying consolidated statement of comprehensive loss for the year ended December 31, 2020.  In December 2021, the remaining balance of $11.6&#160;million was repaid in cash.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mortgage Loan. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;In August 2018, a wholly owned subsidiary of Lexicon entered into a term loan and security agreement refinancing the previously existing mortgage on its facilities in The Woodlands, Texas (the &#8220;Property&#8221;).  The Company recorded the refinancing as a debt extinguishment, with no recognition of gain or loss on the transaction.  The loan agreement provided for a $12.9&#160;million mortgage on the Property and had a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzIzNzk_9029d41a-c8aa-4619-a57b-c3c4b9a9cbad">two</span>-year term with a 10-year amortization.  The mortgage loan bore interest at a rate per annum equal to the greater of (a) the 30-day LIBOR rate plus 5.5% and (b) 7.5% and provided for a balloon payment of $10.3&#160;million, which was paid in full in August 2020.  </span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BioPharma Term Loan.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;In December 2017, Lexicon entered into a loan agreement with BioPharma Credit PLC and BioPharma Credit Investments IV Sub </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LP under which $150 million was funded in December 2017 (the &#8220;BioPharma Term Loan&#8221;).  The BioPharma Term Loan was scheduled to mature in December 2022, bore interest at 9% per year, subject to additional interest if an event of default occurred and was continuing, and was payable quarterly.   </span></div>The BioPharma Term Loan was subject to mandatory prepayment provisions that required prepayment upon a change of control or receipt of proceeds from certain non-ordinary course transfers of assets.  The Company repaid the BioPharma Term Loan in whole, together with required prepayment and make-whole premiums, upon closing of the sale of XERMELO and related assets to TerSera Therapeutics LLC in September 2020.  The Company recorded the repayment under the accounting requirements for debt extinguishment and as a result, a loss of $8.6&#160;million was recognized and is included in the accompanying consolidated statement of comprehensive loss for the year ended December 31, 2020.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_DebtObligationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Obligations [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_DebtObligationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140625031969232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Awards<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_EquityIncentiveAwardsAbstract', window );"><strong>Equity Incentive Awards [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity Incentive Awards</a></td>
<td class="text">Equity Incentive Awards<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Incentive Plans</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2017 Equity Incentive Plan:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;In September 1995, Lexicon adopted the 1995 Stock Option Plan, which was subsequently amended and renamed the 2017 Equity Incentive Plan (the &#8220;Equity Incentive Plan&#8221;).</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Equity Incentive Plan permits the grant of incentive stock options to employees and nonstatutory stock options to employees, directors and consultants of the Company. The plan also permits the grant of stock bonus awards, restricted stock awards, restricted stock unit awards, stock appreciation rights and performance stock awards. Incentive and nonstatutory stock options have an exercise price of 100% or more of the fair market value of the Company&#8217;s common stock on the date of grant.&#160;&#160;Most stock options granted under the Equity Incentive Plan become vested and exercisable over a period of four years; however some have been granted with different vesting schedules.&#160;&#160;Stock options granted under the Equity Incentive Plan have a term of ten years from the date of grant.  </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total number of shares of common stock that may be issued pursuant to stock awards under the Equity Incentive Plan shall not exceed in the aggregate 30,000,000 shares at December&#160;31, 2022.&#160;&#160;As of December&#160;31, 2022, options to purchase 11,847,723 shares and 2,559,306 restricted stock units were outstanding, 2,285,702 shares had been issued upon the exercise of stock options, 5,294,942 shares had been issued pursuant to restricted stock units and 113,940 shares had been issued pursuant to stock bonus awards or restricted stock awards granted under the Equity Incentive Plan.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2017 Non-Employee Directors&#8217; Equity Incentive Plan:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;In February 2000, Lexicon adopted the 2000 Non-Employee Directors&#8217; Stock Option Plan, which was subsequently amended and renamed the 2017 Non-Employee Directors&#8217; Equity Incentive Plan (the &#8220;Directors&#8217; Plan&#8221;).&#160;&#160;Under the Directors&#8217; Plan, non-employee directors may be granted awards under the plan with an aggregate grant date fair value of no more than $500,000 during any calendar year, taken together with any cash fees paid to such non-employee director in compensation for service on Lexicon&#8217;s board of directors during such calendar year.&#160;Stock options granted under the Directors&#8217; Plan have an exercise price equal to the fair market value of the Company&#8217;s common stock on the date of grant and a term of ten years from the date of grant.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total number of shares of common stock that may be issued pursuant to stock awards under the Directors&#8217; Plan shall not exceed in the aggregate 1,200,000 shares at December 31, 2022.&#160;&#160;As of December&#160;31, 2022, stock options to purchase 501,224 shares were outstanding, none had been issued upon the exercise of stock options, 74,416 restricted stock units were outstanding and 248,232 shares had been issued pursuant to restricted stock and restricted stock unit awards granted under the Directors&#8217; Plan. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Option Activity:</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of stock option activity under Lexicon&#8217;s equity incentive plans:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:35.649%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.714%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands, except exercise price data)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,367&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.80&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,397&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,695&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.95&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,099&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,808&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(376)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(163)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(191)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(236)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(954)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,271)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,557)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,349&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,367&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,397&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at end of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,747&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,032&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,684&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average estimated grant date fair value of stock options granted during the years ended December&#160;31, 2022, 2021 and 2020 were $2.30, $4.85 and&#160;$2.35, respectively.&#160;&#160;The total intrinsic value of stock options exercised during the year ended December&#160;31, 2022 was $0.&#160; The weighted average remaining contractual term of stock options outstanding and exercisable was 7.2 and 5.3 years, respectively, as of December&#160;31, 2022.&#160;&#160;At December&#160;31, 2022, the aggregate intrinsic value of the outstanding stock options was $0.1 million.  At December&#160;31, 2022, the intrinsic value of exercisable stock options was $0. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Bonus and Restricted Stock Unit Activity:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2022, 2021 and 2020, Lexicon granted its employees restricted stock units in lieu of or in addition to annual stock option awards. These restricted stock units vest in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzM2NTc_da5a4fdb-478f-48e1-83dd-2888411ee7f9">three</span> annual installments.  The total fair value of shares vested in 2022, 2021 and 2020 was $2.9&#160;million, $8.7&#160;million and $3.2&#160;million, respectively.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2022, 2021 and 2020, Lexicon granted its non-employee directors 74,416,  32,192 and 85,104 restricted stock units, respectively. The restricted stock granted in 2022, 2021 and 2020 had weighted average grant date fair values of $1.77, $5.04 and $1.86 per share, respectively.  Vesting of restricted stock units occurs on the first anniversary of the grant date.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of restricted stock units activity under Lexicon&#8217;s stock-based compensation plans for the year ended December&#160;31, 2022:</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.103%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.567%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,854&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,012)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(279)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.03&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,748&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2022, the Company issued $6.3&#160;million of Treasury shares in lieu of issuing additional authorized common shares in order to satisfy the annual vesting of restricted stock units for its employees and officers.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Aggregate Shares Reserved for Issuance</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, an aggregate of 15,096,609 shares of common stock were reserved for issuance upon exercise of outstanding stock options and vesting of outstanding restricted stock units and 8,160,575 additional shares were available for future grants under Lexicon&#8217;s equity incentive plans.&#160;&#160;The Company has a policy of using either authorized and unissued shares or treasury shares, including shares acquired by purchase in the open market or in private transactions, to satisfy equity award exercises.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_EquityIncentiveAwardsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Incentive Awards [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_EquityIncentiveAwardsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140624937444640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_BenefitPlanAbstract', window );"><strong>Benefit Plan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Benefit Plan</a></td>
<td class="text">Benefit Plan<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lexicon maintains a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code.&#160;&#160;The plan covers substantially all full-time employees.&#160;&#160;Participating employees may defer a portion of their pretax earnings, up to the Internal Revenue Service annual contribution limit.&#160;&#160;Beginning in 2000, the Company was required to match employee contributions according to a specified formula.&#160;&#160;The matching contributions totaled $0.7 million, $0.4 million and $0.9 million in the years ended December&#160;31, 2022, 2021 and 2020, respectively.&#160;&#160;Company contributions are vested based on the employee&#8217;s years of service, with full vesting after four years of service.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_BenefitPlanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Benefit Plan [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_BenefitPlanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140624939872992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_CollaborationAndLicenseAgreementsAbstract', window );"><strong>Collaboration and License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration and License Agreements</a></td>
<td class="text">Collaboration and License Agreements<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lexicon has derived substantially all of its revenues from drug discovery and development alliances, target validation collaborations for the development and, in some cases, analysis of the physiological effects of genes altered in knockout mice, product sales, government grants and contracts, technology licenses, subscriptions to its databases and compound library sales.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ipsen.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  In October 2014, Lexicon entered into a License and Collaboration Agreement, which was subsequently amended in March 2015 (collectively, the &#8220;Ipsen Agreement&#8221;), with Ipsen&#160;for the development and commercialization of XERMELO outside of the United States and Japan (the &#8220;Licensed Territory&#8221;).  Revenue for the year ended December&#160;31, 2020 included $0.3 million of royalties from Ipsen and $1.3 million from sales of bulk tablets of XERMELO to Ipsen. The Ipsen Agreement was assigned to TerSera in September 2020 in connection with the XERMELO sale.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_CollaborationAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration and License Agreements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_CollaborationAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140624937366256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation, Policy</a></td>
<td class="text">Basis of Presentation: The accompanying consolidated financial statements include the accounts of Lexicon and its wholly-owned subsidiaries.  Intercompany transactions and balances are eliminated in consolidation.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates, Policy</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The preparation of financial statements in conformity with U. S. generally accepted accounting principles (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents, Policy</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash, Cash Equivalents and Short-Term Investments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lexicon considers all highly-liquid investments with original maturities of three months or less to be cash equivalents.&#160;&#160;As of December&#160;31, 2022 and 2021, short-term investments consist of U.S. treasury bills and corporate debt securities.  The Company&#8217;s short-term investments are classified as available-for-sale securities and are carried at fair value, based on quoted market prices of the securities.&#160;&#160;The Company views its available-for-sale securities as available for use in current operations regardless of the stated maturity date of the security.&#160; The Company does not intend to sell any of its available-for-sale securities prior to their maturity dates. Unrealized gains and losses on such securities are reported as a separate component of stockholders&#8217; equity.&#160;&#160;Net realized gains and losses, interest and dividends are included in interest income.&#160;&#160;The cost of securities sold is based on the specific identification method.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Trade and Other Accounts Receivable, Policy</a></td>
<td class="text">Accounts Receivable:&#160;&#160;Lexicon records trade accounts receivable in the normal course of business related to the sale of products or services, net of an allowance for expected credit losses.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">Concentration Risk Disclosure</a></td>
<td class="text">Concentration of Credit Risk: Lexicon&#8217;s cash equivalents, investments and accounts receivable represent potential concentrations of credit risk. The Company attempts to minimize potential concentrations of risk in cash equivalents and investments by placing investments in high-quality financial instruments. The Company has not experienced any realized losses on its cash equivalents or short-term investments.  The Company&#8217;s accounts receivable are unsecured and are concentrated in pharmaceutical and biotechnology companies located in the United States.&#160;&#160;The Company has not experienced any significant credit losses to date.  In 2022, one customer in the United States represented 100% of revenue.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting Disclosure</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Information and Significant Customers:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lexicon operates in one business segment, which primarily focuses on the discovery, development and commercialization of pharmaceutical products for the treatment of human disease. </span>Substantially all of the Company&#8217;s revenues have been derived from drug discovery alliances, target validation collaborations for the development and, in some cases, analysis of the physiological effects of genes altered in knockout mice, technology licenses, subscriptions to its databases, product sales, government grants and contracts and compound library sales.  In 2022, one customer represented 100% of revenue.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property and Equipment:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Property and equipment that is held and used is carried at cost and depreciated using the straight-line method over the estimated useful life of the assets which ranges from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzM5MTE_558fa410-9f8f-4ae0-80f8-17c88e115072">three</span> to 40 years.&#160;&#160;Maintenance, repairs and minor replacements are charged to expense as incurred.&#160;&#160;Leasehold improvements are amortized over the shorter of the estimated useful life or the remaining lease term.&#160;&#160;Significant renewals and betterments are capitalized.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued liabilities: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Accrued liabilities consisted of the following:</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.163%"><tr><td style="width:1.0%"/><td style="width:52.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.689%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.757%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.788%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,669&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short term lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,089&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,503&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,777&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,972&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment or Disposal of Long-Lived Assets, Policy</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impairment of Long-Lived Assets:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;Long-lived assets and right-of-use assets for leases are reviewed for impairment when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable.  Recoverability of assets to be held and used is measured by comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount that the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. In 2020, the Company recognized an impairment loss of $1.6 million to reduce the carrying value of the assets comprising our campus in The Woodlands, Texas, which were sold in December 2020, to an estimated fair value, less estimated selling costs.  There were no impairments of long-lived assets, in 2022 or 2021.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and Intangible Assets, Policy</a></td>
<td class="text">Goodwill Impairment:&#160;&#160;Goodwill is not amortized, but is tested at least annually for impairment at the reporting unit level.&#160;&#160;The Company has determined that the reporting unit is the single operating segment disclosed in its current financial statements. Impairment is the condition that exists when the carrying amount of goodwill exceeds its implied fair value.&#160;&#160;The first step in the impairment process is to determine the fair value of the reporting unit and then compare it to the carrying value, including goodwill.&#160;&#160;If the fair value exceeds the carrying value, no further action is required and no impairment loss is recognized.&#160;&#160;Additional impairment assessments may be performed on an interim basis if the Company encounters events or changes in circumstances that would indicate that, more likely than not, the carrying value of goodwill has been impaired.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition, Policy</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Product Revenues</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Company&#8217;s sale of XERMELO and related assets to TerSera Therapeutics, LLC (&#8220;TerSera&#8221;) in September 2020, product revenues consisted of commercial sales of XERMELO in the United States and sales of bulk tablets of XERMELO to Ipsen.  Product revenues were recognized when the customer obtained control of the Company&#8217;s product, which occured upon delivery to the customer.  The Company recognized product revenue net of applicable reserves for variable consideration, including allowances for customer credits, estimated rebates, chargebacks, discounts, returns, distribution service fees, and government rebates, such as Medicare Part D coverage gap reimbursements in the United States, as discussed below.  These estimates were based on the most likely amount method for relevant factors such as current contractual and statutory requirements, industry data and forecasted customer buying and payment patterns. Product shipping and handling costs were considered a fulfillment activity when control transfers to the Company&#8217;s customers and such costs were included in cost of sales.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer Credits:  The Company&#8217;s customers were offered various forms of consideration, including allowances, service fees and prompt payment discounts.  The Company expected that its customers would earn prompt payment discounts.  As a result, the Company deducted the full amount of those discounts from total product sales when revenues were recognized.  Service fees were also deducted from product sales as they were earned.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rebates:  Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program.  Rebate amounts are based upon contractual agreements or legal requirements with public sector (e.g., Medicaid) benefit providers.  Rebates are amounts owed after the final dispensing of the product to a benefit plan participant and are based upon contractual agreements or legal requirements with public sector benefit providers.  The allowance for rebates is based on statutory discount rates and expected utilization.  The Company&#8217;s estimates for expected utilization of rebates were based on third party market research data and data received from the specialty pharmacies dispensing XERMELO.  Rebates were generally invoiced and paid in arrears so that the accrual balance consisted of an estimate of the amount expected to be incurred for the current quarter&#8217;s activity, plus an accrual balance for known unpaid rebates from the prior quarter.  If actual future rebates varied from estimates, the Company adjusted prior period accruals, which affected revenue in the period of adjustment.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks:  Chargebacks are discounts that occur when contracted customers purchase directly from a specialty pharmacy or distributor, who acts as a retailer.  Contracted customers, which consisted primarily of Public Health Service Institutions, non-profit clinics, and federal government entities purchasing via the Federal Supply Schedule, generally purchased XERMELO at a discounted price.  The specialty pharmacy or distributor, in turn, charged back to Lexicon the difference between the price paid by the specialty pharmacy or distributor and the discounted price paid to the specialty pharmacy or distributor by the customer.  The allowance for chargeback was based on known sales to contracted customers.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare Part D Coverage Gap:  The Medicare Part D prescription drug benefit mandates manufacturers to fund a portion of the Medicare Part D insurance coverage gap for prescription drugs sold to eligible patients.  The Company&#8217;s estimates for the expected Medicare Part D coverage gap were based on data received from the specialty pharmacies dispensing XERMELO and projections based on historical data.  Funding of the coverage gap was generally invoiced and paid in arrears so that the accrual balance consisted of an estimate of the amount expected to be incurred for the current quarter&#8217;s activity, plus an accrual balance for known prior quarters.  If actual future funding varied from estimates, the Company adjusted prior period accruals, which affected revenues in the period of adjustment.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Co-payment assistance:  Patients with commercial insurance who met certain eligibility requirements were eligible to receive co-payment assistance.  The Company accrued a liability for co-payment assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Collaborative Agreements</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Sales</a></td>
<td class="text">Cost of Sales:  Cost of sales consisted of third-party manufacturing costs, freight and indirect overhead costs associated with sales of XERMELO.  Product shipping and handling costs were included in cost of sales. Cost of sales also included the amortization of the intangible asset for XERMELO using the straight-line method over the estimated useful life of 14 years.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense, Policy</a></td>
<td class="text">Research and Development Expenses: Research and development expenses consist of costs incurred for company-sponsored as well as collaborative research and development activities. These costs include direct and research-related overhead expenses and are expensed as incurred.&#160;&#160;Technology license fees for technologies that are utilized in research and development and have no alternative future use are expensed when incurred.  Substantial portions of the Company&#8217;s preclinical and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors.  For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining.  For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study.  The Company monitors patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to the Company by the vendors and clinical site visits.  The Company&#8217;s estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each program and total program spending.  The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based Compensation, Option and Incentive Plans Policy</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;The Company recognizes compensation expense in its statements of comprehensive loss for share-based payments, including stock options and restricted stock units issued to employees, based on their fair values on the date of the grant, with the compensation expense recognized over the period in which an employee is required to provide service in exchange for the stock award.&#160;&#160;Stock-based compensation expense for awards without performance conditions is recognized based on the terms of vesting, which is typically on a straight-line basis.  Stock-based compensation expense for awards with performance conditions is recognized over the period from the date the performance condition is determined to be probable of occurring through the time the applicable condition is met.&#160;&#160;As of December&#160;31, 2022, future stock-based compensation cost for all outstanding unvested stock options and restricted stock units was $21.0 million, which is expected to be recognized over a weighted-average period of 1.3&#160;years.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options is estimated at the date of grant using the Black-Scholes method.&#160;&#160;The Black-Scholes option-pricing model requires the input of subjective assumptions.&#160;&#160;Because the Company&#8217;s employee stock options have </span></div>characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&#8217;s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options.&#160;&#160;For purposes of determining the fair value of stock options, the Company segregates its options into two homogeneous groups, based on exercise and post-vesting employment termination behaviors, resulting in different assumptions used for expected option lives.&#160;&#160;Historical data is used to estimate the expected option life for each group.  Expected volatility is based on the historical volatility in the Company&#8217;s stock price.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share, Policy</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Loss per Common Share:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Net loss per common share is computed using the weighted average number of shares of common stock outstanding. Shares associated with warrants, stock options and restricted stock units that could potentially dilute earnings per share in the future are not included in the computation of diluted earnings per share because they are antidilutive.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Tax, Policy</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been recognized differently in the financial statements and tax returns. The Company uses the liability method in accounting for income taxes. Under this method, deferred tax liabilities and assets are determined based on the difference between the financial statement carrying amounts and tax bases of liabilities and assets using enacted tax rates and laws in effect in the years in which the differences are expected to reverse. Deferred tax assets are evaluated for realization based on a more-likely-than-not criteria in determining if a valuation allowance should be provided.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a valuation allowance on net operating losses and other deferred tax assets. Accordingly, the Company has not reported any tax benefit relating to the remaining net operating loss carryforwards and income tax credit carryforwards that are available for utilization in future periods. On a periodic basis, the valuation allowance is reassessed on deferred income tax assets, weighing positive and negative evidence to assess the recoverability of the deferred tax assets. In 2022, the Company reassessed the valuation allowance and considered negative evidence, including the cumulative losses over the three years ended December&#160;31, 2022 and positive evidence including the projections of future income. After assessing both the negative and the positive evidence, the Company concluded that it should continue to maintain the valuation allowance on net operating losses and other deferred tax assets as of December&#160;31, 2022 given the significance of the weight of the negative evidence. Based on recent financial performance and future projections, the Company could record a reversal of all, or a portion of the valuation allowance associated with U.S. deferred tax assets in future periods. However, any such change is subject to actual performance and other considerations that may present positive or negative evidence at the time of the assessment. The total gross deferred tax asset balance subject to the valuation allowance assessment was approximately $347.1&#160;million at December&#160;31, 2022. </span></div>Significant judgment is required in making these assessments to maintain or reverse valuation allowances and, to the extent future expectations change the Company would have to assess the recoverability of these deferred tax assets at that time.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 705<br> -URI https://asc.fasb.org/topic&amp;trid=2122478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI https://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140624939038528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expected Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Risk-free Interest Rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expected Term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Dividend<br/>Rate</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Officers and non-employee directors</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Officers and non-employee directors</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Officers and non-employee directors</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140624937379456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash Equivalents and Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract', window );"><strong>Cash and Cash Equivalents and Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Schedule of Cash, Cash Equivalents and Short-term Investments</a></td>
<td class="text"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"/><td style="width:42.727%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.485%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities maturing within one year:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,022&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(342)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,418&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,332&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,440&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(428)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,012&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,785&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(428)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,357&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"/><td style="width:42.881%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.331%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities maturing within one year:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,012&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,018&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,012&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,084&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,077&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash and Cash Equivalents and Investments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_CashAndCashEquivalentsAndInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140624938968032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_FairValueMeasurementsAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Fair Value, by Balance Sheet Grouping</a></td>
<td class="text"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.988%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets and Liabilities at Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,680&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,332&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,012&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,025&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,332&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,357&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.988%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets and Liabilities at Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,561&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,678&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,626&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,117&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,743&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_FairValueMeasurementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Measurements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_FairValueMeasurementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13467-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140624939038528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_PropertyAndEquipmentAbstract', window );"><strong>Property and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:56.231%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.178%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.272%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.178%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.539%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Useful Lives</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">In Years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computers and software</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-5</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,027&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5-7</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,794&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,692&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-7</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,052&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,310&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,055&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,029&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,984)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,853)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,071&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,176&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_PropertyAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Property and Equipment [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_PropertyAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140624939087600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251,331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,427&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Orphan drug credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,524&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,524&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,813&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,770&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,445&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,163&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347,056&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326,630&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,295)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(412)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,295)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(412)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(345,761)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(326,218)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the statutory tax rate to the effective tax rate for the years ended December&#160;31, 2022, 2021 and 2020 consists of the following:</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"/><td style="width:51.921%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.739%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.437%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.139%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected income tax expense (benefit) at 21%</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,408)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,429)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,300)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(269)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,627&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">851&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,777&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write off of credit carryover due to 382 study</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,053&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,543&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,418)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140624939128400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_CommitmentsAndContingenciesAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of Future Minimum Rental Payments for Operating Leases</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:80.744%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.056%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">805&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">865&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,644&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted operating lease liability</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,793&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: amount of lease payments representing interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,078)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of future lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,715&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: short-term operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,291)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liability</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,424&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_CommitmentsAndContingenciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments and Contingencies</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_CommitmentsAndContingenciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140624938985696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Awards (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_EquityIncentiveAwardsAbstract', window );"><strong>Equity Incentive Awards [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Share-based Compensation, Stock Options, Activity</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:35.649%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.714%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands, except exercise price data)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,367&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.80&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,397&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,695&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.95&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,099&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,808&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(376)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(163)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(191)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(236)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(954)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,271)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,557)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,349&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,367&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,397&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at end of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,747&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,032&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,684&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Nonvested Restricted Stock Units Activity</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.103%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.567%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,854&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,012)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(279)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.03&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,748&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_EquityIncentiveAwardsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Incentive Awards [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_EquityIncentiveAwardsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140625023466192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Concentration of Credit Risk (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent', window );">Disclosure on Geographic Areas, Revenue from External Customers Attributed to Entity's Country of Domicile, Percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany', window );">Disclosure On Geographic Areas Revenue From External Customers Attributed to Germany</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">76.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenues from external customers attributed to the entity's country of domicile as a percentage of total revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure On Geographic Areas Revenue From External Customers Attributed to Germany</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140624941924256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Segment Information and Signficant Customers (Details) - segment<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_LXRXDiplomatcustomerconcentration', window );">LXRX Diplomat customer concentration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_LXRXBiologicscustomerconcentration', window );">Biologics customer concentration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76.00%<span></span>
</td>
<td class="nump">65.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_LXRXBiologicscustomerconcentration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>LXRX Biologics customer concentration - represents percent of revenue that Biologics contributes to total revenues</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_LXRXBiologicscustomerconcentration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_LXRXDiplomatcustomerconcentration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>LXRX Diplomat customer concentration - represents the percent of revenue that Diplomat contributes to revenues</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_LXRXDiplomatcustomerconcentration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140624941714672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of assets</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_AccruedResearchAndDevelopmentServicesCurrent', window );">Accrued research and development services current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,252<span></span>
</td>
<td class="nump">$ 3,669<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_AccruedCompensationAndBenefitsCurrent', window );">Accrued compensation and benefits current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,830<span></span>
</td>
<td class="nump">5,711<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating Lease, Liability, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,291<span></span>
</td>
<td class="nump">1,089<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other Accrued Liabilities, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">404<span></span>
</td>
<td class="nump">2,503<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,777<span></span>
</td>
<td class="nump">$ 12,972<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">40 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_AccruedCompensationAndBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued compensation and benefits current - due within 1 year</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_AccruedCompensationAndBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_AccruedResearchAndDevelopmentServicesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development services current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_AccruedResearchAndDevelopmentServicesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140624938284000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Impairment of Long-Lived Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of Intangible Assets (Excluding Goodwill)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140624938973744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Cost of Sales (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In-Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life</a></td>
<td class="text">14 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140624937338496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Stock-Based Compensation (Details 1)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Employee Service Share-based Compensation, Outstanding, Weighted Average Remaining Vesting Period</a></td>
<td class="text">1 year 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Employees</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Employee</a></td>
<td class="nump">2.80%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected VolatilityRate, Employees</a></td>
<td class="nump">109.00%<span></span>
</td>
<td class="nump">104.00%<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Employees</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Officers and Non-employee Directors</a></td>
<td class="nump">1.90%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Officers and Non-employee Directors</a></td>
<td class="nump">91.00%<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Officers and Non-employee Directors</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Officers and Non-employee Directors</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the employees' option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the officers' and non-employee directors' option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected term assumption that is used in valuing an option on its own shares for employees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected term assumption that is used in valuing an option on its own shares for officers and non-employee directors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For officers and non-employee directors, the estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For employees, the estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares for employees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares for officers and non-employee directors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140624939054464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Stock-based Compensation (Details 2)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized</a></td>
<td class="nump">$ 21.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Employee Service Share-based Compensation, Outstanding, Weighted Average Remaining Vesting Period</a></td>
<td class="text">1 year 3 months 18 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140624940057088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Recent Accounting Pronouncements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">$ 6,800<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140624936358560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash Equivalents and Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RealizedInvestmentGainsLosses', window );">Realized Investment Gains (Losses)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Available-for-sale Securities, Amortized Cost Basis</a></td>
<td class="nump">18,418<span></span>
</td>
<td class="nump">$ 26,018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale Securities, Gross Unrealized Gain Accumulated in Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale Securities, Gross Unrealized Losses</a></td>
<td class="num">(86)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Available-for-sale Securities, Current</a></td>
<td class="nump">18,332<span></span>
</td>
<td class="nump">26,012<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CashMember', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Available-for-sale Securities, Amortized Cost Basis</a></td>
<td class="nump">46,345<span></span>
</td>
<td class="nump">64,066<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale Securities, Gross Unrealized Gain Accumulated in Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale Securities, Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Available-for-sale Securities, Current</a></td>
<td class="nump">46,345<span></span>
</td>
<td class="nump">64,065<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember', window );">US Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Available-for-sale Securities, Amortized Cost Basis</a></td>
<td class="nump">74,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale Securities, Gross Unrealized Gain Accumulated in Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale Securities, Gross Unrealized Losses</a></td>
<td class="num">(342)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Available-for-sale Securities, Current</a></td>
<td class="nump">73,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Available-for-sale Securities, Amortized Cost Basis</a></td>
<td class="nump">92,440<span></span>
</td>
<td class="nump">26,018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale Securities, Gross Unrealized Gain Accumulated in Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale Securities, Gross Unrealized Losses</a></td>
<td class="num">(428)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Available-for-sale Securities, Current</a></td>
<td class="nump">92,012<span></span>
</td>
<td class="nump">26,012<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_InvestmentsMember', window );">Cash and Cash Equivalents and Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Available-for-sale Securities, Amortized Cost Basis</a></td>
<td class="nump">138,785<span></span>
</td>
<td class="nump">90,084<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale Securities, Gross Unrealized Gain Accumulated in Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale Securities, Gross Unrealized Losses</a></td>
<td class="num">(428)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Available-for-sale Securities, Current</a></td>
<td class="nump">$ 138,357<span></span>
</td>
<td class="nump">$ 90,077<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedInvestmentGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.3(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedInvestmentGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_InvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_InvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140624936340304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details 1) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and Cash Equivalents, Fair Value Disclosure</a></td>
<td class="nump">$ 46,345<span></span>
</td>
<td class="nump">$ 64,065<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale Securities, Fair Value Disclosure</a></td>
<td class="nump">92,012<span></span>
</td>
<td class="nump">22,678<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments, Fair Value Disclosure</a></td>
<td class="nump">138,357<span></span>
</td>
<td class="nump">86,743<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and Cash Equivalents, Fair Value Disclosure</a></td>
<td class="nump">46,345<span></span>
</td>
<td class="nump">64,065<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale Securities, Fair Value Disclosure</a></td>
<td class="nump">73,680<span></span>
</td>
<td class="nump">7,561<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments, Fair Value Disclosure</a></td>
<td class="nump">120,025<span></span>
</td>
<td class="nump">71,626<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and Cash Equivalents, Fair Value Disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale Securities, Fair Value Disclosure</a></td>
<td class="nump">18,332<span></span>
</td>
<td class="nump">15,117<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments, Fair Value Disclosure</a></td>
<td class="nump">18,332<span></span>
</td>
<td class="nump">15,117<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and Cash Equivalents, Fair Value Disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale Securities, Fair Value Disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments, Fair Value Disclosure</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140624937294544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,055,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,029,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,984,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,853,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,071,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,176,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfBuildings', window );">Proceeds from Sale of Buildings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,013,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1', window );">Noncash or Part Noncash Divestiture, Amount of Consideration Received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment', window );">Payments to Acquire Other Property, Plant, and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">40 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers and Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,209,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,027,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers and Software | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers and Software | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,794,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,692,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,052,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,310,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember', window );">Leasehold Improvements | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember', window );">Leasehold Improvements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash consideration received for selling an asset or business through a noncash (or part noncash) transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from the acquisition of or improvements to long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfBuildings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sale of buildings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfBuildings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140624941725264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details 1) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Deferred Tax Assets and Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Deferred Tax Assets, Operating Loss Carryforwards</a></td>
<td class="nump">$ 251,331<span></span>
</td>
<td class="nump">$ 229,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Deferred Tax Assets, Tax Credit Carryforwards, Research</a></td>
<td class="nump">29,290<span></span>
</td>
<td class="nump">29,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug', window );">Deferred Tax Assets, Tax Credit Carryforwards, Orphan Drug</a></td>
<td class="nump">24,524<span></span>
</td>
<td class="nump">24,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Deferred Tax Assets, In Process Research and Development</a></td>
<td class="nump">33,813<span></span>
</td>
<td class="nump">36,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</a></td>
<td class="nump">5,445<span></span>
</td>
<td class="nump">5,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Deferred Tax Assets, Other</a></td>
<td class="nump">2,255<span></span>
</td>
<td class="nump">1,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred Tax Assets, Gross</a></td>
<td class="nump">347,056<span></span>
</td>
<td class="nump">326,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Deferred Tax Liabilities, Other</a></td>
<td class="num">(1,295)<span></span>
</td>
<td class="num">(412)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Deferred Tax Liabilities, Gross</a></td>
<td class="num">(1,295)<span></span>
</td>
<td class="num">(412)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred Tax Assets, Valuation Allowance</a></td>
<td class="num">(345,761)<span></span>
</td>
<td class="num">(326,218)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Deferred Tax Liabilities, Net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Income Tax Benefit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_A2020FederalNOLIncrease', window );">2020 Federal NOL increase</a></td>
<td class="nump">104,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_DeferredTaxAssetsSection163j_LXRX', window );">Deferred Tax Assets, Section 163j_LXRX</a></td>
<td class="nump">398<span></span>
</td>
<td class="nump">$ 148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards, Federal</a></td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</a></td>
<td class="nump">$ 446,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_A2020FederalNOLIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>2020 Federal NOL increase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_A2020FederalNOLIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_DeferredTaxAssetsSection163j_LXRX">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Section 163j_LXRX - represents the disallowed interest expense deduction as a result of adoption of the Tax Act in 2017</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_DeferredTaxAssetsSection163j_LXRX</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible orphan drug credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140624941633728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details 2) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Income Tax Benefit</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation Allowance, Deferred Tax Asset, Change in Amount</a></td>
<td class="nump">19,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards, Federal</a></td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">Operating Loss Carryforwards, State</a></td>
<td class="nump">86,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems', window );"><strong>Investments, Owned, Federal Income Tax Note [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Deferred Tax Assets, Tax Credit Carryforwards, Research</a></td>
<td class="nump">$ 29,290<span></span>
</td>
<td class="nump">$ 29,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140624941635392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details 3) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">Current State and Local Tax Expense (Benefit)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (269)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount', window );">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount</a></td>
<td class="nump">1,627<span></span>
</td>
<td class="nump">851<span></span>
</td>
<td class="nump">1,777<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</a></td>
<td class="nump">19,543<span></span>
</td>
<td class="nump">17,210<span></span>
</td>
<td class="num">(20,418)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</a></td>
<td class="num">(21,408)<span></span>
</td>
<td class="num">(18,429)<span></span>
</td>
<td class="num">(12,300)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_WriteOffOfTaxCredits', window );">Write-off of tax credits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">31,053<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</a></td>
<td class="nump">238<span></span>
</td>
<td class="nump">368<span></span>
</td>
<td class="nump">157<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Income Tax Benefit</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_WriteOffOfTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Write-off of tax credits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_WriteOffOfTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 740<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126970579&amp;loc=d3e23163-113944<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140624938142480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jul. 30, 2010</div></th>
<th class="th"><div>Jul. 12, 2001</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_GoodwillAbstract', window );"><strong>Goodwill [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_CoelacanthGoodwill', window );">Coelacanth Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_CoelacanthPurchasePrice', window );">Coelacanth Purchase Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_SymphonyIconGoodwill', window );">Symphony Icon Goodwill</a></td>
<td class="nump">$ 18.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_CoelacanthGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>On July 12, 2001, Lexicon completed the acquisition of Coelacanth Corporation in a merger. Goodwill associated with the acquisition of $25.8 million, which represents the excess of the $36.0 million purchase price over the fair value of the underlying net identifiable assets, was assigned to the consolidated entity, Lexicon. This represents the goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_CoelacanthGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_CoelacanthPurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>On July 12, 2001, Lexicon completed the acquisition of Coelacanth Corporation in a merger. Goodwill associated with the acquisition of $25.8 million, which represents the excess of the $36.0 million purchase price over the fair value of the underlying net identifiable assets, was assigned to the consolidated entity, Lexicon. This represents the purchase price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_CoelacanthPurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_GoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Goodwill [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_GoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SymphonyIconGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>On July 30, 2010, Lexicon exercised its Purchase Option and completed the acquisition of Symphony Icon. Goodwill associated with the acquisition of $18.7 million, which represents the assets recognized in connection with the deferred tax liability acquired and did not result from excess purchase price, was assigned to the consolidated entity, Lexicon.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SymphonyIconGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140624932544736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Obligations - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="6">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2018</div></th>
<th class="th"><div>Nov. 30, 2014</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2027</div></th>
<th class="th"><div>Dec. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Aug. 30, 2018</div></th>
<th class="th"><div>Dec. 18, 2017</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 87,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage', window );">Convertible Debt Instrument Interest Rate Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Recognition of gain or loss on extinguishment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,003,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of assets</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_ConvertibleDebtExchangeTotalCashConsideration', window );">Convertible Debt Exchange - Total cash consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_A2020ConvertibleDebtExchangeSharePaymentTotal', window );">2020 Convertible debt exchange - share payment total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,368,956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_A2020ConvertibleDebtExchangePercentageOfPrincipal', window );">2020 convertible debt exchange - percentage of principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_A2020ConvertibleDebtExchangeAccruedInterest', window );">2020 convertible debt exchange - accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_ConvertibleDebtExchange', window );">Convertible debt exchange</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX', window );">Mortgage Debt Interest Rate_Base_Revere_LXRX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX', window );">Mortgage Debt Interest Rate BasePlus_Revere_LXRX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_MortgageDebtInstrument_Revere_LXRX', window );">Mortgage Debt Instrument_Revere_LXRX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_MortgageDebtBalloonPayment_LXRX', window );">Mortgage Debt Balloon Payment_LXRX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate', window );">Long-Term Debt, Percentage Bearing Fixed Interest, Percentage Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.01%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.01%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_TermLoanAWarrantExercisePrice', window );">Term Loan A Warrant Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubordinatedBorrowingInterestRate', window );">Subordinated Borrowing, Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.04%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_TermLoanDWarrant', window );">Term Loan D Warrant %</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_TermLoanAFinalPayment', window );">Term Loan A Final Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_FinalPaymentWithExtention', window );">Final Payment % with extention</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_FinalPaymentWithNoExtention', window );">Final Payment % with no extention</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_TermLoanADebtIssuanceCosts', window );">Term Loan A Debt Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_OxfordFacilityFee', window );">Oxford Facility Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_TermLoanANetCashReceipt', window );">Term Loan A Net Cash Receipt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Adjustments to Additional Paid in Capital, Warrant Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,780,000<span></span>
</td>
<td class="nump">$ 802,000<span></span>
</td>
<td class="nump">$ 14,544,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_TermLoanADebtDiscount', window );">Term Loan A Debt Discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_TermLoanCWarrant', window );">Term Loan C Warrant %</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_TermLoanAWarrantsNumber', window );">Term Loan A Warrants Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">224,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">224,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">420,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_TermLoanABWarrant', window );">Term Loan A&amp;B Warrant %</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_TermLoanB', window );">Term Loan B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_A2026OxfordPrincipalPayments', window );">2026 Oxford Principal Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_OxfordLoanFacility', window );">Oxford Loan Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_OxfordAmendmentFee', window );">Oxford Amendment Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_TermLoanA', window );">Term Loan A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_TermLoanC', window );">Term Loan C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_TermLoanD', window );">Term Loan D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term Debt, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-Term Debt, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (48,579,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (48,579,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_A2027OxfordPrincipalPaymentsA', window );">2027 Oxford Principal Payments A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_A2025OxfordPrincipalPaymentA', window );">2025 Oxford Principal Payment A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_A2025OxfordPrincipalPaymentsB', window );">2025 Oxford Principal Payments B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_A2026OxfordPrincipalPaymentsB', window );">2026 Oxford Principal Payments B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_A2027OxfordPrincipalPaymentsB', window );">2027 Oxford Principal Payments B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Debt, Weighted Average Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_TermLoanBNetCashReceipt', window );">Term Loan B Net Cash Receipt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,960,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,960,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_TermLoanBDebtDiscount', window );">Term Loan B Debt Discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseInterestBearingLiability', window );">Interest Expense, Interest-Bearing Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_A2020ConvertibleDebtExchangeAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>2020 convertible debt exchange - accrued interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_A2020ConvertibleDebtExchangeAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_A2020ConvertibleDebtExchangePercentageOfPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>2020 convertible debt exchange - percentage of principal</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_A2020ConvertibleDebtExchangePercentageOfPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_A2020ConvertibleDebtExchangeSharePaymentTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>2020 Convertible debt exchange - share payment total</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_A2020ConvertibleDebtExchangeSharePaymentTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_A2025OxfordPrincipalPaymentA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>2025 Oxford Principal Payment A</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_A2025OxfordPrincipalPaymentA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_A2025OxfordPrincipalPaymentsB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>2025 Oxford Principal Payments B</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_A2025OxfordPrincipalPaymentsB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_A2026OxfordPrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>2026 Oxford Principal Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_A2026OxfordPrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_A2026OxfordPrincipalPaymentsB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>2026 Oxford Principal Payments B</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_A2026OxfordPrincipalPaymentsB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_A2027OxfordPrincipalPaymentsA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>2027 Oxford Principal Payments A</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_A2027OxfordPrincipalPaymentsA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_A2027OxfordPrincipalPaymentsB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>2027 Oxford Principal Payments B</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_A2027OxfordPrincipalPaymentsB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ConvertibleDebtExchange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible debt exchange</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ConvertibleDebtExchange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ConvertibleDebtExchangeTotalCashConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible Debt Exchange - Total cash consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ConvertibleDebtExchangeTotalCashConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed under convertible debt, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_FinalPaymentWithExtention">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Final Payment % with extention</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_FinalPaymentWithExtention</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_FinalPaymentWithNoExtention">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Final Payment % with no extention</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_FinalPaymentWithNoExtention</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_MortgageDebtBalloonPayment_LXRX">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Mortgage Debt Balloon Payment_LXRX - Balloon payment due at the end of the 2-year maturity date of mortgage loan with Revere.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_MortgageDebtBalloonPayment_LXRX</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_MortgageDebtInstrument_Revere_LXRX">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Mortgage Debt Instrument_Revere_LXRX - Principal loan amount borrowed, using Woodlands Campus as collateral</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_MortgageDebtInstrument_Revere_LXRX</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Mortgage Debt Interest Rate BasePlus_Revere_LXRX - represents a base for the range of the interest rate that will be charged on the Revere loan. Interest charged will be greater of 30-day LIBOR plus 5.5% or 7.5%</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Mortgage Debt Interest Rate_Base_Revere_LXRX - interest rate in Revere loan agreement is 30-day LIBOR plus 5.5% as base rate. Interest charged is the greater of base or 7.5%</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_MortgageDebtInterestRate_Base_Revere_LXRX</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_OxfordAmendmentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Oxford Amendment Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_OxfordAmendmentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_OxfordFacilityFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Oxford Facility Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_OxfordFacilityFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_OxfordLoanFacility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Oxford Loan Facility</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_OxfordLoanFacility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TermLoanA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term Loan A</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_TermLoanA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TermLoanABWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term Loan A&amp;B Warrant %</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_TermLoanABWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TermLoanADebtDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term Loan A Debt Discount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_TermLoanADebtDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TermLoanADebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term Loan A Debt Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_TermLoanADebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TermLoanAFinalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term Loan A Final Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_TermLoanAFinalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TermLoanANetCashReceipt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term Loan A Net Cash Receipt</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_TermLoanANetCashReceipt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TermLoanAWarrantExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term Loan A Warrant Exercise Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_TermLoanAWarrantExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TermLoanAWarrantsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term Loan A Warrants Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_TermLoanAWarrantsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TermLoanB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term Loan B</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_TermLoanB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TermLoanBDebtDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term Loan B Debt Discount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_TermLoanBDebtDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TermLoanBNetCashReceipt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term Loan B Net Cash Receipt</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_TermLoanBNetCashReceipt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TermLoanC">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term Loan C</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_TermLoanC</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TermLoanCWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term Loan C Warrant %</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_TermLoanCWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TermLoanD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term Loan D</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_TermLoanD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TermLoanDWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term Loan D Warrant %</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_TermLoanDWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of debt outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseInterestBearingLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on interest-bearing liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph (a)<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph (b)<br> -Subparagraph (1)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseInterestBearingLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a set, unchanging rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtPercentageBearingFixedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubordinatedBorrowingInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stated interest rate of the subordinated debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubordinatedBorrowingInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140624939065984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt Obligations (Details 1)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_DebtObligationsAbstract', window );"><strong>Debt Obligations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term Debt, Excluding Current Maturities</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_DebtObligationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Obligations [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_DebtObligationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140624938394528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">$ 6,800<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Other Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Operating Leases, Rent Expense</a></td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Finance Lease, Weighted Average Remaining Lease Term</a></td>
<td class="text">9 years 6 months<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_DeferredCompensationArrangementWithIndividualPaymentPeriod', window );">Payment period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_DeferredCompensationArrangementWithIndividualPaymentPeriod', window );">Payment period</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_DeferredCompensationArrangementWithIndividualPaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Compensation Arrangement With Individual, Payment Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_DeferredCompensationArrangementWithIndividualPaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140624942723904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 2) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_CommitmentsAndContingenciesAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">Operating Leases, Future Minimum Payments Due, Next Twelve Months</a></td>
<td class="nump">$ 805,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">Operating Leases, Future Minimum Payments, Due in Two Years</a></td>
<td class="nump">1,378,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">Operating Leases, Future Minimum Payments, Due in Three Years</a></td>
<td class="nump">1,220,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">Operating Leases, Future Minimum Payments, Due in Four Years</a></td>
<td class="nump">865,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">Operating Leases, Future Minimum Payments, Due in Five Years</a></td>
<td class="nump">881,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">Operating Leases, Future Minimum Payments, Due Thereafter</a></td>
<td class="nump">5,644,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Operating Leases, Future Minimum Payments Due</a></td>
<td class="nump">10,793,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_InterestOnLeasePayments', window );">Interest on Lease Payments</a></td>
<td class="num">(4,078,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_PresentValueOfFutureLeasePayments', window );">Present Value of Future Lease Payments</a></td>
<td class="nump">6,715,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCommitmentAmount', window );">Short-term Lease Commitment, Amount</a></td>
<td class="num">(1,291,000)<span></span>
</td>
<td class="num">$ (1,100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term Debt and Lease Obligation</a></td>
<td class="nump">5,424,000<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">6,800,000<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Operating Leases, Rent Expense</a></td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_CommitmentsAndContingenciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments and Contingencies</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_CommitmentsAndContingenciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_InterestOnLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest on Lease Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_InterestOnLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_PresentValueOfFutureLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present Value of Future Lease Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_PresentValueOfFutureLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease commitment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918705-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140624941681360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Payments for Rent</a></td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Finance Lease, Weighted Average Remaining Lease Term</a></td>
<td class="text">9 years 6 months<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Finance Lease, Weighted Average Discount Rate, Percent</a></td>
<td class="nump">9.60%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">$ 6,800<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140624940480752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Awards - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock', window );">Stock Option Exercise Price as Percent of Value of Common Stock</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan', window );">Total Shares That May be Issued, Equity Incentive Plan</a></td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_OptionsOutstandingEquityIncentivePlan', window );">Options Outstanding, Equity Incentive Plan</a></td>
<td class="nump">11,847,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan', window );">Restricted Stock Units Outstanding, Equity Incentive Plan</a></td>
<td class="nump">2,559,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_StockOptionsExercisedEquityIncentivePlan', window );">Stock Options Exercised, Equity Incentive Plan</a></td>
<td class="nump">2,285,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan', window );">Shares Issued Pursuant to Restricted Stock Units, Equity Incentive Plan</a></td>
<td class="nump">5,294,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan', window );">Shares Issued Pursuant to Stock Bonus Awards, Equity Incentive Plan</a></td>
<td class="nump">113,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_Totalvalueofsharesbynonemployeeinayear', window );">Total value of shares by nonemployee in a year</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan', window );">Total Shares That May Be Issued, Non-Employee Directors Equity Incentive Plan</a></td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan', window );">Options Outstanding, Non-Employee Directors Equity Incentive Plan</a></td>
<td class="nump">501,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan', window );">Stock Options Exercised, Non-Employee Directors Equity Incentive Plan</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan', window );">Shares Issued Pursuant to Restricted Stock Awards, Non-Employee Directors Equity Incentive Plan</a></td>
<td class="nump">248,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</a></td>
<td class="nump">15,096,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</a></td>
<td class="nump">8,160,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_RestrictedStockUnitsOutstandingNonEmployeeDirectorsEquityIncentivePlan', window );">Restricted Stock Units Outstanding, Non-Employee Directors Equity Incentive Plan</a></td>
<td class="nump">74,416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury Stock, Value</a></td>
<td class="nump">$ 2,061,000<span></span>
</td>
<td class="nump">$ 7,518,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCarryingBasis', window );">Unearned ESOP Shares</a></td>
<td class="nump">6,321,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockPreferredValue', window );">Treasury Stock, Preferred, Value</a></td>
<td class="nump">$ 6,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Award term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_OptionsOutstandingEquityIncentivePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Options to purchase shares outstanding under the Equity Incentive Plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_OptionsOutstandingEquityIncentivePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Options to purchase shares outstanding under the Non-Employee Directors Equity Incentive Plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restricted stock units outstanding under the Equity Incentive Plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_RestrictedStockUnitsOutstandingNonEmployeeDirectorsEquityIncentivePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restricted Stock Units Outstanding, Non-Employee Directors Equity Incentive Plan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_RestrictedStockUnitsOutstandingNonEmployeeDirectorsEquityIncentivePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issued pursuant to restricted stock awards under the Non-Employee Directors Equity Incentive Plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issued pursuant to restricted stock units under the Equity Incentive Plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issued pursuant to stock bonus awards or restricted stock awards under the Equity Incentive Plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Incentive and nonstatutory stock options have an exercise price of 100% or more of the fair market value of common stock on the date of grant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_StockOptionsExercisedEquityIncentivePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issued upon the exercise of stock options under the Equity Incentive Plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_StockOptionsExercisedEquityIncentivePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issued upon the exercise of stock options under the Non-Employee Directors Equity Incentive Plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total number of shares of common stock that may be issued pursuant to stock awards under the Equity Incentive Plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total number of shares of common stock that may be issued pursuant to stock awards under the Non-Employee Directors Equity Incentive Plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_Totalvalueofsharesbynonemployeeinayear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total value of shares by nonemployee in a year - represents amounts under which non-employee director may be granted awards under the Non-Employee Directors Equity Incentive Plan such that the aggregate grant date fair value may not exceed $500,000 in any calendar year</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_Totalvalueofsharesbynonemployeeinayear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCarryingBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost basis for treasury stock acquired for purposes other than retirement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCarryingBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockPreferredValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount allocated to previously issued preferred shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockPreferredValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140624937207056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Awards (Details 2) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 2.30<span></span>
</td>
<td class="nump">$ 4.85<span></span>
</td>
<td class="nump">$ 2.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Total Intrinsic Value</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">7 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</a></td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="nump">12,349<span></span>
</td>
<td class="nump">8,367<span></span>
</td>
<td class="nump">8,397<span></span>
</td>
<td class="nump">7,695<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 5.10<span></span>
</td>
<td class="nump">$ 6.80<span></span>
</td>
<td class="nump">$ 7.12<span></span>
</td>
<td class="nump">$ 8.95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="nump">5,099<span></span>
</td>
<td class="nump">1,808<span></span>
</td>
<td class="nump">3,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</a></td>
<td class="nump">$ 2.97<span></span>
</td>
<td class="nump">$ 6.39<span></span>
</td>
<td class="nump">$ 3.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(376)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4.37<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</a></td>
<td class="num">(163)<span></span>
</td>
<td class="num">(191)<span></span>
</td>
<td class="num">(236)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</a></td>
<td class="nump">$ 12.50<span></span>
</td>
<td class="nump">$ 12.50<span></span>
</td>
<td class="nump">$ 12.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</a></td>
<td class="num">(954)<span></span>
</td>
<td class="num">(1,271)<span></span>
</td>
<td class="num">(2,557)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</a></td>
<td class="nump">$ 7.41<span></span>
</td>
<td class="nump">$ 8.17<span></span>
</td>
<td class="nump">$ 6.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</a></td>
<td class="nump">5,747<span></span>
</td>
<td class="nump">5,032<span></span>
</td>
<td class="nump">4,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</a></td>
<td class="nump">$ 7.00<span></span>
</td>
<td class="nump">$ 7.99<span></span>
</td>
<td class="nump">$ 9.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140624938120080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Awards (Details 3) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Stock Bonus and Restricted Stock, Grants in Period</a></td>
<td class="nump">74,416<span></span>
</td>
<td class="nump">32,192<span></span>
</td>
<td class="nump">85,104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Stock Bonus and Restricted Stock to Consultants, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 1.77<span></span>
</td>
<td class="nump">$ 5.04<span></span>
</td>
<td class="nump">$ 1.86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</a></td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="nump">$ 8,700<span></span>
</td>
<td class="nump">$ 3,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants of stock bonus and restricted stock awards made during the period under equity incentive plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant date fair value for grants of stock bonus and restricted stock awards made to consultants during the period under equity incentive plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140624936312336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Awards (Details 4) - Restricted Stock Units (RSUs) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</a></td>
<td class="nump">2,748<span></span>
</td>
<td class="nump">1,854<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 3.78<span></span>
</td>
<td class="nump">$ 5.16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</a></td>
<td class="nump">2,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 3.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</a></td>
<td class="num">(1,012)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 4.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</a></td>
<td class="num">(279)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period, Weighted Average Fair Value</a></td>
<td class="nump">$ 4.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140624942847584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Benefit Plan (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_BenefitPlanAbstract', window );"><strong>Benefit Plan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Defined Contribution Plan, Cost</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_DefinedContributionPlanRequisiteServicePeriod', window );">Years of service</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_BenefitPlanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Benefit Plan [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_BenefitPlanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_DefinedContributionPlanRequisiteServicePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Contribution Plan, Requisite Service Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_DefinedContributionPlanRequisiteServicePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140624937310608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_CollaborationAndLicenseAgreementsAbstract', window );"><strong>Collaboration and License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_IpsenRevenueRecognized', window );">Ipsen Revenue Recognized</a></td>
<td class="nump">$ 0.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_Ipsenproductsales', window );">Ipsen product sales</a></td>
<td class="nump">$ 1.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_CollaborationAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration and License Agreements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_CollaborationAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_IpsenRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the revenue recognized in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_IpsenRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_Ipsenproductsales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl outside the United States and Japan. This represents the amount of product sales to Ipsen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_Ipsenproductsales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140624940233984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
<td class="num">$ (101,944)<span></span>
</td>
<td class="num">$ (87,758)<span></span>
</td>
<td class="num">$ (58,574)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings Per Share, Basic</a></td>
<td class="num">$ (0.62)<span></span>
</td>
<td class="num">$ (0.60)<span></span>
</td>
<td class="num">$ (0.53)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic', window );">Weighted Average Number of Shares Issued, Basic</a></td>
<td class="nump">165,733<span></span>
</td>
<td class="nump">145,652<span></span>
</td>
<td class="nump">110,841<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e2646-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesIssuedBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140624937191936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Quarterly Financial Data (Unaudited) - Quarterly Financial Information (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 139<span></span>
</td>
<td class="nump">$ 298<span></span>
</td>
<td class="nump">$ 23,995<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (Loss) From Operations</a></td>
<td class="num">(100,760)<span></span>
</td>
<td class="num">(87,090)<span></span>
</td>
<td class="num">(47,800)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (101,944)<span></span>
</td>
<td class="num">$ (87,758)<span></span>
</td>
<td class="num">$ (58,574)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic', window );">Weighted Average Number of Shares Issued, Basic</a></td>
<td class="nump">165,733<span></span>
</td>
<td class="nump">145,652<span></span>
</td>
<td class="nump">110,841<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings Per Share, Basic</a></td>
<td class="num">$ (0.62)<span></span>
</td>
<td class="num">$ (0.60)<span></span>
</td>
<td class="num">$ (0.53)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedFinancialStatementsCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedFinancialStatementsCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e2646-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesIssuedBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140624938215120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Asset Sale (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetRetirementObligationDisclosureAbstract', window );"><strong>Asset Retirement Obligation Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Proceeds from Sale of Productive Assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 160,385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax', window );">Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,200)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_GainOnSaleOfNonFinancialAssets', window );">Gain on sale of non-financial assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">132,585<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_FinalConsiderationIncludingAmountsReleasedToSettle', window );">Final Consideration including amounts released to settle</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfProvedProperty', window );">Gain (Loss) on Disposition of Proved Property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(132,585)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=naics_ZZ541713', window );">541713 Research and Development in Nanotechnology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetRetirementObligationDisclosureAbstract', window );"><strong>Asset Retirement Obligation Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetRetirementObligationDisclosureAbstract', window );"><strong>Asset Retirement Obligation Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_FinalConsiderationIncludingAmountsReleasedToSettle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Final Consideration including amounts released to settle</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_FinalConsiderationIncludingAmountsReleasedToSettle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_GainOnSaleOfNonFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain on sale of non-financial assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_GainOnSaleOfNonFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetRetirementObligationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetRetirementObligationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfProvedProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property with proven oil and gas reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfProvedProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=naics_ZZ541713">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=naics_ZZ541713</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140624940736560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Capital Agreements (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of Stock, Number of Shares Issued in Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,312,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_ProceedsFromDecember2020CommonStockOffering', window );">Proceeds from December 2020 common stock offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_CommissionsFromDecember2020CommonStockOffering', window );">Commissions from December 2020 Common Stock Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_OfferingExpensesFromDecember20CommonStockOffering', window );">Offering expenses from December 20 common stock offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_SharesSoldInNov2020ATMOffering', window );">Shares sold in Nov 2020 ATM Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,709,233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_SharePriceInNovember20ATMOffering', window );">Share price in November 20 ATM Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.992<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_ProceedsFromNov2020ATMOffering', window );">Proceeds from Nov 2020 ATM Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_SharesSoldInJanuary2021ATMOffering', window );">Shares sold in January 2021 ATM offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_SharePriceInJanuary2021ATMOffering', window );">Share price in January 2021 ATM Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_ProceedsFromJanuary2021ATMOffering', window );">Proceeds from January 2021 ATM Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_SharesSoldInSeptember2021ATMOffering', window );">Shares sold in September 2021 ATM offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,176,953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_SharePriceInSeptember2021ATMOffering', window );">Share Price in September 2021 ATM Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_ProceedsFromSeptember2021ATMOffering', window );">Proceeds from September 2021 ATM Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_ProceedsFromJuly2022Offering', window );">Proceeds from July 2022 Offering</a></td>
<td class="nump">$ 94,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_SharesSoldInJuly2022Offering', window );">Shares sold in July 2022 Offering</a></td>
<td class="nump">39,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_SharePriceInJuly2022Offering', window );">Share Price in July 2022 Offering</a></td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_ATMOffering2020Total', window );">ATM Offering 2020 Total</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ATMOffering2020Total">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ATM Offering 2020 Total</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ATMOffering2020Total</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_CommissionsFromDecember2020CommonStockOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commissions from December 2020 Common Stock Offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_CommissionsFromDecember2020CommonStockOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_OfferingExpensesFromDecember20CommonStockOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Offering expenses from December 20 common stock offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_OfferingExpensesFromDecember20CommonStockOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ProceedsFromDecember2020CommonStockOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from December 2020 common stock offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ProceedsFromDecember2020CommonStockOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ProceedsFromJanuary2021ATMOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from January 2021 ATM Offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ProceedsFromJanuary2021ATMOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ProceedsFromJuly2022Offering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from July 2022 Offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ProceedsFromJuly2022Offering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ProceedsFromNov2020ATMOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Nov 2020 ATM Offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ProceedsFromNov2020ATMOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ProceedsFromSeptember2021ATMOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from September 2021 ATM Offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ProceedsFromSeptember2021ATMOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SharePriceInJanuary2021ATMOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share price in January 2021 ATM Offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SharePriceInJanuary2021ATMOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SharePriceInJuly2022Offering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Price in July 2022 Offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SharePriceInJuly2022Offering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SharePriceInNovember20ATMOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share price in November 20 ATM Offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SharePriceInNovember20ATMOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SharePriceInSeptember2021ATMOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Price in September 2021 ATM Offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SharePriceInSeptember2021ATMOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SharesSoldInJanuary2021ATMOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares sold in January 2021 ATM offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SharesSoldInJanuary2021ATMOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SharesSoldInJuly2022Offering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares sold in July 2022 Offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SharesSoldInJuly2022Offering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SharesSoldInNov2020ATMOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares sold in Nov 2020 ATM Offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SharesSoldInNov2020ATMOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SharesSoldInSeptember2021ATMOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares sold in September 2021 ATM offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SharesSoldInSeptember2021ATMOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>lxrx-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:lxrx="http://www.lexpharma.com/20221231"
  xmlns:naics="http://xbrl.sec.gov/naics/2022"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="lxrx-20221231.xsd" xlink:type="simple"/>
    <context id="ied714a94cdc9470b8062452bba89125d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="icf43ab9deda34d99b2dc4e7beae89d69_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iba28186a17904066a6f7804d947264f5_I20230301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2023-03-01</instant>
        </period>
    </context>
    <context id="i024c9d1784a74539a536ca837e05f772_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if253b46ef2a74bc69b4c2082a05ba597_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i55a81403781f47ae9d02222240bdb36d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i940ed9833e654f3e88d67e4c166a14f2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i26b899de75ec4971bee2701c59fba66c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i25c577e3042140158482c3aaff32919b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4d199e0bcee94bea905035d961fbf255_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0476085741da4ed6ae45811b14d11523_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i45c9e62c4e06465f8dea40fec66356eb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9edf2464575242e584cd5272e2783ba2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ica463ea57f7c4e77aece9c9b75812753_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3e407eae82ed45778d1645f5a4b283c9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icb1c532e55244fa7aaed402560483d25_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i08c5d241fccc478597d48a4e079af792_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4f65a415e8d8463d8ca0eb8a49eab0a1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic9c28386ac3f4264b971d6c2d1d20518_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie40de31d8a53466dbe16c3026141f0bf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i127c83dde28a497289a43680bd2d274e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i811c34b23fae41e08987de7c90d2a75f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9a9aae42bd8341688cde38a2a191ea99_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ief9b221acfd5465cb83500067a09fff2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i99a04acc720b46cabd4ee3c5a2dd0674_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib42da41ca5a14b988815a9effcc674cd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7d1bda838f674f4eaaa6f31e5ff61ec4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1922c7bd454f43a4af07205eb1f1b25a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idbbc5e8a454e4cb5bff0e55c593bf0bd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4acd250f6fd84660b1b2a85f4f5e4a20_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i325272f405d94467a8e21c4ffc1fe333_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9a0a6b3dd9e245ab82da25e46d931740_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8d9d5924ae0a4ce3964a5ae029dd6486_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1198e2c5aacd45858d7c4371b727d5b2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i56c0cc327a1d4ed19387c28bde2e3ffb_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ifd14ef30697244ac8b81d3b8376f5d6b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia9a66cc8a08d4b5d95fc1a3de8f017a0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4961ca3cf71d48c3a2dc88cfab3d52f8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9f6ebc10d76e49c0bef5f073adb72d4b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i959cffadb372413d8e83d72e239e6ded_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2fcd93af513045eba562f9ff41a202ac_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib1e8bc9bcf1a4a439d70f50e536be574_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i38cd1975ba6645358dfa68c819a70fb8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ief3a42398bf74858b5aa075d327d0116_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0126e8a6d33142d5912c3766ac53314e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if1ed3c23317249048fd1e594aaae930b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic47b53ad6bac40f099489e67c81c19de_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9f10e15a388c4c8a99f1402fbd71ee00_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i841f2e01285341bc84e68db28065de33_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i05102cf0094245939ba4bd0df2517905_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib86823c5a00d40e98853633ef7fadf56_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5904a39d50aa48738bfa16090d0521a4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idde6749a549b4ccc8f95351b92d40bce_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i45721c6af18946ed9ca1743c070424b5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i512fe0c004b04e38b6d7b9742c09feab_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9dfe8c84430c424597db1dafc1f3fd2e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i70df917b1e21470f80121f484c414360_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4663c2e38d1a45debc09ce327eed516d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i116622a8a31c498b8b13d9c3ba470fd3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5d9a3d2b722d442a81512dcfc7684e90_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i80407335c811483eb7ec1795e3a17f08_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iada15b389ba44ae5ad53399ba96f0121_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ifaa3a61f9810465ab321c51897417ed6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie3c76eaf4e9546efa476fcd01ad729ac_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i152a1c1f46d945e2acc800b6dd644332_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib432f651cb92444fa72128093d268fb8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib2362482683d4d88854d2053c48290a6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if1b08918d03a41e9ba2aa7258f976949_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3c2e209ef7da4beea635d107d3eae5eb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie3fa401e333b4caead7644933a30b5df_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i572e39a39bbe428abb0ea4530d55ece2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia7709100c2ea472b8bf3b0dacf1d3df5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2e34aff763f34fe18a41ebd0245a5197_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5c4b46c8c9cd4829a9a8f58250be63e9_I20010712">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2001-07-12</instant>
        </period>
    </context>
    <context id="i7ca5f952951f4661bc87adf40c2f03b1_I20100730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2010-07-30</instant>
        </period>
    </context>
    <context id="i2e6700e3a4984b19b27e50bda5764ecb_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5082f56c08c74c63a4b9fbd86c1e2db5_D20250101-20251231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="ic2f7712d90c8455ebf945f797fd6c4c5_D20260101-20261231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-12-31</endDate>
        </period>
    </context>
    <context id="i58efde7a50b54415affc844b791d1774_D20270101-20271231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2027-01-01</startDate>
            <endDate>2027-12-31</endDate>
        </period>
    </context>
    <context id="if284e805242a400b99ebf80651bc00de_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ifaed8b1899ba47ddb389bc7180e9188b_D20141101-20141130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2014-11-01</startDate>
            <endDate>2014-11-30</endDate>
        </period>
    </context>
    <context id="idb9d77e7bb0d49ef814ea91873a8ee6f_D20180801-20180831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2018-08-01</startDate>
            <endDate>2018-08-31</endDate>
        </period>
    </context>
    <context id="i84cdb8b224f3426da99041ee143ab064_I20180830">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2018-08-30</instant>
        </period>
    </context>
    <context id="i4d539018a70542119bc755c3276bee16_I20171218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2017-12-18</instant>
        </period>
    </context>
    <context id="i28b8859c0c154ed482c84e3ab218642d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8686f139ef8d4193a880a31b12d0ce30_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i038e4801d2d648b38d0de7b8dab0f316_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib525d01afa1f498e883536f24362d124_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1be397a2eed340ea9795e0c692981bed_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i94f2adcb200344b890fec8dc81de1ae6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1754ae6b09344ad1a9be3815a19dcd30_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i431b23e0248d40349e27b0f5be856e54_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idba6d48abf934e46bb6d9906a7959407_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id0b2ee1a17b243b4a95803b356639783_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idc54e15956a14d6a8516b3a8816e8281_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4aff0769c8dc406faa9ff4224da35cc9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">naics:ZZ541713</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id9c84c90905348f0bcea48d159d00b8e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="segment">
        <measure>lxrx:segment</measure>
    </unit>
    <unit id="rate">
        <measure>utr:Rate</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y180L2ZyYWc6MWY2MGQ5ZGY4NjNlNGI3Njk2NTQxZDVhNTJiMGE1ZTgvdGFibGU6YjZmMzk2ZDZhNjllNGRkNmI2N2E3MWE5MzgyOGZiYmMvdGFibGVyYW5nZTpiNmYzOTZkNmE2OWU0ZGQ2YjY3YTcxYTkzODI4ZmJiY180LTEtMS0xLTMzMjAz_ef5abe66-3c7b-491d-a4b2-b13f869b5e65">0001062822</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y180L2ZyYWc6MWY2MGQ5ZGY4NjNlNGI3Njk2NTQxZDVhNTJiMGE1ZTgvdGFibGU6YjZmMzk2ZDZhNjllNGRkNmI2N2E3MWE5MzgyOGZiYmMvdGFibGVyYW5nZTpiNmYzOTZkNmE2OWU0ZGQ2YjY3YTcxYTkzODI4ZmJiY181LTEtMS0xLTMzMjAz_a26bcd1d-b12f-47a7-b7aa-4a34d853fb72">2019</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y180L2ZyYWc6MWY2MGQ5ZGY4NjNlNGI3Njk2NTQxZDVhNTJiMGE1ZTgvdGFibGU6YjZmMzk2ZDZhNjllNGRkNmI2N2E3MWE5MzgyOGZiYmMvdGFibGVyYW5nZTpiNmYzOTZkNmE2OWU0ZGQ2YjY3YTcxYTkzODI4ZmJiY182LTEtMS0xLTMzMjAz_33395e2d-f04d-4387-b832-a82139b31a8d">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y180L2ZyYWc6MWY2MGQ5ZGY4NjNlNGI3Njk2NTQxZDVhNTJiMGE1ZTgvdGFibGU6YjZmMzk2ZDZhNjllNGRkNmI2N2E3MWE5MzgyOGZiYmMvdGFibGVyYW5nZTpiNmYzOTZkNmE2OWU0ZGQ2YjY3YTcxYTkzODI4ZmJiY183LTEtMS0xLTMzMjAz_1d0c1d46-4a68-4c01-ab7f-bb8382ba59b8">false</dei:AmendmentFlag>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i38cd1975ba6645358dfa68c819a70fb8_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzM5MTE_558fa410-9f8f-4ae0-80f8-17c88e115072">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:DebtInstrumentTerm
      contextRef="idb9d77e7bb0d49ef814ea91873a8ee6f_D20180801-20180831"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzIzNzk_9029d41a-c8aa-4619-a57b-c3c4b9a9cbad">P2Y</us-gaap:DebtInstrumentTerm>
    <lxrx:DeferredCompensationArrangementWithIndividualPaymentPeriod
      contextRef="i38cd1975ba6645358dfa68c819a70fb8_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzgvZnJhZzplN2M4MTQ2M2ZkZWE0YWU5ODVmMWZmN2Q0YjI1ZTliNy90ZXh0cmVnaW9uOmU3YzgxNDYzZmRlYTRhZTk4NWYxZmY3ZDRiMjVlOWI3XzEzMzM_0e763c45-71c7-4867-9a1b-bb54280dc662">P6M</lxrx:DeferredCompensationArrangementWithIndividualPaymentPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i431b23e0248d40349e27b0f5be856e54_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzM2NTc_da5a4fdb-478f-48e1-83dd-2888411ee7f9">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xL2ZyYWc6ODMzN2RkMDhiM2IzNDVhN2ExNDdkZDVlNzUwNTA1NzMvdGV4dHJlZ2lvbjo4MzM3ZGQwOGIzYjM0NWE3YTE0N2RkNWU3NTA1MDU3M184NA_fbb7b189-e056-4e85-a2d9-858bf8134d83">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xL2ZyYWc6ODMzN2RkMDhiM2IzNDVhN2ExNDdkZDVlNzUwNTA1NzMvdGFibGU6ZjhmNzAyMDJhZTJmNDc2ZThkZWM1NTBkY2UyODBiMWIvdGFibGVyYW5nZTpmOGY3MDIwMmFlMmY0NzZlOGRlYzU1MGRjZTI4MGIxYl8xLTAtMS0xLTMzMjAz_89d58c01-fd4a-45b8-908a-e5e95927cf1b">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xL2ZyYWc6ODMzN2RkMDhiM2IzNDVhN2ExNDdkZDVlNzUwNTA1NzMvdGFibGU6ZjhmNzAyMDJhZTJmNDc2ZThkZWM1NTBkY2UyODBiMWIvdGFibGVyYW5nZTpmOGY3MDIwMmFlMmY0NzZlOGRlYzU1MGRjZTI4MGIxYl8zLTItMS0xLTMzMjAz_e307e203-a105-4330-846d-9e1af664e1bd">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xL2ZyYWc6ODMzN2RkMDhiM2IzNDVhN2ExNDdkZDVlNzUwNTA1NzMvdGFibGU6ZjhmNzAyMDJhZTJmNDc2ZThkZWM1NTBkY2UyODBiMWIvdGFibGVyYW5nZTpmOGY3MDIwMmFlMmY0NzZlOGRlYzU1MGRjZTI4MGIxYl8zLTItMS0xLTMzMjAz_092776f3-6f03-4220-9ad5-6c05936ce1ba">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xL2ZyYWc6ODMzN2RkMDhiM2IzNDVhN2ExNDdkZDVlNzUwNTA1NzMvdGFibGU6MTdhNzQ3NWJjM2UyNGYxNjlkYmUxMWJmMDE3YTFmZDkvdGFibGVyYW5nZToxN2E3NDc1YmMzZTI0ZjE2OWRiZTExYmYwMTdhMWZkOV8wLTAtMS0xLTMzMjAz_2a327825-5519-4592-a797-e8c5fbf49c89">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xL2ZyYWc6ODMzN2RkMDhiM2IzNDVhN2ExNDdkZDVlNzUwNTA1NzMvdGV4dHJlZ2lvbjo4MzM3ZGQwOGIzYjM0NWE3YTE0N2RkNWU3NTA1MDU3M18xMTg_1eb24bdd-ab03-4245-afea-1aec7196f983">000-30111</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xL2ZyYWc6ODMzN2RkMDhiM2IzNDVhN2ExNDdkZDVlNzUwNTA1NzMvdGV4dHJlZ2lvbjo4MzM3ZGQwOGIzYjM0NWE3YTE0N2RkNWU3NTA1MDU3M18zNDQ2_3820ce96-4453-4a17-bd2b-866b6b2f9a75">Lexicon Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xL2ZyYWc6ODMzN2RkMDhiM2IzNDVhN2ExNDdkZDVlNzUwNTA1NzMvdGFibGU6MmQ0YTJmZmEwMTU4NGM4NzgzNTU2NTRiMzRkZWEwOWEvdGFibGVyYW5nZToyZDRhMmZmYTAxNTg0Yzg3ODM1NTY1NGIzNGRlYTA5YV8wLTEtMS0xLTMzMjAz_11a6bed2-62e6-4da1-8d93-fb8d4be406da">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xL2ZyYWc6ODMzN2RkMDhiM2IzNDVhN2ExNDdkZDVlNzUwNTA1NzMvdGFibGU6MmQ0YTJmZmEwMTU4NGM4NzgzNTU2NTRiMzRkZWEwOWEvdGFibGVyYW5nZToyZDRhMmZmYTAxNTg0Yzg3ODM1NTY1NGIzNGRlYTA5YV8wLTMtMS0xLTMzMjAz_5f31f940-8a9b-40bf-8e63-3502ff09607a">76-0474169</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xL2ZyYWc6ODMzN2RkMDhiM2IzNDVhN2ExNDdkZDVlNzUwNTA1NzMvdGFibGU6NWVhMmRiNzIzOGU1NDkyYmI0YjAyYmZiNjJiZDc3NDIvdGFibGVyYW5nZTo1ZWEyZGI3MjM4ZTU0OTJiYjRiMDJiZmI2MmJkNzc0Ml8wLTEtMS0xLTMzMjAz_1f6be936-447b-45e4-9f8c-8b085aba81a6">2445 Technology Forest Blvd., 11th Floor</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xL2ZyYWc6ODMzN2RkMDhiM2IzNDVhN2ExNDdkZDVlNzUwNTA1NzMvdGFibGU6NWVhMmRiNzIzOGU1NDkyYmI0YjAyYmZiNjJiZDc3NDIvdGFibGVyYW5nZTo1ZWEyZGI3MjM4ZTU0OTJiYjRiMDJiZmI2MmJkNzc0Ml8xLTEtMS0xLTMzMjAz_aeeff42e-8f4d-413e-880a-688e205991eb">The Woodlands,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xL2ZyYWc6ODMzN2RkMDhiM2IzNDVhN2ExNDdkZDVlNzUwNTA1NzMvdGFibGU6NWVhMmRiNzIzOGU1NDkyYmI0YjAyYmZiNjJiZDc3NDIvdGFibGVyYW5nZTo1ZWEyZGI3MjM4ZTU0OTJiYjRiMDJiZmI2MmJkNzc0Ml8xLTItMS0xLTMzMjAz_eb856af6-11ca-4290-a1f2-c8279f77e0df">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xL2ZyYWc6ODMzN2RkMDhiM2IzNDVhN2ExNDdkZDVlNzUwNTA1NzMvdGFibGU6NWVhMmRiNzIzOGU1NDkyYmI0YjAyYmZiNjJiZDc3NDIvdGFibGVyYW5nZTo1ZWEyZGI3MjM4ZTU0OTJiYjRiMDJiZmI2MmJkNzc0Ml8xLTMtMS0xLTMzMjAz_129e4ae6-73d0-4aa6-855c-3c8d3cc10fc9">77381</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xL2ZyYWc6ODMzN2RkMDhiM2IzNDVhN2ExNDdkZDVlNzUwNTA1NzMvdGFibGU6NWVhMmRiNzIzOGU1NDkyYmI0YjAyYmZiNjJiZDc3NDIvdGFibGVyYW5nZTo1ZWEyZGI3MjM4ZTU0OTJiYjRiMDJiZmI2MmJkNzc0Ml8xLTUtMS0xLTQwOTQy_07d496d6-ca65-4ba3-972f-375dc74d2a9f">(281)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xL2ZyYWc6ODMzN2RkMDhiM2IzNDVhN2ExNDdkZDVlNzUwNTA1NzMvdGFibGU6NWVhMmRiNzIzOGU1NDkyYmI0YjAyYmZiNjJiZDc3NDIvdGFibGVyYW5nZTo1ZWEyZGI3MjM4ZTU0OTJiYjRiMDJiZmI2MmJkNzc0Ml8xLTYtMS0xLTQwOTQy_002d890f-44e9-4a85-8b4d-b6a889103407">863-3000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xL2ZyYWc6ODMzN2RkMDhiM2IzNDVhN2ExNDdkZDVlNzUwNTA1NzMvdGFibGU6MGUxOGMwY2M0NGM1NDU5YTg4YmIxNzAzYWE0ZGFmZDUvdGFibGVyYW5nZTowZTE4YzBjYzQ0YzU0NTlhODhiYjE3MDNhYTRkYWZkNV8xLTEtMS0xLTMzMjAz_7e323f52-cb28-45f4-b507-01d952890053">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xL2ZyYWc6ODMzN2RkMDhiM2IzNDVhN2ExNDdkZDVlNzUwNTA1NzMvdGFibGU6MGUxOGMwY2M0NGM1NDU5YTg4YmIxNzAzYWE0ZGFmZDUvdGFibGVyYW5nZTowZTE4YzBjYzQ0YzU0NTlhODhiYjE3MDNhYTRkYWZkNV8xLTItMS0xLTMzMjAz_5d36a8b8-ea8b-4ce4-bd2f-39e0383af31d">LXRX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xL2ZyYWc6ODMzN2RkMDhiM2IzNDVhN2ExNDdkZDVlNzUwNTA1NzMvdGFibGU6MGUxOGMwY2M0NGM1NDU5YTg4YmIxNzAzYWE0ZGFmZDUvdGFibGVyYW5nZTowZTE4YzBjYzQ0YzU0NTlhODhiYjE3MDNhYTRkYWZkNV8xLTMtMS0xLTMzMjAz_18ab8b72-5cda-4543-a5dc-a6b71b69d5c0">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xL2ZyYWc6ODMzN2RkMDhiM2IzNDVhN2ExNDdkZDVlNzUwNTA1NzMvdGV4dHJlZ2lvbjo4MzM3ZGQwOGIzYjM0NWE3YTE0N2RkNWU3NTA1MDU3M180NzI_39efe224-f399-4252-b081-7d07c1787513">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xL2ZyYWc6ODMzN2RkMDhiM2IzNDVhN2ExNDdkZDVlNzUwNTA1NzMvdGV4dHJlZ2lvbjo4MzM3ZGQwOGIzYjM0NWE3YTE0N2RkNWU3NTA1MDU3M182Mzk_a48a486f-90df-40ba-9de9-fd914a9c6acc">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xL2ZyYWc6ODMzN2RkMDhiM2IzNDVhN2ExNDdkZDVlNzUwNTA1NzMvdGV4dHJlZ2lvbjo4MzM3ZGQwOGIzYjM0NWE3YTE0N2RkNWU3NTA1MDU3M185OTA_1a61a59d-953b-43f4-b642-c84e7031ec24">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xL2ZyYWc6ODMzN2RkMDhiM2IzNDVhN2ExNDdkZDVlNzUwNTA1NzMvdGV4dHJlZ2lvbjo4MzM3ZGQwOGIzYjM0NWE3YTE0N2RkNWU3NTA1MDU3M18xMjkz_030e8f5e-00b9-4801-a895-0ea8f75aeb28">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xL2ZyYWc6ODMzN2RkMDhiM2IzNDVhN2ExNDdkZDVlNzUwNTA1NzMvdGV4dHJlZ2lvbjo4MzM3ZGQwOGIzYjM0NWE3YTE0N2RkNWU3NTA1MDU3M18xNzA4_f1b619aa-01e9-4f5e-b45d-ca4a08262900">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xL2ZyYWc6ODMzN2RkMDhiM2IzNDVhN2ExNDdkZDVlNzUwNTA1NzMvdGV4dHJlZ2lvbjo4MzM3ZGQwOGIzYjM0NWE3YTE0N2RkNWU3NTA1MDU3M18zNDQ3_659e23c8-07a5-4fc2-bf84-286d73cf69c3">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xL2ZyYWc6ODMzN2RkMDhiM2IzNDVhN2ExNDdkZDVlNzUwNTA1NzMvdGV4dHJlZ2lvbjo4MzM3ZGQwOGIzYjM0NWE3YTE0N2RkNWU3NTA1MDU3M18xNzky_c2e99485-3f2f-4028-bb31-2bdce9c0cec8">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xL2ZyYWc6ODMzN2RkMDhiM2IzNDVhN2ExNDdkZDVlNzUwNTA1NzMvdGV4dHJlZ2lvbjo4MzM3ZGQwOGIzYjM0NWE3YTE0N2RkNWU3NTA1MDU3M18zNDQ4_bbd5ad2b-4eee-4006-85a5-5dbec16f68fc">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xL2ZyYWc6ODMzN2RkMDhiM2IzNDVhN2ExNDdkZDVlNzUwNTA1NzMvdGV4dHJlZ2lvbjo4MzM3ZGQwOGIzYjM0NWE3YTE0N2RkNWU3NTA1MDU3M18yNTQz_09105619-3530-48a2-bd21-41769bd59760">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="icf43ab9deda34d99b2dc4e7beae89d69_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xL2ZyYWc6ODMzN2RkMDhiM2IzNDVhN2ExNDdkZDVlNzUwNTA1NzMvdGV4dHJlZ2lvbjo4MzM3ZGQwOGIzYjM0NWE3YTE0N2RkNWU3NTA1MDU3M18yNzMx_60e2b2bc-b215-43a5-b51d-e275cc7d22bb"
      unitRef="usd">134400000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="iba28186a17904066a6f7804d947264f5_I20230301"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xL2ZyYWc6ODMzN2RkMDhiM2IzNDVhN2ExNDdkZDVlNzUwNTA1NzMvdGV4dHJlZ2lvbjo4MzM3ZGQwOGIzYjM0NWE3YTE0N2RkNWU3NTA1MDU3M18xMDk5NTExNjMxNDA0_e163cafe-ead7-4921-b980-be464d84fe19"
      unitRef="shares">188725743</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xL2ZyYWc6ODMzN2RkMDhiM2IzNDVhN2ExNDdkZDVlNzUwNTA1NzMvdGV4dHJlZ2lvbjo4MzM3ZGQwOGIzYjM0NWE3YTE0N2RkNWU3NTA1MDU3M18zNDQ5_2f375968-bb89-4895-92c1-bcb4826093fe">Certain sections of the registrant&#x2019;s definitive proxy statement relating to the registrant&#x2019;s 2023 annual meeting of stockholders, which proxy statement will be filed under the Securities Exchange Act of 1934 within 120 days of the end of the registrant&#x2019;s fiscal year ended December&#160;31, 2022, are incorporated by reference into Part III of this annual report on Form 10-K.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorName
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y184NS9mcmFnOmUwZDEzMTA1Zjk3OTRjY2I5NGM3NzZhNmZiMDJiNWFjL3RleHRyZWdpb246ZTBkMTMxMDVmOTc5NGNjYjk0Yzc3NmE2ZmIwMmI1YWNfMjU0NA_0d20f740-20f4-4348-bf42-9893788a6da7">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y184NS9mcmFnOmUwZDEzMTA1Zjk3OTRjY2I5NGM3NzZhNmZiMDJiNWFjL3RleHRyZWdpb246ZTBkMTMxMDVmOTc5NGNjYjk0Yzc3NmE2ZmIwMmI1YWNfMjU0NQ_f68411df-fee5-445c-9a89-be02c4eb9c9c">Houston, Texas</dei:AuditorLocation>
    <dei:AuditorFirmId
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y184NS9mcmFnOmUwZDEzMTA1Zjk3OTRjY2I5NGM3NzZhNmZiMDJiNWFjL3RleHRyZWdpb246ZTBkMTMxMDVmOTc5NGNjYjk0Yzc3NmE2ZmIwMmI1YWNfMjU0Ng_dce591cb-5fce-4301-a7c0-d1b8076d68fc">42</dei:AuditorFirmId>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzQtMS0xLTEtMzMyMDM_925732dc-9b01-492f-ac38-54ac5a55da6a"
      unitRef="usd">46345000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzQtMy0xLTEtMzMyMDM_eab74309-30fc-4fc0-a30e-467a686670ce"
      unitRef="usd">64065000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzUtMS0xLTEtMzMyMDM_fb2e20e7-5337-4a75-b4fe-81e7990058fd"
      unitRef="usd">92012000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzUtMy0xLTEtMzMyMDM_0e11d4e2-cc5e-4110-a8d3-045fd7371ce7"
      unitRef="usd">22678000</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzYtMS0xLTEtMzMyMDM_5aa20657-5203-497a-990b-c834f8b40e4c"
      unitRef="usd">28000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzYtMy0xLTEtMzMyMDM_0623ae8b-43fb-4754-a021-b16b1dc21790"
      unitRef="usd">14000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzktMS0xLTEtMzMyMDM_667c7a4d-734e-41c7-8e69-a6840404ac45"
      unitRef="usd">2481000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzktMy0xLTEtMzMyMDM_4636498f-2bb9-417b-9a12-eef73715903c"
      unitRef="usd">2164000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzEwLTEtMS0xLTMzMjAz_643b7a53-39d8-4636-bb6a-973da986fdb4"
      unitRef="usd">140866000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzEwLTMtMS0xLTMzMjAz_ba31cd7f-3f95-4504-9129-59693a9f5273"
      unitRef="usd">88921000</us-gaap:AssetsCurrent>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzExLTAtMS0xLTMzMjAzL3RleHRyZWdpb246YzA2NmM4MjhiYWVkNGU1YWJkMTM1MzgyMDcyOGExNzFfODA_9a7fe9a6-6adb-48c8-9b0a-de234559aa6d"
      unitRef="usd">3984000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzExLTAtMS0xLTMzMjAzL3RleHRyZWdpb246YzA2NmM4MjhiYWVkNGU1YWJkMTM1MzgyMDcyOGExNzFfODc_6b02c76c-5b60-4b76-9b31-9b53196b0974"
      unitRef="usd">4853000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzExLTEtMS0xLTMzMjAz_e061369a-962b-4881-be2e-9233b3ff18b3"
      unitRef="usd">2071000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzExLTMtMS0xLTMzMjAz_0b30fe86-21dd-4e74-87b7-6dc81a99cc64"
      unitRef="usd">1176000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Goodwill
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzEyLTEtMS0xLTMzMjAz_876a854f-45a6-48cc-8609-2080732b34d7"
      unitRef="usd">44543000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzEyLTMtMS0xLTMzMjAz_9154821e-478b-4234-bf22-49eb02a3a7e2"
      unitRef="usd">44543000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzE0LTEtMS0xLTMzMjAz_4230a92b-dd44-444f-b0b4-0e2fa25fd36f"
      unitRef="usd">6819000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssets
      contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzE0LTMtMS0xLTMzMjAz_ff06db99-f4dd-4b47-85f4-0895c8f44278"
      unitRef="usd">2269000</us-gaap:OtherAssets>
    <us-gaap:Assets
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzE1LTEtMS0xLTMzMjAz_3ecc51a9-241e-49e9-8ec5-92cbae817530"
      unitRef="usd">194299000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzE1LTMtMS0xLTMzMjAz_e4a6827c-071b-46e7-bd99-53b5f5102c8a"
      unitRef="usd">136909000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzE4LTEtMS0xLTMzMjAz_afa964c3-8b7e-43f8-a7b6-30f4984f3a84"
      unitRef="usd">10395000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzE4LTMtMS0xLTMzMjAz_0a72f02b-ff69-4825-bcb1-046d1ae76d85"
      unitRef="usd">9152000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzE5LTEtMS0xLTMzMjAz_6f99c203-71a5-4e6a-8650-badb3f80af9b"
      unitRef="usd">12777000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzE5LTMtMS0xLTMzMjAz_9f88ea08-d338-4e6e-971e-876362297635"
      unitRef="usd">12972000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzIyLTEtMS0xLTMzMjAz_54579009-3d17-4da5-8159-9aece3367c6b"
      unitRef="usd">23172000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzIyLTMtMS0xLTMzMjAz_83e21b3c-9263-42da-adee-3895033111c4"
      unitRef="usd">22124000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzI0LTEtMS0xLTMzMjAz_4613baca-314d-4cbc-bf0f-972f6cec7d74"
      unitRef="usd">-48579000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzI0LTMtMS0xLTMzMjAz_37a56631-5208-4b3a-999b-946eabf5e7bb"
      unitRef="usd">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzI2LTEtMS0xLTMzMjAz_f5d826d5-25f6-4107-8dcf-65a0a4c985a0"
      unitRef="usd">5424000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzI2LTMtMS0xLTMzMjAz_973bd826-6b1c-42f4-a2e4-6dc9c1b70ed4"
      unitRef="usd">1190000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzI3LTEtMS0xLTMzMjAz_a9fc19b7-f867-40ac-85e4-ec1ba2ea1ae9"
      unitRef="usd">77175000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzI3LTMtMS0xLTMzMjAz_489d2c69-b613-41ab-a5ac-80ab1c82a7ba"
      unitRef="usd">23314000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzI4LTEtMS0xLTMzMjAz_d0cfd92e-6552-480b-87d9-6ff6963716bb"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzI4LTMtMS0xLTMzMjAz_5a55192b-7aba-4f66-8c3a-a60fa722efef"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzMwLTAtMS0xLTMzMjAzL3RleHRyZWdpb246OGNhNjAwODZlZDY1NDQ0MmIzZjBmNzAzZWQxOGY0OThfMjE_8944aa3b-70bd-4ecb-94b1-231e2fb59d3f"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzMwLTAtMS0xLTMzMjAzL3RleHRyZWdpb246OGNhNjAwODZlZDY1NDQ0MmIzZjBmNzAzZWQxOGY0OThfMjE_f40ea794-2900-471e-968a-b0da17137904"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzMwLTAtMS0xLTMzMjAzL3RleHRyZWdpb246OGNhNjAwODZlZDY1NDQ0MmIzZjBmNzAzZWQxOGY0OThfMzU_4cfcbc8d-32b4-4c08-b63c-5c7298b46a1f"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzMwLTAtMS0xLTMzMjAzL3RleHRyZWdpb246OGNhNjAwODZlZDY1NDQ0MmIzZjBmNzAzZWQxOGY0OThfMzU_8ff54584-a513-4b4d-b2e4-0fbe77abe331"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzMwLTAtMS0xLTMzMjAzL3RleHRyZWdpb246OGNhNjAwODZlZDY1NDQ0MmIzZjBmNzAzZWQxOGY0OThfNTc_0f89c543-e7f7-42f5-afd6-bad6c5c8d1a8"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzMwLTAtMS0xLTMzMjAzL3RleHRyZWdpb246OGNhNjAwODZlZDY1NDQ0MmIzZjBmNzAzZWQxOGY0OThfNTc_a625297b-9277-4952-ba75-32246c8a4dd1"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzMwLTAtMS0xLTMzMjAzL3RleHRyZWdpb246OGNhNjAwODZlZDY1NDQ0MmIzZjBmNzAzZWQxOGY0OThfNTc_ac3520a6-e374-4e5a-a909-91bc7da25120"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzMwLTAtMS0xLTMzMjAzL3RleHRyZWdpb246OGNhNjAwODZlZDY1NDQ0MmIzZjBmNzAzZWQxOGY0OThfNTc_f19a8ffd-2659-4dc7-9772-ca27974fa792"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzMwLTEtMS0xLTMzMjAz_b5da95ab-758d-425b-9bb2-e4c6cb44b316"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzMwLTMtMS0xLTMzMjAz_f4a4ccf5-2077-423f-9cf6-22ffb87089aa"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzMxLTAtMS0xLTMzMjAzL3RleHRyZWdpb246MGViODExNzAyYmI2NGI1Y2I0ODU0ZTEzMjUwMGVkYmJfMTg_20a064d6-4b87-4d13-8ad3-44a677d67bb8"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzMxLTAtMS0xLTMzMjAzL3RleHRyZWdpb246MGViODExNzAyYmI2NGI1Y2I0ODU0ZTEzMjUwMGVkYmJfMTg_f34d9112-53e9-4df1-a9ab-75220106aa1a"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzMxLTAtMS0xLTMzMjAzL3RleHRyZWdpb246MGViODExNzAyYmI2NGI1Y2I0ODU0ZTEzMjUwMGVkYmJfMzI_56e5b451-4fb5-42a5-b1e1-07dc659c525e"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzMxLTAtMS0xLTMzMjAzL3RleHRyZWdpb246MGViODExNzAyYmI2NGI1Y2I0ODU0ZTEzMjUwMGVkYmJfMzI_f30188f5-85a1-47b4-972c-20761336dd45"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i55a81403781f47ae9d02222240bdb36d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzMxLTAtMS0xLTMzMjAzL3RleHRyZWdpb246MGViODExNzAyYmI2NGI1Y2I0ODU0ZTEzMjUwMGVkYmJfNTQ_1ff92a5a-0d47-47ec-b688-42ef1da84c50"
      unitRef="shares">189214000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i940ed9833e654f3e88d67e4c166a14f2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzMxLTAtMS0xLTMzMjAzL3RleHRyZWdpb246MGViODExNzAyYmI2NGI1Y2I0ODU0ZTEzMjUwMGVkYmJfNjE_89746655-8b90-4ab5-b1cd-bc120b681a3d"
      unitRef="shares">150082000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzMxLTEtMS0xLTMzMjAz_975cc197-ee66-4f89-babd-7adb2c8d66fc"
      unitRef="usd">189000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzMxLTMtMS0xLTMzMjAz_4914c01b-d80a-42a6-a9f3-d6a77094e680"
      unitRef="usd">150000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzMyLTEtMS0xLTMzMjAz_f34125f0-3459-4d39-a5f9-13888504bcbb"
      unitRef="usd">1709144000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzMyLTMtMS0xLTMzMjAz_52a93dc2-b1ae-4691-893d-1f032547f655"
      unitRef="usd">1608749000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzMzLTEtMS0xLTMzMjAz_bf360594-2d88-4cd1-8fe1-691784c6a3bb"
      unitRef="usd">-1589720000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzMzLTMtMS0xLTMzMjAz_3a345e15-54c6-4ca2-a57c-ae1572208f15"
      unitRef="usd">-1487776000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzM0LTEtMS0xLTMzMjAz_5a7d013d-9e37-4c1a-ab29-8b33f02de10d"
      unitRef="usd">-428000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzM0LTMtMS0xLTMzMjAz_8c85c817-cc59-4080-8ecb-befdf2490c73"
      unitRef="usd">-10000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:TreasuryStockShares
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzM1LTAtMS0xLTMzMjAzL3RleHRyZWdpb246MTRlMjU1OGVlNmM3NGQwOWFiNDcyZmRhYTU4YmY3ZmRfMjk_71b6dba2-bc99-40d9-8383-8fa2b9e3226c"
      unitRef="shares">488000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzM1LTAtMS0xLTMzMjAzL3RleHRyZWdpb246MTRlMjU1OGVlNmM3NGQwOWFiNDcyZmRhYTU4YmY3ZmRfMzY_ffa3f60e-7304-43ce-82c1-0e0d7209442d"
      unitRef="shares">1165000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzM1LTEtMS0xLTMzMjAz_1b1d86ac-ee08-4a9e-aa74-b429d3198ed8"
      unitRef="usd">2061000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzM1LTMtMS0xLTMzMjAz_21d93460-9ad5-4bce-9a5e-2461fcd4715d"
      unitRef="usd">7518000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquity
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzM2LTEtMS0xLTMzMjAz_cf112a64-e530-4523-b220-c1557ce6ab99"
      unitRef="usd">117124000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzM2LTMtMS0xLTMzMjAz_09a74a3f-7a3e-4fbe-bb73-d5e3180e337f"
      unitRef="usd">113595000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzM3LTEtMS0xLTMzMjAz_45ada8df-b9b5-4a82-b17f-fa5d9850e8a0"
      unitRef="usd">194299000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzMvZnJhZzo2MzI5YzY2NDY3OGI0ZGVkYjgwOTJiMDg5YWU4NTE0Zi90YWJsZTphNDQ3YjliY2QwNTY0MzBmYjdmYWU1ZWMzMjJhYzIyZi90YWJsZXJhbmdlOmE0NDdiOWJjZDA1NjQzMGZiN2ZhZTVlYzMyMmFjMjJmXzM3LTMtMS0xLTMzMjAz_8b16f056-1e4e-4e42-85fd-0d37d1c2c082"
      unitRef="usd">136909000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzMtMS0xLTEtMzMyMDM_3147083f-5f86-4e02-b1eb-2cec4ef07906"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzMtMy0xLTEtMzMyMDM_ddf79040-d624-4cef-be72-77f570bfef78"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzMtNS0xLTEtMzMyMDM_8c5152f3-c2ea-42e0-9872-7b103b4624f0"
      unitRef="usd">23404000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzQtMS0xLTEtMzMyMDM_cad085b4-8214-45f3-9380-16015d2a9f4b"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzQtMy0xLTEtMzMyMDM_dfa06747-5d8b-4fc5-85db-2039ce4b6ef3"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzQtNS0xLTEtMzMyMDM_8dcad617-139a-42fa-a515-d13de0a7d6f1"
      unitRef="usd">33000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RoyaltyIncomeNonoperating
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzUtMS0xLTEtMzMyMDM_e3a384a5-6dc3-4460-91a8-1a0015b26c02"
      unitRef="usd">139000</us-gaap:RoyaltyIncomeNonoperating>
    <us-gaap:RoyaltyIncomeNonoperating
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzUtMy0xLTEtMzMyMDM_c61e382e-ebdd-4674-8bbb-535198bed173"
      unitRef="usd">298000</us-gaap:RoyaltyIncomeNonoperating>
    <us-gaap:RoyaltyIncomeNonoperating
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzUtNS0xLTEtMzMyMDM_43a801c7-8e35-4b01-9e21-9ecc4e845c94"
      unitRef="usd">558000</us-gaap:RoyaltyIncomeNonoperating>
    <us-gaap:Revenues
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzYtMS0xLTEtMzMyMDM_771262d0-10db-41d0-b69c-b3137046f09c"
      unitRef="usd">139000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzYtMy0xLTEtMzMyMDM_7de636c8-be35-498d-8516-ba30a7a80847"
      unitRef="usd">298000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzYtNS0xLTEtMzMyMDM_33c336c9-851b-4831-8bd9-22fecae276e9"
      unitRef="usd">23995000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzgtMS0xLTEtMzMyMDM_054f5d46-c8c4-4e2e-a53d-b257c59a4ad8"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzgtMy0xLTEtMzMyMDM_1fdb649b-bbaf-4955-8106-459122d2d444"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzgtNS0xLTEtMzMyMDM_9ae55a43-6829-4be8-987b-fb6063cf1e27"
      unitRef="usd">1929000</us-gaap:CostOfGoodsAndServicesSold>
    <lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzktMC0xLTEtMzMyMDMvdGV4dHJlZ2lvbjpiODc4YjdiZTdjM2I0NjgzOTFkMDM2Y2I0OWRiMWFmOF82OA_a6b7e64c-16b3-46dc-9c29-786934093e85"
      unitRef="usd">4253000</lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense>
    <lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzktMC0xLTEtMzMyMDMvdGV4dHJlZ2lvbjpiODc4YjdiZTdjM2I0NjgzOTFkMDM2Y2I0OWRiMWFmOF83Mg_9adb9afe-9d13-42d0-9079-281946780e17"
      unitRef="usd">4284000</lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense>
    <lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzktMC0xLTEtMzMyMDMvdGV4dHJlZ2lvbjpiODc4YjdiZTdjM2I0NjgzOTFkMDM2Y2I0OWRiMWFmOF83OQ_176794b1-9989-4c4f-94d7-1f8bb4c62f26"
      unitRef="usd">6376000</lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzktMS0xLTEtMzMyMDM_193204c8-bc1f-4674-a155-e577311b0c93"
      unitRef="usd">52816000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzktMy0xLTEtMzMyMDM_67d68ec8-d8f3-4a29-8b4c-4c0e57df96f1"
      unitRef="usd">55046000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzktNS0xLTEtMzMyMDM_c34938fb-852a-4869-a8ab-464441fb41eb"
      unitRef="usd">153621000</us-gaap:ResearchAndDevelopmentExpense>
    <lxrx:StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzExLTAtMS0xLTMzMjAzL3RleHRyZWdpb246N2U1OGRhZmJmYTY0NDQwN2JjNjA5MjZlMWI5ZDllYTZfNzk_2bf5c633-a75a-4cde-bd83-e6d117ec7f3d"
      unitRef="usd">7267000</lxrx:StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense>
    <lxrx:StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzExLTAtMS0xLTMzMjAzL3RleHRyZWdpb246N2U1OGRhZmJmYTY0NDQwN2JjNjA5MjZlMWI5ZDllYTZfODM_bd422360-6018-4990-87ab-35f59cbd049d"
      unitRef="usd">6293000</lxrx:StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense>
    <lxrx:StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzExLTAtMS0xLTMzMjAzL3RleHRyZWdpb246N2U1OGRhZmJmYTY0NDQwN2JjNjA5MjZlMWI5ZDllYTZfOTA_07889794-51c6-4fee-a289-e34574abd61d"
      unitRef="usd">6898000</lxrx:StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzExLTEtMS0xLTMzMjAz_f9d1b5fd-d98f-4eb0-80ac-e3f974e56f2b"
      unitRef="usd">48083000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzExLTMtMS0xLTMzMjAz_ec50baba-81ed-4a76-928b-ef13d8df3af8"
      unitRef="usd">32342000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzExLTUtMS0xLTMzMjAz_8799b324-784e-4734-b129-9abdff7c711e"
      unitRef="usd">47230000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzEyLTEtMS0xLTMzMjAz_8336170e-b3fa-4193-b274-f8e024e04524"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzEyLTMtMS0xLTMzMjAz_5393f314-a9c0-469b-ab62-7c395a615449"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzEyLTUtMS0xLTMzMjAz_0fd3b24b-cb5c-4dcf-bb13-4e8da4a5ce67"
      unitRef="usd">1600000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:OperatingExpenses
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzE0LTEtMS0xLTMzMjAz_7d59db53-a5b7-4ad3-822b-a9cc1ddaa7fa"
      unitRef="usd">100899000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzE0LTMtMS0xLTMzMjAz_a86a0adf-35c0-4b86-98cb-c2a93d2c14ff"
      unitRef="usd">87388000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzE0LTUtMS0xLTMzMjAz_78aba307-5235-4f78-980b-4f5b7e8c8b39"
      unitRef="usd">204380000</us-gaap:OperatingExpenses>
    <lxrx:GainOnSaleOfNonFinancialAssets
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzE2LTEtMS0xLTMzMjAz_29624906-d38c-4f2d-b088-4c50ae946472"
      unitRef="usd">0</lxrx:GainOnSaleOfNonFinancialAssets>
    <lxrx:GainOnSaleOfNonFinancialAssets
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzE2LTMtMS0xLTMzMjAz_dbd426a8-c799-4e65-9cb3-0b7c82d0aa77"
      unitRef="usd">0</lxrx:GainOnSaleOfNonFinancialAssets>
    <us-gaap:GainLossOnSaleOfProvedProperty
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzE2LTUtMS0xLTMzMjAz_6318db77-247d-4318-b10d-eb4f8a7072b0"
      unitRef="usd">132585000</us-gaap:GainLossOnSaleOfProvedProperty>
    <us-gaap:OperatingIncomeLoss
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzE3LTEtMS0xLTMzMjAz_f5f8d9bb-5e9a-4d17-936d-ef6b3678c900"
      unitRef="usd">-100760000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzE3LTMtMS0xLTMzMjAz_4aadfe98-7ded-443f-be18-07f3f776b5f2"
      unitRef="usd">-87090000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzE3LTUtMS0xLTMzMjAz_5dc77a7d-a163-4589-8977-f8c1cf54d30a"
      unitRef="usd">-47800000</us-gaap:OperatingIncomeLoss>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzIwLTEtMS0xLTMzMjAz_b44b8a3d-5a83-4963-9681-3ac8ee688c81"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzIwLTMtMS0xLTMzMjAz_9ba2b3c9-8bff-4776-9a1b-4d6c98ee73dd"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzIwLTUtMS0xLTMzMjAz_4e2e0cb9-93d1-4992-af8e-8a0f2c8fd876"
      unitRef="usd">1003000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:InterestExpense
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzIxLTEtMS0xLTMzMjAz_df845922-e024-4389-9b2e-46bcd834c11c"
      unitRef="usd">2780000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzIxLTMtMS0xLTMzMjAz_74948de9-efc9-45a2-b843-d6289d9f4a9c"
      unitRef="usd">802000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzIxLTUtMS0xLTMzMjAz_095f42f4-bb8e-4338-a2c3-e71095e70358"
      unitRef="usd">14544000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzIyLTEtMS0xLTMzMjAz_4a575f2e-b725-4525-8521-c56fc63b7fa4"
      unitRef="usd">1596000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzIyLTMtMS0xLTMzMjAz_0cfcc080-d176-48f9-b34a-360947ef6db9"
      unitRef="usd">134000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzIyLTUtMS0xLTMzMjAz_8c2356fc-ff97-4b73-8158-fbd167352ada"
      unitRef="usd">2767000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzI1LTEtMS0xLTMzMjAz_181bb79d-8c2e-4c9b-a0b0-d6590c32dc62"
      unitRef="usd">-101944000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzI1LTMtMS0xLTMzMjAz_444e4420-d5d2-43f3-9e7c-65410142aceb"
      unitRef="usd">-87758000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzI1LTUtMS0xLTMzMjAz_258a3d81-1248-4b46-b727-916835a3b10b"
      unitRef="usd">-58574000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzI2LTEtMS0xLTMzMjAz_91269c32-a4e3-42a1-8051-c4bfb352b355"
      unitRef="usdPerShare">-0.62</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzI2LTMtMS0xLTMzMjAz_2b8b52b6-91aa-4cb9-bdbe-332b98ad1289"
      unitRef="usdPerShare">-0.60</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzI2LTUtMS0xLTMzMjAz_f2a1b3dc-1a9e-4a76-901f-d7fae3e99b5b"
      unitRef="usdPerShare">-0.53</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzI4LTEtMS0xLTMzMjAz_978584a9-79ea-4b3a-8b7d-23a9f5a1379e"
      unitRef="shares">165733000</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzI4LTMtMS0xLTMzMjAz_9d7031b3-5fd8-4ab5-93ca-f872211df33d"
      unitRef="shares">145652000</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzI4LTUtMS0xLTMzMjAz_1f9e95af-ad05-4ade-b2bc-96158490f607"
      unitRef="shares">110841000</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzMyLTEtMS0xLTMzMjAz_8b3c674d-2890-47f8-8795-73733a8391ba"
      unitRef="usd">-418000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzMyLTMtMS0xLTMzMjAz_86b05dbf-a64e-4fe6-ad57-f547aed16077"
      unitRef="usd">-4000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzMyLTUtMS0xLTMzMjAz_2d7753f2-c789-4ea0-b656-8be740454e23"
      unitRef="usd">-90000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzMzLTEtMS0xLTMzMjAz_8a2a436f-00d9-4968-a10e-7750756fbcb7"
      unitRef="usd">-102362000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzMzLTMtMS0xLTMzMjAz_1e7aa44d-c337-4c5c-9e34-ac799409e984"
      unitRef="usd">-87762000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzYvZnJhZzoyNDQ5ZjM4MzQ4NDg0MDZlOTk3ZmMwYmMxZTE5NmRhMi90YWJsZTo5ZDBhYzY1MTRiZGQ0MjhjYWMyMzY1MjRmMGRiMzJkMy90YWJsZXJhbmdlOjlkMGFjNjUxNGJkZDQyOGNhYzIzNjUyNGYwZGIzMmQzXzMzLTUtMS0xLTMzMjAz_bb79d626-89d6-4ae5-b7ed-c4b10126a6bb"
      unitRef="usd">-58664000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i26b899de75ec4971bee2701c59fba66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzI1LTEtMS0xLTMzMjAz_13610d78-a1f3-4880-adfb-b9dcd18826df"
      unitRef="shares">106679000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i26b899de75ec4971bee2701c59fba66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzI1LTMtMS0xLTMzMjAz_4ae32ec8-0c6d-4275-9f09-28144ff76c26"
      unitRef="usd">106000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i25c577e3042140158482c3aaff32919b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzI1LTUtMS0xLTMzMjAz_33d1073f-3e2f-4093-b039-96a6fe6b703f"
      unitRef="usd">1462172000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4d199e0bcee94bea905035d961fbf255_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzI1LTctMS0xLTMzMjAz_a0acb733-4723-4bc3-b32a-25c78569dbd3"
      unitRef="usd">-1341444000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0476085741da4ed6ae45811b14d11523_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzI1LTktMS0xLTMzMjAz_e159e96e-efa7-4432-a126-15c061517157"
      unitRef="usd">84000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i45c9e62c4e06465f8dea40fec66356eb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzI1LTExLTEtMS0zMzIwMw_9845805a-9bd7-4fbb-9719-8e770a24e9fe"
      unitRef="usd">-3817000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9edf2464575242e584cd5272e2783ba2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzI1LTEzLTEtMS0zMzIwMw_d444a61a-7305-41c2-a957-afd6d2b09a4b"
      unitRef="usd">117101000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ica463ea57f7c4e77aece9c9b75812753_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzI3LTMtMS0xLTMzMjAz_841fc3fd-f736-449d-9228-848ebff69d4e"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i3e407eae82ed45778d1645f5a4b283c9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzI3LTUtMS0xLTMzMjAz_03d61324-f8af-4f05-8e69-c8668d237780"
      unitRef="usd">13274000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="icb1c532e55244fa7aaed402560483d25_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzI3LTctMS0xLTMzMjAz_dde5caaa-1287-4b10-9e5e-6009eba229b4"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i08c5d241fccc478597d48a4e079af792_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzI3LTktMS0xLTMzMjAz_2d35d5cf-5e42-4bb7-ae49-3ae65de8ca6a"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i4f65a415e8d8463d8ca0eb8a49eab0a1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzI3LTExLTEtMS0zMzIwMw_5dd96bd5-db1b-4521-9e22-1d3641d843cb"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzI3LTEzLTEtMS0zMzIwMw_8756fa4c-34a0-44b9-8592-bfa3a6b3741d"
      unitRef="usd">13274000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ica463ea57f7c4e77aece9c9b75812753_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzI5LTEtMS0xLTMzMjAz_b9042cde-38a8-4f06-8abf-07799ac96c54"
      unitRef="shares">3709000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ica463ea57f7c4e77aece9c9b75812753_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzI5LTMtMS0xLTMzMjAz_458862b5-30ca-4781-88b8-300160580ad7"
      unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i3e407eae82ed45778d1645f5a4b283c9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzI5LTUtMS0xLTMzMjAz_72d13295-6797-44a0-9ed1-9743967441c4"
      unitRef="usd">6959000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="icb1c532e55244fa7aaed402560483d25_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzI5LTctMS0xLTMzMjAz_f924cb6f-7060-4ea3-8d03-1cb846b5b7f2"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i08c5d241fccc478597d48a4e079af792_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzI5LTktMS0xLTMzMjAz_25b367e0-1b6f-44d0-b671-b787f5f3c977"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i4f65a415e8d8463d8ca0eb8a49eab0a1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzI5LTExLTEtMS0zMzIwMw_9f4257c8-303b-4bc9-96c1-4ce3bce17888"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzI5LTEzLTEtMS0zMzIwMw_ffc5910d-7693-4635-9c55-609053c1b049"
      unitRef="usd">6963000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ica463ea57f7c4e77aece9c9b75812753_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzMwLTEtMS0xLTMzMjAz_a75e67e3-bc28-4f32-84d4-f53ea27f7696"
      unitRef="shares">20313000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="ica463ea57f7c4e77aece9c9b75812753_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzMwLTMtMS0xLTMzMjAz_610f3a59-23b9-4ce3-a1d6-b0ace6f00624"
      unitRef="usd">20000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="i3e407eae82ed45778d1645f5a4b283c9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzMwLTUtMS0xLTMzMjAz_1bfcfc82-672c-48ac-8b31-d7005b3806f9"
      unitRef="usd">62987000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="icb1c532e55244fa7aaed402560483d25_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzMwLTctMS0xLTMzMjAz_6e231fa1-d0f3-46d4-a9cc-9a621c165a5b"
      unitRef="usd">0</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="i08c5d241fccc478597d48a4e079af792_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzMwLTktMS0xLTMzMjAz_569b6aac-779b-4097-aeec-d647f4050786"
      unitRef="usd">0</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="i4f65a415e8d8463d8ca0eb8a49eab0a1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzMwLTExLTEtMS0zMzIwMw_e84d8a38-1fad-42cd-8571-1e368f0f1d93"
      unitRef="usd">0</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzMwLTEzLTEtMS0zMzIwMw_1f85ed56-5956-4ae3-9d7c-b87243218a67"
      unitRef="usd">63007000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="ica463ea57f7c4e77aece9c9b75812753_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzMxLTEtMS0xLTMzMjAz_c5a5cbfe-3d3a-4e71-a75f-ceecb3248e6f"
      unitRef="shares">10369000</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ConversionOfStockAmountIssued1
      contextRef="ica463ea57f7c4e77aece9c9b75812753_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzMxLTMtMS0xLTMzMjAz_4bd92f4c-7a01-4cf0-8d5d-d78d56963c04"
      unitRef="usd">10000</us-gaap:ConversionOfStockAmountIssued1>
    <us-gaap:ConversionOfStockAmountIssued1
      contextRef="i3e407eae82ed45778d1645f5a4b283c9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzMxLTUtMS0xLTMzMjAz_9e397a3f-cb11-4cc3-9a0f-fb4251465fde"
      unitRef="usd">15704000</us-gaap:ConversionOfStockAmountIssued1>
    <us-gaap:ConversionOfStockAmountIssued1
      contextRef="icb1c532e55244fa7aaed402560483d25_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzMxLTctMS0xLTMzMjAz_d25442a9-5f7d-4979-b300-116bfde1c403"
      unitRef="usd">0</us-gaap:ConversionOfStockAmountIssued1>
    <us-gaap:ConversionOfStockAmountIssued1
      contextRef="i08c5d241fccc478597d48a4e079af792_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzMxLTktMS0xLTMzMjAz_a5a97a01-6385-4d20-bc7e-b29bd115ba3b"
      unitRef="usd">0</us-gaap:ConversionOfStockAmountIssued1>
    <us-gaap:ConversionOfStockAmountIssued1
      contextRef="i4f65a415e8d8463d8ca0eb8a49eab0a1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzMxLTExLTEtMS0zMzIwMw_5fd726b3-9126-430a-8da1-c8ebc60f8fde"
      unitRef="usd">0</us-gaap:ConversionOfStockAmountIssued1>
    <us-gaap:ConversionOfStockAmountIssued1
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzMxLTEzLTEtMS0zMzIwMw_75b23632-eb3d-4b25-b969-da10161c29e7"
      unitRef="usd">15714000</us-gaap:ConversionOfStockAmountIssued1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="ica463ea57f7c4e77aece9c9b75812753_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzMyLTEtMS0xLTMzMjAz_bdaafe60-7743-4c5f-802c-bf4c81f62442"
      unitRef="shares">1219000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ica463ea57f7c4e77aece9c9b75812753_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzMyLTMtMS0xLTMzMjAz_97209685-29d1-407d-87d8-ac2f366a91fc"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i3e407eae82ed45778d1645f5a4b283c9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzMyLTUtMS0xLTMzMjAz_7eceae64-037f-44a7-aac7-13adf5a1ca13"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="icb1c532e55244fa7aaed402560483d25_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzMyLTctMS0xLTMzMjAz_bfcf1bff-f2a6-4657-832e-9b239eb100a1"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i08c5d241fccc478597d48a4e079af792_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzMyLTktMS0xLTMzMjAz_74520e15-92c9-4b92-b28c-7cbe005979be"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i4f65a415e8d8463d8ca0eb8a49eab0a1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzMyLTExLTEtMS0zMzIwMw_caa7299a-762b-4ee5-b12b-08ec3f8436ef"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzMyLTEzLTEtMS0zMzIwMw_6bfbbd9b-c28c-4aba-a420-91e964cee5ec"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ica463ea57f7c4e77aece9c9b75812753_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzM1LTMtMS0xLTMzMjAz_efc9207f-6281-45be-a14f-fae93c1cb2eb"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i3e407eae82ed45778d1645f5a4b283c9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzM1LTUtMS0xLTMzMjAz_d0f1cc46-07c8-48ad-ac7e-4935a5438a08"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="icb1c532e55244fa7aaed402560483d25_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzM1LTctMS0xLTMzMjAz_730c099a-1c26-4796-bc4c-6975fb6a66e0"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i08c5d241fccc478597d48a4e079af792_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzM1LTktMS0xLTMzMjAz_65c9abb0-8cce-413e-b05e-496e027179ee"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i4f65a415e8d8463d8ca0eb8a49eab0a1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzM1LTExLTEtMS0zMzIwMw_ef862e1f-3062-4650-b9fb-ec527fa24f51"
      unitRef="usd">1026000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzM1LTEzLTEtMS0zMzIwMw_698ec997-6cc5-45b1-8b37-4805a19ee854"
      unitRef="usd">1026000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:NetIncomeLoss
      contextRef="ica463ea57f7c4e77aece9c9b75812753_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzM2LTMtMS0xLTMzMjAz_657284d5-3bf4-4976-ad0c-a0be456629cb"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3e407eae82ed45778d1645f5a4b283c9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzM2LTUtMS0xLTMzMjAz_d8455f85-3494-4d79-839d-be4b32ed03fd"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icb1c532e55244fa7aaed402560483d25_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzM2LTctMS0xLTMzMjAz_29c5e71d-a168-4205-adc8-e07218bc5618"
      unitRef="usd">-58574000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i08c5d241fccc478597d48a4e079af792_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzM2LTktMS0xLTMzMjAz_33994f92-2fd9-41bf-8d30-2adcca42835a"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4f65a415e8d8463d8ca0eb8a49eab0a1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzM2LTExLTEtMS0zMzIwMw_c9bd8799-1bca-4bb9-879a-bfd9cdc15ec5"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzM2LTEzLTEtMS0zMzIwMw_6aa755f6-66e2-44a2-bef3-cfafcd66a9e6"
      unitRef="usd">-58574000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ica463ea57f7c4e77aece9c9b75812753_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzM3LTMtMS0xLTMzMjAz_f89a591b-7e10-442d-bef7-1b42423c8ba1"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i3e407eae82ed45778d1645f5a4b283c9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzM3LTUtMS0xLTMzMjAz_9177560b-3f60-40e5-acd3-34e7a35112bc"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="icb1c532e55244fa7aaed402560483d25_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzM3LTctMS0xLTMzMjAz_38e3097f-cc7c-4d02-9853-56eee4d6c303"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i08c5d241fccc478597d48a4e079af792_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzM3LTktMS0xLTMzMjAz_733153d5-d505-49c0-b40d-af770ad61fe4"
      unitRef="usd">-90000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i4f65a415e8d8463d8ca0eb8a49eab0a1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzM3LTExLTEtMS0zMzIwMw_423b9502-6957-4ece-8a68-baadb4fc327c"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzM3LTEzLTEtMS0zMzIwMw_667f03b5-725f-4296-a600-905e3e57b03a"
      unitRef="usd">-90000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic9c28386ac3f4264b971d6c2d1d20518_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzM5LTEtMS0xLTMzMjAz_2bd533e2-6664-4eb8-8135-5facf8e0cbb9"
      unitRef="shares">142289000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ic9c28386ac3f4264b971d6c2d1d20518_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzM5LTMtMS0xLTMzMjAz_095177ba-4f5a-4581-9614-7da6739917f6"
      unitRef="usd">142000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie40de31d8a53466dbe16c3026141f0bf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzM5LTUtMS0xLTMzMjAz_6aa76457-bb75-4c52-9503-e2e7102326a1"
      unitRef="usd">1561096000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i127c83dde28a497289a43680bd2d274e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzM5LTctMS0xLTMzMjAz_858d53de-ef88-46f4-9723-6c4171585193"
      unitRef="usd">-1400018000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i811c34b23fae41e08987de7c90d2a75f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzM5LTktMS0xLTMzMjAz_02dccbe5-e553-4b82-ac89-edd9a867efeb"
      unitRef="usd">-6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9a9aae42bd8341688cde38a2a191ea99_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzM5LTExLTEtMS0zMzIwMw_00434b29-4509-431c-9762-0d68bd5ea5e1"
      unitRef="usd">-4843000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ief9b221acfd5465cb83500067a09fff2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzM5LTEzLTEtMS0zMzIwMw_09ab450b-0b52-4024-97f6-1b5fa2185115"
      unitRef="usd">156371000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i99a04acc720b46cabd4ee3c5a2dd0674_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQwLTMtMS0xLTMzMjAz_e7cf471f-6869-409b-8888-7889f6bdefc7"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib42da41ca5a14b988815a9effcc674cd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQwLTUtMS0xLTMzMjAz_b9a23847-a21d-473e-a04c-fe5bcdfcc193"
      unitRef="usd">10577000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i7d1bda838f674f4eaaa6f31e5ff61ec4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQwLTctMS0xLTMzMjAz_e67e3549-510c-44a8-8ba0-c20f9e494433"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1922c7bd454f43a4af07205eb1f1b25a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQwLTktMS0xLTMzMjAz_df4eb40a-23f2-4f01-91d0-d0c81a674c89"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="idbbc5e8a454e4cb5bff0e55c593bf0bd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQwLTExLTEtMS0zMzIwMw_9f0e9464-6706-44cb-9e41-08df20892973"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQwLTEzLTEtMS0zMzIwMw_3f49aab9-39d7-4ef8-a778-f03cfb733531"
      unitRef="usd">10577000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i99a04acc720b46cabd4ee3c5a2dd0674_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQxLTEtMS0xLTMzMjAz_68ab35fe-cea9-40bb-b223-1f2d89309640"
      unitRef="shares">6177000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i99a04acc720b46cabd4ee3c5a2dd0674_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQxLTMtMS0xLTMzMjAz_87ad03fb-f927-47a4-af5e-0ecb844385bf"
      unitRef="usd">6000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ib42da41ca5a14b988815a9effcc674cd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQxLTUtMS0xLTMzMjAz_d7532a6a-839c-4729-9bee-1a4a9b71f2e4"
      unitRef="usd">35485000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i7d1bda838f674f4eaaa6f31e5ff61ec4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQxLTctMS0xLTMzMjAz_c4d427ff-c598-4975-b7e0-6e036388b165"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i1922c7bd454f43a4af07205eb1f1b25a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQxLTktMS0xLTMzMjAz_7e32113d-d97a-4b22-bd00-4dde009f6444"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="idbbc5e8a454e4cb5bff0e55c593bf0bd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQxLTExLTEtMS0zMzIwMw_12bd5394-ad11-4a33-aeb1-5e128bbe2265"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQxLTEzLTEtMS0zMzIwMw_bd9a21b3-a952-4ebd-a57b-204f9de0f427"
      unitRef="usd">35491000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i99a04acc720b46cabd4ee3c5a2dd0674_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQyLTEtMS0xLTMzMjAz_276006ad-51ac-4aac-9840-b23ea2c3e177"
      unitRef="shares">1616000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i99a04acc720b46cabd4ee3c5a2dd0674_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQyLTMtMS0xLTMzMjAz_dddcc4ed-82fe-487c-b73a-6ca6a062ef3c"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ib42da41ca5a14b988815a9effcc674cd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQyLTUtMS0xLTMzMjAz_9735978d-6551-41cc-9ef1-9f210502284c"
      unitRef="usd">1591000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i7d1bda838f674f4eaaa6f31e5ff61ec4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQyLTctMS0xLTMzMjAz_c309f5bf-a58c-43bd-9b9e-24c564a99653"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i1922c7bd454f43a4af07205eb1f1b25a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQyLTktMS0xLTMzMjAz_dee276d5-a989-4421-853b-ebb10c3d056c"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="idbbc5e8a454e4cb5bff0e55c593bf0bd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQyLTExLTEtMS0zMzIwMw_7f9c2c53-8a87-4885-9cd6-9c1bae1b6e9b"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQyLTEzLTEtMS0zMzIwMw_c3030faa-23ce-41c6-b09d-971da40320cf"
      unitRef="usd">1593000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i99a04acc720b46cabd4ee3c5a2dd0674_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQzLTMtMS0xLTMzMjAz_2b63c9a9-5daa-40bc-b307-c60c3a943309"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ib42da41ca5a14b988815a9effcc674cd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQzLTUtMS0xLTMzMjAz_9f187c0e-bc84-4ea5-9cf8-fd437a1198ad"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i7d1bda838f674f4eaaa6f31e5ff61ec4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQzLTctMS0xLTMzMjAz_4fb1a803-3170-4815-82b8-a871cca06f02"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i1922c7bd454f43a4af07205eb1f1b25a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQzLTktMS0xLTMzMjAz_7027817c-3c8e-4c71-bba7-3cc843bbde63"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="idbbc5e8a454e4cb5bff0e55c593bf0bd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQzLTExLTEtMS0zMzIwMw_34bff38b-8900-4d5e-8a23-b72f4f4dd701"
      unitRef="usd">2675000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQzLTEzLTEtMS0zMzIwMw_f3d0e58c-b02a-488a-9c4e-6e63a3cae920"
      unitRef="usd">2675000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:NetIncomeLoss
      contextRef="i99a04acc720b46cabd4ee3c5a2dd0674_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ0LTMtMS0xLTMzMjAz_33d984ea-9a81-4468-8b0b-26cc5c333f74"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib42da41ca5a14b988815a9effcc674cd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ0LTUtMS0xLTMzMjAz_296b010d-8098-4816-bcc7-56a8e4980611"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7d1bda838f674f4eaaa6f31e5ff61ec4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ0LTctMS0xLTMzMjAz_117b8b0c-2d46-4223-bbb8-91c71c4331b7"
      unitRef="usd">-87758000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1922c7bd454f43a4af07205eb1f1b25a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ0LTktMS0xLTMzMjAz_2c26ca00-9690-41e6-b699-ace78e0dee99"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="idbbc5e8a454e4cb5bff0e55c593bf0bd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ0LTExLTEtMS0zMzIwMw_3d173a4a-ba55-411c-8247-425d6fce72e0"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ0LTEzLTEtMS0zMzIwMw_def718d5-e942-4fb4-8185-cc5aaa3ceec1"
      unitRef="usd">-87758000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i99a04acc720b46cabd4ee3c5a2dd0674_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ1LTMtMS0xLTMzMjAz_5101a6ee-c8c2-47d2-887e-6608d13adef7"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ib42da41ca5a14b988815a9effcc674cd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ1LTUtMS0xLTMzMjAz_11af6875-ea57-4ecd-8b0a-8739ed6757d4"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i7d1bda838f674f4eaaa6f31e5ff61ec4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ1LTctMS0xLTMzMjAz_6a7d8c03-b6d3-492e-9cad-3459ad47faf0"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i1922c7bd454f43a4af07205eb1f1b25a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ1LTktMS0xLTMzMjAz_6731f3fd-c971-4720-b78e-d4b4f5f6e8c2"
      unitRef="usd">-4000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="idbbc5e8a454e4cb5bff0e55c593bf0bd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ1LTExLTEtMS0zMzIwMw_9402b2b0-3d57-4e5c-91bb-26f6b955dfcf"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ1LTEzLTEtMS0zMzIwMw_087c47c9-b60f-4539-84d3-771b0d19851e"
      unitRef="usd">-4000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i940ed9833e654f3e88d67e4c166a14f2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ2LTEtMS0xLTMzMjAz_444b76c0-21de-4255-bc1b-8f52d70df885"
      unitRef="shares">150082000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i940ed9833e654f3e88d67e4c166a14f2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ2LTMtMS0xLTMzMjAz_179ef32f-757c-44e0-ba87-1d29cfc144f4"
      unitRef="usd">150000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4acd250f6fd84660b1b2a85f4f5e4a20_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ2LTUtMS0xLTMzMjAz_54715ad0-016b-4895-8205-787095e77832"
      unitRef="usd">1608749000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i325272f405d94467a8e21c4ffc1fe333_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ2LTctMS0xLTMzMjAz_d4e13a9c-0828-45e6-97bc-72a9b8631254"
      unitRef="usd">-1487776000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9a0a6b3dd9e245ab82da25e46d931740_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ2LTktMS0xLTMzMjAz_b669c9ab-12db-4e9d-b54c-5a8e2ce66488"
      unitRef="usd">-10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8d9d5924ae0a4ce3964a5ae029dd6486_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ2LTExLTEtMS0zMzIwMw_c9a055f8-e308-4878-8124-2b6b39820a1e"
      unitRef="usd">-7518000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ2LTEzLTEtMS0zMzIwMw_a11d6b36-6133-4624-a221-aa63fe18888a"
      unitRef="usd">113595000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1198e2c5aacd45858d7c4371b727d5b2_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ3LTMtMS0xLTM5NzA4_d5823c2a-3aba-48b3-8545-83fd8fcc3e96"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i56c0cc327a1d4ed19387c28bde2e3ffb_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ3LTUtMS0xLTM5NzA4_e36bc658-7f24-4ec8-b233-e9ae20ba5327"
      unitRef="usd">11520000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ifd14ef30697244ac8b81d3b8376f5d6b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ3LTctMS0xLTM5NzA4_548c2dc8-c7aa-4bc2-973f-b5013868f930"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia9a66cc8a08d4b5d95fc1a3de8f017a0_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ3LTktMS0xLTM5NzA4_24883f3a-e20d-4016-9de2-03abf2682d7f"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i4961ca3cf71d48c3a2dc88cfab3d52f8_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ3LTExLTEtMS0zOTcwOA_d6a5775a-0351-453a-98cc-a754109b50d4"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ3LTEzLTEtMS0zOTcwOA_0a2c8871-8b0c-47af-96be-046f3542c2a1"
      unitRef="usd">11520000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i1198e2c5aacd45858d7c4371b727d5b2_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ4LTEtMS0xLTM5NzE4_79cd1f94-5a68-4be3-8cdc-562d307cb00c"
      unitRef="shares">32000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i1198e2c5aacd45858d7c4371b727d5b2_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ4LTMtMS0xLTM5NzE4_1910794c-256e-4e9a-9232-eb3342676b2c"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i56c0cc327a1d4ed19387c28bde2e3ffb_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ4LTUtMS0xLTM5NzE4_96564e4b-f329-466b-a361-541db15aebea"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ifd14ef30697244ac8b81d3b8376f5d6b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ4LTctMS0xLTM5NzE4_764bbc64-19bf-4d7e-a313-4c2e52a25916"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ia9a66cc8a08d4b5d95fc1a3de8f017a0_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ4LTktMS0xLTM5NzE4_83a78deb-9191-4ba7-a29d-efbd00e0af7e"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i4961ca3cf71d48c3a2dc88cfab3d52f8_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ4LTExLTEtMS0zOTcxOA_39107c73-ae97-4b1a-8235-6d0e2df12558"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ4LTEzLTEtMS0zOTcxOA_1bab1241-760e-4626-b856-7d305936c09d"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i1198e2c5aacd45858d7c4371b727d5b2_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ5LTEtMS0xLTM5NzEw_be19456e-f0f2-4d87-bb29-3caa85f79a28"
      unitRef="shares">39100000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i1198e2c5aacd45858d7c4371b727d5b2_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ5LTMtMS0xLTM5NzEw_9620cebf-b7c4-4163-8fc9-1badb5856339"
      unitRef="usd">39000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i56c0cc327a1d4ed19387c28bde2e3ffb_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ5LTUtMS0xLTM5NzEw_fc9f370d-0d11-4300-904b-84c6be3d9a7f"
      unitRef="usd">94166000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ifd14ef30697244ac8b81d3b8376f5d6b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ5LTctMS0xLTM5NzEw_3142d6c1-2901-40a9-9e0d-576f3a3bd8e4"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ia9a66cc8a08d4b5d95fc1a3de8f017a0_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ5LTktMS0xLTM5NzEw_3bdcd14a-2c7d-4d7e-9c03-6ccf0f5f4f64"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i4961ca3cf71d48c3a2dc88cfab3d52f8_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ5LTExLTEtMS0zOTcxMA_05ad6785-3be1-46d0-a273-f58ef971ed5e"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzQ5LTEzLTEtMS0zOTcxMA_07d35f07-e47d-4518-9253-7353d64d9397"
      unitRef="usd">94205000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="i1198e2c5aacd45858d7c4371b727d5b2_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzUwLTMtMS0xLTM5NzE2_e2dcad44-0a41-44eb-b677-200bd9a52a09"
      unitRef="usd">0</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="i56c0cc327a1d4ed19387c28bde2e3ffb_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzUwLTUtMS0xLTM5NzE2_40a7f883-0d67-47bb-9f75-908230acf6c6"
      unitRef="usd">1030000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="ifd14ef30697244ac8b81d3b8376f5d6b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzUwLTctMS0xLTM5NzE2_675b2b87-5d03-4745-9caa-bf7ec87c71bd"
      unitRef="usd">0</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="ia9a66cc8a08d4b5d95fc1a3de8f017a0_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzUwLTktMS0xLTM5NzE2_ee96264a-da11-405e-b287-ed64a7a16648"
      unitRef="usd">0</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="i4961ca3cf71d48c3a2dc88cfab3d52f8_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzUwLTExLTEtMS0zOTcxNg_dbe522c4-58b2-4216-b1c2-f1432df15ace"
      unitRef="usd">0</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzUwLTEzLTEtMS0zOTcxNg_51d48a3b-196f-4649-b76e-ccc9b00322ac"
      unitRef="usd">1030000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued
      contextRef="i1198e2c5aacd45858d7c4371b727d5b2_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzUxLTEtMS0xLTM5NzE2_6642bbe3-8b27-411e-8fe9-69aaa3d5d5c4"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i1198e2c5aacd45858d7c4371b727d5b2_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzUxLTMtMS0xLTM5NzE2_502b5c76-43cc-4cc4-bd44-18921ec9fd16"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i56c0cc327a1d4ed19387c28bde2e3ffb_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzUxLTUtMS0xLTM5NzE2_cd2b0ec8-8d1a-425a-b5fd-3aa89fdbf6ff"
      unitRef="usd">6321000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="ifd14ef30697244ac8b81d3b8376f5d6b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzUxLTctMS0xLTM5NzE2_5877b19d-bbd5-4edf-ac4d-fe69f6a17596"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="ia9a66cc8a08d4b5d95fc1a3de8f017a0_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzUxLTktMS0xLTM5NzE2_f8076bf9-3f15-4ad4-8f0e-8c79dacee8fa"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i4961ca3cf71d48c3a2dc88cfab3d52f8_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzUxLTExLTEtMS0zOTcxNg_4dd5d289-cdf1-4141-89c6-499f502718ef"
      unitRef="usd">6321000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzUxLTEzLTEtMS0zOTcxNg_12787b36-9209-42b6-92e1-603c3f0418ca"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i1198e2c5aacd45858d7c4371b727d5b2_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzUyLTMtMS0xLTM5NzEy_b24bd6b2-82e9-4fb5-9ad1-22e020e771f5"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i56c0cc327a1d4ed19387c28bde2e3ffb_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzUyLTUtMS0xLTM5NzEy_b3f80840-0553-4873-aad2-5d646765b27d"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ifd14ef30697244ac8b81d3b8376f5d6b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzUyLTctMS0xLTM5NzEy_6d5e2bef-6226-4d93-a046-b1c2e974ba48"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ia9a66cc8a08d4b5d95fc1a3de8f017a0_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzUyLTktMS0xLTM5NzEy_5fe245d2-ebb4-4da6-9895-fa145d4019a3"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i4961ca3cf71d48c3a2dc88cfab3d52f8_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzUyLTExLTEtMS0zOTcxMg_737c0e84-3c71-456f-835d-1bded4355e5f"
      unitRef="usd">864000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzUyLTEzLTEtMS0zOTcxMg_175b06d1-1c71-46e6-a98b-8d92531a5f0e"
      unitRef="usd">864000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:NetIncomeLoss
      contextRef="i1198e2c5aacd45858d7c4371b727d5b2_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzUzLTMtMS0xLTM5NzEy_31d5d7aa-f537-4aa8-a186-39053689608f"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i56c0cc327a1d4ed19387c28bde2e3ffb_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzUzLTUtMS0xLTM5NzEy_0f102ad9-c5e0-47bf-a53a-114081c45833"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ifd14ef30697244ac8b81d3b8376f5d6b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzUzLTctMS0xLTM5NzEy_a1325d65-42a2-4306-9221-9f03588cb0b6"
      unitRef="usd">-101944000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia9a66cc8a08d4b5d95fc1a3de8f017a0_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzUzLTktMS0xLTM5NzEy_edb59a51-ec64-4e51-8cd2-3c165e64e632"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4961ca3cf71d48c3a2dc88cfab3d52f8_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzUzLTExLTEtMS0zOTcxMg_6f33566e-c57a-412f-8881-e82e4dba6e39"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzUzLTEzLTEtMS0zOTcxMg_f1873106-934e-43e7-b098-15c541bc9970"
      unitRef="usd">-101944000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i1198e2c5aacd45858d7c4371b727d5b2_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzU0LTMtMS0xLTM5NzEy_510a9d41-29f1-4261-bb5d-e1651c2d5ae1"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i56c0cc327a1d4ed19387c28bde2e3ffb_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzU0LTUtMS0xLTM5NzEy_40b3f02f-ebda-470c-aeb5-86094cbe24e9"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ifd14ef30697244ac8b81d3b8376f5d6b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzU0LTctMS0xLTM5NzEy_a303d11f-2e25-4957-8a4a-e18d9a00d4e6"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ia9a66cc8a08d4b5d95fc1a3de8f017a0_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzU0LTktMS0xLTM5NzEy_2f8cd24c-59c5-4e82-a90c-80bf8e70734b"
      unitRef="usd">-418000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i4961ca3cf71d48c3a2dc88cfab3d52f8_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzU0LTExLTEtMS0zOTcxMg_0edd965c-0e49-491f-95e2-78373b853940"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzU0LTEzLTEtMS0zOTcxMg_8b52d143-7670-4bcc-9257-3202bf8518b2"
      unitRef="usd">-418000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i55a81403781f47ae9d02222240bdb36d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzU1LTEtMS0xLTM5NzE0_e3c7fe0d-0ca8-458c-953e-91e1eabb5ca9"
      unitRef="shares">189214000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i55a81403781f47ae9d02222240bdb36d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzU1LTMtMS0xLTM5NzE0_e714cd89-fc32-4528-a197-5faae45187b9"
      unitRef="usd">189000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9f6ebc10d76e49c0bef5f073adb72d4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzU1LTUtMS0xLTM5NzE0_6bd20451-ee76-4a34-9488-036fed64e536"
      unitRef="usd">1709144000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i959cffadb372413d8e83d72e239e6ded_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzU1LTctMS0xLTM5NzE0_0d28fc3f-1306-43ad-b5d0-a2750c82dfd9"
      unitRef="usd">-1589720000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2fcd93af513045eba562f9ff41a202ac_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzU1LTktMS0xLTM5NzE0_17b39ad8-672b-4389-a9d8-a516d8419241"
      unitRef="usd">-428000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib1e8bc9bcf1a4a439d70f50e536be574_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzU1LTExLTEtMS0zOTcxNA_74c56366-77c1-43dd-b7ff-ecf075637955"
      unitRef="usd">-2061000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xMzkvZnJhZzozNzEzZGRlZjljYjc0YjhjODM0ZGQ4OGFlNDRhZmE5YS90YWJsZTphYTk1ZDViNDhiMTQ0NjU0YTJiYTk1MjNjMGJhNzE2Yy90YWJsZXJhbmdlOmFhOTVkNWI0OGIxNDQ2NTRhMmJhOTUyM2MwYmE3MTZjXzU1LTEzLTEtMS0zOTcxNA_d1540253-48ce-485b-964f-843dd787e15c"
      unitRef="usd">117124000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzMtMS0xLTEtMzMyMDM_ec0a8c0b-9eef-4918-9eff-f05b6add70d1"
      unitRef="usd">-101944000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzMtMy0xLTEtMzMyMDM_5fb61578-349b-4168-8600-0d8fe529a382"
      unitRef="usd">-87758000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzMtNS0xLTEtMzMyMDM_59e2013f-02c4-4b6d-81f2-5bfefe8998f6"
      unitRef="usd">-58574000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzUtMS0xLTEtMzMyMDM_c5578ce1-74f8-402e-ba6f-4febdd8057fe"
      unitRef="usd">427000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzUtMy0xLTEtMzMyMDM_11d1f6d5-bbdb-4405-bb62-31db24ee5c17"
      unitRef="usd">292000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzUtNS0xLTEtMzMyMDM_841b681d-87ee-4c86-a60b-10798e59ea85"
      unitRef="usd">2934000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzYtMS0xLTEtMzMyMDM_833e7de3-65ac-40b7-a86d-565d0c3877f4"
      unitRef="usd">11520000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzYtMy0xLTEtMzMyMDM_df5360cf-1654-492f-b681-963c73761978"
      unitRef="usd">10577000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzYtNS0xLTEtMzMyMDM_2677e1a4-1eb8-45c6-b1b1-119952913d27"
      unitRef="usd">13274000</us-gaap:ShareBasedCompensation>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzctMS0xLTEtMzMyMDM_d4c04083-b1b5-49a1-92ad-f9efa1d13e93"
      unitRef="usd">741000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzctMy0xLTEtMzMyMDM_ca9f9ce2-60b8-459c-a4cf-edfb47bdc8c8"
      unitRef="usd">54000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzctNS0xLTEtMzMyMDM_fa2fb441-7f72-45bb-a5cc-2c87f3ebf191"
      unitRef="usd">1013000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <lxrx:GainOnSaleOfNonFinancialAssets
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzktMS0xLTEtMzMyMDM_b7312896-5ed3-4264-b7a3-8078eef1c5aa"
      unitRef="usd">0</lxrx:GainOnSaleOfNonFinancialAssets>
    <lxrx:GainOnSaleOfNonFinancialAssets
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzktMy0xLTEtMzMyMDM_311098f2-5383-402d-bcf5-4156ac5e6129"
      unitRef="usd">0</lxrx:GainOnSaleOfNonFinancialAssets>
    <lxrx:GainOnSaleOfNonFinancialAssets
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzktNS0xLTEtMzMyMDM_6c3e1dc4-6bc0-440a-a533-407176a5a0e1"
      unitRef="usd">132585000</lxrx:GainOnSaleOfNonFinancialAssets>
    <us-gaap:ImpairmentOfRealEstate
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzEwLTEtMS0xLTMzMjAz_9591ab1c-d61c-44df-8092-6bf4e7183a07"
      unitRef="usd">0</us-gaap:ImpairmentOfRealEstate>
    <us-gaap:ImpairmentOfRealEstate
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzEwLTMtMS0xLTMzMjAz_91a1a945-fc46-4ff8-b68e-1661fe2ca9a8"
      unitRef="usd">0</us-gaap:ImpairmentOfRealEstate>
    <us-gaap:ImpairmentOfRealEstate
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzEwLTUtMS0xLTMzMjAz_f5b53255-259f-4dc4-8ad0-77f363d189c0"
      unitRef="usd">1600000</us-gaap:ImpairmentOfRealEstate>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzEzLTEtMS0xLTMzMjAz_4f1e0640-52f3-4899-af53-69b7d057c58e"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzEzLTMtMS0xLTMzMjAz_dbfc7909-d2b4-4cd8-a77c-560e9bc4bf75"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ExtinguishmentOfDebtGainLossNetOfTax
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzEzLTUtMS0xLTMzMjAz_d60a0fc5-ed1c-4772-bd02-8ee43d45c741"
      unitRef="usd">-1003000</us-gaap:ExtinguishmentOfDebtGainLossNetOfTax>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzE0LTEtMS0xLTMzMjAz_9333a362-7c3f-4ed4-b434-d8157d720ea6"
      unitRef="usd">-3000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzE0LTMtMS0xLTMzMjAz_afab56bf-9996-4ea1-826f-36f16c62b575"
      unitRef="usd">-49000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzE0LTUtMS0xLTMzMjAz_888baf9a-0b21-4a3f-ba17-9a491179fa48"
      unitRef="usd">707000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzE2LTEtMS0xLTMzMjAz_2679ed4f-688b-485d-997f-4a4198678c6c"
      unitRef="usd">14000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzE2LTMtMS0xLTMzMjAz_2343c03f-86df-4ceb-92d5-88e0ce79b2ec"
      unitRef="usd">-381000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzE2LTUtMS0xLTMzMjAz_c0d348da-77b3-4652-82b6-f74bf0bb1c14"
      unitRef="usd">-53227000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzE3LTEtMS0xLTMzMjAz_e3be3928-e6f9-486e-aab7-57f575cf60d8"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzE3LTMtMS0xLTMzMjAz_62cd3dcf-e652-41a0-b839-9f10df0a9df3"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzE3LTUtMS0xLTMzMjAz_f98c1b8a-ec63-4b7d-a41f-b54ad4cdd589"
      unitRef="usd">-345000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzE4LTEtMS0xLTMzMjAz_79bae6f2-df7b-434d-83ba-0790cea0faf1"
      unitRef="usd">316000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzE4LTMtMS0xLTMzMjAz_4b2641dc-a44a-419a-9462-d02c28ed4cc4"
      unitRef="usd">-2885000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzE4LTUtMS0xLTMzMjAz_2094a957-cb93-48de-ba5b-993e800ce0dc"
      unitRef="usd">1948000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzE5LTEtMS0xLTMzMjAz_9d02eee3-c43e-45ae-9fa1-820f3c143c81"
      unitRef="usd">-656000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzE5LTMtMS0xLTMzMjAz_ddffe301-d97e-4e97-a75d-80a81e6f47eb"
      unitRef="usd">-661000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzE5LTUtMS0xLTMzMjAz_aa711a8b-e8b2-4fa0-9cac-5b0ac52b92b7"
      unitRef="usd">-424000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzIwLTEtMS0xLTMzMjAz_99cfcdc2-a708-45e9-8615-b0607187adfa"
      unitRef="usd">76000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzIwLTMtMS0xLTMzMjAz_13e860f3-4be3-460b-9341-e1825466c424"
      unitRef="usd">-14158000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzIwLTUtMS0xLTMzMjAz_892fc4d3-fdf5-4bcd-a843-976acc469693"
      unitRef="usd">-20969000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzIyLTEtMS0xLTMzMjAz_b00cb19a-eb8a-49fe-83c7-8706bcfeb6a4"
      unitRef="usd">-88851000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzIyLTMtMS0xLTMzMjAz_19fdd8a7-702a-4160-865c-877c72f85749"
      unitRef="usd">-87017000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzIyLTUtMS0xLTMzMjAz_ddf34341-ffd8-4633-8f87-628b10117fb7"
      unitRef="usd">-142969000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzI0LTEtMS0xLTMzMjAz_a13deab8-788b-49e9-a5bd-84bdd873c5e6"
      unitRef="usd">1326000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzI0LTMtMS0xLTMzMjAz_b8a53f66-2c63-438b-916f-31ee31401f57"
      unitRef="usd">1221000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzI0LTUtMS0xLTMzMjAz_db795a05-1f7f-4fd5-ae0c-851ead558f9d"
      unitRef="usd">87000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzI1LTEtMS0xLTMzMjAz_c7f60108-6a9e-41ef-b11d-110e97e680b6"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzI1LTMtMS0xLTMzMjAz_ee3f74a3-8f02-4f8a-9342-97be64653fd5"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzI1LTUtMS0xLTMzMjAz_a9626978-bb2a-477e-8c3c-61c28ab46549"
      unitRef="usd">160385000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzI2LTEtMS0xLTMzMjAz_d59ed7a3-134a-4e2d-bbaf-1c6cc722d621"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzI2LTMtMS0xLTMzMjAz_2aa4c879-8535-499f-b943-92faa0a12b36"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfBuildings
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzI2LTUtMS0xLTMzMjAz_af124a5f-903f-4b3d-bfa9-eee7d5336ab9"
      unitRef="usd">11013000</us-gaap:ProceedsFromSaleOfBuildings>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzI3LTEtMS0xLTMzMjAz_07103564-6b32-48ad-a24e-f8f8402c54e5"
      unitRef="usd">133949000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzI3LTMtMS0xLTMzMjAz_f8df386c-389e-4aa6-95be-5a4759b45e77"
      unitRef="usd">34261000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzI3LTUtMS0xLTMzMjAz_c8b5dc54-a93c-437c-a8ac-efcec5b7014b"
      unitRef="usd">58555000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzI4LTEtMS0xLTMzMjAz_35b0c3d9-98b3-4cbd-b0cc-a3ac23745f89"
      unitRef="usd">64197000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzI4LTMtMS0xLTMzMjAz_0f313816-eec6-4126-a5b9-40aa8eafe8ad"
      unitRef="usd">37592000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzI4LTUtMS0xLTMzMjAz_f5c6a315-1c45-434c-a05d-62ad8690c451"
      unitRef="usd">268000000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzI5LTEtMS0xLTMzMjAz_881ccc1a-c6de-4a76-bb4c-8f1bea9e481e"
      unitRef="usd">-71078000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzI5LTMtMS0xLTMzMjAz_01bab126-153f-4190-bd7c-e285c9994e67"
      unitRef="usd">2110000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzI5LTUtMS0xLTMzMjAz_3c546691-9b85-46c1-b724-47cc626dad52"
      unitRef="usd">380756000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzMxLTEtMS0xLTMzMjAz_47c1e526-677b-45af-9459-31e53ed0fb5c"
      unitRef="usd">94205000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzMxLTMtMS0xLTMzMjAz_2da0dc62-191c-4634-8f28-3e8fdc463e9f"
      unitRef="usd">37084000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzMxLTUtMS0xLTMzMjAz_9463e4f8-3f86-4fe2-9ea8-b448bd9405fb"
      unitRef="usd">69970000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzMyLTEtMS0xLTMzMjAz_57e3dc4a-1489-492a-85ea-0630a5bfc958"
      unitRef="usd">864000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzMyLTMtMS0xLTMzMjAz_eb508a37-d34a-4daa-bf1e-4006d162775d"
      unitRef="usd">2675000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzMyLTUtMS0xLTMzMjAz_d7845178-070f-43a2-a5fa-618a38280b68"
      unitRef="usd">1026000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzM0LTEtMS0xLTMzMjAz_6498653f-0b42-42a3-bd9f-f9584a69b479"
      unitRef="usd">-48868000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzM0LTMtMS0xLTMzMjAz_060432c0-edde-4193-a3c9-66e4684ed167"
      unitRef="usd">11700000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzM0LTUtMS0xLTMzMjAz_bf3193e6-8de7-44a0-aff0-0ec48c8607e9"
      unitRef="usd">216580000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzM2LTEtMS0xLTMzMjAz_9e39a87d-9bc8-4c1f-8d65-310394229b7c"
      unitRef="usd">142209000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzM2LTMtMS0xLTMzMjAz_a1e34ef0-ea2c-4508-801c-f4b928942a37"
      unitRef="usd">22709000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzM2LTUtMS0xLTMzMjAz_5ee5ab59-5488-4f6e-93e8-6be46db08957"
      unitRef="usd">-147636000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzM3LTEtMS0xLTMzMjAz_454eafa9-06fc-4738-b66c-20078b54faa6"
      unitRef="usd">-17720000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzM3LTMtMS0xLTMzMjAz_edb62856-8981-4d2d-9983-1cf7a271b01d"
      unitRef="usd">-62198000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzM3LTUtMS0xLTMzMjAz_f39cefb8-4e33-43fd-81ec-37c335dd3dcf"
      unitRef="usd">90151000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzM4LTEtMS0xLTMzMjAz_d978472c-6d33-44e9-8143-d0bddcdf1e1c"
      unitRef="usd">64065000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ief9b221acfd5465cb83500067a09fff2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzM4LTMtMS0xLTMzMjAz_1550191a-105c-43b6-9131-817f0d39e370"
      unitRef="usd">126263000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i9edf2464575242e584cd5272e2783ba2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzM4LTUtMS0xLTMzMjAz_8390eb01-a7e2-4cf0-a13e-35b8fd60ea8b"
      unitRef="usd">36112000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzM5LTEtMS0xLTMzMjAz_d531e1da-059b-4890-a284-153c608b9d41"
      unitRef="usd">46345000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzM5LTMtMS0xLTMzMjAz_c3d23364-d353-4a84-9111-0b303d4bf023"
      unitRef="usd">64065000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ief9b221acfd5465cb83500067a09fff2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzM5LTUtMS0xLTMzMjAz_d112633a-1bc2-42da-a0de-7743b0958f1a"
      unitRef="usd">126263000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:InterestPaidNet
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzQyLTEtMS0xLTMzMjAz_e6c284e6-6c67-4050-a659-628baf11a5ba"
      unitRef="usd">2289000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzQyLTMtMS0xLTMzMjAz_7b88e369-1acf-479a-a914-9b2f3c5effd2"
      unitRef="usd">799000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzQyLTUtMS0xLTMzMjAz_009e3924-6b63-4484-8da1-f888ae05a8ca"
      unitRef="usd">17353000</us-gaap:InterestPaidNet>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzQ4LTEtMS0xLTMzMjAz_5d2f8503-c88e-4fd1-b158-5e4b8c84f9e5"
      unitRef="usd">5206000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzQ4LTMtMS0xLTMzMjAz_b94488fa-db84-43f7-9cc1-eaedce685a26"
      unitRef="usd">1704000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ief9b221acfd5465cb83500067a09fff2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzQ4LTUtMS0xLTMzMjAz_c5fd7156-c691-4826-b5c9-0601252af93d"
      unitRef="usd">0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzQ5LTEtMS0xLTM5NzIw_22fb7e5c-ecb5-49df-85a6-faa2a9213992"
      unitRef="usd">1030000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzQ5LTMtMS0xLTM5NzIy_475d2106-0d1d-4e9b-8b48-032ce136d4bf"
      unitRef="usd">0</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzQ5LTUtMS0xLTM5NzI0_915575b3-f6ff-49c2-8923-e7fd76923492"
      unitRef="usd">0</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:TreasuryStockCarryingBasis
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzUwLTEtMS0xLTM5NzIw_e8c88eaf-a220-4cd0-90f6-2f6897f563af"
      unitRef="usd">6321000</us-gaap:TreasuryStockCarryingBasis>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzUwLTMtMS0xLTM5NzIy_b7adc09c-a5f6-4475-8575-3b16ae4ca312"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzUwLTUtMS0xLTM5NzI0_de9acce8-5c51-497c-8fb1-11947351a7cb"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:BusinessExitCosts1
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzUxLTEtMS0xLTM5NzIw_3d9ea378-597d-43e9-8ddf-aad887584e5c"
      unitRef="usd">1500000</us-gaap:BusinessExitCosts1>
    <us-gaap:BusinessExitCosts1
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzUxLTMtMS0xLTM5NzIy_7100f97b-24cd-490e-babf-518a4bc0bc14"
      unitRef="usd">0</us-gaap:BusinessExitCosts1>
    <us-gaap:BusinessExitCosts1
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzUxLTUtMS0xLTM5NzI0_67ff4de2-51f4-4d9f-9b66-e441da7b07a2"
      unitRef="usd">0</us-gaap:BusinessExitCosts1>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzQ5LTEtMS0xLTMzMjAz_a7bf0272-6af5-49b5-88eb-c9450a33364b"
      unitRef="usd">0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzQ5LTMtMS0xLTMzMjAz_1c207315-b78f-4fe0-b8b0-81702e0725e7"
      unitRef="usd">0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="ief9b221acfd5465cb83500067a09fff2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzQ5LTUtMS0xLTMzMjAz_66550881-1b49-400b-a01f-1b215d590a93"
      unitRef="usd">3437000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzUwLTEtMS0xLTMzMjAz_e317e693-3e6f-4251-a197-336f5534a4c0"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzUwLTMtMS0xLTMzMjAz_fa58c453-4241-4fb3-b556-5bf81fefac07"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDIvZnJhZzo1NDk5MjRmOWI2YWY0NzQ5YTc5YWQ2ODk3NzQyZmVjOC90YWJsZTpmZWIxZTBlNmE2MDU0OWQxODE5Y2UyZDM3M2E4NWI2Mi90YWJsZXJhbmdlOmZlYjFlMGU2YTYwNTQ5ZDE4MTljZTJkMzczYTg1YjYyXzUwLTUtMS0xLTMzMjAz_d7f3b008-3765-4e0c-96c1-919aa8a5c9ad"
      unitRef="usd">15714000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNDgvZnJhZzpjZDNkNmMyMmIwNzc0M2U1YmQ2ZDgwNWQ4ZWRjZGZhMy90ZXh0cmVnaW9uOmNkM2Q2YzIyYjA3NzQzZTViZDZkODA1ZDhlZGNkZmEzXzE4MDg_5faaeedc-1e22-4b87-acca-008cd1a01c3f">Organization and Operations&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lexicon Pharmaceuticals, Inc. (&#x201c;Lexicon&#x201d; or the &#x201c;Company&#x201d;) is a Delaware corporation incorporated on July&#160;7, 1995. Lexicon was organized to discover the functions and pharmaceutical utility of genes and use those gene function discoveries in the discovery and development of pharmaceutical products for the treatment of human disease.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lexicon has financed its operations from inception primarily through sales of common and preferred stock, contract and milestone payments to it under strategic collaborations and other research and development collaborations, target validation, database subscription and technology license agreements, product sales, government grants and contracts and financing under debt and lease arrangements. The Company&#x2019;s future success is dependent upon many factors, including, but not limited to, the success of its commercialization efforts for any approved products; ongoing nonclinical and clinical development efforts and its ability to obtain necessary regulatory approvals of the drug candidates which are the subject of such efforts; its success in establishing new collaborations and licenses and its receipt of milestones, royalties and other payments under such arrangements; the amount and timing of research, development and commercialization expenditures; its resources devoted to developing and supporting its products; general and industry-specific economic conditions which may affect research, development and commercialization expenditures; and its ability to obtain and enforce patents and other proprietary rights in its discoveries, comply with federal and state regulations, and maintain sufficient capital to fund its activities.&#160;&#160;As a result of the aforementioned factors and the related uncertainties, there can be no assurance of the Company&#x2019;s future success.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzIzMDg4_43d49930-2031-4103-8ae4-a622ae328f28">Summary of Significant Accounting Policies&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%"&gt;Basis of Presentation:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt; The accompanying consolidated financial statements include the accounts of Lexicon and its wholly-owned subsidiaries.  Intercompany transactions and balances are eliminated in consolidation.    &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of Estimates:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The preparation of financial statements in conformity with U. S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash, Cash Equivalents and Short-Term Investments:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Lexicon considers all highly-liquid investments with original maturities of three months or less to be cash equivalents.&#160;&#160;As of December&#160;31, 2022 and 2021, short-term investments consist of U.S. treasury bills and corporate debt securities.  The Company&#x2019;s short-term investments are classified as available-for-sale securities and are carried at fair value, based on quoted market prices of the securities.&#160;&#160;The Company views its available-for-sale securities as available for use in current operations regardless of the stated maturity date of the security.&#160; The Company does not intend to sell any of its available-for-sale securities prior to their maturity dates. Unrealized gains and losses on such securities are reported as a separate component of stockholders&#x2019; equity.&#160;&#160;Net realized gains and losses, interest and dividends are included in interest income.&#160;&#160;The cost of securities sold is based on the specific identification method.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounts Receivable:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;Lexicon records trade accounts receivable in the normal course of business related to the sale of products or services, net of an allowance for expected credit losses.&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Concentration of Credit Risk:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Lexicon&#x2019;s cash equivalents, investments and accounts receivable represent potential concentrations of credit risk. The Company attempts to minimize potential concentrations of risk in cash equivalents and investments by placing investments in high-quality financial instruments. The Company has not experienced any realized losses on its cash equivalents or short-term investments.  The Company&#x2019;s accounts receivable are unsecured and are concentrated in pharmaceutical and biotechnology companies located in the United States.&#160;&#160;The Company has not experienced any significant credit losses to date.  In 2022, one customer in the United States represented 100% of revenue.&#160;&#160; In 2021, customers in Switzerland and the United States represented 76% and 24% of revenue, respectively.&#160;In 2020, customers in the United States represented 98% of revenue.&#160;At December&#160;31, 2022, management believes that the Company has no significant concentrations of credit risk.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Information and Significant Customers:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Lexicon operates in one business segment, which primarily focuses on the discovery, development and commercialization of pharmaceutical products for the treatment of human disease. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Substantially all of the Company&#x2019;s revenues have been derived from drug discovery alliances, target validation collaborations for the development and, in some cases, analysis of the physiological effects of genes altered in knockout mice, technology licenses, subscriptions to its databases, product sales, government grants and contracts and compound library sales.  In 2022, one customer represented 100% of revenue.  In 2021, one customer represented 76% of revenues and another customer represented 24% of revenues, respectively.  In 2020, two customers represented 65% and 22% of revenues, respectively.   &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property and Equipment:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Property and equipment that is held and used is carried at cost and depreciated using the straight-line method over the estimated useful life of the assets which ranges from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzM5MTE_558fa410-9f8f-4ae0-80f8-17c88e115072"&gt;three&lt;/span&gt; to 40 years.&#160;&#160;Maintenance, repairs and minor replacements are charged to expense as incurred.&#160;&#160;Leasehold improvements are amortized over the shorter of the estimated useful life or the remaining lease term.&#160;&#160;Significant renewals and betterments are capitalized.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accrued liabilities: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Accrued liabilities consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.163%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.757%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued research and development services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short term lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Impairment of Long-Lived Assets:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;Long-lived assets and right-of-use assets for leases are reviewed for impairment when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable.  Recoverability of assets to be held and used is measured by comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount that the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. In 2020, the Company recognized an impairment loss of $1.6 million to reduce the carrying value of the assets comprising our campus in The Woodlands, Texas, which were sold in December 2020, to an estimated fair value, less estimated selling costs.  There were no impairments of long-lived assets, in 2022 or 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill Impairment:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;Goodwill is not amortized, but is tested at least annually for impairment at the reporting unit level.&#160;&#160;The Company has determined that the reporting unit is the single operating segment disclosed in its current financial statements. Impairment is the condition that exists when the carrying amount of goodwill exceeds its implied fair value.&#160;&#160;The first step in the impairment process is to determine the fair value of the reporting unit and then compare it to the carrying value, including goodwill.&#160;&#160;If the fair value exceeds the carrying value, no further action is required and no impairment loss is recognized.&#160;&#160;Additional impairment assessments may be performed on an interim basis if the Company encounters events or changes in circumstances that would indicate that, more likely than not, the carrying value of goodwill has been impaired.&#160;&#160;There was no impairment of goodwill in 2022, 2021 or 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Lexicon determines if a contract is or contains a lease at inception or upon modification of the contract. A contract is or contains a lease if it conveys the right to control the use of an identified asset for a period in exchange for consideration. Control over the use of the identified asset means the lessee has both (a) the right to obtain substantially all of the economic benefits from the use of the asset and (b) the right to direct the use of the asset. Lexicon does not apply this accounting to those leases with terms of twelve (12) months or less. Operating lease right-of-use assets and associated lease liabilities are recorded in the balance sheet at the lease commencement date based on the present value of future lease payments to be made over the expected lease term. As the implicit rate is not determinable in its leases, Lexicon used a borrowing rate ranging between 9% and 9.7% at the commencement date in determining the present value of future payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Product Revenues&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the Company&#x2019;s sale of XERMELO and related assets to TerSera Therapeutics, LLC (&#x201c;TerSera&#x201d;) in September 2020, product revenues consisted of commercial sales of XERMELO in the United States and sales of bulk tablets of XERMELO to Ipsen.  Product revenues were recognized when the customer obtained control of the Company&#x2019;s product, which occured upon delivery to the customer.  The Company recognized product revenue net of applicable reserves for variable consideration, including allowances for customer credits, estimated rebates, chargebacks, discounts, returns, distribution service fees, and government rebates, such as Medicare Part D coverage gap reimbursements in the United States, as discussed below.  These estimates were based on the most likely amount method for relevant factors such as current contractual and statutory requirements, industry data and forecasted customer buying and payment patterns. Product shipping and handling costs were considered a fulfillment activity when control transfers to the Company&#x2019;s customers and such costs were included in cost of sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Customer Credits:  The Company&#x2019;s customers were offered various forms of consideration, including allowances, service fees and prompt payment discounts.  The Company expected that its customers would earn prompt payment discounts.  As a result, the Company deducted the full amount of those discounts from total product sales when revenues were recognized.  Service fees were also deducted from product sales as they were earned.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rebates:  Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program.  Rebate amounts are based upon contractual agreements or legal requirements with public sector (e.g., Medicaid) benefit providers.  Rebates are amounts owed after the final dispensing of the product to a benefit plan participant and are based upon contractual agreements or legal requirements with public sector benefit providers.  The allowance for rebates is based on statutory discount rates and expected utilization.  The Company&#x2019;s estimates for expected utilization of rebates were based on third party market research data and data received from the specialty pharmacies dispensing XERMELO.  Rebates were generally invoiced and paid in arrears so that the accrual balance consisted of an estimate of the amount expected to be incurred for the current quarter&#x2019;s activity, plus an accrual balance for known unpaid rebates from the prior quarter.  If actual future rebates varied from estimates, the Company adjusted prior period accruals, which affected revenue in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Chargebacks:  Chargebacks are discounts that occur when contracted customers purchase directly from a specialty pharmacy or distributor, who acts as a retailer.  Contracted customers, which consisted primarily of Public Health Service Institutions, non-profit clinics, and federal government entities purchasing via the Federal Supply Schedule, generally purchased XERMELO at a discounted price.  The specialty pharmacy or distributor, in turn, charged back to Lexicon the difference between the price paid by the specialty pharmacy or distributor and the discounted price paid to the specialty pharmacy or distributor by the customer.  The allowance for chargeback was based on known sales to contracted customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medicare Part D Coverage Gap:  The Medicare Part D prescription drug benefit mandates manufacturers to fund a portion of the Medicare Part D insurance coverage gap for prescription drugs sold to eligible patients.  The Company&#x2019;s estimates for the expected Medicare Part D coverage gap were based on data received from the specialty pharmacies dispensing XERMELO and projections based on historical data.  Funding of the coverage gap was generally invoiced and paid in arrears so that the accrual balance consisted of an estimate of the amount expected to be incurred for the current quarter&#x2019;s activity, plus an accrual balance for known prior quarters.  If actual future funding varied from estimates, the Company adjusted prior period accruals, which affected revenues in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Co-payment assistance:  Patients with commercial insurance who met certain eligibility requirements were eligible to receive co-payment assistance.  The Company accrued a liability for co-payment assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Collaborative Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues under collaborative agreements include both license revenue and contract research revenue.  The Company performs the following five steps in determining the amount of revenue to recognize as it fulfills its performance obligations under each of its collaborative agreements:  (i) identify the contract(s) with a customer; (ii) identify the performance obligation in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligation.  The Company applies this five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.  At contract inception, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;service is distinct.  The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.  The Company develops assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At contract inception, the Company evaluates whether development milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method.  If it is probable that a significant revenue reversal will not occur, the associated development milestone value is included in the transaction price.  Development milestones that are not within the control of the Company or the licensee, including those requiring regulatory approval, are not considered probable of being achieved until those approvals are received.  The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue when (or as) the performance obligation is satisfied.  At the end of each reporting period, the Company re-evaluates the probability of achievement of the development milestones and any related constraint, and if necessary, adjusts its estimates of the overall transaction price.  Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In agreements in which a license to the Company&#x2019;s intellectual property is determined distinct from other performance obligations identified in the agreement, the Company recognizes revenue when the license is transferred to the licensee and the licensee is able to use and benefit from the license.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For agreements that include sales-based royalties, including milestones based on a level of sales, the license is deemed to be the predominant item to which the royalties relate and the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may receive payments from its licensees based on billing schedules established in each contract.  Upfront payments and fees are recorded as deferred revenue upon receipt or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under these agreements.  Amounts are recorded as accounts receivable when the Company&#x2019;s right to consideration is unconditional.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of Sales: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Cost of sales consisted of third-party manufacturing costs, freight and indirect overhead costs associated with sales of XERMELO.  Product shipping and handling costs were included in cost of sales. Cost of sales also included the amortization of the intangible asset for XERMELO using the straight-line method over the estimated useful life of 14 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Expenses:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Research and development expenses consist of costs incurred for company-sponsored as well as collaborative research and development activities. These costs include direct and research-related overhead expenses and are expensed as incurred.&#160;&#160;Technology license fees for technologies that are utilized in research and development and have no alternative future use are expensed when incurred.  Substantial portions of the Company&#x2019;s preclinical and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors.  For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining.  For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study.  The Company monitors patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to the Company by the vendors and clinical site visits.  The Company&#x2019;s estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each program and total program spending.  The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-Based Compensation:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;The Company recognizes compensation expense in its statements of comprehensive loss for share-based payments, including stock options and restricted stock units issued to employees, based on their fair values on the date of the grant, with the compensation expense recognized over the period in which an employee is required to provide service in exchange for the stock award.&#160;&#160;Stock-based compensation expense for awards without performance conditions is recognized based on the terms of vesting, which is typically on a straight-line basis.  Stock-based compensation expense for awards with performance conditions is recognized over the period from the date the performance condition is determined to be probable of occurring through the time the applicable condition is met.&#160;&#160;As of December&#160;31, 2022, future stock-based compensation cost for all outstanding unvested stock options and restricted stock units was $21.0 million, which is expected to be recognized over a weighted-average period of 1.3&#160;years.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of stock options is estimated at the date of grant using the Black-Scholes method.&#160;&#160;The Black-Scholes option-pricing model requires the input of subjective assumptions.&#160;&#160;Because the Company&#x2019;s employee stock options have &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&#x2019;s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options.&#160;&#160;For purposes of determining the fair value of stock options, the Company segregates its options into two homogeneous groups, based on exercise and post-vesting employment termination behaviors, resulting in different assumptions used for expected option lives.&#160;&#160;Historical data is used to estimate the expected option life for each group.  Expected volatility is based on the historical volatility in the Company&#x2019;s stock price.&#160;&#160;The following weighted-average assumptions were used for stock options granted in the years ended December&#160;31, 2022, 2021 and 2020, respectively:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Expected Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Risk-free Interest Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Expected Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Dividend&lt;br/&gt;Rate&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2022:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Officers and non-employee directors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Officers and non-employee directors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2020:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Officers and non-employee directors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been recognized differently in the financial statements and tax returns. The Company uses the liability method in accounting for income taxes. Under this method, deferred tax liabilities and assets are determined based on the difference between the financial statement carrying amounts and tax bases of liabilities and assets using enacted tax rates and laws in effect in the years in which the differences are expected to reverse. Deferred tax assets are evaluated for realization based on a more-likely-than-not criteria in determining if a valuation allowance should be provided.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains a valuation allowance on net operating losses and other deferred tax assets. Accordingly, the Company has not reported any tax benefit relating to the remaining net operating loss carryforwards and income tax credit carryforwards that are available for utilization in future periods. On a periodic basis, the valuation allowance is reassessed on deferred income tax assets, weighing positive and negative evidence to assess the recoverability of the deferred tax assets. In 2022, the Company reassessed the valuation allowance and considered negative evidence, including the cumulative losses over the three years ended December&#160;31, 2022 and positive evidence including the projections of future income. After assessing both the negative and the positive evidence, the Company concluded that it should continue to maintain the valuation allowance on net operating losses and other deferred tax assets as of December&#160;31, 2022 given the significance of the weight of the negative evidence. Based on recent financial performance and future projections, the Company could record a reversal of all, or a portion of the valuation allowance associated with U.S. deferred tax assets in future periods. However, any such change is subject to actual performance and other considerations that may present positive or negative evidence at the time of the assessment. The total gross deferred tax asset balance subject to the valuation allowance assessment was approximately $347.1&#160;million at December&#160;31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant judgment is required in making these assessments to maintain or reverse valuation allowances and, to the extent future expectations change the Company would have to assess the recoverability of these deferred tax assets at that time. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net Loss per Common Share:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Net loss per common share is computed using the weighted average number of shares of common stock outstanding. Shares associated with warrants, stock options and restricted stock units that could potentially dilute earnings per share in the future are not included in the computation of diluted earnings per share because they are antidilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzIzMDE0_edbf7b9a-eb87-4a54-b928-886e8dd9be32">Basis of Presentation: The accompanying consolidated financial statements include the accounts of Lexicon and its wholly-owned subsidiaries.  Intercompany transactions and balances are eliminated in consolidation.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzIzMDYy_c7027eb2-c2b5-4f25-82ad-d26e176e5045">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of Estimates:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The preparation of financial statements in conformity with U. S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.&lt;/span&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzIzMDUz_fe3d4e22-a004-454d-a745-469a9865f6eb">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash, Cash Equivalents and Short-Term Investments:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Lexicon considers all highly-liquid investments with original maturities of three months or less to be cash equivalents.&#160;&#160;As of December&#160;31, 2022 and 2021, short-term investments consist of U.S. treasury bills and corporate debt securities.  The Company&#x2019;s short-term investments are classified as available-for-sale securities and are carried at fair value, based on quoted market prices of the securities.&#160;&#160;The Company views its available-for-sale securities as available for use in current operations regardless of the stated maturity date of the security.&#160; The Company does not intend to sell any of its available-for-sale securities prior to their maturity dates. Unrealized gains and losses on such securities are reported as a separate component of stockholders&#x2019; equity.&#160;&#160;Net realized gains and losses, interest and dividends are included in interest income.&#160;&#160;The cost of securities sold is based on the specific identification method.&lt;/span&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzIzMDY3_a150e800-a41a-4d12-96d1-010f229272a6">Accounts Receivable:&#160;&#160;Lexicon records trade accounts receivable in the normal course of business related to the sale of products or services, net of an allowance for expected credit losses.</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:ConcentrationRiskDisclosureTextBlock
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzIzMDM5_69164596-9241-4812-9a52-43dc3dcd807d">Concentration of Credit Risk: Lexicon&#x2019;s cash equivalents, investments and accounts receivable represent potential concentrations of credit risk. The Company attempts to minimize potential concentrations of risk in cash equivalents and investments by placing investments in high-quality financial instruments. The Company has not experienced any realized losses on its cash equivalents or short-term investments.  The Company&#x2019;s accounts receivable are unsecured and are concentrated in pharmaceutical and biotechnology companies located in the United States.&#160;&#160;The Company has not experienced any significant credit losses to date.  In 2022, one customer in the United States represented 100% of revenue.</us-gaap:ConcentrationRiskDisclosureTextBlock>
    <lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzEwOTk1MTE2NTIxNjA_2984eac8-c625-4f6f-acdc-0c3981953301"
      unitRef="number">1</lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany>
    <lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzI0NjM_126449e4-27af-4979-924a-da8f4200fe9b"
      unitRef="number">0.76</lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany>
    <lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzI0NzA_e89ec413-e1af-4e46-9d31-49d63a6e6827"
      unitRef="number">0.24</lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent>
    <lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzI1NDk_96dcddcc-a927-4a0d-89d1-71ea20af0f2b"
      unitRef="number">0.98</lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzIzMDA3_5cc3ec0b-c30b-46a2-8b43-cb740d42fee6">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Information and Significant Customers:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Lexicon operates in one business segment, which primarily focuses on the discovery, development and commercialization of pharmaceutical products for the treatment of human disease. &lt;/span&gt;Substantially all of the Company&#x2019;s revenues have been derived from drug discovery alliances, target validation collaborations for the development and, in some cases, analysis of the physiological effects of genes altered in knockout mice, technology licenses, subscriptions to its databases, product sales, government grants and contracts and compound library sales.  In 2022, one customer represented 100% of revenue.</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzI4Mjk_98aeccdf-9605-417b-9f49-60e73cbe20f0"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzEwOTk1MTE2NTIyMzY_2984eac8-c625-4f6f-acdc-0c3981953301"
      unitRef="number">1</lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany>
    <lxrx:LXRXBiologicscustomerconcentration
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzMzOTU_499d72bd-ec4f-469b-a759-82b259a8f856"
      unitRef="number">0.76</lxrx:LXRXBiologicscustomerconcentration>
    <lxrx:LXRXDiplomatcustomerconcentration
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzM0NDY_eeef8488-367b-454c-abeb-65882d4f6ee3"
      unitRef="number">0.24</lxrx:LXRXDiplomatcustomerconcentration>
    <lxrx:LXRXBiologicscustomerconcentration
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzM1NjE_e927ae28-eb7c-49d5-8843-ca8952ed552c"
      unitRef="number">0.65</lxrx:LXRXBiologicscustomerconcentration>
    <lxrx:LXRXDiplomatcustomerconcentration
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzM1Njg_8a6788a5-cc0e-4a7d-94be-c70fb5565e33"
      unitRef="number">0.22</lxrx:LXRXDiplomatcustomerconcentration>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzIzMDg5_22c908fc-887d-4bf4-a0be-dbc513debd79">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property and Equipment:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Property and equipment that is held and used is carried at cost and depreciated using the straight-line method over the estimated useful life of the assets which ranges from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzM5MTE_558fa410-9f8f-4ae0-80f8-17c88e115072"&gt;three&lt;/span&gt; to 40 years.&#160;&#160;Maintenance, repairs and minor replacements are charged to expense as incurred.&#160;&#160;Leasehold improvements are amortized over the shorter of the estimated useful life or the remaining lease term.&#160;&#160;Significant renewals and betterments are capitalized.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accrued liabilities: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Accrued liabilities consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.163%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.757%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued research and development services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short term lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ief3a42398bf74858b5aa075d327d0116_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzM5MTc_e5d5dc12-42dc-49a9-860a-ffce31534b2c">P40Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <lxrx:AccruedResearchAndDevelopmentServicesCurrent
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90YWJsZTo3MDMzYmY0N2YzNGU0NGYxOTJlMTEwOTJiMTlmMTAzYy90YWJsZXJhbmdlOjcwMzNiZjQ3ZjM0ZTQ0ZjE5MmUxMTA5MmIxOWYxMDNjXzMtMi0xLTEtMzMyMDM_ce7d3ef0-6043-4613-b384-32f3813c118c"
      unitRef="usd">3252000</lxrx:AccruedResearchAndDevelopmentServicesCurrent>
    <lxrx:AccruedResearchAndDevelopmentServicesCurrent
      contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90YWJsZTo3MDMzYmY0N2YzNGU0NGYxOTJlMTEwOTJiMTlmMTAzYy90YWJsZXJhbmdlOjcwMzNiZjQ3ZjM0ZTQ0ZjE5MmUxMTA5MmIxOWYxMDNjXzMtNC0xLTEtMzMyMDM_db7c3e25-9376-4e49-8b92-a18f2ef7da75"
      unitRef="usd">3669000</lxrx:AccruedResearchAndDevelopmentServicesCurrent>
    <lxrx:AccruedCompensationAndBenefitsCurrent
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90YWJsZTo3MDMzYmY0N2YzNGU0NGYxOTJlMTEwOTJiMTlmMTAzYy90YWJsZXJhbmdlOjcwMzNiZjQ3ZjM0ZTQ0ZjE5MmUxMTA5MmIxOWYxMDNjXzQtMi0xLTEtMzMyMDM_f572b939-3e4e-41a0-86cc-33e3c6bf2543"
      unitRef="usd">7830000</lxrx:AccruedCompensationAndBenefitsCurrent>
    <lxrx:AccruedCompensationAndBenefitsCurrent
      contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90YWJsZTo3MDMzYmY0N2YzNGU0NGYxOTJlMTEwOTJiMTlmMTAzYy90YWJsZXJhbmdlOjcwMzNiZjQ3ZjM0ZTQ0ZjE5MmUxMTA5MmIxOWYxMDNjXzQtNC0xLTEtMzMyMDM_9cb3e3c4-f026-4f9c-9103-064e890eda60"
      unitRef="usd">5711000</lxrx:AccruedCompensationAndBenefitsCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90YWJsZTo3MDMzYmY0N2YzNGU0NGYxOTJlMTEwOTJiMTlmMTAzYy90YWJsZXJhbmdlOjcwMzNiZjQ3ZjM0ZTQ0ZjE5MmUxMTA5MmIxOWYxMDNjXzUtMi0xLTEtMzMyMDM_b071f5dd-7337-4f78-af25-5314a0bae291"
      unitRef="usd">1291000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90YWJsZTo3MDMzYmY0N2YzNGU0NGYxOTJlMTEwOTJiMTlmMTAzYy90YWJsZXJhbmdlOjcwMzNiZjQ3ZjM0ZTQ0ZjE5MmUxMTA5MmIxOWYxMDNjXzUtNC0xLTEtMzMyMDM_8633b4ee-fde4-4697-adeb-cf350de80fb0"
      unitRef="usd">1089000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90YWJsZTo3MDMzYmY0N2YzNGU0NGYxOTJlMTEwOTJiMTlmMTAzYy90YWJsZXJhbmdlOjcwMzNiZjQ3ZjM0ZTQ0ZjE5MmUxMTA5MmIxOWYxMDNjXzYtMi0xLTEtMzMyMDM_8076cfec-6e70-4000-8407-4bb86a19ebcd"
      unitRef="usd">404000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90YWJsZTo3MDMzYmY0N2YzNGU0NGYxOTJlMTEwOTJiMTlmMTAzYy90YWJsZXJhbmdlOjcwMzNiZjQ3ZjM0ZTQ0ZjE5MmUxMTA5MmIxOWYxMDNjXzYtNC0xLTEtMzMyMDM_529a50d7-3c50-44c0-84c8-865b2455d8f7"
      unitRef="usd">2503000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90YWJsZTo3MDMzYmY0N2YzNGU0NGYxOTJlMTEwOTJiMTlmMTAzYy90YWJsZXJhbmdlOjcwMzNiZjQ3ZjM0ZTQ0ZjE5MmUxMTA5MmIxOWYxMDNjXzctMi0xLTEtMzMyMDM_889e74e0-1315-4d94-b003-9cb9ff831083"
      unitRef="usd">12777000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90YWJsZTo3MDMzYmY0N2YzNGU0NGYxOTJlMTEwOTJiMTlmMTAzYy90YWJsZXJhbmdlOjcwMzNiZjQ3ZjM0ZTQ0ZjE5MmUxMTA5MmIxOWYxMDNjXzctNC0xLTEtMzMyMDM_5542e6fc-3955-4e13-b63f-1d3b7c3858bb"
      unitRef="usd">12972000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzIzMDg3_27d1b8f4-534d-4400-a9b1-45e6a42c609e">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Impairment of Long-Lived Assets:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;Long-lived assets and right-of-use assets for leases are reviewed for impairment when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable.  Recoverability of assets to be held and used is measured by comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount that the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. In 2020, the Company recognized an impairment loss of $1.6 million to reduce the carrying value of the assets comprising our campus in The Woodlands, Texas, which were sold in December 2020, to an estimated fair value, less estimated selling costs.  There were no impairments of long-lived assets, in 2022 or 2021.&lt;/span&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzEwOTk1MTE2NTA5MDA_0fd3b24b-cb5c-4dcf-bb13-4e8da4a5ce67"
      unitRef="usd">1600000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzUyMTQ_0c846189-acad-4c5c-9ef3-b59101e6c5c0"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzUyMTQ_f5551571-421c-4969-b7f8-78f978ab9b77"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzIzMDUx_22694926-406c-4732-bb59-ddbad140a974">Goodwill Impairment:&#160;&#160;Goodwill is not amortized, but is tested at least annually for impairment at the reporting unit level.&#160;&#160;The Company has determined that the reporting unit is the single operating segment disclosed in its current financial statements. Impairment is the condition that exists when the carrying amount of goodwill exceeds its implied fair value.&#160;&#160;The first step in the impairment process is to determine the fair value of the reporting unit and then compare it to the carrying value, including goodwill.&#160;&#160;If the fair value exceeds the carrying value, no further action is required and no impairment loss is recognized.&#160;&#160;Additional impairment assessments may be performed on an interim basis if the Company encounters events or changes in circumstances that would indicate that, more likely than not, the carrying value of goodwill has been impaired.</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzIzMDMx_5c00d881-9aeb-48a5-bf95-3400124378a2">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Product Revenues&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the Company&#x2019;s sale of XERMELO and related assets to TerSera Therapeutics, LLC (&#x201c;TerSera&#x201d;) in September 2020, product revenues consisted of commercial sales of XERMELO in the United States and sales of bulk tablets of XERMELO to Ipsen.  Product revenues were recognized when the customer obtained control of the Company&#x2019;s product, which occured upon delivery to the customer.  The Company recognized product revenue net of applicable reserves for variable consideration, including allowances for customer credits, estimated rebates, chargebacks, discounts, returns, distribution service fees, and government rebates, such as Medicare Part D coverage gap reimbursements in the United States, as discussed below.  These estimates were based on the most likely amount method for relevant factors such as current contractual and statutory requirements, industry data and forecasted customer buying and payment patterns. Product shipping and handling costs were considered a fulfillment activity when control transfers to the Company&#x2019;s customers and such costs were included in cost of sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Customer Credits:  The Company&#x2019;s customers were offered various forms of consideration, including allowances, service fees and prompt payment discounts.  The Company expected that its customers would earn prompt payment discounts.  As a result, the Company deducted the full amount of those discounts from total product sales when revenues were recognized.  Service fees were also deducted from product sales as they were earned.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rebates:  Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program.  Rebate amounts are based upon contractual agreements or legal requirements with public sector (e.g., Medicaid) benefit providers.  Rebates are amounts owed after the final dispensing of the product to a benefit plan participant and are based upon contractual agreements or legal requirements with public sector benefit providers.  The allowance for rebates is based on statutory discount rates and expected utilization.  The Company&#x2019;s estimates for expected utilization of rebates were based on third party market research data and data received from the specialty pharmacies dispensing XERMELO.  Rebates were generally invoiced and paid in arrears so that the accrual balance consisted of an estimate of the amount expected to be incurred for the current quarter&#x2019;s activity, plus an accrual balance for known unpaid rebates from the prior quarter.  If actual future rebates varied from estimates, the Company adjusted prior period accruals, which affected revenue in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Chargebacks:  Chargebacks are discounts that occur when contracted customers purchase directly from a specialty pharmacy or distributor, who acts as a retailer.  Contracted customers, which consisted primarily of Public Health Service Institutions, non-profit clinics, and federal government entities purchasing via the Federal Supply Schedule, generally purchased XERMELO at a discounted price.  The specialty pharmacy or distributor, in turn, charged back to Lexicon the difference between the price paid by the specialty pharmacy or distributor and the discounted price paid to the specialty pharmacy or distributor by the customer.  The allowance for chargeback was based on known sales to contracted customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medicare Part D Coverage Gap:  The Medicare Part D prescription drug benefit mandates manufacturers to fund a portion of the Medicare Part D insurance coverage gap for prescription drugs sold to eligible patients.  The Company&#x2019;s estimates for the expected Medicare Part D coverage gap were based on data received from the specialty pharmacies dispensing XERMELO and projections based on historical data.  Funding of the coverage gap was generally invoiced and paid in arrears so that the accrual balance consisted of an estimate of the amount expected to be incurred for the current quarter&#x2019;s activity, plus an accrual balance for known prior quarters.  If actual future funding varied from estimates, the Company adjusted prior period accruals, which affected revenues in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Co-payment assistance:  Patients with commercial insurance who met certain eligibility requirements were eligible to receive co-payment assistance.  The Company accrued a liability for co-payment assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Collaborative Agreements&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:CostOfSalesPolicyTextBlock
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzIzMDMy_65614d83-3760-47c7-899d-7e00f181f2ea">Cost of Sales:  Cost of sales consisted of third-party manufacturing costs, freight and indirect overhead costs associated with sales of XERMELO.  Product shipping and handling costs were included in cost of sales. Cost of sales also included the amortization of the intangible asset for XERMELO using the straight-line method over the estimated useful life of 14 years.</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i0126e8a6d33142d5912c3766ac53314e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzE2MjE2_1bea4d4a-ab9a-4e24-b15c-c9036a7b3a74">P14Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzIzMDE1_1a985477-ebdb-4b71-8f6e-ea3a427e3be0">Research and Development Expenses: Research and development expenses consist of costs incurred for company-sponsored as well as collaborative research and development activities. These costs include direct and research-related overhead expenses and are expensed as incurred.&#160;&#160;Technology license fees for technologies that are utilized in research and development and have no alternative future use are expensed when incurred.  Substantial portions of the Company&#x2019;s preclinical and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors.  For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining.  For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study.  The Company monitors patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to the Company by the vendors and clinical site visits.  The Company&#x2019;s estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each program and total program spending.  The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives.</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzIzMDQ0_cee28f99-f760-4d9b-8b7d-b3bceaf0d5ae">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-Based Compensation:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;The Company recognizes compensation expense in its statements of comprehensive loss for share-based payments, including stock options and restricted stock units issued to employees, based on their fair values on the date of the grant, with the compensation expense recognized over the period in which an employee is required to provide service in exchange for the stock award.&#160;&#160;Stock-based compensation expense for awards without performance conditions is recognized based on the terms of vesting, which is typically on a straight-line basis.  Stock-based compensation expense for awards with performance conditions is recognized over the period from the date the performance condition is determined to be probable of occurring through the time the applicable condition is met.&#160;&#160;As of December&#160;31, 2022, future stock-based compensation cost for all outstanding unvested stock options and restricted stock units was $21.0 million, which is expected to be recognized over a weighted-average period of 1.3&#160;years.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of stock options is estimated at the date of grant using the Black-Scholes method.&#160;&#160;The Black-Scholes option-pricing model requires the input of subjective assumptions.&#160;&#160;Because the Company&#x2019;s employee stock options have &lt;/span&gt;&lt;/div&gt;characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&#x2019;s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options.&#160;&#160;For purposes of determining the fair value of stock options, the Company segregates its options into two homogeneous groups, based on exercise and post-vesting employment termination behaviors, resulting in different assumptions used for expected option lives.&#160;&#160;Historical data is used to estimate the expected option life for each group.  Expected volatility is based on the historical volatility in the Company&#x2019;s stock price.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzE4OTQ3_57565856-ee0d-4471-bcce-44b7a40432e0"
      unitRef="usd">21000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzE5MDIw_c8ae7b40-c74a-4526-93a5-e244a39ab2c1">P1Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzIzMDY1_6b25bc2c-d6b7-46d5-ab5c-a82c604af7bb">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Expected Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Risk-free Interest Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Expected Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Dividend&lt;br/&gt;Rate&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2022:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Officers and non-employee directors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Officers and non-employee directors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2020:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Officers and non-employee directors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees
      contextRef="if1ed3c23317249048fd1e594aaae930b_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90YWJsZTpmZDkwNGE5Y2QwYjA0YzhjOGI1ZTY0ZTc2ODEyODg2YS90YWJsZXJhbmdlOmZkOTA0YTljZDBiMDRjOGM4YjVlNjRlNzY4MTI4ODZhXzItMS0xLTEtMzMyMDM_5851ec66-243a-4ae1-8f46-afc5d9edad67"
      unitRef="number">1.09</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee
      contextRef="if1ed3c23317249048fd1e594aaae930b_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90YWJsZTpmZDkwNGE5Y2QwYjA0YzhjOGI1ZTY0ZTc2ODEyODg2YS90YWJsZXJhbmdlOmZkOTA0YTljZDBiMDRjOGM4YjVlNjRlNzY4MTI4ODZhXzItMy0xLTEtMzMyMDM_a7f4ae83-d24e-444e-a5d2-07d4cfe58f20"
      unitRef="number">0.028</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees
      contextRef="if1ed3c23317249048fd1e594aaae930b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90YWJsZTpmZDkwNGE5Y2QwYjA0YzhjOGI1ZTY0ZTc2ODEyODg2YS90YWJsZXJhbmdlOmZkOTA0YTljZDBiMDRjOGM4YjVlNjRlNzY4MTI4ODZhXzItNS0xLTEtMzMyMDM_6e9ab1c5-2ce8-410c-988c-ed83b0007715">P4Y</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees
      contextRef="if1ed3c23317249048fd1e594aaae930b_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90YWJsZTpmZDkwNGE5Y2QwYjA0YzhjOGI1ZTY0ZTc2ODEyODg2YS90YWJsZXJhbmdlOmZkOTA0YTljZDBiMDRjOGM4YjVlNjRlNzY4MTI4ODZhXzItNy0xLTEtMzMyMDM_21c3aa43-5177-45df-9640-755db0014bdf"
      unitRef="number">0</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors
      contextRef="if1ed3c23317249048fd1e594aaae930b_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90YWJsZTpmZDkwNGE5Y2QwYjA0YzhjOGI1ZTY0ZTc2ODEyODg2YS90YWJsZXJhbmdlOmZkOTA0YTljZDBiMDRjOGM4YjVlNjRlNzY4MTI4ODZhXzMtMS0xLTEtMzMyMDM_542516f4-e99a-4487-8186-f22038dbc7e2"
      unitRef="number">0.91</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors
      contextRef="if1ed3c23317249048fd1e594aaae930b_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90YWJsZTpmZDkwNGE5Y2QwYjA0YzhjOGI1ZTY0ZTc2ODEyODg2YS90YWJsZXJhbmdlOmZkOTA0YTljZDBiMDRjOGM4YjVlNjRlNzY4MTI4ODZhXzMtMy0xLTEtMzMyMDM_75e9dd7a-7c5d-4df6-8d48-2d72580d594a"
      unitRef="number">0.019</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors
      contextRef="if1ed3c23317249048fd1e594aaae930b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90YWJsZTpmZDkwNGE5Y2QwYjA0YzhjOGI1ZTY0ZTc2ODEyODg2YS90YWJsZXJhbmdlOmZkOTA0YTljZDBiMDRjOGM4YjVlNjRlNzY4MTI4ODZhXzMtNS0xLTEtMzMyMDM_8a3dd602-56ba-40a5-9b23-914843fafc04">P7Y</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors
      contextRef="if1ed3c23317249048fd1e594aaae930b_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90YWJsZTpmZDkwNGE5Y2QwYjA0YzhjOGI1ZTY0ZTc2ODEyODg2YS90YWJsZXJhbmdlOmZkOTA0YTljZDBiMDRjOGM4YjVlNjRlNzY4MTI4ODZhXzMtNy0xLTEtMzMyMDM_54b0fa34-8fff-4041-9ce8-a6ba9ce12a77"
      unitRef="number">0</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees
      contextRef="ic47b53ad6bac40f099489e67c81c19de_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90YWJsZTpmZDkwNGE5Y2QwYjA0YzhjOGI1ZTY0ZTc2ODEyODg2YS90YWJsZXJhbmdlOmZkOTA0YTljZDBiMDRjOGM4YjVlNjRlNzY4MTI4ODZhXzUtMS0xLTEtMzMyMDM_2fb0b072-ca6f-4888-b0c5-3652fb7011fc"
      unitRef="number">1.04</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee
      contextRef="ic47b53ad6bac40f099489e67c81c19de_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90YWJsZTpmZDkwNGE5Y2QwYjA0YzhjOGI1ZTY0ZTc2ODEyODg2YS90YWJsZXJhbmdlOmZkOTA0YTljZDBiMDRjOGM4YjVlNjRlNzY4MTI4ODZhXzUtMy0xLTEtMzMyMDM_983f9178-2282-408a-8938-17bd3efdc13a"
      unitRef="number">0.007</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees
      contextRef="ic47b53ad6bac40f099489e67c81c19de_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90YWJsZTpmZDkwNGE5Y2QwYjA0YzhjOGI1ZTY0ZTc2ODEyODg2YS90YWJsZXJhbmdlOmZkOTA0YTljZDBiMDRjOGM4YjVlNjRlNzY4MTI4ODZhXzUtNS0xLTEtMzMyMDM_2fad9141-70d5-4a17-8f20-78205605dba4">P4Y</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees
      contextRef="ic47b53ad6bac40f099489e67c81c19de_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90YWJsZTpmZDkwNGE5Y2QwYjA0YzhjOGI1ZTY0ZTc2ODEyODg2YS90YWJsZXJhbmdlOmZkOTA0YTljZDBiMDRjOGM4YjVlNjRlNzY4MTI4ODZhXzUtNy0xLTEtMzMyMDM_ab152c4d-881b-4378-9c4a-931755ab2737"
      unitRef="number">0</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors
      contextRef="ic47b53ad6bac40f099489e67c81c19de_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90YWJsZTpmZDkwNGE5Y2QwYjA0YzhjOGI1ZTY0ZTc2ODEyODg2YS90YWJsZXJhbmdlOmZkOTA0YTljZDBiMDRjOGM4YjVlNjRlNzY4MTI4ODZhXzYtMS0xLTEtMzMyMDM_32e3dcf0-0685-44bf-acb5-a2a71a88d059"
      unitRef="number">0.90</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors
      contextRef="ic47b53ad6bac40f099489e67c81c19de_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90YWJsZTpmZDkwNGE5Y2QwYjA0YzhjOGI1ZTY0ZTc2ODEyODg2YS90YWJsZXJhbmdlOmZkOTA0YTljZDBiMDRjOGM4YjVlNjRlNzY4MTI4ODZhXzYtMy0xLTEtMzMyMDM_dcd10521-1b52-4fa6-93c9-ca298ace1bd7"
      unitRef="number">0.010</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors
      contextRef="ic47b53ad6bac40f099489e67c81c19de_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90YWJsZTpmZDkwNGE5Y2QwYjA0YzhjOGI1ZTY0ZTc2ODEyODg2YS90YWJsZXJhbmdlOmZkOTA0YTljZDBiMDRjOGM4YjVlNjRlNzY4MTI4ODZhXzYtNS0xLTEtMzMyMDM_1537773b-fc4e-48dd-921c-f44970f73431">P6Y</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors
      contextRef="ic47b53ad6bac40f099489e67c81c19de_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90YWJsZTpmZDkwNGE5Y2QwYjA0YzhjOGI1ZTY0ZTc2ODEyODg2YS90YWJsZXJhbmdlOmZkOTA0YTljZDBiMDRjOGM4YjVlNjRlNzY4MTI4ODZhXzYtNy0xLTEtMzMyMDM_f4390936-a36d-46da-8a87-86f1f90f2208"
      unitRef="number">0</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees
      contextRef="i9f10e15a388c4c8a99f1402fbd71ee00_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90YWJsZTpmZDkwNGE5Y2QwYjA0YzhjOGI1ZTY0ZTc2ODEyODg2YS90YWJsZXJhbmdlOmZkOTA0YTljZDBiMDRjOGM4YjVlNjRlNzY4MTI4ODZhXzgtMS0xLTEtMzMyMDM_12967f28-8cfb-43ee-ad1b-bf5e48e39f1a"
      unitRef="number">0.98</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee
      contextRef="i9f10e15a388c4c8a99f1402fbd71ee00_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90YWJsZTpmZDkwNGE5Y2QwYjA0YzhjOGI1ZTY0ZTc2ODEyODg2YS90YWJsZXJhbmdlOmZkOTA0YTljZDBiMDRjOGM4YjVlNjRlNzY4MTI4ODZhXzgtMy0xLTEtMzMyMDM_b36c35f4-aeac-40e0-9429-5ed451a5b8f3"
      unitRef="number">0.013</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees
      contextRef="i9f10e15a388c4c8a99f1402fbd71ee00_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90YWJsZTpmZDkwNGE5Y2QwYjA0YzhjOGI1ZTY0ZTc2ODEyODg2YS90YWJsZXJhbmdlOmZkOTA0YTljZDBiMDRjOGM4YjVlNjRlNzY4MTI4ODZhXzgtNS0xLTEtMzMyMDM_1db923c8-43ad-4794-a02a-d8fe616a499a">P4Y</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees
      contextRef="i9f10e15a388c4c8a99f1402fbd71ee00_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90YWJsZTpmZDkwNGE5Y2QwYjA0YzhjOGI1ZTY0ZTc2ODEyODg2YS90YWJsZXJhbmdlOmZkOTA0YTljZDBiMDRjOGM4YjVlNjRlNzY4MTI4ODZhXzgtNy0xLTEtMzMyMDM_d17fc1e2-b7a2-437b-a02f-1ce1028b5ca4"
      unitRef="number">0</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors
      contextRef="i9f10e15a388c4c8a99f1402fbd71ee00_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90YWJsZTpmZDkwNGE5Y2QwYjA0YzhjOGI1ZTY0ZTc2ODEyODg2YS90YWJsZXJhbmdlOmZkOTA0YTljZDBiMDRjOGM4YjVlNjRlNzY4MTI4ODZhXzktMS0xLTEtMzMyMDM_9b4bb40d-9b86-45b2-adcc-fa6ca9a228d4"
      unitRef="number">0.85</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors
      contextRef="i9f10e15a388c4c8a99f1402fbd71ee00_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90YWJsZTpmZDkwNGE5Y2QwYjA0YzhjOGI1ZTY0ZTc2ODEyODg2YS90YWJsZXJhbmdlOmZkOTA0YTljZDBiMDRjOGM4YjVlNjRlNzY4MTI4ODZhXzktMy0xLTEtMzMyMDM_2bbb39a0-4630-4da6-ac3c-4e5e317eaf04"
      unitRef="number">0.014</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors
      contextRef="i9f10e15a388c4c8a99f1402fbd71ee00_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90YWJsZTpmZDkwNGE5Y2QwYjA0YzhjOGI1ZTY0ZTc2ODEyODg2YS90YWJsZXJhbmdlOmZkOTA0YTljZDBiMDRjOGM4YjVlNjRlNzY4MTI4ODZhXzktNS0xLTEtMzMyMDM_6184e6db-e4c7-41d6-baa0-a551bddd6d01">P7Y</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors
      contextRef="i9f10e15a388c4c8a99f1402fbd71ee00_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90YWJsZTpmZDkwNGE5Y2QwYjA0YzhjOGI1ZTY0ZTc2ODEyODg2YS90YWJsZXJhbmdlOmZkOTA0YTljZDBiMDRjOGM4YjVlNjRlNzY4MTI4ODZhXzktNy0xLTEtMzMyMDM_ae2ece78-979a-4c76-9c48-1f3f88bfc34c"
      unitRef="number">0</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzIzMDE3_31931784-2ed8-4bdc-9abd-34a033935fd4">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been recognized differently in the financial statements and tax returns. The Company uses the liability method in accounting for income taxes. Under this method, deferred tax liabilities and assets are determined based on the difference between the financial statement carrying amounts and tax bases of liabilities and assets using enacted tax rates and laws in effect in the years in which the differences are expected to reverse. Deferred tax assets are evaluated for realization based on a more-likely-than-not criteria in determining if a valuation allowance should be provided.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains a valuation allowance on net operating losses and other deferred tax assets. Accordingly, the Company has not reported any tax benefit relating to the remaining net operating loss carryforwards and income tax credit carryforwards that are available for utilization in future periods. On a periodic basis, the valuation allowance is reassessed on deferred income tax assets, weighing positive and negative evidence to assess the recoverability of the deferred tax assets. In 2022, the Company reassessed the valuation allowance and considered negative evidence, including the cumulative losses over the three years ended December&#160;31, 2022 and positive evidence including the projections of future income. After assessing both the negative and the positive evidence, the Company concluded that it should continue to maintain the valuation allowance on net operating losses and other deferred tax assets as of December&#160;31, 2022 given the significance of the weight of the negative evidence. Based on recent financial performance and future projections, the Company could record a reversal of all, or a portion of the valuation allowance associated with U.S. deferred tax assets in future periods. However, any such change is subject to actual performance and other considerations that may present positive or negative evidence at the time of the assessment. The total gross deferred tax asset balance subject to the valuation allowance assessment was approximately $347.1&#160;million at December&#160;31, 2022. &lt;/span&gt;&lt;/div&gt;Significant judgment is required in making these assessments to maintain or reverse valuation allowances and, to the extent future expectations change the Company would have to assess the recoverability of these deferred tax assets at that time.</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzIyMzE5_a71a53da-9e0a-4f18-beee-4f45922d8beb"
      unitRef="usd">347100000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTEvZnJhZzo2NjlmM2YxZGNlMTY0YmM5YTU0Y2Q1NTQ5YzdkNjUwYS90ZXh0cmVnaW9uOjY2OWYzZjFkY2UxNjRiYzlhNTRjZDU1NDljN2Q2NTBhXzIzMDU1_2b7dac93-f99d-4a7f-8d67-9a960d88ecc8">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net Loss per Common Share:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Net loss per common share is computed using the weighted average number of shares of common stock outstanding. Shares associated with warrants, stock options and restricted stock units that could potentially dilute earnings per share in the future are not included in the computation of diluted earnings per share because they are antidilutive.&lt;/span&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNTQvZnJhZzoxN2E5YTZmMTg0ZTc0YzU1YjY2NTliMjc4OTE2MDVjYi90ZXh0cmVnaW9uOjE3YTlhNmYxODRlNzRjNTViNjY1OWIyNzg5MTYwNWNiXzI0NjE_d6afad73-7136-4441-9de4-e024a7a852b8">Recent Accounting Pronouncements&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40), which removes the separation models for convertible debt with cash conversion or beneficial conversion features. ASU 2020-06 also requires the application of the if-converted method for calculating earnings per diluted share, as the treasury stock method will no longer be permitted for convertible instruments. The adoption of ASU 2020-06 during the first quarter of 2022 did not have a material impact on the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:CashAndCashEquivalentsDisclosureTextBlock
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90ZXh0cmVnaW9uOjUyMThlODA3YWMwNjQwODViZjY2MGMxZGM4MGFhZGYxXzIzMw_54f4bd65-ff85-4b77-81f3-844c4e5fb1bc">Cash, Cash Equivalents and Investments&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of cash and cash equivalents and investments held at December&#160;31, 2022 and 2021 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.727%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.325%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.325%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.325%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.485%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Securities maturing within one year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(342)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(86)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(428)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(428)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.881%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.325%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.325%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.325%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.331%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Securities maturing within one year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;There were no realized gains or losses for the years ended December&#160;31, 2022, 2021, and 2020.</us-gaap:CashAndCashEquivalentsDisclosureTextBlock>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90ZXh0cmVnaW9uOjUyMThlODA3YWMwNjQwODViZjY2MGMxZGM4MGFhZGYxXzI0MA_3e9e4eaf-5323-494c-8218-e2e3deb8ee75">&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.727%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.325%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.325%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.325%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.485%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Securities maturing within one year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(342)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(86)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(428)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(428)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.881%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.325%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.325%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.325%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.331%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Securities maturing within one year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="i841f2e01285341bc84e68db28065de33_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZTo2M2FkYmVkMWFkZGU0M2Q1OTRjMDAzMzhmZmEzYzNhNy90YWJsZXJhbmdlOjYzYWRiZWQxYWRkZTQzZDU5NGMwMDMzOGZmYTNjM2E3XzMtMS0xLTEtMzMyMDM_378cc64e-dd13-4a78-b289-9bd8fab37332"
      unitRef="usd">46345000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i841f2e01285341bc84e68db28065de33_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZTo2M2FkYmVkMWFkZGU0M2Q1OTRjMDAzMzhmZmEzYzNhNy90YWJsZXJhbmdlOjYzYWRiZWQxYWRkZTQzZDU5NGMwMDMzOGZmYTNjM2E3XzMtMy0xLTEtMzMyMDM_a3e71e60-ebfd-4a4a-867d-b7d2f378af97"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i841f2e01285341bc84e68db28065de33_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZTo2M2FkYmVkMWFkZGU0M2Q1OTRjMDAzMzhmZmEzYzNhNy90YWJsZXJhbmdlOjYzYWRiZWQxYWRkZTQzZDU5NGMwMDMzOGZmYTNjM2E3XzMtNS0xLTEtMzMyMDM_e44626b2-ea03-4e8a-b8bd-5987d099f9f2"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i841f2e01285341bc84e68db28065de33_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZTo2M2FkYmVkMWFkZGU0M2Q1OTRjMDAzMzhmZmEzYzNhNy90YWJsZXJhbmdlOjYzYWRiZWQxYWRkZTQzZDU5NGMwMDMzOGZmYTNjM2E3XzMtNy0xLTEtMzMyMDM_b55435df-b26c-4718-bea3-93b161d2825e"
      unitRef="usd">46345000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="i05102cf0094245939ba4bd0df2517905_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZTo2M2FkYmVkMWFkZGU0M2Q1OTRjMDAzMzhmZmEzYzNhNy90YWJsZXJhbmdlOjYzYWRiZWQxYWRkZTQzZDU5NGMwMDMzOGZmYTNjM2E3XzUtMS0xLTEtMzMyMDM_7160f422-ff0f-49ea-a7b8-0d55fb55151f"
      unitRef="usd">74022000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i05102cf0094245939ba4bd0df2517905_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZTo2M2FkYmVkMWFkZGU0M2Q1OTRjMDAzMzhmZmEzYzNhNy90YWJsZXJhbmdlOjYzYWRiZWQxYWRkZTQzZDU5NGMwMDMzOGZmYTNjM2E3XzUtMy0xLTEtMzMyMDM_e2a47d13-fe66-420d-9785-2b5c3ea6febd"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i05102cf0094245939ba4bd0df2517905_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZTo2M2FkYmVkMWFkZGU0M2Q1OTRjMDAzMzhmZmEzYzNhNy90YWJsZXJhbmdlOjYzYWRiZWQxYWRkZTQzZDU5NGMwMDMzOGZmYTNjM2E3XzUtNS0xLTEtMzMyMDM_9ca91b25-6deb-45eb-94ac-93343227f03a"
      unitRef="usd">342000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i05102cf0094245939ba4bd0df2517905_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZTo2M2FkYmVkMWFkZGU0M2Q1OTRjMDAzMzhmZmEzYzNhNy90YWJsZXJhbmdlOjYzYWRiZWQxYWRkZTQzZDU5NGMwMDMzOGZmYTNjM2E3XzUtNy0xLTEtMzMyMDM_2ed57356-53b5-44cc-af99-2330d62a0d10"
      unitRef="usd">73680000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZTo2M2FkYmVkMWFkZGU0M2Q1OTRjMDAzMzhmZmEzYzNhNy90YWJsZXJhbmdlOjYzYWRiZWQxYWRkZTQzZDU5NGMwMDMzOGZmYTNjM2E3XzYtMS0xLTEtMzMyMDM_393a9df8-faf6-4174-8c98-30d3230bebf8"
      unitRef="usd">18418000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZTo2M2FkYmVkMWFkZGU0M2Q1OTRjMDAzMzhmZmEzYzNhNy90YWJsZXJhbmdlOjYzYWRiZWQxYWRkZTQzZDU5NGMwMDMzOGZmYTNjM2E3XzYtMy0xLTEtMzMyMDM_c1278168-6c6e-4a13-a653-a4711563273e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZTo2M2FkYmVkMWFkZGU0M2Q1OTRjMDAzMzhmZmEzYzNhNy90YWJsZXJhbmdlOjYzYWRiZWQxYWRkZTQzZDU5NGMwMDMzOGZmYTNjM2E3XzYtNS0xLTEtMzMyMDM_d39309f2-df5f-4a8a-8242-c834715b244d"
      unitRef="usd">86000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZTo2M2FkYmVkMWFkZGU0M2Q1OTRjMDAzMzhmZmEzYzNhNy90YWJsZXJhbmdlOjYzYWRiZWQxYWRkZTQzZDU5NGMwMDMzOGZmYTNjM2E3XzYtNy0xLTEtMzMyMDM_3e272602-dbb6-4340-8136-1490c69f2f8c"
      unitRef="usd">18332000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="ib86823c5a00d40e98853633ef7fadf56_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZTo2M2FkYmVkMWFkZGU0M2Q1OTRjMDAzMzhmZmEzYzNhNy90YWJsZXJhbmdlOjYzYWRiZWQxYWRkZTQzZDU5NGMwMDMzOGZmYTNjM2E3XzctMS0xLTEtMzMyMDM_010a7e03-a771-4e4d-8d65-90a9c74e828f"
      unitRef="usd">92440000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib86823c5a00d40e98853633ef7fadf56_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZTo2M2FkYmVkMWFkZGU0M2Q1OTRjMDAzMzhmZmEzYzNhNy90YWJsZXJhbmdlOjYzYWRiZWQxYWRkZTQzZDU5NGMwMDMzOGZmYTNjM2E3XzctMy0xLTEtMzMyMDM_aed68f04-fe0b-4c29-b68b-f9dba265e27a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib86823c5a00d40e98853633ef7fadf56_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZTo2M2FkYmVkMWFkZGU0M2Q1OTRjMDAzMzhmZmEzYzNhNy90YWJsZXJhbmdlOjYzYWRiZWQxYWRkZTQzZDU5NGMwMDMzOGZmYTNjM2E3XzctNS0xLTEtMzMyMDM_1b159653-c78e-4a16-9af5-31655cacfbb2"
      unitRef="usd">428000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="ib86823c5a00d40e98853633ef7fadf56_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZTo2M2FkYmVkMWFkZGU0M2Q1OTRjMDAzMzhmZmEzYzNhNy90YWJsZXJhbmdlOjYzYWRiZWQxYWRkZTQzZDU5NGMwMDMzOGZmYTNjM2E3XzctNy0xLTEtMzMyMDM_c46cf538-1794-4a23-b402-5f58dc25e497"
      unitRef="usd">92012000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="i5904a39d50aa48738bfa16090d0521a4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZTo2M2FkYmVkMWFkZGU0M2Q1OTRjMDAzMzhmZmEzYzNhNy90YWJsZXJhbmdlOjYzYWRiZWQxYWRkZTQzZDU5NGMwMDMzOGZmYTNjM2E3XzgtMS0xLTEtMzMyMDM_3d2e9ffb-c345-463e-a301-8d6f261e2fc1"
      unitRef="usd">138785000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5904a39d50aa48738bfa16090d0521a4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZTo2M2FkYmVkMWFkZGU0M2Q1OTRjMDAzMzhmZmEzYzNhNy90YWJsZXJhbmdlOjYzYWRiZWQxYWRkZTQzZDU5NGMwMDMzOGZmYTNjM2E3XzgtMy0xLTEtMzMyMDM_c79b24b3-3c36-47e1-93d1-9900bfa7513e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5904a39d50aa48738bfa16090d0521a4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZTo2M2FkYmVkMWFkZGU0M2Q1OTRjMDAzMzhmZmEzYzNhNy90YWJsZXJhbmdlOjYzYWRiZWQxYWRkZTQzZDU5NGMwMDMzOGZmYTNjM2E3XzgtNS0xLTEtMzMyMDM_71fe2101-89f4-438f-82ac-480583d6a3cf"
      unitRef="usd">428000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i5904a39d50aa48738bfa16090d0521a4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZTo2M2FkYmVkMWFkZGU0M2Q1OTRjMDAzMzhmZmEzYzNhNy90YWJsZXJhbmdlOjYzYWRiZWQxYWRkZTQzZDU5NGMwMDMzOGZmYTNjM2E3XzgtNy0xLTEtMzMyMDM_6b00a9a7-234e-4ff2-9d08-eb74d26c5915"
      unitRef="usd">138357000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="idde6749a549b4ccc8f95351b92d40bce_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZToxZTAwZmE1Nzk0NmI0ZTc4Yjc1YjY0YTUwYzg4MzU4Zi90YWJsZXJhbmdlOjFlMDBmYTU3OTQ2YjRlNzhiNzViNjRhNTBjODgzNThmXzMtMS0xLTEtMzMyMDM_4e3f30bc-1509-4806-8710-6301e6115811"
      unitRef="usd">64066000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="idde6749a549b4ccc8f95351b92d40bce_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZToxZTAwZmE1Nzk0NmI0ZTc4Yjc1YjY0YTUwYzg4MzU4Zi90YWJsZXJhbmdlOjFlMDBmYTU3OTQ2YjRlNzhiNzViNjRhNTBjODgzNThmXzMtMy0xLTEtMzMyMDM_289a6fa7-0eb5-4045-9f2f-a077447223f4"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="idde6749a549b4ccc8f95351b92d40bce_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZToxZTAwZmE1Nzk0NmI0ZTc4Yjc1YjY0YTUwYzg4MzU4Zi90YWJsZXJhbmdlOjFlMDBmYTU3OTQ2YjRlNzhiNzViNjRhNTBjODgzNThmXzMtNS0xLTEtMzMyMDM_52999812-9085-4cd7-a59f-c8d766155219"
      unitRef="usd">-1000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="idde6749a549b4ccc8f95351b92d40bce_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZToxZTAwZmE1Nzk0NmI0ZTc4Yjc1YjY0YTUwYzg4MzU4Zi90YWJsZXJhbmdlOjFlMDBmYTU3OTQ2YjRlNzhiNzViNjRhNTBjODgzNThmXzMtNy0xLTEtMzMyMDM_fcdb8a68-f4d3-47a3-abad-22807d55c381"
      unitRef="usd">64065000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZToxZTAwZmE1Nzk0NmI0ZTc4Yjc1YjY0YTUwYzg4MzU4Zi90YWJsZXJhbmdlOjFlMDBmYTU3OTQ2YjRlNzhiNzViNjRhNTBjODgzNThmXzUtMS0xLTEtMzk3MjY_ef4f6308-8a83-46ce-962e-a04349f1e705"
      unitRef="usd">26018000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZToxZTAwZmE1Nzk0NmI0ZTc4Yjc1YjY0YTUwYzg4MzU4Zi90YWJsZXJhbmdlOjFlMDBmYTU3OTQ2YjRlNzhiNzViNjRhNTBjODgzNThmXzUtMy0xLTEtMzk3MjY_f8c20521-b059-4073-8fba-7ba4de5d7d32"
      unitRef="usd">5000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZToxZTAwZmE1Nzk0NmI0ZTc4Yjc1YjY0YTUwYzg4MzU4Zi90YWJsZXJhbmdlOjFlMDBmYTU3OTQ2YjRlNzhiNzViNjRhNTBjODgzNThmXzUtNS0xLTEtMzk3MjY_68ea5ab6-0b6b-47af-bc1e-f858d68aafc5"
      unitRef="usd">11000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZToxZTAwZmE1Nzk0NmI0ZTc4Yjc1YjY0YTUwYzg4MzU4Zi90YWJsZXJhbmdlOjFlMDBmYTU3OTQ2YjRlNzhiNzViNjRhNTBjODgzNThmXzUtNy0xLTEtMzMyMDM_ec0c2f4f-fa14-47f8-b006-fb1bc68e1026"
      unitRef="usd">26012000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="i45721c6af18946ed9ca1743c070424b5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZToxZTAwZmE1Nzk0NmI0ZTc4Yjc1YjY0YTUwYzg4MzU4Zi90YWJsZXJhbmdlOjFlMDBmYTU3OTQ2YjRlNzhiNzViNjRhNTBjODgzNThmXzctMS0xLTEtMzMyMDM_b9bcf509-f923-4e14-96aa-291a8741d8dc"
      unitRef="usd">26018000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i45721c6af18946ed9ca1743c070424b5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZToxZTAwZmE1Nzk0NmI0ZTc4Yjc1YjY0YTUwYzg4MzU4Zi90YWJsZXJhbmdlOjFlMDBmYTU3OTQ2YjRlNzhiNzViNjRhNTBjODgzNThmXzctMy0xLTEtMzMyMDM_0cd11a19-adf6-47f2-bf78-98e7848ec360"
      unitRef="usd">5000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i45721c6af18946ed9ca1743c070424b5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZToxZTAwZmE1Nzk0NmI0ZTc4Yjc1YjY0YTUwYzg4MzU4Zi90YWJsZXJhbmdlOjFlMDBmYTU3OTQ2YjRlNzhiNzViNjRhNTBjODgzNThmXzctNS0xLTEtMzMyMDM_be5bea61-c3de-4f6e-ae0d-2a619d52caab"
      unitRef="usd">11000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i45721c6af18946ed9ca1743c070424b5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZToxZTAwZmE1Nzk0NmI0ZTc4Yjc1YjY0YTUwYzg4MzU4Zi90YWJsZXJhbmdlOjFlMDBmYTU3OTQ2YjRlNzhiNzViNjRhNTBjODgzNThmXzctNy0xLTEtMzMyMDM_43f44c9a-d5d3-4557-93cf-2b27cbd069f7"
      unitRef="usd">26012000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="i512fe0c004b04e38b6d7b9742c09feab_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZToxZTAwZmE1Nzk0NmI0ZTc4Yjc1YjY0YTUwYzg4MzU4Zi90YWJsZXJhbmdlOjFlMDBmYTU3OTQ2YjRlNzhiNzViNjRhNTBjODgzNThmXzgtMS0xLTEtMzMyMDM_fcbe10fe-8c6d-46e0-ade5-1739036bcf33"
      unitRef="usd">90084000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i512fe0c004b04e38b6d7b9742c09feab_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZToxZTAwZmE1Nzk0NmI0ZTc4Yjc1YjY0YTUwYzg4MzU4Zi90YWJsZXJhbmdlOjFlMDBmYTU3OTQ2YjRlNzhiNzViNjRhNTBjODgzNThmXzgtMy0xLTEtMzMyMDM_914dbb0b-73c8-435c-85b7-bb09de73e45c"
      unitRef="usd">5000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i512fe0c004b04e38b6d7b9742c09feab_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZToxZTAwZmE1Nzk0NmI0ZTc4Yjc1YjY0YTUwYzg4MzU4Zi90YWJsZXJhbmdlOjFlMDBmYTU3OTQ2YjRlNzhiNzViNjRhNTBjODgzNThmXzgtNS0xLTEtMzMyMDM_b36ad272-e59f-4a52-8283-c89b293efd12"
      unitRef="usd">12000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i512fe0c004b04e38b6d7b9742c09feab_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90YWJsZToxZTAwZmE1Nzk0NmI0ZTc4Yjc1YjY0YTUwYzg4MzU4Zi90YWJsZXJhbmdlOjFlMDBmYTU3OTQ2YjRlNzhiNzViNjRhNTBjODgzNThmXzgtNy0xLTEtMzMyMDM_7fbef510-ba95-4877-86cf-b16cc7fcbd6e"
      unitRef="usd">90077000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjAvZnJhZzo1MjE4ZTgwN2FjMDY0MDg1YmY2NjBjMWRjODBhYWRmMS90ZXh0cmVnaW9uOjUyMThlODA3YWMwNjQwODViZjY2MGMxZGM4MGFhZGYxXzE2MQ_34b74050-5934-47c7-9489-cd2bf81f92b3"
      unitRef="usd">0</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjMvZnJhZzo4N2U5MWY4YzgwYTk0YTUwOTEzMjkxNzBlYTY5NjMzNC90ZXh0cmVnaW9uOjg3ZTkxZjhjODBhOTRhNTA5MTMyOTE3MGVhNjk2MzM0XzE0NzY_f0aeb314-206d-4845-b25a-f3318cf63165">Fair Value Measurements&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis.&#160;&#160;Assets and liabilities recorded at fair value in the consolidated balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value.&#160;&#160;The following levels are directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 &#x2013; quoted prices in active markets for identical assets, which include U.S. treasury securities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 &#x2013; other significant observable inputs (including quoted prices for similar investments, market corroborated inputs, etc.), which include corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 &#x2013; significant unobservable inputs &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&#160;The inputs or methodology used for valuing securities are not necessarily an indication of the credit risk associated with investing in those securities.&#160;&#160;The following tables provide the fair value measurements of applicable Company assets and liabilities that are measured at fair value on a recurring basis according to the fair value levels defined above as of December&#160;31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&#160;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.579%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets and Liabilities at Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="21" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.579%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets and Liabilities at Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="21" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not have any Level 3 assets or liabilities at December&#160;31, 2022 or 2021. Transfers between levels are recognized at the actual date of circumstance that caused the transfer.  There were no transfers between Level 1 and Level 2 during the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to Note 9, Debt Obligations, for fair value measurements of debt obligations.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjMvZnJhZzo4N2U5MWY4YzgwYTk0YTUwOTEzMjkxNzBlYTY5NjMzNC90ZXh0cmVnaW9uOjg3ZTkxZjhjODBhOTRhNTA5MTMyOTE3MGVhNjk2MzM0XzE0ODA_04914d6e-1b01-4d30-98d8-5a07298fb3ff">&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.579%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets and Liabilities at Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="21" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.579%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets and Liabilities at Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="21" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i9dfe8c84430c424597db1dafc1f3fd2e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjMvZnJhZzo4N2U5MWY4YzgwYTk0YTUwOTEzMjkxNzBlYTY5NjMzNC90YWJsZTo1NGNhNTgwNmRmMTU0YzEzYTU4ZTFkZjVhMDFlMGU0YS90YWJsZXJhbmdlOjU0Y2E1ODA2ZGYxNTRjMTNhNThlMWRmNWEwMWUwZTRhXzUtMS0xLTEtMzMyMDM_d2b00575-7e32-4602-b2e8-a2be6a50b859"
      unitRef="usd">46345000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i70df917b1e21470f80121f484c414360_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjMvZnJhZzo4N2U5MWY4YzgwYTk0YTUwOTEzMjkxNzBlYTY5NjMzNC90YWJsZTo1NGNhNTgwNmRmMTU0YzEzYTU4ZTFkZjVhMDFlMGU0YS90YWJsZXJhbmdlOjU0Y2E1ODA2ZGYxNTRjMTNhNThlMWRmNWEwMWUwZTRhXzUtMy0xLTEtMzMyMDM_7ff1b94d-af0b-4503-9a5a-ed5819c65477"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4663c2e38d1a45debc09ce327eed516d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjMvZnJhZzo4N2U5MWY4YzgwYTk0YTUwOTEzMjkxNzBlYTY5NjMzNC90YWJsZTo1NGNhNTgwNmRmMTU0YzEzYTU4ZTFkZjVhMDFlMGU0YS90YWJsZXJhbmdlOjU0Y2E1ODA2ZGYxNTRjMTNhNThlMWRmNWEwMWUwZTRhXzUtNS0xLTEtMzMyMDM_ba0a0255-21a9-4012-852d-9e34c8a74290"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjMvZnJhZzo4N2U5MWY4YzgwYTk0YTUwOTEzMjkxNzBlYTY5NjMzNC90YWJsZTo1NGNhNTgwNmRmMTU0YzEzYTU4ZTFkZjVhMDFlMGU0YS90YWJsZXJhbmdlOjU0Y2E1ODA2ZGYxNTRjMTNhNThlMWRmNWEwMWUwZTRhXzUtNy0xLTEtMzMyMDM_ac85ceea-72f9-48c5-a611-5b1b3cae5cb9"
      unitRef="usd">46345000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecurities
      contextRef="i9dfe8c84430c424597db1dafc1f3fd2e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjMvZnJhZzo4N2U5MWY4YzgwYTk0YTUwOTEzMjkxNzBlYTY5NjMzNC90YWJsZTo1NGNhNTgwNmRmMTU0YzEzYTU4ZTFkZjVhMDFlMGU0YS90YWJsZXJhbmdlOjU0Y2E1ODA2ZGYxNTRjMTNhNThlMWRmNWEwMWUwZTRhXzYtMS0xLTEtMzMyMDM_b1677e03-e80b-4cde-86e6-b7dd62c510d8"
      unitRef="usd">73680000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="i70df917b1e21470f80121f484c414360_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjMvZnJhZzo4N2U5MWY4YzgwYTk0YTUwOTEzMjkxNzBlYTY5NjMzNC90YWJsZTo1NGNhNTgwNmRmMTU0YzEzYTU4ZTFkZjVhMDFlMGU0YS90YWJsZXJhbmdlOjU0Y2E1ODA2ZGYxNTRjMTNhNThlMWRmNWEwMWUwZTRhXzYtMy0xLTEtMzMyMDM_82ecd5bc-b87f-48fe-90af-3a245fc32721"
      unitRef="usd">18332000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="i4663c2e38d1a45debc09ce327eed516d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjMvZnJhZzo4N2U5MWY4YzgwYTk0YTUwOTEzMjkxNzBlYTY5NjMzNC90YWJsZTo1NGNhNTgwNmRmMTU0YzEzYTU4ZTFkZjVhMDFlMGU0YS90YWJsZXJhbmdlOjU0Y2E1ODA2ZGYxNTRjMTNhNThlMWRmNWEwMWUwZTRhXzYtNS0xLTEtMzMyMDM_006e3828-0b8a-46f9-991a-79af74e5d7bc"
      unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjMvZnJhZzo4N2U5MWY4YzgwYTk0YTUwOTEzMjkxNzBlYTY5NjMzNC90YWJsZTo1NGNhNTgwNmRmMTU0YzEzYTU4ZTFkZjVhMDFlMGU0YS90YWJsZXJhbmdlOjU0Y2E1ODA2ZGYxNTRjMTNhNThlMWRmNWEwMWUwZTRhXzYtNy0xLTEtMzMyMDM_26f5f09b-856f-4d23-9db4-37475ecbde83"
      unitRef="usd">92012000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i9dfe8c84430c424597db1dafc1f3fd2e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjMvZnJhZzo4N2U5MWY4YzgwYTk0YTUwOTEzMjkxNzBlYTY5NjMzNC90YWJsZTo1NGNhNTgwNmRmMTU0YzEzYTU4ZTFkZjVhMDFlMGU0YS90YWJsZXJhbmdlOjU0Y2E1ODA2ZGYxNTRjMTNhNThlMWRmNWEwMWUwZTRhXzctMS0xLTEtMzMyMDM_9ca6843c-d985-46ae-b917-b097a33a8260"
      unitRef="usd">120025000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i70df917b1e21470f80121f484c414360_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjMvZnJhZzo4N2U5MWY4YzgwYTk0YTUwOTEzMjkxNzBlYTY5NjMzNC90YWJsZTo1NGNhNTgwNmRmMTU0YzEzYTU4ZTFkZjVhMDFlMGU0YS90YWJsZXJhbmdlOjU0Y2E1ODA2ZGYxNTRjMTNhNThlMWRmNWEwMWUwZTRhXzctMy0xLTEtMzMyMDM_54d199d2-69cf-40fc-9edc-4e049f4e7bc3"
      unitRef="usd">18332000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i4663c2e38d1a45debc09ce327eed516d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjMvZnJhZzo4N2U5MWY4YzgwYTk0YTUwOTEzMjkxNzBlYTY5NjMzNC90YWJsZTo1NGNhNTgwNmRmMTU0YzEzYTU4ZTFkZjVhMDFlMGU0YS90YWJsZXJhbmdlOjU0Y2E1ODA2ZGYxNTRjMTNhNThlMWRmNWEwMWUwZTRhXzctNS0xLTEtMzMyMDM_0e702326-ec80-4970-bc56-8320a58dddec"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjMvZnJhZzo4N2U5MWY4YzgwYTk0YTUwOTEzMjkxNzBlYTY5NjMzNC90YWJsZTo1NGNhNTgwNmRmMTU0YzEzYTU4ZTFkZjVhMDFlMGU0YS90YWJsZXJhbmdlOjU0Y2E1ODA2ZGYxNTRjMTNhNThlMWRmNWEwMWUwZTRhXzctNy0xLTEtMzMyMDM_f7ac4ee6-da17-497c-93fb-e4ea48f44899"
      unitRef="usd">138357000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i116622a8a31c498b8b13d9c3ba470fd3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjMvZnJhZzo4N2U5MWY4YzgwYTk0YTUwOTEzMjkxNzBlYTY5NjMzNC90YWJsZTozOGFiZWY3ZTEyZmE0ODAwYjBjMWFiMDJkZTFiMjI2MS90YWJsZXJhbmdlOjM4YWJlZjdlMTJmYTQ4MDBiMGMxYWIwMmRlMWIyMjYxXzUtMS0xLTEtMzMyMDM_007165ee-0e77-49c6-aa3f-c6c376bad777"
      unitRef="usd">64065000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i5d9a3d2b722d442a81512dcfc7684e90_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjMvZnJhZzo4N2U5MWY4YzgwYTk0YTUwOTEzMjkxNzBlYTY5NjMzNC90YWJsZTozOGFiZWY3ZTEyZmE0ODAwYjBjMWFiMDJkZTFiMjI2MS90YWJsZXJhbmdlOjM4YWJlZjdlMTJmYTQ4MDBiMGMxYWIwMmRlMWIyMjYxXzUtMy0xLTEtMzMyMDM_bc7743f9-8ae6-460b-8785-c232749d59aa"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i80407335c811483eb7ec1795e3a17f08_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjMvZnJhZzo4N2U5MWY4YzgwYTk0YTUwOTEzMjkxNzBlYTY5NjMzNC90YWJsZTozOGFiZWY3ZTEyZmE0ODAwYjBjMWFiMDJkZTFiMjI2MS90YWJsZXJhbmdlOjM4YWJlZjdlMTJmYTQ4MDBiMGMxYWIwMmRlMWIyMjYxXzUtNS0xLTEtMzMyMDM_27e89480-b39f-4f01-910e-cf072c3e1148"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjMvZnJhZzo4N2U5MWY4YzgwYTk0YTUwOTEzMjkxNzBlYTY5NjMzNC90YWJsZTozOGFiZWY3ZTEyZmE0ODAwYjBjMWFiMDJkZTFiMjI2MS90YWJsZXJhbmdlOjM4YWJlZjdlMTJmYTQ4MDBiMGMxYWIwMmRlMWIyMjYxXzUtNy0xLTEtMzMyMDM_cfce145b-cc60-4945-a119-448f3bd27539"
      unitRef="usd">64065000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecurities
      contextRef="i116622a8a31c498b8b13d9c3ba470fd3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjMvZnJhZzo4N2U5MWY4YzgwYTk0YTUwOTEzMjkxNzBlYTY5NjMzNC90YWJsZTozOGFiZWY3ZTEyZmE0ODAwYjBjMWFiMDJkZTFiMjI2MS90YWJsZXJhbmdlOjM4YWJlZjdlMTJmYTQ4MDBiMGMxYWIwMmRlMWIyMjYxXzYtMS0xLTEtMzMyMDM_a2520a23-ef0b-479b-af0d-348ce3422b5e"
      unitRef="usd">7561000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="i5d9a3d2b722d442a81512dcfc7684e90_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjMvZnJhZzo4N2U5MWY4YzgwYTk0YTUwOTEzMjkxNzBlYTY5NjMzNC90YWJsZTozOGFiZWY3ZTEyZmE0ODAwYjBjMWFiMDJkZTFiMjI2MS90YWJsZXJhbmdlOjM4YWJlZjdlMTJmYTQ4MDBiMGMxYWIwMmRlMWIyMjYxXzYtMy0xLTEtMzMyMDM_91bffe4b-39f8-480e-aac1-284f2f7452ff"
      unitRef="usd">15117000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="i80407335c811483eb7ec1795e3a17f08_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjMvZnJhZzo4N2U5MWY4YzgwYTk0YTUwOTEzMjkxNzBlYTY5NjMzNC90YWJsZTozOGFiZWY3ZTEyZmE0ODAwYjBjMWFiMDJkZTFiMjI2MS90YWJsZXJhbmdlOjM4YWJlZjdlMTJmYTQ4MDBiMGMxYWIwMmRlMWIyMjYxXzYtNS0xLTEtMzMyMDM_2b5f28e4-96cc-4110-ae27-217c81243804"
      unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjMvZnJhZzo4N2U5MWY4YzgwYTk0YTUwOTEzMjkxNzBlYTY5NjMzNC90YWJsZTozOGFiZWY3ZTEyZmE0ODAwYjBjMWFiMDJkZTFiMjI2MS90YWJsZXJhbmdlOjM4YWJlZjdlMTJmYTQ4MDBiMGMxYWIwMmRlMWIyMjYxXzYtNy0xLTEtMzMyMDM_b439f2ac-3694-4eee-ad5d-316c89fa0436"
      unitRef="usd">22678000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i116622a8a31c498b8b13d9c3ba470fd3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjMvZnJhZzo4N2U5MWY4YzgwYTk0YTUwOTEzMjkxNzBlYTY5NjMzNC90YWJsZTozOGFiZWY3ZTEyZmE0ODAwYjBjMWFiMDJkZTFiMjI2MS90YWJsZXJhbmdlOjM4YWJlZjdlMTJmYTQ4MDBiMGMxYWIwMmRlMWIyMjYxXzctMS0xLTEtMzMyMDM_d5f68d0c-75d4-4418-9ce1-8b4d7c69e66d"
      unitRef="usd">71626000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i5d9a3d2b722d442a81512dcfc7684e90_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjMvZnJhZzo4N2U5MWY4YzgwYTk0YTUwOTEzMjkxNzBlYTY5NjMzNC90YWJsZTozOGFiZWY3ZTEyZmE0ODAwYjBjMWFiMDJkZTFiMjI2MS90YWJsZXJhbmdlOjM4YWJlZjdlMTJmYTQ4MDBiMGMxYWIwMmRlMWIyMjYxXzctMy0xLTEtMzMyMDM_79e96bbf-b06e-4cd7-b18f-afb3115bdc41"
      unitRef="usd">15117000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i80407335c811483eb7ec1795e3a17f08_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjMvZnJhZzo4N2U5MWY4YzgwYTk0YTUwOTEzMjkxNzBlYTY5NjMzNC90YWJsZTozOGFiZWY3ZTEyZmE0ODAwYjBjMWFiMDJkZTFiMjI2MS90YWJsZXJhbmdlOjM4YWJlZjdlMTJmYTQ4MDBiMGMxYWIwMmRlMWIyMjYxXzctNS0xLTEtMzMyMDM_7046c03a-4cde-46ec-946d-32d3f29b8c1c"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjMvZnJhZzo4N2U5MWY4YzgwYTk0YTUwOTEzMjkxNzBlYTY5NjMzNC90YWJsZTozOGFiZWY3ZTEyZmE0ODAwYjBjMWFiMDJkZTFiMjI2MS90YWJsZXJhbmdlOjM4YWJlZjdlMTJmYTQ4MDBiMGMxYWIwMmRlMWIyMjYxXzctNy0xLTEtMzMyMDM_f6d3ea37-b24e-43d1-b417-03bc8e18efd6"
      unitRef="usd">86743000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjYvZnJhZzo4NGM3ZmQwYTRhOGI0ZjY0YmQ3MDIxNjBmZDNmODhmYi90ZXh0cmVnaW9uOjg0YzdmZDBhNGE4YjRmNjRiZDcwMjE2MGZkM2Y4OGZiXzEwNDc_516cba84-f106-4ed0-a1e5-d46dc7076c9a">Property and Equipment&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment at December&#160;31, 2022 and 2021 are as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.231%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.178%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.272%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.178%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Useful Lives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;In Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computers and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5-7&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-7&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,984)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,853)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjYvZnJhZzo4NGM3ZmQwYTRhOGI0ZjY0YmQ3MDIxNjBmZDNmODhmYi90ZXh0cmVnaW9uOjg0YzdmZDBhNGE4YjRmNjRiZDcwMjE2MGZkM2Y4OGZiXzEwNDI_e1f517b8-905e-4682-83a6-b776a6aa0cf1">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.231%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.178%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.272%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.178%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Useful Lives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;In Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computers and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5-7&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-7&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,984)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,853)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="iada15b389ba44ae5ad53399ba96f0121_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjYvZnJhZzo4NGM3ZmQwYTRhOGI0ZjY0YmQ3MDIxNjBmZDNmODhmYi90YWJsZTpkNjQ2NzQ5YTY3Yzc0ZGUxOWE4NjAzNDc2ODAyYTg1OS90YWJsZXJhbmdlOmQ2NDY3NDlhNjdjNzRkZTE5YTg2MDM0NzY4MDJhODU5XzMtMS0xLTEtMzMyMDMvdGV4dHJlZ2lvbjplZWVhYTFkY2FjM2Q0ZTFkOWYyOWE2ZGQyOTFhMzM5M180_ca409140-de0e-4c4c-9889-86255d2cc825">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ifaa3a61f9810465ab321c51897417ed6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjYvZnJhZzo4NGM3ZmQwYTRhOGI0ZjY0YmQ3MDIxNjBmZDNmODhmYi90YWJsZTpkNjQ2NzQ5YTY3Yzc0ZGUxOWE4NjAzNDc2ODAyYTg1OS90YWJsZXJhbmdlOmQ2NDY3NDlhNjdjNzRkZTE5YTg2MDM0NzY4MDJhODU5XzMtMS0xLTEtMzMyMDMvdGV4dHJlZ2lvbjplZWVhYTFkY2FjM2Q0ZTFkOWYyOWE2ZGQyOTFhMzM5M183_49d3ee6b-ee53-4120-bdb1-09e13a86bb0c">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie3c76eaf4e9546efa476fcd01ad729ac_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjYvZnJhZzo4NGM3ZmQwYTRhOGI0ZjY0YmQ3MDIxNjBmZDNmODhmYi90YWJsZTpkNjQ2NzQ5YTY3Yzc0ZGUxOWE4NjAzNDc2ODAyYTg1OS90YWJsZXJhbmdlOmQ2NDY3NDlhNjdjNzRkZTE5YTg2MDM0NzY4MDJhODU5XzMtNS0xLTEtMzMyMDM_9624ffdb-d0d7-48e6-84f8-88bf3e0cb828"
      unitRef="usd">2209000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i152a1c1f46d945e2acc800b6dd644332_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjYvZnJhZzo4NGM3ZmQwYTRhOGI0ZjY0YmQ3MDIxNjBmZDNmODhmYi90YWJsZTpkNjQ2NzQ5YTY3Yzc0ZGUxOWE4NjAzNDc2ODAyYTg1OS90YWJsZXJhbmdlOmQ2NDY3NDlhNjdjNzRkZTE5YTg2MDM0NzY4MDJhODU5XzMtNy0xLTEtMzMyMDM_babc2001-84f6-4038-8d69-89071bd27f0f"
      unitRef="usd">3027000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ib432f651cb92444fa72128093d268fb8_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjYvZnJhZzo4NGM3ZmQwYTRhOGI0ZjY0YmQ3MDIxNjBmZDNmODhmYi90YWJsZTpkNjQ2NzQ5YTY3Yzc0ZGUxOWE4NjAzNDc2ODAyYTg1OS90YWJsZXJhbmdlOmQ2NDY3NDlhNjdjNzRkZTE5YTg2MDM0NzY4MDJhODU5XzQtMS0xLTEtMzMyMDMvdGV4dHJlZ2lvbjpkMjk0ZjE1ZTY5ODA0YzA3OTAzYTRlOWY2MGRjMzkxNl80_207d204b-ecfb-4f58-82de-9995eaf8a506">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ib2362482683d4d88854d2053c48290a6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjYvZnJhZzo4NGM3ZmQwYTRhOGI0ZjY0YmQ3MDIxNjBmZDNmODhmYi90YWJsZTpkNjQ2NzQ5YTY3Yzc0ZGUxOWE4NjAzNDc2ODAyYTg1OS90YWJsZXJhbmdlOmQ2NDY3NDlhNjdjNzRkZTE5YTg2MDM0NzY4MDJhODU5XzQtMS0xLTEtMzMyMDMvdGV4dHJlZ2lvbjpkMjk0ZjE1ZTY5ODA0YzA3OTAzYTRlOWY2MGRjMzkxNl83_da8ffb3c-b4db-4878-8b00-64813e082728">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if1b08918d03a41e9ba2aa7258f976949_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjYvZnJhZzo4NGM3ZmQwYTRhOGI0ZjY0YmQ3MDIxNjBmZDNmODhmYi90YWJsZTpkNjQ2NzQ5YTY3Yzc0ZGUxOWE4NjAzNDc2ODAyYTg1OS90YWJsZXJhbmdlOmQ2NDY3NDlhNjdjNzRkZTE5YTg2MDM0NzY4MDJhODU5XzQtNS0xLTEtMzMyMDM_be2ee978-dc9d-4342-8496-0dc315662012"
      unitRef="usd">1794000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i3c2e209ef7da4beea635d107d3eae5eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjYvZnJhZzo4NGM3ZmQwYTRhOGI0ZjY0YmQ3MDIxNjBmZDNmODhmYi90YWJsZTpkNjQ2NzQ5YTY3Yzc0ZGUxOWE4NjAzNDc2ODAyYTg1OS90YWJsZXJhbmdlOmQ2NDY3NDlhNjdjNzRkZTE5YTg2MDM0NzY4MDJhODU5XzQtNy0xLTEtMzMyMDM_a2f35a8a-0fe9-4068-b442-260f12329f0f"
      unitRef="usd">1692000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ie3fa401e333b4caead7644933a30b5df_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjYvZnJhZzo4NGM3ZmQwYTRhOGI0ZjY0YmQ3MDIxNjBmZDNmODhmYi90YWJsZTpkNjQ2NzQ5YTY3Yzc0ZGUxOWE4NjAzNDc2ODAyYTg1OS90YWJsZXJhbmdlOmQ2NDY3NDlhNjdjNzRkZTE5YTg2MDM0NzY4MDJhODU5XzYtMS0xLTEtMzMyMDMvdGV4dHJlZ2lvbjphYTQwMjY0YmM3ZmE0OWMzODNjNjJhZWZmZjE4NjI2MF80_975b155b-7182-42f7-8614-e49417f27df4">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i572e39a39bbe428abb0ea4530d55ece2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjYvZnJhZzo4NGM3ZmQwYTRhOGI0ZjY0YmQ3MDIxNjBmZDNmODhmYi90YWJsZTpkNjQ2NzQ5YTY3Yzc0ZGUxOWE4NjAzNDc2ODAyYTg1OS90YWJsZXJhbmdlOmQ2NDY3NDlhNjdjNzRkZTE5YTg2MDM0NzY4MDJhODU5XzYtMS0xLTEtMzMyMDMvdGV4dHJlZ2lvbjphYTQwMjY0YmM3ZmE0OWMzODNjNjJhZWZmZjE4NjI2MF83_431ba652-94d6-41aa-bc26-4bfc44e4119c">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia7709100c2ea472b8bf3b0dacf1d3df5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjYvZnJhZzo4NGM3ZmQwYTRhOGI0ZjY0YmQ3MDIxNjBmZDNmODhmYi90YWJsZTpkNjQ2NzQ5YTY3Yzc0ZGUxOWE4NjAzNDc2ODAyYTg1OS90YWJsZXJhbmdlOmQ2NDY3NDlhNjdjNzRkZTE5YTg2MDM0NzY4MDJhODU5XzYtNS0xLTEtMzMyMDM_1406041d-7f4e-4572-a138-6ccdb83c9245"
      unitRef="usd">2052000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i2e34aff763f34fe18a41ebd0245a5197_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjYvZnJhZzo4NGM3ZmQwYTRhOGI0ZjY0YmQ3MDIxNjBmZDNmODhmYi90YWJsZTpkNjQ2NzQ5YTY3Yzc0ZGUxOWE4NjAzNDc2ODAyYTg1OS90YWJsZXJhbmdlOmQ2NDY3NDlhNjdjNzRkZTE5YTg2MDM0NzY4MDJhODU5XzYtNy0xLTEtMzMyMDM_f5ebe080-1ebc-44cd-8b2a-0281145baade"
      unitRef="usd">1310000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjYvZnJhZzo4NGM3ZmQwYTRhOGI0ZjY0YmQ3MDIxNjBmZDNmODhmYi90YWJsZTpkNjQ2NzQ5YTY3Yzc0ZGUxOWE4NjAzNDc2ODAyYTg1OS90YWJsZXJhbmdlOmQ2NDY3NDlhNjdjNzRkZTE5YTg2MDM0NzY4MDJhODU5XzktNS0xLTEtMzMyMDM_f0d8ab2a-1332-4179-9aeb-10575f283fab"
      unitRef="usd">6055000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjYvZnJhZzo4NGM3ZmQwYTRhOGI0ZjY0YmQ3MDIxNjBmZDNmODhmYi90YWJsZTpkNjQ2NzQ5YTY3Yzc0ZGUxOWE4NjAzNDc2ODAyYTg1OS90YWJsZXJhbmdlOmQ2NDY3NDlhNjdjNzRkZTE5YTg2MDM0NzY4MDJhODU5XzktNy0xLTEtMzMyMDM_fb6f7e6f-c9ce-4889-8f0c-1c18185c53a3"
      unitRef="usd">6029000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjYvZnJhZzo4NGM3ZmQwYTRhOGI0ZjY0YmQ3MDIxNjBmZDNmODhmYi90YWJsZTpkNjQ2NzQ5YTY3Yzc0ZGUxOWE4NjAzNDc2ODAyYTg1OS90YWJsZXJhbmdlOmQ2NDY3NDlhNjdjNzRkZTE5YTg2MDM0NzY4MDJhODU5XzEwLTUtMS0xLTMzMjAz_b72d0c82-b2a3-42e6-82f6-bed768eea293"
      unitRef="usd">3984000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjYvZnJhZzo4NGM3ZmQwYTRhOGI0ZjY0YmQ3MDIxNjBmZDNmODhmYi90YWJsZTpkNjQ2NzQ5YTY3Yzc0ZGUxOWE4NjAzNDc2ODAyYTg1OS90YWJsZXJhbmdlOmQ2NDY3NDlhNjdjNzRkZTE5YTg2MDM0NzY4MDJhODU5XzEwLTctMS0xLTMzMjAz_14ff725f-62cf-4986-9b44-b9f5f801957c"
      unitRef="usd">4853000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjYvZnJhZzo4NGM3ZmQwYTRhOGI0ZjY0YmQ3MDIxNjBmZDNmODhmYi90YWJsZTpkNjQ2NzQ5YTY3Yzc0ZGUxOWE4NjAzNDc2ODAyYTg1OS90YWJsZXJhbmdlOmQ2NDY3NDlhNjdjNzRkZTE5YTg2MDM0NzY4MDJhODU5XzExLTUtMS0xLTMzMjAz_7a1ba291-3bed-4ccc-aae6-32b48fb3d298"
      unitRef="usd">2071000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjYvZnJhZzo4NGM3ZmQwYTRhOGI0ZjY0YmQ3MDIxNjBmZDNmODhmYi90YWJsZTpkNjQ2NzQ5YTY3Yzc0ZGUxOWE4NjAzNDc2ODAyYTg1OS90YWJsZXJhbmdlOmQ2NDY3NDlhNjdjNzRkZTE5YTg2MDM0NzY4MDJhODU5XzExLTctMS0xLTMzMjAz_cd68b4f8-cf51-4111-830d-7726267bbac8"
      unitRef="usd">1176000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="6"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjYvZnJhZzo4NGM3ZmQwYTRhOGI0ZjY0YmQ3MDIxNjBmZDNmODhmYi90ZXh0cmVnaW9uOjg0YzdmZDBhNGE4YjRmNjRiZDcwMjE2MGZkM2Y4OGZiXzcyNw_2c61b886-7754-41c5-a5fe-8b094d3d3573"
      unitRef="usd">1300000</us-gaap:NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1>
    <us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjYvZnJhZzo4NGM3ZmQwYTRhOGI0ZjY0YmQ3MDIxNjBmZDNmODhmYi90ZXh0cmVnaW9uOjg0YzdmZDBhNGE4YjRmNjRiZDcwMjE2MGZkM2Y4OGZiXzEwOTk1MTE2Mjg4ODI_bfaa7505-6926-45b7-b170-84b4565f7ed0"
      unitRef="usd">1300000</us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90ZXh0cmVnaW9uOmU0YTg4MTBjYTNiZTRjNmFiOGQ2ZmVlMDhiODU4MjhkXzQzMTU_46ab9dfd-2927-4d0d-a552-3b897d34681f">Income Taxes &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Coronavirus Aid, Relief and Economic Security Act (&#x201c;CARES Act&#x201d;) was enacted on March 27, 2020 &lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in the United States to provide emergency assistance to individuals and businesses affected by the COVID-19 pandemic. The CARES Act includes temporary changes to both income and non-income based tax laws.  Future regulatory guidance under the CARES Act or additional legislation enacted by Congress in connection with the COVID-19 pandemic could impact our tax provision in future periods.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lexicon recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been recognized differently in the financial statements and tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between the financial statement carrying amounts and tax bases of liabilities and assets using enacted tax rates and laws in effect in the years in which the differences are expected to reverse. Deferred tax assets are evaluated for realization based on a more-likely-than-not criteria in determining if a valuation allowance should be provided.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of Lexicon&#x2019;s deferred tax assets (liabilities) at December&#160;31, 2022 and 2021 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Orphan drug credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,295)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(412)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,295)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(412)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(345,761)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(326,218)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the statutory tax rate to the effective tax rate for the years ended December&#160;31, 2022, 2021 and 2020 consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.921%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.582%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.437%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.582%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected income tax expense (benefit) at 21%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,408)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,429)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,300)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(269)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Write off of credit carryover due to 382 study&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,418)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Other is primarily comprised of expiring Research and Development credits for the year ended December&#160;31, 2020 and nondeductible expenses for the years ended December&#160;31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Section 382 of the Internal Revenue Code of 1986, contains rules that limit the ability of a company that undergoes an &#x201c;ownership change&#x201d; to utilize its net operating loss and tax credit carryovers and certain built-in losses recognized in years after the &#x201c;ownership change.&#x201d; An &#x201c;ownership change&#x201d; is generally defined as any change in ownership of more than 50% of a corporation&#x2019;s stock over a rolling three-year period by stockholders that own (directly or indirectly) 5% or more of the stock of a corporation, or arising from a new issuance of stock by a corporation. If an ownership change occurs, Section 382 generally imposes an annual limitation on the use of pre-ownership change net operating loss carryovers to offset taxable income earned after the ownership change. The Company completed a Section 382 study and determined that historical ownership changes occurred. The Section 382 annual limitation related to historical ownership changes impacts our ability to utilize our tax attributes. In 2020, the federal deferred tax assets and valuation allowance decreased due to the write-off of attributes that will expire still subject to limitation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;At December&#160;31, 2022, Lexicon had both federal and state NOL carryforwards of approximately $1.2 billion and $86.9 million, respectively.&#160;&#160;In 2022, federal NOLs increased by $104.0 million related to a current year NOL. The Company had $446.3 million of U.S. federal NOL carryforwards as of December 31, 2022, which can be carried forward indefinitely. The remaining federal and state NOL carryforwards will begin to expire in 2022.&#160;Based on the federal tax law limits and the Company&#x2019;s cumulative loss position, the Company concluded it was appropriate to establish a full valuation allowance for its net deferred tax assets until an appropriate level of profitability is sustained.&#160;&#160;During the year ended December&#160;31, 2022, the valuation allowance increased $19.5 million, primarily due to NOLs generated partially offset by decreases in deferred tax assets associated with capitalized research and development expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As of December&#160;31, 2022 and 2021, the Company did not have any unrecognized tax benefits.  Any interest and penalties related to uncertain tax positions will be reflected as a component of income tax expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is primarily subject to U.S. federal and New Jersey and Texas state income taxes.&#160;&#160;The tax years 1999 to current remain open to examination by U.S. federal authorities and 2012 to current remain open to examination by state authorities.&#160;&#160;The Company&#x2019;s policy is to recognize interest and penalties related to income tax matters in income tax expense.&#160;&#160;As of December&#160;31, 2022 and 2021, the Company had no accruals for interest or penalties related to income tax matters.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90ZXh0cmVnaW9uOmU0YTg4MTBjYTNiZTRjNmFiOGQ2ZmVlMDhiODU4MjhkXzQzMTk_210920f7-a5e5-44db-870d-aae68febe15b">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Orphan drug credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,295)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(412)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,295)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(412)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(345,761)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(326,218)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTo3NTRlNjQ0ZmFhZDA0ODI3YWI1MjI3NDg2MDc5NzRjZC90YWJsZXJhbmdlOjc1NGU2NDRmYWFkMDQ4MjdhYjUyMjc0ODYwNzk3NGNkXzQtMS0xLTEtMzMyMDM_616b4ec7-e07e-4525-9915-4d992f3d26f8"
      unitRef="usd">251331000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTo3NTRlNjQ0ZmFhZDA0ODI3YWI1MjI3NDg2MDc5NzRjZC90YWJsZXJhbmdlOjc1NGU2NDRmYWFkMDQ4MjdhYjUyMjc0ODYwNzk3NGNkXzQtMy0xLTEtMzMyMDM_0d0a3272-6f5c-4d5e-a92b-f1130e118b36"
      unitRef="usd">229427000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTo3NTRlNjQ0ZmFhZDA0ODI3YWI1MjI3NDg2MDc5NzRjZC90YWJsZXJhbmdlOjc1NGU2NDRmYWFkMDQ4MjdhYjUyMjc0ODYwNzk3NGNkXzUtMS0xLTEtMzMyMDM_61acee36-33d2-432a-8e15-2ff2f52ba10f"
      unitRef="usd">29290000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTo3NTRlNjQ0ZmFhZDA0ODI3YWI1MjI3NDg2MDc5NzRjZC90YWJsZXJhbmdlOjc1NGU2NDRmYWFkMDQ4MjdhYjUyMjc0ODYwNzk3NGNkXzUtMy0xLTEtMzMyMDM_5bf26494-638f-4828-96c9-ab53360412ff"
      unitRef="usd">29290000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <lxrx:DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTo3NTRlNjQ0ZmFhZDA0ODI3YWI1MjI3NDg2MDc5NzRjZC90YWJsZXJhbmdlOjc1NGU2NDRmYWFkMDQ4MjdhYjUyMjc0ODYwNzk3NGNkXzYtMS0xLTEtMzMyMDM_9a9d561c-f47e-4fd2-acd1-f73b3dd56946"
      unitRef="usd">24524000</lxrx:DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug>
    <lxrx:DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug
      contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTo3NTRlNjQ0ZmFhZDA0ODI3YWI1MjI3NDg2MDc5NzRjZC90YWJsZXJhbmdlOjc1NGU2NDRmYWFkMDQ4MjdhYjUyMjc0ODYwNzk3NGNkXzYtMy0xLTEtMzMyMDM_15e20af5-7537-4c22-8ca5-c3cfd19a5084"
      unitRef="usd">24524000</lxrx:DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTo3NTRlNjQ0ZmFhZDA0ODI3YWI1MjI3NDg2MDc5NzRjZC90YWJsZXJhbmdlOjc1NGU2NDRmYWFkMDQ4MjdhYjUyMjc0ODYwNzk3NGNkXzctMS0xLTEtMzMyMDM_92c1cc88-63d8-469c-adb4-e203ac12d0bd"
      unitRef="usd">33813000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTo3NTRlNjQ0ZmFhZDA0ODI3YWI1MjI3NDg2MDc5NzRjZC90YWJsZXJhbmdlOjc1NGU2NDRmYWFkMDQ4MjdhYjUyMjc0ODYwNzk3NGNkXzctMy0xLTEtMzMyMDM_d841a8d5-b5ce-4e78-9c6d-9e046224d378"
      unitRef="usd">36770000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTo3NTRlNjQ0ZmFhZDA0ODI3YWI1MjI3NDg2MDc5NzRjZC90YWJsZXJhbmdlOjc1NGU2NDRmYWFkMDQ4MjdhYjUyMjc0ODYwNzk3NGNkXzgtMS0xLTEtMzMyMDM_e372100a-d0f0-4131-bf0f-166cf89d5962"
      unitRef="usd">5445000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTo3NTRlNjQ0ZmFhZDA0ODI3YWI1MjI3NDg2MDc5NzRjZC90YWJsZXJhbmdlOjc1NGU2NDRmYWFkMDQ4MjdhYjUyMjc0ODYwNzk3NGNkXzgtMy0xLTEtMzMyMDM_67ae60cb-3df2-4b25-8f9f-36ec8fd356bb"
      unitRef="usd">5163000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <lxrx:DeferredTaxAssetsSection163j_LXRX
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTo3NTRlNjQ0ZmFhZDA0ODI3YWI1MjI3NDg2MDc5NzRjZC90YWJsZXJhbmdlOjc1NGU2NDRmYWFkMDQ4MjdhYjUyMjc0ODYwNzk3NGNkXzEwLTEtMS0xLTMzMjAz_64625095-e5de-4d2b-bdc1-fbbedeaa76a5"
      unitRef="usd">398000</lxrx:DeferredTaxAssetsSection163j_LXRX>
    <lxrx:DeferredTaxAssetsSection163j_LXRX
      contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTo3NTRlNjQ0ZmFhZDA0ODI3YWI1MjI3NDg2MDc5NzRjZC90YWJsZXJhbmdlOjc1NGU2NDRmYWFkMDQ4MjdhYjUyMjc0ODYwNzk3NGNkXzEwLTMtMS0xLTMzMjAz_3beb7834-6a4b-4b2c-a367-399b03995e2b"
      unitRef="usd">148000</lxrx:DeferredTaxAssetsSection163j_LXRX>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTo3NTRlNjQ0ZmFhZDA0ODI3YWI1MjI3NDg2MDc5NzRjZC90YWJsZXJhbmdlOjc1NGU2NDRmYWFkMDQ4MjdhYjUyMjc0ODYwNzk3NGNkXzExLTEtMS0xLTMzMjAz_9270bc00-0311-4275-84f9-fde3ffc5ac9d"
      unitRef="usd">2255000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTo3NTRlNjQ0ZmFhZDA0ODI3YWI1MjI3NDg2MDc5NzRjZC90YWJsZXJhbmdlOjc1NGU2NDRmYWFkMDQ4MjdhYjUyMjc0ODYwNzk3NGNkXzExLTMtMS0xLTMzMjAz_87ba7b32-3e37-4752-a973-90e753e09c6e"
      unitRef="usd">1308000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTo3NTRlNjQ0ZmFhZDA0ODI3YWI1MjI3NDg2MDc5NzRjZC90YWJsZXJhbmdlOjc1NGU2NDRmYWFkMDQ4MjdhYjUyMjc0ODYwNzk3NGNkXzEyLTEtMS0xLTMzMjAz_59ceeebd-ea9b-4af9-b626-3942ef405a31"
      unitRef="usd">347056000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTo3NTRlNjQ0ZmFhZDA0ODI3YWI1MjI3NDg2MDc5NzRjZC90YWJsZXJhbmdlOjc1NGU2NDRmYWFkMDQ4MjdhYjUyMjc0ODYwNzk3NGNkXzEyLTMtMS0xLTMzMjAz_77c578cd-de98-4de3-8efc-a0930cfa2233"
      unitRef="usd">326630000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTo3NTRlNjQ0ZmFhZDA0ODI3YWI1MjI3NDg2MDc5NzRjZC90YWJsZXJhbmdlOjc1NGU2NDRmYWFkMDQ4MjdhYjUyMjc0ODYwNzk3NGNkXzE1LTEtMS0xLTMzMjAz_909686fb-0439-4f62-b7f2-9b9ddf9c995b"
      unitRef="usd">1295000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTo3NTRlNjQ0ZmFhZDA0ODI3YWI1MjI3NDg2MDc5NzRjZC90YWJsZXJhbmdlOjc1NGU2NDRmYWFkMDQ4MjdhYjUyMjc0ODYwNzk3NGNkXzE1LTMtMS0xLTMzMjAz_bfd7cdd6-6a26-41c7-bb0c-e8a49cdf9121"
      unitRef="usd">412000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTo3NTRlNjQ0ZmFhZDA0ODI3YWI1MjI3NDg2MDc5NzRjZC90YWJsZXJhbmdlOjc1NGU2NDRmYWFkMDQ4MjdhYjUyMjc0ODYwNzk3NGNkXzE2LTEtMS0xLTMzMjAz_b6063e2d-e0b0-4d19-a4ab-cf3b292bbd70"
      unitRef="usd">1295000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTo3NTRlNjQ0ZmFhZDA0ODI3YWI1MjI3NDg2MDc5NzRjZC90YWJsZXJhbmdlOjc1NGU2NDRmYWFkMDQ4MjdhYjUyMjc0ODYwNzk3NGNkXzE2LTMtMS0xLTMzMjAz_5cee8e36-6eb9-483e-be74-2698357321df"
      unitRef="usd">412000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTo3NTRlNjQ0ZmFhZDA0ODI3YWI1MjI3NDg2MDc5NzRjZC90YWJsZXJhbmdlOjc1NGU2NDRmYWFkMDQ4MjdhYjUyMjc0ODYwNzk3NGNkXzE3LTEtMS0xLTMzMjAz_44898143-da27-45ea-9509-3d24cf6ddeaf"
      unitRef="usd">345761000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTo3NTRlNjQ0ZmFhZDA0ODI3YWI1MjI3NDg2MDc5NzRjZC90YWJsZXJhbmdlOjc1NGU2NDRmYWFkMDQ4MjdhYjUyMjc0ODYwNzk3NGNkXzE3LTMtMS0xLTMzMjAz_5e3242fe-7716-480e-86bf-0434bee118f1"
      unitRef="usd">326218000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTo3NTRlNjQ0ZmFhZDA0ODI3YWI1MjI3NDg2MDc5NzRjZC90YWJsZXJhbmdlOjc1NGU2NDRmYWFkMDQ4MjdhYjUyMjc0ODYwNzk3NGNkXzE4LTEtMS0xLTMzMjAz_83c8982d-c9d9-4b30-b654-6604e1a6c769"
      unitRef="usd">0</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTo3NTRlNjQ0ZmFhZDA0ODI3YWI1MjI3NDg2MDc5NzRjZC90YWJsZXJhbmdlOjc1NGU2NDRmYWFkMDQ4MjdhYjUyMjc0ODYwNzk3NGNkXzE4LTMtMS0xLTMzMjAz_750e2c46-03bc-4a8f-b4b7-0712fd5eb897"
      unitRef="usd">0</us-gaap:DeferredTaxLiabilities>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90ZXh0cmVnaW9uOmU0YTg4MTBjYTNiZTRjNmFiOGQ2ZmVlMDhiODU4MjhkXzQzMTQ_a145305e-2b6e-4bcf-b789-2882a1dd4a85">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the statutory tax rate to the effective tax rate for the years ended December&#160;31, 2022, 2021 and 2020 consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.921%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.582%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.437%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.582%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected income tax expense (benefit) at 21%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,408)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,429)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,300)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(269)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Write off of credit carryover due to 382 study&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,418)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTowZDI2YzMxNjZmODc0NzQzOGZlYjZlN2E0ZWM2ZTFmNy90YWJsZXJhbmdlOjBkMjZjMzE2NmY4NzQ3NDM4ZmViNmU3YTRlYzZlMWY3XzMtMC0xLTEtMzMyMDMvdGV4dHJlZ2lvbjoyMGZhM2U3ZGRiMzQ0NzRhYTdhM2IzNThhOTM3MzU0ZF80NQ_4ad31183-524e-431d-ba01-90c8149619c5"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTowZDI2YzMxNjZmODc0NzQzOGZlYjZlN2E0ZWM2ZTFmNy90YWJsZXJhbmdlOjBkMjZjMzE2NmY4NzQ3NDM4ZmViNmU3YTRlYzZlMWY3XzMtMS0xLTEtMzMyMDM_3e6d47fc-b21a-4c85-ae86-25f067a32110"
      unitRef="usd">-21408000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTowZDI2YzMxNjZmODc0NzQzOGZlYjZlN2E0ZWM2ZTFmNy90YWJsZXJhbmdlOjBkMjZjMzE2NmY4NzQ3NDM4ZmViNmU3YTRlYzZlMWY3XzMtMy0xLTEtMzMyMDM_00339b9c-9af3-4734-8e6b-7d9b36848642"
      unitRef="usd">-18429000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTowZDI2YzMxNjZmODc0NzQzOGZlYjZlN2E0ZWM2ZTFmNy90YWJsZXJhbmdlOjBkMjZjMzE2NmY4NzQ3NDM4ZmViNmU3YTRlYzZlMWY3XzMtNS0xLTEtMzMyMDM_f38a50e2-fc51-4719-91a6-4d8aad0a0a04"
      unitRef="usd">-12300000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTowZDI2YzMxNjZmODc0NzQzOGZlYjZlN2E0ZWM2ZTFmNy90YWJsZXJhbmdlOjBkMjZjMzE2NmY4NzQ3NDM4ZmViNmU3YTRlYzZlMWY3XzQtMS0xLTEtMzMyMDM_d5a3d8c1-2e76-4d48-89ee-7d253e859edf"
      unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTowZDI2YzMxNjZmODc0NzQzOGZlYjZlN2E0ZWM2ZTFmNy90YWJsZXJhbmdlOjBkMjZjMzE2NmY4NzQ3NDM4ZmViNmU3YTRlYzZlMWY3XzQtMy0xLTEtMzMyMDM_d1768f66-5085-423b-a1f2-de1fcef9d1b3"
      unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTowZDI2YzMxNjZmODc0NzQzOGZlYjZlN2E0ZWM2ZTFmNy90YWJsZXJhbmdlOjBkMjZjMzE2NmY4NzQ3NDM4ZmViNmU3YTRlYzZlMWY3XzQtNS0xLTEtMzMyMDM_376cf674-348a-4285-90a8-58f75decbefd"
      unitRef="usd">-269000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTowZDI2YzMxNjZmODc0NzQzOGZlYjZlN2E0ZWM2ZTFmNy90YWJsZXJhbmdlOjBkMjZjMzE2NmY4NzQ3NDM4ZmViNmU3YTRlYzZlMWY3XzUtMS0xLTEtMzMyMDM_d31c5666-c035-4c74-b8c3-c3e9dd423074"
      unitRef="usd">1627000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTowZDI2YzMxNjZmODc0NzQzOGZlYjZlN2E0ZWM2ZTFmNy90YWJsZXJhbmdlOjBkMjZjMzE2NmY4NzQ3NDM4ZmViNmU3YTRlYzZlMWY3XzUtMy0xLTEtMzMyMDM_c62ea3e1-8387-4052-ad00-b85d06cb97ca"
      unitRef="usd">851000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTowZDI2YzMxNjZmODc0NzQzOGZlYjZlN2E0ZWM2ZTFmNy90YWJsZXJhbmdlOjBkMjZjMzE2NmY4NzQ3NDM4ZmViNmU3YTRlYzZlMWY3XzUtNS0xLTEtMzMyMDM_ab34a106-b921-4ee9-bdde-3564926bb6c6"
      unitRef="usd">1777000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <lxrx:WriteOffOfTaxCredits
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTowZDI2YzMxNjZmODc0NzQzOGZlYjZlN2E0ZWM2ZTFmNy90YWJsZXJhbmdlOjBkMjZjMzE2NmY4NzQ3NDM4ZmViNmU3YTRlYzZlMWY3XzExLTEtMS0xLTMzMjAz_dfa78ff0-5174-42c1-b991-fd6a854b977f"
      unitRef="usd">0</lxrx:WriteOffOfTaxCredits>
    <lxrx:WriteOffOfTaxCredits
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTowZDI2YzMxNjZmODc0NzQzOGZlYjZlN2E0ZWM2ZTFmNy90YWJsZXJhbmdlOjBkMjZjMzE2NmY4NzQ3NDM4ZmViNmU3YTRlYzZlMWY3XzExLTMtMS0xLTMzMjAz_c249e9c1-b734-4282-bba9-208c44f7824e"
      unitRef="usd">0</lxrx:WriteOffOfTaxCredits>
    <lxrx:WriteOffOfTaxCredits
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTowZDI2YzMxNjZmODc0NzQzOGZlYjZlN2E0ZWM2ZTFmNy90YWJsZXJhbmdlOjBkMjZjMzE2NmY4NzQ3NDM4ZmViNmU3YTRlYzZlMWY3XzExLTUtMS0xLTMzMjAz_e86aeb43-4026-4598-b288-32a3125b47d3"
      unitRef="usd">31053000</lxrx:WriteOffOfTaxCredits>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTowZDI2YzMxNjZmODc0NzQzOGZlYjZlN2E0ZWM2ZTFmNy90YWJsZXJhbmdlOjBkMjZjMzE2NmY4NzQ3NDM4ZmViNmU3YTRlYzZlMWY3XzEyLTEtMS0xLTMzMjAz_6662d7bd-4c02-497c-8cc6-d79809b7df50"
      unitRef="usd">19543000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTowZDI2YzMxNjZmODc0NzQzOGZlYjZlN2E0ZWM2ZTFmNy90YWJsZXJhbmdlOjBkMjZjMzE2NmY4NzQ3NDM4ZmViNmU3YTRlYzZlMWY3XzEyLTMtMS0xLTMzMjAz_bb7784b8-7dc3-421a-8b80-b0745b247ee5"
      unitRef="usd">17210000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTowZDI2YzMxNjZmODc0NzQzOGZlYjZlN2E0ZWM2ZTFmNy90YWJsZXJhbmdlOjBkMjZjMzE2NmY4NzQ3NDM4ZmViNmU3YTRlYzZlMWY3XzEyLTUtMS0xLTMzMjAz_d2c993e7-16f5-4d1d-b0b9-9004a7f9e612"
      unitRef="usd">-20418000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTowZDI2YzMxNjZmODc0NzQzOGZlYjZlN2E0ZWM2ZTFmNy90YWJsZXJhbmdlOjBkMjZjMzE2NmY4NzQ3NDM4ZmViNmU3YTRlYzZlMWY3XzEzLTEtMS0xLTMzMjAz_dff300ac-ba77-4a0d-b815-08941607ffc7"
      unitRef="usd">238000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTowZDI2YzMxNjZmODc0NzQzOGZlYjZlN2E0ZWM2ZTFmNy90YWJsZXJhbmdlOjBkMjZjMzE2NmY4NzQ3NDM4ZmViNmU3YTRlYzZlMWY3XzEzLTMtMS0xLTMzMjAz_3c694516-e8ca-4c61-bf82-3375fb1faa49"
      unitRef="usd">368000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTowZDI2YzMxNjZmODc0NzQzOGZlYjZlN2E0ZWM2ZTFmNy90YWJsZXJhbmdlOjBkMjZjMzE2NmY4NzQ3NDM4ZmViNmU3YTRlYzZlMWY3XzEzLTUtMS0xLTMzMjAz_de23c51e-96af-4c39-8a55-045e29815219"
      unitRef="usd">157000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTowZDI2YzMxNjZmODc0NzQzOGZlYjZlN2E0ZWM2ZTFmNy90YWJsZXJhbmdlOjBkMjZjMzE2NmY4NzQ3NDM4ZmViNmU3YTRlYzZlMWY3XzE0LTEtMS0xLTMzMjAz_16956b0f-4b5a-4396-97f3-a763280a164c"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTowZDI2YzMxNjZmODc0NzQzOGZlYjZlN2E0ZWM2ZTFmNy90YWJsZXJhbmdlOjBkMjZjMzE2NmY4NzQ3NDM4ZmViNmU3YTRlYzZlMWY3XzE0LTMtMS0xLTMzMjAz_924a7dc3-5676-44d3-8217-e64923009dec"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90YWJsZTowZDI2YzMxNjZmODc0NzQzOGZlYjZlN2E0ZWM2ZTFmNy90YWJsZXJhbmdlOjBkMjZjMzE2NmY4NzQ3NDM4ZmViNmU3YTRlYzZlMWY3XzE0LTUtMS0xLTMzMjAz_68abb239-8998-494b-b50a-f6e783bf7897"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90ZXh0cmVnaW9uOmU0YTg4MTBjYTNiZTRjNmFiOGQ2ZmVlMDhiODU4MjhkXzI4ODQ_3712e3c7-cc9d-4bf8-950e-19522fcd3ce9"
      unitRef="usd">1200000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90ZXh0cmVnaW9uOmU0YTg4MTBjYTNiZTRjNmFiOGQ2ZmVlMDhiODU4MjhkXzI4OTE_6fd9dc84-d07f-48a5-97f2-c340d461bf29"
      unitRef="usd">86900000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <lxrx:A2020FederalNOLIncrease
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90ZXh0cmVnaW9uOmU0YTg4MTBjYTNiZTRjNmFiOGQ2ZmVlMDhiODU4MjhkXzI5NDU_cd78e867-346d-45d8-b524-c65f8dff6789"
      unitRef="usd">104000000</lxrx:A2020FederalNOLIncrease>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90ZXh0cmVnaW9uOmU0YTg4MTBjYTNiZTRjNmFiOGQ2ZmVlMDhiODU4MjhkXzI5OTU_c24b5736-dfca-4e83-b884-b93efb8c043e"
      unitRef="usd">446300000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90ZXh0cmVnaW9uOmU0YTg4MTBjYTNiZTRjNmFiOGQ2ZmVlMDhiODU4MjhkXzM0OTI_d1a0bd93-2e24-413c-b49f-9cca811d42d2"
      unitRef="usd">19500000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90ZXh0cmVnaW9uOmU0YTg4MTBjYTNiZTRjNmFiOGQ2ZmVlMDhiODU4MjhkXzQyMzU_1b4d282b-6a8b-468c-ac84-b3ca7d2ff347"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNjkvZnJhZzplNGE4ODEwY2EzYmU0YzZhYjhkNmZlZTA4Yjg1ODI4ZC90ZXh0cmVnaW9uOmU0YTg4MTBjYTNiZTRjNmFiOGQ2ZmVlMDhiODU4MjhkXzQyMzU_b800fa70-0b08-4fe9-b23b-f2aafb2e8820"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzIvZnJhZzphYjZmYzU0N2FmMGQ0ZmM5YTc0NmY5ZGQ2M2U2NTVjNC90ZXh0cmVnaW9uOmFiNmZjNTQ3YWYwZDRmYzlhNzQ2ZjlkZDYzZTY1NWM0XzEzMTM_ae944d30-5f24-45d0-8cbb-1bf98f622942">Goodwill&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2001, Lexicon completed the acquisition of Coelacanth Corporation in a merger. Coelacanth, now Lexicon Pharmaceuticals (New Jersey), Inc., formed the core of the Company&#x2019;s division responsible for small molecule compound discovery.&#160;&#160;The results of Lexicon Pharmaceuticals (New Jersey), Inc. are included in the Company&#x2019;s results of operations for the period subsequent to the acquisition.  Goodwill associated with the acquisition of $25.8 million, which represents the excess of the $36.0 million purchase price over the fair value of the underlying net identifiable assets, was assigned to the consolidated entity, Lexicon.&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2007, Lexicon entered into an arrangement providing for the financing of the clinical development of certain of its drug candidates.  Under the arrangement, Lexicon licensed to Symphony Icon, Inc. its intellectual property rights relating to the drug candidates and obtained an exclusive purchase option that gave Lexicon the right to acquire all the equity of Symphony Icon.  In July 2010, Lexicon exercised its purchase option and completed the acquisition of Symphony Icon.  Goodwill associated with the acquisition of $18.7 million, which represents the assets recognized in connection with the deferred tax liability acquired and did not result from excess purchase price, was assigned to the consolidated entity, Lexicon.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill is not subject to amortization, but is tested at least annually for impairment at the reporting unit level, which is the Company&#x2019;s single operating segment.&#160;&#160;The Company performed an impairment test of goodwill on its annual impairment assessment date.&#160;&#160;This test did not result in an impairment of goodwill.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <lxrx:CoelacanthGoodwill
      contextRef="i5c4b46c8c9cd4829a9a8f58250be63e9_I20010712"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzIvZnJhZzphYjZmYzU0N2FmMGQ0ZmM5YTc0NmY5ZGQ2M2U2NTVjNC90ZXh0cmVnaW9uOmFiNmZjNTQ3YWYwZDRmYzlhNzQ2ZjlkZDYzZTY1NWM0XzQ2NQ_da82dd58-c803-42da-9d82-663789dd9135"
      unitRef="usd">25800000</lxrx:CoelacanthGoodwill>
    <lxrx:CoelacanthPurchasePrice
      contextRef="i5c4b46c8c9cd4829a9a8f58250be63e9_I20010712"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzIvZnJhZzphYjZmYzU0N2FmMGQ0ZmM5YTc0NmY5ZGQ2M2U2NTVjNC90ZXh0cmVnaW9uOmFiNmZjNTQ3YWYwZDRmYzlhNzQ2ZjlkZDYzZTY1NWM0XzUwNA_ca019c35-8f7a-4aa9-98af-831f1b872d63"
      unitRef="usd">36000000</lxrx:CoelacanthPurchasePrice>
    <lxrx:SymphonyIconGoodwill
      contextRef="i7ca5f952951f4661bc87adf40c2f03b1_I20100730"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzIvZnJhZzphYjZmYzU0N2FmMGQ0ZmM5YTc0NmY5ZGQ2M2U2NTVjNC90ZXh0cmVnaW9uOmFiNmZjNTQ3YWYwZDRmYzlhNzQ2ZjlkZDYzZTY1NWM0Xzc5Mg_090dfcd8-5d7e-4e2c-813a-9114adab5b1a"
      unitRef="usd">18700000</lxrx:SymphonyIconGoodwill>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzQwOTA_87320180-6997-4b94-bdaa-c7441f206c58">Debt Obligations&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Oxford Term Loans.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 17, 2022, Lexicon and one of its subsidiaries entered into a loan and security agreement with Oxford Finance LLC (&#x201c;Oxford&#x201d;) that provides up to $150&#160;million in borrowing capacity (the &#x201c;Oxford Term Loans&#x201d;) available in four tranches, each maturing in March 2027. Monthly interest-only payments are due during an initial 36-month period, which may be extended at Lexicon&#x2019;s option to 48 months if Lexicon maintains compliance with a financial covenant relating to net sales of sotagliflozin following regulatory approval. The interest-only period will be followed by an amortization period extending through the maturity date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 29, 2022, the Company entered into a first amendment to the loan and security agreement modifying the period during which the second $25 million tranche under the facility would be available for draw in exchange for $0.3&#160;million of cash consideration.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The first $25&#160;million tranche was funded at closing. The second $25&#160;million tranche was funded on December 30, 2022.  The third $50&#160;million tranche is available for draw at Lexicon&#x2019;s option prior to June 30, 2023, but within 60 days of U.S. regulatory approval of sotagliflozin for heart failure. The fourth $50&#160;million tranche is available for draw at Lexicon&#x2019;s option, subject to Oxford&#x2019;s consent, at any time prior to the expiration of the interest-only payment period.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Principal payments of $8.7&#160;million, $13.0&#160;million, and $4.8&#160;million will be due during the fiscal years ended December 31, 2025, December 31, 2026 and December 31, 2027, respectively, with respect to the first tranche.  Principal payments of $8.7&#160;million, $13.0&#160;million, and $4.8&#160;million will be due during the fiscal years ended December 31, 2025, December 31, 2026 and December 31, 2027, respectively, with respect to the second tranche.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The loan and security agreement provides that, upon funding of the first three tranches, Lexicon will grant Oxford a warrant to purchase shares of its common stock having a value equal to 3.50%, 1.75% and 0.875%, respectively, of each such tranche, as determined by reference to a 10-day average closing price of the shares. Each warrant will have an exercise price equal to such average closing price, be exercisable for a five-year period from the date of issuance and feature a net cashless exercise provision. Concurrent with the funding of the first tranche, Lexicon granted Oxford a warrant to purchase 420,673 shares of Lexicon&#x2019;s common stock at an exercise price of $2.08 per share.  Concurrent with the funding of the second tranche, Lexicon granted Oxford a warrant to purchase 224,128 shares of Lexicon&#x2019;s common stock at an exercise price of $1.95 per share. The warrants are exercisable for five years from their respective grant dates and are classified as equity instruments.  The Company allocated the proceeds from each tranche to the corresponding warrant using the relative fair value method and used the Black-Scholes model to calculate the fair value of the warrants.  The fair value of the first tranche warrant of $0.7&#160;million was recognized as equity with a corresponding debt discount of $0.7&#160;million. The fair value of the second tranche warrant of $0.3&#160;million was recognized as equity with a corresponding debt discount of $0.3&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Oxford Term Loans bear interest at a floating rate equal to the 30-day U.S. Dollar LIBOR plus 7.90%, but not less than 8.01%, subject to additional interest if an event of default occurs and is continuing.  As of December&#160;31, 2022, the interest rate was 12.04%. If an event of default occurs and is continuing, Oxford may declare all amounts outstanding under the loan and security agreement to be immediately due and payable. Lexicon may prepay the Oxford Term Loans in whole at its option at any time. Any prepayment of the Oxford Term Loans is subject to prepayment fees for up to three years after the funding of each tranche of the loans.  A final payment exit fee equal to 6% of the amount funded under the Oxford Term Loans is due upon prepayment or maturity, which final payment will be adjusted to 7% of the amount funded upon extension of the interest-only payment period.  The final payment exit fee of $1.5&#160;million was recorded once for each tranche as a debt discount on the funding date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During March 2022, in connection with the first tranche of the loan and security agreement, the Company received cash proceeds of $24.15&#160;million, net of debt issuance costs of $0.35&#160;million and a facility fee of $0.50&#160;million. The debt &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;issuance costs and facility fee have been recorded as a debt discount on the consolidated balance sheet, which together with the final payment exit fee of $1.5&#160;million and warrant fair value of $0.7&#160;million are being amortized to interest expense throughout the life of the term loan using the effective interest rate method.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 30, 2022, in connection with the second tranche of the loan and security agreement, the Company received cash proceeds of $24.96&#160;million, net of debt issuance costs of $0.04&#160;million. The debt issuance costs were recorded as a debt discount on the consolidated balance sheet, which together with the final payment exit fee of $1.5&#160;million and warrant fair value of $0.3&#160;million are being amortized to interest expense throughout the life of the term loan using the effective interest rate method. As of December&#160;31, 2022, the balance of the debt discount was $4.4&#160;million. During the year ended December&#160;31, 2022, the Company recognized interest expense of $2.8&#160;million.  As of December&#160;31, 2022, the carrying value of the Oxford Term Loans was $48.6&#160;million.  The carrying value of the Oxford Term Loans approximates its fair value, as the loans bear interest at a rate that approximates prevailing market rates for instruments with similar characteristics. The fair value of the Oxford Term Loans is determined under Level 2 in the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lexicon&#x2019;s obligations under the Oxford Term Loans are secured by a first lien security interest in all of the assets of the Company and its subsidiaries. The loan and security agreement contains certain customary representations and warranties, affirmative and negative covenants and events of default applicable to Lexicon and its subsidiaries. In addition to the financial covenant, additional covenants include those restricting dispositions, fundamental changes to its business, mergers or acquisitions, indebtedness, encumbrances, distributions, investments, transactions with affiliates and subordinated debt. The Company was in compliance with its debt covenants as of December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Convertible Notes.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In November 2014, Lexicon completed an offering of $87.5 million in aggregate principal amount of 5.25% Convertible Senior Notes due 2021 (the &#x201c;Convertible Notes&#x201d;).  The conversion feature did not meet the criteria for bifurcation as required by generally accepted accounting principles and the entire principal amount was recorded as long-term debt on the Company&#x2019;s consolidated balance sheets.  The Convertible Notes were governed by an indenture between the Company and Wells Fargo Bank, N.A., as trustee.  The Convertible Notes bore interest at a rate of 5.25%&#160;per year, which was payable semiannually in arrears on June&#160;1 and December&#160;1 of each year, beginning on June&#160;1, 2015.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2020, the Company entered into separate, privately negotiated exchange agreements to exchange $75.8 million aggregate principal amount of the Convertible Notes for consideration valued at 85% of the principal amount of the Convertible Notes.  In September and October 2020, the Company issued 10,368,956 shares of the Company&#x2019;s common stock and paid $50.0 million in cash, which included $1.3 million of accrued interest, to exchange such Convertible Notes.  The Company recorded the exchanges under the accounting requirements for debt extinguishment of convertible instruments.  As a result, a debt extinguishment gain of $9.6 million was recorded and is included in the accompanying consolidated statement of comprehensive loss for the year ended December 31, 2020.  In December 2021, the remaining balance of $11.6&#160;million was repaid in cash.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Mortgage Loan. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;In August 2018, a wholly owned subsidiary of Lexicon entered into a term loan and security agreement refinancing the previously existing mortgage on its facilities in The Woodlands, Texas (the &#x201c;Property&#x201d;).  The Company recorded the refinancing as a debt extinguishment, with no recognition of gain or loss on the transaction.  The loan agreement provided for a $12.9&#160;million mortgage on the Property and had a &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzIzNzk_9029d41a-c8aa-4619-a57b-c3c4b9a9cbad"&gt;two&lt;/span&gt;-year term with a 10-year amortization.  The mortgage loan bore interest at a rate per annum equal to the greater of (a) the 30-day LIBOR rate plus 5.5% and (b) 7.5% and provided for a balloon payment of $10.3&#160;million, which was paid in full in August 2020.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;BioPharma Term Loan.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;In December 2017, Lexicon entered into a loan agreement with BioPharma Credit PLC and BioPharma Credit Investments IV Sub &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;LP under which $150 million was funded in December 2017 (the &#x201c;BioPharma Term Loan&#x201d;).  The BioPharma Term Loan was scheduled to mature in December 2022, bore interest at 9% per year, subject to additional interest if an event of default occurred and was continuing, and was payable quarterly.   &lt;/span&gt;&lt;/div&gt;The BioPharma Term Loan was subject to mandatory prepayment provisions that required prepayment upon a change of control or receipt of proceeds from certain non-ordinary course transfers of assets.  The Company repaid the BioPharma Term Loan in whole, together with required prepayment and make-whole premiums, upon closing of the sale of XERMELO and related assets to TerSera Therapeutics LLC in September 2020.  The Company recorded the repayment under the accounting requirements for debt extinguishment and as a result, a loss of $8.6&#160;million was recognized and is included in the accompanying consolidated statement of comprehensive loss for the year ended December 31, 2020.</us-gaap:DebtDisclosureTextBlock>
    <lxrx:OxfordLoanFacility
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2MzIwMzI_f9735c40-60f9-40fc-ace9-b8caca9aab4d"
      unitRef="usd">150000000</lxrx:OxfordLoanFacility>
    <lxrx:OxfordAmendmentFee
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzQ5NDc4MDIzMzgyNzE_1f86aaeb-7231-4194-8ab4-268682b7f9c0"
      unitRef="usd">300000</lxrx:OxfordAmendmentFee>
    <lxrx:TermLoanA
      contextRef="i2e6700e3a4984b19b27e50bda5764ecb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2MzI2NjM_cd843c7c-84a8-4a15-9be0-df50e3eba87e"
      unitRef="usd">25000000</lxrx:TermLoanA>
    <lxrx:TermLoanB
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2MzI3MDk_52599d30-4dc9-4f78-b153-8f929d6224c4"
      unitRef="usd">25000000</lxrx:TermLoanB>
    <lxrx:TermLoanC
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2MzI4MTY_4daf8a93-b70f-453f-8ead-b321d81cecfb"
      unitRef="usd">50000000</lxrx:TermLoanC>
    <lxrx:TermLoanD
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2MzI5ODg_0859246d-f1c5-4840-ae70-3dbeefbf64e7"
      unitRef="usd">50000000</lxrx:TermLoanD>
    <lxrx:A2025OxfordPrincipalPaymentA
      contextRef="i5082f56c08c74c63a4b9fbd86c1e2db5_D20250101-20251231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzQ5NDc4MDIzMzc0MzI_d05d779b-b10d-455b-b9ec-ad320f8797d9"
      unitRef="usd">8700000</lxrx:A2025OxfordPrincipalPaymentA>
    <lxrx:A2026OxfordPrincipalPayments
      contextRef="ic2f7712d90c8455ebf945f797fd6c4c5_D20260101-20261231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzQ5NDc4MDIzMzc0Mzc_307a4818-96f9-4395-b9bd-39f73b7e1df9"
      unitRef="usd">13000000</lxrx:A2026OxfordPrincipalPayments>
    <lxrx:A2027OxfordPrincipalPaymentsA
      contextRef="i58efde7a50b54415affc844b791d1774_D20270101-20271231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzQ5NDc4MDIzMzc0NDY_5e469e44-f9aa-4600-b9d8-260b7b0ada69"
      unitRef="usd">4800000</lxrx:A2027OxfordPrincipalPaymentsA>
    <lxrx:A2025OxfordPrincipalPaymentsB
      contextRef="i5082f56c08c74c63a4b9fbd86c1e2db5_D20250101-20251231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2NDIyODc_112772ce-58ab-4edb-8b8d-31c687f888c8"
      unitRef="usd">8700000</lxrx:A2025OxfordPrincipalPaymentsB>
    <lxrx:A2026OxfordPrincipalPaymentsB
      contextRef="ic2f7712d90c8455ebf945f797fd6c4c5_D20260101-20261231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2NDIyOTY_aa928d34-b01b-445d-9d48-4850a57b9107"
      unitRef="usd">13000000</lxrx:A2026OxfordPrincipalPaymentsB>
    <lxrx:A2027OxfordPrincipalPaymentsB
      contextRef="i58efde7a50b54415affc844b791d1774_D20270101-20271231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2NDIzMDQ_4c2275bf-7c09-4cd8-80ea-2760f13f588a"
      unitRef="usd">4800000</lxrx:A2027OxfordPrincipalPaymentsB>
    <lxrx:TermLoanABWarrant
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2MzMzMzQ_6f15df05-2b64-4fb2-bdf2-7a61d7f5f4ac"
      unitRef="number">0.0350</lxrx:TermLoanABWarrant>
    <lxrx:TermLoanCWarrant
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2MzMzMzk_85b8e8f6-6dd3-4530-bb5f-870bfcf81c08"
      unitRef="number">0.0175</lxrx:TermLoanCWarrant>
    <lxrx:TermLoanDWarrant
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2MzMzNDc_d44f7ed7-7c35-4ca0-9ccb-c4d5e1d69b1a"
      unitRef="number">0.00875</lxrx:TermLoanDWarrant>
    <lxrx:TermLoanAWarrantsNumber
      contextRef="icf43ab9deda34d99b2dc4e7beae89d69_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2MzM3NDg_3a0aecbf-5308-4d04-8f13-a7949c449f6d"
      unitRef="shares">420673</lxrx:TermLoanAWarrantsNumber>
    <lxrx:TermLoanAWarrantExercisePrice
      contextRef="icf43ab9deda34d99b2dc4e7beae89d69_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2MzM4MDk_5f3ce998-1624-4c8f-a18c-f19d978f56f0"
      unitRef="usdPerShare">2.08</lxrx:TermLoanAWarrantExercisePrice>
    <lxrx:TermLoanAWarrantsNumber
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2Mzc1OTU_9442eea9-11d0-40c3-a514-5d8d5a92f2e1"
      unitRef="shares">224128</lxrx:TermLoanAWarrantsNumber>
    <lxrx:TermLoanAWarrantExercisePrice
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2Mzc2MDU_9c1a9572-c320-4581-942d-e272bd24176c"
      unitRef="usdPerShare">1.95</lxrx:TermLoanAWarrantExercisePrice>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2MzQxMzk_4446c9b6-fe4b-4dc4-8b28-cc290c0132cb"
      unitRef="usd">700000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2MzQyMDY_4446c9b6-fe4b-4dc4-8b28-cc290c0132cb"
      unitRef="usd">700000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="if284e805242a400b99ebf80651bc00de_D20221001-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2Mzc4ODM_a3f4511e-6cc0-457b-a34b-9a451a1a124a"
      unitRef="usd">300000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="if284e805242a400b99ebf80651bc00de_D20221001-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2Mzc4OTU_a3f4511e-6cc0-457b-a34b-9a451a1a124a"
      unitRef="usd">300000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2MzQzMTA_b48409a4-ce13-4513-8ad8-ee113800093c"
      unitRef="number">0.0790</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtPercentageBearingFixedInterestRate
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2MzQzMzM_3f5156d3-c723-4074-8919-c3cfb1419351"
      unitRef="number">0.0801</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:SubordinatedBorrowingInterestRate
      contextRef="if284e805242a400b99ebf80651bc00de_D20221001-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2Mzc5MDY_70490766-062e-490a-b64d-091c11591202"
      unitRef="number">0.1204</us-gaap:SubordinatedBorrowingInterestRate>
    <lxrx:FinalPaymentWithNoExtention
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2MzQ4NzQ_66f59108-a857-4b38-8d57-f1794337a237"
      unitRef="rate">0.06</lxrx:FinalPaymentWithNoExtention>
    <lxrx:FinalPaymentWithExtention
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2MzUwMDM_6acc3c27-229f-4d9c-bd4d-8588390b61f6"
      unitRef="rate">0.07</lxrx:FinalPaymentWithExtention>
    <lxrx:TermLoanAFinalPayment
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2MzUxMTE_b58d62c3-c35c-4a9c-b5ba-409139e52060"
      unitRef="usd">1500000</lxrx:TermLoanAFinalPayment>
    <lxrx:TermLoanANetCashReceipt
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2MzUzMjA_840b195b-2d81-4500-8b8a-b75924a8956e"
      unitRef="usd">24150000</lxrx:TermLoanANetCashReceipt>
    <lxrx:TermLoanADebtIssuanceCosts
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2MzUzNTU_4f735794-62d4-45a6-adff-64b79bcc2970"
      unitRef="usd">350000</lxrx:TermLoanADebtIssuanceCosts>
    <lxrx:OxfordFacilityFee
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2MzUzODE_c1e4270f-ebcd-4109-9a04-ef7258ba1884"
      unitRef="usd">500000</lxrx:OxfordFacilityFee>
    <lxrx:TermLoanAFinalPayment
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2MzU1NjA_b58d62c3-c35c-4a9c-b5ba-409139e52060"
      unitRef="usd">1500000</lxrx:TermLoanAFinalPayment>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2MzU1OTA_4446c9b6-fe4b-4dc4-8b28-cc290c0132cb"
      unitRef="usd">700000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <lxrx:TermLoanBNetCashReceipt
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2Mzg1NzM_ed0ed99d-a7e3-4f95-9c67-e6d3e3a6ef06"
      unitRef="usd">24960000</lxrx:TermLoanBNetCashReceipt>
    <lxrx:TermLoanBDebtDiscount
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2Mzg1ODI_c9660de4-e3d0-4a4d-a4d3-a14aae101c01"
      unitRef="usd">40000.00</lxrx:TermLoanBDebtDiscount>
    <lxrx:TermLoanAFinalPayment
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2MzgzNzc_b58d62c3-c35c-4a9c-b5ba-409139e52060"
      unitRef="usd">1500000</lxrx:TermLoanAFinalPayment>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="if284e805242a400b99ebf80651bc00de_D20221001-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2Mzg2NDQ_a3f4511e-6cc0-457b-a34b-9a451a1a124a"
      unitRef="usd">300000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <lxrx:TermLoanADebtDiscount
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2Mzg2NTk_fe5b9522-0f91-468d-9ba5-d10c2d706ae8"
      unitRef="usd">4400000</lxrx:TermLoanADebtDiscount>
    <us-gaap:InterestExpenseInterestBearingLiability
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2NDIzNDU_be52f0c8-4d69-4e57-a6e3-d9001d0e27f5"
      unitRef="usd">2800000</us-gaap:InterestExpenseInterestBearingLiability>
    <us-gaap:LongTermDebt
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwOTk1MTE2NDIzMzc_43cc741a-b670-435e-a462-9714182c8506"
      unitRef="usd">48600000</us-gaap:LongTermDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="ifaed8b1899ba47ddb389bc7180e9188b_D20141101-20141130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2Xzk4_4c233633-d318-4a82-871d-fa431c3802fd"
      unitRef="usd">87500000</us-gaap:ProceedsFromConvertibleDebt>
    <lxrx:ConvertibleDebtInstrumentInterestRateStatedPercentage
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEzNA_8008a6c8-b8b9-4254-9833-bb301a2784f0"
      unitRef="number">0.0525</lxrx:ConvertibleDebtInstrumentInterestRateStatedPercentage>
    <lxrx:ConvertibleDebtInstrumentInterestRateStatedPercentage
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzU5Mg_8008a6c8-b8b9-4254-9833-bb301a2784f0"
      unitRef="number">0.0525</lxrx:ConvertibleDebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzgwOQ_69dc93d3-7746-4b1c-97d8-5683a102d3dc"
      unitRef="usd">75800000</us-gaap:ProceedsFromConvertibleDebt>
    <lxrx:A2020ConvertibleDebtExchangePercentageOfPrincipal
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2Xzg5Mg_ad6c539b-10c5-499d-a540-a4f18f56e0c9"
      unitRef="number">0.85</lxrx:A2020ConvertibleDebtExchangePercentageOfPrincipal>
    <lxrx:A2020ConvertibleDebtExchangeSharePaymentTotal
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2Xzk3Mg_2a77d94f-9628-417f-ae2d-a6c1035d6eff"
      unitRef="shares">10368956</lxrx:A2020ConvertibleDebtExchangeSharePaymentTotal>
    <lxrx:ConvertibleDebtExchangeTotalCashConsideration
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwMjE_27d1b1ef-b894-4bbf-886a-1d75e24d0b1f"
      unitRef="usd">50000000</lxrx:ConvertibleDebtExchangeTotalCashConsideration>
    <lxrx:A2020ConvertibleDebtExchangeAccruedInterest
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEwNDg_b46b5d46-1856-4e79-9ca4-755024fb9c62"
      unitRef="usd">1300000</lxrx:A2020ConvertibleDebtExchangeAccruedInterest>
    <lxrx:ConvertibleDebtExchange
      contextRef="ief9b221acfd5465cb83500067a09fff2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzEyNzQ_cb31239b-27ea-48a8-bd00-f6655ec01e28"
      unitRef="usd">9600000</lxrx:ConvertibleDebtExchange>
    <us-gaap:ConvertibleDebt
      contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzE1MTk_f3e8a292-f3c7-4fb4-a62a-483a69a97f1e"
      unitRef="usd">11600000</us-gaap:ConvertibleDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="idb9d77e7bb0d49ef814ea91873a8ee6f_D20180801-20180831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzIyNTU_5bf3c8dd-c475-4fef-bc71-028748d9bf14"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <lxrx:MortgageDebtInstrument_Revere_LXRX
      contextRef="i84cdb8b224f3426da99041ee143ab064_I20180830"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzIzNDE_af1076ce-d391-4fc6-afdd-0efe7c1ec005"
      unitRef="usd">12900000</lxrx:MortgageDebtInstrument_Revere_LXRX>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="idb9d77e7bb0d49ef814ea91873a8ee6f_D20180801-20180831"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzIzOTk_fb6a89f4-b3c7-47a5-95c4-b03e7fb2fc4f">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <lxrx:MortgageDebtInterestRate_Base_Revere_LXRX
      contextRef="i84cdb8b224f3426da99041ee143ab064_I20180830"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzI1Mjg_1ad93c32-d19a-43e9-8608-09908634d6fe"
      unitRef="number">0.055</lxrx:MortgageDebtInterestRate_Base_Revere_LXRX>
    <lxrx:MortgageDebtInterestRate_Base_Revere_LXRX
      contextRef="i84cdb8b224f3426da99041ee143ab064_I20180830"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzI1Mjg_74973e68-5733-47a5-a377-897d19c1cd1b"
      unitRef="number">0.055</lxrx:MortgageDebtInterestRate_Base_Revere_LXRX>
    <lxrx:MortgageDebtInterestRateBasePlus_Revere_LXRX
      contextRef="i84cdb8b224f3426da99041ee143ab064_I20180830"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzI1Mzg_81da859f-f7c3-4431-af39-8cbd7ba5936e"
      unitRef="number">0.075</lxrx:MortgageDebtInterestRateBasePlus_Revere_LXRX>
    <lxrx:MortgageDebtInterestRateBasePlus_Revere_LXRX
      contextRef="i84cdb8b224f3426da99041ee143ab064_I20180830"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzI1Mzg_e84df751-99bf-4a8c-ab75-eb14779d9701"
      unitRef="number">0.075</lxrx:MortgageDebtInterestRateBasePlus_Revere_LXRX>
    <lxrx:MortgageDebtBalloonPayment_LXRX
      contextRef="i84cdb8b224f3426da99041ee143ab064_I20180830"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzI1Nzk_30a507f1-d0c1-493c-858f-9a637bb13ded"
      unitRef="usd">10300000</lxrx:MortgageDebtBalloonPayment_LXRX>
    <lxrx:MortgageDebtBalloonPayment_LXRX
      contextRef="i84cdb8b224f3426da99041ee143ab064_I20180830"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzI1Nzk_6bdcb825-1741-43fe-8038-a53f18a39b72"
      unitRef="usd">10300000</lxrx:MortgageDebtBalloonPayment_LXRX>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i4d539018a70542119bc755c3276bee16_I20171218"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzI3ODQ_83e38d83-4507-4dd5-8b29-23ab346cad59"
      unitRef="usd">150000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzUvZnJhZzozYTkxMjM0ZjRmMGU0NGJlODMzNWJmNDgzZThmYzA5Ni90ZXh0cmVnaW9uOjNhOTEyMzRmNGYwZTQ0YmU4MzM1YmY0ODNlOGZjMDk2XzI5Mjg_66f5342d-7917-49a9-b37b-34e768bf8c33"
      unitRef="number">0.09</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzgvZnJhZzplN2M4MTQ2M2ZkZWE0YWU5ODVmMWZmN2Q0YjI1ZTliNy90ZXh0cmVnaW9uOmU3YzgxNDYzZmRlYTRhZTk4NWYxZmY3ZDRiMjVlOWI3XzQzNQ_f5569e29-5635-473d-b4fb-869458329672"
      unitRef="usd">6800000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzgvZnJhZzplN2M4MTQ2M2ZkZWE0YWU5ODVmMWZmN2Q0YjI1ZTliNy90ZXh0cmVnaW9uOmU3YzgxNDYzZmRlYTRhZTk4NWYxZmY3ZDRiMjVlOWI3XzEwOTk1MTE2MzM1NDc_0d2bf1c8-9549-4cf5-9837-4b7ff91047bb"
      unitRef="usd">2300000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:ShortTermLeaseCommitmentAmount
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzgvZnJhZzplN2M4MTQ2M2ZkZWE0YWU5ODVmMWZmN2Q0YjI1ZTliNy90ZXh0cmVnaW9uOmU3YzgxNDYzZmRlYTRhZTk4NWYxZmY3ZDRiMjVlOWI3XzU3Mg_c3bfff95-8fa9-4040-90c4-ca30790a2f4b"
      unitRef="usd">1300000</us-gaap:ShortTermLeaseCommitmentAmount>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzgvZnJhZzplN2M4MTQ2M2ZkZWE0YWU5ODVmMWZmN2Q0YjI1ZTliNy90ZXh0cmVnaW9uOmU3YzgxNDYzZmRlYTRhZTk4NWYxZmY3ZDRiMjVlOWI3XzU3OQ_5a966bdb-d8d5-4e7a-b8a9-6f3c47b4fa65"
      unitRef="usd">5400000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:ShortTermLeaseCommitmentAmount
      contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzgvZnJhZzplN2M4MTQ2M2ZkZWE0YWU5ODVmMWZmN2Q0YjI1ZTliNy90ZXh0cmVnaW9uOmU3YzgxNDYzZmRlYTRhZTk4NWYxZmY3ZDRiMjVlOWI3XzEwOTk1MTE2MzExMTY_1a3be916-b749-406c-ae73-3f459e3fb5c0"
      unitRef="usd">1100000</us-gaap:ShortTermLeaseCommitmentAmount>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzgvZnJhZzplN2M4MTQ2M2ZkZWE0YWU5ODVmMWZmN2Q0YjI1ZTliNy90ZXh0cmVnaW9uOmU3YzgxNDYzZmRlYTRhZTk4NWYxZmY3ZDRiMjVlOWI3XzEwOTk1MTE2MzExMjA_6d8d9d87-60f5-423f-9de0-58df7097b86a"
      unitRef="usd">1200000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LeaseAndRentalExpense
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzgvZnJhZzplN2M4MTQ2M2ZkZWE0YWU5ODVmMWZmN2Q0YjI1ZTliNy90ZXh0cmVnaW9uOmU3YzgxNDYzZmRlYTRhZTk4NWYxZmY3ZDRiMjVlOWI3XzEwOTk1MTE2MzQyOTg_78caed27-1a41-423f-b37e-f9420d4557c6"
      unitRef="usd">1800000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzgvZnJhZzplN2M4MTQ2M2ZkZWE0YWU5ODVmMWZmN2Q0YjI1ZTliNy90ZXh0cmVnaW9uOmU3YzgxNDYzZmRlYTRhZTk4NWYxZmY3ZDRiMjVlOWI3XzEwOTk1MTE2MzM1MDE_7ba66f4c-2870-4b63-8719-b8876561ef11"
      unitRef="usd">1700000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:PaymentsForRent
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzgvZnJhZzplN2M4MTQ2M2ZkZWE0YWU5ODVmMWZmN2Q0YjI1ZTliNy90ZXh0cmVnaW9uOmU3YzgxNDYzZmRlYTRhZTk4NWYxZmY3ZDRiMjVlOWI3XzEwOTk1MTE2MzI4OTM_f71c11a5-5159-422a-ae87-c1af846852ec"
      unitRef="usd">1100000</us-gaap:PaymentsForRent>
    <us-gaap:PaymentsForRent
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzgvZnJhZzplN2M4MTQ2M2ZkZWE0YWU5ODVmMWZmN2Q0YjI1ZTliNy90ZXh0cmVnaW9uOmU3YzgxNDYzZmRlYTRhZTk4NWYxZmY3ZDRiMjVlOWI3XzEwOTk1MTE2MzI4OTY_91ebf393-189d-44a2-87a5-8a552ceb4d2d"
      unitRef="usd">800000</us-gaap:PaymentsForRent>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzgvZnJhZzplN2M4MTQ2M2ZkZWE0YWU5ODVmMWZmN2Q0YjI1ZTliNy90ZXh0cmVnaW9uOmU3YzgxNDYzZmRlYTRhZTk4NWYxZmY3ZDRiMjVlOWI3XzEwOTk1MTE2MzQyOTU_f130da7c-5f1b-4057-a5d0-0d70e5eda417">P9Y6M</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzgvZnJhZzplN2M4MTQ2M2ZkZWE0YWU5ODVmMWZmN2Q0YjI1ZTliNy90ZXh0cmVnaW9uOmU3YzgxNDYzZmRlYTRhZTk4NWYxZmY3ZDRiMjVlOWI3XzEwOTk1MTE2MzQyOTQ_6f8c0e31-5b56-4db0-90c4-c4a24f30843d">P2Y10M24D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzgvZnJhZzplN2M4MTQ2M2ZkZWE0YWU5ODVmMWZmN2Q0YjI1ZTliNy90ZXh0cmVnaW9uOmU3YzgxNDYzZmRlYTRhZTk4NWYxZmY3ZDRiMjVlOWI3XzEwOTk1MTE2MzMwNTE_d13332e8-8dbc-433b-abf8-9ff7432f74a6"
      unitRef="number">0.096</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="if253b46ef2a74bc69b4c2082a05ba597_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzgvZnJhZzplN2M4MTQ2M2ZkZWE0YWU5ODVmMWZmN2Q0YjI1ZTliNy90ZXh0cmVnaW9uOmU3YzgxNDYzZmRlYTRhZTk4NWYxZmY3ZDRiMjVlOWI3XzEwOTk1MTE2MzMwNDI_c6a87564-5a11-438f-b565-f993614af527"
      unitRef="number">0.090</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzgvZnJhZzplN2M4MTQ2M2ZkZWE0YWU5ODVmMWZmN2Q0YjI1ZTliNy90ZXh0cmVnaW9uOmU3YzgxNDYzZmRlYTRhZTk4NWYxZmY3ZDRiMjVlOWI3XzE4MDY_d46c4c40-0ee2-472b-876b-375282fdc522">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.744%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.056%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total undiscounted operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: amount of lease payments representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,078)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of future lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: short-term operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,291)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzgvZnJhZzplN2M4MTQ2M2ZkZWE0YWU5ODVmMWZmN2Q0YjI1ZTliNy90YWJsZTpjMzFlNGFiNDU2Zjc0YzMwODIxNTFiYmI0MDViYzY0NS90YWJsZXJhbmdlOmMzMWU0YWI0NTZmNzRjMzA4MjE1MWJiYjQwNWJjNjQ1XzItMS0xLTEtMzMyMDM_cf7a9c6d-284a-4b90-a225-ed03827bc27b"
      unitRef="usd">805000000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzgvZnJhZzplN2M4MTQ2M2ZkZWE0YWU5ODVmMWZmN2Q0YjI1ZTliNy90YWJsZTpjMzFlNGFiNDU2Zjc0YzMwODIxNTFiYmI0MDViYzY0NS90YWJsZXJhbmdlOmMzMWU0YWI0NTZmNzRjMzA4MjE1MWJiYjQwNWJjNjQ1XzMtMS0xLTEtMzMyMDM_4f304515-8449-4a6d-9ed1-9b22507349ff"
      unitRef="usd">1378000000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzgvZnJhZzplN2M4MTQ2M2ZkZWE0YWU5ODVmMWZmN2Q0YjI1ZTliNy90YWJsZTpjMzFlNGFiNDU2Zjc0YzMwODIxNTFiYmI0MDViYzY0NS90YWJsZXJhbmdlOmMzMWU0YWI0NTZmNzRjMzA4MjE1MWJiYjQwNWJjNjQ1XzQtMS0xLTEtMzMyMDM_9046b323-61b4-482b-9372-d127c9c21d94"
      unitRef="usd">1220000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzgvZnJhZzplN2M4MTQ2M2ZkZWE0YWU5ODVmMWZmN2Q0YjI1ZTliNy90YWJsZTpjMzFlNGFiNDU2Zjc0YzMwODIxNTFiYmI0MDViYzY0NS90YWJsZXJhbmdlOmMzMWU0YWI0NTZmNzRjMzA4MjE1MWJiYjQwNWJjNjQ1XzUtMS0xLTEtMzMyMDM_a4b9c57a-eff9-456b-88e0-bf9a332ad8ca"
      unitRef="usd">865000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzgvZnJhZzplN2M4MTQ2M2ZkZWE0YWU5ODVmMWZmN2Q0YjI1ZTliNy90YWJsZTpjMzFlNGFiNDU2Zjc0YzMwODIxNTFiYmI0MDViYzY0NS90YWJsZXJhbmdlOmMzMWU0YWI0NTZmNzRjMzA4MjE1MWJiYjQwNWJjNjQ1XzYtMS0xLTEtMzMyMDM_94a7b5b9-67dd-479f-9304-57b6b641b6f8"
      unitRef="usd">881000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzgvZnJhZzplN2M4MTQ2M2ZkZWE0YWU5ODVmMWZmN2Q0YjI1ZTliNy90YWJsZTpjMzFlNGFiNDU2Zjc0YzMwODIxNTFiYmI0MDViYzY0NS90YWJsZXJhbmdlOmMzMWU0YWI0NTZmNzRjMzA4MjE1MWJiYjQwNWJjNjQ1XzctMS0xLTEtMzMyMDM_a93c52f8-4948-4461-937f-82b8dd6b05b6"
      unitRef="usd">5644000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzgvZnJhZzplN2M4MTQ2M2ZkZWE0YWU5ODVmMWZmN2Q0YjI1ZTliNy90YWJsZTpjMzFlNGFiNDU2Zjc0YzMwODIxNTFiYmI0MDViYzY0NS90YWJsZXJhbmdlOmMzMWU0YWI0NTZmNzRjMzA4MjE1MWJiYjQwNWJjNjQ1XzgtMS0xLTEtMzMyMDM_77c7dce1-a418-4085-ba6f-59b276ab7906"
      unitRef="usd">10793000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <lxrx:InterestOnLeasePayments
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzgvZnJhZzplN2M4MTQ2M2ZkZWE0YWU5ODVmMWZmN2Q0YjI1ZTliNy90YWJsZTpjMzFlNGFiNDU2Zjc0YzMwODIxNTFiYmI0MDViYzY0NS90YWJsZXJhbmdlOmMzMWU0YWI0NTZmNzRjMzA4MjE1MWJiYjQwNWJjNjQ1XzktMS0xLTEtMzMyMDM_0941fa98-8866-4d9d-81c4-7314353eae55"
      unitRef="usd">-4078000</lxrx:InterestOnLeasePayments>
    <lxrx:PresentValueOfFutureLeasePayments
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzgvZnJhZzplN2M4MTQ2M2ZkZWE0YWU5ODVmMWZmN2Q0YjI1ZTliNy90YWJsZTpjMzFlNGFiNDU2Zjc0YzMwODIxNTFiYmI0MDViYzY0NS90YWJsZXJhbmdlOmMzMWU0YWI0NTZmNzRjMzA4MjE1MWJiYjQwNWJjNjQ1XzEwLTEtMS0xLTMzMjAz_6dddd8cf-dc91-433a-9aed-a15972dcd87b"
      unitRef="usd">6715000</lxrx:PresentValueOfFutureLeasePayments>
    <us-gaap:ShortTermLeaseCommitmentAmount
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzgvZnJhZzplN2M4MTQ2M2ZkZWE0YWU5ODVmMWZmN2Q0YjI1ZTliNy90YWJsZTpjMzFlNGFiNDU2Zjc0YzMwODIxNTFiYmI0MDViYzY0NS90YWJsZXJhbmdlOmMzMWU0YWI0NTZmNzRjMzA4MjE1MWJiYjQwNWJjNjQ1XzExLTEtMS0xLTMzMjAz_9ee651be-02e3-4c75-8bca-9c2979b57e07"
      unitRef="usd">1291000</us-gaap:ShortTermLeaseCommitmentAmount>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzgvZnJhZzplN2M4MTQ2M2ZkZWE0YWU5ODVmMWZmN2Q0YjI1ZTliNy90YWJsZTpjMzFlNGFiNDU2Zjc0YzMwODIxNTFiYmI0MDViYzY0NS90YWJsZXJhbmdlOmMzMWU0YWI0NTZmNzRjMzA4MjE1MWJiYjQwNWJjNjQ1XzEyLTEtMS0xLTMzMjAz_b2f3510e-d727-4723-9f37-31ead70015aa"
      unitRef="usd">5424000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <lxrx:DeferredCompensationArrangementWithIndividualPaymentPeriod
      contextRef="ief3a42398bf74858b5aa075d327d0116_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzgvZnJhZzplN2M4MTQ2M2ZkZWE0YWU5ODVmMWZmN2Q0YjI1ZTliNy90ZXh0cmVnaW9uOmU3YzgxNDYzZmRlYTRhZTk4NWYxZmY3ZDRiMjVlOWI3XzEzMzk_7d374a9c-ccca-41e2-9651-db47f57ee265">P12M</lxrx:DeferredCompensationArrangementWithIndividualPaymentPeriod>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzQ3ODc_70fd6037-f7f0-418e-97aa-94a8ca2e1e57">Equity Incentive Awards&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity Incentive Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2017 Equity Incentive Plan:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;In September 1995, Lexicon adopted the 1995 Stock Option Plan, which was subsequently amended and renamed the 2017 Equity Incentive Plan (the &#x201c;Equity Incentive Plan&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Equity Incentive Plan permits the grant of incentive stock options to employees and nonstatutory stock options to employees, directors and consultants of the Company. The plan also permits the grant of stock bonus awards, restricted stock awards, restricted stock unit awards, stock appreciation rights and performance stock awards. Incentive and nonstatutory stock options have an exercise price of 100% or more of the fair market value of the Company&#x2019;s common stock on the date of grant.&#160;&#160;Most stock options granted under the Equity Incentive Plan become vested and exercisable over a period of four years; however some have been granted with different vesting schedules.&#160;&#160;Stock options granted under the Equity Incentive Plan have a term of ten years from the date of grant.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total number of shares of common stock that may be issued pursuant to stock awards under the Equity Incentive Plan shall not exceed in the aggregate 30,000,000 shares at December&#160;31, 2022.&#160;&#160;As of December&#160;31, 2022, options to purchase 11,847,723 shares and 2,559,306 restricted stock units were outstanding, 2,285,702 shares had been issued upon the exercise of stock options, 5,294,942 shares had been issued pursuant to restricted stock units and 113,940 shares had been issued pursuant to stock bonus awards or restricted stock awards granted under the Equity Incentive Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2017 Non-Employee Directors&#x2019; Equity Incentive Plan:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;In February 2000, Lexicon adopted the 2000 Non-Employee Directors&#x2019; Stock Option Plan, which was subsequently amended and renamed the 2017 Non-Employee Directors&#x2019; Equity Incentive Plan (the &#x201c;Directors&#x2019; Plan&#x201d;).&#160;&#160;Under the Directors&#x2019; Plan, non-employee directors may be granted awards under the plan with an aggregate grant date fair value of no more than $500,000 during any calendar year, taken together with any cash fees paid to such non-employee director in compensation for service on Lexicon&#x2019;s board of directors during such calendar year.&#160;Stock options granted under the Directors&#x2019; Plan have an exercise price equal to the fair market value of the Company&#x2019;s common stock on the date of grant and a term of ten years from the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total number of shares of common stock that may be issued pursuant to stock awards under the Directors&#x2019; Plan shall not exceed in the aggregate 1,200,000 shares at December 31, 2022.&#160;&#160;As of December&#160;31, 2022, stock options to purchase 501,224 shares were outstanding, none had been issued upon the exercise of stock options, 74,416 restricted stock units were outstanding and 248,232 shares had been issued pursuant to restricted stock and restricted stock unit awards granted under the Directors&#x2019; Plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Option Activity:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of stock option activity under Lexicon&#x2019;s equity incentive plans:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.649%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands, except exercise price data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(376)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(163)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(191)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(236)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(954)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,271)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,557)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average estimated grant date fair value of stock options granted during the years ended December&#160;31, 2022, 2021 and 2020 were $2.30, $4.85 and&#160;$2.35, respectively.&#160;&#160;The total intrinsic value of stock options exercised during the year ended December&#160;31, 2022 was $0.&#160; The weighted average remaining contractual term of stock options outstanding and exercisable was 7.2 and 5.3 years, respectively, as of December&#160;31, 2022.&#160;&#160;At December&#160;31, 2022, the aggregate intrinsic value of the outstanding stock options was $0.1 million.  At December&#160;31, 2022, the intrinsic value of exercisable stock options was $0. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Bonus and Restricted Stock Unit Activity:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2022, 2021 and 2020, Lexicon granted its employees restricted stock units in lieu of or in addition to annual stock option awards. These restricted stock units vest in &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzM2NTc_da5a4fdb-478f-48e1-83dd-2888411ee7f9"&gt;three&lt;/span&gt; annual installments.  The total fair value of shares vested in 2022, 2021 and 2020 was $2.9&#160;million, $8.7&#160;million and $3.2&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2022, 2021 and 2020, Lexicon granted its non-employee directors 74,416,  32,192 and 85,104 restricted stock units, respectively. The restricted stock granted in 2022, 2021 and 2020 had weighted average grant date fair values of $1.77, $5.04 and $1.86 per share, respectively.  Vesting of restricted stock units occurs on the first anniversary of the grant date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of restricted stock units activity under Lexicon&#x2019;s stock-based compensation plans for the year ended December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.103%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.567%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,012)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(279)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2022, the Company issued $6.3&#160;million of Treasury shares in lieu of issuing additional authorized common shares in order to satisfy the annual vesting of restricted stock units for its employees and officers.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Aggregate Shares Reserved for Issuance&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, an aggregate of 15,096,609 shares of common stock were reserved for issuance upon exercise of outstanding stock options and vesting of outstanding restricted stock units and 8,160,575 additional shares were available for future grants under Lexicon&#x2019;s equity incentive plans.&#160;&#160;The Company has a policy of using either authorized and unissued shares or treasury shares, including shares acquired by purchase in the open market or in private transactions, to satisfy equity award exercises.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <lxrx:StockOptionExercisePriceAsPercentOfValueOfCommonStock
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzY2OQ_0dcbd528-4064-46c0-8223-a3775b001e03"
      unitRef="number">1</lxrx:StockOptionExercisePriceAsPercentOfValueOfCommonStock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i28b8859c0c154ed482c84e3ab218642d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0Xzg2NA_16413875-7588-4ee1-bbfa-41a99b630cfb">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i28b8859c0c154ed482c84e3ab218642d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzEwMDM_a900bbf6-8b6c-45fc-b05c-2acf6fbb47b2">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <lxrx:TotalSharesThatMayBeIssuedEquityIncentivePlan
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzExODc_70a8ebe2-667d-4775-8014-930f2096d325"
      unitRef="shares">30000000</lxrx:TotalSharesThatMayBeIssuedEquityIncentivePlan>
    <lxrx:OptionsOutstandingEquityIncentivePlan
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzEyMzU_7e8aff77-0b49-4fe7-a86b-9548126b4e75"
      unitRef="shares">11847723</lxrx:OptionsOutstandingEquityIncentivePlan>
    <lxrx:RestrictedStockUnitsOutstandingEquityIncentivePlan
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzEyNDk_bf6c34e9-6512-4096-864e-8ca7909f5b6c"
      unitRef="shares">2559306</lxrx:RestrictedStockUnitsOutstandingEquityIncentivePlan>
    <lxrx:StockOptionsExercisedEquityIncentivePlan
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzEyOTM_ff52d29d-a1c4-4ade-8338-46bd335eadf6"
      unitRef="shares">2285702</lxrx:StockOptionsExercisedEquityIncentivePlan>
    <lxrx:SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzEzNTU_49ec1c84-22e1-4248-8341-ca58f3abb020"
      unitRef="shares">5294942</lxrx:SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan>
    <lxrx:SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzE0MjA_7b9f9853-3fa7-4fac-be81-e3d5b97b5ff5"
      unitRef="shares">113940</lxrx:SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan>
    <lxrx:Totalvalueofsharesbynonemployeeinayear
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzE5NTI_a10f5764-e89e-46a3-b628-ef6ed1b6b173"
      unitRef="usd">500000</lxrx:Totalvalueofsharesbynonemployeeinayear>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i28b8859c0c154ed482c84e3ab218642d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzIzMDQ_298fdeee-48f4-4085-b9f9-f2e1477ae836">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <lxrx:TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzI0ODA_1469bff7-9627-4bc8-b851-05feaf0e5aa9"
      unitRef="shares">1200000</lxrx:TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan>
    <lxrx:OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzI1Mjg_31f498b9-52c2-4378-aed3-b581b5bbc652"
      unitRef="shares">501224</lxrx:OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan>
    <lxrx:StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzI1NTY_698d5814-1de5-4661-842e-d25da6566d29"
      unitRef="shares">0</lxrx:StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan>
    <lxrx:RestrictedStockUnitsOutstandingNonEmployeeDirectorsEquityIncentivePlan
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzI2MTE_9dc1bd14-b8be-44b5-813c-31e7d465be6e"
      unitRef="shares">74416</lxrx:RestrictedStockUnitsOutstandingNonEmployeeDirectorsEquityIncentivePlan>
    <lxrx:SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzI2NTg_8e8711b2-6521-48dd-bc6d-63d9ed341029"
      unitRef="shares">248232</lxrx:SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzQ3OTU_1e932a84-646a-427f-87b7-cfd3aa52c50e">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.649%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands, except exercise price data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(376)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(163)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(191)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(236)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(954)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,271)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,557)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i8686f139ef8d4193a880a31b12d0ce30_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzItMi0xLTEtMzMyMDM_09382399-a669-4de2-b080-c3bc441077cd"
      unitRef="shares">8367000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i8686f139ef8d4193a880a31b12d0ce30_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzItNC0xLTEtMzMyMDM_8f8b1636-d9fd-4251-bbc2-ca3c553dbac2"
      unitRef="usdPerShare">6.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i038e4801d2d648b38d0de7b8dab0f316_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzItNi0xLTEtMzMyMDM_ad11bccf-dc53-435c-9335-804299b5b279"
      unitRef="shares">8397000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i038e4801d2d648b38d0de7b8dab0f316_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzItOC0xLTEtMzMyMDM_8239faa0-30e3-48db-9c80-fe0ef4f91b99"
      unitRef="usdPerShare">7.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ib525d01afa1f498e883536f24362d124_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzItMTAtMS0xLTMzMjAz_6c048fd4-20a4-4323-a736-59772b6b5a39"
      unitRef="shares">7695000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ib525d01afa1f498e883536f24362d124_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzItMTItMS0xLTMzMjAz_6e1eb832-785c-487e-a734-eb063a7f9d12"
      unitRef="usdPerShare">8.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i28b8859c0c154ed482c84e3ab218642d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzMtMi0xLTEtMzMyMDM_2a5470af-b899-44da-bb36-bb9559b6c00e"
      unitRef="shares">5099000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i28b8859c0c154ed482c84e3ab218642d_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzMtNC0xLTEtMzMyMDM_9f7b9ac2-b1c5-4b96-9e2b-36b50b0e8edb"
      unitRef="usdPerShare">2.97</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i1be397a2eed340ea9795e0c692981bed_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzMtNi0xLTEtMzMyMDM_b1c44db3-b38b-49f3-8ccc-99f633ddeb5c"
      unitRef="shares">1808000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i1be397a2eed340ea9795e0c692981bed_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzMtOC0xLTEtMzMyMDM_fdcd44c7-e862-493e-84d0-085eb51eff77"
      unitRef="usdPerShare">6.39</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i94f2adcb200344b890fec8dc81de1ae6_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzMtMTAtMS0xLTMzMjAz_eb6a13df-5c60-4862-ac46-61ed42370315"
      unitRef="shares">3495000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i94f2adcb200344b890fec8dc81de1ae6_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzMtMTItMS0xLTMzMjAz_54c1ff1e-e63d-4c0e-9a03-1df2278876bd"
      unitRef="usdPerShare">3.24</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i28b8859c0c154ed482c84e3ab218642d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzQtMi0xLTEtMzMyMDM_2b059b94-f244-4e8e-8cc7-fc053d6d7c86"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i28b8859c0c154ed482c84e3ab218642d_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzQtNC0xLTEtMzMyMDM_fc6e1f16-88da-4990-94f2-348498560d3d"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i1be397a2eed340ea9795e0c692981bed_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzQtNi0xLTEtMzMyMDM_db29a242-ca37-4544-a339-de2bea089586"
      unitRef="shares">376000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i1be397a2eed340ea9795e0c692981bed_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzQtOC0xLTEtMzMyMDM_7b217ca7-9ddd-436e-a877-fa94762ac496"
      unitRef="usdPerShare">4.37</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i94f2adcb200344b890fec8dc81de1ae6_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzQtMTAtMS0xLTMzMjAz_a554c195-c21b-4bf8-80ee-82276f524567"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i94f2adcb200344b890fec8dc81de1ae6_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzQtMTItMS0xLTMzMjAz_97d16b67-4b16-4721-8607-4391d3c0a6e2"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="i28b8859c0c154ed482c84e3ab218642d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzUtMi0xLTEtMzMyMDM_33260959-d32f-4786-9e85-d0875ece08b7"
      unitRef="shares">163000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i28b8859c0c154ed482c84e3ab218642d_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzUtNC0xLTEtMzMyMDM_705715c7-be71-4bb8-a7da-ab2de676ffa8"
      unitRef="usdPerShare">12.50</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="i1be397a2eed340ea9795e0c692981bed_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzUtNi0xLTEtMzMyMDM_4f9f0d56-8209-4d14-b843-81cae81919ea"
      unitRef="shares">191000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i1be397a2eed340ea9795e0c692981bed_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzUtOC0xLTEtMzMyMDM_5f1d32fc-e9de-4348-b169-6018facd261f"
      unitRef="usdPerShare">12.50</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="i94f2adcb200344b890fec8dc81de1ae6_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzUtMTAtMS0xLTMzMjAz_e49b0c5e-a5b9-4437-baf1-179a723592ce"
      unitRef="shares">236000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i94f2adcb200344b890fec8dc81de1ae6_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzUtMTItMS0xLTMzMjAz_38532430-7996-4374-aa99-96187184d924"
      unitRef="usdPerShare">12.91</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i28b8859c0c154ed482c84e3ab218642d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzYtMi0xLTEtMzMyMDM_267875ca-85ce-4540-b8b8-4615878e0094"
      unitRef="shares">954000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i28b8859c0c154ed482c84e3ab218642d_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzYtNC0xLTEtMzMyMDM_11fec490-4366-405b-ad18-9ddc95a2f60f"
      unitRef="usdPerShare">7.41</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i1be397a2eed340ea9795e0c692981bed_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzYtNi0xLTEtMzMyMDM_cb908454-20ac-4232-875a-9f4764c56c60"
      unitRef="shares">1271000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i1be397a2eed340ea9795e0c692981bed_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzYtOC0xLTEtMzMyMDM_32a7df7d-47a8-412c-987c-ce0d6f3be685"
      unitRef="usdPerShare">8.17</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i94f2adcb200344b890fec8dc81de1ae6_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzYtMTAtMS0xLTMzMjAz_a776072c-bd53-4027-8b13-af1891d60caa"
      unitRef="shares">2557000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i94f2adcb200344b890fec8dc81de1ae6_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzYtMTItMS0xLTMzMjAz_7bec1555-10f4-4026-9c00-8ddda2e10ba3"
      unitRef="usdPerShare">6.78</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i1754ae6b09344ad1a9be3815a19dcd30_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzctMi0xLTEtMzMyMDM_300560f8-287d-4094-bd77-3f6872890b02"
      unitRef="shares">12349000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i1754ae6b09344ad1a9be3815a19dcd30_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzctNC0xLTEtMzMyMDM_adf08100-478c-4867-93e9-d54c7ca045a8"
      unitRef="usdPerShare">5.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i8686f139ef8d4193a880a31b12d0ce30_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzctNi0xLTEtMzMyMDM_e37aadac-8783-4130-8118-706a47ea8397"
      unitRef="shares">8367000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i8686f139ef8d4193a880a31b12d0ce30_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzctOC0xLTEtMzMyMDM_4d30e464-c4ad-413d-8843-1d57359a4a69"
      unitRef="usdPerShare">6.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i038e4801d2d648b38d0de7b8dab0f316_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzctMTAtMS0xLTMzMjAz_306ae95d-555b-4b33-8c1c-2784e735b287"
      unitRef="shares">8397000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i038e4801d2d648b38d0de7b8dab0f316_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzctMTItMS0xLTMzMjAz_59d24c41-1473-4732-af1c-265bea4b0d94"
      unitRef="usdPerShare">7.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i1754ae6b09344ad1a9be3815a19dcd30_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzgtMi0xLTEtMzMyMDM_058ce809-6636-4578-b9fc-7ba8ed899301"
      unitRef="shares">5747000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i1754ae6b09344ad1a9be3815a19dcd30_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzgtNC0xLTEtMzMyMDM_4958e93f-f0fc-4225-b6aa-bffef599b47b"
      unitRef="usdPerShare">7.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i8686f139ef8d4193a880a31b12d0ce30_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzgtNi0xLTEtMzMyMDM_b4b7e9f3-d88b-48de-8a7d-f8aa0d0cf906"
      unitRef="shares">5032000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i8686f139ef8d4193a880a31b12d0ce30_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzgtOC0xLTEtMzMyMDM_cf2b38c0-3152-4eef-aed0-ffdbccfc7322"
      unitRef="usdPerShare">7.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i038e4801d2d648b38d0de7b8dab0f316_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzgtMTAtMS0xLTMzMjAz_2967d9b5-7b5d-46ba-b8b5-72d12dd7b9d5"
      unitRef="shares">4684000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i038e4801d2d648b38d0de7b8dab0f316_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTo2MWRmY2RjOTg0ZWU0MWU3YjcwMDg5MjZmMTNjZWEwNS90YWJsZXJhbmdlOjYxZGZjZGM5ODRlZTQxZTdiNzAwODkyNmYxM2NlYTA1XzgtMTItMS0xLTMzMjAz_f2ae6b26-9dde-439e-819c-ca7153c94d29"
      unitRef="usdPerShare">9.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzMwMjE_b7c1006f-0a6f-4ee6-bb08-639b2016c5cd"
      unitRef="usdPerShare">2.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzMwMjU_8c824552-d243-4745-8b63-a1264c046936"
      unitRef="usdPerShare">4.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzMwMzI_6c707046-9e02-47ea-b872-fb1640152fa3"
      unitRef="usdPerShare">2.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzMxMzM_2d10d082-7559-4eca-aa82-68dac69b164a"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzMyMzU_ff4e3143-f9b1-4048-a007-e656b36181c8">P7Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzMyNDI_4bd2def6-f274-4421-808d-54eff7e36356">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzMzNTE_7397a8fb-86fd-4ae4-8d2d-80c716764408"
      unitRef="usd">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzM0MTY_2c394726-d216-4775-a8a4-5bd44813dde0"
      unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzM3NDE_66bc099d-c85a-42f4-9c0a-8701a0183d7d"
      unitRef="usd">2900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzM3NDU_a840f37d-ded3-4254-ba11-27441f7ff4f9"
      unitRef="usd">8700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzM3NTI_fd11d2e3-bc96-4b23-98ca-445245cf1bbd"
      unitRef="usd">3200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzEwOTk1MTE2MzI1ODc_d68241ad-979e-42a6-82d0-f0452d2919e3"
      unitRef="shares">74416</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzM4NTI_4fadc2c3-80ad-4cc9-9a41-77877b287cbd"
      unitRef="shares">32192</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzM4NTY_cc0e28c6-c055-4997-b1d4-faefac2b60ff"
      unitRef="shares">85104</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod>
    <lxrx:SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzEwOTk1MTE2MzI2MTA_402fadfa-3a12-42dc-80b1-5b3d6d5e5dd4"
      unitRef="usdPerShare">1.77</lxrx:SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue>
    <lxrx:SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzM5OTc_dc10afeb-72b3-4e4f-9cd7-b759f85ae050"
      unitRef="usdPerShare">5.04</lxrx:SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue>
    <lxrx:SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzQwMDE_5ba8f9e2-c938-4f3d-94c2-c85e1aea26f7"
      unitRef="usdPerShare">1.86</lxrx:SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzQ4MDE_7dac6ea3-6dc5-40d5-87f6-3284442f1678">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.103%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.567%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,012)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(279)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="idba6d48abf934e46bb6d9906a7959407_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTpiMTYwM2Q5YWM4Zjk0MGRkYjU5Yjg3Zjc1ZmU0OGMyZS90YWJsZXJhbmdlOmIxNjAzZDlhYzhmOTQwZGRiNTliODdmNzVmZTQ4YzJlXzItMi0xLTEtMzMyMDM_5aa4964e-f213-42d6-a2fd-c20fed5e754f"
      unitRef="shares">1854000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="idba6d48abf934e46bb6d9906a7959407_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTpiMTYwM2Q5YWM4Zjk0MGRkYjU5Yjg3Zjc1ZmU0OGMyZS90YWJsZXJhbmdlOmIxNjAzZDlhYzhmOTQwZGRiNTliODdmNzVmZTQ4YzJlXzItNC0xLTEtMzMyMDM_0be6f739-8ce5-4e44-8e76-275e772998b2"
      unitRef="usdPerShare">5.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="id0b2ee1a17b243b4a95803b356639783_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTpiMTYwM2Q5YWM4Zjk0MGRkYjU5Yjg3Zjc1ZmU0OGMyZS90YWJsZXJhbmdlOmIxNjAzZDlhYzhmOTQwZGRiNTliODdmNzVmZTQ4YzJlXzMtMi0xLTEtMzMyMDM_b5b7c7c9-928f-45a0-accc-d015eb74f19d"
      unitRef="shares">2185000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="id0b2ee1a17b243b4a95803b356639783_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTpiMTYwM2Q5YWM4Zjk0MGRkYjU5Yjg3Zjc1ZmU0OGMyZS90YWJsZXJhbmdlOmIxNjAzZDlhYzhmOTQwZGRiNTliODdmNzVmZTQ4YzJlXzMtNC0xLTEtMzMyMDM_22d5d54d-5603-4eb3-b135-be8f5c29c615"
      unitRef="usdPerShare">3.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="id0b2ee1a17b243b4a95803b356639783_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTpiMTYwM2Q5YWM4Zjk0MGRkYjU5Yjg3Zjc1ZmU0OGMyZS90YWJsZXJhbmdlOmIxNjAzZDlhYzhmOTQwZGRiNTliODdmNzVmZTQ4YzJlXzQtMi0xLTEtMzMyMDM_bfc2ff1a-4693-4aab-bf37-6d1f97bb28c9"
      unitRef="shares">1012000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="id0b2ee1a17b243b4a95803b356639783_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTpiMTYwM2Q5YWM4Zjk0MGRkYjU5Yjg3Zjc1ZmU0OGMyZS90YWJsZXJhbmdlOmIxNjAzZDlhYzhmOTQwZGRiNTliODdmNzVmZTQ4YzJlXzQtNC0xLTEtMzMyMDM_5106c131-9faf-461d-bab3-617f71abdf30"
      unitRef="usdPerShare">4.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="id0b2ee1a17b243b4a95803b356639783_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTpiMTYwM2Q5YWM4Zjk0MGRkYjU5Yjg3Zjc1ZmU0OGMyZS90YWJsZXJhbmdlOmIxNjAzZDlhYzhmOTQwZGRiNTliODdmNzVmZTQ4YzJlXzUtMi0xLTEtMzMyMDM_10f79c71-3ec9-484c-a064-2279d2fb813b"
      unitRef="shares">279000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue
      contextRef="id0b2ee1a17b243b4a95803b356639783_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTpiMTYwM2Q5YWM4Zjk0MGRkYjU5Yjg3Zjc1ZmU0OGMyZS90YWJsZXJhbmdlOmIxNjAzZDlhYzhmOTQwZGRiNTliODdmNzVmZTQ4YzJlXzUtNC0xLTEtMzMyMDM_e7a4299f-2b33-4078-a533-670514eb6d77"
      unitRef="usdPerShare">4.03</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="idc54e15956a14d6a8516b3a8816e8281_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTpiMTYwM2Q5YWM4Zjk0MGRkYjU5Yjg3Zjc1ZmU0OGMyZS90YWJsZXJhbmdlOmIxNjAzZDlhYzhmOTQwZGRiNTliODdmNzVmZTQ4YzJlXzYtMi0xLTEtMzMyMDM_32a3bc8b-a4c8-4f34-ae2d-4a04059fa7b3"
      unitRef="shares">2748000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="idc54e15956a14d6a8516b3a8816e8281_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90YWJsZTpiMTYwM2Q5YWM4Zjk0MGRkYjU5Yjg3Zjc1ZmU0OGMyZS90YWJsZXJhbmdlOmIxNjAzZDlhYzhmOTQwZGRiNTliODdmNzVmZTQ4YzJlXzYtNC0xLTEtMzMyMDM_b0a33b0e-363e-4797-b3c1-e422517bfd36"
      unitRef="usdPerShare">3.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:TreasuryStockPreferredValue
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzEwOTk1MTE2MzMwNTc_371d67bd-fe57-465b-8ba2-4987dcd05da0"
      unitRef="usd">6300000</us-gaap:TreasuryStockPreferredValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzQzMjU_b0becdee-614a-48b7-95ea-480e0dd081e7"
      unitRef="shares">15096609</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i024c9d1784a74539a536ca837e05f772_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODEvZnJhZzphMjAzODFmMzMyMjQ0NGJmOWU1MDBlNjU0ODllYTkzNC90ZXh0cmVnaW9uOmEyMDM4MWYzMzIyNDQ0YmY5ZTUwMGU2NTQ4OWVhOTM0XzQ0NzU_71008da4-a86b-4db3-ad21-7afe34562bee"
      unitRef="shares">8160575</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODQvZnJhZzowZTBjNjM1MmEyNTE0ODVmOGY2Y2M5YTUzZDA4YmUwYy90ZXh0cmVnaW9uOjBlMGM2MzUyYTI1MTQ4NWY4ZjZjYzlhNTNkMDhiZTBjXzY0NQ_6fec91d8-f7e1-46dc-8dc3-a0deecef6670">Benefit Plan&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lexicon maintains a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code.&#160;&#160;The plan covers substantially all full-time employees.&#160;&#160;Participating employees may defer a portion of their pretax earnings, up to the Internal Revenue Service annual contribution limit.&#160;&#160;Beginning in 2000, the Company was required to match employee contributions according to a specified formula.&#160;&#160;The matching contributions totaled $0.7 million, $0.4 million and $0.9 million in the years ended December&#160;31, 2022, 2021 and 2020, respectively.&#160;&#160;Company contributions are vested based on the employee&#x2019;s years of service, with full vesting after four years of service.&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODQvZnJhZzowZTBjNjM1MmEyNTE0ODVmOGY2Y2M5YTUzZDA4YmUwYy90ZXh0cmVnaW9uOjBlMGM2MzUyYTI1MTQ4NWY4ZjZjYzlhNTNkMDhiZTBjXzQ2Ng_0ecd2d60-48b8-4b69-9959-fc91b17c9769"
      unitRef="usd">700000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODQvZnJhZzowZTBjNjM1MmEyNTE0ODVmOGY2Y2M5YTUzZDA4YmUwYy90ZXh0cmVnaW9uOjBlMGM2MzUyYTI1MTQ4NWY4ZjZjYzlhNTNkMDhiZTBjXzQ3MA_fd8b0733-cc48-438c-b343-5540c1b349b6"
      unitRef="usd">400000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODQvZnJhZzowZTBjNjM1MmEyNTE0ODVmOGY2Y2M5YTUzZDA4YmUwYy90ZXh0cmVnaW9uOjBlMGM2MzUyYTI1MTQ4NWY4ZjZjYzlhNTNkMDhiZTBjXzQ3Nw_8f175efa-d3cd-4ecf-8ab7-37cd0fbdd985"
      unitRef="usd">900000</us-gaap:DefinedContributionPlanCostRecognized>
    <lxrx:DefinedContributionPlanRequisiteServicePeriod
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODQvZnJhZzowZTBjNjM1MmEyNTE0ODVmOGY2Y2M5YTUzZDA4YmUwYy90ZXh0cmVnaW9uOjBlMGM2MzUyYTI1MTQ4NWY4ZjZjYzlhNTNkMDhiZTBjXzYyOA_a49907eb-4d5e-434a-99d2-a4a7a0f4ba0e">P4Y</lxrx:DefinedContributionPlanRequisiteServicePeriod>
    <lxrx:FinalConsiderationIncludingAmountsReleasedToSettle
      contextRef="ief9b221acfd5465cb83500067a09fff2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzg2L2ZyYWc6MTkxMzYwNmNhYTc4NDBlNzkyYmY3ZDhlOTA0ODI1MDIvdGV4dHJlZ2lvbjoxOTEzNjA2Y2FhNzg0MGU3OTJiZjdkOGU5MDQ4MjUwMl81NDk3NTU4MTM5MTQ3_c6bc81ad-1a72-4cc4-b081-a2781eb5c44c"
      unitRef="usd">160000000</lxrx:FinalConsiderationIncludingAmountsReleasedToSettle>
    <lxrx:GainOnSaleOfNonFinancialAssets
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzg2L2ZyYWc6MTkxMzYwNmNhYTc4NDBlNzkyYmY3ZDhlOTA0ODI1MDIvdGV4dHJlZ2lvbjoxOTEzNjA2Y2FhNzg0MGU3OTJiZjdkOGU5MDQ4MjUwMl8xMDk5NTExNjI4ODY4_7275c45d-c702-4970-bbbe-04fe642ce7c8"
      unitRef="usd">132600000</lxrx:GainOnSaleOfNonFinancialAssets>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzg2L2ZyYWc6MTkxMzYwNmNhYTc4NDBlNzkyYmY3ZDhlOTA0ODI1MDIvdGV4dHJlZ2lvbjoxOTEzNjA2Y2FhNzg0MGU3OTJiZjdkOGU5MDQ4MjUwMl81NDk3NTU4MTM5NDYw_c36b5206-29d9-4569-81a4-dbf0a94f8b4a"
      unitRef="usd">-12200000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:SeveranceCosts1
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzg2L2ZyYWc6MTkxMzYwNmNhYTc4NDBlNzkyYmY3ZDhlOTA0ODI1MDIvdGV4dHJlZ2lvbjoxOTEzNjA2Y2FhNzg0MGU3OTJiZjdkOGU5MDQ4MjUwMl81NDk3NTU4MTM5Njc2_77708c85-b540-4531-8c48-7bf8ebd1a1cb"
      unitRef="usd">5500000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="i4aff0769c8dc406faa9ff4224da35cc9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzg2L2ZyYWc6MTkxMzYwNmNhYTc4NDBlNzkyYmY3ZDhlOTA0ODI1MDIvdGV4dHJlZ2lvbjoxOTEzNjA2Y2FhNzg0MGU3OTJiZjdkOGU5MDQ4MjUwMl81NDk3NTU4MTM5Njk3_9209a695-9c12-49f5-903f-3694860dc4d6"
      unitRef="usd">2500000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="id9c84c90905348f0bcea48d159d00b8e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xNzg2L2ZyYWc6MTkxMzYwNmNhYTc4NDBlNzkyYmY3ZDhlOTA0ODI1MDIvdGV4dHJlZ2lvbjoxOTEzNjA2Y2FhNzg0MGU3OTJiZjdkOGU5MDQ4MjUwMl81NDk3NTU4MTM5NzU0_a86d334b-32b5-4c9c-8356-fa7676c7cfe7"
      unitRef="usd">3000000</us-gaap:SeveranceCosts1>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODcvZnJhZzo4YjU4NDQwZWMxYjM0ZWI0YWNlMTExOGQyMzEwNmFjOC90ZXh0cmVnaW9uOjhiNTg0NDBlYzFiMzRlYjRhY2UxMTE4ZDIzMTA2YWM4XzUxNTM_a5f2bfa4-ca02-4b92-8340-10e6eb177940">Collaboration and License Agreements&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lexicon has derived substantially all of its revenues from drug discovery and development alliances, target validation collaborations for the development and, in some cases, analysis of the physiological effects of genes altered in knockout mice, product sales, government grants and contracts, technology licenses, subscriptions to its databases and compound library sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Ipsen.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  In October 2014, Lexicon entered into a License and Collaboration Agreement, which was subsequently amended in March 2015 (collectively, the &#x201c;Ipsen Agreement&#x201d;), with Ipsen&#160;for the development and commercialization of XERMELO outside of the United States and Japan (the &#x201c;Licensed Territory&#x201d;).  Revenue for the year ended December&#160;31, 2020 included $0.3 million of royalties from Ipsen and $1.3 million from sales of bulk tablets of XERMELO to Ipsen. The Ipsen Agreement was assigned to TerSera in September 2020 in connection with the XERMELO sale.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <lxrx:IpsenRevenueRecognized
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODcvZnJhZzo4YjU4NDQwZWMxYjM0ZWI0YWNlMTExOGQyMzEwNmFjOC90ZXh0cmVnaW9uOjhiNTg0NDBlYzFiMzRlYjRhY2UxMTE4ZDIzMTA2YWM4XzE5ODg_d53afa67-0a5d-4d94-b1aa-27543dff73e9"
      unitRef="usd">300000</lxrx:IpsenRevenueRecognized>
    <lxrx:Ipsenproductsales
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xODcvZnJhZzo4YjU4NDQwZWMxYjM0ZWI0YWNlMTExOGQyMzEwNmFjOC90ZXh0cmVnaW9uOjhiNTg0NDBlYzFiMzRlYjRhY2UxMTE4ZDIzMTA2YWM4XzIwNTU_435a1941-2934-4c44-888a-dbdbe3b36c20"
      unitRef="usd">1300000</lxrx:Ipsenproductsales>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xOTMvZnJhZzpiZWNkYTkwMDMzNTM0YTk3OGU1OTk2Yzk0OGYzN2FlYy90ZXh0cmVnaW9uOmJlY2RhOTAwMzM1MzRhOTc4ZTU5OTZjOTQ4ZjM3YWVjXzgy_7ed46289-38e4-4c1b-86c2-17a6ea15a931"
      unitRef="shares">20312500</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="ief9b221acfd5465cb83500067a09fff2_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xOTMvZnJhZzpiZWNkYTkwMDMzNTM0YTk3OGU1OTk2Yzk0OGYzN2FlYy90ZXh0cmVnaW9uOmJlY2RhOTAwMzM1MzRhOTc4ZTU5OTZjOTQ4ZjM3YWVjXzEyNg_8f5b4327-40fd-4cee-8665-e2ff3fa2738e"
      unitRef="usdPerShare">3.20</us-gaap:SharesIssuedPricePerShare>
    <lxrx:ProceedsFromDecember2020CommonStockOffering
      contextRef="ief9b221acfd5465cb83500067a09fff2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xOTMvZnJhZzpiZWNkYTkwMDMzNTM0YTk3OGU1OTk2Yzk0OGYzN2FlYy90ZXh0cmVnaW9uOmJlY2RhOTAwMzM1MzRhOTc4ZTU5OTZjOTQ4ZjM3YWVjXzI3Mw_a1037295-7369-4039-aac5-99ddc3874587"
      unitRef="usd">63000000</lxrx:ProceedsFromDecember2020CommonStockOffering>
    <lxrx:CommissionsFromDecember2020CommonStockOffering
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xOTMvZnJhZzpiZWNkYTkwMDMzNTM0YTk3OGU1OTk2Yzk0OGYzN2FlYy90ZXh0cmVnaW9uOmJlY2RhOTAwMzM1MzRhOTc4ZTU5OTZjOTQ4ZjM3YWVjXzMzNQ_d383aee6-91ac-408e-a974-3204d1213dab"
      unitRef="usd">1800000</lxrx:CommissionsFromDecember2020CommonStockOffering>
    <lxrx:OfferingExpensesFromDecember20CommonStockOffering
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xOTMvZnJhZzpiZWNkYTkwMDMzNTM0YTk3OGU1OTk2Yzk0OGYzN2FlYy90ZXh0cmVnaW9uOmJlY2RhOTAwMzM1MzRhOTc4ZTU5OTZjOTQ4ZjM3YWVjXzM2Mw_0f14db88-e86a-4616-a719-63749618be1f"
      unitRef="usd">200000</lxrx:OfferingExpensesFromDecember20CommonStockOffering>
    <lxrx:ATMOffering2020Total
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xOTMvZnJhZzpiZWNkYTkwMDMzNTM0YTk3OGU1OTk2Yzk0OGYzN2FlYy90ZXh0cmVnaW9uOmJlY2RhOTAwMzM1MzRhOTc4ZTU5OTZjOTQ4ZjM3YWVjXzEwOTk1MTE2MzI0MTc_b9826152-f003-493d-986a-6bbdee00f54c"
      unitRef="usd">50000000</lxrx:ATMOffering2020Total>
    <lxrx:SharesSoldInNov2020ATMOffering
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xOTMvZnJhZzpiZWNkYTkwMDMzNTM0YTk3OGU1OTk2Yzk0OGYzN2FlYy90ZXh0cmVnaW9uOmJlY2RhOTAwMzM1MzRhOTc4ZTU5OTZjOTQ4ZjM3YWVjXzEwOTk1MTE2MzA1NjA_002ef5ba-00b8-4ef9-abf7-d47b610e01c3"
      unitRef="shares">3709233</lxrx:SharesSoldInNov2020ATMOffering>
    <lxrx:SharePriceInNovember20ATMOffering
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xOTMvZnJhZzpiZWNkYTkwMDMzNTM0YTk3OGU1OTk2Yzk0OGYzN2FlYy90ZXh0cmVnaW9uOmJlY2RhOTAwMzM1MzRhOTc4ZTU5OTZjOTQ4ZjM3YWVjXzEwOTk1MTE2MzA2MDU_be3aeba9-87ff-4667-97a4-693d32db8a29"
      unitRef="usd">1.992</lxrx:SharePriceInNovember20ATMOffering>
    <lxrx:ProceedsFromNov2020ATMOffering
      contextRef="i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xOTMvZnJhZzpiZWNkYTkwMDMzNTM0YTk3OGU1OTk2Yzk0OGYzN2FlYy90ZXh0cmVnaW9uOmJlY2RhOTAwMzM1MzRhOTc4ZTU5OTZjOTQ4ZjM3YWVjXzEwOTk1MTE2MzA2ODE_68d0a6ae-60db-437c-bfd4-e8e1f9c05b3d"
      unitRef="usd">7000000</lxrx:ProceedsFromNov2020ATMOffering>
    <lxrx:SharesSoldInJanuary2021ATMOffering
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xOTMvZnJhZzpiZWNkYTkwMDMzNTM0YTk3OGU1OTk2Yzk0OGYzN2FlYy90ZXh0cmVnaW9uOmJlY2RhOTAwMzM1MzRhOTc4ZTU5OTZjOTQ4ZjM3YWVjXzEwOTk1MTE2MzA3MTc_e47069a5-3461-4232-8d07-39a02ea5b4c0"
      unitRef="shares">2000000</lxrx:SharesSoldInJanuary2021ATMOffering>
    <lxrx:SharePriceInJanuary2021ATMOffering
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xOTMvZnJhZzpiZWNkYTkwMDMzNTM0YTk3OGU1OTk2Yzk0OGYzN2FlYy90ZXh0cmVnaW9uOmJlY2RhOTAwMzM1MzRhOTc4ZTU5OTZjOTQ4ZjM3YWVjXzEwOTk1MTE2MzA3NjI_0e1c429c-f440-4cdd-81a2-8b3b42a44bc7"
      unitRef="shares">8.463</lxrx:SharePriceInJanuary2021ATMOffering>
    <lxrx:ProceedsFromJanuary2021ATMOffering
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xOTMvZnJhZzpiZWNkYTkwMDMzNTM0YTk3OGU1OTk2Yzk0OGYzN2FlYy90ZXh0cmVnaW9uOmJlY2RhOTAwMzM1MzRhOTc4ZTU5OTZjOTQ4ZjM3YWVjXzEwOTk1MTE2MzA4Mzg_854b09d3-ecc5-493c-bddc-497e5e13412f"
      unitRef="usd">16400000</lxrx:ProceedsFromJanuary2021ATMOffering>
    <lxrx:SharesSoldInSeptember2021ATMOffering
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xOTMvZnJhZzpiZWNkYTkwMDMzNTM0YTk3OGU1OTk2Yzk0OGYzN2FlYy90ZXh0cmVnaW9uOmJlY2RhOTAwMzM1MzRhOTc4ZTU5OTZjOTQ4ZjM3YWVjXzEwOTk1MTE2MzA5MDI_71cc7521-3536-4403-8592-42fa7b931465"
      unitRef="usd">4176953</lxrx:SharesSoldInSeptember2021ATMOffering>
    <lxrx:SharePriceInSeptember2021ATMOffering
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xOTMvZnJhZzpiZWNkYTkwMDMzNTM0YTk3OGU1OTk2Yzk0OGYzN2FlYy90ZXh0cmVnaW9uOmJlY2RhOTAwMzM1MzRhOTc4ZTU5OTZjOTQ4ZjM3YWVjXzEwOTk1MTE2MzA5NDc_97812d59-433d-427b-a29a-65ca6359f5cf"
      unitRef="usd">4.732</lxrx:SharePriceInSeptember2021ATMOffering>
    <lxrx:ProceedsFromSeptember2021ATMOffering
      contextRef="i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xOTMvZnJhZzpiZWNkYTkwMDMzNTM0YTk3OGU1OTk2Yzk0OGYzN2FlYy90ZXh0cmVnaW9uOmJlY2RhOTAwMzM1MzRhOTc4ZTU5OTZjOTQ4ZjM3YWVjXzEwOTk1MTE2MzEwMjM_d0460e22-21b8-46b4-95af-62da5e30d252"
      unitRef="usd">19100000</lxrx:ProceedsFromSeptember2021ATMOffering>
    <lxrx:SharesSoldInJuly2022Offering
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xOTMvZnJhZzpiZWNkYTkwMDMzNTM0YTk3OGU1OTk2Yzk0OGYzN2FlYy90ZXh0cmVnaW9uOmJlY2RhOTAwMzM1MzRhOTc4ZTU5OTZjOTQ4ZjM3YWVjXzEwOTk1MTE2Mjk5MTM_7615ec3d-a3d6-415a-a802-f3492bb32493"
      unitRef="shares">39100000</lxrx:SharesSoldInJuly2022Offering>
    <lxrx:SharePriceInJuly2022Offering
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xOTMvZnJhZzpiZWNkYTkwMDMzNTM0YTk3OGU1OTk2Yzk0OGYzN2FlYy90ZXh0cmVnaW9uOmJlY2RhOTAwMzM1MzRhOTc4ZTU5OTZjOTQ4ZjM3YWVjXzEwOTk1MTE2Mjk5NTg_53a6a494-e691-49ed-a3ba-e6b22113e9b9"
      unitRef="usd">2.50</lxrx:SharePriceInJuly2022Offering>
    <lxrx:ProceedsFromJuly2022Offering
      contextRef="ied714a94cdc9470b8062452bba89125d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyMmQzYWUzZDczMjQ1YjU4NWJkN2YwNDBhZmQ3OTVjL3NlYzoxMjJkM2FlM2Q3MzI0NWI1ODViZDdmMDQwYWZkNzk1Y18xOTMvZnJhZzpiZWNkYTkwMDMzNTM0YTk3OGU1OTk2Yzk0OGYzN2FlYy90ZXh0cmVnaW9uOmJlY2RhOTAwMzM1MzRhOTc4ZTU5OTZjOTQ4ZjM3YWVjXzEwOTk1MTE2MzAwODk_89595b1f-86c3-4670-861d-d1184615e9c7"
      unitRef="usd">94200000</lxrx:ProceedsFromJuly2022Offering>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>71
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( "X[8U8'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    "  N.V-6-G^3Y>T    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M2L0P$(9?17)OITW10^CVLN))07!!\18FL[O!I@G)2+MO;UIWNX@^@)!+9OY\
M\PVDQ:#01WJ./E!D2^EF<OV0%(:-.#('!9#P2$ZG,B>&W-S[Z#3G:SQ T/BA
M#P2RJN[ $6NC6<,,+,)*%%UK4&$DS3Z>\097?/B,_0(S"-23HX$3U&4-HILG
MAM/4MW %S#"FZ-)W@<Q*7*I_8I<.B'-R2G9-C>-8CLV2RSO4\/;T^+*L6]@A
ML1Z0\JMD%9\";<1E\FNSO=\]B$Y6LBFJ^>QJJ>2MJIOWV?6'WU78>6/W]A\;
M7P2[%G[]B^X+4$L#!!0    ( "X[8U:97)PC$ 8  )PG   3    >&PO=&AE
M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X?
MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@
MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?<D3$L/<@HL(2W@4R]9<
MX%L:+R/6ZK3;W5:$:6RA&$=D8'U>+&A T%116F]?(+3E'S/X%<M4C66C 1-7
M02:YB+3R^6S%_-K>/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1
MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP
M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?=
MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP
M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%,
M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I
MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88<G;CL3<CH<9T)\S_;VD:4E
M,L_O^0KK3CQG'U:6L%W/S^2>C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ
MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A
M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;S<HY=8%0&7&-\TJC4LQ=9XE<#QK9P\
M'1,2S90+!D&&ER0F$JDY?DU($_XKI=K^G-- \)0O)/I*D8]ILR.G=";-Z#,:
MP4:O&W6':-(\>OX%^9PU"AR1&QT"9QNS1B&$:;OP'J\DCIJMPA$K0CYB&38:
M<K46@;9QJ81@6A+&T7A.TK01_%FL-9,^8,CLS9%USM:1#A&27C="/F+.BY 1
MOQZ&.$J:[:)Q6 3]GE[#2<'H@LMF_;A^AM4S;"R.]T?4%TKD#R:G/^DR- >C
MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_
M+GW/I>^Y]#VATK<W(WUGP=.+6]Y&;EO$^ZXQVM<T+BAC5W+-R,=4KY,IV#F?
MP.S]:#Z>\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE"<M4TV4WBA*>
M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT
ML<QP3A[+##MG/)(=MG>@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3
M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.'
M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\
M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^
M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON<K2<15.+]%,[82EQB\X^;'
M<4Y3N!)VM@\",KF[.:EZ93%GIO+?+0P)+%N(61+B35WMU>>;G*YZ(G;ZEW?!
M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4<!A87,N10[I*0
M!A,!S93)1/ "@F2F'("8^@N]\@RY*17.K3XY?T4L@X9.7M(E$A2*L P%(1=R
MX^_ODVIWC-?Z+(%MA%0R9-47RD.)P3TS<D/85"7SKMHF"X7;XE3-NQJ^)F!+
MPWING2TG_]M>U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83
M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL'
M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M$-H YQ><JY>!;ESJ1G7R%U!+ P04    "  N.V-6YR+ JE &  #I&0  &
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M4%D'.E]*:7:&_4#W7TK_ E!+ P04    "  N.V-6)E>+^T$+  "*6P  &
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MEH6DXLS'WN%9<(OQ!?Q[DD?XWC%RG+DUW2 $F,_@;3Q\J >'7,*7=L8UMEZ
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MN)1JW8,=W_5DN\"#@A?]T]P[$@Y!6C:BEAUZ1O!RKW:MKM#2YU_#JVAQYW^
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M+RDKB6B>LQ1:,AS-%C,7,&13@%\%$1EN#.*>!_@2VN,[2F\6;@4"%.O0H=X
M',)O.M2#V1'3$"4 A9AP=C#&44$YDFD*IQI?:P*X)#3!JGFZ@.@$?6:*4J)
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M:'.^T1C!"[A=B']!3AR8GL(P2W@ Y+<-)=0]B\PCF@ ]B^.9,FJN Q=2FKQ
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M,-@F[B:QY;T&+;$&CV\UB&WD4Y(!(B$N[Z6MJ.&,M=YM=,DTQJRNM956\<I
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MGC?@^]JY.+ZP@^E&O/P74$L#!!0    ( "X[8U:(;^>%C0T  &4H   9
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MK64SK D[Q?5??YD%@7?12T%K_L69R_X$RGXF&Z&*S&B2M5*\-$PN6=;2:#)
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MVJZ%I_9W=*9*.M*4*&&"$EKO@'[ KD&1L<,-F@X]K)UMH'1=!:7RTF[0[6*
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M Y>>Q#0)MHW/T,H&>M3BL*9_$>C8@/;7UH;]A ,,_TN6_P%02P,$%     @
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M4U9%M=XI0<ID2(HJ"Z-($SZ6EC[=MFQ'4^W[%DXT21@X4 HZ5C+-C-397\_
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MCCBL9I[^XE^_[0#P=NHVV\"64R&WE^W E+P'Z; ]D;5"?.;+U=_ *#I-H+B
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M:LM_4E+9.'H!WZ\J(%+_@1:(O^3T\E]02P,$%     @ +CMC5OZ'2=W( @
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M=5Y[<%N40FV1DA%'5PU(FMT&M"&"!CSD5*FH#3!"2B7/<6<*&=?$KNCJ*FY
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M4-D-M+Z6TNP5&Z#_VYC]!5!+ P04    "  N.V-6Y^HM\.$"  !!!P  &0
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M;U36@<Y3*<W.L!>T_X/97U!+ P04    "  N.V-6B&/.A50$  #Q"0  &0
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MQ)#0*L=[L?T"C1Z;8"1R97_)MHGU'!)5"D71@'4&!>/UE3XV/NP!_-$10-
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M%5 V )^OI32/$[M!^P&4_ -02P,$%     @ +CMC5DD3Y= ,!   XQ,  !D
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M?'10 BFNJ+KC]1=H\[$!QIQ*^T1UZ^LY**ZDXD4+UA$4A#5O_-CJL 'PS[8
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M77P@DKII0\W"JMJ7_EQ9:B1^6E+G1NT,Z'RAE-TOW 7MOR#[ U!+ P04
M"  N.V-6HIP!8$\"   8!@  &0   'AL+W=O<FMS:&5E=',O<VAE970S-2YX
M;6RM55%OFS 0_BL6JZ966@*!-*DZ0&J#IE7:IBA9MX=I#PX<8-78S#:A^_>S
M#<F2E4QYZ O<V?=]Y_O,'6'+Q9,L 11ZKBB3D5,J5=^ZKDQ+J+ <\QJ8WLFY
MJ+#2KBA<60O F055U/4];^96F# G#NW:4L0A;Q0E#)8"R::JL/A]#Y2WD3-Q
M=@LK4I3*++AQ6.,"UJ >ZZ70GKMGR4@%3!+.D( \<NXFMTE@XFW -P*M/+"1
MJ63#^9-Q'K+(\<R!@$*J# /6KRTL@%)#I(_QJ^=T]BD-\-#>L7^PM>M:-EC"
M@M/O)%-EY-PX*(,<-U2M>/L1^GJN#5_*J;1/U':Q\[F#TD8J7O5@?8**L.Z-
MGWL=#@"3Z0F WP/\<P%!#PC.!4Q[P-0JTY5B=4BPPG$H>(N$B=9LQK!B6K0N
MGS!S[6LE]"[1.!6O( 6FT%V:\H8IP@JT%)QI.P5]N4JBRP04)E1>H1%Z7"?H
M\N(*72#"T->2-Q*S3(:NT@<Q=&[:)[WODOHGDB:0CE$P>8=\S_<'X(OSX9,!
M>'(^W#N&NUJ]O83^7D+?\@4G^+[HC_NT?ER@18E9 4:SHS#"4E)30#\^:4+T
MH*"2/X>T[+)/A[.;L7 K:YQ"Y.B^ER"VX,1OWTQFWOLA95^3+'DELB/5@[WJ
MP?_88SN@1CP?-1(0EA+4X(?8D5Q;$C,"M_'LQM.WOCT4Y660'_P;E+P,^AO1
M5> >M*&9F9^Q* B3B$*N,=YXKL&BFT.=HWAM.W/#E>YS:Y9Z=(,P 7H_YUSM
M'-/L^Y]!_ =02P,$%     @ +CMC5@;_8A'W!   NQT  !D   !X;"]W;W)K
M<VAE971S+W-H965T,S8N>&ULQ5EA;YLX&/XK%C>=-FDIV!!">FFD-MWM)MVD
MJEGO/KN)VZ !SFR3;/?KSQ"* 3M>4^C=EQ;(^SY^'_O-DP=[MJ?L*]\0(L#W
M-,GXA;,18GONNGRU(2GF9W1+,OG) V4I%O*6/;I\RPA>ETEIXB+/"]T4QYDS
MGY7/;MA\1G.1Q!FY88#G:8K9CRN2T/V% YVG![?QXT84#]SY;(L?R9*(N^T-
MDW=NC;*.4Y+QF&: D8<+YQ*>+WQ4))01?\5DSQO7H*!R3^G7XN;3^L+QBHI(
M0E:B@,#RWXXL2)(42+*.;Q6H4X]9)#:OG]!_+\E+,O>8DP5-_H[78G/A1 Y8
MDP><)^*6[O\@%:%Q@;>B"2__@GT5ZSE@E7-!TRI95I#&V>$__EY-1",!AD<2
M4)6 N@G!D02_2O!+HH?*2EK76.#YC-$]8$6T1"LNRKDILR6;."N6<2F8_#26
M>6*^P'P#<+8&Y<6';WF\PPG)!"\??LIVA(NTO'][302.$_X.C,#=\AJ\??,.
MO %Q!KYL:,YE-)^Y0E94X+JK:O2KP^CHR.@0@<\T$QL./F1KLFX#N))*S0<]
M\;E"5L1KLCH#/GP/D(>0H:#%\].AI1R_GEZ_Q/-/G5[37!V@ C-4\7T^YUN\
M(A>._,)RPG;$F?_Z"PR]WTP\!P)KL0YJUH$-?7Y+<!+_0YK] SY*29%-]"?E
MG/!W)OH'S'&)6:C/;N[-W%V3DW74%W(:UYS&5DZ7.]G\^#XA(ZF=(RY7$2S)
M*F>QB E_#RY3RD3)>4&Y %>8Q\8U/@P2-DC"*(!1A^A8FPH4>HVH%H.P9A#V
M8?"1R:4!=QE[6KQBQ<#E:I6G>8*%?"!O&X)@8A=J[+I+J$>,S:PF-:O)H*P.
M#6@J?J*5-HK"3OF&& C-!**:0-2'P")G3$ZWJ>#(T$N^CSHEZU%%+R%ST=.Z
MZ*FUZ$+.3"59LTZ5L(' 6@2AIWX8O>&DN\(:B/A0:&WF#4L _PNIJT9I=EX0
M^L&XTY^&L##PPM#<H! I%NC_EKNJ IO>64/:S)2G@-8?[P$EKQK(2D /.2)X
M4-D#:/<'+Y>\"OBG/:6'%3UUY*<&*@\ [2;@;@F^R&GE.?O1J-A8J!7H9$$8
M"*U-6QD'& XHA587<C+S@=#:S)6Y@+W<Q;.E4/<-DZ!\06FWK;68EY)51@3V
M<B*#**;N1C3!L1;YTDE0Q@;:G<V XCK5S:(?:&O^&BX'*9>#K%ZBAQ17P*V>
M]L.HNYSV\5_*3WD99/<RRXW\AHX$8>G/6M,.=*IN#876IJW,#T+#*3:R&JF3
MF0^$UF:NS!'J98Z>J]A(MSU3% 1:=^MAEC=UI!P2ZN60AI!BI'LDC9T><L1"
M(66A4*]]E!/T%>E[*:, =;=23%''7MF1<D2HUUZ*33;U'9 I:KZ/5V7K89;7
M=J0,#;(;FF?O]QIK'\B?5!1?P^T@Y790-*!$#F1**N:O87&0LCBHE\5YMD3J
M_@;ZT23JOHP9XJ:>%P7F5O:5=?%[69<A--+7/4Y7(PTA1S325Z;%[[4!<X)&
M^OKFBD$C35''I,97'L3OM0%CT<@*>-SN+'\\Z=:MQ\G.FDPZE;N-X[&4L,?R
MU)"#%<TS<3@IJY_6)Y.7Y7F<J\(/QYJ?,7LLSC$2\B!3O;.)')L=3@H/-X)N
MR\.V>RH$3<O+#<%KPHH ^?D#I>+IIAB@/J^=_PM02P,$%     @ +CMC5B2=
MJM2[ P  AQ,  !D   !X;"]W;W)K<VAE971S+W-H965T,S<N>&ULO5A=CYLX
M%/TK%JVJ5IH9, 3(3)-(G:2S6ZF51DW;??:0F\2JP:EMDNZ_7QL8/@+#-A+)
M2X+AWN-S+O;-B2<'+G[*+8!"OV.6R*FU56IW9]LRVD),Y W?0:*?K+F(B=)#
ML;'E3@!994DQLUW'">R8T,2:3;)[CV(VX:EB-(%'@60:QT3\>P^,'Z86MIYO
M?*6;K3(W[-ED1S:P!/5]]RCTR"Y15C2&1%*>( 'KJ?4!W\U=QR1D$3\H'&3M
M&ADI3YS_-(-/JZGE&$; (%(&@NBO/<R!,8.D>?PJ0*UR3I-8OWY&?\C$:S%/
M1,*<LW_H2FVGUMA"*UB3E*FO_/ W%()\@Q=Q)K-/=,AC ]]"42H5CXMDS2"F
M2?Y-?A>%J"7@T0L);I'@_FF"5R1XF="<629K0129300_(&&B-9JYR&J396LU
M-#&O<:F$?DIUGIH]$"K0#\)20%^ R%2 ?D=*HK<+4(0RB? [=(V^+Q?H[>MW
MZ#6B"?JVY:DDR4I.;*49&!P[*F:[SV=S7YAM =$-\O 5<AW7[4B?_WDZ;J;;
M6G<IWBW%NQF>][_BK] ]822) "VSS?.7X.F.)ILK]$ 3?9\2AI:*J*PZ:$YV
M9@UV%B"?<=0]H]F4=W)'(IA:>M=)$'NP9F]>X<!YWU6.@< :Q?'*XGA]Z+,Y
MD5ND7S/*+C[^2NF>,+,V=$VJ1;.@,F+<K)NN8N0S^-D,IJ'L9Z/ &_D3>U]7
MV8X*1DY0137HCTKZHU[Z'_9Z^9(G!M>ZUUU+31TM(4H%511.D9#/$M3(W;H.
M=H\DM*-<-PC'W1+\4H+?*^%3L@>IXA-K[K>H8&_L^>$1XW;8. A'7C?CH&0<
M]#*N;ZC/L >&<!?%7I!3]\A 8 V]8:DWO'@#"8<LSD!@C>*,R^*,S]Y QJU5
MVM5 VE$]#>2VI'][D09RVR(7>L'8.9+0$>4'N%L!=JH?=^<,':0 ;;00;0O=
MX[)WQ(4X<(,76-<L"3ZQBW1YA?M^E%-WRE!H3<V5$\&7MR)X4"\R%%JS0)4;
MP>>W(\44]05[O ][0YK4*R>"+V-%<-MEX+'G'7N1KC ?X_ %&94;P>>P([C#
MCW21[@CK(5T9$GRJ(_$Z60YJ289":VJN3 F^O"O!@]J2H=":!:J,"3Z_,\%M
MT]'J)7TA3>J5*<&7<26X;3A:]/M"FO^W*T/BGL.0%*!^#]G>D)RL73LE,4=4
M7XC8T$0B!FN=X]R$.EGDIS[Y0/%==G#RQ)7B<7:Y!;("80+T\S7GZGE@SF+*
ML[?9?U!+ P04    "  N.V-6UFMXQ!L'  "&1   &0   'AL+W=O<FMS:&5E
M=',O<VAE970S."YX;6RUG%UOVS84AO\*X0U#"Z2U1,E?66(@,=FN0+,%#;I=
M#+M093H6*HDN1>5CV(\?)3NF&4O'47!\DUBRSD/RO-*Q7E/FV;U4WXNE$)H\
M9&E>G/>66J].^_TB7HHL*M[+E<C-.PNILDB;377;+U9*1/,Z*$O[U/.&_2Q*
M\M[TK-YWK:9GLM1IDHMK18HRRR+U>"E2>7_>\WM/.[XDMTM=[>A/SU;1K;@1
M^NOJ6IFM_I8R3S*1%XG,B1*+\]Z%?\K#H JHC_@S$??%SFM2#>6;E-^KC4_S
M\YY7]4BD(M85(C+_[L1,I&E%,OWXL8'VMFU6@;NOG^@?ZL&;P7R+"C&3Z5_)
M7"_/>^,>F8M%5*;ZB[S_36P&-*AXL4R+^B^YWQSK]4A<%EIFFV#3@RS)U_^C
MATTB=@(,ISF ;@+H\X!A2T"P"0B>!X0M >$F('QIP& 34 ^]OQY[G3@6Z6AZ
MIN0]4=71AE:]J+-?1YM\)7EUHMQH9=Y-3)R>7BMSSBG]2*)\3OB/,EF9LT"3
M-TSH*$F+M^0=^7K#R)N?WY[UM6FOBNK'&_;EFDU;V#ZYDKE>%H3G<S%OB)\=
MB*< H&\&NATM?1KM)06)%^7M>Q+X)X1Z_KBI0W X$_%3.*4-X>SEX5Y#.']Y
MN \D(]A*']2\X(#T)^0ZC8SF[AGP]V=S./FD15;\TR3]FATVLZOR=EJLHEB<
M]TS]*H2Z$[WI+S_Y0^_7IK1CPA@FC"/!'('"K4 A1)_R0B>F%(HY^5J(19F2
MSZ:F%DUBP!S?(X\B4DV1,S"R:^8Q81P)YF1^L,W\ ,P8>&F<D(]*%HTZ@-2N
M%\4:-JAAU>?]W73H#0:>9TK'W6[6,1OE38W2R6ZC3D*'VX0.P81>Q'&9E6E]
M,C-A.A(G476C<%)MI6)]SV"2?)%)I9-_-^\]D^'$U:%) + 77058PX8[N7@7
M3,;AO@*8K?*&5L/Q(&B58+258 1*\+NYZUSM?MH+*)$@JVLB1WM#HM[(W\\C
M9J-\OU'?'PU;TSC>IG%\J#3$0LP+LE R(S=1*HA<D,LR2>=)?MM8%4!@UUQB
MPMAX[VKW?<\/]I3A2*TZ&9]L,SZ!3UR9QU&Q)%*1ZTAI\K3-JD]#G>A2B9.J
M<)2F4!LI9M*XF+E0=0TA7T0LS'%-=Y^78+-==9GLGVY5'O?.<<Q&.1+,D<7W
MK'7PX$LA>JS*1T&T)!>QJ29*D#_T4JA7%&ZXJ:YB;&B#@VJ@-LNQ:*X>.U;.
M!_6X2O(D*[/&](*1G=.+26.H-(Y%<S6@5@-Z1%.U@6/)A$ECJ#2.17-ELM;7
M!XU;!VL%@SI+ G<K:#5J#+4?'(OFIM\:6Q]VI%?10VNEPC21,U0:0Z5Q+)JK
M@;6X_N"8E0K5ZJ+2&"J-8]%<F:QQ]F'GW*%2H9K? ]T*V[]38J@=X5@T-__6
M-?NP;9[);%5JH8KZ KF1"WT?*=&8?U3/C$ICJ#2.17,EL0[<'Q^S<J':<50:
M0Z5Q+)HKD[7M/NS;7_LE*HSM+-!DSPI2ZDT:K""J,_?WOP\(/#IJ_?J)6M=-
M8=?=7)#(?P2P?S"R:TI1:0R5QK%HKCC6@E/_B*6)HKIT5!I#I7$LFBN3=>D4
MM)<=;JI@4&=)X&X!]@^U'QR+YJ;?NF\*V]SV$M;N"V%D9R%09YQ1:1R+YHIC
MO3D-CUG"4.T[*HVATC@6S97)VG<*3U%W*&&H5OU MP9 "4.UY5@T-_W6EE/8
M_WXH55Y//=77QX?DH7K=G'Y46XY*8Z@TCD5S);%.G8Z.6;A0W3LJC:'2.!;-
ME<FZ=WIP OU5MA#&=A:H8>I[-&EXM@.U6;ZA.=/$PPEMMX76;5/8;3<7I .V
M$-5IH](8*HUCT=P'+:UG#[PCEJ8 U;VCTA@JC6/17)FL>P_@"?27WU/!H,Z2
MP-T"[JE0^\&Q:&[ZK2L/8/O;7L+:;2&,["P$ZHPY*HUCT5QQ=AX6/^K3XKB/
MB^,^+X[[P/@QW'M@W7L SZQW*&&H3OU MT9 "4-UY5@T-_W6E0>P_?TLHD(L
M93HGG[*5DG>B?D"N,?VHKAR5QE!I'(OF2F*=>C \9N%"=>^H-(9*XU@T5R;K
MW@-XGOVUMA#&=A9HM#];Z WHOBU$;98W-.L'OM=J"P/KM@/8;3<7)-@6PLC.
M*46=(4>E<2R:*X[U[,'DF*4)U;VCTA@JC6/1W%_A6?<>PC/N'7Z'A^K4#W0+
MF"U$[0?'HKGIMZX\A.UO>PEKMX4PLK,0J#/IJ#2.17/%L9X]/.;S[B&J>T>E
M,50:QZ*Y,EGW'F(][PZ#.DL"=PNPA:C]X%BT=?K[.^LM9$+=U@M=%"2N?H*V
M7HQ@NW>[F,9%O83$L_TS_Y2ME\2PF/4*'5>1NDWR@J1B89#>^Y&Y-U3K12_6
M&UJNZE4=ODFM95:_7(IH+E1U@'E_(:5^VJ@:V"X],OT?4$L#!!0    ( "X[
M8U:RZ1F"M@0  )06   9    >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;+58
M;7.;.!#^*QJN<]/.)#$2+[93VS.):>\RDS:9I&_?;A2\-EP!^20Y3O_]28"Q
M#0IU&.>++<3N:I^'13S:T9KQGR("D.@I33(QMB(IE^>]G@@C2*DX8TO(U)TY
MXRF5ZI(O>F+)@<YRIS3I$=OV>RF-,VLRRN=N^63$5C*),[CE2*S2E/)?EY"P
M]=C"UF;B+EY$4D_T)J,E7< ]R*_+6ZZN>E6469Q")F*6(0[SL76!SP,\U ZY
MQ;<8UF)GC#24!\9^ZHNKV=BR=4:00"AU"*K^'F$*2:(CJ3S^*X-:U9K:<7>\
MB?XQ!Z_ /% !4Y9\CV<R&EL#"\U@3E>)O&/KOZ$$Y.EX(4M$_HO6I:UMH7 E
M)$M+9Y5!&F?%/WTJB=AQP/XS#J1T('4']QD'IW1P#G5P2P<W9Z: DO,04$DG
M(\[6B&MK%4T/<C)S;P4_SO1SOY=<W8V5GYQ<92%+ 7VA3R#0VP DC1.!\#MT
MBK[>!^CMFW?H#8HS]"5B*T&SF1CUI%I6._?"<HG+8@GRS!*8H$\LDY% '[(9
MS/8#]%2^5=)DD_0E:8T80'B&''R"B$V((:'IX>[8X!X<[FZWH'&J1^#D\9QG
MX\V!<YCIAX NA  ID&(:7<?T(4YB&8.1]"*H:PZJMXMSL:0AC"VU'PC@CV!-
M_OP#^_9[$V''#!8<*=@>F6Y%IML6W43F";I9 J<RSA;HF@F!II3S7VK+7%-N
MKN=B"2]?0F^<CQ/B8<=1M?*X2YK!C Q=TM\W"UH3[DB'5]'AO9P./9ZJR5CN
M4W&"[E0"E(>1B91B(7\7[9 ,[1HG!UD%K4EWI,2O*/&/2<D-7T8T0P%?+4RL
M^$V\KD?<&BL'606M>7=DI5^QTG\Y*U<9NN4L!/7.;"HCWYD">%2"8:D^_]+$
M2;^!UG$&V*EQ8K#R^_UZI;1FW9&30<7)H%NE5#<^/"G])> $35FJ1[30,HJB
M2\A@'FN'^XAR.-7:9+9O-F7"2-^@08SGNEZ-/8,1]FL4!ZWP.I(WK,@;=MB(
M903<A'G8?$&(5\?<-,*./:AA;LVJ(V9L;]64_7+4?W'UU3'J)KOY#KA]V_-K
MP$UVQ/>=^LO2GEQ7\#M2$A\.?D>]M#SW,N(NLE-,AO4G;S)S,:G#;TVO*WRR
MA4\ZPG^^ ,AA\ UF!OBMZ76%OU6QN%77F4O_&TU6Q6YWD:@C)LU",/+@- $Z
MKM?WZY++:$A\@NO;0'NR7<G8JE#\ AFZ5PN?P;CIE_%V@=6EU>]-@O:LNJ+>
MBDW<KC:WA\G-]\\(M:D1&U!_:Q*4)I[19#__K3+$[=)0'^C01YBITT*"/M]<
MJX-OR$%]N8TPFJ(.VZYM-[ <2=:5L%]#).*M2L0=9.)]V<-1 N3??ZY_W/TP
MTF70>\-!G:M^XZ%BM_%JOX8FQ%M1B-M58=MA\F13/48&FIH-$]LV5,R1=%M)
MUVNH0+R5@;B+#FSE,%";B)!Q:"1QV*@0UU5*J,'AD71@R>%1565OIUV7 E_D
M;4^!0K;*9-$$JV:KUNI%WE"LS5_JEFO>!MR&*?JUGRA?Q)E "<Q52/NLKPCC
M10NTN)!LF3<%'YB4+,V'$5!5N]I W9\S)C<7>H&J$3WY'U!+ P04    "  N
M.V-61[5U))<#  "7#0  &0   'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6RM
ME]MNVS@0AE^%T!9%"Z31P;9B9VT#MK5% _00)$U[4>P%(XTMHA+IDI2=[M/O
MD%)4V5:4I/6-S=/\G/DH<LCQ5LCO*@70Y"[/N)HXJ=;K<]=5<0HY5:=B#1Q[
MED+F5&-5KERUED 3:Y1G;N!YH9M3QIWIV+9=RNE8%#IC'"XE446>4_ES#IG8
M3AS?N6^X8JM4FP9W.E[3%5R#OEE?2JRYM4K"<N"*"4XD+"?.S#^/?,\8V!%?
M&&Q5HTQ,*+="?#>5BV3B>,8CR"#61H+BWP86D&5&"?WX48DZ]9S&L%F^5W]K
M@\=@;JF"A<B^LD2G$V?HD 26M,CTE=B^@RJ@@=&+1:;L+]F68\.10^)":9%7
MQNA!SGCY3^\J$ T#/WS (*@,@GV#_@,&O<J@]U2#?F70MV3*4"R'B&HZ'4NQ
M)=*,1C53L#"M-8;/N%GW:RVQEZ&=GE[P6.1 /M,[4.15!)JR3)'@-7E#;JXC
M\NK%:_*",$X^IZ)0E"=J[&J<UAB[<37%O)PB>& */R ?!->I(O_P!))= 1?]
MK9T.[IV>!YV*$<2GI.>?D, +@A:'%D\W]UO,HZ>;>QW1].HEZ%F]WJ-+0"*F
MXDRH0@+Y-KM56N*V^+>->*G8;U<T9\6Y6M,8)@X>!@KD!ISIR[_\T/N[C=8Q
MQ:(CB>V0[-<D^UWJ39)SX+!DNHU=J3&P&N98W$QQ%3=-((^.B+I&[+@^J%T?
M=+K^A68%M2?A+,.SF/(83D@$2Y 2$AO13"G0)V214KX"LR5GN2AX:X3E5&'#
M.W\T\/:C['3HN<M^)+$==F'-+NQD]VD-$MGQ%7DOE"(+*N5/S(A;*A-U0MY"
M@MU9&Z?PD!/F2^^ 5.?TSR5U)+$=4F<UJ;,_('6MJ88V3F<'G(;AZ(!2Y]3/
MI70DL1U*PYK2L)/2#9<0BQ5G_U5;KSI,$%'CA+D$3C/-,&UB6L0.#>B))K,X
MEL5^EBLQ#@\P[B-\=$34Z?EO<AG57$:/)*H-1HB7/D/BTY9#4N^N)IB/0F/Z
M>H_&Y$)#KEH3V.B8">R88M&1Q'8(^]ZOZYC7^>T='OG(VI07V,CT_I:]0A>H
MC-/66YEWD*2"43#:_^:>-BSJ]ONY7-S&C34'N;(W?T5BD]'*>V#=6K\N9O9.
MO=<^-Z\.>Q/^)5,^63Y0N6)<D0R6*.F=GF&$LGP%E!4MUO9>?"LTWK)M,<67
M$T@S /N7 C_DJF(FJ-]BT_\!4$L#!!0    ( "X[8U8)$8AAW ,  *(-   9
M    >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;*U776_B.!3]*U9VM&JETGP2
MH M(0#K:D7:TJ,S'PV@?W.2&9">Q6=LI[;]?VTE3&MS0D7B!V#GW^)YC^\:>
M[BG[R3, @1[+@O"9E0FQN[%M'F=08GY-=T#DFY2R$@O99%N;[QC@1 >5A>TY
M3FB7."?6?*K[UFP^I94H<@)KAGA5EI@]+:&@^YGE6L\==_DV$ZK#GD]W> L;
M$%]W:R9;=LN2Y"40GE."&*0S:^'>1*X.T(AO.>SYP3-24NXI_:D:GY*9Y:B,
MH(!8* HL_QY@!46AF&0>_S6D5CNF"CQ\?F;_J,5+,?>8PXH6W_-$9#-K;*$$
M4EP5XH[N_X1&T%#QQ;3@^A?M&ZQCH;CB@I9-L,R@S$G]CQ\;(PX"W/"- *\)
M\+H!P1L!?A/@OS<@: ("[4PM1?L088'G4T;WB"FT9%,/VDP=+>7G1,W[1C#Y
M-I=Q8OZ)Q+0$] 4_ D<7$0B<%QSYEVB OFXB=/'A$GU .4%?,EIQ3!(^M84<
M5@7;<3/$LA[">V,(UT.?*1$91[<D@>0U@2WS;9/VGI->>KV,$<37R'>OD.=X
MGB&AU?O#74-X]/YPIT>-WTZ!K_G\DU. HIS'!>45 _1C<<\%D]OB'Y/C-6-@
M9E2UXH;O< PS2Q8##NP!K/GOO[FA\X?)K7.216<B>^5DT#H9]+'/5Q5C0 3:
M""P R=6*_J(Q+K2UMX^R5') %TL@D.;BTF1K33_4]*IB/LSE!#\<>G42$1TC
M!EXX:4&OA U;8<->8;=I"KI HH/%<J=$WD%,29P7.59E],HL]0IM,LQ@H ID
M@M;XJ50N+1C#9 OJ^0HM2EH18?*DSBP\T..&WJACRS%H/'0[QAB(1J.1V9BP
M-28\DS&K3(E5I2R"%.0Z231VP3D(CK[AHM) M"CDIQ"3&/H\"8^E3(:!WS'%
M@!IY;G>]'*,&GA.X8[,QH]:8T5F,05B@CY  D]M$;9M*4/;4C>FS8F1(WPV<
M<<<+ \P=!]ZD8X8)YOF.8S9CW)HQ[C7C.\L%#&B:(IHB(47%<OIS8?R6C8\R
MZ): DXCH&.&[SM WBYBT(B9G6NI_BPP86B3_RN.#VMV\;_XF1[EZ?G?RCC%^
MV,%$QQAW^,;F=IV7PXG3J_E :5/+C,</YV39/@V)>B&O\S\X7+EG+T^W1'[T
MF^I4;[XUL!C,L]>,KW)_R?K:<[OR>]/\U4_\N=AJ4^V#PVL);*LO 1S%:L'6
M1\*VM[UH+/3QNM._5!<0?2A^H:EO+Y\QV^:$HP)22>E<C^0DL_I"4#<$W>DC
M\CT5\L"M'S-YB0*F /)]2JEX;J@!VFO9_']02P,$%     @ +CMC5@5@#^-5
M @  J 8  !D   !X;"]W;W)K<VAE971S+W-H965T-#(N>&ULK95=;YLP%(;_
MBL6JJ96VF(^01AD@M8FV=5*EJ%&WBVD7#IP$JP8SVPG-OY]M"$HURE)I-^!C
M^WU]'AL?HIJ+)YD#*/1<L%+&3JY4-<-8ICD41(YX!:4>V7!1$*5#L<6R$D R
M*RH8]EUW@@M"2R>);-]2)!'?*49+6 HD=T5!Q.$6&*]CQW..'0]TFRO3@9.H
M(EM8@7JLED)'N'/): &EI+Q$ C:Q<^/-YJ&9;R=\IU#+DS8R)&O.GTQPE\6.
M:Q("!JDR#D2_]C 'QHR13N-WZ^ET2QKA:?OH_MFR:Y8UD3#G[ ?-5!X[4P=E
ML"$[IAYX_15:'IM@RIFT3U0W<\>!@]*=5+QHQ3J#@I;-FSRW^W B\,:O"/Q6
MX)\K"%I!8$&;S"S6@BB21(+72)C9VLTT[-Y8M::AI3G%E1)ZE&J=2KYPGM64
M,72Y $4HDU?H(WI<+=#EQ16Z0+1$]WI4;[B,L-+K&15.6^_;QMM_Q?O;CHU0
MX'Y ONNY/?+Y&7+/-W+7>RG'FK)#]3M4W_H%_T+]>;.62N@/Z%<?4V,R[C<Q
MEVHF*Y)"[.A;(T'LP4G>O_,F[J<^PO]D]H(WZ'B#(?=DSH&1E)0J1T?T/MY!
MD[?R-F9><Z2F@NP3/QQ-([SO 1EW(.-S098[D>;ZUJ*EH"GTX0Q:O16G,0M/
M:())/TO8L82#+*M#4>6\/*"[5!>QH7,)_]Y*;SJZ[I9O,AQ<[:T?&#ZI(Z:&
MWQ.QI:5$##;:WAU=Z]5$4Q>;0/'*EI8U5[I0V6:N?R4@S 0]ON%<'0-3K;J?
M4_('4$L#!!0    ( "X[8U9MGWY(&!   &'?   9    >&PO=V]R:W-H965T
M<R]S:&5E=#0S+GAM;+7=;7/:VKG&\:^B\6D[[4P2(P$&IXYG;.OYJ9ZD/;OO
M]LBPC'4V(%>2D^QO7PG+",%B6;3_DQ>)35B_&P3K1@\7TM6/+/^M>!*BU'ZN
MENOBR]E363Y_/C\O9D]BE12?LF>QKO[G,<M725G]FB_.B^=<)//-H-7RW!@,
M+LY72;H^N[[:W':?7U]E+^4R78O[7"M>5JLD__U6++,?7\[TL[<;OJ:+I[*^
MX?SZZCE9B&^B_,?S?5[]=KY5YNE*K(LT6VNY>/QR=J-_CL>C>L#F'O^;BA_%
MSL]:_50>LNRW^A=O_N5L4#\BL12SLB:2ZI_OXDXLE[54/8Y_->C9MF8]</?G
M-]W>//GJR3PDA;C+EK^D\_+IR]GT3)N+Q^1E67[-?KBB>4+CVIMERV+SM_;C
M];X7DS-M]E*4V:H97#V"5;I^_3?YV2R(G0&5(Q]@- .,_0&C(P.&S8!AWPJC
M9L!H?\#%D0'C9L"X[T.Z: 9<]!TP:09,^@Z8-@.F?0=<-@,N^P[0!V^OW*#W
MD.V+??!J'QWR]G+KO5]O_>T%UP]>\:-#WEYR??.:G[^^?3?O?3,ID^NK//NA
MY?7]*Z_^83.!-N.KMWRZKN?ZMS*O_C>MQI77IG@HM;\]+--%4L^]0ONHQ4F>
M)_4,U/YLBC))E\5?JEO_\<W4_OR'OUR=EU75>NSYK*EP^UK!.%)!UZ)L73X5
MFK6>B[EDO*D>/WQOO/5.?4,!G%>+:[O,C+=E=FLHQ9N7Q2=MJ'_0C($^E3R@
M._7P./M>#1]LAH]DRT,]W!2SM^J&(5L<_8=/),/M_L,O),.=_L/'DN'N?_?<
MO?[#=<EPO__P@61XH![NOZS?7G?I@P_5PZ,D5S[WJ,^;=G#T31OW>.[Z=#-\
MHIA#PVW?&6Z\H:KO>.NBS%^J-8=2UE9>@9$<J->!/A?/R4Q\.:M6<@J1?Q=G
MUW_Z'_UB\%?9E"0QD\0L$K-)S"$QE\0\$O-)+""QD,0B$HLAK-,Z1MO6,5+I
MU_=Y-A-B7FB/>;;2[K+U=Y&7Z<-2:'53D742I7=J)WG%QANLWI+Z?CV=C ?U
MGZOS[[M=@JQJD9A-8@Z)N23FD9A_^+)/QE/)RQZ054,2BT@LAK!.!QAO.\!8
MV0'VY_S.BD3U8RFJBJ7V-2F%]JVL_IYK]R*?5?^9+(2L/2B+G=H>2,Q\Q71]
MYUTW^#08UZO.N^\YBRQJDYA#8F[/Q>&117T2"T@L)+&(Q&((ZS2'BVUSN% V
MATU#2+<-X8-6]8.5;-JK&4/[721Y(9OBRH&G3G$2LTC,)C&'Q%P2\TC,)[&
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M:-V8TKH=HHT.COJ>!/%.VB'0U""JF:/#]-N1;02TKHUJ#JJYO9>)A];U42U
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MS]6V[IGVD)5EMMK\^"22N<CK.U3__YAEY=LO=8$?6?[;YNE<_QM02P,$%
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M3).*]2%AFBUF4AQ!&C2IF88UT[(I_8*;;=]H2;,%\?3BXX^ZT _PA:?(S0[
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MKXGN4E$8 [V^X%QM!V:#JN\=_0!02P,$%     @ +CMC5N2?HP:* @  J <
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M971S+W-H965T-3,N>&ULI51M;],P$/XK5IC0)J'FI2^@DD9J5Q"3J%2U&GQ
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M#X#K +6_8$QN#7U ^\41_P502P,$%     @ +CMC5CD,TM%A P  - H  !D
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M^B/Q?D;I%Y(UW:G]S*2: ;K+4HUUP#5 W=\P)E\6^@?&03']'U!+ P04
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M8("G<8S9]WL2T>/4@<[IQ)=PNQ/9B>YLLL=;LB3BZW[!Y%&W5%F',4EX2!/
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M++M ?KZA5)P.L@3E?N+L/U!+ P04    "  N.V-6 E-'04L#   .%0  #0
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M-"^:%8W%1NLQMDW-K975[I]*NW]9O?\74$L#!!0    ( "X[8U;S((MYZ0$
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M?#;\MW'U"E!+ 0(4 Q0    ( "X[8U8'04UB@0   +$    0
M  "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ +CMC5C9_D^7M
M    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L!
M A0#%     @ +CMC5IE<G",0!@  G"<  !,              ( !RP$  'AL
M+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  N.V-65M^6-NH(  "J.0
M&               @($,"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L!
M A0#%     @ +CMC5LD@QKF/!@  8!P  !@              ("!+!$  'AL
M+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( "X[8U9MQ*ZL* ,
M +0*   8              " @?$7  !X;"]W;W)K<VAE971S+W-H965T,RYX
M;6Q02P$"% ,4    "  N.V-6YR+ JE &  #I&0  &               @(%/
M&P  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ +CMC5M!R
ML8^5 @  HP8  !@              ("!U2$  'AL+W=O<FMS:&5E=',O<VAE
M970U+GAM;%!+ 0(4 Q0    ( "X[8U8F5XO[00L  (I;   8
M  " @: D  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    "  N
M.V-6%:75OXH*  #3-0  &               @($7,   >&PO=V]R:W-H965T
M<R]S:&5E=#<N>&UL4$L! A0#%     @ +CMC5IP&]DTI!0  _PL  !@
M         ("!USH  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0
M   ( "X[8U;N<$:.&1X  .5<   8              " @39   !X;"]W;W)K
M<VAE971S+W-H965T.2YX;6Q02P$"% ,4    "  N.V-6Q%A*S)T#  #Q!P
M&0              @(&%7@  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+
M 0(4 Q0    ( "X[8U9GZQ!A40,  /$(   9              " @5EB  !X
M;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ +CMC5J(=&X@X
M!0  3@T  !D              ("!X64  'AL+W=O<FMS:&5E=',O<VAE970Q
M,BYX;6Q02P$"% ,4    "  N.V-6@%!W&=X"  !F!@  &0
M@(%0:P  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( "X[
M8U;=AIM7-0H  )P9   9              " @65N  !X;"]W;W)K<VAE971S
M+W-H965T,30N>&UL4$L! A0#%     @ +CMC5EI92D.V!   '0L  !D
M         ("!T7@  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
M    "  N.V-6B&_GA8T-  !E*   &0              @(&^?0  >&PO=V]R
M:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( "X[8U8 &;,#* D  ((<
M   9              " @8*+  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL
M4$L! A0#%     @ +CMC5EMS,4I! P  +@<  !D              ("!X90
M 'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    "  N.V-6YF?A
M*=@#  "C"   &0              @(%9F   >&PO=V]R:W-H965T<R]S:&5E
M=#$Y+GAM;%!+ 0(4 Q0    ( "X[8U8]JRN4I1<  -5)   9
M  " @6B<  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @
M+CMC5OZ'2=W( @  8@8  !D              ("!1+0  'AL+W=O<FMS:&5E
M=',O<VAE970R,2YX;6Q02P$"% ,4    "  N.V-6^H:?^D0#  !Y"   &0
M            @(%#MP  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4
M Q0    ( "X[8U;GZBWPX0(  $$'   9              " @;ZZ  !X;"]W
M;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ +CMC5N]?]PS8 @
M&P8  !D              ("!UKT  'AL+W=O<FMS:&5E=',O<VAE970R-"YX
M;6Q02P$"% ,4    "  N.V-6B&/.A50$  #Q"0  &0              @('E
MP   >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( "X[8U8<
M#B[UTP(  $0&   9              " @7#%  !X;"]W;W)K<VAE971S+W-H
M965T,C8N>&UL4$L! A0#%     @ +CMC5F#0NGNJ P  JP@  !D
M     ("!>L@  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "X[8U:/]=;V8@(  (X%   9              "
M@:K9  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ +CMC
M5IN3;$T^!   J!0  !D              ("!0]P  'AL+W=O<FMS:&5E=',O
M<VAE970S,RYX;6Q02P$"% ,4    "  N.V-6"NWS-JP"   7!@  &0
M        @(&XX   >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0
M   ( "X[8U:BG %@3P(  !@&   9              " @9OC  !X;"]W;W)K
M<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ +CMC5@;_8A'W!   NQT
M !D              ("!(>8  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q0
M2P$"% ,4    "  N.V-6))VJU+L#  "'$P  &0              @(%/ZP
M>&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( "X[8U;6:WC$
M&P<  (9$   9              " @4'O  !X;"]W;W)K<VAE971S+W-H965T
M,S@N>&UL4$L! A0#%     @ +CMC5K+I&8*V!   E!8  !D
M ("!D_8  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    "  N
M.V-61[5U))<#  "7#0  &0              @(& ^P  >&PO=V]R:W-H965T
M<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( "X[8U8)$8AAW ,  *(-   9
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M970T-2YX;6Q02P$"% ,4    "  N.V-6W;%4()\$  !K%@  &0
M    @(&A' $ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    (
M "X[8U9 \:[;&@,  -H)   9              " @7<A 0!X;"]W;W)K<VAE
M971S+W-H965T-#<N>&UL4$L! A0#%     @ +CMC5O=\N>%P!0  +1T  !D
M             ("!R"0! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"
M% ,4    "  N.V-6I'3H'M0%  #:)0  &0              @(%O*@$ >&PO
M=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( "X[8U8CP*+F-P,
M +X)   9              " @7HP 0!X;"]W;W)K<VAE971S+W-H965T-3 N
M>&UL4$L! A0#%     @ +CMC5BG)#\UQ P   P\  !D              ("!
MZ#,! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    "  N.V-6
MY)^C!HH"  "H!P  &0              @(&0-P$ >&PO=V]R:W-H965T<R]S
M:&5E=#4R+GAM;%!+ 0(4 Q0    ( "X[8U8K!G%&3 (  $@%   9
M      " @5$Z 0!X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%
M  @ +CMC5B2-C23R @  ?0@  !D              ("!U#P! 'AL+W=O<FMS
M:&5E=',O<VAE970U-"YX;6Q02P$"% ,4    "  N.V-6.0S2T6$#   T"@
M&0              @(']/P$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+
M 0(4 Q0    ( "X[8U:VMJ:-N00  .(:   9              " @95# 0!X
M;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ +CMC5E\QB SV
M!   6QP  !D              ("!A4@! 'AL+W=O<FMS:&5E=',O<VAE970U
M-RYX;6Q02P$"% ,4    "  N.V-6 E-'04L#   .%0  #0
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:+GAM;%!+!08     00!! +X1   %6P$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>99</ContextCount>
  <ElementCount>374</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>24</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="lxrx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="lxrx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="lxrx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Balance Sheet Parentheticals</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/BalanceSheetParentheticals</Role>
      <ShortName>Balance Sheet Parentheticals</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="lxrx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="lxrx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Statements of Comprehensive Loss Parentheticals (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/StatementsofComprehensiveLossParentheticalsParentheticals</Role>
      <ShortName>Statements of Comprehensive Loss Parentheticals (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="lxrx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="lxrx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="lxrx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Organization and Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/OrganizationandOperations</Role>
      <ShortName>Organization and Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="lxrx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="lxrx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Recent Accounting Pronouncements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/RecentAccountingPronouncements</Role>
      <ShortName>Recent Accounting Pronouncements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="lxrx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Cash and Cash Equivalents and Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments</Role>
      <ShortName>Cash and Cash Equivalents and Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="lxrx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="lxrx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/PropertyandEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="lxrx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="lxrx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/Goodwill</Role>
      <ShortName>Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="lxrx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Debt Obligations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/DebtObligations</Role>
      <ShortName>Debt Obligations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="lxrx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Equity Incentive Awards</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/EquityIncentiveAwards</Role>
      <ShortName>Equity Incentive Awards</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="lxrx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/BenefitPlan</Role>
      <ShortName>Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="lxrx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Collaboration and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CollaborationandLicenseAgreements</Role>
      <ShortName>Collaboration and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="lxrx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="lxrx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="lxrx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Cash and Cash Equivalents and Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables</Role>
      <ShortName>Cash and Cash Equivalents and Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="lxrx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/FairValueMeasurements</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="lxrx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/PropertyandEquipment</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="lxrx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/IncomeTaxes</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="lxrx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="lxrx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Equity Incentive Awards (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/EquityIncentiveAwardsTables</Role>
      <ShortName>Equity Incentive Awards (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/EquityIncentiveAwards</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="lxrx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Summary of Significant Accounting Policies Concentration of Credit Risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails</Role>
      <ShortName>Summary of Significant Accounting Policies Concentration of Credit Risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="lxrx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Summary of Significant Accounting Policies Segment Information and Signficant Customers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationandSignficantCustomersDetails</Role>
      <ShortName>Summary of Significant Accounting Policies Segment Information and Signficant Customers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="lxrx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="lxrx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Summary of Significant Accounting Policies Impairment of Long-Lived Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesImpairmentofLongLivedAssetsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies Impairment of Long-Lived Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="lxrx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Summary of Significant Accounting Policies - Cost of Sales (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesCostofSalesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Cost of Sales (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="lxrx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Summary of Significant Accounting Policies Stock-Based Compensation (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1</Role>
      <ShortName>Summary of Significant Accounting Policies Stock-Based Compensation (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="lxrx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Summary of Significant Accounting Policies Stock-based Compensation (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationDetails2</Role>
      <ShortName>Summary of Significant Accounting Policies Stock-based Compensation (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="lxrx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Recent Accounting Pronouncements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/RecentAccountingPronouncementsDetails</Role>
      <ShortName>Recent Accounting Pronouncements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/RecentAccountingPronouncements</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="lxrx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Cash and Cash Equivalents and Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails</Role>
      <ShortName>Cash and Cash Equivalents and Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="lxrx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Fair Value Measurements (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/FairValueMeasurementsDetails1</Role>
      <ShortName>Fair Value Measurements (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="lxrx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/PropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="lxrx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - Income Taxes (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/IncomeTaxesDetails1</Role>
      <ShortName>Income Taxes (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="lxrx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - Income Taxes (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/IncomeTaxesDetails2</Role>
      <ShortName>Income Taxes (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="lxrx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - Income Taxes (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/IncomeTaxesDetails3</Role>
      <ShortName>Income Taxes (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="lxrx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/GoodwillDetails</Role>
      <ShortName>Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/Goodwill</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="lxrx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - Debt Obligations - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/DebtObligationsNarrativeDetails</Role>
      <ShortName>Debt Obligations - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="lxrx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - Debt Obligations (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/DebtObligationsDetails1</Role>
      <ShortName>Debt Obligations (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/DebtObligations</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="lxrx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - Commitments and Contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CommitmentsandContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="lxrx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000062 - Disclosure - Commitments and Contingencies (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CommitmentsandContingenciesDetails2</Role>
      <ShortName>Commitments and Contingencies (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/CommitmentsandContingenciesTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="lxrx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000063 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/CommitmentsandContingenciesTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="lxrx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000064 - Disclosure - Equity Incentive Awards - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails</Role>
      <ShortName>Equity Incentive Awards - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="lxrx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000065 - Disclosure - Equity Incentive Awards (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2</Role>
      <ShortName>Equity Incentive Awards (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/EquityIncentiveAwardsTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="lxrx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000066 - Disclosure - Equity Incentive Awards (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3</Role>
      <ShortName>Equity Incentive Awards (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/EquityIncentiveAwardsTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="lxrx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000067 - Disclosure - Equity Incentive Awards (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4</Role>
      <ShortName>Equity Incentive Awards (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/EquityIncentiveAwardsTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="lxrx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000068 - Disclosure - Benefit Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/BenefitPlanDetails</Role>
      <ShortName>Benefit Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/BenefitPlan</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="lxrx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000069 - Disclosure - Collaboration and License Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails</Role>
      <ShortName>Collaboration and License Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/CollaborationandLicenseAgreements</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="lxrx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000070 - Disclosure - Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/EarningsPerShareDetails</Role>
      <ShortName>Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="lxrx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000071 - Disclosure - Selected Quarterly Financial Data (Unaudited) - Quarterly Financial Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedQuarterlyFinancialInformationDetails</Role>
      <ShortName>Selected Quarterly Financial Data (Unaudited) - Quarterly Financial Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="lxrx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000072 - Disclosure - Asset Sale (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/AssetSaleDetails</Role>
      <ShortName>Asset Sale (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="lxrx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000073 - Disclosure - Other Capital Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/OtherCapitalAgreementsDetails</Role>
      <ShortName>Other Capital Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept CashAndCashEquivalentsPeriodIncreaseDecrease in us-gaap/2022 used in 3 facts was deprecated in us-gaap/2022 as of 2022 and should not be used. lxrx-20221231.htm 4</Log>
    <Log type="Warning">[dq-0540-EntityFilerCategory-Value] In submission type 10-K, EntityFilerCategory value "Accelerated Filer", is not equivalent to header element acceleratedFilerStatus value "Non-Accelerated Filer" in the Required Context. lxrx-20221231.htm 4</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 4 fact(s) appearing in ix:hidden were eligible for transformation: lxrx:DeferredCompensationArrangementWithIndividualPaymentPeriod, us-gaap:DebtInstrumentTerm, us-gaap:PropertyPlantAndEquipmentUsefulLife, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 -  lxrx-20221231.htm 4</Log>
    <Log type="Warning">[dqc-0015-Negative-Values] Fact us-gaap:DebtInstrumentCarryingAmount has a value of -48579000 which is less than zero. This element should not have a negative value. The preparer should consider if the value is input correctly for this assertion and, after considering the appropriateness of the input, if incorrect, input the amount as a positive (i.e., absolute) value and provide a negated label. The properties of this us-gaap:DebtInstrumentCarryingAmount fact are: Context: i024c9d1784a74539a536ca837e05f772_I20221231, Unit: usd, Rule Element Id: 7182. lxrx-20221231.htm 4</Log>
    <Log type="Warning">[dqc-0015-Negative-Values] Fact us-gaap:RepaymentsOfLongTermDebt has a value of -48868000 which is less than zero. This element should not have a negative value. The preparer should consider if the value is input correctly for this assertion and, after considering the appropriateness of the input, if incorrect, input the amount as a positive (i.e., absolute) value and provide a negated label. The properties of this us-gaap:RepaymentsOfLongTermDebt fact are: Context: ied714a94cdc9470b8062452bba89125d_D20220101-20221231, Unit: usd, Rule Element Id: 2761. lxrx-20221231.htm 4</Log>
    <Log type="Warning">[dqc-0015-Negative-Values] Fact us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax has a value of -1000 which is less than zero. This element should not have a negative value. The preparer should consider if the value is input correctly for this assertion and, after considering the appropriateness of the input, if incorrect, input the amount as a positive (i.e., absolute) value and provide a negated label. The properties of this us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax fact are: Context: idde6749a549b4ccc8f95351b92d40bce_I20211231, Unit: usd, Rule Element Id: 310. lxrx-20221231.htm 4</Log>
    <Log type="Warning">[dqc-0048-Required-Calculation-Parent-Element-In-The-Cash-Flow-Statement] The filing should include in the cash flow statement calculation linkbase(s) http://www.lexpharma.com/role/OtherCapitalAgreementsDetails - 0000073 - Disclosure - Other Capital Agreements (Details) one of the following elements as the root(first element) of the calculation tree to represent the aggregate change in cash for the period: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect, CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect, NetCashProvidedByUsedInContinuingOperations (As long as the element NetCashProvidedByUsedInDiscontinuedOperations is also included the reconciliation between opening and closing cash). The calculation linkbase in the filing has the following root elements defined: CashAndCashEquivalentsPeriodIncreaseDecrease. Rule Element Id: 7482. lxrx-20221231.htm </Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="lxrx-20221231.htm">lxrx-20221231.htm</File>
    <File>exh1010officerrestrictedst.htm</File>
    <File>exh231ernstyoungconsent2022.htm</File>
    <File>exh311certificationofprinc.htm</File>
    <File>exh312certificationofprinc.htm</File>
    <File>exh321certificationofprinc.htm</File>
    <File>lxrx-20221231.xsd</File>
    <File>lxrx-20221231_cal.xml</File>
    <File>lxrx-20221231_def.xml</File>
    <File>lxrx-20221231_lab.xml</File>
    <File>lxrx-20221231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>lxrx-20221231_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="687">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>77
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "lxrx-20221231.htm": {
   "axisCustom": 0,
   "axisStandard": 8,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 687,
    "http://xbrl.sec.gov/dei/2022": 37
   },
   "contextCount": 99,
   "dts": {
    "calculationLink": {
     "local": [
      "lxrx-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "lxrx-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "lxrx-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "lxrx-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lxrx-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "lxrx-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd"
     ]
    }
   },
   "elementCount": 597,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 3,
    "http://www.lexpharma.com/20221231": 1,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 8
   },
   "keyCustom": 99,
   "keyStandard": 275,
   "memberCustom": 0,
   "memberStandard": 24,
   "nsprefix": "lxrx",
   "nsuri": "http://www.lexpharma.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ied714a94cdc9470b8062452bba89125d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.lexpharma.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ied714a94cdc9470b8062452bba89125d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ied714a94cdc9470b8062452bba89125d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Recent Accounting Pronouncements",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.lexpharma.com/role/RecentAccountingPronouncements",
     "shortName": "Recent Accounting Pronouncements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ied714a94cdc9470b8062452bba89125d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ied714a94cdc9470b8062452bba89125d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Cash and Cash Equivalents and Investments",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments",
     "shortName": "Cash and Cash Equivalents and Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ied714a94cdc9470b8062452bba89125d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ied714a94cdc9470b8062452bba89125d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Fair Value Measurements",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.lexpharma.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ied714a94cdc9470b8062452bba89125d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ied714a94cdc9470b8062452bba89125d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Property and Equipment",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.lexpharma.com/role/PropertyandEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ied714a94cdc9470b8062452bba89125d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ied714a94cdc9470b8062452bba89125d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.lexpharma.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ied714a94cdc9470b8062452bba89125d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ied714a94cdc9470b8062452bba89125d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Goodwill",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.lexpharma.com/role/Goodwill",
     "shortName": "Goodwill",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ied714a94cdc9470b8062452bba89125d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ied714a94cdc9470b8062452bba89125d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Debt Obligations",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.lexpharma.com/role/DebtObligations",
     "shortName": "Debt Obligations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ied714a94cdc9470b8062452bba89125d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ied714a94cdc9470b8062452bba89125d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Equity Incentive Awards",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.lexpharma.com/role/EquityIncentiveAwards",
     "shortName": "Equity Incentive Awards",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ied714a94cdc9470b8062452bba89125d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ied714a94cdc9470b8062452bba89125d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Benefit Plan",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.lexpharma.com/role/BenefitPlan",
     "shortName": "Benefit Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ied714a94cdc9470b8062452bba89125d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ied714a94cdc9470b8062452bba89125d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Collaboration and License Agreements",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.lexpharma.com/role/CollaborationandLicenseAgreements",
     "shortName": "Collaboration and License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ied714a94cdc9470b8062452bba89125d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "i024c9d1784a74539a536ca837e05f772_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.lexpharma.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "i024c9d1784a74539a536ca837e05f772_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ied714a94cdc9470b8062452bba89125d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "20",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ied714a94cdc9470b8062452bba89125d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ied714a94cdc9470b8062452bba89125d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ied714a94cdc9470b8062452bba89125d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ied714a94cdc9470b8062452bba89125d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Cash and Cash Equivalents and Investments (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables",
     "shortName": "Cash and Cash Equivalents and Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ied714a94cdc9470b8062452bba89125d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ied714a94cdc9470b8062452bba89125d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://www.lexpharma.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ied714a94cdc9470b8062452bba89125d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ied714a94cdc9470b8062452bba89125d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Property and Equipment (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://www.lexpharma.com/role/PropertyandEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ied714a94cdc9470b8062452bba89125d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ied714a94cdc9470b8062452bba89125d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.lexpharma.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ied714a94cdc9470b8062452bba89125d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ied714a94cdc9470b8062452bba89125d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Commitments and Contingencies (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.lexpharma.com/role/CommitmentsandContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ied714a94cdc9470b8062452bba89125d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ied714a94cdc9470b8062452bba89125d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Equity Incentive Awards (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.lexpharma.com/role/EquityIncentiveAwardsTables",
     "shortName": "Equity Incentive Awards (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ied714a94cdc9470b8062452bba89125d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Summary of Significant Accounting Policies Concentration of Credit Risk (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails",
     "shortName": "Summary of Significant Accounting Policies Concentration of Credit Risk (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "i6301d5ee07fe4b0e9f5fcaf2bdc15828_D20210101-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ied714a94cdc9470b8062452bba89125d_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Summary of Significant Accounting Policies Segment Information and Signficant Customers (Details)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationandSignficantCustomersDetails",
     "shortName": "Summary of Significant Accounting Policies Segment Information and Signficant Customers (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ied714a94cdc9470b8062452bba89125d_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "i024c9d1784a74539a536ca837e05f772_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Balance Sheet Parentheticals",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.lexpharma.com/role/BalanceSheetParentheticals",
     "shortName": "Balance Sheet Parentheticals",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "i024c9d1784a74539a536ca837e05f772_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "idb9d77e7bb0d49ef814ea91873a8ee6f_D20180801-20180831",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails",
     "shortName": "Summary of Significant Accounting Policies - Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "i024c9d1784a74539a536ca837e05f772_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "lxrx:AccruedResearchAndDevelopmentServicesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ied714a94cdc9470b8062452bba89125d_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Summary of Significant Accounting Policies Impairment of Long-Lived Assets (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesImpairmentofLongLivedAssetsDetails",
     "shortName": "Summary of Significant Accounting Policies Impairment of Long-Lived Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "i0126e8a6d33142d5912c3766ac53314e_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Summary of Significant Accounting Policies - Cost of Sales (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesCostofSalesDetails",
     "shortName": "Summary of Significant Accounting Policies - Cost of Sales (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "i0126e8a6d33142d5912c3766ac53314e_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ied714a94cdc9470b8062452bba89125d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Summary of Significant Accounting Policies Stock-Based Compensation (Details 1)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1",
     "shortName": "Summary of Significant Accounting Policies Stock-Based Compensation (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "if1ed3c23317249048fd1e594aaae930b_D20220101-20221231",
      "decimals": null,
      "lang": "en-US",
      "name": "lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "i024c9d1784a74539a536ca837e05f772_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Summary of Significant Accounting Policies Stock-based Compensation (Details 2)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationDetails2",
     "shortName": "Summary of Significant Accounting Policies Stock-based Compensation (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "i024c9d1784a74539a536ca837e05f772_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "i024c9d1784a74539a536ca837e05f772_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Recent Accounting Pronouncements (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.lexpharma.com/role/RecentAccountingPronouncementsDetails",
     "shortName": "Recent Accounting Pronouncements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ied714a94cdc9470b8062452bba89125d_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RealizedInvestmentGainsLosses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Cash and Cash Equivalents and Investments (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails",
     "shortName": "Cash and Cash Equivalents and Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ied714a94cdc9470b8062452bba89125d_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RealizedInvestmentGainsLosses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "i024c9d1784a74539a536ca837e05f772_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Fair Value Measurements (Details 1)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.lexpharma.com/role/FairValueMeasurementsDetails1",
     "shortName": "Fair Value Measurements (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "i024c9d1784a74539a536ca837e05f772_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "idb9d77e7bb0d49ef814ea91873a8ee6f_D20180801-20180831",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Property and Equipment (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.lexpharma.com/role/PropertyandEquipmentDetails",
     "shortName": "Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "i024c9d1784a74539a536ca837e05f772_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "i024c9d1784a74539a536ca837e05f772_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - Income Taxes (Details 1)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.lexpharma.com/role/IncomeTaxesDetails1",
     "shortName": "Income Taxes (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "i024c9d1784a74539a536ca837e05f772_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ied714a94cdc9470b8062452bba89125d_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Consolidated Statements of Comprehensive Loss",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss",
     "shortName": "Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ied714a94cdc9470b8062452bba89125d_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ied714a94cdc9470b8062452bba89125d_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredIncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - Income Taxes (Details 2)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.lexpharma.com/role/IncomeTaxesDetails2",
     "shortName": "Income Taxes (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ied714a94cdc9470b8062452bba89125d_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ied714a94cdc9470b8062452bba89125d_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - Income Taxes (Details 3)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.lexpharma.com/role/IncomeTaxesDetails3",
     "shortName": "Income Taxes (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ied714a94cdc9470b8062452bba89125d_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "i5c4b46c8c9cd4829a9a8f58250be63e9_I20010712",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:CoelacanthGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - Goodwill (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.lexpharma.com/role/GoodwillDetails",
     "shortName": "Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "i5c4b46c8c9cd4829a9a8f58250be63e9_I20010712",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:CoelacanthGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ifaed8b1899ba47ddb389bc7180e9188b_D20141101-20141130",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromConvertibleDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - Debt Obligations - Narrative (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails",
     "shortName": "Debt Obligations - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ifaed8b1899ba47ddb389bc7180e9188b_D20141101-20141130",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromConvertibleDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "if253b46ef2a74bc69b4c2082a05ba597_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - Debt Obligations (Details 1)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.lexpharma.com/role/DebtObligationsDetails1",
     "shortName": "Debt Obligations (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "i024c9d1784a74539a536ca837e05f772_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - Commitments and Contingencies - Narrative (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.lexpharma.com/role/CommitmentsandContingenciesNarrativeDetails",
     "shortName": "Commitments and Contingencies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "if253b46ef2a74bc69b4c2082a05ba597_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "i024c9d1784a74539a536ca837e05f772_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000062 - Disclosure - Commitments and Contingencies (Details 2)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails2",
     "shortName": "Commitments and Contingencies (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "i024c9d1784a74539a536ca837e05f772_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ied714a94cdc9470b8062452bba89125d_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsForRent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000063 - Disclosure - Commitments and Contingencies (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ied714a94cdc9470b8062452bba89125d_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsForRent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ied714a94cdc9470b8062452bba89125d_D20220101-20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:StockOptionExercisePriceAsPercentOfValueOfCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000064 - Disclosure - Equity Incentive Awards - Narrative (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails",
     "shortName": "Equity Incentive Awards - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ied714a94cdc9470b8062452bba89125d_D20220101-20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:StockOptionExercisePriceAsPercentOfValueOfCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ied714a94cdc9470b8062452bba89125d_D20220101-20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000065 - Disclosure - Equity Incentive Awards (Details 2)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2",
     "shortName": "Equity Incentive Awards (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ied714a94cdc9470b8062452bba89125d_D20220101-20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ied714a94cdc9470b8062452bba89125d_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Statements of Comprehensive Loss Parentheticals (Parentheticals)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.lexpharma.com/role/StatementsofComprehensiveLossParentheticalsParentheticals",
     "shortName": "Statements of Comprehensive Loss Parentheticals (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ied714a94cdc9470b8062452bba89125d_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ied714a94cdc9470b8062452bba89125d_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000066 - Disclosure - Equity Incentive Awards (Details 3)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3",
     "shortName": "Equity Incentive Awards (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ied714a94cdc9470b8062452bba89125d_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "idc54e15956a14d6a8516b3a8816e8281_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000067 - Disclosure - Equity Incentive Awards (Details 4)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4",
     "shortName": "Equity Incentive Awards (Details 4)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "idc54e15956a14d6a8516b3a8816e8281_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ied714a94cdc9470b8062452bba89125d_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000068 - Disclosure - Benefit Plan (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.lexpharma.com/role/BenefitPlanDetails",
     "shortName": "Benefit Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ied714a94cdc9470b8062452bba89125d_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:IpsenRevenueRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000069 - Disclosure - Collaboration and License Agreements (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails",
     "shortName": "Collaboration and License Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:IpsenRevenueRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ied714a94cdc9470b8062452bba89125d_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000070 - Disclosure - Earnings Per Share (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.lexpharma.com/role/EarningsPerShareDetails",
     "shortName": "Earnings Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ied714a94cdc9470b8062452bba89125d_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000071 - Disclosure - Selected Quarterly Financial Data (Unaudited) - Quarterly Financial Information (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedQuarterlyFinancialInformationDetails",
     "shortName": "Selected Quarterly Financial Data (Unaudited) - Quarterly Financial Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ied714a94cdc9470b8062452bba89125d_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromSaleOfProductiveAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000072 - Disclosure - Asset Sale (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.lexpharma.com/role/AssetSaleDetails",
     "shortName": "Asset Sale (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000073 - Disclosure - Other Capital Agreements (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails",
     "shortName": "Other Capital Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "i91ec933ea58e4495bf1da3d5833f1111_D20200101-20201231",
      "decimals": "0",
      "lang": "en-US",
      "name": "lxrx:SharesSoldInNov2020ATMOffering",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "i26b899de75ec4971bee2701c59fba66c_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Consolidated Statements of Stockholders' Equity",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "i26b899de75ec4971bee2701c59fba66c_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ied714a94cdc9470b8062452bba89125d_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ied714a94cdc9470b8062452bba89125d_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ied714a94cdc9470b8062452bba89125d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - Organization and Operations",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.lexpharma.com/role/OrganizationandOperations",
     "shortName": "Organization and Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ied714a94cdc9470b8062452bba89125d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ied714a94cdc9470b8062452bba89125d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20221231.htm",
      "contextRef": "ied714a94cdc9470b8062452bba89125d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 24,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r663",
      "r664",
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r663",
      "r664",
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r663",
      "r664",
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r663",
      "r664",
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]",
        "terseLabel": "Document Information",
        "verboseLabel": "Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage",
      "http://www.lexpharma.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]",
        "terseLabel": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r663",
      "r664",
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "lxrx_A2020ConvertibleDebtExchangeAccruedInterest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 convertible debt exchange - accrued interest",
        "label": "2020 convertible debt exchange - accrued interest",
        "terseLabel": "2020 convertible debt exchange - accrued interest"
       }
      }
     },
     "localname": "A2020ConvertibleDebtExchangeAccruedInterest",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_A2020ConvertibleDebtExchangePercentageOfPrincipal": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 convertible debt exchange - percentage of principal",
        "label": "2020 convertible debt exchange - percentage of principal",
        "terseLabel": "2020 convertible debt exchange - percentage of principal"
       }
      }
     },
     "localname": "A2020ConvertibleDebtExchangePercentageOfPrincipal",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_A2020ConvertibleDebtExchangeSharePaymentTotal": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Convertible debt exchange - share payment total",
        "label": "2020 Convertible debt exchange - share payment total",
        "terseLabel": "2020 Convertible debt exchange - share payment total"
       }
      }
     },
     "localname": "A2020ConvertibleDebtExchangeSharePaymentTotal",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_A2020FederalNOLIncrease": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Federal NOL increase",
        "label": "2020 Federal NOL increase",
        "terseLabel": "2020 Federal NOL increase"
       }
      }
     },
     "localname": "A2020FederalNOLIncrease",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_A2025OxfordPrincipalPaymentA": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2025 Oxford Principal Payment A",
        "label": "2025 Oxford Principal Payment A",
        "terseLabel": "2025 Oxford Principal Payment A"
       }
      }
     },
     "localname": "A2025OxfordPrincipalPaymentA",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_A2025OxfordPrincipalPaymentsB": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2025 Oxford Principal Payments B",
        "label": "2025 Oxford Principal Payments B",
        "terseLabel": "2025 Oxford Principal Payments B"
       }
      }
     },
     "localname": "A2025OxfordPrincipalPaymentsB",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_A2026OxfordPrincipalPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2026 Oxford Principal Payments",
        "label": "2026 Oxford Principal Payments",
        "terseLabel": "2026 Oxford Principal Payments"
       }
      }
     },
     "localname": "A2026OxfordPrincipalPayments",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_A2026OxfordPrincipalPaymentsB": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2026 Oxford Principal Payments B",
        "label": "2026 Oxford Principal Payments B",
        "terseLabel": "2026 Oxford Principal Payments B"
       }
      }
     },
     "localname": "A2026OxfordPrincipalPaymentsB",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_A2027OxfordPrincipalPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2027 Oxford Principal Payments",
        "label": "2027 Oxford Principal Payments",
        "terseLabel": "2027 Oxford Principal Payments"
       }
      }
     },
     "localname": "A2027OxfordPrincipalPayments",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_A2027OxfordPrincipalPaymentsA": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2027 Oxford Principal Payments A",
        "label": "2027 Oxford Principal Payments A",
        "terseLabel": "2027 Oxford Principal Payments A"
       }
      }
     },
     "localname": "A2027OxfordPrincipalPaymentsA",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_A2027OxfordPrincipalPaymentsB": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2027 Oxford Principal Payments B",
        "label": "2027 Oxford Principal Payments B",
        "terseLabel": "2027 Oxford Principal Payments B"
       }
      }
     },
     "localname": "A2027OxfordPrincipalPaymentsB",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_ATMOffering2020Total": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ATM Offering 2020 Total",
        "label": "ATM Offering 2020 Total",
        "terseLabel": "ATM Offering 2020 Total"
       }
      }
     },
     "localname": "ATMOffering2020Total",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_ATMOfferingTotal": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ATM Offering Total",
        "label": "ATM Offering Total",
        "terseLabel": "ATM Offering Total"
       }
      }
     },
     "localname": "ATMOfferingTotal",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_AccruedCompensationAndBenefitsCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued compensation and benefits current - due within 1 year",
        "label": "Accrued compensation and benefits current",
        "terseLabel": "Accrued compensation and benefits current"
       }
      }
     },
     "localname": "AccruedCompensationAndBenefitsCurrent",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_AccruedResearchAndDevelopmentServicesCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development services current",
        "label": "Accrued research and development services current",
        "terseLabel": "Accrued research and development services current"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentServicesCurrent",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_BalanceSheetParentheticalsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Balance Sheet Parentheticals [Abstract]",
        "label": "Balance Sheet Parentheticals [Abstract]",
        "terseLabel": "Balance Sheet Parentheticals [Abstract]"
       }
      }
     },
     "localname": "BalanceSheetParentheticalsAbstract",
     "nsuri": "http://www.lexpharma.com/20221231",
     "xbrltype": "stringItemType"
    },
    "lxrx_BenefitPlanAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Benefit Plan [Abstract]",
        "label": "Benefit Plan [Abstract]",
        "terseLabel": "Benefit Plan [Abstract]"
       }
      }
     },
     "localname": "BenefitPlanAbstract",
     "nsuri": "http://www.lexpharma.com/20221231",
     "xbrltype": "stringItemType"
    },
    "lxrx_CashAndCashEquivalentsAndInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and Cash Equivalents and Investments [Abstract]",
        "label": "Cash and Cash Equivalents and Investments [Abstract]",
        "terseLabel": "Cash and Cash Equivalents and Investments [Abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAndInvestmentsAbstract",
     "nsuri": "http://www.lexpharma.com/20221231",
     "xbrltype": "stringItemType"
    },
    "lxrx_CoelacanthGoodwill": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "On July 12, 2001, Lexicon completed the acquisition of Coelacanth Corporation in a merger. Goodwill associated with the acquisition of $25.8 million, which represents the excess of the $36.0 million purchase price over the fair value of the underlying net identifiable assets, was assigned to the consolidated entity, Lexicon. This represents the goodwill.",
        "label": "Coelacanth Goodwill",
        "terseLabel": "Coelacanth Goodwill"
       }
      }
     },
     "localname": "CoelacanthGoodwill",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/GoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_CoelacanthPurchasePrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "On July 12, 2001, Lexicon completed the acquisition of Coelacanth Corporation in a merger. Goodwill associated with the acquisition of $25.8 million, which represents the excess of the $36.0 million purchase price over the fair value of the underlying net identifiable assets, was assigned to the consolidated entity, Lexicon. This represents the purchase price.",
        "label": "Coelacanth Purchase Price",
        "terseLabel": "Coelacanth Purchase Price"
       }
      }
     },
     "localname": "CoelacanthPurchasePrice",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/GoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_CollaborationAndLicenseAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and License Agreements [Abstract]",
        "label": "Collaboration and License Agreements [Abstract]",
        "terseLabel": "Collaboration and License Agreements [Abstract]"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementsAbstract",
     "nsuri": "http://www.lexpharma.com/20221231",
     "xbrltype": "stringItemType"
    },
    "lxrx_CommissionsFromDecember2020CommonStockOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commissions from December 2020 Common Stock Offering",
        "label": "Commissions from December 2020 Common Stock Offering",
        "terseLabel": "Commissions from December 2020 Common Stock Offering"
       }
      }
     },
     "localname": "CommissionsFromDecember2020CommonStockOffering",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_CommitmentsAndContingenciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and Contingencies",
        "label": "Commitments and Contingencies [Abstract]",
        "terseLabel": "Commitments and Contingencies [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesAbstract",
     "nsuri": "http://www.lexpharma.com/20221231",
     "xbrltype": "stringItemType"
    },
    "lxrx_ConsolidatedBalanceSheetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consolidated Balance Sheets [Abstract]",
        "label": "Consolidated Balance Sheets [Abstract]",
        "terseLabel": "Consolidated Balance Sheets [Abstract]"
       }
      }
     },
     "localname": "ConsolidatedBalanceSheetsAbstract",
     "nsuri": "http://www.lexpharma.com/20221231",
     "xbrltype": "stringItemType"
    },
    "lxrx_ConsolidatedStatementsOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consolidated Statements of Cash Flows [Abstract]",
        "label": "Consolidated Statements of Cash Flows [Abstract]",
        "terseLabel": "Consolidated Statements of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "ConsolidatedStatementsOfCashFlowsAbstract",
     "nsuri": "http://www.lexpharma.com/20221231",
     "xbrltype": "stringItemType"
    },
    "lxrx_ConsolidatedStatementsOfOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consolidated Statements of Operations [Abstract]",
        "label": "Consolidated Statements of Operations [Abstract]",
        "terseLabel": "Consolidated Statements of Operations [Abstract]"
       }
      }
     },
     "localname": "ConsolidatedStatementsOfOperationsAbstract",
     "nsuri": "http://www.lexpharma.com/20221231",
     "xbrltype": "stringItemType"
    },
    "lxrx_ConsolidatedStatementsOfOperationsParentheticalsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consolidated Statements of Operations Parentheticals [Abstract]",
        "label": "Consolidated Statements of Operations Parentheticals [Abstract]",
        "terseLabel": "Consolidated Statements of Operations Parentheticals [Abstract]"
       }
      }
     },
     "localname": "ConsolidatedStatementsOfOperationsParentheticalsAbstract",
     "nsuri": "http://www.lexpharma.com/20221231",
     "xbrltype": "stringItemType"
    },
    "lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consolidated Statements of Stockholders\u2019 Equity [Abstract]",
        "label": "Consolidated Statements of Stockholders\u2019 Equity [Abstract]",
        "terseLabel": "Consolidated Statements of Stockholders\u2019 Equity [Abstract]"
       }
      }
     },
     "localname": "ConsolidatedStatementsOfStockholdersEquityAbstract",
     "nsuri": "http://www.lexpharma.com/20221231",
     "xbrltype": "stringItemType"
    },
    "lxrx_ConvertibleDebtExchange": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible debt exchange",
        "label": "Convertible debt exchange",
        "terseLabel": "Convertible debt exchange"
       }
      }
     },
     "localname": "ConvertibleDebtExchange",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_ConvertibleDebtExchangeTotalCashConsideration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Debt Exchange - Total cash consideration",
        "label": "Convertible Debt Exchange - Total cash consideration",
        "terseLabel": "Convertible Debt Exchange - Total cash consideration"
       }
      }
     },
     "localname": "ConvertibleDebtExchangeTotalCashConsideration",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed under convertible debt, under the debt agreement.",
        "label": "Convertible Debt Instrument Interest Rate Stated Percentage",
        "terseLabel": "Convertible Debt Instrument Interest Rate Stated Percentage"
       }
      }
     },
     "localname": "ConvertibleDebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_DebtInstrumentRepurchasePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Repurchase Percentage",
        "label": "Debt Instrument, Repurchase Percentage",
        "terseLabel": "Repurchase price"
       }
      }
     },
     "localname": "DebtInstrumentRepurchasePercentage",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_DebtObligationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Obligations [Abstract]",
        "label": "Debt Obligations [Abstract]",
        "terseLabel": "Debt Obligations [Abstract]"
       }
      }
     },
     "localname": "DebtObligationsAbstract",
     "nsuri": "http://www.lexpharma.com/20221231",
     "xbrltype": "stringItemType"
    },
    "lxrx_DecreaseInNOLs": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in NOLs",
        "label": "Decrease in NOLs",
        "terseLabel": "Decrease in NOLs"
       }
      }
     },
     "localname": "DecreaseInNOLs",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_DeferredCompensationArrangementWithIndividualPaymentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Compensation Arrangement With Individual, Payment Period",
        "label": "Deferred Compensation Arrangement With Individual, Payment Period",
        "terseLabel": "Payment period"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualPaymentPeriod",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lxrx_DeferredTaxAssetsSection163j_LXRX": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Section 163j_LXRX - represents the disallowed interest expense deduction as a result of adoption of the Tax Act in 2017",
        "label": "Deferred Tax Assets, Section 163j_LXRX",
        "terseLabel": "Deferred Tax Assets, Section 163j_LXRX"
       }
      }
     },
     "localname": "DeferredTaxAssetsSection163j_LXRX",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible orphan drug credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Orphan Drug",
        "terseLabel": "Deferred Tax Assets, Tax Credit Carryforwards, Orphan Drug"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs. Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million and issued 13,237,519 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation. Lexicon also agreed to make up to $45 million in additional payments, which will consist of 50% of any consideration Lexicon receives pursuant to any licensing transaction under which Lexicon grants a third party rights to commercialize LX1032, LX1033 or other pharmaceutical compositions modulating the same target as those drug candidates. This represents the deferred tax liability relating to the tax impact of future amortization or possible impairments associated with intangible assets acquired with Symphony Icon, which are not deductible for tax purposes.",
        "label": "Deferred Tax Liability Related to Acquisition of Symphony Icon",
        "terseLabel": "Deferred Tax Liability Related to Acquisition of Symphony Icon"
       }
      }
     },
     "localname": "DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_DefinedContributionPlanRequisiteServicePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Contribution Plan, Requisite Service Period",
        "label": "Defined Contribution Plan, Requisite Service Period",
        "terseLabel": "Years of service"
       }
      }
     },
     "localname": "DefinedContributionPlanRequisiteServicePeriod",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/BenefitPlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenues from external customers attributed to the entity's country of domicile as a percentage of total revenue.",
        "label": "Disclosure on Geographic Areas, Revenue from External Customers Attributed to Entity's Country of Domicile, Percent",
        "terseLabel": "Disclosure on Geographic Areas, Revenue from External Customers Attributed to Entity's Country of Domicile, Percent"
       }
      }
     },
     "localname": "DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure On Geographic Areas Revenue From External Customers Attributed to Germany",
        "label": "Disclosure On Geographic Areas Revenue From External Customers Attributed to Germany",
        "terseLabel": "Disclosure On Geographic Areas Revenue From External Customers Attributed to Germany"
       }
      }
     },
     "localname": "DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_EntityWideRevenueSanofiPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of revenue generated from Sanofi that accounts for 10 percent or more of an entity's revenues.",
        "label": "Entity Wide Revenue Sanofi Percentage",
        "terseLabel": "Entity Wide Revenue Sanofi Percentage"
       }
      }
     },
     "localname": "EntityWideRevenueSanofiPercentage",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationandSignficantCustomersDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_EquityIncentiveAwardsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Incentive Awards [Abstract]",
        "label": "Equity Incentive Awards [Abstract]",
        "terseLabel": "Equity Incentive Awards [Abstract]"
       }
      }
     },
     "localname": "EquityIncentiveAwardsAbstract",
     "nsuri": "http://www.lexpharma.com/20221231",
     "xbrltype": "stringItemType"
    },
    "lxrx_FairValueMeasurementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Measurements [Abstract]",
        "label": "Fair Value Measurements [Abstract]",
        "terseLabel": "Fair Value Measurements [Abstract]"
       }
      }
     },
     "localname": "FairValueMeasurementsAbstract",
     "nsuri": "http://www.lexpharma.com/20221231",
     "xbrltype": "stringItemType"
    },
    "lxrx_FinalConsiderationIncludingAmountsReleasedToSettle": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Final Consideration including amounts released to settle",
        "label": "Final Consideration including amounts released to settle",
        "terseLabel": "Final Consideration including amounts released to settle"
       }
      }
     },
     "localname": "FinalConsiderationIncludingAmountsReleasedToSettle",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/AssetSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_FinalPaymentWithExtention": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Final Payment % with extention",
        "label": "Final Payment % with extention",
        "terseLabel": "Final Payment % with extention"
       }
      }
     },
     "localname": "FinalPaymentWithExtention",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_FinalPaymentWithNoExtention": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Final Payment % with no extention",
        "label": "Final Payment % with no extention",
        "terseLabel": "Final Payment % with no extention"
       }
      }
     },
     "localname": "FinalPaymentWithNoExtention",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_GainOnSaleOfNonFinancialAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain on sale of non-financial assets",
        "label": "Gain on sale of non-financial assets",
        "negatedTerseLabel": "Gain on sale of non-financial assets",
        "terseLabel": "Gain on sale of non-financial assets"
       }
      }
     },
     "localname": "GainOnSaleOfNonFinancialAssets",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/AssetSaleDetails",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_GoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Goodwill [Abstract]",
        "label": "Goodwill [Abstract]",
        "terseLabel": "Goodwill [Abstract]"
       }
      }
     },
     "localname": "GoodwillAbstract",
     "nsuri": "http://www.lexpharma.com/20221231",
     "xbrltype": "stringItemType"
    },
    "lxrx_InterestOnLeasePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest on Lease Payments",
        "label": "Interest on Lease Payments",
        "terseLabel": "Interest on Lease Payments"
       }
      }
     },
     "localname": "InterestOnLeasePayments",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_IpsenMaximumRegulatoryAndCommercialMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the maximum regulatory and commercial launch milestone payments.",
        "label": "Ipsen Maximum Regulatory And Commercial Milestones",
        "terseLabel": "Ipsen Maximum Regulatory And Commercial Milestones"
       }
      }
     },
     "localname": "IpsenMaximumRegulatoryAndCommercialMilestones",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_IpsenMaximumSalesMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the maximum sales milestones payments.",
        "label": "Ipsen Maximum Sales Milestones",
        "terseLabel": "Ipsen Maximum Sales Milestones"
       }
      }
     },
     "localname": "IpsenMaximumSalesMilestones",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_IpsenMilestonePaymentReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl outside the United States and Japan. This represents the amount of milestone payments earned during the period.",
        "label": "Ipsen Milestone Payment Received",
        "terseLabel": "Ipsen Milestone Payment Received"
       }
      }
     },
     "localname": "IpsenMilestonePaymentReceived",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This is the amount of the upfront payment allocated to the committee participation deliverable.",
        "label": "Ipsen Revenue Allocated to Committee Deliverable",
        "terseLabel": "Ipsen Revenue Allocated to Committee Deliverable"
       }
      }
     },
     "localname": "IpsenRevenueAllocatedtoCommitteeDeliverable",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the amount of the upfront payment allocated to the development services deliverable.",
        "label": "Ipsen Revenue Allocated to Development Deliverable",
        "terseLabel": "Ipsen Revenue Allocated to Development Deliverable"
       }
      }
     },
     "localname": "IpsenRevenueAllocatedtoDevelopmentDeliverable",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_IpsenRevenueAllocatedtoLicenseDeliverable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the amount of the upfront payment allocated to the license deliverable.",
        "label": "Ipsen Revenue Allocated to License Deliverable",
        "terseLabel": "Ipsen Revenue Allocated to License Deliverable"
       }
      }
     },
     "localname": "IpsenRevenueAllocatedtoLicenseDeliverable",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_IpsenRevenueRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the revenue recognized in the period.",
        "label": "Ipsen Revenue Recognized",
        "terseLabel": "Ipsen Revenue Recognized"
       }
      }
     },
     "localname": "IpsenRevenueRecognized",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_IpsenTotalPaymentsToDate": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl outside the United States and Japan. This represents the total all payments under the agreement to date.",
        "label": "Ipsen Total Payments To Date",
        "terseLabel": "Ipsen Total Payments To Date"
       }
      }
     },
     "localname": "IpsenTotalPaymentsToDate",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_IpsenTotalUpfrontPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the total of the upfront payments under the agreement.",
        "label": "Ipsen Total Upfront Payments",
        "terseLabel": "Ipsen Total Upfront Payments"
       }
      }
     },
     "localname": "IpsenTotalUpfrontPayments",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_Ipsenproductsales": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl outside the United States and Japan. This represents the amount of product sales to Ipsen.",
        "label": "Ipsen product sales",
        "terseLabel": "Ipsen product sales"
       }
      }
     },
     "localname": "Ipsenproductsales",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_LXRXBiologicscustomerconcentration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "LXRX Biologics customer concentration - represents percent of revenue that Biologics contributes to total revenues",
        "label": "LXRX Biologics customer concentration",
        "terseLabel": "Biologics customer concentration"
       }
      }
     },
     "localname": "LXRXBiologicscustomerconcentration",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationandSignficantCustomersDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_LXRXDiplomatcustomerconcentration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "LXRX Diplomat customer concentration - represents the percent of revenue that Diplomat contributes to revenues",
        "label": "LXRX Diplomat customer concentration",
        "terseLabel": "LXRX Diplomat customer concentration"
       }
      }
     },
     "localname": "LXRXDiplomatcustomerconcentration",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationandSignficantCustomersDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_LexiconBorrowingRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lexicon borrowing rate",
        "label": "Lexicon borrowing rate",
        "terseLabel": "Lexicon borrowing rate"
       }
      }
     },
     "localname": "LexiconBorrowingRate",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_Lxrx_Sanofiterminationcashpayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "lxrx_Sanofi termination cash payment - represents the cash payment from Sanofi to terminate the collaboration alliance",
        "label": "lxrx_Sanofi termination cash payment",
        "terseLabel": "lxrx_Sanofi termination cash payment"
       }
      }
     },
     "localname": "Lxrx_Sanofiterminationcashpayment",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_MortgageDebtBalloonPayment_LXRX": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mortgage Debt Balloon Payment_LXRX - Balloon payment due at the end of the 2-year maturity date of mortgage loan with Revere.",
        "label": "Mortgage Debt Balloon Payment_LXRX",
        "terseLabel": "Mortgage Debt Balloon Payment_LXRX"
       }
      }
     },
     "localname": "MortgageDebtBalloonPayment_LXRX",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_MortgageDebtInstrument_Revere_LXRX": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mortgage Debt Instrument_Revere_LXRX - Principal loan amount borrowed, using Woodlands Campus as collateral",
        "label": "Mortgage Debt Instrument_Revere_LXRX",
        "terseLabel": "Mortgage Debt Instrument_Revere_LXRX"
       }
      }
     },
     "localname": "MortgageDebtInstrument_Revere_LXRX",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mortgage Debt Interest Rate BasePlus_Revere_LXRX - represents a base for the range of the interest rate that will be charged on the Revere loan. Interest charged will be greater of 30-day LIBOR plus 5.5% or 7.5%",
        "label": "Mortgage Debt Interest Rate BasePlus_Revere_LXRX",
        "terseLabel": "Mortgage Debt Interest Rate BasePlus_Revere_LXRX"
       }
      }
     },
     "localname": "MortgageDebtInterestRateBasePlus_Revere_LXRX",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_MortgageDebtInterestRate_Base_Revere_LXRX": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mortgage Debt Interest Rate_Base_Revere_LXRX - interest rate in Revere loan agreement is 30-day LIBOR plus 5.5% as base rate. Interest charged is the greater of base or 7.5%",
        "label": "Mortgage Debt Interest Rate_Base_Revere_LXRX",
        "terseLabel": "Mortgage Debt Interest Rate_Base_Revere_LXRX"
       }
      }
     },
     "localname": "MortgageDebtInterestRate_Base_Revere_LXRX",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_OfferingExpensesFromDecember20CommonStockOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Offering expenses from December 20 common stock offering",
        "label": "Offering expenses from December 20 common stock offering",
        "terseLabel": "Offering expenses from December 20 common stock offering"
       }
      }
     },
     "localname": "OfferingExpensesFromDecember20CommonStockOffering",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_OptionsOutstandingEquityIncentivePlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options to purchase shares outstanding under the Equity Incentive Plan.",
        "label": "Options Outstanding, Equity Incentive Plan",
        "terseLabel": "Options Outstanding, Equity Incentive Plan"
       }
      }
     },
     "localname": "OptionsOutstandingEquityIncentivePlan",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options to purchase shares outstanding under the Non-Employee Directors Equity Incentive Plan.",
        "label": "Options Outstanding, Non-Employee Directors Equity Incentive Plan",
        "terseLabel": "Options Outstanding, Non-Employee Directors Equity Incentive Plan"
       }
      }
     },
     "localname": "OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_OrganizationAndOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization and Operations [Abstract]",
        "label": "Organization and Operations [Abstract]",
        "terseLabel": "Organization and Operations [Abstract]"
       }
      }
     },
     "localname": "OrganizationAndOperationsAbstract",
     "nsuri": "http://www.lexpharma.com/20221231",
     "xbrltype": "stringItemType"
    },
    "lxrx_OtherCapitalAgreementsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Capital Agreements",
        "label": "Other Capital Agreements [Text Block]",
        "terseLabel": "Other Capital Agreements"
       }
      }
     },
     "localname": "OtherCapitalAgreementsTextBlock",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.lexpharma.com/role/OtherCapitalAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lxrx_OxfordAmendmentFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oxford Amendment Fee",
        "label": "Oxford Amendment Fee",
        "terseLabel": "Oxford Amendment Fee"
       }
      }
     },
     "localname": "OxfordAmendmentFee",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_OxfordFacilityFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oxford Facility Fee",
        "label": "Oxford Facility Fee",
        "terseLabel": "Oxford Facility Fee"
       }
      }
     },
     "localname": "OxfordFacilityFee",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_OxfordLoanFacility": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oxford Loan Facility",
        "label": "Oxford Loan Facility",
        "terseLabel": "Oxford Loan Facility"
       }
      }
     },
     "localname": "OxfordLoanFacility",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_PresentValueOfFutureLeasePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present Value of Future Lease Payments",
        "label": "Present Value of Future Lease Payments",
        "terseLabel": "Present Value of Future Lease Payments"
       }
      }
     },
     "localname": "PresentValueOfFutureLeasePayments",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_PrincipalAmountOfConvertibleNotes": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Principal amount of convertible notes",
        "label": "Principal amount of convertible notes",
        "terseLabel": "Principal amount of convertible notes"
       }
      }
     },
     "localname": "PrincipalAmountOfConvertibleNotes",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_ProceedsFromDecember2020CommonStockOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from December 2020 common stock offering",
        "label": "Proceeds from December 2020 common stock offering",
        "terseLabel": "Proceeds from December 2020 common stock offering"
       }
      }
     },
     "localname": "ProceedsFromDecember2020CommonStockOffering",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_ProceedsFromJanuary2021ATMOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from January 2021 ATM Offering",
        "label": "Proceeds from January 2021 ATM Offering",
        "terseLabel": "Proceeds from January 2021 ATM Offering"
       }
      }
     },
     "localname": "ProceedsFromJanuary2021ATMOffering",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_ProceedsFromJuly2022Offering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from July 2022 Offering",
        "label": "Proceeds from July 2022 Offering",
        "terseLabel": "Proceeds from July 2022 Offering"
       }
      }
     },
     "localname": "ProceedsFromJuly2022Offering",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_ProceedsFromNov2020ATMOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Nov 2020 ATM Offering",
        "label": "Proceeds from Nov 2020 ATM Offering",
        "terseLabel": "Proceeds from Nov 2020 ATM Offering"
       }
      }
     },
     "localname": "ProceedsFromNov2020ATMOffering",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_ProceedsFromSeptember2021ATMOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from September 2021 ATM Offering",
        "label": "Proceeds from September 2021 ATM Offering",
        "terseLabel": "Proceeds from September 2021 ATM Offering"
       }
      }
     },
     "localname": "ProceedsFromSeptember2021ATMOffering",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_PropertyAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property and Equipment [Abstract]",
        "label": "Property and Equipment [Abstract]",
        "terseLabel": "Property and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyAndEquipmentAbstract",
     "nsuri": "http://www.lexpharma.com/20221231",
     "xbrltype": "stringItemType"
    },
    "lxrx_RDSeveranceCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "R&amp;D severance costs",
        "label": "R&amp;D severance costs [Member]",
        "terseLabel": "R&amp;D severance costs"
       }
      }
     },
     "localname": "RDSeveranceCostsMember",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "domainItemType"
    },
    "lxrx_RDTaxCreditDecrease": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "R&amp;D Tax Credit Decrease",
        "label": "R&amp;D Tax Credit Decrease",
        "terseLabel": "R&amp;D Tax Credit Decrease"
       }
      }
     },
     "localname": "RDTaxCreditDecrease",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_RecentAccountingPronouncementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recent Accounting Pronouncements [Abstract]",
        "label": "Recent Accounting Pronouncements [Abstract]",
        "terseLabel": "Recent Accounting Pronouncements [Abstract]"
       }
      }
     },
     "localname": "RecentAccountingPronouncementsAbstract",
     "nsuri": "http://www.lexpharma.com/20221231",
     "xbrltype": "stringItemType"
    },
    "lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialCostsFundedPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Arrangement, Contract To Perform For Others, Commercial Costs, Funded Percentage",
        "label": "Research And Development Arrangement, Contract To Perform For Others, Commercial Costs, Funded Percentage",
        "terseLabel": "Funded commercialization costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialCostsFundedPercentage",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentCostsPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Arrangement, Contract To Perform For Others, Development Costs Period",
        "label": "Research And Development Arrangement, Contract To Perform For Others, Development Costs Period",
        "terseLabel": "Development costs period"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentCostsPeriod",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Arrangement, Contract To Perform For Others, Expiration Period",
        "label": "Research And Development Arrangement, Contract To Perform For Others, Expiration Period",
        "terseLabel": "Expiration period"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfCommercialMilestones": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Arrangement, Contract To Perform For Others, Number Of Commercial Milestones",
        "label": "Research And Development Arrangement, Contract To Perform For Others, Number Of Commercial Milestones",
        "terseLabel": "Number of commercial milestones"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfCommercialMilestones",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfDevelopmentMilestones": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Arrangement, Contract To Perform For Others, Number Of Development Milestones",
        "label": "Research And Development Arrangement, Contract To Perform For Others, Number Of Development Milestones",
        "terseLabel": "Number of development milestones"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfDevelopmentMilestones",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfRegulatoryMilestones": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Arrangement, Contract To Perform For Others, Number Of Regulatory Milestones",
        "label": "Research And Development Arrangement, Contract To Perform For Others, Number Of Regulatory Milestones",
        "terseLabel": "Number of regulatory milestones"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfRegulatoryMilestones",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltiesPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Arrangement, Contract To Perform For Others, Royalties Percentage",
        "label": "Research And Development Arrangement, Contract To Perform For Others, Royalties Percentage",
        "terseLabel": "Royalties percentage"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltiesPercentage",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted stock units outstanding under the Equity Incentive Plan.",
        "label": "Restricted Stock Units Outstanding, Equity Incentive Plan",
        "terseLabel": "Restricted Stock Units Outstanding, Equity Incentive Plan"
       }
      }
     },
     "localname": "RestrictedStockUnitsOutstandingEquityIncentivePlan",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_RestrictedStockUnitsOutstandingNonEmployeeDirectorsEquityIncentivePlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Stock Units Outstanding, Non-Employee Directors Equity Incentive Plan",
        "label": "Restricted Stock Units Outstanding, Non-Employee Directors Equity Incentive Plan",
        "terseLabel": "Restricted Stock Units Outstanding, Non-Employee Directors Equity Incentive Plan"
       }
      }
     },
     "localname": "RestrictedStockUnitsOutstandingNonEmployeeDirectorsEquityIncentivePlan",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_SaleOfNonFinancialAssetsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Non-Financial Assets",
        "label": "Sale of Non-Financial Assets [Text Block]",
        "terseLabel": "Sale of Non-Financial Assets"
       }
      }
     },
     "localname": "SaleOfNonFinancialAssetsTextBlock",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/AssetSale"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lxrx_SanofiCommercializationCostsFundedbyLexiconMaximumAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate satagliflozin. This represents the maximum amount that Lexicon will fund of the planned type 2 diabetes development costs.",
        "label": "Sanofi Commercialization Costs Funded by Lexicon Maximum Amount",
        "terseLabel": "Sanofi Development Costs Funded by Lexicon Maximum Amount"
       }
      }
     },
     "localname": "SanofiCommercializationCostsFundedbyLexiconMaximumAmount",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_SanofiDeferredRevenueFromTermination": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sanofi Deferred Revenue from Termination",
        "label": "Sanofi Deferred Revenue from Termination",
        "terseLabel": "Sanofi Deferred Revenue from Termination"
       }
      }
     },
     "localname": "SanofiDeferredRevenueFromTermination",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_SanofiDevelopmentMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate satagliflozin. This represents the development milestones relating to the achievement of positive results in certain Phase 3 clinical trials in type 2 diabetes patients.",
        "label": "Sanofi Development Milestones",
        "terseLabel": "Sanofi Development Milestones"
       }
      }
     },
     "localname": "SanofiDevelopmentMilestones",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_SanofiOutcomesStudyMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate satagliflozin. This represents the milestone based on the results of an outcomes study in type 2 diabetes patients the completion of which would likely occur after initial regulatory approval.",
        "label": "Sanofi Outcomes Study Milestone",
        "terseLabel": "Sanofi Outcomes Study Milestone"
       }
      }
     },
     "localname": "SanofiOutcomesStudyMilestone",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_SanofiRegulatoryMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the regulatory milestones relating to the first commercial sale following regulatory approval of sotagliflozin for type 1 and type 2 diabetes in each of the United States and Europe.",
        "label": "Sanofi Regulatory Milestones",
        "terseLabel": "Sanofi Regulatory Milestones"
       }
      }
     },
     "localname": "SanofiRegulatoryMilestones",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the amount of the upfront payment allocated to the development services deliverable.",
        "label": "Sanofi Revenue Allocated to Development Deliverable",
        "terseLabel": "Sanofi Revenue Allocated to Development Deliverable"
       }
      }
     },
     "localname": "SanofiRevenueAllocatedtoDevelopmentDeliverable",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_SanofiRevenueAllocatedtoFundingDeliverable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the amount of the upfront payment allocated to the funding deliverable.",
        "label": "Sanofi Revenue Allocated to Funding Deliverable",
        "terseLabel": "Sanofi Revenue Allocated to Funding Deliverable"
       }
      }
     },
     "localname": "SanofiRevenueAllocatedtoFundingDeliverable",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_SanofiRevenueAllocatedtoLicenseDeliverable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the amount of the upfront payment allocated to the license deliverable.",
        "label": "Sanofi Revenue Allocated to License Deliverable",
        "terseLabel": "Sanofi Revenue Allocated to License Deliverable"
       }
      }
     },
     "localname": "SanofiRevenueAllocatedtoLicenseDeliverable",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_SanofiRevenueRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the revenue recognized in the period.",
        "label": "Sanofi Revenue Recognized",
        "terseLabel": "Sanofi Revenue Recognized"
       }
      }
     },
     "localname": "SanofiRevenueRecognized",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_SanofiSalesMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate satagliflozin. This represents the potential sales milestones payments under the agreement.",
        "label": "Sanofi Sales Milestone Payments",
        "terseLabel": "Sanofi Sales Milestone Payments"
       }
      }
     },
     "localname": "SanofiSalesMilestonePayments",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_SanofiTerminationAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sanofi Termination Agreement",
        "label": "Sanofi Termination Agreement",
        "terseLabel": "Sanofi Termination Agreement"
       }
      }
     },
     "localname": "SanofiTerminationAgreement",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_SanofiUpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate satagliflozin. This represents the upfront payment under the agreement.",
        "label": "Sanofi Upfront Payment",
        "terseLabel": "Sanofi Upfront Payment"
       }
      }
     },
     "localname": "SanofiUpfrontPayment",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_SettlementPaymentFromTermination": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Settlement Payment from Termination",
        "label": "Settlement Payment from Termination",
        "terseLabel": "Settlement Payment from Termination"
       }
      }
     },
     "localname": "SettlementPaymentFromTermination",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period, Weighted Average Fair Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period, Weighted Average Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4"
     ],
     "xbrltype": "perShareItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the employees' option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Employees",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Employees"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the officers' and non-employee directors' option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Officers and Non-employee Directors",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Officers and Non-employee Directors"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The expected term assumption that is used in valuing an option on its own shares for employees.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Employees",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Employees"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1"
     ],
     "xbrltype": "durationItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The expected term assumption that is used in valuing an option on its own shares for officers and non-employee directors.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Officers and Non-employee Directors",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Officers and Non-employee Directors"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1"
     ],
     "xbrltype": "durationItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For officers and non-employee directors, the estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Officers and Non-employee Directors",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Officers and Non-employee Directors"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For employees, the estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, ExpectedVolatilityRate, Employees",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected VolatilityRate, Employees"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares for employees.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Employee",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Employee"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares for officers and non-employee directors.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Officers and Non-employee Directors",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Officers and Non-employee Directors"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants of stock bonus and restricted stock awards made during the period under equity incentive plans.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Stock Bonus And Restricted Stock Grants In Period",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Stock Bonus and Restricted Stock, Grants in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_SharePriceInJanuary2021ATMOffering": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share price in January 2021 ATM Offering",
        "label": "Share price in January 2021 ATM Offering",
        "terseLabel": "Share price in January 2021 ATM Offering"
       }
      }
     },
     "localname": "SharePriceInJanuary2021ATMOffering",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_SharePriceInJuly2022Offering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Price in July 2022 Offering",
        "label": "Share Price in July 2022 Offering",
        "terseLabel": "Share Price in July 2022 Offering"
       }
      }
     },
     "localname": "SharePriceInJuly2022Offering",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_SharePriceInNovember20ATMOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share price in November 20 ATM Offering",
        "label": "Share price in November 20 ATM Offering",
        "terseLabel": "Share price in November 20 ATM Offering"
       }
      }
     },
     "localname": "SharePriceInNovember20ATMOffering",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_SharePriceInSeptember2021ATMOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Price in September 2021 ATM Offering",
        "label": "Share Price in September 2021 ATM Offering",
        "terseLabel": "Share Price in September 2021 ATM Offering"
       }
      }
     },
     "localname": "SharePriceInSeptember2021ATMOffering",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant date fair value for grants of stock bonus and restricted stock awards made to consultants during the period under equity incentive plans.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Stock Bonus and Restricted Stock to Consultants, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Stock Bonus and Restricted Stock to Consultants, Grants in Period, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3"
     ],
     "xbrltype": "perShareItemType"
    },
    "lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued pursuant to restricted stock awards under the Non-Employee Directors Equity Incentive Plan.",
        "label": "Shares Issued Pursuant to Restricted Stock Awards, Non-Employee Directors Equity Incentive Plan",
        "terseLabel": "Shares Issued Pursuant to Restricted Stock Awards, Non-Employee Directors Equity Incentive Plan"
       }
      }
     },
     "localname": "SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued pursuant to restricted stock units under the Equity Incentive Plan.",
        "label": "Shares Issued Pursuant to Restricted Stock Units, Equity Incentive Plan",
        "terseLabel": "Shares Issued Pursuant to Restricted Stock Units, Equity Incentive Plan"
       }
      }
     },
     "localname": "SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued pursuant to stock bonus awards or restricted stock awards under the Equity Incentive Plan.",
        "label": "Shares Issued Pursuant to Stock Bonus Awards, Equity Incentive Plan",
        "terseLabel": "Shares Issued Pursuant to Stock Bonus Awards, Equity Incentive Plan"
       }
      }
     },
     "localname": "SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_SharesSoldInJanuary2021ATMOffering": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares sold in January 2021 ATM offering",
        "label": "Shares sold in January 2021 ATM offering",
        "terseLabel": "Shares sold in January 2021 ATM offering"
       }
      }
     },
     "localname": "SharesSoldInJanuary2021ATMOffering",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_SharesSoldInJuly2022Offering": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares sold in July 2022 Offering",
        "label": "Shares sold in July 2022 Offering",
        "terseLabel": "Shares sold in July 2022 Offering"
       }
      }
     },
     "localname": "SharesSoldInJuly2022Offering",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_SharesSoldInNov2020ATMOffering": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares sold in Nov 2020 ATM Offering",
        "label": "Shares sold in Nov 2020 ATM Offering",
        "terseLabel": "Shares sold in Nov 2020 ATM Offering"
       }
      }
     },
     "localname": "SharesSoldInNov2020ATMOffering",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_SharesSoldInSeptember2021ATMOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares sold in September 2021 ATM offering",
        "label": "Shares sold in September 2021 ATM offering",
        "terseLabel": "Shares sold in September 2021 ATM offering"
       }
      }
     },
     "localname": "SharesSoldInSeptember2021ATMOffering",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock-based compensation expense associated with general and administrative expense.",
        "label": "Stock-based compensation expense associated with general and administrative expense",
        "terseLabel": "Stock-based compensation expense associated with general and administrative expense"
       }
      }
     },
     "localname": "StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/StatementsofComprehensiveLossParentheticalsParentheticals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock-based compensation expense included in research and development expense.",
        "label": "Stock-based compensation expense associated with research and development expense",
        "terseLabel": "Stock-based compensation expense associated with research and development expense"
       }
      }
     },
     "localname": "StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/StatementsofComprehensiveLossParentheticalsParentheticals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incentive and nonstatutory stock options have an exercise price of 100% or more of the fair market value of common stock on the date of grant.",
        "label": "Stock Option Exercise Price as Percent of Value of Common Stock",
        "terseLabel": "Stock Option Exercise Price as Percent of Value of Common Stock"
       }
      }
     },
     "localname": "StockOptionExercisePriceAsPercentOfValueOfCommonStock",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_StockOptionsExercisedEquityIncentivePlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued upon the exercise of stock options under the Equity Incentive Plan.",
        "label": "Stock Options Exercised, Equity Incentive Plan",
        "terseLabel": "Stock Options Exercised, Equity Incentive Plan"
       }
      }
     },
     "localname": "StockOptionsExercisedEquityIncentivePlan",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued upon the exercise of stock options under the Non-Employee Directors Equity Incentive Plan.",
        "label": "Stock Options Exercised, Non-Employee Directors Equity Incentive Plan",
        "terseLabel": "Stock Options Exercised, Non-Employee Directors Equity Incentive Plan"
       }
      }
     },
     "localname": "StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_SymphonyIconGoodwill": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "On July 30, 2010, Lexicon exercised its Purchase Option and completed the acquisition of Symphony Icon. Goodwill associated with the acquisition of $18.7 million, which represents the assets recognized in connection with the deferred tax liability acquired and did not result from excess purchase price, was assigned to the consolidated entity, Lexicon.",
        "label": "Symphony Icon Goodwill",
        "terseLabel": "Symphony Icon Goodwill"
       }
      }
     },
     "localname": "SymphonyIconGoodwill",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/GoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TerSera Maximum Development, Regulatory and Commercial Milestones",
        "label": "TerSera Maximum Development, Regulatory and Commercial Milestones",
        "terseLabel": "TerSera Maximum Development, Regulatory and Commercial Milestones"
       }
      }
     },
     "localname": "TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/AssetSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_TermLoanA": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan A",
        "label": "Term Loan A",
        "terseLabel": "Term Loan A"
       }
      }
     },
     "localname": "TermLoanA",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_TermLoanABWarrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan A&amp;B Warrant %",
        "label": "Term Loan A&amp;B Warrant %",
        "terseLabel": "Term Loan A&amp;B Warrant %"
       }
      }
     },
     "localname": "TermLoanABWarrant",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_TermLoanADebtDiscount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan A Debt Discount",
        "label": "Term Loan A Debt Discount",
        "terseLabel": "Term Loan A Debt Discount"
       }
      }
     },
     "localname": "TermLoanADebtDiscount",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_TermLoanADebtIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan A Debt Issuance Costs",
        "label": "Term Loan A Debt Issuance Costs",
        "terseLabel": "Term Loan A Debt Issuance Costs"
       }
      }
     },
     "localname": "TermLoanADebtIssuanceCosts",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_TermLoanAFinalPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan A Final Payment",
        "label": "Term Loan A Final Payment",
        "terseLabel": "Term Loan A Final Payment"
       }
      }
     },
     "localname": "TermLoanAFinalPayment",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_TermLoanANetCashReceipt": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan A Net Cash Receipt",
        "label": "Term Loan A Net Cash Receipt",
        "terseLabel": "Term Loan A Net Cash Receipt"
       }
      }
     },
     "localname": "TermLoanANetCashReceipt",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_TermLoanAWarrantExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan A Warrant Exercise Price",
        "label": "Term Loan A Warrant Exercise Price",
        "terseLabel": "Term Loan A Warrant Exercise Price"
       }
      }
     },
     "localname": "TermLoanAWarrantExercisePrice",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "lxrx_TermLoanAWarrantsNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan A Warrants Number",
        "label": "Term Loan A Warrants Number",
        "terseLabel": "Term Loan A Warrants Number"
       }
      }
     },
     "localname": "TermLoanAWarrantsNumber",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_TermLoanB": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan B",
        "label": "Term Loan B",
        "terseLabel": "Term Loan B"
       }
      }
     },
     "localname": "TermLoanB",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_TermLoanBDebtDiscount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan B Debt Discount",
        "label": "Term Loan B Debt Discount",
        "terseLabel": "Term Loan B Debt Discount"
       }
      }
     },
     "localname": "TermLoanBDebtDiscount",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_TermLoanBNetCashReceipt": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan B Net Cash Receipt",
        "label": "Term Loan B Net Cash Receipt",
        "terseLabel": "Term Loan B Net Cash Receipt"
       }
      }
     },
     "localname": "TermLoanBNetCashReceipt",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_TermLoanC": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan C",
        "label": "Term Loan C",
        "terseLabel": "Term Loan C"
       }
      }
     },
     "localname": "TermLoanC",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_TermLoanCWarrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan C Warrant %",
        "label": "Term Loan C Warrant %",
        "terseLabel": "Term Loan C Warrant %"
       }
      }
     },
     "localname": "TermLoanCWarrant",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_TermLoanD": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan D",
        "label": "Term Loan D",
        "terseLabel": "Term Loan D"
       }
      }
     },
     "localname": "TermLoanD",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_TermLoanDWarrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan D Warrant %",
        "label": "Term Loan D Warrant %",
        "terseLabel": "Term Loan D Warrant %"
       }
      }
     },
     "localname": "TermLoanDWarrant",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total number of shares of common stock that may be issued pursuant to stock awards under the Equity Incentive Plan.",
        "label": "Total Shares That May be Issued, Equity Incentive Plan",
        "terseLabel": "Total Shares That May be Issued, Equity Incentive Plan"
       }
      }
     },
     "localname": "TotalSharesThatMayBeIssuedEquityIncentivePlan",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total number of shares of common stock that may be issued pursuant to stock awards under the Non-Employee Directors Equity Incentive Plan.",
        "label": "Total Shares That May Be Issued, Non-Employee Directors Equity Incentive Plan",
        "terseLabel": "Total Shares That May Be Issued, Non-Employee Directors Equity Incentive Plan"
       }
      }
     },
     "localname": "TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_Totalvalueofsharesbynonemployeeinayear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total value of shares by nonemployee in a year - represents amounts under which non-employee director may be granted awards under the Non-Employee Directors Equity Incentive Plan such that the aggregate grant date fair value may not exceed $500,000 in any calendar year",
        "label": "Total value of shares by nonemployee in a year",
        "terseLabel": "Total value of shares by nonemployee in a year"
       }
      }
     },
     "localname": "Totalvalueofsharesbynonemployeeinayear",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_WriteOffOfTaxCredits": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Write-off of tax credits",
        "label": "Write-off of tax credits",
        "terseLabel": "Write-off of tax credits"
       }
      }
     },
     "localname": "WriteOffOfTaxCredits",
     "nsuri": "http://www.lexpharma.com/20221231",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "naics_ZZ541713": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "541713 Research and Development in Nanotechnology [Member]",
        "terseLabel": "541713 Research and Development in Nanotechnology"
       }
      }
     },
     "localname": "ZZ541713",
     "nsuri": "http://xbrl.sec.gov/naics/2022",
     "presentation": [
      "http://www.lexpharma.com/role/AssetSaleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CondensedFinancialStatementsCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Financial Statements, Captions [Line Items]",
        "terseLabel": "Condensed Financial Statements, Captions"
       }
      }
     },
     "localname": "CondensedFinancialStatementsCaptionsLineItems",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedQuarterlyFinancialInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r342",
      "r343",
      "r344",
      "r345",
      "r409",
      "r568",
      "r590",
      "r624",
      "r625",
      "r645",
      "r649",
      "r657",
      "r705",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails",
      "http://www.lexpharma.com/role/PropertyandEquipmentDetails",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r342",
      "r343",
      "r344",
      "r345",
      "r409",
      "r568",
      "r590",
      "r624",
      "r625",
      "r645",
      "r649",
      "r657",
      "r705",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails",
      "http://www.lexpharma.com/role/PropertyandEquipmentDetails",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r342",
      "r343",
      "r344",
      "r345",
      "r392",
      "r409",
      "r442",
      "r443",
      "r444",
      "r567",
      "r568",
      "r590",
      "r624",
      "r625",
      "r645",
      "r649",
      "r657",
      "r701",
      "r705",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3",
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails",
      "http://www.lexpharma.com/role/PropertyandEquipmentDetails",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r342",
      "r343",
      "r344",
      "r345",
      "r392",
      "r409",
      "r442",
      "r443",
      "r444",
      "r567",
      "r568",
      "r590",
      "r624",
      "r625",
      "r645",
      "r649",
      "r657",
      "r701",
      "r705",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3",
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails",
      "http://www.lexpharma.com/role/PropertyandEquipmentDetails",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAxis": {
     "auth_ref": [
      "r184",
      "r230",
      "r231",
      "r232",
      "r236",
      "r237",
      "r241",
      "r242",
      "r243",
      "r244",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r270",
      "r321",
      "r322",
      "r473",
      "r503",
      "r508",
      "r509",
      "r510",
      "r546",
      "r560",
      "r561",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Axis]",
        "terseLabel": "Restatement [Axis]"
       }
      }
     },
     "localname": "RestatementAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RestatementDomain": {
     "auth_ref": [
      "r184",
      "r230",
      "r231",
      "r232",
      "r236",
      "r237",
      "r241",
      "r242",
      "r243",
      "r244",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r270",
      "r321",
      "r322",
      "r473",
      "r503",
      "r508",
      "r509",
      "r510",
      "r546",
      "r560",
      "r561",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Domain]",
        "terseLabel": "Restatement [Domain]"
       }
      }
     },
     "localname": "RestatementDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r251",
      "r410",
      "r670",
      "r690"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario, Unspecified [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.lexpharma.com/role/BalanceSheetParentheticals",
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.lexpharma.com/role/StatementsofComprehensiveLossParentheticalsParentheticals"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfCondensedFinancialStatementsTable": {
     "auth_ref": [
      "r229",
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Financial Statements [Table]",
        "terseLabel": "Schedule of Condensed Financial Statements [Table]"
       }
      }
     },
     "localname": "ScheduleOfCondensedFinancialStatementsTable",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedQuarterlyFinancialInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r251",
      "r410",
      "r670",
      "r672",
      "r690"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Statement, Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.lexpharma.com/role/BalanceSheetParentheticals",
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.lexpharma.com/role/StatementsofComprehensiveLossParentheticalsParentheticals"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of receivable.",
        "label": "Receivable Type [Axis]",
        "terseLabel": "Receivable Type [Axis]"
       }
      }
     },
     "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r19",
      "r656"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r305",
      "r306"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net of allowances of $4"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r153",
      "r169"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.",
        "label": "Accrued Liabilities",
        "terseLabel": "Accrued Liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r88",
      "r193"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Accumulated depreciation and amortization, property and equipment"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/BalanceSheetParentheticals",
      "http://www.lexpharma.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r33",
      "r34",
      "r35",
      "r201",
      "r587",
      "r598",
      "r602"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r32",
      "r35",
      "r131",
      "r561",
      "r593",
      "r594",
      "r679",
      "r680",
      "r681",
      "r687",
      "r688",
      "r689"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Gain (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r14",
      "r656"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r450",
      "r451",
      "r452",
      "r687",
      "r688",
      "r689",
      "r740"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r236",
      "r237",
      "r238",
      "r240",
      "r251",
      "r310",
      "r311",
      "r315",
      "r316",
      "r317",
      "r318",
      "r321",
      "r322",
      "r450",
      "r451",
      "r452",
      "r470",
      "r471",
      "r472",
      "r473",
      "r485",
      "r486",
      "r487",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r529",
      "r530",
      "r538",
      "r539",
      "r543",
      "r544",
      "r545",
      "r546",
      "r555",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r575",
      "r576",
      "r577",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]",
        "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/RecentAccountingPronouncementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r119",
      "r120",
      "r413"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r94",
      "r100",
      "r106"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Adjustments to Additional Paid in Capital, Warrant Issued"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile consolidated net loss to net cash provided by (used in) operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r377",
      "r541",
      "r643",
      "r644",
      "r682"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r59",
      "r86"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Asset Impairment Charges"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.lexpharma.com/role/PropertyandEquipmentDetails",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesImpairmentofLongLivedAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetRetirementObligationDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Retirement Obligation Disclosure [Abstract]"
       }
      }
     },
     "localname": "AssetRetirementObligationDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r146",
      "r163",
      "r196",
      "r227",
      "r287",
      "r291",
      "r296",
      "r314",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r492",
      "r497",
      "r519",
      "r656",
      "r703",
      "r704",
      "r744"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r188",
      "r205",
      "r227",
      "r314",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r492",
      "r497",
      "r519",
      "r656",
      "r703",
      "r704",
      "r744"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Assets, Current [Abstract]"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.",
        "label": "Available-for-Sale Securities",
        "terseLabel": "Available-for-sale Securities, Fair Value Disclosure"
       }
      }
     },
     "localname": "AvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r77"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.",
        "label": "Available-for-Sale Securities, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Available-for-sale Securities, Gross Unrealized Gain Accumulated in Investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.",
        "label": "Available-for-Sale Securities, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Available-for-sale Securities, Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAmortizedCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.",
        "label": "Available-for-Sale Securities, Amortized Cost Basis",
        "terseLabel": "Available-for-sale Securities, Amortized Cost Basis"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.",
        "label": "Available-for-Sale Securities, Current",
        "terseLabel": "Available-for-sale Securities, Current"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r417",
      "r418",
      "r419",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2",
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3",
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4",
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BuildingAndBuildingImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.",
        "label": "Building and Building Improvements [Member]",
        "terseLabel": "Buildings"
       }
      }
     },
     "localname": "BuildingAndBuildingImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "auth_ref": [
      "r129"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessExitCosts1": {
     "auth_ref": [
      "r59"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Business Exit Costs",
        "terseLabel": "Business Exit Costs"
       }
      }
     },
     "localname": "BusinessExitCosts1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r61",
      "r191",
      "r627"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and cash equivalents at end of year",
        "periodStartLabel": "Cash and cash equivalents at beginning of year",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsDisclosureTextBlock": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.",
        "label": "Cash and Cash Equivalents Disclosure [Text Block]",
        "terseLabel": "Cash and Cash Equivalents and Investments"
       }
      }
     },
     "localname": "CashAndCashEquivalentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and Cash Equivalents, Fair Value Disclosure"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Cash and Cash Equivalents [Line Items]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease": {
     "auth_ref": [],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.",
        "label": "Cash and Cash Equivalents, Period Increase (Decrease) (Deprecated 2022)",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents, Policy"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosure of noncash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashMember": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.",
        "label": "Cash [Member]",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "CashMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r198",
      "r199",
      "r200",
      "r227",
      "r256",
      "r260",
      "r264",
      "r266",
      "r274",
      "r275",
      "r314",
      "r346",
      "r348",
      "r349",
      "r350",
      "r353",
      "r354",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r519",
      "r626",
      "r669",
      "r683",
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/BalanceSheetParentheticals",
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r488",
      "r489",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaboration and License Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r28",
      "r154",
      "r168"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r92",
      "r340",
      "r341",
      "r620",
      "r702"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r687",
      "r688",
      "r740"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/BalanceSheetParentheticals",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value per share (usd per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/BalanceSheetParentheticals",
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/BalanceSheetParentheticals",
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/BalanceSheetParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r13",
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Balance, shares",
        "periodStartLabel": "Balance, shares"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r13",
      "r656"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $.001 par value; 225,000 shares authorized; 106,679 and 106,162 shares issued, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r36",
      "r209",
      "r211",
      "r218",
      "r583",
      "r588"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "terseLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computers and Software"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskDisclosureTextBlock": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.",
        "label": "Concentration Risk Disclosure [Text Block]",
        "terseLabel": "Concentration Risk Disclosure"
       }
      }
     },
     "localname": "ConcentrationRiskDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r130",
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Consolidation, Policy"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConversionOfStockAmountIssued1": {
     "auth_ref": [
      "r63",
      "r64",
      "r65"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Amount Issued",
        "terseLabel": "Conversion of Stock, Amount Issued"
       }
      }
     },
     "localname": "ConversionOfStockAmountIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "auth_ref": [
      "r63",
      "r64",
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "ConversionOfStockSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConvertibleDebt": {
     "auth_ref": [
      "r9",
      "r149",
      "r164"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.",
        "label": "Convertible Debt",
        "terseLabel": "Convertible Debt"
       }
      }
     },
     "localname": "ConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r41",
      "r573"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of sales (including finite-lived intangible asset amortization)"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "auth_ref": [
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "terseLabel": "Cost of Sales"
       }
      }
     },
     "localname": "CostOfSalesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r686",
      "r738",
      "r739"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "Current State and Local Tax Expense (Benefit)"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r99",
      "r226",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r371",
      "r378",
      "r379",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt Obligations"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r7",
      "r8",
      "r9",
      "r147",
      "r149",
      "r160",
      "r229",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r361",
      "r367",
      "r368",
      "r369",
      "r370",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r542",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r684"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r9",
      "r149",
      "r160",
      "r382"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-Term Debt, Gross",
        "terseLabel": "Long-Term Debt, Gross"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r95",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Debt Instrument, Convertible, Conversion Price"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "auth_ref": [
      "r25",
      "r101",
      "r102",
      "r104",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "terseLabel": "Debt Instrument, Convertible, Conversion Ratio"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal": {
     "auth_ref": [
      "r96"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount by which the convertible debt's if-converted value exceeds its principle amount at the balance sheet date, regardless of whether the instrument is currently convertible. This element applies to public companies only.",
        "label": "Debt Instrument, Convertible, If-converted Value in Excess of Principal",
        "terseLabel": "Debt Instrument, Convertible, If-converted Value in Excess of Principal"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r141",
      "r143",
      "r355",
      "r542",
      "r641",
      "r642"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt Instrument, Face Amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r369",
      "r518",
      "r641",
      "r642"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Debt Instrument, Fair Value Disclosure"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r24",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/AssetSaleDetails",
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r26",
      "r229",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r361",
      "r367",
      "r368",
      "r369",
      "r370",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r542",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r684"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r26",
      "r101",
      "r103",
      "r104",
      "r105",
      "r140",
      "r141",
      "r143",
      "r158",
      "r229",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r361",
      "r367",
      "r368",
      "r369",
      "r370",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r380",
      "r542",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r684"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/AssetSaleDetails",
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Debt instrument, term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtWeightedAverageInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average interest rate of debt outstanding.",
        "label": "Debt, Weighted Average Interest Rate",
        "terseLabel": "Debt, Weighted Average Interest Rate"
       }
      }
     },
     "localname": "DebtWeightedAverageInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]",
        "terseLabel": "Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails2",
      "http://www.lexpharma.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "auth_ref": [
      "r142"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Gross",
        "terseLabel": "Debt Issuance Costs, Gross"
       }
      }
     },
     "localname": "DeferredFinanceCostsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r59",
      "r128",
      "r468",
      "r478",
      "r479",
      "r686"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax benefit",
        "terseLabel": "Income Tax Benefit",
        "verboseLabel": "Deferred tax benefit"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.lexpharma.com/role/IncomeTaxesDetails1",
      "http://www.lexpharma.com/role/IncomeTaxesDetails2",
      "http://www.lexpharma.com/role/IncomeTaxesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r10",
      "r11",
      "r148",
      "r159",
      "r462"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/IncomeTaxesDetails1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Deferred Tax Liabilities, Gross"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetDomain": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the deferred tax asset for which a valuation reserve exists.",
        "label": "Deferred Tax Asset [Domain]",
        "terseLabel": "Deferred Tax Asset [Domain]"
       }
      }
     },
     "localname": "DeferredTaxAssetDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails1",
      "http://www.lexpharma.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r463"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "terseLabel": "Deferred Tax Assets, Gross"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r127",
      "r737"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Deferred Tax Assets, In Process Research and Development"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r127",
      "r737"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Deferred Tax Assets, Operating Loss Carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": {
     "auth_ref": [
      "r127",
      "r737"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Domestic",
        "terseLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Domestic"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "auth_ref": [
      "r127",
      "r737"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local",
        "terseLabel": "Operating Loss Carryforwards, State"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r127",
      "r737"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Deferred Tax Assets, Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r126",
      "r127",
      "r737"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Deferred Tax Assets, Tax Credit Carryforwards, Research"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails1",
      "http://www.lexpharma.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r127",
      "r737"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r464"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedTerseLabel": "Deferred Tax Assets, Valuation Allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r122",
      "r736"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTerseLabel": "Deferred Tax Liabilities, Net"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r127",
      "r737"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/IncomeTaxesDetails1": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "negatedTerseLabel": "Deferred Tax Liabilities, Other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r408"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Defined Contribution Plan, Cost"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/BenefitPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r59",
      "r286"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise of dilutive convertible securities excluding adjustments related to ESOP convertible preferred stock, stock options, and restrictive stock units.",
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities",
        "terseLabel": "Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities"
       }
      }
     },
     "localname": "DilutiveSecuritiesEffectOnBasicEarningsPerShareOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r416",
      "r446",
      "r447",
      "r449",
      "r454",
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Equity Incentive Awards"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwards"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r5",
      "r38",
      "r170"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax",
        "terseLabel": "Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax"
       }
      }
     },
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/AssetSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r219",
      "r241",
      "r242",
      "r244",
      "r245",
      "r246",
      "r254",
      "r256",
      "r264",
      "r265",
      "r266",
      "r270",
      "r509",
      "r510",
      "r584",
      "r589",
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Earnings Per Share, Basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.lexpharma.com/role/EarningsPerShareDetails",
      "http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedQuarterlyFinancialInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r219",
      "r241",
      "r242",
      "r244",
      "r245",
      "r246",
      "r256",
      "r264",
      "r265",
      "r266",
      "r270",
      "r509",
      "r510",
      "r584",
      "r589",
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Earnings Per Share, Diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.lexpharma.com/role/EarningsPerShareDetails",
      "http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedQuarterlyFinancialInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r70",
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Earnings Per Share, Policy"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r267",
      "r268",
      "r269",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Earnings Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/EarningsPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r480",
      "r735"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails3"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": {
     "auth_ref": [
      "r734",
      "r735"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r448"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Employee Service Share-based Compensation, Outstanding, Weighted Average Remaining Vesting Period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationDetails2"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2",
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Laboratory Equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Stockholders' Equity:"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r100",
      "r183",
      "r213",
      "r214",
      "r215",
      "r230",
      "r231",
      "r232",
      "r237",
      "r247",
      "r250",
      "r273",
      "r318",
      "r389",
      "r450",
      "r451",
      "r452",
      "r472",
      "r473",
      "r508",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r561",
      "r593",
      "r594",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/BalanceSheetParentheticals",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ExtinguishmentOfDebtGainLossNetOfTax": {
     "auth_ref": [
      "r97"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the reacquisition price and the net carrying amount of the extinguished debt recognized currently as a component of income in the period of extinguishment, net of tax.",
        "label": "Extinguishment of Debt, Gain (Loss), Net of Tax",
        "terseLabel": "Extinguishment of Debt, Gain (Loss), Net of Tax"
       }
      }
     },
     "localname": "ExtinguishmentOfDebtGainLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r133",
      "r137",
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
     "auth_ref": [
      "r133",
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r369",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r516",
      "r564",
      "r565",
      "r566",
      "r641",
      "r642",
      "r646",
      "r647",
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r135",
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r369",
      "r394",
      "r399",
      "r516",
      "r564",
      "r646",
      "r647",
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Fair Value, Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r369",
      "r394",
      "r399",
      "r516",
      "r565",
      "r641",
      "r642",
      "r646",
      "r647",
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Fair Value, Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r369",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r516",
      "r566",
      "r641",
      "r642",
      "r646",
      "r647",
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Fair Value, Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r134",
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r369",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r564",
      "r565",
      "r566",
      "r641",
      "r642",
      "r646",
      "r647",
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FederalIncomeTaxNoteTable": {
     "auth_ref": [
      "r754"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table of federal income tax note for schedule of investments. The federal income tax note may be qualified for security investments, non-security investments and/or for the combination of security and non-security investments.",
        "label": "Federal Income Tax Note [Table]",
        "terseLabel": "Federal Income Tax Note [Table]"
       }
      }
     },
     "localname": "FederalIncomeTaxNoteTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails1",
      "http://www.lexpharma.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r553",
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for finance lease calculated at point in time.",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Finance Lease, Weighted Average Discount Rate, Percent"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r552",
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Finance Lease, Weighted Average Remaining Lease Term"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.lexpharma.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Estimated useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesCostofSalesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r330",
      "r331",
      "r332",
      "r333",
      "r574",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesCostofSalesDetails",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleassetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure": {
     "auth_ref": [
      "r741"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of assets, excluding financial assets, that lack physical substance, having a limited useful life.",
        "label": "Finite-Lived Intangible Assets, Fair Value Disclosure",
        "terseLabel": "Finite-lived Intangible Assets, Fair Value Disclosure"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleassetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesCostofSalesDetails",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleassetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r79",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesCostofSalesDetails",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleassetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and Fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets": {
     "auth_ref": [
      "r682",
      "r698",
      "r700"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property",
        "negatedTerseLabel": "Loss on disposal of property and equipment"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfBusiness": {
     "auth_ref": [
      "r496",
      "r682"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.",
        "label": "Gain (Loss) on Disposition of Business",
        "terseLabel": "Gain (Loss) on Disposition of Business"
       }
      }
     },
     "localname": "GainLossOnSaleOfBusiness",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/AssetSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfOtherAssets": {
     "auth_ref": [
      "r682"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of other assets.",
        "label": "Gain (Loss) on Disposition of Other Assets",
        "terseLabel": "Gain (Loss) on Disposition of Other Assets"
       }
      }
     },
     "localname": "GainLossOnSaleOfOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/AssetSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfProvedProperty": {
     "auth_ref": [
      "r59"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property with proven oil and gas reserves.",
        "label": "Gain (Loss) on Disposition of Proved Property",
        "negatedTerseLabel": "Gain (Loss) on Disposition of Proved Property"
       }
      }
     },
     "localname": "GainLossOnSaleOfProvedProperty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/AssetSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r59",
      "r97",
      "r98"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedTerseLabel": "Recognition of gain or loss on extinguishment",
        "terseLabel": "Recognition of gain or loss on extinguishment"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "Selling, general and administrative, including stock-based compensation of $7,267, $6,293 and $6,898, respectively"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative Expense"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/AssetSaleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r194",
      "r326",
      "r582",
      "r639",
      "r656",
      "r695",
      "r696"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetImpairment": {
     "auth_ref": [],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.",
        "label": "Goodwill and Intangible Asset Impairment",
        "terseLabel": "Goodwill and Intangible Asset Impairment"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetImpairment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleassetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/Goodwill"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for indefinite-lived intangible assets (that is, those intangible assets not subject to amortization). This accounting policy also may address how the entity assesses whether events and circumstances continue to support an indefinite useful life and how the entity assesses and measures impairment of such assets.",
        "label": "Goodwill and Intangible Assets, Intangible Assets, Indefinite-Lived, Policy [Policy Text Block]",
        "terseLabel": "Goodwill and Intangible Assets, Intangible Assets, Indefinite-Lived, Policy"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r78",
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Goodwill and Intangible Assets, Policy"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r59",
      "r327",
      "r328",
      "r329",
      "r639"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Goodwill, Impairment Loss"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r59",
      "r83"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Impairment of Intangible Assets (Excluding Goodwill)"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesImpairmentofLongLivedAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "auth_ref": [
      "r682",
      "r697"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.",
        "label": "Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)",
        "terseLabel": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesImpairmentofLongLivedAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfRealEstate": {
     "auth_ref": [
      "r682",
      "r699"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The charge against earnings in the period to reduce the carrying amount of real property to fair value.",
        "label": "Impairment of Real Estate",
        "terseLabel": "Impairment of Real Estate"
       }
      }
     },
     "localname": "ImpairmentOfRealEstate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r85",
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment or Disposal of Long-Lived Assets, Policy"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "In-Process Research and Development"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesCostofSalesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r37",
      "r144",
      "r155",
      "r172",
      "r287",
      "r290",
      "r295",
      "r298",
      "r585",
      "r638"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Net loss before taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r334",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]",
        "verboseLabel": "Information by Financial Statement Line Item [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedQuarterlyFinancialInformationDetails",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]",
        "verboseLabel": "Financial Statement Line Items with Differences in Reported Amount and Reporting Currency Denominated Amounts [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedQuarterlyFinancialInformationDetails",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r228",
      "r458",
      "r460",
      "r467",
      "r477",
      "r481",
      "r482",
      "r483",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r212",
      "r455",
      "r456",
      "r460",
      "r461",
      "r466",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Tax, Policy"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r735"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r457"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment": {
     "auth_ref": [
      "r735"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible research and development expense.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount",
        "negatedTerseLabel": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r735"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Increase (decrease) in accounts payable and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "(Increase) decrease in accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r629"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Deferred Revenue",
        "terseLabel": "Decrease in deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Increase in inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedTerseLabel": "(Increase) decrease in other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "(Increase) decrease in prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities": {
     "auth_ref": [
      "r261",
      "r262",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities",
        "terseLabel": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToConversionOfDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r257",
      "r258",
      "r259",
      "r266",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "terseLabel": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "auth_ref": [
      "r81",
      "r570",
      "r571",
      "r572",
      "r574",
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "terseLabel": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestAndDebtExpense": {
     "auth_ref": [
      "r139"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest and debt related expenses associated with nonoperating financing activities of the entity.",
        "label": "Interest and Debt Expense",
        "negatedTerseLabel": "Interest and Debt Expense"
       }
      }
     },
     "localname": "InterestAndDebtExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r142",
      "r157",
      "r216",
      "r285",
      "r540"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense",
        "terseLabel": "Interest Expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseInterestBearingLiability": {
     "auth_ref": [
      "r755",
      "r756"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense on interest-bearing liability.",
        "label": "Interest Expense, Interest-Bearing Liability",
        "terseLabel": "Interest Expense, Interest-Bearing Liability"
       }
      }
     },
     "localname": "InterestExpenseInterestBearingLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r220",
      "r223",
      "r224"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryBuildingsAndImprovements": {
     "auth_ref": [
      "r677"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of building structures held as inventory including any additions, improvements, or renovations to those structures.",
        "label": "Inventory, Buildings and Improvements",
        "terseLabel": "Inventory, Buildings and Improvements"
       }
      }
     },
     "localname": "InventoryBuildingsAndImprovements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r674"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Inventory, Finished Goods, Gross"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r203",
      "r628",
      "r656"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r190",
      "r202",
      "r272",
      "r323",
      "r324",
      "r325",
      "r569",
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r676"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Inventory, Raw Materials, Gross"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r675"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Inventory, Work in Process, Gross"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r515"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Investments, Fair Value Disclosure"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets held for their financial return, rather than for the entity's operations.",
        "label": "Investments [Member]",
        "terseLabel": "Cash and Cash Equivalents and Investments"
       }
      }
     },
     "localname": "InvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Investments, Owned, Federal Income Tax Note [Line Items]",
        "terseLabel": "Investments, Owned, Federal Income Tax Note [Line Items]"
       }
      }
     },
     "localname": "InvestmentsOwnedFederalIncomeTaxNoteLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "auth_ref": [
      "r59"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.",
        "label": "Issuance of Stock and Warrants for Services or Claims",
        "terseLabel": "Issuance of Stock and Warrants for Services or Claims"
       }
      }
     },
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Land": {
     "auth_ref": [
      "r673"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.",
        "label": "Land",
        "terseLabel": "Land"
       }
      }
     },
     "localname": "Land",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LandMember": {
     "auth_ref": [
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Part of earth's surface not covered by water.",
        "label": "Land [Member]",
        "terseLabel": "Land"
       }
      }
     },
     "localname": "LandMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseAndRentalExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "Operating Leases, Rent Expense",
        "terseLabel": "Operating Leases, Rent Expense"
       }
      }
     },
     "localname": "LeaseAndRentalExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails2",
      "http://www.lexpharma.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdsAndLeaseholdImprovementsMember": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset held by lessee under finance lease and addition or improvement to asset held under lease arrangement.",
        "label": "Leaseholds and Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements"
       }
      }
     },
     "localname": "LeaseholdsAndLeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LegalFees": {
     "auth_ref": [
      "r42"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.",
        "label": "Legal Fees",
        "terseLabel": "Legal Fees"
       }
      }
     },
     "localname": "LegalFees",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r21",
      "r227",
      "r314",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r493",
      "r497",
      "r498",
      "r519",
      "r637",
      "r703",
      "r744",
      "r745"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r18",
      "r150",
      "r166",
      "r656",
      "r685",
      "r694",
      "r742"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r23",
      "r189",
      "r227",
      "r314",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r493",
      "r497",
      "r498",
      "r519",
      "r656",
      "r703",
      "r744",
      "r745"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Liabilities, Current [Abstract]"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r9",
      "r149",
      "r164",
      "r368",
      "r383",
      "r641",
      "r642"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "terseLabel": "Long-term Debt, Gross"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligations": {
     "auth_ref": [
      "r9"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent.",
        "label": "Long-Term Debt and Lease Obligation",
        "terseLabel": "Long-term Debt and Lease Obligation"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-Term Debt, Current Maturities",
        "negatedLabel": "Long-term Debt, Current Maturities",
        "terseLabel": "Current portion of long-term debt, net of deferred issuance costs"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.lexpharma.com/role/DebtObligationsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r197"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt, net of issuance costs",
        "verboseLabel": "Long-term Debt, Excluding Current Maturities"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.lexpharma.com/role/DebtObligationsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtPercentageBearingFixedInterestRate": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a set, unchanging rate.",
        "label": "Long-Term Debt, Percentage Bearing Fixed Interest, Percentage Rate",
        "terseLabel": "Long-Term Debt, Percentage Bearing Fixed Interest, Percentage Rate"
       }
      }
     },
     "localname": "LongTermDebtPercentageBearingFixedInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r26",
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MortgageLoansOnRealEstate": {
     "auth_ref": [
      "r618"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in mortgage loan on real estate by entity with substantial portion of business acquiring and holding investment real estate or interest in real estate.",
        "label": "SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate",
        "terseLabel": "SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate"
       }
      }
     },
     "localname": "MortgageLoansOnRealEstate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r222"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r222"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r55",
      "r57",
      "r60"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r39",
      "r60",
      "r156",
      "r171",
      "r187",
      "r208",
      "r210",
      "r215",
      "r227",
      "r236",
      "r241",
      "r242",
      "r244",
      "r245",
      "r249",
      "r250",
      "r263",
      "r287",
      "r290",
      "r295",
      "r298",
      "r314",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r510",
      "r519",
      "r638",
      "r703"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.lexpharma.com/role/EarningsPerShareDetails",
      "http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedQuarterlyFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the quantification of the effect of adopting the new accounting standard or change in accounting principle expected by the entity to have a significant effect on the entity's financial statements.",
        "label": "New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification (Deprecated 2020)",
        "terseLabel": "New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification"
       }
      }
     },
     "localname": "NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r186",
      "r234",
      "r235",
      "r238",
      "r239",
      "r251",
      "r252",
      "r253",
      "r312",
      "r313",
      "r319",
      "r320",
      "r474",
      "r475",
      "r476",
      "r506",
      "r512",
      "r513",
      "r514",
      "r526",
      "r527",
      "r528",
      "r547",
      "r548",
      "r556",
      "r562",
      "r578",
      "r579",
      "r580",
      "r597",
      "r598",
      "r599",
      "r600",
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]",
        "terseLabel": "New Accounting Pronouncements and Changes in Accounting Principles [Text Block]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/RecentAccountingPronouncements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/RecentAccountingPronouncementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r67",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r233",
      "r236",
      "r237",
      "r238",
      "r240",
      "r244",
      "r251",
      "r270",
      "r310",
      "r311",
      "r315",
      "r316",
      "r317",
      "r318",
      "r321",
      "r322",
      "r450",
      "r451",
      "r452",
      "r470",
      "r471",
      "r472",
      "r473",
      "r485",
      "r486",
      "r487",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r529",
      "r530",
      "r538",
      "r539",
      "r543",
      "r544",
      "r545",
      "r546",
      "r555",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r575",
      "r576",
      "r577",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/RecentAccountingPronouncementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1": {
     "auth_ref": [
      "r63",
      "r64",
      "r65"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash consideration received for selling an asset or business through a noncash (or part noncash) transaction.",
        "label": "Noncash or Part Noncash Divestiture, Amount of Consideration Received",
        "terseLabel": "Noncash or Part Noncash Divestiture, Amount of Consideration Received"
       }
      }
     },
     "localname": "NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r693"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationandSignficantCustomersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r287",
      "r290",
      "r295",
      "r298",
      "r638"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Income (Loss) From Operations",
        "totalLabel": "Income (loss) from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedQuarterlyFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r743"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating Lease, Expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r550"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating Lease, Liability, Current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r549"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails2",
      "http://www.lexpharma.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.lexpharma.com/role/RecentAccountingPronouncementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": {
     "auth_ref": [
      "r178",
      "r179"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.",
        "label": "Operating Leases, Future Minimum Payments Due",
        "terseLabel": "Operating Leases, Future Minimum Payments Due"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": {
     "auth_ref": [
      "r178",
      "r179"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments Due, Next 12 Months",
        "terseLabel": "Operating Leases, Future Minimum Payments Due, Next Twelve Months"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": {
     "auth_ref": [
      "r178",
      "r179"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Five Years",
        "terseLabel": "Operating Leases, Future Minimum Payments, Due in Five Years"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": {
     "auth_ref": [
      "r178",
      "r179"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Four Years",
        "terseLabel": "Operating Leases, Future Minimum Payments, Due in Four Years"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": {
     "auth_ref": [
      "r178",
      "r179"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Three Years",
        "terseLabel": "Operating Leases, Future Minimum Payments, Due in Three Years"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": {
     "auth_ref": [
      "r178",
      "r179"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Two Years",
        "terseLabel": "Operating Leases, Future Minimum Payments, Due in Two Years"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": {
     "auth_ref": [
      "r178",
      "r179"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due Thereafter",
        "terseLabel": "Operating Leases, Future Minimum Payments, Due Thereafter"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r126"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating Loss Carryforwards, Federal"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails1",
      "http://www.lexpharma.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r6",
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization and Operations"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/OrganizationandOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r22"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other Accrued Liabilities, Current"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssets": {
     "auth_ref": [
      "r145",
      "r162",
      "r195"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets classified as other.",
        "label": "Other Assets",
        "terseLabel": "Other Assets"
       }
      }
     },
     "localname": "OtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r204",
      "r656"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r195"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Operating lease right-of-use-assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of other commitment.",
        "label": "Other Commitments [Axis]",
        "terseLabel": "Other Commitments [Axis]"
       }
      }
     },
     "localname": "OtherCommitmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other future obligation.",
        "label": "Other Commitments [Domain]",
        "terseLabel": "Other Commitments [Domain]"
       }
      }
     },
     "localname": "OtherCommitmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Other Commitments [Line Items]",
        "terseLabel": "Other Commitments [Line Items]"
       }
      }
     },
     "localname": "OtherCommitmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about obligations resulting from other commitments.",
        "label": "Other Commitments [Table]",
        "terseLabel": "Other Commitments [Table]"
       }
      }
     },
     "localname": "OtherCommitmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r206",
      "r207"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized gain (loss) on investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIntangibleAssetsNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other.",
        "label": "Other Intangible Assets, Net",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "OtherIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleassetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Long-term operating lease liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Interest and other income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentOfFinancingAndStockIssuanceCosts": {
     "auth_ref": [
      "r54"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.",
        "label": "Payment of Financing and Stock Issuance Costs",
        "terseLabel": "Debt Issuance Cost"
       }
      }
     },
     "localname": "PaymentOfFinancingAndStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRent": {
     "auth_ref": [
      "r56"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash payments to lessor's for use of assets under operating leases.",
        "label": "Payments for Rent",
        "terseLabel": "Payments for Rent"
       }
      }
     },
     "localname": "PaymentsForRent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedTerseLabel": "Repurchase of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedTerseLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment": {
     "auth_ref": [
      "r48"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from the acquisition of or improvements to long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.",
        "label": "Payments to Acquire Other Property, Plant, and Equipment",
        "terseLabel": "Payments to Acquire Other Property, Plant, and Equipment"
       }
      }
     },
     "localname": "PaymentsToAcquireOtherPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r392",
      "r393",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r411",
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Benefit Plan"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/BenefitPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r12",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value per share (usd per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/BalanceSheetParentheticals",
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/BalanceSheetParentheticals",
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r12",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/BalanceSheetParentheticals",
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/BalanceSheetParentheticals",
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r12",
      "r656"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $.01 par value; 5,000 shares authorized; no shares issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of a reclassification adjustment made to prior period financial statement amounts.",
        "label": "Prior Period Reclassification Adjustment",
        "terseLabel": "Adjustments for New Accounting Pronouncement"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r51"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Proceeds from Convertible Debt",
        "terseLabel": "Proceeds from Convertible Debt"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock, net of fees"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "terseLabel": "Proceeds from debt borrowings, net of fees"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "terseLabel": "Maturities of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfBuildings": {
     "auth_ref": [
      "r46"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sale of buildings.",
        "label": "Proceeds from Sale of Buildings",
        "terseLabel": "Proceeds from Sale of Buildings"
       }
      }
     },
     "localname": "ProceedsFromSaleOfBuildings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.lexpharma.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfProductiveAssets": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Proceeds from Sale of Productive Assets",
        "terseLabel": "Proceeds from Sale of Productive Assets"
       }
      }
     },
     "localname": "ProceedsFromSaleOfProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/AssetSaleDetails",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from Sale of Property, Plant, and Equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r187",
      "r208",
      "r210",
      "r221",
      "r227",
      "r236",
      "r249",
      "r250",
      "r287",
      "r290",
      "r295",
      "r298",
      "r314",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r491",
      "r494",
      "r495",
      "r510",
      "r519",
      "r585",
      "r638",
      "r653",
      "r654",
      "r681",
      "r703"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r91",
      "r621",
      "r622",
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/PropertyandEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r87",
      "r192"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property, Plant and Equipment, Gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/PropertyandEquipmentDetails",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r89",
      "r167",
      "r586",
      "r656"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net of accumulated depreciation and amortization of $61,741 and $60,006, respectively",
        "verboseLabel": "Net property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.lexpharma.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r89",
      "r621",
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/PropertyandEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful life of assets",
        "verboseLabel": "Estimated Useful Lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails",
      "http://www.lexpharma.com/role/PropertyandEquipmentDetails",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Quarterly Financial Information Disclosure [Abstract]",
        "terseLabel": "Quarterly Financial Information Disclosure [Abstract]"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RealizedInvestmentGainsLosses": {
     "auth_ref": [
      "r173"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment.",
        "label": "Realized Investment Gains (Losses)",
        "terseLabel": "Realized Investment Gains (Losses)"
       }
      }
     },
     "localname": "RealizedInvestmentGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivableTypeDomain": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates.",
        "label": "Receivable [Domain]",
        "terseLabel": "Receivable [Domain]"
       }
      }
     },
     "localname": "ReceivableTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-Term Debt",
        "negatedTerseLabel": "Repayment of debt borrowings"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r121",
      "r174",
      "r752"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development, including stock-based compensation of $4,253, $4,284 and $6,376 respectively"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expense, Policy"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [
      "r335",
      "r336",
      "r338",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/AssetSaleDetails",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r15",
      "r106",
      "r165",
      "r597",
      "r602",
      "r656"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r183",
      "r230",
      "r231",
      "r232",
      "r237",
      "r247",
      "r250",
      "r318",
      "r450",
      "r451",
      "r452",
      "r472",
      "r473",
      "r508",
      "r593",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r283",
      "r284",
      "r289",
      "r293",
      "r294",
      "r300",
      "r301",
      "r303",
      "r390",
      "r391",
      "r573"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Net product revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r283",
      "r284",
      "r289",
      "r293",
      "r294",
      "r300",
      "r301",
      "r303",
      "r390",
      "r391",
      "r573"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "terseLabel": "Collaborative agreements"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r633",
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition, Policy"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r217",
      "r227",
      "r283",
      "r284",
      "r289",
      "r293",
      "r294",
      "r300",
      "r301",
      "r303",
      "r314",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r519",
      "r585",
      "r703"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenues",
        "totalLabel": "Total revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedQuarterlyFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "auth_ref": [
      "r551",
      "r655"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "terseLabel": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r551",
      "r655"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyIncomeNonoperating": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ancillary revenue earned during the period from the consideration paid to the entity for the use of its rights and property by another party. Examples include licensing the use of copyrighted materials and leasing the extraction of natural resources.",
        "label": "Royalty Income, Nonoperating",
        "terseLabel": "Royalties and other revenue"
       }
      }
     },
     "localname": "RoyaltyIncomeNonoperating",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.",
        "label": "Sale of Stock, Consideration Received Per Transaction",
        "terseLabel": "Sale of Stock, Consideration Received Per Transaction"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedPerTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Sale of Stock, Number of Shares Issued in Transaction"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances.",
        "label": "Schedule of Cash and Cash Equivalents [Table]",
        "terseLabel": "Schedule of Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "terseLabel": "Schedule of Cash, Cash Equivalents and Short-term Investments"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable": {
     "auth_ref": [
      "r109",
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule, table or text reflecting arrangements that are not equity-based payments, or pension and other postretirement benefits, with individual employees. The arrangements (for example, profit sharing, deferred bonuses or certain split-dollar life insurance arrangements) are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain amounts at designated future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period and the carrying amount as of the balance sheet date of the related liability.",
        "label": "Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]",
        "terseLabel": "Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]"
       }
      }
     },
     "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails2",
      "http://www.lexpharma.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r692"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/EarningsPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r79",
      "r81",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesCostofSalesDetails",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleassetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.",
        "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Rental Payments for Operating Leases"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Schedule of Nonvested Restricted Stock Units Activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/PropertyandEquipmentDetails",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r412",
      "r414",
      "r417",
      "r418",
      "r419",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2",
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3",
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4",
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r111",
      "r113",
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Share-based Compensation, Stock Options, Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r280",
      "r281",
      "r282",
      "r287",
      "r288",
      "r292",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r302",
      "r303",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Reporting Disclosure"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeveranceCosts1": {
     "auth_ref": [
      "r59"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Severance Costs",
        "terseLabel": "Severance Costs"
       }
      }
     },
     "localname": "SeveranceCosts1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/AssetSaleDetails",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r429",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r429",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r436"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2",
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3",
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4",
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r436"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Total Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "negatedTerseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r715"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Issuance of common stock under Equity Incentive Plans, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r118"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r421",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r421",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r417",
      "r418",
      "r419",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2",
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3",
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4",
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r420",
      "r439",
      "r440",
      "r441",
      "r442",
      "r445",
      "r453",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-based Compensation, Option and Incentive Plans Policy"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Award term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r118"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Shares Issued, Price Per Share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r151",
      "r152",
      "r161",
      "r678"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-Term Investments",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "auth_ref": [
      "r615",
      "r616",
      "r617",
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.",
        "label": "Short-Term Investments [Member]",
        "terseLabel": "Short-term Investments"
       }
      }
     },
     "localname": "ShortTermInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortTermLeaseCommitmentAmount": {
     "auth_ref": [
      "r554"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease commitment.",
        "label": "Short-Term Lease Commitment, Amount",
        "negatedTerseLabel": "Short-term Lease Commitment, Amount"
       }
      }
     },
     "localname": "ShortTermLeaseCommitmentAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r66",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r198",
      "r199",
      "r200",
      "r227",
      "r256",
      "r260",
      "r264",
      "r266",
      "r274",
      "r275",
      "r314",
      "r346",
      "r348",
      "r349",
      "r350",
      "r353",
      "r354",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r519",
      "r626",
      "r669",
      "r683",
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/BalanceSheetParentheticals",
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r30",
      "r100",
      "r183",
      "r213",
      "r214",
      "r215",
      "r230",
      "r231",
      "r232",
      "r237",
      "r247",
      "r250",
      "r273",
      "r318",
      "r389",
      "r450",
      "r451",
      "r452",
      "r472",
      "r473",
      "r508",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r561",
      "r593",
      "r594",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Statement, Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/BalanceSheetParentheticals",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/BalanceSheetParentheticals",
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.lexpharma.com/role/StatementsofComprehensiveLossParentheticalsParentheticals"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r230",
      "r231",
      "r232",
      "r273",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/BalanceSheetParentheticals",
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.lexpharma.com/role/StatementsofComprehensiveLossParentheticalsParentheticals"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r12",
      "r13",
      "r100",
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Stock Issued During Period, Shares, New Issues"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r12",
      "r13",
      "r100",
      "r106",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued": {
     "auth_ref": [
      "r13",
      "r100",
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.",
        "label": "Stock Issued During Period, Shares, Treasury Stock Reissued",
        "terseLabel": "Stock Issued During Period, Shares, Treasury Stock Reissued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesTreasuryStockReissued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r30",
      "r100",
      "r106"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Common stock, $.001 par value; 225,000 shares authorized; 106,679 and 106,162 shares issued, respectively"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r12",
      "r13",
      "r100",
      "r106"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Stock Issued During Period, Value, New Issues"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r12",
      "r13",
      "r106",
      "r114"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock under Equity Incentive Plans, value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued": {
     "auth_ref": [
      "r12",
      "r13",
      "r100",
      "r106",
      "r107"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.",
        "label": "Stock Issued During Period, Value, Treasury Stock Reissued",
        "negatedTerseLabel": "Issuance of Treasury Stock",
        "terseLabel": "Stock Issued During Period, Value, Treasury Stock Reissued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueTreasuryStockReissued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]",
        "terseLabel": "Equity Option [Member]"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r13",
      "r16",
      "r17",
      "r76",
      "r656",
      "r685",
      "r694",
      "r742"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance, value",
        "periodStartLabel": "Balance, value",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubordinatedBorrowingInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stated interest rate of the subordinated debt.",
        "label": "Subordinated Borrowing, Interest Rate",
        "terseLabel": "Subordinated Borrowing, Interest Rate"
       }
      }
     },
     "localname": "SubordinatedBorrowingInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails",
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r537",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails",
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r537",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails",
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r537",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails",
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r537",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails",
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r175",
      "r176",
      "r177",
      "r307",
      "r308",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Trade and Other Accounts Receivable, Policy"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TreasuryStockCarryingBasis": {
     "auth_ref": [
      "r107"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost basis for treasury stock acquired for purposes other than retirement.",
        "label": "Treasury Stock, Carrying Basis",
        "terseLabel": "Unearned ESOP Shares"
       }
      }
     },
     "localname": "TreasuryStockCarryingBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r29",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockPreferredValue": {
     "auth_ref": [
      "r107",
      "r108"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount allocated to previously issued preferred shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Preferred, Value",
        "terseLabel": "Treasury Stock, Preferred, Value"
       }
      }
     },
     "localname": "TreasuryStockPreferredValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r29",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "terseLabel": "Treasury stock, shares"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/BalanceSheetParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r29",
      "r107",
      "r108"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedTerseLabel": "Treasury stock, at cost, 407 and 236 shares, respectively",
        "terseLabel": "Treasury Stock, Value"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r100",
      "r106",
      "r107"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedTerseLabel": "Repurchase of common stock"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r236",
      "r237",
      "r238",
      "r240",
      "r251",
      "r310",
      "r311",
      "r315",
      "r316",
      "r317",
      "r318",
      "r321",
      "r322",
      "r450",
      "r451",
      "r452",
      "r470",
      "r471",
      "r472",
      "r473",
      "r485",
      "r486",
      "r487",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r529",
      "r530",
      "r538",
      "r539",
      "r543",
      "r544",
      "r545",
      "r546",
      "r555",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r575",
      "r576",
      "r577",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]",
        "terseLabel": "Type of Adoption [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/RecentAccountingPronouncementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [
      "r335",
      "r336",
      "r338",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/AssetSaleDetails",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r635",
      "r646",
      "r648",
      "r753"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "US Treasury Securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnamortizedDebtIssuanceExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.",
        "label": "Unamortized Debt Issuance Expense",
        "terseLabel": "Unamortized Debt Issuance Expense"
       }
      }
     },
     "localname": "UnamortizedDebtIssuanceExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r459"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r72",
      "r73",
      "r74",
      "r276",
      "r277",
      "r278",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates, Policy"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceByDeferredTaxAssetAxis": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of deferred tax consequences attributable to deductible temporary differences.",
        "label": "Valuation Allowance by Deferred Tax Asset [Axis]",
        "terseLabel": "Valuation Allowance by Deferred Tax Asset [Axis]"
       }
      }
     },
     "localname": "ValuationAllowanceByDeferredTaxAssetAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails1",
      "http://www.lexpharma.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r465"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Valuation Allowance, Deferred Tax Asset, Change in Amount"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r255",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted Average Number of Shares Outstanding, Diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.lexpharma.com/role/EarningsPerShareDetails",
      "http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedQuarterlyFinancialInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesIssuedBasic": {
     "auth_ref": [
      "r68",
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).",
        "label": "Weighted Average Number of Shares Issued, Basic",
        "terseLabel": "Weighted Average Number of Shares Issued, Basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesIssuedBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.lexpharma.com/role/EarningsPerShareDetails",
      "http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedQuarterlyFinancialInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "https://asc.fasb.org/extlink&oid=6409733&loc=d3e19524-108361",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "https://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.3(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(Note 3)",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123403562&loc=d3e38371-112697",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "https://asc.fasb.org/topic&trid=2122394",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2029-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "https://asc.fasb.org/topic&trid=2134510",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(2)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(14))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918705-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(b)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(1)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(2)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(3)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Column G))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r626": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r659": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r661": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r662": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r663": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r664": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r665": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r666": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r667": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r668": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=d3e5283-111683",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2646-109256",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2443-110228",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "705",
   "URI": "https://asc.fasb.org/topic&trid=2122478",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "740",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126970579&loc=d3e23163-113944",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(h)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=126898976&loc=d3e600178-122990",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r755": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r756": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "https://asc.fasb.org/topic&trid=2144416",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>78
<FILENAME>0001062822-23-000007-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001062822-23-000007-xbrl.zip
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MCE2J].$/7?ISA'>V$Y[)=''XMZ',A&%G8L[.5<;SOW4,',*V$5HF]D$C_RV
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MOMEX#F@!0R/(T0'NC6&&,?@R#9=GB4MUDW1!]RJ[ICN(+@Z=B8@+=*1@(_O
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M;XX'GX>GQV_>7W38Z=GQGXH1;Q>-3U \++-QNR_ 7OE9V,=T-G7ZWZL\%RE
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M7?@0$5_:W5UVX6'G$>+JUQ]H=D>KS_X/4$L#!!0    ( "X[8U9Y\O <(P4
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MWUSNEN:OR[G"C=C/OF3I190$ZQG"?VKVG4Y@\UW+IJ&M$A)0U=0]3:4DU-7
MU1TO=!RNL1#8][^O++L<EOV2Y@6-3Z*!C%:^,NRM##L5JB&ZQ[&*ENH83%--
M2FW5M:Q -0*7&4% M##P-K8<QW 7;WD^=N#@V>56/V8"*O)VQNDK/]^1GX]*
M?OYZN=_].OJA.<ST;&:K ;4MU?2IH7J.'JJ&8[' ,9E./5# ;W27_/;XF5 O
ME$<_IS#%+[TT6>=LD:?FT^,I/M5TAJ4GP>'D'NA=UP)?$Q"O;U,7B* 9IN9L
M;+D8- <VN3W!>36AE7[$6,Q7%+PM(0!&N+]D %BC 8V5W2L>#+$XC;(?AE$
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M'RB_?$*C=?'":WF9&7BI,D-%.JW*'O0ZP(N'?MXG?05XSYU3?F6 ]\!R*J\
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MP5\TB@&6@BW!L"WTJ  0#(89.BK@M$B@F7%4-:5GH1RU#EL #5,F$WG%R!E
M&G%U33WXCSAX?* '??N<@P\(<G.*OAN,!-P#7B@R([@&H6UPS'1G4]$UW2A[
MQOZ^ ,\'6300SXKNCH @F'JG; >%\FU/]/=EY^CC]N0T\N$ D:S$GQ(@7M0
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M.PO(#R0 2XK!.,R*=<TZ]6ZNV"V4-KDCDBC5*5X&MAK(GPD:@B$L$YB53*1
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MH]#&#0%DLPP'3P:0Q^%O^Z:7C:F7[Q$NOBE$K<V?M(@9ZU.!.@FI0U$X#D-
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ML5XD ^/!Y%H9PARG;4-&D\V-W8H#RY*V-NH./!=OG@/F$XF[)!!%0AT0>*4
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M!,&/9,G^ L*1I#-C'7[I3"G2RS,KN/["8@?C51HRWXBWK"&8IO4:+CT9"5.
M>D.<VS18=4MSA<%-@]LV-$B2SK\;2V"F_G!P@U-U).@< Q>)&PD?5TZP+"5#
M@%;%$<I1Z36U JOU"LWT&]'^";X_!\6Y*S.9/@!3F;-;%\72(IN-H<L:]K,W
M18X7K'I 4^MBQ8H2<ATJY!,'$Q6WQ=L<*:O,[2_7;82M\/!(S5"87SOL11*V
M56!,+!JA10.PZGCYI2MSP- 06HRJFEH)./P#<2S349]9,V+=R'08@]?H0N9_
MX%J0MM_BJ4="[]9=IO'7%XQ,!R3=.,IVW'1@+XO?2:U[N2MCE;LR0G3E6\#2
M=NM0]FR8Y$ZI>C5'$@DR]0%2]KZ:/7Q@#^!(2WP$+<Y3C0@KU&*_C7TS4M1A
M8(=/A'QPU#WZV$F,!$?375@V$ML4^W#G^#V[!,@933-![>]VQ6:[&X@;  <2
M,#3>>,XR 3<2RR&#592[L8UNW$12HY0ZB&W@CL]3 T4-TXDEF=!])B0ZV8"9
M2)%.KH*$97-@J8NHYE<Y,VGQ9XC K;@A&O,7#(].A!T>T(,G75)Y%7"2?L\2
M .9:!NLW8@0S43@!R_?DL@ECYJ@\:TSKYVNE[,\(D$<EV/0[9J41LWLIU;,:
M9XPSYI>T@6ID #_DB;J[;W+04_(?+]&0WL'I"L+4S;Z'>6-VRFO5%@C_]#R_
MP=UC<D%#J,#DPV'RI(L-'P3]$]?%RIG76_)/B%.F$XQEQ&$[0KFEVG<6- YA
M>4%6F056)(5,=/7#OA*UFMY3UK!EQD5*<4INHY.J3Y7:+O;X24B6@IH6S"\P
M(K0(,.U$LWB D+O6-*O8>15 CY[[C8M#G=:@4P+CHKNL]+JB>,.&41WJ#Y)3
M-/'"_<&C5:@.80C164]_XG)8*5I%NJ4,KJ*_P55>,_?ELCX'/9 %!CJ2$ F*
MYV>678T)68Y<KE:B3^AA#' J,M=+TR!-'+P_ BJG)'W+\N0,2;!Y2CJ-M>NG
M:76?N$H+,R G+>2)^ SO7 2J%ZP;F,TZ9&8>/22%]90^W]/:/F6 (8?IU#0.
MOU$Y##]'6FSG"IR7G81[&B?+DP;@D@3?<%:XUZ*UZ5MO-=W(&S T?3!/@EI)
M\_F<SVDUBVAJU:4XS:JQ2PHGBEQ);BBL:9PC"4&;-9"P/-'GJW(.V]]"8TDZ
M)?)X<*RQ(/U(GLAB6&6[S?><XM/BX 7KUMD9_Q^N&1(;V'0 ;K+&%C:&09/9
M-M:7YX*>#+C_&>]L*SY"LIVST%:YBP&ZHEZS DB=M%&VURJF-.P7O*V8H\-/
MKK\%5UD8NVJG 15QE\D 37S'P9 .LZR_WYF^YV_X\_P-T88+ARK2)N<F?"-"
MFNBO:GT127DUNVA:-(RR,TQ?6A?5-IS2L7<^X-]5BSD--.IQ2I[$G Q2*):B
MW0#@W2<Y^BL3V]R+S_NUQ#U/BOFB;P"@+>*B,4#+L.BNWVQR3A [_3V6C*AB
MTBHY4YW=5G%6N7O!A"@-^9LA4O<B\1=K%*XTC";I:L#XEG>=FO]J_'+DA:Z1
MAC[3YD;3@5H0<M'R;3 HQ<_ADA$-^HN]SC95HZR(1<+<W.R:A7$;)&$0JYG@
M6^Z>-^CF[YV$:E?/>+3'1F[,KFFJ@&!B9C71+0PD;2^K)F2'VN$XXJ66OR,!
M\%F"*1[>-C#%+7/Q4L<J!P%#-SM5P,/#AU\%[ 7J.*&&)%WO($STN1?-LFAK
M*^,^$0C7PR=/O@FFT**B6W2EL=%!?)[T;;&QZ-"[G1=OLL_A:#7Y4H)"XNRM
M.'Y]Q4>1^X+D1;67AGW+\)AK#DH]JL8\*IUO(')]U]<YW\_93"DW4#K7! ?J
M[ 5:][4!&98E()K)-S$#E\G\I&H1/N[EQ$_\&[K:EXMDW-,M.6,?SMEO_0YI
M9CLO"9#D,ZF!]\T?#Y*<#PH/) D7OP?4!<OVHNGK'5O>4H@]%5ZW@$Q2K)1Y
MQ@I!0HZ(,O"66%W:,:OXH<U#*U]E=H'1U7"S8063C&YG5\EEA.Z&.[&/:63?
MM;=L#S!/K]PB7#9"(_JZ*)2=31G*A\M5UM;.WIXZ[ 7@=J,14,?@"\C%FOZB
MG<R[M%O]#ST9L06-@<8']1H'!B]+ 2)AU4OCZ$^>SX_5D)]/4[&%)3EVAVF/
MPB&+&GCG1ZQI%HBFDXW L;18C."\!(/'E:L2# /X!NG*;95+D(#_$:DU.+NI
M%:55PXW*X>_3+NY,0_,-$&!.$!,O-Y]H[/B?7*V1"D3"Q<)L?4E=AG"H<_L#
M!T]*"/B]$\2!XA<G".(5)9]/X[]92.01'"A<*E;X7X1R]N/9/T-%R>0',GYZ
MRA-D.BM,C$&<);J\G' ]#(_JAQ=HI<"R_330:*T,\LDE$B\]?O$G+M3^9V>I
MWFZ4Z&5\.AQ3P0QNRUJ)\4H+C]OORLY#GE3;A.'R<(3,+[1 5RHGAU%<E$N%
MAH75CAA!/RQ'GID=?!$CUCI&[==G57%P<RVW3(>B5'1E50U%:%,PVK_3!LJQ
MC/7Y@NP?\*/]4A:+-9)#NT(;I/_:M!?Y/B06?OCA1->L-A<J'4AD/,C4J/3R
M(7PGS":!ZL S-3?]E]RPXBL2T>4L7"AHD82]$XA82C0IF5:2A9/35R!(TPE=
M-JXTUS]6UX.E#0VIK-Q+QB_UE?(>-CKY3?]BFDF;ZJ4;S'51&NCBD@PEI_,7
M8\'E4'89"O68HD_](%%FLBI:0Y[(J7F%7_']]T(^>BH?I3F_>G&JZW1 )6!=
M>\1@+M9%6CM?UH'<CF>P+W8*[[7AYP>GS5*X3T8.P*DJ'VO5L[2<:EQHW.:R
M#6+FN ?(6BJ#Y"[,G2=(9AFY["(^$P(A.;#)^:N\TV,N542B#3LF)D-M1]=9
MUF_X:=66J60)".G :OG>%ATRR;O1+C^5OB_%,MEA-AZ>\@+\+I"E)]K]A@/^
M!N>8FH^;@]3S*DT3/4UL."6!"PQ_C9-[6[#X$,.-)_L5BJ[R,[1\B+PT\=UF
M4I"INN6Z9@$+0 R4WD,[X:BNW>3"O-=)0;H=R+A6!Q2R74V85:=:?*YM1[ B
M8)'R&W90]2MERJJOLG<>_FY(1GGXO&LQ%&^!RE0J0 L,OQXIID_4DGIJ )?+
M%E<M4%M;\47&#1XVP?Y(KALABNG9_E#MR5GZP051Y1>>X%'03>\>FYQW#X#B
MY$I7[/P]UA9K 71DQB6)QC5'"A&=S7.AR6M&72\E*LG?XY^K\DU1[6.2)^I3
MDT!FN+!@ID?EBO^CAGHRJ"%>'Q/()C&O]A(Z%8"UJ<' B%Z="E[(1;?6H4?G
M5&[P)"ZH]US#B@=6[RD<B,%&PD-D,>K"VM$\L?+"+(1?PD=6J%9$=D0NS!U&
M;M,'&M]X<!H:[)E9+M[?2XFJC7%1<Q.>PL@](:FQEH=456R2:?3+Y^59*3LN
M2VVLF6#DZF*7,07%TMB9DB>"2PY(XQVG![\DL,*4*:%8Q-<9)1!'*3KZS=58
MA :!$3R\BHT[%DG+V7K*;G3MUX;8U(,FD53X'\-6F0H<C$MTV-68-IC+.LFM
M1#2_NH4!QA-JZ,O\K&Z8.DS9IDJAZDN68 0Z!-APW3:&[%L6<XECIVAYQ1(S
M#@4,H[(T-)G'&.A#JSIK.Q<F&T__?0>=CX:=&9!R.&2'_^>0M4S-06FM'9N@
MBY0* 9:QT.J!F\&*]""#HGW[VNM?B;]Y/KQI$0K58%T?L'^D'C0HRM\0)B#$
M923_M5'%YBHP)A7CJ'I\B%NL1U)[H.Y+;$'?IUMNF+8P]'S=I$U=3>@+$#K3
M/YEF;W(CL]%.)AHN<'<9@['#BO*KL^16M#L( 3R'/W47D 3>1%3-%F/^7V,C
M_#1M*:?W#AR^65'_T>Q=E)/9[4R+6<&*3T))A=_NNJ5P3JUJ$TYS<0<.X)H9
MTA$:V75#;O(VT]Y"@9X\X73V.&2M(K-;=UR)%\\+/.1("SDQ&;V,R4SH%\J9
M5[[5Z0L9(UY11,++5;DB.P<?4#413E&QC)9:0J$]<04(QX>%6>E$^6T0*U.>
MCC6KXW/]H@7](LR6M)E\H4!5.X6SR5G_FL4Y7H*[GU3[+.$ C^X"'.!6I3A_
MBIGKF.V\;J;V;EP./X[X35S:7M@BHKI9M7FOK-QSZP"A[MR@+]QYKAUIP /#
MX4QEGD 1AECL*$_OVQD]")D$#;A<%$Q)/29VPLTMC[@HM 9YA>24KR4)#$R!
M,LT>GGGN=KKX6G/L8DOOM$(+##9;+D<)9>#*'85B-[4@]-9@0IC0O%2KZI@P
M.%:TRSM#.4!&(XOT39&&]6]R<>B>G("ZXQ]&W0&WI^=6X&SKTPC7Y;Q$N>@4
M8S,I)Q!<L2T< H&9%%&J(;S-]U+-09:NKD@6D17*]24_94).@9M/#77ZVJYO
MV714,ZQO%VLM3TK[FJC!25/<J/U]#E(E2S[R5619+)NZ$\)0_>*=<$\K$CE%
M#(C_G6!N]%D37%TC,A7Y,W^0%K/8P>06<3+)35?]4/\F.N#ELD?B&<:KL1QQ
M,A6,ML@%[9GF"W_C#2'_"JP/UG?=_HAXIXYO)7LEU%=XDDT^"S//@@DT\RR!
M4N\PBP1N/&T0FN(@]Y7$;5-/80Q7"+1',X1)SO/*",M]L#*?HSVU+;E?,K6;
M!+/$HM,MZ#@$?.=>RRPJ[:7F6\KP!*3J^3+)$'NUWLO7\5)/;R;#5*\X\0V8
MU=FHG /S"/M*X#L0 S,+'*S"\HA2.D_X2)]JVMVG2L+X:[\I6KC+TT18_G:0
MWP:%/^>N(5C6" N5K_A[9O+B""=R_%*D>3$D!@IK!$V>*JB(070M"YV*4-16
M-9TV.Y!8!/=TBMS!L]EO Q@.7U<0BDQ1&L[SSF280S#&^,U<5^2ZR1UX=\)7
MLFFZW4#4$:QM$5AN),[S5IMD2%<3Y0U,$#Y2E$TG@+ZS<0@>H_0>[T VXDB=
MNLI3EM* )Q"KB>9AC=]>HN6A:QYWLN"5M5]%S.37G#UF(&;,D83'1?EX72S6
M=>QC]]3"T_I1*Z3[Z?G+DQ-?#Z\ZC:D2[7YSD^3/.\-BGC+GC@@>X>[1AZ-"
M#[UQ3?VC;E4I\7U7>B_KO#&YO/N(2=!1\HH;8^\/U90,9(&NNA:X3<@IN-@+
M+@T0[^\TU&&+PA8+.'6K6/;I("J $W2+?!LX!L+V<\S<G3IKN]5)Z1%R= $A
M1*-%PIA3W<RN@%([H='<0 2P[ZMFT7,1\64O4?C' 1:.:&I%0R^A,1:7E_:-
M3PJ?5UVZ/T*27?-K(M2LQR[18+* :HNJN&@9(5T'*M@"<1<[B2<NYQ*M)3@6
MQ@F#:/<^AW,84HFJ(CW [)^S9UB6E[I.S\K 3THK=GI!:S0S,Y[/5&V?MV7,
M4M9+!98I@7-01[SVRGPQ$2/B#CG%[D)Z+IF&//S9@SB^8>#7DX^/<8B.ZC60
M>QB/ATE.%!B[SLM:Z-T'O,S<VFZ=MW.$Z0L0KY?=QO;QCZ+9HOGVOXJP.:*[
M<WNT<)O2EY=69!VI9;U=$:E@/TVC8-3P*Q"[SEZ*H=K-3ONZ6Z/'(&ME.X+@
M>\C;$.M]J3=1%%6Y*&!2+5ES/H7FTYOBT8.'#P*@Z>0IJ6PY>DMG'KJ[R5U-
M]M??:&?B$(/]Z,&*L3= 6N#,) W&J"*(B5#ER^&=+H+=1H[)J?@\ M][^N(T
M4V(S4DZ!%]Q&%<NF6/A61:OTI%4?[@"Y]2-AK:<G5VZ<)3>!#9^Q*TAO$H@T
MECM0L4/3\7U#?B_B),I&'?B$A7F+OE[!K6LYK)E@OIH+/&Q=;AVM[":05!?(
M%'"31[J*!@/?"3-R2 2+R"K\H1M:1G*[!$*']':)27_'U>IW=[RI3(HM^]D%
M;\?NI8"4C='PU&ASE\' ^><LD.M<Z%DW Y=FVFV&EH;)XOFE*6%N;LV61)F1
MWTPZ@$?9CU8(K$JR;17DE7'!.5]HP\K,71R]WP@KZ]0<3=_ZM@^J"Z<L)984
M=9I=8;FA%Y@.E\GD0E>U8-]'%,PGJC)_9+6%*%9H1!V)(D+RUNS J82WV<7#
M: <;KNRX&C-$ EV(MZMK[@;1+F;#9AYS82J)QKVY\&=&NQ:.41@[)]Q6/&@F
M\8[1.'E>]P7W^.F5B" ,WFLL"QWQ8?_='6Y/DVF/T1;Q]G[NG1Z,7O3?CM2Y
M*ERG/4<93A?K C$/^[-RR07=/"CP,NY]W9R('7'\S[XO!MX1%$)@#K'U2ON)
MFV81& I6(J\65E3#V5);LK@Q::\/*[9E3B(VW*&5Z!$I$%<R4CO.'X-OS4L
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MUS'^$LQ^9E)X)9[&2V6NXM&;"2;8SQ'!YIJ\Z26<F15*E? /1F[S/VD/I0"
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MO=#<\ZL&VR9VQ:7[\B*)H,7-N?.<^+=$BT*P6P5=JIFN[N'(1>FBLX\\#=]
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M.A*$!!XXN0BP]<V'!I3>N]S737Y]B+U=DEL(>-A,>_2QQQZ]7;_W(/$64H8
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M-$J*Q*+8L#-@Z+!$C>O1J*.P$VO$M"$=BQ#RD-KV:ZTD8U,:*0GA,M^T](N
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M[^$6'0\W.[3>.S0<[FVV:,VWZ*H!^<T6W=X6;13=NF_1[F4#)->X1624_IV
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M"NRZJL!64/_?>=G/_O'5;(U-Z<\/(1X/]WH+L#>BL:D*VU2%W4YRO[- K %
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M<P,? 8,NG:6T6_0O,-W2\5QM0M"U>#615148?70=O8"3#;? JQRM%(3CO<]
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M=PZ#1^CHX,W.UK^B\%LE$G[NPF_K+"2X=RY"E:M XAWMS+<H &LB E8*/Z(
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M,96"9D2)D)8'&T0^NO)P_0)&$9-6%).JKCT6,6F>F#29*JPXSB#6(,M2":C
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M6?B'4^%]1%"DPCE3X82P88HQ%"I-<J45H%F: F&( BJ%F>(8N\QE-U+A<\@
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MBJG6FL<W8OV.ZK9#+\+A>]\$.AW!.HRP?A=8GZX6Z3<EE=X^!XHZ KS:BH"
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M[Q\?GNV=_^4__WBYAT.C@AVR=_SYZ[]_[:*IOE>(I A:'KI=9010(2!0-M-
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M-Y=7MWQ0E^&CS1^J:P\NPHV]=_[&?F^W71R+COA8(3Y>3I< M4IE+H6 <TH
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MPG-R1+*0B4V"$H[X1>,(E2CEJR"^__CM/2)2\7L]^-VNAW,A6>,<82%Z(D-
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MO=JE4L'@J: 3\1$6!'4FDQA-)#)13IQ5@B@- #+I*.KHM3M+!9?Q.O40^+G
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MY:F]#[Y)^T?EA8M_X N7BZ>S%2E6GKL<S\DS%=)H%#V1;XR+B64GB?+:$AE
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MI*FG.2H"J?B"C>$D),J)!9 B216-7.7YT>T\OQJBN@&D%BR,_O864?'WUM1
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M@/?-V!T5WM<,[^[X(N]EM,81JX0BTKE,@BM%-#Q[3SWC0?3G5JCP'BZ\;\
M^?EX,BTK6"V/GC'=M3PRX]*K3%R92R:#0)&=O2, 8)(20OM0+ \VIDP,"-(/
M+:)Q-D=JE>K8AOH>6#QC6(E13S_O0R6I'DEJ>W01-8P*I27107 BK4_$<PDD
MVVPEY5%)4$A20HR='$CY;G5ZWKUDJ KH:P-TQY+(-F5A=23"E@"E]YJ@%@E$
M>6F4"U*!,67PR9A_H0%@Q?.]P//UYS]5/%\;GKMC3VU0"<4P\4Y$(H6)Q%L?
M">0(405#F0P[N\J.E=H.7PRQO<9]BUP\\\OCIBV*ZE@0*Q.N_JP_:[#JUH)5
M:W2>[,W2H_ET"NT5+?9S%6#7(\"VAU@)%6@4R1%GR]SN&!+!)U"*"1^Y,%+E
M,HE/RS%S5Y[;73W;PX7ZM0>N*M1O'.H=VY-FP81EF@!$323CNM35.2*I]Q9\
M!NL3VIYFK!RO4+^_4+_V(%:%^HU#O3M?5T7M!5.$1:G*:$H4Z%0EHKE/5CN*
MS[*=7:[M&$_E@+#>9W3K3K4]_-NZ[^'?2T)=VQ)G%$Z^V-OC*I&OV@3Q!IL@
M/MUL7NUE="VLMSTARUH68V2>1)V*<]UH$@)2G\TL@'<@+8.=7</&U/30WGHP
M31![]+S?-X*X30.HTL)MT4+7[F'!AV+M,%4R?9BC)"03"7"KHG-.@C9E<"]C
M5U:%*C7<1VKHW6"JU'!;U-"QDT0L8R\<(RY8M)-T9"08+HDT,6JNDT^*[^P*
M2\?FZG,U;XH<>HKP#<1P^K8NB'DR\[/81Q?$;W4CW?!G#&M3>N^">#,K-CPI
MU$<7Q#N>X7NNM'"R6!PCD*$$Z^/\\'!>KF<>WXU',UB6)S/4Z7RW%+!]NMZ;
M_?RHW9G?R\94!:4_!>79QRV7!BHB#!3:+MJ84(9^9^*D<J5=FA*0: XJ[NPZ
M.>9T2.71-6EPZ-Z)"NP;!G:WI#!YFM#&(,RQ6/JN2V(SMT2 S2GB[[C%;3"6
MVBN/$*[ 'BZPKS486X%] \#NN!1<P:[,B.1L-9$9.''@+0E2VI"<I"J'G5WM
MQL[TY6X<D-/@KE@=+^!H75G8M30>6#;H("H+?YDWGS>D0U:5CR[#1]N3X90!
M@0J%)TQ:1Z3CGE@%GE!4*3V*F^B4W=FU>EO+J.V6[P5JKZU\\&NHK2I&GY#N
M]D,,BEHO#$EMMZ'D/4&U$0B>%9V8YL:H5 *:VEREYJB">L"@OK8:P@KJFP)U
MM[&ZL5(Q8PDU-!,I/"=>94\T0Z@C3=.@;1F,0(<R]:3.Z7[ P9J_-7"T8HR_
M%P,J05B.PKQIYA]*ZZ(:H+GY+-07FPU9[.=?Y[.W+Z$Y?(S;4FF[1]K>'E:E
MI;.E S6A07(BN1<D))=)1K-*>NV"-&YG5]JQU=LYI]6/.VQ@WZJ950%],X#N
M9HMJ*@6/E$ J2>3,">)%=$1KD-I*0 /+M'WAS!<J9VJ'EGN!Y=ZMJXKEF\%R
MQZ8*62!^01.;P! I/24^9THH1&FCU=0 "F?.]%C9@8"Y6E4]!Z/N5!G@V>*_
MSR6!7TINO4J8Z@&G\O<>PKH@E?^7S9;55/YKX?KM%OP.A//6).)"M$1&EI'U
MM2*"4>$DYRZ8B'J;Y&-.MUME?E_)\V#J?'ITG%]X3_><&6ZJ_J\RP[4SP[/N
M/'$0$E#M \\CD8I:8BF+),O@N'7%9U/J_SA:=-=.#)45!L *-VP*7JYM0.6'
M:^>'CI6(I*]\4(XH:5%SR!H(&HV6Z !2IT"M:T>22S/6HH?8V_5R0T\!J<&;
M2W_#X]^ 7\#?T41:/<('*RNJC")K'Y1Y9.\1'%<<&'#?[*5AM$TIY%<Z1.$_
M3S[OTV]X2W.DP=66/EYO<F7 'AEP>\R 5!)\&7Y"=48-R0A+@M81=Y0:&Y3,
MWFMD0#,VO <WV6"LIIOHCG#?^:$'LZGRP^#XH9MPF(+F5FEBG65$)IZ(<U80
M%K/QW+" 9V!G5_,Q<]?96*F2PP#(X3;#:)42;H\2NATFA8N0 ]I+( 21(B=B
M<;N),%$(E9)(,>_L.CIF:GN02<^-4X94 #5HP^G11=;1R"]' =Y.9K,299KG
MT0GX9@B]^8?S\X'5A5V"YC-7(D@-F7LC0RPY;Y%3RSU5P2MGWCS]-H?YE]E]
M;_G(-\T)+M__^>EQI?4^:7U['$!RQDK#(]&IT+H$A[0N!4DTI!139L!B.PZ
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MMA\UDT/?X*7@IC7SX[<';<+T8A7K;4/"[<%J($/30%H%B,<M+18W0_M7O!/
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M@YD[J_DXA\;4M=+J9'IB1D?3(EQ^#*M>161/;A:.@]-!L_.C#H@;'XW$GR$
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M/" !9_-A[9F($8&TU'>5=V)]\4!:H^#!+4D+**;$&N@L[UF8SGZ@L^(O$.1
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M[0X(Y:E@FB?.4Y5R;9),<T.QI H+K426-I;>:L-439$"Y=<1+C0R)@EW(+A
MBI ,<2X]TY:F@F4K:.D]+T=QDX=QE7Q0+SQGS"-!T7P>1D4%Q8HRY&)N_333
M(<N^18Q+XQBG5 NWL9UNBH2L4,J8)O73BCII&C9^)#:N:109T=X[KA'8/1*!
M!>204H8@*KFG/N6">K^Q3<0F(?>^_M/P\>KR\;)<&2\W#>.CL?"<[T(+3Z7C
M*$N,09P0C)2C*:(DA=VDG,'>-FD87P /+\O8;V3Q(S%R_9B$@Q"FRB"69!QQ
MYT 66P$J-4F,S+S"G"4;VY1N)JE<(3YNTC V:1B;5 S/PYO2I&)X+/B?3\-H
MA4^DQ0:EP@+\<R)19AQ!4G.;@C1W26(WME.RF=#DV61B:/+;-*"ZJJ"Z+-]6
M ZJ/"*KU$K"9RQ*M/=(X<:%<4(HTD1XIKQDA0EO#R;+\6PVH-J#:@.HC.1I?
M=A;&1\/3NK,QQ3PQF*FB\AI/G$$93RQBU#)/,RT-:;(P-H#: .K:>7T;+?41
M4;6>A3&QS"D&NBGE@*K,$J0Y21%FVDA'I/,VV=B6R6;*V;,!U2;S6I/2;KV>
M;!:V6=CU>G)!$L8@/H("D7='*LJ/NZ5ES+L65(17+(F:[2/K1C2>OYVXUIO>
M&?1\V;(@D[J]8>M$?7>M\$&9/J:EBFQGO7ZK,YOLK$K$54C-,AL7#0\&-6FK
M=="'H7G7'[2T&UXXUVUU0I/P;M^U^L[TCKLP5AN:&L) 0 :/5*=EU="%-%\F
M[YO1V6"HNL;!]_"04:,!/!Z>'99-;[5:, =H[B+\Z/;&7TSZ+#-$%=G:BOQ$
M+3OJ@\B-+9W#RO7LH'7>=X.0,<1NW773UF.K0<-U_=:PU]KKP?IFF[![>MC:
MUZ!-1-H=; :UM.5# KOO06%MG3D5U-6HQH8-L>&%WN2%VD(M9(:912@TE]/1
M8)C[RS]69%UJ*M]X]Z+R32C8XLHQFS+*A192:)MZS+'R-LV$^4J29&.[GI+U
M$1.KQ"DDXYUX^@5\BOF7%M[>Z S>-[,FG;,IX2KCQIJ,IUA+G,!.4JV5S @5
M]NMNP"Q,,$&3#/NSUMQ?_1Z Q/#RKX[J#G>Z-MS:.0]<,3'I#J"_UYV>^?;D
M1MOAQ&A[WV;0%AAL'T_VWW_ 1Z>'^!#:;N]^@.=>GQWM[IWM[YZ<'>89/OK/
M"39G_W35EVRT?WJ,#Z\L?/_Z9._]6WYX^O%L[_0C]&<NVJ=O:?O]$8SGD.^_
M/\K_<_46QFR^"I(86%&./,$)XLYBI(@3R/+$FA2GB<E486L#.CB[$VQ?F3%/
M/?&9U)Q3C)5,,T.IT,YE*M.P#0Y,X?, 'OT12.%J&R*0C_>@,N'*S:_!< V2
MBLVYL>,;D&O%@*H<QFQFYJ1R5ST]P,[LFZOV[2?Z0W@N*!!135 #$$N=3N]B
M\*J:^A-Q^\OF\0]?'?&"I%JB#(O@KI842:82I-,T48E2V/@YGGW\5., -K^2
M:EPD6T +2\\QS;=(NOP$YG2+IG2%QGI3[F[V(+F[V<,D&G^@P2XET?A*7.)<
M2N+'[#9S6KT,CF]! 3@#^]2V/@^<'W5:?^;?W6U2&MX8<3]9D.>3[W(^7??S
MR7FY9"[XE<FNWH9_Z+8.G>H_>8[/Y\-"04MM\C>ORE;<L]+ #2$-=VEC'9=U
MZ<4,[K(6#[[8]^G@+MK!<Z*(%YXF^YJ<PKVS\]$PG& $1\B@YX<7JN\>2(?X
MZ>QO*"/VA,$\"YT_RBHB-).95IPK)Y0%:RZ#O[+$8T+)?9P_A;K_9^YGHW=@
M&N:5'?4O0>M94[=0$:]S_FWO]&^Z=_6W.#PX9(=7!A^]__QC_\M;OG>Z<[6W
M:^C^[L[EX<$QV:_'ZYS!>[N';&^W<[)W:D_WKCY^.SIX"^T<T_9N&^]='?+V
M[K]/]G<_B_]<M>M7=;[;]_]P^[__[AS1SG=]>MXY^O+/R>'!NV^']-TIS!N'
MJJW[7PXO82STZ/W?E_L'[T[@7=$F$G\UBN.,<(RLPR$DG1N429DAF5 A+#5&
M4K&QS>I.8O0S,O)*,94$]S#!/!%*,TJ,(#)+.4F=31HR>F9DQ+[RS#+G$HV<
M$PQQ0C'25A.$,T>8DHG6V&QLBY^?-2S3V+D+HC^W^-1%4WPV$::.F31QRG.7
MB1!HJGB:>&,Q43:EF3*WK?-]+<*\[_<&:Y-;8#V@IAZWGR64>V\ULMBFB$N7
M(,F]1%)JSQPV6E()YN(FQ=D*I19HD*E!II]>>Q=4$4,\3VS&A:,*E">,=6)M
MPCEC]+:Q[PTR/2(RU;.>*&TH!L44\"A!'#, )9N .ISAE(2<IAY[4(<W,5VE
M!&0OH5#0NU$?6&\4 AK J/= _/#[]7[R6_A[7HA1KSFC/A'$Z(QRSKU*03N2
M.&.6)M)KV5AC3P]$?]]DC7UKGWZ#\;XE1P>' OK$AU<[L"8[5S"7#EAEM/W^
MXVG[ZMN/O0X8]12GEF(.UICQ&G$O ,6H=2C+,@&JLU0")PNLL9\:]9HRT-HD
MT RSW$HI!8<^!#/P68958]0_-S)B7ZV2WFMFD.:@JW.9 AEIC%'")0$U7=(T
MJ.GI$HWZVWKS?Y9=[[95 M9:U_1$8YD1:3%3G+A,*ZH V(7T69ID/&NLX-7C
MS;H5K!UU+@.FLB:SB#-.0>O,$H2M840D"8 IW=@FFVG&5RA]?L/*2V9E9JBC
M.',^M8IKYU3"A"4@P9E33CC=F(TKR,J7]?SSG@DE%<+>96 V)A*%R'A$$^QA
MYV@6S4:RF61TA5BYN>CX0@[$_W1JX$YZ'=O*S\[[O>_NY^5 F@/QR6&#5QP3
MQQC3W"BG;)IPGC&F&-;"^L;H>7HTGJL&4C=Z3@X/_KYHQ_&&.;S%^U_:5_N[
M>Z=[IS"W+T=G8!#!F#[0]CNPG;-4:"*$1BF1%''J4R03PI'C&2>IIZGU_*X'
MXB*ECF6*95H[3J72&CO%!<-6"&<<;<CHF9$1^\H9T2H1%&7<)H@3I9 V%'[3
MWG#N."&96:[MW&2FOZ7"K=(49_ 6Z-V*IU2'0T>-K3*>6&:]:&SGU>/-NNU,
M0,?&G%B4^I"C"  6*<(D2HRQ6C*342[""3(6]U:X5^\$N6'EBI5!K'+E?9HP
MS[AW1 9GF+88=E\)<OMT8PTK/R(KU].-":<=EAC!SAG$N;%(:@JF- U).856
MRKI@.S."5XB5&]NY6805<DH\BRHFYPOS'-SG8LN*W-JXY2K<_R+/HURE>22O
M_[77<9ZY3@/*B\DL2257*1<L4X(E1DF6.BQ\FM+&/%DUG>;;G'GBL94J*#&$
M,0K6?YJA3#F-"!9IJ(_'O-(;VPF8)\NJC'T[;EFC0[^7RO[+RJ#<L/\CLG_=
MI-&)3UWBD<F,0SS>I_+8(&*()%(8P12+[$_O'=_^*.S_,L[(!H-7K1UC1F>C
M3DQ08MUY'QBBR'L65%)UUH/Q7L4/EI&@X=EKI4M,2/$H;3Q/?]IO3Z!\3O'1
M[A0;P>\=%WX!@;0SQ4W7"JM&3BU/3KV]^//@<WG*!9(*VOZJ4VJQD12!KLH0
MI^$B%O4)TLZFB71.T8R%ZPZ9G ]!^[WQH#\'CE]:G>:&XU>2X\TLQQ/N?4J%
M1PDU'O%,)@AVG".=>>$E)IE(S<8VWY1BOK;'DW#\2W.%[KEAXPA]]H[06]IS
M3?&MIOC6"GF. 9L:\;Q$\?QC3B%/%=&@=!/$0 5'W!B#E *MG%'-I=?,TBQF
M1L I>3:EMQI(;2!U52'UP;WQ#:0N'5)K%H^QB=0ANXSQ@B!."$&288M ("8T
M237P@PSQ121-G@VDSE;:JH<8KWWE+2* BW>+"E1.F9.0)#M4H@K![H.6@Z'9
MF:39LU4Q-N.S5=&NOAOF?7C^?^Z2@^I7BF1,X"&IH\->KVO4X&2__Y?J#\L_
M=D->]&',>+%S!D0VW/=O>MU!#H03]^LCS \>L>1V\)&L*7S\>LT-<[EW\96:
MA&@I$^!VP8'YC4!*>!?NL6?<,LM$RH#YMZXK9 ITVPG$$*JI+<PJ6F0C69B;
M9+-U<9(#<9XHV]*ACIH?=3J7DV,E9[=:2R+B\U'?G*C!XY+Q BFG+N/-LH/>
MC@$!UW?[,,C^/5U]+X]RWU[L'WPC[0/X_/28[^]^^*J]4JG  B59N$,B=(HT
M23&27'.1@''G+%Y,QJTI"B[+$ 9"[N>!6."SSL*K@9NWHO:M4#GPFA9BZ2'M
M G&7QZ:AO^^A@%XH5'A^W@'A%61B?+T%/9W=4#;P5K7O;B.Z%I6BNN&]4O!P
MNI4&_^%Y;Y"'U7W5=QT X^^NK)Y3JI=3+Y8Z )Z\HC2(>UC9:U]9@7N1L>K4
M.T1X[3K2U,^3?C6><W7LD.X[]0TI#\-]I3H7ZG*P\:_9XEIY%]56L;X U^_$
M_??QMK4(LXWMIZY%F#:U"!^R.MF'+D";.U _5K'VX+=2TIQW@I38WWU[<4C?
M7AV>?0;I<71R>'KR;>_LJ'-TL ,2!$REW0_\Z$U-TH1G#XYY^^#UZ>'!7GYT
M\/%T[^Q=OO_^;WIT]D^GO7N2@ZG$V]#6?Z[^OFH??/[*$Z4SZRVB&4T1MV <
M*2$H8EIFJ64\D<37:P\ZAF7*,,N(DUP ^W#F'&BCS%IF&,GJ=<R*96_!N@.E
M_$+)P9O[FQU?&@SVS"7"&L-!U9.9$YGGPJ3P1I:EUV+N2I<H7-TBL$4=Y'ZO
MJ[[G_=&@M9/;S=9'U\F=+\I-PO;TSH"?/SD#.N_PLK5CAJW?_N__)X%?_WBS
M\_'MI_!)_)O\\7OK0@4=&)28H#9T6VT%"FZ+IE$+QJV?X!.-_SW@3&-M!=?Z
M##H0C.W3$!3Y0:@*''0?L,Y:H/_TCUW77 9]*Z^J+_=:L$<Y/#!2G4*GTJ,!
MM TJ&?SIO8LSU9>%6K__SX==1+(63,\Z6+5"TQJO$K1E.B,;^G5GY[V^ZE^V
M0/_O'A<C :7C)#P2&"[T!)R&RC]U-!*&ZD>KHRX&6ZW6NU&T6_KN.)S=]Z"A
MXU%NXYA'T'>AKDTZ[O5;P3T1^%)U0'<[S@>=@DNKS8(I@)UZ#/;/ ,80N++K
M"DOD(H=A+9P>/#4J]$<5^ACUXPCC@@XB @3;*8ZSK#7]I"*R=5?/R,K[4V@1
M /DCA]V:E!4?@*WG7;]?$<QTZ?(0#5E8$Z'D==A4]^.\H.%RI\(KT-S _7<$
MS.!B(3/W/9H&L11Y+)(>S>*I.N8V!T[HPT-@)Y=\YO,N4&,.U#8(K%8:%]UB
M3'T'?76!CC^7M)H/6F=N>-(#\+G-X(.18ETP/F Y;,D=O:+C:BS&C0NA7S.>
MEE']_F5IZHRFQQ<:C#._IO\  <=CUHDSBG 2'@D,&A;!17"HEJ/P#L ?A6]A
M=J#%A,8[ 5#0AR7O#\!2VYU>C:G9NU"I/(:[AHT$+;Y3!NA,%D.UP(!SJ)-_
M<YU+!)O71:'*O0$4!TI383#5&H;9Y #XK:+5&#@;2L]&/!F<1"[7KH+*FPK%
MKXM ?GK>#=(A6.R];E5JON3F($])^D>-E<O]_VV**G^_1SGA9>+@@^YY\@M;
M_K#6R"=SXNRHX_9]Q:"@(>_$[=GIVC\G^W,0G"4OVU#Y]I42G%'L4S!/G$ \
M9"65:;!6E$ND=]H1H=>V@'**MV3&FT*_+%U&H=_5OI/R6+5/GT])NV57PEVE
M#/@K5>9Q+:CAEXNZWF4EEE#PLBGJV@#S,P?F9=8:7250OF4LV0*[^M4R M?7
M8>ZK%::_IBNV)+@L0E*S%9]_N-P2@D'4,'B*.KW!H/"=^5[_0O7M7$KB>]_-
M6[D5:&JE+?6JPIS79+^BKC^!N-Y,T]:ZA-G^FFNE"+/ML;V#CYV]T[_QT=F[
MDZ/='0S?LT/HKWWZ@>WMAI!9(_:N/IZ.WZG";$\-V7O_F>[M?CP[_/+N&XR+
MMT\M]/?YLGUJH!V8V]4WMO=^[]N"0C-?$Y)H[DR*'$Y#0DXJ4)81@;C-,NI#
MK2D?+BX(LLG8O:\NK-Z%X@:HGBE0+>L"0 -43P54M=P\V&+%:$I1XH4!>!(.
MJ8QJY EAV!$B-4L J&BVR9]CC<?UT!,_NH&+$1_AZ,FZ[Z[3BQ'#Q:DRL%'^
MD_(5+[ZBT(,I5_#+F[CX,WA5;5:#6\O#K<\+%"P%8,(2Q$"90IQ1A:0#!8MZ
M3[V@6I%08@A@BV;WSI/\$^A8@\R!SYNY'TPA:9C[$9F[II0([6G",XX2)CWB
MDDJ4)29#2@O&0J$#X/(59.X7Y;O:[Y^?0*^V/SJ^EPJROFFE'E$%Z?SH_[@M
M1!4;LPO[TH#4\D!JKA[2UTQE5B3$(,^#B\>#&J*,)<BG3#,+7V4\6$Y\4]![
M%RQ=/0]/P]O+TD :WEX!WJXI($0XBI47*!4L1;"?%$FC!#+,>$L OK'D*\C;
M+\HI\D:=Y\,0G^ULJW^-@Z1QBCRZ4^1#R&5IW&!L*NUT[>YD1QK<6AYNF7F=
MA!IBC)1@.%F)>)(9I*SF"-",*4.HQ=IN;#.V*<EU*1X:K\@SX.X'\XHTW/V8
MW%W32JSD1$DKD!:ACH)+)<I,\O^S]^:];23'^_A;(8P$V !JI>]C]_,SX%W9
M^W6PDM9>.5[['Z%/B39%*CQL2Z_^5]TS0_'2?5'V)(@BBYR9GN[JIYXZNBH@
M$S&7E/+ E(;=+3>4:MTBC[1)_QH/_&=4'1;+1Y!B?W1Q@X0?WGZZS_!,\[>7
MW_)"Q-]F%@2 Z]?8CZD['OUU:(?QU[QDLU_X;3!J\>P.\>Q@B:U$IBB(BT4!
M)XPX802YA!,B4OJD31!&TF?/Q0;GMVX+U3I0UA< [C.$TP+ 6@'  J&1RD:)
MO4,L)(JXHP+I9!)B,GJ= A/2N0P 1-[:6OF1>]W^4&ZAU_E$2!RUKI\'#D;]
M594U@:WZ:?^/O]_^W8+CM< Q]R9Y.5^I5X)1)[ 1*(H YEZ@#KG@"4K.Q1"M
M5=(*,/>,7B-;K_7DK!DY:C?K/6W6[?G-REQT2C..I.4N4QF/+),*,6,<AA\B
M4J RA*_39OVA'#.E]F[KA7GX$TAYWELSZ@[!Y]L24S!48><Q1I@1@CA58$?Q
M9% *D:7DA86ES6U2Z.W[:[>.E/7=P_=W.*?=PW>_AQ<(A%;.*L<H8C&GG"A!
MD36*(8.C$BQBXV7,?3D8OC6%6-.,$X;7OQWAWF!L>ZNJQ]W&W7"[3DM/&K+N
MC7;\/AR,VJ.#=PE9)TNT0Q@ DN@"BM: S6.!<3A))=@\G,;$L;"P;,\95QM8
MW'$SH;5OO];N_\>E+.W^OX?]OT!9E/)":1]@1HU&'(P-I&/RR&+#L$^64I;;
MI5.Y(=E=):0\3*^PIUJOZR95FF:JWMZL5-,3G(!;E&JZJC7Z_<]8&P==YP6[
MN;_SZ<95?GI<RV.F/G7K,;EK^D&6O9[82"V30Y@S@WB2%#F5*#+.A)",-T;D
MD,L&-<M>SW^UP='O81/?@_FPO(G;?7K-?;I@)K@4E ]!(FESMT;B%7(.>Q2U
MY<;#3B64/'O."5V/7?I#1457^#-G[(';A$N_-Z?&8W*+:9.^&7!JR<4=@A9=
M(A=.8LDB#2ABAQ$/Q"#+K4,^,4<-=2XH?'MR<8/RUT\EU/HC[_^[IB6K]W^[
MQ:^YQ1=XB0!!U;F$F(P.[ ?-(G)1<42ET;D1.B4AW9:7/-0&_Z%<&W_$T>CG
M53W56G?'PP=:_]LLPXMF%5IF<H>PQ9:8">?::,(9"C:W)Q;1(B.P02S $B<9
M0K0I1UW%AI++I:5;Q\=WL9WO+6[:;N?[WLZ++"0RRFF*2"DB@87@B+1T*3LU
MN8NY G,B51"5DN7,KR?O(7D*25^Y3<=572179()U)RP&LQ &D]R1\=JML+[3
MNOEW.$'K#?=K$ZN:!_C4_18#.HW#08OMU\-VOD35-// U2B(N E@83J&D9."
M(RDQC\1*KZ3)H74-:_?+'67UWMW^6?,>(BV2MDBZ#OF&+9+>!Y(NIAH*'*GG
M$F'F/.)6)^2X4P@K0E,0T6FCOC\D+43[WZ7Y]O/FI>K6Z\_KAO'YKUG"N_W*
M;"LMY*_>7_[:7>GKC<?IILJT_7@PZN;'_CR,/7C^EUCW_:XWYLR%]33BLTNL
M@QF;C,^_9*G1Y\/C"\UC>H6(F)^0V9^'PV8\Q_8@(C>,]C.R"8;[L^U]M2>C
M9_^>>ZNC;A\MS.+B!)R_$M7/A36O,$5E2#-1BN ]-SQH$X5)7'C%0C!Y>_S?
MG 3- V,,BG!KN _><(6=QI)R09VSVA JPOY6IIB88(+.N.8\)O[E#V.8].)N
M>IE2/F#^)4X#%V_M.+Z-\$0/4%D&O9>E>@^>_VMOX#\_45S\^/<A]D?_[=OW
M9K*;O[MWP+?W?OWT86^G^W'O[:>=HU?=W=_?T(]'_^UM;QUV=[?> >X=YDY,
MI]M[;_8M 3J/1434R0@$T0.L*6T0U:"22 @ =.)9)X+V.,[[83B)*W;(\AY^
MZ WRHC.<6]O<FWQ\&&$8=CP9#X8GQ6H>@@QTQH/R26PDY.P34)WEHY-HAZ-.
MA)<*TP;G%8 SLM')PE=^DE+K%W[!69!'W=%XU#PV#;+O*H/O'8$?J(LLK6=0
M5G ?9K=GCT?QY^:77YJDTVZ_S%&YZ)<C.SR +5_C7][N"YA?QE)]7".!D9M*
MLPP&M9>E?G"-$YL%)Q;46/69()N&DG,_QIOG?W;1;0G95,S<^6W9IM#T/@;+
MF7HZ@R57G-G;NMW.=:<3<8MP_M-JS_T!P*7S<@Y;.@ K=]JG^S;=F[^3:<XH
M?9M&V)=/PQU,<HW("P_X?E: M"OPR"N [[2U>8O?SY[_U.T#Q1M,X!9A]*\[
MA>WK^@"G=MI#N[MR+5,_!@W6+=958="QJF_:^<E5)4W_U;'CSKE^L?XD*[YG
M=V !GOG(7N^\6C0(KV(&_G9H^P?PA9=]F]^I_L[488;H$[4,:X_9UX];K^F'
MTVVXS\>CW2V/=\#RV_W]8^_#IX^]'?H2?WR_33_NO3K:.5GTF/WZ>?O3QT_;
MIR_ISM$'#M>QG:UM#I9D=^?H'?NP]Q;>Y6-O^_T']O?I]GC[M[G2JE_"[__E
MX?_]I_>1]KZX3X.3[=\_'F[3=^SC[V^[VZ=O8!QO#S_L!?C;Z].=O</#W;UM
MF(MW^.,KC7?>[',;&"&:(4$Y&*:,!.0LK+S!7A-N)#%> ,0MYY?\<\%?<8.P
M]/?FCE_UBNOM4+].)LHM82.[UD?PPO#;(GR<H<8<8DS_7-=TKHLXOQB_BJ#A
M;.^OQNDPASH_1!;+PZ'-0B5W%F7@*GGD*+&(>RV0C5HB*A*6RC)*",YPL<%7
M5"]ZRBEI+:Y]K[@F&29!Q(A5BMSA:))(WB::2_ *377!-=+@VLJ088MK3P[7
M%@K48\R8<<8C8Q-#7#&.=)0.J6 <DYIKR>FSYT1O<&I:7&MQ[0G@FB'1&\:B
M%3IR;H1+)%@6A&8L$?A/P37<X!IN<>U[P+6=!;Z6F+8YHP(E+PC@&C'($"L1
M#]K:@"W\EP.NT0V&EPLW/>6<X[6&J+P3XHQ7)XXV.OTXSF'-5.V53NW>:>M8
MWZ,Y.H]JOTV&P]@?E[5YT0]_#&!.EL#L>T_\>B"@>K-D6 8!NDE[6*RH,CQQ
MC;2)$0@8%2QJ86(^HWFW>5]KE /;[NL[-,?:??V(^WJQE2E14B<ID<!:($Z9
M0Y8D"@2/)!^3"<2Q=E\_U7V]'O;(%7=XNY.OM9,730FFI$]2<<2XMK"383L;
M;#42.BD!Z^1BRKTGY&W\(^M7L'ZM[8B7_YMTQR>W;S_\=(]2/Z;!<)6H]^J&
MHR^_Y<[J<$'C(CF"U?@Q6I ^$'R]6S8P&/%" A'QF $1\0!D3GN&/(LF!" F
M6&5/R(:D:HTZ=[4%%=;=O+A[%&@W^O4V^H+%X26-ED6"--,*<9S[ZP2,8;>+
M@*5W1GG[[+D6RRDM[3;_;K;Y'1@;K;)_.ABP:*M8Q[@E6")G*$$\1H-<"!$Q
M(;FATCGI95;V2JV3LG]R=?8?H7;_^@VXG81V$MI)6*]^'D\P)OQ^V!W'SB"E
M' 7VPQBZXXZWP^') $;9"9-RHI9I"N.:A),V+GSO;I[24+VLRFY*NPD(W&]E
M5;[[XA\/Q-I6M#<.R2J=$D:"*(XX]00(G"$H!6FUX&"ZJ38(_"-LXCOSTK2;
M^/XW\4(%'T^YB29OW9Q%RZFF",#7P$)ISWE2FO+8;N(?8!/?F0_FBINX=:+<
M=B>_F]_)44L;'6>(X]S/1QB-'-4:,6H94"G'5<AM/\D&%FR--O*/$/FM3M-V
MNOVV.OZCQH#/285O#CNW5;<?%L.66Y=+*6E0+B#N,47<*(^T]Q(%930V3H4D
M<GL?LR'XK3&L#0BM[\Z_\[AON_/7;><O=B-T2FGN-%+! X7)YY4U #YR6''A
M*%<Q"MCY:@.6O=WY3VSGKT?B:8L!ZX8!"Q9,H-X8%A4B,HG<W"_ ]G<&&8RY
M5<E$26@NX+3!O[.6&^M?W*CTW.TT4WRG(Y";X@I#6%'2.!?-0FQS1>E.9T<Q
MWP"0A_QK=>6;UO'ST%96$:$7X=-D-#Z*_?%WTRGQH?#R=$4 )C&,K4?.*H6X
MQ8"7F@B$M>% B%1*7@%>LF6P;/VVW\WV?2A3J=V^M]Z^"R8/\])P022*VN?J
M3)(@ES1%C"F1'$G6<O/L.9/M]OV.M^^=I[ZVV_>^MN^BM1(I\X)$9*1-L'V9
M0=H*T+Y<1&I #U,"VY>(6^>LML&6:VV^UV?E5\\IRW&],L@+'6:N6++W.ZV^
M="=3\]V ]YV;3DN=Y=NZ!_<!YGC)E"+2".DPX+@3P,68D<BHQ)!5DE&-+9'<
MWUD:S!WNI36O1]<B:8NDCV/%MDCZ4$BZ8-4:RFV)X0F92T/QP!" ID(QG^5B
M&!M8M19)6R1MD?2).!1:)'TH)%UP,$AMG:/9K6",1MQPAYS %B49E68NJ;ML
MKKH&2#K?5G7:1G6VN>HM6@4^=,R2WD7,\H&QIG2-[%2QWNZH<SP$4!C"$TK-
MHF%W%$,^[A:_'7>'L-B=MW$4[= ?EI:/6_%+[ V.LW.Q/A WFNL=>5'K2%SN
M  L-WYB ^&:!JUOGC*[1@+)I/4DVSUG_F[7>?>@%^"M6()^/#]:M,U_GAD]]
MVX,I_Q+[D]CY;1#R\<,.,5IN% 5@N_U19SCIP3C&AW;<Z76/NN-R<=4'^R1_
MW9:5M/V3ZCNP_^/P8 "7P%MF(*'XE\'7?AR.#KO''5\28\J?R2_Y/.-D##<Z
MC9V\M*4 [G$<@EB#)/0&HU&9_>QU6SP.67WB0=QAC!TWZ?;R+)=KX,FY1>E!
M'VZ;&R?5BUS:]):QGS.HS694+RX=-\CQ 6BJH>V!' ?06'UXDLUC.JF_F9][
M=C7,TM%@&/,$]3L"_[.9MN'Q8%@\Z05PU2\C$(N!_]PI!SYM9SCH]?),C ^'
M,:(B\# [W4'HN)/JFX>#7LB3468>GM?Y*73AY<<P+)!P$+OZ7__JB'_FOY11
M3#NVED<MC&0C?PTVZ"@_. T'1_!Q'V2P.QI-<KI2OJ"Z$L8P=^5FYW7*:[XX
M:9V!]Y/A:*,S*X-GT]<] D2KI,7V^Q.0QR)E=7/9?AGJ9%2>>SR,:.GN*X1F
M1DI P@8IC> [($6EL6M=<QDFLRS:5"J6Q*&S=YCW1"7:6<1[,7?BLG/O48[B
M%ED,\.GPJ$A"68W#+DS3,(/QTJU'U92 2%</F;WA\AP4G,]W'5Q\3YA(4--P
M[\EPNCUG-EC^<]Y)=CP>=MUD'$>P8/V"E!M5*]VZ[G2HN5GU[9*U5EYPQ3&#
MS/&&,9<[:8XGYQM]S>=T4'V.^>QQU;1\[?9Z%=IG"<S_&$W<)YB ?/796R^C
M[<UT]/K ,,D-95^,S^US_$?\U@7,[1Q:V-Z#\>%T/?+<CTJY\)W=/RK9!O7U
MU0Y#Z8)LCX^'@V^@5,<1=M,_KL'J,>7>!*(T&-=<,&,%D]YJIB(622FZ_WJE
M@UDLDOG=9O?] 9OOM]GQ72VWT3Q1,G_SCN"OX1EO]IDB-#*OD(=E0-PEC8S
M$1$C*$T^,!]SL&^3+O'P#FSO7MF)(!N/L>1+>:WGR\!<3=:K"83\$05B[^6^
M3,$$KSD*6"7$M14Y8$"19QP'+HE+% 1"R\WE JN=HTHB-D!=C(ZK.E6]D\T*
M9*J?%=@#TC3  G RRNJP1G!W/?2X;9Q*S)WM?)'U4-TE!,;UNAY5*R_GR(O8
MV7JW[X/244N%&)< (")H,.8I1UZ*I$-*$JQY !#,-Y>/-S0",TLO@,Y5=90K
MXPK689X$9=7T &ASKK?H"FBS!=P.:(5O!><\P=G=>Y</Z#NAF$0AY2RQJ!ER
M&G#'&1:3TQYS%I\]YUQN+I^(FPH.<(]WFW]MSL+) CNQA:#,-E^O$>CK81<L
M? _\R\5R#:!)I[XL6RW9HNIF/E/)WS >@957#)(K<*+",%T\R.V#!PW5[%;@
M5P-BJ=#7&!?-/3/=[=FO%0FM+<\SX9]::'YR-*D<+Y6QT?AC-F:_G?>![TVR
M6P&LUJ_9-,PT[7C8S6/.PQIEGU1W= B;+DU@P*O8=?92-';Q*E8^Z0.!+H;3
MS,U[V6=264N#!&RZM@3 9!U-1ME:!JMC5BUL38:5C7FY2X56[[AJJ&=JY%%T
M2(,4R\=K%K&C.9ESG1J,/QY,;./=O=?[@5CL@F&(1M JG#"/'#<)&0\H3DC@
M-.26>&937,!'SAQ^M8E8:$=E_V>]<VR'XV[Q!-2&NCN9FI69GJRV1T>C@>^6
MZ[]VQQE*CD'4>\7C,YSU((89#V+C_?M>;<LYM#W'BSF/4J&;/:1C4.R 9OD/
MD_Z,ZVPFVVVTV>F\@,^[V6<(V%7N![-I>^-N\;=-.<2DWSCE\N4-.$Y1&;Z:
M>E5+\PR*Q:\RZ.?5@;$O-SG__I:J>&-G2=6<3WS&%S*G6_-TYV?_)PY'L?(W
M[<5O=E0KP=D^8G/@GA^4I[-R@1)C3+YUP_(JO9J]9[6JA'?M5\@.FW!^ )/Q
MX6#8+:M=R1*A5[]5-<J9>RP-<E'+'@]Z75\F!^XVE<DKR-^,# &NC[,/$,:U
M0K)F1W"#K9.Y\#4T7:*".2YCHD"%G9?&<4^QIA8+9X51A0I?(07EW<P&/2LH
M/)K&4?]LY@0L[M?U9+WP?CB)X;L-JMY<S;TYV3Y]MT\<#U13AZ35#G&I/;+9
M"G?,6Q5H2HRK:X7+[\KN:1?[[A<;."9.5F&$'=:(IUP7.K>D@HUIDZ-1:XJ?
M/>\/EAC-,L6Q>:IAZ2J>WB#38'A58%I0;OG^68RZ_8K"+BNN*JB;CUMTT\DC
MJ:Z%%("I@BW"1"@-S$86% ,>[X06+JB$.;8I*"/\/E'TV?U%T)=>0:U\!;WY
MF*'P^0E\C/?_O[D$B#NPR.91Z_?!(&2V5X$26%LY]%[Y;;:Z(P]&\V08@;V,
M?^T-_.?'AJ'3UPT, >1\//IP^@[OT%='V[^_P1^/ML6'/8]WCCZ(CP IV_0=
MW8'G["S!T*LN0-6GG;TW[,/[#U\_;KV%^_0.=TX!AC[U/G_< D#;^T!VWF_C
M?.IG>V][WT:3TQ@Q$BF;5B)@I+USB+AD=)*4&DXKK0)P$,.+#.2,4*6XD88D
MP[&++A%I4R3.)"&4!6,X K@?9[0 %?#L>;,02QDO<YMW 76JY;C\4?-#DRQ*
M^+8W B[#EMHD W$  #%XIIE\]K3 ;+VLA=?]SG\F8!SD#+NS..%91+KD8_C_
M3;J5K96I[&\#4#S>]L$T_NTL0I^9L.V $!S$X>;,=S; "/PZO?&?AQ:8@X^3
MDDDTZOQT9GC\:Z,#Y&-SHY"+^LE^)J5@D<7#7,*@BI-Y!&;>J"3A9&TY LK3
MZQP-P!2<]&)E!4ZRN0X D0/W)TL& MQATAL7GG[U@79L<?TUGKC^RD'.W+G.
M(\CV:I,A5"=<@&$VBO^;9%.GCG+/S#@8Q\U>6_),K%B<ZWC(A.=@-GCMC0]<
M4V.-U4EH*F!3PJ8SF4H"&BM"+PBNG*UT,\PGXO=Z<'!^0W?>[ >K:0A"(Z]Q
M+AL5+#)!4R0E4]J$8 @3SYY3L;E\B/K,[56YN(?Q.+NC^N-1$818&L$TN^41
MY>#/R= ?VE'\$_3!4PFR/;@PO/NZ\V+?6TR,9P+II"SBUAIDM$U(,Y*(TXH&
MF2N@RHM";,?U;&='3\Z@^E*G'"7;'19O^A1 2_)<[R0[Y+/3OYM53S=U2^)2
MY?K<J*()HUR/JC(L*A#NE\39@COYFO')5%/,0>EU38YK>]AJS<7IILH)J<O9
MJE^[87S8I*#/7%BG!^.S2ZR#=YJ,S[]DAD?XF.VO1U+0KQ"1"Q,[\_-PV(SG
MV!Y$Y(;1?D8E[^QGV_MJ3T;/_CWW5D?=/EJ8Q<4).'\E+N!T-^!H:\)]^C%S
M'W7&?<IB%XV>H]9 :H;#'-4I7O[CX>!+-Y1@8:W"4[=O^S[_I=YE'IY3DNAF
MHP.YYT;MN<ZN:$#L,)P<Y"!E*/LJN\#?Y>U9J?2S)YX-JP>[NS^J=N5?)T?'
MAX/^2>>US^J@L)%\T^PGZ&4/>,[RRU$[>.9)IV2RU^Z"$HVKMO7""(HK<N"J
M(%Y^;] GO<DHAR*G$#,X+BM><NT.LEN_&5R^7WE,B?1G1@+<*+.PHIBJ-K+P
MXG/CAE<^(Y\$SRS MSCT)7<[O]/BPTMJ[D7T=/$A]\6>E+<B&4&-((E+29S7
MRH;$L:<),T>RUH1=I1B^0&LV@\UC;?G3Q2K3B^V#?6QP2#YH)(**B$?JD28,
M2!0AW ;KA"/VV7.B-Y>K6%S"G^KHWWQZ-RQ+OTZ@G<K,7,RPUVV"X+78ARHT
M6 >_*OY?Y3K7!&U>8=] Y78ZWV?@:KI1NZ,R=S/Q*GLT&(Z[IW42N9N,2_ F
MCDJH;]SI15O"-CF[&>"DN$S!#NL."_C:ZE0!+'>^"0!@WM15*D,C"MW12NLM
MYZGWXDP&^"@>Y%N>%V'*!EUMO<+TS0QA7)RWJ7/0O&+6FR4/I"1DSPXVGS$8
ME5_SZB\\J7[K1?'*IO?<\V8>=2>.X/,$Z*J.6?'XCEG3.F;OTS&[%=UX'3VP
M[VHE-3C]L/<9KMW&'S^]!24%RNKW__1VM[9/X5E'.UL'H&@.0?F\$#O=!27U
M:>=P=P_&>?KV:.=W4%)[;_"'HW=\^W2;?#CZ@'>W=GJ[OW_\M+WUF8*1_W5W
M[\6^AJV B<9(&J,0=X8C%ZQ%7G%.$L72"[WHYG36*J,%;!LB. M2*VE<HHXI
M0618]L#F&>_L.MBME5?I!I[8RQ^Y.$2L<8K,@Z+E7& G>$P&+%7M(P^4/$U/
M[)$='H!95-N(A#;'S1]$(Y8[_ESRB_P57F7W&^B7G)\Q/.K\,8!;S["!QYC:
MW7YGN^1#$;5XUJ38$_W8&#S9R0FFDQWFT.6\C=7I#6SU_5'TDV$A4P?#6)E<
MA7;5K_VJ&%M@=OSQ6^>G^AA=]5%]>.Y?E6U2F6GPG,EQ9@\/F59<6'TUIKP^
MKZPO[/"I</J'ALN7 )>?R?;>2PIC^PK_VT]&,>$Y0"=.!G&<<L)$#J1K;[TU
M%I GY"IUYQ75;_QB^>3F8#@<?,V\#7 3%@+DZJ>9,YI+>VDJ1/:+[?;J WVP
M</EP&UCD_C".-CK1@K3#2E:9K=U&_D$JU&9G&T3IL'>6RH8&??C7L3TI)0Q+
MQ" G*H;JXLS90!*[P "91$?YVCHDT/#2(WN2\]I .JO,69#M>GM-.6ICDP\Z
M7'?*/4:=[ED<(V=.54=MB]'<+?NG["G;^"[@\3DN K^/YYP$V4DXLOE\;CZ6
M.1C;@UXW]0:G94YR"FS^WC >Y(SEP?"D2A3^8GM57O7"%%21CB91K[J^.A>2
MM_X,O6^^6KUS?4)U,#FH;*]JXF$A"SE>3TB_##!?3 Y '7:HF<U[;BR(!61,
MW6&V;$!\PM%,?.@BP#P:!%"U3=IU/9NUQ%5250[HYF*;H?,/*J:>Y%K&*S]Q
M[4.NT*OS=3#IA;QP9SLC&UEA:+_F+0"6;75>-O_QD=#V13-'K^*3"3H\.#D5
M.UN>;V^]/MT^/3C9.7VY3Y*6UD:'%,PQX@2(J@:$151JJ:E3R7C\[#E><51C
M'FVS@]..#HOCHAOJ0.>U$VP?(U6VVF'7$5H:)9A8D5EN-'?$.*HB<&'@RTKR
MZ%TEM)A=*+19ZV2E\Z*5U2LP [KS:7O?!\V9SQVVN-6(@\V"C(L8Y1Y;D44P
M5E7,H=-+1+6!N>QW2Y-&K6;#%1"RTET-.#XTDC5"\6LK%%<0"@9_VQ=4&)-S
MG7CP0!>3TL@1P9!.AIH@*2P+OYE0P%_/3I?A2E>#M56RW@^[PT<4C]]:\;B"
M>/#MO0_[/-BDK6'(J5PK5;"$=+0!.49)T,1'G]RSYY<:$XUX=$>K&-#YK/P8
MR-<PD[829ZREB%4>[$S"@3M)#%SV9#0]\;B"4*_BW\/.8;3#<0[S]R;#NJ!(
M-E6 V3^:8&ZU@GD%P12[6P?[6 M#\\GJ1+Q 7(/!:Z/"B 478W()F(2Z/\'<
MF VNG'E0JC.H0.%*Y-F.R[&M,3"N,T&N,HV.NW727QWT7FGOUK;'=WK,ZD\P
MJ'SW. ?:&_/^NNEW6-,DI,?:*^XE\$EGD@M:>A)I<*)XW47C=1>7[,%<Y$!4
M2SD=VI_5R%J.>05[R./L?0I8!*6, Q*!<]4# ;^9Z)$-C.*DE5$A5\E8$5V>
MVY<;UQ($3P%I"0T&>PV/C"X9#N!K5 K2<U\)@FP$05Y!$.1J0;ABS9Q6$/P^
MP\IR330R,KLAF1$@""X@9I)B3D424BY_P5:DYBU(PG7+Z @=4XC*EO *)\*F
M!&+!G3($]+3B11I4(PWJ"M*@SI&&%A>N) X[6Q_V1>321,Y1,M8B+C$&<0@:
MP;9TRF$;K 1QX"NR=N?U=>, G?$"5UED>:Y75HQL*EN(C:4_R;J.Y?Q?U7R9
MGHW*VUO_J5'AE=>C9@]@U3PA;39JK>-+6>;.UNN3W2V_3_)1&^HC$MHZQ&-P
MN4DQH!CQ4JNDM?;Z":NS5A*N)@E@"%MKJ Z,(X<)2 (7 9G -5@> ENAG"%8
M/75]UHK#5<3A%,:SSSVE2KB$E,= ;W)"I<;1(JHD3H0EH;5]2OJL]M@V"NU)
MEU/>NR3 -\UNR+D.&YW),:Q#]EG.)*'7ZCV7]IT)73<QX;)H!\,<[ZUCX+;S
MM22=E_F<)JB.#NVPBO[F! X_.#H:].OZO(?V2XE@UR=,XO]R&B-<>RXNP&:$
M-;T3Y]/KG5>K0RF_OJ]>8KK3$?V!MSI\#O]]LR\3$2%A@:B3'/'D*'(A4:2L
M)$$ED;CUSYZSS16^IG]N/.J"_M:NY])Z?M[7PNFHDT0R!)9=VF"*.)&05M@E
MGS0!"IXKNZKEF,<_"Z0\YI)NM4NZL*1@:>X'SI.*08$V9@*TL<6Y#)I#G@<1
M29"F'&K FWK5FBZJQ]SP(.<HC28YU:,"_XU<$&NFB+@[R;6RXC#F;*"2:$(P
M"A:TS)<XM >Q"8<VAPKKHNY%'VQV7N;;-PJC*).ZQM?TZ$Y]W50ME+&LO/=&
ME=]4+ILZKW/>RY?YHO3E!$4Y?9&K/665U-2,SR*=8LX+BJ6<_+AD(O3R48N9
MX0RJP^+Y9'J_J2LU/=&Q6GLV4]>HS:(Q8?(NU)GG;JYJ\A9-I<29=0;XD64\
M&.-H\#PJ%VW4!M:]3B60\V>(\&KU5V^MT4Z]C:_"A?&/O?L8W'>?66RC!RX,
M4 H&4< <:># R"K#C>?<)!F "U.\(=6*DJ5G+&DQUC+'F$HT97&#7.9C^3,.
M_\JWOQ.QH1>*S<MZ9/6I[58^LGSPDF*0<K%THQ&1N9R*UPE9HCU*Q 2C=!(R
MX6?/Z29><60?T*L2D,W.59!GWHRY5^BYF5YOH>>.1,N37"O9<$YCM 81$C#B
MV /J",*1"#H(:VBBD8!H4;Y!Z KI>@3HN9G8M-!S;?F@VUL@'YY8(U2NTD]!
M/H0FR' :4*2*ND Y4=)GKF]6%,F=@9Z]DME4;=&2A+Y(N#+=JKTU#='J#F=X
M9>TM.#LHGF_B>_G8:NI6Y5;K4][=_F@\G!1W7)TLU60VYWK.WC:'MH&1^1A#
M_;Q"6)M<AND9V&%5V:< 9 -XDU'C8VJ*/LQ6NCB*X\-!=0)W,JJ?]&O/^L_H
M+W\XR*GL1X,0"R4%(?,YT2:>4RVCF:_Z+9:_,,<2I^.[9M3DED6J\>(QO!<A
M'[4JT[\W>!%".=F>/:3=\+K_6U7(N-YUKX% +]9R;%VFJ_;BFV_9[N:<2V^<
M1+GA;TXW!)KHJ$;>4X,])HQZEXVT2V(I)<5PYI#YV=:I3V7,RWW(I_Q*Y:I)
M*UW?IW2=;&]]N"OIVCP'K.:)Y4W1*E'-H\:"<FHYQLZ8Z!((E2#.8QQB)4\$
MM_+TF,R!P_WW+4M<$!*1]#XS!^40V(H.&0M_MO!?RNU5#G8\(%JUTO4TI OL
MECN2KJ<?IULZ0]IQV6EY5DI^G)V9O4%UJ#(WI3ASBF9<9I7;M61^;PUZ/;CV
MC]>_[K[M'/<FHX?VU,_6<G@]Y?%-\>^W,/C2;RV;AKDDFCV(K1N_UN&GVWLO
M]EU.XX8M@'PD.3(#/[0-&L5("-,@C(:!M:8VS<I(6SX3D&NZ%,]U:>;Z2,O_
MQZ!_D 4ZB\'94O\*<@TR_"I7>Y\5B58$IB)PNKW/DB!"!H:\HB "6 &-,\2
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MS2 *.H-QZ6T0!B!K1?'2N8AK7=.^NR#]<U&(%?MY(2"QXAOE[B-_&,.D5Q7
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M-<7&K*NY4K0Q&RS5,F1]VSOI.%M*M6125_&*4=;8P_(5F,U_""S+VQ:]W_<
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M?5OU56TQ>B5&BYV]U_N6X"24Y"AJ$X$J6H:<I!K%)&,@3CJB&.CZ\QP7H>H
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M(,YD1%8KX/_6<"6I]=P #/!-=E='%ULP>'0P>*"P1VOD/YJ1OQC0L"*[,8U
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M459F&)2F(V87 4F%,;O^K?A:3?JEF*+)GZJ'QZR>2E#B9:4(CZ)IKYJ"GX1
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M$2I';BX  .$!\-\'_9/^F]%":!'OCA&A5.8HN$-+.6871PX:1YPAEW\Z\E$
M+XB':(;%M&NG"@E8'?"".&<Q/#L^9@'Y,,>,4 ^:_.G(BQ.3)/MMG#Q!+'[
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M+*B$/C[5MED5I/LR=[;*C6V=![-Q6F8&]06LG[#!#EPGI?E=*FVS>9=)6AR
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MLO^P*QB3N^NKGYU=?GSE^D]R=37WWN^N_O7SI4-WW85T6[[[[W^]?I?V\2!
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M, &%W<8+9Z41K8OVMZ.:4I&F,3\:FZ1EW7:-8Q6:D2L[['$?%T/W$5\MTO(
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M%DD$H<0U4[Y:MP_5])5(9%4JAB7>.DFX!L;FR^ ?<7%$M$TZR<"1Z&]K9[Q
M#XY[ R(FQS2W7I?6)9KULZ<T0VQJZ:MKV@_0;[OX=RW-K\>'-$0(1@@LFM56
M-Z8<>;G$@7(O2JRY0V5*KIN%M\7:-8A[3@O;765L;?#-5+ZQY:NCGOTS=(N]
MQ;LPQ[U"H?AOW2(L4A?F9T$^"\P$A0ZDU'5=J 3*Q;,%%:01=0=4B/(V]W^'
MYTRIE-'*RJW5VW ?V5JNWTAXFBU)V".2]TQPFCU_P;+LSSH@WH=C''X]'OM
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M,_JKE_3M^.-RG9?3JKE0SN44(*D8ZRM%!B'Z#$71]S*;R'/K':JOM3Q"L.[
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M#L1V+O;#SSIN13>6Y1I==\Y]N[<JYD9NUCL<+GYMH(,B<\(EB#&'"IF#R]D
MHF=.,9]T\RO#W5$>+7$.I)@U%6YMRK@W9'ZN1VR*)1M4%# 631VB;,$Y$E"Q
MJ9CL'";9NLA_9Y"GRJ1&:EE#I-:]QTS0AGR50#MCG9!B>0!G(@.;1$+-LA?-
MI\\^G=YCG12_MQ@?N_?8G24L$ZUJ M]D7*VE16^>PJPMF"R0U8N@<LQD"WM.
M_FT6C&6;I6U?47T/H"?2FVPG16_B3&>!]] \XA:FBW;%6X#:I4_9#FQ8"^BP
M_<IZ4-SMB3/-I'XP2DA9DQ7($F*L]H,0FO9/)Q4$\I]LC%)DT]JN." 5-O0P
M>RPF["+L?L;3782V?ET85@,7N/!!2+"%6U QU'$8/D(0T1>5O36\=>^@.R .
M;S4V4,[FEE%[2+:'/E$;6L>LP)D0E4C1@ NU:)H9 U'0V9<]KP5D.:!SC=5^
M+Z!3H$ [B??PYK_#.:T/\\5(M!4JJYG6V2$YOT@['/F]0'9R@)B59R))*YNG
M!JY'<@H$:"#C'AHN/4OI_.Q\5#LO;BKL60%-RIH2)1UR6I KJWR]_4('B86L
MBA4QN=9GP=;@3H$?_6BBA_Y+-R(=%Y"LR3ZF0,>9K"7L*D(,EA:>N&/&&\&:
M5]2L@7$*-.@JW8V=E [3Y_9%F'UZ-9K\L=>XF(<_M,^NMAN@WVIFRZQCFAF,
M7EF5M0PI:J^28]:[E*/9V,SVZN.;][!E@8Z)[")PEU4MV*O=TRT'PXOTQA#;
M4NN&,NU[V/Z&\RJBM]/)ER&)^_FWWV>UDN+-YT6KG_''9VD^_+(L(KT8^(PV
MDQ*< \L+O6=84W4*&A!HT7#F=-&M[=3=43Z)J/<N#%E38]ZG8GKP;@AJ&<X7
M)?$^*Z--%&19:5<[T9&AY50&H1SW244N5>O67%=//[SJ^];5G7K/O03==S?<
MVM5TG(8CO-$>X<-D5]'DX()74H#VKJ;IUW$E6">!*XS&*6]M:GU=TL<Z3IZ&
MCZ[\'ARSETC6?YUQ1(JBKT>XT-@X/SN;3.?#?R^+4E,T3&9?Z"VK]Q,Y2G \
M1] 8K$M)F!Q:]T_9!M?A"??X#)CTK+X^!E.M[R$5>0Q9&@-%^>IM%'(T5- 0
MHL7H6+$IM&Z%^E0:>#TY&C5040][TU5GEY?#V>?);*&5-^79;(;SV4!&KIS(
M"+'H6M[(:C!+$+]%39Z)&%1I;7+="^A/&C546 _QI)=8<#JMRZ_"^1"^KA*O
MG^.8=#4?&,'(KTX(:$JN[4(D1!%U%8$.UF>A?.LH] .0_F144Z7UT?Q[G&H<
M#5_B\L]K@KA(%[Z00D 38F 9F,JL[J42O'8!DC/D,'-TJGE<>WMT?S*M+U7V
MT#7\+M)5FYG9LDWU(J5(,1:,%X31(AW=LHXK8Z8 ,S8R;9+#YJ?C-K@.3[2^
M]/H@?3HJI0=#_"[&U^,O] 9.IO02#:0R,1FF@"M=-]"<P0=RCW6,BG$MHBVI
M=\9< _0=465?-?1@<]\%]W:*G\,P7YS$%Z.1Q\OKPY5METM63*,&H^K$76,5
M>*4,H+:&U<B<5:TOYO9#^AVQJKGB>C#*UPBG@KLZY)<H38S2%41@LIIYUEDZ
MV,E_2,PZ%7(F7[1UA'0[9-\1G3HKYB#V]\6I^S9\JT=N#86E-#W'_,LPQ.%H
M82\.F&)2N<2A<%F[K"KR1'VFPUA;9:4/2JK6:>C[(?V.Z-5<<0>QO"\VUUHA
M.#['@<N>AXP6"CDB!-"0![+HO61,S"2G%%7K888/@OJ.2-1%'3T,Z-G^?FK@
M>1%:UTE40F,]AQ'H1Q:2)J-/\1A1M,ZMV![=R=_L]:2H'@RF#4BK!S';(!@Z
MHXMSWD&QZ$@P@8'S6H"P*G-6 A/8^K3;'>6IIJ^T4DP/X8#5Q* ZX74YP(.P
M$^'GW]Z.PGA.!W#-.OR\*(!7Q1FM-8,D:Z%RIM<J)";I\+4\,>ZY$ZV/M>W1
M/9G=J9FN;Z>_]*.H/BAUK=/5LGDQ_22?5W'@RF-07G-G:/DQ%SKP4RU!R$$!
MEPYYU"%*V3J7X&%4IT^AMHKI(?"T%N$&EGLZV+F)$K1%\CH3&8W.D1N0',^Z
M8 C*M+ZJVP'>]TFF!JKJP5RZLW4N9;+XV8!;[F)(&KP(EGR/>GF8DX48@]:"
MQ.-4ZXCW?7A.GS>ME-%#).DVIW\-\SI+Z!N1^<5D-,)%C_W9FW(=LHRV%%$\
M:(PUKTIS\/5BIVC+;-%!V=2Z:'D/F*=/JYY5UT,@:7L)D;^)S)14($=![P6+
M CQYG80Y&\TR"FP^AG5[="?/K9X4=;A8TZOA.(S3AHB)-IACJ"$27T!Q60@Q
M^0ZR2,=E*,JZUE[=[BA/-3#02C$]F^*U#17A)!OO6G.!@7#1.18]B6(Y:\:!
M"[J T][(7(IDLG6T\D%03V8O:J;9>\ZY[FKI,:#T:C)]AY_/I^E3F-U"Z"WW
M*!SALE[3^K.HK0@T>0>$+F4MBS,]F=R;49T^<]HJYF!;SB^3\<</.#VK[3@'
MG/;?P$*J*>B&R.T7C=4\L#J[G"DCG6@=QGX8U>E3IZUB>G#QB=$K>M_!Q46H
M8]!B-)F6[>@K7Q!JSR3GBW&>M2;,)BPG3Y,F2NC!K=]># .3#&->)LART:<[
M<G!2,$@IA!R-RK8<Z 9V#;J3)U!/BNK!=Z\P:VB!_JAASB]A5&F_;-%Z.R-A
MX&5D0FD.J!.998%Y\+4QJTM&&_J*B^99_[O@.WKGJC=E]'!0K<?ZC'@_G7XC
MBB_Z^PZ"2[1>;R$FI)=(Z52G]GEP.<3LDV4B-)^3N0VP$Z5*%_'W<%YM!U(C
MB4$F!#+-2 R*(UE<M-%F*:/U/MK8/":X!T=V7_W[\\^?E_V(P^BBC\WK<9E,
MSY:SO2\.&F:RK%<"X&U.H+)2= +P5"M^LN%HK8^M+VZVA';T;TD?*N@AVOEZ
M/,<ISN:UR2&9#@-:GM.FVI4EU+'9]04.TI$1XD4ISG,3VA>OW(#P")KO0U5W
M4BSWEW,?K6-7R_QM,D[TY548?IS76(HOA[/:^OQ\BE?IID8:<D(,D,-J01D6
M('!Z/R2]$A&SUZ:Y3]@5\]%O*0=5VEW2=1YL?M\XANLSN)=?SX=QA.\QU2O(
MA;<B@@BZU):[157P#H)&$J2T/ FD%Y&WCGAV GST=#N<NNYRK?/0].?G,Q+"
M;/9B<A;IW:B"K\71'\?#?Y,[G$E(PS)<U$<LDK96>1297J5K91+T=^=G-PLG
MO&/6$G1@D3;O11]HATF!)\>9I8@NWA[6UIF%/2WEZ/GY%%1\E[F=YU)=[SCT
MIEQN["\F,UK#.-=M?5'?,TA,2>NE@H*9# >9!.WFGI.;52Q&2?]5K;-FML5V
M]-SJ10EK[+AN0^%KFY@WXV7F(!D%*YAAM$I$=61$REK5552=?QH=<=CQ##DY
MADQPYMVM8L\-T^KN?\[1*KNU#-?HMWNK@;//83BM:WU3WF$8_3RK:Q]@4#Q'
MY8 ;PJ8"%G!B49FE&28M5=+-"R_7(CE:Y3<4\!J]=V\?< T6^8YA_'%X>9+]
M_#6-SC-M1W^?3/(?P]%H8&5B5CD.C-D BM7Y=]7BXC$S3P98MK)Y3YQ= )X4
M2]JJ8PUY.@?(%[BN(+_X%*8?R;#!')2-(D,PRH-"(G;,PH+UB15MJPO8W&!8
MB^3HZ=! P&OTWCGH7<^R6>WXA+,WXY^_UMC ^7#V:4G;Q2VR8TXOP46WJ.TD
MA!$]\**43UFBTJT#W@^".GHVM!7[&F)TOFJ]6VCR_'PXJGO6;""U]5R; "PX
MLG L[5,^1MJLD'O-#//DK?=> W0)Y^C)T$K4:VC0.=C_OHY?KHE'"S^&#[(S
MFHQ;!UF71-RTGFA)QJW0@4=KG-*LM ZIW81P].KN(M(U*NX<8[VLM/^EWM2_
M&W[\1'O0[[.EJ3)0S@>K)(?:U;%>W"L(SM*:LS42>6;%M[[=N1?0T:N_G;C7
MD*%S$/06GC=Q.='J-1U2Z1/9L/AJ,KVY@HLXV+>!(D-5H"T0BL6Z5R'9L-H!
M"N\$ABBC:5U>W 'NT1/I4*I:0[/.$<NK=-;%E<&S<?Y'F-*FN,B3?H_3+\-$
MEM'TQ2@,ZUQG,H5TT>14Q]JH1@19=\@ZA\)E'1.=AZSU$)B= !X]E?I3QYI\
M]<ZS7V[,S[I(@GD>9D,RE[S6DM&F:83*-3_1@ ]*@$XEH- I!-.Z6=UF-$=/
MBT:"7L.!!E/O-]\TWH#]#H>+WQI(RZVIG:I#E8%2QH//UH(I/@:5DB;+ZX"7
MP6M!'CUC^E7+&B)UCII>7 G^_'4X7QGDKFA,C)//M6B1G^L%3582DE?.6"R9
MR=;N[5T41T^%CH)=H^O.0<YU@9:+N0F_D055/H2O Q$9H^/,@JRY5HJ..HB.
M*Y!*(T9O?(BM/=QM<!T]'YH+?PU#.H=#M[&IE_=]>,NBELHGAM[6O.#:_4DD
M< H%\,Q+E-R;$%OG&NT-]NBY=!@UK2%8Y[#JI2 ^++K2:U;0("/'RW&RIVW,
MX)RTH$.6W'#I4_-1 3<1-*1"&(T.:&?L+<9UJ;$_U$7E^5]K]B/FO_TXGY[C
MU0\GXSE^G?^\S/?]VX\S_'BWU=3V3)A-YU?PWR<<![*0GGTEFUJAT3EPLJ21
MZWH'6,#'E"!G%VJ-@7=EJ_@)/>$:$>B[*Q)L?'A#'GPB 4S3>42@G];9UI/Q
M%KS80Y&3E@)MF#&] +3"\?MX]AG3L S)(%Y.CMX&U( 4$,Y'\Q;:W@2DY2%P
MH6>XA?M*WXV4-.E+P@=3OU$8D9P:L#I:\G=JDJMG&JSR*B09 IJM8EE/2^W+
MCWY4K>\BV![*(][AC$Z--%]XO=7?>3;.]#.<?L'%@I.)UCO%(9?:F$AY#T[6
MR%FRQC,OI8^M2YP?@'3$6WX?0N^AL\8'^KV:(G8-Y(JLVP#;Y1#8)5ZY"=1A
M#X1>5'@[?ME4_CUL&IL!2F$$<A_!Y$6QE[ 0DB%'.&5?4J:W(C</9!^6&!N.
MC,?EQ2YB;\B'15KQNY<W,P-^7?C4 VF-<T88L+;0_EAK_UP(@2"IJ$P0!OVM
MO-T-*=GK/__PL8!&TI^T%=U=;:[NJ?[CIUN2(0_V7XN_6/R\KOP=EA_JG[^_
M>WTII3_^^.,O(_SZ^5.8GH6_I,G93PL9O3\_.PO3;Y/R?OAQ3.9+JDU[E^-7
M:K1\,AJF(<ZN\D5#C6^\Q'D8CF8WH<Z&9Y]'^)#F.SWOIZMEWES^ZJ$W:-'[
M@LD'QW'&_.,/0W+1AS:B%5F%8@57/"L?;"GUZEI;6X=1##H]N=N^_JK*"G\9
M?JDQJ9NIOU?Q#RQ1<*T]U*J/VKLI@/<HH>ABF60VI]#Z5GL;7)W3B>JLJMN?
M7NN7,7MN,VW1K/#:CBB3\2^Y U-$YIG>;HW-,XDV8#G\IM><$7?2BEJ(?>,F
MV,NK\"H,IXN;P:NZXX$,-D>)#KADJF[9KE8>DW-09+8REAZ&..V&\ 2ITZ.*
M>K"9+THFR!Z\A?8JNWZ W" 9AXL9KV%)>D)-EH2TS&?";UCKO68;7"=(GN;J
MZ,$/?Y\^83ZOB=7WB&,9C1!&1<9<A&12(5&0M1B#%'5$&I=HLG*F=;7#]N@.
M=5G3.VEZ4LAC7^UL(;_GWWX-_S6IF72SV<*/#2)E7;/G&%FNY/.H"$$E#\8*
MJ8T6KMC6A-L!WJ/%"'LBR/8G7R=%]7#LW0/U"NAOX0Q7OO0V<'N*,.X(]7'B
MCKVI?GN*-=/;$Z";T<4K)CQ(KT3M@%%3RPEVEBQQF1)*WKK)R9.@V0-1S*?*
MLEW4M9%=CQ$9NYAV%:X-NNH]/';?0P\7(]MZZ;<"9:HX%56)!@,2GXRSGJ=2
MA(T>4]%ZRT#9?8_O7&JZ?H+9E;&95"K<20796U='"'-R)=*"OC:6.OO%MMY>
M'D;5H,1V_1-^GV$Y'_TR+#CPS$EKR%]2.9-U$U% U*R&L&O\N@Z6]#V,VWL(
MUN']V,8<65."VU05#0-IBPN.U3SV>@%&'UJ[P;[$+SB:+#!>%.B\.)].J[<M
MH]=%L BZR#K.#1-YVS& #M9J4QB:VW5X&VZ,=GGJR5"B7WFWOC1< 7TQ.?M,
M)LFR^>@X/\<Q*6!^B3 FEUU1 7!1K9.9I^.>8&IG57#<2._D+HRX_W$G286&
M$NXAPK6ASO,"'0],ZA00BLP(BF4)(24#*7%72R]8"JV3C^Y'=#(4Z4$!/;2_
M7UP.K8A\K6_A!3J6B[?*9\CT3XF\-90G68$L'(LE*>E4<WK<B^CTZ-%. 3UT
MOM\(C 11.P>O4-;[]D P(1 X4%B;6=NDP!07G:@EGZDU3;9#=G)TZ4$A/4QC
MN0K2;A3',D3KM4@6,X=LU:*J"R&&G,&7:+T@HD?=VHG9%MNAKE1Z)DPOJGCL
MZY2:[_VN5G,MPF-9*^.#,B"<E82<:XA&U2Z;QDI,3G.W%8D>2)R_?.#C7WVT
M5.6DJT@;%T@L0*S2]+:!T; BYMJC#U\#LZ?P;ZNO@^1Z5"1SPBB!$8A_=!YY
M+\#G*$$45NJ\.5G\5DG+CZW >ZI9VNIO%X$UUMNO)*FS\[,5$)ZU]APM2%5'
MD'IG@(Z<"-K'F)+6RFXW*>$!S=UXZ.&LMDYBG[206<-XX )(^'H-B(OD4%H=
M0 B'M=VP!$\<!"8=1B8*]]OEK#RDO.L//4+E[2VS)W4!5O/;Z5?""&>]WWNM
M>=;AKKL>6NBM6RZI=&3:,:%E4CZX$*-S)7A5I.!&A"UON=8\]0"IX)IV#VN,
M 6<,<9H< 0A)D_\?<_+<NTRGRQ&F@F]^QK5K%6MI<2H&>I\S;:-"!8@2Z3 M
M0=2IQL*PUE&%;7 ]T53-79BR?9+ GNKH(5U\A\0O9;-P7AA GPRHI!C$.II6
M8_+9ZY)X:7TG?*2IFEU(TY-"'CNVL$^"3E&!,QXCR"@X*";K'4]FX"R+(GF?
M5&C=W_2T4C5W(DB'5,U=%/4$<N>V@?MGJF8/JN^81+>/WIX W20CF]@P ]S7
MJEB&!#N3&XM9!2&#37Z[0.JQT:QAJN8A6;:+NGI@U^OQ8CS!;+8^%V;E3J-D
MFG BF8F1+ SC$;R7#G0Q(;#,O32M6V9N!>Q)6?'=U7MG0G!KW3RI*OA%H]CG
M878S^6;EEM_JY]8R[/' <P\7 ME% +?"(9@S*TS*(NO@,88N<!62JUP+3LMM
MDWX?0-#1UR.AX)T/?U8;CW]<6/G/OUW]RMOPK?[HV1]AFJ\\&T?OB\1<@-O:
M1BHF!D&D!!P51UUHO;9Y4^?.J#LE_.W]^,M2WL7\TL_U7\U^_OH9TQSS!YR>
M_4POT.0;XFP0=;$9-0.K10UL(QULV9=ZO1&4MDGX8A]ZTPZ$]1$ZF1Z6M#=2
M$9^8[ELG.3==WKOA[%^OIHAT".,49_-W88X7RQR8;)PU:, 4$KZB+\%+*<F<
MB\+S;*S:<LSIP2#_2?3'9T+KW.U>7N<ODQ%]3,T]G5Y;YVP@2O*&! XRU9FD
MR0IP,EK(.0=FC<Q1BL?;U#>@_I/U3X(/#1/6^UOHR^&78283^-V-9:*/M?VG
MIU-,U\3KA.2D\P1,%\$QEMJSY/%HOQ;SGZ1_ EQHF(1_F!/M32$?#J>S98;P
MQ:)?#J<DD,ET-@@Y"Q&U@"2XI(..UUYX)I,8O&,NV*AN=\1Y+)/G@97\^7H\
M6=XT+$WH;V_XWY<'XC;+SS7'7FH%TML"JK@(KIJ+K&2F41CKC'F\\V.GM?SY
MXCQA[C0LSSC,L?K0XI,L/K,HP!>3ZF&KP0LG($<>,XD!$]NN"/FQ5_+G:_-D
M>7/WI=E[WG6_\;6'%LVB#%8X#CY)1\Y8K>+P/@-B,<%[,DR=?[R798L5_/F2
M/#F>W'TY.D\*OP"T:H"P7@P$_ O9EI@7*YY]F,S#Z/K?UPS;WR;S_X/S=Y@F
M'\?#?Y.,%E,B7TVFJQ_5W^,##$H:2[:F2=;4Z;("ZG19"-HC2TX6;5HG^!UV
MA=_-6W,$!+K[NG2>I7Z5&?>@V&>;Y+Y,G)-&"!3(P#)?2_V2!6\T0DW5M5KR
MH$/S:\Y6X \V8>YQJ?TXRGXJ:;1+^/3+R_2HPHHPB8XIEQ2]=]J3#5=G<[B8
M?&T$+&SK)MXW #Q^*NQ!.7"[><#>NN@A?6Q_05PM8YQK!?3UQ,LMUM13PFP?
MZWF<K-H.-+F]]3T5'1\+?]%DJ02MB,Z:2&:\L.!BUI!,,4AFBL3MJFU/DK</
MI.D^<=KNHMH^Z%KS]=XL',N+&4@E).5Y@)PCV31.D7 R%V!+R<$7K[!Y>=T=
M$$_0S^E=MW<&%G=13 ^%=J_':7*&5V.9ZS^H(JIO%=/::"9#G8I-;Y5+CMXJ
M8T"FXKER6>K2ND+@'CC?MS772D\]-!W< &WUMFP#KB<C[5Y@CV-M-5/C=O3H
MH(->:DCN RE2B)'E""A*;9_J$T3.$*)R/M:$=6_9\1/D ;/F<?BQB^@/U 7C
M'2:\48DPG8SIR[3<9SNTO-CN@UL4=^RQA%O5&]%9[8IEC"NA!/>1(T_!D(T@
M8P[.#[9[1+>W]C?\8],#WDQ??*IGW^OQ]=\8CM.0%'$53[/>.=2EC@C*=;2S
MC. 86BC&<ZE<X*RTC@-U!MVV$^^[X<=/\S?E]]FR!&R0LO5"YPQD_1EZE;,"
M9Q@9!BD9$8-/3/;;B/<6H,-;YH=EU?UM>KMHIP>3?%_1+(U,:[*V1CA 2?\A
MS\)"-"26)+E5@=EB7>N@0B? A[H7>%S"'4ZG3^8J(/_7^6R^6.&KR?2>]2]L
M&\55<"DJ2*K67Q0=(:90R +)S.<29,;6<\YW OA8SN<!>7/[^J W_?7@62QG
MB3_+D^N1E6TP]>1YKL/S2.']_M0XZ4D'A^*'3"G&0KMX0!%JZ0LY/))<'Y2)
M6>F4*Y$?+2\>"I\_+BUV$?V!',X784;;::Y_U ;+7\*H+C_4<;8U#:6KV[G+
MQ[=P/O=>SBT7U/&83)*,,W([G??!:X>>E.>L+U;SP2X/ZO82UT<\N_.D*_M,
MJL"5<@90!TFDD@%\IG.O9*&,2\H$U=J&> !2UVWK'89136NZ$N7?Z:V>_3(A
M-V4V2%:8F+V#%.LP$4FO4V3,@&4J9Q]U[13?>+WW CJ\$]F2$;?WK7:R[\%%
M?/:%WJ=JXM'F79N4OL=T/ET,B'AV-IG.*^Z:'C?0A3G./8=<R/93Q4OP(6HP
M6HC,I2S<E-9F]7;03HLL?>BC!S/H'I@IG9^=C\(<\]^G1/'?Q],5_ROKGV.9
M3,FG^#HH-I'+J\CIS8F$E"4M@)4"/OH2I<Z:L]8=:CN#_FZHUH,.>[@NW&<!
M==>]6H! GR)&038CV:2J, 5>I *,61,\R\G;U@TX.X/^DX3[Z["'26B;%W Q
MBTM[A](Y!L8%5@N0"CBC.-BDDXN80V3N8"1[M'EHCT.B?730PSRTJ\R/]6)8
M!MDP!6=1"S Q<E V!(B8(DATA0[T@"A:]SS<"MBA NM]4J2]!IY*>/S*K;A,
M8I2( 6/U)#!E4*%6J-1$H9CJ, /)G1&M=YR[*!X_RZJ9IN^D0'22>"_Y,-<1
MO: S\^-D.OQWN!XHVP)A;]E3#Z%[K!2J;GJ\EQ;-E/ X=(FE!.U5'?UHZCB;
M9" RP4!+'D.V)CK=.J3]6#1Y,)'JT"S91?8]L*/NERLD&HOE,@70:#3MDBAI
MC2: #)DSLK0-IM;^T=73#V^CMM;-I(E@>XCZ_?[^ SE3L_/IMRM3>86,&*Q4
M<AZDC@64Y!X6,\F0Q6 $YPQ=ZQKIS6A.C@*-!-]+7=)D.J\M Z[=MJR0>1>9
M9>0\96D$*!X]U-PE8%*CC<A9BLWGXFQ$<W*4:"3X7M+Q;P,JOC >:A9;#)8X
M:AWXZE43CJR9D9KQW)M5<*H$Z";FC2&MMI?:EXU&?EUL7S?2@O?JG'__![:X
MN-X!\NW1?Z(H[SF]<-DHPARYX49;^G^GD.LXN/^C.TY?N?CLYV$4QK6G!>+\
M[]/)^>?A^..KX9A^-@RCRP3\%V'9]>5ZF"1Y+J4&GDOMZ:(9U!QO*#$B'24R
M"=[Z-K<KYA8FZUU/_Q+5R^&L1F1(40,M0Q I<"BLGK(I!G"!._+[ U.L:"MY
MZWSIK<$]PFR10W)MG3G<7FD'O2,?Y%!H=Y<>F JJ9O)R<(7.ZB0=8]%*P73K
MPL;-:+XS_C122Z_QE;5TYM$)KV("R4QMX\@%^(@%L%;B,*^P_8#2^Q%]9\1I
MJ)X>K.XKT7Q;)YQ5/C9S7D?FP7(4%:,'9X6KEUJ!E2*T;SZF9AM<!QM2^ICT
M::Z@IW*3=&UAEU_^SR%."=FG;[_4,6"+Z">F5!P3&2)JVEQ%G70N&#DKMF@F
MI/,66]<%;8?LL6Z<VA-B,^-:*::'4V^M4W07[T7OBRW ]C6C=!>@CS2AM >-
M;R)5;^IZ=(XI7X/IN?;;\XQ !P.N(K=9EZ"2\*)YE\,GP*V'QI(^-6KMHJ4^
M*?5Z_/E\/EM(@%^$]5+T-IL(Y$Y(4'6@IA>*[$$GK4\RY:!:1[[O@?.(9GI[
M16ZB3$<M].#^KX,F5M ,O27>.0E"V\5-<(80N"%\DG"*S!AO72ER#YSOC2#[
M:.% .XA<06-%AU1$G>2L#2B;"D1>#(3LN2 /A#S+UGD4]\#YW@BRCQ8VNO2'
MNU"YM9MUOU 1O5^HW()\ZT*%$U"&R>6"0JG(/>,9#7K+N728[[]0$:TN5'X9
MAEAGK2SNW!>/R6_&[VK4<$INVO,P&\Y^'T_B#*=?JLNVX%%M_SU.]*_"2F"K
M ()6//,<:Y_($$$A"Q"8RU XQR)S,J*TSHSI8QW-MK[NF%9NLJ\%3-9!T3R!
M,KJ KZE5UD:NM$#N2NL;YM9K.'@0[+%XO7$'?@PR/,$@VH48OKT8A=FR_AU5
MU%PQ 6[1>4W08NC(TY =)A:E,IZWKGJ[%]"CA\P>A2J;PVL=5=:G<=E=4K>7
M=Q':V6*!?4?B^EK<HT?ONA*JORVV(1N.DO;*<*Y229 \YZ BVEJW&H%;2:X!
M!I-T;[&=XZ+[]@'%HV/[+B0X4/N8M],)':3S;V&<:UK,YVJ4=&@7<]_'M7 *
MMX9[NR.IE<F;PB7&K&)R7C-EF"[9DMRSSH/[/KC;WG+QR;4;^_S9M8^_,H,5
MY\+'+.LHYPSTG87 #?'"(#,FDA4<6\?U'D;5=4_=^(3?9UC.1[\,"PZ4TZ;X
M:$%(%^AU98D6KC4@.BT4-RYCZ][)6\ Z?-RJ,4=N[VRM5=%#V'LCQ$4U_D [
M9-))#R[6&BBA,P3+R&\,Q;/LE7+8VE&_']'WPY'=%=!'!YBK]@PO\?,4T_*<
MI:]'N!#[.*\ZUBQ^OG$Q R&,#]$@1"[I"$:O(+)D8-&A6G#T7#7OP=$(^\E1
M[E&4VD,.W49@O]6FS(D[4W2 +.L01U,$$*3:C=#E>I48C&T=@[D/S\F1J)GP
M>^C60M@28IZ](J'4G.$WY?GY<)3)B9@-(CI)1RLMUPE>;Q$-1&T2Z"RD%XHQ
MG5NW.+L'SBG2HHGH>VC/\@OY&+1E1:NM)$M+&TMK*PZBB C:ABB\\>3(MFZ:
M49][<GK>69AW%:I;)."/Z5>^75*,UOGZ[/-T\F5YM3A@V81D? 8I4ZF3?'V]
M$<[ 1,R:BU*L:=UKYT%0)T>%MFJXRQ/3V8BM4QH(4!A.%WGBG\+T(\X&0@MO
MM:25LES[VM4&Q9:,[.28,U+K[&QJ;9*N17)RC&@@\+LTZ#R&_K?).(79IS?3
MMV$Z7WWS<EB+1(;S\RF2R7L^GK\I+R;CV3 OYGU,:O01Z5<R'V2TP2>=0*0L
M0*DZ[LCR"(GY5*+*+NO6L:).@$^.5(=3WUWN=9[IOAKN-_LP>99(+%-\,_^$
MT\V>5499K,, DN5:&QZK9Q4M9,&",,9+YYO'77:#>'+\ZE-%=QGEVS4;W AQ
M>6<>L[6:.0D9#>VZ6C@(RANHE9,R\QR$:SU-:UMLA\JAZ9DYO:CBJ62Z;%S2
M\V^7G;*\K7Y^\2"R(N%%LO0\&@88>"Q*8XRB=:GK%K >OS5A2SIL&W[94RT]
MQ(XWKYX^8'4SNPW$GK)2MH#W.'DES56[+74ZZN61*&1J'\_L-$A3VR<%3!"U
M]Q"R<TB;=[:L]?GV:-1Y($?C*3!G%W7TT=9P<O;Y?([32VBKV@!TRF/B 5ST
MG,[WVL2^1B%IV=G1KJM+:!WVW0#E"1G.^ZKM=HN7!C+OHZ+K?#I>NH;C_&KX
MM7YUT7I+<Q^3YP@RH:N!2PD!"T*2BD[D8K6-K0V6S6A.CQ"-)-_#]G";HI(S
MSUBP8"S6S+#@(:*WP+A$'K@NIGG7_I/?#KK(N(=;XL7(WD^34:YAZ<MOKL>G
M5SBSE8J;0-1DMH RBLSQY IPZ>E43$GKW#K"MRVVTR-)+UKIX2KYXDZ#4%Y\
MN09DB480E2.$XFNC7Q/!LR0),^:@4^3*M\YNV0K8Z?&FO3YZNFF^L($RYY[1
M\VM'A3H;'"%X52 +GXIRJ13>^I+IZNFGI_X])=OP\GDVG0_>U3G*"V_*D@,E
MB5H00[T&CT%!E$R!=#(J+37*L%6<GC[UFFKINRNUWGC@2<:T]A=I0W/A$L2*
M7MO V"4RM8V&'V-,1@?AWU9?!\DU-/5OP]%*,:&T ><U$B,M@BO. V'D$<GG
M*'RK1F:/K< -L9_V^MM%8(WU]BM)ZNS\[&*'KSU?-*,G+_(%D YPQT6@<\,%
MQU*BU6W55>,!S=UXZ.&.S$YBG[206<.8RP)(^'H-"'=::#J:R03+B4RPF@):
MSWLZ 53F*>HLMRHQ>4AYUQ]ZA,K;6V8'JE-[/:8OZP1&[-0'?MW'M*A+>Q#>
MK7HTJTD30DJE5%0RNJ!BY-YDJ1!5\&RP[@/W>R4R#@<O)^F\VD:OQV5"N&\V
M88@V*1\+!RS>TJM:$'RV"G0D$\J8A+G<EYPXP_27CY,O/]%SEB\(?7'U;CST
M]*XNSDN".YUB)DDMLKUF;SXO<F[&'^O<SA=A.OU&#_TC3/-LP(P3@LE:;RF(
MUL%D6J@IX (=4D:)$$3K&YH=X!UNTVC*B-N>45\*Z2$P?P<J??&"OA_.;\!\
MAS.L;:,&UDE);Z@&I^N95K0@GZ]VAV>R.%4PH&U=P[TCQ%/E4$/%-+04Z_&R
M+=8W4SHRQB^GYQ\'W%JOLT]@(B/)Z)C T9%*MG'B1C"DLTH]=([M]^@CI\<!
MY-U#W/\.X-?C17'*[)*_S\;Y9>T?-UDF]*7 M2O& F*J)0V"S#?+R:0SQL<0
MG#.B=1!W5XQ'3J2#J*:'2X!UW+_XV<]?/Y.'CO4.G/X,J_K)YS@FY<QG[\E>
MQ>=AAOGZ+[R8S.8#,CZ=UL76.W%:$YGX$'G,0+L-]_0W5NC6D>$^UG&JE#RT
MBGNXAKAK$M:,YH&OM3@^&F!>UU,["XAU[$Z=F%(<B];(UI6QZY&<*G5V%W,/
MQ7%W4*WZ"43:0B-C$$LMQ4)EP">?(1G:2LEFRT:T[E2['LFI*G]W,?=0\78-
MU;6F2DM>"IVY3*(0-,*G,MEFCI4(KFC-=5#:;Q>8VX\!M^&<'@TZ";R'LK<+
M:)>1K6L !RY(%CC!LID9,JR4A.B,AV"8Y#9:%53K*2_WX3DQ-G06>0^5:'<V
MK-IZ;6G3C$:3/^I<FX'FO"8)"^"E3H5P+H/+-?NF&)F#Y[:8UIE06\ Z,7*T
M4D /M67K=[,:-O1*2@;$5&)N3:WQ 048GZ-F07'G6B=+KD=R>DS85\QKHFK-
MPK.7N]?*_UDY/(.D@F7>,DB^-G?!8"$HFZ$HP9,32)YZZWD[#T Z,3ZT$/P:
M8G2+MSXCI;!76"NK1[^]^84PUA'W.! <#=9R:FV2!^5Y[0'*'!0I$7WT6.RM
MPHH-4=4-#SARW3:3W1J%[ATB705TERA>CPG2;(#<6!>=AIB5("L5.00D \4S
MM"EBXL*GK?1X\W-/07T=)+5&:WM'(Q=8WKV\C+M?P!HD%$%G)L&1-D"I>@,C
MI0)T7K"$)@JFMU+=F@\_!?UUE=D:)>X=FUM_E_(>4UTK-_*_!K_\\]T_![QD
MK9EUD)QVQ+&:2J*U!JTQ>1.9E(9O^38^\*A34'!;>:Y1=^=HW#V7\9'IDHRC
M4UU56[^F;7GR L';8H//=$ T'[1Z\LD0C<2]A@DM0W,/Y6F\)"MP-A^F04%F
M P^%##]-FQ77) H9!>@BBT*?BA$]ANRVA7DBW.E;06M(U3G&M[(M+QV'WR9S
M7.;CEY1R,4X FGH%)6I*(>9$)F9)P1?-O6E]R[@13-_M7GJE11L1/Y6N+G=C
M3L^_W2;^(J'<")(0%[1=FGJ+)8R#D',$GX2USDN65.M0X+;8'FVJ41LF3 Z@
MD1XJJ&]CNBCJV@)53XU<UB-ZG-XM_6CQ@1.J@PH.1Q!+;T*) L'$>B-:4H0H
M1(94BE/:*Y5-C\'CWHGQ0&>6Q^3%+I)_M*J"O8:AKON8?JH*[A]\RIA367%A
MK-?*)HPN&.<$9J.,-**LJ2KH.NZT-MV=S1<USV_^&&->=RA=&3YJ42F?+#CC
M$ZC:YRXP)D&B=+4Q>VH_;W,G@*VB*9?3G][A8KS!JI?C;$&"-^7]M[//GR;C
M;Z_)JAH(DYA70D.P=625JC7B=4:4S)P[-"$IN5W@>K_G'[XVNS_*; K&]*6.
MIU"3D+UAL41 GSWMTV3EN1(D(/HB GH>>=_'V9.I23@<P0ZAK3[&'&[T&"0Z
M<D!=@!@SL9Z'#%ZCA1S)62"L+JO6D9U'<\\/3Y,V<C\ZGUTK7G@4$ES,')1C
M!5PBK]1RSE!+)EQN'?,Y7I]])R;LZ[/OHI'#N63;H/K39]]3B]OY9ONHX' $
M85ID,K\,1*-I[RU!@Y-DG;&(GI%ORCG^Z;/WPHM=)'\@G_TEQOF;.!I^7,AD
M]AL96O35%^PPM?:ACVSAR^\$^Y9?7\CP$"6A#LFH(N@/X;212G/MA?9Q\-"'
M=WTKX_SU>$:VQ<U>]<S'*!V1 X-EH+S6X*4H((TT)42=60[-7\NU4%H.:GLQ
M(;MP.A_2H5R?-F!2^YR, ZD,'<P8 P1/YS17LM;[%25SZS3#>^ <WIMJH?W[
MIK-UD7=#!WP1,[B%Y6K9K\F2GI*W\"[,\?V\QA#>DM%'?Q$^XB F[4JR'H*J
MC451%O#>1(@L^&*XD5:;A[:@_1]_W(PXD-A[L56N([VVA.67]6A_5[=C/B"S
M'HVW"@)MW:"L3. S':=:E+J+%\]\^T+'+<$=-WOZU44OS0 >!/IV.DS(!XX(
MK32K74,=65Z\EN?DD" YSTG;BK>?O+0UN.^&-'OHHF'9_RJ,?1WE._Q\/DV?
MP@RO;82L%!V(RF!="54($KQ2$2P=FS*BU4J+K<Z?AY]UW)KO0Z ]U,NO)H"]
M*:^&8W+WEEV&W\\GZ5^O9[/SZ@#6JO[90&J;4!$XRX,')8L"KVUM9.^]MU'+
MU'Z$\';0CILF?>JAEPK[ZTO_@-.S02K>:NLUZ%QX;5:.X(,W$)C@I4XZ#;E]
M"YG;*$Z#!!VEVT-1_>_C<#:AD^K?F!?@5EQ<%6D-@D,D1RF!L;&R46IPJ60H
M+!='_V,86N=QWX_H-'C04.J]%-=?7_&K,)S6J"$./";!F&00/;E'*GFR7,B-
MALA%,)G%Z'O>""ZAG 8+6LBYAV+ZOY,\9C4M'&=OQC]_K4GBY\/9I^7IM8BJ
M<,9+MC%#1$X "1!X8RQ8%H.U2C+RFAL3X4%0IT&)MK+OH8I^8Z?\WV=8SD>_
M# L.G'!Y,2*+.TU'FO#D(#.;R0 V_W][W_K;UI'L^7W_BL%\KYE^/Q9[%_ C
M&01(XJSCS #W"]&/ZIA[9=)7I#SV_O5;34J611]*ASQ]2(H2!M X2GRZNNK7
MW?6NXG5,W)6#3<Z\)>L\ -*:_^/4VO=VNW&-'+7SX'A0=-6E %'3#\<39NF"
M"W9<;];Y.D-'ED;+6OP;4G\AG>A/(N3G>9C1_?<6P\4/BTKDQ"EF,+L(00>Z
M]5QM'\%-'7SN9-:Y%KVVOE*V$G,>L&C#ZY8%_-O4HH0O/LRO9LN)=3FF0K:P
MLG2;*2^Q]A^S4.>2(R=3F<7VS26[:3D/##3A=,MN )L)!&M?R=HSLNY!YX-C
MAML(-C$RC>H4B!"<!;22<1\Q,356@]'OB#D7$+3@=<MV C>4;09S*S5<. 4\
MU)YS-EJZF(@>R[.)3!!BF^N59QDP'\+7EGT$NL*U/WQ.[^L(DG?S9;AX%1;O
MZ=\OIGE5K#R?311''@/C0+I)!)6U@*@X XTN>GJJG/%[1<?O7_9QBWUD-K?L
M)W#;6&@+O:N^Q->N]!7M$X-2J*(,B,QJB85;)95E8,HK%B/74=M>B-AIV3-
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M[@TZH2VW*>YV#.\N<$:"',*ZCDXXPWQ47XEZ>0,O6;*0ADO(Z*NQ%F--<F'
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M$GURZ#>'L^QLWO<DY0F"ZV"2ZW"!#AL3\+T5VI=LZ;CD==PM4YQNU:A=I5B
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MX<U<Y.C-7#9(WFCF4I@PU5,2F/+*)OJ1..=9FY)#+NS^9B[R^,U<C,K>1F4
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M99'-7(R69%!'LJ65X1JB,1%L4I8+)WT<IQ7((3;W*-,\=L'[X=(\AL#FE";
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MFQOYVL?=6J0[Q]71N J4JQW(E)0@4LE*\J+$9DO1YB YMFMIL(@?P,P^K#[
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MB(J)[Y8]("=_4$%=XZBFUC'MDZ<,3QL9FYRQO&AE;6-[R<[UBMM5=P]/KX#
MFT'!\)!;X1&14='W8F*3DA^FI*8]>IR>D9F5G9.;EU]07E%955WSNK:N!=?:
MUM[Q]MW[OOZ!P:'A3R.CDX2IZ:_?9F:_SY%65M?6R1O@YM:/<;$ K"S_]_-/
MQ\7/'->V'VO \6-<+-N"?U3@W\ZV3XU=X+@%A_-UP?V'[^P0.I'XLJR94_K(
M!:*PRXU>+A$9]4E9TH^A_6UD_\\&=O<_-;)_']AOXQH%=K*R,!>/E1^  C1J
M1JP\\$LJG*OIROX>K)UNZ^!8U5C_7ME72+U"^$+07IEM'6+ @\-&^['JJ(D,
M6%4'501'YZ01LQG Q,OQ@ZAP[0Z<HZA#?\=]?4[/.KTQKUM^CX.#A8N\I8K<
MVKY,),$3O^PW#B]S2SCEL(NOWTNQ'>4-C856CJ,GE/E:H&587)?$>3!Z2A&C
M:-9 ZL!()4[6GXKK>CV@P1:^D;1C=8_B]BNZR0ZG#^?)W 09P"1LL9<!L!G0
M[F,G,J$\4&<\>+"<JDT:CM0_A@L3Q6%B4+R!,6L;Y0.+^P0ZW6_Z2^^R8=<0
M$Z=M01^],;['LF5FB$@AN9(_@/DD=SJ7- /@':"E( RS/79'1S:PZSJ27#OJ
M$I)I+[9T!<\DVGX/"EJ8C5KR)00E.?9V ).2GWT&:5$,P+=4'&%%>T%70[:@
M*K4]O4FF$SFY5X;M<N(\AH:0!SZ63MC'\5R0E_R,.]"^4K*?=R[IME797D-@
MZVZL_(MM_R?]OY.PNMB)QN<L#.!NG"<#V)Y,SJ<]UC\ LMH0;9J?@(CK!$CX
MN"Q1YSWBN$@Z6Z>IWDBM\S7ET:.UQB+RAWJE8W;;9I8VZ0:X$6BFS=KMSX@4
MQXJ^=4J\ D&/SW) R:RK,7OJ=(MX=H2VN(6,PH<[#U]M]Q-_NWFZAWR#^<5,
M>B\4T/ ?B2;CP1XBLL.0I/),)9G  (2IBGTW]Q7,C9Y][_JZ)DJQ_)6MF;I2
M;]6;U;L<+HF*OF[ E@39"IQWIIQ'?H#Q8CW-5$^FG:T![TR$*;9>^U[1-%-I
M/V9<<DKVE:;PZM&E=MXCXTUAO4UB(\AQ&/$\BA/Y:>/HO"I.=83>8=NO+P9S
M523X"^ +[+WLGCH^?S\DANS<^4SVV9+,R7+Y<3/,&(5L1BNA*] _C$O14E$3
M&*A(@R"QU*"R.MIL6&:HLK,^VE=J7&LJ^FPU12<_2C3^[(VF2;G4;9DJW[Q6
M(1'8<CFJ"+VC37\7,;>M9XS)?[)I.$?(Q5?TSQ_U):AJO@KDJ3/5@7+FU8^2
ME"^<.L[IT5(N+1EI+,3RC0$0S];KG>B@\XK3L()MDU&%RFEWO_;?S_SF+9A+
MC0R[*#?2(74[*!?!XGB.0N=] WX/R8S2]HU>J,\>\SZ+N>:D]RU%AJ6,ZG3^
MP7TR>]-+L),B")\WHM54+H/R:0NY^7 DOD-4BBNY14J/B(UU?SYF1CKW\,"E
MQ2S-HZ3WY+2@E1=CFLF'X(]:K0RL=V/*8 M0Z,(R29J0MJA'<F^SUI<!JTBY
MCE4#NK[%GM6^;"DIV5G;QLS[BOI.NU/T*J7]'\T@NB]]4K':Q3IK)Y]Q6Q=+
MJ(F$>NO!VGI"B"@"-G(M7NC-':4J7\ZE P(LJV77C+:O"<_8;<2C?/@B4$(-
MG).8&*@P0JW@$UCOY M]WT<]ZG*EQ4_V,>9._PN-M6*XZF(  Y#%3;C3T,P-
M-1L+D%7+X'AZ>! ,W(EJ1_^4KY9_L1/U/ZRL< X]I:QHGF;QQ+;2+5+S<''9
M.YKWBR*\& -X6Q;* !QX .N[^/:*EN22JJNL>9=YRI;T*QG 3RU45BYO<C0S
M:]IL<J7?5J.W3:&V>$90$VH,8+?^SR^?,OX'EA[[5*+K>K18Y4%=8Q[<Y9)X
M?,UV2'MQ6%P[ UB3*&< ;USIZI=0;Y>94^ED@3IB+\2")JM*,("/?IT,@ 4-
M]O[R-M3V/[^\&_\9WF%>6U659E/E>E,U-=+W-8?X3'K5KV0$V";W+ -8WT*M
M"?Z?2?N[\D''_5/MVFT5CL<+1_,NV1V6&GN:WU$<:(6>0&UN-V4 L K4[$7@
MUTWXRYM&F2'@2OO_5;EA6/%WS2'RZ)<!FVU+YBJJ^Y7K>8\D/Z\JLZ7+,H '
M36CFM.4R@./J+&6&0N=9_E63$S?%@0&\NP:*,P#7S]BM_8US#:+D6@:0-$D\
M0N^H1:T9 J&#0A8&;'^4KH(==,,X_-:$]YD*A"L#V-^V3+NFSA)PCCD3",AZ
M&^I!?H&D#OTX$34L3#^1\Z<0<&>HZJ;D,FK^O>HW;Y>R!>QT<",#*)7'/BZ.
M!>0S_CAUD%2ID6NH+1ITB[,X]M>W/R56A+QA "L[TNC8JTSV*'0IH_(Q@+TQ
MJ'FR/XWK]M$_)V_%KH@R+9GY-:;J/U#]=^]_WL!_9WI/&HXK0K!,Q+MWI&?'
M?QVLCLEV@'VV]QQJ]XYQC3J0F"0__'A/Y+Z+-TQ8&Y'>R!%H931UCS3E !4R
MB)UXD9X;C63%PR5PNWA<VZ#;BGQ+W0;5NW9)]LU<E)'9N-8:?(9T9Y?\0HQ"
MG@U-OS25:57FB#1)TW+H$N,,H/EH$Y\7FZX)R?4,!1)_\]Y#;;AIR^&W+M@!
M.4G=$<*E8F47K<-=TEKL.IXCP"&HMRJH$)5,+*5S;A)SR6V@::8M#MJAY]IB
M9WZW1/?R'L^M/>E$$X'5"_R'R^Z."LHD*6BG>;1P&(RUH>]C*VT6Y2@"R(^H
M;51^TDD"$D/2Q*%V(X(0$F%^32)HLX$U7\.%;[51].&%%:&D+K/ZK-XS1;,R
M1H*2V4YI5&'+-Y R31P,/' 658[N@$0$.^TE(BO5H='XG52.#,<BT8W1#_&2
MU?&>;CIWE;\9Q4.Z+[]/Q.US2PR0H-I0]LHMFC!-F$RF91%%W4=[AIHH%GA'
M\C])TG\&"6< 5WO09GGF-T4C59<,+@5Z2C]4&5D23_KL6$=[23!^<"P<$30!
M":#:TBKT%1"7F&W<8P"X*J@;C-_3COWEI#\+6A1A2UK*S&( 'OKH[7U9UMJ.
MS^JU]]4_@3_+2@N\_D;+*%A" ^6,'?-NAPFC/*#W8:\PB[SI=M0+X,'\$8VA
M_(Q1C2I,3*4B*$+ 78SE"#[TKJRA\%YX7=8+81]C?B23E>^ZC<R)0(G7>A;!
MYZH[-2[Y-(BJ/'6#'+%]!IU6G'NIWZVUQEJE,\$U%XPG!G%TF';M4>OW@;I]
M41FSNT*Y2UI6S]_+@R:L1$2XOU)GV;KY3V5.76DL7@HIB] G!8 !+0R@0C56
MU]+CE4RX=9][I/-5Y_?.W3=TAJ.H5\ 1$C>!H\,_/!'$D(-(<I&1F'CN-UM%
M'U_5*4OUY;]:MUC=0W[!]RJO" 6:W$1M":FBEK,SZ0*.,'HD-Y[RW8/5);:#
M 42DV3" ER<VZ%MVT$G9029KGF?*EZ94)G_^=0@5-=NA*TI.#&"8]3P#:#$M
M9 JLETQ8&*9L05)IS/\\JWG>;#(NSRIC[_N%U[   TGV9TQ1!D+G8QG /DMK
MX;1[ZQ<K8D1;;.YO/\/*[B"E/8 E)LTQ-9P\LTV\J8&$D#64*E.'I7&)8C?Z
MF#*,4Z64 9R(7*:M53)UFNNOWX3\Y6G9TJ@)&]CUKZ*K&F4.V26U>:6Q?B5I
MN&"E9=_=E2QI-VZ;'ZC\82C_1;?+?Y:03X!IN<&,F.JWGP&\2/]48NDPK"&^
M+GG41%<S0#QANESZ\+>3-2^*H;^U_H(G5A'RTQ=^:1WXE%'VZS2B_\*4'40H
M]2X3[Y6.8-<4?IFX"EW%$J^C=8&)N,GZQ\VUB7&9*BS*_<07O"7_8@O\7T)8
M1F6:#?O"('2L.?WNKU.:C2IP\M+N3JVQ4R<_4=6W5.,(?G_+Y;;V#V<,U[](
M4D-*Y[::(%B+#(E)8;M5!9N>*<P*PJ...;7KE&>=7BV2,29%-;M=X&:YW?D4
MW=T3B7H%H^YA(=ZY.8;E9J*;4T@VLP(XYE+:19)4?3Y5L?;YAD4=0J$RZ0CM
M[12GD,5MZ5CY7GZKBUPTY8S;^H8@<U*WX\%BBC&]%<]+%T!XT')D!Y!'J%JD
MIL<DCI-@YH$',E7F(B.?.V\D2<AZ-)=)(8;F_8J>.!^\+RQ<2[(GGP/G*5=!
MS*0_5:/]V80C-P[+C=SK2=<RTVR^U?@M5[^^^)-,QMO*&NOJEO81F8<?2&RO
M0[BRD%YY 7+] ^<Y/N#%42[^DLQUJB8SE02; .WANBK?&$B8:KX /]G1)$HZ
MNSKFV72P+Z)3KS+JV_@QI[ZE\8L25U>N\@F*Q>9QX2S)BK3H&=HSN@SB BVW
M20DLZ&C%B#2ISU?71<=7%1_M>E%>7EEYV]YSRRK=^ ,#<*^.\%W=L_RX4X?M
M?488MR$@9&$("$]@JWJH:7QW,&0]IEV:H3A>V(SRQFRJ0%BA"Z%I#.#4>8Y&
M"T,AX(^2M?]]U+0M<X.6L%<6_J8A#435?_(JO>S'3D,X:-=ATPI>?VY/, V^
MQ/$->D,&_6JUHE0GW2@4O[42MYG^Z<_-&-3?"<^BO__#GSO#?[% JG^U3_*8
M'/JGY#\QHO??\>6?D_^WIO\V@P2@Z6>\QH[@IJ*CH)ZE(\MO\)7^=XM5?-=0
M4G"C<R3VQ[[P%V8[15-[/^_7VN-O]8 UX3"OXA0J&DJT\H_%[(%.5-Z26_ F
MSN.&#B'$:T%8L=<6*N9 #1\T5K6H-#*K)K7/?;H\ 3YS1P+2Y'$EQ?1TKQI
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M./&GGA2FO]3Z_JU'H,O3F[\YU5/\C=K8N;<L\92+#*#95E>2Z$KG_$*DD/M
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M1"JCV?M;R#FF<+2K\CLI.SF*Z6NNE\P.FB_&D# SI UTD;Z$1U_8(J3E4>W
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M V%WI4?V-+!A76>V-EMMYIQB#"0;?"4+[0F98X=D[YPP#99_YJ]Q^N#[ZN2
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M^18YBN%=+Q2JK1XSN"X0[C<5:B:D_&LFANWDG1_Z\M E<=5K]FIE&9FG]M]
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M&O4.&U]PT&DO1[WR].?P;U39N'TW^\JYOD,?V_+JUUYVQK=,+J_OK%;*\V[
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MW_$T$*1*Y@A:4O\> +QQWC"EY5-ONNX^487KC5C--R.B(0<>0N,G&72E,AP
M6"84[% 6;8T2?T\WFDWW3+9\-0K4?_=^LQ_)5D@QX1S'<'9WT!]2F;F0H(E
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MOKH[>\3QYIOG"\:9:_="7ZWYMB_H+"E4=U3!$[K-"6( #5;@!3)-I6>UF+B
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M9= ,"-&AC$J:02MQ+WR4ZDOY8R*.=%F;<Q_Q?QF0,RBWQ'RHD/CE48GAU%>
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M1%4*-XOXE1F=\OUQ?K"1:LDI\D]V_28DCBC-XJ-A&.\ X?>LL[F4N,)CV:2
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MF-U:W;\CQQ;X/L, 9>RR$E,+=:4"Z*(9D()]/)2&WN88G35#V7^8WF/IZ5/
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MS'E\U]#7M&#W<-99'!=?M)YC B# 495.C&"'M+3L?-L9=6.OHDN0^=)T%]T
MB:@_^R\%WH/7 4;<I6OG,HH+RV>8-^8=>DR6+UXO%*,Q9TY?MO\MWJ+)6O=$
MIQU&>-V93UP/PIBC-=OLLHXD5]04E\V;2AK;'&VL[R^VX[_?+9\WU)8SQ%ZQ
M.4@XV6;XCFN@](M[4?W&'M"I.8X Y'4P!3)A.J>3>?!F$4LNFA:%"0[1]H,
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M21+;90O^$;)-#DT4QY(?DG::[;6 ;BP-QA-EM=:XQK7FY99N/,CL^X"59P=
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MS3JU9>7";X^U7T;01!BKE/7E/CK6&9AB&+G^*/9E=)N]*?KVW6V.]''@T,E
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M< ?EXPN4[MY.F0YJ?AK0^)1T?DA?,*8^*]NNXFA%7.B-BSEG7MV_';UE)7,
M((%^%K-G,__G 8:B;@,IKD&M;?BL[L.+?Q:<<L;NZOB&T/V([7!O4YQ%:TZ
M_5X58(LP@EKI$IW3'S?"&QA8V]RQ)QG&D;@ZM\7P+'>?::3>TJW8RFS!@GM)
M3FD'[0SPCIPR8B IGE2'Z'03H;H_H.CL1I\>-?$Q<01E WLO?>:<?'XQU<_K
M3K54U</#)[>V5^EE[^R7#$[MJ;WHS#=51DB!>1 !S<W3/=,1S((V3D*; 68
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ML"3!JLF6=5W;SR4+P;@CGY&'8RJW?";2@\XU/6/;,!9H%8S^GMKZW"]$EE-
MN!/N8'\?TC=)B[R0EU[T63)<).D!5S"6JF6UF3LF!XR&?W#%_+X; =@SP&Q)
M0*/C6VQX]D:&/S3PAE&09\#.8,Y0_A@),XC8;@+*I&TO./6;N^1W6=!C>Y4U
M 5L&J3L8]:-SO6T;?>U55>\#JJ&TQ>C:3 5J2\9>DWC#)R\.-2XV9UCO*E-O
M *NSQ'3S(.*@7LV3H"[09%@GOM;X87<3?762;N-2T=9/NB*4^M@JS)MO>9 K
MPY=\WU@7Q:A'K=RM_N5R\<\#X:"0CW\KP%9282C>F6":C"2"C5_3W]B=JYRL
MW*2>J#(<&%^H_\S5!K,'84BQ]''NG]_/9_S\,EE:_25A$)MP2:8G&0L<#^B%
M-FBM+J\SA$F4ZI?T[?WM&XA4=7K<\'1_14D%_QO'4VVA-VAS)NL6*9*JS^UE
M.: 4A^^&"J",'1FH(9V?L.6JHY&#R[.'QDI?-7\O]/E>D+C%3S6P^2)D_Y_1
M1A\$WB*V2W#E$5SA'PRK^>N%-&4E8 OYD4Z"LFS(C^XP&OS-V,_R\VLN*DWR
MIB_[5-:3@E\3GFLL0(']ZATZ4+8L)[E>"3[OF*R5T(VX=SNK8'XP47KBR,-<
MT0"7EY'?JHKLMS@V67LTS*3Q/U>J^+KX6W]:4(UR[6I3>P3'=\OKR:06^XM$
ME7(*# 2U+RI)7Q1(;3>^PE17N2\(X+G"$W3'/N8BL,0RYG;GR]6ZIEIU\2#2
M>J0DL^-CXKJ@+N9!$O0:7IQM3O/,8GZYV!@=AM6FT!T%--9@(/4\R?;@Y!)]
MHERIZLLLEBZ HTZD.B<C1 %85XW.JK:;<^7$45V=S.N/;BX?[?M\4>XZ+I[+
MAYF#-:UWPD07C^4K@YB L@,G,/N WE_:+?!Y@FS [<#'\B4EBS6J3:+B]Z>G
M3C7;'U?9\;Q+UNYEDS'$C:$,@MP<C%PU:$,*=M?;/CB 91V8=0=N3PV^SI:Y
M="?MUJARVAM8UNG%F@,T>\QX_KY1-$CX!2RX;V^BKEDEP170X@S+."KBP/S@
M\Z8$.V(<5.G"Y<X4W8^W)RHPD[#:IAYX H)NAX\!(\I%9+S9CF:&UYP\/7,U
MFGL4B.PZYDVH#C5.5QW?B,M\>7,D*I?1_V9KCAKJL6!7[9723OC4HSY\ Y0M
MU8@$#JYW(Q(V!N-:%.@L2C0=WFFJTLT4]2GW;W*2&-#GUFD5_9G[7NM!0V7P
M^W*-U/=#3T1:^)) B]#*>) X%DNPT1#:"$TX :/+:2P2@0.ERP/T9F8/)X&K
MMIG&2M[$/U^./I%HHG5TT7U_UH73:]@]5>\BJMTRP\TUC[SMR#GI_%KSR2=T
M*ZCJRN@1O= D!!3F+=2VD[V%,9BBU2;#_3!MD((.CJ+P(*(#FO+AF0([J9;"
M=6\2U/OO-:/O[A*"L'S84H7,:T#QWS:H'FY3X[X'*2_SI=H#*E(>Y3]M*^B?
MJ)7XXHB;Z^RC@W?ON(O56XFX/K_1C)YO@<B>%_CBTXZ8<:*2:.94; R6?F8S
M\[9C?9L"/8K9X%F-$J,6&6F-2L.4M-9898^L&G4O5V(]K(O2-!+"3^[_<.Q;
M\K6'>CS(*ZE?,V /H("=#ELJF2D^C/4:%,6\R3>@X[HK6A%_X,^]8,!CJ_58
MB/B)PY?;@U:='+Q=7>.2IH+V6=1DA>/?7;PH[#+/V16O*WE0XO3[BR>T.:X?
M61_XRGXS;RJJO^8Z)=;;#.X,:+0)\2R[]";P5M G6M9!R8J"ON.'3K,#%N#
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M,QHKS!Y19G>^=E_*5QG35O*(WQN?_V7%QRQ:5U>BL_HX9,NO*#+(],5AWE!
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M@:K[D[P,@)&_2*W[K=JK/ KP@Q;MQRO]U^5*[UW IRS7YC6X+LL\H:N2T*4
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M\!;M=5_X42#C(&(08\DA0H[:V,A(0,I9&/B(N"&U\LN>&6]NG_M:7%!H>:]
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M*/;=*(81]]3"0E  ,0\1]&5$.(T1IXY57HS1J'.S=&]3V$@-/F^W&]@2W+9
MJ GV9H0].*(C4_!M"LZ!.4+E8RN4!BO2:3+FQ*4X+6 X++AI<W./8P;U7+6S
M9\KDJQH^Z-Z#V[G#[_ZV4D;X;14@F3P+W:IU$5$N&7<EY+%'=)Z/#S$.7.C$
M/(Y1R&*/FQ\;V(\_-Z;::  J%:K^C<5NP8%:#;#6 VA%+'RW/6;)P#D_+O8C
M<]I,8;=P@8\+_V0N[?4T%-4TK*IIR#9ZJ-\H+JJ<V4?G8R@G=7\X.YW./1X[
MG1.YO\X[3N$+'G-AE^[/@F7W:?)WP1?4)R+V/0PE"I79&V(.,64.#!V?!H'K
M(^:$O5IR;\:8V]*QVR5Z(V?/?M!;8!JP_^40C6VUCH9.S];8_5#ZKS[84_3!
M;J.F\O4<:0=1DWFE=NYC=+D^?!^,6UIOW?HZ_:L/93_9K/K(I:_CA7^?Y5(D
MN@KLQL,:>XS&W!,PY Q!Y,0>C'5 /I?2"V3HA@$.7\$+?T34_PN\\%M:OY87
M_M@[,HT7ON^4_^-YX>VF>7(O?,=$S,0+?TS"?R@O? ?$0WOANX;JMPPU@]S)
M]TE*4J83+])ZXZ,K7JG?B)NL*(N%'SB(AE)W_@HX1#+F,"9! %D8>C0,A5K>
MK3)Q#<>=VR:E:N_42@BTB':,;@JW&4N/ .+(S-NRJ#**US)7UFSMMMI!=L#\
M+4N@!F)&TU$G93M+*/89S/;VR[H//"9EW=D@TV4Z%[X7($&QA#C RKX-O! 2
M%OLPQH(Y,6$T8D;.]NYAYL8YZT+UK9C@MUI0RXS]$Z":4<WE4(W,+#U0ZEVP
M_S@( Q?AWQOD50KK'U?T5+'\$U?W\(IN/4S1BZ[-JXA&*+H1Q::]B(,<QA&"
MU*6ZO0AFB@Q""D/7DRY&*&2.4<]STP'G1@O;KWKMO]H2VJ1?13_8#9RI X,Y
M,G&\$HX6;M>!\9S(!]N)ZT .2 MD.KV1)L^9SC5IH=6.G]+F/CM2UDWLWS:O
MS76:KLCRLWC*\G+A>BC&GN]![F-/;0MU!H*'J,Z:9)B@2&!AM"T\-<#<2+>5
M$=1"@EI*,VHX"6(WI0X!S<@4:HF*\3=^3O4C%E<AV$_WV?//ZM;:V%(_;&RL
MDP^<Y.,^IT[[,9^]KM^F:MU6_LW+)J-@28JB*J,=(<(=A-6GZT3J2R9$[:VP
MH_Z(0N*X+,1$&-75-!IM;I_U6D)0B=BK*GDWO&:[K,% &_F#M\3+>J-EA,-
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M>@4'ZIXK6'!XPV6]RY7YM)6K4FW*%SC KI"$09^Z/D0841A'W(&!XSL\I+%
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M><KU+W_X\!?7\;T?0;8J"]VR28_S:YKHQGU?U)6B;D+S)_)$3O1CJG>9Q[L
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M#J\(]LPA#7B]$H<U(-Y25)WK;^!L59;J'R:NLGWQPH.@*FTYES3E$<(0T32
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M+J]M/^?<),,!UP\+63DIE#G^ZN$S5[[FEO;'?#$5/W(A@=A4HRZ3O5;]_*4
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M.8E"G.G_H!B;E)II! 7&88I4ACGG7N[Y]SH>FU75R+U[R^_I8G\?] MO]R^
MLF<B.N,R40D.OM?_VXMIY8I:WPX ^]V.PPO@!!C6K@"GWN_*5C4AECY.=W1Q
MNRC=645YB'HG%Z7;TR0**5*Q-IM2&DEM15$,<9QF$*N,\$ E09I)-ZZRZ79\
M3-6L]K5KXC-=@!<CL:E=7SDJFN-!L?GU= &N2X;#EL5\@]P[AS7XUNZ-6F8]
MFRL':U%=*@$M=^7VZ).X7(#R1EM6G0Y,6BY '%*6T]L=:P(?S5B[50_UW>OF
MD;I<ZK5)KUX7OOS-I!8J;F9W92J WQ:F_E\@4,P2HB!1-(8(I012'F<P((SC
M*(E)1)V"('N0<6Q4>#(K^9:6YAA]^[EU\5JCZM6FF'"E;IDWM538_(M6V;&V
M< _SPHYFWWBT>^;DDSG)CP[T.Z\#[5Z<N+^A\%6MN <)ARU?W!_$!_6,>^S*
M/0/OQ]DRU^;XBFGS^]-T3I<3FG$1LXQ#GDD$49C%D,4RAED8Q9)P12@EMJEW
M#UH?&^%7 H)*0E"*:)]J]Q"[=FJ]&)&>2=$%#*><NB>5[I1,]["UP;+HGE1D
M.WWNZ8>Z>MJ(W'SY='I'<W$S>T^?\R6=_EY6PYL$F".J8@4#RK"V\D@ 6: B
M&& 6)0D*J<1.!<%:>QO;Y[L1%AAIX<T,U/*Z^JNT06SK>.()N-X]2'8QR]>8
M@>^5L%Z=/RQ \>;%T=;7P.X8%FH?^E78O-0A0.8WFL]N9]_H5-ZJ+_/9IWQ&
M9R9LO"YJ$64\$BJF$&5,0$02#"GF$JHDPQ$7&5.QE3>$15]CXP\CK?'<+;2\
M)I9]-I]!U8CL5%C$!FBN$H(DI1 +&4*D(OU3DC(8*LZ"4,4D#5.'2UM?> ]_
M63LL[.WT[7G6]DS>PR+G$-#D#\&!XIHN0M(MQ,D.F]9(IS--#!?P9*?+3MR3
MY2M=*L*;$]EZ6]SD52^OE):O-UH5;8>_2'/3-#%%8_2,()#P3.]I,0TAU?RK
M?V4T#I*(1*%]\B7;7L>VV)5R-\=6ZT3_X@I4LH.U\.5=JTN]<MMAL&#B/L#M
M^RSQS7%UJ0+? [X#,7:5J@+D1;&2 JR>-7F;U$*RJ5BA2;R\P 3S>BA6,\TC
MY3-'1\);275'2-L+JMLV-F Y=4?]=HNIN[[<O8C8I[S@>N]4'HM^TO]63)(D
MB^,DCF"6)3%$B=[4$*3W."3.,L:Q%$$:NU81.^AE;#2_+I%525I?2H!25O<R
M8H>@GC_C] )5SZ3=":5.A<1.HG!1);'#5@<O)792L6.UQ$X__#87Y@T7K2]2
M[N=+.KV9+1?YK,AY>;>O^4-E,A$A) %-($KC#!(E HAQ0D5(N KL3D:&%'IL
M=.3S2GVM__9E:XD!6(-0^=,,>\MN-9F&N7;W/47^1/?P1V>'[;P8_%+>9:!&
M<DMO)?*?ZMK>91!\W^,[]=VU9E"QO%4F>*FXGHEO<O&2<UE\FT_%)$D)"B1F
M,$M,&L[0U-Y440(31##+>,QQXA1I?[JKL2U(1M)RKTBGFBI^R6=\NC)E0(#*
M3>);."T3RN6;&+[R+- DO%TLZT2[CNZO+<-@MRCX ;=G*F]P+<4L'?4;08&1
MU&?1FW-H>"MY<[*C@0O>G%/XL-S-V3>Z,<K?9/[PN)3BVN0&?I!?5N9N\E9]
MR*<K_:^'A9U2'.#$%"9+62@@0HI DJ48DE *&<@XH-S*F:AC_V/CGD9\4,L/
M*@7,9U.?;FT)?P5JM=S8QG6(["BH1^![YB7/F#O354?D/'&8:^^#$EM':/;9
MKFLS78VJ\MRR2M[_-2_^?BS= 24H#0(EH4B8A"A5"K(X9)!30J5@429=S:OS
MG8Z-['9D!D;HK3P(KA:4!>:VMI1?)'NWJEI ["F9A M$WDPMBRX'-KKL03@T
MOQS>[>@4ROGJ:34U'CL?3*U@7F5WTS]/9;D/G8GKK1W+R;C+"6,!SF1$8( #
MKIDJ,A::"B -XDQO!950U"D&TI=@8V.S+;V V%*LW.EL;PZO3%JU3>BW[!;Z
M[6U\<4IBD@D!4VUP0T1(#%G(&%1)G 1)*%FB5Z+:]VN$([SKG#;@&&^K=@76
MRI5C>KTSW'LQZE>71/Q[&W:[Q? M/M:>%\Q!Q]#=']HSX+Y<IWV)-:R7M6<P
M#QRR?;??;:E_M\JG9M^BFVQ^O'DRJ3O+4^:B#E((!4EY0CA4/$@@HHI!@G ,
M!8]%FAEX,Z>[2JM>Q[9(-Y(Z1MG:(6Q'J=YQZYDO&R%+QEO_LBUR#V$A3B!Y
MXCB[/@<E,"<8]MG)[>7.NPQ3YJ_X*KG,RXS2];>0!DIR(A.H@CB"*$B1R9Q"
MH<PXR[1AR23!CKN&HQV-C6 :.<%&4&<#[SBBU@;;Q3CU;X#M0]1'8-D9(/P9
M1L>[&=K0:57VB.'2_KR[D^4-5XOKE<CUJ%POE[*HG'T_3>G#A&)"(HE-8I%$
M<P$E"C(B(A@C;8Y0$:0RL X8/]W-V)C@YOVGKZ 6%6S)"HRP]GZ6+;BV,X(_
MM'KF@VY .;E:GL>ADZ]E2[.#.5N>5VW;V]+BZ<MRTE;!.]+<+Q=5-AD1IIR1
MC,$8AQPB9NHZBE1!3 .$,RQ(&#M9 B=[&AL!F!I.X*8H5D9,4,K9*<7/:6CM
M3 (O@/7, 1VPZIQ!]B0.GO/&'O;S)MEB3ZI[*D?LZ1>Z4<,ZJ_]G20M9?%HM
M5POY>S[+GU9/M=M;\6$E[Q_E0E*EO\R)E"G*DE#;"LC$0=.(0TKB!*(H,75>
M$ NX4W4Q9PG&1B6;6AR5!E>@T@'42C0NK_H/6@^P4<2-:=Q'RHZ!>L6_9V;R
M#[TS<76&SQ.AN?<_*-%UAF>? +LW='E1VIM9L5R4@3 W,]VRMLR^TJ6L\DC>
MR86Y+:8/<B+CE",E)8P2;O)Q9 )B10F4<1AFG"E,$ZMD/MU%&!LU;I<?K:R(
MM1J@T0,819ITJAM5NE=TM1RM=G8<9@QZIL<QP]^]W*[_81BN&&]9+FE%I\9#
MO8)_8>!7>G.M5C-1 #9?+.8_3(1T&?[,]^KW7FV%19?U?.G#0I9'QK[BH2\"
MVZ7>KV7+;U8-V$WSMEK!CBUU=6Q\>IK/RH#M*F*-8!%AJC ,>$H@,KMZ1A'5
MJY&(TR#!F6"!FQ/C;@?C6VN,?$T6]'_Y:Q"$FUSH_PZB*+D*@J#*@%X NEH^
MSA?Y/Z3X=Q &Z56:D?(.S?P<IE'S6)6NX KHGY^EJ7LFIZ^NSH][XV)GE5^"
M=N^K2@ETG0Z]KJI[4P+ETXOQN/[>/!;WFA_8._&X<H>>B">>ZWH,N,U%7_00
M?Y@_T7PV25*I4IIE4'(LM>&:4HA9&$".<!0G J=1ZN3O?*JCL5'&GDUT!8RH
MX'LE[.GK+C=P;<\!+X=LD&- 9[0Z' 6V0^'M)/!$-P,?!+8K>W@.>.;YCJX"
M+S2?FJO&3_.%R?7US12EKFI\5CY2)DZV6$YDDJ$(!2E,61IIHR**($ED @F1
M81CR2*'4R:BP['=LQ+$6&VK+'99)Z#:27X&U[.5A>55/WM'1P'(\[,BE!Y1[
MYII=@+]=!+"[=X(;7+Z<%2Q['=9WP0V* U<&Q]<['-5]HOFB-(Y^E]2$:)0'
M@>NJXZE0B)$TA)JU8OT?DD"<8,U<29!(A5&0!?9'<JU=C8VBC+!U=:)M<6V*
MA+N";'&2Y@VZGGEG0-0<#L"\H3?00=<%*+H=5ED!TWHHU=["<(=/5IKL'#+9
MO=$E+VO7U"AKB:Z+8O74Y$DQYR92?,A-,?F9,"=?MTKE7%/@]4Q\F<\^/CU/
MYZ]2?L@7^LGYHI@(&6DK,V,PD '6V]$X@S@4'!),4BQ%2H-8V.=[?6-MQK8N
M>,CHM?5Y;V%C4CA5Z( &GO)NX0HT")4';!HC*&N0P!HEE[RJ;ST]+9:[MY9Q
M1"OJ/^?;Q73HD!_X3S3O!K)%[DV2X6*9/U6QO\U,*:_=?J&F*&I]_V)2BIAK
MM:IBZO-"Z_DK6,X!T[_07(!?9#/=FD:*\N^/\ZDPDZU^O;R?F[X:GY3Z#F'^
M4E_8S6OP_E).S-GVQ!0-@G^I\Q__I0!Z-7CREN5X)!.C/7OR6PLY8%;FMU;U
MF$4Y&J$&3BK;)+1N3E6+6_VU+NX?Z>QHT;Z]A#7E'S]H[=8H3)(P"G$<!##D
M"8>(B@RR5$60AR*A* WC3#EE91B-9O\#C=EU<ODU1J $23,VG;65"3W(3%4^
M @Q>6Q;+0*ELO4]ANX/ET<@[.H/WHJ2X;S4GATNCV]?XOW6N7>]Z_3D2\O8U
MG-ZR]O8FH ]/C"UWL>K'HLQ'H4VE<,)5*#AF&4PC%6A30A)(2*:@# 2.DY0&
M2>Q4(-2ZY[$M]0?>!UNR-[\8Z4$I_B6^&VW#T<69PQ/(0WMW=,/W0F\/"ZQZ
M<?]HZ_<-_4$LX&AW$+%IH!N%?95T:NYO;W2KQ=+T92K%%9_G12&+22)IA+3Z
M,,(B@2@3*:1QFD!,)<N82$E*K4JV6?4V-JIJA 4;:4$I+OBE$M@Q WD[U':4
MY W GFGH NR<J<<*$T]TT][7H!1CI?8^K=B]=,'!#3MOU;'V6@S&SV2W $,X
M"8DI]H,RR.,X@TB$"&*94LC2*-._!&F(0N>3F%Y$'1N)]5#YAY:FQ.6U?OJ9
M*@XG'F\^ <9_A''9V'<[B.AU6'R>+/0CZ/!'!;T"?G3OWV^/W9:O]:' YYRR
M?%JZ-]8^.>)V]M6X/.K>'DHGU3]F<U;(Q4LEQ?-JJ?^L ==OE=K<FW^?(!J%
M:2@0C"6*(,)A!IED(<Q2&:*,"\&HTY[?MX!C6ZHV)YM78$O%QO=,F$+A:RTK
M9^$KL*TH*#4%NZJ"[Z6RCF$@WB>#W;+TED,\F$OFH*/KO 3U-02>%A[OX@VZ
MW/0%[OXBTUL_W9:6NT6=]J>, :QJH5RO(U<G:<CCB*8,8JHBD[TK@#1$ J)(
M)8+*+$.A4_:N]N[&1OMK:9N8WX/07C?J/@.V'1'[@[!G6MV@5P?RUN64KL^C
MYTR-=J!X(KHSG0U*6W:*[Y.0Y5O=\MH4\VDNC"]<F7^@N@M3=7(=_==-Y$R:
MQBK-!(R(""$B,H(X2PG$49J5U2=YF+HDL['L=VPDLRTYV(ANO/TVPG<+#W$8
MC';NZ1'BGDEH'.BZI:+I >7A\L_X0=LYHXPC9N?2R-@V-VCN&$<=]Q/&N+[>
M@?UWKP:_RF<]L1YI(;>R,@68($25@"$+3,7/6!,^$J:H5$##A$<93A-KUC_?
MW]C8?B-CY0#NP#<6X%JPN%_(AG89V(*O4R8Q"PP=N-HOE@-Q](68NC&S/4*M
MC&S1S'!,;*_3#@,[O-:%>=<5!&]GO\GYPX(^/^;\>B%I\56^R-E*?M):?/RI
M.6Y&I^]7>D/[9/SDE\M%SDP9U/OY;W+Q1&>ODPS':21P 'DF.$0BB2&580AY
M3*F,(RD3DMDSM#>YQL;D6V4V;V=@HQLHE0.U=L"H!QK]P%I!L-'0A/C4.KHP
MF;\!MUDUWF08^UY=_L>,H,N:]28C.=3:-N2(.JZ$WG%O7S']=3?@RNH=H]T5
MV'_S'5;J^_F23JLCM_M'NOR=OKZ356[#8Q%KC5NY,1'R%VEJ!TYXFI(T4BED
M>K\$41PS2*A D 12)2R)!596+D=^Q!G;NEPJU)PU&Y6 U@F\DW4"R:LR7OOC
M0;SV)B2FUJVL].E YY>/J\4Z/.AH];S\_GD'RF&Y'73 !@QX7Y:#-UN9LF'F
M>*^)1%> ;V7)->%D2_"DAY7).M,MT/L>4^=E:9;8ZB%J?&B*K;S3+@/O*W[=
MVT"U+LN7]S+<:NP-D9U%V%^K71,/%55W=_4\O)^7EV#OYK-547IS'?WD$5(:
MP"2$890RO>:J!)*("BB89$0@%.#0_MBRLQAC6VMK\JXT 7=;7W:I#"BUJ1PV
MBZN+B;O[Z%FLK(.,2<\KZI]E.%SSS?0]+ .MF]^V,[X?60=9.3SU:CA?F)3P
M>N=1)H0YL5#VNB)>#/WY5"R=6A\XA\HE"!PF/[FHM8Z9E\5_KZJ FN)^?BU$
M;F8YG=[17-S,WM/G7"_(?Z/&RWE9"3>) IQ@',0P4\*X!V<8TC!%T%1KI2Q0
M022MTN-UEF!LZ]R6 N9SW:@ C XF/T*MQ16H]3A7KL#32+4O;(/@W_.:YA]Z
M]VS-7>'SE;?9N?]A,SAWA><@EW/GAKH7M,FK_JYGPM1.RF</<L9S66R."N_E
MS^4[K>[?)S)E,DUX"$5F\CO',H TPR%, Q:3B @EJ!,KNG4_-DK<DKY,-K<C
MOWL!&X=QL..\_M#MF?!:@05;-QS?C?2@%-]CD$$WW#P6S7'H?/"2.N[ '"NX
MTZ&5;@2W%6+P?K58F'"UQB-16W8X#G$,18 P1&&401PK!5D0,)&D*)#$J<S&
MZ:[&1EQ;DEZ!6E9G!U +A.UHR@]N/5-25\B<R><\&IZ(IJ6C04GEO,+[!&+Q
M1M=(H#F74A3F#K0IQ7ZK/L]G#_=R\62\ER:<1E*11.\&*<HT:60IU-M$ N-(
M9DPAB7CDE.O@?)=C(X]&8F"&LJJ/6=73U"RNOXV97)HK$"5=32 +\.WXQ"^D
M/?/*+IJ-N 9!(S T$I=597W&"=G"XRU6Z&R' \<+V0)P&#-D_6:'FYEKC5QR
M^U/I%^X6N;:'GLW&KPJQGR@J8L6(@ 'GFG?2.(04)PD4@H4!CU*2QK'UY4M;
M3V.C&R,JJ&0%:V$WB3 <#NM;\;6X'O&%6L^,,A!@#A<8OH ;Z(ZB*X!N5PLV
MH+3>'K0V,-P%@8T>.W< 5B]<7)YY^Z9A@EF(!4H3*#'5.SV91)!@J2"/%8[B
M0 .;6-U<G^EG;-2Y6ZQYI]ARY_+*.[C:'T-=B-8 YTV;8LN5D+U66SZ&@_^B
MRSN]O%7MY6.JMI1@/OIX!V/JYKF0L]_IS_QI]62*(A:_Y_H_R_E,%I-,<1Y$
M0D&::#,*):F$1&EVR$(59R$76"%F;4NU=#0V/BA%!;6LH!06;*1U, S:P+4P
MI#Q!UC,I#(*6@Q7E";6!C*B;&;CER[EQC8R"$%V!S_)GKMD#Z*ZE28B1SY9S
M0,'GG,M9(>MC_JG6=KZHT^ ]+&25!.]'OGP$U7#<:7IXHN#;]3>@#8C2 43(
M%SF=/Y=/FE:,\Z5)0F92:58MF<UTU?M?"B 6JP? ]8-E(#!8ZG>7B[S0> "Y
MS)^KDD6?_RL,XNA7,%\MBUS(LI\_9ODZI+NZEO@/^DQG?P7WCWD!%O)9PU==
MT>J'G^II4Y33YFD]4N"YLG0*7QXJ%K.BU8IL>W\X(])"BQT;TN;Y;B;DS4S/
M'WE/?^[F&2HSV6]=SDZ"0,@@H0D,"!80!22%C)GRB9'@$=53/I-.U6<L^QW;
MDO)1*<E+MZM* : U* O$[64"NZIK:VRI4A:87LU.GVQ=-#YVIFD/J/>\*O4)
MN+-%ZPB?)PO7MM=!+5Y'*/8M8-?7.Z4E>GK2FS^3Y\*<7WZ07)K(!0UOL&5_
MW^KY99*O3:3@ <I,?@H1IQ!IFQD2D7(8&"_P1'$5"/OZL&Y]CXWDMJ2OCND;
M^8%1 &SO'D&C@U,2':>!L3"P^X-[@(WX>)!V2EG4%^*#I2WRB+QKZJ(NV)U)
M7^34Y) IC+KHNI?&J%,3EYC#ZVQ)G\U(ZIX_S)]H/IO$6+&4*P4I#PE$- ST
M3VD">9)EF$L:,;<2C*V]C6U5J.VOM;2@$1=\KP1V]*-IAUJ2&-% 1GH19A0B
M) 5D)$AAP(-,(1GQB*63%[E@\\'!WNZU/[@_Y3,Z,[OZ;<3SF;:#]2]%=4;P
M(3>S7NK/L"S8]U4^SQ=EH;[2[BWW[-6_F23&E>L(?]5,-YL_Z=8W3Q:]#*'+
MEL3#L/1]/-9]^G?<9YS!Q.ONXE1?;["G.*/V\9W$N9<Z[!^^RD+J-QZO9^+#
MYLAMJS2 \>0T3ECW\SNY4//%TZ?YHMS %%_*&.E;]54^K*9FK%^WCD"#C!-.
MPA@F+-3,AK&"V.1:8EA36I9$4F7$>J/1DY!C6WN^K(/.%VMIMTX9'4SBOD;5
M8I<R@K'JF2,;#8%6$6SIN%WBI2S[5ZH)[N>@5A1H3:L#G.(*U(-]J\!&W6XW
M$7T-ML-&:02#/M".ZFT'WVT+UO.HM.[5^NI[N$U=S^CM[/[Z[JMC?"WGBY44
M1QRS9R:G!:]^F5 2\%3(#&+",40LCB#-N(0*$<K"D%#)K9P8W;H=V^)=2[U=
M9\4Q1M8.;;O]AG\,>UY47>!SCW-U0L-7<*M=I\-&M#H!<1#&ZO:V&^D(F4^N
M-=4)0W>?IO1A@K)(H( 3*#%1$,7Z/SA-,4Q2(D*"N:"Q52370<NCHXY&.&"D
MLV.-0[C:B>$B$/K^]NWTM_[L3^IZY,LN)/_KP_SE7_4[U4>M?]A\RX<M#?*Y
MGE2@^2)//]"Q#E]NW& ^YR^F2NU2CXVI>GU=%'+Y1R'5:OHY5W(BHTBR (60
M1(DR!6$32,(D@URE*DT)"67@Y&]KT^G8/M6/Q3)_*L\45Z6,8*J%="QS9X.U
MW2KO&\&>O_-*7%C*"S8"@U+B*U#)##ZW(>I>6LX!(E_EXFRZ'+8$G ,(!V7=
M7-[MQCY?Y/(]+1[O%O.77$CQ[E6WK#NKZF7GLX=KXQI3VAN3($)9RJ, QHQ(
MB+#>=1"D-QR1BE(:A1E5@DW*%(YV'&3?M1,3K07H\;!0+@'7HH/G6G9353AO
MY 9T+;@;.SF,A1U']8-PSTQEP#52@[LM<'\QDFN(?P5KX<'U>9B=*<L=,4_$
MY=#QH/3E#L@^B75HH1N5[=;">#_7'2R6AC%O5/V+%&61S)O9QY]<%L6M6H=+
M362:,4(Q@B23!*(DD!"+@.M=3X*00F',N7(QL"X19FR&UT%QERUUKL"-@KS1
MJ"IX:VZ**Z7,?<I:+3<RO&@T[>AQJ#'JF3#['AYG$O6!JR=:O4B408G6!VC[
MU.NE31]D_$G/W,H19!)D@LHX)3",0Z&)-HHACA(&*<JB.(TS04+>G6@W'8V>
M1(VHG1SV3T+;A?6Z 38TH]E@=2%-'0+1"P5M=?.&]'*H;#MU''F^J_>CL?I,
MD_>Z@>N?>3%A:9:R%"N8\9A"I'@(,>,)9 F5)J8TB"/DYO*XW\78J& C(3 B
M@N]&2&?'N ,@[3[_R^#I^<-W1*:#V]LIY;WYNAUT,+"#VRD%#[W:3C[9=<6O
MJG^_GS\]RUE1^H)LW:+_+5\^WLR$WNJ)%9UJ<V.Z$GKW5T:GOZ-Z2UAGK# 9
M#._FFGCD,E^4;[Z3,ZGR9?$YG\G2-75"@S26A.K-6HQCB"12D,A$\T9$1)!&
M:9H(*P>WX44?&Q4UFH-MU;?]:>I0X;7V5V"M?Y76 3*#0)/,I0KCW04!-"B
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MB/6N9R*$65Y $EQ_4E]F7GE[1KW=.C[VSH<*7"7ZE$B9K.IIG5__ KS4O5@
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M4^@%81+CF"+.C")+3HX^-X'5T6=R.!M@9V!>78/(R.+$,1@6EM4UH$QD5]F
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M0ZQ&\W.'IOZL5[6(?&DB5CY^9\LUUSEJ]]FR!OL74FV?U[]XR.J0P^YW[JQ
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MXMBPMGI[B.JM[P>:0(*]4(';ZK/ZESK#[N6_D.5:W,NFDU7]_(*$22 8#:%
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MZ@&I!%YSL$9QS,)80H22"**4A3!-/ [#- UE++PHE$;QI*-2.3?AI9@$6R;
M'IMJ34'#*,CR_:=:7F] PZT.Y>[XO0'['-N)PG$^#3/I^>8+/K+ '7^MP0\?
M="=AIOW60$E([T=W GW4U7%T!HQ#XZ3'QJ@P'YXTXTYF'S+VH368*EWZNGS1
M?;D%?_?Z1;?Y$XJR[64EY43Z,?*A"#S=PS-%D*(001FKLR;D7D3,>GA:S3JW
MPV-#.-BE'-!7L*'=/,S,'/M^:3X:HB-+9P,P'5\)#T)J4.R:^2R3Q;-9,[X;
MXV;_\C!%^5-&:+;,5IFH;O.FH<I3L53O5TW$QL(+L"=X[,%8ZH*OF&KKFR 8
M>Z$@,0[2-/ 6JV)%EF8Z[Z4)K2309MKQ-LV#G@,LMU3795FJ';K_QW_#@9_\
M$Q U_7;*Z$7XS?1*EZ".+(0^'2#YL1\U:R7.% I'^MC%Z295K4R9/]22C-]S
MDLHMRN=%XK& 4L:5%8VPLJ=C94J'@=)SH@ Q3GR&?*MKY>,I9J?*Z/3C;$/B
M#=")W%?E:VL<S>3#=>B,K9;LYV7?@(<^8*Y-RM[A?9R<;#W!6Z9D[S!X(2-[
M]\EA&[M+M+^7']H^Y0_D>Q.EHN3(CE2IL[^W^K6G.Z(ERJ*),?/4[A<$IG[H
M0>(+&25^$$IAU<YB(!US$Q&[=0LZ1NJN6@TK]7FYPXR=\!BZ5F829H(5&%D,
M68+?5H\8I[+>E6@Z$FQ#J9A4^ET)U:&(O':X 8$IV\C;W=C<G3CM=Z]'P;EU
M]/PFJ5'1MWZN_525;@/"FAZ.SQ^?7Y;%JQ#5PJ,\3I(X@2'A 40B\"#&$8*$
M1 (SZD=I$A@'MHQ/[^SD<AU'3^LX^EV>]X+IZ2O8?6X3;Z\YOP';I&"PP_T-
MZ/BOE1[USPX"B_B0";Z?_C-@AE_%V&?%_^L?A$7 T;P^C(D"EAZ>!!#=2M85
MN\B&";!Z(LH2K,!:?Q99#KXI)NLJ)#EH;AN +DZB5 Y=W+S2V%1 %B40'<,_
M.0ITFFYI>@.E)B!CND"KZ3#="]2:<-J!CN8B?]0;0=N@.NCC]GM6+2@1PD_"
M%(8A2R$*)%'"DGN0>4D@*0]D3*SLP%.3S$V9V"_B=P,TG>!W3:EE3-=)1 W]
MQ5?B-+:/>*]FGQE$]H[B'@Q<.8=/33&M0[B'R2,G<-^S S>],IK;\$*9D% *
MWX."IA%$21Q!XGD<TC06Q"-^PIE1;/WQT+/;X(HRRYV\A<EP_PYB?NQ=JSTD
M[@L<'?/J:G=N!YYV3QXQ=+03CY\8&EW-ROKTUQ74GI^+O-8!JMM54[ZW=F$4
MQWK!5FNH%B&/ RS\$$HI$X@\D< TD"%D@4_]A#'./607?7TM27/;[SL<@8:E
MQNZKP"Y3NJ3@AVRY;EKL;N+<3EJ(.\S:AGE?O=YF FC:51Q9<#E8P+,U%APF
M/KO#W%D\^M4$31RO[@K XWAV9R,/<"!_$950;SS=YOR#+FQ7O!R,WO7W>R@^
MBU(6Y?//15DGE%>:6E&R3--=K:J?USE7Y#7)EN11+-1G[OE!G$(1ZV9:'D^4
MPL8(%('D1-(D%=Q(^H],Y]R.A(8^P#94M[D-ZC>5J4P?>VD-?+KS6+"1I7_'
M)%!<@ATV=Z7XS;8GZD,!6EZ!8A8TW-Z +;^@9O@&M-_ EN=Y++N%YW8>RS^1
MQ_;M/P,[W^WXB]/KLQUQ^NE\M>-CN.>CG6"ZH?%Y!U?=OY2Z4*-/0B9]YD&U
M8U*()!:0^-B#+ II&/H$B=#*]#L]S=S.[A.Q'S>@IM0V6.\DJ&;VU?50C7QJ
M#D!I0.1>'PC.HO=.3C)Q!%\?H\=1?+U/#XSDTS&_=2M?_F%=ZE2HNH=38\<\
ME()4Z_*U?NB+R.K'%C['OL<B#/U04ET;E\.4)!2&A.!0)H&7"*N\?'L2YB8Z
M:N*:+M1*AZAY:'N5W;0>A1O0,0*:ASM6+&/Y[%?+3.Z,NP9C1V6, +]]Z-Y@
M!%U%[=D3,&W WF" CF+UAH\TP,ORJ;YF)WDA,WU+EN6U0<)(]?32N',6$4Y2
ME)  DCA@$/$HA"3E5)<'\%/F^XPFS-A9<G&ZN0F_Y99@L$,QT"2#EF8+$_@R
MW 8.#*<@CBR])L?/PA/@%,>)#'H3/ $$I2XG4-59L<K2VO^K%EZ@&Z+8C"*:
M)XNEPJ=H>TF1Y3(C?=G(=M:],>"]1OKE4::SM8TYVC.9S=]RU^LIV/1Z$J'O
M8PQY%"GSE^C,5\8#&'.!B<1(^EY\;:^G8)XA#,>]GH+K>ST%5_=Z&H#6R$+[
M?*^G8*)>3\%DO9Z"N?1Z"NQ[/1V^,DQ:;"JC%[?L/]99*78*C"THBYA'*(*Q
MT.(B9#Y,_3B&<<IC%I. XE@N<O%(FL!*4ZG1-Z?11DB;C7 T\WB;XK,:Z(E4
MHFY%GVW)M1,AO6";R9"KL9M&B'1D:AVC)13<&<!F+3],\' D0'JGFE2"F#!]
M*$*,WK$O_O-^7>H2FC]G%2/+?Q.D_)CS#VI7+IB(>(08ASB4NE%QH'Y":0!3
MW3U.MT8(?*/@R+Y)YJ9CM'2"AE"@*04?]=V;HM6\IL]92/LEA"N@1I8,@S"R
MJLYS"81!Q7C.#CI9[9U+;.V6VKGX[#!EX2]Y*5CQF&=_KUWU[T0NE!%3U_-Y
M%NH7GT5.EFW%C;M<[3@E8&X9*QO7>BA#G1\?QKX/$4(I3 EFD..8)3Z*DC2R
M:C-[!2US$QN[K-273QTS-Z!AI_[EAJ$Z;;MC";0\V2DBURRDF9XRT?*,+*Q&
M71EK7<<!IHY4H6LHF513<@#9H2+E8LC!;6ZRE?B4?1-Z8/6=9G0IFOO23UDN
M[E;BN5I$J>18\A#*5!ENR--5B(2(81)&B1?A0%++=MX&D\Y-H#8TPYIHL*6Z
M*WOQNR8<U)1;YJ<9K8"A,\@QKF-[A1Q .J11C3%&[MK37)YRZJ8TQB"<:$5C
M_NXPH?21E'F6/U:?15G?4M;Y!$I-0&'*8LPP9(FNSZ&%$8Y% H47(Q;&<<I]
MHUJO%^:9F^CIR-2W],T-_0UH2;43->=P-9,N#M :6: , <I:@%R P9',.#?+
MI&+B JN'DN'2XT.*_M1W6@_;.ZW;QU+40: +P2.6!K&V^Y0J@BB62BE)(TC2
MA/LTBI$7&G49N##/W(1!>\^Z0RK8T&I3_.0\L/W2P"%<(TN#\9&R*>_B!+&)
M8@(&(6=94^4B'OVU4,Z_/F$-DXL\[-<>N?SXE&71ZHBO=T6^UD;E%V50EIDN
M9E+_^A?UMC8_FTBQ!4_C)"(IA4&HT]N0C" 6A,)$4.EYL8>(-*H_,A7!LY/9
MU]?!:N(P:^YKC]"6_^9/.JI<0Z +)34@3%$)R^(;,CE5YO5EC'T\:5; N_Z/
MXEW[48!WQQ_%WC=Q>^*;Z#Z)NYE^$E-41QOGTYBP/%J^UA$9.D3@L5E-]5-=
M5A_0C3 HMPO?_(EHUBOP3+@ O(GPUK%X+S6C0&=%E6T=?B4O='*43M9_47._
M?<TT^P4;IVB:!1U_@JII]JBZ*9LV8-Z!,4=EP83@U<\*L*]$%Z95OU'?^^KU
ML_JL5VIV7:*_SB1<T%1Z3%*MOWC*<A1^"M-8)A CAB23:9)&5D7U+>:>FV;2
MD=[%\#9UG3OR;T#-P,VF \6+N>TT9&',_% CP3WR<>\4:?N0)GO,7$4X6<P\
M;<"3/21'\4\#AIBV<,F7XK6Y.-PM;1#ZC'FI@ QQ'Z(HUM7E? F9X"RE:8QB
M9N1%'X&VN8G'#8E:=9JT/L6IA3,PH=YN.486GV[J3FS7<^IZ(R<WXB0U1JY<
MUS]571&K]9VLD$C/"HQ5/.34E'^*@B$]6+DJ$M(WQ<"J $/-H_K__8LRBS99
MN?Y""IYZ(?75\1P)W80"0>R'*62A)QA.J? ]8E4OP"%Q<SN?6^I:QX9E<0"7
MBV9FN;S54DSAR807/)D;]_8)3^9-Z]#LEO."M]*^V, (N+LJ0^"2M&D+%(P
MZE'I@C'F&&"!M0&9VJJ[I55]KBP"A,.$20F#,%1R.O%#7?$WAL1'R*."A3$Q
M;Q9T8H*YR=J6Q-I1 7[OJ#0,=CR+HH%-<R4V(PN_<6"Q, VNA&<B_=X6)COE
MO >#7@W[U'O3J<D]5._INGW/#5-8;_F_K]L\O8?BEO-,+SY9?B89O\O?DY=L
M19:U8*6'LO>+OC:JLI7X*LIO&1.-</W21*_K!^J4X@7%5 C&,4PY]B"B =--
M*]7_DS2,F4<BRJQ<[&,3/#=A6U^0M)$ ;(<;.Q5W]&4V4WOGM'@CGP:WG^_>
MWUPJ=EXG^NBZ2Z+N5Z5+58(=GMSIO5,![T@7'IW<2?7CJ< _U)DGFW> 'OVY
MS'*6O9#E[7.QSE?W\GV1?Q/E2J<0_%:LA&YU11,JN([IURV/=0M.BI" -,8A
M\M4OL4B-M>J+T\U-[&\(!J2F6%\1LBW-(-=$6ZB6E_$VT+^=HCCZ+>O4 %IH
MZDZ!G$AOOPY0.RW>&)]>G?[R*--I^,8<[>G[YF\YS_G<% 7ZD%5L653K4BQD
M'/K("S#T?1%!Q*6 .*(Q#&3H\YBDA BKEF1VT\]-1+=)B\O328M[#6NW3#C+
M"#VU/F9*^'BHCRS2^[-$;0%WF2_:@]OXF:.G)I]+#FD/,!;9I'VC#-(]=X)U
M%']UI3.%N'_[\.N]E$)'R2X$8V',PDCIFWX"$1$$I@%+8*16)HAI*I+(/#;&
M9,:YB;>#,+6.:J#)!HINT!%NI409(&^DB+K%<W1=](V@M%))W4(ZF59Z+;2V
MFJDY3!>44X.!IM1/S?DZ4%$M7AS8%#<C-%MF.E"C+3VU\&*/R3#",(ETY?!8
M8$@DBR"F ?=#3BA+\6)5K,C23!,]GL)*'&\F&N]#?]!S -;6-UMNZ;7LG'N,
MI9G6>!U"(PO8'>)N0$N>PX:Z9UEWU5CW>()I&^R>9?"HT>[Y)X?M[3H0J]'R
MNN\1I2(6'A,PC$+9-+[&Q&,P%$+ZH1^&?FS5X_YXBOFI6N*%9!R([]H#VU;Z
M*C39FPU/:OKM]OH);,WV^G6(C;S7:^(V-I_SS7Z>=T>;_<0$DV[V\PP>;O:>
M)P=87;\6Y>J1/(H/@JZZRF5?=.%1?3NV^"*^J=\L/OWKEW]=^*D7!P)3F$8)
MA8CC!!(O2&&8($IH$"+.C:Z,[::=FU#H" >:\FW=OY.T6]@-YLM@8(>- N[(
M\N/-<;4PRD;!=R++S 9G $'6/5#J?B%9#IH_@V5!<D"Z^A@@JT#H04Y>P:>[
M=_=?P,MR78'HI^B_JQ,2Z'O,^OV?MO.Q)U(^"JY?U(G/:B#U]SJ+NGZZ*$&B
MWG9D'5JO5Z^):#[:=':B-8=[QJ+]VP,.FEN%9'+_7:H7-O<G77WRVT4<T("P
MA$'N^4J[Y,B'*9(IC&.",9'$#Y%YSZG>J>9VH&A:04,LV%[F;6KIWUH(NWZ(
M#0X.9\"-?%A,AIG%H> ,NXD.@L$8VLE>(UAZY6W_"-/)6"-.]N2JV1L#9*FN
M4?5)G<#O_TITU-IJ01+.$QZ$,(D3)3Y]H71S*2GT?4PP(5Z8$G/=_'#TN4E,
M31_0!(+WH"41G%<5#- SD(S78#*R,'0.AX70NP:6J6KT6,%C)]S.L=\KSXY>
MFDZ$G:-W3VJ=?6AH\;NJZ6WZ>5U6:S7>0W%09^8O>;:J/M;5CNZZ8D<ZEGX1
MA6&$J AAY">1DFK4AR0A D:Q3'F4"@\+\\O>JTB9FPALF.EZ!'?LZ,9+1S7&
M:I9N0,,4V'!5)WK8UAL;O)(&$G:R]1E9'/_9EL:VR-L42S15&=5FJ9J>RN!E
M9ZF."K:M-5=M83;ML#BY9DYKLUV+\^6J:X-GF+B>VK5('%=*NWK$*\H0'$7U
M'V?+TL-LV8_?7[*F06];F1&E >$I9U!B=3RBU$M@&@<>]$@8,2%DF 9&4?C.
M*9O;0=GDK>N>NP.*#SA9*K.[O3=9@"E.PNO*#FRY&Z?F@$O$718<<$+7]-4&
M7,)YLM2 TPFN<+S<UJ[R2I\>3.C\P&I!/:3L$B^%,68((J%^2B,9P(B%6/T#
M*^O%W%@Y/\_<!.S6O+YMKY1::NNT29M4GAYL+1PTUR$VF:MF1+ &N&^N VUR
M1XX=>,-<.N<A,7+NG'A]>C?/>1Y..GQZ'I^R[\$FK>!6D?+\HM^JOF35WWXN
MA=B]G?SX_+(L7H582!:') E2&'"FE&$248@9D=#S$^8E0J0Q-D])G8SLN0ER
M!ST0=C)]=D"X 1H&H''8CS=0ZEV+Q11U[ZT_*U.?U=P^EDFT^O_Z3C;?R11=
M$L;\7B;LE5 JDJ'4"[P?5T0V7('5$ZG#B=;ZN\ER\$UQK4O.J6._:)Y0_].^
MN.*/'%2- T\7Z1 MYV_?(&'H6HW3)L&:FC]!LX2A"+MIF3!X]D&5Q;7W\98Q
MG6>N2^651:Y^9**)(>BJD1$2ISSV) Q0I#0@+ G$%",8$1Y*2620Q)Y%Q7"3
M.>>FOC14@RW98)_N8:7?#/$W4!7<HSKR.?^F@%I5WG8-[&05M:\'V+9$M@U4
M%TI?&PTU94EK&]X.2E5;O6HGQKG(%A_5L*O76\[5YU.U__F4Y<)?X #')/!"
MG5,A(.))"E/,8B@27R:A%!$VZY':.\O<1'5#*&A)O.E^ )I8<)\;:OG]P/9+
M9&=PC2R#!R-E+!>,D#AQLU$)]M-C\>U_JO>;2PWUP_8NHW_4282"$6.=&#![
M>(#^=O=2B?S7;*E4PB(7K1:IY8VNI['P!69"XA@BWR<0419 ',<2^F&44#_"
MR!.QL=K6.]7<1$!-+-A0NW$0=/1::!3]$!MH9LZ &UD83(:9A?+E#+N)=*Z[
M'-RS5=&4HO#1#?@DOF=*D@!1&V[:X[ J %$"ENF4WSKC]WVQ5/P6Y4&?9?!'
MMGH"S:)\5H;B,P%?;[_6O@@=(,1W6J3H45CQ_"Q*EI%E]O=FI$)VL_]C!7BY
M?@1,/9AQ[1!9J7=7958I/(!8/;TN0;%>51D7]=@Z/*4.(E./-EG)_TQ>2/X3
M>'C**E"*%P59K4'JA[=EX9XWG\Y+%^4O2)FKD8Y:4+IRHAA]'[V*9O\(T^F7
M1ISLJ95F;PPX5':JS>D;FX_?V9/V6=2E*-Z3ZDG]77\JS0>["(7/21A$2L5D
M$40>3R'U(@0Y(2'A?H)"'QL?,E93S^W0V2&^N4#LR <0M'4\% NZ>N*6!PNA
M:K<L!@?3:&"/?%#-"F>+PVPTO"<ZW)SB;B?G!T'7*_?M1ISN'!C$Z=ZY,&R$
M(<9'ZXR^SS_I6N9=YME"U\A+:1+#2.A(I42&$'O(@PE"+!428>8957+IFV1N
MLG]SH:@4KYK03::CC=I\!E 3(^-ZF,8V+\9$R,:DN!ZIR8P):\0LM>=^*/KU
MYC/O3J@Q]U._KRM?>'98O/W=\PO)2CW2O3PL7GJ7<R'KVJ9UI6 EA9=KKHR@
M7XJ"_Y$MEPOFQ0G!B0=Y[/E:2J80"YK P$]TJFV0IL0JQ/X:8F8G33>\:+OR
M1,W?+4-M(>8?-CR!CJD?[2+RKUK,?@D]]1*-+<DM5N>3_>I81]J[@-51</U5
MI$P:3^\"M,,0>B=C#@D%?7U^>2KRUSO%^V9+QC2,(H]', D\"9$G*:0I1U H
MZ1KY49RDW.CJZ^P,<Q.:'8U $[G99S8A;:=@-- ]KP5G9'$U#BXV47E7XC.1
MNGF?@W]>+U]!Z-UHY[6WX[S^KCW+=<#<JM(IQ\JB5-KH?1,OUWJ?7Y9".XUK
MES!K^@BU7NB]!?AILP(Z*J]@&=%OU;[N$Z_^@X]_2K1C>:E^<0/^>,K8TY$#
MNI8OZK=UFZ*_-V%]:J9<L'J8S=A* (E2.^%7Y/NFE.YK,Z7^M6:$9URW--$)
MNNOEJBDO+;XS?2GZTO']4F9,*&)(I>?.'K6'>U744VC?1[&L?>Q<^_S5^!L8
MG04.]GQ._3%^IUZ<,!ROA^[]R+F^!X=IZN^7:J7N99U\^Z%X)EF^2*20080(
MY (SB*)8P!2%%!)/)IS*U,>I59OMXRGF=D#4%-8;LDXY_[VATC"ZJ@=),^7W
M.GS&=BE;0F.MHY[GWI'F>6*"2?7)\PP>:HD]3PZ)8/WP5=</W*04_5I7HE_P
M6*8L\1(8^SB!B <<4LXDC%#"$8NQ[Q'S6ZG3<\QM>W_Y'^3YY9\^@*JC59U&
M=DE_9[ T4 &O1VCD#7X&'/![0ZE5B.F9+\XBI/1JM*8*(;7\I"S#17MAZ \/
M/?WJA.&@O;3OAW_V/SJXA9L>L/9F_E5DCT]*X;S5LSR*+T++5&5:UW_4R9?^
M(J6)YP<)@R).,$24(HBC.(04^5Y"$HG3R$K9L9M^;I*RI;YQJM^ C@'0<@ V
M++1N]P?K\AZ6RV.F08T'^LC"URG>0QJX#8#-70,WF\FG;N V )@3#=R&C#)
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M'N:4)7X$_=1/((HHAB1-4TA9R) ?,B8"(ZEE-MW<1-4NP?6^VI)L[=(V!-S
M#' *X\@2Z0T0M,EO<XGD5/ENUR%JF0)G"E!_2MS%429,D3/E:#]ESOBM*]I
MW*EO)W_,Z%+4G1)U&<N%] +$T@C#), Q1#[BD+!0P#BA28A#&2AETKJ-PXF)
MYB9YMR0"4M-X W)AV4WP+*AF"J +J,:6KG4AA1VL;ENL?NO!:EBW@AX@7'8;
M.#7-]-T">I@]6>V_[_FA*7/OA39DEW<Y%]__MWA=4,93*9@')6($(N+I0GB,
M0R823&@2I5%J%'QP=H:YB8 VX:NE$M1D D6G;6K<(9#]N]\)/"-O>VMD!J3
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MFG) U)!@7,]$?8C.7!9O:.H281[^%M[Q3[__U/V%_R.B57[_Z;]02P,$%
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MB3E.-K2A66DK[@YP<Y/^"^3+@.2V^P3:1U/O$<EIUT%!DM(B2UZ9,.A.=@?
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M@DM< D=IC<A,,?58X?S>CLD66H[KPC8&2A.!]P*<"^H7\W39TYM<[D!BJ/,
ML Z6<>"-">"=<BI)5)$_]B[G0'?VFI#C>K1C0.8@47> EW/Z)\9$F[BR=5:Z
MK7YX)CD0U4KE8GS0F876\<[YRL?U84>Y -A)F!UXKK]-0YS.INLIWO/F@].:
M#)V $ UY\U$QXD15B7BI0W)"/CIZ?!]8/$S-<6IJ1X)*(Z'W8$$N,H0?PH^:
M'KP,WYCU: PJ0$\B4883/\$D"-P($U#7Y]4CY65O4W+<*Z%6>GX@+7N T/N
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M4N\4/S>[%4NC8ZI]4EBI;<.LK-&ED< L>BEEYHJW]KB?(&D8DEY*>7M+^7<
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MO#8!4&'6EMIRBN*@.DT\9HC.4\RB,Q&3;9:V]=O91PGJQ"O;0],/@>9@L7>
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M_O;[='T1Z[BB,3%.H?!FS%6NMY5924A>.6.Q9"9;IR#N4S$,1B\EO7Z@E#O
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M]3:FY$&"&F6@KSY_2X^BB 20VH273HOZ+,^3*QMJ08H.2097T#<_L1\AI\'
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MGXE?PUK;N"%T'3?I.SKPFJOFA6?UMC59'3VU]]BBSYG?&\S\^$F^HD0602M
M3G!6VCEP.B7(#$OV5@HK6H=YSY'D>[@3ZL8A]EHDBYE#M@J)ZX#D$.<,OD3K
MA60EZO$:!CQ.6[<)OEV0\G""KZ%BCGC@KI;KR4<RXK@)[[-6Q@=5[WGKW9WF
M&B)%7%"4L1*3T]P-0A-]Z@TDT=^N471KP5Y2<2UUN3A4L#V@X:]8RT8FS%'
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M&P/H8*TVA:$Q=RKL'RCLVV75XUJOD> TKNP[ =7-KI7$W$4/NBN.8G+9%14
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M_=F9?#U@^3'Y/<>AZ40J&,%9=9^S.RQ?_;@DY7VL*N03JQP:;\EB"QU U;C
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MNOQR9:'763;.>,DV9HC(B2%B +PQ%BR+P5HE662MD^-/$C70C-<^\=16$2-
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M'28<:HU#DEXA%H4AMT+BU9+#8/$(96VK^P#)#:SPOT]GTZ^77S>$&ZYBDK)
M8!E!:2/K/(8$.12M#<^1Q4X-QI]0^;U%!U;Z(2J;MY#?T(H//^X0CM'%*'P
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M%]?--D@0P2F)@*Z.F]/>0N2U];HJS 15;.Q6HK!/A>-#A'0KG/^+H^]X%8X
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MF7@;B\KDX5$<'(DYJ2#FI,!$C*H4'U-@C8'6C;)N@#O/JX<>=#."(^WQ2JV
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M\V__!U!+ 0(4 Q0    ( "X[8U9CAOC9L!(  +Y?   >              "
M 0    !E>&@Q,#$P;V9F:6-E<G)E<W1R:6-T961S="YH=&U02P$"% ,4
M"  N.V-61)G!X-4#  "*#0  'P              @ 'L$@  97AH,C,Q97)N
M<W1Y;W5N9V-O;G-E;G0R,#(R+FAT;5!+ 0(4 Q0    ( "X[8U:^#/;EY0<
M ,$M   >              "  ?X6  !E>&@S,3%C97)T:69I8V%T:6]N;V9P
M<FEN8RYH=&U02P$"% ,4    "  N.V-6H=MQ%O '  "U+0  '@
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M,#(R,3(S,5]D968N>&UL4$L! A0#%     @ +CMC5NSLS+[\# $ V&0! !0
M             ( !FX@# &QX<G@M,C R,C$R,S%?9S$N:G!G4$L! A0#%
M  @ +CMC5B$+HK$=)@$ !@\, !4              ( !R94$ &QX<G@M,C R
M,C$R,S%?;&%B+GAM;%!+ 0(4 Q0    ( "X[8U:%[K5PIJD  "E_!P 5
M          "  1F\!0!L>')X+3(P,C(Q,C,Q7W!R92YX;6Q02P4&      P
,# !) P  \F4&

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
